product_id,company_id,company_name,company_type_name,drug_id,brand_name,molecule,technology,phase_name,business_development_status,launch_yr_us,launch_yr_row,generic_entry_us,generic_entry_row,drug_class_id,drug_class_name,drug_group_id,drug_group_name,therapy_area_id,therapy_area_name,reporting_currency_id,region_name,company_revenue_type,Previous5,Previous4,Previous3,Previous2,Previous1,current,Forecast1,Forecast2,Forecast3,Forecast4,Forecast5,Forecast6,7_yr_cagr,drug_profile_id,indication,extract_date
5,46,GlaxoSmithKline,Large Pharma,4305,Mekinist,trametinib,Small Molecule (Chemical),Launched,Licensed (Development),Jul-13,Feb-14,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,34,Melanoma,7/7/14 12:28
5,46,GlaxoSmithKline,Large Pharma,4305,Mekinist,trametinib,Small Molecule (Chemical),Launched,Licensed (Development),Jul-13,Feb-14,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,4,Global,Sales,0,0,0,0,15.63414028,40.02287516,58.94688179,64.92908478,58.68016539,58.62996924,69.93398405,78.84385066,26.00411586,34,Melanoma,7/7/14 12:28
5,46,GlaxoSmithKline,Large Pharma,4305,Mekinist,trametinib,Small Molecule (Chemical),Launched,Licensed (Development),Jul-13,Feb-14,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,34,Melanoma,7/7/14 12:28
5,46,GlaxoSmithKline,Large Pharma,4305,Mekinist,trametinib,Small Molecule (Chemical),Launched,Licensed (Development),Jul-13,Feb-14,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,4,ROW,Sales,0,0,0,0,1.563414028,21.52068817,35.40156537,41.69633308,37.84571875,38.70806384,48.5399011,57.29183018,67.27499217,34,Melanoma,7/7/14 12:28
5,46,GlaxoSmithKline,Large Pharma,4305,Mekinist,trametinib,Small Molecule (Chemical),Launched,Licensed (Development),Jul-13,Feb-14,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,34,Melanoma,7/7/14 12:28
5,46,GlaxoSmithKline,Large Pharma,4305,Mekinist,trametinib,Small Molecule (Chemical),Launched,Licensed (Development),Jul-13,Feb-14,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,4,US,Sales,0,0,0,0,14.07072625,18.502187,23.54531642,23.2327517,20.83444664,19.9219054,21.39408296,21.55202048,6.280366097,34,Melanoma,7/7/14 12:28
7,24,Bristol-Myers Squibb,Large Pharma,801,11-beta HSD Inhibitor,,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,45,Type II Diabetes,7/7/14 12:28
7,24,Bristol-Myers Squibb,Large Pharma,801,11-beta HSD Inhibitor,,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,45,Type II Diabetes,7/7/14 12:28
7,24,Bristol-Myers Squibb,Large Pharma,801,11-beta HSD Inhibitor,,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,45,Type II Diabetes,7/7/14 12:28
7,24,Bristol-Myers Squibb,Large Pharma,801,11-beta HSD Inhibitor,,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,45,Type II Diabetes,7/7/14 12:28
7,24,Bristol-Myers Squibb,Large Pharma,801,11-beta HSD Inhibitor,,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,45,Type II Diabetes,7/7/14 12:28
7,24,Bristol-Myers Squibb,Large Pharma,801,11-beta HSD Inhibitor,,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,45,Type II Diabetes,7/7/14 12:28
10,46,GlaxoSmithKline,Large Pharma,612,1322322,1322322,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,38,Bacterial Infections,7/7/14 12:28
10,46,GlaxoSmithKline,Large Pharma,612,1322322,1322322,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,38,Bacterial Infections,7/7/14 12:28
10,46,GlaxoSmithKline,Large Pharma,612,1322322,1322322,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,38,Bacterial Infections,7/7/14 12:28
10,46,GlaxoSmithKline,Large Pharma,612,1322322,1322322,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,38,Bacterial Infections,7/7/14 12:28
10,46,GlaxoSmithKline,Large Pharma,612,1322322,1322322,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,38,Bacterial Infections,7/7/14 12:28
10,46,GlaxoSmithKline,Large Pharma,612,1322322,1322322,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,38,Bacterial Infections,7/7/14 12:28
12,46,GlaxoSmithKline,Large Pharma,2512,foretinib,mesenchymal-epithelial transition factor (C-met) kinase inhibitor,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,39,Cancer,7/7/14 12:28
12,46,GlaxoSmithKline,Large Pharma,2512,foretinib,mesenchymal-epithelial transition factor (C-met) kinase inhibitor,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,39,Cancer,7/7/14 12:28
12,46,GlaxoSmithKline,Large Pharma,2512,foretinib,mesenchymal-epithelial transition factor (C-met) kinase inhibitor,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,39,Cancer,7/7/14 12:28
12,46,GlaxoSmithKline,Large Pharma,2512,foretinib,mesenchymal-epithelial transition factor (C-met) kinase inhibitor,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,39,Cancer,7/7/14 12:28
12,46,GlaxoSmithKline,Large Pharma,2512,foretinib,mesenchymal-epithelial transition factor (C-met) kinase inhibitor,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,39,Cancer,7/7/14 12:28
12,46,GlaxoSmithKline,Large Pharma,2512,foretinib,mesenchymal-epithelial transition factor (C-met) kinase inhibitor,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,39,Cancer,7/7/14 12:28
17,46,GlaxoSmithKline,Large Pharma,785,1614235,1614235,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,43,Type II Diabetes,7/7/14 12:28
17,46,GlaxoSmithKline,Large Pharma,785,1614235,1614235,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,43,Type II Diabetes,7/7/14 12:28
17,46,GlaxoSmithKline,Large Pharma,785,1614235,1614235,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,43,Type II Diabetes,7/7/14 12:28
17,46,GlaxoSmithKline,Large Pharma,785,1614235,1614235,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,43,Type II Diabetes,7/7/14 12:28
17,46,GlaxoSmithKline,Large Pharma,785,1614235,1614235,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,43,Type II Diabetes,7/7/14 12:28
17,46,GlaxoSmithKline,Large Pharma,785,1614235,1614235,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,43,Type II Diabetes,7/7/14 12:28
21,46,GlaxoSmithKline,Large Pharma,1176,2190915,2190915,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,44,Asthma,7/7/14 12:28
21,46,GlaxoSmithKline,Large Pharma,1176,2190915,2190915,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,44,Asthma,7/7/14 12:28
21,46,GlaxoSmithKline,Large Pharma,1176,2190915,2190915,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,44,Asthma,7/7/14 12:28
21,46,GlaxoSmithKline,Large Pharma,1176,2190915,2190915,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,44,Asthma,7/7/14 12:28
21,46,GlaxoSmithKline,Large Pharma,1176,2190915,2190915,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,44,Asthma,7/7/14 12:28
21,46,GlaxoSmithKline,Large Pharma,1176,2190915,2190915,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,44,Asthma,7/7/14 12:28
33,46,GlaxoSmithKline,Large Pharma,4682,umeclidinium,umeclidinium,Small Molecule (Chemical),Filed,In-House,Jul-14,Jul-14,N/A,Sep-22,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,10,COPD,7/7/14 12:28
33,46,GlaxoSmithKline,Large Pharma,4682,umeclidinium,umeclidinium,Small Molecule (Chemical),Filed,In-House,Jul-14,Jul-14,N/A,Sep-22,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,53.27194417,138.1248602,222.8133924,277.7865676,313.1391061,343.3511358,369.0488568,0,10,COPD,7/7/14 12:28
33,46,GlaxoSmithKline,Large Pharma,4682,umeclidinium,umeclidinium,Small Molecule (Chemical),Filed,In-House,Jul-14,Jul-14,N/A,Sep-22,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,10,COPD,7/7/14 12:28
33,46,GlaxoSmithKline,Large Pharma,4682,umeclidinium,umeclidinium,Small Molecule (Chemical),Filed,In-House,Jul-14,Jul-14,N/A,Sep-22,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,25.13049167,53.70050273,75.85253628,97.99395442,116.1489386,132.290242,146.7313745,0,10,COPD,7/7/14 12:28
33,46,GlaxoSmithKline,Large Pharma,4682,umeclidinium,umeclidinium,Small Molecule (Chemical),Filed,In-House,Jul-14,Jul-14,N/A,Sep-22,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,10,COPD,7/7/14 12:28
33,46,GlaxoSmithKline,Large Pharma,4682,umeclidinium,umeclidinium,Small Molecule (Chemical),Filed,In-House,Jul-14,Jul-14,N/A,Sep-22,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,28.1414525,84.42435751,146.9608561,179.7926132,196.9901675,211.0608938,222.3174823,0,10,COPD,7/7/14 12:28
38,46,GlaxoSmithKline,Large Pharma,2491,vilanterol,vilanterol,Small Molecule (Chemical),Phase III,In-House,,Apr-15,N/A,Sep-22,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,15,COPD,7/7/14 12:28
38,46,GlaxoSmithKline,Large Pharma,2491,vilanterol,vilanterol,Small Molecule (Chemical),Phase III,In-House,,Apr-15,N/A,Sep-22,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,16.41584729,32.83169459,47.42341293,62.01512286,73.9803548,84.60313289,0,15,COPD,7/7/14 12:28
38,46,GlaxoSmithKline,Large Pharma,2491,vilanterol,vilanterol,Small Molecule (Chemical),Phase III,In-House,,Apr-15,N/A,Sep-22,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,15,COPD,7/7/14 12:28
38,46,GlaxoSmithKline,Large Pharma,2491,vilanterol,vilanterol,Small Molecule (Chemical),Phase III,In-House,,Apr-15,N/A,Sep-22,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,16.41584729,32.83169459,47.42341293,62.01512286,73.9803548,84.60313289,0,15,COPD,7/7/14 12:28
38,46,GlaxoSmithKline,Large Pharma,2491,vilanterol,vilanterol,Small Molecule (Chemical),Phase III,In-House,,Apr-15,N/A,Sep-22,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,15,COPD,7/7/14 12:28
38,46,GlaxoSmithKline,Large Pharma,2491,vilanterol,vilanterol,Small Molecule (Chemical),Phase III,In-House,,Apr-15,N/A,Sep-22,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,15,COPD,7/7/14 12:28
45,46,GlaxoSmithKline,Large Pharma,767,742457,742457,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,21,Alzheimer's Disease,7/7/14 12:28
45,46,GlaxoSmithKline,Large Pharma,767,742457,742457,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,21,Alzheimer's Disease,7/7/14 12:28
45,46,GlaxoSmithKline,Large Pharma,767,742457,742457,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,21,Alzheimer's Disease,7/7/14 12:28
45,46,GlaxoSmithKline,Large Pharma,767,742457,742457,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,21,Alzheimer's Disease,7/7/14 12:28
45,46,GlaxoSmithKline,Large Pharma,767,742457,742457,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,21,Alzheimer's Disease,7/7/14 12:28
45,46,GlaxoSmithKline,Large Pharma,767,742457,742457,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,21,Alzheimer's Disease,7/7/14 12:28
54,46,GlaxoSmithKline,Large Pharma,1470,961081,MABA081,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,29,COPD,7/7/14 12:28
54,46,GlaxoSmithKline,Large Pharma,1470,961081,MABA081,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,29,COPD,7/7/14 12:28
54,46,GlaxoSmithKline,Large Pharma,1470,961081,MABA081,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,29,COPD,7/7/14 12:28
54,46,GlaxoSmithKline,Large Pharma,1470,961081,MABA081,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,29,COPD,7/7/14 12:28
54,46,GlaxoSmithKline,Large Pharma,1470,961081,MABA081,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,29,COPD,7/7/14 12:28
54,46,GlaxoSmithKline,Large Pharma,1470,961081,MABA081,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,29,COPD,7/7/14 12:28
55,46,GlaxoSmithKline,Large Pharma,4324,camicinal,camicinal,Small Molecule (Chemical),Phase II,In-House,,,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,30,Gastroparesis,7/7/14 12:28
55,46,GlaxoSmithKline,Large Pharma,4324,camicinal,camicinal,Small Molecule (Chemical),Phase II,In-House,,,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,30,Gastroparesis,7/7/14 12:28
55,46,GlaxoSmithKline,Large Pharma,4324,camicinal,camicinal,Small Molecule (Chemical),Phase II,In-House,,,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,30,Gastroparesis,7/7/14 12:28
55,46,GlaxoSmithKline,Large Pharma,4324,camicinal,camicinal,Small Molecule (Chemical),Phase II,In-House,,,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,30,Gastroparesis,7/7/14 12:28
55,46,GlaxoSmithKline,Large Pharma,4324,camicinal,camicinal,Small Molecule (Chemical),Phase II,In-House,,,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,30,Gastroparesis,7/7/14 12:28
55,46,GlaxoSmithKline,Large Pharma,4324,camicinal,camicinal,Small Molecule (Chemical),Phase II,In-House,,,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,30,Gastroparesis,7/7/14 12:28
56,41,Enzon,Small Biotech,1226,Abelcet,amphotericin liposomal,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-96,Jul-95,Jul-14,Expired,93,Polyenes,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,23.834,0,0,0,0,0,0,0,0,0,0,0,0,47,invasive fungal infections,7/7/14 12:28
56,41,Enzon,Small Biotech,1226,Abelcet,amphotericin liposomal,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-96,Jul-95,Jul-14,Expired,93,Polyenes,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,5.10755,0,0,0,0,0,0,0,0,0,0,0,0,47,invasive fungal infections,7/7/14 12:28
56,41,Enzon,Small Biotech,1226,Abelcet,amphotericin liposomal,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-96,Jul-95,Jul-14,Expired,93,Polyenes,25,Fungal Infection,7,Anti-infectives,6,US,Sales,18.72645,0,0,0,0,0,0,0,0,0,0,0,0,47,invasive fungal infections,7/7/14 12:28
57,24,Bristol-Myers Squibb,Large Pharma,326,Abilify,aripiprazole,Small Molecule (Chemical),Launched,Licensed (Development),Nov-02,Jul-03,Apr-15,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1324,Schizophrenia,7/7/14 12:28
57,24,Bristol-Myers Squibb,Large Pharma,326,Abilify,aripiprazole,Small Molecule (Chemical),Launched,Licensed (Development),Nov-02,Jul-03,Apr-15,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,2592,2565,2758,2827,2289,1930,900,0,0,0,0,0,-100,1324,Schizophrenia,7/7/14 12:28
57,24,Bristol-Myers Squibb,Large Pharma,326,Abilify,aripiprazole,Small Molecule (Chemical),Launched,Licensed (Development),Nov-02,Jul-03,Apr-15,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1324,Schizophrenia,7/7/14 12:28
57,24,Bristol-Myers Squibb,Large Pharma,326,Abilify,aripiprazole,Small Molecule (Chemical),Launched,Licensed (Development),Nov-02,Jul-03,Apr-15,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,510,607,721,725,770,430,0,0,0,0,0,0,-100,1324,Schizophrenia,7/7/14 12:28
57,24,Bristol-Myers Squibb,Large Pharma,326,Abilify,aripiprazole,Small Molecule (Chemical),Launched,Licensed (Development),Nov-02,Jul-03,Apr-15,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1324,Schizophrenia,7/7/14 12:28
57,24,Bristol-Myers Squibb,Large Pharma,326,Abilify,aripiprazole,Small Molecule (Chemical),Launched,Licensed (Development),Nov-02,Jul-03,Apr-15,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,2082,1958,2037,2102,1519,1500,900,0,0,0,0,0,-100,1324,Schizophrenia,7/7/14 12:28
58,73,Otsuka,Regional & Specialty Pharma,326,Abilify,aripiprazole,Small Molecule (Chemical),Launched,In-House,Nov-02,Jul-03,Apr-15,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Alliance Revenue,2490.831507,2501.605015,2620.450903,2540.174281,2003.476727,1953.29971,1426.032206,517.4809234,518.2863412,513.4538345,513.4538345,512.4873332,-17.69727709,1324,Schizophrenia,7/7/14 12:28
58,73,Otsuka,Regional & Specialty Pharma,326,Abilify,aripiprazole,Small Molecule (Chemical),Launched,In-House,Nov-02,Jul-03,Apr-15,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Sales,1547.040092,2079.935566,2591.360738,2732.794132,3543.83823,4078.937668,2074.856878,1266.573824,1107.194532,1069.024354,1016.553975,985.5281178,-16.70874925,1324,Schizophrenia,7/7/14 12:28
58,73,Otsuka,Regional & Specialty Pharma,326,Abilify,aripiprazole,Small Molecule (Chemical),Launched,In-House,Nov-02,Jul-03,Apr-15,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Alliance Revenue,350.8312019,414.3389091,478.9209733,457.4721454,493.31839,513.4538345,513.4538345,517.4809234,518.2863412,513.4538345,513.4538345,512.4873332,0.546073715,1324,Schizophrenia,7/7/14 12:28
58,73,Otsuka,Regional & Specialty Pharma,326,Abilify,aripiprazole,Small Molecule (Chemical),Launched,In-House,Nov-02,Jul-03,Apr-15,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Sales,391.0693268,568.4670067,730.2675936,770.4794027,604.0633347,583.4245041,362.3373236,322.2436265,297.7923509,279.5148441,257.9928407,239.5278585,-12.37852386,1324,Schizophrenia,7/7/14 12:28
58,73,Otsuka,Regional & Specialty Pharma,326,Abilify,aripiprazole,Small Molecule (Chemical),Launched,In-House,Nov-02,Jul-03,Apr-15,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Alliance Revenue,2140.000305,2087.266106,2141.52993,2082.702135,1510.158337,1439.845876,912.5783719,0,0,0,0,0,-100,1324,Schizophrenia,7/7/14 12:28
58,73,Otsuka,Regional & Specialty Pharma,326,Abilify,aripiprazole,Small Molecule (Chemical),Launched,In-House,Nov-02,Jul-03,Apr-15,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Sales,1155.970765,1511.468559,1861.093144,1962.314729,2939.774896,3495.513164,1712.519554,944.3301976,809.4021814,789.5095099,758.5611344,746.0002594,-17.79127206,1324,Schizophrenia,7/7/14 12:28
59,53,Johnson & Johnson,Large Pharma,3674,Zytiga,abiraterone,Small Molecule (Chemical),Launched,Corporate Acquisition,May-11,Sep-11,Apr-16,Sep-22,107,Anti-androgens,55,Hormonals,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,48,Prostate Cancer,7/7/14 12:28
59,53,Johnson & Johnson,Large Pharma,3674,Zytiga,abiraterone,Small Molecule (Chemical),Launched,Corporate Acquisition,May-11,Sep-11,Apr-16,Sep-22,107,Anti-androgens,55,Hormonals,3,Oncology,6,Global,Sales,0,0,301,961,1698,2310.937254,2508.181391,1924.138404,1779.433907,1686.300952,1688.152174,1655.970018,-0.357418477,48,Prostate Cancer,7/7/14 12:28
59,53,Johnson & Johnson,Large Pharma,3674,Zytiga,abiraterone,Small Molecule (Chemical),Launched,Corporate Acquisition,May-11,Sep-11,Apr-16,Sep-22,107,Anti-androgens,55,Hormonals,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,48,Prostate Cancer,7/7/14 12:28
59,53,Johnson & Johnson,Large Pharma,3674,Zytiga,abiraterone,Small Molecule (Chemical),Launched,Corporate Acquisition,May-11,Sep-11,Apr-16,Sep-22,107,Anti-androgens,55,Hormonals,3,Oncology,6,ROW,Sales,0,0,83,498,948,1205.937254,1290.631391,1327.170558,1340.214023,1349.581072,1353.234373,1355.905112,5.245363441,48,Prostate Cancer,7/7/14 12:28
59,53,Johnson & Johnson,Large Pharma,3674,Zytiga,abiraterone,Small Molecule (Chemical),Launched,Corporate Acquisition,May-11,Sep-11,Apr-16,Sep-22,107,Anti-androgens,55,Hormonals,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,48,Prostate Cancer,7/7/14 12:28
59,53,Johnson & Johnson,Large Pharma,3674,Zytiga,abiraterone,Small Molecule (Chemical),Launched,Corporate Acquisition,May-11,Sep-11,Apr-16,Sep-22,107,Anti-androgens,55,Hormonals,3,Oncology,6,US,Sales,0,0,218,463,750,1105,1217.55,596.9678462,439.2198846,336.7198806,334.9178011,300.0649061,-12.26661101,48,Prostate Cancer,7/7/14 12:28
60,26,Abraxis BioScience,Regional & Specialty Pharma,498,Abraxane,nab-paclitaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,Sep-06,Mar-24,Sep-22,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Proforma,314,278.7,0,0,0,0,0,0,0,0,0,0,0,49,Breast Cancer,7/7/14 12:28
60,26,Abraxis BioScience,Regional & Specialty Pharma,498,Abraxane,nab-paclitaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,Sep-06,Mar-24,Sep-22,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Proforma,38,46.7,0,0,0,0,0,0,0,0,0,0,0,49,Breast Cancer,7/7/14 12:28
60,26,Abraxis BioScience,Regional & Specialty Pharma,498,Abraxane,nab-paclitaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,Sep-06,Mar-24,Sep-22,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Proforma,276,232,0,0,0,0,0,0,0,0,0,0,0,49,Breast Cancer,7/7/14 12:28
60,26,Celgene,Regional & Specialty Pharma,498,Abraxane,nab-paclitaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,Sep-06,Mar-24,Sep-22,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,49,Breast Cancer,7/7/14 12:28
60,26,Celgene,Regional & Specialty Pharma,498,Abraxane,nab-paclitaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,Sep-06,Mar-24,Sep-22,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Sales,0,70.3,386.25,427,649,778.64,888.6048,995.900736,1077.81454,1126.769406,1166.605949,1200.523102,9.184450816,49,Breast Cancer,7/7/14 12:28
60,26,Celgene,Regional & Specialty Pharma,498,Abraxane,nab-paclitaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,Sep-06,Mar-24,Sep-22,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,49,Breast Cancer,7/7/14 12:28
60,26,Celgene,Regional & Specialty Pharma,498,Abraxane,nab-paclitaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,Sep-06,Mar-24,Sep-22,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,11.92,65.25,93,144,191.64,233.6048,275.700736,309.0345395,334.8674059,355.8941489,373.1824825,14.5723348,49,Breast Cancer,7/7/14 12:28
60,26,Celgene,Regional & Specialty Pharma,498,Abraxane,nab-paclitaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,Sep-06,Mar-24,Sep-22,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,49,Breast Cancer,7/7/14 12:28
60,26,Celgene,Regional & Specialty Pharma,498,Abraxane,nab-paclitaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,Sep-06,Mar-24,Sep-22,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Sales,0,58.38,321,334,505,587,655,720.2,768.78,791.902,810.7118,827.34062,7.306872264,49,Breast Cancer,7/7/14 12:28
61,2221,AbbVie,Large Pharma,618,ABT-072,ABT-072,Small Molecule (Chemical),Phase II,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,50,Hepatitis C,7/7/14 12:28
61,2221,AbbVie,Large Pharma,618,ABT-072,ABT-072,Small Molecule (Chemical),Phase II,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,50,Hepatitis C,7/7/14 12:28
61,2221,AbbVie,Large Pharma,618,ABT-072,ABT-072,Small Molecule (Chemical),Phase II,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,50,Hepatitis C,7/7/14 12:28
3931,67,Novartis,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Mar-14,Mar-14,N/A,Aug-17,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,ROW,Sales,0,0,0,0,0,6.666664,12.44446169,17.77778463,23.11112003,27.17778811,30.70278755,33.73966297,0,1570,Chronic idiopathic urticaria,7/7/14 12:28
3931,67,Novartis,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Mar-14,Mar-14,N/A,Aug-17,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,US,Sales,0,0,0,0,0,6.666664,17,28.86039,40.72085587,40.72085587,40.72085587,40.72085587,0,1570,Chronic idiopathic urticaria,7/7/14 12:28
3932,86,Roche,Large Pharma,4049,RG7598,RG7598,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3817,Multiple Myeloma,7/7/14 12:28
3932,86,Roche,Large Pharma,4049,RG7598,RG7598,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3817,Multiple Myeloma,7/7/14 12:28
3932,86,Roche,Large Pharma,4049,RG7598,RG7598,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3817,Multiple Myeloma,7/7/14 12:28
3934,86,Roche,Large Pharma,4051,RG7314,RO5028442,Small Molecule (Chemical),Phase II,In-House,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3819,Autism,7/7/14 12:28
3934,86,Roche,Large Pharma,4051,RG7314,RO5028442,Small Molecule (Chemical),Phase II,In-House,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3819,Autism,7/7/14 12:28
3934,86,Roche,Large Pharma,4051,RG7314,RO5028442,Small Molecule (Chemical),Phase II,In-House,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3819,Autism,7/7/14 12:28
3935,86,Roche,Large Pharma,4052,RG7652,RG7652,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3820,Hypercholesterolemia - PCSK9 inhibitor,7/7/14 12:28
3935,86,Roche,Large Pharma,4052,RG7652,RG7652,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3820,Hypercholesterolemia - PCSK9 inhibitor,7/7/14 12:28
3935,86,Roche,Large Pharma,4052,RG7652,RG7652,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3820,Hypercholesterolemia - PCSK9 inhibitor,7/7/14 12:28
3936,86,Roche,Large Pharma,4053,RG1577,RO-4602522,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3821,Alzheimer's Disease,7/7/14 12:28
3936,86,Roche,Large Pharma,4053,RG1577,RO-4602522,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3821,Alzheimer's Disease,7/7/14 12:28
3936,86,Roche,Large Pharma,4053,RG1577,RO-4602522,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3821,Alzheimer's Disease,7/7/14 12:28
3939,29,Chugai,Regional & Specialty Pharma,1827,lebrikizumab,RG3637,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Feb-19,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,616,Asthma,7/7/14 12:28
3939,29,Chugai,Regional & Specialty Pharma,1827,lebrikizumab,RG3637,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Feb-19,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,616,Asthma,7/7/14 12:28
3939,29,Chugai,Regional & Specialty Pharma,1827,lebrikizumab,RG3637,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Feb-19,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,616,Asthma,7/7/14 12:28
3942,873,ARIAD Pharmaceuticals,Regional & Specialty Pharma,4058,Iclusig,ponatinib,Small Molecule (Chemical),Launched,In-House,Jan-13,Jul-13,Dec-26,,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,45.55,85,133.5,174.713775,204.3957065,230.3431245,251.6509655,269.0994248,28.88529616,3823,Chronic Myeloid Leukemia,7/7/14 12:28
3942,873,ARIAD Pharmaceuticals,Regional & Specialty Pharma,4058,Iclusig,ponatinib,Small Molecule (Chemical),Launched,In-House,Jan-13,Jul-13,Dec-26,,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,10.11,43,64.5,85.999785,100.2665205,110.9965024,119.3634836,125.516983,43.31069627,3823,Chronic Myeloid Leukemia,7/7/14 12:28
3942,873,ARIAD Pharmaceuticals,Regional & Specialty Pharma,4058,Iclusig,ponatinib,Small Molecule (Chemical),Launched,In-House,Jan-13,Jul-13,Dec-26,,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,35.44,42,69,88.71399,104.129186,119.346622,132.2874818,143.5824418,22.12399478,3823,Chronic Myeloid Leukemia,7/7/14 12:28
3944,26,Celgene,Regional & Specialty Pharma,4060,ACE-536,ACE-536,Recombinant Protein,Phase II,Licensed (Development),,,,,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3827,Anemia,7/7/14 12:28
3944,26,Celgene,Regional & Specialty Pharma,4060,ACE-536,ACE-536,Recombinant Protein,Phase II,Licensed (Development),,,,,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3827,Anemia,7/7/14 12:28
3944,26,Celgene,Regional & Specialty Pharma,4060,ACE-536,ACE-536,Recombinant Protein,Phase II,Licensed (Development),,,,,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3827,Anemia,7/7/14 12:28
3945,887,CorMedix,Regional & Specialty Pharma,4061,CRMD001,deferiprone,Small Molecule (Chemical),Phase II,In-House,,,,,56,Iron Chelators,59,Iron Overload,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3826,Contrast-induced Nephropathy,7/7/14 12:28
3945,887,CorMedix,Regional & Specialty Pharma,4061,CRMD001,deferiprone,Small Molecule (Chemical),Phase II,In-House,,,,,56,Iron Chelators,59,Iron Overload,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3826,Contrast-induced Nephropathy,7/7/14 12:28
3945,887,CorMedix,Regional & Specialty Pharma,4061,CRMD001,deferiprone,Small Molecule (Chemical),Phase II,In-House,,,,,56,Iron Chelators,59,Iron Overload,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3826,Contrast-induced Nephropathy,7/7/14 12:28
3950,888,Galenica,Regional & Specialty Pharma,4071,Ferinject ,ferric carboxymaltose,Small Molecule (Chemical),Launched,In-House,,Nov-07,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,5,Global,Sales,38.21304154,66.74877064,96.5283038,135.5508018,170.7172752,190.911985,208.3724127,221.2728762,230.7092574,237.9575065,243.3785854,247.4419597,5.445477855,3808,Iron-deficiency Anemia,7/7/14 12:28
3950,888,Galenica,Regional & Specialty Pharma,4071,Ferinject ,ferric carboxymaltose,Small Molecule (Chemical),Launched,In-House,,Nov-07,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,5,ROW,Sales,38.21304154,66.74877064,96.5283038,135.5508018,170.7172752,190.911985,208.3724127,221.2728762,230.7092574,237.9575065,243.3785854,247.4419597,5.445477855,3808,Iron-deficiency Anemia,7/7/14 12:28
3950,888,Galenica,Regional & Specialty Pharma,4071,Ferinject ,ferric carboxymaltose,Small Molecule (Chemical),Launched,In-House,,Nov-07,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3808,Iron-deficiency Anemia,7/7/14 12:28
3951,888,Galenica,Regional & Specialty Pharma,1525,Venofer,iron sucrose,Small Molecule (Chemical),Launched,In-House,,Jan-00,N/A,Jun-09,161,Other Anemia Treatments,24,Anemia,14,Hematology,5,Global,Sales,168.9660994,177.0376876,188.2132971,152.1880363,138.9910559,131.6314364,127.7707655,125.8066234,124.7933831,124.2739787,124.0069567,123.869862,-1.631936613,1246,Iron-deficiency Anemia,7/7/14 12:28
3951,888,Galenica,Regional & Specialty Pharma,1525,Venofer,iron sucrose,Small Molecule (Chemical),Launched,In-House,,Jan-00,N/A,Jun-09,161,Other Anemia Treatments,24,Anemia,14,Hematology,5,ROW,Sales,168.9660994,177.0376876,188.2132971,152.1880363,138.9910559,131.6314364,127.7707655,125.8066234,124.7933831,124.2739787,124.0069567,123.869862,-1.631936613,1246,Iron-deficiency Anemia,7/7/14 12:28
3951,888,Galenica,Regional & Specialty Pharma,1525,Venofer,iron sucrose,Small Molecule (Chemical),Launched,In-House,,Jan-00,N/A,Jun-09,161,Other Anemia Treatments,24,Anemia,14,Hematology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1246,Iron-deficiency Anemia,7/7/14 12:28
3952,889,LG Life Sciences,Regional & Specialty Pharma,4074,Declage / Eutropin Plus,sustained-release somatropin,Recombinant Protein,Launched,In-House,,Mar-07,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,11,Global,Sales,3.13317972,5.190464828,5.41479593,7.990529743,9.171352471,10.07927272,10.9801645,11.61910266,12.15902713,12.60830255,12.96838443,13.26435036,5.412765138,3829,Growth Hormone Disorders,7/7/14 12:28
3952,889,LG Life Sciences,Regional & Specialty Pharma,4074,Declage / Eutropin Plus,sustained-release somatropin,Recombinant Protein,Launched,In-House,,Mar-07,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,11,ROW,Sales,3.13317972,5.190464828,5.41479593,7.990529743,9.171352471,10.07927272,10.9801645,11.61910266,12.15902713,12.60830255,12.96838443,13.26435036,5.412765138,3829,Growth Hormone Disorders,7/7/14 12:28
3952,889,LG Life Sciences,Regional & Specialty Pharma,4074,Declage / Eutropin Plus,sustained-release somatropin,Recombinant Protein,Launched,In-House,,Mar-07,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,11,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3829,Growth Hormone Disorders,7/7/14 12:28
3954,889,LG Life Sciences,Regional & Specialty Pharma,4076,Eutropin,somatropin,Recombinant Protein,Launched,In-House,,Jan-93,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,11,Global,Sales,33.29003453,36.33325379,37.00110552,36.40130216,35.51346552,34.62562888,33.73779225,32.84995561,31.96211897,31.07428233,30.18644569,29.23242058,-2.742177017,3829,Growth Hormone Disorders,7/7/14 12:28
3954,889,LG Life Sciences,Regional & Specialty Pharma,4076,Eutropin,somatropin,Recombinant Protein,Launched,In-House,,Jan-93,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,11,ROW,Sales,33.29003453,36.33325379,37.00110552,36.40130216,35.51346552,34.62562888,33.73779225,32.84995561,31.96211897,31.07428233,30.18644569,29.23242058,-2.742177017,3829,Growth Hormone Disorders,7/7/14 12:28
3954,889,LG Life Sciences,Regional & Specialty Pharma,4076,Eutropin,somatropin,Recombinant Protein,Launched,In-House,,Jan-93,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,11,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3829,Growth Hormone Disorders,7/7/14 12:28
3955,213,Isis Pharmaceuticals,Small Biotech,4077,ISIS-APOCIIIRx,,DNA/RNA Therapy,Phase II,In-House,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3831,Hypertriglyceridemia,7/7/14 12:28
3955,213,Isis Pharmaceuticals,Small Biotech,4077,ISIS-APOCIIIRx,,DNA/RNA Therapy,Phase II,In-House,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3831,Hypertriglyceridemia,7/7/14 12:28
3955,213,Isis Pharmaceuticals,Small Biotech,4077,ISIS-APOCIIIRx,,DNA/RNA Therapy,Phase II,In-House,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3831,Hypertriglyceridemia,7/7/14 12:28
3957,89,Sanofi,Large Pharma,4079,StarGen,StarGen,Gene Therapy,Phase I,Licensed (Development),,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3841,Stargardt Disease,7/7/14 12:28
3957,89,Sanofi,Large Pharma,4079,StarGen,StarGen,Gene Therapy,Phase I,Licensed (Development),,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3841,Stargardt Disease,7/7/14 12:28
3957,89,Sanofi,Large Pharma,4079,StarGen,StarGen,Gene Therapy,Phase I,Licensed (Development),,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3841,Stargardt Disease,7/7/14 12:28
3958,2221,AbbVie,Large Pharma,4081,ABT-348,ilorasertib,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3832,Solid Tumors,7/7/14 12:28
3958,2221,AbbVie,Large Pharma,4081,ABT-348,ilorasertib,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3832,Solid Tumors,7/7/14 12:28
3958,2221,AbbVie,Large Pharma,4081,ABT-348,ilorasertib,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3832,Solid Tumors,7/7/14 12:28
3960,2221,AbbVie,Large Pharma,4083,ABT-700,ABT-700,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3834,Solid Tumors,7/7/14 12:28
3960,2221,AbbVie,Large Pharma,4083,ABT-700,ABT-700,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3834,Solid Tumors,7/7/14 12:28
3960,2221,AbbVie,Large Pharma,4083,ABT-700,ABT-700,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3834,Solid Tumors,7/7/14 12:28
3961,2221,AbbVie,Large Pharma,4084,ABT-652,ABT-652,Small Molecule (Chemical),Phase II,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3835,Pain,7/7/14 12:28
3961,2221,AbbVie,Large Pharma,4084,ABT-652,ABT-652,Small Molecule (Chemical),Phase II,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3835,Pain,7/7/14 12:28
3961,2221,AbbVie,Large Pharma,4084,ABT-652,ABT-652,Small Molecule (Chemical),Phase II,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3835,Pain,7/7/14 12:28
3962,712,Receptos,Small Biotech,4085,ABT-308, ,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3836,Asthma,7/7/14 12:28
3962,712,Receptos,Small Biotech,4085,ABT-308, ,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3836,Asthma,7/7/14 12:28
3962,712,Receptos,Small Biotech,4085,ABT-308, ,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3836,Asthma,7/7/14 12:28
3964,2221,AbbVie,Large Pharma,3860,tregalizumab,tregalizumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3724,Psoriasis,7/7/14 12:28
3964,2221,AbbVie,Large Pharma,3860,tregalizumab,tregalizumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3724,Psoriasis,7/7/14 12:28
3964,2221,AbbVie,Large Pharma,3860,tregalizumab,tregalizumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3724,Psoriasis,7/7/14 12:28
3966,53,Johnson & Johnson,Large Pharma,4087,FluCell,,Vaccine,Phase II,Acquisition (Development),,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3838,influenza vaccine,7/7/14 12:28
3966,53,Johnson & Johnson,Large Pharma,4087,FluCell,,Vaccine,Phase II,Acquisition (Development),,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3838,influenza vaccine,7/7/14 12:28
3966,53,Johnson & Johnson,Large Pharma,4087,FluCell,,Vaccine,Phase II,Acquisition (Development),,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3838,influenza vaccine,7/7/14 12:28
3968,91,Santen,Regional & Specialty Pharma,4094,DE112,ATL313,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3842,Glaucoma,7/7/14 12:28
3968,91,Santen,Regional & Specialty Pharma,4094,DE112,ATL313,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3842,Glaucoma,7/7/14 12:28
3968,91,Santen,Regional & Specialty Pharma,4094,DE112,ATL313,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3842,Glaucoma,7/7/14 12:28
3970,894,Biothera,Small Biotech,4096,Imprime PGG,betafectin PGG glucan,Other (Protein),Phase III,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3848,Colorectal Cancer,7/7/14 12:28
3970,894,Biothera,Small Biotech,4096,Imprime PGG,betafectin PGG glucan,Other (Protein),Phase III,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3848,Colorectal Cancer,7/7/14 12:28
3970,894,Biothera,Small Biotech,4096,Imprime PGG,betafectin PGG glucan,Other (Protein),Phase III,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3848,Colorectal Cancer,7/7/14 12:28
3971,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4099,MT-1303,MT-1303,Small Molecule (Chemical),Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3859,Multiple Sclerosis,7/7/14 12:28
3971,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4099,MT-1303,MT-1303,Small Molecule (Chemical),Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3859,Multiple Sclerosis,7/7/14 12:28
3971,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4099,MT-1303,MT-1303,Small Molecule (Chemical),Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3859,Multiple Sclerosis,7/7/14 12:28
3973,61,Merck & Co,Large Pharma,4102,Juvisync,sitagliptin + simvastatin,Small Molecule (Chemical),Launched,In-House,Oct-11,,Jul-22,Jul-22,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,10,22,16,0,0,0,0,0,0,0,-100,3854,Type II Diabetics with high CV risk,7/7/14 12:28
3973,61,Merck & Co,Large Pharma,4102,Juvisync,sitagliptin + simvastatin,Small Molecule (Chemical),Launched,In-House,Oct-11,,Jul-22,Jul-22,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3854,Type II Diabetics with high CV risk,7/7/14 12:28
3973,61,Merck & Co,Large Pharma,4102,Juvisync,sitagliptin + simvastatin,Small Molecule (Chemical),Launched,In-House,Oct-11,,Jul-22,Jul-22,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,10,22,16,0,0,0,0,0,0,0,-100,3854,Type II Diabetics with high CV risk,7/7/14 12:28
3974,89,Sanofi,Large Pharma,4103,SAR126119,,Small Molecule (Chemical),Phase I,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3844,Acute ischemic stroke,7/7/14 12:28
3974,89,Sanofi,Large Pharma,4103,SAR126119,,Small Molecule (Chemical),Phase I,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3844,Acute ischemic stroke,7/7/14 12:28
3974,89,Sanofi,Large Pharma,4103,SAR126119,,Small Molecule (Chemical),Phase I,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3844,Acute ischemic stroke,7/7/14 12:28
3975,70,Ono,Regional & Specialty Pharma,251,Orencia,abatacept,Antibody/Antibody Derivative,Launched,Licensed (Development),,Aug-13,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,6.750237946,14.62553805,21.37580888,28.12607557,33.70629526,38.63849047,41.98528464,45.41130839,31.29961227,826,Rheumatoid Arthritis,7/7/14 12:28
3975,70,Ono,Regional & Specialty Pharma,251,Orencia,abatacept,Antibody/Antibody Derivative,Launched,Licensed (Development),,Aug-13,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,6.750237946,14.62553805,21.37580888,28.12607557,33.70629526,38.63849047,41.98528464,45.41130839,31.29961227,826,Rheumatoid Arthritis,7/7/14 12:28
3975,70,Ono,Regional & Specialty Pharma,251,Orencia,abatacept,Antibody/Antibody Derivative,Launched,Licensed (Development),,Aug-13,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,826,Rheumatoid Arthritis,7/7/14 12:28
3976,166,Keryx Biopharmaceuticals,Regional & Specialty Pharma,4106,Zerenex,ferric citrate,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-14,Apr-14,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,10.74,41.2500258,72.42670541,94.57350642,120.2362883,147.2715618,168.8615609,0,3853,Hyperphosphatemia,7/7/14 12:28
3976,166,Keryx Biopharmaceuticals,Regional & Specialty Pharma,4106,Zerenex,ferric citrate,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-14,Apr-14,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,3,9,15.66666,22.33329383,32,45,54.66000476,0,3853,Hyperphosphatemia,7/7/14 12:28
3976,166,Keryx Biopharmaceuticals,Regional & Specialty Pharma,4106,Zerenex,ferric citrate,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-14,Apr-14,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,7.74,32.2500258,56.76004541,72.24021259,88.2362883,102.2715618,114.2015562,0,3853,Hyperphosphatemia,7/7/14 12:28
3977,100,Takeda,Large Pharma,4107,Ecard,candesartan + hydrochlorothiazide,Small Molecule (Chemical),Launched,In-House,,Mar-09,N/A,Dec-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,7.541281784,121.3974717,166.107574,149.2803843,125.8465281,126.6519454,124.7503538,120.7821004,103.6050891,95.00142013,90.1725568,83.86889786,-5.63241541,3845,Hypertension,7/7/14 12:28
3977,100,Takeda,Large Pharma,4107,Ecard,candesartan + hydrochlorothiazide,Small Molecule (Chemical),Launched,In-House,,Mar-09,N/A,Dec-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,7.541281784,121.3974717,166.107574,149.2803843,125.8465281,126.6519454,124.7503538,120.7821004,103.6050891,95.00142013,90.1725568,83.86889786,-5.63241541,3845,Hypertension,7/7/14 12:28
3977,100,Takeda,Large Pharma,4107,Ecard,candesartan + hydrochlorothiazide,Small Molecule (Chemical),Launched,In-House,,Mar-09,N/A,Dec-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3845,Hypertension,7/7/14 12:28
3978,100,Takeda,Large Pharma,4108,Unisia,candesartan + amlodipine,Small Molecule (Chemical),Launched,In-House,,Jun-10,N/A,Dec-15,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,54.86231893,224.1113888,268.4639169,243.3542325,259.1736238,263.1031948,224.1855558,208.9902013,198.5924963,187.9951363,177.5668573,-4.402581891,3846,Hypertension,7/7/14 12:28
3978,100,Takeda,Large Pharma,4108,Unisia,candesartan + amlodipine,Small Molecule (Chemical),Launched,In-House,,Jun-10,N/A,Dec-15,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,54.86231893,224.1113888,268.4639169,243.3542325,259.1736238,263.1031948,224.1855558,208.9902013,198.5924963,187.9951363,177.5668573,-4.402581891,3846,Hypertension,7/7/14 12:28
3978,100,Takeda,Large Pharma,4108,Unisia,candesartan + amlodipine,Small Molecule (Chemical),Launched,In-House,,Jun-10,N/A,Dec-15,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3846,Hypertension,7/7/14 12:28
3979,58,Lundbeck,Regional & Specialty Pharma,3654,brexpiprazole,brexpiprazole,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-15,Sep-16,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,Global,Alliance Revenue,0,0,0,0,0,0,49.8604353,119.3088988,180.209859,240.7546733,297.025736,334.2429895,0,3570,Schizophrenia,7/7/14 12:28
3979,58,Lundbeck,Regional & Specialty Pharma,3654,brexpiprazole,brexpiprazole,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-15,Sep-16,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3570,Schizophrenia,7/7/14 12:28
3979,58,Lundbeck,Regional & Specialty Pharma,3654,brexpiprazole,brexpiprazole,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-15,Sep-16,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,15.13620357,35.25845068,50.39465425,70.51690135,80.48898841,0,3570,Schizophrenia,7/7/14 12:28
3979,58,Lundbeck,Regional & Specialty Pharma,3654,brexpiprazole,brexpiprazole,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-15,Sep-16,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3570,Schizophrenia,7/7/14 12:28
3979,58,Lundbeck,Regional & Specialty Pharma,3654,brexpiprazole,brexpiprazole,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-15,Sep-16,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,US,Alliance Revenue,0,0,0,0,0,0,49.8604353,104.1726952,144.9514083,190.3600191,226.5088346,253.7540011,0,3570,Schizophrenia,7/7/14 12:28
3979,58,Lundbeck,Regional & Specialty Pharma,3654,brexpiprazole,brexpiprazole,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-15,Sep-16,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3570,Schizophrenia,7/7/14 12:28
3980,58,Lundbeck,Regional & Specialty Pharma,4630,Abilify Maintena,aripiprazole depot,Small Molecule (Chemical),Launched,Licensed (Development),Mar-13,Mar-14,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,Global,Alliance Revenue,0,0,0,0,12.46510882,43.4498079,78.35211261,102.9261843,122.3361395,135.8696862,143.5268245,149.0470869,42.54323803,1324,Schizophrenia,7/7/14 12:28
3980,58,Lundbeck,Regional & Specialty Pharma,4630,Abilify Maintena,aripiprazole depot,Small Molecule (Chemical),Launched,Licensed (Development),Mar-13,Mar-14,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1324,Schizophrenia,7/7/14 12:28
3980,58,Lundbeck,Regional & Specialty Pharma,4630,Abilify Maintena,aripiprazole depot,Small Molecule (Chemical),Launched,Licensed (Development),Mar-13,Mar-14,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,ROW,Alliance Revenue,0,0,0,0,0,7.479065295,22.43719588,34.90230471,42.38137,49.8604353,53.59996795,56.09298971,0,1324,Schizophrenia,7/7/14 12:28
3980,58,Lundbeck,Regional & Specialty Pharma,4630,Abilify Maintena,aripiprazole depot,Small Molecule (Chemical),Launched,Licensed (Development),Mar-13,Mar-14,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1324,Schizophrenia,7/7/14 12:28
3980,58,Lundbeck,Regional & Specialty Pharma,4630,Abilify Maintena,aripiprazole depot,Small Molecule (Chemical),Launched,Licensed (Development),Mar-13,Mar-14,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,US,Alliance Revenue,0,0,0,0,12.46510882,35.97074261,55.91491673,68.02387959,79.95476946,86.00925089,89.92685652,92.95409724,33.24566368,1324,Schizophrenia,7/7/14 12:28
3980,58,Lundbeck,Regional & Specialty Pharma,4630,Abilify Maintena,aripiprazole depot,Small Molecule (Chemical),Launched,Licensed (Development),Mar-13,Mar-14,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1324,Schizophrenia,7/7/14 12:28
3981,102,Teva,Regional & Specialty Pharma,4112,Granix,tbo-filgrastim,Recombinant Protein,Launched,In-House,Nov-13,,N/A,N/A,118,G-CSFs,78,Neutropenia,3,Oncology,6,Global,Sales,0,0,0,0,9,46,129,160,150,91,70,66,32.9273558,3849,Neutropenia,7/7/14 12:28
3981,102,Teva,Regional & Specialty Pharma,4112,Granix,tbo-filgrastim,Recombinant Protein,Launched,In-House,Nov-13,,N/A,N/A,118,G-CSFs,78,Neutropenia,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3849,Neutropenia,7/7/14 12:28
3981,102,Teva,Regional & Specialty Pharma,4112,Granix,tbo-filgrastim,Recombinant Protein,Launched,In-House,Nov-13,,N/A,N/A,118,G-CSFs,78,Neutropenia,3,Oncology,6,US,Sales,0,0,0,0,9,46,129,160,150,91,70,66,32.9273558,3849,Neutropenia,7/7/14 12:28
3987,23,Boehringer Ingelheim,Large Pharma,4644,empagliflozin + Tradjenta,empagliflozin + linagliptin,Small Molecule (Chemical),Filed,In-House,Feb-15,Feb-15,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,36.29949734,111.3131163,180.8536115,242.425885,295.7466923,342.9788401,0,3855,Type II Diabetes,7/7/14 12:28
3987,23,Boehringer Ingelheim,Large Pharma,4644,empagliflozin + Tradjenta,empagliflozin + linagliptin,Small Molecule (Chemical),Filed,In-House,Feb-15,Feb-15,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,11.9522706,32.95934236,54.69075515,76.42212671,93.69134589,109.2915888,0,3855,Type II Diabetes,7/7/14 12:28
3987,23,Boehringer Ingelheim,Large Pharma,4644,empagliflozin + Tradjenta,empagliflozin + linagliptin,Small Molecule (Chemical),Filed,In-House,Feb-15,Feb-15,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,2,US,Sales,0,0,0,0,0,0,24.34722674,78.35377393,126.1628563,166.0037583,202.0553464,233.6872514,0,3855,Type II Diabetes,7/7/14 12:28
3988,39,Eli Lilly,Large Pharma,4644,empagliflozin + Tradjenta,empagliflozin + linagliptin,Small Molecule (Chemical),Filed,Licensed (Development),Feb-15,Feb-15,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,18,55,90,125.7615,148,171,0,3855,Type II Diabetes,7/7/14 12:28
3988,39,Eli Lilly,Large Pharma,4644,empagliflozin + Tradjenta,empagliflozin + linagliptin,Small Molecule (Chemical),Filed,Licensed (Development),Feb-15,Feb-15,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3855,Type II Diabetes,7/7/14 12:28
3988,39,Eli Lilly,Large Pharma,4644,empagliflozin + Tradjenta,empagliflozin + linagliptin,Small Molecule (Chemical),Filed,Licensed (Development),Feb-15,Feb-15,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,6,16,27,37.72845,47,54,0,3855,Type II Diabetes,7/7/14 12:28
3988,39,Eli Lilly,Large Pharma,4644,empagliflozin + Tradjenta,empagliflozin + linagliptin,Small Molecule (Chemical),Filed,Licensed (Development),Feb-15,Feb-15,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3855,Type II Diabetes,7/7/14 12:28
3988,39,Eli Lilly,Large Pharma,4644,empagliflozin + Tradjenta,empagliflozin + linagliptin,Small Molecule (Chemical),Filed,Licensed (Development),Feb-15,Feb-15,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,12,39,63,88.03305,101,117,0,3855,Type II Diabetes,7/7/14 12:28
3988,39,Eli Lilly,Large Pharma,4644,empagliflozin + Tradjenta,empagliflozin + linagliptin,Small Molecule (Chemical),Filed,Licensed (Development),Feb-15,Feb-15,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3855,Type II Diabetes,7/7/14 12:28
3990,896,Intarcia Therapeutics,,4120,ITCA-650,exenatide implant,Synthetic Peptide,Phase III,In-House,Mar-16,Jun-16,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,43.74998,178,314.4521,438.9041461,500,0,3856,Type II Diabetes,7/7/14 12:28
3990,896,Intarcia Therapeutics,,4120,ITCA-650,exenatide implant,Synthetic Peptide,Phase III,In-House,Mar-16,Jun-16,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,14.583325,68,105,130,145,0,3856,Type II Diabetes,7/7/14 12:28
3990,896,Intarcia Therapeutics,,4120,ITCA-650,exenatide implant,Synthetic Peptide,Phase III,In-House,Mar-16,Jun-16,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,29.166655,110,209.4521,308.9041461,355,0,3856,Type II Diabetes,7/7/14 12:28
3994,897,ACT Biotech,Small Biotech,4126,telatinib,telatinib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3850,Gastric Cancer,7/7/14 12:28
3994,897,ACT Biotech,Small Biotech,4126,telatinib,telatinib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3850,Gastric Cancer,7/7/14 12:28
3994,897,ACT Biotech,Small Biotech,4126,telatinib,telatinib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3850,Gastric Cancer,7/7/14 12:28
3996,61,Merck & Co,Large Pharma,4128,MK-8931,SCH-900931,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3847,Alzheimer's Disease,7/7/14 12:28
3996,61,Merck & Co,Large Pharma,4128,MK-8931,SCH-900931,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3847,Alzheimer's Disease,7/7/14 12:28
3996,61,Merck & Co,Large Pharma,4128,MK-8931,SCH-900931,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3847,Alzheimer's Disease,7/7/14 12:28
3998,45,Gilead,Regional & Specialty Pharma,4262,darunavir/emtricitabine/tenofovir alafenamide/cobicistat FDC,darunavir/emtricitabine/GS 7340/cobicistat FDC,Small Molecule (Chemical),Phase II,Licensed (Development),Feb-18,Oct-18,,,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,162.50005,388.66675,623.3334314,0,3857,HIV,7/7/14 12:28
3998,45,Gilead,Regional & Specialty Pharma,4262,darunavir/emtricitabine/tenofovir alafenamide/cobicistat FDC,darunavir/emtricitabine/GS 7340/cobicistat FDC,Small Molecule (Chemical),Phase II,Licensed (Development),Feb-18,Oct-18,,,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,25,141.66675,308.3334314,0,3857,HIV,7/7/14 12:28
3998,45,Gilead,Regional & Specialty Pharma,4262,darunavir/emtricitabine/tenofovir alafenamide/cobicistat FDC,darunavir/emtricitabine/GS 7340/cobicistat FDC,Small Molecule (Chemical),Phase II,Licensed (Development),Feb-18,Oct-18,,,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,137.50005,247,315,0,3857,HIV,7/7/14 12:28
4001,95,Shionogi,Regional & Specialty Pharma,1702,Intuniv / Intuniv XR,guanfacine ER,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,563,ADHD,7/7/14 12:28
4001,95,Shionogi,Regional & Specialty Pharma,1702,Intuniv / Intuniv XR,guanfacine ER,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,563,ADHD,7/7/14 12:28
4001,95,Shionogi,Regional & Specialty Pharma,1702,Intuniv / Intuniv XR,guanfacine ER,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,563,ADHD,7/7/14 12:28
4002,24,Bristol-Myers Squibb,Large Pharma,4135,exenatide suspension,exenatide ,Synthetic Peptide,Phase III,Corporate Acquisition,,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3864,Type II Diabetes,7/7/14 12:28
4002,24,Bristol-Myers Squibb,Large Pharma,4135,exenatide suspension,exenatide ,Synthetic Peptide,Phase III,Corporate Acquisition,,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3864,Type II Diabetes,7/7/14 12:28
4002,24,Bristol-Myers Squibb,Large Pharma,4135,exenatide suspension,exenatide ,Synthetic Peptide,Phase III,Corporate Acquisition,,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3864,Type II Diabetes,7/7/14 12:28
4004,45,Gilead,Regional & Specialty Pharma,4137,GS-9669,GS-9669,Small Molecule (Chemical),Phase II,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3862,Hepatitis C,7/7/14 12:28
4004,45,Gilead,Regional & Specialty Pharma,4137,GS-9669,GS-9669,Small Molecule (Chemical),Phase II,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3862,Hepatitis C,7/7/14 12:28
4004,45,Gilead,Regional & Specialty Pharma,4137,GS-9669,GS-9669,Small Molecule (Chemical),Phase II,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3862,Hepatitis C,7/7/14 12:28
4010,63,Merck KGaA,Regional & Specialty Pharma,4142,pimasertib,MEK inhibitor,Small Molecule (Chemical),Phase II,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3867,Melanoma,7/7/14 12:28
4010,63,Merck KGaA,Regional & Specialty Pharma,4142,pimasertib,MEK inhibitor,Small Molecule (Chemical),Phase II,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3867,Melanoma,7/7/14 12:28
4010,63,Merck KGaA,Regional & Specialty Pharma,4142,pimasertib,MEK inhibitor,Small Molecule (Chemical),Phase II,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3867,Melanoma,7/7/14 12:28
4011,63,Merck KGaA,Regional & Specialty Pharma,4143,NHS-IL-12,NHS-IL-12,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3868,Solid Tumors,7/7/14 12:28
4011,63,Merck KGaA,Regional & Specialty Pharma,4143,NHS-IL-12,NHS-IL-12,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3868,Solid Tumors,7/7/14 12:28
4011,63,Merck KGaA,Regional & Specialty Pharma,4143,NHS-IL-12,NHS-IL-12,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3868,Solid Tumors,7/7/14 12:28
4012,26,Celgene,Regional & Specialty Pharma,4144,ARRY-382,ARRY-382,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3869,Solid Tumors,7/7/14 12:28
4012,26,Celgene,Regional & Specialty Pharma,4144,ARRY-382,ARRY-382,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3869,Solid Tumors,7/7/14 12:28
4012,26,Celgene,Regional & Specialty Pharma,4144,ARRY-382,ARRY-382,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3869,Solid Tumors,7/7/14 12:28
4014,91,Santen,Regional & Specialty Pharma,545,Rivoglitazone,Rivoglitazone,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3871,Dry Eye,7/7/14 12:28
4014,91,Santen,Regional & Specialty Pharma,545,Rivoglitazone,Rivoglitazone,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3871,Dry Eye,7/7/14 12:28
4014,91,Santen,Regional & Specialty Pharma,545,Rivoglitazone,Rivoglitazone,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3871,Dry Eye,7/7/14 12:28
4015,26,Celgene,Regional & Specialty Pharma,4146,CC-122,CC-122,Small Molecule (Chemical),Phase I,In-House,,,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3873,Solid tumors,7/7/14 12:28
4015,26,Celgene,Regional & Specialty Pharma,4146,CC-122,CC-122,Small Molecule (Chemical),Phase I,In-House,,,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3873,Solid tumors,7/7/14 12:28
4015,26,Celgene,Regional & Specialty Pharma,4146,CC-122,CC-122,Small Molecule (Chemical),Phase I,In-House,,,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3873,Solid tumors,7/7/14 12:28
4016,91,Santen,Regional & Specialty Pharma,4147,DE102,Betamethasone sustained-release,Small Molecule (Chemical),Phase II,In-House,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3872,Diabetic Macular Edema,7/7/14 12:28
4016,91,Santen,Regional & Specialty Pharma,4147,DE102,Betamethasone sustained-release,Small Molecule (Chemical),Phase II,In-House,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3872,Diabetic Macular Edema,7/7/14 12:28
4016,91,Santen,Regional & Specialty Pharma,4147,DE102,Betamethasone sustained-release,Small Molecule (Chemical),Phase II,In-House,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3872,Diabetic Macular Edema,7/7/14 12:28
4018,91,Santen,Regional & Specialty Pharma,4149,DE110,,Small Molecule (Chemical),Phase II,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3875,Dry Eye,7/7/14 12:28
4018,91,Santen,Regional & Specialty Pharma,4149,DE110,,Small Molecule (Chemical),Phase II,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3875,Dry Eye,7/7/14 12:28
4018,91,Santen,Regional & Specialty Pharma,4149,DE110,,Small Molecule (Chemical),Phase II,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3875,Dry Eye,7/7/14 12:28
4019,91,Santen,Regional & Specialty Pharma,4150,DE098,ARG098,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3876,Rheumatoid Arthritis,7/7/14 12:28
4019,91,Santen,Regional & Specialty Pharma,4150,DE098,ARG098,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3876,Rheumatoid Arthritis,7/7/14 12:28
4019,91,Santen,Regional & Specialty Pharma,4150,DE098,ARG098,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3876,Rheumatoid Arthritis,7/7/14 12:28
4020,919,Nektar Therapeutics,Regional & Specialty Pharma,4152,NKTR-102,pegylated irinotecan,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3907,Breast Cancer,7/7/14 12:28
4020,919,Nektar Therapeutics,Regional & Specialty Pharma,4152,NKTR-102,pegylated irinotecan,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3907,Breast Cancer,7/7/14 12:28
4020,919,Nektar Therapeutics,Regional & Specialty Pharma,4152,NKTR-102,pegylated irinotecan,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3907,Breast Cancer,7/7/14 12:28
4021,243,Gedeon Richter,Regional & Specialty Pharma,4153,Airtal / Aflamin,aceclofenac,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-08,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,10,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,89,Pain,7/7/14 12:28
4021,243,Gedeon Richter,Regional & Specialty Pharma,4153,Airtal / Aflamin,aceclofenac,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-08,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,10,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,89,Pain,7/7/14 12:28
4021,243,Gedeon Richter,Regional & Specialty Pharma,4153,Airtal / Aflamin,aceclofenac,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-08,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,89,Pain,7/7/14 12:28
4022,921,Symphogen,Small Biotech,4154,rozrolimupab,SYM001,Antibody/Antibody Derivative,Phase II,In-House,,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3878,Immune Thrombocytopenic Purpura,7/7/14 12:28
4022,921,Symphogen,Small Biotech,4154,rozrolimupab,SYM001,Antibody/Antibody Derivative,Phase II,In-House,,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3878,Immune Thrombocytopenic Purpura,7/7/14 12:28
4022,921,Symphogen,Small Biotech,4154,rozrolimupab,SYM001,Antibody/Antibody Derivative,Phase II,In-House,,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3878,Immune Thrombocytopenic Purpura,7/7/14 12:28
4023,922,SuppreMol,Small Biotech,4155,SM101,SM101,Antibody/Antibody Derivative,Phase II,In-House,,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3877,Idiopathic Thrombocytopenic Purpura,7/7/14 12:28
4023,922,SuppreMol,Small Biotech,4155,SM101,SM101,Antibody/Antibody Derivative,Phase II,In-House,,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3877,Idiopathic Thrombocytopenic Purpura,7/7/14 12:28
4023,922,SuppreMol,Small Biotech,4155,SM101,SM101,Antibody/Antibody Derivative,Phase II,In-House,,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3877,Idiopathic Thrombocytopenic Purpura,7/7/14 12:28
4024,923,Ablynx,Small Biotech,4156,ALX-0081/0681,ALX-0681,Antibody/Antibody Derivative,Phase II,In-House,,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3908,Thrombotic Thrombocytopenic Purpura,7/7/14 12:28
4024,923,Ablynx,Small Biotech,4156,ALX-0081/0681,ALX-0681,Antibody/Antibody Derivative,Phase II,In-House,,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3908,Thrombotic Thrombocytopenic Purpura,7/7/14 12:28
4024,923,Ablynx,Small Biotech,4156,ALX-0081/0681,ALX-0681,Antibody/Antibody Derivative,Phase II,In-House,,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3908,Thrombotic Thrombocytopenic Purpura,7/7/14 12:28
4025,18,Baxter Healthcare,Regional & Specialty Pharma,4157,BAX111,recombinant von Willebrand factor,Recombinant Protein,Phase III,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3879,Von Willebrand Disease,7/7/14 12:28
4025,18,Baxter Healthcare,Regional & Specialty Pharma,4157,BAX111,recombinant von Willebrand factor,Recombinant Protein,Phase III,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3879,Von Willebrand Disease,7/7/14 12:28
4025,18,Baxter Healthcare,Regional & Specialty Pharma,4157,BAX111,recombinant von Willebrand factor,Recombinant Protein,Phase III,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3879,Von Willebrand Disease,7/7/14 12:28
4026,924,Relypsa,Regional & Specialty Pharma,4158,RLY5016,patiromer calcium,Small Molecule (Chemical),Phase III,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3905,Hyperkalemia,7/7/14 12:28
4026,924,Relypsa,Regional & Specialty Pharma,4158,RLY5016,patiromer calcium,Small Molecule (Chemical),Phase III,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3905,Hyperkalemia,7/7/14 12:28
4026,924,Relypsa,Regional & Specialty Pharma,4158,RLY5016,patiromer calcium,Small Molecule (Chemical),Phase III,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3905,Hyperkalemia,7/7/14 12:28
4027,16,AstraZeneca,Large Pharma,4388,lesinurad,RDEA-594,Small Molecule (Chemical),Phase III,Corporate Acquisition,Sep-15,Sep-15,,,151,Gout Treatments,64,Gout,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,10.333323,48.22220844,99.88892924,151.555479,200.4665472,250.7553904,0,3881,Gout,7/7/14 12:28
4027,16,AstraZeneca,Large Pharma,4388,lesinurad,RDEA-594,Small Molecule (Chemical),Phase III,Corporate Acquisition,Sep-15,Sep-15,,,151,Gout Treatments,64,Gout,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,3.33333,15.55555111,32.22223524,48.88886419,64.66662813,80.88883561,0,3881,Gout,7/7/14 12:28
4027,16,AstraZeneca,Large Pharma,4388,lesinurad,RDEA-594,Small Molecule (Chemical),Phase III,Corporate Acquisition,Sep-15,Sep-15,,,151,Gout Treatments,64,Gout,8,Metabolism,6,US,Sales,0,0,0,0,0,0,6.999993,32.66665733,67.666694,102.6666148,135.7999191,169.8665548,0,3881,Gout,7/7/14 12:28
4028,925,Hanmi Pharmaceutical,Regional & Specialty Pharma,4160,LAPS-hGH,LAPS-hGH,Recombinant Protein,Phase II,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,11,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3880,Growth Disorders,7/7/14 12:28
4028,925,Hanmi Pharmaceutical,Regional & Specialty Pharma,4160,LAPS-hGH,LAPS-hGH,Recombinant Protein,Phase II,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,11,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3880,Growth Disorders,7/7/14 12:28
4028,925,Hanmi Pharmaceutical,Regional & Specialty Pharma,4160,LAPS-hGH,LAPS-hGH,Recombinant Protein,Phase II,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,11,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3880,Growth Disorders,7/7/14 12:28
4029,926,Helsinn Therapeutics,,4161,anamorelin,anamorelin,Small Molecule (Chemical),Phase III,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,818,Cachexia,7/7/14 12:28
4029,926,Helsinn Therapeutics,,4161,anamorelin,anamorelin,Small Molecule (Chemical),Phase III,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,818,Cachexia,7/7/14 12:28
4029,926,Helsinn Therapeutics,,4161,anamorelin,anamorelin,Small Molecule (Chemical),Phase III,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,818,Cachexia,7/7/14 12:28
4030,927,Versartis,Small Biotech,4162,VRS-317,hGH-XTEN,Recombinant Protein,Phase II,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3882,Growth Disorders,7/7/14 12:28
4030,927,Versartis,Small Biotech,4162,VRS-317,hGH-XTEN,Recombinant Protein,Phase II,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3882,Growth Disorders,7/7/14 12:28
4030,927,Versartis,Small Biotech,4162,VRS-317,hGH-XTEN,Recombinant Protein,Phase II,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3882,Growth Disorders,7/7/14 12:28
4031,171,BioMarin,Small Biotech,4163,Vimizim,elosulfase alfa,Recombinant Protein,Launched,In-House,Feb-14,May-14,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,34.416681,100.3612873,172.0278847,243.694763,300.1126347,351.3464898,396.8470216,0,3883,Morquio A Syndrome,7/7/14 12:28
4031,171,BioMarin,Small Biotech,4163,Vimizim,elosulfase alfa,Recombinant Protein,Launched,In-House,Feb-14,May-14,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,13.33334,42.22228778,75.55551731,108.8891004,134.8447404,158.5603731,179.6093531,0,3883,Morquio A Syndrome,7/7/14 12:28
4031,171,BioMarin,Small Biotech,4163,Vimizim,elosulfase alfa,Recombinant Protein,Launched,In-House,Feb-14,May-14,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,21.083341,58.13899947,96.47236739,134.8056626,165.2678943,192.7861167,217.2376685,0,3883,Morquio A Syndrome,7/7/14 12:28
4032,928,LYSOGENE,Small Biotech,4547,SAF-301,AAV-based gene therapy,Gene Therapy,Phase II,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3884,Sanfilippo A Syndrome,7/7/14 12:28
4032,928,LYSOGENE,Small Biotech,4547,SAF-301,AAV-based gene therapy,Gene Therapy,Phase II,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3884,Sanfilippo A Syndrome,7/7/14 12:28
4032,928,LYSOGENE,Small Biotech,4547,SAF-301,AAV-based gene therapy,Gene Therapy,Phase II,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3884,Sanfilippo A Syndrome,7/7/14 12:28
4033,929,AesRx,Regional & Specialty Pharma,4165,Aes-103,Aes-103,Small Molecule (Chemical),Phase I,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3885,Sickle Cell Anemia,7/7/14 12:28
4033,929,AesRx,Regional & Specialty Pharma,4165,Aes-103,Aes-103,Small Molecule (Chemical),Phase I,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3885,Sickle Cell Anemia,7/7/14 12:28
4033,929,AesRx,Regional & Specialty Pharma,4165,Aes-103,Aes-103,Small Molecule (Chemical),Phase I,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3885,Sickle Cell Anemia,7/7/14 12:28
4034,930,Synageva BioPharma,Small Biotech,4548,sebelipase alfa,recombinant human lysosomal acid lipase,Recombinant Protein,Phase III,In-House,Oct-16,Oct-16,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,16,130.28576,238.1714893,303.5424179,359.2223089,0,3886,Lysosomal Acid Lipase (LAL) Deficiency,7/7/14 12:28
4034,930,Synageva BioPharma,Small Biotech,4548,sebelipase alfa,recombinant human lysosomal acid lipase,Recombinant Protein,Phase III,In-House,Oct-16,Oct-16,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,10,81.4286,148.8571808,189.7140112,224.5139431,0,3886,Lysosomal Acid Lipase (LAL) Deficiency,7/7/14 12:28
4034,930,Synageva BioPharma,Small Biotech,4548,sebelipase alfa,recombinant human lysosomal acid lipase,Recombinant Protein,Phase III,In-House,Oct-16,Oct-16,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,6,48.85716,89.31430848,113.8284067,134.7083658,0,3886,Lysosomal Acid Lipase (LAL) Deficiency,7/7/14 12:28
4035,931,Zymenex,Small Biotech,4167,Lamazym,recombinant human alpha-mannosidase,Recombinant Protein,Phase III,In-House,Dec-15,Sep-15,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,1,Global,Sales,0,0,0,0,0,0,11.02972265,86.49109346,157.8735453,201.1345589,239.3745299,269.725181,0,3887,Alpha-Mannosidosis,7/7/14 12:28
4035,931,Zymenex,Small Biotech,4167,Lamazym,recombinant human alpha-mannosidase,Recombinant Protein,Phase III,In-House,Dec-15,Sep-15,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,1,ROW,Sales,0,0,0,0,0,0,9.704977585,58.22986551,102.8729565,130.046848,157.5604859,180.6886894,0,3887,Alpha-Mannosidosis,7/7/14 12:28
4035,931,Zymenex,Small Biotech,4167,Lamazym,recombinant human alpha-mannosidase,Recombinant Protein,Phase III,In-House,Dec-15,Sep-15,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,1,US,Sales,0,0,0,0,0,0,1.32474506,28.26122795,55.00058877,71.08771098,81.81404395,89.03649161,0,3887,Alpha-Mannosidosis,7/7/14 12:28
4036,932,Radius Health,Small Biotech,4170,BA-058,abaloparatide SC,Recombinant Protein,Phase III,In-House,Jul-16,Oct-16,,,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,16,63.66672,125.333384,187.0000138,234.0933403,0,3889,Osteoporosis,7/7/14 12:28
4036,932,Radius Health,Small Biotech,4170,BA-058,abaloparatide SC,Recombinant Protein,Phase III,In-House,Jul-16,Oct-16,,,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,2.5,14.166675,30.83334314,47.49999844,60.03332891,0,3889,Osteoporosis,7/7/14 12:28
4036,932,Radius Health,Small Biotech,4170,BA-058,abaloparatide SC,Recombinant Protein,Phase III,In-House,Jul-16,Oct-16,,,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,13.5,49.500045,94.50004091,139.5000154,174.0600114,0,3889,Osteoporosis,7/7/14 12:28
4038,91,Santen,Regional & Specialty Pharma,4172,Catioprost,latanoprost (ophthalmic suspension),Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3890,Glaucoma,7/7/14 12:28
4038,91,Santen,Regional & Specialty Pharma,4172,Catioprost,latanoprost (ophthalmic suspension),Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3890,Glaucoma,7/7/14 12:28
4038,91,Santen,Regional & Specialty Pharma,4172,Catioprost,latanoprost (ophthalmic suspension),Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3890,Glaucoma,7/7/14 12:28
4039,934,QLT,Small Biotech,4175,punctal plug latanoprost,latanoprost,Small Molecule (Chemical),Phase II,In-House,,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3892,Glaucoma ,7/7/14 12:28
4039,934,QLT,Small Biotech,4175,punctal plug latanoprost,latanoprost,Small Molecule (Chemical),Phase II,In-House,,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3892,Glaucoma ,7/7/14 12:28
4039,934,QLT,Small Biotech,4175,punctal plug latanoprost,latanoprost,Small Molecule (Chemical),Phase II,In-House,,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3892,Glaucoma ,7/7/14 12:28
4041,67,Novartis,Large Pharma,4179,ESBA105,ESBA105,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3893,Dry eye,7/7/14 12:28
4041,67,Novartis,Large Pharma,4179,ESBA105,ESBA105,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3893,Dry eye,7/7/14 12:28
4041,67,Novartis,Large Pharma,4179,ESBA105,ESBA105,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3893,Dry eye,7/7/14 12:28
4044,53,Johnson & Johnson,Large Pharma,4182,darunavir / cobicistat FDC,darunavir / cobicistat,Small Molecule (Chemical),Filed,In-House,Jul-15,Dec-14,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,2.9166655,62.36119239,180.6945349,314.027929,413.3529002,467.9510273,508.4194817,0,3896,HIV,7/7/14 12:28
4044,53,Johnson & Johnson,Large Pharma,4182,darunavir / cobicistat FDC,darunavir / cobicistat,Small Molecule (Chemical),Filed,In-House,Jul-15,Dec-14,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,2.9166655,39.86119239,98.19445994,156.5278608,180.8528746,199.4510058,212.1694683,0,3896,HIV,7/7/14 12:28
4044,53,Johnson & Johnson,Large Pharma,4182,darunavir / cobicistat FDC,darunavir / cobicistat,Small Molecule (Chemical),Filed,In-House,Jul-15,Dec-14,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,22.5,82.500075,157.5000682,232.5000256,268.5000215,296.2500134,0,3896,HIV,7/7/14 12:28
4047,15,Astellas Pharma,Regional & Specialty Pharma,4185,ASP-1707,ASP-1707,Small Molecule (Chemical),Phase I,In-House,,,,,33,LHRH Analogs,55,Hormonals,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3899,Prostate Cancer,7/7/14 12:28
4047,15,Astellas Pharma,Regional & Specialty Pharma,4185,ASP-1707,ASP-1707,Small Molecule (Chemical),Phase I,In-House,,,,,33,LHRH Analogs,55,Hormonals,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3899,Prostate Cancer,7/7/14 12:28
4047,15,Astellas Pharma,Regional & Specialty Pharma,4185,ASP-1707,ASP-1707,Small Molecule (Chemical),Phase I,In-House,,,,,33,LHRH Analogs,55,Hormonals,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3899,Prostate Cancer,7/7/14 12:28
4049,15,Astellas Pharma,Regional & Specialty Pharma,4187,ASG-22ME,AGS-22M6E,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3901,Cancer,7/7/14 12:28
4049,15,Astellas Pharma,Regional & Specialty Pharma,4187,ASG-22ME,AGS-22M6E,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3901,Cancer,7/7/14 12:28
4049,15,Astellas Pharma,Regional & Specialty Pharma,4187,ASG-22ME,AGS-22M6E,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3901,Cancer,7/7/14 12:28
4050,15,Astellas Pharma,Regional & Specialty Pharma,4210,ASP7373,ASP7373,Vaccine,Phase II,Licensed (Development),,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3902,H5N1 influenza vaccine,7/7/14 12:28
4050,15,Astellas Pharma,Regional & Specialty Pharma,4210,ASP7373,ASP7373,Vaccine,Phase II,Licensed (Development),,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3902,H5N1 influenza vaccine,7/7/14 12:28
4050,15,Astellas Pharma,Regional & Specialty Pharma,4210,ASP7373,ASP7373,Vaccine,Phase II,Licensed (Development),,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3902,H5N1 influenza vaccine,7/7/14 12:28
4051,15,Astellas Pharma,Regional & Specialty Pharma,4211,ASP7374,ASP7374,Vaccine,Phase III,Licensed (Development),,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3903,seasonal influenza vaccine,7/7/14 12:28
4051,15,Astellas Pharma,Regional & Specialty Pharma,4211,ASP7374,ASP7374,Vaccine,Phase III,Licensed (Development),,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3903,seasonal influenza vaccine,7/7/14 12:28
4051,15,Astellas Pharma,Regional & Specialty Pharma,4211,ASP7374,ASP7374,Vaccine,Phase III,Licensed (Development),,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3903,seasonal influenza vaccine,7/7/14 12:28
4052,15,Astellas Pharma,Regional & Specialty Pharma,4190,ASP-0306,ASP-0306,Small Molecule (Chemical),Phase I,In-House,,,,,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3904,Symptoms associated with BPH,7/7/14 12:28
4052,15,Astellas Pharma,Regional & Specialty Pharma,4190,ASP-0306,ASP-0306,Small Molecule (Chemical),Phase I,In-House,,,,,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3904,Symptoms associated with BPH,7/7/14 12:28
4052,15,Astellas Pharma,Regional & Specialty Pharma,4190,ASP-0306,ASP-0306,Small Molecule (Chemical),Phase I,In-House,,,,,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3904,Symptoms associated with BPH,7/7/14 12:28
4054,70,Ono,Regional & Specialty Pharma,4454,Velcalcetide,Velcalcetide,Synthetic Peptide,Phase II,Licensed (Development),,Jan-17,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,0,2.516930561,11.74568434,18.45752075,25.16941359,33.22348341,0,3906,Secondary Hyperparathyroidism,7/7/14 12:28
4054,70,Ono,Regional & Specialty Pharma,4454,Velcalcetide,Velcalcetide,Synthetic Peptide,Phase II,Licensed (Development),,Jan-17,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,0,2.516930561,11.74568434,18.45752075,25.16941359,33.22348341,0,3906,Secondary Hyperparathyroidism,7/7/14 12:28
4054,70,Ono,Regional & Specialty Pharma,4454,Velcalcetide,Velcalcetide,Synthetic Peptide,Phase II,Licensed (Development),,Jan-17,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3906,Secondary Hyperparathyroidism,7/7/14 12:28
4057,942,Telik,Regional & Specialty Pharma,4196,Telintra,ezatiostat hydrochloride,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3911,Myelodysplastic Syndrome,7/7/14 12:28
4057,942,Telik,Regional & Specialty Pharma,4196,Telintra,ezatiostat hydrochloride,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3911,Myelodysplastic Syndrome,7/7/14 12:28
4057,942,Telik,Regional & Specialty Pharma,4196,Telintra,ezatiostat hydrochloride,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3911,Myelodysplastic Syndrome,7/7/14 12:28
4058,942,Telik,Regional & Specialty Pharma,4197,Telcyta,canfosfamide,Small Molecule (Chemical),Phase II,In-House,,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3912,Hematological Malignancies,7/7/14 12:28
4058,942,Telik,Regional & Specialty Pharma,4197,Telcyta,canfosfamide,Small Molecule (Chemical),Phase II,In-House,,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3912,Hematological Malignancies,7/7/14 12:28
4058,942,Telik,Regional & Specialty Pharma,4197,Telcyta,canfosfamide,Small Molecule (Chemical),Phase II,In-House,,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3912,Hematological Malignancies,7/7/14 12:28
4059,943,Pharmacyclics,Regional & Specialty Pharma,4198,Imbruvica,ibrutinib,Small Molecule (Chemical),Launched,Licensed (Development),Nov-13,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,13.6,113.6506926,363.2669978,551,670.7599505,806.7199036,933.2780971,1034.331448,85.66552806,3913,Non-Hodgkin's Lymphoma,7/7/14 12:28
4059,943,Pharmacyclics,Regional & Specialty Pharma,4198,Imbruvica,ibrutinib,Small Molecule (Chemical),Launched,Licensed (Development),Nov-13,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3913,Non-Hodgkin's Lymphoma,7/7/14 12:28
4059,943,Pharmacyclics,Regional & Specialty Pharma,4198,Imbruvica,ibrutinib,Small Molecule (Chemical),Launched,Licensed (Development),Nov-13,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,13.6,113.6506926,363.2669978,551,670.7599505,806.7199036,933.2780971,1034.331448,85.66552806,3913,Non-Hodgkin's Lymphoma,7/7/14 12:28
4060,943,Pharmacyclics,Regional & Specialty Pharma,4199,PCI-27483,Factor VIIa inhibitor,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3914,Pancreatic Cancer,7/7/14 12:28
4060,943,Pharmacyclics,Regional & Specialty Pharma,4199,PCI-27483,Factor VIIa inhibitor,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3914,Pancreatic Cancer,7/7/14 12:28
4060,943,Pharmacyclics,Regional & Specialty Pharma,4199,PCI-27483,Factor VIIa inhibitor,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3914,Pancreatic Cancer,7/7/14 12:28
4063,944,Celator Pharmaceuticals,Regional & Specialty Pharma,4201,CPX-351,liposomal cytarabine + daunorubicin,Small Molecule (Chemical),Phase III,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3917,Acute Myeloid Leukemia,7/7/14 12:28
4063,944,Celator Pharmaceuticals,Regional & Specialty Pharma,4201,CPX-351,liposomal cytarabine + daunorubicin,Small Molecule (Chemical),Phase III,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3917,Acute Myeloid Leukemia,7/7/14 12:28
4063,944,Celator Pharmaceuticals,Regional & Specialty Pharma,4201,CPX-351,liposomal cytarabine + daunorubicin,Small Molecule (Chemical),Phase III,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3917,Acute Myeloid Leukemia,7/7/14 12:28
4064,67,Novartis,Large Pharma,4202,Zykadia,ceritinib,Small Molecule (Chemical),Approved,In-House,Jun-14,Apr-15,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,14.583325,67.30549266,132.9720853,205.7501999,261.0279149,298.5912811,328.5436535,0,3918,Non-small-cell Lung Cancer,7/7/14 12:28
4064,67,Novartis,Large Pharma,4202,Zykadia,ceritinib,Small Molecule (Chemical),Approved,In-House,Jun-14,Apr-15,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,18,42,73.11108,104.2220379,122.0353196,136.7126062,0,3918,Non-small-cell Lung Cancer,7/7/14 12:28
4064,67,Novartis,Large Pharma,4202,Zykadia,ceritinib,Small Molecule (Chemical),Approved,In-House,Jun-14,Apr-15,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,14.583325,49.30549266,90.97208534,132.6391199,156.805877,176.5559615,191.8310473,0,3918,Non-small-cell Lung Cancer,7/7/14 12:28
4065,67,Novartis,Large Pharma,4203,LGX818,encorafenib,Small Molecule (Chemical),Phase III,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3919,Melanoma,7/7/14 12:28
4065,67,Novartis,Large Pharma,4203,LGX818,encorafenib,Small Molecule (Chemical),Phase III,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3919,Melanoma,7/7/14 12:28
4065,67,Novartis,Large Pharma,4203,LGX818,encorafenib,Small Molecule (Chemical),Phase III,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3919,Melanoma,7/7/14 12:28
4066,203,Cell Therapeutics,Regional & Specialty Pharma,4204,tosedostat,CHR-2797,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3920,Acute Myeloid Leukemia,7/7/14 12:28
4066,203,Cell Therapeutics,Regional & Specialty Pharma,4204,tosedostat,CHR-2797,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3920,Acute Myeloid Leukemia,7/7/14 12:28
4066,203,Cell Therapeutics,Regional & Specialty Pharma,4204,tosedostat,CHR-2797,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3920,Acute Myeloid Leukemia,7/7/14 12:28
4068,945,Chroma Therapeutics,Regional & Specialty Pharma,4204,tosedostat,CHR-2797,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3920,Acute Myeloid Leukemia,7/7/14 12:28
4068,945,Chroma Therapeutics,Regional & Specialty Pharma,4204,tosedostat,CHR-2797,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3920,Acute Myeloid Leukemia,7/7/14 12:28
4068,945,Chroma Therapeutics,Regional & Specialty Pharma,4204,tosedostat,CHR-2797,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3920,Acute Myeloid Leukemia,7/7/14 12:28
4069,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2113,DSP-8658,DSP-8658,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,387,Alzheimer's Disease,7/7/14 12:28
4069,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2113,DSP-8658,DSP-8658,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,387,Alzheimer's Disease,7/7/14 12:28
4069,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2113,DSP-8658,DSP-8658,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,387,Alzheimer's Disease,7/7/14 12:28
4070,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4205,DSP-1053,DSP-1053,Small Molecule (Chemical),Phase I,In-House,,,,,127,Serotonergics,49,Depression,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3921,Depression,7/7/14 12:28
4070,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4205,DSP-1053,DSP-1053,Small Molecule (Chemical),Phase I,In-House,,,,,127,Serotonergics,49,Depression,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3921,Depression,7/7/14 12:28
4070,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4205,DSP-1053,DSP-1053,Small Molecule (Chemical),Phase I,In-House,,,,,127,Serotonergics,49,Depression,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3921,Depression,7/7/14 12:28
4071,100,Takeda,Large Pharma,4206,TAK-361S,TAK-361S,Vaccine,Phase II,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3922,DTaP and polio,7/7/14 12:28
4071,100,Takeda,Large Pharma,4206,TAK-361S,TAK-361S,Vaccine,Phase II,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3922,DTaP and polio,7/7/14 12:28
4071,100,Takeda,Large Pharma,4206,TAK-361S,TAK-361S,Vaccine,Phase II,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3922,DTaP and polio,7/7/14 12:28
4073,15,Astellas Pharma,Regional & Specialty Pharma,4212,Encevac,KD-287,Vaccine,Launched,Licensed (Marketed),,Apr-11,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,7,Global,Sales,0,0,6.330830193,42.01179691,49.46845626,63.60208889,77.51187361,88.76145222,98.86101321,107.826302,115.6362448,122.527821,13.83407419,3924,Japanese encephalitis,7/7/14 12:28
4073,15,Astellas Pharma,Regional & Specialty Pharma,4212,Encevac,KD-287,Vaccine,Launched,Licensed (Marketed),,Apr-11,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,7,ROW,Sales,0,0,6.330830193,42.01179691,49.46845626,63.60208889,77.51187361,88.76145222,98.86101321,107.826302,115.6362448,122.527821,13.83407419,3924,Japanese encephalitis,7/7/14 12:28
4073,15,Astellas Pharma,Regional & Specialty Pharma,4212,Encevac,KD-287,Vaccine,Launched,Licensed (Marketed),,Apr-11,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3924,Japanese encephalitis,7/7/14 12:28
4074,19,Bayer,Large Pharma,4213,Sivextro,tedizolid,Small Molecule (Chemical),Phase III,Licensed (Development),,Jul-17,,,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,9.9602255,26.56063453,39.8409518,53.12113626,0,3925,Bacterial Infections,7/7/14 12:28
4074,19,Bayer,Large Pharma,4213,Sivextro,tedizolid,Small Molecule (Chemical),Phase III,Licensed (Development),,Jul-17,,,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,9.9602255,26.56063453,39.8409518,53.12113626,0,3925,Bacterial Infections,7/7/14 12:28
4074,19,Bayer,Large Pharma,4213,Sivextro,tedizolid,Small Molecule (Chemical),Phase III,Licensed (Development),,Jul-17,,,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3925,Bacterial Infections,7/7/14 12:28
4075,32,Cubist Pharmaceuticals,Small Biotech,4213,Sivextro,tedizolid,Small Molecule (Chemical),Approved,Corporate Acquisition,Nov-14,Oct-15,,,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,4.166675,32.48618656,79.61356945,134.7576927,174.3934624,199.7230297,224.6744343,0,3925,Bacterial Infections,7/7/14 12:28
4075,32,Cubist Pharmaceuticals,Small Biotech,4213,Sivextro,tedizolid,Small Molecule (Chemical),Approved,Corporate Acquisition,Nov-14,Oct-15,,,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,1.5,11.15500485,32.15997558,51.61507241,61.20669461,69.64931407,0,3925,Bacterial Infections,7/7/14 12:28
4075,32,Cubist Pharmaceuticals,Small Biotech,4213,Sivextro,tedizolid,Small Molecule (Chemical),Approved,Corporate Acquisition,Nov-14,Oct-15,,,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,4.166675,30.98618656,68.4585646,102.5977171,122.77839,138.5163351,155.0251202,0,3925,Bacterial Infections,7/7/14 12:28
4079,966,Alchemia,Small Biotech,4219,HA-irinotecan,HA-irinotecan,Small Molecule (Chemical),Phase III,In-House,Apr-15,Jan-15,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,12,Global,Sales,0,0,0,0,0,0,11.05620545,19.34838718,27.33341094,35.31835036,40.14619827,43.99004459,0,3927,Colorectal Cancer,7/7/14 12:28
4079,966,Alchemia,Small Biotech,4219,HA-irinotecan,HA-irinotecan,Small Molecule (Chemical),Phase III,In-House,Apr-15,Jan-15,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,12,ROW,Sales,0,0,0,0,0,0,8.292154089,13.82028446,19.34839824,24.8764291,28.19327448,30.84674731,0,3927,Colorectal Cancer,7/7/14 12:28
4079,966,Alchemia,Small Biotech,4219,HA-irinotecan,HA-irinotecan,Small Molecule (Chemical),Phase III,In-House,Apr-15,Jan-15,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,12,US,Sales,0,0,0,0,0,0,2.764051363,5.528102726,7.985012702,10.44192126,11.95292379,13.14329728,0,3927,Colorectal Cancer,7/7/14 12:28
4082,151,Yakult Honsha,Regional & Specialty Pharma,356,Neu-Up,nartograstim,Recombinant Protein,Launched,Acquisition (Marketed),,Jun-94,N/A,N/A,118,G-CSFs,78,Neutropenia,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,771,Neutropenia,7/7/14 12:28
4082,151,Yakult Honsha,Regional & Specialty Pharma,356,Neu-Up,nartograstim,Recombinant Protein,Launched,Acquisition (Marketed),,Jun-94,N/A,N/A,118,G-CSFs,78,Neutropenia,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,771,Neutropenia,7/7/14 12:28
4082,151,Yakult Honsha,Regional & Specialty Pharma,356,Neu-Up,nartograstim,Recombinant Protein,Launched,Acquisition (Marketed),,Jun-94,N/A,N/A,118,G-CSFs,78,Neutropenia,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,771,Neutropenia,7/7/14 12:28
4083,149,BioDelivery Sciences,Regional & Specialty Pharma,4226,BEMA Buprenorphine,buprenorphine - BEMA,Small Molecule (Chemical),Phase III,Licensed (Development),Sep-15,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,16.66665,61.11110556,94.44415808,127.7772792,155.7771226,179.8836379,0,3929,Chronic Pain,7/7/14 12:28
4083,149,BioDelivery Sciences,Regional & Specialty Pharma,4226,BEMA Buprenorphine,buprenorphine - BEMA,Small Molecule (Chemical),Phase III,Licensed (Development),Sep-15,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3929,Chronic Pain,7/7/14 12:28
4083,149,BioDelivery Sciences,Regional & Specialty Pharma,4226,BEMA Buprenorphine,buprenorphine - BEMA,Small Molecule (Chemical),Phase III,Licensed (Development),Sep-15,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,16.66665,61.11110556,94.44415808,127.7772792,155.7771226,179.8836379,0,3929,Chronic Pain,7/7/14 12:28
4084,34,Daiichi-Sankyo,Regional & Specialty Pharma,4227,Sprix,intranasal ketorolac,Small Molecule (Chemical),Launched,Corporate Acquisition,May-11,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3930,Pain,7/7/14 12:28
4084,34,Daiichi-Sankyo,Regional & Specialty Pharma,4227,Sprix,intranasal ketorolac,Small Molecule (Chemical),Launched,Corporate Acquisition,May-11,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3930,Pain,7/7/14 12:28
4084,34,Daiichi-Sankyo,Regional & Specialty Pharma,4227,Sprix,intranasal ketorolac,Small Molecule (Chemical),Launched,Corporate Acquisition,May-11,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3930,Pain,7/7/14 12:28
4087,53,Johnson & Johnson,Large Pharma,4307,JNJ-40411813,ADX71149,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3933,Schizophrenia,7/7/14 12:28
4087,53,Johnson & Johnson,Large Pharma,4307,JNJ-40411813,ADX71149,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3933,Schizophrenia,7/7/14 12:28
4087,53,Johnson & Johnson,Large Pharma,4307,JNJ-40411813,ADX71149,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3933,Schizophrenia,7/7/14 12:28
4088,96,Shire,Regional & Specialty Pharma,4242,lifitegrast,lifitegrast,Small Molecule (Chemical),Phase III,Corporate Acquisition,Dec-15,,May-26,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,3.333332,45.55564844,112.2222399,178.8889838,222.1334527,260.6023558,0,3934,Dry Eye,7/7/14 12:28
4088,96,Shire,Regional & Specialty Pharma,4242,lifitegrast,lifitegrast,Small Molecule (Chemical),Phase III,Corporate Acquisition,Dec-15,,May-26,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3934,Dry Eye,7/7/14 12:28
4088,96,Shire,Regional & Specialty Pharma,4242,lifitegrast,lifitegrast,Small Molecule (Chemical),Phase III,Corporate Acquisition,Dec-15,,May-26,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,3.333332,45.55564844,112.2222399,178.8889838,222.1334527,260.6023558,0,3934,Dry Eye,7/7/14 12:28
4089,53,Johnson & Johnson,Large Pharma,4198,Imbruvica,ibrutinib,Small Molecule (Chemical),Filed,Licensed (Development),,Nov-14,N/A,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,16.15,72.323899,206.5728347,415.9839142,554.4844144,688.3407671,815.9229076,0,3913,Non-Hodgkin's Lymphoma,7/7/14 12:28
4089,53,Johnson & Johnson,Large Pharma,4198,Imbruvica,ibrutinib,Small Molecule (Chemical),Filed,Licensed (Development),,Nov-14,N/A,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,16.15,72.323899,206.5728347,415.9839142,554.4844144,688.3407671,815.9229076,0,3913,Non-Hodgkin's Lymphoma,7/7/14 12:28
4089,53,Johnson & Johnson,Large Pharma,4198,Imbruvica,ibrutinib,Small Molecule (Chemical),Filed,Licensed (Development),,Nov-14,N/A,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3913,Non-Hodgkin's Lymphoma,7/7/14 12:28
4090,53,Johnson & Johnson,Large Pharma,3871,AAB-003,PF-05236812,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3546,Alzheimer's Disease,7/7/14 12:28
4090,53,Johnson & Johnson,Large Pharma,3871,AAB-003,PF-05236812,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3546,Alzheimer's Disease,7/7/14 12:28
4090,53,Johnson & Johnson,Large Pharma,3871,AAB-003,PF-05236812,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3546,Alzheimer's Disease,7/7/14 12:28
4091,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4245,Paxil CR,paroxetine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-12,,Jun-17,127,Serotonergics,49,Depression,12,Central Nervous System,7,Global,Sales,0,0,0,7.352057842,13.72386581,19.60550298,25.48715388,29.84144672,32.18733617,31.24472222,30.632775,30.19037394,11.92139075,846,Depression,7/7/14 12:28
4091,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4245,Paxil CR,paroxetine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-12,,Jun-17,127,Serotonergics,49,Depression,12,Central Nervous System,7,ROW,Sales,0,0,0,7.352057842,13.72386581,19.60550298,25.48715388,29.84144672,32.18733617,31.24472222,30.632775,30.19037394,11.92139075,846,Depression,7/7/14 12:28
4091,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4245,Paxil CR,paroxetine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-12,,Jun-17,127,Serotonergics,49,Depression,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,846,Depression,7/7/14 12:28
4095,67,Novartis,Large Pharma,4250,Tandospirone,AL8309B,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3938,Geographic atrophy in AMD,7/7/14 12:28
4095,67,Novartis,Large Pharma,4250,Tandospirone,AL8309B,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3938,Geographic atrophy in AMD,7/7/14 12:28
4095,67,Novartis,Large Pharma,4250,Tandospirone,AL8309B,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3938,Geographic atrophy in AMD,7/7/14 12:28
4096,1983,Alimera Sciences,Small Biotech,4252,Iluvien,fluocinolone acetonide intraocular implant,Small Molecule (Chemical),Launched,Licensed (Development),Nov-14,Apr-13,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,Global,Sales,0,0,0,0,2,13.525,37.4273865,57.69653745,75.17238763,85.54969383,93.2811818,99.05843419,74.63159636,3939,Diabetic Macular Edema,7/7/14 12:28
4096,1983,Alimera Sciences,Small Biotech,4252,Iluvien,fluocinolone acetonide intraocular implant,Small Molecule (Chemical),Launched,Licensed (Development),Nov-14,Apr-13,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,ROW,Sales,0,0,0,0,2,8,16,27.47728,31.212736,33.9771008,35.89641088,36.91083315,51.6612584,3939,Diabetic Macular Edema,7/7/14 12:28
4096,1983,Alimera Sciences,Small Biotech,4252,Iluvien,fluocinolone acetonide intraocular implant,Small Molecule (Chemical),Launched,Licensed (Development),Nov-14,Apr-13,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,US,Sales,0,0,0,0,0,5.525,21.4273865,30.21925745,43.95965163,51.57259303,57.38477092,62.14760104,0,3939,Diabetic Macular Edema,7/7/14 12:28
4097,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,4253,Fusilev,levoleucovorin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-08,,Dec-19,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3940,Osteosarcoma,7/7/14 12:28
4097,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,4253,Fusilev,levoleucovorin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-08,,Dec-19,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3940,Osteosarcoma,7/7/14 12:28
4097,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,4253,Fusilev,levoleucovorin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-08,,Dec-19,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3940,Osteosarcoma,7/7/14 12:28
4099,24,Bristol-Myers Squibb,Large Pharma,4255,BMS-866949,BMS-866949,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3942,Depression,7/7/14 12:28
4099,24,Bristol-Myers Squibb,Large Pharma,4255,BMS-866949,BMS-866949,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3942,Depression,7/7/14 12:28
4099,24,Bristol-Myers Squibb,Large Pharma,4255,BMS-866949,BMS-866949,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3942,Depression,7/7/14 12:28
4101,67,Novartis,Large Pharma,4256,BCT197,BCT197,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3943,COPD,7/7/14 12:28
4101,67,Novartis,Large Pharma,4256,BCT197,BCT197,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3943,COPD,7/7/14 12:28
4101,67,Novartis,Large Pharma,4256,BCT197,BCT197,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3943,COPD,7/7/14 12:28
4104,67,Novartis,Large Pharma,4258,LFF571,LFF571,Synthetic Peptide,Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3945,Clostridium Difficile Infection,7/7/14 12:28
4104,67,Novartis,Large Pharma,4258,LFF571,LFF571,Synthetic Peptide,Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3945,Clostridium Difficile Infection,7/7/14 12:28
4104,67,Novartis,Large Pharma,4258,LFF571,LFF571,Synthetic Peptide,Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3945,Clostridium Difficile Infection,7/7/14 12:28
4105,67,Novartis,Large Pharma,4259,MEK162,binimetinib,Small Molecule (Chemical),Phase III,Licensed (Development),Jan-16,Mar-16,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,28.999994,51.3334188,72.66674743,93.99996406,106.9199392,0,3946,Melanoma,7/7/14 12:28
4105,67,Novartis,Large Pharma,4259,MEK162,binimetinib,Small Molecule (Chemical),Phase III,Licensed (Development),Jan-16,Mar-16,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,14.999994,28.0000388,40.00001543,52.00002006,59.32002261,0,3946,Melanoma,7/7/14 12:28
4105,67,Novartis,Large Pharma,4259,MEK162,binimetinib,Small Molecule (Chemical),Phase III,Licensed (Development),Jan-16,Mar-16,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,14,23.33338,32.666732,41.999944,47.59991656,0,3946,Melanoma,7/7/14 12:28
4106,45,Gilead,Regional & Specialty Pharma,4261,elvitegravir/emtricitabine/tenofovir alafenamide/cobicistat FDC,elvitegravir/emtricitabine/GS 7340/cobicistat FDC,Small Molecule (Chemical),Phase III,In-House,Jun-15,Jun-16,Jan-29,Jan-27,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,144.3,551.750586,981.3481309,1276.823244,1371.923502,1494,0,3947,HIV,7/7/14 12:28
4106,45,Gilead,Regional & Specialty Pharma,4261,elvitegravir/emtricitabine/tenofovir alafenamide/cobicistat FDC,elvitegravir/emtricitabine/GS 7340/cobicistat FDC,Small Molecule (Chemical),Phase III,In-House,Jun-15,Jun-16,Jan-29,Jan-27,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,55.5,190.86561,304.0317388,374.1505788,384,0,3947,HIV,7/7/14 12:28
4106,45,Gilead,Regional & Specialty Pharma,4261,elvitegravir/emtricitabine/tenofovir alafenamide/cobicistat FDC,elvitegravir/emtricitabine/GS 7340/cobicistat FDC,Small Molecule (Chemical),Phase III,In-House,Jun-15,Jun-16,Jan-29,Jan-27,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,144.3,496.250586,790.4825209,972.7915048,997.7729237,1110,0,3947,HIV,7/7/14 12:28
4108,67,Novartis,Large Pharma,4527,Cilodex,AL60371,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3949,Otitis,7/7/14 12:28
4108,67,Novartis,Large Pharma,4527,Cilodex,AL60371,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3949,Otitis,7/7/14 12:28
4108,67,Novartis,Large Pharma,4527,Cilodex,AL60371,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3949,Otitis,7/7/14 12:28
4109,637,Impax Pharmaceuticals,Small Biotech,812,Zomig,zolmitriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-98,,May-13,,117,Triptans,8,Migraine,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1316,Migraine,7/7/14 12:28
4109,637,Impax Pharmaceuticals,Small Biotech,812,Zomig,zolmitriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-98,,May-13,,117,Triptans,8,Migraine,12,Central Nervous System,6,Global,Sales,0,0,0,118.121,112,14,8.55758,6,6,5.6288484,6,6.014846064,-34.14745894,1316,Migraine,7/7/14 12:28
4109,637,Impax Pharmaceuticals,Small Biotech,812,Zomig,zolmitriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-98,,May-13,,117,Triptans,8,Migraine,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1316,Migraine,7/7/14 12:28
4109,637,Impax Pharmaceuticals,Small Biotech,812,Zomig,zolmitriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-98,,May-13,,117,Triptans,8,Migraine,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1316,Migraine,7/7/14 12:28
4109,637,Impax Pharmaceuticals,Small Biotech,812,Zomig,zolmitriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-98,,May-13,,117,Triptans,8,Migraine,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1316,Migraine,7/7/14 12:28
4109,637,Impax Pharmaceuticals,Small Biotech,812,Zomig,zolmitriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-98,,May-13,,117,Triptans,8,Migraine,12,Central Nervous System,6,US,Sales,0,0,0,118.121,112,14,8.55758,6,6,5.6288484,6,6.014846064,-34.14745894,1316,Migraine,7/7/14 12:28
4110,29,Chugai,Regional & Specialty Pharma,4272,Rivotril / Klonopin,clonazepam,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-80,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,Global,Alliance Revenue,10.68721462,16.40916558,18.06229611,18.1507775,18.23892644,20.61212058,22.27335648,23.43622162,24.25022721,24.82003112,25.21889386,25.49809778,4.902758702,2089,Epilepsy,7/7/14 12:28
4110,29,Chugai,Regional & Specialty Pharma,4272,Rivotril / Klonopin,clonazepam,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-80,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,ROW,Alliance Revenue,10.68721462,16.40916558,18.06229611,18.1507775,18.23892644,20.61212058,22.27335648,23.43622162,24.25022721,24.82003112,25.21889386,25.49809778,4.902758702,2089,Epilepsy,7/7/14 12:28
4110,29,Chugai,Regional & Specialty Pharma,4272,Rivotril / Klonopin,clonazepam,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-80,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2089,Epilepsy,7/7/14 12:28
4112,1984,AB Science,Regional & Specialty Pharma,4273,Masican,masitinib,Small Molecule (Chemical),Phase III,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3959,Gastrointestinal Stromal Tumors,7/7/14 12:28
4112,1984,AB Science,Regional & Specialty Pharma,4273,Masican,masitinib,Small Molecule (Chemical),Phase III,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3959,Gastrointestinal Stromal Tumors,7/7/14 12:28
4112,1984,AB Science,Regional & Specialty Pharma,4273,Masican,masitinib,Small Molecule (Chemical),Phase III,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3959,Gastrointestinal Stromal Tumors,7/7/14 12:28
4113,86,Roche,Large Pharma,4276,RG7116,HER3 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3951,Solid Tumors,7/7/14 12:28
4113,86,Roche,Large Pharma,4276,RG7116,HER3 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3951,Solid Tumors,7/7/14 12:28
4113,86,Roche,Large Pharma,4276,RG7116,HER3 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3951,Solid Tumors,7/7/14 12:28
4114,86,Roche,Large Pharma,4277,RG7155,anti-CSF1R MAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3952,Solid Tumors,7/7/14 12:28
4114,86,Roche,Large Pharma,4277,RG7155,anti-CSF1R MAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3952,Solid Tumors,7/7/14 12:28
4114,86,Roche,Large Pharma,4277,RG7155,anti-CSF1R MAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3952,Solid Tumors,7/7/14 12:28
4116,86,Roche,Large Pharma,4279,RG7388,MDM2 antagonist,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3954,Various Malignancies,7/7/14 12:28
4116,86,Roche,Large Pharma,4279,RG7388,MDM2 antagonist,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3954,Various Malignancies,7/7/14 12:28
4116,86,Roche,Large Pharma,4279,RG7388,MDM2 antagonist,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3954,Various Malignancies,7/7/14 12:28
4117,86,Roche,Large Pharma,4280,RG7600,RG7600,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3955,Solid Tumors,7/7/14 12:28
4117,86,Roche,Large Pharma,4280,RG7600,RG7600,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3955,Solid Tumors,7/7/14 12:28
4117,86,Roche,Large Pharma,4280,RG7600,RG7600,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3955,Solid Tumors,7/7/14 12:28
4118,86,Roche,Large Pharma,4281,RG7624,anti-IL17 MAb,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3956,Autoimmune Disease,7/7/14 12:28
4118,86,Roche,Large Pharma,4281,RG7624,anti-IL17 MAb,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3956,Autoimmune Disease,7/7/14 12:28
4118,86,Roche,Large Pharma,4281,RG7624,anti-IL17 MAb,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3956,Autoimmune Disease,7/7/14 12:28
4119,86,Roche,Large Pharma,4282,RG7667,RG7667,Small Molecule (Chemical),Phase II,In-House,,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3957,CMV,7/7/14 12:28
4119,86,Roche,Large Pharma,4282,RG7667,RG7667,Small Molecule (Chemical),Phase II,In-House,,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3957,CMV,7/7/14 12:28
4119,86,Roche,Large Pharma,4282,RG7667,RG7667,Small Molecule (Chemical),Phase II,In-House,,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3957,CMV,7/7/14 12:28
4120,32,Cubist Pharmaceuticals,Small Biotech,4283,Surotomycin,CB-315,Small Molecule (Chemical),Phase III,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3958,C difficile,7/7/14 12:28
4120,32,Cubist Pharmaceuticals,Small Biotech,4283,Surotomycin,CB-315,Small Molecule (Chemical),Phase III,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3958,C difficile,7/7/14 12:28
4120,32,Cubist Pharmaceuticals,Small Biotech,4283,Surotomycin,CB-315,Small Molecule (Chemical),Phase III,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3958,C difficile,7/7/14 12:28
4122,68,Novo Nordisk,Regional & Specialty Pharma,4285,NN8640,Long-acting Growth Hormone,Recombinant Protein,Phase I,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3962,Growth Disorders,7/7/14 12:28
4122,68,Novo Nordisk,Regional & Specialty Pharma,4285,NN8640,Long-acting Growth Hormone,Recombinant Protein,Phase I,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3962,Growth Disorders,7/7/14 12:28
4122,68,Novo Nordisk,Regional & Specialty Pharma,4285,NN8640,Long-acting Growth Hormone,Recombinant Protein,Phase I,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3962,Growth Disorders,7/7/14 12:28
4123,26,Celgene,Regional & Specialty Pharma,2639,Refludan,lepirudin,Recombinant Protein,Launched,Licensed (Marketed),,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2081,,7/7/14 12:28
4123,26,Celgene,Regional & Specialty Pharma,2639,Refludan,lepirudin,Recombinant Protein,Launched,Licensed (Marketed),,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2081,,7/7/14 12:28
4123,26,Celgene,Regional & Specialty Pharma,2639,Refludan,lepirudin,Recombinant Protein,Launched,Licensed (Marketed),,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2081,,7/7/14 12:28
4124,96,Shire,Regional & Specialty Pharma,4286,Cinryze,C1 esterase inhibitor [human],Recombinant Protein,Launched,Corporate Acquisition,Dec-08,Oct-11,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,422.6,498.468,529.1652,551.577,568.518996,581.3193828,590.8984741,0,3963,Hereditary Angioedema,7/7/14 12:28
4124,96,Shire,Regional & Specialty Pharma,4286,Cinryze,C1 esterase inhibitor [human],Recombinant Protein,Launched,Corporate Acquisition,Dec-08,Oct-11,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,26.6,32.4,36.96,40.38,42.8748,44.78604,46.218876,0,3963,Hereditary Angioedema,7/7/14 12:28
4124,96,Shire,Regional & Specialty Pharma,4286,Cinryze,C1 esterase inhibitor [human],Recombinant Protein,Launched,Corporate Acquisition,Dec-08,Oct-11,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,396,466.068,492.2052,511.197,525.644196,536.5333428,544.6795981,0,3963,Hereditary Angioedema,7/7/14 12:28
4124,96,ViroPharma,Regional & Specialty Pharma,4286,Cinryze,C1 esterase inhibitor [human],Recombinant Protein,Launched,Corporate Acquisition,Dec-08,Oct-11,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Proforma,97,177,251,327,408,38.4,0,0,0,0,0,0,-100,3963,Hereditary Angioedema,7/7/14 12:28
4124,96,ViroPharma,Regional & Specialty Pharma,4286,Cinryze,C1 esterase inhibitor [human],Recombinant Protein,Launched,Corporate Acquisition,Dec-08,Oct-11,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,ROW,Proforma,0,0,1,7,18,2.4,0,0,0,0,0,0,-100,3963,Hereditary Angioedema,7/7/14 12:28
4124,96,ViroPharma,Regional & Specialty Pharma,4286,Cinryze,C1 esterase inhibitor [human],Recombinant Protein,Launched,Corporate Acquisition,Dec-08,Oct-11,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Proforma,97,177,250,320,390,36,0,0,0,0,0,0,-100,3963,Hereditary Angioedema,7/7/14 12:28
4125,34,Daiichi-Sankyo,Regional & Specialty Pharma,4288,mirogabalin,mirogabalin,Small Molecule (Chemical),Phase II,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3964,Chronic Pain,7/7/14 12:28
4125,34,Daiichi-Sankyo,Regional & Specialty Pharma,4288,mirogabalin,mirogabalin,Small Molecule (Chemical),Phase II,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3964,Chronic Pain,7/7/14 12:28
4125,34,Daiichi-Sankyo,Regional & Specialty Pharma,4288,mirogabalin,mirogabalin,Small Molecule (Chemical),Phase II,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3964,Chronic Pain,7/7/14 12:28
4126,15,Astellas Pharma,Regional & Specialty Pharma,3355,ASP-3652,ASP-3652,Small Molecule (Chemical),Phase II,In-House,,,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3965,Prostatitis,7/7/14 12:28
4126,15,Astellas Pharma,Regional & Specialty Pharma,3355,ASP-3652,ASP-3652,Small Molecule (Chemical),Phase II,In-House,,,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3965,Prostatitis,7/7/14 12:28
4126,15,Astellas Pharma,Regional & Specialty Pharma,3355,ASP-3652,ASP-3652,Small Molecule (Chemical),Phase II,In-House,,,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3965,Prostatitis,7/7/14 12:28
4128,89,Sanofi,Large Pharma,4292,Toujeo,insulin glargine,Recombinant Protein,Filed,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3966,Diabetes,7/7/14 12:28
4128,89,Sanofi,Large Pharma,4292,Toujeo,insulin glargine,Recombinant Protein,Filed,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3966,Diabetes,7/7/14 12:28
4128,89,Sanofi,Large Pharma,4292,Toujeo,insulin glargine,Recombinant Protein,Filed,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3966,Diabetes,7/7/14 12:28
4131,89,Sanofi,Large Pharma,3423,SAR100842,SAR100842,Small Molecule (Chemical),Phase II,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3427,Scleroderma,7/7/14 12:28
4131,89,Sanofi,Large Pharma,3423,SAR100842,SAR100842,Small Molecule (Chemical),Phase II,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3427,Scleroderma,7/7/14 12:28
4131,89,Sanofi,Large Pharma,3423,SAR100842,SAR100842,Small Molecule (Chemical),Phase II,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3427,Scleroderma,7/7/14 12:28
4132,89,Sanofi,Large Pharma,4579,SAR402663,sFLT01,Gene Therapy,Phase I,Corporate Acquisition,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3968,Age-related Macular Degeneration,7/7/14 12:28
4132,89,Sanofi,Large Pharma,4579,SAR402663,sFLT01,Gene Therapy,Phase I,Corporate Acquisition,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3968,Age-related Macular Degeneration,7/7/14 12:28
4132,89,Sanofi,Large Pharma,4579,SAR402663,sFLT01,Gene Therapy,Phase I,Corporate Acquisition,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3968,Age-related Macular Degeneration,7/7/14 12:28
4133,108,Vertex,Regional & Specialty Pharma,4298,Kalydeco+VX-661,ivacaftor+VX-661,Small Molecule (Chemical),Phase II,In-House,,,,,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3969,Cystic Fibrosis,7/7/14 12:28
4133,108,Vertex,Regional & Specialty Pharma,4298,Kalydeco+VX-661,ivacaftor+VX-661,Small Molecule (Chemical),Phase II,In-House,,,,,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3969,Cystic Fibrosis,7/7/14 12:28
4133,108,Vertex,Regional & Specialty Pharma,4298,Kalydeco+VX-661,ivacaftor+VX-661,Small Molecule (Chemical),Phase II,In-House,,,,,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3969,Cystic Fibrosis,7/7/14 12:28
4135,1985,Cempra Pharmaceuticals,Small Biotech,4300,CEM-102,CEM-102,Small Molecule (Chemical),Phase II,In-House,Aug-15,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3970,Gram-positive infections,7/7/14 12:28
4135,1985,Cempra Pharmaceuticals,Small Biotech,4300,CEM-102,CEM-102,Small Molecule (Chemical),Phase II,In-House,Aug-15,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3970,Gram-positive infections,7/7/14 12:28
4135,1985,Cempra Pharmaceuticals,Small Biotech,4300,CEM-102,CEM-102,Small Molecule (Chemical),Phase II,In-House,Aug-15,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3970,Gram-positive infections,7/7/14 12:28
4136,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4306,ceftaroline,ceftaroline,Small Molecule (Chemical),Phase I,Licensed (Development),,,N/A,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1385,MRSA,7/7/14 12:28
4136,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4306,ceftaroline,ceftaroline,Small Molecule (Chemical),Phase I,Licensed (Development),,,N/A,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1385,MRSA,7/7/14 12:28
4136,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4306,ceftaroline,ceftaroline,Small Molecule (Chemical),Phase I,Licensed (Development),,,N/A,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1385,MRSA,7/7/14 12:28
4139,32,Cubist Pharmaceuticals,Small Biotech,4309,CXA-201,CXA-101 plus tazobactam,Small Molecule (Chemical),Phase III,Corporate Acquisition,Jul-14,Jul-15,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,9.415,57.2856376,133.0741817,188.1549299,237.3839962,276.7915227,308.6335657,0,3973,Gram-negative pathogens,7/7/14 12:28
4139,32,Cubist Pharmaceuticals,Small Biotech,4309,CXA-201,CXA-101 plus tazobactam,Small Molecule (Chemical),Phase III,Corporate Acquisition,Jul-14,Jul-15,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,5,18.33335,35.00001515,51.66667237,62.86667107,72.62000176,0,3973,Gram-negative pathogens,7/7/14 12:28
4139,32,Cubist Pharmaceuticals,Small Biotech,4309,CXA-201,CXA-101 plus tazobactam,Small Molecule (Chemical),Phase III,Corporate Acquisition,Jul-14,Jul-15,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,9.415,52.2856376,114.7408317,153.1549148,185.7173239,213.9248517,236.0135639,0,3973,Gram-negative pathogens,7/7/14 12:28
4140,1986,Rib-X Pharmaceuticals,Small Biotech,4310,delafloxacin,delafloxacin,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-16,Jul-17,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,8,24.83336,41.333385,56.66663083,63.66664333,0,3978,gram-positive pathogens,7/7/14 12:28
4140,1986,Rib-X Pharmaceuticals,Small Biotech,4310,delafloxacin,delafloxacin,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-16,Jul-17,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,3.5,9.333345,14.0000175,18.66664333,0,3978,gram-positive pathogens,7/7/14 12:28
4140,1986,Rib-X Pharmaceuticals,Small Biotech,4310,delafloxacin,delafloxacin,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-16,Jul-17,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,8,21.33336,32.00004,42.66661333,45,0,3978,gram-positive pathogens,7/7/14 12:28
4143,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3075,Permax,pergolide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-10,,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,3,Global,Sales,0,23.93003314,25.08652237,21.29792032,18.79228264,18.57085035,18.41337981,18.47770163,18.44801828,18.43449866,18.43309843,18.4277521,-0.27944416,2213,Parkinson's disease,7/7/14 12:28
4143,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3075,Permax,pergolide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-10,,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,3,ROW,Sales,0,23.93003314,25.08652237,21.29792032,18.79228264,18.57085035,18.41337981,18.47770163,18.44801828,18.43449866,18.43309843,18.4277521,-0.27944416,2213,Parkinson's disease,7/7/14 12:28
4143,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3075,Permax,pergolide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-10,,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2213,Parkinson's disease,7/7/14 12:28
4147,91,Santen,Regional & Specialty Pharma,4315,Cosopt,dorzolamide + timolol,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,Dec-17,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,Global,Sales,0,34.25976724,79.40127229,108.4208985,118.7991225,127.51183,133.0024787,136.2979727,137.8092176,133.531446,119.368038,110.094601,-1.081169173,1205,Glaucoma,7/7/14 12:28
4147,91,Santen,Regional & Specialty Pharma,4315,Cosopt,dorzolamide + timolol,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,Dec-17,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,ROW,Sales,0,34.25976724,79.40127229,108.4208985,118.7991225,127.51183,133.0024787,136.2979727,137.8092176,133.531446,119.368038,110.094601,-1.081169173,1205,Glaucoma,7/7/14 12:28
4147,91,Santen,Regional & Specialty Pharma,4315,Cosopt,dorzolamide + timolol,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,Dec-17,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1205,Glaucoma,7/7/14 12:28
4148,58,Lundbeck,Regional & Specialty Pharma,1708,Treanda,bendamustine,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,1,Global,Sales,0,0,0,3.453282129,22.97141483,35.50117306,48.03095707,55.67915285,61.22809446,65.39428195,68.29686041,70.392874,17.34840996,1359,Chronic Lymphocytic Leukemia,7/7/14 12:28
4148,58,Lundbeck,Regional & Specialty Pharma,1708,Treanda,bendamustine,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,1,ROW,Sales,0,0,0,3.453282129,22.97141483,35.50117306,48.03095707,55.67915285,61.22809446,65.39428195,68.29686041,70.392874,17.34840996,1359,Chronic Lymphocytic Leukemia,7/7/14 12:28
4148,58,Lundbeck,Regional & Specialty Pharma,1708,Treanda,bendamustine,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1359,Chronic Lymphocytic Leukemia,7/7/14 12:28
4149,5,Actelion,Small Biotech,1943,Xiaflex,collagenase,Recombinant Protein,Launched,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1401,Dupuytren's Disease,7/7/14 12:28
4149,5,Actelion,Small Biotech,1943,Xiaflex,collagenase,Recombinant Protein,Launched,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1401,Dupuytren's Disease,7/7/14 12:28
4149,5,Actelion,Small Biotech,1943,Xiaflex,collagenase,Recombinant Protein,Launched,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1401,Dupuytren's Disease,7/7/14 12:28
4150,2221,AbbVie,Large Pharma,4320,GLPG-0634,GLPG-0634,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3981,Rheumatoid Arthritis,7/7/14 12:28
4150,2221,AbbVie,Large Pharma,4320,GLPG-0634,GLPG-0634,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3981,Rheumatoid Arthritis,7/7/14 12:28
4150,2221,AbbVie,Large Pharma,4320,GLPG-0634,GLPG-0634,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3981,Rheumatoid Arthritis,7/7/14 12:28
4151,11,Amgen,Large Pharma,4321,blinatumomab,MT103,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3979,Acute Lymphoblastic Leukemia,7/7/14 12:28
4151,11,Amgen,Large Pharma,4321,blinatumomab,MT103,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3979,Acute Lymphoblastic Leukemia,7/7/14 12:28
4151,11,Amgen,Large Pharma,4321,blinatumomab,MT103,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3979,Acute Lymphoblastic Leukemia,7/7/14 12:28
4152,262,Anacor,Small Biotech,4322,AN2898,AN2898,Small Molecule (Chemical),Phase II,In-House,,,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3980,Atopic dermatitis,7/7/14 12:28
4152,262,Anacor,Small Biotech,4322,AN2898,AN2898,Small Molecule (Chemical),Phase II,In-House,,,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3980,Atopic dermatitis,7/7/14 12:28
4152,262,Anacor,Small Biotech,4322,AN2898,AN2898,Small Molecule (Chemical),Phase II,In-House,,,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3980,Atopic dermatitis,7/7/14 12:28
4153,1987,Biota Holdings Limited,Small Biotech,3274,Inavir,laninamivir,Small Molecule (Chemical),Phase II,In-House,,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,12,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,342,influenza,7/7/14 12:28
4153,1987,Biota Holdings Limited,Small Biotech,3274,Inavir,laninamivir,Small Molecule (Chemical),Phase II,In-House,,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,12,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,342,influenza,7/7/14 12:28
4153,1987,Biota Holdings Limited,Small Biotech,3274,Inavir,laninamivir,Small Molecule (Chemical),Phase II,In-House,,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,12,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,342,influenza,7/7/14 12:28
4154,1988,BioCryst Pharmaceuticals,Small Biotech,4326,peramivir,peramivir,Small Molecule (Chemical),Phase III,In-House,Nov-14,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0.2875,3.66985125,6.937193215,8.909090386,9.173352529,10,10,0,955,influenza,7/7/14 12:28
4154,1988,BioCryst Pharmaceuticals,Small Biotech,4326,peramivir,peramivir,Small Molecule (Chemical),Phase III,In-House,Nov-14,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,955,influenza,7/7/14 12:28
4154,1988,BioCryst Pharmaceuticals,Small Biotech,4326,peramivir,peramivir,Small Molecule (Chemical),Phase III,In-House,Nov-14,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0.2875,3.66985125,6.937193215,8.909090386,9.173352529,10,10,0,955,influenza,7/7/14 12:28
4155,34,Daiichi-Sankyo,Regional & Specialty Pharma,2108,Invokana / Vokanamet,canagliflozin / canagliflozin + metformin,Small Molecule (Chemical),Filed,Licensed (Development),,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,0,0,5.313234076,13.21396002,23.77125337,40.93552458,54.26499338,68.19046781,80.54177796,0,1373,Type II Diabetes,7/7/14 12:28
4155,34,Daiichi-Sankyo,Regional & Specialty Pharma,2108,Invokana / Vokanamet,canagliflozin / canagliflozin + metformin,Small Molecule (Chemical),Filed,Licensed (Development),,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,0,0,5.313234076,13.21396002,23.77125337,40.93552458,54.26499338,68.19046781,80.54177796,0,1373,Type II Diabetes,7/7/14 12:28
4155,34,Daiichi-Sankyo,Regional & Specialty Pharma,2108,Invokana / Vokanamet,canagliflozin / canagliflozin + metformin,Small Molecule (Chemical),Filed,Licensed (Development),,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1373,Type II Diabetes,7/7/14 12:28
4156,34,Daiichi-Sankyo,Regional & Specialty Pharma,4607,Tenelia,teneligliptin,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,N/A,Dec-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,12.50211841,14.09481114,30.20316674,44.87888545,53.26276835,60.94338166,66.98228159,71.53254844,75.18745038,27.01918989,1176,Type II Diabetes,7/7/14 12:28
4156,34,Daiichi-Sankyo,Regional & Specialty Pharma,4607,Tenelia,teneligliptin,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,N/A,Dec-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,12.50211841,14.09481114,30.20316674,44.87888545,53.26276835,60.94338166,66.98228159,71.53254844,75.18745038,27.01918989,1176,Type II Diabetes,7/7/14 12:28
4156,34,Daiichi-Sankyo,Regional & Specialty Pharma,4607,Tenelia,teneligliptin,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,N/A,Dec-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1176,Type II Diabetes,7/7/14 12:28
4157,11,Amgen,Large Pharma,4330,AMG 110,solitomab,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3984,Various Cancer Types,7/7/14 12:28
4157,11,Amgen,Large Pharma,4330,AMG 110,solitomab,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3984,Various Cancer Types,7/7/14 12:28
4157,11,Amgen,Large Pharma,4330,AMG 110,solitomab,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3984,Various Cancer Types,7/7/14 12:28
4158,24,Bristol-Myers Squibb,Large Pharma,4333,HIV Maturation Inhibitor,HIV Maturation Inhibitor,Small Molecule (Chemical),Phase I,,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3982,HIV,7/7/14 12:28
4158,24,Bristol-Myers Squibb,Large Pharma,4333,HIV Maturation Inhibitor,HIV Maturation Inhibitor,Small Molecule (Chemical),Phase I,,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3982,HIV,7/7/14 12:28
4158,24,Bristol-Myers Squibb,Large Pharma,4333,HIV Maturation Inhibitor,HIV Maturation Inhibitor,Small Molecule (Chemical),Phase I,,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3982,HIV,7/7/14 12:28
4160,11,Amgen,Large Pharma,4335,rilotumumab,rilotumumab,Antibody/Antibody Derivative,Phase III,In-House,Mar-17,Jun-17,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,45.999978,96.66665276,140.6665761,184.6662261,0,3985,Gastric Cancer,7/7/14 12:28
4160,11,Amgen,Large Pharma,4335,rilotumumab,rilotumumab,Antibody/Antibody Derivative,Phase III,In-House,Mar-17,Jun-17,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,20.999988,49.99992143,73.99988371,97.999526,0,3985,Gastric Cancer,7/7/14 12:28
4160,11,Amgen,Large Pharma,4335,rilotumumab,rilotumumab,Antibody/Antibody Derivative,Phase III,In-House,Mar-17,Jun-17,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,24.99999,46.66673133,66.66669238,86.6667001,0,3985,Gastric Cancer,7/7/14 12:28
4162,11,Amgen,Large Pharma,4337,AMG 729,CD19 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3987,Systemic Lupus Erythematosus,7/7/14 12:28
4162,11,Amgen,Large Pharma,4337,AMG 729,CD19 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3987,Systemic Lupus Erythematosus,7/7/14 12:28
4162,11,Amgen,Large Pharma,4337,AMG 729,CD19 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3987,Systemic Lupus Erythematosus,7/7/14 12:28
4163,11,Amgen,Large Pharma,4338,AMG 876,,Recombinant Protein,Phase I,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3988,Type II Diabetes,7/7/14 12:28
4163,11,Amgen,Large Pharma,4338,AMG 876,,Recombinant Protein,Phase I,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3988,Type II Diabetes,7/7/14 12:28
4163,11,Amgen,Large Pharma,4338,AMG 876,,Recombinant Protein,Phase I,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3988,Type II Diabetes,7/7/14 12:28
4164,24,Bristol-Myers Squibb,Large Pharma,4344,Alpha-7 nicotinic agonist,Alpha-7 nicotinic agonist,Small Molecule (Chemical),Phase I,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3989,Schizophrenia,7/7/14 12:28
4164,24,Bristol-Myers Squibb,Large Pharma,4344,Alpha-7 nicotinic agonist,Alpha-7 nicotinic agonist,Small Molecule (Chemical),Phase I,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3989,Schizophrenia,7/7/14 12:28
4164,24,Bristol-Myers Squibb,Large Pharma,4344,Alpha-7 nicotinic agonist,Alpha-7 nicotinic agonist,Small Molecule (Chemical),Phase I,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3989,Schizophrenia,7/7/14 12:28
4165,24,Bristol-Myers Squibb,Large Pharma,3433,BMS-241027,BMS-241027,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3990,Alzheimer's Disease,7/7/14 12:28
4165,24,Bristol-Myers Squibb,Large Pharma,3433,BMS-241027,BMS-241027,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3990,Alzheimer's Disease,7/7/14 12:28
4165,24,Bristol-Myers Squibb,Large Pharma,3433,BMS-241027,BMS-241027,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3990,Alzheimer's Disease,7/7/14 12:28
4167,24,Bristol-Myers Squibb,Large Pharma,4347,CCR2 / 5,,Small Molecule (Chemical),Phase I,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3992,Atherosclerosis,7/7/14 12:28
4167,24,Bristol-Myers Squibb,Large Pharma,4347,CCR2 / 5,,Small Molecule (Chemical),Phase I,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3992,Atherosclerosis,7/7/14 12:28
4167,24,Bristol-Myers Squibb,Large Pharma,4347,CCR2 / 5,,Small Molecule (Chemical),Phase I,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3992,Atherosclerosis,7/7/14 12:28
4168,24,Bristol-Myers Squibb,Large Pharma,4348,BMS-817399,CCR1 antagonist,Small Molecule (Chemical),Phase II,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3993,Rheumatoid Arthritis,7/7/14 12:28
4168,24,Bristol-Myers Squibb,Large Pharma,4348,BMS-817399,CCR1 antagonist,Small Molecule (Chemical),Phase II,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3993,Rheumatoid Arthritis,7/7/14 12:28
4168,24,Bristol-Myers Squibb,Large Pharma,4348,BMS-817399,CCR1 antagonist,Small Molecule (Chemical),Phase II,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3993,Rheumatoid Arthritis,7/7/14 12:28
4170,10,Almirall,Regional & Specialty Pharma,4354,LAS41008,dimethyl fumarate,Small Molecule (Chemical),Phase III,In-House,,,,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3995,Psoriasis,7/7/14 12:28
4170,10,Almirall,Regional & Specialty Pharma,4354,LAS41008,dimethyl fumarate,Small Molecule (Chemical),Phase III,In-House,,,,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3995,Psoriasis,7/7/14 12:28
4170,10,Almirall,Regional & Specialty Pharma,4354,LAS41008,dimethyl fumarate,Small Molecule (Chemical),Phase III,In-House,,,,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3995,Psoriasis,7/7/14 12:28
4172,2221,AbbVie,Large Pharma,4357,ABT-122,,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3997,Rheumatoid Arthritis,7/7/14 12:28
4172,2221,AbbVie,Large Pharma,4357,ABT-122,,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3997,Rheumatoid Arthritis,7/7/14 12:28
4172,2221,AbbVie,Large Pharma,4357,ABT-122,,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3997,Rheumatoid Arthritis,7/7/14 12:28
4173,2221,AbbVie,Large Pharma,4358,ABT-981,IL-1 inhibitor ,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3998,Osteoarthritis,7/7/14 12:28
4173,2221,AbbVie,Large Pharma,4358,ABT-981,IL-1 inhibitor ,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3998,Osteoarthritis,7/7/14 12:28
4173,2221,AbbVie,Large Pharma,4358,ABT-981,IL-1 inhibitor ,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3998,Osteoarthritis,7/7/14 12:28
4176,15,Astellas Pharma,Regional & Specialty Pharma,4191,ASP-4901,ASP-4901,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4001,Symptoms associated with BPH,7/7/14 12:28
4176,15,Astellas Pharma,Regional & Specialty Pharma,4191,ASP-4901,ASP-4901,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4001,Symptoms associated with BPH,7/7/14 12:28
4176,15,Astellas Pharma,Regional & Specialty Pharma,4191,ASP-4901,ASP-4901,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4001,Symptoms associated with BPH,7/7/14 12:28
4177,682,Nymox,Small Biotech,4732,NX-1207,NX-1207,Recombinant Protein,Phase III,In-House,Mar-15,,Jan-23,,176,Other BPH Treatments,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,14.25,21.273825,30.35328077,45.39758085,54.71818227,63.50976778,0,3665,Symptoms associated with BPH,7/7/14 12:28
4177,682,Nymox,Small Biotech,4732,NX-1207,NX-1207,Recombinant Protein,Phase III,In-House,Mar-15,,Jan-23,,176,Other BPH Treatments,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3665,Symptoms associated with BPH,7/7/14 12:28
4177,682,Nymox,Small Biotech,4732,NX-1207,NX-1207,Recombinant Protein,Phase III,In-House,Mar-15,,Jan-23,,176,Other BPH Treatments,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,14.25,21.273825,30.35328077,45.39758085,54.71818227,63.50976778,0,3665,Symptoms associated with BPH,7/7/14 12:28
4180,103,The Medicines Company,Small Biotech,4364,MDCO-216,MDCO-216,Synthetic Peptide,Phase I,Licensed (Development),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4004,Atherosclerosis,7/7/14 12:28
4180,103,The Medicines Company,Small Biotech,4364,MDCO-216,MDCO-216,Synthetic Peptide,Phase I,Licensed (Development),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4004,Atherosclerosis,7/7/14 12:28
4180,103,The Medicines Company,Small Biotech,4364,MDCO-216,MDCO-216,Synthetic Peptide,Phase I,Licensed (Development),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4004,Atherosclerosis,7/7/14 12:28
4181,103,The Medicines Company,Small Biotech,4365,Argatroban Injection,Argatroban ,Small Molecule (Chemical),Launched,Licensed (Development),Sep-11,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,7.3,11.2,15.152928,18.3774528,20.88215136,22.98935598,24.70429777,26.09769817,27.24053473,13.538319,4002,Thrombosis,7/7/14 12:28
4181,103,The Medicines Company,Small Biotech,4365,Argatroban Injection,Argatroban ,Small Molecule (Chemical),Launched,Licensed (Development),Sep-11,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4002,Thrombosis,7/7/14 12:28
4181,103,The Medicines Company,Small Biotech,4365,Argatroban Injection,Argatroban ,Small Molecule (Chemical),Launched,Licensed (Development),Sep-11,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,7.3,11.2,15.152928,18.3774528,20.88215136,22.98935598,24.70429777,26.09769817,27.24053473,13.538319,4002,Thrombosis,7/7/14 12:28
4185,128,Ligand,,4371,clopidogrel - intravenous,clopidogrel - intravenous,Small Molecule (Chemical),Phase III,In-House,,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,0,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4005,Acute Coronary Syndrome,7/7/14 12:28
4185,128,Ligand,,4371,clopidogrel - intravenous,clopidogrel - intravenous,Small Molecule (Chemical),Phase III,In-House,,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,0,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4005,Acute Coronary Syndrome,7/7/14 12:28
4185,128,Ligand,,4371,clopidogrel - intravenous,clopidogrel - intravenous,Small Molecule (Chemical),Phase III,In-House,,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,0,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4005,Acute Coronary Syndrome,7/7/14 12:28
4186,76,Pfizer,Large Pharma,4373,EXC 001,EXC 001,DNA/RNA Therapy,Phase II,Corporate Acquisition,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4006,Dermal scarring,7/7/14 12:28
4186,76,Pfizer,Large Pharma,4373,EXC 001,EXC 001,DNA/RNA Therapy,Phase II,Corporate Acquisition,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4006,Dermal scarring,7/7/14 12:28
4186,76,Pfizer,Large Pharma,4373,EXC 001,EXC 001,DNA/RNA Therapy,Phase II,Corporate Acquisition,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4006,Dermal scarring,7/7/14 12:28
4187,76,Pfizer,Large Pharma,719,PD-360324,,Recombinant Protein,Phase I,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4018,cutaneous lupus erythematosus,7/7/14 12:28
4187,76,Pfizer,Large Pharma,719,PD-360324,,Recombinant Protein,Phase I,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4018,cutaneous lupus erythematosus,7/7/14 12:28
4187,76,Pfizer,Large Pharma,719,PD-360324,,Recombinant Protein,Phase I,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4018,cutaneous lupus erythematosus,7/7/14 12:28
4189,76,Pfizer,Large Pharma,4374,GMI-1070,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4008,Sickle cell disease,7/7/14 12:28
4189,76,Pfizer,Large Pharma,4374,GMI-1070,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4008,Sickle cell disease,7/7/14 12:28
4189,76,Pfizer,Large Pharma,4374,GMI-1070,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4008,Sickle cell disease,7/7/14 12:28
4190,76,Pfizer,Large Pharma,4536,PF-05280602,,Recombinant Protein,Phase I,,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4009,Hemophilia,7/7/14 12:28
4190,76,Pfizer,Large Pharma,4536,PF-05280602,,Recombinant Protein,Phase I,,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4009,Hemophilia,7/7/14 12:28
4190,76,Pfizer,Large Pharma,4536,PF-05280602,,Recombinant Protein,Phase I,,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4009,Hemophilia,7/7/14 12:28
4191,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4224,Espo,epoetin alfa,Recombinant Protein,Launched,Corporate Acquisition,,Jan-90,N/A,Aug-19,102,ESAs,24,Anemia,14,Hematology,3,Global,Sales,145.3461188,123.0687419,66.47928428,48.85993485,33.12339861,26.47262603,23.58534822,21.90241408,20.83918236,20.27429928,19.94600002,19.7548087,-7.11747286,1752,Renal Anemia,7/7/14 12:28
4191,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4224,Espo,epoetin alfa,Recombinant Protein,Launched,Corporate Acquisition,,Jan-90,N/A,Aug-19,102,ESAs,24,Anemia,14,Hematology,3,ROW,Sales,145.3461188,123.0687419,66.47928428,48.85993485,33.12339861,26.47262603,23.58534822,21.90241408,20.83918236,20.27429928,19.94600002,19.7548087,-7.11747286,1752,Renal Anemia,7/7/14 12:28
4191,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4224,Espo,epoetin alfa,Recombinant Protein,Launched,Corporate Acquisition,,Jan-90,N/A,Aug-19,102,ESAs,24,Anemia,14,Hematology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1752,Renal Anemia,7/7/14 12:28
4192,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4225,Nesp,darbepoetin alpha,Recombinant Protein,Launched,Corporate Acquisition,,Jul-07,N/A,Jun-20,102,ESAs,24,Anemia,14,Hematology,3,Global,Sales,377.258676,475.1820867,707.4399308,727.8877474,573.4488385,586.8418494,588.8088443,589.1378551,591.0261184,591.816047,592.381032,583.4744501,0.247905676,1413,Renal Anemia,7/7/14 12:28
4192,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4225,Nesp,darbepoetin alpha,Recombinant Protein,Launched,Corporate Acquisition,,Jul-07,N/A,Jun-20,102,ESAs,24,Anemia,14,Hematology,3,ROW,Sales,377.258676,475.1820867,707.4399308,727.8877474,573.4488385,586.8418494,588.8088443,589.1378551,591.0261184,591.816047,592.381032,583.4744501,0.247905676,1413,Renal Anemia,7/7/14 12:28
4192,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4225,Nesp,darbepoetin alpha,Recombinant Protein,Launched,Corporate Acquisition,,Jul-07,N/A,Jun-20,102,ESAs,24,Anemia,14,Hematology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1413,Renal Anemia,7/7/14 12:28
4193,189,Valeant,Regional & Specialty Pharma,4379,IDP-118,,Small Molecule (Chemical),Phase II,In-House,,,,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4010,Psoriasis,7/7/14 12:28
4193,189,Valeant,Regional & Specialty Pharma,4379,IDP-118,,Small Molecule (Chemical),Phase II,In-House,,,,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4010,Psoriasis,7/7/14 12:28
4193,189,Valeant,Regional & Specialty Pharma,4379,IDP-118,,Small Molecule (Chemical),Phase II,In-House,,,,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4010,Psoriasis,7/7/14 12:28
4195,15,Astellas Pharma,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-13,,Jun-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,30.20316674,40.27088898,50.33861123,64.72085584,70.83334755,75.5255794,90.60950021,95.69556436,17.90939307,1388,Rheumatoid Arthritis,7/7/14 12:28
4195,15,Astellas Pharma,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-13,,Jun-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,30.20316674,40.27088898,50.33861123,64.72085584,70.83334755,75.5255794,90.60950021,95.69556436,17.90939307,1388,Rheumatoid Arthritis,7/7/14 12:28
4195,15,Astellas Pharma,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-13,,Jun-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1388,Rheumatoid Arthritis,7/7/14 12:28
4196,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4384,BBI608,BBI608,Small Molecule (Chemical),Phase III,Corporate Acquisition,Sep-16,Sep-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,70.47405572,123.4247375,165.8724946,246.4699397,284.6438513,0,4012,Colorectal Cancer,7/7/14 12:28
4196,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4384,BBI608,BBI608,Small Molecule (Chemical),Phase III,Corporate Acquisition,Sep-16,Sep-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,30.20316674,52.89631606,75.26299435,111.8332833,129.55355,0,4012,Colorectal Cancer,7/7/14 12:28
4196,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4384,BBI608,BBI608,Small Molecule (Chemical),Phase III,Corporate Acquisition,Sep-16,Sep-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,40.27088898,70.52842142,90.60950021,134.6366564,155.0903013,0,4012,Colorectal Cancer,7/7/14 12:28
4197,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4385,BBI503,BBI503,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4013,Solid Tumors,7/7/14 12:28
4197,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4385,BBI503,BBI503,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4013,Solid Tumors,7/7/14 12:28
4197,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4385,BBI503,BBI503,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4013,Solid Tumors,7/7/14 12:28
4198,19,Bayer,Large Pharma,4386,Xofigo,radium-223,Other,Launched,Licensed (Development),Jun-13,Dec-13,Jan-20,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,0,0,0,0,55.11324776,199.20451,309.4310055,445.8165061,550.0337994,642.0894761,725.7455773,797.9761471,46.49370519,4014,Prostate Cancer,7/7/14 12:28
4198,19,Bayer,Large Pharma,4386,Xofigo,radium-223,Other,Launched,Licensed (Development),Jun-13,Dec-13,Jan-20,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,0,0,0,0,9.9602255,106.2424053,169.9878485,245.283966,306.2606004,358.9215932,406.6677614,448.1611284,72.25276202,4014,Prostate Cancer,7/7/14 12:28
4198,19,Bayer,Large Pharma,4386,Xofigo,radium-223,Other,Launched,Licensed (Development),Jun-13,Dec-13,Jan-20,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Sales,0,0,0,0,45.15302226,92.96210466,139.443157,200.5325401,243.773199,283.1678829,319.0778159,349.8150187,33.97431152,4014,Prostate Cancer,7/7/14 12:28
4199,102,Teva,Regional & Specialty Pharma,4392,TL-011,rituximab biosimilar,Antibody/Antibody Derivative,Phase III,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4161,Rheumatoid arthritis,7/7/14 12:28
4199,102,Teva,Regional & Specialty Pharma,4392,TL-011,rituximab biosimilar,Antibody/Antibody Derivative,Phase III,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4161,Rheumatoid arthritis,7/7/14 12:28
4199,102,Teva,Regional & Specialty Pharma,4392,TL-011,rituximab biosimilar,Antibody/Antibody Derivative,Phase III,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4161,Rheumatoid arthritis,7/7/14 12:28
4200,67,Novartis,Large Pharma,4389,BGS649,BGS649,Small Molecule (Chemical),Phase II,In-House,,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4015,Hypogonadism,7/7/14 12:28
4200,67,Novartis,Large Pharma,4389,BGS649,BGS649,Small Molecule (Chemical),Phase II,In-House,,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4015,Hypogonadism,7/7/14 12:28
4200,67,Novartis,Large Pharma,4389,BGS649,BGS649,Small Molecule (Chemical),Phase II,In-House,,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4015,Hypogonadism,7/7/14 12:28
4201,67,Novartis,Large Pharma,4390,MenABCWY,,Vaccine,Phase II,,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4016,Meningococcal disease (ABCYW),7/7/14 12:28
4201,67,Novartis,Large Pharma,4390,MenABCWY,,Vaccine,Phase II,,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4016,Meningococcal disease (ABCYW),7/7/14 12:28
4201,67,Novartis,Large Pharma,4390,MenABCWY,,Vaccine,Phase II,,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4016,Meningococcal disease (ABCYW),7/7/14 12:28
4203,67,Novartis,Large Pharma,4393,Jetrea,ocriplasmin,Recombinant Protein,Launched,Licensed (Development),,Apr-13,,Mar-23,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,Global,Sales,0,0,0,0,16,38,82,140.82106,169.027378,193.3570642,212.7916345,226.3861073,46.01242218,4019,Vitreomacular Adhesion,7/7/14 12:28
4203,67,Novartis,Large Pharma,4393,Jetrea,ocriplasmin,Recombinant Protein,Launched,Licensed (Development),,Apr-13,,Mar-23,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,ROW,Sales,0,0,0,0,16,38,82,140.82106,169.027378,193.3570642,212.7916345,226.3861073,46.01242218,4019,Vitreomacular Adhesion,7/7/14 12:28
4203,67,Novartis,Large Pharma,4393,Jetrea,ocriplasmin,Recombinant Protein,Launched,Licensed (Development),,Apr-13,,Mar-23,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4019,Vitreomacular Adhesion,7/7/14 12:28
4204,2003,ThromboGenics,Small Biotech,4393,Jetrea,ocriplasmin,Recombinant Protein,Launched,In-House,Jan-13,,Jan-25,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,Global,Sales,0,0,0,0,26.56060133,53.12120266,92.96210466,159.3640064,189.6432114,215.4602235,236.6238122,251.2534556,37.85116859,4019,Vitreomacular Adhesion,7/7/14 12:28
4204,2003,ThromboGenics,Small Biotech,4393,Jetrea,ocriplasmin,Recombinant Protein,Launched,In-House,Jan-13,,Jan-25,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4019,Vitreomacular Adhesion,7/7/14 12:28
4204,2003,ThromboGenics,Small Biotech,4393,Jetrea,ocriplasmin,Recombinant Protein,Launched,In-House,Jan-13,,Jan-25,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,US,Sales,0,0,0,0,26.56060133,53.12120266,92.96210466,159.3640064,189.6432114,215.4602235,236.6238122,251.2534556,37.85116859,4019,Vitreomacular Adhesion,7/7/14 12:28
4205,111,Actavis,Regional & Specialty Pharma,4394,Lo Loestrin Fe,norethindrone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-11,Apr-14,Feb-29,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,0,0,53,279.6429,341.3193425,392.7343518,436.7120666,469.0486882,494.8176959,515.2153675,38.38904339,4020,Female contraception,7/7/14 12:28
4205,111,Actavis,Regional & Specialty Pharma,4394,Lo Loestrin Fe,norethindrone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-11,Apr-14,Feb-29,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,22.5,45,64.9998,84.99958846,98.32448071,109.1550034,117.8732498,0,4020,Female contraception,7/7/14 12:28
4205,111,Actavis,Regional & Specialty Pharma,4394,Lo Loestrin Fe,norethindrone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-11,Apr-14,Feb-29,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,53,257.1429,296.3193425,327.7345518,351.7124781,370.7242075,385.6626924,397.3421177,33.34722418,4020,Female contraception,7/7/14 12:28
4205,111,Warner Chilcott ,Regional & Specialty Pharma,4394,Lo Loestrin Fe,norethindrone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-11,Apr-14,Feb-29,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Proforma,0,0,63,137,157,0,0,0,0,0,0,0,-100,4020,Female contraception,7/7/14 12:28
4205,111,Warner Chilcott ,Regional & Specialty Pharma,4394,Lo Loestrin Fe,norethindrone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-11,Apr-14,Feb-29,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Proforma,0,0,63,137,157,0,0,0,0,0,0,0,-100,4020,Female contraception,7/7/14 12:28
4207,84,Recordati,Regional & Specialty Pharma,4396,Procto-Glyvenol,tribenoside + lidocaine,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4044,Hemorrhoids,7/7/14 12:28
4207,84,Recordati,Regional & Specialty Pharma,4396,Procto-Glyvenol,tribenoside + lidocaine,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4044,Hemorrhoids,7/7/14 12:28
4207,84,Recordati,Regional & Specialty Pharma,4396,Procto-Glyvenol,tribenoside + lidocaine,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4044,Hemorrhoids,7/7/14 12:28
4208,100,Takeda,Large Pharma,4397,Takeda Measles  / Rubella vaccine,pediatric vaccine,Vaccine,Launched,In-House,,Jan-06,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,Global,Sales,88.34072948,96.88452066,102.5594491,63.80532554,48.5611875,44.62072447,41.45410712,40.15035863,39.31387541,38.80893404,38.54147617,38.38309837,-3.304277703,4021,measles / rubella,7/7/14 12:28
4208,100,Takeda,Large Pharma,4397,Takeda Measles  / Rubella vaccine,pediatric vaccine,Vaccine,Launched,In-House,,Jan-06,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,ROW,Sales,88.34072948,96.88452066,102.5594491,63.80532554,48.5611875,44.62072447,41.45410712,40.15035863,39.31387541,38.80893404,38.54147617,38.38309837,-3.304277703,4021,measles / rubella,7/7/14 12:28
4208,100,Takeda,Large Pharma,4397,Takeda Measles  / Rubella vaccine,pediatric vaccine,Vaccine,Launched,In-House,,Jan-06,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4021,measles / rubella,7/7/14 12:28
4209,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4398,Mearubik,measles / rubella vaccine,Vaccine,Launched,Licensed (Marketed),,Dec-05,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,Global,Sales,127.1244644,136.5721556,120.2857737,96.30992534,73.76318827,67.58840442,63.51776165,60.89602437,59.01251526,57.74131311,56.87881248,56.28415608,-3.789838799,4022,measles / rubella vaccine,7/7/14 12:28
4209,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4398,Mearubik,measles / rubella vaccine,Vaccine,Launched,Licensed (Marketed),,Dec-05,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,ROW,Sales,127.1244644,136.5721556,120.2857737,96.30992534,73.76318827,67.58840442,63.51776165,60.89602437,59.01251526,57.74131311,56.87881248,56.28415608,-3.789838799,4022,measles / rubella vaccine,7/7/14 12:28
4209,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4398,Mearubik,measles / rubella vaccine,Vaccine,Launched,Licensed (Marketed),,Dec-05,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4022,measles / rubella vaccine,7/7/14 12:28
4210,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4399,Influenza vaccines - MTP,influenza vaccine,Vaccine,Launched,Licensed (Marketed),,Jan-05,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,7,Global,Sales,68.94886203,82.87712008,113.9549435,92.69830314,77.52146129,77.47112265,76.14973408,75.81183611,75.52411947,75.26936675,75.12873128,75.02658784,-0.46622734,4023,influenza prevention,7/7/14 12:28
4210,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4399,Influenza vaccines - MTP,influenza vaccine,Vaccine,Launched,Licensed (Marketed),,Jan-05,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,7,ROW,Sales,68.94886203,82.87712008,113.9549435,92.69830314,77.52146129,77.47112265,76.14973408,75.81183611,75.52411947,75.26936675,75.12873128,75.02658784,-0.46622734,4023,influenza prevention,7/7/14 12:28
4210,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4399,Influenza vaccines - MTP,influenza vaccine,Vaccine,Launched,Licensed (Marketed),,Jan-05,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4023,influenza prevention,7/7/14 12:28
4211,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4400,JEBIK V,encephalitis vaccine,Vaccine,Launched,Licensed (Marketed),,Jun-09,,,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,7,Global,Sales,21.54651938,80.54255332,89.89778875,57.7859552,41.31143557,37.21461265,35.3425388,34.41572933,33.9693844,33.75240926,33.64726962,33.59626693,-2.910021771,4024,encephalitis,7/7/14 12:28
4211,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4400,JEBIK V,encephalitis vaccine,Vaccine,Launched,Licensed (Marketed),,Jun-09,,,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,7,ROW,Sales,21.54651938,80.54255332,89.89778875,57.7859552,41.31143557,37.21461265,35.3425388,34.41572933,33.9693844,33.75240926,33.64726962,33.59626693,-2.910021771,4024,encephalitis,7/7/14 12:28
4211,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4400,JEBIK V,encephalitis vaccine,Vaccine,Launched,Licensed (Marketed),,Jun-09,,,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4024,encephalitis,7/7/14 12:28
4214,2007,Gene Signal,,4404,Aganirsen,GS-101,DNA/RNA Therapy,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4054,Age-related Macular Degeneration,7/7/14 12:28
4214,2007,Gene Signal,,4404,Aganirsen,GS-101,DNA/RNA Therapy,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4054,Age-related Macular Degeneration,7/7/14 12:28
4214,2007,Gene Signal,,4404,Aganirsen,GS-101,DNA/RNA Therapy,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4054,Age-related Macular Degeneration,7/7/14 12:28
4215,2008,Daval International,Small Biotech,4405,Aimspro,hyperimmune goat serum,Antibody/Antibody Derivative,Phase II,In-House,,,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4027,MS-associated bladder dysfunction,7/7/14 12:28
4215,2008,Daval International,Small Biotech,4405,Aimspro,hyperimmune goat serum,Antibody/Antibody Derivative,Phase II,In-House,,,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4027,MS-associated bladder dysfunction,7/7/14 12:28
4215,2008,Daval International,Small Biotech,4405,Aimspro,hyperimmune goat serum,Antibody/Antibody Derivative,Phase II,In-House,,,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4027,MS-associated bladder dysfunction,7/7/14 12:28
4218,923,Ablynx,Small Biotech,4408,ALX-0061,,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4030,Rheumatoid arthritis,7/7/14 12:28
4218,923,Ablynx,Small Biotech,4408,ALX-0061,,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4030,Rheumatoid arthritis,7/7/14 12:28
4218,923,Ablynx,Small Biotech,4408,ALX-0061,,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4030,Rheumatoid arthritis,7/7/14 12:28
4219,2015,arGentis,Small Biotech,4409,ARG-301,,Synthetic Peptide,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4029,Rheumatoid Arthritis,7/7/14 12:28
4219,2015,arGentis,Small Biotech,4409,ARG-301,,Synthetic Peptide,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4029,Rheumatoid Arthritis,7/7/14 12:28
4219,2015,arGentis,Small Biotech,4409,ARG-301,,Synthetic Peptide,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4029,Rheumatoid Arthritis,7/7/14 12:28
4221,46,GlaxoSmithKline,Large Pharma,4412,MOR-103,MOR-04357,Antibody/Antibody Derivative,Phase I,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4038,Multiple sclerosis,7/7/14 12:28
4221,46,GlaxoSmithKline,Large Pharma,4412,MOR-103,MOR-04357,Antibody/Antibody Derivative,Phase I,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4038,Multiple sclerosis,7/7/14 12:28
4221,46,GlaxoSmithKline,Large Pharma,4412,MOR-103,MOR-04357,Antibody/Antibody Derivative,Phase I,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4038,Multiple sclerosis,7/7/14 12:28
4222,2018,Pergamum,Small Biotech,4413,DPK-060,DPK-060,Synthetic Peptide,Phase II,Licensed (Development),,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4032,Atopic dermatitis,7/7/14 12:28
4222,2018,Pergamum,Small Biotech,4413,DPK-060,DPK-060,Synthetic Peptide,Phase II,Licensed (Development),,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4032,Atopic dermatitis,7/7/14 12:28
4222,2018,Pergamum,Small Biotech,4413,DPK-060,DPK-060,Synthetic Peptide,Phase II,Licensed (Development),,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4032,Atopic dermatitis,7/7/14 12:28
4224,2122,Invion,Small Biotech,4415,INV-103,INV-103,Recombinant Protein,Phase II,Licensed (Development),,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,12,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4041,Multiple sclerosis,7/7/14 12:28
4224,2122,Invion,Small Biotech,4415,INV-103,INV-103,Recombinant Protein,Phase II,Licensed (Development),,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,12,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4041,Multiple sclerosis,7/7/14 12:28
4224,2122,Invion,Small Biotech,4415,INV-103,INV-103,Recombinant Protein,Phase II,Licensed (Development),,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,12,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4041,Multiple sclerosis,7/7/14 12:28
4225,53,Johnson & Johnson,Large Pharma,4416,CNTO-5825,,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4034,inflammatory disease,7/7/14 12:28
4225,53,Johnson & Johnson,Large Pharma,4416,CNTO-5825,,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4034,inflammatory disease,7/7/14 12:28
4225,53,Johnson & Johnson,Large Pharma,4416,CNTO-5825,,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4034,inflammatory disease,7/7/14 12:28
4227,2008,Daval International,Small Biotech,4405,Aimspro,hyperimmune goat serum,Antibody/Antibody Derivative,Phase II,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4027,Scleroderma,7/7/14 12:28
4227,2008,Daval International,Small Biotech,4405,Aimspro,hyperimmune goat serum,Antibody/Antibody Derivative,Phase II,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4027,Scleroderma,7/7/14 12:28
4227,2008,Daval International,Small Biotech,4405,Aimspro,hyperimmune goat serum,Antibody/Antibody Derivative,Phase II,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4027,Scleroderma,7/7/14 12:28
4228,46,GlaxoSmithKline,Large Pharma,4412,MOR-103,MOR-04357,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4038,Rheumatoid Arthritis,7/7/14 12:28
4228,46,GlaxoSmithKline,Large Pharma,4412,MOR-103,MOR-04357,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4038,Rheumatoid Arthritis,7/7/14 12:28
4228,46,GlaxoSmithKline,Large Pharma,4412,MOR-103,MOR-04357,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4038,Rheumatoid Arthritis,7/7/14 12:28
4229,2023,AnGes MG,Regional & Specialty Pharma,4418,S-414114,NF-kappa B decoy oligo,DNA/RNA Therapy,Phase II,In-House,,,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4039,Atopic dermatitis,7/7/14 12:28
4229,2023,AnGes MG,Regional & Specialty Pharma,4418,S-414114,NF-kappa B decoy oligo,DNA/RNA Therapy,Phase II,In-House,,,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4039,Atopic dermatitis,7/7/14 12:28
4229,2023,AnGes MG,Regional & Specialty Pharma,4418,S-414114,NF-kappa B decoy oligo,DNA/RNA Therapy,Phase II,In-House,,,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4039,Atopic dermatitis,7/7/14 12:28
4230,76,Pfizer,Large Pharma,4419,Dekavil,F8-IL10,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4048,Rheumatoid Arthritis,7/7/14 12:28
4230,76,Pfizer,Large Pharma,4419,Dekavil,F8-IL10,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4048,Rheumatoid Arthritis,7/7/14 12:28
4230,76,Pfizer,Large Pharma,4419,Dekavil,F8-IL10,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4048,Rheumatoid Arthritis,7/7/14 12:28
4231,2122,Invion,Small Biotech,4415,INV-103,INV-103,Recombinant Protein,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,12,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4041,Systemic Lupus Erythematosus,7/7/14 12:28
4231,2122,Invion,Small Biotech,4415,INV-103,INV-103,Recombinant Protein,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,12,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4041,Systemic Lupus Erythematosus,7/7/14 12:28
4231,2122,Invion,Small Biotech,4415,INV-103,INV-103,Recombinant Protein,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,12,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4041,Systemic Lupus Erythematosus,7/7/14 12:28
4232,2122,Invion,Small Biotech,4415,INV-103,INV-103,Recombinant Protein,Phase II,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,12,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4041,Psoriasis,7/7/14 12:28
4232,2122,Invion,Small Biotech,4415,INV-103,INV-103,Recombinant Protein,Phase II,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,12,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4041,Psoriasis,7/7/14 12:28
4232,2122,Invion,Small Biotech,4415,INV-103,INV-103,Recombinant Protein,Phase II,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,12,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4041,Psoriasis,7/7/14 12:28
4233,46,GlaxoSmithKline,Large Pharma,4664,2586184,2586184,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4042,Systemic lupus erythematosus,7/7/14 12:28
4233,46,GlaxoSmithKline,Large Pharma,4664,2586184,2586184,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4042,Systemic lupus erythematosus,7/7/14 12:28
4233,46,GlaxoSmithKline,Large Pharma,4664,2586184,2586184,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4042,Systemic lupus erythematosus,7/7/14 12:28
4234,2025,Digna Biotech,Small Biotech,4421,disitertide,disitertide,Synthetic Peptide,Phase II,Licensed (Development),,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4043,Scleroderma,7/7/14 12:28
4234,2025,Digna Biotech,Small Biotech,4421,disitertide,disitertide,Synthetic Peptide,Phase II,Licensed (Development),,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4043,Scleroderma,7/7/14 12:28
4234,2025,Digna Biotech,Small Biotech,4421,disitertide,disitertide,Synthetic Peptide,Phase II,Licensed (Development),,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4043,Scleroderma,7/7/14 12:28
4236,2026,Trident Pharmaceuticals,Small Biotech,4422,HF-1020,HF-1020,Recombinant Protein,Phase I,Licensed (Development),,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4191,Allergic Rhinitis,7/7/14 12:28
4236,2026,Trident Pharmaceuticals,Small Biotech,4422,HF-1020,HF-1020,Recombinant Protein,Phase I,Licensed (Development),,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4191,Allergic Rhinitis,7/7/14 12:28
4236,2026,Trident Pharmaceuticals,Small Biotech,4422,HF-1020,HF-1020,Recombinant Protein,Phase I,Licensed (Development),,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4191,Allergic Rhinitis,7/7/14 12:28
4238,286,Idera,Small Biotech,4424,IMO-3100,IMO-3100,DNA/RNA Therapy,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4046,Psoriasis,7/7/14 12:28
4238,286,Idera,Small Biotech,4424,IMO-3100,IMO-3100,DNA/RNA Therapy,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4046,Psoriasis,7/7/14 12:28
4238,286,Idera,Small Biotech,4424,IMO-3100,IMO-3100,DNA/RNA Therapy,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4046,Psoriasis,7/7/14 12:28
4239,2028,Biocon Biopharmaceuticals,Regional & Specialty Pharma,4425,Alzumab,Itolizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Aug-13,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,3.12,6.5361504,9.275385671,13.69621999,16.48278336,18.93331763,21.14236989,22.9401192,32.97719655,4069,Psoriasis,7/7/14 12:28
4239,2028,Biocon Biopharmaceuticals,Regional & Specialty Pharma,4425,Alzumab,Itolizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Aug-13,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,3.12,6.5361504,9.275385671,13.69621999,16.48278336,18.93331763,21.14236989,22.9401192,32.97719655,4069,Psoriasis,7/7/14 12:28
4239,2028,Biocon Biopharmaceuticals,Regional & Specialty Pharma,4425,Alzumab,Itolizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Aug-13,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4069,Psoriasis,7/7/14 12:28
4240,2026,Trident Pharmaceuticals,Small Biotech,4422,HF-1020,HF-1020,Recombinant Protein,Phase I,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4191,Psoriasis,7/7/14 12:28
4240,2026,Trident Pharmaceuticals,Small Biotech,4422,HF-1020,HF-1020,Recombinant Protein,Phase I,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4191,Psoriasis,7/7/14 12:28
4240,2026,Trident Pharmaceuticals,Small Biotech,4422,HF-1020,HF-1020,Recombinant Protein,Phase I,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4191,Psoriasis,7/7/14 12:28
4243,87,Salix,Small Biotech,4428,SAN-300,VLA-1 mAb,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4052,humanized VLA-1 mAb for Rheumatoid Arthritis,7/7/14 12:28
4243,87,Salix,Small Biotech,4428,SAN-300,VLA-1 mAb,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4052,humanized VLA-1 mAb for Rheumatoid Arthritis,7/7/14 12:28
4243,87,Salix,Small Biotech,4428,SAN-300,VLA-1 mAb,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4052,humanized VLA-1 mAb for Rheumatoid Arthritis,7/7/14 12:28
4245,2032,Morphotek,Small Biotech,4430,MORab-022,MORab-022,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4071,Rheumatoid Arthritis,7/7/14 12:28
4245,2032,Morphotek,Small Biotech,4430,MORab-022,MORab-022,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4071,Rheumatoid Arthritis,7/7/14 12:28
4245,2032,Morphotek,Small Biotech,4430,MORab-022,MORab-022,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4071,Rheumatoid Arthritis,7/7/14 12:28
4247,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Aug-17,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,3,Global,Sales,0,0,0,0,0,0,0,0,8.540810551,26.19184749,39.85718201,53.52261543,0,114,Psoriasis,7/7/14 12:28
4247,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Aug-17,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,3,ROW,Sales,0,0,0,0,0,0,0,0,8.540810551,26.19184749,39.85718201,53.52261543,0,114,Psoriasis,7/7/14 12:28
4247,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Aug-17,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,114,Psoriasis,7/7/14 12:28
4248,2007,Gene Signal,,4404,Aganirsen,GS-101,DNA/RNA Therapy,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4054,Psoriasis,7/7/14 12:28
4248,2007,Gene Signal,,4404,Aganirsen,GS-101,DNA/RNA Therapy,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4054,Psoriasis,7/7/14 12:28
4248,2007,Gene Signal,,4404,Aganirsen,GS-101,DNA/RNA Therapy,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4054,Psoriasis,7/7/14 12:28
4249,2033,NovImmune,Small Biotech,4434,NI-0501,anti-IFN gamma,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4073,Systemic Lupus Erythematosus,7/7/14 12:28
4249,2033,NovImmune,Small Biotech,4434,NI-0501,anti-IFN gamma,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4073,Systemic Lupus Erythematosus,7/7/14 12:28
4249,2033,NovImmune,Small Biotech,4434,NI-0501,anti-IFN gamma,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4073,Systemic Lupus Erythematosus,7/7/14 12:28
4250,2033,NovImmune,Small Biotech,4435,NI-0801,NI-0801,Antibody/Antibody Derivative,Phase II,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4074,Primary Biliary Cirrhosis,7/7/14 12:28
4250,2033,NovImmune,Small Biotech,4435,NI-0801,NI-0801,Antibody/Antibody Derivative,Phase II,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4074,Primary Biliary Cirrhosis,7/7/14 12:28
4250,2033,NovImmune,Small Biotech,4435,NI-0801,NI-0801,Antibody/Antibody Derivative,Phase II,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4074,Primary Biliary Cirrhosis,7/7/14 12:28
4251,252,BioLineRx,Small Biotech,4436,BL-7040,,DNA/RNA Therapy,Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4055,Ulcerative Colitis,7/7/14 12:28
4251,252,BioLineRx,Small Biotech,4436,BL-7040,,DNA/RNA Therapy,Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4055,Ulcerative Colitis,7/7/14 12:28
4251,252,BioLineRx,Small Biotech,4436,BL-7040,,DNA/RNA Therapy,Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4055,Ulcerative Colitis,7/7/14 12:28
4252,2034,Noxxon,Small Biotech,4437,NOX-E36,NOX-E36,Recombinant Protein,Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4075,Diabetic Complications,7/7/14 12:28
4252,2034,Noxxon,Small Biotech,4437,NOX-E36,NOX-E36,Recombinant Protein,Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4075,Diabetic Complications,7/7/14 12:28
4252,2034,Noxxon,Small Biotech,4437,NOX-E36,NOX-E36,Recombinant Protein,Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4075,Diabetic Complications,7/7/14 12:28
4253,2009,Mentrik Biotech,Small Biotech,4406,ocaratuzumab,ocaratuzumab,Antibody/Antibody Derivative,Phase III,Acquisition (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4189,Rheumatoid Arthritis,7/7/14 12:28
4253,2009,Mentrik Biotech,Small Biotech,4406,ocaratuzumab,ocaratuzumab,Antibody/Antibody Derivative,Phase III,Acquisition (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4189,Rheumatoid Arthritis,7/7/14 12:28
4253,2009,Mentrik Biotech,Small Biotech,4406,ocaratuzumab,ocaratuzumab,Antibody/Antibody Derivative,Phase III,Acquisition (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4189,Rheumatoid Arthritis,7/7/14 12:28
4257,2027,Neovacs,Small Biotech,4440,TNF alpha kinoid,,Vaccine,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4059,Rheumatoid Arthritis,7/7/14 12:28
4257,2027,Neovacs,Small Biotech,4440,TNF alpha kinoid,,Vaccine,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4059,Rheumatoid Arthritis,7/7/14 12:28
4257,2027,Neovacs,Small Biotech,4440,TNF alpha kinoid,,Vaccine,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4059,Rheumatoid Arthritis,7/7/14 12:28
4258,2033,NovImmune,Small Biotech,4441,NI-0401,IFNgamma,Antibody/Antibody Derivative,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4076,Crohn's Disease,7/7/14 12:28
4258,2033,NovImmune,Small Biotech,4441,NI-0401,IFNgamma,Antibody/Antibody Derivative,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4076,Crohn's Disease,7/7/14 12:28
4258,2033,NovImmune,Small Biotech,4441,NI-0401,IFNgamma,Antibody/Antibody Derivative,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4076,Crohn's Disease,7/7/14 12:28
4261,2024,XBiotech,Small Biotech,4444,RA-18C3,,Antibody/Antibody Derivative,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4062,Psoriasis,7/7/14 12:28
4261,2024,XBiotech,Small Biotech,4444,RA-18C3,,Antibody/Antibody Derivative,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4062,Psoriasis,7/7/14 12:28
4261,2024,XBiotech,Small Biotech,4444,RA-18C3,,Antibody/Antibody Derivative,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4062,Psoriasis,7/7/14 12:28
4263,2037,LTT Biopharma,Regional & Specialty Pharma,4446,midismase,midismase,Recombinant Protein,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4064,Ulcerative Colitis,7/7/14 12:28
4263,2037,LTT Biopharma,Regional & Specialty Pharma,4446,midismase,midismase,Recombinant Protein,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4064,Ulcerative Colitis,7/7/14 12:28
4263,2037,LTT Biopharma,Regional & Specialty Pharma,4446,midismase,midismase,Recombinant Protein,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4064,Ulcerative Colitis,7/7/14 12:28
4264,2038,InDex,Small Biotech,4447,Kappaproct,DIMS-0150,DNA/RNA Therapy,Phase III,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4065,Ulcerative Colitis,7/7/14 12:28
4264,2038,InDex,Small Biotech,4447,Kappaproct,DIMS-0150,DNA/RNA Therapy,Phase III,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4065,Ulcerative Colitis,7/7/14 12:28
4264,2038,InDex,Small Biotech,4447,Kappaproct,DIMS-0150,DNA/RNA Therapy,Phase III,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4065,Ulcerative Colitis,7/7/14 12:28
4265,219,Celldex Therapeutics,Small Biotech,4449,rindopepimut,CDX-110,Vaccine,Phase III,Licensed (Development),Jan-18,Apr-18,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,70.5,125.00016,177.000024,0,4077,Glioblastome Multiforme,7/7/14 12:28
4265,219,Celldex Therapeutics,Small Biotech,4449,rindopepimut,CDX-110,Vaccine,Phase III,Licensed (Development),Jan-18,Apr-18,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,22.5,45,64.9998,0,4077,Glioblastome Multiforme,7/7/14 12:28
4265,219,Celldex Therapeutics,Small Biotech,4449,rindopepimut,CDX-110,Vaccine,Phase III,Licensed (Development),Jan-18,Apr-18,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,48,80.00016,112.000224,0,4077,Glioblastome Multiforme,7/7/14 12:28
4267,89,Sanofi,Large Pharma,1780,fresolimumab,fresolimumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1482,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
4267,89,Sanofi,Large Pharma,1780,fresolimumab,fresolimumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1482,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
4267,89,Sanofi,Large Pharma,1780,fresolimumab,fresolimumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1482,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
4268,273,Vanda Pharmaceuticals,Small Biotech,4457,VLY-686,LY-686017,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4078,Alcohol Addiction,7/7/14 12:28
4268,273,Vanda Pharmaceuticals,Small Biotech,4457,VLY-686,LY-686017,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4078,Alcohol Addiction,7/7/14 12:28
4268,273,Vanda Pharmaceuticals,Small Biotech,4457,VLY-686,LY-686017,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4078,Alcohol Addiction,7/7/14 12:28
4269,86,Roche,Large Pharma,4458,RG7636,RG7636,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4080,Melanoma,7/7/14 12:28
4269,86,Roche,Large Pharma,4458,RG7636,RG7636,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4080,Melanoma,7/7/14 12:28
4269,86,Roche,Large Pharma,4458,RG7636,RG7636,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4080,Melanoma,7/7/14 12:28
4270,67,Novartis,Large Pharma,4459,LFG316,LFG316,Antibody/Antibody Derivative,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4079,Age-related Macular Degeneration,7/7/14 12:28
4270,67,Novartis,Large Pharma,4459,LFG316,LFG316,Antibody/Antibody Derivative,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4079,Age-related Macular Degeneration,7/7/14 12:28
4270,67,Novartis,Large Pharma,4459,LFG316,LFG316,Antibody/Antibody Derivative,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4079,Age-related Macular Degeneration,7/7/14 12:28
4271,388,Lpath,Small Biotech,4460,iSONEP,sonepcizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4081,Age-related Macular Degeneration,7/7/14 12:28
4271,388,Lpath,Small Biotech,4460,iSONEP,sonepcizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4081,Age-related Macular Degeneration,7/7/14 12:28
4271,388,Lpath,Small Biotech,4460,iSONEP,sonepcizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4081,Age-related Macular Degeneration,7/7/14 12:28
4272,76,Pfizer,Large Pharma,4460,iSONEP,sonepcizumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4081,AMD,7/7/14 12:28
4272,76,Pfizer,Large Pharma,4460,iSONEP,sonepcizumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4081,AMD,7/7/14 12:28
4272,76,Pfizer,Large Pharma,4460,iSONEP,sonepcizumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4081,AMD,7/7/14 12:28
4273,2045,Advanced Cell Technology,Small Biotech,4461,MA09-hRPE,Embryonic stem-derived retinal pigment epithelial (RPE) cells ,Cell Therapy,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4082,AMD,7/7/14 12:28
4273,2045,Advanced Cell Technology,Small Biotech,4461,MA09-hRPE,Embryonic stem-derived retinal pigment epithelial (RPE) cells ,Cell Therapy,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4082,AMD,7/7/14 12:28
4273,2045,Advanced Cell Technology,Small Biotech,4461,MA09-hRPE,Embryonic stem-derived retinal pigment epithelial (RPE) cells ,Cell Therapy,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4082,AMD,7/7/14 12:28
4274,749,Oxford BioMedica,Small Biotech,4462,UshStat,UshStat,Cell Therapy,Phase II,In-House,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4083,Usher Syndrome,7/7/14 12:28
4274,749,Oxford BioMedica,Small Biotech,4462,UshStat,UshStat,Cell Therapy,Phase II,In-House,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4083,Usher Syndrome,7/7/14 12:28
4274,749,Oxford BioMedica,Small Biotech,4462,UshStat,UshStat,Cell Therapy,Phase II,In-House,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4083,Usher Syndrome,7/7/14 12:28
4275,1592,Replidyne,Small Biotech,4463,RT101,fenretinide ,Small Molecule (Chemical),Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4085,AMD,7/7/14 12:28
4275,1592,Replidyne,Small Biotech,4463,RT101,fenretinide ,Small Molecule (Chemical),Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4085,AMD,7/7/14 12:28
4275,1592,Replidyne,Small Biotech,4463,RT101,fenretinide ,Small Molecule (Chemical),Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4085,AMD,7/7/14 12:28
4277,24,Bristol-Myers Squibb,Large Pharma,4464,BMS-936564,Anti-CXCR4,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4086,Hematological Malignancies,7/7/14 12:28
4277,24,Bristol-Myers Squibb,Large Pharma,4464,BMS-936564,Anti-CXCR4,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4086,Hematological Malignancies,7/7/14 12:28
4277,24,Bristol-Myers Squibb,Large Pharma,4464,BMS-936564,Anti-CXCR4,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4086,Hematological Malignancies,7/7/14 12:28
4279,788,Alkermes,Small Biotech,4465,aripiprazole lauroxil,aripiprazole lauroxil / aripiprazole pro-drug depot,Small Molecule (Chemical),Phase III,In-House,Oct-15,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,6,48.85716,89.31430848,113.8284067,123.7180944,129.8352453,0,4087,Schizophrenia,7/7/14 12:28
4279,788,Alkermes,Small Biotech,4465,aripiprazole lauroxil,aripiprazole lauroxil / aripiprazole pro-drug depot,Small Molecule (Chemical),Phase III,In-House,Oct-15,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4087,Schizophrenia,7/7/14 12:28
4279,788,Alkermes,Small Biotech,4465,aripiprazole lauroxil,aripiprazole lauroxil / aripiprazole pro-drug depot,Small Molecule (Chemical),Phase III,In-House,Oct-15,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,6,48.85716,89.31430848,113.8284067,123.7180944,129.8352453,0,4087,Schizophrenia,7/7/14 12:28
4280,487,Cytokinetics,Small Biotech,4466,tirasemtiv,CK-2017357,Small Molecule (Chemical),Phase II,In-House,Sep-17,Apr-18,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,1.333332,9.388888444,16.55553265,22.22218234,0,4088,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4280,487,Cytokinetics,Small Biotech,4466,tirasemtiv,CK-2017357,Small Molecule (Chemical),Phase II,In-House,Sep-17,Apr-18,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,4.5,9,12,0,4088,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4280,487,Cytokinetics,Small Biotech,4466,tirasemtiv,CK-2017357,Small Molecule (Chemical),Phase II,In-House,Sep-17,Apr-18,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,1.333332,4.888888444,7.555532646,10.22218234,0,4088,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4281,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1795,Calsed,amrubicin,Small Molecule (Chemical),Filed,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,121,Small-Cell Lung Cancer,7/7/14 12:28
4281,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1795,Calsed,amrubicin,Small Molecule (Chemical),Filed,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,121,Small-Cell Lung Cancer,7/7/14 12:28
4281,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1795,Calsed,amrubicin,Small Molecule (Chemical),Filed,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,121,Small-Cell Lung Cancer,7/7/14 12:28
4282,55,Kowa,Regional & Specialty Pharma,4467,K115,K115,Small Molecule (Chemical),Filed,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4089,Glaucoma,7/7/14 12:28
4282,55,Kowa,Regional & Specialty Pharma,4467,K115,K115,Small Molecule (Chemical),Filed,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4089,Glaucoma,7/7/14 12:28
4282,55,Kowa,Regional & Specialty Pharma,4467,K115,K115,Small Molecule (Chemical),Filed,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4089,Glaucoma,7/7/14 12:28
4283,206,Cytos Biotechnology ,Small Biotech,4468,CYT003-QbG10,CYT003-QbG10,Vaccine,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4090,Asthma,7/7/14 12:28
4283,206,Cytos Biotechnology ,Small Biotech,4468,CYT003-QbG10,CYT003-QbG10,Vaccine,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4090,Asthma,7/7/14 12:28
4283,206,Cytos Biotechnology ,Small Biotech,4468,CYT003-QbG10,CYT003-QbG10,Vaccine,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4090,Asthma,7/7/14 12:28
4284,444,Xoma,Small Biotech,4471,gevokizumab,gevokizumab,Antibody/Antibody Derivative,Phase III,In-House,Apr-16,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,6,12.97674,22.95351725,39.41876377,48.25346688,0,4179,Uveitis,7/7/14 12:28
4284,444,Xoma,Small Biotech,4471,gevokizumab,gevokizumab,Antibody/Antibody Derivative,Phase III,In-House,Apr-16,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4179,Uveitis,7/7/14 12:28
4284,444,Xoma,Small Biotech,4471,gevokizumab,gevokizumab,Antibody/Antibody Derivative,Phase III,In-House,Apr-16,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,6,12.97674,22.95351725,39.41876377,48.25346688,0,4179,Uveitis,7/7/14 12:28
4285,444,Xoma,Small Biotech,4471,gevokizumab,gevokizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4179,Acne ,7/7/14 12:28
4285,444,Xoma,Small Biotech,4471,gevokizumab,gevokizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,160,Acne Treatments,73,Acne,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4179,Acne ,7/7/14 12:28
4285,444,Xoma,Small Biotech,4471,gevokizumab,gevokizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4179,Acne ,7/7/14 12:28
4287,76,Pfizer,Large Pharma,387,PF-4236921,anti-IL6,Small Molecule (Chemical),Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,878,Crohn's Disease,7/7/14 12:28
4287,76,Pfizer,Large Pharma,387,PF-4236921,anti-IL6,Small Molecule (Chemical),Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,878,Crohn's Disease,7/7/14 12:28
4287,76,Pfizer,Large Pharma,387,PF-4236921,anti-IL6,Small Molecule (Chemical),Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,878,Crohn's Disease,7/7/14 12:28
4288,2047,PolyMedix,Small Biotech,4602,brilacidin,PMX-30063,Small Molecule (Chemical),Phase II,,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4142,skin infections due to Staph aureus,7/7/14 12:28
4288,2047,PolyMedix,Small Biotech,4602,brilacidin,PMX-30063,Small Molecule (Chemical),Phase II,,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4142,skin infections due to Staph aureus,7/7/14 12:28
4288,2047,PolyMedix,Small Biotech,4602,brilacidin,PMX-30063,Small Molecule (Chemical),Phase II,,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4142,skin infections due to Staph aureus,7/7/14 12:28
4289,2048,Delenex Therapeutics,Small Biotech,4473,DLX-105,ESBA-105,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4092,Osteoarthritis,7/7/14 12:28
4289,2048,Delenex Therapeutics,Small Biotech,4473,DLX-105,ESBA-105,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4092,Osteoarthritis,7/7/14 12:28
4289,2048,Delenex Therapeutics,Small Biotech,4473,DLX-105,ESBA-105,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4092,Osteoarthritis,7/7/14 12:28
4290,70,Ono,Regional & Specialty Pharma,4474,salirasib,salirasib,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4093,Pancreatic Cancer,7/7/14 12:28
4290,70,Ono,Regional & Specialty Pharma,4474,salirasib,salirasib,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4093,Pancreatic Cancer,7/7/14 12:28
4290,70,Ono,Regional & Specialty Pharma,4474,salirasib,salirasib,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4093,Pancreatic Cancer,7/7/14 12:28
4291,70,Ono,Regional & Specialty Pharma,4475,ono-2952,ono-2952,Small Molecule (Chemical),Phase II,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4094,IBS-D,7/7/14 12:28
4291,70,Ono,Regional & Specialty Pharma,4475,ono-2952,ono-2952,Small Molecule (Chemical),Phase II,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4094,IBS-D,7/7/14 12:28
4291,70,Ono,Regional & Specialty Pharma,4475,ono-2952,ono-2952,Small Molecule (Chemical),Phase II,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4094,IBS-D,7/7/14 12:28
4292,70,Ono,Regional & Specialty Pharma,4476,ono-4053,ono-4053,Small Molecule (Chemical),Phase II,In-House,,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4095,Allergic Rhinitis,7/7/14 12:28
4292,70,Ono,Regional & Specialty Pharma,4476,ono-4053,ono-4053,Small Molecule (Chemical),Phase II,In-House,,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4095,Allergic Rhinitis,7/7/14 12:28
4292,70,Ono,Regional & Specialty Pharma,4476,ono-4053,ono-4053,Small Molecule (Chemical),Phase II,In-House,,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4095,Allergic Rhinitis,7/7/14 12:28
4293,70,Ono,Regional & Specialty Pharma,4477,ono-9054,ono-9054,Small Molecule (Chemical),Phase I,In-House,,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4096,glaucoma,7/7/14 12:28
4293,70,Ono,Regional & Specialty Pharma,4477,ono-9054,ono-9054,Small Molecule (Chemical),Phase I,In-House,,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4096,glaucoma,7/7/14 12:28
4293,70,Ono,Regional & Specialty Pharma,4477,ono-9054,ono-9054,Small Molecule (Chemical),Phase I,In-House,,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4096,glaucoma,7/7/14 12:28
4295,15,Astellas Pharma,Regional & Specialty Pharma,4480,ASP9226,ASP9226,Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4098,Neuropathic Pain,7/7/14 12:28
4295,15,Astellas Pharma,Regional & Specialty Pharma,4480,ASP9226,ASP9226,Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4098,Neuropathic Pain,7/7/14 12:28
4295,15,Astellas Pharma,Regional & Specialty Pharma,4480,ASP9226,ASP9226,Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4098,Neuropathic Pain,7/7/14 12:28
4297,15,Astellas Pharma,Regional & Specialty Pharma,4482,ASP-7991,ASP-7991,Small Molecule (Chemical),Phase II,In-House,,,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4100,Secondary hyperparathyroidism,7/7/14 12:28
4297,15,Astellas Pharma,Regional & Specialty Pharma,4482,ASP-7991,ASP-7991,Small Molecule (Chemical),Phase II,In-House,,,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4100,Secondary hyperparathyroidism,7/7/14 12:28
4297,15,Astellas Pharma,Regional & Specialty Pharma,4482,ASP-7991,ASP-7991,Small Molecule (Chemical),Phase II,In-House,,,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4100,Secondary hyperparathyroidism,7/7/14 12:28
4299,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4484,MT-3995,MT-3995,Small Molecule (Chemical),Phase I,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4102,Hypertension,7/7/14 12:28
4299,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4484,MT-3995,MT-3995,Small Molecule (Chemical),Phase I,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4102,Hypertension,7/7/14 12:28
4299,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4484,MT-3995,MT-3995,Small Molecule (Chemical),Phase I,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4102,Hypertension,7/7/14 12:28
4300,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4485,MP-157,MP-157,Small Molecule (Chemical),Phase I,In-House,,,,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4103,Hypertension,7/7/14 12:28
4300,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4485,MP-157,MP-157,Small Molecule (Chemical),Phase I,In-House,,,,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4103,Hypertension,7/7/14 12:28
4300,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4485,MP-157,MP-157,Small Molecule (Chemical),Phase I,In-House,,,,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4103,Hypertension,7/7/14 12:28
4301,2049,AIM Therapeutics,Small Biotech,4486,AIM-102,AIM-102,Synthetic Peptide,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,8,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4104,Asthma,7/7/14 12:28
4301,2049,AIM Therapeutics,Small Biotech,4486,AIM-102,AIM-102,Synthetic Peptide,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,8,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4104,Asthma,7/7/14 12:28
4301,2049,AIM Therapeutics,Small Biotech,4486,AIM-102,AIM-102,Synthetic Peptide,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,8,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4104,Asthma,7/7/14 12:28
4302,2050,BioMarck Pharmaceuticals,Small Biotech,4487,BIO-11006,BIO-11006,Synthetic Peptide,Phase II,Licensed (Development),,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4105,COPD,7/7/14 12:28
4302,2050,BioMarck Pharmaceuticals,Small Biotech,4487,BIO-11006,BIO-11006,Synthetic Peptide,Phase II,Licensed (Development),,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4105,COPD,7/7/14 12:28
4302,2050,BioMarck Pharmaceuticals,Small Biotech,4487,BIO-11006,BIO-11006,Synthetic Peptide,Phase II,Licensed (Development),,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4105,COPD,7/7/14 12:28
4303,53,Johnson & Johnson,Large Pharma,4488,CNTO-3157,CNTO-3157,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4106,Asthma,7/7/14 12:28
4303,53,Johnson & Johnson,Large Pharma,4488,CNTO-3157,CNTO-3157,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4106,Asthma,7/7/14 12:28
4303,53,Johnson & Johnson,Large Pharma,4488,CNTO-3157,CNTO-3157,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4106,Asthma,7/7/14 12:28
4304,2017,MorphoSys,Small Biotech,4488,CNTO-3157,CNTO-3157,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4106,Asthma,7/7/14 12:28
4304,2017,MorphoSys,Small Biotech,4488,CNTO-3157,CNTO-3157,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4106,Asthma,7/7/14 12:28
4304,2017,MorphoSys,Small Biotech,4488,CNTO-3157,CNTO-3157,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4106,Asthma,7/7/14 12:28
4305,2051,ZaBeCor Pharmaceutical Co,Small Biotech,4489,Excellair,Excellair,DNA/RNA Therapy,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4107,Asthma,7/7/14 12:28
4305,2051,ZaBeCor Pharmaceutical Co,Small Biotech,4489,Excellair,Excellair,DNA/RNA Therapy,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4107,Asthma,7/7/14 12:28
4305,2051,ZaBeCor Pharmaceutical Co,Small Biotech,4489,Excellair,Excellair,DNA/RNA Therapy,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4107,Asthma,7/7/14 12:28
4306,2331,Bioxyne,Small Biotech,4490,HI-1640V,HI-1640V,Vaccine,Phase II,Corporate Acquisition,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,12,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4108,COPD,7/7/14 12:28
4306,2331,Bioxyne,Small Biotech,4490,HI-1640V,HI-1640V,Vaccine,Phase II,Corporate Acquisition,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,12,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4108,COPD,7/7/14 12:28
4306,2331,Bioxyne,Small Biotech,4490,HI-1640V,HI-1640V,Vaccine,Phase II,Corporate Acquisition,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,12,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4108,COPD,7/7/14 12:28
4309,100,Takeda,Large Pharma,4493,MLN2480,MLN2480,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4111,Solid Tumor,7/7/14 12:28
4309,100,Takeda,Large Pharma,4493,MLN2480,MLN2480,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4111,Solid Tumor,7/7/14 12:28
4309,100,Takeda,Large Pharma,4493,MLN2480,MLN2480,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4111,Solid Tumor,7/7/14 12:28
4315,34,Daiichi-Sankyo,Regional & Specialty Pharma,4499,DS-2248,DS-2248,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4117,Cancer,7/7/14 12:28
4315,34,Daiichi-Sankyo,Regional & Specialty Pharma,4499,DS-2248,DS-2248,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4117,Cancer,7/7/14 12:28
4315,34,Daiichi-Sankyo,Regional & Specialty Pharma,4499,DS-2248,DS-2248,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4117,Cancer,7/7/14 12:28
4318,34,Daiichi-Sankyo,Regional & Specialty Pharma,4502,CS-4771,CS-4771,Small Molecule (Chemical),Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4120,Sepsis,7/7/14 12:28
4318,34,Daiichi-Sankyo,Regional & Specialty Pharma,4502,CS-4771,CS-4771,Small Molecule (Chemical),Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4120,Sepsis,7/7/14 12:28
4318,34,Daiichi-Sankyo,Regional & Specialty Pharma,4502,CS-4771,CS-4771,Small Molecule (Chemical),Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4120,Sepsis,7/7/14 12:28
4319,34,Daiichi-Sankyo,Regional & Specialty Pharma,4503,DS-8587,DS-8587,Small Molecule (Chemical),Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4121,Bacterial Infections,7/7/14 12:28
4319,34,Daiichi-Sankyo,Regional & Specialty Pharma,4503,DS-8587,DS-8587,Small Molecule (Chemical),Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4121,Bacterial Infections,7/7/14 12:28
4319,34,Daiichi-Sankyo,Regional & Specialty Pharma,4503,DS-8587,DS-8587,Small Molecule (Chemical),Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4121,Bacterial Infections,7/7/14 12:28
4320,34,Daiichi-Sankyo,Regional & Specialty Pharma,4504,PLX-5622,PLX-5622,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4122,Rheumatoid Arthritis,7/7/14 12:28
4320,34,Daiichi-Sankyo,Regional & Specialty Pharma,4504,PLX-5622,PLX-5622,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4122,Rheumatoid Arthritis,7/7/14 12:28
4320,34,Daiichi-Sankyo,Regional & Specialty Pharma,4504,PLX-5622,PLX-5622,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4122,Rheumatoid Arthritis,7/7/14 12:28
4321,34,Daiichi-Sankyo,Regional & Specialty Pharma,4505,SUN13837,SUN13837,Small Molecule (Chemical),Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4143,Spinal cord injury,7/7/14 12:28
4321,34,Daiichi-Sankyo,Regional & Specialty Pharma,4505,SUN13837,SUN13837,Small Molecule (Chemical),Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4143,Spinal cord injury,7/7/14 12:28
4321,34,Daiichi-Sankyo,Regional & Specialty Pharma,4505,SUN13837,SUN13837,Small Molecule (Chemical),Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4143,Spinal cord injury,7/7/14 12:28
4322,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4506,DSP-6952,DSP-6952,Small Molecule (Chemical),Phase II,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4123,IBS-C,7/7/14 12:28
4322,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4506,DSP-6952,DSP-6952,Small Molecule (Chemical),Phase II,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4123,IBS-C,7/7/14 12:28
4322,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4506,DSP-6952,DSP-6952,Small Molecule (Chemical),Phase II,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4123,IBS-C,7/7/14 12:28
4324,91,Santen,Regional & Specialty Pharma,4508,DE109,sirolimus opthalmic injection,Small Molecule (Chemical),Phase III,Licensed (Development),Mar-16,Jul-16,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,2.013544449,38.39158754,57.76217781,82.69278172,114.3779965,131.7356534,0,4125,Uveitis,7/7/14 12:28
4324,91,Santen,Regional & Specialty Pharma,4508,DE109,sirolimus opthalmic injection,Small Molecule (Chemical),Phase III,Licensed (Development),Mar-16,Jul-16,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,24.16253339,37.76096555,53.83203249,80.35453658,93.87600465,0,4125,Uveitis,7/7/14 12:28
4324,91,Santen,Regional & Specialty Pharma,4508,DE109,sirolimus opthalmic injection,Small Molecule (Chemical),Phase III,Licensed (Development),Mar-16,Jul-16,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,2.013544449,14.22905415,20.00121226,28.86074923,34.02345994,37.85964879,0,4125,Uveitis,7/7/14 12:28
4325,2053,Atlantic Healthcare,Regional & Specialty Pharma,4509,alicaforsen,ISIS 2302,DNA/RNA Therapy,Phase III,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4126,Crohn's Disease,7/7/14 12:28
4325,2053,Atlantic Healthcare,Regional & Specialty Pharma,4509,alicaforsen,ISIS 2302,DNA/RNA Therapy,Phase III,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4126,Crohn's Disease,7/7/14 12:28
4325,2053,Atlantic Healthcare,Regional & Specialty Pharma,4509,alicaforsen,ISIS 2302,DNA/RNA Therapy,Phase III,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4126,Crohn's Disease,7/7/14 12:28
4326,2054,Immune Response Biopharma,Small Biotech,4510,CrohnsVax,IR-7777,Vaccine,Phase I,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4127,Crohn's Disease,7/7/14 12:28
4326,2054,Immune Response Biopharma,Small Biotech,4510,CrohnsVax,IR-7777,Vaccine,Phase I,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4127,Crohn's Disease,7/7/14 12:28
4326,2054,Immune Response Biopharma,Small Biotech,4510,CrohnsVax,IR-7777,Vaccine,Phase I,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4127,Crohn's Disease,7/7/14 12:28
4327,26,Celgene,Regional & Specialty Pharma,4511,GED-0301,GED-0301,DNA/RNA Therapy,Phase II,Acquisition (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4128,Crohn's Disease,7/7/14 12:28
4327,26,Celgene,Regional & Specialty Pharma,4511,GED-0301,GED-0301,DNA/RNA Therapy,Phase II,Acquisition (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4128,Crohn's Disease,7/7/14 12:28
4327,26,Celgene,Regional & Specialty Pharma,4511,GED-0301,GED-0301,DNA/RNA Therapy,Phase II,Acquisition (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4128,Crohn's Disease,7/7/14 12:28
4328,444,Xoma,Small Biotech,4471,gevokizumab,gevokizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4179,osteoarthritis,7/7/14 12:28
4328,444,Xoma,Small Biotech,4471,gevokizumab,gevokizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4179,osteoarthritis,7/7/14 12:28
4328,444,Xoma,Small Biotech,4471,gevokizumab,gevokizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4179,osteoarthritis,7/7/14 12:28
4329,2033,NovImmune,Small Biotech,4441,NI-0401,IFNgamma,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4076,Transplant,7/7/14 12:28
4329,2033,NovImmune,Small Biotech,4441,NI-0401,IFNgamma,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4076,Transplant,7/7/14 12:28
4329,2033,NovImmune,Small Biotech,4441,NI-0401,IFNgamma,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4076,Transplant,7/7/14 12:28
4330,2055,Sterna Biologicals,,4512,SB-010,SB-010,DNA/RNA Therapy,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4129,Asthma,7/7/14 12:28
4330,2055,Sterna Biologicals,,4512,SB-010,SB-010,DNA/RNA Therapy,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4129,Asthma,7/7/14 12:28
4330,2055,Sterna Biologicals,,4512,SB-010,SB-010,DNA/RNA Therapy,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4129,Asthma,7/7/14 12:28
4331,2056,Stempeutics,Small Biotech,4513,Stempeucel,Stempeucel,Cell Therapy,Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4130,COPD,7/7/14 12:28
4331,2056,Stempeutics,Small Biotech,4513,Stempeucel,Stempeucel,Cell Therapy,Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4130,COPD,7/7/14 12:28
4331,2056,Stempeutics,Small Biotech,4513,Stempeucel,Stempeucel,Cell Therapy,Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4130,COPD,7/7/14 12:28
4332,1261,Cipla,Small Biotech,4513,Stempeucel,Stempeucel,Cell Therapy,Phase II,Licensed (Development),,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4130,COPD,7/7/14 12:28
4332,1261,Cipla,Small Biotech,4513,Stempeucel,Stempeucel,Cell Therapy,Phase II,Licensed (Development),,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4130,COPD,7/7/14 12:28
4332,1261,Cipla,Small Biotech,4513,Stempeucel,Stempeucel,Cell Therapy,Phase II,Licensed (Development),,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4130,COPD,7/7/14 12:28
4333,2057,Synairgen,Small Biotech,4514,SYN-101,SYN-101,Recombinant Protein,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4131,Asthma,7/7/14 12:28
4333,2057,Synairgen,Small Biotech,4514,SYN-101,SYN-101,Recombinant Protein,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4131,Asthma,7/7/14 12:28
4333,2057,Synairgen,Small Biotech,4514,SYN-101,SYN-101,Recombinant Protein,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4131,Asthma,7/7/14 12:28
4334,246,Senju,Regional & Specialty Pharma,4515,Aiphagan,brimonidine,Small Molecule (Chemical),Launched,Licensed (Development),,,N/A,Jun-21,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4132,Glaucoma,7/7/14 12:28
4334,246,Senju,Regional & Specialty Pharma,4515,Aiphagan,brimonidine,Small Molecule (Chemical),Launched,Licensed (Development),,,N/A,Jun-21,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4132,Glaucoma,7/7/14 12:28
4334,246,Senju,Regional & Specialty Pharma,4515,Aiphagan,brimonidine,Small Molecule (Chemical),Launched,Licensed (Development),,,N/A,Jun-21,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4132,Glaucoma,7/7/14 12:28
4338,46,GlaxoSmithKline,Large Pharma,4519,2140944,2140944,Small Molecule (Chemical),Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4135,Bacterial Infections,7/7/14 12:28
4338,46,GlaxoSmithKline,Large Pharma,4519,2140944,2140944,Small Molecule (Chemical),Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4135,Bacterial Infections,7/7/14 12:28
4338,46,GlaxoSmithKline,Large Pharma,4519,2140944,2140944,Small Molecule (Chemical),Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4135,Bacterial Infections,7/7/14 12:28
4339,2059,Opsona Therapeutics,Small Biotech,4518,OPN-305,OPN-305,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4136,Transplant Rejection,7/7/14 12:28
4339,2059,Opsona Therapeutics,Small Biotech,4518,OPN-305,OPN-305,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4136,Transplant Rejection,7/7/14 12:28
4339,2059,Opsona Therapeutics,Small Biotech,4518,OPN-305,OPN-305,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4136,Transplant Rejection,7/7/14 12:28
4341,713,Xencor,Small Biotech,4521,XmAb-5871,XmAb-5871,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4138,Rheumatoid Arthritis,7/7/14 12:28
4341,713,Xencor,Small Biotech,4521,XmAb-5871,XmAb-5871,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4138,Rheumatoid Arthritis,7/7/14 12:28
4341,713,Xencor,Small Biotech,4521,XmAb-5871,XmAb-5871,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4138,Rheumatoid Arthritis,7/7/14 12:28
4342,2054,Immune Response Biopharma,Small Biotech,4522,Zorcell,IR-502,Vaccine,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4139,Psoriasis,7/7/14 12:28
4342,2054,Immune Response Biopharma,Small Biotech,4522,Zorcell,IR-502,Vaccine,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4139,Psoriasis,7/7/14 12:28
4342,2054,Immune Response Biopharma,Small Biotech,4522,Zorcell,IR-502,Vaccine,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4139,Psoriasis,7/7/14 12:28
4343,67,Novartis,Large Pharma,4523,AL78898A,POT4,Synthetic Peptide,Phase II,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4140,AMD,7/7/14 12:28
4343,67,Novartis,Large Pharma,4523,AL78898A,POT4,Synthetic Peptide,Phase II,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4140,AMD,7/7/14 12:28
4343,67,Novartis,Large Pharma,4523,AL78898A,POT4,Synthetic Peptide,Phase II,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4140,AMD,7/7/14 12:28
4344,46,GlaxoSmithKline,Large Pharma,4524,darapladib,darapladib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4186,Diabetic Macular Edema,7/7/14 12:28
4344,46,GlaxoSmithKline,Large Pharma,4524,darapladib,darapladib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4186,Diabetic Macular Edema,7/7/14 12:28
4344,46,GlaxoSmithKline,Large Pharma,4524,darapladib,darapladib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4186,Diabetic Macular Edema,7/7/14 12:28
4346,46,GlaxoSmithKline,Large Pharma,1497,933776,933776,Antibody/Antibody Derivative,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4150,Geographic Retinal Atrophy,7/7/14 12:28
4346,46,GlaxoSmithKline,Large Pharma,1497,933776,933776,Antibody/Antibody Derivative,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4150,Geographic Retinal Atrophy,7/7/14 12:28
4346,46,GlaxoSmithKline,Large Pharma,1497,933776,933776,Antibody/Antibody Derivative,Phase II,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4150,Geographic Retinal Atrophy,7/7/14 12:28
4350,84,Recordati,Regional & Specialty Pharma,4532,REC-1819,REC-1819,Small Molecule (Chemical),Phase I,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4147,Overactive bladder,7/7/14 12:28
4350,84,Recordati,Regional & Specialty Pharma,4532,REC-1819,REC-1819,Small Molecule (Chemical),Phase I,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4147,Overactive bladder,7/7/14 12:28
4350,84,Recordati,Regional & Specialty Pharma,4532,REC-1819,REC-1819,Small Molecule (Chemical),Phase I,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4147,Overactive bladder,7/7/14 12:28
4351,84,Recordati,Regional & Specialty Pharma,4533,REC-0438,REC-0438,Small Molecule (Chemical),Phase I,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4148,Overactive bladder,7/7/14 12:28
4351,84,Recordati,Regional & Specialty Pharma,4533,REC-0438,REC-0438,Small Molecule (Chemical),Phase I,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4148,Overactive bladder,7/7/14 12:28
4351,84,Recordati,Regional & Specialty Pharma,4533,REC-0438,REC-0438,Small Molecule (Chemical),Phase I,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4148,Overactive bladder,7/7/14 12:28
4352,2221,AbbVie,Large Pharma,4534,ABT-719,melanocyte-stimulating hormone peptide analog,Synthetic Peptide,Phase II,Acquisition (Development),,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4149,Acute Kidney Injury,7/7/14 12:28
4352,2221,AbbVie,Large Pharma,4534,ABT-719,melanocyte-stimulating hormone peptide analog,Synthetic Peptide,Phase II,Acquisition (Development),,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4149,Acute Kidney Injury,7/7/14 12:28
4352,2221,AbbVie,Large Pharma,4534,ABT-719,melanocyte-stimulating hormone peptide analog,Synthetic Peptide,Phase II,Acquisition (Development),,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4149,Acute Kidney Injury,7/7/14 12:28
4353,67,Novartis,Large Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-12,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
4353,67,Novartis,Large Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-12,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
4353,67,Novartis,Large Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-12,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
4355,95,Shionogi,Regional & Specialty Pharma,1437,Vyvanse / Elvanse,lisdexamphetamine,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,121,Stimulants,37,ADHD,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1274,ADHD,7/7/14 12:28
4355,95,Shionogi,Regional & Specialty Pharma,1437,Vyvanse / Elvanse,lisdexamphetamine,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,121,Stimulants,37,ADHD,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1274,ADHD,7/7/14 12:28
4355,95,Shionogi,Regional & Specialty Pharma,1437,Vyvanse / Elvanse,lisdexamphetamine,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,121,Stimulants,37,ADHD,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1274,ADHD,7/7/14 12:28
4356,95,Shionogi,Regional & Specialty Pharma,4538,OxiFast,oxycodone - injectable,Small Molecule (Chemical),Launched,Licensed (Development),,May-12,,Jun-19,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,5.307259082,7.6513162,10.9241667,16.36418324,19.40530446,22.07029943,24.40328544,26.20523646,27.69894568,20.1760916,4151,Cancer pain,7/7/14 12:28
4356,95,Shionogi,Regional & Specialty Pharma,4538,OxiFast,oxycodone - injectable,Small Molecule (Chemical),Launched,Licensed (Development),,May-12,,Jun-19,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,5.307259082,7.6513162,10.9241667,16.36418324,19.40530446,22.07029943,24.40328544,26.20523646,27.69894568,20.1760916,4151,Cancer pain,7/7/14 12:28
4356,95,Shionogi,Regional & Specialty Pharma,4538,OxiFast,oxycodone - injectable,Small Molecule (Chemical),Launched,Licensed (Development),,May-12,,Jun-19,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4151,Cancer pain,7/7/14 12:28
4357,95,Shionogi,Regional & Specialty Pharma,4539,S-117957,S-117957,Small Molecule (Chemical),Phase II,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4152,Neuropathic pain,7/7/14 12:28
4357,95,Shionogi,Regional & Specialty Pharma,4539,S-117957,S-117957,Small Molecule (Chemical),Phase II,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4152,Neuropathic pain,7/7/14 12:28
4357,95,Shionogi,Regional & Specialty Pharma,4539,S-117957,S-117957,Small Molecule (Chemical),Phase II,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4152,Neuropathic pain,7/7/14 12:28
4358,108,Vertex,Regional & Specialty Pharma,4541,VX-135,ALS-2200,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4153,Hepatitis C,7/7/14 12:28
4358,108,Vertex,Regional & Specialty Pharma,4541,VX-135,ALS-2200,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4153,Hepatitis C,7/7/14 12:28
4358,108,Vertex,Regional & Specialty Pharma,4541,VX-135,ALS-2200,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4153,Hepatitis C,7/7/14 12:28
4361,24,Bristol-Myers Squibb,Large Pharma,4553,GPR119 agonists,GPR119 agonists,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4156,Type II Diabetes,7/7/14 12:28
4361,24,Bristol-Myers Squibb,Large Pharma,4553,GPR119 agonists,GPR119 agonists,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4156,Type II Diabetes,7/7/14 12:28
4361,24,Bristol-Myers Squibb,Large Pharma,4553,GPR119 agonists,GPR119 agonists,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4156,Type II Diabetes,7/7/14 12:28
4362,19,Bayer,Large Pharma,4554,BAY 1026153,BAY 1026153,Small Molecule (Chemical),Phase I,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4157,Endometriosis,7/7/14 12:28
4362,19,Bayer,Large Pharma,4554,BAY 1026153,BAY 1026153,Small Molecule (Chemical),Phase I,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4157,Endometriosis,7/7/14 12:28
4362,19,Bayer,Large Pharma,4554,BAY 1026153,BAY 1026153,Small Molecule (Chemical),Phase I,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4157,Endometriosis,7/7/14 12:28
4363,8,Allergan,Regional & Specialty Pharma,4555,bimatoprost,bimatoprost,Small Molecule (Chemical),Phase II,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4158,Alopecia (androgenic),7/7/14 12:28
4363,8,Allergan,Regional & Specialty Pharma,4555,bimatoprost,bimatoprost,Small Molecule (Chemical),Phase II,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4158,Alopecia (androgenic),7/7/14 12:28
4363,8,Allergan,Regional & Specialty Pharma,4555,bimatoprost,bimatoprost,Small Molecule (Chemical),Phase II,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4158,Alopecia (androgenic),7/7/14 12:28
4364,2065,Furiex,Small Biotech,4567,eluxadoline,eluxadoline,Small Molecule (Chemical),Phase III,Licensed (Development),Nov-15,Aug-15,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,13.833354,85.05574331,188.3895242,291.7236311,376.7196722,459.4117225,0,4159,IBS-D,7/7/14 12:28
4364,2065,Furiex,Small Biotech,4567,eluxadoline,eluxadoline,Small Molecule (Chemical),Phase III,Licensed (Development),Nov-15,Aug-15,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,5.833338,23.72226064,47.05571344,70.38923006,88.184893,104.6365546,0,4159,IBS-D,7/7/14 12:28
4364,2065,Furiex,Small Biotech,4567,eluxadoline,eluxadoline,Small Molecule (Chemical),Phase III,Licensed (Development),Nov-15,Aug-15,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,8.000016,61.33348267,141.3338108,221.334401,288.5347792,354.7751679,0,4159,IBS-D,7/7/14 12:28
4365,1513,Lexicon Genetics,Small Biotech,4568,LX-1033,LX-1033,Small Molecule (Chemical),Phase II,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4160,IBS-D,7/7/14 12:28
4365,1513,Lexicon Genetics,Small Biotech,4568,LX-1033,LX-1033,Small Molecule (Chemical),Phase II,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4160,IBS-D,7/7/14 12:28
4365,1513,Lexicon Genetics,Small Biotech,4568,LX-1033,LX-1033,Small Molecule (Chemical),Phase II,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4160,IBS-D,7/7/14 12:28
4366,63,Merck KGaA,Regional & Specialty Pharma,4569,TH-302,TH-302,Small Molecule (Chemical),Phase III,Licensed (Development),Aug-16,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,24.90058367,76.36187292,116.2029165,156.0442484,185.5599143,0,4162,Pancreatic Cancer,7/7/14 12:28
4366,63,Merck KGaA,Regional & Specialty Pharma,4569,TH-302,TH-302,Small Molecule (Chemical),Phase III,Licensed (Development),Aug-16,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4162,Pancreatic Cancer,7/7/14 12:28
4366,63,Merck KGaA,Regional & Specialty Pharma,4569,TH-302,TH-302,Small Molecule (Chemical),Phase III,Licensed (Development),Aug-16,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,24.90058367,76.36187292,116.2029165,156.0442484,185.5599143,0,4162,Pancreatic Cancer,7/7/14 12:28
4367,76,Pfizer,Large Pharma,4570,PF-05280586,rituximab biosimilar,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4163,Rheumatoid arthritis,7/7/14 12:28
4367,76,Pfizer,Large Pharma,4570,PF-05280586,rituximab biosimilar,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4163,Rheumatoid arthritis,7/7/14 12:28
4367,76,Pfizer,Large Pharma,4570,PF-05280586,rituximab biosimilar,Antibody/Antibody Derivative,Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4163,Rheumatoid arthritis,7/7/14 12:28
4369,24,Bristol-Myers Squibb,Large Pharma,4580,nivolumab,nivolumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Apr-15,Jun-15,Apr-27,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,134.7,353.348125,773.2848805,1572.697689,2084.153167,2499.851316,0,815,Non-small-cell Lung Cancer,7/7/14 12:28
4369,24,Bristol-Myers Squibb,Large Pharma,4580,nivolumab,nivolumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Apr-15,Jun-15,Apr-27,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,69.7,150.069095,347.8426162,618.562925,811.9442856,974.440042,0,815,Non-small-cell Lung Cancer,7/7/14 12:28
4369,24,Bristol-Myers Squibb,Large Pharma,4580,nivolumab,nivolumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Apr-15,Jun-15,Apr-27,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,65,203.27903,425.4422643,954.1347636,1272.208881,1525.411274,0,815,Non-small-cell Lung Cancer,7/7/14 12:28
4370,19,Bayer,Large Pharma,4581,vericiguat,vericiguat,Small Molecule (Chemical),Phase II,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4165,Heart Failure,7/7/14 12:28
4370,19,Bayer,Large Pharma,4581,vericiguat,vericiguat,Small Molecule (Chemical),Phase II,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4165,Heart Failure,7/7/14 12:28
4370,19,Bayer,Large Pharma,4581,vericiguat,vericiguat,Small Molecule (Chemical),Phase II,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4165,Heart Failure,7/7/14 12:28
4371,19,Bayer,Large Pharma,4582,Vasopressin Receptor Antagonist ,BAY86-8050,Small Molecule (Chemical),Phase I,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4166,Heart Failure,7/7/14 12:28
4371,19,Bayer,Large Pharma,4582,Vasopressin Receptor Antagonist ,BAY86-8050,Small Molecule (Chemical),Phase I,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4166,Heart Failure,7/7/14 12:28
4371,19,Bayer,Large Pharma,4582,Vasopressin Receptor Antagonist ,BAY86-8050,Small Molecule (Chemical),Phase I,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4166,Heart Failure,7/7/14 12:28
4372,19,Bayer,Large Pharma,4583,Partial Adenosine A1 Agonist ,BAY1067197,Small Molecule (Chemical),Phase I,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4167,Heart Failure,7/7/14 12:28
4372,19,Bayer,Large Pharma,4583,Partial Adenosine A1 Agonist ,BAY1067197,Small Molecule (Chemical),Phase I,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4167,Heart Failure,7/7/14 12:28
4372,19,Bayer,Large Pharma,4583,Partial Adenosine A1 Agonist ,BAY1067197,Small Molecule (Chemical),Phase I,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4167,Heart Failure,7/7/14 12:28
4374,89,Sanofi,Large Pharma,4588,SAR391786,REGN1033,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4169,Post-orthopedic surgery rehabilitation,7/7/14 12:28
4374,89,Sanofi,Large Pharma,4588,SAR391786,REGN1033,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4169,Post-orthopedic surgery rehabilitation,7/7/14 12:28
4374,89,Sanofi,Large Pharma,4588,SAR391786,REGN1033,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4169,Post-orthopedic surgery rehabilitation,7/7/14 12:28
4375,89,Sanofi,Large Pharma,4589,SAR228810,SAR228810,Antibody/Antibody Derivative,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4170,Alzheimer's Disease,7/7/14 12:28
4375,89,Sanofi,Large Pharma,4589,SAR228810,SAR228810,Antibody/Antibody Derivative,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4170,Alzheimer's Disease,7/7/14 12:28
4375,89,Sanofi,Large Pharma,4589,SAR228810,SAR228810,Antibody/Antibody Derivative,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4170,Alzheimer's Disease,7/7/14 12:28
4377,2068,Nabriva Therapeutics,Small Biotech,4595,BC-3781,BC-3781,Small Molecule (Chemical),Phase II,In-House,Jan-20,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4172,Bacterial infections,7/7/14 12:28
4377,2068,Nabriva Therapeutics,Small Biotech,4595,BC-3781,BC-3781,Small Molecule (Chemical),Phase II,In-House,Jan-20,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4172,Bacterial infections,7/7/14 12:28
4377,2068,Nabriva Therapeutics,Small Biotech,4595,BC-3781,BC-3781,Small Molecule (Chemical),Phase II,In-House,Jan-20,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4172,Bacterial infections,7/7/14 12:28
4378,42,Forest,Regional & Specialty Pharma,4595,BC-3781,BC-3781,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4172,bacterial infection,7/7/14 12:28
4378,42,Forest,Regional & Specialty Pharma,4595,BC-3781,BC-3781,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4172,bacterial infection,7/7/14 12:28
4378,42,Forest,Regional & Specialty Pharma,4595,BC-3781,BC-3781,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4172,bacterial infection,7/7/14 12:28
4380,45,Gilead,Regional & Specialty Pharma,4597,Ranolazine + Dronedarone ,Ranolazine + Dronedarone ,Small Molecule (Chemical),Phase II,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4174,Atrial Fibrillation,7/7/14 12:28
4380,45,Gilead,Regional & Specialty Pharma,4597,Ranolazine + Dronedarone ,Ranolazine + Dronedarone ,Small Molecule (Chemical),Phase II,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4174,Atrial Fibrillation,7/7/14 12:28
4380,45,Gilead,Regional & Specialty Pharma,4597,Ranolazine + Dronedarone ,Ranolazine + Dronedarone ,Small Molecule (Chemical),Phase II,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4174,Atrial Fibrillation,7/7/14 12:28
4381,15,Astellas Pharma,Regional & Specialty Pharma,4599,Quattrovac ,IPV / DPT vaccine,Vaccine,Launched,Licensed (Development),,Nov-12,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,Global,Sales,0,0,0,6.553837041,14.85492901,26.95382304,46.48025061,57.16764279,66.70262501,75.017921,81.42685577,86.75109261,28.67264531,4177, IPV /DPT vaccine,7/7/14 12:28
4381,15,Astellas Pharma,Regional & Specialty Pharma,4599,Quattrovac ,IPV / DPT vaccine,Vaccine,Launched,Licensed (Development),,Nov-12,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,ROW,Sales,0,0,0,6.553837041,14.85492901,26.95382304,46.48025061,57.16764279,66.70262501,75.017921,81.42685577,86.75109261,28.67264531,4177, IPV /DPT vaccine,7/7/14 12:28
4381,15,Astellas Pharma,Regional & Specialty Pharma,4599,Quattrovac ,IPV / DPT vaccine,Vaccine,Launched,Licensed (Development),,Nov-12,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4177, IPV /DPT vaccine,7/7/14 12:28
4382,39,Eli Lilly,Large Pharma,4343,ixekizumab,LY-2439821,Antibody/Antibody Derivative,Phase III,In-House,Sep-15,Sep-15,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,14.999985,69.99998,145.0000586,219.9998889,257.4720782,287.1741343,0,128,Psoriasis,7/7/14 12:28
4382,39,Eli Lilly,Large Pharma,4343,ixekizumab,LY-2439821,Antibody/Antibody Derivative,Phase III,In-House,Sep-15,Sep-15,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,8.333325,38.88887778,80.5555881,122.2221605,143.9165859,161.3408755,0,128,Psoriasis,7/7/14 12:28
4382,39,Eli Lilly,Large Pharma,4343,ixekizumab,LY-2439821,Antibody/Antibody Derivative,Phase III,In-House,Sep-15,Sep-15,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,6.66666,31.11110222,64.44447048,97.77772839,113.5554923,125.8332588,0,128,Psoriasis,7/7/14 12:28
4383,39,Eli Lilly,Large Pharma,4600,IMC-CS4,LY3022855,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4175,Cancer,7/7/14 12:28
4383,39,Eli Lilly,Large Pharma,4600,IMC-CS4,LY3022855,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4175,Cancer,7/7/14 12:28
4383,39,Eli Lilly,Large Pharma,4600,IMC-CS4,LY3022855,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4175,Cancer,7/7/14 12:28
4385,2065,Furiex,Small Biotech,4601,avarofloxacin,JnJ-Q2,Small Molecule (Chemical),Phase II,Licensed (Development),Jul-16,Jul-17,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,8,24.83336,41.333385,56.66663083,62.66664333,0,4192,bacterial infections including cSSSI CAP,7/7/14 12:28
4385,2065,Furiex,Small Biotech,4601,avarofloxacin,JnJ-Q2,Small Molecule (Chemical),Phase II,Licensed (Development),Jul-16,Jul-17,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,3.5,9.333345,14.0000175,18.66664333,0,4192,bacterial infections including cSSSI CAP,7/7/14 12:28
4385,2065,Furiex,Small Biotech,4601,avarofloxacin,JnJ-Q2,Small Molecule (Chemical),Phase II,Licensed (Development),Jul-16,Jul-17,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,8,21.33336,32.00004,42.66661333,44,0,4192,bacterial infections including cSSSI CAP,7/7/14 12:28
4386,21,Biogen Idec,Regional & Specialty Pharma,4603,ISIS-SMN,SMN-Rx,DNA/RNA Therapy,Phase II,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4182,Spinal Muscular Atrophy,7/7/14 12:28
4386,21,Biogen Idec,Regional & Specialty Pharma,4603,ISIS-SMN,SMN-Rx,DNA/RNA Therapy,Phase II,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4182,Spinal Muscular Atrophy,7/7/14 12:28
4386,21,Biogen Idec,Regional & Specialty Pharma,4603,ISIS-SMN,SMN-Rx,DNA/RNA Therapy,Phase II,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4182,Spinal Muscular Atrophy,7/7/14 12:28
4387,21,Biogen Idec,Regional & Specialty Pharma,4604,STX-100,STX-100,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4183,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
4387,21,Biogen Idec,Regional & Specialty Pharma,4604,STX-100,STX-100,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4183,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
4387,21,Biogen Idec,Regional & Specialty Pharma,4604,STX-100,STX-100,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4183,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
4388,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4605,DSP-2230,DSP-2230,Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4193,Neuropathic Pain,7/7/14 12:28
4388,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4605,DSP-2230,DSP-2230,Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4193,Neuropathic Pain,7/7/14 12:28
4388,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4605,DSP-2230,DSP-2230,Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4193,Neuropathic Pain,7/7/14 12:28
4389,96,Shire,Regional & Specialty Pharma,4606,Vascugel,,Cell Therapy,Phase II,Acquisition (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4195,Hemodialysis Access,7/7/14 12:28
4389,96,Shire,Regional & Specialty Pharma,4606,Vascugel,,Cell Therapy,Phase II,Acquisition (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4195,Hemodialysis Access,7/7/14 12:28
4389,96,Shire,Regional & Specialty Pharma,4606,Vascugel,,Cell Therapy,Phase II,Acquisition (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4195,Hemodialysis Access,7/7/14 12:28
4390,102,Teva,Regional & Specialty Pharma,3980,Adasuve,staccato loxapine,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-14,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,12.48,27.1623456,36.85278402,43.16603445,46.76612479,49.01896798,50.4066075,0,4194,Schizophrenia,7/7/14 12:28
4390,102,Teva,Regional & Specialty Pharma,3980,Adasuve,staccato loxapine,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-14,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4194,Schizophrenia,7/7/14 12:28
4390,102,Teva,Regional & Specialty Pharma,3980,Adasuve,staccato loxapine,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-14,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,0,0,0,0,12.48,27.1623456,36.85278402,43.16603445,46.76612479,49.01896798,50.4066075,0,4194,Schizophrenia,7/7/14 12:28
4391,869,Grupo Ferrer,Regional & Specialty Pharma,3980,Adasuve,staccato loxapine,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-13,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,2,Global,Sales,0,0,0,0,1.670852724,3.500302789,4.967244684,7.334732845,8.329591177,9.080123173,9.653733738,10.00920201,29.14148813,4194,Schizophrenia,7/7/14 12:28
4391,869,Grupo Ferrer,Regional & Specialty Pharma,3980,Adasuve,staccato loxapine,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-13,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,2,ROW,Sales,0,0,0,0,1.670852724,3.500302789,4.967244684,7.334732845,8.329591177,9.080123173,9.653733738,10.00920201,29.14148813,4194,Schizophrenia,7/7/14 12:28
4391,869,Grupo Ferrer,Regional & Specialty Pharma,3980,Adasuve,staccato loxapine,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-13,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4194,Schizophrenia,7/7/14 12:28
4393,207,CytRx,Regional & Specialty Pharma,4609,bafetinib,bafetinib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4197,Chronic Myeloid Leukemia,7/7/14 12:28
4393,207,CytRx,Regional & Specialty Pharma,4609,bafetinib,bafetinib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4197,Chronic Myeloid Leukemia,7/7/14 12:28
4393,207,CytRx,Regional & Specialty Pharma,4609,bafetinib,bafetinib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4197,Chronic Myeloid Leukemia,7/7/14 12:28
4395,61,Merck & Co,Large Pharma,4613,letermovir,AIC246,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4199,CMV prophylaxis,7/7/14 12:28
4395,61,Merck & Co,Large Pharma,4613,letermovir,AIC246,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4199,CMV prophylaxis,7/7/14 12:28
4395,61,Merck & Co,Large Pharma,4613,letermovir,AIC246,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4199,CMV prophylaxis,7/7/14 12:28
4396,485,Medtronic,Small Biotech,4228,InFuse,rhBMP-2,Recombinant Protein,Launched,Licensed (Marketed),Jul-02,Jul-03,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Sales,764,773,760,624,528,437.92,352.828,283.424,221.55552,165.980448,118.265344,85.18232832,-22.94219655,1421,Bone Synthesis,7/7/14 12:28
4396,485,Medtronic,Small Biotech,4228,InFuse,rhBMP-2,Recombinant Protein,Launched,Licensed (Marketed),Jul-02,Jul-03,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Sales,294,315,325,284,240,197.2,158.7,127.6,99.8,74.5,53.2,43.4,-21.67560789,1421,Bone Synthesis,7/7/14 12:28
4396,485,Medtronic,Small Biotech,4228,InFuse,rhBMP-2,Recombinant Protein,Launched,Licensed (Marketed),Jul-02,Jul-03,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Sales,470,458,435,340,288,240.72,194.128,155.824,121.75552,91.480448,65.065344,41.78232832,-24.10228299,1421,Bone Synthesis,7/7/14 12:28
4397,189,Valeant,Regional & Specialty Pharma,332,Xyrem,sodium oxybate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-07,,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1638,Cataplexy,7/7/14 12:28
4397,189,Valeant,Regional & Specialty Pharma,332,Xyrem,sodium oxybate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-07,,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1638,Cataplexy,7/7/14 12:28
4397,189,Valeant,Regional & Specialty Pharma,332,Xyrem,sodium oxybate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-07,,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1638,Cataplexy,7/7/14 12:28
4398,696,Nippon Shinyaku,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Development),,,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,280,Alcohol Addiction,7/7/14 12:28
4398,696,Nippon Shinyaku,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Development),,,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,280,Alcohol Addiction,7/7/14 12:28
4398,696,Nippon Shinyaku,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Development),,,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,280,Alcohol Addiction,7/7/14 12:28
4399,10,Almirall,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-97,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,280,Alcohol Addiction,7/7/14 12:28
4399,10,Almirall,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-97,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,280,Alcohol Addiction,7/7/14 12:28
4399,10,Almirall,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-97,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,280,Alcohol Addiction,7/7/14 12:28
4400,46,GlaxoSmithKline,Large Pharma,4615,raxibacumab,raxibacumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4200,anthrax,7/7/14 12:28
4400,46,GlaxoSmithKline,Large Pharma,4615,raxibacumab,raxibacumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4200,anthrax,7/7/14 12:28
4400,46,GlaxoSmithKline,Large Pharma,4615,raxibacumab,raxibacumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4200,anthrax,7/7/14 12:28
4401,1706,Covidien,Small Biotech,3254,Pennsaid,diclofenac sodium - topical,Small Molecule (Chemical),Launched,Licensed (Development),Apr-10,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2325,Osteoarthritis Pain,7/7/14 12:28
4401,1706,Covidien,Small Biotech,3254,Pennsaid,diclofenac sodium - topical,Small Molecule (Chemical),Launched,Licensed (Development),Apr-10,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2325,Osteoarthritis Pain,7/7/14 12:28
4401,1706,Covidien,Small Biotech,3254,Pennsaid,diclofenac sodium - topical,Small Molecule (Chemical),Launched,Licensed (Development),Apr-10,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2325,Osteoarthritis Pain,7/7/14 12:28
4402,15,Astellas Pharma,Regional & Specialty Pharma,597,Caduet,atorvastatin + amlodipine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-09,N/A,Dec-14,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,62.13184067,120.0203368,111.3788704,120.8967012,114.2531653,112.5920064,110.6207912,108.8048578,105.6759045,101.744401,-1.284165462,276,hypertension - hypercholesterolemia,7/7/14 12:28
4402,15,Astellas Pharma,Regional & Specialty Pharma,597,Caduet,atorvastatin + amlodipine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-09,N/A,Dec-14,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,62.13184067,120.0203368,111.3788704,120.8967012,114.2531653,112.5920064,110.6207912,108.8048578,105.6759045,101.744401,-1.284165462,276,hypertension - hypercholesterolemia,7/7/14 12:28
4402,15,Astellas Pharma,Regional & Specialty Pharma,597,Caduet,atorvastatin + amlodipine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-09,N/A,Dec-14,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,276,hypertension - hypercholesterolemia,7/7/14 12:28
4403,67,Novartis,Large Pharma,831,QAX576,QAX576,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,946,Asthma,7/7/14 12:28
4403,67,Novartis,Large Pharma,831,QAX576,QAX576,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,946,Asthma,7/7/14 12:28
4403,67,Novartis,Large Pharma,831,QAX576,QAX576,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,946,Asthma,7/7/14 12:28
4404,370,Global Alliance for TB Drug Development,Small Biotech,4617,PA-824,PA-824,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4201,tuberculosis,7/7/14 12:28
4404,370,Global Alliance for TB Drug Development,Small Biotech,4617,PA-824,PA-824,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4201,tuberculosis,7/7/14 12:28
4404,370,Global Alliance for TB Drug Development,Small Biotech,4617,PA-824,PA-824,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4201,tuberculosis,7/7/14 12:28
4405,53,Johnson & Johnson,Large Pharma,1289,Vivitrol,naltrexone depot,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-09,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1264,Alcohol Addiction,7/7/14 12:28
4405,53,Johnson & Johnson,Large Pharma,1289,Vivitrol,naltrexone depot,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-09,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1264,Alcohol Addiction,7/7/14 12:28
4405,53,Johnson & Johnson,Large Pharma,1289,Vivitrol,naltrexone depot,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-09,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1264,Alcohol Addiction,7/7/14 12:28
4406,1,Abbott,Regional & Specialty Pharma,907,Amitiza,lubiprostone,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-12,N/A,Dec-23,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,5,15.1,34.795685,54.49143454,63.37972467,70.52572814,75.61504748,78.84810684,81.13436993,27.15052862,1532,IBS-C,7/7/14 12:28
4406,1,Abbott,Regional & Specialty Pharma,907,Amitiza,lubiprostone,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-12,N/A,Dec-23,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,5,15.1,34.795685,54.49143454,63.37972467,70.52572814,75.61504748,78.84810684,81.13436993,27.15052862,1532,IBS-C,7/7/14 12:28
4406,1,Abbott,Regional & Specialty Pharma,907,Amitiza,lubiprostone,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-12,N/A,Dec-23,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1532,IBS-C,7/7/14 12:28
4407,53,Johnson & Johnson,Large Pharma,4621,JNJ-54452840,COR-1,Synthetic Peptide,Phase II,Acquisition (Development),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4202,Heart failure,7/7/14 12:28
4407,53,Johnson & Johnson,Large Pharma,4621,JNJ-54452840,COR-1,Synthetic Peptide,Phase II,Acquisition (Development),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4202,Heart failure,7/7/14 12:28
4407,53,Johnson & Johnson,Large Pharma,4621,JNJ-54452840,COR-1,Synthetic Peptide,Phase II,Acquisition (Development),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4202,Heart failure,7/7/14 12:28
4409,61,Merck & Co,Large Pharma,4623,CMX157,CMX157,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4203,HIV,7/7/14 12:28
4409,61,Merck & Co,Large Pharma,4623,CMX157,CMX157,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4203,HIV,7/7/14 12:28
4409,61,Merck & Co,Large Pharma,4623,CMX157,CMX157,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4203,HIV,7/7/14 12:28
4410,46,GlaxoSmithKline,Large Pharma,4624,WBI-1001,WBI-1001,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4204,cytokine modulator for Psoriasis,7/7/14 12:28
4410,46,GlaxoSmithKline,Large Pharma,4624,WBI-1001,WBI-1001,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4204,cytokine modulator for Psoriasis,7/7/14 12:28
4410,46,GlaxoSmithKline,Large Pharma,4624,WBI-1001,WBI-1001,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4204,cytokine modulator for Psoriasis,7/7/14 12:28
4411,68,Novo Nordisk,Regional & Specialty Pharma,4626,liraglutide 3mg,liraglutide,Synthetic Peptide,Filed,Licensed (Development),Dec-14,Dec-14,,,80,Obesity Treatments,38,Obesity,8,Metabolism,1,Global,Sales,0,0,0,0,0,8.057799267,110.1235252,271.2793933,432.4356297,562.2315188,678.6123101,782.1006378,0,4442,Obesity,7/7/14 12:28
4411,68,Novo Nordisk,Regional & Specialty Pharma,4626,liraglutide 3mg,liraglutide,Synthetic Peptide,Filed,Licensed (Development),Dec-14,Dec-14,,,80,Obesity Treatments,38,Obesity,8,Metabolism,1,ROW,Sales,0,0,0,0,0,2.87884541,39.34431657,96.92118288,154.4981808,197.1819032,237.2861703,272.7842902,0,4442,Obesity,7/7/14 12:28
4411,68,Novo Nordisk,Regional & Specialty Pharma,4626,liraglutide 3mg,liraglutide,Synthetic Peptide,Filed,Licensed (Development),Dec-14,Dec-14,,,80,Obesity Treatments,38,Obesity,8,Metabolism,1,US,Sales,0,0,0,0,0,5.178953857,70.77920868,174.3582104,277.9374489,365.0496156,441.3261398,509.3163476,0,4442,Obesity,7/7/14 12:28
4412,61,Merck & Co,Large Pharma,4628,doravirine,doravirine,Small Molecule (Chemical),Phase II,In-House,,,,,91,NNRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4205,HIV,7/7/14 12:28
4412,61,Merck & Co,Large Pharma,4628,doravirine,doravirine,Small Molecule (Chemical),Phase II,In-House,,,,,91,NNRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4205,HIV,7/7/14 12:28
4412,61,Merck & Co,Large Pharma,4628,doravirine,doravirine,Small Molecule (Chemical),Phase II,In-House,,,,,91,NNRTIs,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4205,HIV,7/7/14 12:28
4414,86,Roche,Large Pharma,4634,RG7741,GDC0575,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4207,Cancer,7/7/14 12:28
4414,86,Roche,Large Pharma,4634,RG7741,GDC0575,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4207,Cancer,7/7/14 12:28
4414,86,Roche,Large Pharma,4634,RG7741,GDC0575,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4207,Cancer,7/7/14 12:28
4416,23,Boehringer Ingelheim,Large Pharma,4638,empagliflozin + metformin,empagliflozin + metformin,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4210,Type II Diabetes,7/7/14 12:28
4416,23,Boehringer Ingelheim,Large Pharma,4638,empagliflozin + metformin,empagliflozin + metformin,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4210,Type II Diabetes,7/7/14 12:28
4416,23,Boehringer Ingelheim,Large Pharma,4638,empagliflozin + metformin,empagliflozin + metformin,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4210,Type II Diabetes,7/7/14 12:28
4418,23,Boehringer Ingelheim,Large Pharma,4640,BI-655066,BI-655066,Small Molecule (Chemical),Phase I,In-House,,,,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4211,Psoriasis,7/7/14 12:28
4418,23,Boehringer Ingelheim,Large Pharma,4640,BI-655066,BI-655066,Small Molecule (Chemical),Phase I,In-House,,,,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4211,Psoriasis,7/7/14 12:28
4418,23,Boehringer Ingelheim,Large Pharma,4640,BI-655066,BI-655066,Small Molecule (Chemical),Phase I,In-House,,,,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4211,Psoriasis,7/7/14 12:28
4419,23,Boehringer Ingelheim,Large Pharma,4641,BI-695502,BI-695502,Small Molecule (Chemical),Phase I,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4212,Cancer,7/7/14 12:28
4419,23,Boehringer Ingelheim,Large Pharma,4641,BI-695502,BI-695502,Small Molecule (Chemical),Phase I,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4212,Cancer,7/7/14 12:28
4419,23,Boehringer Ingelheim,Large Pharma,4641,BI-695502,BI-695502,Small Molecule (Chemical),Phase I,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4212,Cancer,7/7/14 12:28
4422,46,GlaxoSmithKline,Large Pharma,4673,dabrafenib + trametinib,dabrafenib + trametinib,Small Molecule (Chemical),Launched,Licensed (Development),Apr-14,Feb-14,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,4,Global,Sales,0,0,0,0,0,66.18454386,78.82457344,112.7747726,187.2182664,203.2390474,217.6246132,226.9682458,0,4243,Melanoma,7/7/14 12:28
4422,46,GlaxoSmithKline,Large Pharma,4673,dabrafenib + trametinib,dabrafenib + trametinib,Small Molecule (Chemical),Launched,Licensed (Development),Apr-14,Feb-14,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,4,ROW,Sales,0,0,0,0,0,20.32438236,27.40056344,49.26874518,91.91017018,101.2337833,110.7110693,117.1680847,0,4243,Melanoma,7/7/14 12:28
4422,46,GlaxoSmithKline,Large Pharma,4673,dabrafenib + trametinib,dabrafenib + trametinib,Small Molecule (Chemical),Launched,Licensed (Development),Apr-14,Feb-14,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,4,US,Sales,0,0,0,0,0,45.8601615,51.42401001,63.5060274,95.30809622,102.0052641,106.9135438,109.8001611,0,4243,Melanoma,7/7/14 12:28
4423,23,Boehringer Ingelheim,Large Pharma,4646,BI-1021958,BI-1021958,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4215,Asthma,7/7/14 12:28
4423,23,Boehringer Ingelheim,Large Pharma,4646,BI-1021958,BI-1021958,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4215,Asthma,7/7/14 12:28
4423,23,Boehringer Ingelheim,Large Pharma,4646,BI-1021958,BI-1021958,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4215,Asthma,7/7/14 12:28
4424,23,Boehringer Ingelheim,Large Pharma,4647,BI-144807,BI-144807,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4216,Asthma,7/7/14 12:28
4424,23,Boehringer Ingelheim,Large Pharma,4647,BI-144807,BI-144807,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4216,Asthma,7/7/14 12:28
4424,23,Boehringer Ingelheim,Large Pharma,4647,BI-144807,BI-144807,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4216,Asthma,7/7/14 12:28
4426,16,AstraZeneca,Large Pharma,4649,AZD1208,AZD1208,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4242,Hematological Malignancies,7/7/14 12:28
4426,16,AstraZeneca,Large Pharma,4649,AZD1208,AZD1208,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4242,Hematological Malignancies,7/7/14 12:28
4426,16,AstraZeneca,Large Pharma,4649,AZD1208,AZD1208,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4242,Hematological Malignancies,7/7/14 12:28
4427,16,AstraZeneca,Large Pharma,4650,MEDI-0639,,Antibody/Antibody Derivative,Phase I,,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4218,Solid tumors,7/7/14 12:28
4427,16,AstraZeneca,Large Pharma,4650,MEDI-0639,,Antibody/Antibody Derivative,Phase I,,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4218,Solid tumors,7/7/14 12:28
4427,16,AstraZeneca,Large Pharma,4650,MEDI-0639,,Antibody/Antibody Derivative,Phase I,,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4218,Solid tumors,7/7/14 12:28
4430,16,AstraZeneca,Large Pharma,4653,AMG-139,MEDI-2070,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4221,Crohn's Disease,7/7/14 12:28
4430,16,AstraZeneca,Large Pharma,4653,AMG-139,MEDI-2070,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4221,Crohn's Disease,7/7/14 12:28
4430,16,AstraZeneca,Large Pharma,4653,AMG-139,MEDI-2070,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4221,Crohn's Disease,7/7/14 12:28
4432,16,AstraZeneca,Large Pharma,3598,AMG-181,AMG-181,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3487,Crohn's Disease,7/7/14 12:28
4432,16,AstraZeneca,Large Pharma,3598,AMG-181,AMG-181,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3487,Crohn's Disease,7/7/14 12:28
4432,16,AstraZeneca,Large Pharma,3598,AMG-181,AMG-181,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3487,Crohn's Disease,7/7/14 12:28
4434,16,AstraZeneca,Large Pharma,4657,MEDI-9929,AMG 157,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1803,Asthma,7/7/14 12:28
4434,16,AstraZeneca,Large Pharma,4657,MEDI-9929,AMG 157,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1803,Asthma,7/7/14 12:28
4434,16,AstraZeneca,Large Pharma,4657,MEDI-9929,AMG 157,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1803,Asthma,7/7/14 12:28
4436,46,GlaxoSmithKline,Large Pharma,4658,1995057,1995057,Antibody/Antibody Derivative,Phase I,In-House,,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4226,Respiratory Distress Syndrome,7/7/14 12:28
4436,46,GlaxoSmithKline,Large Pharma,4658,1995057,1995057,Antibody/Antibody Derivative,Phase I,In-House,,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4226,Respiratory Distress Syndrome,7/7/14 12:28
4436,46,GlaxoSmithKline,Large Pharma,4658,1995057,1995057,Antibody/Antibody Derivative,Phase I,In-House,,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4226,Respiratory Distress Syndrome,7/7/14 12:28
4437,46,GlaxoSmithKline,Large Pharma,4659,2374697,2374697,Small Molecule (Chemical),Phase I,In-House,,,,,80,Obesity Treatments,38,Obesity,8,Metabolism,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4227,GLP1 agonist for Obesity,7/7/14 12:28
4437,46,GlaxoSmithKline,Large Pharma,4659,2374697,2374697,Small Molecule (Chemical),Phase I,In-House,,,,,80,Obesity Treatments,38,Obesity,8,Metabolism,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4227,GLP1 agonist for Obesity,7/7/14 12:28
4437,46,GlaxoSmithKline,Large Pharma,4659,2374697,2374697,Small Molecule (Chemical),Phase I,In-House,,,,,80,Obesity Treatments,38,Obesity,8,Metabolism,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4227,GLP1 agonist for Obesity,7/7/14 12:28
4438,46,GlaxoSmithKline,Large Pharma,4662,2330672,2330672,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4228,Ileal bile acid transfer inhibitor for Type II Diabetes,7/7/14 12:28
4438,46,GlaxoSmithKline,Large Pharma,4662,2330672,2330672,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4228,Ileal bile acid transfer inhibitor for Type II Diabetes,7/7/14 12:28
4438,46,GlaxoSmithKline,Large Pharma,4662,2330672,2330672,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4228,Ileal bile acid transfer inhibitor for Type II Diabetes,7/7/14 12:28
4440,46,GlaxoSmithKline,Large Pharma,4669,356278,356278,Small Molecule (Chemical),Phase I,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4230,PDE4 inhibitor for Huntington's Disease ,7/7/14 12:28
4440,46,GlaxoSmithKline,Large Pharma,4669,356278,356278,Small Molecule (Chemical),Phase I,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4230,PDE4 inhibitor for Huntington's Disease ,7/7/14 12:28
4440,46,GlaxoSmithKline,Large Pharma,4669,356278,356278,Small Molecule (Chemical),Phase I,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4230,PDE4 inhibitor for Huntington's Disease ,7/7/14 12:28
4441,46,GlaxoSmithKline,Large Pharma,279,rilapladib,rilapladib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4231,Alzheimer's Disease,7/7/14 12:28
4441,46,GlaxoSmithKline,Large Pharma,279,rilapladib,rilapladib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4231,Alzheimer's Disease,7/7/14 12:28
4441,46,GlaxoSmithKline,Large Pharma,279,rilapladib,rilapladib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4231,Alzheimer's Disease,7/7/14 12:28
4445,696,Nippon Shinyaku,Regional & Specialty Pharma,4674,Tramal,tramadol,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-10,,Dec-17,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,3.501850144,2.532332077,5.489665744,22.30747131,29.8515846,37.5335854,45.25162731,51.13263448,48.84269213,48.79875324,49.1336891,11.94116244,1223,Cancer pain,7/7/14 12:28
4445,696,Nippon Shinyaku,Regional & Specialty Pharma,4674,Tramal,tramadol,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-10,,Dec-17,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,3.501850144,2.532332077,5.489665744,22.30747131,29.8515846,37.5335854,45.25162731,51.13263448,48.84269213,48.79875324,49.1336891,11.94116244,1223,Cancer pain,7/7/14 12:28
4445,696,Nippon Shinyaku,Regional & Specialty Pharma,4674,Tramal,tramadol,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-10,,Dec-17,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1223,Cancer pain,7/7/14 12:28
4446,46,GlaxoSmithKline,Large Pharma,4675,2245035,2245035,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4236,Asthma,7/7/14 12:28
4446,46,GlaxoSmithKline,Large Pharma,4675,2245035,2245035,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4236,Asthma,7/7/14 12:28
4446,46,GlaxoSmithKline,Large Pharma,4675,2245035,2245035,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4236,Asthma,7/7/14 12:28
4447,46,GlaxoSmithKline,Large Pharma,4676,2269557,2269557,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4237,Asthma,7/7/14 12:28
4447,46,GlaxoSmithKline,Large Pharma,4676,2269557,2269557,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4237,Asthma,7/7/14 12:28
4447,46,GlaxoSmithKline,Large Pharma,4676,2269557,2269557,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4237,Asthma,7/7/14 12:28
4448,46,GlaxoSmithKline,Large Pharma,4677,2339345,2339345,Small Molecule (Chemical),Phase I,In-House,,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4238,Cough,7/7/14 12:28
4448,46,GlaxoSmithKline,Large Pharma,4677,2339345,2339345,Small Molecule (Chemical),Phase I,In-House,,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4238,Cough,7/7/14 12:28
4448,46,GlaxoSmithKline,Large Pharma,4677,2339345,2339345,Small Molecule (Chemical),Phase I,In-House,,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4238,Cough,7/7/14 12:28
4450,46,GlaxoSmithKline,Large Pharma,4688,2696273,2696273,Gene Therapy,Phase III,Licensed (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4240,ADA-SCID,7/7/14 12:28
4450,46,GlaxoSmithKline,Large Pharma,4688,2696273,2696273,Gene Therapy,Phase III,Licensed (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4240,ADA-SCID,7/7/14 12:28
4450,46,GlaxoSmithKline,Large Pharma,4688,2696273,2696273,Gene Therapy,Phase III,Licensed (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4240,ADA-SCID,7/7/14 12:28
4452,11,Amgen,Large Pharma,4692,oprozomib,oprozomib,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4244,Multiple Myeloma,7/7/14 12:28
4452,11,Amgen,Large Pharma,4692,oprozomib,oprozomib,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4244,Multiple Myeloma,7/7/14 12:28
4452,11,Amgen,Large Pharma,4692,oprozomib,oprozomib,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4244,Multiple Myeloma,7/7/14 12:28
4453,37,Eisai,Regional & Specialty Pharma,4693,E7016,E7016,Small Molecule (Chemical),Phase II,In-House,,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4245,Melanoma,7/7/14 12:28
4453,37,Eisai,Regional & Specialty Pharma,4693,E7016,E7016,Small Molecule (Chemical),Phase II,In-House,,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4245,Melanoma,7/7/14 12:28
4453,37,Eisai,Regional & Specialty Pharma,4693,E7016,E7016,Small Molecule (Chemical),Phase II,In-House,,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4245,Melanoma,7/7/14 12:28
4454,23,Boehringer Ingelheim,Large Pharma,4694,FX125L,FX125L,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4250,Asthma,7/7/14 12:28
4454,23,Boehringer Ingelheim,Large Pharma,4694,FX125L,FX125L,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4250,Asthma,7/7/14 12:28
4454,23,Boehringer Ingelheim,Large Pharma,4694,FX125L,FX125L,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4250,Asthma,7/7/14 12:28
4455,357,Japan Tobacco,Small Biotech,3177,Emtriva,emtricitabine,Small Molecule (Chemical),Launched,Licensed (Development),,,,Mar-13,104,NRTIs,32,HIV,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2252,HIV,7/7/14 12:28
4455,357,Japan Tobacco,Small Biotech,3177,Emtriva,emtricitabine,Small Molecule (Chemical),Launched,Licensed (Development),,,,Mar-13,104,NRTIs,32,HIV,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2252,HIV,7/7/14 12:28
4455,357,Japan Tobacco,Small Biotech,3177,Emtriva,emtricitabine,Small Molecule (Chemical),Launched,Licensed (Development),,,,Mar-13,104,NRTIs,32,HIV,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2252,HIV,7/7/14 12:28
4456,357,Japan Tobacco,Small Biotech,1515,Viread,tenofovir,Small Molecule (Chemical),Launched,Licensed (Development),,,,Apr-19,104,NRTIs,32,HIV,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1261,HIV,7/7/14 12:28
4456,357,Japan Tobacco,Small Biotech,1515,Viread,tenofovir,Small Molecule (Chemical),Launched,Licensed (Development),,,,Apr-19,104,NRTIs,32,HIV,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1261,HIV,7/7/14 12:28
4456,357,Japan Tobacco,Small Biotech,1515,Viread,tenofovir,Small Molecule (Chemical),Launched,Licensed (Development),,,,Apr-19,104,NRTIs,32,HIV,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1261,HIV,7/7/14 12:28
4457,357,Japan Tobacco,Small Biotech,1535,Truvada,tenofovir disoproxil + emtricitabine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-05,,,104,NRTIs,32,HIV,7,Anti-infectives,7,Global,Sales,66.12626799,96.32422463,125.9202125,144.9495609,121.5042223,127.4324592,120.8126669,110.7449447,100.6772225,100.6772225,70.47405572,60.20497903,-9.544604305,1206,HIV,7/7/14 12:28
4457,357,Japan Tobacco,Small Biotech,1535,Truvada,tenofovir disoproxil + emtricitabine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-05,,,104,NRTIs,32,HIV,7,Anti-infectives,7,ROW,Sales,66.12626799,96.32422463,125.9202125,144.9495609,121.5042223,127.4324592,120.8126669,110.7449447,100.6772225,100.6772225,70.47405572,60.20497903,-9.544604305,1206,HIV,7/7/14 12:28
4457,357,Japan Tobacco,Small Biotech,1535,Truvada,tenofovir disoproxil + emtricitabine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-05,,,104,NRTIs,32,HIV,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1206,HIV,7/7/14 12:28
4458,95,Shionogi,Regional & Specialty Pharma,4698,Actair,S-524101,Vaccine,Phase III,Licensed (Development),,Nov-15,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,Global,Sales,0,0,0,0,0,0,4.194887625,12.86433603,19.57617471,20.13544449,22.55449151,25.16930561,0,4246,Dust Mite Allergy,7/7/14 12:28
4458,95,Shionogi,Regional & Specialty Pharma,4698,Actair,S-524101,Vaccine,Phase III,Licensed (Development),,Nov-15,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,ROW,Sales,0,0,0,0,0,0,4.194887625,12.86433603,19.57617471,20.13544449,22.55449151,25.16930561,0,4246,Dust Mite Allergy,7/7/14 12:28
4458,95,Shionogi,Regional & Specialty Pharma,4698,Actair,S-524101,Vaccine,Phase III,Licensed (Development),,Nov-15,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4246,Dust Mite Allergy,7/7/14 12:28
4459,95,Shionogi,Regional & Specialty Pharma,3746,Myalept,metreleptin,Recombinant Protein,Launched,Licensed (Development),,Jul-13,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,7,Global,Sales,0,0,0,0,3.797006946,7.594013892,10.96909743,14.34417901,17.45769953,20.37757083,23.13967814,25.73142537,31.43692028,3628,Complications in Lipodystrophy,7/7/14 12:28
4459,95,Shionogi,Regional & Specialty Pharma,3746,Myalept,metreleptin,Recombinant Protein,Launched,Licensed (Development),,Jul-13,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,7,ROW,Sales,0,0,0,0,3.797006946,7.594013892,10.96909743,14.34417901,17.45769953,20.37757083,23.13967814,25.73142537,31.43692028,3628,Complications in Lipodystrophy,7/7/14 12:28
4459,95,Shionogi,Regional & Specialty Pharma,3746,Myalept,metreleptin,Recombinant Protein,Launched,Licensed (Development),,Jul-13,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3628,Complications in Lipodystrophy,7/7/14 12:28
4460,68,Novo Nordisk,Regional & Specialty Pharma,4699,LATIN T1D,NN9211,Synthetic Peptide,Phase III,Licensed (Development),,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4251,Type I Diabetes,7/7/14 12:28
4460,68,Novo Nordisk,Regional & Specialty Pharma,4699,LATIN T1D,NN9211,Synthetic Peptide,Phase III,Licensed (Development),,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4251,Type I Diabetes,7/7/14 12:28
4460,68,Novo Nordisk,Regional & Specialty Pharma,4699,LATIN T1D,NN9211,Synthetic Peptide,Phase III,Licensed (Development),,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4251,Type I Diabetes,7/7/14 12:28
4460,68,Novo Nordisk,Regional & Specialty Pharma,4699,LATIN T1D,NN9211,Synthetic Peptide,Phase III,Licensed (Development),,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4251,Type I Diabetes,7/7/14 12:28
4460,68,Novo Nordisk,Regional & Specialty Pharma,4699,LATIN T1D,NN9211,Synthetic Peptide,Phase III,Licensed (Development),,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4251,Type I Diabetes,7/7/14 12:28
4460,68,Novo Nordisk,Regional & Specialty Pharma,4699,LATIN T1D,NN9211,Synthetic Peptide,Phase III,Licensed (Development),,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4251,Type I Diabetes,7/7/14 12:28
4462,68,Novo Nordisk,Regional & Specialty Pharma,4701,OI362GT,NN1954,Recombinant Protein,Phase I,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4252,Diabetes,7/7/14 12:28
4462,68,Novo Nordisk,Regional & Specialty Pharma,4701,OI362GT,NN1954,Recombinant Protein,Phase I,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4252,Diabetes,7/7/14 12:28
4462,68,Novo Nordisk,Regional & Specialty Pharma,4701,OI362GT,NN1954,Recombinant Protein,Phase I,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4252,Diabetes,7/7/14 12:28
4463,68,Novo Nordisk,Regional & Specialty Pharma,4702,OG987GT,NN9926,Synthetic Peptide,Phase I,Licensed (Development),,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4253,Type II Diabetes,7/7/14 12:28
4463,68,Novo Nordisk,Regional & Specialty Pharma,4702,OG987GT,NN9926,Synthetic Peptide,Phase I,Licensed (Development),,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4253,Type II Diabetes,7/7/14 12:28
4463,68,Novo Nordisk,Regional & Specialty Pharma,4702,OG987GT,NN9926,Synthetic Peptide,Phase I,Licensed (Development),,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4253,Type II Diabetes,7/7/14 12:28
4464,184,Theravance,Small Biotech,1296,Vibativ,telavancin,Small Molecule (Chemical),Launched,In-House,Aug-13,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,1.666668,6.777788756,13.44448955,20.11120859,22.65344615,24.49523601,25.70200001,26.3677466,48.36024145,1254,cSSSIs HAP,7/7/14 12:28
4464,184,Theravance,Small Biotech,1296,Vibativ,telavancin,Small Molecule (Chemical),Launched,In-House,Aug-13,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1254,cSSSIs HAP,7/7/14 12:28
4464,184,Theravance,Small Biotech,1296,Vibativ,telavancin,Small Molecule (Chemical),Launched,In-House,Aug-13,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,1.666668,6.777788756,13.44448955,20.11120859,22.65344615,24.49523601,25.70200001,26.3677466,48.36024145,1254,cSSSIs HAP,7/7/14 12:28
4466,1986,Rib-X Pharmaceuticals,Small Biotech,4704,radezolid,radezolid,Small Molecule (Chemical),Phase II,In-House,Jul-17,,,,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,6.5,17.333355,26.0000325,34.66662333,0,4247,uSSSI and CAP,7/7/14 12:28
4466,1986,Rib-X Pharmaceuticals,Small Biotech,4704,radezolid,radezolid,Small Molecule (Chemical),Phase II,In-House,Jul-17,,,,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4247,uSSSI and CAP,7/7/14 12:28
4466,1986,Rib-X Pharmaceuticals,Small Biotech,4704,radezolid,radezolid,Small Molecule (Chemical),Phase II,In-House,Jul-17,,,,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,6.5,17.333355,26.0000325,34.66662333,0,4247,uSSSI and CAP,7/7/14 12:28
4469,11,Amgen,Large Pharma,4454,Velcalcetide,Velcalcetide,Synthetic Peptide,Phase III,Acquisition (Development),Nov-15,Nov-16,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,7.500015,53.333465,125.2222778,180.5556444,230.3290251,276.5503662,0,3906,Secondary Hyperparathyroidism,7/7/14 12:28
4469,11,Amgen,Large Pharma,4454,Velcalcetide,Velcalcetide,Synthetic Peptide,Phase III,Acquisition (Development),Nov-15,Nov-16,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,3.33334,22.22227778,35.55564444,48.88901111,58,0,3906,Secondary Hyperparathyroidism,7/7/14 12:28
4469,11,Amgen,Large Pharma,4454,Velcalcetide,Velcalcetide,Synthetic Peptide,Phase III,Acquisition (Development),Nov-15,Nov-16,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,7.500015,50.000125,103,145,181.440014,218.5503662,0,3906,Secondary Hyperparathyroidism,7/7/14 12:28
4470,39,Eli Lilly,Large Pharma,4707,LY2606368,Chk1 Inhibitor II,Small Molecule (Chemical),Phase II,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4254,Cancer,7/7/14 12:28
4470,39,Eli Lilly,Large Pharma,4707,LY2606368,Chk1 Inhibitor II,Small Molecule (Chemical),Phase II,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4254,Cancer,7/7/14 12:28
4470,39,Eli Lilly,Large Pharma,4707,LY2606368,Chk1 Inhibitor II,Small Molecule (Chemical),Phase II,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4254,Cancer,7/7/14 12:28
4471,39,Eli Lilly,Large Pharma,4708,LY2495655,Anti-myostatin MAb,Antibody/Antibody Derivative,Phase II,,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4255,Muscle Atrophy,7/7/14 12:28
4471,39,Eli Lilly,Large Pharma,4708,LY2495655,Anti-myostatin MAb,Antibody/Antibody Derivative,Phase II,,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4255,Muscle Atrophy,7/7/14 12:28
4471,39,Eli Lilly,Large Pharma,4708,LY2495655,Anti-myostatin MAb,Antibody/Antibody Derivative,Phase II,,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4255,Muscle Atrophy,7/7/14 12:28
4472,39,Eli Lilly,Large Pharma,4709,LY2979165,LY2979165,Small Molecule (Chemical),Phase I,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4256,Bipolar Disorder,7/7/14 12:28
4472,39,Eli Lilly,Large Pharma,4709,LY2979165,LY2979165,Small Molecule (Chemical),Phase I,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4256,Bipolar Disorder,7/7/14 12:28
4472,39,Eli Lilly,Large Pharma,4709,LY2979165,LY2979165,Small Molecule (Chemical),Phase I,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4256,Bipolar Disorder,7/7/14 12:28
4473,39,Eli Lilly,Large Pharma,4710,LY2940094,LY2940094,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4257,Depression,7/7/14 12:28
4473,39,Eli Lilly,Large Pharma,4710,LY2940094,LY2940094,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4257,Depression,7/7/14 12:28
4473,39,Eli Lilly,Large Pharma,4710,LY2940094,LY2940094,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4257,Depression,7/7/14 12:28
4476,24,Bristol-Myers Squibb,Large Pharma,4713,Factor XIa Inhibitor Parenteral,Factor XIa Inhibitor,Small Molecule (Chemical),Phase I,,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4260,Venous Thromboembolism,7/7/14 12:28
4476,24,Bristol-Myers Squibb,Large Pharma,4713,Factor XIa Inhibitor Parenteral,Factor XIa Inhibitor,Small Molecule (Chemical),Phase I,,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4260,Venous Thromboembolism,7/7/14 12:28
4476,24,Bristol-Myers Squibb,Large Pharma,4713,Factor XIa Inhibitor Parenteral,Factor XIa Inhibitor,Small Molecule (Chemical),Phase I,,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4260,Venous Thromboembolism,7/7/14 12:28
4477,24,Bristol-Myers Squibb,Large Pharma,4714,BMS-981164,BMS-981164,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4261,Atopic dermatitis,7/7/14 12:28
4477,24,Bristol-Myers Squibb,Large Pharma,4714,BMS-981164,BMS-981164,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4261,Atopic dermatitis,7/7/14 12:28
4477,24,Bristol-Myers Squibb,Large Pharma,4714,BMS-981164,BMS-981164,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4261,Atopic dermatitis,7/7/14 12:28
4482,1559,FibroGen,Small Biotech,4718,FG-3019,FG-3019,Antibody/Antibody Derivative,Phase II,In-House,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4264,Pulmonary Fibrosis,7/7/14 12:28
4482,1559,FibroGen,Small Biotech,4718,FG-3019,FG-3019,Antibody/Antibody Derivative,Phase II,In-House,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4264,Pulmonary Fibrosis,7/7/14 12:28
4482,1559,FibroGen,Small Biotech,4718,FG-3019,FG-3019,Antibody/Antibody Derivative,Phase II,In-House,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4264,Pulmonary Fibrosis,7/7/14 12:28
4483,46,GlaxoSmithKline,Large Pharma,4340,sirukumab,sirukumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Sep-16,Sep-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,Global,Sales,0,0,0,0,0,0,0,12.50729972,58.36744037,120.904067,183.4404866,227.8414061,0,320,Rheumatoid arthritis,7/7/14 12:28
4483,46,GlaxoSmithKline,Large Pharma,4340,sirukumab,sirukumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Sep-16,Sep-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,ROW,Sales,0,0,0,0,0,0,0,7.295924835,34.04767355,70.52737242,107.0069505,132.9074869,0,320,Rheumatoid arthritis,7/7/14 12:28
4483,46,GlaxoSmithKline,Large Pharma,4340,sirukumab,sirukumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Sep-16,Sep-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,US,Sales,0,0,0,0,0,0,0,5.211374882,24.31976682,50.37669459,76.43353609,94.9339192,0,320,Rheumatoid arthritis,7/7/14 12:28
4485,100,Takeda,Large Pharma,4720,TAK-063,TAK-063,Small Molecule (Chemical),Phase I,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4266,Schizophrenia,7/7/14 12:28
4485,100,Takeda,Large Pharma,4720,TAK-063,TAK-063,Small Molecule (Chemical),Phase I,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4266,Schizophrenia,7/7/14 12:28
4485,100,Takeda,Large Pharma,4720,TAK-063,TAK-063,Small Molecule (Chemical),Phase I,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4266,Schizophrenia,7/7/14 12:28
4486,100,Takeda,Large Pharma,4721,ITI-214,ITI-214,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4267,Cognitive impairment associated with schizophrenia,7/7/14 12:28
4486,100,Takeda,Large Pharma,4721,ITI-214,ITI-214,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4267,Cognitive impairment associated with schizophrenia,7/7/14 12:28
4486,100,Takeda,Large Pharma,4721,ITI-214,ITI-214,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4267,Cognitive impairment associated with schizophrenia,7/7/14 12:28
4489,255,Kyorin,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Phase II,Licensed (Development),,Jan-17,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,3,Global,Sales,0,0,0,0,0,0,0,0,1.014647482,2.972199694,5.021992587,7.071785479,0,1326,COPD,7/7/14 12:28
4489,255,Kyorin,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Phase II,Licensed (Development),,Jan-17,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,3,ROW,Sales,0,0,0,0,0,0,0,0,1.014647482,2.972199694,5.021992587,7.071785479,0,1326,COPD,7/7/14 12:28
4489,255,Kyorin,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Phase II,Licensed (Development),,Jan-17,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1326,COPD,7/7/14 12:28
4491,5,Actelion,Small Biotech,4722,Actelion - Unknown Compound,Metabolic Disease ,Small Molecule (Chemical),Phase I,In-House,,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4271,Lipid storage disorders,7/7/14 12:28
4491,5,Actelion,Small Biotech,4722,Actelion - Unknown Compound,Metabolic Disease ,Small Molecule (Chemical),Phase I,In-House,,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4271,Lipid storage disorders,7/7/14 12:28
4491,5,Actelion,Small Biotech,4722,Actelion - Unknown Compound,Metabolic Disease ,Small Molecule (Chemical),Phase I,In-House,,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4271,Lipid storage disorders,7/7/14 12:28
4492,16,AstraZeneca,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Corporate Acquisition,Apr-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,111,357,33,0.44,0,0,0,0,0,-100,1459,Type II Diabetes,7/7/14 12:28
4492,16,AstraZeneca,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Corporate Acquisition,Apr-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,721,845,891.7,875,867,855.93,833.1355,0,1459,Type II Diabetes,7/7/14 12:28
4492,16,AstraZeneca,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Corporate Acquisition,Apr-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,74,8,0.44,0,0,0,0,0,-100,1459,Type II Diabetes,7/7/14 12:28
4492,16,AstraZeneca,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Corporate Acquisition,Apr-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,170,225,268,299,323,343.93,360.6355,0,1459,Type II Diabetes,7/7/14 12:28
4492,16,AstraZeneca,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Corporate Acquisition,Apr-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,111,283,25,0,0,0,0,0,0,-100,1459,Type II Diabetes,7/7/14 12:28
4492,16,AstraZeneca,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Corporate Acquisition,Apr-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,551,620,623.7,576,544,512,472.5,0,1459,Type II Diabetes,7/7/14 12:28
4493,189,Medicis,Regional & Specialty Pharma,4740,Ziana,clindamycin + tretinoin,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-06,,Jul-16,,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Proforma,50,72,73,66,0,0,0,0,0,0,0,0,0,3814,Acne,7/7/14 12:28
4493,189,Medicis,Regional & Specialty Pharma,4740,Ziana,clindamycin + tretinoin,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-06,,Jul-16,,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Proforma,50,72,73,66,0,0,0,0,0,0,0,0,0,3814,Acne,7/7/14 12:28
4493,189,Valeant,Regional & Specialty Pharma,4740,Ziana,clindamycin + tretinoin,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-06,,Jul-16,,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Sales,0,0,0,4,68,66.98,65.954,39.13356,7.116571,5.14267024,3.710667357,2.932391765,-36.17964638,3814,Acne,7/7/14 12:28
4493,189,Valeant,Regional & Specialty Pharma,4740,Ziana,clindamycin + tretinoin,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-06,,Jul-16,,160,Acne Treatments,73,Acne,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3814,Acne,7/7/14 12:28
4493,189,Valeant,Regional & Specialty Pharma,4740,Ziana,clindamycin + tretinoin,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-06,,Jul-16,,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Sales,0,0,0,4,68,66.98,65.954,39.13356,7.116571,5.14267024,3.710667357,2.932391765,-36.17964638,3814,Acne,7/7/14 12:28
4494,189,Medicis,Regional & Specialty Pharma,4723,Solodyn,minocycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-06,,Nov-11,,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Proforma,333,395,364,340,0,0,0,0,0,0,0,0,0,4272,Acne,7/7/14 12:28
4494,189,Medicis,Regional & Specialty Pharma,4723,Solodyn,minocycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-06,,Nov-11,,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Proforma,333,395,364,340,0,0,0,0,0,0,0,0,0,4272,Acne,7/7/14 12:28
4494,189,Valeant,Regional & Specialty Pharma,4723,Solodyn,minocycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-06,,Nov-11,,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4272,Acne,7/7/14 12:28
4494,189,Valeant,Regional & Specialty Pharma,4723,Solodyn,minocycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-06,,Nov-11,,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Sales,0,0,0,20,355,347.62,344.5144,341.027728,338.3492474,336.4228201,334.7605037,333.500971,-0.888485859,4272,Acne,7/7/14 12:28
4494,189,Valeant,Regional & Specialty Pharma,4723,Solodyn,minocycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-06,,Nov-11,,160,Acne Treatments,73,Acne,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4272,Acne,7/7/14 12:28
4494,189,Valeant,Regional & Specialty Pharma,4723,Solodyn,minocycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-06,,Nov-11,,160,Acne Treatments,73,Acne,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4272,Acne,7/7/14 12:28
4494,189,Valeant,Regional & Specialty Pharma,4723,Solodyn,minocycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-06,,Nov-11,,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4272,Acne,7/7/14 12:28
4494,189,Valeant,Regional & Specialty Pharma,4723,Solodyn,minocycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-06,,Nov-11,,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Sales,0,0,0,20,355,347.62,344.5144,341.027728,338.3492474,336.4228201,334.7605037,333.500971,-0.888485859,4272,Acne,7/7/14 12:28
4495,243,Gedeon Richter,Regional & Specialty Pharma,3975,Rexetin,paroxetine,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,127,Serotonergics,49,Depression,12,Central Nervous System,10,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,846,Depression,7/7/14 12:28
4495,243,Gedeon Richter,Regional & Specialty Pharma,3975,Rexetin,paroxetine,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,127,Serotonergics,49,Depression,12,Central Nervous System,10,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,846,Depression,7/7/14 12:28
4495,243,Gedeon Richter,Regional & Specialty Pharma,3975,Rexetin,paroxetine,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,127,Serotonergics,49,Depression,12,Central Nervous System,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,846,Depression,7/7/14 12:28
4496,53,Johnson & Johnson,Large Pharma,4724,daratumumab,daratumumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Sep-16,Mar-17,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,20,165.75,321.9609825,423.8716306,491.0487356,0,4268,Multiple Myeloma,7/7/14 12:28
4496,53,Johnson & Johnson,Large Pharma,4724,daratumumab,daratumumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Sep-16,Mar-17,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,45.75,109.9605825,155.8713249,185.2483935,0,4268,Multiple Myeloma,7/7/14 12:28
4496,53,Johnson & Johnson,Large Pharma,4724,daratumumab,daratumumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Sep-16,Mar-17,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,20,120,212.0004,268.0003057,305.8003421,0,4268,Multiple Myeloma,7/7/14 12:28
4498,23,Boehringer Ingelheim,Large Pharma,3704,Abasria,insulin glargine,Recombinant Protein,Approved,Licensed (Development),Jul-16,Dec-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,3.9840902,25.23257127,107.5704354,199.20451,284.1984343,373.1764487,418.329471,0,3596,Diabetes,7/7/14 12:28
4498,23,Boehringer Ingelheim,Large Pharma,3704,Abasria,insulin glargine,Recombinant Protein,Approved,Licensed (Development),Jul-16,Dec-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3596,Diabetes,7/7/14 12:28
4498,23,Boehringer Ingelheim,Large Pharma,3704,Abasria,insulin glargine,Recombinant Protein,Approved,Licensed (Development),Jul-16,Dec-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,3.9840902,25.23257127,53.12120266,79.681804,104.9143753,132.8030067,143.4272472,0,3596,Diabetes,7/7/14 12:28
4498,23,Boehringer Ingelheim,Large Pharma,3704,Abasria,insulin glargine,Recombinant Protein,Approved,Licensed (Development),Jul-16,Dec-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3596,Diabetes,7/7/14 12:28
4498,23,Boehringer Ingelheim,Large Pharma,3704,Abasria,insulin glargine,Recombinant Protein,Approved,Licensed (Development),Jul-16,Dec-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,54.44923273,119.522706,179.284059,240.3734421,274.9022238,0,3596,Diabetes,7/7/14 12:28
4498,23,Boehringer Ingelheim,Large Pharma,3704,Abasria,insulin glargine,Recombinant Protein,Approved,Licensed (Development),Jul-16,Dec-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3596,Diabetes,7/7/14 12:28
4499,2119,Euthymics Bioscience,Small Biotech,4727,amitifadine,EB-1010,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4270,Depression,7/7/14 12:28
4499,2119,Euthymics Bioscience,Small Biotech,4727,amitifadine,EB-1010,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4270,Depression,7/7/14 12:28
4499,2119,Euthymics Bioscience,Small Biotech,4727,amitifadine,EB-1010,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4270,Depression,7/7/14 12:28
4501,85,Regeneron,Small Biotech,2426,dupilumab,dupilumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1055,Atopic dermatitis,7/7/14 12:28
4501,85,Regeneron,Small Biotech,2426,dupilumab,dupilumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1055,Atopic dermatitis,7/7/14 12:28
4501,85,Regeneron,Small Biotech,2426,dupilumab,dupilumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1055,Atopic dermatitis,7/7/14 12:28
4502,85,Regeneron,Small Biotech,2426,dupilumab,dupilumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1055,Asthma,7/7/14 12:28
4502,85,Regeneron,Small Biotech,2426,dupilumab,dupilumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1055,Asthma,7/7/14 12:28
4502,85,Regeneron,Small Biotech,2426,dupilumab,dupilumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1055,Asthma,7/7/14 12:28
4504,52,Jazz Pharmaceuticals,Small Biotech,2873,Prialt,ziconotide,Synthetic Peptide,Launched,Corporate Acquisition,Jan-05,,Dec-16,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,8,12.9,20.6,26.4,27.1,29.0965,30.3990375,31.07016684,15.58614642,12.57953765,10.74763318,9.183833091,-14.32284773,2071,Pain,7/7/14 12:28
4504,52,Jazz Pharmaceuticals,Small Biotech,2873,Prialt,ziconotide,Synthetic Peptide,Launched,Corporate Acquisition,Jan-05,,Dec-16,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2071,Pain,7/7/14 12:28
4504,52,Jazz Pharmaceuticals,Small Biotech,2873,Prialt,ziconotide,Synthetic Peptide,Launched,Corporate Acquisition,Jan-05,,Dec-16,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,8,12.9,20.6,26.4,27.1,29.0965,30.3990375,31.07016684,15.58614642,12.57953765,10.74763318,9.183833091,-14.32284773,2071,Pain,7/7/14 12:28
4505,46,GlaxoSmithKline,Large Pharma,2940,Toctino,alitretinoin,Small Molecule (Chemical),Launched,Acquisition (Marketed),Feb-15,Feb-09,,Dec-23,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,4,Global,Sales,0,0,0,25.36046198,50.72092397,60.89969251,84.13309249,101.3131692,115.6698145,128.9146156,138.1992334,145.7207103,16.27229316,2132,Chronic hand eczema,7/7/14 12:28
4505,46,GlaxoSmithKline,Large Pharma,2940,Toctino,alitretinoin,Small Molecule (Chemical),Launched,Acquisition (Marketed),Feb-15,Feb-09,,Dec-23,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,4,ROW,Sales,0,0,0,25.36046198,50.72092397,60.89969251,69.80179202,76.12476214,80.05869645,82.88083549,84.80875741,86.10745218,7.853984301,2132,Chronic hand eczema,7/7/14 12:28
4505,46,GlaxoSmithKline,Large Pharma,2940,Toctino,alitretinoin,Small Molecule (Chemical),Launched,Acquisition (Marketed),Feb-15,Feb-09,,Dec-23,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,4,US,Sales,0,0,0,0,0,0,14.33130047,25.18840708,35.61111804,46.03378007,53.39047601,59.61325815,0,2132,Chronic hand eczema,7/7/14 12:28
4506,70,Ono,Regional & Specialty Pharma,4580,nivolumab,nivolumab,Antibody/Antibody Derivative,Filed,Licensed (Development),,Dec-14,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,3.355904059,12.30499274,65.04929871,85.44182041,133.5365302,226.7193659,289.7583527,0,815,Melanoma,7/7/14 12:28
4506,70,Ono,Regional & Specialty Pharma,4580,nivolumab,nivolumab,Antibody/Antibody Derivative,Filed,Licensed (Development),,Dec-14,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,3.355904059,12.30499274,65.04929871,85.44182041,133.5365302,226.7193659,289.7583527,0,815,Melanoma,7/7/14 12:28
4506,70,Ono,Regional & Specialty Pharma,4580,nivolumab,nivolumab,Antibody/Antibody Derivative,Filed,Licensed (Development),,Dec-14,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,815,Melanoma,7/7/14 12:28
4507,15,Astellas Pharma,Regional & Specialty Pharma,4729,Vesomni,solifenacin + tamsulosin,Small Molecule (Chemical),Launched,In-House,,Apr-13,,Aug-30,176,Other BPH Treatments,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,Global,Sales,0,0,0,0,0,30.20316674,42.28443343,54.36551891,66.92996378,76.78820491,85.67994181,93.61292563,0,4274,Symptoms associated with BPH,7/7/14 12:28
4507,15,Astellas Pharma,Regional & Specialty Pharma,4729,Vesomni,solifenacin + tamsulosin,Small Molecule (Chemical),Launched,In-House,,Apr-13,,Aug-30,176,Other BPH Treatments,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,ROW,Sales,0,0,0,0,0,30.20316674,42.28443343,54.36551891,66.92996378,76.78820491,85.67994181,93.61292563,0,4274,Symptoms associated with BPH,7/7/14 12:28
4507,15,Astellas Pharma,Regional & Specialty Pharma,4729,Vesomni,solifenacin + tamsulosin,Small Molecule (Chemical),Launched,In-House,,Apr-13,,Aug-30,176,Other BPH Treatments,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4274,Symptoms associated with BPH,7/7/14 12:28
4509,150,Taisho,Regional & Specialty Pharma,4730,Kolbet,iguratimod,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,5.167448436,7.611638656,10.83014395,16.09251089,19.49633417,22.6357924,25.55047199,28.01442552,30.20184335,21.76088968,284,Rheumatoid Arthritis,7/7/14 12:28
4509,150,Taisho,Regional & Specialty Pharma,4730,Kolbet,iguratimod,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,5.167448436,7.611638656,10.83014395,16.09251089,19.49633417,22.6357924,25.55047199,28.01442552,30.20184335,21.76088968,284,Rheumatoid Arthritis,7/7/14 12:28
4509,150,Taisho,Regional & Specialty Pharma,4730,Kolbet,iguratimod,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,284,Rheumatoid Arthritis,7/7/14 12:28
4511,53,Johnson & Johnson,Large Pharma,1879,Priligy,dapoxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-09,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,6,Global,Sales,7,12,18,13,0,0,0,0,0,0,0,0,0,926,Premature ejaculation,7/7/14 12:28
4511,53,Johnson & Johnson,Large Pharma,1879,Priligy,dapoxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-09,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,6,ROW,Sales,7,12,18,13,0,0,0,0,0,0,0,0,0,926,Premature ejaculation,7/7/14 12:28
4511,53,Johnson & Johnson,Large Pharma,1879,Priligy,dapoxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-09,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,926,Premature ejaculation,7/7/14 12:28
4512,2065,Furiex,Small Biotech,1879,Priligy,dapoxetine,Small Molecule (Chemical),Phase III,Acquisition (Marketed),Sep-14,,Aug-20,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,6,Global,Sales,0,0,0,0,0,4.999995,18.33333167,28.33324742,38.33318377,46.86647196,54.27975848,60.89305206,0,926,Premature ejaculation,7/7/14 12:28
4512,2065,Furiex,Small Biotech,1879,Priligy,dapoxetine,Small Molecule (Chemical),Phase III,Acquisition (Marketed),Sep-14,,Aug-20,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,926,Premature ejaculation,7/7/14 12:28
4512,2065,Furiex,Small Biotech,1879,Priligy,dapoxetine,Small Molecule (Chemical),Phase III,Acquisition (Marketed),Sep-14,,Aug-20,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,6,US,Sales,0,0,0,0,0,4.999995,18.33333167,28.33324742,38.33318377,46.86647196,54.27975848,60.89305206,0,926,Premature ejaculation,7/7/14 12:28
4514,2123,Plethora Solutions,Small Biotech,2876,Prilocaine Lidocaine Plethora,lidocaine + prilocaine,Small Molecule (Chemical),Approved,Licensed (Development),,Sep-14,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,4,Global,Sales,0,0,0,0,0,10.63121539,15.32670429,21.88270205,32.77985002,39.4634269,45.8011328,51.68381729,0,2078,Premature ejaculation,7/7/14 12:28
4514,2123,Plethora Solutions,Small Biotech,2876,Prilocaine Lidocaine Plethora,lidocaine + prilocaine,Small Molecule (Chemical),Approved,Licensed (Development),,Sep-14,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,4,ROW,Sales,0,0,0,0,0,10.63121539,15.32670429,21.88270205,32.77985002,39.4634269,45.8011328,51.68381729,0,2078,Premature ejaculation,7/7/14 12:28
4514,2123,Plethora Solutions,Small Biotech,2876,Prilocaine Lidocaine Plethora,lidocaine + prilocaine,Small Molecule (Chemical),Approved,Licensed (Development),,Sep-14,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2078,Premature ejaculation,7/7/14 12:28
4515,1437,ALK Abello,Small Biotech,4734,Grazax,MK-7243,Vaccine,Launched,In-House,,Nov-06,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,1,Global,Sales,24.81806307,28.81575261,34.15246369,34.8781495,35.43652366,35.36851556,36.05033159,36.56356114,37.16256558,37.62757102,38.05017091,38.81991034,1.311238701,500,Grass Pollen Allergy,7/7/14 12:28
4515,1437,ALK Abello,Small Biotech,4734,Grazax,MK-7243,Vaccine,Launched,In-House,,Nov-06,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,1,ROW,Sales,24.81806307,28.81575261,34.15246369,34.8781495,35.43652366,35.36851556,36.05033159,36.56356114,37.16256558,37.62757102,38.05017091,38.81991034,1.311238701,500,Grass Pollen Allergy,7/7/14 12:28
4515,1437,ALK Abello,Small Biotech,4734,Grazax,MK-7243,Vaccine,Launched,In-House,,Nov-06,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,500,Grass Pollen Allergy,7/7/14 12:28
4516,1437,ALK Abello,Small Biotech,4735,Mitizax,SCH-900237,Vaccine,Phase III,In-House,,Jun-15,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,1,Global,Sales,0,0,0,0,0,0,3.531778816,8.408988771,12.44530338,16.48156417,19.00424424,20.97193295,0,1887,Dust Mite Allergy,7/7/14 12:28
4516,1437,ALK Abello,Small Biotech,4735,Mitizax,SCH-900237,Vaccine,Phase III,In-House,,Jun-15,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,1,ROW,Sales,0,0,0,0,0,0,3.531778816,8.408988771,12.44530338,16.48156417,19.00424424,20.97193295,0,1887,Dust Mite Allergy,7/7/14 12:28
4516,1437,ALK Abello,Small Biotech,4735,Mitizax,SCH-900237,Vaccine,Phase III,In-House,,Jun-15,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1887,Dust Mite Allergy,7/7/14 12:28
4518,24,Bristol-Myers Squibb,Large Pharma,4737,atazanavir / cobicistat FDC,atazanavir / cobicistat,Small Molecule (Chemical),Filed,Licensed (Development),Sep-15,May-16,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,13.33332,95.55555444,201.1113104,301.1113386,366.0003584,399.1670423,0,4278,HIV,7/7/14 12:28
4518,24,Bristol-Myers Squibb,Large Pharma,4737,atazanavir / cobicistat FDC,atazanavir / cobicistat,Small Molecule (Chemical),Filed,Licensed (Development),Sep-15,May-16,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,33.33335,72.22236944,105.5558818,138.8893738,147.5005247,0,4278,HIV,7/7/14 12:28
4518,24,Bristol-Myers Squibb,Large Pharma,4737,atazanavir / cobicistat FDC,atazanavir / cobicistat,Small Molecule (Chemical),Filed,Licensed (Development),Sep-15,May-16,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,13.33332,62.22220444,128.888941,195.5554568,227.1109846,251.6665176,0,4278,HIV,7/7/14 12:28
4519,283,Peregrine Pharmaceuticals ,Small Biotech,3201,bavituximab,bavituximab,Antibody/Antibody Derivative,Phase III,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2235,Non-small-cell Lung Cancer,7/7/14 12:28
4519,283,Peregrine Pharmaceuticals ,Small Biotech,3201,bavituximab,bavituximab,Antibody/Antibody Derivative,Phase III,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2235,Non-small-cell Lung Cancer,7/7/14 12:28
4519,283,Peregrine Pharmaceuticals ,Small Biotech,3201,bavituximab,bavituximab,Antibody/Antibody Derivative,Phase III,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2235,Non-small-cell Lung Cancer,7/7/14 12:28
4521,39,Eli Lilly,Large Pharma,4638,empagliflozin + metformin,empagliflozin + metformin,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4210,Type II Diabetes,7/7/14 12:28
4521,39,Eli Lilly,Large Pharma,4638,empagliflozin + metformin,empagliflozin + metformin,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4210,Type II Diabetes,7/7/14 12:28
4521,39,Eli Lilly,Large Pharma,4638,empagliflozin + metformin,empagliflozin + metformin,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4210,Type II Diabetes,7/7/14 12:28
4522,14,Asahi Kasei Pharma,Regional & Specialty Pharma,4739,Teribone,teriparatide,Synthetic Peptide,Launched,In-House,,Nov-11,,Jun-19,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,0,0,27.85565285,204.6585913,273.3845001,356.3973675,417.5834823,463.1496194,497.7945053,523.7322096,543.2175367,557.889308,10.72696745,4277,Osteoporosis,7/7/14 12:28
4522,14,Asahi Kasei Pharma,Regional & Specialty Pharma,4739,Teribone,teriparatide,Synthetic Peptide,Launched,In-House,,Nov-11,,Jun-19,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,27.85565285,204.6585913,273.3845001,356.3973675,417.5834823,463.1496194,497.7945053,523.7322096,543.2175367,557.889308,10.72696745,4277,Osteoporosis,7/7/14 12:28
4522,14,Asahi Kasei Pharma,Regional & Specialty Pharma,4739,Teribone,teriparatide,Synthetic Peptide,Launched,In-House,,Nov-11,,Jun-19,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4277,Osteoporosis,7/7/14 12:28
4523,16,AstraZeneca,Large Pharma,101,Symlin,pramlintide,Synthetic Peptide,Launched,Corporate Acquisition,Jun-05,,Mar-19,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,25,42,5,0,0,0,0,0,0,-100,1130,Diabetes,7/7/14 12:28
4523,16,AstraZeneca,Large Pharma,101,Symlin,pramlintide,Synthetic Peptide,Launched,Corporate Acquisition,Jun-05,,Mar-19,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,109,124,127,131,135,138,140,0,1130,Diabetes,7/7/14 12:28
4523,16,AstraZeneca,Large Pharma,101,Symlin,pramlintide,Synthetic Peptide,Launched,Corporate Acquisition,Jun-05,,Mar-19,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1130,Diabetes,7/7/14 12:28
4523,16,AstraZeneca,Large Pharma,101,Symlin,pramlintide,Synthetic Peptide,Launched,Corporate Acquisition,Jun-05,,Mar-19,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1130,Diabetes,7/7/14 12:28
4523,16,AstraZeneca,Large Pharma,101,Symlin,pramlintide,Synthetic Peptide,Launched,Corporate Acquisition,Jun-05,,Mar-19,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,25,42,5,0,0,0,0,0,0,-100,1130,Diabetes,7/7/14 12:28
4523,16,AstraZeneca,Large Pharma,101,Symlin,pramlintide,Synthetic Peptide,Launched,Corporate Acquisition,Jun-05,,Mar-19,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,109,124,127,131,135,138,140,0,1130,Diabetes,7/7/14 12:28
4524,16,AstraZeneca,Large Pharma,3746,Myalept,metreleptin,Recombinant Protein,Approved,Corporate Acquisition,May-14,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3628,Complications in Lipodystrophy,7/7/14 12:28
4524,16,AstraZeneca,Large Pharma,3746,Myalept,metreleptin,Recombinant Protein,Approved,Corporate Acquisition,May-14,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,10.000005,21.66671083,31.66676455,41.66681213,50.96685509,59.65189694,67.87118594,0,3628,Complications in Lipodystrophy,7/7/14 12:28
4524,16,AstraZeneca,Large Pharma,3746,Myalept,metreleptin,Recombinant Protein,Approved,Corporate Acquisition,May-14,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3628,Complications in Lipodystrophy,7/7/14 12:28
4524,16,AstraZeneca,Large Pharma,3746,Myalept,metreleptin,Recombinant Protein,Approved,Corporate Acquisition,May-14,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3628,Complications in Lipodystrophy,7/7/14 12:28
4524,16,AstraZeneca,Large Pharma,3746,Myalept,metreleptin,Recombinant Protein,Approved,Corporate Acquisition,May-14,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3628,Complications in Lipodystrophy,7/7/14 12:28
4524,16,AstraZeneca,Large Pharma,3746,Myalept,metreleptin,Recombinant Protein,Approved,Corporate Acquisition,May-14,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,10.000005,21.66671083,31.66676455,41.66681213,50.96685509,59.65189694,67.87118594,0,3628,Complications in Lipodystrophy,7/7/14 12:28
4525,614,Kissei,Regional & Specialty Pharma,2444,Glufast,mitiglinide,Small Molecule (Chemical),Launched,In-House,,May-04,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,Global,Sales,52.78897249,60.69873583,54.44513966,41.5336553,34.23025563,29.9112028,26.7350378,25.42545262,23.40087685,21.96935292,21.04027085,20.06373397,-7.347443465,496,Type II Diabetes,7/7/14 12:28
4525,614,Kissei,Regional & Specialty Pharma,2444,Glufast,mitiglinide,Small Molecule (Chemical),Launched,In-House,,May-04,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,ROW,Sales,52.78897249,60.69873583,54.44513966,41.5336553,34.23025563,29.9112028,26.7350378,25.42545262,23.40087685,21.96935292,21.04027085,20.06373397,-7.347443465,496,Type II Diabetes,7/7/14 12:28
4525,614,Kissei,Regional & Specialty Pharma,2444,Glufast,mitiglinide,Small Molecule (Chemical),Launched,In-House,,May-04,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,496,Type II Diabetes,7/7/14 12:28
4526,2436,Ophthotech,Small Biotech,4744,Fovista,E-10030,Small Molecule (Chemical),Phase III,Licensed (Development),Feb-18,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,146.66672,257.7784937,364.4446567,0,4281,AMD,7/7/14 12:28
4526,2436,Ophthotech,Small Biotech,4744,Fovista,E-10030,Small Molecule (Chemical),Phase III,Licensed (Development),Feb-18,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4281,AMD,7/7/14 12:28
4526,2436,Ophthotech,Small Biotech,4744,Fovista,E-10030,Small Molecule (Chemical),Phase III,Licensed (Development),Feb-18,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,146.66672,257.7784937,364.4446567,0,4281,AMD,7/7/14 12:28
4527,89,Sanofi,Large Pharma,4462,UshStat,UshStat,Cell Therapy,Phase I,Licensed (Development),,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4083,Usher Syndrome,7/7/14 12:28
4527,89,Sanofi,Large Pharma,4462,UshStat,UshStat,Cell Therapy,Phase I,Licensed (Development),,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4083,Usher Syndrome,7/7/14 12:28
4527,89,Sanofi,Large Pharma,4462,UshStat,UshStat,Cell Therapy,Phase I,Licensed (Development),,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4083,Usher Syndrome,7/7/14 12:28
4532,217,Zealand Pharma,Regional & Specialty Pharma,4747,ZP-2929,ZP-2929,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4283,Type II diabetes,7/7/14 12:28
4532,217,Zealand Pharma,Regional & Specialty Pharma,4747,ZP-2929,ZP-2929,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4283,Type II diabetes,7/7/14 12:28
4532,217,Zealand Pharma,Regional & Specialty Pharma,4747,ZP-2929,ZP-2929,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4283,Type II diabetes,7/7/14 12:28
4535,95,Shionogi,Regional & Specialty Pharma,4750,S-556971,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4286,Dyslipidemia,7/7/14 12:28
4535,95,Shionogi,Regional & Specialty Pharma,4750,S-556971,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4286,Dyslipidemia,7/7/14 12:28
4535,95,Shionogi,Regional & Specialty Pharma,4750,S-556971,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4286,Dyslipidemia,7/7/14 12:28
4537,2134,Stallergenes,Small Biotech,4698,Actair,S-524101,Vaccine,Phase III,In-House,,Nov-14,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,2,Global,Sales,0,0,0,0,0,6.569636319,9.807810061,13.99368532,20.92951551,24.15230296,26.86989366,27.8886314,0,4246,Dust Mite Allergy,7/7/14 12:28
4537,2134,Stallergenes,Small Biotech,4698,Actair,S-524101,Vaccine,Phase III,In-House,,Nov-14,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,2,ROW,Sales,0,0,0,0,0,6.569636319,9.807810061,13.99368532,20.92951551,24.15230296,26.86989366,27.8886314,0,4246,Dust Mite Allergy,7/7/14 12:28
4537,2134,Stallergenes,Small Biotech,4698,Actair,S-524101,Vaccine,Phase III,In-House,,Nov-14,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4246,Dust Mite Allergy,7/7/14 12:28
4538,1260,Dr Reddys,Small Biotech,1012,Augmentin,amoxicillin  +  clavulanic acid,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,Expired,Apr-16,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,170,bacterial infection,7/7/14 12:28
4538,1260,Dr Reddys,Small Biotech,1012,Augmentin,amoxicillin  +  clavulanic acid,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,Expired,Apr-16,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,170,bacterial infection,7/7/14 12:28
4538,1260,Dr Reddys,Small Biotech,1012,Augmentin,amoxicillin  +  clavulanic acid,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,Expired,Apr-16,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,170,bacterial infection,7/7/14 12:28
4539,753,Newron Pharmaceuticals,Small Biotech,4752,sNN-0029,recombinant VEGF,Recombinant Protein,Phase II,Licensed (Development),,,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4287,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4539,753,Newron Pharmaceuticals,Small Biotech,4752,sNN-0029,recombinant VEGF,Recombinant Protein,Phase II,Licensed (Development),,,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4287,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4539,753,Newron Pharmaceuticals,Small Biotech,4752,sNN-0029,recombinant VEGF,Recombinant Protein,Phase II,Licensed (Development),,,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4287,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4540,2137,Neuraltus,Small Biotech,4753,NP001,NP001,Small Molecule (Chemical),Phase II,In-House,,,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4288,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4540,2137,Neuraltus,Small Biotech,4753,NP001,NP001,Small Molecule (Chemical),Phase II,In-House,,,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4288,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4540,2137,Neuraltus,Small Biotech,4753,NP001,NP001,Small Molecule (Chemical),Phase II,In-House,,,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4288,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4541,652,Medivir,Small Biotech,3837,Olysio / Sovriad,simeprevir,Small Molecule (Chemical),Launched,In-House,,,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1189,Hepatitis C,7/7/14 12:28
4541,652,Medivir,Small Biotech,3837,Olysio / Sovriad,simeprevir,Small Molecule (Chemical),Launched,In-House,,,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1189,Hepatitis C,7/7/14 12:28
4541,652,Medivir,Small Biotech,3837,Olysio / Sovriad,simeprevir,Small Molecule (Chemical),Launched,In-House,,,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1189,Hepatitis C,7/7/14 12:28
4542,63,Merck KGaA,Regional & Specialty Pharma,4754,Sym004,Sym004,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4290,Solid Tumors,7/7/14 12:28
4542,63,Merck KGaA,Regional & Specialty Pharma,4754,Sym004,Sym004,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4290,Solid Tumors,7/7/14 12:28
4542,63,Merck KGaA,Regional & Specialty Pharma,4754,Sym004,Sym004,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4290,Solid Tumors,7/7/14 12:28
4543,86,Roche,Large Pharma,4755,RG7697,RG7697,Synthetic Peptide,Phase I,Acquisition (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4291,Type II Diabetes,7/7/14 12:28
4543,86,Roche,Large Pharma,4755,RG7697,RG7697,Synthetic Peptide,Phase I,Acquisition (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4291,Type II Diabetes,7/7/14 12:28
4543,86,Roche,Large Pharma,4755,RG7697,RG7697,Synthetic Peptide,Phase I,Acquisition (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4291,Type II Diabetes,7/7/14 12:28
4544,29,Chugai,Regional & Specialty Pharma,4756,CIM331,anti-IL-31 humanized monoclonal antibody,Antibody/Antibody Derivative,Phase II,In-House,,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4292,Atopic Dermatitis,7/7/14 12:28
4544,29,Chugai,Regional & Specialty Pharma,4756,CIM331,anti-IL-31 humanized monoclonal antibody,Antibody/Antibody Derivative,Phase II,In-House,,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4292,Atopic Dermatitis,7/7/14 12:28
4544,29,Chugai,Regional & Specialty Pharma,4756,CIM331,anti-IL-31 humanized monoclonal antibody,Antibody/Antibody Derivative,Phase II,In-House,,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4292,Atopic Dermatitis,7/7/14 12:28
4545,29,Chugai,Regional & Specialty Pharma,4757,ACE910,ACE910,Antibody/Antibody Derivative,Phase I,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4293,Hemophilia A,7/7/14 12:28
4545,29,Chugai,Regional & Specialty Pharma,4757,ACE910,ACE910,Antibody/Antibody Derivative,Phase I,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4293,Hemophilia A,7/7/14 12:28
4545,29,Chugai,Regional & Specialty Pharma,4757,ACE910,ACE910,Antibody/Antibody Derivative,Phase I,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4293,Hemophilia A,7/7/14 12:28
4546,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4758,glycopyrrolate bromide,glycopyrrolate bromide,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4298,COPD,7/7/14 12:28
4546,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4758,glycopyrrolate bromide,glycopyrrolate bromide,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4298,COPD,7/7/14 12:28
4546,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4758,glycopyrrolate bromide,glycopyrrolate bromide,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4298,COPD,7/7/14 12:28
4547,37,Eisai,Regional & Specialty Pharma,4759,E2609,E2609,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4294,Alzheimer's Disease,7/7/14 12:28
4547,37,Eisai,Regional & Specialty Pharma,4759,E2609,E2609,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4294,Alzheimer's Disease,7/7/14 12:28
4547,37,Eisai,Regional & Specialty Pharma,4759,E2609,E2609,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4294,Alzheimer's Disease,7/7/14 12:28
4548,111,Actavis,Regional & Specialty Pharma,4760,Vaginal ring contraceptive,esterol + progestin,Small Molecule (Chemical),Phase III,In-House,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4295,Female contraception,7/7/14 12:28
4548,111,Actavis,Regional & Specialty Pharma,4760,Vaginal ring contraceptive,esterol + progestin,Small Molecule (Chemical),Phase III,In-House,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4295,Female contraception,7/7/14 12:28
4548,111,Actavis,Regional & Specialty Pharma,4760,Vaginal ring contraceptive,esterol + progestin,Small Molecule (Chemical),Phase III,In-House,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4295,Female contraception,7/7/14 12:28
4549,111,Actavis,Regional & Specialty Pharma,4761,rFSH ,recombinant follicle stimulating hormone,Recombinant Protein,Phase I,Acquisition (Development),Oct-17,Jun-18,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,1.12,5.708,8.90031092,12.85001542,0,4296,Female infertility,7/7/14 12:28
4549,111,Actavis,Regional & Specialty Pharma,4761,rFSH ,recombinant follicle stimulating hormone,Recombinant Protein,Phase I,Acquisition (Development),Oct-17,Jun-18,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,2.46,4.308321,6.130051452,0,4296,Female infertility,7/7/14 12:28
4549,111,Actavis,Regional & Specialty Pharma,4761,rFSH ,recombinant follicle stimulating hormone,Recombinant Protein,Phase I,Acquisition (Development),Oct-17,Jun-18,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,1.12,3.248,4.59198992,6.719963969,0,4296,Female infertility,7/7/14 12:28
4550,76,Pfizer,Large Pharma,4762,Quillivant XR,methylphenidate XR,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-13,,,,121,Stimulants,37,ADHD,12,Central Nervous System,6,Global,Sales,0,0,0,0,20,33.3334,46.66676,59.99992,66.666554,71.6665225,75.24982572,77.56231021,21.36363988,4297,ADHD,7/7/14 12:28
4550,76,Pfizer,Large Pharma,4762,Quillivant XR,methylphenidate XR,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-13,,,,121,Stimulants,37,ADHD,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4297,ADHD,7/7/14 12:28
4550,76,Pfizer,Large Pharma,4762,Quillivant XR,methylphenidate XR,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-13,,,,121,Stimulants,37,ADHD,12,Central Nervous System,6,US,Sales,0,0,0,0,20,33.3334,46.66676,59.99992,66.666554,71.6665225,75.24982572,77.56231021,21.36363988,4297,ADHD,7/7/14 12:28
4551,19,Bayer,Large Pharma,4763,BAY 94-9343,BAY 94-9343,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4299,Cancer,7/7/14 12:28
4551,19,Bayer,Large Pharma,4763,BAY 94-9343,BAY 94-9343,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4299,Cancer,7/7/14 12:28
4551,19,Bayer,Large Pharma,4763,BAY 94-9343,BAY 94-9343,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4299,Cancer,7/7/14 12:28
4552,108,Vertex,Regional & Specialty Pharma,4764,VX-787,VX-787,Small Molecule (Chemical),Phase II,In-House,,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4300,influenza,7/7/14 12:28
4552,108,Vertex,Regional & Specialty Pharma,4764,VX-787,VX-787,Small Molecule (Chemical),Phase II,In-House,,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4300,influenza,7/7/14 12:28
4552,108,Vertex,Regional & Specialty Pharma,4764,VX-787,VX-787,Small Molecule (Chemical),Phase II,In-House,,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4300,influenza,7/7/14 12:28
4553,29,Chugai,Regional & Specialty Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Filed,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,992,Melanoma,7/7/14 12:28
4553,29,Chugai,Regional & Specialty Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Filed,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,992,Melanoma,7/7/14 12:28
4553,29,Chugai,Regional & Specialty Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Filed,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,992,Melanoma,7/7/14 12:28
4557,61,Merck & Co,Large Pharma,4766,pembrolizumab,pembrolizumab,Antibody/Antibody Derivative,Filed,Acquisition (Development),Jan-15,Sep-15,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,79.66665,325.7112604,598.2122509,825.2454271,980.5124035,1127.442501,0,4303,Melanoma,7/7/14 12:28
4557,61,Merck & Co,Large Pharma,4766,pembrolizumab,pembrolizumab,Antibody/Antibody Derivative,Filed,Acquisition (Development),Jan-15,Sep-15,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,16.66665,79.43626039,221.4626896,369.1459692,449.6818133,534.1498388,0,4303,Melanoma,7/7/14 12:28
4557,61,Merck & Co,Large Pharma,4766,pembrolizumab,pembrolizumab,Antibody/Antibody Derivative,Filed,Acquisition (Development),Jan-15,Sep-15,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,63,246.275,376.7495612,456.0994579,530.8305902,593.2926621,0,4303,Melanoma,7/7/14 12:28
4558,243,Gedeon Richter,Regional & Specialty Pharma,4767,Xeter,rosuvastatin,Small Molecule (Chemical),Launched,In-House,,Feb-10,,,113,Statins,20,Lipid Disorders,10,Cardiovasculars,10,Global,Sales,0,8.28010676,26.24729749,24.82534838,32.09123134,36.73587741,39.80800477,42.63603554,44.75801436,46.39850004,47.71308775,48.73608071,6.15083971,1624,Dyslipidemia,7/7/14 12:28
4558,243,Gedeon Richter,Regional & Specialty Pharma,4767,Xeter,rosuvastatin,Small Molecule (Chemical),Launched,In-House,,Feb-10,,,113,Statins,20,Lipid Disorders,10,Cardiovasculars,10,ROW,Sales,0,8.28010676,26.24729749,24.82534838,32.09123134,36.73587741,39.80800477,42.63603554,44.75801436,46.39850004,47.71308775,48.73608071,6.15083971,1624,Dyslipidemia,7/7/14 12:28
4558,243,Gedeon Richter,Regional & Specialty Pharma,4767,Xeter,rosuvastatin,Small Molecule (Chemical),Launched,In-House,,Feb-10,,,113,Statins,20,Lipid Disorders,10,Cardiovasculars,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1624,Dyslipidemia,7/7/14 12:28
4559,45,Gilead,Regional & Specialty Pharma,3977,simtuzumab,simtuzumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3792,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
4559,45,Gilead,Regional & Specialty Pharma,3977,simtuzumab,simtuzumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3792,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
4559,45,Gilead,Regional & Specialty Pharma,3977,simtuzumab,simtuzumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3792,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
4560,61,Merck & Co,Large Pharma,4768,MK-8742,MK-8742,Small Molecule (Chemical),Phase II,In-House,Jul-16,Nov-16,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,171,392,517,707,827,0,4307,Hepatitis C,7/7/14 12:28
4560,61,Merck & Co,Large Pharma,4768,MK-8742,MK-8742,Small Molecule (Chemical),Phase II,In-House,Jul-16,Nov-16,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,43,130,179,220,262,0,4307,Hepatitis C,7/7/14 12:28
4560,61,Merck & Co,Large Pharma,4768,MK-8742,MK-8742,Small Molecule (Chemical),Phase II,In-House,Jul-16,Nov-16,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,128,262,338,487,565,0,4307,Hepatitis C,7/7/14 12:28
4562,273,Vanda Pharmaceuticals,Small Biotech,4770,Fanapt / Fanaptum,iloperidone,Small Molecule (Chemical),Filed,Licensed (Development),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,438,Schizophrenia,7/7/14 12:28
4562,273,Vanda Pharmaceuticals,Small Biotech,4770,Fanapt / Fanaptum,iloperidone,Small Molecule (Chemical),Filed,Licensed (Development),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,438,Schizophrenia,7/7/14 12:28
4562,273,Vanda Pharmaceuticals,Small Biotech,4770,Fanapt / Fanaptum,iloperidone,Small Molecule (Chemical),Filed,Licensed (Development),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,438,Schizophrenia,7/7/14 12:28
4563,8,Allergan,Regional & Specialty Pharma,4771,AGN 208397,AGN 208397,Small Molecule (Chemical),Phase II,In-House,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4306,Retinal Vein Occlusion,7/7/14 12:28
4563,8,Allergan,Regional & Specialty Pharma,4771,AGN 208397,AGN 208397,Small Molecule (Chemical),Phase II,In-House,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4306,Retinal Vein Occlusion,7/7/14 12:28
4563,8,Allergan,Regional & Specialty Pharma,4771,AGN 208397,AGN 208397,Small Molecule (Chemical),Phase II,In-House,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4306,Retinal Vein Occlusion,7/7/14 12:28
4564,91,Santen,Regional & Specialty Pharma,4772,DE-117,DE-117,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4308,Glaucoma,7/7/14 12:28
4564,91,Santen,Regional & Specialty Pharma,4772,DE-117,DE-117,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4308,Glaucoma,7/7/14 12:28
4564,91,Santen,Regional & Specialty Pharma,4772,DE-117,DE-117,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4308,Glaucoma,7/7/14 12:28
4565,2489,Auven Therapeutics,Small Biotech,4773,RX-10045,RX-10045,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4309,Dry Eye,7/7/14 12:28
4565,2489,Auven Therapeutics,Small Biotech,4773,RX-10045,RX-10045,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4309,Dry Eye,7/7/14 12:28
4565,2489,Auven Therapeutics,Small Biotech,4773,RX-10045,RX-10045,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4309,Dry Eye,7/7/14 12:28
4566,16,AstraZeneca,Large Pharma,4774,RDX-5791,tenapanor,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,173,Other Nephrology Treatments,82,Renal Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4310,Complications in ESRD and CKD,7/7/14 12:28
4566,16,AstraZeneca,Large Pharma,4774,RDX-5791,tenapanor,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,173,Other Nephrology Treatments,82,Renal Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4310,Complications in ESRD and CKD,7/7/14 12:28
4566,16,AstraZeneca,Large Pharma,4774,RDX-5791,tenapanor,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,173,Other Nephrology Treatments,82,Renal Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4310,Complications in ESRD and CKD,7/7/14 12:28
4567,16,AstraZeneca,Large Pharma,4775,RDEA-3170,URAT-1 Inhibitor,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,151,Gout Treatments,64,Gout,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4311,Gout,7/7/14 12:28
4567,16,AstraZeneca,Large Pharma,4775,RDEA-3170,URAT-1 Inhibitor,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,151,Gout Treatments,64,Gout,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4311,Gout,7/7/14 12:28
4567,16,AstraZeneca,Large Pharma,4775,RDEA-3170,URAT-1 Inhibitor,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,151,Gout Treatments,64,Gout,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4311,Gout,7/7/14 12:28
4569,89,Sanofi,Large Pharma,3640,tofogliflozin,CSG-452,Small Molecule (Chemical),Filed,Licensed (Development),,Jun-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1615,Type II Diabetes,7/7/14 12:28
4569,89,Sanofi,Large Pharma,3640,tofogliflozin,CSG-452,Small Molecule (Chemical),Filed,Licensed (Development),,Jun-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,Global,Sales,0,0,0,0,0,14.59918348,34.7599259,48.73715164,59.27491416,72.76911162,85.47298426,95.6181648,0,1615,Type II Diabetes,7/7/14 12:28
4569,89,Sanofi,Large Pharma,3640,tofogliflozin,CSG-452,Small Molecule (Chemical),Filed,Licensed (Development),,Jun-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1615,Type II Diabetes,7/7/14 12:28
4569,89,Sanofi,Large Pharma,3640,tofogliflozin,CSG-452,Small Molecule (Chemical),Filed,Licensed (Development),,Jun-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,ROW,Sales,0,0,0,0,0,14.59918348,34.7599259,48.73715164,59.27491416,72.76911162,85.47298426,95.6181648,0,1615,Type II Diabetes,7/7/14 12:28
4569,89,Sanofi,Large Pharma,3640,tofogliflozin,CSG-452,Small Molecule (Chemical),Filed,Licensed (Development),,Jun-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1615,Type II Diabetes,7/7/14 12:28
4569,89,Sanofi,Large Pharma,3640,tofogliflozin,CSG-452,Small Molecule (Chemical),Filed,Licensed (Development),,Jun-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1615,Type II Diabetes,7/7/14 12:28
4571,16,AstraZeneca,Large Pharma,4777,PT003,formoterol + glycopyrrolate,Small Molecule (Chemical),Phase III,Corporate Acquisition,Apr-16,Feb-17,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,9.75,37.500003,65.41668527,93.08321688,116.0697792,0,4314,COPD,7/7/14 12:28
4571,16,AstraZeneca,Large Pharma,4777,PT003,formoterol + glycopyrrolate,Small Molecule (Chemical),Phase III,Corporate Acquisition,Apr-16,Feb-17,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,8.250003,14.50004027,20.50001194,26.49995543,0,4314,COPD,7/7/14 12:28
4571,16,AstraZeneca,Large Pharma,4777,PT003,formoterol + glycopyrrolate,Small Molecule (Chemical),Phase III,Corporate Acquisition,Apr-16,Feb-17,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,9.75,29.25,50.916645,72.58320495,89.56982373,0,4314,COPD,7/7/14 12:28
4572,95,Shionogi,Regional & Specialty Pharma,2116,Aimix,irbesartan + amlodipine,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-12,,Jun-18,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,18.75317762,43.75741445,67.62489616,91.49242701,106.3177805,117.9256399,122.2438605,114.5546943,109.2774206,13.96792114,386,Hypertension,7/7/14 12:28
4572,95,Shionogi,Regional & Specialty Pharma,2116,Aimix,irbesartan + amlodipine,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-12,,Jun-18,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,18.75317762,43.75741445,67.62489616,91.49242701,106.3177805,117.9256399,122.2438605,114.5546943,109.2774206,13.96792114,386,Hypertension,7/7/14 12:28
4572,95,Shionogi,Regional & Specialty Pharma,2116,Aimix,irbesartan + amlodipine,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-12,,Jun-18,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,386,Hypertension,7/7/14 12:28
4573,2153,Oncolytics Biotech,Small Biotech,4778,Reolysin,Reolysin,Recombinant Protein,Phase III,In-House,Jun-15,Sep-15,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,8,Global,Sales,0,0,0,0,0,0,19.01037887,70.5136553,135.2298364,199.946366,243.3980081,281.2568194,0,4315,Head & Neck Cancer,7/7/14 12:28
4573,2153,Oncolytics Biotech,Small Biotech,4778,Reolysin,Reolysin,Recombinant Protein,Phase III,In-House,Jun-15,Sep-15,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,8,ROW,Sales,0,0,0,0,0,0,4.853712205,22.65067314,46.91928386,71.18781424,87.26978265,101.3924685,0,4315,Head & Neck Cancer,7/7/14 12:28
4573,2153,Oncolytics Biotech,Small Biotech,4778,Reolysin,Reolysin,Recombinant Protein,Phase III,In-House,Jun-15,Sep-15,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,8,US,Sales,0,0,0,0,0,0,14.15666667,47.86298216,88.3105525,128.7585518,156.1282254,179.8643509,0,4315,Head & Neck Cancer,7/7/14 12:28
4574,25,Cardiome,Regional & Specialty Pharma,3919,vernakalant - oral,vernakalant - oral,Small Molecule (Chemical),Phase II,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,8,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,725,Atrial Fibrillation,7/7/14 12:28
4574,25,Cardiome,Regional & Specialty Pharma,3919,vernakalant - oral,vernakalant - oral,Small Molecule (Chemical),Phase II,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,8,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,725,Atrial Fibrillation,7/7/14 12:28
4574,25,Cardiome,Regional & Specialty Pharma,3919,vernakalant - oral,vernakalant - oral,Small Molecule (Chemical),Phase II,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,8,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,725,Atrial Fibrillation,7/7/14 12:28
4575,34,Daiichi-Sankyo,Regional & Specialty Pharma,4779,DS-8500,DS-8500,Small Molecule (Chemical),Phase I,In-House,,,,,48,PPAR Modulators,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4317,Diabetes,7/7/14 12:28
4575,34,Daiichi-Sankyo,Regional & Specialty Pharma,4779,DS-8500,DS-8500,Small Molecule (Chemical),Phase I,In-House,,,,,48,PPAR Modulators,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4317,Diabetes,7/7/14 12:28
4575,34,Daiichi-Sankyo,Regional & Specialty Pharma,4779,DS-8500,DS-8500,Small Molecule (Chemical),Phase I,In-House,,,,,48,PPAR Modulators,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4317,Diabetes,7/7/14 12:28
4576,34,Daiichi-Sankyo,Regional & Specialty Pharma,4780,DS-1442,,Small Molecule (Chemical),Phase I,In-House,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4318,Dyslipidemia - CETP inhibitor,7/7/14 12:28
4576,34,Daiichi-Sankyo,Regional & Specialty Pharma,4780,DS-1442,,Small Molecule (Chemical),Phase I,In-House,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4318,Dyslipidemia - CETP inhibitor,7/7/14 12:28
4576,34,Daiichi-Sankyo,Regional & Specialty Pharma,4780,DS-1442,,Small Molecule (Chemical),Phase I,In-House,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4318,Dyslipidemia - CETP inhibitor,7/7/14 12:28
4577,42,Forest,Regional & Specialty Pharma,4781,Arimenda,memantine XR + donepezil,Small Molecule (Chemical),Filed,Licensed (Development),Jun-15,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,34.999986,65.33342387,93.33336933,121.3333801,138.4133861,151.9373833,0,4319,Alzheimer's Disease,7/7/14 12:28
4577,42,Forest,Regional & Specialty Pharma,4781,Arimenda,memantine XR + donepezil,Small Molecule (Chemical),Filed,Licensed (Development),Jun-15,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4319,Alzheimer's Disease,7/7/14 12:28
4577,42,Forest,Regional & Specialty Pharma,4781,Arimenda,memantine XR + donepezil,Small Molecule (Chemical),Filed,Licensed (Development),Jun-15,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,34.999986,65.33342387,93.33336933,121.3333801,138.4133861,151.9373833,0,4319,Alzheimer's Disease,7/7/14 12:28
4578,34,Daiichi-Sankyo,Regional & Specialty Pharma,3962,tivantinib,ARQ197,Small Molecule (Chemical),Phase III,Licensed (Development),Jan-18,Mar-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,17.61851091,142.6263121,229.8802267,317.1348087,0,1350,Hepatocellular Carcinoma,7/7/14 12:28
4578,34,Daiichi-Sankyo,Regional & Specialty Pharma,3962,tivantinib,ARQ197,Small Molecule (Chemical),Phase III,Licensed (Development),Jan-18,Mar-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,7.550788664,95.64357476,156.0501437,216.4571543,0,1350,Hepatocellular Carcinoma,7/7/14 12:28
4578,34,Daiichi-Sankyo,Regional & Specialty Pharma,3962,tivantinib,ARQ197,Small Molecule (Chemical),Phase III,Licensed (Development),Jan-18,Mar-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,10.06772225,46.98273737,73.83008299,100.6776544,0,1350,Hepatocellular Carcinoma,7/7/14 12:28
4579,70,Ono,Regional & Specialty Pharma,4692,oprozomib,oprozomib,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4244,Multiple Myeloma,7/7/14 12:28
4579,70,Ono,Regional & Specialty Pharma,4692,oprozomib,oprozomib,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4244,Multiple Myeloma,7/7/14 12:28
4579,70,Ono,Regional & Specialty Pharma,4692,oprozomib,oprozomib,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4244,Multiple Myeloma,7/7/14 12:28
4580,16,AstraZeneca,Large Pharma,4774,RDX-5791,tenapanor,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4310,IBS-C,7/7/14 12:28
4580,16,AstraZeneca,Large Pharma,4774,RDX-5791,tenapanor,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4310,IBS-C,7/7/14 12:28
4580,16,AstraZeneca,Large Pharma,4774,RDX-5791,tenapanor,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4310,IBS-C,7/7/14 12:28
4581,1578,Curis,Small Biotech,4782,CUDC-427,RG-7459,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4320,Cancer,7/7/14 12:28
4581,1578,Curis,Small Biotech,4782,CUDC-427,RG-7459,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4320,Cancer,7/7/14 12:28
4581,1578,Curis,Small Biotech,4782,CUDC-427,RG-7459,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4320,Cancer,7/7/14 12:28
4582,106,United Therapeutics,Small Biotech,4783,treprostinil - self-injectable,treprostinil,Small Molecule (Chemical),Phase I,In-House,,,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4322,Pulmonary Hypertension,7/7/14 12:28
4582,106,United Therapeutics,Small Biotech,4783,treprostinil - self-injectable,treprostinil,Small Molecule (Chemical),Phase I,In-House,,,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4322,Pulmonary Hypertension,7/7/14 12:28
4582,106,United Therapeutics,Small Biotech,4783,treprostinil - self-injectable,treprostinil,Small Molecule (Chemical),Phase I,In-House,,,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4322,Pulmonary Hypertension,7/7/14 12:28
4583,106,United Therapeutics,Small Biotech,4784,Remodulin - Implantable Pump,treprostinil,Small Molecule (Chemical),Phase III,In-House,Jan-16,Apr-16,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,122.5,211.667,298.3336,384.9991885,450.3738191,0,4321,Pulmonary Hypertension,7/7/14 12:28
4583,106,United Therapeutics,Small Biotech,4784,Remodulin - Implantable Pump,treprostinil,Small Molecule (Chemical),Phase III,In-House,Jan-16,Apr-16,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,22.5,45,64.9998,84.99958846,100.3744641,0,4321,Pulmonary Hypertension,7/7/14 12:28
4583,106,United Therapeutics,Small Biotech,4784,Remodulin - Implantable Pump,treprostinil,Small Molecule (Chemical),Phase III,In-House,Jan-16,Apr-16,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,100,166.667,233.3338,299.9996,349.999355,0,4321,Pulmonary Hypertension,7/7/14 12:28
4586,16,AstraZeneca,Large Pharma,4786,fidaxomicin,fidaxomicin,Small Molecule (Chemical),Launched,Licensed (Development),,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2293,Clostridium difficile infection ,7/7/14 12:28
4586,16,AstraZeneca,Large Pharma,4786,fidaxomicin,fidaxomicin,Small Molecule (Chemical),Launched,Licensed (Development),,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2293,Clostridium difficile infection ,7/7/14 12:28
4586,16,AstraZeneca,Large Pharma,4786,fidaxomicin,fidaxomicin,Small Molecule (Chemical),Launched,Licensed (Development),,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2293,Clostridium difficile infection ,7/7/14 12:28
4587,2155,Aegerion Pharmaceuticals,Regional & Specialty Pharma,4787,Juxtapid,lomitapide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-13,Sep-13,Jun-20,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,48.5,183,360.49224,537.9846696,648.02399,742.3733558,818.7067013,708.7262183,46.68672061,4325,Hypercholesterolemia,7/7/14 12:28
4587,2155,Aegerion Pharmaceuticals,Regional & Specialty Pharma,4787,Juxtapid,lomitapide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-13,Sep-13,Jun-20,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,6.3,39,103.35,167.699844,211.2147855,251.6641035,286.2759361,314.8837112,74.85854068,4325,Hypercholesterolemia,7/7/14 12:28
4587,2155,Aegerion Pharmaceuticals,Regional & Specialty Pharma,4787,Juxtapid,lomitapide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-13,Sep-13,Jun-20,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,42.2,144,257.14224,370.2848256,436.8092045,490.7092524,532.4307652,393.8425072,37.58552269,4325,Hypercholesterolemia,7/7/14 12:28
4588,95,Shionogi,Regional & Specialty Pharma,4788,S-120083,S-120083,Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4326,Pain,7/7/14 12:28
4588,95,Shionogi,Regional & Specialty Pharma,4788,S-120083,S-120083,Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4326,Pain,7/7/14 12:28
4588,95,Shionogi,Regional & Specialty Pharma,4788,S-120083,S-120083,Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4326,Pain,7/7/14 12:28
4589,303,XenoPort,Small Biotech,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,In-House,Jun-12,,Nov-22,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,1.5,2.13426,3.171296934,3.675695168,4.020776266,4.286409969,4.455020383,4.571526152,17.25692344,1479,Post-herpetic Neuralgia,7/7/14 12:28
4589,303,XenoPort,Small Biotech,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,In-House,Jun-12,,Nov-22,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1479,Post-herpetic Neuralgia,7/7/14 12:28
4589,303,XenoPort,Small Biotech,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,In-House,Jun-12,,Nov-22,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,1.5,2.13426,3.171296934,3.675695168,4.020776266,4.286409969,4.455020383,4.571526152,17.25692344,1479,Post-herpetic Neuralgia,7/7/14 12:28
4590,303,XenoPort,Small Biotech,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,In-House,Jul-11,,Nov-22,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,4.6,6.816464,8.06058,9.1640786,9.84821705,10.30918805,10.63740143,10.85701427,13.05216568,1479,Restless Legs Syndrome,7/7/14 12:28
4590,303,XenoPort,Small Biotech,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,In-House,Jul-11,,Nov-22,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1479,Restless Legs Syndrome,7/7/14 12:28
4590,303,XenoPort,Small Biotech,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,In-House,Jul-11,,Nov-22,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,4.6,6.816464,8.06058,9.1640786,9.84821705,10.30918805,10.63740143,10.85701427,13.05216568,1479,Restless Legs Syndrome,7/7/14 12:28
4591,2157,Ampio Pharmaceuticals,Small Biotech,4789,Optina,danazol ,Small Molecule (Chemical),Phase III,In-House,Jan-16,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,15,30,39,45.00015,51.0902025,0,4327,Diabetic Macular Edema,7/7/14 12:28
4591,2157,Ampio Pharmaceuticals,Small Biotech,4789,Optina,danazol ,Small Molecule (Chemical),Phase III,In-House,Jan-16,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4327,Diabetic Macular Edema,7/7/14 12:28
4591,2157,Ampio Pharmaceuticals,Small Biotech,4789,Optina,danazol ,Small Molecule (Chemical),Phase III,In-House,Jan-16,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,15,30,39,45.00015,51.0902025,0,4327,Diabetic Macular Edema,7/7/14 12:28
4592,55,Kowa,Regional & Specialty Pharma,3640,tofogliflozin,CSG-452,Small Molecule (Chemical),Filed,Licensed (Development),,Jun-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,0,0,16.77953036,31.32184594,44.74544946,58.1690843,69.08697357,78.8235782,87.48629505,0,1615,Type II Diabetes,7/7/14 12:28
4592,55,Kowa,Regional & Specialty Pharma,3640,tofogliflozin,CSG-452,Small Molecule (Chemical),Filed,Licensed (Development),,Jun-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,0,0,16.77953036,31.32184594,44.74544946,58.1690843,69.08697357,78.8235782,87.48629505,0,1615,Type II Diabetes,7/7/14 12:28
4592,55,Kowa,Regional & Specialty Pharma,3640,tofogliflozin,CSG-452,Small Molecule (Chemical),Filed,Licensed (Development),,Jun-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1615,Type II Diabetes,7/7/14 12:28
4593,70,Ono,Regional & Specialty Pharma,4790,ONO-8055,ONO-8055,Small Molecule (Chemical),Phase I,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4328, Dysuria,7/7/14 12:28
4593,70,Ono,Regional & Specialty Pharma,4790,ONO-8055,ONO-8055,Small Molecule (Chemical),Phase I,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4328, Dysuria,7/7/14 12:28
4593,70,Ono,Regional & Specialty Pharma,4790,ONO-8055,ONO-8055,Small Molecule (Chemical),Phase I,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4328, Dysuria,7/7/14 12:28
4594,1988,BioCryst Pharmaceuticals,Small Biotech,4791,ulodesine,BCX-4208,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,151,Gout Treatments,64,Gout,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4329,Gout,7/7/14 12:28
4594,1988,BioCryst Pharmaceuticals,Small Biotech,4791,ulodesine,BCX-4208,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,151,Gout Treatments,64,Gout,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4329,Gout,7/7/14 12:28
4594,1988,BioCryst Pharmaceuticals,Small Biotech,4791,ulodesine,BCX-4208,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,151,Gout Treatments,64,Gout,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4329,Gout,7/7/14 12:28
4595,24,Bristol-Myers Squibb,Large Pharma,4792,beclabuvir,beclabuvir,Small Molecule (Chemical),Phase II,In-House,Jul-15,Oct-15,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,31.5375,76.52951513,103.8798488,99,88,53,0,4330,Hepatitis C,7/7/14 12:28
4595,24,Bristol-Myers Squibb,Large Pharma,4792,beclabuvir,beclabuvir,Small Molecule (Chemical),Phase II,In-House,Jul-15,Oct-15,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,16.8,48.72,68.8798488,62,57,25,0,4330,Hepatitis C,7/7/14 12:28
4595,24,Bristol-Myers Squibb,Large Pharma,4792,beclabuvir,beclabuvir,Small Molecule (Chemical),Phase II,In-House,Jul-15,Oct-15,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,14.7375,27.80951513,35,37,31,28,0,4330,Hepatitis C,7/7/14 12:28
4596,67,Novartis,Large Pharma,1985,Lusefi,luseogliflozin,Small Molecule (Chemical),Launched,Licensed (Development),,May-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,9.333338,16,24,31.57896,38,44,52,0,1208,Diabetes,7/7/14 12:28
4596,67,Novartis,Large Pharma,1985,Lusefi,luseogliflozin,Small Molecule (Chemical),Launched,Licensed (Development),,May-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,9.333338,16,24,31.57896,38,44,52,0,1208,Diabetes,7/7/14 12:28
4596,67,Novartis,Large Pharma,1985,Lusefi,luseogliflozin,Small Molecule (Chemical),Launched,Licensed (Development),,May-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1208,Diabetes,7/7/14 12:28
4597,102,Teva,Regional & Specialty Pharma,4793,XEN402,XEN402,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4331,Neuropathic Pain,7/7/14 12:28
4597,102,Teva,Regional & Specialty Pharma,4793,XEN402,XEN402,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4331,Neuropathic Pain,7/7/14 12:28
4597,102,Teva,Regional & Specialty Pharma,4793,XEN402,XEN402,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4331,Neuropathic Pain,7/7/14 12:28
4598,357,Japan Tobacco,Small Biotech,1884,Stribild,elvitegravir / cobicistat / tenofovir / emtricitabine FDC,Small Molecule (Chemical),Launched,Licensed (Development),,May-13,,,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,7,Global,Sales,0,0,0,0,15.18802778,40.27088898,90.60950021,100.6772225,110.7449447,70.47405572,40.27088898,33.97856258,12.19089432,950,HIV,7/7/14 12:28
4598,357,Japan Tobacco,Small Biotech,1884,Stribild,elvitegravir / cobicistat / tenofovir / emtricitabine FDC,Small Molecule (Chemical),Launched,Licensed (Development),,May-13,,,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,7,ROW,Sales,0,0,0,0,15.18802778,40.27088898,90.60950021,100.6772225,110.7449447,70.47405572,40.27088898,33.97856258,12.19089432,950,HIV,7/7/14 12:28
4598,357,Japan Tobacco,Small Biotech,1884,Stribild,elvitegravir / cobicistat / tenofovir / emtricitabine FDC,Small Molecule (Chemical),Launched,Licensed (Development),,May-13,,,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,950,HIV,7/7/14 12:28
4603,1391,Galen,Small Biotech,4798,DaunoXome,daunorubicin ,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,Expired,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4333,advanced HIV-associated Kaposis sarcoma,7/7/14 12:28
4603,1391,Galen,Small Biotech,4798,DaunoXome,daunorubicin ,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,Expired,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4333,advanced HIV-associated Kaposis sarcoma,7/7/14 12:28
4603,1391,Galen,Small Biotech,4798,DaunoXome,daunorubicin ,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,Expired,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4333,advanced HIV-associated Kaposis sarcoma,7/7/14 12:28
4604,37,Eisai,Regional & Specialty Pharma,4799,Gliadel Wafer,carmustine intracranial implant wafer,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4334,,7/7/14 12:28
4604,37,Eisai,Regional & Specialty Pharma,4799,Gliadel Wafer,carmustine intracranial implant wafer,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4334,,7/7/14 12:28
4604,37,Eisai,Regional & Specialty Pharma,4799,Gliadel Wafer,carmustine intracranial implant wafer,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4334,,7/7/14 12:28
4606,37,Eisai,Regional & Specialty Pharma,4801,BAN2401,BAN2401,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4336,Alzheimer's Disease,7/7/14 12:28
4606,37,Eisai,Regional & Specialty Pharma,4801,BAN2401,BAN2401,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4336,Alzheimer's Disease,7/7/14 12:28
4606,37,Eisai,Regional & Specialty Pharma,4801,BAN2401,BAN2401,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4336,Alzheimer's Disease,7/7/14 12:28
4607,19,Bayer,Large Pharma,4802,Skyla / Jaydess,levonorgestrel,Small Molecule (Chemical),Launched,In-House,Feb-13,May-13,,,89,Contraceptives,3,Contraception,2,Genitourinary,2,Global,Sales,0,0,0,0,23.39193814,49.90070294,88.10542289,151.2606702,189.9333043,226.6723725,260.7542715,289.3920289,43.2385431,4337,Female contraception,7/7/14 12:28
4607,19,Bayer,Large Pharma,4802,Skyla / Jaydess,levonorgestrel,Small Molecule (Chemical),Launched,In-House,Feb-13,May-13,,,89,Contraceptives,3,Contraception,2,Genitourinary,2,ROW,Sales,0,0,0,0,10.28217061,23.13488387,41.12873385,70.6900113,88.8894804,106.1429906,122.1420717,135.5944616,44.5513957,4337,Female contraception,7/7/14 12:28
4607,19,Bayer,Large Pharma,4802,Skyla / Jaydess,levonorgestrel,Small Molecule (Chemical),Launched,In-House,Feb-13,May-13,,,89,Contraceptives,3,Contraception,2,Genitourinary,2,US,Sales,0,0,0,0,13.10976753,26.76581907,46.97668904,80.57065891,101.0438239,120.5293819,138.6121998,153.7975673,42.15586173,4337,Female contraception,7/7/14 12:28
4609,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1759,SEP-225289,SEP-225289,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4339,ADHD,7/7/14 12:28
4609,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1759,SEP-225289,SEP-225289,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4339,ADHD,7/7/14 12:28
4609,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1759,SEP-225289,SEP-225289,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4339,ADHD,7/7/14 12:28
4610,53,Johnson & Johnson,Large Pharma,4804,esketamine,I.V. esketamine,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4340,Depression,7/7/14 12:28
4610,53,Johnson & Johnson,Large Pharma,4804,esketamine,I.V. esketamine,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4340,Depression,7/7/14 12:28
4610,53,Johnson & Johnson,Large Pharma,4804,esketamine,I.V. esketamine,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4340,Depression,7/7/14 12:28
4611,2449,Forum Pharmaceuticals,Small Biotech,4805,EVP-0962,EVP-0962,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4341,Alzheimer's Disease,7/7/14 12:28
4611,2449,Forum Pharmaceuticals,Small Biotech,4805,EVP-0962,EVP-0962,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4341,Alzheimer's Disease,7/7/14 12:28
4611,2449,Forum Pharmaceuticals,Small Biotech,4805,EVP-0962,EVP-0962,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4341,Alzheimer's Disease,7/7/14 12:28
4612,2205,Allon Therapeutics,Small Biotech,4806,davunetide,AL-208,Synthetic Peptide,Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,8,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4342,Alzheimer's Disease,7/7/14 12:28
4612,2205,Allon Therapeutics,Small Biotech,4806,davunetide,AL-208,Synthetic Peptide,Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,8,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4342,Alzheimer's Disease,7/7/14 12:28
4612,2205,Allon Therapeutics,Small Biotech,4806,davunetide,AL-208,Synthetic Peptide,Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,8,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4342,Alzheimer's Disease,7/7/14 12:28
4613,2204,TauRx Therapeutics,Small Biotech,4807,LMT-X,TRx0237,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4343,Alzheimer's Disease,7/7/14 12:28
4613,2204,TauRx Therapeutics,Small Biotech,4807,LMT-X,TRx0237,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4343,Alzheimer's Disease,7/7/14 12:28
4613,2204,TauRx Therapeutics,Small Biotech,4807,LMT-X,TRx0237,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4343,Alzheimer's Disease,7/7/14 12:28
4614,2115,Synergy Pharmaceuticals,Small Biotech,4808,plecanatide,plecanatide,Small Molecule (Chemical),Phase II,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4344,IBS-C,7/7/14 12:28
4614,2115,Synergy Pharmaceuticals,Small Biotech,4808,plecanatide,plecanatide,Small Molecule (Chemical),Phase II,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4344,IBS-C,7/7/14 12:28
4614,2115,Synergy Pharmaceuticals,Small Biotech,4808,plecanatide,plecanatide,Small Molecule (Chemical),Phase II,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4344,IBS-C,7/7/14 12:28
4615,86,Roche,Large Pharma,4809,RG7221,ANG2-VEGF MAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4345,Solid Tumors,7/7/14 12:28
4615,86,Roche,Large Pharma,4809,RG7221,ANG2-VEGF MAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4345,Solid Tumors,7/7/14 12:28
4615,86,Roche,Large Pharma,4809,RG7221,ANG2-VEGF MAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4345,Solid Tumors,7/7/14 12:28
4616,86,Roche,Large Pharma,4810,RG7203,RG7203,Small Molecule (Chemical),Phase I,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4346,Schizophrenia,7/7/14 12:28
4616,86,Roche,Large Pharma,4810,RG7203,RG7203,Small Molecule (Chemical),Phase I,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4346,Schizophrenia,7/7/14 12:28
4616,86,Roche,Large Pharma,4810,RG7203,RG7203,Small Molecule (Chemical),Phase I,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4346,Schizophrenia,7/7/14 12:28
4617,281,Idenix,Small Biotech,4811,IDX719,IDX719,Small Molecule (Chemical),Phase I,In-House,,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4347,Hepatitis C,7/7/14 12:28
4617,281,Idenix,Small Biotech,4811,IDX719,IDX719,Small Molecule (Chemical),Phase I,In-House,,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4347,Hepatitis C,7/7/14 12:28
4617,281,Idenix,Small Biotech,4811,IDX719,IDX719,Small Molecule (Chemical),Phase I,In-House,,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4347,Hepatitis C,7/7/14 12:28
4618,53,Johnson & Johnson,Large Pharma,4812,TMC647055,TMC647055,Small Molecule (Chemical),Phase II,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4348,Hepatitis C,7/7/14 12:28
4618,53,Johnson & Johnson,Large Pharma,4812,TMC647055,TMC647055,Small Molecule (Chemical),Phase II,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4348,Hepatitis C,7/7/14 12:28
4618,53,Johnson & Johnson,Large Pharma,4812,TMC647055,TMC647055,Small Molecule (Chemical),Phase II,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4348,Hepatitis C,7/7/14 12:28
4619,111,Actavis,Regional & Specialty Pharma,4813,E4,esterol + progestin,Small Molecule (Chemical),Phase III,Acquisition (Development),Nov-18,Jul-18,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,4.7925,14.28851088,26.18074081,0,4350,Female contraception,7/7/14 12:28
4619,111,Actavis,Regional & Specialty Pharma,4813,E4,esterol + progestin,Small Molecule (Chemical),Phase III,Acquisition (Development),Nov-18,Jul-18,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,3.6025,8.959381475,16.1174793,0,4350,Female contraception,7/7/14 12:28
4619,111,Actavis,Regional & Specialty Pharma,4813,E4,esterol + progestin,Small Molecule (Chemical),Phase III,Acquisition (Development),Nov-18,Jul-18,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,1.19,5.3291294,10.0632615,0,4350,Female contraception,7/7/14 12:28
4620,111,Actavis,Regional & Specialty Pharma,4814,Levosert,levonorgestrel,Small Molecule (Chemical),Launched,Acquisition (Development),Apr-15,Nov-13,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4351,Female contraception,7/7/14 12:28
4620,111,Actavis,Regional & Specialty Pharma,4814,Levosert,levonorgestrel,Small Molecule (Chemical),Launched,Acquisition (Development),Apr-15,Nov-13,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,0,0,1.02,3.9558252,6.607361041,8.309245994,9.747130029,11.30066495,12.45943704,13.59185505,44.76654359,4351,Female contraception,7/7/14 12:28
4620,111,Actavis,Regional & Specialty Pharma,4814,Levosert,levonorgestrel,Small Molecule (Chemical),Launched,Acquisition (Development),Apr-15,Nov-13,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4351,Female contraception,7/7/14 12:28
4620,111,Actavis,Regional & Specialty Pharma,4814,Levosert,levonorgestrel,Small Molecule (Chemical),Launched,Acquisition (Development),Apr-15,Nov-13,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,0,1.02,3.9558252,5.467361041,6.492502394,6.99270796,6.964600933,7.210786907,7.79983629,33.72483224,4351,Female contraception,7/7/14 12:28
4620,111,Actavis,Regional & Specialty Pharma,4814,Levosert,levonorgestrel,Small Molecule (Chemical),Launched,Acquisition (Development),Apr-15,Nov-13,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4351,Female contraception,7/7/14 12:28
4620,111,Actavis,Regional & Specialty Pharma,4814,Levosert,levonorgestrel,Small Molecule (Chemical),Launched,Acquisition (Development),Apr-15,Nov-13,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,1.14,1.8167436,2.75442207,4.336064015,5.248650136,5.792018762,0,4351,Female contraception,7/7/14 12:28
4621,111,Actavis,Regional & Specialty Pharma,3718,Esmya / Fibristal,ulipristal acetate,Small Molecule (Chemical),Launched,Licensed (Marketed),Oct-16,Nov-13,May-28,Feb-28,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,Global,Sales,0,0,0,0,1,6,11,28.5,82.333375,120.2168155,157.5230363,186.0724085,110.9793541,4276,Uterine fibroids,7/7/14 12:28
4621,111,Actavis,Regional & Specialty Pharma,3718,Esmya / Fibristal,ulipristal acetate,Small Molecule (Chemical),Launched,Licensed (Marketed),Oct-16,Nov-13,May-28,Feb-28,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,ROW,Sales,0,0,0,0,1,6,11,16,24,28.55,32.5225,35.988375,66.84326064,4276,Uterine fibroids,7/7/14 12:28
4621,111,Actavis,Regional & Specialty Pharma,3718,Esmya / Fibristal,ulipristal acetate,Small Molecule (Chemical),Launched,Licensed (Marketed),Oct-16,Nov-13,May-28,Feb-28,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,12.5,58.333375,91.66681548,125.0005363,150.0840335,0,4276,Uterine fibroids,7/7/14 12:28
4622,111,Actavis,Regional & Specialty Pharma,4815,Colvir,cidofovir,Small Molecule (Chemical),Phase I,Acquisition (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4352,HPV lesions,7/7/14 12:28
4622,111,Actavis,Regional & Specialty Pharma,4815,Colvir,cidofovir,Small Molecule (Chemical),Phase I,Acquisition (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4352,HPV lesions,7/7/14 12:28
4622,111,Actavis,Regional & Specialty Pharma,4815,Colvir,cidofovir,Small Molecule (Chemical),Phase I,Acquisition (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4352,HPV lesions,7/7/14 12:28
4623,111,Actavis,Regional & Specialty Pharma,4816,Progestin only patch,norethindrone acetate,Small Molecule (Chemical),Filed,In-House,Jan-15,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,20,33.3334,46.66676,59.99992,69.3332076,77.26649226,0,4353,Female contraception,7/7/14 12:28
4623,111,Actavis,Regional & Specialty Pharma,4816,Progestin only patch,norethindrone acetate,Small Molecule (Chemical),Filed,In-House,Jan-15,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4353,Female contraception,7/7/14 12:28
4623,111,Actavis,Regional & Specialty Pharma,4816,Progestin only patch,norethindrone acetate,Small Molecule (Chemical),Filed,In-House,Jan-15,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,20,33.3334,46.66676,59.99992,69.3332076,77.26649226,0,4353,Female contraception,7/7/14 12:28
4624,45,Gilead,Regional & Specialty Pharma,4817,momelotinib,momelotinib,Small Molecule (Chemical),Phase III,Corporate Acquisition,Jul-17,Dec-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,11.425,29.84634875,42.24192516,61.97768252,0,4355,Myelofibrosis,7/7/14 12:28
4624,45,Gilead,Regional & Specialty Pharma,4817,momelotinib,momelotinib,Small Molecule (Chemical),Phase III,Corporate Acquisition,Jul-17,Dec-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,1.6,11.306672,15.89333656,22.93328999,0,4355,Myelofibrosis,7/7/14 12:28
4624,45,Gilead,Regional & Specialty Pharma,4817,momelotinib,momelotinib,Small Molecule (Chemical),Phase III,Corporate Acquisition,Jul-17,Dec-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,9.825,18.53967675,26.3485886,39.04439253,0,4355,Myelofibrosis,7/7/14 12:28
4625,18,Baxter Healthcare,Regional & Specialty Pharma,4818,pacritinib,pacritinib,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-16,Nov-16,May-26,May-26,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,17.33334,59.55565778,91.55571444,123.5555844,145.6844546,0,4356,Myelofibrosis,7/7/14 12:28
4625,18,Baxter Healthcare,Regional & Specialty Pharma,4818,pacritinib,pacritinib,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-16,Nov-16,May-26,May-26,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,3.33334,22.22227778,35.55564444,48.88901111,58.27792369,0,4356,Myelofibrosis,7/7/14 12:28
4625,18,Baxter Healthcare,Regional & Specialty Pharma,4818,pacritinib,pacritinib,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-16,Nov-16,May-26,May-26,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,14,37.33338,56.00007,74.66657333,87.40653087,0,4356,Myelofibrosis,7/7/14 12:28
4628,68,Novo Nordisk,Regional & Specialty Pharma,4821,OG987SC,NN9927,Synthetic Peptide,Phase I,In-House,,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4359,Type II Diabetes,7/7/14 12:28
4628,68,Novo Nordisk,Regional & Specialty Pharma,4821,OG987SC,NN9927,Synthetic Peptide,Phase I,In-House,,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4359,Type II Diabetes,7/7/14 12:28
4628,68,Novo Nordisk,Regional & Specialty Pharma,4821,OG987SC,NN9927,Synthetic Peptide,Phase I,In-House,,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4359,Type II Diabetes,7/7/14 12:28
4629,68,Novo Nordisk,Regional & Specialty Pharma,4822,LAI287,NN1436,Recombinant Protein,Phase I,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4360,Type I and II Diabetes,7/7/14 12:28
4629,68,Novo Nordisk,Regional & Specialty Pharma,4822,LAI287,NN1436,Recombinant Protein,Phase I,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4360,Type I and II Diabetes,7/7/14 12:28
4629,68,Novo Nordisk,Regional & Specialty Pharma,4822,LAI287,NN1436,Recombinant Protein,Phase I,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4360,Type I and II Diabetes,7/7/14 12:28
4630,2216,Nereus,Small Biotech,4823,marizomib,NPI-0052,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4391,Multiple Myeloma,7/7/14 12:28
4630,2216,Nereus,Small Biotech,4823,marizomib,NPI-0052,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4391,Multiple Myeloma,7/7/14 12:28
4630,2216,Nereus,Small Biotech,4823,marizomib,NPI-0052,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4391,Multiple Myeloma,7/7/14 12:28
4631,86,Roche,Large Pharma,4824,Octreolin,oral octreotide,Synthetic Peptide,Phase III,Licensed (Development),Dec-15,Dec-15,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,Global,Sales,0,0,0,0,0,0,3.884843178,29.78381065,57.62512116,100.3581823,124.7872843,146.2091963,0,4362,Acromegaly,7/7/14 12:28
4631,86,Roche,Large Pharma,4824,Octreolin,oral octreotide,Synthetic Peptide,Phase III,Licensed (Development),Dec-15,Dec-15,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,ROW,Sales,0,0,0,0,0,0,1.510772347,11.58259303,22.40976934,39.02818199,48.52838834,56.8591319,0,4362,Acromegaly,7/7/14 12:28
4631,86,Roche,Large Pharma,4824,Octreolin,oral octreotide,Synthetic Peptide,Phase III,Licensed (Development),Dec-15,Dec-15,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,US,Sales,0,0,0,0,0,0,2.374070831,18.20121762,35.21535182,61.33000027,76.25889596,89.35006442,0,4362,Acromegaly,7/7/14 12:28
4632,181,PTC Therapeutics,Small Biotech,2053,ataluren,ataluren,Small Molecule (Chemical),Filed,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,165,Duchenne Muscular Dystrophy,7/7/14 12:28
4632,181,PTC Therapeutics,Small Biotech,2053,ataluren,ataluren,Small Molecule (Chemical),Filed,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,165,Duchenne Muscular Dystrophy,7/7/14 12:28
4632,181,PTC Therapeutics,Small Biotech,2053,ataluren,ataluren,Small Molecule (Chemical),Filed,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,165,Duchenne Muscular Dystrophy,7/7/14 12:28
4634,96,Shire,Regional & Specialty Pharma,4826,SHP611,human arylsulfatase A,Recombinant Protein,Phase II,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4364,Metachromatic Leukodystrophy,7/7/14 12:28
4634,96,Shire,Regional & Specialty Pharma,4826,SHP611,human arylsulfatase A,Recombinant Protein,Phase II,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4364,Metachromatic Leukodystrophy,7/7/14 12:28
4634,96,Shire,Regional & Specialty Pharma,4826,SHP611,human arylsulfatase A,Recombinant Protein,Phase II,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4364,Metachromatic Leukodystrophy,7/7/14 12:28
4635,192,Seattle Genetics,Small Biotech,4827,SGN-CD19A,anti-CD19 ADC,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4388,Hematological Malignancies,7/7/14 12:28
4635,192,Seattle Genetics,Small Biotech,4827,SGN-CD19A,anti-CD19 ADC,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4388,Hematological Malignancies,7/7/14 12:28
4635,192,Seattle Genetics,Small Biotech,4827,SGN-CD19A,anti-CD19 ADC,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4388,Hematological Malignancies,7/7/14 12:28
4637,851,Nordic Group,Small Biotech,2641,Trasylol ,aprotinin,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2140,Blood loss in cardiothoracic surgery,7/7/14 12:28
4637,851,Nordic Group,Small Biotech,2641,Trasylol ,aprotinin,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2140,Blood loss in cardiothoracic surgery,7/7/14 12:28
4637,851,Nordic Group,Small Biotech,2641,Trasylol ,aprotinin,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2140,Blood loss in cardiothoracic surgery,7/7/14 12:28
4639,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Launched,In-House,Dec-13,Mar-11,Aug-21,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,15,25,55,88.9,118.05214,145.8694324,157.2678689,165.127114,170.4507031,173.7250225,17.85744633,1676,Psoriatic Arthritis,7/7/14 12:28
4639,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Launched,In-House,Dec-13,Mar-11,Aug-21,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,15,25,43,55.9,64.21,71.185,76.3213,80.11489,83.014501,85.1835865,10.25859465,1676,Psoriatic Arthritis,7/7/14 12:28
4639,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Launched,In-House,Dec-13,Mar-11,Aug-21,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,12,33,53.84214,74.68443239,80.94656885,85.01222404,87.43620214,88.54143601,33.04388588,1676,Psoriatic Arthritis,7/7/14 12:28
4642,1810,Alfresa Pharma,Small Biotech,4832,Choreazine,tetrabenazine,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-13,,Jun-24,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1280,Huntington's Disease,7/7/14 12:28
4642,1810,Alfresa Pharma,Small Biotech,4832,Choreazine,tetrabenazine,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-13,,Jun-24,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1280,Huntington's Disease,7/7/14 12:28
4642,1810,Alfresa Pharma,Small Biotech,4832,Choreazine,tetrabenazine,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-13,,Jun-24,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1280,Huntington's Disease,7/7/14 12:28
4645,480,Array Biopharma,Small Biotech,4835,filanesib,ARRY-520,Small Molecule (Chemical),Phase II,In-House,Oct-17,Feb-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,7,41.5,80.20832,139.6666091,0,4366,Multiple Myeloma,7/7/14 12:28
4645,480,Array Biopharma,Small Biotech,4835,filanesib,ARRY-520,Small Molecule (Chemical),Phase II,In-House,Oct-17,Feb-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,17,34.70839,60.91669529,0,4366,Multiple Myeloma,7/7/14 12:28
4645,480,Array Biopharma,Small Biotech,4835,filanesib,ARRY-520,Small Molecule (Chemical),Phase II,In-House,Oct-17,Feb-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,7,24.5,45.49993,78.74991385,0,4366,Multiple Myeloma,7/7/14 12:28
4647,18,Baxter Healthcare,Regional & Specialty Pharma,4837,BAX 855,BAX 855,Recombinant Protein,Phase III,,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4387,Hemophilia A,7/7/14 12:28
4647,18,Baxter Healthcare,Regional & Specialty Pharma,4837,BAX 855,BAX 855,Recombinant Protein,Phase III,,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4387,Hemophilia A,7/7/14 12:28
4647,18,Baxter Healthcare,Regional & Specialty Pharma,4837,BAX 855,BAX 855,Recombinant Protein,Phase III,,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4387,Hemophilia A,7/7/14 12:28
4648,111,Actavis,Regional & Specialty Pharma,4838,Delzicol,mesalamine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-13,,Jul-15,N/A,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,17,156,100.8,76.44,73.488,67.4,58.77888,47.066304,15.65917884,1542,ulcerative colitis,7/7/14 12:28
4648,111,Actavis,Regional & Specialty Pharma,4838,Delzicol,mesalamine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-13,,Jul-15,N/A,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1542,ulcerative colitis,7/7/14 12:28
4648,111,Actavis,Regional & Specialty Pharma,4838,Delzicol,mesalamine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-13,,Jul-15,N/A,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,17,156,100.8,76.44,73.488,67.4,58.77888,47.066304,15.65917884,1542,ulcerative colitis,7/7/14 12:28
4648,111,Warner Chilcott ,Regional & Specialty Pharma,4838,Delzicol,mesalamine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-13,,Jul-15,N/A,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Proforma,0,0,0,0,117,0,0,0,0,0,0,0,-100,1542,ulcerative colitis,7/7/14 12:28
4648,111,Warner Chilcott ,Regional & Specialty Pharma,4838,Delzicol,mesalamine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-13,,Jul-15,N/A,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Proforma,0,0,0,0,117,0,0,0,0,0,0,0,-100,1542,ulcerative colitis,7/7/14 12:28
4649,24,Bristol-Myers Squibb,Large Pharma,4839,Factor XIa Inhibitor Oral,Factor XIa Inhibitor,Small Molecule (Chemical),Phase I,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4367,Venous Thromboembolism,7/7/14 12:28
4649,24,Bristol-Myers Squibb,Large Pharma,4839,Factor XIa Inhibitor Oral,Factor XIa Inhibitor,Small Molecule (Chemical),Phase I,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4367,Venous Thromboembolism,7/7/14 12:28
4649,24,Bristol-Myers Squibb,Large Pharma,4839,Factor XIa Inhibitor Oral,Factor XIa Inhibitor,Small Molecule (Chemical),Phase I,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4367,Venous Thromboembolism,7/7/14 12:28
4650,24,Bristol-Myers Squibb,Large Pharma,4840,PEG-Relaxin ,PEG-Relaxin,Synthetic Peptide,Phase I,Licensed (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4377,Heart Failure,7/7/14 12:28
4650,24,Bristol-Myers Squibb,Large Pharma,4840,PEG-Relaxin ,PEG-Relaxin,Synthetic Peptide,Phase I,Licensed (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4377,Heart Failure,7/7/14 12:28
4650,24,Bristol-Myers Squibb,Large Pharma,4840,PEG-Relaxin ,PEG-Relaxin,Synthetic Peptide,Phase I,Licensed (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4377,Heart Failure,7/7/14 12:28
4651,2221,AbbVie,Large Pharma,1024,Depakote,valproate semi-sodium,Small Molecule (Chemical),Launched,Licensed (Development),Jul-83,,Jul-08,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,0,0,0,0,58,49,44.5,42.25,41.125,40.5625,40.28125,39,-5.511994085,364,Epilepsy,7/7/14 12:28
4651,2221,AbbVie,Large Pharma,1024,Depakote,valproate semi-sodium,Small Molecule (Chemical),Launched,Licensed (Development),Jul-83,,Jul-08,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,364,Epilepsy,7/7/14 12:28
4651,2221,AbbVie,Large Pharma,1024,Depakote,valproate semi-sodium,Small Molecule (Chemical),Launched,Licensed (Development),Jul-83,,Jul-08,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,0,0,0,0,58,49,44.5,42.25,41.125,40.5625,40.28125,39,-5.511994085,364,Epilepsy,7/7/14 12:28
4652,2221,AbbVie,Large Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-86,,Jun-08,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1428,Appetite Stimulant,7/7/14 12:28
4652,2221,AbbVie,Large Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-86,,Jun-08,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1428,Appetite Stimulant,7/7/14 12:28
4652,2221,AbbVie,Large Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-86,,Jun-08,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1428,Appetite Stimulant,7/7/14 12:28
4653,2221,AbbVie,Large Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jan-90,Jan-90,Expired,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,Global,Sales,0,0,0,0,47.04,46,44,43.6,43.26,43.022,42.3504,42,-1.605944565,1517,Endometriosis,7/7/14 12:28
4653,2221,AbbVie,Large Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jan-90,Jan-90,Expired,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,ROW,Sales,0,0,0,0,13.14,13,12,12,11.82,11.646,11,11,-2.507533765,1517,Endometriosis,7/7/14 12:28
4653,2221,AbbVie,Large Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jan-90,Jan-90,Expired,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,US,Sales,0,0,0,0,33.9,33,32,31.6,31.44,31.376,31.3504,31,-1.269412977,1517,Endometriosis,7/7/14 12:28
4654,2221,AbbVie,Large Pharma,122,Androgel,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-00,Mar-06,Aug-15,N/A,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,Global,Sales,0,0,0,0,1035,965,740.72,288.225,183.6935341,136.6591547,105.3926415,84.118168,-30.13194565,1658,Hypogonadism,7/7/14 12:28
4654,2221,AbbVie,Large Pharma,122,Androgel,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-00,Mar-06,Aug-15,N/A,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1658,Hypogonadism,7/7/14 12:28
4654,2221,AbbVie,Large Pharma,122,Androgel,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-00,Mar-06,Aug-15,N/A,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,US,Sales,0,0,0,0,1035,965,740.72,288.225,183.6935341,136.6591547,105.3926415,84.118168,-30.13194565,1658,Hypogonadism,7/7/14 12:28
4655,2134,Stallergenes,Small Biotech,4841,Oralair,Oralair,Vaccine,Launched,In-House,May-14,Nov-09,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,2,Global,Sales,1.667398083,10.73051396,16.96333186,20.82139548,29.48226748,41.45047842,54.01845497,64.64438507,74.47883091,82.49675416,89.40297097,95.39435921,18.26374153,4368,Grass Pollen Allergy,7/7/14 12:28
4655,2134,Stallergenes,Small Biotech,4841,Oralair,Oralair,Vaccine,Launched,In-House,May-14,Nov-09,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,2,ROW,Sales,1.667398083,10.73051396,16.96333186,20.82139548,29.48226748,33.48229404,36.75402891,39.41173581,41.27796334,42.70882702,43.79293191,44.59966614,6.091723945,4368,Grass Pollen Allergy,7/7/14 12:28
4655,2134,Stallergenes,Small Biotech,4841,Oralair,Oralair,Vaccine,Launched,In-House,May-14,Nov-09,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,2,US,Sales,0,0,0,0,0,7.968184384,17.26442606,25.23264926,33.20086757,39.78792713,45.61003906,50.79469306,0,4368,Grass Pollen Allergy,7/7/14 12:28
4656,2221,AbbVie,Large Pharma,111,Prometrium,progesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Sales,0,0,0,0,50,49,48,47,46.2,45.48,44.84,44.2832,-1.719579403,1599,Estrogen deficiency,7/7/14 12:28
4656,2221,AbbVie,Large Pharma,111,Prometrium,progesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1599,Estrogen deficiency,7/7/14 12:28
4656,2221,AbbVie,Large Pharma,111,Prometrium,progesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Sales,0,0,0,0,50,49,48,47,46.2,45.48,44.84,44.2832,-1.719579403,1599,Estrogen deficiency,7/7/14 12:28
4657,105,UCB,Regional & Specialty Pharma,4632,AMG 785,romosozumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,Apr-17,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,9.87915236,39.51660944,73.04165366,109.1519864,0,1347,Osteoporosis,7/7/14 12:28
4657,105,UCB,Regional & Specialty Pharma,4632,AMG 785,romosozumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,Apr-17,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,9.87915236,39.51660944,73.04165366,109.1519864,0,1347,Osteoporosis,7/7/14 12:28
4657,105,UCB,Regional & Specialty Pharma,4632,AMG 785,romosozumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,Apr-17,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1347,Osteoporosis,7/7/14 12:28
4658,2224,Clarus Therapeutics,Regional & Specialty Pharma,4843,Rextoro,testosterone undecanoate,Small Molecule (Chemical),Filed,In-House,Oct-14,Oct-14,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,Global,Sales,0,0,0,0,0,5,28.33335,61.66668627,94.99999687,116.9333252,136.2766524,152.3194794,0,4369,Hypogonadism,7/7/14 12:28
4658,2224,Clarus Therapeutics,Regional & Specialty Pharma,4843,Rextoro,testosterone undecanoate,Small Molecule (Chemical),Filed,In-House,Oct-14,Oct-14,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,2,11.33334,24.66667451,37.99999875,46.77333008,54.51066097,60.92779175,0,4369,Hypogonadism,7/7/14 12:28
4658,2224,Clarus Therapeutics,Regional & Specialty Pharma,4843,Rextoro,testosterone undecanoate,Small Molecule (Chemical),Filed,In-House,Oct-14,Oct-14,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,US,Sales,0,0,0,0,0,3,17.00001,37.00001176,56.99999812,70.15999512,81.76599145,91.39168763,0,4369,Hypogonadism,7/7/14 12:28
4659,2225,Repros Therapeutics,Regional & Specialty Pharma,4844,Androxal,Enclomiphene citrate,Small Molecule (Chemical),Phase III,In-House,Aug-15,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,5.000004,20.33336627,40.33346866,60.33362576,71.7736948,81.20575608,0,4370,Hypogonadism,7/7/14 12:28
4659,2225,Repros Therapeutics,Regional & Specialty Pharma,4844,Androxal,Enclomiphene citrate,Small Molecule (Chemical),Phase III,In-House,Aug-15,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4370,Hypogonadism,7/7/14 12:28
4659,2225,Repros Therapeutics,Regional & Specialty Pharma,4844,Androxal,Enclomiphene citrate,Small Molecule (Chemical),Phase III,In-House,Aug-15,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,5.000004,20.33336627,40.33346866,60.33362576,71.7736948,81.20575608,0,4370,Hypogonadism,7/7/14 12:28
4660,2226,Trimel Pharmaceuticals,Regional & Specialty Pharma,4845,Natesto,testosterone,Small Molecule (Chemical),Approved,In-House,,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,8,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4371,Hypogonadism,7/7/14 12:28
4660,2226,Trimel Pharmaceuticals,Regional & Specialty Pharma,4845,Natesto,testosterone,Small Molecule (Chemical),Approved,In-House,,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,8,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4371,Hypogonadism,7/7/14 12:28
4660,2226,Trimel Pharmaceuticals,Regional & Specialty Pharma,4845,Natesto,testosterone,Small Molecule (Chemical),Approved,In-House,,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,8,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4371,Hypogonadism,7/7/14 12:28
4661,61,Merck & Co,Large Pharma,4846,Andriol Testocaps,testosterone undecanoate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jun-81,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4372,hypogonadism,7/7/14 12:28
4661,61,Merck & Co,Large Pharma,4846,Andriol Testocaps,testosterone undecanoate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jun-81,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4372,hypogonadism,7/7/14 12:28
4661,61,Merck & Co,Large Pharma,4846,Andriol Testocaps,testosterone undecanoate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jun-81,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4372,hypogonadism,7/7/14 12:28
4662,102,Teva,Regional & Specialty Pharma,4352,Lonquex,lipegfilgrastim,Recombinant Protein,Launched,Corporate Acquisition,,Nov-13,,,118,G-CSFs,78,Neutropenia,3,Oncology,6,Global,Sales,0,0,0,0,2.55,22,57,104,131,144,145,146,78.28542694,4373,Neutropenia,7/7/14 12:28
4662,102,Teva,Regional & Specialty Pharma,4352,Lonquex,lipegfilgrastim,Recombinant Protein,Launched,Corporate Acquisition,,Nov-13,,,118,G-CSFs,78,Neutropenia,3,Oncology,6,ROW,Sales,0,0,0,0,2.55,22,57,104,131,144,145,146,78.28542694,4373,Neutropenia,7/7/14 12:28
4662,102,Teva,Regional & Specialty Pharma,4352,Lonquex,lipegfilgrastim,Recombinant Protein,Launched,Corporate Acquisition,,Nov-13,,,118,G-CSFs,78,Neutropenia,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4373,Neutropenia,7/7/14 12:28
4663,39,Eli Lilly,Large Pharma,4361,PCSK9 Mab,PCSK9 Mab,Antibody/Antibody Derivative,Phase II,In-House,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4374,CV Disease,7/7/14 12:28
4663,39,Eli Lilly,Large Pharma,4361,PCSK9 Mab,PCSK9 Mab,Antibody/Antibody Derivative,Phase II,In-House,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4374,CV Disease,7/7/14 12:28
4663,39,Eli Lilly,Large Pharma,4361,PCSK9 Mab,PCSK9 Mab,Antibody/Antibody Derivative,Phase II,In-House,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4374,CV Disease,7/7/14 12:28
4664,2227,Presidio Pharmaceuticals,Small Biotech,4848,PPI-668,PPI-668,Small Molecule (Chemical),Phase I,In-House,,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4375,Hepatitis C,7/7/14 12:28
4664,2227,Presidio Pharmaceuticals,Small Biotech,4848,PPI-668,PPI-668,Small Molecule (Chemical),Phase I,In-House,,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4375,Hepatitis C,7/7/14 12:28
4664,2227,Presidio Pharmaceuticals,Small Biotech,4848,PPI-668,PPI-668,Small Molecule (Chemical),Phase I,In-House,,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4375,Hepatitis C,7/7/14 12:28
4665,2221,AbbVie,Large Pharma,184,Duodopa / Duopa,levodopa + carbidopa,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-14,Apr-05,N/A,Jan-14,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,178,202.23999,231.3319133,264.4240898,288.6159182,261.3798425,245.9359001,234.6909462,4.028837361,2177,Parkinson's Disease,7/7/14 12:28
4665,2221,AbbVie,Large Pharma,184,Duodopa / Duopa,levodopa + carbidopa,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-14,Apr-05,N/A,Jan-14,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,178,192.24,194.66525,207.757595,211.9495506,174.0468647,150.9363057,134.1747188,-3.957290846,2177,Parkinson's Disease,7/7/14 12:28
4665,2221,AbbVie,Large Pharma,184,Duodopa / Duopa,levodopa + carbidopa,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-14,Apr-05,N/A,Jan-14,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,9.99999,36.66666333,56.66649485,76.66636754,87.33297777,94.99959439,100.5162273,0,2177,Parkinson's Disease,7/7/14 12:28
4666,2221,AbbVie,Large Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-83,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,0,0,116,113,110,107,105,102,99,95,-2.812729286,1474,Depression,7/7/14 12:28
4666,2221,AbbVie,Large Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-83,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,116,113,110,107,105,102,99,95,-2.812729286,1474,Depression,7/7/14 12:28
4666,2221,AbbVie,Large Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-83,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
4667,2221,AbbVie,Large Pharma,1254,Vicodin / Vicoprofen,hydrocodone  +  acetaminophen / hydrocodone  +  ibuprofen,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-78,Aug-78,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,82.8,83.6,83.41,84.2295,84.408025,83.89512375,84.74036756,85.2325,0.414495612,1255,Pain,7/7/14 12:28
4667,2221,AbbVie,Large Pharma,1254,Vicodin / Vicoprofen,hydrocodone  +  acetaminophen / hydrocodone  +  ibuprofen,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-78,Aug-78,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,80,81,81,82,82.35,82,83,83.2325,0.567478698,1255,Pain,7/7/14 12:28
4667,2221,AbbVie,Large Pharma,1254,Vicodin / Vicoprofen,hydrocodone  +  acetaminophen / hydrocodone  +  ibuprofen,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-78,Aug-78,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,2.8,2.6,2.41,2.2295,2.058025,1.89512375,1.740367563,2,-4.693046561,1255,Pain,7/7/14 12:28
4668,2221,AbbVie,Large Pharma,2729,Ultane / Sevorane,sevoflurane,Small Molecule (Chemical),Launched,Licensed (Development),Dec-98,Jul-94,Apr-06,Apr-06,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,568,496,445,381,318.85,259.4075,206.537125,185.4,-14.78080813,1222,Anesthetic,7/7/14 12:28
4668,2221,AbbVie,Large Pharma,2729,Ultane / Sevorane,sevoflurane,Small Molecule (Chemical),Launched,Licensed (Development),Dec-98,Jul-94,Apr-06,Apr-06,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,491,430,387,330,275.85,224.4075,175.537125,155,-15.18661697,1222,Anesthetic,7/7/14 12:28
4668,2221,AbbVie,Large Pharma,2729,Ultane / Sevorane,sevoflurane,Small Molecule (Chemical),Launched,Licensed (Development),Dec-98,Jul-94,Apr-06,Apr-06,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,77,66,58,51,43,35,31,30.4,-12.43300106,1222,Anesthetic,7/7/14 12:28
4670,2229,Novan Therapeutics,Small Biotech,4850,SB204,SB204,Small Molecule (Chemical),Phase II,In-House,,,,,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4376,Acne,7/7/14 12:28
4670,2229,Novan Therapeutics,Small Biotech,4850,SB204,SB204,Small Molecule (Chemical),Phase II,In-House,,,,,160,Acne Treatments,73,Acne,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4376,Acne,7/7/14 12:28
4670,2229,Novan Therapeutics,Small Biotech,4850,SB204,SB204,Small Molecule (Chemical),Phase II,In-House,,,,,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4376,Acne,7/7/14 12:28
4671,234,Galderma,Regional & Specialty Pharma,4851,Oracea / Apprilon,doxycycline,Small Molecule (Chemical),Launched,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4389,Rosacea,7/7/14 12:28
4671,234,Galderma,Regional & Specialty Pharma,4851,Oracea / Apprilon,doxycycline,Small Molecule (Chemical),Launched,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4389,Rosacea,7/7/14 12:28
4671,234,Galderma,Regional & Specialty Pharma,4851,Oracea / Apprilon,doxycycline,Small Molecule (Chemical),Launched,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4389,Rosacea,7/7/14 12:28
4672,2221,AbbVie,Large Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jan-13,Jan-13,Expired,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,6,Global,Sales,0,0,0,0,737.8,798,815,826,830,833.48,835.536,837.5616,1.828253047,1517,Prostate Cancer,7/7/14 12:28
4672,2221,AbbVie,Large Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jan-13,Jan-13,Expired,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,6,ROW,Sales,0,0,0,0,205.8,208,200,198,195,193.52,192.704,193,-0.913156177,1517,Prostate Cancer,7/7/14 12:28
4672,2221,AbbVie,Large Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jan-13,Jan-13,Expired,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,6,US,Sales,0,0,0,0,532,590,615,628,635,639.96,642.832,644.5616,2.779743718,1517,Prostate Cancer,7/7/14 12:28
4673,103,The Medicines Company,Small Biotech,4852,ALN-PCS program,ALN-PCS,DNA/RNA Therapy,Phase I,Licensed (Development),,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4378,Hypercholesterolemia,7/7/14 12:28
4673,103,The Medicines Company,Small Biotech,4852,ALN-PCS program,ALN-PCS,DNA/RNA Therapy,Phase I,Licensed (Development),,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4378,Hypercholesterolemia,7/7/14 12:28
4673,103,The Medicines Company,Small Biotech,4852,ALN-PCS program,ALN-PCS,DNA/RNA Therapy,Phase I,Licensed (Development),,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4378,Hypercholesterolemia,7/7/14 12:28
4675,2225,Repros Therapeutics,Regional & Specialty Pharma,4854,Proellex,telapristone acetate,Small Molecule (Chemical),Phase II,Licensed (Development),Nov-16,Nov-16,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,5,7,10.64124,16.27345,16.27345,0,4379,Uterine fibroids,7/7/14 12:28
4675,2225,Repros Therapeutics,Regional & Specialty Pharma,4854,Proellex,telapristone acetate,Small Molecule (Chemical),Phase II,Licensed (Development),Nov-16,Nov-16,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,2,3,5,7.27345,7.27345,0,4379,Uterine fibroids,7/7/14 12:28
4675,2225,Repros Therapeutics,Regional & Specialty Pharma,4854,Proellex,telapristone acetate,Small Molecule (Chemical),Phase II,Licensed (Development),Nov-16,Nov-16,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,3,4,5.64124,9,9,0,4379,Uterine fibroids,7/7/14 12:28
4676,1,Abbott,Regional & Specialty Pharma,483,Advicor,Extended-release niacin  +  lovastatin,Small Molecule (Chemical),Launched,In-House,Jan-02,,Sep-13,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,65,43,19,13,0,0,0,0,0,0,0,0,0,1562,Dyslipidemia,7/7/14 12:28
4676,1,Abbott,Regional & Specialty Pharma,483,Advicor,Extended-release niacin  +  lovastatin,Small Molecule (Chemical),Launched,In-House,Jan-02,,Sep-13,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1562,Dyslipidemia,7/7/14 12:28
4676,1,Abbott,Regional & Specialty Pharma,483,Advicor,Extended-release niacin  +  lovastatin,Small Molecule (Chemical),Launched,In-House,Jan-02,,Sep-13,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,65,43,19,13,0,0,0,0,0,0,0,0,0,1562,Dyslipidemia,7/7/14 12:28
4677,2221,AbbVie,Large Pharma,292,Isoptin,verapamil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-77,Aug-93,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,573,Hypertension,7/7/14 12:28
4677,2221,AbbVie,Large Pharma,292,Isoptin,verapamil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-77,Aug-93,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,573,Hypertension,7/7/14 12:28
4677,2221,AbbVie,Large Pharma,292,Isoptin,verapamil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-77,Aug-93,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,573,Hypertension,7/7/14 12:28
4678,2221,AbbVie,Large Pharma,650,Mavik / Tarka,trandolapril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Jan-93,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,6,6,5.5,5.5,5,5,5,4.5,-4.026435077,666,Hypertension,7/7/14 12:28
4678,2221,AbbVie,Large Pharma,650,Mavik / Tarka,trandolapril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Jan-93,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,666,Hypertension,7/7/14 12:28
4678,2221,AbbVie,Large Pharma,650,Mavik / Tarka,trandolapril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Jan-93,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,6,6,5.5,5.5,5,5,5,4.5,-4.026435077,666,Hypertension,7/7/14 12:28
4679,2221,AbbVie,Large Pharma,1273,Teveten,eprosartan,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Jul-97,Dec-11,Apr-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,3,3,3,3,3,3,3,3,0,1446,Hypertension,7/7/14 12:28
4679,2221,AbbVie,Large Pharma,1273,Teveten,eprosartan,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Jul-97,Dec-11,Apr-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1446,Hypertension,7/7/14 12:28
4679,2221,AbbVie,Large Pharma,1273,Teveten,eprosartan,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Jul-97,Dec-11,Apr-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,3,3,3,3,3,3,3,3,0,1446,Hypertension,7/7/14 12:28
4680,2221,AbbVie,Large Pharma,902,Tricor,fenofibrate,Small Molecule (Chemical),Launched,Licensed (Development),Jun-98,,Nov-12,,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,303,121,83,59,48,41,37,34,-26.83707936,1461,Dyslipidemia,7/7/14 12:28
4680,2221,AbbVie,Large Pharma,902,Tricor,fenofibrate,Small Molecule (Chemical),Launched,Licensed (Development),Jun-98,,Nov-12,,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1461,Dyslipidemia,7/7/14 12:28
4680,2221,AbbVie,Large Pharma,902,Tricor,fenofibrate,Small Molecule (Chemical),Launched,Licensed (Development),Jun-98,,Nov-12,,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,303,121,83,59,48,41,37,34,-26.83707936,1461,Dyslipidemia,7/7/14 12:28
4681,1,Abbott,Regional & Specialty Pharma,501,Niaspan,Extended-release niacin,Small Molecule (Chemical),Launched,In-House,Aug-97,,Sep-13,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,855,927,976,911,0,0,0,0,0,0,0,0,0,1561,Dyslipidemia,7/7/14 12:28
4681,1,Abbott,Regional & Specialty Pharma,501,Niaspan,Extended-release niacin,Small Molecule (Chemical),Launched,In-House,Aug-97,,Sep-13,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1561,Dyslipidemia,7/7/14 12:28
4681,1,Abbott,Regional & Specialty Pharma,501,Niaspan,Extended-release niacin,Small Molecule (Chemical),Launched,In-House,Aug-97,,Sep-13,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,855,927,976,911,0,0,0,0,0,0,0,0,0,1561,Dyslipidemia,7/7/14 12:28
4682,1,Abbott,Regional & Specialty Pharma,1548,Simcor,Extended-release niacin  +  simvastatin,Small Molecule (Chemical),Launched,In-House,Mar-08,,Sep-13,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,169,242,176,114,0,0,0,0,0,0,0,0,0,1090,Dyslipidemia,7/7/14 12:28
4682,1,Abbott,Regional & Specialty Pharma,1548,Simcor,Extended-release niacin  +  simvastatin,Small Molecule (Chemical),Launched,In-House,Mar-08,,Sep-13,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1090,Dyslipidemia,7/7/14 12:28
4682,1,Abbott,Regional & Specialty Pharma,1548,Simcor,Extended-release niacin  +  simvastatin,Small Molecule (Chemical),Launched,In-House,Mar-08,,Sep-13,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,169,242,176,114,0,0,0,0,0,0,0,0,0,1090,Dyslipidemia,7/7/14 12:28
4683,28,Chiesi,Regional & Specialty Pharma,4855,Cardene,nicardipine ,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-90,,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4380,Hypertension,7/7/14 12:28
4683,28,Chiesi,Regional & Specialty Pharma,4855,Cardene,nicardipine ,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-90,,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4380,Hypertension,7/7/14 12:28
4683,28,Chiesi,Regional & Specialty Pharma,4855,Cardene,nicardipine ,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-90,,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4380,Hypertension,7/7/14 12:28
4684,94,Servier,Regional & Specialty Pharma,4471,gevokizumab,gevokizumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Aug-16,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,Global,Sales,0,0,0,0,0,0,0,12.08507361,32.56830656,59.09421521,101.9044285,123.6531203,0,4179,Uveitis,7/7/14 12:28
4684,94,Servier,Regional & Specialty Pharma,4471,gevokizumab,gevokizumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Aug-16,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,ROW,Sales,0,0,0,0,0,0,0,12.08507361,32.56830656,59.09421521,101.9044285,123.6531203,0,4179,Uveitis,7/7/14 12:28
4684,94,Servier,Regional & Specialty Pharma,4471,gevokizumab,gevokizumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Aug-16,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4179,Uveitis,7/7/14 12:28
4686,61,Merck & Co,Large Pharma,4857,MK-8175A,nomegestrol acetate + estradiol vaginal ring,Small Molecule (Chemical),Phase II,In-House,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4381,Female contraception,7/7/14 12:28
4686,61,Merck & Co,Large Pharma,4857,MK-8175A,nomegestrol acetate + estradiol vaginal ring,Small Molecule (Chemical),Phase II,In-House,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4381,Female contraception,7/7/14 12:28
4686,61,Merck & Co,Large Pharma,4857,MK-8175A,nomegestrol acetate + estradiol vaginal ring,Small Molecule (Chemical),Phase II,In-House,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4381,Female contraception,7/7/14 12:28
4687,19,Bayer,Large Pharma,4858,LCS-16,levonorgestrel,Small Molecule (Chemical),Phase III,In-House,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4383,Female contraception,7/7/14 12:28
4687,19,Bayer,Large Pharma,4858,LCS-16,levonorgestrel,Small Molecule (Chemical),Phase III,In-House,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4383,Female contraception,7/7/14 12:28
4687,19,Bayer,Large Pharma,4858,LCS-16,levonorgestrel,Small Molecule (Chemical),Phase III,In-House,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4383,Female contraception,7/7/14 12:28
4689,1364,Leo Pharmaceuticals,Small Biotech,4860,Picato,Ingenol mebutate gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-12,Nov-12,Aug-18,Nov-22,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,6,Global,Sales,0,0,0,5,18.33335,30,44.59253,49.3164427,52.51904974,54.62316768,55.68754526,56.34136526,17.39646156,4385,Actinic keratosis,7/7/14 12:28
4689,1364,Leo Pharmaceuticals,Small Biotech,4860,Picato,Ingenol mebutate gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-12,Nov-12,Aug-18,Nov-22,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,6,ROW,Sales,0,0,0,1,7.66667,13,20.35852,22.3422979,23.62213119,24.43415739,24.79017299,24.99344768,18.39053513,4385,Actinic keratosis,7/7/14 12:28
4689,1364,Leo Pharmaceuticals,Small Biotech,4860,Picato,Ingenol mebutate gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-12,Nov-12,Aug-18,Nov-22,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,6,US,Sales,0,0,0,4,10.66668,17,24.23401,26.9741448,28.89691856,30.18901029,30.89737227,31.34791757,16.64945358,4385,Actinic keratosis,7/7/14 12:28
4690,2221,AbbVie,Large Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,0,412,425,464.03,495.7745,504.828875,511.3858362,515.0889442,516.7777994,3.289952155,1579,Pancreatic Insufficiency,7/7/14 12:28
4690,2221,AbbVie,Large Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1579,Pancreatic Insufficiency,7/7/14 12:28
4690,2221,AbbVie,Large Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,412,425,464.03,495.7745,504.828875,511.3858362,515.0889442,516.7777994,3.289952155,1579,Pancreatic Insufficiency,7/7/14 12:28
4691,2221,AbbVie,Large Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,Mar-08,Jan-17,May-18,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,2832,2930,3092,3230,3308.463591,3034.158617,2954.761641,2938.415529,0.528352136,1327,Psoriasis,7/7/14 12:28
4691,2221,AbbVie,Large Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,Mar-08,Jan-17,May-18,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,1514,1536,1586,1622,1642.57,1493.700075,1462.792411,1444.904383,-0.66509212,1327,Psoriasis,7/7/14 12:28
4691,2221,AbbVie,Large Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,Mar-08,Jan-17,May-18,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,1318,1394,1506,1608,1665.893591,1540.458542,1491.96923,1493.511146,1.801960888,1327,Psoriasis,7/7/14 12:28
4692,615,Kaken Pharmaceutical,Regional & Specialty Pharma,3725,Jublia,efinaconazole,Small Molecule (Chemical),Approved,In-House,,Jun-14,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,1.093934924,13.8565455,22.6080625,31.3596435,38.0472809,43.45099838,47.97192469,51.62529881,73.42999136,3609,Onychomycosis,7/7/14 12:28
4692,615,Kaken Pharmaceutical,Regional & Specialty Pharma,3725,Jublia,efinaconazole,Small Molecule (Chemical),Approved,In-House,,Jun-14,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,1.093934924,13.8565455,22.6080625,31.3596435,38.0472809,43.45099838,47.97192469,51.62529881,73.42999136,3609,Onychomycosis,7/7/14 12:28
4692,615,Kaken Pharmaceutical,Regional & Specialty Pharma,3725,Jublia,efinaconazole,Small Molecule (Chemical),Approved,In-House,,Jun-14,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3609,Onychomycosis,7/7/14 12:28
4693,2221,AbbVie,Large Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1428,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
4693,2221,AbbVie,Large Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1428,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
4693,2221,AbbVie,Large Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1428,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
4694,2221,AbbVie,Large Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-07,Sep-07,Jan-17,May-18,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,1672,1847,1993,2081.29,2119.4918,2020.97637,2008.878294,1990.459576,2.521916513,1327,inflammatory bowel disease,7/7/14 12:28
4694,2221,AbbVie,Large Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-07,Sep-07,Jan-17,May-18,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,868,1001,1082,1141.47,1203.7882,1203.688536,1236.809677,1250.851193,5.358455328,1327,inflammatory bowel disease,7/7/14 12:28
4694,2221,AbbVie,Large Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-07,Sep-07,Jan-17,May-18,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,804,846,911,939.82,915.7036,817.2878341,772.0686173,739.6083824,-1.185465225,1327,inflammatory bowel disease,7/7/14 12:28
4695,2221,AbbVie,Large Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-03,Sep-03,Jan-17,May-18,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,6155,6308,6726,7073,6951.784348,6404.191038,5756.26374,5662.758756,-1.183702604,1327,Rheumatoid Arthritis,7/7/14 12:28
4695,2221,AbbVie,Large Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-03,Sep-03,Jan-17,May-18,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,3041,3121,3275,3405,3519,3306.165002,3110.930812,3056.315592,7.18E-02,1327,Rheumatoid Arthritis,7/7/14 12:28
4695,2221,AbbVie,Large Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-03,Sep-03,Jan-17,May-18,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,3114,3187,3451,3668,3432.784348,3098.026036,2645.332927,2606.443164,-2.509703832,1327,Rheumatoid Arthritis,7/7/14 12:28
4696,2221,AbbVie,Large Pharma,230,Biaxin,clarithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-91,,May-05,N/A,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,1.71,1.7955,1.851075,1.89061875,1.895973187,1.898538722,1.899618507,1.899856551,1.515438171,1396,bacterial infection,7/7/14 12:28
4696,2221,AbbVie,Large Pharma,230,Biaxin,clarithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-91,,May-05,N/A,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1396,bacterial infection,7/7/14 12:28
4696,2221,AbbVie,Large Pharma,230,Biaxin,clarithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-91,,May-05,N/A,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,1.71,1.7955,1.851075,1.89061875,1.895973187,1.898538722,1.899618507,1.899856551,1.515438171,1396,bacterial infection,7/7/14 12:28
4697,1,Abbott,Regional & Specialty Pharma,82,Kaletra,lopinavir  +  ritonavir,Small Molecule (Chemical),Launched,In-House,Sep-00,Feb-02,Jun-16,Dec-16,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Sales,1373,1223,1170,1013,0,0,0,0,0,0,0,0,0,589,HIV,7/7/14 12:28
4697,1,Abbott,Regional & Specialty Pharma,82,Kaletra,lopinavir  +  ritonavir,Small Molecule (Chemical),Launched,In-House,Sep-00,Feb-02,Jun-16,Dec-16,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Sales,926,860,844,734,0,0,0,0,0,0,0,0,0,589,HIV,7/7/14 12:28
4697,1,Abbott,Regional & Specialty Pharma,82,Kaletra,lopinavir  +  ritonavir,Small Molecule (Chemical),Launched,In-House,Sep-00,Feb-02,Jun-16,Dec-16,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Sales,447,363,326,279,0,0,0,0,0,0,0,0,0,589,HIV,7/7/14 12:28
4698,1,Abbott,Regional & Specialty Pharma,1175,Norvir,ritonavir,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-96,Jan-14,Dec-13,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Sales,349,344,419,389,0,0,0,0,0,0,0,0,0,798,HIV,7/7/14 12:28
4698,1,Abbott,Regional & Specialty Pharma,1175,Norvir,ritonavir,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-96,Jan-14,Dec-13,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Sales,103,103,130,113,0,0,0,0,0,0,0,0,0,798,HIV,7/7/14 12:28
4698,1,Abbott,Regional & Specialty Pharma,1175,Norvir,ritonavir,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-96,Jan-14,Dec-13,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Sales,246,241,289,276,0,0,0,0,0,0,0,0,0,798,HIV,7/7/14 12:28
4699,2221,AbbVie,Large Pharma,763,Synthroid,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-57,,Expired,N/A,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,622,645,660,680,700,715,725,730,2.313561093,1525,Hypothyroidism,7/7/14 12:28
4699,2221,AbbVie,Large Pharma,763,Synthroid,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-57,,Expired,N/A,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1525,Hypothyroidism,7/7/14 12:28
4699,2221,AbbVie,Large Pharma,763,Synthroid,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-57,,Expired,N/A,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,US,Sales,0,0,0,0,622,645,660,680,700,715,725,730,2.313561093,1525,Hypothyroidism,7/7/14 12:28
4700,2221,AbbVie,Large Pharma,191,Zemplar,paricalcitol,Small Molecule (Chemical),Launched,In-House,Nov-98,Dec-03,Oct-13,N/A,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,389,367,365,365,360,355,350,350,-1.497897971,1300,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
4700,2221,AbbVie,Large Pharma,191,Zemplar,paricalcitol,Small Molecule (Chemical),Launched,In-House,Nov-98,Dec-03,Oct-13,N/A,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,171,182,195,205,210,215,220,225,3.998389189,1300,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
4700,2221,AbbVie,Large Pharma,191,Zemplar,paricalcitol,Small Molecule (Chemical),Launched,In-House,Nov-98,Dec-03,Oct-13,N/A,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,US,Sales,0,0,0,0,218,185,170,160,150,140,130,125,-7.637985986,1300,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
4701,2157,Ampio Pharmaceuticals,Small Biotech,4861,Zertane,tramadol,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4386,Premature ejaculation,7/7/14 12:28
4701,2157,Ampio Pharmaceuticals,Small Biotech,4861,Zertane,tramadol,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4386,Premature ejaculation,7/7/14 12:28
4701,2157,Ampio Pharmaceuticals,Small Biotech,4861,Zertane,tramadol,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4386,Premature ejaculation,7/7/14 12:28
4702,2221,AbbVie,Large Pharma,1007,Omnicef,cefdinir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-98,,May-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,4,4.4,4,4.144,4.1504,4.14368,4.149152,4.149552,0.525748357,1383,Bacterial infections,7/7/14 12:28
4702,2221,AbbVie,Large Pharma,1007,Omnicef,cefdinir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-98,,May-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1383,Bacterial infections,7/7/14 12:28
4702,2221,AbbVie,Large Pharma,1007,Omnicef,cefdinir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-98,,May-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,4,4.4,4,4.144,4.1504,4.14368,4.149152,4.149552,0.525748357,1383,Bacterial infections,7/7/14 12:28
4703,2221,AbbVie,Large Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Licensed (Marketed),,Jul-99,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,384,403.2,415.68,424.56,425.7624,426.33852,426.580998,426.6344535,1.515438171,1577,RSV prevention,7/7/14 12:28
4703,2221,AbbVie,Large Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Licensed (Marketed),,Jul-99,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,384,403.2,415.68,424.56,425.7624,426.33852,426.580998,426.6344535,1.515438171,1577,RSV prevention,7/7/14 12:28
4703,2221,AbbVie,Large Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Licensed (Marketed),,Jul-99,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1577,RSV prevention,7/7/14 12:28
4705,498,Merrimack,Small Biotech,4863,MM-398,MM-398,Small Molecule (Chemical),Phase III,,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4392,Pancreatic Cancer,7/7/14 12:28
4705,498,Merrimack,Small Biotech,4863,MM-398,MM-398,Small Molecule (Chemical),Phase III,,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4392,Pancreatic Cancer,7/7/14 12:28
4705,498,Merrimack,Small Biotech,4863,MM-398,MM-398,Small Molecule (Chemical),Phase III,,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4392,Pancreatic Cancer,7/7/14 12:28
4706,2235,Axelar AB,Small Biotech,4864,AXL1717,AXL1717,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,9,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4393,Non-small-cell Lung Cancer,7/7/14 12:28
4706,2235,Axelar AB,Small Biotech,4864,AXL1717,AXL1717,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,9,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4393,Non-small-cell Lung Cancer,7/7/14 12:28
4706,2235,Axelar AB,Small Biotech,4864,AXL1717,AXL1717,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4393,Non-small-cell Lung Cancer,7/7/14 12:28
4708,40,Endo Health Solutions,Regional & Specialty Pharma,4866,Supprelin LA,histrelin,Synthetic Peptide,Launched,Corporate Acquisition,Jun-07,,Jun-26,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Sales,27.8,46.91,50.115,57.416,58.3,60.59131,62.6010485,63.90939208,65.11014081,66.08651841,66.8635759,67.50869015,2.117158883,4395,Central Precocious Puberty,7/7/14 12:28
4708,40,Endo Health Solutions,Regional & Specialty Pharma,4866,Supprelin LA,histrelin,Synthetic Peptide,Launched,Corporate Acquisition,Jun-07,,Jun-26,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4395,Central Precocious Puberty,7/7/14 12:28
4708,40,Endo Health Solutions,Regional & Specialty Pharma,4866,Supprelin LA,histrelin,Synthetic Peptide,Launched,Corporate Acquisition,Jun-07,,Jun-26,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Sales,27.8,46.91,50.115,57.416,58.3,60.59131,62.6010485,63.90939208,65.11014081,66.08651841,66.8635759,67.50869015,2.117158883,4395,Central Precocious Puberty,7/7/14 12:28
4708,40,Indevus Pharmaceuticals,Regional & Specialty Pharma,4866,Supprelin LA,histrelin,Synthetic Peptide,Launched,Corporate Acquisition,Jun-07,,Jun-26,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Proforma,7,0,0,0,0,0,0,0,0,0,0,0,0,4395,Central Precocious Puberty,7/7/14 12:28
4708,40,Indevus Pharmaceuticals,Regional & Specialty Pharma,4866,Supprelin LA,histrelin,Synthetic Peptide,Launched,Corporate Acquisition,Jun-07,,Jun-26,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Proforma,7,0,0,0,0,0,0,0,0,0,0,0,0,4395,Central Precocious Puberty,7/7/14 12:28
4709,2239,Covis Pharmaceuticals,Regional & Specialty Pharma,2466,Rilutek,riluzole,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-96,,Jun-13,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,24,14,10,8,6,5,5,4,-22.58312319,1015,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4709,2239,Covis Pharmaceuticals,Regional & Specialty Pharma,2466,Rilutek,riluzole,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-96,,Jun-13,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1015,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4709,2239,Covis Pharmaceuticals,Regional & Specialty Pharma,2466,Rilutek,riluzole,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-96,,Jun-13,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,24,14,10,8,6,5,5,4,-22.58312319,1015,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4710,16,AstraZeneca,Large Pharma,4867,ACP-501,MEDI-6012,Recombinant Protein,Phase I,Corporate Acquisition,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4396,Dyslipidemia,7/7/14 12:28
4710,16,AstraZeneca,Large Pharma,4867,ACP-501,MEDI-6012,Recombinant Protein,Phase I,Corporate Acquisition,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4396,Dyslipidemia,7/7/14 12:28
4710,16,AstraZeneca,Large Pharma,4867,ACP-501,MEDI-6012,Recombinant Protein,Phase I,Corporate Acquisition,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4396,Dyslipidemia,7/7/14 12:28
4711,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,4868,SPI-2012,long-acting G-CSF,Recombinant Protein,Phase II,Licensed (Development),,,,,118,G-CSFs,78,Neutropenia,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4397,Neutropenia,7/7/14 12:28
4711,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,4868,SPI-2012,long-acting G-CSF,Recombinant Protein,Phase II,Licensed (Development),,,,,118,G-CSFs,78,Neutropenia,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4397,Neutropenia,7/7/14 12:28
4711,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,4868,SPI-2012,long-acting G-CSF,Recombinant Protein,Phase II,Licensed (Development),,,,,118,G-CSFs,78,Neutropenia,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4397,Neutropenia,7/7/14 12:28
4712,108,Vertex,Regional & Specialty Pharma,4869,Kalydeco+VX-983,ivacaftor+VX-983,Small Molecule (Chemical),Phase I,In-House,,,,,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4398,Cystic Fibrosis,7/7/14 12:28
4712,108,Vertex,Regional & Specialty Pharma,4869,Kalydeco+VX-983,ivacaftor+VX-983,Small Molecule (Chemical),Phase I,In-House,,,,,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4398,Cystic Fibrosis,7/7/14 12:28
4712,108,Vertex,Regional & Specialty Pharma,4869,Kalydeco+VX-983,ivacaftor+VX-983,Small Molecule (Chemical),Phase I,In-House,,,,,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4398,Cystic Fibrosis,7/7/14 12:28
4713,67,Novartis,Large Pharma,4870,Simbrinza,brinzolamide + brimonidine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Aug-14,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Sales,0,0,0,0,13.33334,50.55562778,109.4444611,176.1115482,232.1563284,274.0165264,309.7703917,338.9211554,58.75846924,4399,Glaucoma,7/7/14 12:28
4713,67,Novartis,Large Pharma,4870,Simbrinza,brinzolamide + brimonidine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Aug-14,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,8.33334,33.88894378,67.22244777,100.5560429,122.8006216,142.2529697,158.3993564,0,4399,Glaucoma,7/7/14 12:28
4713,67,Novartis,Large Pharma,4870,Simbrinza,brinzolamide + brimonidine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Aug-14,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Sales,0,0,0,0,13.33334,42.22228778,75.55551731,108.8891004,131.6002854,151.2159048,167.517422,180.521799,45.096071,4399,Glaucoma,7/7/14 12:28
4714,1900,Halozyme Therapeutics,Small Biotech,4871,PEGPH20,Pegylated recombinant human hyaluronidase,Recombinant Protein,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4400,Pancreatic Cancer,7/7/14 12:28
4714,1900,Halozyme Therapeutics,Small Biotech,4871,PEGPH20,Pegylated recombinant human hyaluronidase,Recombinant Protein,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4400,Pancreatic Cancer,7/7/14 12:28
4714,1900,Halozyme Therapeutics,Small Biotech,4871,PEGPH20,Pegylated recombinant human hyaluronidase,Recombinant Protein,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4400,Pancreatic Cancer,7/7/14 12:28
4715,207,CytRx,Regional & Specialty Pharma,4872,aldoxorubicin,aldoxorubicin,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4401,Soft Tissue Sarcoma,7/7/14 12:28
4715,207,CytRx,Regional & Specialty Pharma,4872,aldoxorubicin,aldoxorubicin,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4401,Soft Tissue Sarcoma,7/7/14 12:28
4715,207,CytRx,Regional & Specialty Pharma,4872,aldoxorubicin,aldoxorubicin,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4401,Soft Tissue Sarcoma,7/7/14 12:28
4716,111,Actavis,Regional & Specialty Pharma,4873,Minastrin 24 Fe,norethindrone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-13,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,0,0,37,107.55843,152.8620407,226.5170864,262.8352617,292.4250557,316.677871,333.6380595,36.91120309,4403,Female contraception,7/7/14 12:28
4716,111,Actavis,Regional & Specialty Pharma,4873,Minastrin 24 Fe,norethindrone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-13,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4403,Female contraception,7/7/14 12:28
4716,111,Actavis,Regional & Specialty Pharma,4873,Minastrin 24 Fe,norethindrone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-13,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,37,107.55843,152.8620407,226.5170864,262.8352617,292.4250557,316.677871,333.6380595,36.91120309,4403,Female contraception,7/7/14 12:28
4716,111,Warner Chilcott ,Regional & Specialty Pharma,4873,Minastrin 24 Fe,norethindrone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-13,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Proforma,0,0,0,0,21,0,0,0,0,0,0,0,-100,4403,Female contraception,7/7/14 12:28
4716,111,Warner Chilcott ,Regional & Specialty Pharma,4873,Minastrin 24 Fe,norethindrone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-13,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Proforma,0,0,0,0,21,0,0,0,0,0,0,0,-100,4403,Female contraception,7/7/14 12:28
4719,16,AstraZeneca,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,114,Psoriasis,7/7/14 12:28
4719,16,AstraZeneca,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,114,Psoriasis,7/7/14 12:28
4719,16,AstraZeneca,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,114,Psoriasis,7/7/14 12:28
4720,11,Amgen,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,114,Asthma,7/7/14 12:28
4720,11,Amgen,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,114,Asthma,7/7/14 12:28
4720,11,Amgen,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,114,Asthma,7/7/14 12:28
4721,16,AstraZeneca,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,114,Asthma,7/7/14 12:28
4721,16,AstraZeneca,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,114,Asthma,7/7/14 12:28
4721,16,AstraZeneca,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,114,Asthma,7/7/14 12:28
4722,46,GlaxoSmithKline,Large Pharma,4876,2647544,2647544,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4404,Alzheimer's Disease,7/7/14 12:28
4722,46,GlaxoSmithKline,Large Pharma,4876,2647544,2647544,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4404,Alzheimer's Disease,7/7/14 12:28
4722,46,GlaxoSmithKline,Large Pharma,4876,2647544,2647544,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4404,Alzheimer's Disease,7/7/14 12:28
4723,46,GlaxoSmithKline,Large Pharma,38,239512,239512,Small Molecule (Chemical),Phase II,In-House,,,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4405,H3 Receptor Antagonist for Multiple Sclerosis,7/7/14 12:28
4723,46,GlaxoSmithKline,Large Pharma,38,239512,239512,Small Molecule (Chemical),Phase II,In-House,,,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4405,H3 Receptor Antagonist for Multiple Sclerosis,7/7/14 12:28
4723,46,GlaxoSmithKline,Large Pharma,38,239512,239512,Small Molecule (Chemical),Phase II,In-House,,,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4405,H3 Receptor Antagonist for Multiple Sclerosis,7/7/14 12:28
4725,100,Takeda,Large Pharma,4878,DENVax,Dengue fever vaccine,Vaccine,Phase II,Corporate Acquisition,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4407,Dengue fever,7/7/14 12:28
4725,100,Takeda,Large Pharma,4878,DENVax,Dengue fever vaccine,Vaccine,Phase II,Corporate Acquisition,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4407,Dengue fever,7/7/14 12:28
4725,100,Takeda,Large Pharma,4878,DENVax,Dengue fever vaccine,Vaccine,Phase II,Corporate Acquisition,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4407,Dengue fever,7/7/14 12:28
4726,2070,Drais Pharma,Regional & Specialty Pharma,3360,ASP-7035,ASP-7035,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,161,Nocturia,7/7/14 12:28
4726,2070,Drais Pharma,Regional & Specialty Pharma,3360,ASP-7035,ASP-7035,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,161,Nocturia,7/7/14 12:28
4726,2070,Drais Pharma,Regional & Specialty Pharma,3360,ASP-7035,ASP-7035,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,161,Nocturia,7/7/14 12:28
4727,61,Merck & Co,Large Pharma,4561,PF-04971729,ertugliflozin,Small Molecule (Chemical),Phase III,Licensed (Development),Jan-18,Jan-18,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,15.6,41.600052,67.6000845,0,2054,Type II Diabetes,7/7/14 12:28
4727,61,Merck & Co,Large Pharma,4561,PF-04971729,ertugliflozin,Small Molecule (Chemical),Phase III,Licensed (Development),Jan-18,Jan-18,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,3.6,9.600012,15.6000195,0,2054,Type II Diabetes,7/7/14 12:28
4727,61,Merck & Co,Large Pharma,4561,PF-04971729,ertugliflozin,Small Molecule (Chemical),Phase III,Licensed (Development),Jan-18,Jan-18,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,12,32.00004,52.000065,0,2054,Type II Diabetes,7/7/14 12:28
4728,169,Auxilium,Regional & Specialty Pharma,1943,Xiaflex,collagenase,Recombinant Protein,Approved,In-House,May-14,,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,6,Global,Sales,0,0,0,0,0,11,18.15,25.849956,38.49989047,42.52587208,45.46505702,47.54800656,0,1401,Peyronie's Disease,7/7/14 12:28
4728,169,Auxilium,Regional & Specialty Pharma,1943,Xiaflex,collagenase,Recombinant Protein,Approved,In-House,May-14,,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1401,Peyronie's Disease,7/7/14 12:28
4728,169,Auxilium,Regional & Specialty Pharma,1943,Xiaflex,collagenase,Recombinant Protein,Approved,In-House,May-14,,,,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,6,US,Sales,0,0,0,0,0,11,18.15,25.849956,38.49989047,42.52587208,45.46505702,47.54800656,0,1401,Peyronie's Disease,7/7/14 12:28
4729,2247,Eleven Biotherapeutics,Small Biotech,4879,EBI-005,EBI-005,Recombinant Protein,Phase I,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4409,Dry Eye,7/7/14 12:28
4729,2247,Eleven Biotherapeutics,Small Biotech,4879,EBI-005,EBI-005,Recombinant Protein,Phase I,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4409,Dry Eye,7/7/14 12:28
4729,2247,Eleven Biotherapeutics,Small Biotech,4879,EBI-005,EBI-005,Recombinant Protein,Phase I,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4409,Dry Eye,7/7/14 12:28
4731,169,Auxilium,Regional & Specialty Pharma,4881,Testopel,Testosterone pellet,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-13,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,Global,Sales,0,0,0,0,60,78,88,105,112.7,118.52,124.507,127.9037,11.41961334,4411,Hypogonadism,7/7/14 12:28
4731,169,Auxilium,Regional & Specialty Pharma,4881,Testopel,Testosterone pellet,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-13,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4411,Hypogonadism,7/7/14 12:28
4731,169,Auxilium,Regional & Specialty Pharma,4881,Testopel,Testosterone pellet,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-13,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,US,Sales,0,0,0,0,60,78,88,105,112.7,118.52,124.507,127.9037,11.41961334,4411,Hypogonadism,7/7/14 12:28
4732,2017,MorphoSys,Small Biotech,4882,MOR208,anti-CD19 antibody,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4412,Non-Hodgkin's Lymphoma,7/7/14 12:28
4732,2017,MorphoSys,Small Biotech,4882,MOR208,anti-CD19 antibody,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4412,Non-Hodgkin's Lymphoma,7/7/14 12:28
4732,2017,MorphoSys,Small Biotech,4882,MOR208,anti-CD19 antibody,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4412,Non-Hodgkin's Lymphoma,7/7/14 12:28
4734,89,Sanofi,Large Pharma,4883,SAR245409 ,SAR245409 ,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4413,Ovarian cancer,7/7/14 12:28
4734,89,Sanofi,Large Pharma,4883,SAR245409 ,SAR245409 ,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4413,Ovarian cancer,7/7/14 12:28
4734,89,Sanofi,Large Pharma,4883,SAR245409 ,SAR245409 ,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4413,Ovarian cancer,7/7/14 12:28
4735,1985,Cempra Pharmaceuticals,Small Biotech,4884,solithromycin,CEM-101,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4414,bacterial infection,7/7/14 12:28
4735,1985,Cempra Pharmaceuticals,Small Biotech,4884,solithromycin,CEM-101,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4414,bacterial infection,7/7/14 12:28
4735,1985,Cempra Pharmaceuticals,Small Biotech,4884,solithromycin,CEM-101,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4414,bacterial infection,7/7/14 12:28
4736,1524,Toyama Chemical,Small Biotech,4884,solithromycin,CEM-101,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4414,bacterial infections,7/7/14 12:28
4736,1524,Toyama Chemical,Small Biotech,4884,solithromycin,CEM-101,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4414,bacterial infections,7/7/14 12:28
4736,1524,Toyama Chemical,Small Biotech,4884,solithromycin,CEM-101,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4414,bacterial infections,7/7/14 12:28
4737,2254,Trevena,Small Biotech,4885,TRV027,,Small Molecule (Chemical),Phase II,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4415,Acute heart failure,7/7/14 12:28
4737,2254,Trevena,Small Biotech,4885,TRV027,,Small Molecule (Chemical),Phase II,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4415,Acute heart failure,7/7/14 12:28
4737,2254,Trevena,Small Biotech,4885,TRV027,,Small Molecule (Chemical),Phase II,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4415,Acute heart failure,7/7/14 12:28
4738,23,Boehringer Ingelheim,Large Pharma,724,BEA-2180-BR,BEA-2180-BR,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4416,COPD,7/7/14 12:28
4738,23,Boehringer Ingelheim,Large Pharma,724,BEA-2180-BR,BEA-2180-BR,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4416,COPD,7/7/14 12:28
4738,23,Boehringer Ingelheim,Large Pharma,724,BEA-2180-BR,BEA-2180-BR,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4416,COPD,7/7/14 12:28
4739,23,Boehringer Ingelheim,Large Pharma,4886,BI-655064,BI-655064,Small Molecule (Chemical),Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4417,Rheumatoid Arthritis,7/7/14 12:28
4739,23,Boehringer Ingelheim,Large Pharma,4886,BI-655064,BI-655064,Small Molecule (Chemical),Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4417,Rheumatoid Arthritis,7/7/14 12:28
4739,23,Boehringer Ingelheim,Large Pharma,4886,BI-655064,BI-655064,Small Molecule (Chemical),Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4417,Rheumatoid Arthritis,7/7/14 12:28
4740,2263,Alvine,Small Biotech,4887,ALV003,ALV003,Recombinant Protein,Phase II,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4432,Celiac Disease,7/7/14 12:28
4740,2263,Alvine,Small Biotech,4887,ALV003,ALV003,Recombinant Protein,Phase II,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4432,Celiac Disease,7/7/14 12:28
4740,2263,Alvine,Small Biotech,4887,ALV003,ALV003,Recombinant Protein,Phase II,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4432,Celiac Disease,7/7/14 12:28
4742,53,Johnson & Johnson,Large Pharma,4889,TMC310911,TMC310911,Small Molecule (Chemical),Phase II,In-House,,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4419,HIV,7/7/14 12:28
4742,53,Johnson & Johnson,Large Pharma,4889,TMC310911,TMC310911,Small Molecule (Chemical),Phase II,In-House,,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4419,HIV,7/7/14 12:28
4742,53,Johnson & Johnson,Large Pharma,4889,TMC310911,TMC310911,Small Molecule (Chemical),Phase II,In-House,,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4419,HIV,7/7/14 12:28
4743,434,Bial,Small Biotech,4890,opicapone,opicapone,Small Molecule (Chemical),Phase III,In-House,,,,,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4420,Parkinson's Disease,7/7/14 12:28
4743,434,Bial,Small Biotech,4890,opicapone,opicapone,Small Molecule (Chemical),Phase III,In-House,,,,,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4420,Parkinson's Disease,7/7/14 12:28
4743,434,Bial,Small Biotech,4890,opicapone,opicapone,Small Molecule (Chemical),Phase III,In-House,,,,,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4420,Parkinson's Disease,7/7/14 12:28
4744,19,Bayer,Large Pharma,4891,BAY 2010112,PSMA/CD3-bispecific BiTE antibody,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4421,Prostate Cancer,7/7/14 12:28
4744,19,Bayer,Large Pharma,4891,BAY 2010112,PSMA/CD3-bispecific BiTE antibody,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4421,Prostate Cancer,7/7/14 12:28
4744,19,Bayer,Large Pharma,4891,BAY 2010112,PSMA/CD3-bispecific BiTE antibody,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4421,Prostate Cancer,7/7/14 12:28
4745,11,Amgen,Large Pharma,4891,BAY 2010112,PSMA/CD3-bispecific BiTE antibody,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4421,Prostate Cancer,7/7/14 12:28
4745,11,Amgen,Large Pharma,4891,BAY 2010112,PSMA/CD3-bispecific BiTE antibody,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4421,Prostate Cancer,7/7/14 12:28
4745,11,Amgen,Large Pharma,4891,BAY 2010112,PSMA/CD3-bispecific BiTE antibody,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4421,Prostate Cancer,7/7/14 12:28
4747,2271,AOP Orphan Pharmaceuticals,Small Biotech,4892,Resimmune,Recombinant anti-CDR-bi-singlechain- Fv-diphtheria toxin fusion protein,Antibody/Antibody Derivative,Phase II,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4422,T-cell Lymphoma,7/7/14 12:28
4747,2271,AOP Orphan Pharmaceuticals,Small Biotech,4892,Resimmune,Recombinant anti-CDR-bi-singlechain- Fv-diphtheria toxin fusion protein,Antibody/Antibody Derivative,Phase II,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4422,T-cell Lymphoma,7/7/14 12:28
4747,2271,AOP Orphan Pharmaceuticals,Small Biotech,4892,Resimmune,Recombinant anti-CDR-bi-singlechain- Fv-diphtheria toxin fusion protein,Antibody/Antibody Derivative,Phase II,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4422,T-cell Lymphoma,7/7/14 12:28
4748,2271,AOP Orphan Pharmaceuticals,Small Biotech,4893,PEG-IFN-alpha 2b,AOP-2014,Recombinant Protein,Phase II,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4423,Polycythemia Vera,7/7/14 12:28
4748,2271,AOP Orphan Pharmaceuticals,Small Biotech,4893,PEG-IFN-alpha 2b,AOP-2014,Recombinant Protein,Phase II,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4423,Polycythemia Vera,7/7/14 12:28
4748,2271,AOP Orphan Pharmaceuticals,Small Biotech,4893,PEG-IFN-alpha 2b,AOP-2014,Recombinant Protein,Phase II,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4423,Polycythemia Vera,7/7/14 12:28
4749,2271,AOP Orphan Pharmaceuticals,Small Biotech,4894,Anagrelide Retard,anagrelide retard,Small Molecule (Chemical),Launched,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4424,Essential Thrombocythemia ,7/7/14 12:28
4749,2271,AOP Orphan Pharmaceuticals,Small Biotech,4894,Anagrelide Retard,anagrelide retard,Small Molecule (Chemical),Launched,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4424,Essential Thrombocythemia ,7/7/14 12:28
4749,2271,AOP Orphan Pharmaceuticals,Small Biotech,4894,Anagrelide Retard,anagrelide retard,Small Molecule (Chemical),Launched,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4424,Essential Thrombocythemia ,7/7/14 12:28
4750,2271,AOP Orphan Pharmaceuticals,Small Biotech,4895,Ferric Trimaltol,ferric trimaltol,Small Molecule (Chemical),Phase III,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4425,Iron Deficiency Anemia in Morbus Crohn / Colitis Ulcerosa,7/7/14 12:28
4750,2271,AOP Orphan Pharmaceuticals,Small Biotech,4895,Ferric Trimaltol,ferric trimaltol,Small Molecule (Chemical),Phase III,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4425,Iron Deficiency Anemia in Morbus Crohn / Colitis Ulcerosa,7/7/14 12:28
4750,2271,AOP Orphan Pharmaceuticals,Small Biotech,4895,Ferric Trimaltol,ferric trimaltol,Small Molecule (Chemical),Phase III,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4425,Iron Deficiency Anemia in Morbus Crohn / Colitis Ulcerosa,7/7/14 12:28
4753,2271,AOP Orphan Pharmaceuticals,Small Biotech,4898,landiolol IV,AOP-200704,Small Molecule (Chemical),Phase II,In-House,,,,,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4428,Tachycardia,7/7/14 12:28
4753,2271,AOP Orphan Pharmaceuticals,Small Biotech,4898,landiolol IV,AOP-200704,Small Molecule (Chemical),Phase II,In-House,,,,,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4428,Tachycardia,7/7/14 12:28
4753,2271,AOP Orphan Pharmaceuticals,Small Biotech,4898,landiolol IV,AOP-200704,Small Molecule (Chemical),Phase II,In-House,,,,,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4428,Tachycardia,7/7/14 12:28
4755,2271,AOP Orphan Pharmaceuticals,Small Biotech,4900,Thromboreductin,anagrelide,Small Molecule (Chemical),Launched,In-House,,Jul-04,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1345,Essential Thrombocythemia ,7/7/14 12:28
4755,2271,AOP Orphan Pharmaceuticals,Small Biotech,4900,Thromboreductin,anagrelide,Small Molecule (Chemical),Launched,In-House,,Jul-04,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1345,Essential Thrombocythemia ,7/7/14 12:28
4755,2271,AOP Orphan Pharmaceuticals,Small Biotech,4900,Thromboreductin,anagrelide,Small Molecule (Chemical),Launched,In-House,,Jul-04,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1345,Essential Thrombocythemia ,7/7/14 12:28
4756,2271,AOP Orphan Pharmaceuticals,Small Biotech,4901,Busilvex,busulfan,Small Molecule (Chemical),Launched,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1847,Stem Cell Transplant Conditioning,7/7/14 12:28
4756,2271,AOP Orphan Pharmaceuticals,Small Biotech,4901,Busilvex,busulfan,Small Molecule (Chemical),Launched,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1847,Stem Cell Transplant Conditioning,7/7/14 12:28
4756,2271,AOP Orphan Pharmaceuticals,Small Biotech,4901,Busilvex,busulfan,Small Molecule (Chemical),Launched,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1847,Stem Cell Transplant Conditioning,7/7/14 12:28
4757,2271,AOP Orphan Pharmaceuticals,Small Biotech,4902,Canemes,nabilone,Small Molecule (Chemical),Launched,In-House,,,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4429,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
4757,2271,AOP Orphan Pharmaceuticals,Small Biotech,4902,Canemes,nabilone,Small Molecule (Chemical),Launched,In-House,,,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4429,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
4757,2271,AOP Orphan Pharmaceuticals,Small Biotech,4902,Canemes,nabilone,Small Molecule (Chemical),Launched,In-House,,,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4429,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
4758,111,Actavis,Regional & Specialty Pharma,4903,metronidazole,metronidazole,Small Molecule (Chemical),Approved,Licensed (Development),Jun-14,Jul-17,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,2,5.33334,8.00001,11.64915333,14.48061447,16.88083227,19.50210568,0,4430,bacterial vaginosis,7/7/14 12:28
4758,111,Actavis,Regional & Specialty Pharma,4903,metronidazole,metronidazole,Small Molecule (Chemical),Approved,Licensed (Development),Jun-14,Jul-17,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0.9825,1.853967675,2.63485886,3.904439253,0,4430,bacterial vaginosis,7/7/14 12:28
4758,111,Actavis,Regional & Specialty Pharma,4903,metronidazole,metronidazole,Small Molecule (Chemical),Approved,Licensed (Development),Jun-14,Jul-17,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,2,5.33334,8.00001,10.66665333,12.6266468,14.24597341,15.59766642,0,4430,bacterial vaginosis,7/7/14 12:28
4759,2271,AOP Orphan Pharmaceuticals,Small Biotech,4904,Tadim / Promixin,inhaled colistimethate ,Small Molecule (Chemical),Launched,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4431,Pseudomonas aeruginosa infections,7/7/14 12:28
4759,2271,AOP Orphan Pharmaceuticals,Small Biotech,4904,Tadim / Promixin,inhaled colistimethate ,Small Molecule (Chemical),Launched,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4431,Pseudomonas aeruginosa infections,7/7/14 12:28
4759,2271,AOP Orphan Pharmaceuticals,Small Biotech,4904,Tadim / Promixin,inhaled colistimethate ,Small Molecule (Chemical),Launched,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4431,Pseudomonas aeruginosa infections,7/7/14 12:28
4760,2271,AOP Orphan Pharmaceuticals,Small Biotech,1309,Remodulin,treprostinil,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1673,Pulmonary Hypertension,7/7/14 12:28
4760,2271,AOP Orphan Pharmaceuticals,Small Biotech,1309,Remodulin,treprostinil,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1673,Pulmonary Hypertension,7/7/14 12:28
4760,2271,AOP Orphan Pharmaceuticals,Small Biotech,1309,Remodulin,treprostinil,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1673,Pulmonary Hypertension,7/7/14 12:28
4761,2271,AOP Orphan Pharmaceuticals,Small Biotech,4905,Esmocard,esmolol,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4433,Tachycardia,7/7/14 12:28
4761,2271,AOP Orphan Pharmaceuticals,Small Biotech,4905,Esmocard,esmolol,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4433,Tachycardia,7/7/14 12:28
4761,2271,AOP Orphan Pharmaceuticals,Small Biotech,4905,Esmocard,esmolol,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4433,Tachycardia,7/7/14 12:28
4764,2271,AOP Orphan Pharmaceuticals,Small Biotech,4908,Adepend / Naltrexone AOP,naltrexone,Small Molecule (Chemical),Launched,In-House,,,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4436,Alcohol Addiction,7/7/14 12:28
4764,2271,AOP Orphan Pharmaceuticals,Small Biotech,4908,Adepend / Naltrexone AOP,naltrexone,Small Molecule (Chemical),Launched,In-House,,,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4436,Alcohol Addiction,7/7/14 12:28
4764,2271,AOP Orphan Pharmaceuticals,Small Biotech,4908,Adepend / Naltrexone AOP,naltrexone,Small Molecule (Chemical),Launched,In-House,,,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4436,Alcohol Addiction,7/7/14 12:28
4767,1984,AB Science,Regional & Specialty Pharma,4273,Masican,masitinib,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3959,Alzheimer's Disease,7/7/14 12:28
4767,1984,AB Science,Regional & Specialty Pharma,4273,Masican,masitinib,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3959,Alzheimer's Disease,7/7/14 12:28
4767,1984,AB Science,Regional & Specialty Pharma,4273,Masican,masitinib,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3959,Alzheimer's Disease,7/7/14 12:28
4769,621,Concordia,Small Biotech,3327,Kapvay,clonidine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-11,,Oct-13,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,Global,Sales,0,0,0,0,32,49.2,40.95,35,26.29,16.0926,10.8607,5.4653105,-22.31230559,3372,ADHD,7/7/14 12:28
4769,621,Concordia,Small Biotech,3327,Kapvay,clonidine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-11,,Oct-13,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3372,ADHD,7/7/14 12:28
4769,621,Concordia,Small Biotech,3327,Kapvay,clonidine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-11,,Oct-13,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,US,Sales,0,0,0,0,32,49.2,40.95,35,26.29,16.0926,10.8607,5.4653105,-22.31230559,3372,ADHD,7/7/14 12:28
4771,100,Takeda,Large Pharma,4912,Vepacel,BLB-750,Vaccine,Approved,Licensed (Development),,Aug-14,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,7,Global,Sales,0,0,0,0,0,10.06772225,26.84729288,43.62685093,60.40661033,70.47440708,78.52864976,84.77069711,0,4439,Pandemic Influenza,7/7/14 12:28
4771,100,Takeda,Large Pharma,4912,Vepacel,BLB-750,Vaccine,Approved,Licensed (Development),,Aug-14,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,7,ROW,Sales,0,0,0,0,0,10.06772225,26.84729288,43.62685093,60.40661033,70.47440708,78.52864976,84.77069711,0,4439,Pandemic Influenza,7/7/14 12:28
4771,100,Takeda,Large Pharma,4912,Vepacel,BLB-750,Vaccine,Approved,Licensed (Development),,Aug-14,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4439,Pandemic Influenza,7/7/14 12:28
4772,445,Bausch & Lomb,Small Biotech,4913,latanoprostene bunod,BOL-303259-X,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4440,Glaucoma,7/7/14 12:28
4772,445,Bausch & Lomb,Small Biotech,4913,latanoprostene bunod,BOL-303259-X,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4440,Glaucoma,7/7/14 12:28
4772,445,Bausch & Lomb,Small Biotech,4913,latanoprostene bunod,BOL-303259-X,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4440,Glaucoma,7/7/14 12:28
4773,291,Meiji-Seika ,Regional & Specialty Pharma,1615,safinamide,ME2125,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1045,Parkinson's Disease,7/7/14 12:28
4773,291,Meiji-Seika ,Regional & Specialty Pharma,1615,safinamide,ME2125,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1045,Parkinson's Disease,7/7/14 12:28
4773,291,Meiji-Seika ,Regional & Specialty Pharma,1615,safinamide,ME2125,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1045,Parkinson's Disease,7/7/14 12:28
4775,45,Gilead,Regional & Specialty Pharma,4915,GS-9973,Syk Inhibitor,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4443,Hematological Malignancies,7/7/14 12:28
4775,45,Gilead,Regional & Specialty Pharma,4915,GS-9973,Syk Inhibitor,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4443,Hematological Malignancies,7/7/14 12:28
4775,45,Gilead,Regional & Specialty Pharma,4915,GS-9973,Syk Inhibitor,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4443,Hematological Malignancies,7/7/14 12:28
4777,45,Gilead,Regional & Specialty Pharma,4917,GS-5745,MMP9 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4445,Solid Tumors,7/7/14 12:28
4777,45,Gilead,Regional & Specialty Pharma,4917,GS-5745,MMP9 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4445,Solid Tumors,7/7/14 12:28
4777,45,Gilead,Regional & Specialty Pharma,4917,GS-5745,MMP9 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4445,Solid Tumors,7/7/14 12:28
4778,111,Actavis,Regional & Specialty Pharma,2925,Didronel,etidronate,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1880,Osteoporosis,7/7/14 12:28
4778,111,Actavis,Regional & Specialty Pharma,2925,Didronel,etidronate,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1880,Osteoporosis,7/7/14 12:28
4778,111,Actavis,Regional & Specialty Pharma,2925,Didronel,etidronate,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1880,Osteoporosis,7/7/14 12:28
4779,901,Aslan Pharmaceuticals,Small Biotech,4918,ASLAN001 / ARRY-543,varlitinib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4446,Gastric Cancer,7/7/14 12:28
4779,901,Aslan Pharmaceuticals,Small Biotech,4918,ASLAN001 / ARRY-543,varlitinib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4446,Gastric Cancer,7/7/14 12:28
4779,901,Aslan Pharmaceuticals,Small Biotech,4918,ASLAN001 / ARRY-543,varlitinib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4446,Gastric Cancer,7/7/14 12:28
4780,480,Array Biopharma,Small Biotech,4918,ASLAN001 / ARRY-543,varlitinib,Small Molecule (Chemical),Phase II,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4446,Solid Tumors,7/7/14 12:28
4780,480,Array Biopharma,Small Biotech,4918,ASLAN001 / ARRY-543,varlitinib,Small Molecule (Chemical),Phase II,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4446,Solid Tumors,7/7/14 12:28
4780,480,Array Biopharma,Small Biotech,4918,ASLAN001 / ARRY-543,varlitinib,Small Molecule (Chemical),Phase II,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4446,Solid Tumors,7/7/14 12:28
4781,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3673,mogamulizumab,mogalizumab,Antibody/Antibody Derivative,Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,595,Asthma,7/7/14 12:28
4781,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3673,mogamulizumab,mogalizumab,Antibody/Antibody Derivative,Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,595,Asthma,7/7/14 12:28
4781,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3673,mogamulizumab,mogalizumab,Antibody/Antibody Derivative,Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,595,Asthma,7/7/14 12:28
4782,16,AstraZeneca,Large Pharma,4919,AZD3965,AZD3965,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4447,Cancer,7/7/14 12:28
4782,16,AstraZeneca,Large Pharma,4919,AZD3965,AZD3965,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4447,Cancer,7/7/14 12:28
4782,16,AstraZeneca,Large Pharma,4919,AZD3965,AZD3965,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4447,Cancer,7/7/14 12:28
4784,70,Ono,Regional & Specialty Pharma,4890,opicapone,opicapone,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4420,Parkinson's Disease,7/7/14 12:28
4784,70,Ono,Regional & Specialty Pharma,4890,opicapone,opicapone,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4420,Parkinson's Disease,7/7/14 12:28
4784,70,Ono,Regional & Specialty Pharma,4890,opicapone,opicapone,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4420,Parkinson's Disease,7/7/14 12:28
4784,70,Ono,Regional & Specialty Pharma,4890,opicapone,opicapone,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4420,Parkinson's Disease,7/7/14 12:28
4784,70,Ono,Regional & Specialty Pharma,4890,opicapone,opicapone,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4420,Parkinson's Disease,7/7/14 12:28
4784,70,Ono,Regional & Specialty Pharma,4890,opicapone,opicapone,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4420,Parkinson's Disease,7/7/14 12:28
4785,73,Otsuka,Regional & Specialty Pharma,2084,Lu AE58054,Lu AE58054,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,644,Alzheimer's Disease,7/7/14 12:28
4785,73,Otsuka,Regional & Specialty Pharma,2084,Lu AE58054,Lu AE58054,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,644,Alzheimer's Disease,7/7/14 12:28
4785,73,Otsuka,Regional & Specialty Pharma,2084,Lu AE58054,Lu AE58054,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,644,Alzheimer's Disease,7/7/14 12:28
4786,76,Pfizer,Large Pharma,4921,PF-06687859,RG3039,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4449,Spinal Muscular Atrophy,7/7/14 12:28
4786,76,Pfizer,Large Pharma,4921,PF-06687859,RG3039,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4449,Spinal Muscular Atrophy,7/7/14 12:28
4786,76,Pfizer,Large Pharma,4921,PF-06687859,RG3039,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4449,Spinal Muscular Atrophy,7/7/14 12:28
4787,84,Recordati,Regional & Specialty Pharma,4922,Graspa,erythrocyte-encapsulated L-asparaginase,Other (Biologic),Phase III,Licensed (Development),,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4450,Acute Lymphoblastic Leukemia,7/7/14 12:28
4787,84,Recordati,Regional & Specialty Pharma,4922,Graspa,erythrocyte-encapsulated L-asparaginase,Other (Biologic),Phase III,Licensed (Development),,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4450,Acute Lymphoblastic Leukemia,7/7/14 12:28
4787,84,Recordati,Regional & Specialty Pharma,4922,Graspa,erythrocyte-encapsulated L-asparaginase,Other (Biologic),Phase III,Licensed (Development),,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4450,Acute Lymphoblastic Leukemia,7/7/14 12:28
4788,745,Targacept,Small Biotech,4923,dexmecamylamine,dexmecamylamine,Small Molecule (Chemical),Phase II,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4451,Overactive bladder,7/7/14 12:28
4788,745,Targacept,Small Biotech,4923,dexmecamylamine,dexmecamylamine,Small Molecule (Chemical),Phase II,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4451,Overactive bladder,7/7/14 12:28
4788,745,Targacept,Small Biotech,4923,dexmecamylamine,dexmecamylamine,Small Molecule (Chemical),Phase II,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4451,Overactive bladder,7/7/14 12:28
4789,100,Takeda,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-13,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,30.37605557,60.75211114,87.75277941,114.7534321,136.8940225,156.5505222,174.0469682,189.305601,29.87296505,1168,Rheumatoid Arthritis,7/7/14 12:28
4789,100,Takeda,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-13,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,30.37605557,60.75211114,87.75277941,114.7534321,136.8940225,156.5505222,174.0469682,189.305601,29.87296505,1168,Rheumatoid Arthritis,7/7/14 12:28
4789,100,Takeda,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-13,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1168,Rheumatoid Arthritis,7/7/14 12:28
4790,15,Astellas Pharma,Regional & Specialty Pharma,4924,ASP3662,ASP3662,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4452,Alzheimer's Disease,7/7/14 12:28
4790,15,Astellas Pharma,Regional & Specialty Pharma,4924,ASP3662,ASP3662,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4452,Alzheimer's Disease,7/7/14 12:28
4790,15,Astellas Pharma,Regional & Specialty Pharma,4924,ASP3662,ASP3662,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4452,Alzheimer's Disease,7/7/14 12:28
4791,15,Astellas Pharma,Regional & Specialty Pharma,4925,Dormicum,midazolam,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4453,Anxiety,7/7/14 12:28
4791,15,Astellas Pharma,Regional & Specialty Pharma,4925,Dormicum,midazolam,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4453,Anxiety,7/7/14 12:28
4791,15,Astellas Pharma,Regional & Specialty Pharma,4925,Dormicum,midazolam,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4453,Anxiety,7/7/14 12:28
4792,15,Astellas Pharma,Regional & Specialty Pharma,2191,ASP015K,peficitinib,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,152,Rheumatoid Arthritis,7/7/14 12:28
4792,15,Astellas Pharma,Regional & Specialty Pharma,2191,ASP015K,peficitinib,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,152,Rheumatoid Arthritis,7/7/14 12:28
4792,15,Astellas Pharma,Regional & Specialty Pharma,2191,ASP015K,peficitinib,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,152,Rheumatoid Arthritis,7/7/14 12:28
4793,53,Johnson & Johnson,Large Pharma,2191,ASP015K,peficitinib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,152,Rheumatoid Arthritis,7/7/14 12:28
4793,53,Johnson & Johnson,Large Pharma,2191,ASP015K,peficitinib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,152,Rheumatoid Arthritis,7/7/14 12:28
4793,53,Johnson & Johnson,Large Pharma,2191,ASP015K,peficitinib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,152,Rheumatoid Arthritis,7/7/14 12:28
4794,96,Shire,Regional & Specialty Pharma,4926,Premiplex,mecasermin rinfabate,Recombinant Protein,Phase II,Corporate Acquisition,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4454,Retinopathy of Prematurity,7/7/14 12:28
4794,96,Shire,Regional & Specialty Pharma,4926,Premiplex,mecasermin rinfabate,Recombinant Protein,Phase II,Corporate Acquisition,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4454,Retinopathy of Prematurity,7/7/14 12:28
4794,96,Shire,Regional & Specialty Pharma,4926,Premiplex,mecasermin rinfabate,Recombinant Protein,Phase II,Corporate Acquisition,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4454,Retinopathy of Prematurity,7/7/14 12:28
4795,51,Ipsen,Regional & Specialty Pharma,4927,BN82451,BN82451,Small Molecule (Chemical),Phase II,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4455,Huntington's Disease,7/7/14 12:28
4795,51,Ipsen,Regional & Specialty Pharma,4927,BN82451,BN82451,Small Molecule (Chemical),Phase II,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4455,Huntington's Disease,7/7/14 12:28
4795,51,Ipsen,Regional & Specialty Pharma,4927,BN82451,BN82451,Small Molecule (Chemical),Phase II,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4455,Huntington's Disease,7/7/14 12:28
4797,2280,AltheRx,Regional & Specialty Pharma,288,Solabegron,solabegron,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,187,Beta-3 Agonists,60,Incontinence,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4456,Overactive bladder,7/7/14 12:28
4797,2280,AltheRx,Regional & Specialty Pharma,288,Solabegron,solabegron,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,187,Beta-3 Agonists,60,Incontinence,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4456,Overactive bladder,7/7/14 12:28
4797,2280,AltheRx,Regional & Specialty Pharma,288,Solabegron,solabegron,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,187,Beta-3 Agonists,60,Incontinence,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4456,Overactive bladder,7/7/14 12:28
4798,3,Acorda Therapeutics,Small Biotech,4928,Plumiaz,diazepam,Small Molecule (Chemical),Filed,Acquisition (Development),,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4457,Epilepsy,7/7/14 12:28
4798,3,Acorda Therapeutics,Small Biotech,4928,Plumiaz,diazepam,Small Molecule (Chemical),Filed,Acquisition (Development),,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4457,Epilepsy,7/7/14 12:28
4798,3,Acorda Therapeutics,Small Biotech,4928,Plumiaz,diazepam,Small Molecule (Chemical),Filed,Acquisition (Development),,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4457,Epilepsy,7/7/14 12:28
4799,15,Astellas Pharma,Regional & Specialty Pharma,4929,CK-2127107,CK-2127107,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4458,muscle wasting,7/7/14 12:28
4799,15,Astellas Pharma,Regional & Specialty Pharma,4929,CK-2127107,CK-2127107,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4458,muscle wasting,7/7/14 12:28
4799,15,Astellas Pharma,Regional & Specialty Pharma,4929,CK-2127107,CK-2127107,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4458,muscle wasting,7/7/14 12:28
4802,18,Baxter Healthcare,Regional & Specialty Pharma,4930,Rixubis,recombinant factor IX,Recombinant Protein,Launched,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4460,Hemophilia B,7/7/14 12:28
4802,18,Baxter Healthcare,Regional & Specialty Pharma,4930,Rixubis,recombinant factor IX,Recombinant Protein,Launched,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4460,Hemophilia B,7/7/14 12:28
4802,18,Baxter Healthcare,Regional & Specialty Pharma,4930,Rixubis,recombinant factor IX,Recombinant Protein,Launched,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4460,Hemophilia B,7/7/14 12:28
4803,26,Celgene,Regional & Specialty Pharma,4931,MOR202,anti-CD38 MAb,Antibody/Antibody Derivative,Phase II,Acquisition (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4462,Multiple Myeloma,7/7/14 12:28
4803,26,Celgene,Regional & Specialty Pharma,4931,MOR202,anti-CD38 MAb,Antibody/Antibody Derivative,Phase II,Acquisition (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4462,Multiple Myeloma,7/7/14 12:28
4803,26,Celgene,Regional & Specialty Pharma,4931,MOR202,anti-CD38 MAb,Antibody/Antibody Derivative,Phase II,Acquisition (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4462,Multiple Myeloma,7/7/14 12:28
4804,555,Hisamitsu,Small Biotech,4932,Brisdelle,paroxetine,Small Molecule (Chemical),Launched,Acquisition (Development),Nov-13,,,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Sales,0,0,0,0,5,38.33335,88.33345507,138.333724,171.6671322,209.0005841,242.974062,270.7032102,76.86665105,4459,Menopausal symptoms,7/7/14 12:28
4804,555,Hisamitsu,Small Biotech,4932,Brisdelle,paroxetine,Small Molecule (Chemical),Launched,Acquisition (Development),Nov-13,,,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4459,Menopausal symptoms,7/7/14 12:28
4804,555,Hisamitsu,Small Biotech,4932,Brisdelle,paroxetine,Small Molecule (Chemical),Launched,Acquisition (Development),Nov-13,,,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Sales,0,0,0,0,5,38.33335,88.33345507,138.333724,171.6671322,209.0005841,242.974062,270.7032102,76.86665105,4459,Menopausal symptoms,7/7/14 12:28
4805,1093,Orexo,Small Biotech,4933,Zubsolv,buprenorphine + naloxone,Small Molecule (Chemical),Launched,In-House,Sep-13,,,,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,9,Global,Sales,0,0,0,0,1.120925608,4.1100643,6.351898872,8.59373806,10.53666802,12.23448749,13.77017795,15.12557434,45.02661406,4464,Opioid Dependence,7/7/14 12:28
4805,1093,Orexo,Small Biotech,4933,Zubsolv,buprenorphine + naloxone,Small Molecule (Chemical),Launched,In-House,Sep-13,,,,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,9,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4464,Opioid Dependence,7/7/14 12:28
4805,1093,Orexo,Small Biotech,4933,Zubsolv,buprenorphine + naloxone,Small Molecule (Chemical),Launched,In-House,Sep-13,,,,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,9,US,Sales,0,0,0,0,1.120925608,4.1100643,6.351898872,8.59373806,10.53666802,12.23448749,13.77017795,15.12557434,45.02661406,4464,Opioid Dependence,7/7/14 12:28
4807,53,Johnson & Johnson,Large Pharma,4934,ARN-509,androgen receptor antagonist,Small Molecule (Chemical),Phase III,Corporate Acquisition,Mar-17,Jan-18,,,107,Anti-androgens,55,Hormonals,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,105.225,352.9093397,558.5040473,686.0713051,0,4467,Prostate Cancer,7/7/14 12:28
4807,53,Johnson & Johnson,Large Pharma,4934,ARN-509,androgen receptor antagonist,Small Molecule (Chemical),Phase III,Corporate Acquisition,Mar-17,Jan-18,,,107,Anti-androgens,55,Hormonals,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,100,200,260,0,4467,Prostate Cancer,7/7/14 12:28
4807,53,Johnson & Johnson,Large Pharma,4934,ARN-509,androgen receptor antagonist,Small Molecule (Chemical),Phase III,Corporate Acquisition,Mar-17,Jan-18,,,107,Anti-androgens,55,Hormonals,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,105.225,252.9093397,358.5040473,426.0713051,0,4467,Prostate Cancer,7/7/14 12:28
4808,2310,Ohr Pharmaceutical,Small Biotech,4935,squalamine,squalamine,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4466,AMD,7/7/14 12:28
4808,2310,Ohr Pharmaceutical,Small Biotech,4935,squalamine,squalamine,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4466,AMD,7/7/14 12:28
4808,2310,Ohr Pharmaceutical,Small Biotech,4935,squalamine,squalamine,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4466,AMD,7/7/14 12:28
4810,2311,Akebia Therapeutics,,4937,AKB-6548,AKB-6548,Small Molecule (Chemical),Phase II,,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4469,Renal Anemia,7/7/14 12:28
4810,2311,Akebia Therapeutics,,4937,AKB-6548,AKB-6548,Small Molecule (Chemical),Phase II,,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4469,Renal Anemia,7/7/14 12:28
4810,2311,Akebia Therapeutics,,4937,AKB-6548,AKB-6548,Small Molecule (Chemical),Phase II,,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4469,Renal Anemia,7/7/14 12:28
4811,173,Alexion Pharmaceuticals,Small Biotech,2422,Soliris,eculizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1108,Neuromyelitis optica,7/7/14 12:28
4811,173,Alexion Pharmaceuticals,Small Biotech,2422,Soliris,eculizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1108,Neuromyelitis optica,7/7/14 12:28
4811,173,Alexion Pharmaceuticals,Small Biotech,2422,Soliris,eculizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1108,Neuromyelitis optica,7/7/14 12:28
4812,2312,Adynxx,Small Biotech,4938,AYX1,AYX1,DNA/RNA Therapy,Phase II,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4470,Chronic Pain,7/7/14 12:28
4812,2312,Adynxx,Small Biotech,4938,AYX1,AYX1,DNA/RNA Therapy,Phase II,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4470,Chronic Pain,7/7/14 12:28
4812,2312,Adynxx,Small Biotech,4938,AYX1,AYX1,DNA/RNA Therapy,Phase II,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4470,Chronic Pain,7/7/14 12:28
4813,2317,Auspex Pharmaceuticals,Small Biotech,4939,SD-809,"tetrabenazine, deuterium-substituted analogue ",Small Molecule (Chemical),Phase III,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4471,Huntington's disease,7/7/14 12:28
4813,2317,Auspex Pharmaceuticals,Small Biotech,4939,SD-809,"tetrabenazine, deuterium-substituted analogue ",Small Molecule (Chemical),Phase III,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4471,Huntington's disease,7/7/14 12:28
4813,2317,Auspex Pharmaceuticals,Small Biotech,4939,SD-809,"tetrabenazine, deuterium-substituted analogue ",Small Molecule (Chemical),Phase III,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4471,Huntington's disease,7/7/14 12:28
4814,2317,Auspex Pharmaceuticals,Small Biotech,4940,SD-254,"venlafaxine, deuterated",Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4472,Neuropathic pain,7/7/14 12:28
4814,2317,Auspex Pharmaceuticals,Small Biotech,4940,SD-254,"venlafaxine, deuterated",Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4472,Neuropathic pain,7/7/14 12:28
4814,2317,Auspex Pharmaceuticals,Small Biotech,4940,SD-254,"venlafaxine, deuterated",Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4472,Neuropathic pain,7/7/14 12:28
4815,192,Seattle Genetics,Small Biotech,4941,SGN-CD33A,SGN-CD33A,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4473,Acute Myeloid Leukemia,7/7/14 12:28
4815,192,Seattle Genetics,Small Biotech,4941,SGN-CD33A,SGN-CD33A,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4473,Acute Myeloid Leukemia,7/7/14 12:28
4815,192,Seattle Genetics,Small Biotech,4941,SGN-CD33A,SGN-CD33A,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4473,Acute Myeloid Leukemia,7/7/14 12:28
4816,2281,Immunocore,Small Biotech,4942,IMCgp100,ImmTAC-gp100,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4474,Melanoma,7/7/14 12:28
4816,2281,Immunocore,Small Biotech,4942,IMCgp100,ImmTAC-gp100,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4474,Melanoma,7/7/14 12:28
4816,2281,Immunocore,Small Biotech,4942,IMCgp100,ImmTAC-gp100,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4474,Melanoma,7/7/14 12:28
4817,2315,Mimetogen Pharmaceuticals,Small Biotech,4943,MIM-D3,NGF peptidomimetic,Small Molecule (Chemical),Phase III,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,8,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4475,Dry Eye,7/7/14 12:28
4817,2315,Mimetogen Pharmaceuticals,Small Biotech,4943,MIM-D3,NGF peptidomimetic,Small Molecule (Chemical),Phase III,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,8,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4475,Dry Eye,7/7/14 12:28
4817,2315,Mimetogen Pharmaceuticals,Small Biotech,4943,MIM-D3,NGF peptidomimetic,Small Molecule (Chemical),Phase III,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,8,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4475,Dry Eye,7/7/14 12:28
4818,425,Alnylam,Small Biotech,4944,patisiran,ALN-TTR02,DNA/RNA Therapy,Phase III,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4476,TTR Amyloidosis,7/7/14 12:28
4818,425,Alnylam,Small Biotech,4944,patisiran,ALN-TTR02,DNA/RNA Therapy,Phase III,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4476,TTR Amyloidosis,7/7/14 12:28
4818,425,Alnylam,Small Biotech,4944,patisiran,ALN-TTR02,DNA/RNA Therapy,Phase III,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4476,TTR Amyloidosis,7/7/14 12:28
4819,16,AstraZeneca,Large Pharma,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Licensed (Development),,May-12,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,2,4.5,8.00001,13.75001719,15.96252048,17.72814839,19.07643158,19.89959689,20.48419348,24.17363234,1412,Staph aureus BSI,7/7/14 12:28
4819,16,AstraZeneca,Large Pharma,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Licensed (Development),,May-12,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,2,4.5,8.00001,13.75001719,15.96252048,17.72814839,19.07643158,19.89959689,20.48419348,24.17363234,1412,Staph aureus BSI,7/7/14 12:28
4819,16,AstraZeneca,Large Pharma,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Licensed (Development),,May-12,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1412,Staph aureus BSI,7/7/14 12:28
4820,102,Teva,Regional & Specialty Pharma,4945,MDT-637,MDT-637,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4477,RSV,7/7/14 12:28
4820,102,Teva,Regional & Specialty Pharma,4945,MDT-637,MDT-637,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4477,RSV,7/7/14 12:28
4820,102,Teva,Regional & Specialty Pharma,4945,MDT-637,MDT-637,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4477,RSV,7/7/14 12:28
4821,2318,Sarepta Therapeutics,Small Biotech,4946,eteplirsen,eteplirsen,DNA/RNA Therapy,Phase II,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4494,Duchenne Muscular Dystrophy,7/7/14 12:28
4821,2318,Sarepta Therapeutics,Small Biotech,4946,eteplirsen,eteplirsen,DNA/RNA Therapy,Phase II,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4494,Duchenne Muscular Dystrophy,7/7/14 12:28
4821,2318,Sarepta Therapeutics,Small Biotech,4946,eteplirsen,eteplirsen,DNA/RNA Therapy,Phase II,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4494,Duchenne Muscular Dystrophy,7/7/14 12:28
4822,111,Actavis,Regional & Specialty Pharma,4947,Lo Minastarin Fe,norethindrone acetate + ethinyl estradiol chewable tablets,Small Molecule (Chemical),Approved,Corporate Acquisition,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4478,Female contraception,7/7/14 12:28
4822,111,Actavis,Regional & Specialty Pharma,4947,Lo Minastarin Fe,norethindrone acetate + ethinyl estradiol chewable tablets,Small Molecule (Chemical),Approved,Corporate Acquisition,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4478,Female contraception,7/7/14 12:28
4822,111,Actavis,Regional & Specialty Pharma,4947,Lo Minastarin Fe,norethindrone acetate + ethinyl estradiol chewable tablets,Small Molecule (Chemical),Approved,Corporate Acquisition,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4478,Female contraception,7/7/14 12:28
4822,111,Actavis,Regional & Specialty Pharma,4947,Lo Minastarin Fe,norethindrone acetate + ethinyl estradiol chewable tablets,Small Molecule (Chemical),Approved,Corporate Acquisition,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4478,Female contraception,7/7/14 12:28
4822,111,Actavis,Regional & Specialty Pharma,4947,Lo Minastarin Fe,norethindrone acetate + ethinyl estradiol chewable tablets,Small Molecule (Chemical),Approved,Corporate Acquisition,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4478,Female contraception,7/7/14 12:28
4822,111,Actavis,Regional & Specialty Pharma,4947,Lo Minastarin Fe,norethindrone acetate + ethinyl estradiol chewable tablets,Small Molecule (Chemical),Approved,Corporate Acquisition,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4478,Female contraception,7/7/14 12:28
4823,67,Novartis,Large Pharma,4220,secukinumab,AIN457,Antibody/Antibody Derivative,Phase II,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1346,Uveitis,7/7/14 12:28
4823,67,Novartis,Large Pharma,4220,secukinumab,AIN457,Antibody/Antibody Derivative,Phase II,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1346,Uveitis,7/7/14 12:28
4823,67,Novartis,Large Pharma,4220,secukinumab,AIN457,Antibody/Antibody Derivative,Phase II,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1346,Uveitis,7/7/14 12:28
4824,2320,Brainstorm Cell Therapeutics,Small Biotech,4948,NurOwn,MSC-NTF,Cell Therapy,Phase II,In-House,,,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4479,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4824,2320,Brainstorm Cell Therapeutics,Small Biotech,4948,NurOwn,MSC-NTF,Cell Therapy,Phase II,In-House,,,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4479,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4824,2320,Brainstorm Cell Therapeutics,Small Biotech,4948,NurOwn,MSC-NTF,Cell Therapy,Phase II,In-House,,,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4479,Amyotrophic Lateral Sclerosis,7/7/14 12:28
4825,16,AstraZeneca,Large Pharma,1911,Roxadustat,ASP1517,Small Molecule (Chemical),Phase II,Licensed (Development),Jun-19,Jan-17,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,10,35,86.99995,242.74368,0,154,Renal Anemia,7/7/14 12:28
4825,16,AstraZeneca,Large Pharma,1911,Roxadustat,ASP1517,Small Molecule (Chemical),Phase II,Licensed (Development),Jun-19,Jan-17,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,10,35,49.99995,59.99994,0,154,Renal Anemia,7/7/14 12:28
4825,16,AstraZeneca,Large Pharma,1911,Roxadustat,ASP1517,Small Molecule (Chemical),Phase II,Licensed (Development),Jun-19,Jan-17,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,37,182.74374,0,154,Renal Anemia,7/7/14 12:28
4826,2223,Clinigen Group,Regional & Specialty Pharma,1296,Vibativ,telavancin,Small Molecule (Chemical),Approved,Licensed (Marketed),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1254,HAP,7/7/14 12:28
4826,2223,Clinigen Group,Regional & Specialty Pharma,1296,Vibativ,telavancin,Small Molecule (Chemical),Approved,Licensed (Marketed),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1254,HAP,7/7/14 12:28
4826,2223,Clinigen Group,Regional & Specialty Pharma,1296,Vibativ,telavancin,Small Molecule (Chemical),Approved,Licensed (Marketed),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1254,HAP,7/7/14 12:28
4830,39,Eli Lilly,Large Pharma,4952,LY3022859,TGF beta R2 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4483,Solid tumors,7/7/14 12:28
4830,39,Eli Lilly,Large Pharma,4952,LY3022859,TGF beta R2 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4483,Solid tumors,7/7/14 12:28
4830,39,Eli Lilly,Large Pharma,4952,LY3022859,TGF beta R2 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4483,Solid tumors,7/7/14 12:28
4833,15,Astellas Pharma,Regional & Specialty Pharma,4335,rilotumumab,rilotumumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3985,Gastric Cancer,7/7/14 12:28
4833,15,Astellas Pharma,Regional & Specialty Pharma,4335,rilotumumab,rilotumumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3985,Gastric Cancer,7/7/14 12:28
4833,15,Astellas Pharma,Regional & Specialty Pharma,4335,rilotumumab,rilotumumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3985,Gastric Cancer,7/7/14 12:28
4834,15,Astellas Pharma,Regional & Specialty Pharma,4955,ASG-15ME,ASG-15ME,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4493,Cancer,7/7/14 12:28
4834,15,Astellas Pharma,Regional & Specialty Pharma,4955,ASG-15ME,ASG-15ME,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4493,Cancer,7/7/14 12:28
4834,15,Astellas Pharma,Regional & Specialty Pharma,4955,ASG-15ME,ASG-15ME,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4493,Cancer,7/7/14 12:28
4836,67,Novartis,Large Pharma,4957,BGJ398,FGFR kinase inhibitor,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4487,Solid Tumors,7/7/14 12:28
4836,67,Novartis,Large Pharma,4957,BGJ398,FGFR kinase inhibitor,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4487,Solid Tumors,7/7/14 12:28
4836,67,Novartis,Large Pharma,4957,BGJ398,FGFR kinase inhibitor,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4487,Solid Tumors,7/7/14 12:28
4838,11,Amgen,Large Pharma,4959,AMG 232,AMG 232,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4489,Various Cancer Types,7/7/14 12:28
4838,11,Amgen,Large Pharma,4959,AMG 232,AMG 232,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4489,Various Cancer Types,7/7/14 12:28
4838,11,Amgen,Large Pharma,4959,AMG 232,AMG 232,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4489,Various Cancer Types,7/7/14 12:28
4839,11,Amgen,Large Pharma,4960,AMG 172,AMG 172,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4490,Various Cancer Types,7/7/14 12:28
4839,11,Amgen,Large Pharma,4960,AMG 172,AMG 172,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4490,Various Cancer Types,7/7/14 12:28
4839,11,Amgen,Large Pharma,4960,AMG 172,AMG 172,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4490,Various Cancer Types,7/7/14 12:28
4840,26,Celgene,Regional & Specialty Pharma,4961,EPZ-5676,DOT 1L inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4491,Acute Myeloid Leukemia,7/7/14 12:28
4840,26,Celgene,Regional & Specialty Pharma,4961,EPZ-5676,DOT 1L inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4491,Acute Myeloid Leukemia,7/7/14 12:28
4840,26,Celgene,Regional & Specialty Pharma,4961,EPZ-5676,DOT 1L inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4491,Acute Myeloid Leukemia,7/7/14 12:28
4841,26,Celgene,Regional & Specialty Pharma,4920,CC-220,CC-220,Small Molecule (Chemical),Phase I,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4497,Systemic sclerosis,7/7/14 12:28
4841,26,Celgene,Regional & Specialty Pharma,4920,CC-220,CC-220,Small Molecule (Chemical),Phase I,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4497,Systemic sclerosis,7/7/14 12:28
4841,26,Celgene,Regional & Specialty Pharma,4920,CC-220,CC-220,Small Molecule (Chemical),Phase I,In-House,,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4497,Systemic sclerosis,7/7/14 12:28
4842,86,Roche,Large Pharma,4962,RG7842 ,GDC0094,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4492,Solid Tumors,7/7/14 12:28
4842,86,Roche,Large Pharma,4962,RG7842 ,GDC0094,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4492,Solid Tumors,7/7/14 12:28
4842,86,Roche,Large Pharma,4962,RG7842 ,GDC0094,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4492,Solid Tumors,7/7/14 12:28
4845,16,AstraZeneca,Large Pharma,4965,AZD9291,AZD9291,Small Molecule (Chemical),Phase I,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4504,Solid Tumors,7/7/14 12:28
4845,16,AstraZeneca,Large Pharma,4965,AZD9291,AZD9291,Small Molecule (Chemical),Phase I,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4504,Solid Tumors,7/7/14 12:28
4845,16,AstraZeneca,Large Pharma,4965,AZD9291,AZD9291,Small Molecule (Chemical),Phase I,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4504,Solid Tumors,7/7/14 12:28
4847,111,Actavis,Regional & Specialty Pharma,4967,Albaconazole,albaconazole,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4499,fungal infections,7/7/14 12:28
4847,111,Actavis,Regional & Specialty Pharma,4967,Albaconazole,albaconazole,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4499,fungal infections,7/7/14 12:28
4847,111,Actavis,Regional & Specialty Pharma,4967,Albaconazole,albaconazole,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4499,fungal infections,7/7/14 12:28
4848,34,Daiichi-Sankyo,Regional & Specialty Pharma,4968,DS-1040,DS-1040,Small Molecule (Chemical),Phase I,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4500,Acute ischemic stroke  - TAFIa inhibitor,7/7/14 12:28
4848,34,Daiichi-Sankyo,Regional & Specialty Pharma,4968,DS-1040,DS-1040,Small Molecule (Chemical),Phase I,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4500,Acute ischemic stroke  - TAFIa inhibitor,7/7/14 12:28
4848,34,Daiichi-Sankyo,Regional & Specialty Pharma,4968,DS-1040,DS-1040,Small Molecule (Chemical),Phase I,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4500,Acute ischemic stroke  - TAFIa inhibitor,7/7/14 12:28
4849,100,Takeda,Large Pharma,67,relugolix,TAK-385,Small Molecule (Chemical),Phase I,In-House,,,,,33,LHRH Analogs,55,Hormonals,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1146,Prostate Cancer,7/7/14 12:28
4849,100,Takeda,Large Pharma,67,relugolix,TAK-385,Small Molecule (Chemical),Phase I,In-House,,,,,33,LHRH Analogs,55,Hormonals,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1146,Prostate Cancer,7/7/14 12:28
4849,100,Takeda,Large Pharma,67,relugolix,TAK-385,Small Molecule (Chemical),Phase I,In-House,,,,,33,LHRH Analogs,55,Hormonals,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1146,Prostate Cancer,7/7/14 12:28
4850,100,Takeda,Large Pharma,4969,MLN0264,MLN0264,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4503,Solid Tumors,7/7/14 12:28
4850,100,Takeda,Large Pharma,4969,MLN0264,MLN0264,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4503,Solid Tumors,7/7/14 12:28
4850,100,Takeda,Large Pharma,4969,MLN0264,MLN0264,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4503,Solid Tumors,7/7/14 12:28
4851,213,Isis Pharmaceuticals,Small Biotech,4970,ISIS-TTRRx,ISIS-TTRRx,DNA/RNA Therapy,Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4501,TTR Amyloidosis,7/7/14 12:28
4851,213,Isis Pharmaceuticals,Small Biotech,4970,ISIS-TTRRx,ISIS-TTRRx,DNA/RNA Therapy,Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4501,TTR Amyloidosis,7/7/14 12:28
4851,213,Isis Pharmaceuticals,Small Biotech,4970,ISIS-TTRRx,ISIS-TTRRx,DNA/RNA Therapy,Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4501,TTR Amyloidosis,7/7/14 12:28
4852,102,Teva,Regional & Specialty Pharma,4971,Zecuity,sumatriptan transdermal patch,Small Molecule (Chemical),Approved,Corporate Acquisition,Mar-14,,,,117,Triptans,8,Migraine,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,22.875,89.29279125,146.6812682,183.4014569,202.9455351,215.8518516,223.7160194,0,4502,Migraine,7/7/14 12:28
4852,102,Teva,Regional & Specialty Pharma,4971,Zecuity,sumatriptan transdermal patch,Small Molecule (Chemical),Approved,Corporate Acquisition,Mar-14,,,,117,Triptans,8,Migraine,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4502,Migraine,7/7/14 12:28
4852,102,Teva,Regional & Specialty Pharma,4971,Zecuity,sumatriptan transdermal patch,Small Molecule (Chemical),Approved,Corporate Acquisition,Mar-14,,,,117,Triptans,8,Migraine,12,Central Nervous System,6,US,Sales,0,0,0,0,0,22.875,89.29279125,146.6812682,183.4014569,202.9455351,215.8518516,223.7160194,0,4502,Migraine,7/7/14 12:28
4853,94,Servier,Regional & Specialty Pharma,4972,S38844,,Small Molecule (Chemical),Phase II,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4505,Heart Failure,7/7/14 12:28
4853,94,Servier,Regional & Specialty Pharma,4972,S38844,,Small Molecule (Chemical),Phase II,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4505,Heart Failure,7/7/14 12:28
4853,94,Servier,Regional & Specialty Pharma,4972,S38844,,Small Molecule (Chemical),Phase II,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4505,Heart Failure,7/7/14 12:28
4854,15,Astellas Pharma,Regional & Specialty Pharma,2541,AMG 145,evolocumab ,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Jun-20,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1801,Hypercholesterolemia,7/7/14 12:28
4854,15,Astellas Pharma,Regional & Specialty Pharma,2541,AMG 145,evolocumab ,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Jun-20,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1801,Hypercholesterolemia,7/7/14 12:28
4854,15,Astellas Pharma,Regional & Specialty Pharma,2541,AMG 145,evolocumab ,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Jun-20,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1801,Hypercholesterolemia,7/7/14 12:28
4855,1,Abbott,Regional & Specialty Pharma,4973,Cholib,fenofibrate + simvastatin,Small Molecule (Chemical),Launched,In-House,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4506,Dyslipidemia,7/7/14 12:28
4855,1,Abbott,Regional & Specialty Pharma,4973,Cholib,fenofibrate + simvastatin,Small Molecule (Chemical),Launched,In-House,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4506,Dyslipidemia,7/7/14 12:28
4855,1,Abbott,Regional & Specialty Pharma,4973,Cholib,fenofibrate + simvastatin,Small Molecule (Chemical),Launched,In-House,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4506,Dyslipidemia,7/7/14 12:28
4856,29,Chugai,Regional & Specialty Pharma,4052,RG7652,RG7652,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3820,Hypercholesterolemia,7/7/14 12:28
4856,29,Chugai,Regional & Specialty Pharma,4052,RG7652,RG7652,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3820,Hypercholesterolemia,7/7/14 12:28
4856,29,Chugai,Regional & Specialty Pharma,4052,RG7652,RG7652,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3820,Hypercholesterolemia,7/7/14 12:28
4857,42,Forest,Regional & Specialty Pharma,4885,TRV027,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4415,Acute heart failure,7/7/14 12:28
4857,42,Forest,Regional & Specialty Pharma,4885,TRV027,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4415,Acute heart failure,7/7/14 12:28
4857,42,Forest,Regional & Specialty Pharma,4885,TRV027,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4415,Acute heart failure,7/7/14 12:28
4858,45,Gilead,Regional & Specialty Pharma,4974,GS-6615,,Small Molecule (Chemical),Phase I,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4507,Arrhythmias ,7/7/14 12:28
4858,45,Gilead,Regional & Specialty Pharma,4974,GS-6615,,Small Molecule (Chemical),Phase I,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4507,Arrhythmias ,7/7/14 12:28
4858,45,Gilead,Regional & Specialty Pharma,4974,GS-6615,,Small Molecule (Chemical),Phase I,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4507,Arrhythmias ,7/7/14 12:28
4860,70,Ono,Regional & Specialty Pharma,4977,ONO-1162,ivabradine,Small Molecule (Chemical),Phase I,Licensed (Marketed),,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,931,Chronic Heart Failure,7/7/14 12:28
4860,70,Ono,Regional & Specialty Pharma,4977,ONO-1162,ivabradine,Small Molecule (Chemical),Phase I,Licensed (Marketed),,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,931,Chronic Heart Failure,7/7/14 12:28
4860,70,Ono,Regional & Specialty Pharma,4977,ONO-1162,ivabradine,Small Molecule (Chemical),Phase I,Licensed (Marketed),,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,931,Chronic Heart Failure,7/7/14 12:28
4861,73,Otsuka,Regional & Specialty Pharma,4978,OPC-108459,,Small Molecule (Chemical),Phase I,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4509,Atrial fibrillation ,7/7/14 12:28
4861,73,Otsuka,Regional & Specialty Pharma,4978,OPC-108459,,Small Molecule (Chemical),Phase I,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4509,Atrial fibrillation ,7/7/14 12:28
4861,73,Otsuka,Regional & Specialty Pharma,4978,OPC-108459,,Small Molecule (Chemical),Phase I,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4509,Atrial fibrillation ,7/7/14 12:28
4862,76,Pfizer,Large Pharma,4979,PF-06282999,,Small Molecule (Chemical),Phase I,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4510,Acute coronary syndrome ,7/7/14 12:28
4862,76,Pfizer,Large Pharma,4979,PF-06282999,,Small Molecule (Chemical),Phase I,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4510,Acute coronary syndrome ,7/7/14 12:28
4862,76,Pfizer,Large Pharma,4979,PF-06282999,,Small Molecule (Chemical),Phase I,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4510,Acute coronary syndrome ,7/7/14 12:28
4863,89,Sanofi,Large Pharma,4980,SAR-407899,,Small Molecule (Chemical),Phase I,In-House,,,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4511,Pulmonary hypertension ,7/7/14 12:28
4863,89,Sanofi,Large Pharma,4980,SAR-407899,,Small Molecule (Chemical),Phase I,In-House,,,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4511,Pulmonary hypertension ,7/7/14 12:28
4863,89,Sanofi,Large Pharma,4980,SAR-407899,,Small Molecule (Chemical),Phase I,In-House,,,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4511,Pulmonary hypertension ,7/7/14 12:28
4864,42,Forest,Regional & Specialty Pharma,4981,Namenda XR,memantine,Small Molecule (Chemical),Launched,In-House,Jun-13,,,,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,75,663.5889698,2548.960253,2657.016942,2718.178083,2748.266982,2745.023867,2731.480352,67.12749114,4512,Alzheimer's Disease,7/7/14 12:28
4864,42,Forest,Regional & Specialty Pharma,4981,Namenda XR,memantine,Small Molecule (Chemical),Launched,In-House,Jun-13,,,,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4512,Alzheimer's Disease,7/7/14 12:28
4864,42,Forest,Regional & Specialty Pharma,4981,Namenda XR,memantine,Small Molecule (Chemical),Launched,In-House,Jun-13,,,,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,75,663.5889698,2548.960253,2657.016942,2718.178083,2748.266982,2745.023867,2731.480352,67.12749114,4512,Alzheimer's Disease,7/7/14 12:28
4865,76,Pfizer,Large Pharma,1379,Bosulif,bosutinib,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,173,Other Nephrology Treatments,82,Renal Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,268,Polycystic Kidney Disease,7/7/14 12:28
4865,76,Pfizer,Large Pharma,1379,Bosulif,bosutinib,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,173,Other Nephrology Treatments,82,Renal Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,268,Polycystic Kidney Disease,7/7/14 12:28
4865,76,Pfizer,Large Pharma,1379,Bosulif,bosutinib,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,173,Other Nephrology Treatments,82,Renal Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,268,Polycystic Kidney Disease,7/7/14 12:28
4866,2328,Specialised Therapeutics Australia,Regional & Specialty Pharma,3668,Dificid,fidaxomicin,Small Molecule (Chemical),Launched,Licensed (Development),,May-13,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,12,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2293,Clostridium difficile infection ,7/7/14 12:28
4866,2328,Specialised Therapeutics Australia,Regional & Specialty Pharma,3668,Dificid,fidaxomicin,Small Molecule (Chemical),Launched,Licensed (Development),,May-13,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,12,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2293,Clostridium difficile infection ,7/7/14 12:28
4866,2328,Specialised Therapeutics Australia,Regional & Specialty Pharma,3668,Dificid,fidaxomicin,Small Molecule (Chemical),Launched,Licensed (Development),,May-13,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,12,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2293,Clostridium difficile infection ,7/7/14 12:28
4869,300,Sinovac,Regional & Specialty Pharma,4984,Anflu,seasonal influenza vaccine,Vaccine,Launched,In-House,,Sep-06,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,15.2,7.6,8.1,9.2,10.1,10.788,11.43824,12.0044352,12.4903273,12.91818513,13.29189086,13.6174696,4.361250173,4515,seasonal influenza prevention,7/7/14 12:28
4869,300,Sinovac,Regional & Specialty Pharma,4984,Anflu,seasonal influenza vaccine,Vaccine,Launched,In-House,,Sep-06,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,15.2,7.6,8.1,9.2,10.1,10.788,11.43824,12.0044352,12.4903273,12.91818513,13.29189086,13.6174696,4.361250173,4515,seasonal influenza prevention,7/7/14 12:28
4869,300,Sinovac,Regional & Specialty Pharma,4984,Anflu,seasonal influenza vaccine,Vaccine,Launched,In-House,,Sep-06,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4515,seasonal influenza prevention,7/7/14 12:28
4870,18,Baxter Healthcare,Regional & Specialty Pharma,4985,Vepacel,BLB-750,Vaccine,Approved,In-House,,Aug-14,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,11.25,33.75,58.749975,83.74985186,98.44981042,110.3597728,119.5787393,0,4439,Pandemic Influenza,7/7/14 12:28
4870,18,Baxter Healthcare,Regional & Specialty Pharma,4985,Vepacel,BLB-750,Vaccine,Approved,In-House,,Aug-14,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,11.25,33.75,58.749975,83.74985186,98.44981042,110.3597728,119.5787393,0,4439,Pandemic Influenza,7/7/14 12:28
4870,18,Baxter Healthcare,Regional & Specialty Pharma,4985,Vepacel,BLB-750,Vaccine,Approved,In-House,,Aug-14,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4439,Pandemic Influenza,7/7/14 12:28
4871,86,Roche,Large Pharma,4986,cobimetinib+vemurafenib,cobimetinib+vemurafenib,Small Molecule (Chemical),Phase III,Licensed (Development),Jun-16,Sep-16,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,42.89510997,120.8617878,178.1848071,227.9536608,248.6912702,0,4516,Melanoma,7/7/14 12:28
4871,86,Roche,Large Pharma,4986,cobimetinib+vemurafenib,cobimetinib+vemurafenib,Small Molecule (Chemical),Phase III,Licensed (Development),Jun-16,Sep-16,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,20.86302583,73.38037114,107.9123105,134.8903881,148.631224,0,4516,Melanoma,7/7/14 12:28
4871,86,Roche,Large Pharma,4986,cobimetinib+vemurafenib,cobimetinib+vemurafenib,Small Molecule (Chemical),Phase III,Licensed (Development),Jun-16,Sep-16,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,22.03208414,47.48141662,70.27249659,93.06327269,100.0600463,0,4516,Melanoma,7/7/14 12:28
4872,67,Novartis,Large Pharma,4987,bimagrumab,bimagrumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4517,Sporadic Inclusion Body Myositis,7/7/14 12:28
4872,67,Novartis,Large Pharma,4987,bimagrumab,bimagrumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4517,Sporadic Inclusion Body Myositis,7/7/14 12:28
4872,67,Novartis,Large Pharma,4987,bimagrumab,bimagrumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4517,Sporadic Inclusion Body Myositis,7/7/14 12:28
4873,86,Roche,Large Pharma,4988,Lampalizumab,lampalizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,188,Dry AMD Treatments,30,AMD,4,Ophthalmology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4518,AMD,7/7/14 12:28
4873,86,Roche,Large Pharma,4988,Lampalizumab,lampalizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,188,Dry AMD Treatments,30,AMD,4,Ophthalmology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4518,AMD,7/7/14 12:28
4873,86,Roche,Large Pharma,4988,Lampalizumab,lampalizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,188,Dry AMD Treatments,30,AMD,4,Ophthalmology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4518,AMD,7/7/14 12:28
4874,102,Teva,Regional & Specialty Pharma,4989,Neugranin,balugrastim,Recombinant Protein,Filed,Corporate Acquisition,,,,,118,G-CSFs,78,Neutropenia,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4528,Neutropenia,7/7/14 12:28
4874,102,Teva,Regional & Specialty Pharma,4989,Neugranin,balugrastim,Recombinant Protein,Filed,Corporate Acquisition,,,,,118,G-CSFs,78,Neutropenia,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4528,Neutropenia,7/7/14 12:28
4874,102,Teva,Regional & Specialty Pharma,4989,Neugranin,balugrastim,Recombinant Protein,Filed,Corporate Acquisition,,,,,118,G-CSFs,78,Neutropenia,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4528,Neutropenia,7/7/14 12:28
4875,1369,Upsher-Smith Laboratories,Small Biotech,4990,Qudexy XR,topiramate,Small Molecule (Chemical),Launched,In-House,,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4519,Epilepsy,7/7/14 12:28
4875,1369,Upsher-Smith Laboratories,Small Biotech,4990,Qudexy XR,topiramate,Small Molecule (Chemical),Launched,In-House,,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4519,Epilepsy,7/7/14 12:28
4875,1369,Upsher-Smith Laboratories,Small Biotech,4990,Qudexy XR,topiramate,Small Molecule (Chemical),Launched,In-House,,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4519,Epilepsy,7/7/14 12:28
4876,73,Otsuka,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
4876,73,Otsuka,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
4876,73,Otsuka,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
4879,21,Biogen Idec,Regional & Specialty Pharma,1148,ocrelizumab,ocrelizumab,Antibody/Antibody Derivative,Phase II,,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,807,Multiple Sclerosis,7/7/14 12:28
4879,21,Biogen Idec,Regional & Specialty Pharma,1148,ocrelizumab,ocrelizumab,Antibody/Antibody Derivative,Phase II,,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,807,Multiple Sclerosis,7/7/14 12:28
4879,21,Biogen Idec,Regional & Specialty Pharma,1148,ocrelizumab,ocrelizumab,Antibody/Antibody Derivative,Phase II,,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,807,Multiple Sclerosis,7/7/14 12:28
4880,47,Grunenthal,Regional & Specialty Pharma,4992,Versatis,transdermal lidocaine,Small Molecule (Chemical),Launched,Licensed (Development),,Mar-07,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,2,Global,Sales,38.90595527,54.31494721,94.54971855,123.3860473,145.5422594,161.9139194,175.1108496,184.2333836,191.4054323,196.9049666,200.9990143,204.127966,4.951247928,625,Post-herpetic Neuralgia,7/7/14 12:28
4880,47,Grunenthal,Regional & Specialty Pharma,4992,Versatis,transdermal lidocaine,Small Molecule (Chemical),Launched,Licensed (Development),,Mar-07,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,2,ROW,Sales,38.90595527,54.31494721,94.54971855,123.3860473,145.5422594,161.9139194,175.1108496,184.2333836,191.4054323,196.9049666,200.9990143,204.127966,4.951247928,625,Post-herpetic Neuralgia,7/7/14 12:28
4880,47,Grunenthal,Regional & Specialty Pharma,4992,Versatis,transdermal lidocaine,Small Molecule (Chemical),Launched,Licensed (Development),,Mar-07,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,625,Post-herpetic Neuralgia,7/7/14 12:28
4881,46,GlaxoSmithKline,Large Pharma,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,Licensed (Development),Jul-11,,Nov-22,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,4,Global,Sales,0,0,3.206361421,7.92514437,3.239624204,0,0,0,0,0,0,0,-100,1479,Restless Legs Syndrome,7/7/14 12:28
4881,46,GlaxoSmithKline,Large Pharma,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,Licensed (Development),Jul-11,,Nov-22,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1479,Restless Legs Syndrome,7/7/14 12:28
4881,46,GlaxoSmithKline,Large Pharma,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,Licensed (Development),Jul-11,,Nov-22,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,4,US,Sales,0,0,3.206361421,7.92514437,3.239624204,0,0,0,0,0,0,0,-100,1479,Restless Legs Syndrome,7/7/14 12:28
4882,3,Acorda Therapeutics,Small Biotech,4993,NP-1998,NP-1998,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4521,Neuropathic Pain,7/7/14 12:28
4882,3,Acorda Therapeutics,Small Biotech,4993,NP-1998,NP-1998,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4521,Neuropathic Pain,7/7/14 12:28
4882,3,Acorda Therapeutics,Small Biotech,4993,NP-1998,NP-1998,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4521,Neuropathic Pain,7/7/14 12:28
4883,3,Acorda Therapeutics,Small Biotech,266,Qutenza,capsaicin,Small Molecule (Chemical),Launched,Acquisition (Marketed),Apr-10,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,1,4,4.9,5.675,7,7.5375,7.948125,9,36.8737677,1377,Post-herpetic Neuralgia,7/7/14 12:28
4883,3,Acorda Therapeutics,Small Biotech,266,Qutenza,capsaicin,Small Molecule (Chemical),Launched,Acquisition (Marketed),Apr-10,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1377,Post-herpetic Neuralgia,7/7/14 12:28
4883,3,Acorda Therapeutics,Small Biotech,266,Qutenza,capsaicin,Small Molecule (Chemical),Launched,Acquisition (Marketed),Apr-10,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,1,4,4.9,5.675,7,7.5375,7.948125,9,36.8737677,1377,Post-herpetic Neuralgia,7/7/14 12:28
4884,213,Isis Pharmaceuticals,Small Biotech,3346,ISIS-CRPRx,,DNA/RNA Therapy,Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4522,Coronary Artery Disease,7/7/14 12:28
4884,213,Isis Pharmaceuticals,Small Biotech,3346,ISIS-CRPRx,,DNA/RNA Therapy,Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4522,Coronary Artery Disease,7/7/14 12:28
4884,213,Isis Pharmaceuticals,Small Biotech,3346,ISIS-CRPRx,,DNA/RNA Therapy,Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4522,Coronary Artery Disease,7/7/14 12:28
4885,213,Isis Pharmaceuticals,Small Biotech,4994,ISIS-APOARx,,DNA/RNA Therapy,Phase I,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4523,Coronary Artery Disease,7/7/14 12:28
4885,213,Isis Pharmaceuticals,Small Biotech,4994,ISIS-APOARx,,DNA/RNA Therapy,Phase I,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4523,Coronary Artery Disease,7/7/14 12:28
4885,213,Isis Pharmaceuticals,Small Biotech,4994,ISIS-APOARx,,DNA/RNA Therapy,Phase I,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4523,Coronary Artery Disease,7/7/14 12:28
4887,67,Novartis,Large Pharma,4996,Ilevro,nepafenac ophthalmic suspension,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4524,Pain and inflammation associated with cataract surgery,7/7/14 12:28
4887,67,Novartis,Large Pharma,4996,Ilevro,nepafenac ophthalmic suspension,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4524,Pain and inflammation associated with cataract surgery,7/7/14 12:28
4887,67,Novartis,Large Pharma,4996,Ilevro,nepafenac ophthalmic suspension,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4524,Pain and inflammation associated with cataract surgery,7/7/14 12:28
4889,2339,Rockwell Medical,Regional & Specialty Pharma,4998,Triferic,Soluble Ferric Pyrophosphate,Small Molecule (Chemical),Filed,Licensed (Development),May-15,Jul-15,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,Global,Sales,0,0,0,0,0,0,16.29,51.7037536,80.60132374,98.59142139,115.9143708,129.8009834,0,4526,Anemia,7/7/14 12:28
4889,2339,Rockwell Medical,Regional & Specialty Pharma,4998,Triferic,Soluble Ferric Pyrophosphate,Small Molecule (Chemical),Filed,Licensed (Development),May-15,Jul-15,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,2.69,10.9037536,18.04145974,22.43166856,26.61708544,30.00320406,0,4526,Anemia,7/7/14 12:28
4889,2339,Rockwell Medical,Regional & Specialty Pharma,4998,Triferic,Soluble Ferric Pyrophosphate,Small Molecule (Chemical),Filed,Licensed (Development),May-15,Jul-15,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,US,Sales,0,0,0,0,0,0,13.6,40.8,62.559864,76.15975283,89.29728537,99.79777937,0,4526,Anemia,7/7/14 12:28
4890,888,Galenica,Regional & Specialty Pharma,4999,Velphoro,sucroferric oxyhydroxide,Small Molecule (Chemical),Approved,In-House,May-14,Sep-14,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,5,Global,Sales,0,0,0,0,0,25.89896423,85.25083914,155.3936674,225.5370896,284.5437339,339.2295815,389.2391637,0,4527,Hyperphosphatemia,7/7/14 12:28
4890,888,Galenica,Regional & Specialty Pharma,4999,Velphoro,sucroferric oxyhydroxide,Small Molecule (Chemical),Approved,In-House,May-14,Sep-14,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,5,ROW,Sales,0,0,0,0,0,2.158244052,10.07181277,20.86305512,31.65426176,37.95633389,42.81497159,46.34592655,0,4527,Hyperphosphatemia,7/7/14 12:28
4890,888,Galenica,Regional & Specialty Pharma,4999,Velphoro,sucroferric oxyhydroxide,Small Molecule (Chemical),Approved,In-House,May-14,Sep-14,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,5,US,Sales,0,0,0,0,0,23.74072018,75.17902637,134.5306123,193.8828279,246.5874,296.4146099,342.8932371,0,4527,Hyperphosphatemia,7/7/14 12:28
4891,614,Kissei,Regional & Specialty Pharma,4999,Velphoro,sucroferric oxyhydroxide,Small Molecule (Chemical),Approved,Licensed (Development),,Feb-16,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,3.375124036,25.87596219,59.62727347,80.54177796,100.6080286,110.7449447,0,4527,Hyperphosphatemia,7/7/14 12:28
4891,614,Kissei,Regional & Specialty Pharma,4999,Velphoro,sucroferric oxyhydroxide,Small Molecule (Chemical),Approved,Licensed (Development),,Feb-16,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,3.375124036,25.87596219,59.62727347,80.54177796,100.6080286,110.7449447,0,4527,Hyperphosphatemia,7/7/14 12:28
4891,614,Kissei,Regional & Specialty Pharma,4999,Velphoro,sucroferric oxyhydroxide,Small Molecule (Chemical),Approved,Licensed (Development),,Feb-16,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4527,Hyperphosphatemia,7/7/14 12:28
4892,87,Salix,Small Biotech,5000,Uceris,budesonide MMX,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-13,Nov-13,,,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,1.70001,63.33346061,113.333559,163.3336488,197.400384,226.823774,251.2759874,270.7825169,106.3456308,1894,Ulcerative Colitis,7/7/14 12:28
4892,87,Salix,Small Biotech,5000,Uceris,budesonide MMX,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-13,Nov-13,,,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,1.66667,12.77780889,29.44454391,46.11133355,57.00028372,66.64478501,74.64039055,80.98865078,74.15621597,1894,Ulcerative Colitis,7/7/14 12:28
4892,87,Salix,Small Biotech,5000,Uceris,budesonide MMX,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-13,Nov-13,,,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,3.33E-02,50.55565172,83.88901512,117.2223153,140.4001003,160.178989,176.6355969,189.7938661,243.9325346,1894,Ulcerative Colitis,7/7/14 12:28
4893,68,Novo Nordisk,Regional & Specialty Pharma,5001,semaglutide oral,semaglutide,Synthetic Peptide,Phase II,In-House,,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1078,Type II Diabetes,7/7/14 12:28
4893,68,Novo Nordisk,Regional & Specialty Pharma,5001,semaglutide oral,semaglutide,Synthetic Peptide,Phase II,In-House,,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1078,Type II Diabetes,7/7/14 12:28
4893,68,Novo Nordisk,Regional & Specialty Pharma,5001,semaglutide oral,semaglutide,Synthetic Peptide,Phase II,In-House,,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1078,Type II Diabetes,7/7/14 12:28
4894,89,Sanofi,Large Pharma,5002,GZ402671,,Small Molecule (Chemical),Phase I,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4529,Fabry Disease,7/7/14 12:28
4894,89,Sanofi,Large Pharma,5002,GZ402671,,Small Molecule (Chemical),Phase I,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4529,Fabry Disease,7/7/14 12:28
4894,89,Sanofi,Large Pharma,5002,GZ402671,,Small Molecule (Chemical),Phase I,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4529,Fabry Disease,7/7/14 12:28
4895,39,Eli Lilly,Large Pharma,5003,LY2409021,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4530,Diabetes,7/7/14 12:28
4895,39,Eli Lilly,Large Pharma,5003,LY2409021,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4530,Diabetes,7/7/14 12:28
4895,39,Eli Lilly,Large Pharma,5003,LY2409021,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4530,Diabetes,7/7/14 12:28
4896,39,Eli Lilly,Large Pharma,5004,Oxyntomodulin Peptide,,Synthetic Peptide,Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4531,Diabetes,7/7/14 12:28
4896,39,Eli Lilly,Large Pharma,5004,Oxyntomodulin Peptide,,Synthetic Peptide,Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4531,Diabetes,7/7/14 12:28
4896,39,Eli Lilly,Large Pharma,5004,Oxyntomodulin Peptide,,Synthetic Peptide,Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4531,Diabetes,7/7/14 12:28
4897,76,Pfizer,Large Pharma,4266,PF-04634817,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4532,Diabetic nephropathy,7/7/14 12:28
4897,76,Pfizer,Large Pharma,4266,PF-04634817,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4532,Diabetic nephropathy,7/7/14 12:28
4897,76,Pfizer,Large Pharma,4266,PF-04634817,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4532,Diabetic nephropathy,7/7/14 12:28
4898,76,Pfizer,Large Pharma,5005,PF-06291874,,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4533,Type II Diabetes,7/7/14 12:28
4898,76,Pfizer,Large Pharma,5005,PF-06291874,,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4533,Type II Diabetes,7/7/14 12:28
4898,76,Pfizer,Large Pharma,5005,PF-06291874,,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4533,Type II Diabetes,7/7/14 12:28
4899,67,Novartis,Large Pharma,5006,LIK066,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4534,Type II Diabetes,7/7/14 12:28
4899,67,Novartis,Large Pharma,5006,LIK066,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4534,Type II Diabetes,7/7/14 12:28
4899,67,Novartis,Large Pharma,5006,LIK066,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4534,Type II Diabetes,7/7/14 12:28
4900,46,GlaxoSmithKline,Large Pharma,5007,2890457,2890457,Small Molecule (Chemical),Phase II,In-House,,,,,80,Obesity Treatments,38,Obesity,8,Metabolism,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4535,Obesity,7/7/14 12:28
4900,46,GlaxoSmithKline,Large Pharma,5007,2890457,2890457,Small Molecule (Chemical),Phase II,In-House,,,,,80,Obesity Treatments,38,Obesity,8,Metabolism,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4535,Obesity,7/7/14 12:28
4900,46,GlaxoSmithKline,Large Pharma,5007,2890457,2890457,Small Molecule (Chemical),Phase II,In-House,,,,,80,Obesity Treatments,38,Obesity,8,Metabolism,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4535,Obesity,7/7/14 12:28
4901,86,Roche,Large Pharma,5008,RG7410,,Synthetic Peptide,Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4536,Diabetes,7/7/14 12:28
4901,86,Roche,Large Pharma,5008,RG7410,,Synthetic Peptide,Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4536,Diabetes,7/7/14 12:28
4901,86,Roche,Large Pharma,5008,RG7410,,Synthetic Peptide,Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4536,Diabetes,7/7/14 12:28
4902,89,Sanofi,Large Pharma,5009,SAR113244,anti-CXCR5,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4537,Systemic Lupus Erythematosus,7/7/14 12:28
4902,89,Sanofi,Large Pharma,5009,SAR113244,anti-CXCR5,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4537,Systemic Lupus Erythematosus,7/7/14 12:28
4902,89,Sanofi,Large Pharma,5009,SAR113244,anti-CXCR5,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4537,Systemic Lupus Erythematosus,7/7/14 12:28
4903,76,Pfizer,Large Pharma,5010,PF-06305591,,Small Molecule (Chemical),Phase I,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4538,Chronic Pain,7/7/14 12:28
4903,76,Pfizer,Large Pharma,5010,PF-06305591,,Small Molecule (Chemical),Phase I,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4538,Chronic Pain,7/7/14 12:28
4903,76,Pfizer,Large Pharma,5010,PF-06305591,,Small Molecule (Chemical),Phase I,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4538,Chronic Pain,7/7/14 12:28
4904,76,Pfizer,Large Pharma,5011,PF-06273340,PF-06273340,Small Molecule (Chemical),Phase I,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4544,Pain,7/7/14 12:28
4904,76,Pfizer,Large Pharma,5011,PF-06273340,PF-06273340,Small Molecule (Chemical),Phase I,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4544,Pain,7/7/14 12:28
4904,76,Pfizer,Large Pharma,5011,PF-06273340,PF-06273340,Small Molecule (Chemical),Phase I,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4544,Pain,7/7/14 12:28
4905,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,5012,KHK-4083,,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4540,Autoimmune diseases,7/7/14 12:28
4905,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,5012,KHK-4083,,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4540,Autoimmune diseases,7/7/14 12:28
4905,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,5012,KHK-4083,,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4540,Autoimmune diseases,7/7/14 12:28
4906,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,5013,KHK-4577,,Small Molecule (Chemical),Phase II,In-House,,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4539,atopic dermatitis,7/7/14 12:28
4906,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,5013,KHK-4577,,Small Molecule (Chemical),Phase II,In-House,,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4539,atopic dermatitis,7/7/14 12:28
4906,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,5013,KHK-4577,,Small Molecule (Chemical),Phase II,In-House,,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4539,atopic dermatitis,7/7/14 12:28
4907,29,Chugai,Regional & Specialty Pharma,1877,rontalizumab,RG7415,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1024,Systemic Lupus Erythematosus,7/7/14 12:28
4907,29,Chugai,Regional & Specialty Pharma,1877,rontalizumab,RG7415,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1024,Systemic Lupus Erythematosus,7/7/14 12:28
4907,29,Chugai,Regional & Specialty Pharma,1877,rontalizumab,RG7415,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1024,Systemic Lupus Erythematosus,7/7/14 12:28
4908,16,AstraZeneca,Large Pharma,3391,AZD5213,,Small Molecule (Chemical),Phase II,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4541,Neuropathic Pain,7/7/14 12:28
4908,16,AstraZeneca,Large Pharma,3391,AZD5213,,Small Molecule (Chemical),Phase II,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4541,Neuropathic Pain,7/7/14 12:28
4908,16,AstraZeneca,Large Pharma,3391,AZD5213,,Small Molecule (Chemical),Phase II,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4541,Neuropathic Pain,7/7/14 12:28
4909,15,Astellas Pharma,Regional & Specialty Pharma,5014,ASP8232,ASP8232,Small Molecule (Chemical),Phase I,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4543,Diabetic Nephropathy,7/7/14 12:28
4909,15,Astellas Pharma,Regional & Specialty Pharma,5014,ASP8232,ASP8232,Small Molecule (Chemical),Phase I,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4543,Diabetic Nephropathy,7/7/14 12:28
4909,15,Astellas Pharma,Regional & Specialty Pharma,5014,ASP8232,ASP8232,Small Molecule (Chemical),Phase I,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4543,Diabetic Nephropathy,7/7/14 12:28
4910,901,Aslan Pharmaceuticals,Small Biotech,5015,LAS186323,DHODH inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4542,Rheumatoid Arthritis,7/7/14 12:28
4910,901,Aslan Pharmaceuticals,Small Biotech,5015,LAS186323,DHODH inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4542,Rheumatoid Arthritis,7/7/14 12:28
4910,901,Aslan Pharmaceuticals,Small Biotech,5015,LAS186323,DHODH inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4542,Rheumatoid Arthritis,7/7/14 12:28
4911,16,AstraZeneca,Large Pharma,5016,AZD3293,AZD3293,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4545,Alzheimer's Disease,7/7/14 12:28
4911,16,AstraZeneca,Large Pharma,5016,AZD3293,AZD3293,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4545,Alzheimer's Disease,7/7/14 12:28
4911,16,AstraZeneca,Large Pharma,5016,AZD3293,AZD3293,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4545,Alzheimer's Disease,7/7/14 12:28
4912,16,AstraZeneca,Large Pharma,1291,Recentin,cediranib,Small Molecule (Chemical),Phase III,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4546,Ovarian cancer,7/7/14 12:28
4912,16,AstraZeneca,Large Pharma,1291,Recentin,cediranib,Small Molecule (Chemical),Phase III,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4546,Ovarian cancer,7/7/14 12:28
4912,16,AstraZeneca,Large Pharma,1291,Recentin,cediranib,Small Molecule (Chemical),Phase III,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4546,Ovarian cancer,7/7/14 12:28
4913,24,Bristol-Myers Squibb,Large Pharma,5017,Myostatin Adnectin,Myostatin Adnectin,Antibody/Antibody Derivative,Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4548,,7/7/14 12:28
4913,24,Bristol-Myers Squibb,Large Pharma,5017,Myostatin Adnectin,Myostatin Adnectin,Antibody/Antibody Derivative,Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4548,,7/7/14 12:28
4913,24,Bristol-Myers Squibb,Large Pharma,5017,Myostatin Adnectin,Myostatin Adnectin,Antibody/Antibody Derivative,Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4548,,7/7/14 12:28
4914,16,AstraZeneca,Large Pharma,5018,AZD-7624,AZD-7624,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4547,COPD,7/7/14 12:28
4914,16,AstraZeneca,Large Pharma,5018,AZD-7624,AZD-7624,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4547,COPD,7/7/14 12:28
4914,16,AstraZeneca,Large Pharma,5018,AZD-7624,AZD-7624,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4547,COPD,7/7/14 12:28
4915,46,GlaxoSmithKline,Large Pharma,5019,2256294,2256294,Small Molecule (Chemical),Phase I,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4549,COPD,7/7/14 12:28
4915,46,GlaxoSmithKline,Large Pharma,5019,2256294,2256294,Small Molecule (Chemical),Phase I,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4549,COPD,7/7/14 12:28
4915,46,GlaxoSmithKline,Large Pharma,5019,2256294,2256294,Small Molecule (Chemical),Phase I,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4549,COPD,7/7/14 12:28
4916,16,AstraZeneca,Large Pharma,5020,PT001,glycopyrronium bromide,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4550,COPD,7/7/14 12:28
4916,16,AstraZeneca,Large Pharma,5020,PT001,glycopyrronium bromide,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4550,COPD,7/7/14 12:28
4916,16,AstraZeneca,Large Pharma,5020,PT001,glycopyrronium bromide,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4550,COPD,7/7/14 12:28
4918,16,AstraZeneca,Large Pharma,5021,fluticasone furoate + umeclidinium + vilanterol,,Small Molecule (Chemical),Phase I,,,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4552,COPD,7/7/14 12:28
4918,16,AstraZeneca,Large Pharma,5021,fluticasone furoate + umeclidinium + vilanterol,,Small Molecule (Chemical),Phase I,,,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4552,COPD,7/7/14 12:28
4918,16,AstraZeneca,Large Pharma,5021,fluticasone furoate + umeclidinium + vilanterol,,Small Molecule (Chemical),Phase I,,,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4552,COPD,7/7/14 12:28
4919,10,Almirall,Regional & Specialty Pharma,5022,LAS-190792,,Small Molecule (Chemical),Phase I,,,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4553,COPD,7/7/14 12:28
4919,10,Almirall,Regional & Specialty Pharma,5022,LAS-190792,,Small Molecule (Chemical),Phase I,,,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4553,COPD,7/7/14 12:28
4919,10,Almirall,Regional & Specialty Pharma,5022,LAS-190792,,Small Molecule (Chemical),Phase I,,,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4553,COPD,7/7/14 12:28
4920,29,Chugai,Regional & Specialty Pharma,4053,RG1577,RO-4602522,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3821,Alzheimer's Disease,7/7/14 12:28
4920,29,Chugai,Regional & Specialty Pharma,4053,RG1577,RO-4602522,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3821,Alzheimer's Disease,7/7/14 12:28
4920,29,Chugai,Regional & Specialty Pharma,4053,RG1577,RO-4602522,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3821,Alzheimer's Disease,7/7/14 12:28
4921,61,Merck & Co,Large Pharma,5023,MK-1029,,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4554,Asthma,7/7/14 12:28
4921,61,Merck & Co,Large Pharma,5023,MK-1029,,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4554,Asthma,7/7/14 12:28
4921,61,Merck & Co,Large Pharma,5023,MK-1029,,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4554,Asthma,7/7/14 12:28
4922,16,AstraZeneca,Large Pharma,5024,PT005,formoterol fumarate,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4555,COPD,7/7/14 12:28
4922,16,AstraZeneca,Large Pharma,5024,PT005,formoterol fumarate,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4555,COPD,7/7/14 12:28
4922,16,AstraZeneca,Large Pharma,5024,PT005,formoterol fumarate,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4555,COPD,7/7/14 12:28
4923,46,GlaxoSmithKline,Large Pharma,5025,GSK-2434735,,Small Molecule (Chemical),Phase I,,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4556,Asthma,7/7/14 12:28
4923,46,GlaxoSmithKline,Large Pharma,5025,GSK-2434735,,Small Molecule (Chemical),Phase I,,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4556,Asthma,7/7/14 12:28
4923,46,GlaxoSmithKline,Large Pharma,5025,GSK-2434735,,Small Molecule (Chemical),Phase I,,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4556,Asthma,7/7/14 12:28
4924,46,GlaxoSmithKline,Large Pharma,2526,2126458,,Small Molecule (Chemical),Phase I,In-House,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4551,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
4924,46,GlaxoSmithKline,Large Pharma,2526,2126458,,Small Molecule (Chemical),Phase I,In-House,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4551,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
4924,46,GlaxoSmithKline,Large Pharma,2526,2126458,,Small Molecule (Chemical),Phase I,In-House,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4551,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
4925,35,Dainippon-Sumitomo,Regional & Specialty Pharma,5026,SEP-363856,SEP-363856,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4557,Schizophrenia,7/7/14 12:28
4925,35,Dainippon-Sumitomo,Regional & Specialty Pharma,5026,SEP-363856,SEP-363856,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4557,Schizophrenia,7/7/14 12:28
4925,35,Dainippon-Sumitomo,Regional & Specialty Pharma,5026,SEP-363856,SEP-363856,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4557,Schizophrenia,7/7/14 12:28
4926,39,Eli Lilly,Large Pharma,5027,LY-3002813,LY-3002813; N3pG-Abeta mAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4558,Alzheimer's Disease,7/7/14 12:28
4926,39,Eli Lilly,Large Pharma,5027,LY-3002813,LY-3002813; N3pG-Abeta mAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4558,Alzheimer's Disease,7/7/14 12:28
4926,39,Eli Lilly,Large Pharma,5027,LY-3002813,LY-3002813; N3pG-Abeta mAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4558,Alzheimer's Disease,7/7/14 12:28
4928,61,Merck & Co,Large Pharma,5029,MK-1602,MK-1602,Small Molecule (Chemical),Phase II,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4560,Migraine,7/7/14 12:28
4928,61,Merck & Co,Large Pharma,5029,MK-1602,MK-1602,Small Molecule (Chemical),Phase II,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4560,Migraine,7/7/14 12:28
4928,61,Merck & Co,Large Pharma,5029,MK-1602,MK-1602,Small Molecule (Chemical),Phase II,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4560,Migraine,7/7/14 12:28
4929,102,Teva,Regional & Specialty Pharma,5030,TV-1380,TV-1380,Recombinant Protein,Phase II,Corporate Acquisition,,,,,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4561,Cocaine Addiction,7/7/14 12:28
4929,102,Teva,Regional & Specialty Pharma,5030,TV-1380,TV-1380,Recombinant Protein,Phase II,Corporate Acquisition,,,,,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4561,Cocaine Addiction,7/7/14 12:28
4929,102,Teva,Regional & Specialty Pharma,5030,TV-1380,TV-1380,Recombinant Protein,Phase II,Corporate Acquisition,,,,,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4561,Cocaine Addiction,7/7/14 12:28
4932,45,Gilead,Regional & Specialty Pharma,3977,simtuzumab,simtuzumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3792,Liver Fibrosis,7/7/14 12:28
4932,45,Gilead,Regional & Specialty Pharma,3977,simtuzumab,simtuzumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3792,Liver Fibrosis,7/7/14 12:28
4932,45,Gilead,Regional & Specialty Pharma,3977,simtuzumab,simtuzumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3792,Liver Fibrosis,7/7/14 12:28
4933,807,Intercept Pharmaceuticals,Small Biotech,5032,obeticholic acid,obeticholic acid,Small Molecule (Chemical),Phase III,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4563,Liver Disease,7/7/14 12:28
4933,807,Intercept Pharmaceuticals,Small Biotech,5032,obeticholic acid,obeticholic acid,Small Molecule (Chemical),Phase III,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4563,Liver Disease,7/7/14 12:28
4933,807,Intercept Pharmaceuticals,Small Biotech,5032,obeticholic acid,obeticholic acid,Small Molecule (Chemical),Phase III,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4563,Liver Disease,7/7/14 12:28
4934,35,Dainippon-Sumitomo,Regional & Specialty Pharma,5033,DSP-1747,obeticholic acid,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4563,non-alcoholic steatohepatitis,7/7/14 12:28
4934,35,Dainippon-Sumitomo,Regional & Specialty Pharma,5033,DSP-1747,obeticholic acid,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4563,non-alcoholic steatohepatitis,7/7/14 12:28
4934,35,Dainippon-Sumitomo,Regional & Specialty Pharma,5033,DSP-1747,obeticholic acid,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4563,non-alcoholic steatohepatitis,7/7/14 12:28
4935,11,Amgen,Large Pharma,4653,AMG-139,MEDI-2070,Antibody/Antibody Derivative,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4221,Crohn's Disease,7/7/14 12:28
4935,11,Amgen,Large Pharma,4653,AMG-139,MEDI-2070,Antibody/Antibody Derivative,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4221,Crohn's Disease,7/7/14 12:28
4935,11,Amgen,Large Pharma,4653,AMG-139,MEDI-2070,Antibody/Antibody Derivative,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4221,Crohn's Disease,7/7/14 12:28
4936,68,Novo Nordisk,Regional & Specialty Pharma,3322,NN-8828,Anti-IL21,Antibody/Antibody Derivative,Phase II,Acquisition (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3352,Crohn's Disease,7/7/14 12:28
4936,68,Novo Nordisk,Regional & Specialty Pharma,3322,NN-8828,Anti-IL21,Antibody/Antibody Derivative,Phase II,Acquisition (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3352,Crohn's Disease,7/7/14 12:28
4936,68,Novo Nordisk,Regional & Specialty Pharma,3322,NN-8828,Anti-IL21,Antibody/Antibody Derivative,Phase II,Acquisition (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3352,Crohn's Disease,7/7/14 12:28
4937,11,Amgen,Large Pharma,5034,AMG 334,AMG 334,Antibody/Antibody Derivative,Phase I,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4565,Migraine Prevention,7/7/14 12:28
4937,11,Amgen,Large Pharma,5034,AMG 334,AMG 334,Antibody/Antibody Derivative,Phase I,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4565,Migraine Prevention,7/7/14 12:28
4937,11,Amgen,Large Pharma,5034,AMG 334,AMG 334,Antibody/Antibody Derivative,Phase I,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4565,Migraine Prevention,7/7/14 12:28
4938,171,BioMarin,Small Biotech,5035,BMN 111,BMN 111,Recombinant Protein,Phase II,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4570,Achondroplasia,7/7/14 12:28
4938,171,BioMarin,Small Biotech,5035,BMN 111,BMN 111,Recombinant Protein,Phase II,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4570,Achondroplasia,7/7/14 12:28
4938,171,BioMarin,Small Biotech,5035,BMN 111,BMN 111,Recombinant Protein,Phase II,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4570,Achondroplasia,7/7/14 12:28
4939,171,BioMarin,Small Biotech,5036,BMN 701,BMN 701,Recombinant Protein,Phase III,Acquisition (Development),,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4568,Pompe Disease,7/7/14 12:28
4939,171,BioMarin,Small Biotech,5036,BMN 701,BMN 701,Recombinant Protein,Phase III,Acquisition (Development),,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4568,Pompe Disease,7/7/14 12:28
4939,171,BioMarin,Small Biotech,5036,BMN 701,BMN 701,Recombinant Protein,Phase III,Acquisition (Development),,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4568,Pompe Disease,7/7/14 12:28
4940,171,BioMarin,Small Biotech,5037,Firdapse,amifampridine phosphate,Small Molecule (Chemical),Launched,In-House,,Apr-10,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Sales,0,6.4,13.1,14.2,15.9,17.664,18.7924,19.79578,20.630887,21.29186025,21.83904656,22.28628113,4.941826576,4566,Lambert-Eaton myasthenic syndrome,7/7/14 12:28
4940,171,BioMarin,Small Biotech,5037,Firdapse,amifampridine phosphate,Small Molecule (Chemical),Launched,In-House,,Apr-10,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Sales,0,6.4,13.1,14.2,15.9,17.664,18.7924,19.79578,20.630887,21.29186025,21.83904656,22.28628113,4.941826576,4566,Lambert-Eaton myasthenic syndrome,7/7/14 12:28
4940,171,BioMarin,Small Biotech,5037,Firdapse,amifampridine phosphate,Small Molecule (Chemical),Launched,In-House,,Apr-10,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4566,Lambert-Eaton myasthenic syndrome,7/7/14 12:28
4941,171,BioMarin,Small Biotech,5038,BMN 673,BMN 673,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4569,Cancer,7/7/14 12:28
4941,171,BioMarin,Small Biotech,5038,BMN 673,BMN 673,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4569,Cancer,7/7/14 12:28
4941,171,BioMarin,Small Biotech,5038,BMN 673,BMN 673,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4569,Cancer,7/7/14 12:28
4942,171,BioMarin,Small Biotech,5039,BMN 190,BMN 190,Recombinant Protein,Phase I,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4571,Batten disease,7/7/14 12:28
4942,171,BioMarin,Small Biotech,5039,BMN 190,BMN 190,Recombinant Protein,Phase I,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4571,Batten disease,7/7/14 12:28
4942,171,BioMarin,Small Biotech,5039,BMN 190,BMN 190,Recombinant Protein,Phase I,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4571,Batten disease,7/7/14 12:28
4943,171,BioMarin,Small Biotech,5040,PEG-PAL,PEGylated recombinant phenylalanine ammonia lyase,Recombinant Protein,Phase III,Acquisition (Development),Jul-17,Jul-17,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,20.175,81.778152,135.3109481,172,0,4567,Phenylketonuria ,7/7/14 12:28
4943,171,BioMarin,Small Biotech,5040,PEG-PAL,PEGylated recombinant phenylalanine ammonia lyase,Recombinant Protein,Phase III,Acquisition (Development),Jul-17,Jul-17,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,10.0875,40.889076,67.65547404,86,0,4567,Phenylketonuria ,7/7/14 12:28
4943,171,BioMarin,Small Biotech,5040,PEG-PAL,PEGylated recombinant phenylalanine ammonia lyase,Recombinant Protein,Phase III,Acquisition (Development),Jul-17,Jul-17,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,10.0875,40.889076,67.65547404,86,0,4567,Phenylketonuria ,7/7/14 12:28
4944,173,Alexion Pharmaceuticals,Small Biotech,5041,ALXN 1102/1103,ALXN 1102/1103,Recombinant Protein,Phase I,Acquisition (Development),,,,,108,Other Hematology Products,81,Other Hematological Disorders,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4572,Paroxysmal nocturnal hemoglobinuria,7/7/14 12:28
4944,173,Alexion Pharmaceuticals,Small Biotech,5041,ALXN 1102/1103,ALXN 1102/1103,Recombinant Protein,Phase I,Acquisition (Development),,,,,108,Other Hematology Products,81,Other Hematological Disorders,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4572,Paroxysmal nocturnal hemoglobinuria,7/7/14 12:28
4944,173,Alexion Pharmaceuticals,Small Biotech,5041,ALXN 1102/1103,ALXN 1102/1103,Recombinant Protein,Phase I,Acquisition (Development),,,,,108,Other Hematology Products,81,Other Hematological Disorders,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4572,Paroxysmal nocturnal hemoglobinuria,7/7/14 12:28
4945,173,Alexion Pharmaceuticals,Small Biotech,5042,Asfotase Alfa,Asfotase Alfa,Recombinant Protein,Phase III,Acquisition (Development),Feb-15,Feb-15,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,46.08,169.4117376,258.8611351,317.1385424,349.3944906,369.9949209,0,4573,Hypophosphatasia,7/7/14 12:28
4945,173,Alexion Pharmaceuticals,Small Biotech,5042,Asfotase Alfa,Asfotase Alfa,Recombinant Protein,Phase III,Acquisition (Development),Feb-15,Feb-15,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,26.88,98.8235136,151.0023288,184.9974831,203.8134528,215.8303705,0,4573,Hypophosphatasia,7/7/14 12:28
4945,173,Alexion Pharmaceuticals,Small Biotech,5042,Asfotase Alfa,Asfotase Alfa,Recombinant Protein,Phase III,Acquisition (Development),Feb-15,Feb-15,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,19.2,70.588224,107.8588063,132.1410593,145.5810377,154.1645504,0,4573,Hypophosphatasia,7/7/14 12:28
4946,173,Alexion Pharmaceuticals,Small Biotech,5043,ALXN 1101,cyclic pyranopterin monophosphate,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4574,Molybdenum cofactor deficiency,7/7/14 12:28
4946,173,Alexion Pharmaceuticals,Small Biotech,5043,ALXN 1101,cyclic pyranopterin monophosphate,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4574,Molybdenum cofactor deficiency,7/7/14 12:28
4946,173,Alexion Pharmaceuticals,Small Biotech,5043,ALXN 1101,cyclic pyranopterin monophosphate,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4574,Molybdenum cofactor deficiency,7/7/14 12:28
4947,34,Daiichi-Sankyo,Regional & Specialty Pharma,5044,DS-7113,DS-7113,Small Molecule (Chemical),Phase III,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4575,Cancer pain,7/7/14 12:28
4947,34,Daiichi-Sankyo,Regional & Specialty Pharma,5044,DS-7113,DS-7113,Small Molecule (Chemical),Phase III,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4575,Cancer pain,7/7/14 12:28
4947,34,Daiichi-Sankyo,Regional & Specialty Pharma,5044,DS-7113,DS-7113,Small Molecule (Chemical),Phase III,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4575,Cancer pain,7/7/14 12:28
4948,19,Bayer,Large Pharma,5045,BAY 1179470,BAY 1179470,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4581,Solid Tumors,7/7/14 12:28
4948,19,Bayer,Large Pharma,5045,BAY 1179470,BAY 1179470,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4581,Solid Tumors,7/7/14 12:28
4948,19,Bayer,Large Pharma,5045,BAY 1179470,BAY 1179470,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4581,Solid Tumors,7/7/14 12:28
4950,23,Boehringer Ingelheim,Large Pharma,5046,BI-836858,BI-836858,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4579,Acute myelogenous leukemia,7/7/14 12:28
4950,23,Boehringer Ingelheim,Large Pharma,5046,BI-836858,BI-836858,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4579,Acute myelogenous leukemia,7/7/14 12:28
4950,23,Boehringer Ingelheim,Large Pharma,5046,BI-836858,BI-836858,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4579,Acute myelogenous leukemia,7/7/14 12:28
4951,23,Boehringer Ingelheim,Large Pharma,5047,XmAb (1),XmAb (1),Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4577,Cancer,7/7/14 12:28
4951,23,Boehringer Ingelheim,Large Pharma,5047,XmAb (1),XmAb (1),Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4577,Cancer,7/7/14 12:28
4951,23,Boehringer Ingelheim,Large Pharma,5047,XmAb (1),XmAb (1),Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4577,Cancer,7/7/14 12:28
4952,23,Boehringer Ingelheim,Large Pharma,5048,XmAb (2),XmAb (2),Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4578,Cancer,7/7/14 12:28
4952,23,Boehringer Ingelheim,Large Pharma,5048,XmAb (2),XmAb (2),Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4578,Cancer,7/7/14 12:28
4952,23,Boehringer Ingelheim,Large Pharma,5048,XmAb (2),XmAb (2),Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4578,Cancer,7/7/14 12:28
4953,23,Boehringer Ingelheim,Large Pharma,5049,small molecule,small molecule from Evotec,Small Molecule (Chemical),Phase I,Acquisition (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4580,Cancer,7/7/14 12:28
4953,23,Boehringer Ingelheim,Large Pharma,5049,small molecule,small molecule from Evotec,Small Molecule (Chemical),Phase I,Acquisition (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4580,Cancer,7/7/14 12:28
4953,23,Boehringer Ingelheim,Large Pharma,5049,small molecule,small molecule from Evotec,Small Molecule (Chemical),Phase I,Acquisition (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4580,Cancer,7/7/14 12:28
4955,34,Daiichi-Sankyo,Regional & Specialty Pharma,5051,DS-3032,DS-3032,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4583,Cancer,7/7/14 12:28
4955,34,Daiichi-Sankyo,Regional & Specialty Pharma,5051,DS-3032,DS-3032,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4583,Cancer,7/7/14 12:28
4955,34,Daiichi-Sankyo,Regional & Specialty Pharma,5051,DS-3032,DS-3032,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4583,Cancer,7/7/14 12:28
4957,102,Teva,Regional & Specialty Pharma,5053,Multikine,leukocyte interleukin,Other (Protein),Phase III,Licensed (Marketed),,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4584,Head and Neck Cancer,7/7/14 12:28
4957,102,Teva,Regional & Specialty Pharma,5053,Multikine,leukocyte interleukin,Other (Protein),Phase III,Licensed (Marketed),,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4584,Head and Neck Cancer,7/7/14 12:28
4957,102,Teva,Regional & Specialty Pharma,5053,Multikine,leukocyte interleukin,Other (Protein),Phase III,Licensed (Marketed),,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4584,Head and Neck Cancer,7/7/14 12:28
4958,102,Teva,Regional & Specialty Pharma,5054,XMT-1107,XMT-1107,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4586,Solid Tumors,7/7/14 12:28
4958,102,Teva,Regional & Specialty Pharma,5054,XMT-1107,XMT-1107,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4586,Solid Tumors,7/7/14 12:28
4958,102,Teva,Regional & Specialty Pharma,5054,XMT-1107,XMT-1107,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4586,Solid Tumors,7/7/14 12:28
4959,34,Daiichi-Sankyo,Regional & Specialty Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Launched,Acquisition (Development),Sep-11,Jan-12,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,7,Global,Alliance Revenue,0,0,74.70379628,36.11622186,56.37924457,60.40633347,69.46728349,62.41987792,59.39956125,57.06384969,55.37247235,51.34538345,-1.327199207,992,Melanoma,7/7/14 12:28
4959,34,Daiichi-Sankyo,Regional & Specialty Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Launched,Acquisition (Development),Sep-11,Jan-12,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,992,Melanoma,7/7/14 12:28
4959,34,Daiichi-Sankyo,Regional & Specialty Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Launched,Acquisition (Development),Sep-11,Jan-12,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,7,ROW,Alliance Revenue,0,0,0,12.03874062,36.24380008,40.27088898,45.3047501,40.27088898,39.26411676,37.25057231,36.24380008,33.22348341,-1.235324865,992,Melanoma,7/7/14 12:28
4959,34,Daiichi-Sankyo,Regional & Specialty Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Launched,Acquisition (Development),Sep-11,Jan-12,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,992,Melanoma,7/7/14 12:28
4959,34,Daiichi-Sankyo,Regional & Specialty Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Launched,Acquisition (Development),Sep-11,Jan-12,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,7,US,Alliance Revenue,0,0,74.70379628,24.07748124,20.13544449,20.13544449,24.16253339,22.14898894,20.13544449,19.81327738,19.12867227,18.12190004,-1.493877973,992,Melanoma,7/7/14 12:28
4959,34,Daiichi-Sankyo,Regional & Specialty Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Launched,Acquisition (Development),Sep-11,Jan-12,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,992,Melanoma,7/7/14 12:28
4960,26,Celgene,Regional & Specialty Pharma,5055,Pomalidomide,Pomalidomide,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,918,Systemic sclerosis,7/7/14 12:28
4960,26,Celgene,Regional & Specialty Pharma,5055,Pomalidomide,Pomalidomide,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,918,Systemic sclerosis,7/7/14 12:28
4960,26,Celgene,Regional & Specialty Pharma,5055,Pomalidomide,Pomalidomide,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,918,Systemic sclerosis,7/7/14 12:28
4961,15,Astellas Pharma,Regional & Specialty Pharma,5056,ASP-3325,ASP-3325,Small Molecule (Chemical),Phase I,In-House,,,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4587,Hyperphosphatemia ,7/7/14 12:28
4961,15,Astellas Pharma,Regional & Specialty Pharma,5056,ASP-3325,ASP-3325,Small Molecule (Chemical),Phase I,In-House,,,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4587,Hyperphosphatemia ,7/7/14 12:28
4961,15,Astellas Pharma,Regional & Specialty Pharma,5056,ASP-3325,ASP-3325,Small Molecule (Chemical),Phase I,In-House,,,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4587,Hyperphosphatemia ,7/7/14 12:28
4962,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,5057,KHK-7580,KHK-7580,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4588,Secondary hyperparathyroidism,7/7/14 12:28
4962,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,5057,KHK-7580,KHK-7580,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4588,Secondary hyperparathyroidism,7/7/14 12:28
4962,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,5057,KHK-7580,KHK-7580,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4588,Secondary hyperparathyroidism,7/7/14 12:28
4963,255,Kyorin,Regional & Specialty Pharma,5058,KRP-203,KRP-203,Small Molecule (Chemical),Phase I,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4589,Transplant Rejection,7/7/14 12:28
4963,255,Kyorin,Regional & Specialty Pharma,5058,KRP-203,KRP-203,Small Molecule (Chemical),Phase I,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4589,Transplant Rejection,7/7/14 12:28
4963,255,Kyorin,Regional & Specialty Pharma,5058,KRP-203,KRP-203,Small Molecule (Chemical),Phase I,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4589,Transplant Rejection,7/7/14 12:28
4964,67,Novartis,Large Pharma,5058,KRP-203,KRP-203,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4589,Transplant Rejection,7/7/14 12:28
4964,67,Novartis,Large Pharma,5058,KRP-203,KRP-203,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4589,Transplant Rejection,7/7/14 12:28
4964,67,Novartis,Large Pharma,5058,KRP-203,KRP-203,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4589,Transplant Rejection,7/7/14 12:28
4965,86,Roche,Large Pharma,5059,RG7929,POL7080,Synthetic Peptide,Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4590,Pseudomonas infections,7/7/14 12:28
4965,86,Roche,Large Pharma,5059,RG7929,POL7080,Synthetic Peptide,Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4590,Pseudomonas infections,7/7/14 12:28
4965,86,Roche,Large Pharma,5059,RG7929,POL7080,Synthetic Peptide,Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4590,Pseudomonas infections,7/7/14 12:28
4966,102,Teva,Regional & Specialty Pharma,5060,VX-15,VX15/2503,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4591,Multiple Sclerosis,7/7/14 12:28
4966,102,Teva,Regional & Specialty Pharma,5060,VX-15,VX15/2503,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4591,Multiple Sclerosis,7/7/14 12:28
4966,102,Teva,Regional & Specialty Pharma,5060,VX-15,VX15/2503,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4591,Multiple Sclerosis,7/7/14 12:28
4969,29,Chugai,Regional & Specialty Pharma,5061,alectinib,alectinib,Small Molecule (Chemical),Filed,In-House,,Oct-14,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,3,Global,Alliance Revenue,0,0,0,0,0,5.124482231,23.91426749,37.57959737,51.24504216,60.0592092,66.80307896,72.05264333,0,4592,Non-small-cell Lung Cancer,7/7/14 12:28
4969,29,Chugai,Regional & Specialty Pharma,5061,alectinib,alectinib,Small Molecule (Chemical),Filed,In-House,,Oct-14,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,3,ROW,Alliance Revenue,0,0,0,0,0,5.124482231,23.91426749,37.57959737,51.24504216,60.0592092,66.80307896,72.05264333,0,4592,Non-small-cell Lung Cancer,7/7/14 12:28
4969,29,Chugai,Regional & Specialty Pharma,5061,alectinib,alectinib,Small Molecule (Chemical),Filed,In-House,,Oct-14,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4592,Non-small-cell Lung Cancer,7/7/14 12:28
4970,29,Chugai,Regional & Specialty Pharma,5062,URC102,URC102,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,151,Gout Treatments,64,Gout,8,Metabolism,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4593,Gout,7/7/14 12:28
4970,29,Chugai,Regional & Specialty Pharma,5062,URC102,URC102,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,151,Gout Treatments,64,Gout,8,Metabolism,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4593,Gout,7/7/14 12:28
4970,29,Chugai,Regional & Specialty Pharma,5062,URC102,URC102,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,151,Gout Treatments,64,Gout,8,Metabolism,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4593,Gout,7/7/14 12:28
4971,86,Roche,Large Pharma,5063,RG7745,RG7745,Antibody/Antibody Derivative,Phase II,Acquisition (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4594,Influenza A,7/7/14 12:28
4971,86,Roche,Large Pharma,5063,RG7745,RG7745,Antibody/Antibody Derivative,Phase II,Acquisition (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4594,Influenza A,7/7/14 12:28
4971,86,Roche,Large Pharma,5063,RG7745,RG7745,Antibody/Antibody Derivative,Phase II,Acquisition (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4594,Influenza A,7/7/14 12:28
4972,86,Roche,Large Pharma,4275,RG7795,RG7795,Small Molecule (Chemical),Phase I,Acquisition (Development),,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4595,Hepatitis B,7/7/14 12:28
4972,86,Roche,Large Pharma,4275,RG7795,RG7795,Small Molecule (Chemical),Phase I,Acquisition (Development),,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4595,Hepatitis B,7/7/14 12:28
4972,86,Roche,Large Pharma,4275,RG7795,RG7795,Small Molecule (Chemical),Phase I,Acquisition (Development),,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4595,Hepatitis B,7/7/14 12:28
4973,86,Roche,Large Pharma,5064,RG7863,RG7863,Small Molecule (Chemical),Phase I,In-House,,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4596,Hepatitis B ,7/7/14 12:28
4973,86,Roche,Large Pharma,5064,RG7863,RG7863,Small Molecule (Chemical),Phase I,In-House,,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4596,Hepatitis B ,7/7/14 12:28
4973,86,Roche,Large Pharma,5064,RG7863,RG7863,Small Molecule (Chemical),Phase I,In-House,,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4596,Hepatitis B ,7/7/14 12:28
4974,23,Boehringer Ingelheim,Large Pharma,5065,Nanobody therapy,Nanobody therapy,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4597,Alzheimer's disease,7/7/14 12:28
4974,23,Boehringer Ingelheim,Large Pharma,5065,Nanobody therapy,Nanobody therapy,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4597,Alzheimer's disease,7/7/14 12:28
4974,23,Boehringer Ingelheim,Large Pharma,5065,Nanobody therapy,Nanobody therapy,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4597,Alzheimer's disease,7/7/14 12:28
4975,23,Boehringer Ingelheim,Large Pharma,5066,BI-113608,BI-113608,Small Molecule (Chemical),Phase I,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4598,COPD,7/7/14 12:28
4975,23,Boehringer Ingelheim,Large Pharma,5066,BI-113608,BI-113608,Small Molecule (Chemical),Phase I,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4598,COPD,7/7/14 12:28
4975,23,Boehringer Ingelheim,Large Pharma,5066,BI-113608,BI-113608,Small Molecule (Chemical),Phase I,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4598,COPD,7/7/14 12:28
4978,96,Shire,Regional & Specialty Pharma,5069,VP 20621,VP 20621,Other (Biologic),Phase II,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4601,Clostridium difficile,7/7/14 12:28
4978,96,Shire,Regional & Specialty Pharma,5069,VP 20621,VP 20621,Other (Biologic),Phase II,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4601,Clostridium difficile,7/7/14 12:28
4978,96,Shire,Regional & Specialty Pharma,5069,VP 20621,VP 20621,Other (Biologic),Phase II,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4601,Clostridium difficile,7/7/14 12:28
4979,96,Shire,Regional & Specialty Pharma,5070,SHP622,SHP622,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4602,Friedreich's Ataxia,7/7/14 12:28
4979,96,Shire,Regional & Specialty Pharma,5070,SHP622,SHP622,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4602,Friedreich's Ataxia,7/7/14 12:28
4979,96,Shire,Regional & Specialty Pharma,5070,SHP622,SHP622,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4602,Friedreich's Ataxia,7/7/14 12:28
4980,23,Boehringer Ingelheim,Large Pharma,5071,BI-655075,BI-655075,Antibody/Antibody Derivative,Phase I,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4603,Bleeding,7/7/14 12:28
4980,23,Boehringer Ingelheim,Large Pharma,5071,BI-655075,BI-655075,Antibody/Antibody Derivative,Phase I,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4603,Bleeding,7/7/14 12:28
4980,23,Boehringer Ingelheim,Large Pharma,5071,BI-655075,BI-655075,Antibody/Antibody Derivative,Phase I,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4603,Bleeding,7/7/14 12:28
4981,23,Boehringer Ingelheim,Large Pharma,5072,BI-409306,BI-409306,Small Molecule (Chemical),Phase I,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4604,Schizophrenia,7/7/14 12:28
4981,23,Boehringer Ingelheim,Large Pharma,5072,BI-409306,BI-409306,Small Molecule (Chemical),Phase I,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4604,Schizophrenia,7/7/14 12:28
4981,23,Boehringer Ingelheim,Large Pharma,5072,BI-409306,BI-409306,Small Molecule (Chemical),Phase I,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4604,Schizophrenia,7/7/14 12:28
4982,23,Boehringer Ingelheim,Large Pharma,5073,BI-187004-CL,BI-187004-CL,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4605,Diabetes,7/7/14 12:28
4982,23,Boehringer Ingelheim,Large Pharma,5073,BI-187004-CL,BI-187004-CL,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4605,Diabetes,7/7/14 12:28
4982,23,Boehringer Ingelheim,Large Pharma,5073,BI-187004-CL,BI-187004-CL,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4605,Diabetes,7/7/14 12:28
4983,19,Bayer,Large Pharma,5074,BAY 85-8501,BAY 85-8501,Small Molecule (Chemical),Phase II,In-House,,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4606,Bronchiectasis ,7/7/14 12:28
4983,19,Bayer,Large Pharma,5074,BAY 85-8501,BAY 85-8501,Small Molecule (Chemical),Phase II,In-House,,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4606,Bronchiectasis ,7/7/14 12:28
4983,19,Bayer,Large Pharma,5074,BAY 85-8501,BAY 85-8501,Small Molecule (Chemical),Phase II,In-House,,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4606,Bronchiectasis ,7/7/14 12:28
4984,2385,"Catalyst Pharmaceutical Partners, Inc.",Small Biotech,5037,Firdapse,amifampridine phosphate,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4566,Lambert-Eaton myasthenic syndrome,7/7/14 12:28
4984,2385,"Catalyst Pharmaceutical Partners, Inc.",Small Biotech,5037,Firdapse,amifampridine phosphate,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4566,Lambert-Eaton myasthenic syndrome,7/7/14 12:28
4984,2385,"Catalyst Pharmaceutical Partners, Inc.",Small Biotech,5037,Firdapse,amifampridine phosphate,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4566,Lambert-Eaton myasthenic syndrome,7/7/14 12:28
4985,788,Alkermes,Small Biotech,5075,ALKS-5461,ALKS-5461,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4607,Depression,7/7/14 12:28
4985,788,Alkermes,Small Biotech,5075,ALKS-5461,ALKS-5461,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4607,Depression,7/7/14 12:28
4985,788,Alkermes,Small Biotech,5075,ALKS-5461,ALKS-5461,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4607,Depression,7/7/14 12:28
4987,67,Novartis,Large Pharma,5077,LEE011,cyclin-dependent kinase 4/6 inhibitor,Small Molecule (Chemical),Phase III,Licensed (Development),May-17,Jul-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,60.175,201.778152,319.3105481,392.2367872,0,4609,Breast Cancer,7/7/14 12:28
4987,67,Novartis,Large Pharma,5077,LEE011,cyclin-dependent kinase 4/6 inhibitor,Small Molecule (Chemical),Phase III,Licensed (Development),May-17,Jul-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,20.175,81.778152,135.3109481,168.2375142,0,4609,Breast Cancer,7/7/14 12:28
4987,67,Novartis,Large Pharma,5077,LEE011,cyclin-dependent kinase 4/6 inhibitor,Small Molecule (Chemical),Phase III,Licensed (Development),May-17,Jul-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,40,120,183.9996,223.999273,0,4609,Breast Cancer,7/7/14 12:28
4988,263,Horizon Pharma,Small Biotech,1876,Vimovo,naproxen + esomeprazole,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-10,,Aug-15,Nov-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,33,22.05,1.836,1.178,0.88,0.656,0.546,0,1259,Osteoarthritis,7/7/14 12:28
4988,263,Horizon Pharma,Small Biotech,1876,Vimovo,naproxen + esomeprazole,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-10,,Aug-15,Nov-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1259,Osteoarthritis,7/7/14 12:28
4988,263,Horizon Pharma,Small Biotech,1876,Vimovo,naproxen + esomeprazole,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-10,,Aug-15,Nov-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,33,22.05,1.836,1.178,0.88,0.656,0.546,0,1259,Osteoarthritis,7/7/14 12:28
4989,688,Depomed,Small Biotech,5078,Lazanda,fentanyl - intranasal,Small Molecule (Chemical),Launched,Licensed (Marketed),Oct-11,Oct-11,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2326,Cancer Pain,7/7/14 12:28
4989,688,Depomed,Small Biotech,5078,Lazanda,fentanyl - intranasal,Small Molecule (Chemical),Launched,Licensed (Marketed),Oct-11,Oct-11,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2326,Cancer Pain,7/7/14 12:28
4989,688,Depomed,Small Biotech,5078,Lazanda,fentanyl - intranasal,Small Molecule (Chemical),Launched,Licensed (Marketed),Oct-11,Oct-11,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2326,Cancer Pain,7/7/14 12:28
4990,86,Roche,Large Pharma,5061,alectinib,alectinib,Small Molecule (Chemical),Phase III,In-House,Sep-17,Oct-14,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,Global,Sales,0,0,0,0,0,5.124482231,23.91426749,37.57959737,64.55422136,116.4134542,154.811445,191.7151749,0,4592,Non-small-cell Lung Cancer,7/7/14 12:28
4990,86,Roche,Large Pharma,5061,alectinib,alectinib,Small Molecule (Chemical),Phase III,In-House,Sep-17,Oct-14,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,ROW,Sales,0,0,0,0,0,5.124482231,23.91426749,37.57959737,53.7630011,76.84561058,93.66132116,108.9827264,0,4592,Non-small-cell Lung Cancer,7/7/14 12:28
4990,86,Roche,Large Pharma,5061,alectinib,alectinib,Small Molecule (Chemical),Phase III,In-House,Sep-17,Nov-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,10.79122026,39.56784358,61.15012387,82.73244859,0,4592,Non-small-cell Lung Cancer,7/7/14 12:28
4991,2154,Adamas,Small Biotech,5079,ADS-5102,ADS-5102,Small Molecule (Chemical),Phase III,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4610,Parkinson's disease,7/7/14 12:28
4991,2154,Adamas,Small Biotech,5079,ADS-5102,ADS-5102,Small Molecule (Chemical),Phase III,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4610,Parkinson's disease,7/7/14 12:28
4991,2154,Adamas,Small Biotech,5079,ADS-5102,ADS-5102,Small Molecule (Chemical),Phase III,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4610,Parkinson's disease,7/7/14 12:28
4992,732,GW Pharmaceuticals,Small Biotech,5080,Epidiolex,Epidiolex,Small Molecule (Chemical),Phase I,In-House,,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4611,Dravet Syndrome,7/7/14 12:28
4992,732,GW Pharmaceuticals,Small Biotech,5080,Epidiolex,Epidiolex,Small Molecule (Chemical),Phase I,In-House,,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4611,Dravet Syndrome,7/7/14 12:28
4992,732,GW Pharmaceuticals,Small Biotech,5080,Epidiolex,Epidiolex,Small Molecule (Chemical),Phase I,In-House,,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4611,Dravet Syndrome,7/7/14 12:28
4993,179,Zogenix,Small Biotech,5081,Zohydro,hydrocodone bitartrate,Small Molecule (Chemical),Launched,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4612,Pain,7/7/14 12:28
4993,179,Zogenix,Small Biotech,5081,Zohydro,hydrocodone bitartrate,Small Molecule (Chemical),Launched,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4612,Pain,7/7/14 12:28
4993,179,Zogenix,Small Biotech,5081,Zohydro,hydrocodone bitartrate,Small Molecule (Chemical),Launched,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4612,Pain,7/7/14 12:28
4994,2387,Omeros,Small Biotech,5082,OMS824,OMS824,Small Molecule (Chemical),Phase II,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4613,Huntington's disease,7/7/14 12:28
4994,2387,Omeros,Small Biotech,5082,OMS824,OMS824,Small Molecule (Chemical),Phase II,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4613,Huntington's disease,7/7/14 12:28
4994,2387,Omeros,Small Biotech,5082,OMS824,OMS824,Small Molecule (Chemical),Phase II,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4613,Huntington's disease,7/7/14 12:28
4995,29,Chugai,Regional & Specialty Pharma,4161,anamorelin,anamorelin,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,818,Cachexia,7/7/14 12:28
4995,29,Chugai,Regional & Specialty Pharma,4161,anamorelin,anamorelin,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,818,Cachexia,7/7/14 12:28
4995,29,Chugai,Regional & Specialty Pharma,4161,anamorelin,anamorelin,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,818,Cachexia,7/7/14 12:28
4996,237,Biopartners,Small Biotech,5083,Somatropin BioPartners,sustained-release somatropin,Recombinant Protein,Launched,Licensed (Development),,Feb-13,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,Global,Sales,0,0,0,0,2.728329691,3.933351066,5.615841984,8.412418975,9.913247007,11.26136672,12.43990328,13.81277574,26.07419419,3829,Growth Hormone Disorders,7/7/14 12:28
4996,237,Biopartners,Small Biotech,5083,Somatropin BioPartners,sustained-release somatropin,Recombinant Protein,Launched,Licensed (Development),,Feb-13,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,ROW,Sales,0,0,0,0,2.728329691,3.933351066,5.615841984,8.412418975,9.913247007,11.26136672,12.43990328,13.81277574,26.07419419,3829,Growth Hormone Disorders,7/7/14 12:28
4996,237,Biopartners,Small Biotech,5083,Somatropin BioPartners,sustained-release somatropin,Recombinant Protein,Launched,Licensed (Development),,Feb-13,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3829,Growth Hormone Disorders,7/7/14 12:28
4998,67,Novartis,Large Pharma,5084,LGX818+MEK162,LGX818+MEK162,Small Molecule (Chemical),Phase III,Licensed (Development),Sep-18,Nov-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,13.166673,67.77788389,107.1111699,0,1034702,Melanoma,7/7/14 12:28
4998,67,Novartis,Large Pharma,5084,LGX818+MEK162,LGX818+MEK162,Small Molecule (Chemical),Phase III,Licensed (Development),Sep-18,Nov-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,6.500013,43.33344167,69.33350667,0,1034702,Melanoma,7/7/14 12:28
4998,67,Novartis,Large Pharma,5084,LGX818+MEK162,LGX818+MEK162,Small Molecule (Chemical),Phase III,Licensed (Development),Sep-18,Nov-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,6.66666,24.44444222,37.77766323,0,1034702,Melanoma,7/7/14 12:28
4999,15,Astellas Pharma,Regional & Specialty Pharma,257,AMG 785,romosozumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Jan-19,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,2.531337964,11.81291894,20.13544449,0,1347,Osteoporosis,7/7/14 12:28
4999,15,Astellas Pharma,Regional & Specialty Pharma,257,AMG 785,romosozumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Jan-19,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,2.531337964,11.81291894,20.13544449,0,1347,Osteoporosis,7/7/14 12:28
4999,15,Astellas Pharma,Regional & Specialty Pharma,257,AMG 785,romosozumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Jan-19,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1347,Osteoporosis,7/7/14 12:28
5001,82,Purdue Pharma,Regional & Specialty Pharma,5086,Targiniq,oxycodone HCl/naloxone HCl,Small Molecule (Chemical),Filed,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034703,Pain,7/7/14 12:28
5001,82,Purdue Pharma,Regional & Specialty Pharma,5086,Targiniq,oxycodone HCl/naloxone HCl,Small Molecule (Chemical),Filed,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034703,Pain,7/7/14 12:28
5001,82,Purdue Pharma,Regional & Specialty Pharma,5086,Targiniq,oxycodone HCl/naloxone HCl,Small Molecule (Chemical),Filed,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034703,Pain,7/7/14 12:28
5002,1996,Nuron,Small Biotech,5087,Relonsiv,NU100,Recombinant Protein,Phase III,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034704,Multiple Sclerosis,7/7/14 12:28
5002,1996,Nuron,Small Biotech,5087,Relonsiv,NU100,Recombinant Protein,Phase III,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034704,Multiple Sclerosis,7/7/14 12:28
5002,1996,Nuron,Small Biotech,5087,Relonsiv,NU100,Recombinant Protein,Phase III,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034704,Multiple Sclerosis,7/7/14 12:28
5003,2392,Zafgen,,5088,Beloranib,Beloranib,Small Molecule (Chemical),Phase II,Licensed (Development),Aug-19,,,,80,Obesity Treatments,38,Obesity,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,29.16669,89.44461322,0,1034705,Obesity,7/7/14 12:28
5003,2392,Zafgen,,5088,Beloranib,Beloranib,Small Molecule (Chemical),Phase II,Licensed (Development),Aug-19,,,,80,Obesity Treatments,38,Obesity,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034705,Obesity,7/7/14 12:28
5003,2392,Zafgen,,5088,Beloranib,Beloranib,Small Molecule (Chemical),Phase II,Licensed (Development),Aug-19,,,,80,Obesity Treatments,38,Obesity,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,29.16669,89.44461322,0,1034705,Obesity,7/7/14 12:28
5004,45,Gilead,Regional & Specialty Pharma,3377,ledipasvir,GS-5885,Small Molecule (Chemical),Filed,In-House,Oct-14,Dec-14,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,339,1400,1730,1695,1741,1541,1354,0,1034707,Hepatitis C,7/7/14 12:28
5004,45,Gilead,Regional & Specialty Pharma,3377,ledipasvir,GS-5885,Small Molecule (Chemical),Filed,In-House,Oct-14,Dec-14,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,85,520,620,605,621,571,510,0,1034707,Hepatitis C,7/7/14 12:28
5004,45,Gilead,Regional & Specialty Pharma,3377,ledipasvir,GS-5885,Small Molecule (Chemical),Filed,In-House,Oct-14,Dec-14,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,254,880,1110,1090,1120,970,844,0,1034707,Hepatitis C,7/7/14 12:28
5005,53,Johnson & Johnson,Large Pharma,5089,CSL362,CSL362,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034706,Acute Myeloid Leukemia,7/7/14 12:28
5005,53,Johnson & Johnson,Large Pharma,5089,CSL362,CSL362,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034706,Acute Myeloid Leukemia,7/7/14 12:28
5005,53,Johnson & Johnson,Large Pharma,5089,CSL362,CSL362,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034706,Acute Myeloid Leukemia,7/7/14 12:28
5006,2181,Arbor Pharmaceuticals,Regional & Specialty Pharma,3484,Edarbi,azilsartan medoxomil ,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-13,,Sep-16,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,8.333325,30.55555278,47.22207904,44.97760229,3.983650116,2.804454188,2.232745242,2.222762812,-17.20373077,224,Hypertension,7/7/14 12:28
5006,2181,Arbor Pharmaceuticals,Regional & Specialty Pharma,3484,Edarbi,azilsartan medoxomil ,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-13,,Sep-16,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,224,Hypertension,7/7/14 12:28
5006,2181,Arbor Pharmaceuticals,Regional & Specialty Pharma,3484,Edarbi,azilsartan medoxomil ,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-13,,Sep-16,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,8.333325,30.55555278,47.22207904,44.97760229,3.983650116,2.804454188,2.232745242,2.222762812,-17.20373077,224,Hypertension,7/7/14 12:28
5007,2332,Ultragenyx,Regional & Specialty Pharma,2162,KRN23,KRN23,Recombinant Protein,Phase II,Licensed (Development),,,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,593,Hypophosphatemic Rickets,7/7/14 12:28
5007,2332,Ultragenyx,Regional & Specialty Pharma,2162,KRN23,KRN23,Recombinant Protein,Phase II,Licensed (Development),,,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,593,Hypophosphatemic Rickets,7/7/14 12:28
5007,2332,Ultragenyx,Regional & Specialty Pharma,2162,KRN23,KRN23,Recombinant Protein,Phase II,Licensed (Development),,,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,593,Hypophosphatemic Rickets,7/7/14 12:28
5008,96,Shire,Regional & Specialty Pharma,4286,Cinryze,C1 esterase inhibitor [human],Recombinant Protein,Phase II,Corporate Acquisition,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3963,Transplant Rejection,7/7/14 12:28
5008,96,Shire,Regional & Specialty Pharma,4286,Cinryze,C1 esterase inhibitor [human],Recombinant Protein,Phase II,Corporate Acquisition,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3963,Transplant Rejection,7/7/14 12:28
5008,96,Shire,Regional & Specialty Pharma,4286,Cinryze,C1 esterase inhibitor [human],Recombinant Protein,Phase II,Corporate Acquisition,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3963,Transplant Rejection,7/7/14 12:28
5009,173,Alexion Pharmaceuticals,Small Biotech,2422,Soliris,eculizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1108,Transplant Rejection,7/7/14 12:28
5009,173,Alexion Pharmaceuticals,Small Biotech,2422,Soliris,eculizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1108,Transplant Rejection,7/7/14 12:28
5009,173,Alexion Pharmaceuticals,Small Biotech,2422,Soliris,eculizumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1108,Transplant Rejection,7/7/14 12:28
5010,352,SBI Biotech,Small Biotech,5090,QPI-1002,QPI-1002,DNA/RNA Therapy,Phase II,Corporate Acquisition,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034708,Transplant Rejection,7/7/14 12:28
5010,352,SBI Biotech,Small Biotech,5090,QPI-1002,QPI-1002,DNA/RNA Therapy,Phase II,Corporate Acquisition,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034708,Transplant Rejection,7/7/14 12:28
5010,352,SBI Biotech,Small Biotech,5090,QPI-1002,QPI-1002,DNA/RNA Therapy,Phase II,Corporate Acquisition,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034708,Transplant Rejection,7/7/14 12:28
5011,2025,Digna Biotech,Small Biotech,5091,Cardiotrophin,cardiotrophin-1,Recombinant Protein,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034709,Transplant Rejection,7/7/14 12:28
5011,2025,Digna Biotech,Small Biotech,5091,Cardiotrophin,cardiotrophin-1,Recombinant Protein,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034709,Transplant Rejection,7/7/14 12:28
5011,2025,Digna Biotech,Small Biotech,5091,Cardiotrophin,cardiotrophin-1,Recombinant Protein,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034709,Transplant Rejection,7/7/14 12:28
5012,67,Novartis,Large Pharma,5092,Simulect,basiliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034710,Transplant Rejection,7/7/14 12:28
5012,67,Novartis,Large Pharma,5092,Simulect,basiliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034710,Transplant Rejection,7/7/14 12:28
5012,67,Novartis,Large Pharma,5092,Simulect,basiliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034710,Transplant Rejection,7/7/14 12:28
5013,2408,Tolera Therapeutics,Small Biotech,5093,TOL101,TOL101,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034711,Transplant Rejection,7/7/14 12:28
5013,2408,Tolera Therapeutics,Small Biotech,5093,TOL101,TOL101,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034711,Transplant Rejection,7/7/14 12:28
5013,2408,Tolera Therapeutics,Small Biotech,5093,TOL101,TOL101,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034711,Transplant Rejection,7/7/14 12:28
5014,76,Pfizer,Large Pharma,5094,ATGAM,lymphocyte immune thyglobuline,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034712,Transplant Rejection,7/7/14 12:28
5014,76,Pfizer,Large Pharma,5094,ATGAM,lymphocyte immune thyglobuline,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034712,Transplant Rejection,7/7/14 12:28
5014,76,Pfizer,Large Pharma,5094,ATGAM,lymphocyte immune thyglobuline,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034712,Transplant Rejection,7/7/14 12:28
5015,70,Ono,Regional & Specialty Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),,,Oct-20,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1411,Type II Diabetes,7/7/14 12:28
5015,70,Ono,Regional & Specialty Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),,,Oct-20,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1411,Type II Diabetes,7/7/14 12:28
5015,70,Ono,Regional & Specialty Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),,,Oct-20,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1411,Type II Diabetes,7/7/14 12:28
5017,577,Neurocrine Biosciences,Small Biotech,5096,NBI-98854,valbenazine,Small Molecule (Chemical),Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034713,Tardive Dyskinesia,7/7/14 12:28
5017,577,Neurocrine Biosciences,Small Biotech,5096,NBI-98854,valbenazine,Small Molecule (Chemical),Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034713,Tardive Dyskinesia,7/7/14 12:28
5017,577,Neurocrine Biosciences,Small Biotech,5096,NBI-98854,valbenazine,Small Molecule (Chemical),Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034713,Tardive Dyskinesia,7/7/14 12:28
5018,2154,Adamas,Small Biotech,5097,ADS-8704,,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034714,Alzheimer's Disease,7/7/14 12:28
5018,2154,Adamas,Small Biotech,5097,ADS-8704,,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034714,Alzheimer's Disease,7/7/14 12:28
5018,2154,Adamas,Small Biotech,5097,ADS-8704,,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034714,Alzheimer's Disease,7/7/14 12:28
5019,89,Sanofi,Large Pharma,4944,patisiran,ALN-TTR02,DNA/RNA Therapy,Phase III,Licensed (Development),,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4476,TTR Amyloidosis,7/7/14 12:28
5019,89,Sanofi,Large Pharma,4944,patisiran,ALN-TTR02,DNA/RNA Therapy,Phase III,Licensed (Development),,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4476,TTR Amyloidosis,7/7/14 12:28
5019,89,Sanofi,Large Pharma,4944,patisiran,ALN-TTR02,DNA/RNA Therapy,Phase III,Licensed (Development),,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4476,TTR Amyloidosis,7/7/14 12:28
5020,425,Alnylam,Small Biotech,5098,ALN-TTRsc,ALN-TTRsc,DNA/RNA Therapy,Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034716,Familial Amyloid Cardiomyopathy,7/7/14 12:28
5020,425,Alnylam,Small Biotech,5098,ALN-TTRsc,ALN-TTRsc,DNA/RNA Therapy,Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034716,Familial Amyloid Cardiomyopathy,7/7/14 12:28
5020,425,Alnylam,Small Biotech,5098,ALN-TTRsc,ALN-TTRsc,DNA/RNA Therapy,Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034716,Familial Amyloid Cardiomyopathy,7/7/14 12:28
5021,89,Sanofi,Large Pharma,5098,ALN-TTRsc,ALN-TTRsc,DNA/RNA Therapy,Phase II,Licensed (Development),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034716,Familial Amyloid Cardiomyopathy,7/7/14 12:28
5021,89,Sanofi,Large Pharma,5098,ALN-TTRsc,ALN-TTRsc,DNA/RNA Therapy,Phase II,Licensed (Development),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034716,Familial Amyloid Cardiomyopathy,7/7/14 12:28
5021,89,Sanofi,Large Pharma,5098,ALN-TTRsc,ALN-TTRsc,DNA/RNA Therapy,Phase II,Licensed (Development),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034716,Familial Amyloid Cardiomyopathy,7/7/14 12:28
5023,76,Pfizer,Large Pharma,5100,KUX-1151 ,KUX-1151 ,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,151,Gout Treatments,64,Gout,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034719,Chronic gout,7/7/14 12:28
5023,76,Pfizer,Large Pharma,5100,KUX-1151 ,KUX-1151 ,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,151,Gout Treatments,64,Gout,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034719,Chronic gout,7/7/14 12:28
5023,76,Pfizer,Large Pharma,5100,KUX-1151 ,KUX-1151 ,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,151,Gout Treatments,64,Gout,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034719,Chronic gout,7/7/14 12:28
5024,1518,Intra-Cellular Therapies ,Small Biotech,5101,ITI-007,ITI-007,Small Molecule (Chemical),Phase II,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034717,Schizophrenia,7/7/14 12:28
5024,1518,Intra-Cellular Therapies ,Small Biotech,5101,ITI-007,ITI-007,Small Molecule (Chemical),Phase II,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034717,Schizophrenia,7/7/14 12:28
5024,1518,Intra-Cellular Therapies ,Small Biotech,5101,ITI-007,ITI-007,Small Molecule (Chemical),Phase II,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034717,Schizophrenia,7/7/14 12:28
5025,52,Jazz Pharmaceuticals,Small Biotech,5102,JZP-110,JZP-110,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034720,Excessive daytime sleepiness,7/7/14 12:28
5025,52,Jazz Pharmaceuticals,Small Biotech,5102,JZP-110,JZP-110,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034720,Excessive daytime sleepiness,7/7/14 12:28
5025,52,Jazz Pharmaceuticals,Small Biotech,5102,JZP-110,JZP-110,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034720,Excessive daytime sleepiness,7/7/14 12:28
5026,76,Pfizer,Large Pharma,5103,Prothrombin complex concentrate,Prothrombin complex concentrate,Recombinant Protein,Phase III,Licensed (Development),,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034721,Reversal of vitamin K antagonist in surgery,7/7/14 12:28
5026,76,Pfizer,Large Pharma,5103,Prothrombin complex concentrate,Prothrombin complex concentrate,Recombinant Protein,Phase III,Licensed (Development),,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034721,Reversal of vitamin K antagonist in surgery,7/7/14 12:28
5026,76,Pfizer,Large Pharma,5103,Prothrombin complex concentrate,Prothrombin complex concentrate,Recombinant Protein,Phase III,Licensed (Development),,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034721,Reversal of vitamin K antagonist in surgery,7/7/14 12:28
5027,2405,Octapharma,Small Biotech,5104,Octaplex,Prothrombin complex concentrate,Recombinant Protein,Launched,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034721,Reversal of vitamin K antagonist in surgery,7/7/14 12:28
5027,2405,Octapharma,Small Biotech,5104,Octaplex,Prothrombin complex concentrate,Recombinant Protein,Launched,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034721,Reversal of vitamin K antagonist in surgery,7/7/14 12:28
5027,2405,Octapharma,Small Biotech,5104,Octaplex,Prothrombin complex concentrate,Recombinant Protein,Launched,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034721,Reversal of vitamin K antagonist in surgery,7/7/14 12:28
5028,26,Celgene,Regional & Specialty Pharma,5105,AG-221,AG-221,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034725,Acute Myeloid Leukemia,7/7/14 12:28
5028,26,Celgene,Regional & Specialty Pharma,5105,AG-221,AG-221,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034725,Acute Myeloid Leukemia,7/7/14 12:28
5028,26,Celgene,Regional & Specialty Pharma,5105,AG-221,AG-221,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034725,Acute Myeloid Leukemia,7/7/14 12:28
5029,357,Japan Tobacco,Small Biotech,5106,Riona,ferric citrate,Small Molecule (Chemical),Approved,Licensed (Development),,Oct-14,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,Global,Sales,0,0,0,0,0,3.775395842,21.39392236,30.20316674,42.28443343,52.050123,60.26538194,65.44019459,0,3853,Hyperphosphatemia,7/7/14 12:28
5029,357,Japan Tobacco,Small Biotech,5106,Riona,ferric citrate,Small Molecule (Chemical),Approved,Licensed (Development),,Oct-14,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,ROW,Sales,0,0,0,0,0,3.775395842,21.39392236,30.20316674,42.28443343,52.050123,60.26538194,65.44019459,0,3853,Hyperphosphatemia,7/7/14 12:28
5029,357,Japan Tobacco,Small Biotech,5106,Riona,ferric citrate,Small Molecule (Chemical),Approved,Licensed (Development),,Oct-14,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3853,Hyperphosphatemia,7/7/14 12:28
5030,100,Takeda,Large Pharma,5107,Natura alpha,Natura alpha,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034722,ulcerative colitis,7/7/14 12:28
5030,100,Takeda,Large Pharma,5107,Natura alpha,Natura alpha,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034722,ulcerative colitis,7/7/14 12:28
5030,100,Takeda,Large Pharma,5107,Natura alpha,Natura alpha,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034722,ulcerative colitis,7/7/14 12:28
5031,1124,Sunesis,Small Biotech,5108,vosaroxin,vosaroxin,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034723,Acute Myeloid Leukemia,7/7/14 12:28
5031,1124,Sunesis,Small Biotech,5108,vosaroxin,vosaroxin,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034723,Acute Myeloid Leukemia,7/7/14 12:28
5031,1124,Sunesis,Small Biotech,5108,vosaroxin,vosaroxin,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034723,Acute Myeloid Leukemia,7/7/14 12:28
5032,252,BioLineRx,Small Biotech,5109,BL-8040,BL-8040,Synthetic Peptide,Phase II,Licensed (Development),,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034724,Stem Cell Mobilization,7/7/14 12:28
5032,252,BioLineRx,Small Biotech,5109,BL-8040,BL-8040,Synthetic Peptide,Phase II,Licensed (Development),,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034724,Stem Cell Mobilization,7/7/14 12:28
5032,252,BioLineRx,Small Biotech,5109,BL-8040,BL-8040,Synthetic Peptide,Phase II,Licensed (Development),,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034724,Stem Cell Mobilization,7/7/14 12:28
5033,653,Genmab,Small Biotech,5110,ofatumumab,ofatumumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1568,Multiple Sclerosis,7/7/14 12:28
5033,653,Genmab,Small Biotech,5110,ofatumumab,ofatumumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1568,Multiple Sclerosis,7/7/14 12:28
5033,653,Genmab,Small Biotech,5110,ofatumumab,ofatumumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1568,Multiple Sclerosis,7/7/14 12:28
5034,2449,Forum Pharmaceuticals,Small Biotech,3312,EVP-6124,encenicline,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3361,Alzheimer's Disease,7/7/14 12:28
5034,2449,Forum Pharmaceuticals,Small Biotech,3312,EVP-6124,encenicline,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3361,Alzheimer's Disease,7/7/14 12:28
5034,2449,Forum Pharmaceuticals,Small Biotech,3312,EVP-6124,encenicline,Small Molecule (Chemical),Phase III,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3361,Alzheimer's Disease,7/7/14 12:28
5035,2424,Supernus Pharmaceuticals,,5111,Oxtellar XR,oxcarbazepine extended-release,Small Molecule (Chemical),Launched,In-House,Feb-13,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034726,Epilepsy,7/7/14 12:28
5035,2424,Supernus Pharmaceuticals,,5111,Oxtellar XR,oxcarbazepine extended-release,Small Molecule (Chemical),Launched,In-House,Feb-13,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034726,Epilepsy,7/7/14 12:28
5035,2424,Supernus Pharmaceuticals,,5111,Oxtellar XR,oxcarbazepine extended-release,Small Molecule (Chemical),Launched,In-House,Feb-13,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034726,Epilepsy,7/7/14 12:28
5036,2425,Amarantus BioScience Holdings,Small Biotech,5112,eltoprazine ,eltoprazine ,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034727,Parkinson's disease,7/7/14 12:28
5036,2425,Amarantus BioScience Holdings,Small Biotech,5112,eltoprazine ,eltoprazine ,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034727,Parkinson's disease,7/7/14 12:28
5036,2425,Amarantus BioScience Holdings,Small Biotech,5112,eltoprazine ,eltoprazine ,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034727,Parkinson's disease,7/7/14 12:28
5037,68,Novo Nordisk,Regional & Specialty Pharma,5113,NN1956,NN1956,Recombinant Protein,Phase I,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034728,Diabetes,7/7/14 12:28
5037,68,Novo Nordisk,Regional & Specialty Pharma,5113,NN1956,NN1956,Recombinant Protein,Phase I,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034728,Diabetes,7/7/14 12:28
5037,68,Novo Nordisk,Regional & Specialty Pharma,5113,NN1956,NN1956,Recombinant Protein,Phase I,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034728,Diabetes,7/7/14 12:28
5038,2358,Alcobra Pharma,Small Biotech,5114,MG01Cl,metadoxine extended-release ,Small Molecule (Chemical),Phase II,In-House,,,,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034729,ADHD,7/7/14 12:28
5038,2358,Alcobra Pharma,Small Biotech,5114,MG01Cl,metadoxine extended-release ,Small Molecule (Chemical),Phase II,In-House,,,,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034729,ADHD,7/7/14 12:28
5038,2358,Alcobra Pharma,Small Biotech,5114,MG01Cl,metadoxine extended-release ,Small Molecule (Chemical),Phase II,In-House,,,,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034729,ADHD,7/7/14 12:28
5039,2426,Emergent Biosolutions,Small Biotech,5115,otlertuzumab,otlertuzumab,Antibody/Antibody Derivative,Phase II,Acquisition (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034730,Chronic Lymphocytic Leukemia,7/7/14 12:28
5039,2426,Emergent Biosolutions,Small Biotech,5115,otlertuzumab,otlertuzumab,Antibody/Antibody Derivative,Phase II,Acquisition (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034730,Chronic Lymphocytic Leukemia,7/7/14 12:28
5039,2426,Emergent Biosolutions,Small Biotech,5115,otlertuzumab,otlertuzumab,Antibody/Antibody Derivative,Phase II,Acquisition (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034730,Chronic Lymphocytic Leukemia,7/7/14 12:28
5040,2426,Emergent Biosolutions,Small Biotech,5116,Anthrivig,Human Anthrax Immunoglobulin,Antibody/Antibody Derivative,Phase III,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034739,Anthrax Infection,7/7/14 12:28
5040,2426,Emergent Biosolutions,Small Biotech,5116,Anthrivig,Human Anthrax Immunoglobulin,Antibody/Antibody Derivative,Phase III,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034739,Anthrax Infection,7/7/14 12:28
5040,2426,Emergent Biosolutions,Small Biotech,5116,Anthrivig,Human Anthrax Immunoglobulin,Antibody/Antibody Derivative,Phase III,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034739,Anthrax Infection,7/7/14 12:28
5041,2426,Emergent Biosolutions,Small Biotech,5117,PreviThrax,"Recombinant Protective Antigen Anthrax Vaccine, Purified)",Recombinant Protein,Phase II,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034740,Anthrax vaccination,7/7/14 12:28
5041,2426,Emergent Biosolutions,Small Biotech,5117,PreviThrax,"Recombinant Protective Antigen Anthrax Vaccine, Purified)",Recombinant Protein,Phase II,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034740,Anthrax vaccination,7/7/14 12:28
5041,2426,Emergent Biosolutions,Small Biotech,5117,PreviThrax,"Recombinant Protective Antigen Anthrax Vaccine, Purified)",Recombinant Protein,Phase II,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034740,Anthrax vaccination,7/7/14 12:28
5042,2426,Emergent Biosolutions,Small Biotech,5118,NuThrax,Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant,Vaccine,Phase II,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034741,,7/7/14 12:28
5042,2426,Emergent Biosolutions,Small Biotech,5118,NuThrax,Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant,Vaccine,Phase II,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034741,,7/7/14 12:28
5042,2426,Emergent Biosolutions,Small Biotech,5118,NuThrax,Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant,Vaccine,Phase II,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034741,,7/7/14 12:28
5043,2426,Emergent Biosolutions,Small Biotech,5119,Thravixa,Fully Human Anthrax Monoclonal Antibody,Antibody/Antibody Derivative,Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034742,Symptomatic Anthrax infection,7/7/14 12:28
5043,2426,Emergent Biosolutions,Small Biotech,5119,Thravixa,Fully Human Anthrax Monoclonal Antibody,Antibody/Antibody Derivative,Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034742,Symptomatic Anthrax infection,7/7/14 12:28
5043,2426,Emergent Biosolutions,Small Biotech,5119,Thravixa,Fully Human Anthrax Monoclonal Antibody,Antibody/Antibody Derivative,Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034742,Symptomatic Anthrax infection,7/7/14 12:28
5044,1010,Palatin Technologies,Small Biotech,5120,bremelanotide,bremelanotide,Synthetic Peptide,Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034731,HSDD,7/7/14 12:28
5044,1010,Palatin Technologies,Small Biotech,5120,bremelanotide,bremelanotide,Synthetic Peptide,Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034731,HSDD,7/7/14 12:28
5044,1010,Palatin Technologies,Small Biotech,5120,bremelanotide,bremelanotide,Synthetic Peptide,Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034731,HSDD,7/7/14 12:28
5045,2428,Sprout Pharmaceuticals,Small Biotech,5121,flibanserin,flibanserin,Small Molecule (Chemical),Filed,Licensed (Development),,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034732,HSDD,7/7/14 12:28
5045,2428,Sprout Pharmaceuticals,Small Biotech,5121,flibanserin,flibanserin,Small Molecule (Chemical),Filed,Licensed (Development),,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034732,HSDD,7/7/14 12:28
5045,2428,Sprout Pharmaceuticals,Small Biotech,5121,flibanserin,flibanserin,Small Molecule (Chemical),Filed,Licensed (Development),,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034732,HSDD,7/7/14 12:28
5046,2431,Prana Biotechnology,Small Biotech,5122,PBT2,PBT2,Small Molecule (Chemical),Phase II,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,12,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034734,Huntington's disease,7/7/14 12:28
5046,2431,Prana Biotechnology,Small Biotech,5122,PBT2,PBT2,Small Molecule (Chemical),Phase II,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,12,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034734,Huntington's disease,7/7/14 12:28
5046,2431,Prana Biotechnology,Small Biotech,5122,PBT2,PBT2,Small Molecule (Chemical),Phase II,In-House,,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,12,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034734,Huntington's disease,7/7/14 12:28
5047,2432,Iroko Pharmaceuticals,Regional & Specialty Pharma,5123,Zorvolex,diclofenac,Small Molecule (Chemical),Launched,In-House,,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034733,Pain,7/7/14 12:28
5047,2432,Iroko Pharmaceuticals,Regional & Specialty Pharma,5123,Zorvolex,diclofenac,Small Molecule (Chemical),Launched,In-House,,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034733,Pain,7/7/14 12:28
5047,2432,Iroko Pharmaceuticals,Regional & Specialty Pharma,5123,Zorvolex,diclofenac,Small Molecule (Chemical),Launched,In-House,,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034733,Pain,7/7/14 12:28
5048,2432,Iroko Pharmaceuticals,Regional & Specialty Pharma,5124,Tivorbex,indomethacin,Small Molecule (Chemical),Approved,In-House,,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034735,Pain,7/7/14 12:28
5048,2432,Iroko Pharmaceuticals,Regional & Specialty Pharma,5124,Tivorbex,indomethacin,Small Molecule (Chemical),Approved,In-House,,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034735,Pain,7/7/14 12:28
5048,2432,Iroko Pharmaceuticals,Regional & Specialty Pharma,5124,Tivorbex,indomethacin,Small Molecule (Chemical),Approved,In-House,,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034735,Pain,7/7/14 12:28
5050,2433,Genervon Biopharmaceuticals,Small Biotech,5126,GM6,GM604,Gene Therapy,Phase II,In-House,,,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034745,Amyotrophic Lateral Sclerosis,7/7/14 12:28
5050,2433,Genervon Biopharmaceuticals,Small Biotech,5126,GM6,GM604,Gene Therapy,Phase II,In-House,,,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034745,Amyotrophic Lateral Sclerosis,7/7/14 12:28
5050,2433,Genervon Biopharmaceuticals,Small Biotech,5126,GM6,GM604,Gene Therapy,Phase II,In-House,,,,,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034745,Amyotrophic Lateral Sclerosis,7/7/14 12:28
5051,157,Teijin,Regional & Specialty Pharma,5127,Feburic,febuxostat,Small Molecule (Chemical),Launched,In-House,,May-11,,,151,Gout Treatments,64,Gout,8,Metabolism,7,Global,Sales,0,0,11.39549435,66.21307341,118.7991225,153.5692497,178.6037412,196.6285752,209.6064556,218.9505295,225.6782627,230.5222306,9.933098882,3437,Gout,7/7/14 12:28
5051,157,Teijin,Regional & Specialty Pharma,5127,Feburic,febuxostat,Small Molecule (Chemical),Launched,In-House,,May-11,,,151,Gout Treatments,64,Gout,8,Metabolism,7,ROW,Sales,0,0,11.39549435,66.21307341,118.7991225,153.5692497,178.6037412,196.6285752,209.6064556,218.9505295,225.6782627,230.5222306,9.933098882,3437,Gout,7/7/14 12:28
5051,157,Teijin,Regional & Specialty Pharma,5127,Feburic,febuxostat,Small Molecule (Chemical),Launched,In-House,,May-11,,,151,Gout Treatments,64,Gout,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3437,Gout,7/7/14 12:28
5052,11,Amgen,Large Pharma,5128,ivabradine,ivabradine,Small Molecule (Chemical),Phase III,Licensed (Development),Jun-15,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,25.9,127.920618,259.9474878,341.7529623,422.4848997,495.5352877,0,931,Chronic heart failure,7/7/14 12:28
5052,11,Amgen,Large Pharma,5128,ivabradine,ivabradine,Small Molecule (Chemical),Phase III,Licensed (Development),Jun-15,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,931,Chronic heart failure,7/7/14 12:28
5052,11,Amgen,Large Pharma,5128,ivabradine,ivabradine,Small Molecule (Chemical),Phase III,Licensed (Development),Jun-15,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,25.9,127.920618,259.9474878,341.7529623,422.4848997,495.5352877,0,931,Chronic heart failure,7/7/14 12:28
5053,11,Amgen,Large Pharma,4972,S38844,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4505,Heart Failure,7/7/14 12:28
5053,11,Amgen,Large Pharma,4972,S38844,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4505,Heart Failure,7/7/14 12:28
5053,11,Amgen,Large Pharma,4972,S38844,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4505,Heart Failure,7/7/14 12:28
5054,712,Receptos,Small Biotech,5129,RCP1063,,Small Molecule (Chemical),Phase III,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034746,Multiple Sclerosis,7/7/14 12:28
5054,712,Receptos,Small Biotech,5129,RCP1063,,Small Molecule (Chemical),Phase III,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034746,Multiple Sclerosis,7/7/14 12:28
5054,712,Receptos,Small Biotech,5129,RCP1063,,Small Molecule (Chemical),Phase III,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034746,Multiple Sclerosis,7/7/14 12:28
5056,57,La Jolla Pharmaceuticals,Small Biotech,5131,GCS-100,GCS-100,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034743,Chronic Kidney Disease,7/7/14 12:28
5056,57,La Jolla Pharmaceuticals,Small Biotech,5131,GCS-100,GCS-100,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034743,Chronic Kidney Disease,7/7/14 12:28
5056,57,La Jolla Pharmaceuticals,Small Biotech,5131,GCS-100,GCS-100,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034743,Chronic Kidney Disease,7/7/14 12:28
5057,82,Purdue Pharma,Regional & Specialty Pharma,5132,hydrocodone bitartrate,hydrocodone bitartrate,Small Molecule (Chemical),Filed,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034747,Pain,7/7/14 12:28
5057,82,Purdue Pharma,Regional & Specialty Pharma,5132,hydrocodone bitartrate,hydrocodone bitartrate,Small Molecule (Chemical),Filed,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034747,Pain,7/7/14 12:28
5057,82,Purdue Pharma,Regional & Specialty Pharma,5132,hydrocodone bitartrate,hydrocodone bitartrate,Small Molecule (Chemical),Filed,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034747,Pain,7/7/14 12:28
5058,51,Ipsen,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Filed,Licensed (Development),,,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
5058,51,Ipsen,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Filed,Licensed (Development),,,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
5058,51,Ipsen,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Filed,Licensed (Development),,,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
5059,389,theratechnologies,Small Biotech,3091,Egrifta,tesamorelin,Recombinant Protein,Launched,In-House,Mar-14,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,21.375,30,38,46,52.5,58.3,63.46,0,1180,Lipodystrophy in HIV Patients,7/7/14 12:28
5059,389,theratechnologies,Small Biotech,3091,Egrifta,tesamorelin,Recombinant Protein,Launched,In-House,Mar-14,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1180,Lipodystrophy in HIV Patients,7/7/14 12:28
5059,389,theratechnologies,Small Biotech,3091,Egrifta,tesamorelin,Recombinant Protein,Launched,In-House,Mar-14,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,21.375,30,38,46,52.5,58.3,63.46,0,1180,Lipodystrophy in HIV Patients,7/7/14 12:28
5060,2435,Mallinckrodt,Regional & Specialty Pharma,5133,Xartemis XR,oxycodone HCl + acetaminophen,Small Molecule (Chemical),Approved,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034748,Pain,7/7/14 12:28
5060,2435,Mallinckrodt,Regional & Specialty Pharma,5133,Xartemis XR,oxycodone HCl + acetaminophen,Small Molecule (Chemical),Approved,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034748,Pain,7/7/14 12:28
5060,2435,Mallinckrodt,Regional & Specialty Pharma,5133,Xartemis XR,oxycodone HCl + acetaminophen,Small Molecule (Chemical),Approved,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034748,Pain,7/7/14 12:28
5061,149,BioDelivery Sciences,Regional & Specialty Pharma,5134,Topical clonidine gel,Clonidine,,Phase III,,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034749,Painful Diabetic Neuropathy,7/7/14 12:28
5061,149,BioDelivery Sciences,Regional & Specialty Pharma,5134,Topical clonidine gel,Clonidine,,Phase III,,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034749,Painful Diabetic Neuropathy,7/7/14 12:28
5061,149,BioDelivery Sciences,Regional & Specialty Pharma,5134,Topical clonidine gel,Clonidine,,Phase III,,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034749,Painful Diabetic Neuropathy,7/7/14 12:28
5062,149,BioDelivery Sciences,Regional & Specialty Pharma,5135,Bunavail,Buprenorphine/Naloxone buccal film,Small Molecule (Chemical),Filed,In-House,,,,,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034750,Opioid dependence,7/7/14 12:28
5062,149,BioDelivery Sciences,Regional & Specialty Pharma,5135,Bunavail,Buprenorphine/Naloxone buccal film,Small Molecule (Chemical),Filed,In-House,,,,,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034750,Opioid dependence,7/7/14 12:28
5062,149,BioDelivery Sciences,Regional & Specialty Pharma,5135,Bunavail,Buprenorphine/Naloxone buccal film,Small Molecule (Chemical),Filed,In-House,,,,,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034750,Opioid dependence,7/7/14 12:28
5063,458,Aspen,Small Biotech,1389,Arixtra,fondaparinux,Synthetic Peptide,Launched,Acquisition (Marketed),Feb-02,Mar-02,Expired,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,165,133,120,111,100.64,93.304,87.3008,0,1476,Thrombosis,7/7/14 12:28
5063,458,Aspen,Small Biotech,1389,Arixtra,fondaparinux,Synthetic Peptide,Launched,Acquisition (Marketed),Feb-02,Mar-02,Expired,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,112,87,80,74,66.93,62.2155,58.240725,0,1476,Thrombosis,7/7/14 12:28
5063,458,Aspen,Small Biotech,1389,Arixtra,fondaparinux,Synthetic Peptide,Launched,Acquisition (Marketed),Feb-02,Mar-02,Expired,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,53,46,40,37,33.71,31.0885,29.060075,0,1476,Thrombosis,7/7/14 12:28
5064,91,Santen,Regional & Specialty Pharma,5136,Tapcom,tafluprost + timolol,Small Molecule (Chemical),Approved,In-House,,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034737,Glaucoma,7/7/14 12:28
5064,91,Santen,Regional & Specialty Pharma,5136,Tapcom,tafluprost + timolol,Small Molecule (Chemical),Approved,In-House,,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034737,Glaucoma,7/7/14 12:28
5064,91,Santen,Regional & Specialty Pharma,5136,Tapcom,tafluprost + timolol,Small Molecule (Chemical),Approved,In-House,,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034737,Glaucoma,7/7/14 12:28
5065,458,Aspen,Small Biotech,811,Fraxiparine,nadroparin,Synthetic Peptide,Launched,Acquisition (Marketed),,Jan-88,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,278,272,268,262,257.95,254.48125,251.3692187,0,1558,Thrombosis,7/7/14 12:28
5065,458,Aspen,Small Biotech,811,Fraxiparine,nadroparin,Synthetic Peptide,Launched,Acquisition (Marketed),,Jan-88,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,278,272,268,262,257.95,254.48125,251.3692187,0,1558,Thrombosis,7/7/14 12:28
5065,458,Aspen,Small Biotech,811,Fraxiparine,nadroparin,Synthetic Peptide,Launched,Acquisition (Marketed),,Jan-88,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1558,Thrombosis,7/7/14 12:28
5066,2265,Edison Pharmaceuticals,Small Biotech,5137,EPI-743,vatiquinone ,Small Molecule (Chemical),Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034751,Friedreich's ataxia,7/7/14 12:28
5066,2265,Edison Pharmaceuticals,Small Biotech,5137,EPI-743,vatiquinone ,Small Molecule (Chemical),Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034751,Friedreich's ataxia,7/7/14 12:28
5066,2265,Edison Pharmaceuticals,Small Biotech,5137,EPI-743,vatiquinone ,Small Molecule (Chemical),Phase II,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034751,Friedreich's ataxia,7/7/14 12:28
5068,157,Teijin,Regional & Specialty Pharma,4170,BA-058,abaloparatide SC,Recombinant Protein,Phase III,Licensed (Development),,,,,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3889,Osteoporosis,7/7/14 12:28
5068,157,Teijin,Regional & Specialty Pharma,4170,BA-058,abaloparatide SC,Recombinant Protein,Phase III,Licensed (Development),,,,,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3889,Osteoporosis,7/7/14 12:28
5068,157,Teijin,Regional & Specialty Pharma,4170,BA-058,abaloparatide SC,Recombinant Protein,Phase III,Licensed (Development),,,,,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3889,Osteoporosis,7/7/14 12:28
5069,61,Merck & Co,Large Pharma,5138,MK-8237,HDM-SLIT,Vaccine,Phase III,Licensed (Development),Jul-16,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,10.5,28.000035,42.0000525,55.99993,67.7598908,0,1887,Dust Mite Allergy,7/7/14 12:28
5069,61,Merck & Co,Large Pharma,5138,MK-8237,HDM-SLIT,Vaccine,Phase III,Licensed (Development),Jul-16,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1887,Dust Mite Allergy,7/7/14 12:28
5069,61,Merck & Co,Large Pharma,5138,MK-8237,HDM-SLIT,Vaccine,Phase III,Licensed (Development),Jul-16,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,10.5,28.000035,42.0000525,55.99993,67.7598908,0,1887,Dust Mite Allergy,7/7/14 12:28
5070,2325,Torii Pharmaceutical,Regional & Specialty Pharma,5139,TO-203,TO-203,Vaccine,Phase III,Licensed (Development),,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1887,Dust Mite Allergy,7/7/14 12:28
5070,2325,Torii Pharmaceutical,Regional & Specialty Pharma,5139,TO-203,TO-203,Vaccine,Phase III,Licensed (Development),,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1887,Dust Mite Allergy,7/7/14 12:28
5070,2325,Torii Pharmaceutical,Regional & Specialty Pharma,5139,TO-203,TO-203,Vaccine,Phase III,Licensed (Development),,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1887,Dust Mite Allergy,7/7/14 12:28
5071,106,United Therapeutics,Small Biotech,5140,Orenitram,treprostinil,Small Molecule (Chemical),Approved,In-House,May-14,,Dec-16,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,26.66668,82.75568404,139.0221518,87.11128035,52.64011417,45.36477143,40.20418128,0,1034738,Pulmonary Hypertension,7/7/14 12:28
5071,106,United Therapeutics,Small Biotech,5140,Orenitram,treprostinil,Small Molecule (Chemical),Approved,In-House,May-14,,Dec-16,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034738,Pulmonary Hypertension,7/7/14 12:28
5071,106,United Therapeutics,Small Biotech,5140,Orenitram,treprostinil,Small Molecule (Chemical),Approved,In-House,May-14,,Dec-16,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,26.66668,82.75568404,139.0221518,87.11128035,52.64011417,45.36477143,40.20418128,0,1034738,Pulmonary Hypertension,7/7/14 12:28
5072,42,Forest,Regional & Specialty Pharma,2631,Saphris / Sycrest,asenapine,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,Jun-15,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,159,76.797,12.72,8.745,7.95,4.77,3.18,0,1049,Schizophrenia,7/7/14 12:28
5072,42,Forest,Regional & Specialty Pharma,2631,Saphris / Sycrest,asenapine,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,Jun-15,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1049,Schizophrenia,7/7/14 12:28
5072,42,Forest,Regional & Specialty Pharma,2631,Saphris / Sycrest,asenapine,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,Jun-15,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,0,0,0,0,159,76.797,12.72,8.745,7.95,4.77,3.18,0,1049,Schizophrenia,7/7/14 12:28
5073,1901,Raptor Pharmaceuticals,Small Biotech,5142,Delayed-release cysteamine bitartrate,RP103,Recombinant Protein,Phase III,Acquisition (Development),,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034752,Huntington's disease,7/7/14 12:28
5073,1901,Raptor Pharmaceuticals,Small Biotech,5142,Delayed-release cysteamine bitartrate,RP103,Recombinant Protein,Phase III,Acquisition (Development),,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034752,Huntington's disease,7/7/14 12:28
5073,1901,Raptor Pharmaceuticals,Small Biotech,5142,Delayed-release cysteamine bitartrate,RP103,Recombinant Protein,Phase III,Acquisition (Development),,,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034752,Huntington's disease,7/7/14 12:28
5074,76,Pfizer,Large Pharma,1114,PF-2545920,PF-2545920,Small Molecule (Chemical),Phase II,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034744,Schizophrenia,7/7/14 12:28
5074,76,Pfizer,Large Pharma,1114,PF-2545920,PF-2545920,Small Molecule (Chemical),Phase II,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034744,Schizophrenia,7/7/14 12:28
5074,76,Pfizer,Large Pharma,1114,PF-2545920,PF-2545920,Small Molecule (Chemical),Phase II,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034744,Schizophrenia,7/7/14 12:28
5075,2437,Titan Pharmaceuticals,Small Biotech,5143,Probuphine,buprenorphine HCL,Small Molecule (Chemical),Phase III,In-House,Sep-15,,,,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,8.333325,38.88887778,80.5555881,122.2221605,153.7776884,183.0665505,0,1034753,Opioid Addiction,7/7/14 12:28
5075,2437,Titan Pharmaceuticals,Small Biotech,5143,Probuphine,buprenorphine HCL,Small Molecule (Chemical),Phase III,In-House,Sep-15,,,,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034753,Opioid Addiction,7/7/14 12:28
5075,2437,Titan Pharmaceuticals,Small Biotech,5143,Probuphine,buprenorphine HCL,Small Molecule (Chemical),Phase III,In-House,Sep-15,,,,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,8.333325,38.88887778,80.5555881,122.2221605,153.7776884,183.0665505,0,1034753,Opioid Addiction,7/7/14 12:28
5076,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4225,Nesp,darbepoetin alpha,Recombinant Protein,Filed,Corporate Acquisition,,,,,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1413,Anemia in MDS,7/7/14 12:28
5076,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4225,Nesp,darbepoetin alpha,Recombinant Protein,Filed,Corporate Acquisition,,,,,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1413,Anemia in MDS,7/7/14 12:28
5076,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4225,Nesp,darbepoetin alpha,Recombinant Protein,Filed,Corporate Acquisition,,,,,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1413,Anemia in MDS,7/7/14 12:28
5077,86,Roche,Large Pharma,5144,RG7641,RG7641,Unknown,Phase I,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034756,Renal Disease,7/7/14 12:28
5077,86,Roche,Large Pharma,5144,RG7641,RG7641,Unknown,Phase I,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034756,Renal Disease,7/7/14 12:28
5077,86,Roche,Large Pharma,5144,RG7641,RG7641,Unknown,Phase I,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034756,Renal Disease,7/7/14 12:28
5078,86,Roche,Large Pharma,5145,RG7800,RG7800,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034757,Spinal Muscular Atrophy,7/7/14 12:28
5078,86,Roche,Large Pharma,5145,RG7800,RG7800,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034757,Spinal Muscular Atrophy,7/7/14 12:28
5078,86,Roche,Large Pharma,5145,RG7800,RG7800,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034757,Spinal Muscular Atrophy,7/7/14 12:28
5079,86,Roche,Large Pharma,5146,RG7716,RG7716,Unknown,Phase I,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034758,Wet AMD,7/7/14 12:28
5079,86,Roche,Large Pharma,5146,RG7716,RG7716,Unknown,Phase I,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034758,Wet AMD,7/7/14 12:28
5079,86,Roche,Large Pharma,5146,RG7716,RG7716,Unknown,Phase I,In-House,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034758,Wet AMD,7/7/14 12:28
5080,86,Roche,Large Pharma,5147,RG7813,RG7813,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034759,solid tumors,7/7/14 12:28
5080,86,Roche,Large Pharma,5147,RG7813,RG7813,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034759,solid tumors,7/7/14 12:28
5080,86,Roche,Large Pharma,5147,RG7813,RG7813,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034759,solid tumors,7/7/14 12:28
5081,67,Novartis,Large Pharma,5148,KAE609,cipargaminum,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034754,Malaria,7/7/14 12:28
5081,67,Novartis,Large Pharma,5148,KAE609,cipargaminum,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034754,Malaria,7/7/14 12:28
5081,67,Novartis,Large Pharma,5148,KAE609,cipargaminum,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034754,Malaria,7/7/14 12:28
5082,67,Novartis,Large Pharma,550,LCI699,osilodrostat,Small Molecule (Chemical),Phase II,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034755,Cushing's Disease,7/7/14 12:28
5082,67,Novartis,Large Pharma,550,LCI699,osilodrostat,Small Molecule (Chemical),Phase II,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034755,Cushing's Disease,7/7/14 12:28
5082,67,Novartis,Large Pharma,550,LCI699,osilodrostat,Small Molecule (Chemical),Phase II,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034755,Cushing's Disease,7/7/14 12:28
5083,67,Novartis,Large Pharma,293,AUY922,luminespib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034760,solid tumors,7/7/14 12:28
5083,67,Novartis,Large Pharma,293,AUY922,luminespib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034760,solid tumors,7/7/14 12:28
5083,67,Novartis,Large Pharma,293,AUY922,luminespib,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034760,solid tumors,7/7/14 12:28
5084,67,Novartis,Large Pharma,5149,LJM716,LJM716,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034761,solid tumors,7/7/14 12:28
5084,67,Novartis,Large Pharma,5149,LJM716,LJM716,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034761,solid tumors,7/7/14 12:28
5084,67,Novartis,Large Pharma,5149,LJM716,LJM716,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034761,solid tumors,7/7/14 12:28
5085,67,Novartis,Large Pharma,5150,HSC835,HSC835,Cell Therapy,Phase I,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034762,Stem Cell Transplant,7/7/14 12:28
5085,67,Novartis,Large Pharma,5150,HSC835,HSC835,Cell Therapy,Phase I,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034762,Stem Cell Transplant,7/7/14 12:28
5085,67,Novartis,Large Pharma,5150,HSC835,HSC835,Cell Therapy,Phase I,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034762,Stem Cell Transplant,7/7/14 12:28
5086,86,Roche,Large Pharma,5151,RG6016,ORY-1001,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034763,Acute myeloid leukemia,7/7/14 12:28
5086,86,Roche,Large Pharma,5151,RG6016,ORY-1001,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034763,Acute myeloid leukemia,7/7/14 12:28
5086,86,Roche,Large Pharma,5151,RG6016,ORY-1001,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034763,Acute myeloid leukemia,7/7/14 12:28
5087,89,Sanofi,Large Pharma,5152,RDX002,NaP2b inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,2,Global,Sales,,,,,,,,,,,,,0,1034764,Hyperphosphatemia,7/7/14 12:28
5087,89,Sanofi,Large Pharma,5152,RDX002,NaP2b inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,2,ROW,Sales,,,,,,,,,,,,,0,1034764,Hyperphosphatemia,7/7/14 12:28
5087,89,Sanofi,Large Pharma,5152,RDX002,NaP2b inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,2,US,Sales,,,,,,,,,,,,,0,1034764,Hyperphosphatemia,7/7/14 12:28
5088,150,Taisho,Regional & Specialty Pharma,5153,TS-111,TS-111,Small Molecule (Chemical),Phase I,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,7,Global,Sales,,,,,,,,,,,,,0,1034765,Depression,7/7/14 12:28
5088,150,Taisho,Regional & Specialty Pharma,5153,TS-111,TS-111,Small Molecule (Chemical),Phase I,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,7,ROW,Sales,,,,,,,,,,,,,0,1034765,Depression,7/7/14 12:28
5088,150,Taisho,Regional & Specialty Pharma,5153,TS-111,TS-111,Small Molecule (Chemical),Phase I,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,7,US,Sales,,,,,,,,,,,,,0,1034765,Depression,7/7/14 12:28
5089,150,Taisho,Regional & Specialty Pharma,5154,TS-091,TS-091,Small Molecule (Chemical),Phase I,In-House,,,,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,Global,Sales,,,,,,,,,,,,,0,1034766,Sleep Disorder,7/7/14 12:28
5089,150,Taisho,Regional & Specialty Pharma,5154,TS-091,TS-091,Small Molecule (Chemical),Phase I,In-House,,,,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,ROW,Sales,,,,,,,,,,,,,0,1034766,Sleep Disorder,7/7/14 12:28
5089,150,Taisho,Regional & Specialty Pharma,5154,TS-091,TS-091,Small Molecule (Chemical),Phase I,In-House,,,,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,US,Sales,,,,,,,,,,,,,0,1034766,Sleep Disorder,7/7/14 12:28
5090,16,AstraZeneca,Large Pharma,5155,AZD1775,AZD1775,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034767,Ovarian Cancer,7/7/14 12:28
5090,16,AstraZeneca,Large Pharma,5155,AZD1775,AZD1775,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034767,Ovarian Cancer,7/7/14 12:28
5090,16,AstraZeneca,Large Pharma,5155,AZD1775,AZD1775,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034767,Ovarian Cancer,7/7/14 12:28
5091,16,AstraZeneca,Large Pharma,5156,AZD6738,AZD6738,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034768,Chronic lymphocytic leukemia,7/7/14 12:28
5091,16,AstraZeneca,Large Pharma,5156,AZD6738,AZD6738,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034768,Chronic lymphocytic leukemia,7/7/14 12:28
5091,16,AstraZeneca,Large Pharma,5156,AZD6738,AZD6738,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034768,Chronic lymphocytic leukemia,7/7/14 12:28
5092,16,AstraZeneca,Large Pharma,5157,MEDI-0680,MEDI-0680,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034769,Solid Tumors,7/7/14 12:28
5092,16,AstraZeneca,Large Pharma,5157,MEDI-0680,MEDI-0680,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034769,Solid Tumors,7/7/14 12:28
5092,16,AstraZeneca,Large Pharma,5157,MEDI-0680,MEDI-0680,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034769,Solid Tumors,7/7/14 12:28
5093,76,Pfizer,Large Pharma,5158,PF-05402536,,Vaccine,Phase I,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,,,,,,,,,,,,,0,1034770,Smoking Cessation,7/7/14 12:28
5093,76,Pfizer,Large Pharma,5158,PF-05402536,,Vaccine,Phase I,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,,,,,,,,,,,,,0,1034770,Smoking Cessation,7/7/14 12:28
5093,76,Pfizer,Large Pharma,5158,PF-05402536,,Vaccine,Phase I,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,,,,,,,,,,,,,0,1034770,Smoking Cessation,7/7/14 12:28
5094,76,Pfizer,Large Pharma,5159,PF-06425090,,Vaccine,Phase I,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,,,,,,,,,,,,,0,1034771,Clostridium Difficile colitis,7/7/14 12:28
5094,76,Pfizer,Large Pharma,5159,PF-06425090,,Vaccine,Phase I,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,,,,,,,,,,,,,0,1034771,Clostridium Difficile colitis,7/7/14 12:28
5094,76,Pfizer,Large Pharma,5159,PF-06425090,,Vaccine,Phase I,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,,,,,,,,,,,,,0,1034771,Clostridium Difficile colitis,7/7/14 12:28
5095,76,Pfizer,Large Pharma,5160,PF-06444752,,Vaccine,Phase I,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,,,,,,,,,,,,,0,1034772,asthma,7/7/14 12:28
5095,76,Pfizer,Large Pharma,5160,PF-06444752,,Vaccine,Phase I,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,,,,,,,,,,,,,0,1034772,asthma,7/7/14 12:28
5095,76,Pfizer,Large Pharma,5160,PF-06444752,,Vaccine,Phase I,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,,,,,,,,,,,,,0,1034772,asthma,7/7/14 12:28
5096,11,Amgen,Large Pharma,5161,AMG 595,AMG 595,Antibody/Antibody Derivative,Phase I,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034773,Glioblastoma,7/7/14 12:28
5096,11,Amgen,Large Pharma,5161,AMG 595,AMG 595,Antibody/Antibody Derivative,Phase I,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034773,Glioblastoma,7/7/14 12:28
5096,11,Amgen,Large Pharma,5161,AMG 595,AMG 595,Antibody/Antibody Derivative,Phase I,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034773,Glioblastoma,7/7/14 12:28
5097,21,Biogen Idec,Regional & Specialty Pharma,4801,BAN2401,BAN2401,Antibody/Antibody Derivative,Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,,,,,,,,,,,,,0,4336,Alzheimer's Disease,7/7/14 12:28
5097,21,Biogen Idec,Regional & Specialty Pharma,4801,BAN2401,BAN2401,Antibody/Antibody Derivative,Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,,,,,,,,,,,,,0,4336,Alzheimer's Disease,7/7/14 12:28
5097,21,Biogen Idec,Regional & Specialty Pharma,4801,BAN2401,BAN2401,Antibody/Antibody Derivative,Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,,,,,,,,,,,,,0,4336,Alzheimer's Disease,7/7/14 12:28
5098,21,Biogen Idec,Regional & Specialty Pharma,4759,E2609,E2609,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,,,,,,,,,,,,,0,4294,Alzheimer's Disease,7/7/14 12:28
5098,21,Biogen Idec,Regional & Specialty Pharma,4759,E2609,E2609,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,,,,,,,,,,,,,0,4294,Alzheimer's Disease,7/7/14 12:28
5098,21,Biogen Idec,Regional & Specialty Pharma,4759,E2609,E2609,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,,,,,,,,,,,,,0,4294,Alzheimer's Disease,7/7/14 12:28
5100,72,Orion,Regional & Specialty Pharma,5162,ORM-12741,ORM-12741,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,Global,Sales,,,,,,,,,,,,,0,1034774,Alzheimer's Disease,7/7/14 12:28
5100,72,Orion,Regional & Specialty Pharma,5162,ORM-12741,ORM-12741,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,ROW,Sales,,,,,,,,,,,,,0,1034774,Alzheimer's Disease,7/7/14 12:28
5100,72,Orion,Regional & Specialty Pharma,5162,ORM-12741,ORM-12741,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,US,Sales,,,,,,,,,,,,,0,1034774,Alzheimer's Disease,7/7/14 12:28
5101,53,Johnson & Johnson,Large Pharma,5162,ORM-12741,ORM-12741,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,,,,,,,,,,,,,0,1034774,Alzheimer's Disease,7/7/14 12:28
5101,53,Johnson & Johnson,Large Pharma,5162,ORM-12741,ORM-12741,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,,,,,,,,,,,,,0,1034774,Alzheimer's Disease,7/7/14 12:28
5101,53,Johnson & Johnson,Large Pharma,5162,ORM-12741,ORM-12741,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,,,,,,,,,,,,,0,1034774,Alzheimer's Disease,7/7/14 12:28
5102,86,Roche,Large Pharma,5163,RG7841,RG7841,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,Global,Sales,,,,,,,,,,,,,0,1034775,Solid tumors,7/7/14 12:28
5102,86,Roche,Large Pharma,5163,RG7841,RG7841,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,ROW,Sales,,,,,,,,,,,,,0,1034775,Solid tumors,7/7/14 12:28
5102,86,Roche,Large Pharma,5163,RG7841,RG7841,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,US,Sales,,,,,,,,,,,,,0,1034775,Solid tumors,7/7/14 12:28
5103,86,Roche,Large Pharma,5164,RG7845,GDC0853,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,Global,Sales,,,,,,,,,,,,,0,1034776,Hematological tumors,7/7/14 12:28
5103,86,Roche,Large Pharma,5164,RG7845,GDC0853,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,ROW,Sales,,,,,,,,,,,,,0,1034776,Hematological tumors,7/7/14 12:28
5103,86,Roche,Large Pharma,5164,RG7845,GDC0853,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,US,Sales,,,,,,,,,,,,,0,1034776,Hematological tumors,7/7/14 12:28
5104,67,Novartis,Large Pharma,5165,LGK974,LGK974,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034777,Solid tumors,7/7/14 12:28
5104,67,Novartis,Large Pharma,5165,LGK974,LGK974,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034777,Solid tumors,7/7/14 12:28
5104,67,Novartis,Large Pharma,5165,LGK974,LGK974,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034777,Solid tumors,7/7/14 12:28
5105,67,Novartis,Large Pharma,5166,LGH447,LGH447,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034778,hematological malignancies,7/7/14 12:28
5105,67,Novartis,Large Pharma,5166,LGH447,LGH447,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034778,hematological malignancies,7/7/14 12:28
5105,67,Novartis,Large Pharma,5166,LGH447,LGH447,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034778,hematological malignancies,7/7/14 12:28
5106,53,Johnson & Johnson,Large Pharma,5167,JNJ-42756493,JNJ-42756493,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034779,Solid tumors,7/7/14 12:28
5106,53,Johnson & Johnson,Large Pharma,5167,JNJ-42756493,JNJ-42756493,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034779,Solid tumors,7/7/14 12:28
5106,53,Johnson & Johnson,Large Pharma,5167,JNJ-42756493,JNJ-42756493,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034779,Solid tumors,7/7/14 12:28
5108,24,Bristol-Myers Squibb,Large Pharma,5169,BMS-986115,BMS-986115,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034781,Solid tumors,7/7/14 12:28
5108,24,Bristol-Myers Squibb,Large Pharma,5169,BMS-986115,BMS-986115,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034781,Solid tumors,7/7/14 12:28
5108,24,Bristol-Myers Squibb,Large Pharma,5169,BMS-986115,BMS-986115,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034781,Solid tumors,7/7/14 12:28
5109,76,Pfizer,Large Pharma,5170,PF-06342674,PF-06342674,Unknown,Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,,,,,,,,,,,,,0,1034782,Type 1 diabetes,7/7/14 12:28
5109,76,Pfizer,Large Pharma,5170,PF-06342674,PF-06342674,Unknown,Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,,,,,,,,,,,,,0,1034782,Type 1 diabetes,7/7/14 12:28
5109,76,Pfizer,Large Pharma,5170,PF-06342674,PF-06342674,Unknown,Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,,,,,,,,,,,,,0,1034782,Type 1 diabetes,7/7/14 12:28
5110,76,Pfizer,Large Pharma,5171,PF-06260414,PF-06260414,Unknown,Phase I,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Sales,,,,,,,,,,,,,0,1034783,Cachexia,7/7/14 12:28
5110,76,Pfizer,Large Pharma,5171,PF-06260414,PF-06260414,Unknown,Phase I,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Sales,,,,,,,,,,,,,0,1034783,Cachexia,7/7/14 12:28
5110,76,Pfizer,Large Pharma,5171,PF-06260414,PF-06260414,Unknown,Phase I,In-House,,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Sales,,,,,,,,,,,,,0,1034783,Cachexia,7/7/14 12:28
5111,39,Eli Lilly,Large Pharma,5172,LY2510924,CXCR4 peptide inhibitor,Synthetic Peptide,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034830,Cancer,7/7/14 12:28
5111,39,Eli Lilly,Large Pharma,5172,LY2510924,CXCR4 peptide inhibitor,Synthetic Peptide,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034830,Cancer,7/7/14 12:28
5111,39,Eli Lilly,Large Pharma,5172,LY2510924,CXCR4 peptide inhibitor,Synthetic Peptide,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034830,Cancer,7/7/14 12:28
5112,100,Takeda,Large Pharma,5173,TAK-659,TAK-659,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034784,Solid tumors and Lymphoma,7/7/14 12:28
5112,100,Takeda,Large Pharma,5173,TAK-659,TAK-659,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034784,Solid tumors and Lymphoma,7/7/14 12:28
5112,100,Takeda,Large Pharma,5173,TAK-659,TAK-659,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034784,Solid tumors and Lymphoma,7/7/14 12:28
5113,100,Takeda,Large Pharma,5174,MLN7243,MLN7243,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034785,Solid tumors,7/7/14 12:28
5113,100,Takeda,Large Pharma,5174,MLN7243,MLN7243,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034785,Solid tumors,7/7/14 12:28
5113,100,Takeda,Large Pharma,5174,MLN7243,MLN7243,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034785,Solid tumors,7/7/14 12:28
5114,76,Pfizer,Large Pharma,5175,PF-06263507,PF-06263507,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034786,Solid tumors ,7/7/14 12:28
5114,76,Pfizer,Large Pharma,5175,PF-06263507,PF-06263507,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034786,Solid tumors ,7/7/14 12:28
5114,76,Pfizer,Large Pharma,5175,PF-06263507,PF-06263507,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034786,Solid tumors ,7/7/14 12:28
5115,76,Pfizer,Large Pharma,5176,PF-06463922,PF-06463922,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034787,Cancer,7/7/14 12:28
5115,76,Pfizer,Large Pharma,5176,PF-06463922,PF-06463922,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034787,Cancer,7/7/14 12:28
5115,76,Pfizer,Large Pharma,5176,PF-06463922,PF-06463922,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034787,Cancer,7/7/14 12:28
5116,76,Pfizer,Large Pharma,5177,PF-06647263,PF-06647263,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034788,Solid tumors,7/7/14 12:28
5116,76,Pfizer,Large Pharma,5177,PF-06647263,PF-06647263,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034788,Solid tumors,7/7/14 12:28
5116,76,Pfizer,Large Pharma,5177,PF-06647263,PF-06647263,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034788,Solid tumors,7/7/14 12:28
5117,89,Sanofi,Large Pharma,5178,SAR260301,SAR260301,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,,,,,,,,,,,,,0,1034789,Cancer,7/7/14 12:28
5117,89,Sanofi,Large Pharma,5178,SAR260301,SAR260301,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,,,,,,,,,,,,,0,1034789,Cancer,7/7/14 12:28
5117,89,Sanofi,Large Pharma,5178,SAR260301,SAR260301,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Sales,,,,,,,,,,,,,0,1034789,Cancer,7/7/14 12:28
5118,89,Sanofi,Large Pharma,5179,pimasertib + SAR405838,pimasertib + SAR405838,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,,,,,,,,,,,,,0,1034790,Duplicate,7/7/14 12:28
5118,89,Sanofi,Large Pharma,5179,pimasertib + SAR405838,pimasertib + SAR405838,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,,,,,,,,,,,,,0,1034790,Duplicate,7/7/14 12:28
5118,89,Sanofi,Large Pharma,5179,pimasertib + SAR405838,pimasertib + SAR405838,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Sales,,,,,,,,,,,,,0,1034790,Duplicate,7/7/14 12:28
5119,89,Sanofi,Large Pharma,5180,SAR405838,SAR405838,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,,,,,,,,,,,,,0,1034791,Solid tumors,7/7/14 12:28
5119,89,Sanofi,Large Pharma,5180,SAR405838,SAR405838,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,,,,,,,,,,,,,0,1034791,Solid tumors,7/7/14 12:28
5119,89,Sanofi,Large Pharma,5180,SAR405838,SAR405838,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Sales,,,,,,,,,,,,,0,1034791,Solid tumors,7/7/14 12:28
5120,61,Merck & Co,Large Pharma,5181,MK-8353,SCH-900353,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034792,,7/7/14 12:28
5120,61,Merck & Co,Large Pharma,5181,MK-8353,SCH-900353,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034792,,7/7/14 12:28
5120,61,Merck & Co,Large Pharma,5181,MK-8353,SCH-900353,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034792,,7/7/14 12:28
5122,19,Bayer,Large Pharma,5183,BAY 1136877,BAY 1163877,Antibody/Antibody Derivative,Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,,,,,,,,,,,,,0,1034794,Solid tumors,7/7/14 12:28
5122,19,Bayer,Large Pharma,5183,BAY 1136877,BAY 1163877,Antibody/Antibody Derivative,Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,,,,,,,,,,,,,0,1034794,Solid tumors,7/7/14 12:28
5122,19,Bayer,Large Pharma,5183,BAY 1136877,BAY 1163877,Antibody/Antibody Derivative,Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Sales,,,,,,,,,,,,,0,1034794,Solid tumors,7/7/14 12:28
5123,19,Bayer,Large Pharma,5184,BAY 1125976,BAY 1125976,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,,,,,,,,,,,,,0,1034833,Solid tumors,7/7/14 12:28
5123,19,Bayer,Large Pharma,5184,BAY 1125976,BAY 1125976,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,,,,,,,,,,,,,0,1034833,Solid tumors,7/7/14 12:28
5123,19,Bayer,Large Pharma,5184,BAY 1125976,BAY 1125976,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Sales,,,,,,,,,,,,,0,1034833,Solid tumors,7/7/14 12:28
5124,46,GlaxoSmithKline,Large Pharma,5185,2849330,anti-Her3 mAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,Global,Sales,,,,,,,,,,,,,0,1034795,Solid tumors,7/7/14 12:28
5124,46,GlaxoSmithKline,Large Pharma,5185,2849330,anti-Her3 mAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,ROW,Sales,,,,,,,,,,,,,0,1034795,Solid tumors,7/7/14 12:28
5124,46,GlaxoSmithKline,Large Pharma,5185,2849330,anti-Her3 mAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,US,Sales,,,,,,,,,,,,,0,1034795,Solid tumors,7/7/14 12:28
5125,46,GlaxoSmithKline,Large Pharma,5186,525762,ApoA1 upregulating agent,Small Molecule (Chemical),Phase I,,,,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,Global,Sales,,,,,,,,,,,,,0,1034796,Cancer,7/7/14 12:28
5125,46,GlaxoSmithKline,Large Pharma,5186,525762,ApoA1 upregulating agent,Small Molecule (Chemical),Phase I,,,,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,ROW,Sales,,,,,,,,,,,,,0,1034796,Cancer,7/7/14 12:28
5125,46,GlaxoSmithKline,Large Pharma,5186,525762,ApoA1 upregulating agent,Small Molecule (Chemical),Phase I,,,,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,US,Sales,,,,,,,,,,,,,0,1034796,Cancer,7/7/14 12:28
5127,46,GlaxoSmithKline,Large Pharma,5187,trametinib + 2141795,uprosertib + trametinib,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,4,Global,Sales,,,,,,,,,,,,,0,1034797,duplicate,7/7/14 12:28
5127,46,GlaxoSmithKline,Large Pharma,5187,trametinib + 2141795,uprosertib + trametinib,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,4,ROW,Sales,,,,,,,,,,,,,0,1034797,duplicate,7/7/14 12:28
5127,46,GlaxoSmithKline,Large Pharma,5187,trametinib + 2141795,uprosertib + trametinib,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,4,US,Sales,,,,,,,,,,,,,0,1034797,duplicate,7/7/14 12:28
5129,2447,Dance Biopharm,Small Biotech,5189,Dance 501,Dance 501,Recombinant Protein,Phase II,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,6,Global,Sales,,,,,,,,,,,,,0,1034829,Type 2 diabetes,7/7/14 12:28
5129,2447,Dance Biopharm,Small Biotech,5189,Dance 501,Dance 501,Recombinant Protein,Phase II,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,6,ROW,Sales,,,,,,,,,,,,,0,1034829,Type 2 diabetes,7/7/14 12:28
5129,2447,Dance Biopharm,Small Biotech,5189,Dance 501,Dance 501,Recombinant Protein,Phase II,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,6,US,Sales,,,,,,,,,,,,,0,1034829,Type 2 diabetes,7/7/14 12:28
5130,19,Bayer,Large Pharma,5190,BAY 1143572,BAY 1143572,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,,,,,,,,,,,,,0,1034799,Cancer,7/7/14 12:28
5130,19,Bayer,Large Pharma,5190,BAY 1143572,BAY 1143572,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,,,,,,,,,,,,,0,1034799,Cancer,7/7/14 12:28
5130,19,Bayer,Large Pharma,5190,BAY 1143572,BAY 1143572,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Sales,,,,,,,,,,,,,0,1034799,Cancer,7/7/14 12:28
5131,16,AstraZeneca,Large Pharma,5191,AMP-224,AMP-224,Antibody/Antibody Derivative,Phase I,Acquisition (Development),,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034850,Solid tumors,7/7/14 12:28
5131,16,AstraZeneca,Large Pharma,5191,AMP-224,AMP-224,Antibody/Antibody Derivative,Phase I,Acquisition (Development),,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034850,Solid tumors,7/7/14 12:28
5131,16,AstraZeneca,Large Pharma,5191,AMP-224,AMP-224,Antibody/Antibody Derivative,Phase I,Acquisition (Development),,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034850,Solid tumors,7/7/14 12:28
5132,96,Shire,Regional & Specialty Pharma,5192,SHP620,maribavir,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,Global,Sales,,,,,,,,,,,,,0,1034832,CMV in transplant,7/7/14 12:28
5132,96,Shire,Regional & Specialty Pharma,5192,SHP620,maribavir,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,ROW,Sales,,,,,,,,,,,,,0,1034832,CMV in transplant,7/7/14 12:28
5132,96,Shire,Regional & Specialty Pharma,5192,SHP620,maribavir,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,US,Sales,,,,,,,,,,,,,0,1034832,CMV in transplant,7/7/14 12:28
5133,46,GlaxoSmithKline,Large Pharma,5193,GSK-1265744,cabotegravir,Small Molecule (Chemical),Phase II,In-House,,,,,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,4,Global,Sales,,,,,,,,,,,,,0,1034831,HIV,7/7/14 12:28
5133,46,GlaxoSmithKline,Large Pharma,5193,GSK-1265744,cabotegravir,Small Molecule (Chemical),Phase II,In-House,,,,,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,4,ROW,Sales,,,,,,,,,,,,,0,1034831,HIV,7/7/14 12:28
5133,46,GlaxoSmithKline,Large Pharma,5193,GSK-1265744,cabotegravir,Small Molecule (Chemical),Phase II,In-House,,,,,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,4,US,Sales,,,,,,,,,,,,,0,1034831,HIV,7/7/14 12:28
5134,11,Amgen,Large Pharma,5194,AMG 282,AMG 282,Antibody/Antibody Derivative,Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,,,,,,,,,,,,,0,1034800,Asthma,7/7/14 12:28
5134,11,Amgen,Large Pharma,5194,AMG 282,AMG 282,Antibody/Antibody Derivative,Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,,,,,,,,,,,,,0,1034800,Asthma,7/7/14 12:28
5134,11,Amgen,Large Pharma,5194,AMG 282,AMG 282,Antibody/Antibody Derivative,Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,,,,,,,,,,,,,0,1034800,Asthma,7/7/14 12:28
5135,39,Eli Lilly,Large Pharma,5195,LY2928057,Ferroportin Monoclonal Antibody,Antibody/Antibody Derivative,Phase II,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,Global,Sales,,,,,,,,,,,,,0,1034801,Anemia,7/7/14 12:28
5135,39,Eli Lilly,Large Pharma,5195,LY2928057,Ferroportin Monoclonal Antibody,Antibody/Antibody Derivative,Phase II,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,ROW,Sales,,,,,,,,,,,,,0,1034801,Anemia,7/7/14 12:28
5135,39,Eli Lilly,Large Pharma,5195,LY2928057,Ferroportin Monoclonal Antibody,Antibody/Antibody Derivative,Phase II,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,US,Sales,,,,,,,,,,,,,0,1034801,Anemia,7/7/14 12:28
5136,39,Eli Lilly,Large Pharma,5196,TGF Alpha antibody,TGF Alpha antibody,Antibody/Antibody Derivative,Phase II,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,Global,Sales,,,,,,,,,,,,,0,1034802,Chronic kidney disease,7/7/14 12:28
5136,39,Eli Lilly,Large Pharma,5196,TGF Alpha antibody,TGF Alpha antibody,Antibody/Antibody Derivative,Phase II,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,ROW,Sales,,,,,,,,,,,,,0,1034802,Chronic kidney disease,7/7/14 12:28
5136,39,Eli Lilly,Large Pharma,5196,TGF Alpha antibody,TGF Alpha antibody,Antibody/Antibody Derivative,Phase II,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,US,Sales,,,,,,,,,,,,,0,1034802,Chronic kidney disease,7/7/14 12:28
5137,39,Eli Lilly,Large Pharma,662,tanezumab,tanezumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,,,,,,,,,,,,,0,1164,Pain,7/7/14 12:28
5137,39,Eli Lilly,Large Pharma,662,tanezumab,tanezumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,,,,,,,,,,,,,0,1164,Pain,7/7/14 12:28
5137,39,Eli Lilly,Large Pharma,662,tanezumab,tanezumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,,,,,,,,,,,,,0,1164,Pain,7/7/14 12:28
5138,2221,AbbVie,Large Pharma,5197,ABBV-399,ABBV-399,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034803,Solid tumors,7/7/14 12:28
5138,2221,AbbVie,Large Pharma,5197,ABBV-399,ABBV-399,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034803,Solid tumors,7/7/14 12:28
5138,2221,AbbVie,Large Pharma,5197,ABBV-399,ABBV-399,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034803,Solid tumors,7/7/14 12:28
5139,2221,AbbVie,Large Pharma,5198,ABT-165,Anti-CD20/CD3 DVD-Ig ,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034804,Solid tumors,7/7/14 12:28
5139,2221,AbbVie,Large Pharma,5198,ABT-165,Anti-CD20/CD3 DVD-Ig ,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034804,Solid tumors,7/7/14 12:28
5139,2221,AbbVie,Large Pharma,5198,ABT-165,Anti-CD20/CD3 DVD-Ig ,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034804,Solid tumors,7/7/14 12:28
5140,2221,AbbVie,Large Pharma,5199,ABT-414,ABT-414,Antibody/Antibody Derivative,Phase II,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034805,Solid tumors,7/7/14 12:28
5140,2221,AbbVie,Large Pharma,5199,ABT-414,ABT-414,Antibody/Antibody Derivative,Phase II,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034805,Solid tumors,7/7/14 12:28
5140,2221,AbbVie,Large Pharma,5199,ABT-414,ABT-414,Antibody/Antibody Derivative,Phase II,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034805,Solid tumors,7/7/14 12:28
5141,15,Astellas Pharma,Regional & Specialty Pharma,5200,ASP5878,ASP5878,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034806,Solid tumors,7/7/14 12:28
5141,15,Astellas Pharma,Regional & Specialty Pharma,5200,ASP5878,ASP5878,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034806,Solid tumors,7/7/14 12:28
5141,15,Astellas Pharma,Regional & Specialty Pharma,5200,ASP5878,ASP5878,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034806,Solid tumors,7/7/14 12:28
5142,15,Astellas Pharma,Regional & Specialty Pharma,5201,ASP8273,ASP8273,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034807,Cancer,7/7/14 12:28
5142,15,Astellas Pharma,Regional & Specialty Pharma,5201,ASP8273,ASP8273,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034807,Cancer,7/7/14 12:28
5142,15,Astellas Pharma,Regional & Specialty Pharma,5201,ASP8273,ASP8273,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034807,Cancer,7/7/14 12:28
5143,34,Daiichi-Sankyo,Regional & Specialty Pharma,5202,DS-8273,DS-8273,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034808,Solid tumors,7/7/14 12:28
5143,34,Daiichi-Sankyo,Regional & Specialty Pharma,5202,DS-8273,DS-8273,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034808,Solid tumors,7/7/14 12:28
5143,34,Daiichi-Sankyo,Regional & Specialty Pharma,5202,DS-8273,DS-8273,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034808,Solid tumors,7/7/14 12:28
5144,34,Daiichi-Sankyo,Regional & Specialty Pharma,5203,PLX8394,PLX8394,Small Molecule (Chemical),Phase I,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034809,Advanced Cancer,7/7/14 12:28
5144,34,Daiichi-Sankyo,Regional & Specialty Pharma,5203,PLX8394,PLX8394,Small Molecule (Chemical),Phase I,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034809,Advanced Cancer,7/7/14 12:28
5144,34,Daiichi-Sankyo,Regional & Specialty Pharma,5203,PLX8394,PLX8394,Small Molecule (Chemical),Phase I,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034809,Advanced Cancer,7/7/14 12:28
5145,37,Eisai,Regional & Specialty Pharma,5204,E7438,EPZ-5687,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034834,Cancer,7/7/14 12:28
5145,37,Eisai,Regional & Specialty Pharma,5204,E7438,EPZ-5687,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034834,Cancer,7/7/14 12:28
5145,37,Eisai,Regional & Specialty Pharma,5204,E7438,EPZ-5687,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034834,Cancer,7/7/14 12:28
5146,37,Eisai,Regional & Specialty Pharma,5205,PRI-724,CBP/beta-catenin inhibitor ,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034810,Acute/chronic myeloid leukemia,7/7/14 12:28
5146,37,Eisai,Regional & Specialty Pharma,5205,PRI-724,CBP/beta-catenin inhibitor ,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034810,Acute/chronic myeloid leukemia,7/7/14 12:28
5146,37,Eisai,Regional & Specialty Pharma,5205,PRI-724,CBP/beta-catenin inhibitor ,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034810,Acute/chronic myeloid leukemia,7/7/14 12:28
5147,39,Eli Lilly,Large Pharma,5206,Prostaglandin E receptor 4 antagonist,Prostaglandin E receptor 4 antagonist,,Phase I,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,,,,,,,,,,,,,0,1034811,,7/7/14 12:28
5147,39,Eli Lilly,Large Pharma,5206,Prostaglandin E receptor 4 antagonist,Prostaglandin E receptor 4 antagonist,,Phase I,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,,,,,,,,,,,,,0,1034811,,7/7/14 12:28
5147,39,Eli Lilly,Large Pharma,5206,Prostaglandin E receptor 4 antagonist,Prostaglandin E receptor 4 antagonist,,Phase I,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,,,,,,,,,,,,,0,1034811,,7/7/14 12:28
5148,39,Eli Lilly,Large Pharma,5207,N3pG-amyloid beta monoclonal antibody,N3pG-amyloid beta monoclonal antibody,Antibody/Antibody Derivative,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,,,,,,,,,,,,,0,1034812,,7/7/14 12:28
5148,39,Eli Lilly,Large Pharma,5207,N3pG-amyloid beta monoclonal antibody,N3pG-amyloid beta monoclonal antibody,Antibody/Antibody Derivative,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,,,,,,,,,,,,,0,1034812,,7/7/14 12:28
5148,39,Eli Lilly,Large Pharma,5207,N3pG-amyloid beta monoclonal antibody,N3pG-amyloid beta monoclonal antibody,Antibody/Antibody Derivative,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,,,,,,,,,,,,,0,1034812,,7/7/14 12:28
5149,39,Eli Lilly,Large Pharma,5208,Metabotropic glutamate 2/3 receptor agonist,,,Phase I,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,,,,,,,,,,,,,0,1034813,Chronic Pain,7/7/14 12:28
5149,39,Eli Lilly,Large Pharma,5208,Metabotropic glutamate 2/3 receptor agonist,,,Phase I,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,,,,,,,,,,,,,0,1034813,Chronic Pain,7/7/14 12:28
5149,39,Eli Lilly,Large Pharma,5208,Metabotropic glutamate 2/3 receptor agonist,,,Phase I,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,,,,,,,,,,,,,0,1034813,Chronic Pain,7/7/14 12:28
5150,39,Eli Lilly,Large Pharma,4105,Pomaglumetad methionil,Pomaglumetad methionil,,Phase I,In-House,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,Global,Sales,,,,,,,,,,,,,0,1034814,CNS Disorder,7/7/14 12:28
5150,39,Eli Lilly,Large Pharma,4105,Pomaglumetad methionil,Pomaglumetad methionil,,Phase I,In-House,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,ROW,Sales,,,,,,,,,,,,,0,1034814,CNS Disorder,7/7/14 12:28
5150,39,Eli Lilly,Large Pharma,4105,Pomaglumetad methionil,Pomaglumetad methionil,,Phase I,In-House,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,US,Sales,,,,,,,,,,,,,0,1034814,CNS Disorder,7/7/14 12:28
5151,39,Eli Lilly,Large Pharma,5209,CSF-1R,CSF-1R,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,,,,,,,,,,,,,0,1034815,Cancer,7/7/14 12:28
5151,39,Eli Lilly,Large Pharma,5209,CSF-1R,CSF-1R,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,,,,,,,,,,,,,0,1034815,Cancer,7/7/14 12:28
5151,39,Eli Lilly,Large Pharma,5209,CSF-1R,CSF-1R,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,,,,,,,,,,,,,0,1034815,Cancer,7/7/14 12:28
5152,11,Amgen,Large Pharma,5210,AMG 333,AMG 333,Small Molecule (Chemical),Phase I,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,Global,Sales,,,,,,,,,,,,,0,1034816,Migraine,7/7/14 12:28
5152,11,Amgen,Large Pharma,5210,AMG 333,AMG 333,Small Molecule (Chemical),Phase I,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,ROW,Sales,,,,,,,,,,,,,0,1034816,Migraine,7/7/14 12:28
5152,11,Amgen,Large Pharma,5210,AMG 333,AMG 333,Small Molecule (Chemical),Phase I,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,US,Sales,,,,,,,,,,,,,0,1034816,Migraine,7/7/14 12:28
5153,11,Amgen,Large Pharma,5211,AMG 581,AMG 581,Small Molecule (Chemical),Phase I,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,,,,,,,,,,,,,0,1034817,schizophrenia,7/7/14 12:28
5153,11,Amgen,Large Pharma,5211,AMG 581,AMG 581,Small Molecule (Chemical),Phase I,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,,,,,,,,,,,,,0,1034817,schizophrenia,7/7/14 12:28
5153,11,Amgen,Large Pharma,5211,AMG 581,AMG 581,Small Molecule (Chemical),Phase I,In-House,,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,,,,,,,,,,,,,0,1034817,schizophrenia,7/7/14 12:28
5154,63,Merck KGaA,Regional & Specialty Pharma,2039,NHS-IL2-LT,Selectikine,Antibody/Antibody Derivative,Phase II,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,2,Global,Sales,,,,,,,,,,,,,0,1034818,Melanoma,7/7/14 12:28
5154,63,Merck KGaA,Regional & Specialty Pharma,2039,NHS-IL2-LT,Selectikine,Antibody/Antibody Derivative,Phase II,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,2,ROW,Sales,,,,,,,,,,,,,0,1034818,Melanoma,7/7/14 12:28
5154,63,Merck KGaA,Regional & Specialty Pharma,2039,NHS-IL2-LT,Selectikine,Antibody/Antibody Derivative,Phase II,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,2,US,Sales,,,,,,,,,,,,,0,1034818,Melanoma,7/7/14 12:28
5155,63,Merck KGaA,Regional & Specialty Pharma,5212,MSC-2363318A,Dual p70S6K/AKT inhibitor,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,,,,,,,,,,,,,0,1034819,Solid Tumors,7/7/14 12:28
5155,63,Merck KGaA,Regional & Specialty Pharma,5212,MSC-2363318A,Dual p70S6K/AKT inhibitor,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,,,,,,,,,,,,,0,1034819,Solid Tumors,7/7/14 12:28
5155,63,Merck KGaA,Regional & Specialty Pharma,5212,MSC-2363318A,Dual p70S6K/AKT inhibitor,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Sales,,,,,,,,,,,,,0,1034819,Solid Tumors,7/7/14 12:28
5156,70,Ono,Regional & Specialty Pharma,5213,ONO-7268MX2,ONO-7268MX2,Vaccine,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034820,Hepatocellular Carcinoma,7/7/14 12:28
5156,70,Ono,Regional & Specialty Pharma,5213,ONO-7268MX2,ONO-7268MX2,Vaccine,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034820,Hepatocellular Carcinoma,7/7/14 12:28
5156,70,Ono,Regional & Specialty Pharma,5213,ONO-7268MX2,ONO-7268MX2,Vaccine,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034820,Hepatocellular Carcinoma,7/7/14 12:28
5157,73,Otsuka,Regional & Specialty Pharma,5214,TAS-114,TAS-114,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034821,Solid Tumors,7/7/14 12:28
5157,73,Otsuka,Regional & Specialty Pharma,5214,TAS-114,TAS-114,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034821,Solid Tumors,7/7/14 12:28
5157,73,Otsuka,Regional & Specialty Pharma,5214,TAS-114,TAS-114,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034821,Solid Tumors,7/7/14 12:28
5158,73,Otsuka,Regional & Specialty Pharma,5215,TAS-115,TAS-115,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034822,Solid Tumors,7/7/14 12:28
5158,73,Otsuka,Regional & Specialty Pharma,5215,TAS-115,TAS-115,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034822,Solid Tumors,7/7/14 12:28
5158,73,Otsuka,Regional & Specialty Pharma,5215,TAS-115,TAS-115,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034822,Solid Tumors,7/7/14 12:28
5159,73,Otsuka,Regional & Specialty Pharma,5216,OPB-111077,OPB-111077,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034823,Solid Tumors,7/7/14 12:28
5159,73,Otsuka,Regional & Specialty Pharma,5216,OPB-111077,OPB-111077,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034823,Solid Tumors,7/7/14 12:28
5159,73,Otsuka,Regional & Specialty Pharma,5216,OPB-111077,OPB-111077,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034823,Solid Tumors,7/7/14 12:28
5160,73,Otsuka,Regional & Specialty Pharma,5217,OCV-C02,OCV-C02,Vaccine,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034824,Colon Tumor,7/7/14 12:28
5160,73,Otsuka,Regional & Specialty Pharma,5217,OCV-C02,OCV-C02,Vaccine,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034824,Colon Tumor,7/7/14 12:28
5160,73,Otsuka,Regional & Specialty Pharma,5217,OCV-C02,OCV-C02,Vaccine,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034824,Colon Tumor,7/7/14 12:28
5161,46,GlaxoSmithKline,Large Pharma,5218,2881078,,Small Molecule (Chemical),Phase I,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,Global,Sales,,,,,,,,,,,,,0,1034825,Heart Failure,7/7/14 12:28
5161,46,GlaxoSmithKline,Large Pharma,5218,2881078,,Small Molecule (Chemical),Phase I,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,ROW,Sales,,,,,,,,,,,,,0,1034825,Heart Failure,7/7/14 12:28
5161,46,GlaxoSmithKline,Large Pharma,5218,2881078,,Small Molecule (Chemical),Phase I,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,US,Sales,,,,,,,,,,,,,0,1034825,Heart Failure,7/7/14 12:28
5162,73,Otsuka,Regional & Specialty Pharma,5219,SGI-110,SGI-110,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034826,Acute Myeloid Leukemia,7/7/14 12:28
5162,73,Otsuka,Regional & Specialty Pharma,5219,SGI-110,SGI-110,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034826,Acute Myeloid Leukemia,7/7/14 12:28
5162,73,Otsuka,Regional & Specialty Pharma,5219,SGI-110,SGI-110,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034826,Acute Myeloid Leukemia,7/7/14 12:28
5163,73,Otsuka,Regional & Specialty Pharma,5220,AT13387,AT13387,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034827,Solid Tumors,7/7/14 12:28
5163,73,Otsuka,Regional & Specialty Pharma,5220,AT13387,AT13387,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034827,Solid Tumors,7/7/14 12:28
5163,73,Otsuka,Regional & Specialty Pharma,5220,AT13387,AT13387,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034827,Solid Tumors,7/7/14 12:28
5164,73,Otsuka,Regional & Specialty Pharma,5221,AT7519,AT7519,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,,,,,,,,,,,,,0,1034828,Multiple Myeloma,7/7/14 12:28
5164,73,Otsuka,Regional & Specialty Pharma,5221,AT7519,AT7519,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,,,,,,,,,,,,,0,1034828,Multiple Myeloma,7/7/14 12:28
5164,73,Otsuka,Regional & Specialty Pharma,5221,AT7519,AT7519,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,,,,,,,,,,,,,0,1034828,Multiple Myeloma,7/7/14 12:28
5165,16,AstraZeneca,Large Pharma,5222,AZD4901,AZD4901,Small Molecule (Chemical),Phase II,In-House,,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Sales,,,,,,,,,,,,,0,1034835,Polycystic ovarian syndrome,7/7/14 12:28
5165,16,AstraZeneca,Large Pharma,5222,AZD4901,AZD4901,Small Molecule (Chemical),Phase II,In-House,,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,ROW,Sales,,,,,,,,,,,,,0,1034835,Polycystic ovarian syndrome,7/7/14 12:28
5165,16,AstraZeneca,Large Pharma,5222,AZD4901,AZD4901,Small Molecule (Chemical),Phase II,In-House,,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Sales,,,,,,,,,,,,,0,1034835,Polycystic ovarian syndrome,7/7/14 12:28
5166,16,AstraZeneca,Large Pharma,5223,MEDI-8111,MEDI-8111,Recombinant Protein,Phase I,In-House,,,,,108,Other Hematology Products,81,Other Hematological Disorders,14,Hematology,6,Global,Sales,,,,,,,,,,,,,0,1034836,Trauma/Bleeding,7/7/14 12:28
5166,16,AstraZeneca,Large Pharma,5223,MEDI-8111,MEDI-8111,Recombinant Protein,Phase I,In-House,,,,,108,Other Hematology Products,81,Other Hematological Disorders,14,Hematology,6,ROW,Sales,,,,,,,,,,,,,0,1034836,Trauma/Bleeding,7/7/14 12:28
5166,16,AstraZeneca,Large Pharma,5223,MEDI-8111,MEDI-8111,Recombinant Protein,Phase I,In-House,,,,,108,Other Hematology Products,81,Other Hematological Disorders,14,Hematology,6,US,Sales,,,,,,,,,,,,,0,1034836,Trauma/Bleeding,7/7/14 12:28
5167,16,AstraZeneca,Large Pharma,5224,AZD1419,AZD1419,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,,,,,,,,,,,,,0,1034837,Asthma,7/7/14 12:28
5167,16,AstraZeneca,Large Pharma,5224,AZD1419,AZD1419,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,,,,,,,,,,,,,0,1034837,Asthma,7/7/14 12:28
5167,16,AstraZeneca,Large Pharma,5224,AZD1419,AZD1419,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,,,,,,,,,,,,,0,1034837,Asthma,7/7/14 12:28
5168,16,AstraZeneca,Large Pharma,5225,AZD4721,AZD4721,Small Molecule (Chemical),Phase I,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,,,,,,,,,,,,,0,1034838,COPD,7/7/14 12:28
5168,16,AstraZeneca,Large Pharma,5225,AZD4721,AZD4721,Small Molecule (Chemical),Phase I,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,,,,,,,,,,,,,0,1034838,COPD,7/7/14 12:28
5168,16,AstraZeneca,Large Pharma,5225,AZD4721,AZD4721,Small Molecule (Chemical),Phase I,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,,,,,,,,,,,,,0,1034838,COPD,7/7/14 12:28
5169,16,AstraZeneca,Large Pharma,5226,AZD0914,AZD0914,Small Molecule (Chemical),Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,,,,,,,,,,,,,0,1034839,Serious bacterial infections,7/7/14 12:28
5169,16,AstraZeneca,Large Pharma,5226,AZD0914,AZD0914,Small Molecule (Chemical),Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,,,,,,,,,,,,,0,1034839,Serious bacterial infections,7/7/14 12:28
5169,16,AstraZeneca,Large Pharma,5226,AZD0914,AZD0914,Small Molecule (Chemical),Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,,,,,,,,,,,,,0,1034839,Serious bacterial infections,7/7/14 12:28
5170,16,AstraZeneca,Large Pharma,5227,MEDI-4893,LC-10,Antibody/Antibody Derivative,Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,,,,,,,,,,,,,0,1034840,Hospital-acquired pneumonia,7/7/14 12:28
5170,16,AstraZeneca,Large Pharma,5227,MEDI-4893,LC-10,Antibody/Antibody Derivative,Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,,,,,,,,,,,,,0,1034840,Hospital-acquired pneumonia,7/7/14 12:28
5170,16,AstraZeneca,Large Pharma,5227,MEDI-4893,LC-10,Antibody/Antibody Derivative,Phase I,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,,,,,,,,,,,,,0,1034840,Hospital-acquired pneumonia,7/7/14 12:28
5171,16,AstraZeneca,Large Pharma,5228,MEDI-9287,MEDI-9287,Vaccine,Phase I,In-House,,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,Global,Sales,,,,,,,,,,,,,0,1034841,Influenza virus infection,7/7/14 12:28
5171,16,AstraZeneca,Large Pharma,5228,MEDI-9287,MEDI-9287,Vaccine,Phase I,In-House,,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,ROW,Sales,,,,,,,,,,,,,0,1034841,Influenza virus infection,7/7/14 12:28
5171,16,AstraZeneca,Large Pharma,5228,MEDI-9287,MEDI-9287,Vaccine,Phase I,In-House,,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,US,Sales,,,,,,,,,,,,,0,1034841,Influenza virus infection,7/7/14 12:28
5172,16,AstraZeneca,Large Pharma,5229,AZD6423,AZD6423,Small Molecule (Chemical),Phase I,In-House,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,Global,Sales,,,,,,,,,,,,,0,1034842,Suicidal ideation,7/7/14 12:28
5172,16,AstraZeneca,Large Pharma,5229,AZD6423,AZD6423,Small Molecule (Chemical),Phase I,In-House,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,ROW,Sales,,,,,,,,,,,,,0,1034842,Suicidal ideation,7/7/14 12:28
5172,16,AstraZeneca,Large Pharma,5229,AZD6423,AZD6423,Small Molecule (Chemical),Phase I,In-House,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,US,Sales,,,,,,,,,,,,,0,1034842,Suicidal ideation,7/7/14 12:28
5173,53,Johnson & Johnson,Large Pharma,5230,JNJ-54861911,JNJ-54861911,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,,,,,,,,,,,,,0,1034843,Alzheimer's disease ,7/7/14 12:28
5173,53,Johnson & Johnson,Large Pharma,5230,JNJ-54861911,JNJ-54861911,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,,,,,,,,,,,,,0,1034843,Alzheimer's disease ,7/7/14 12:28
5173,53,Johnson & Johnson,Large Pharma,5230,JNJ-54861911,JNJ-54861911,Small Molecule (Chemical),Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,,,,,,,,,,,,,0,1034843,Alzheimer's disease ,7/7/14 12:28
5174,53,Johnson & Johnson,Large Pharma,5231,JNJ-42165279,JNJ-42165279,Small Molecule (Chemical),Phase I,In-House,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,Global,Sales,,,,,,,,,,,,,0,1034844,Anxiety disorder,7/7/14 12:28
5174,53,Johnson & Johnson,Large Pharma,5231,JNJ-42165279,JNJ-42165279,Small Molecule (Chemical),Phase I,In-House,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,ROW,Sales,,,,,,,,,,,,,0,1034844,Anxiety disorder,7/7/14 12:28
5174,53,Johnson & Johnson,Large Pharma,5231,JNJ-42165279,JNJ-42165279,Small Molecule (Chemical),Phase I,In-House,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,US,Sales,,,,,,,,,,,,,0,1034844,Anxiety disorder,7/7/14 12:28
5175,53,Johnson & Johnson,Large Pharma,5232,CNTO-6785,CNTO-6785,Antibody/Antibody Derivative,Phase II,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,,,,,,,,,,,,,0,1034845,Rheumatoid Arthritis,7/7/14 12:28
5175,53,Johnson & Johnson,Large Pharma,5232,CNTO-6785,CNTO-6785,Antibody/Antibody Derivative,Phase II,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,,,,,,,,,,,,,0,1034845,Rheumatoid Arthritis,7/7/14 12:28
5175,53,Johnson & Johnson,Large Pharma,5232,CNTO-6785,CNTO-6785,Antibody/Antibody Derivative,Phase II,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,,,,,,,,,,,,,0,1034845,Rheumatoid Arthritis,7/7/14 12:28
5176,67,Novartis,Large Pharma,5233,EDP239,EDP239,Small Molecule (Chemical),Phase II,In-House,,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,,,,,,,,,,,,,0,1034846,Hepatitis C ,7/7/14 12:28
5176,67,Novartis,Large Pharma,5233,EDP239,EDP239,Small Molecule (Chemical),Phase II,In-House,,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,,,,,,,,,,,,,0,1034846,Hepatitis C ,7/7/14 12:28
5176,67,Novartis,Large Pharma,5233,EDP239,EDP239,Small Molecule (Chemical),Phase II,In-House,,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,,,,,,,,,,,,,0,1034846,Hepatitis C ,7/7/14 12:28
5177,67,Novartis,Large Pharma,5234,Clostridium difficile vaccine,IC-84,Vaccine,Phase I,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,,,,,,,,,,,,,0,1034851,Clostridium difficile infection ,7/7/14 12:28
5177,67,Novartis,Large Pharma,5234,Clostridium difficile vaccine,IC-84,Vaccine,Phase I,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,,,,,,,,,,,,,0,1034851,Clostridium difficile infection ,7/7/14 12:28
5177,67,Novartis,Large Pharma,5234,Clostridium difficile vaccine,IC-84,Vaccine,Phase I,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,,,,,,,,,,,,,0,1034851,Clostridium difficile infection ,7/7/14 12:28
5178,67,Novartis,Large Pharma,5235,AL60371,EXE-844,Small Molecule (Chemical),Phase III,In-House,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,Global,Sales,,,,,,,,,,,,,0,1034847,Acute external otitis,7/7/14 12:28
5178,67,Novartis,Large Pharma,5235,AL60371,EXE-844,Small Molecule (Chemical),Phase III,In-House,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,ROW,Sales,,,,,,,,,,,,,0,1034847,Acute external otitis,7/7/14 12:28
5178,67,Novartis,Large Pharma,5235,AL60371,EXE-844,Small Molecule (Chemical),Phase III,In-House,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,US,Sales,,,,,,,,,,,,,0,1034847,Acute external otitis,7/7/14 12:28
5179,53,Johnson & Johnson,Large Pharma,5236,JNJ-56914845,JNJ-56914845,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,,,,,,,,,,,,,0,1034848,Hepatitis C virus infection,7/7/14 12:28
5179,53,Johnson & Johnson,Large Pharma,5236,JNJ-56914845,JNJ-56914845,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,,,,,,,,,,,,,0,1034848,Hepatitis C virus infection,7/7/14 12:28
5179,53,Johnson & Johnson,Large Pharma,5236,JNJ-56914845,JNJ-56914845,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,,,,,,,,,,,,,0,1034848,Hepatitis C virus infection,7/7/14 12:28
5180,61,Merck & Co,Large Pharma,5237,MK-1293,insulin glargine,Recombinant Protein,Phase III,Licensed (Development),,,,,83,Insulins,22,Diabetes,8,Metabolism,6,Global,Sales,,,,,,,,,,,,,0,1034849,Diabetes,7/7/14 12:28
5180,61,Merck & Co,Large Pharma,5237,MK-1293,insulin glargine,Recombinant Protein,Phase III,Licensed (Development),,,,,83,Insulins,22,Diabetes,8,Metabolism,6,ROW,Sales,,,,,,,,,,,,,0,1034849,Diabetes,7/7/14 12:28
5180,61,Merck & Co,Large Pharma,5237,MK-1293,insulin glargine,Recombinant Protein,Phase III,Licensed (Development),,,,,83,Insulins,22,Diabetes,8,Metabolism,6,US,Sales,,,,,,,,,,,,,0,1034849,Diabetes,7/7/14 12:28
5181,2221,AbbVie,Large Pharma,2377,test,,Synthetic Peptide,Filed,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Sales,,,,,,,,,,,,,0,,,7/7/14 12:28
5181,2221,AbbVie,Large Pharma,2377,test,,Synthetic Peptide,Filed,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Sales,,,,,,,,,,,,,0,,,7/7/14 12:28
5181,2221,AbbVie,Large Pharma,2377,test,,Synthetic Peptide,Filed,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Sales,,,,,,,,,,,,,0,,,7/7/14 12:28
61,2221,AbbVie,Large Pharma,618,ABT-072,ABT-072,Small Molecule (Chemical),Phase II,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,50,Hepatitis C,7/7/14 12:28
61,2221,AbbVie,Large Pharma,618,ABT-072,ABT-072,Small Molecule (Chemical),Phase II,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,50,Hepatitis C,7/7/14 12:28
61,2221,AbbVie,Large Pharma,618,ABT-072,ABT-072,Small Molecule (Chemical),Phase II,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,50,Hepatitis C,7/7/14 12:28
69,2221,AbbVie,Large Pharma,1486,dasabuvir,dasabuvir,Small Molecule (Chemical),Filed,In-House,May-15,Oct-15,N/A,N/A,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,53,Hepatitis C,7/7/14 12:28
69,2221,AbbVie,Large Pharma,1486,dasabuvir,dasabuvir,Small Molecule (Chemical),Filed,In-House,May-15,Oct-15,N/A,N/A,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,338,485,596,594,518,416,0,53,Hepatitis C,7/7/14 12:28
69,2221,AbbVie,Large Pharma,1486,dasabuvir,dasabuvir,Small Molecule (Chemical),Filed,In-House,May-15,Oct-15,N/A,N/A,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,53,Hepatitis C,7/7/14 12:28
69,2221,AbbVie,Large Pharma,1486,dasabuvir,dasabuvir,Small Molecule (Chemical),Filed,In-House,May-15,Oct-15,N/A,N/A,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,98,180,205,205,193,130,0,53,Hepatitis C,7/7/14 12:28
69,2221,AbbVie,Large Pharma,1486,dasabuvir,dasabuvir,Small Molecule (Chemical),Filed,In-House,May-15,Oct-15,N/A,N/A,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,53,Hepatitis C,7/7/14 12:28
69,2221,AbbVie,Large Pharma,1486,dasabuvir,dasabuvir,Small Molecule (Chemical),Filed,In-House,May-15,Oct-15,N/A,N/A,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,240,305,391,389,325,286,0,53,Hepatitis C,7/7/14 12:28
70,2221,AbbVie,Large Pharma,1660,ABT-450,,Small Molecule (Chemical),Filed,Licensed (Development),Apr-15,Nov-15,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,54,Hepatitis C,7/7/14 12:28
70,2221,AbbVie,Large Pharma,1660,ABT-450,,Small Molecule (Chemical),Filed,Licensed (Development),Apr-15,Nov-15,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,778,1393,1633,1659,1462,1112,0,54,Hepatitis C,7/7/14 12:28
70,2221,AbbVie,Large Pharma,1660,ABT-450,,Small Molecule (Chemical),Filed,Licensed (Development),Apr-15,Nov-15,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,54,Hepatitis C,7/7/14 12:28
70,2221,AbbVie,Large Pharma,1660,ABT-450,,Small Molecule (Chemical),Filed,Licensed (Development),Apr-15,Nov-15,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,262,613,649,664,606,380,0,54,Hepatitis C,7/7/14 12:28
70,2221,AbbVie,Large Pharma,1660,ABT-450,,Small Molecule (Chemical),Filed,Licensed (Development),Apr-15,Nov-15,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,54,Hepatitis C,7/7/14 12:28
70,2221,AbbVie,Large Pharma,1660,ABT-450,,Small Molecule (Chemical),Filed,Licensed (Development),Apr-15,Nov-15,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,516,780,984,995,856,732,0,54,Hepatitis C,7/7/14 12:28
79,2221,AbbVie,Large Pharma,3452,veliparib,ABT-888,Small Molecule (Chemical),Phase III,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,57,Breast Cancer,7/7/14 12:28
79,2221,AbbVie,Large Pharma,3452,veliparib,ABT-888,Small Molecule (Chemical),Phase III,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,57,Breast Cancer,7/7/14 12:28
79,2221,AbbVie,Large Pharma,3452,veliparib,ABT-888,Small Molecule (Chemical),Phase III,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,57,Breast Cancer,7/7/14 12:28
79,2221,AbbVie,Large Pharma,3452,veliparib,ABT-888,Small Molecule (Chemical),Phase III,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,57,Breast Cancer,7/7/14 12:28
79,2221,AbbVie,Large Pharma,3452,veliparib,ABT-888,Small Molecule (Chemical),Phase III,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,57,Breast Cancer,7/7/14 12:28
79,2221,AbbVie,Large Pharma,3452,veliparib,ABT-888,Small Molecule (Chemical),Phase III,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,57,Breast Cancer,7/7/14 12:28
81,89,Sanofi,Large Pharma,1618,ACAM-Cdiff,ACAM-Cdiff,Vaccine,Phase III,Corporate Acquisition,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,60,C. Difficile-Associated Diarrhea,7/7/14 12:28
81,89,Sanofi,Large Pharma,1618,ACAM-Cdiff,ACAM-Cdiff,Vaccine,Phase III,Corporate Acquisition,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,60,C. Difficile-Associated Diarrhea,7/7/14 12:28
81,89,Sanofi,Large Pharma,1618,ACAM-Cdiff,ACAM-Cdiff,Vaccine,Phase III,Corporate Acquisition,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,60,C. Difficile-Associated Diarrhea,7/7/14 12:28
81,89,Sanofi,Large Pharma,1618,ACAM-Cdiff,ACAM-Cdiff,Vaccine,Phase III,Corporate Acquisition,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,60,C. Difficile-Associated Diarrhea,7/7/14 12:28
81,89,Sanofi,Large Pharma,1618,ACAM-Cdiff,ACAM-Cdiff,Vaccine,Phase III,Corporate Acquisition,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,60,C. Difficile-Associated Diarrhea,7/7/14 12:28
81,89,Sanofi,Large Pharma,1618,ACAM-Cdiff,ACAM-Cdiff,Vaccine,Phase III,Corporate Acquisition,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,60,C. Difficile-Associated Diarrhea,7/7/14 12:28
84,16,AstraZeneca,Large Pharma,65,Accolate,zafirlukast,Small Molecule (Chemical),Launched,In-House,Nov-96,Jun-96,Nov-10,Expired,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,63,Asthma,7/7/14 12:28
84,16,AstraZeneca,Large Pharma,65,Accolate,zafirlukast,Small Molecule (Chemical),Launched,In-House,Nov-96,Jun-96,Nov-10,Expired,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,Global,Sales,66,57,21.765,20.013375,18.77687813,17.24567898,16.08064903,14.98568365,13.93043871,12.92224404,11.9476696,11.00332639,-7.350521915,63,Asthma,7/7/14 12:28
84,16,AstraZeneca,Large Pharma,65,Accolate,zafirlukast,Small Molecule (Chemical),Launched,In-House,Nov-96,Jun-96,Nov-10,Expired,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,63,Asthma,7/7/14 12:28
84,16,AstraZeneca,Large Pharma,65,Accolate,zafirlukast,Small Molecule (Chemical),Launched,In-House,Nov-96,Jun-96,Nov-10,Expired,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,18,17,15.765,14.513375,13.37687812,12.24567898,11.14664903,10.08628365,9.054458713,8.053322044,7.082242597,6.139609171,-10.52869821,63,Asthma,7/7/14 12:28
84,16,AstraZeneca,Large Pharma,65,Accolate,zafirlukast,Small Molecule (Chemical),Launched,In-House,Nov-96,Jun-96,Nov-10,Expired,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,63,Asthma,7/7/14 12:28
84,16,AstraZeneca,Large Pharma,65,Accolate,zafirlukast,Small Molecule (Chemical),Launched,In-House,Nov-96,Jun-96,Nov-10,Expired,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,US,Sales,48,40,6,5.5,5.4,5,4.934,4.8994,4.87598,4.868922,4.865427,4.86371722,-1.483118168,63,Asthma,7/7/14 12:28
85,76,Pfizer,Large Pharma,1221,Accupril,quinapril,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-89,Jul-90,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,64,Hypertension,7/7/14 12:28
85,76,Pfizer,Large Pharma,1221,Accupril,quinapril,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-89,Jul-90,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Sales,93,78.59,71.0872,67.003192,64.80346912,63.60764672,62.95521475,62.59685064,62.39863039,62.28807923,62.22585139,62.19046406,-0.586238015,64,Hypertension,7/7/14 12:28
85,76,Pfizer,Large Pharma,1221,Accupril,quinapril,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-89,Jul-90,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,64,Hypertension,7/7/14 12:28
85,76,Pfizer,Large Pharma,1221,Accupril,quinapril,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-89,Jul-90,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,84,70.74,63.6672,59.927592,57.94478112,56.89440448,56.33781591,56.04291013,55.88665108,55.8038563,55.75998687,55.73674234,-0.553475394,64,Hypertension,7/7/14 12:28
85,76,Pfizer,Large Pharma,1221,Accupril,quinapril,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-89,Jul-90,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,64,Hypertension,7/7/14 12:28
85,76,Pfizer,Large Pharma,1221,Accupril,quinapril,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-89,Jul-90,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Sales,9,7.85,7.42,7.0756,6.858688,6.71324224,6.617398835,6.55394051,6.511979305,6.484222928,6.465864522,6.453721722,-0.865647698,64,Hypertension,7/7/14 12:28
86,67,Novartis,Large Pharma,4359,Reclast / Aclasta,zoledronic acid,Small Molecule (Chemical),Launched,In-House,Apr-07,Apr-05,Mar-13,Dec-12,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,67,Osteoporosis,7/7/14 12:28
86,67,Novartis,Large Pharma,4359,Reclast / Aclasta,zoledronic acid,Small Molecule (Chemical),Launched,In-House,Apr-07,Apr-05,Mar-13,Dec-12,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,472,579,613,590,337,242.4,185.52,169.1566,153.124334,139.5666477,130.9000261,123.7444868,-13.33527927,67,Osteoporosis,7/7/14 12:28
86,67,Novartis,Large Pharma,4359,Reclast / Aclasta,zoledronic acid,Small Molecule (Chemical),Launched,In-House,Apr-07,Apr-05,Mar-13,Dec-12,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,67,Osteoporosis,7/7/14 12:28
86,67,Novartis,Large Pharma,4359,Reclast / Aclasta,zoledronic acid,Small Molecule (Chemical),Launched,In-House,Apr-07,Apr-05,Mar-13,Dec-12,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,144,186,227,236,200,175,158.34,144.1566,133.124334,124.5666477,117.8360261,112.5676868,-7.882833475,67,Osteoporosis,7/7/14 12:28
86,67,Novartis,Large Pharma,4359,Reclast / Aclasta,zoledronic acid,Small Molecule (Chemical),Launched,In-House,Apr-07,Apr-05,Mar-13,Dec-12,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,67,Osteoporosis,7/7/14 12:28
86,67,Novartis,Large Pharma,4359,Reclast / Aclasta,zoledronic acid,Small Molecule (Chemical),Launched,In-House,Apr-07,Apr-05,Mar-13,Dec-12,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,328,393,386,354,137,67.4,27.18,25,20,15,13.064,11.1768,-30.09407284,67,Osteoporosis,7/7/14 12:28
87,10,Almirall,Regional & Specialty Pharma,2489,Eklira,aclidinium,Small Molecule (Chemical),Launched,In-House,,Sep-12,N/A,Jul-20,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1325,COPD,7/7/14 12:28
87,10,Almirall,Regional & Specialty Pharma,2489,Eklira,aclidinium,Small Molecule (Chemical),Launched,In-House,,Sep-12,N/A,Jul-20,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,34.70232581,111.6873286,158.2240878,232.6827613,259.2253484,277.1918474,289.9269516,296.7533592,301.0841732,15.21956402,1325,COPD,7/7/14 12:28
87,10,Almirall,Regional & Specialty Pharma,2489,Eklira,aclidinium,Small Molecule (Chemical),Launched,In-House,,Sep-12,N/A,Jul-20,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1325,COPD,7/7/14 12:28
87,10,Almirall,Regional & Specialty Pharma,2489,Eklira,aclidinium,Small Molecule (Chemical),Launched,In-House,,Sep-12,N/A,Jul-20,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,34.70232581,111.6873286,158.2240878,232.6827613,259.2253484,277.1918474,289.9269516,296.7533592,301.0841732,15.21956402,1325,COPD,7/7/14 12:28
87,10,Almirall,Regional & Specialty Pharma,2489,Eklira,aclidinium,Small Molecule (Chemical),Launched,In-House,,Sep-12,N/A,Jul-20,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1325,COPD,7/7/14 12:28
87,10,Almirall,Regional & Specialty Pharma,2489,Eklira,aclidinium,Small Molecule (Chemical),Launched,In-House,,Sep-12,N/A,Jul-20,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1325,COPD,7/7/14 12:28
88,42,Forest,Regional & Specialty Pharma,4317,Tudorza,aclidinium,Small Molecule (Chemical),Launched,Licensed (Development),Dec-12,,N/A,N/A,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1325,COPD,7/7/14 12:28
88,42,Forest,Regional & Specialty Pharma,4317,Tudorza,aclidinium,Small Molecule (Chemical),Launched,Licensed (Development),Dec-12,,N/A,N/A,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,23,85,107,118,130.25,137.1625,141.828125,145.2564063,147.5045703,8.192721319,1325,COPD,7/7/14 12:28
88,42,Forest,Regional & Specialty Pharma,4317,Tudorza,aclidinium,Small Molecule (Chemical),Launched,Licensed (Development),Dec-12,,N/A,N/A,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1325,COPD,7/7/14 12:28
88,42,Forest,Regional & Specialty Pharma,4317,Tudorza,aclidinium,Small Molecule (Chemical),Launched,Licensed (Development),Dec-12,,N/A,N/A,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1325,COPD,7/7/14 12:28
88,42,Forest,Regional & Specialty Pharma,4317,Tudorza,aclidinium,Small Molecule (Chemical),Launched,Licensed (Development),Dec-12,,N/A,N/A,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1325,COPD,7/7/14 12:28
88,42,Forest,Regional & Specialty Pharma,4317,Tudorza,aclidinium,Small Molecule (Chemical),Launched,Licensed (Development),Dec-12,,N/A,N/A,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,23,85,107,118,130.25,137.1625,141.828125,145.2564063,147.5045703,8.192721319,1325,COPD,7/7/14 12:28
89,10,Almirall,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Filed,In-House,,Feb-15,N/A,May-25,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1326,COPD,7/7/14 12:28
89,10,Almirall,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Filed,In-House,,Feb-15,N/A,May-25,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,12.17361337,21.39609939,30.24959135,39.10304175,47.13758474,54.73718925,0,1326,COPD,7/7/14 12:28
89,10,Almirall,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Filed,In-House,,Feb-15,N/A,May-25,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1326,COPD,7/7/14 12:28
89,10,Almirall,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Filed,In-House,,Feb-15,N/A,May-25,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,12.17361337,21.39609939,30.24959135,39.10304175,47.13758474,54.73718925,0,1326,COPD,7/7/14 12:28
89,10,Almirall,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Filed,In-House,,Feb-15,N/A,May-25,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1326,COPD,7/7/14 12:28
89,10,Almirall,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Filed,In-House,,Feb-15,N/A,May-25,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1326,COPD,7/7/14 12:28
90,42,Forest,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1326,COPD,7/7/14 12:28
90,42,Forest,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,26,43.33342,60.666788,77.999896,95.3331444,112.6663746,0,1326,COPD,7/7/14 12:28
90,42,Forest,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1326,COPD,7/7/14 12:28
90,42,Forest,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1326,COPD,7/7/14 12:28
90,42,Forest,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1326,COPD,7/7/14 12:28
90,42,Forest,Regional & Specialty Pharma,4318,formoterol + Tudorza,formoterol + aclidinium,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,26,43.33342,60.666788,77.999896,95.3331444,112.6663746,0,1326,COPD,7/7/14 12:28
93,5,Actelion,Small Biotech,2330,Opsumit,macitentan,Small Molecule (Chemical),Launched,In-House,Nov-13,Jan-14,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,Global,Sales,0,0,0,0,5.395615525,431.469503,743.9751998,964.598159,1093.400437,1232.441551,1358.003541,1488.542411,123.1896073,662,Pulmonary Hypertension,7/7/14 12:28
93,5,Actelion,Small Biotech,2330,Opsumit,macitentan,Small Molecule (Chemical),Launched,In-House,Nov-13,Jan-14,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,ROW,Sales,0,0,0,0,0,176.2472802,309.7686947,437.9478829,509.5138223,604.9752076,700.4738494,792.5080083,0,662,Pulmonary Hypertension,7/7/14 12:28
93,5,Actelion,Small Biotech,2330,Opsumit,macitentan,Small Molecule (Chemical),Launched,In-House,Nov-13,Jan-14,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,US,Sales,0,0,0,0,5.395615525,255.2222228,434.206505,526.6502761,583.8866151,627.4663435,657.5296915,696.0344027,100.2223315,662,Pulmonary Hypertension,7/7/14 12:28
94,29,Chugai,Regional & Specialty Pharma,1587,Actemra / RoActemra,tocilizumab,Antibody/Antibody Derivative,Launched,In-House,,Jun-05,N/A,Jan-18,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,Global,Alliance Revenue,89.77260279,160.6730797,224.0896822,214.232022,209.078875,226.899492,240.8898804,256.1744371,268.4972517,276.7978393,279.0241994,283.255886,4.433150424,1665,Rheumatoid Arthritis,7/7/14 12:28
94,29,Chugai,Regional & Specialty Pharma,1587,Actemra / RoActemra,tocilizumab,Antibody/Antibody Derivative,Launched,In-House,,Jun-05,N/A,Jan-18,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,ROW,Alliance Revenue,89.77260279,160.6730797,224.0896822,214.232022,209.078875,226.899492,240.8898804,256.1744371,268.4972517,276.7978393,279.0241994,283.255886,4.433150424,1665,Rheumatoid Arthritis,7/7/14 12:28
94,29,Chugai,Regional & Specialty Pharma,1587,Actemra / RoActemra,tocilizumab,Antibody/Antibody Derivative,Launched,In-House,,Jun-05,N/A,Jan-18,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1665,Rheumatoid Arthritis,7/7/14 12:28
95,86,Roche,Large Pharma,1587,Actemra / RoActemra,tocilizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Jan-10,Mar-09,Jun-22,Jan-19,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1665,Rheumatoid Arthritis,7/7/14 12:28
95,86,Roche,Large Pharma,1587,Actemra / RoActemra,tocilizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Jan-10,Jun-05,Jun-22,Jan-18,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,Global,Sales,133.9708195,381.2509137,700.8926421,897.8517226,1115.542283,1289.527864,1438.835706,1548.128726,1637.022193,1712.629345,1769.860431,1819.348875,7.237604833,1665,Rheumatoid Arthritis,7/7/14 12:28
95,86,Roche,Large Pharma,1587,Actemra / RoActemra,tocilizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Jan-10,Mar-09,Jun-22,Jan-19,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1665,Rheumatoid Arthritis,7/7/14 12:28
95,86,Roche,Large Pharma,1587,Actemra / RoActemra,tocilizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Jan-10,Jun-05,Jun-22,Jan-18,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,ROW,Sales,133.9708195,325.6269381,541.7207402,640.827779,776.6976282,878.9704194,963.4755676,1027.464273,1076.92288,1114.941491,1139.602501,1160.598206,5.905504767,1665,Rheumatoid Arthritis,7/7/14 12:28
95,86,Roche,Large Pharma,1587,Actemra / RoActemra,tocilizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Jan-10,Mar-09,Jun-22,Jan-19,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1665,Rheumatoid Arthritis,7/7/14 12:28
95,86,Roche,Large Pharma,1587,Actemra / RoActemra,tocilizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Jan-10,Mar-09,Jun-22,Jan-19,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,US,Sales,0,55.62397553,159.1719019,257.0239436,338.844655,410.5574446,475.3601381,520.6644527,560.0993134,597.6878535,630.2579292,658.7506687,9.962785976,1665,Rheumatoid Arthritis,7/7/14 12:28
96,23,Boehringer Ingelheim,Large Pharma,1011,Actilyse,alteplase,Recombinant Protein,Launched,Licensed (Development),,Oct-87,N/A,Expired,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,69,Thrombosis,7/7/14 12:28
96,23,Boehringer Ingelheim,Large Pharma,1011,Actilyse,alteplase,Recombinant Protein,Launched,Licensed (Development),,Oct-87,N/A,Expired,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,Global,Sales,120.886361,123.2260113,135.3134525,131.0976753,139.443157,142.9879966,145.8941483,148.3212598,150.3395954,152.0196681,153.4178482,154.5814952,1.483239415,69,Thrombosis,7/7/14 12:28
96,23,Boehringer Ingelheim,Large Pharma,1011,Actilyse,alteplase,Recombinant Protein,Launched,Licensed (Development),,Oct-87,N/A,Expired,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,69,Thrombosis,7/7/14 12:28
96,23,Boehringer Ingelheim,Large Pharma,1011,Actilyse,alteplase,Recombinant Protein,Launched,Licensed (Development),,Oct-87,N/A,Expired,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,ROW,Sales,120.886361,123.2260113,135.3134525,131.0976753,139.443157,142.9879966,145.8941483,148.3212598,150.3395954,152.0196681,153.4178482,154.5814952,1.483239415,69,Thrombosis,7/7/14 12:28
96,23,Boehringer Ingelheim,Large Pharma,1011,Actilyse,alteplase,Recombinant Protein,Launched,Licensed (Development),,Oct-87,N/A,Expired,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,69,Thrombosis,7/7/14 12:28
96,23,Boehringer Ingelheim,Large Pharma,1011,Actilyse,alteplase,Recombinant Protein,Launched,Licensed (Development),,Oct-87,N/A,Expired,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,69,Thrombosis,7/7/14 12:28
97,102,Cephalon,Regional & Specialty Pharma,1076,Actiq,fentanyl - transmucosal,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-99,Jan-01,Sep-06,Aug-09,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Proforma,146.9,130.9,83.25,0,0,0,0,0,0,0,0,0,0,70,Cancer Pain,7/7/14 12:28
97,102,Cephalon,Regional & Specialty Pharma,1076,Actiq,fentanyl - transmucosal,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-99,Jan-01,Sep-06,Aug-09,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Proforma,71.5,67,42.75,0,0,0,0,0,0,0,0,0,0,70,Cancer Pain,7/7/14 12:28
97,102,Cephalon,Regional & Specialty Pharma,1076,Actiq,fentanyl - transmucosal,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-99,Jan-01,Sep-06,Aug-09,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Proforma,75.4,63.9,40.5,0,0,0,0,0,0,0,0,0,0,70,Cancer Pain,7/7/14 12:28
97,102,Teva,Regional & Specialty Pharma,1076,Actiq,fentanyl - transmucosal,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-99,Jan-01,Sep-06,Aug-09,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,70,Cancer Pain,7/7/14 12:28
97,102,Teva,Regional & Specialty Pharma,1076,Actiq,fentanyl - transmucosal,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-99,Jan-01,Sep-06,Aug-09,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,3.00E-02,-2.00E-02,27.62058,94.360073,80.72414205,69.45200074,60.12540063,52.40156654,45.99932836,40.68784254,36.27741291,32.61201438,-12.14473415,70,Cancer Pain,7/7/14 12:28
97,102,Teva,Regional & Specialty Pharma,1076,Actiq,fentanyl - transmucosal,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-99,Jan-01,Sep-06,Aug-09,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,70,Cancer Pain,7/7/14 12:28
97,102,Teva,Regional & Specialty Pharma,1076,Actiq,fentanyl - transmucosal,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-99,Jan-01,Sep-06,Aug-09,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,3.00E-02,-5.00E-02,14.25,49.04,42.672,37.5776,33.50208,30.241664,27.6333312,25.54666496,23.87733197,22.54186557,-8.713462733,70,Cancer Pain,7/7/14 12:28
97,102,Teva,Regional & Specialty Pharma,1076,Actiq,fentanyl - transmucosal,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-99,Jan-01,Sep-06,Aug-09,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,70,Cancer Pain,7/7/14 12:28
97,102,Teva,Regional & Specialty Pharma,1076,Actiq,fentanyl - transmucosal,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-99,Jan-01,Sep-06,Aug-09,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,3.00E-02,13.37058,45.320073,38.05214205,31.87440074,26.62332063,22.15990254,18.36599716,15.14117758,12.40008095,10.0701488,-17.29676847,70,Cancer Pain,7/7/14 12:28
98,86,Roche,Large Pharma,1182,Activase / TNKase,alteplase / tenecteplase,Recombinant Protein,Launched,Corporate Acquisition,Jul-87,Dec-87,Expired,Expired,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,71,Thrombosis,7/7/14 12:28
98,86,Roche,Large Pharma,1182,Activase / TNKase,alteplase / tenecteplase,Recombinant Protein,Launched,Corporate Acquisition,Jul-87,Dec-87,Expired,Expired,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,5,Global,Sales,418.9622627,439.2375999,510.2371251,622.8298052,737.0410807,780.2437742,817.8273388,842.078469,856.8988624,867.2488338,874.0565602,878.58808,2.541360791,71,Thrombosis,7/7/14 12:28
98,86,Roche,Large Pharma,1182,Activase / TNKase,alteplase / tenecteplase,Recombinant Protein,Launched,Corporate Acquisition,Jul-87,Dec-87,Expired,Expired,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,71,Thrombosis,7/7/14 12:28
98,86,Roche,Large Pharma,1182,Activase / TNKase,alteplase / tenecteplase,Recombinant Protein,Launched,Corporate Acquisition,Jul-87,Dec-87,Expired,Expired,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,5,ROW,Sales,40.515032,41.23846462,46.18040205,52.25798023,51.79790904,53.09285677,54.73312389,55.5273585,56.44590809,57.26638697,57.94210796,58.55627923,1.767414643,71,Thrombosis,7/7/14 12:28
98,86,Roche,Large Pharma,1182,Activase / TNKase,alteplase / tenecteplase,Recombinant Protein,Launched,Corporate Acquisition,Jul-87,Dec-87,Expired,Expired,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,71,Thrombosis,7/7/14 12:28
98,86,Roche,Large Pharma,1182,Activase / TNKase,alteplase / tenecteplase,Recombinant Protein,Launched,Corporate Acquisition,Jul-87,Dec-87,Expired,Expired,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,5,US,Sales,378.4472307,397.9991353,464.056723,570.5718249,685.2431716,727.1509174,763.0942149,786.5511105,800.4529543,809.9824469,816.1144522,820.0318008,2.598460188,71,Thrombosis,7/7/14 12:28
99,37,Eisai,Regional & Specialty Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Licensed (Development),,May-02,N/A,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
99,37,Eisai,Regional & Specialty Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Licensed (Development),,May-02,N/A,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,122.9337334,140.3449549,139.2782643,109.5525401,84.21916374,76.17095656,69.12267707,63.93006048,59.50575697,55.88004214,52.95497188,50.55039469,-7.032629032,1618,Osteoporosis,7/7/14 12:28
99,37,Eisai,Regional & Specialty Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Licensed (Development),,May-02,N/A,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
99,37,Eisai,Regional & Specialty Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Licensed (Development),,May-02,N/A,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,122.9337334,140.3449549,139.2782643,109.5525401,84.21916374,76.17095656,69.12267707,63.93006048,59.50575697,55.88004214,52.95497188,50.55039469,-7.032629032,1618,Osteoporosis,7/7/14 12:28
99,37,Eisai,Regional & Specialty Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Licensed (Development),,May-02,N/A,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
99,37,Eisai,Regional & Specialty Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Licensed (Development),,May-02,N/A,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
100,111,Actavis,Regional & Specialty Pharma,4741,Actonel / Atelvia,risedronate / risedronate delayed-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,Jan-00,Jun-14,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,44,41,39,37,35,34.4,33,32,-4.447403811,1618,Osteoporosis,7/7/14 12:28
100,111,Actavis,Regional & Specialty Pharma,4741,Actonel / Atelvia,risedronate / risedronate delayed-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,Jan-00,Jun-14,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,108,313.92,209.6228,127.771252,98.48478068,93.85932538,90.88811393,86.4,-3.13748832,1618,Osteoporosis,7/7/14 12:28
100,111,Actavis,Regional & Specialty Pharma,4741,Actonel / Atelvia,risedronate / risedronate delayed-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,Jan-00,Jun-14,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,44,41,39,37,35,34.4,33,32,-4.447403811,1618,Osteoporosis,7/7/14 12:28
100,111,Actavis,Regional & Specialty Pharma,4741,Actonel / Atelvia,risedronate / risedronate delayed-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,Jan-00,Jun-14,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,28,78.92,59.6228,47.771252,40.88478068,36.65932538,34.08811393,30,0.990484611,1618,Osteoporosis,7/7/14 12:28
100,111,Actavis,Regional & Specialty Pharma,4741,Actonel / Atelvia,risedronate / risedronate delayed-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,Jan-00,Jun-14,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
100,111,Actavis,Regional & Specialty Pharma,4741,Actonel / Atelvia,risedronate / risedronate delayed-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,Jan-00,Jun-14,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,80,235,150,80,57.6,57.2,56.8,56.4,-4.871039157,1618,Osteoporosis,7/7/14 12:28
100,111,Warner Chilcott ,Regional & Specialty Pharma,4741,Actonel / Atelvia,risedronate / risedronate delayed-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,Jan-00,Jun-14,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Proforma,1094,939,727,535,322,0,0,0,0,0,0,0,-100,1618,Osteoporosis,7/7/14 12:28
100,111,Warner Chilcott ,Regional & Specialty Pharma,4741,Actonel / Atelvia,risedronate / risedronate delayed-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,Jan-00,Jun-14,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Proforma,388,392,253,165,82,0,0,0,0,0,0,0,-100,1618,Osteoporosis,7/7/14 12:28
100,111,Warner Chilcott ,Regional & Specialty Pharma,4741,Actonel / Atelvia,risedronate / risedronate delayed-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,Jan-00,Jun-14,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Proforma,706,547,474,370,240,0,0,0,0,0,0,0,-100,1618,Osteoporosis,7/7/14 12:28
101,89,Sanofi,Large Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,May-00,N/A,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
101,89,Sanofi,Large Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,May-00,N/A,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,2,Global,Sales,366.8275783,315.2916448,232.2029853,171.6933722,132.8030067,102.8434659,82.3638838,66.88242094,55.95033812,48.13681994,42.48134786,38.43433343,-16.23296556,1618,Osteoporosis,7/7/14 12:28
101,89,Sanofi,Large Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,May-00,N/A,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
101,89,Sanofi,Large Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,May-00,N/A,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,2,ROW,Sales,366.8275783,315.2916448,232.2029853,171.6933722,132.8030067,102.8434659,82.3638838,66.88242094,55.95033812,48.13681994,42.48134786,38.43433343,-16.23296556,1618,Osteoporosis,7/7/14 12:28
101,89,Sanofi,Large Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,May-00,N/A,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
101,89,Sanofi,Large Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-98,May-00,N/A,Dec-10,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
102,39,Eli Lilly,Large Pharma,1402,Actos,pioglitazone,Small Molecule (Chemical),Launched,Licensed (Development),Aug-99,Dec-99,Aug-12,Apr-12,48,PPAR Modulators,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,36.7,0,0,0,0,0,0,0,0,0,0,0,0,1590,Type II Diabetes,7/7/14 12:28
102,39,Eli Lilly,Large Pharma,1402,Actos,pioglitazone,Small Molecule (Chemical),Launched,Licensed (Development),Aug-99,Dec-99,Aug-12,Apr-12,48,PPAR Modulators,22,Diabetes,8,Metabolism,6,Global,Sales,170.9,189.5,180,90,57,43.38,32.967,28.19925,25.7297175,24.30541012,23.58344109,23.19878613,-12.05173901,1590,Type II Diabetes,7/7/14 12:28
102,39,Eli Lilly,Large Pharma,1402,Actos,pioglitazone,Small Molecule (Chemical),Launched,Licensed (Development),Aug-99,Dec-99,Aug-12,Apr-12,48,PPAR Modulators,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1590,Type II Diabetes,7/7/14 12:28
102,39,Eli Lilly,Large Pharma,1402,Actos,pioglitazone,Small Molecule (Chemical),Launched,Licensed (Development),Aug-99,Dec-99,Aug-12,Apr-12,48,PPAR Modulators,22,Diabetes,8,Metabolism,6,ROW,Sales,170.9,189.5,180,90,57,43.38,32.967,28.19925,25.7297175,24.30541012,23.58344109,23.19878613,-12.05173901,1590,Type II Diabetes,7/7/14 12:28
102,39,Eli Lilly,Large Pharma,1402,Actos,pioglitazone,Small Molecule (Chemical),Launched,Licensed (Development),Aug-99,Dec-99,Aug-12,Apr-12,48,PPAR Modulators,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,36.7,0,0,0,0,0,0,0,0,0,0,0,0,1590,Type II Diabetes,7/7/14 12:28
102,39,Eli Lilly,Large Pharma,1402,Actos,pioglitazone,Small Molecule (Chemical),Launched,Licensed (Development),Aug-99,Dec-99,Aug-12,Apr-12,48,PPAR Modulators,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1590,Type II Diabetes,7/7/14 12:28
103,100,Takeda,Large Pharma,1402,Actos,pioglitazone,Small Molecule (Chemical),Launched,In-House,Aug-99,Dec-99,Aug-12,Apr-12,48,PPAR Modulators,22,Diabetes,8,Metabolism,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1590,Type II Diabetes,7/7/14 12:28
103,100,Takeda,Large Pharma,1402,Actos,pioglitazone,Small Molecule (Chemical),Launched,In-House,Aug-99,Dec-99,Aug-12,Apr-12,48,PPAR Modulators,22,Diabetes,8,Metabolism,7,Global,Sales,4144.473004,4527.892236,3751.555461,1480.765102,385.593762,242.0989788,172.8718379,141.7822261,116.7813459,105.1205915,97.8556249,88.2925514,-18.98935293,1590,Type II Diabetes,7/7/14 12:28
103,100,Takeda,Large Pharma,1402,Actos,pioglitazone,Small Molecule (Chemical),Launched,In-House,Aug-99,Dec-99,Aug-12,Apr-12,48,PPAR Modulators,22,Diabetes,8,Metabolism,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1590,Type II Diabetes,7/7/14 12:28
103,100,Takeda,Large Pharma,1402,Actos,pioglitazone,Small Molecule (Chemical),Launched,In-House,Aug-99,Dec-99,Aug-12,Apr-12,48,PPAR Modulators,22,Diabetes,8,Metabolism,7,ROW,Sales,1149.506809,1317.862938,811.5179189,445.4334047,309.0790729,197.5980574,146.449226,121.1180587,97.1108466,85.65870611,78.44627527,73.19096803,-18.59952656,1590,Type II Diabetes,7/7/14 12:28
103,100,Takeda,Large Pharma,1402,Actos,pioglitazone,Small Molecule (Chemical),Launched,In-House,Aug-99,Dec-99,Aug-12,Apr-12,48,PPAR Modulators,22,Diabetes,8,Metabolism,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1590,Type II Diabetes,7/7/14 12:28
103,100,Takeda,Large Pharma,1402,Actos,pioglitazone,Small Molecule (Chemical),Launched,In-House,Aug-99,Dec-99,Aug-12,Apr-12,48,PPAR Modulators,22,Diabetes,8,Metabolism,7,US,Sales,2994.966194,3210.029299,2940.037542,1035.331697,76.51468906,44.50092141,26.42261194,20.66416739,19.67049933,19.46188544,19.40934962,15.10158337,-20.69045074,1590,Type II Diabetes,7/7/14 12:28
105,19,Bayer,Large Pharma,605,Adalat,nifedipine,Small Molecule (Chemical),Launched,In-House,Jan-72,Jan-75,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,75,Hypertension,7/7/14 12:28
105,19,Bayer,Large Pharma,605,Adalat,nifedipine,Small Molecule (Chemical),Launched,In-House,Jan-72,Jan-75,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,879.5524889,879.5939636,889.879704,861.1317885,800.8021302,729.2295881,705.0566886,693.5944922,686.9844905,683.5789076,681.783842,678.598505,-2.337728426,75,Hypertension,7/7/14 12:28
105,19,Bayer,Large Pharma,605,Adalat,nifedipine,Small Molecule (Chemical),Launched,In-House,Jan-72,Jan-75,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,75,Hypertension,7/7/14 12:28
105,19,Bayer,Large Pharma,605,Adalat,nifedipine,Small Molecule (Chemical),Launched,In-House,Jan-72,Jan-75,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,873.9944953,874.3381746,885.7083929,858.5612459,795.4900099,727.1056137,703.0399985,690.9384321,684.4159628,680.9787328,679.1543078,675.9673039,-2.299065288,75,Hypertension,7/7/14 12:28
105,19,Bayer,Large Pharma,605,Adalat,nifedipine,Small Molecule (Chemical),Launched,In-House,Jan-72,Jan-75,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,75,Hypertension,7/7/14 12:28
105,19,Bayer,Large Pharma,605,Adalat,nifedipine,Small Molecule (Chemical),Launched,In-House,Jan-72,Jan-75,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,5.557993611,5.255789033,4.171311113,2.570542652,5.312120266,2.123974388,2.016690075,2.656060133,2.568527773,2.600174767,2.629534217,2.631201055,-9.549213264,75,Hypertension,7/7/14 12:28
106,96,Shire,Regional & Specialty Pharma,620,Adderall XR,amphetamine salts,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Feb-04,Apr-09,Oct-19,121,Stimulants,37,ADHD,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,76,ADHD,7/7/14 12:28
106,96,Shire,Regional & Specialty Pharma,620,Adderall XR,amphetamine salts,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Feb-04,Apr-09,Oct-19,121,Stimulants,37,ADHD,12,Central Nervous System,6,Global,Sales,626.86,360.502,532.78,429,375,336.318,309.87648,291.6000288,279.0257993,270.3792049,248.2346012,172.791286,-10.47851614,76,ADHD,7/7/14 12:28
106,96,Shire,Regional & Specialty Pharma,620,Adderall XR,amphetamine salts,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Feb-04,Apr-09,Oct-19,121,Stimulants,37,ADHD,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,76,ADHD,7/7/14 12:28
106,96,Shire,Regional & Specialty Pharma,620,Adderall XR,amphetamine salts,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Feb-04,Apr-09,Oct-19,121,Stimulants,37,ADHD,12,Central Nervous System,6,ROW,Sales,42.36,51.702,79.9,85.8,98,105.658,111.65448,116.0846288,119.4050193,121.8846589,107.528419,37.53695843,-12.81095571,76,ADHD,7/7/14 12:28
106,96,Shire,Regional & Specialty Pharma,620,Adderall XR,amphetamine salts,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Feb-04,Apr-09,Oct-19,121,Stimulants,37,ADHD,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,76,ADHD,7/7/14 12:28
106,96,Shire,Regional & Specialty Pharma,620,Adderall XR,amphetamine salts,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Feb-04,Apr-09,Oct-19,121,Stimulants,37,ADHD,12,Central Nervous System,6,US,Sales,584.5,308.8,452.88,343.2,277,230.66,198.222,175.5154,159.62078,148.494546,140.7061822,135.2543275,-9.733930899,76,ADHD,7/7/14 12:28
109,46,GlaxoSmithKline,Large Pharma,4667,Advair / Seretide,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Apr-01,Feb-99,Jul-15,Jan-14,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1627,Asthma,7/7/14 12:28
109,46,GlaxoSmithKline,Large Pharma,4667,Advair / Seretide,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Apr-01,Feb-99,Jul-15,Jan-14,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,Global,Sales,7760.445429,7939.755298,8113.697576,7998.055698,7796.745758,7095.496095,6362.713903,5671.039643,4970.062465,4655.42973,4345.058599,4213.857681,-8.415111166,1627,Asthma,7/7/14 12:28
109,46,GlaxoSmithKline,Large Pharma,4667,Advair / Seretide,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Apr-01,Feb-99,Jul-15,Jan-14,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1627,Asthma,7/7/14 12:28
109,46,GlaxoSmithKline,Large Pharma,4667,Advair / Seretide,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Apr-01,Feb-99,Jul-15,Jan-14,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,3718.83913,3916.575147,4145.825317,3983.17756,3916.35214,3565.494829,3113.416903,2809.94367,2433.169942,2251.268134,2072.174572,1997.374636,-9.170810009,1627,Asthma,7/7/14 12:28
109,46,GlaxoSmithKline,Large Pharma,4667,Advair / Seretide,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Apr-01,Feb-99,Jul-15,Jan-14,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1627,Asthma,7/7/14 12:28
109,46,GlaxoSmithKline,Large Pharma,4667,Advair / Seretide,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Apr-01,Feb-99,Jul-15,Jan-14,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,US,Sales,4041.606299,4023.180151,3967.872259,4014.878138,3880.393618,3530.001266,3249.297,2861.095973,2536.892523,2404.161596,2272.884027,2216.483045,-7.688554078,1627,Asthma,7/7/14 12:28
110,18,Baxter Healthcare,Regional & Specialty Pharma,132,Advate,octocog alfa,Recombinant Protein,Launched,In-House,Jul-03,Apr-04,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,1710,1790.7,1880.2,1928,2125,2148.488793,2140.706306,2095.327769,2053.99868,2011.849087,1996.036991,1990.079678,-0.932723743,1731,Hemophilia A,7/7/14 12:28
110,18,Baxter Healthcare,Regional & Specialty Pharma,132,Advate,octocog alfa,Recombinant Protein,Launched,In-House,Jul-03,Apr-04,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,890,917.2,940.1,960,1015,1033.635,1026.29325,1016.866987,998.1149281,980.6443472,973.8120347,971.836615,-0.618879137,1731,Hemophilia A,7/7/14 12:28
110,18,Baxter Healthcare,Regional & Specialty Pharma,132,Advate,octocog alfa,Recombinant Protein,Launched,In-House,Jul-03,Apr-04,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,820,873.5,940.1,968,1110,1114.853793,1114.413056,1078.460782,1055.883752,1031.20474,1022.224957,1018.243063,-1.225024354,1731,Hemophilia A,7/7/14 12:28
111,2221,AbbVie,Large Pharma,483,Advicor,Extended-release niacin  +  lovastatin,Small Molecule (Chemical),Launched,In-House,Jan-02,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1562,Dyslipidemia,7/7/14 12:28
111,2221,AbbVie,Large Pharma,483,Advicor,Extended-release niacin  +  lovastatin,Small Molecule (Chemical),Launched,In-House,Jan-02,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,10,9,8,8,7.75,7.5875,7.509375,7.44046875,-4.135634171,1562,Dyslipidemia,7/7/14 12:28
111,2221,AbbVie,Large Pharma,483,Advicor,Extended-release niacin  +  lovastatin,Small Molecule (Chemical),Launched,In-House,Jan-02,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1562,Dyslipidemia,7/7/14 12:28
111,2221,AbbVie,Large Pharma,483,Advicor,Extended-release niacin  +  lovastatin,Small Molecule (Chemical),Launched,In-House,Jan-02,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1562,Dyslipidemia,7/7/14 12:28
111,2221,AbbVie,Large Pharma,483,Advicor,Extended-release niacin  +  lovastatin,Small Molecule (Chemical),Launched,In-House,Jan-02,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1562,Dyslipidemia,7/7/14 12:28
111,2221,AbbVie,Large Pharma,483,Advicor,Extended-release niacin  +  lovastatin,Small Molecule (Chemical),Launched,In-House,Jan-02,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,10,9,8,8,7.75,7.5875,7.509375,7.44046875,-4.135634171,1562,Dyslipidemia,7/7/14 12:28
113,67,Novartis,Large Pharma,3795,Afinitor / Votubia,everolimus,Small Molecule (Chemical),Launched,In-House,Apr-09,Oct-09,Mar-20,Jul-18,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1457,Renal Cell Carcinoma,7/7/14 12:28
113,67,Novartis,Large Pharma,3795,Afinitor / Votubia,everolimus,Small Molecule (Chemical),Launched,In-House,Apr-09,Oct-09,Mar-20,Jul-18,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,69.8,243,443,797,1309,1652.779655,1955.891625,2194.095053,2309.591139,2016.992555,2138.108425,2133.166035,7.225437961,1457,Renal Cell Carcinoma,7/7/14 12:28
113,67,Novartis,Large Pharma,3795,Afinitor / Votubia,everolimus,Small Molecule (Chemical),Launched,In-House,Apr-09,Oct-09,Mar-20,Jul-18,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1457,Renal Cell Carcinoma,7/7/14 12:28
113,67,Novartis,Large Pharma,3795,Afinitor / Votubia,everolimus,Small Molecule (Chemical),Launched,In-House,Apr-09,Oct-09,Mar-20,Jul-18,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,9.8,162,270,385,618,772.965,910.903625,1020.761853,1076.782139,655.8313188,655.2544507,575.0543154,-1.023637481,1457,Renal Cell Carcinoma,7/7/14 12:28
113,67,Novartis,Large Pharma,3795,Afinitor / Votubia,everolimus,Small Molecule (Chemical),Launched,In-House,Apr-09,Oct-09,Mar-20,Jul-18,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1457,Renal Cell Carcinoma,7/7/14 12:28
113,67,Novartis,Large Pharma,3795,Afinitor / Votubia,everolimus,Small Molecule (Chemical),Launched,In-House,Apr-09,Oct-09,Mar-20,Jul-18,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,60,81,173,412,691,879.8146548,1044.988,1173.3332,1232.809,1361.161236,1482.853975,1558.11172,12.3170639,1457,Renal Cell Carcinoma,7/7/14 12:28
115,67,Novartis,Large Pharma,725,AFQ056,mavoglurant,Small Molecule (Chemical),Phase III,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,79,Fragile X Syndrome,7/7/14 12:28
115,67,Novartis,Large Pharma,725,AFQ056,mavoglurant,Small Molecule (Chemical),Phase III,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,79,Fragile X Syndrome,7/7/14 12:28
115,67,Novartis,Large Pharma,725,AFQ056,mavoglurant,Small Molecule (Chemical),Phase III,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,79,Fragile X Syndrome,7/7/14 12:28
115,67,Novartis,Large Pharma,725,AFQ056,mavoglurant,Small Molecule (Chemical),Phase III,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,79,Fragile X Syndrome,7/7/14 12:28
115,67,Novartis,Large Pharma,725,AFQ056,mavoglurant,Small Molecule (Chemical),Phase III,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,79,Fragile X Syndrome,7/7/14 12:28
115,67,Novartis,Large Pharma,725,AFQ056,mavoglurant,Small Molecule (Chemical),Phase III,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,79,Fragile X Syndrome,7/7/14 12:28
116,29,Chugai,Regional & Specialty Pharma,2402,Gazyva / Gazyvaro,obinutuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Jul-17,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,15.37344669,56.36935579,107.6141734,158.8589667,0,1329,Non-Hodgkin's Lymphoma,7/7/14 12:28
116,29,Chugai,Regional & Specialty Pharma,2402,Gazyva / Gazyvaro,obinutuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Jul-17,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,15.37344669,56.36935579,107.6141734,158.8589667,0,1329,Non-Hodgkin's Lymphoma,7/7/14 12:28
116,29,Chugai,Regional & Specialty Pharma,2402,Gazyva / Gazyvaro,obinutuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Jul-17,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1329,Non-Hodgkin's Lymphoma,7/7/14 12:28
117,86,Roche,Large Pharma,2402,Gazyva / Gazyvaro,obinutuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Dec-13,Jun-14,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1329,Non-Hodgkin's Lymphoma,7/7/14 12:28
117,86,Roche,Large Pharma,2402,Gazyva / Gazyvaro,obinutuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Dec-13,Jun-14,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,3.237369315,161.8147761,272.6496544,510.1607342,714.0390253,849.1186237,937.0417419,1019.383724,127.445613,1329,Non-Hodgkin's Lymphoma,7/7/14 12:28
117,86,Roche,Large Pharma,2402,Gazyva / Gazyvaro,obinutuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Dec-13,Jun-14,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1329,Non-Hodgkin's Lymphoma,7/7/14 12:28
117,86,Roche,Large Pharma,2402,Gazyva / Gazyvaro,obinutuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Dec-13,Jun-14,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,49.72956134,118.4035991,207.6473811,313.7409556,410.1522978,487.2874675,560.6742272,0,1329,Non-Hodgkin's Lymphoma,7/7/14 12:28
117,86,Roche,Large Pharma,2402,Gazyva / Gazyvaro,obinutuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Dec-13,Jun-14,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1329,Non-Hodgkin's Lymphoma,7/7/14 12:28
117,86,Roche,Large Pharma,2402,Gazyva / Gazyvaro,obinutuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Dec-13,Jun-14,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,3.237369315,112.0852148,154.2460553,302.513353,400.2980698,438.9663259,449.7542744,458.709497,102.9246297,1329,Non-Hodgkin's Lymphoma,7/7/14 12:28
119,23,Boehringer Ingelheim,Large Pharma,2329,Aggrenox,dipyridamole + aspirin,Small Molecule (Chemical),Launched,In-House,Jan-59,Jan-59,Jul-15,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,83,Thrombosis,7/7/14 12:28
119,23,Boehringer Ingelheim,Large Pharma,2329,Aggrenox,dipyridamole + aspirin,Small Molecule (Chemical),Launched,In-House,Jan-59,Jan-59,Jul-15,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,Global,Sales,482.1559457,462.3376799,502.123187,411.2868244,362.666172,315.9992884,211.8050671,95.84101503,73.2429261,57.494488,45.83003832,35.95009309,-28.12147785,83,Thrombosis,7/7/14 12:28
119,23,Boehringer Ingelheim,Large Pharma,2329,Aggrenox,dipyridamole + aspirin,Small Molecule (Chemical),Launched,In-House,Jan-59,Jan-59,Jul-15,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,83,Thrombosis,7/7/14 12:28
119,23,Boehringer Ingelheim,Large Pharma,2329,Aggrenox,dipyridamole + aspirin,Small Molecule (Chemical),Launched,In-House,Jan-59,Jan-59,Jul-15,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,ROW,Sales,187.5822844,172.2181253,186.8458615,152.9472879,127.4908864,103.0551332,83.50653059,67.86764852,55.35654287,45.34765835,37.34055073,30.93486464,-18.31571202,83,Thrombosis,7/7/14 12:28
119,23,Boehringer Ingelheim,Large Pharma,2329,Aggrenox,dipyridamole + aspirin,Small Molecule (Chemical),Launched,In-House,Jan-59,Jan-59,Jul-15,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,83,Thrombosis,7/7/14 12:28
119,23,Boehringer Ingelheim,Large Pharma,2329,Aggrenox,dipyridamole + aspirin,Small Molecule (Chemical),Launched,In-House,Jan-59,Jan-59,Jul-15,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,US,Sales,294.5736614,290.1195546,315.2773256,258.3395366,235.1752856,212.9441552,128.2985365,27.9733665,17.88638323,12.14682965,8.48948759,5.015228446,-42.28728172,83,Thrombosis,7/7/14 12:28
122,96,Shire,Regional & Specialty Pharma,1914,Xagrid,anagrelide,Small Molecule (Chemical),Launched,Acquisition (Marketed),May-97,Jun-97,Expired,Nov-14,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1345,Thrombocythemia ,7/7/14 12:28
122,96,Shire,Regional & Specialty Pharma,1914,Xagrid,anagrelide,Small Molecule (Chemical),Launched,Acquisition (Marketed),May-97,Jun-97,Expired,Nov-14,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,Global,Sales,84.36505,87,90.6,97.2,99.4,96.49848,51.35712,41.902224,35.581208,30.71124864,26.85379361,23.98426007,-18.38095512,1345,Thrombocythemia ,7/7/14 12:28
122,96,Shire,Regional & Specialty Pharma,1914,Xagrid,anagrelide,Small Molecule (Chemical),Launched,Acquisition (Marketed),May-97,Jun-97,Expired,Nov-14,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1345,Thrombocythemia ,7/7/14 12:28
122,96,Shire,Regional & Specialty Pharma,1914,Xagrid,anagrelide,Small Molecule (Chemical),Launched,Acquisition (Marketed),May-97,Jun-97,Expired,Nov-14,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,ROW,Sales,81.8,87,90.6,97.2,99.4,96.49848,51.35712,41.902224,35.581208,30.71124864,26.85379361,23.98426007,-18.38095512,1345,Thrombocythemia ,7/7/14 12:28
122,96,Shire,Regional & Specialty Pharma,1914,Xagrid,anagrelide,Small Molecule (Chemical),Launched,Acquisition (Marketed),May-97,Jun-97,Expired,Nov-14,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1345,Thrombocythemia ,7/7/14 12:28
122,96,Shire,Regional & Specialty Pharma,1914,Xagrid,anagrelide,Small Molecule (Chemical),Launched,Acquisition (Marketed),May-97,Jun-97,Expired,Nov-14,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,US,Sales,2.56505,0,0,0,0,0,0,0,0,0,0,0,0,1345,Thrombocythemia ,7/7/14 12:28
126,67,Novartis,Large Pharma,4220,secukinumab,AIN457,Antibody/Antibody Derivative,Filed,In-House,Oct-14,Oct-14,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1346,Psoriasis,7/7/14 12:28
126,67,Novartis,Large Pharma,4220,secukinumab,AIN457,Antibody/Antibody Derivative,Filed,In-House,Oct-14,Oct-14,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,20,113.3334,246.6667451,379.9999875,473.999966,559.2499393,632.3686608,0,1346,Psoriasis,7/7/14 12:28
126,67,Novartis,Large Pharma,4220,secukinumab,AIN457,Antibody/Antibody Derivative,Filed,In-House,Oct-14,Oct-14,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1346,Psoriasis,7/7/14 12:28
126,67,Novartis,Large Pharma,4220,secukinumab,AIN457,Antibody/Antibody Derivative,Filed,In-House,Oct-14,Oct-14,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,7.5,42.500025,92.50002941,142.4999953,177.7499873,209.7187272,237.1382478,0,1346,Psoriasis,7/7/14 12:28
126,67,Novartis,Large Pharma,4220,secukinumab,AIN457,Antibody/Antibody Derivative,Filed,In-House,Oct-14,Oct-14,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1346,Psoriasis,7/7/14 12:28
126,67,Novartis,Large Pharma,4220,secukinumab,AIN457,Antibody/Antibody Derivative,Filed,In-House,Oct-14,Oct-14,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,12.5,70.833375,154.1667157,237.4999922,296.2499788,349.5312121,395.230413,0,1346,Psoriasis,7/7/14 12:28
128,10,Almirall,Regional & Specialty Pharma,1230,Airtal,aceclofenac,Small Molecule (Chemical),Launched,In-House,,Jan-92,N/A,Jan-06,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,89,Pain,7/7/14 12:28
128,10,Almirall,Regional & Specialty Pharma,1230,Airtal,aceclofenac,Small Molecule (Chemical),Launched,In-House,,Jan-92,N/A,Jan-06,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,Global,Sales,59.88738115,51.79791307,42.82546076,37.14434133,38.51287193,34.90328621,32.95841274,31.31952696,29.2298241,27.50991607,25.88403025,24.27011642,-6.383519943,89,Pain,7/7/14 12:28
128,10,Almirall,Regional & Specialty Pharma,1230,Airtal,aceclofenac,Small Molecule (Chemical),Launched,In-House,,Jan-92,N/A,Jan-06,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,89,Pain,7/7/14 12:28
128,10,Almirall,Regional & Specialty Pharma,1230,Airtal,aceclofenac,Small Molecule (Chemical),Launched,In-House,,Jan-92,N/A,Jan-06,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,ROW,Sales,59.88738115,51.79791307,42.82546076,37.14434133,38.51287193,34.90328621,32.95841274,31.31952696,29.2298241,27.50991607,25.88403025,24.27011642,-6.383519943,89,Pain,7/7/14 12:28
128,10,Almirall,Regional & Specialty Pharma,1230,Airtal,aceclofenac,Small Molecule (Chemical),Launched,In-House,,Jan-92,N/A,Jan-06,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,89,Pain,7/7/14 12:28
128,10,Almirall,Regional & Specialty Pharma,1230,Airtal,aceclofenac,Small Molecule (Chemical),Launched,In-House,,Jan-92,N/A,Jan-06,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,89,Pain,7/7/14 12:28
131,89,Genzyme,Large Pharma,1306,Aldurazyme,laronidase,Recombinant Protein,Launched,Corporate Acquisition,May-03,Jun-03,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Proforma,154.2343227,166.9191061,45.88442224,0,0,0,0,0,0,0,0,0,0,1512,Hurler Syndrome,7/7/14 12:28
131,89,Genzyme,Large Pharma,1306,Aldurazyme,laronidase,Recombinant Protein,Launched,Corporate Acquisition,May-03,Jun-03,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Proforma,127.833853,139.099255,37.54180001,0,0,0,0,0,0,0,0,0,0,1512,Hurler Syndrome,7/7/14 12:28
131,89,Genzyme,Large Pharma,1306,Aldurazyme,laronidase,Recombinant Protein,Launched,Corporate Acquisition,May-03,Jun-03,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Proforma,26.40046965,27.81985101,8.342622225,0,0,0,0,0,0,0,0,0,0,1512,Hurler Syndrome,7/7/14 12:28
131,89,Sanofi,Large Pharma,1306,Aldurazyme,laronidase,Recombinant Protein,Launched,Corporate Acquisition,May-03,Jun-03,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1512,Hurler Syndrome,7/7/14 12:28
131,89,Sanofi,Large Pharma,1306,Aldurazyme,laronidase,Recombinant Protein,Launched,Corporate Acquisition,May-03,Jun-03,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Sales,0,0,141.8245778,191.5054276,211.1567806,224.118354,235.5415375,245.7156502,254.900488,263.0813455,270.4268629,276.9985313,3.953448837,1512,Hurler Syndrome,7/7/14 12:28
131,89,Sanofi,Large Pharma,1306,Aldurazyme,laronidase,Recombinant Protein,Launched,Corporate Acquisition,May-03,Jun-03,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1512,Hurler Syndrome,7/7/14 12:28
131,89,Sanofi,Large Pharma,1306,Aldurazyme,laronidase,Recombinant Protein,Launched,Corporate Acquisition,May-03,Jun-03,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Sales,0,0,116.7967112,158.0883731,172.6439087,183.0556644,191.733544,199.6070412,206.6980639,213.0003669,218.6721859,223.739346,3.773013227,1512,Hurler Syndrome,7/7/14 12:28
131,89,Sanofi,Large Pharma,1306,Aldurazyme,laronidase,Recombinant Protein,Launched,Corporate Acquisition,May-03,Jun-03,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1512,Hurler Syndrome,7/7/14 12:28
131,89,Sanofi,Large Pharma,1306,Aldurazyme,laronidase,Recombinant Protein,Launched,Corporate Acquisition,May-03,Jun-03,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Sales,0,0,25.02786668,33.41705448,38.51287193,41.06268965,43.80799341,46.10860895,48.20242408,50.08097856,51.75467703,53.25918535,4.740016745,1512,Hurler Syndrome,7/7/14 12:28
134,89,Sanofi,Large Pharma,3431,Lemtrada,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Sep-17,Oct-13,N/A,N/A,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1684,Multiple Sclerosis,7/7/14 12:28
134,89,Sanofi,Large Pharma,3431,Lemtrada,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Sep-17,Oct-13,N/A,N/A,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Sales,0,0,0,0,2.656060133,52.68881259,87.81486327,122.9408086,224.4676639,429.6389461,587.7313106,738.8254075,123.4528638,1684,Multiple Sclerosis,7/7/14 12:28
134,89,Sanofi,Large Pharma,3431,Lemtrada,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Sep-17,Oct-13,N/A,N/A,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1684,Multiple Sclerosis,7/7/14 12:28
134,89,Sanofi,Large Pharma,3431,Lemtrada,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Sep-17,Oct-13,N/A,N/A,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Sales,0,0,0,0,2.656060133,52.68881259,87.81486327,122.9408086,158.066227,186.1667894,211.457266,229.7492015,89.11079052,1684,Multiple Sclerosis,7/7/14 12:28
134,89,Sanofi,Large Pharma,3431,Lemtrada,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Sep-17,Oct-13,N/A,N/A,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1684,Multiple Sclerosis,7/7/14 12:28
134,89,Sanofi,Large Pharma,3431,Lemtrada,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Sep-17,Oct-13,N/A,N/A,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,66.40143693,243.4721567,376.2740446,509.076206,0,1684,Multiple Sclerosis,7/7/14 12:28
135,39,Eli Lilly,Large Pharma,1039,Alimta,pemetrexed,Small Molecule (Chemical),Launched,In-House,Feb-04,Apr-04,May-22,Dec-15,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,94,Non-small-cell Lung Cancer,7/7/14 12:28
135,39,Eli Lilly,Large Pharma,1039,Alimta,pemetrexed,Small Molecule (Chemical),Launched,In-House,Feb-04,Apr-04,May-22,Dec-15,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,Global,Sales,1706,2208.6,2461.1,2594.3,2703,2771.472,2767.206149,2007.407543,1845.578565,1724.89281,1665.044934,1603.054458,-7.191860762,94,Non-small-cell Lung Cancer,7/7/14 12:28
135,39,Eli Lilly,Large Pharma,1039,Alimta,pemetrexed,Small Molecule (Chemical),Launched,In-House,Feb-04,Apr-04,May-22,Dec-15,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,94,Non-small-cell Lung Cancer,7/7/14 12:28
135,39,Eli Lilly,Large Pharma,1039,Alimta,pemetrexed,Small Molecule (Chemical),Launched,In-House,Feb-04,Apr-04,May-22,Dec-15,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,ROW,Sales,890.4,1251.5,1466.5,1471.9,1493.9,1535.615,1511.864599,741.5331808,574.7652513,451.221627,389.8685969,327.0988023,-19.505642,94,Non-small-cell Lung Cancer,7/7/14 12:28
135,39,Eli Lilly,Large Pharma,1039,Alimta,pemetrexed,Small Molecule (Chemical),Launched,In-House,Feb-04,Apr-04,May-22,Dec-15,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,94,Non-small-cell Lung Cancer,7/7/14 12:28
135,39,Eli Lilly,Large Pharma,1039,Alimta,pemetrexed,Small Molecule (Chemical),Launched,In-House,Feb-04,Apr-04,May-22,Dec-15,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,US,Sales,815.6,957.1,994.6,1122.4,1209.1,1235.857,1255.34155,1265.874363,1270.813314,1273.671183,1275.176337,1275.955656,0.771807437,94,Non-small-cell Lung Cancer,7/7/14 12:28
136,89,Sanofi,Large Pharma,1269,Allegra,fexofenadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-96,Mar-97,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1465,Allergic Rhinitis,7/7/14 12:28
136,89,Sanofi,Large Pharma,1269,Allegra,fexofenadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-96,Mar-97,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,Global,Sales,1015.723332,804.1261696,806.4534818,710.7550434,539.180207,505.9794554,440.9059821,419.657501,399.73705,382.4726592,374.8763272,369.4983366,-5.255479641,1465,Allergic Rhinitis,7/7/14 12:28
136,89,Sanofi,Large Pharma,1269,Allegra,fexofenadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-96,Mar-97,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1465,Allergic Rhinitis,7/7/14 12:28
136,89,Sanofi,Large Pharma,1269,Allegra,fexofenadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-96,Mar-97,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,ROW,Sales,590.5368211,609.3872126,802.2821707,710.7550434,539.180207,505.9794554,440.9059821,419.657501,399.73705,382.4726592,374.8763272,369.4983366,-5.255479641,1465,Allergic Rhinitis,7/7/14 12:28
136,89,Sanofi,Large Pharma,1269,Allegra,fexofenadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-96,Mar-97,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1465,Allergic Rhinitis,7/7/14 12:28
136,89,Sanofi,Large Pharma,1269,Allegra,fexofenadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-96,Mar-97,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,US,Sales,425.1865112,194.7389571,4.171311113,0,0,0,0,0,0,0,0,0,0,1465,Allergic Rhinitis,7/7/14 12:28
137,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1526,Allelock,olopatadine,Small Molecule (Chemical),Launched,In-House,,Mar-01,N/A,Dec-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,96,Allergic Rhinitis,7/7/14 12:28
137,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1526,Allelock,olopatadine,Small Molecule (Chemical),Launched,In-House,,Mar-01,N/A,Dec-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,3,Global,Sales,184.8888129,305.3928039,365.0089005,374.5928339,282.8714192,252.4577971,233.5182246,221.0315153,205.7927018,193.6700345,183.1657789,174.2323959,-6.68868865,96,Allergic Rhinitis,7/7/14 12:28
137,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1526,Allelock,olopatadine,Small Molecule (Chemical),Launched,In-House,,Mar-01,N/A,Dec-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,96,Allergic Rhinitis,7/7/14 12:28
137,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1526,Allelock,olopatadine,Small Molecule (Chemical),Launched,In-House,,Mar-01,N/A,Dec-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,3,ROW,Sales,184.8888129,305.3928039,365.0089005,374.5928339,282.8714192,252.4577971,233.5182246,221.0315153,205.7927018,193.6700345,183.1657789,174.2323959,-6.68868865,96,Allergic Rhinitis,7/7/14 12:28
137,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1526,Allelock,olopatadine,Small Molecule (Chemical),Launched,In-House,,Mar-01,N/A,Dec-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,96,Allergic Rhinitis,7/7/14 12:28
137,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1526,Allelock,olopatadine,Small Molecule (Chemical),Launched,In-House,,Mar-01,N/A,Dec-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,96,Allergic Rhinitis,7/7/14 12:28
138,10,Almirall,Regional & Specialty Pharma,1249,Almogran,almotriptan,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Dec-14,117,Triptans,8,Migraine,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1337,Migraine,7/7/14 12:28
138,10,Almirall,Regional & Specialty Pharma,1249,Almogran,almotriptan,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Dec-14,117,Triptans,8,Migraine,12,Central Nervous System,2,Global,Sales,72.25391694,63.85318184,69.10472077,67.21969036,68.49545636,66.07448084,21.22149581,14.15422361,10.63145661,8.552640156,7.091939112,7.031371836,-27.76154149,1337,Migraine,7/7/14 12:28
138,10,Almirall,Regional & Specialty Pharma,1249,Almogran,almotriptan,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Dec-14,117,Triptans,8,Migraine,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1337,Migraine,7/7/14 12:28
138,10,Almirall,Regional & Specialty Pharma,1249,Almogran,almotriptan,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Dec-14,117,Triptans,8,Migraine,12,Central Nervous System,2,ROW,Sales,72.25391694,63.85318184,69.10472077,67.21969036,68.49545636,66.07448084,21.22149581,14.15422361,10.63145661,8.552640156,7.091939112,7.031371836,-27.76154149,1337,Migraine,7/7/14 12:28
138,10,Almirall,Regional & Specialty Pharma,1249,Almogran,almotriptan,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Dec-14,117,Triptans,8,Migraine,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1337,Migraine,7/7/14 12:28
138,10,Almirall,Regional & Specialty Pharma,1249,Almogran,almotriptan,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Dec-14,117,Triptans,8,Migraine,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1337,Migraine,7/7/14 12:28
141,100,Takeda,Large Pharma,2606,Nesina / Liovel / Oseni / Kazano,alogliptin,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Jun-10,N/A,Dec-24,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,97,Type II Diabetes,7/7/14 12:28
141,100,Takeda,Large Pharma,2606,Nesina / Liovel / Oseni / Kazano,alogliptin,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Jun-10,N/A,Dec-24,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,Global,Sales,0,18.6765341,196.255736,455.0643954,425.2787305,535.9098192,643.071318,748.3624228,844.2288206,941.159968,1035.583573,1091.527594,14.41424325,97,Type II Diabetes,7/7/14 12:28
141,100,Takeda,Large Pharma,2606,Nesina / Liovel / Oseni / Kazano,alogliptin,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Jun-10,N/A,Dec-24,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,97,Type II Diabetes,7/7/14 12:28
141,100,Takeda,Large Pharma,2606,Nesina / Liovel / Oseni / Kazano,alogliptin,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Jun-10,N/A,Dec-24,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,ROW,Sales,0,18.6765341,196.255736,455.0643954,412.7766121,490.9021367,552.5975413,594.5856615,641.016297,688.4686897,734.7404049,761.2880308,9.138061658,97,Type II Diabetes,7/7/14 12:28
141,100,Takeda,Large Pharma,2606,Nesina / Liovel / Oseni / Kazano,alogliptin,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Jun-10,N/A,Dec-24,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,97,Type II Diabetes,7/7/14 12:28
141,100,Takeda,Large Pharma,2606,Nesina / Liovel / Oseni / Kazano,alogliptin,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Jun-10,N/A,Dec-24,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,12.50211841,45.00768255,90.47377669,153.7767613,203.2125236,252.6912783,300.8431684,330.2395636,59.6322304,97,Type II Diabetes,7/7/14 12:28
142,37,Eisai,Regional & Specialty Pharma,1015,Aloxi,palonosetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-03,,Apr-15,N/A,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1578,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
142,37,Eisai,Regional & Specialty Pharma,1015,Aloxi,palonosetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-03,,Apr-15,N/A,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,Global,Sales,412.6158462,403.88005,436.8272833,439.4140344,425.264778,439.7130066,179.9899759,50.19777282,34.22294503,25.78159566,20.44812146,18.67017209,-36.01619875,1578,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
142,37,Eisai,Regional & Specialty Pharma,1015,Aloxi,palonosetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-03,,Apr-15,N/A,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1578,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
142,37,Eisai,Regional & Specialty Pharma,1015,Aloxi,palonosetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-03,,Apr-15,N/A,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1578,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
142,37,Eisai,Regional & Specialty Pharma,1015,Aloxi,palonosetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-03,,Apr-15,N/A,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1578,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
142,37,Eisai,Regional & Specialty Pharma,1015,Aloxi,palonosetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-03,,Apr-15,N/A,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,US,Sales,412.6158462,403.88005,436.8272833,439.4140344,425.264778,439.7130066,179.9899759,50.19777282,34.22294503,25.78159566,20.44812146,18.67017209,-36.01619875,1578,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
143,8,Allergan,Regional & Specialty Pharma,3049,Alphagan / Alphagan P / Combigan,brimonidine / brimonidine + timolol,Small Molecule (Chemical),Launched,Licensed (Development),Oct-96,Feb-97,Jan-23,Apr-23,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,99,Glaucoma,7/7/14 12:28
143,8,Allergan,Regional & Specialty Pharma,3049,Alphagan / Alphagan P / Combigan,brimonidine / brimonidine + timolol,Small Molecule (Chemical),Launched,Licensed (Development),Oct-96,Feb-97,Jan-23,Apr-23,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Sales,415,401.3,419.4,453.2,474,470.6828026,467.1630865,461.0394611,456.2617604,451.8368908,447.4231586,444.4568177,-0.915134847,99,Glaucoma,7/7/14 12:28
143,8,Allergan,Regional & Specialty Pharma,3049,Alphagan / Alphagan P / Combigan,brimonidine / brimonidine + timolol,Small Molecule (Chemical),Launched,Licensed (Development),Oct-96,Feb-97,Jan-23,Apr-23,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,99,Glaucoma,7/7/14 12:28
143,8,Allergan,Regional & Specialty Pharma,3049,Alphagan / Alphagan P / Combigan,brimonidine / brimonidine + timolol,Small Molecule (Chemical),Launched,Licensed (Development),Oct-96,Feb-97,Jan-23,Apr-23,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Sales,139,146.2,166.9212,190.344,202,208.799632,213.4321024,216.1070323,217.7418853,218.7604451,219.3743338,219.750127,1.210457925,99,Glaucoma,7/7/14 12:28
143,8,Allergan,Regional & Specialty Pharma,3049,Alphagan / Alphagan P / Combigan,brimonidine / brimonidine + timolol,Small Molecule (Chemical),Launched,Licensed (Development),Oct-96,Feb-97,Jan-23,Apr-23,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,99,Glaucoma,7/7/14 12:28
143,8,Allergan,Regional & Specialty Pharma,3049,Alphagan / Alphagan P / Combigan,brimonidine / brimonidine + timolol,Small Molecule (Chemical),Launched,Licensed (Development),Oct-96,Feb-97,Jan-23,Apr-23,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Sales,276,255.1,252.4788,262.856,272,261.8831706,253.7309841,244.9324288,238.5198751,233.0764457,228.0488247,224.7066907,-2.691764494,99,Glaucoma,7/7/14 12:28
144,46,GlaxoSmithKline,Large Pharma,1739,Altabax,retapamulin,Small Molecule (Chemical),Launched,In-House,Apr-07,Mar-08,Apr-21,Jun-22,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,100,bacterial skin infections,7/7/14 12:28
144,46,GlaxoSmithKline,Large Pharma,1739,Altabax,retapamulin,Small Molecule (Chemical),Launched,In-House,Apr-07,Mar-08,Apr-21,Jun-22,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,Global,Sales,36.14232688,46.82304835,54.39304188,60.55286338,65.81682195,70.24081675,74.089632,77.29433768,79.91003643,82.09592205,83.91047446,85.41610348,3.793897274,100,bacterial skin infections,7/7/14 12:28
144,46,GlaxoSmithKline,Large Pharma,1739,Altabax,retapamulin,Small Molecule (Chemical),Launched,In-House,Apr-07,Mar-08,Apr-21,Jun-22,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,100,bacterial skin infections,7/7/14 12:28
144,46,GlaxoSmithKline,Large Pharma,1739,Altabax,retapamulin,Small Molecule (Chemical),Launched,In-House,Apr-07,Mar-08,Apr-21,Jun-22,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,ROW,Sales,2.866826298,4.027809822,5.236152768,6.169581522,7.012270015,7.782874339,8.470221745,9.078397318,9.609927616,10.07847746,10.49077276,10.85318769,6.43875468,100,bacterial skin infections,7/7/14 12:28
144,46,GlaxoSmithKline,Large Pharma,1739,Altabax,retapamulin,Small Molecule (Chemical),Launched,In-House,Apr-07,Mar-08,Apr-21,Jun-22,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,100,bacterial skin infections,7/7/14 12:28
144,46,GlaxoSmithKline,Large Pharma,1739,Altabax,retapamulin,Small Molecule (Chemical),Launched,In-House,Apr-07,Mar-08,Apr-21,Jun-22,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,US,Sales,33.27550058,42.79523853,49.15688911,54.38328186,58.80455194,62.45794241,65.61941025,68.21594036,70.30010881,72.01744459,73.4197017,74.56291579,3.449944516,100,bacterial skin infections,7/7/14 12:28
146,76,King,Large Pharma,283,Altace,ramipril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Proforma,41,21.7,2.1999,0,0,0,0,0,0,0,0,0,0,1606,,7/7/14 12:28
146,76,King,Large Pharma,283,Altace,ramipril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Proforma,41,21.7,2.1999,0,0,0,0,0,0,0,0,0,0,1606,,7/7/14 12:28
146,76,Pfizer,Large Pharma,283,Altace,ramipril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,-2.00E-02,0,0,0,0,0,0,0,0,0,0,0,1606,,7/7/14 12:28
146,76,Pfizer,Large Pharma,283,Altace,ramipril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,11.0001,11.5,11.16,11.092,11.0784,11.07568,11.075136,11.0750272,11.07500544,11.07500109,-0.109162305,1606,,7/7/14 12:28
146,76,Pfizer,Large Pharma,283,Altace,ramipril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1606,,7/7/14 12:28
146,76,Pfizer,Large Pharma,283,Altace,ramipril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1606,,7/7/14 12:28
146,76,Pfizer,Large Pharma,283,Altace,ramipril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,-2.00E-02,0,0,0,0,0,0,0,0,0,0,0,1606,,7/7/14 12:28
146,76,Pfizer,Large Pharma,283,Altace,ramipril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,11.0001,11.5,11.16,11.092,11.0784,11.07568,11.075136,11.0750272,11.07500544,11.07500109,-0.109162305,1606,,7/7/14 12:28
148,100,Nycomed,Large Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-05,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,Global,Proforma,77.81191505,92.73249367,86.65003433,0,0,0,0,0,0,0,0,0,0,1391,Asthma,7/7/14 12:28
148,100,Nycomed,Large Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-05,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,ROW,Proforma,77.81191505,92.73249367,86.65003433,0,0,0,0,0,0,0,0,0,0,1391,Asthma,7/7/14 12:28
148,100,Takeda,Large Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-05,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1391,Asthma,7/7/14 12:28
148,100,Takeda,Large Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-05,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,Global,Sales,-4.52E-06,1.63E-04,18.06113389,107.6872477,110.7912944,116.0161737,120.0930935,123.1942568,124.7217101,125.725494,126.3576382,126.7267174,1.938326286,1391,Asthma,7/7/14 12:28
148,100,Takeda,Large Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-05,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1391,Asthma,7/7/14 12:28
148,100,Takeda,Large Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-05,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,ROW,Sales,-4.52E-06,1.63E-04,18.06113389,107.6872477,110.7912944,116.0161737,120.0930935,123.1942568,124.7217101,125.725494,126.3576382,126.7267174,1.938326286,1391,Asthma,7/7/14 12:28
148,100,Takeda,Large Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-05,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1391,Asthma,7/7/14 12:28
148,100,Takeda,Large Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-05,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1391,Asthma,7/7/14 12:28
149,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-08,,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1391,Asthma,7/7/14 12:28
149,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-08,,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,Global,Sales,11.31192268,29.18208453,35.45264908,37.32009607,41.51394261,42.83023835,43.43775946,43.94402705,44.36321662,44.65300419,45.3047501,45.60273839,1.351021142,1391,Asthma,7/7/14 12:28
149,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-08,,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1391,Asthma,7/7/14 12:28
149,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-08,,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1391,Asthma,7/7/14 12:28
149,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-08,,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1391,Asthma,7/7/14 12:28
149,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-08,,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,US,Sales,11.31192268,29.18208453,35.45264908,37.32009607,41.51394261,42.83023835,43.43775946,43.94402705,44.36321662,44.65300419,45.3047501,45.60273839,1.351021142,1391,Asthma,7/7/14 12:28
149,35,Sepracor,Regional & Specialty Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-08,,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,Global,Proforma,10.23459671,0,0,0,0,0,0,0,0,0,0,0,0,1391,Asthma,7/7/14 12:28
149,35,Sepracor,Regional & Specialty Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-08,,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,US,Proforma,10.23459671,0,0,0,0,0,0,0,0,0,0,0,0,1391,Asthma,7/7/14 12:28
151,89,Sanofi,Large Pharma,380,Amaryl,glimepiride,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-96,Oct-95,Expired,Expired,10,Sulphonylureas,22,Diabetes,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1485,Type II Diabetes,7/7/14 12:28
151,89,Sanofi,Large Pharma,380,Amaryl,glimepiride,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-96,Oct-95,Expired,Expired,10,Sulphonylureas,22,Diabetes,8,Metabolism,2,Global,Sales,578.0313355,633.2327992,606.2305484,541.4147254,498.011275,458.3393841,432.6767067,416.0579923,405.2868409,398.3010989,393.7681199,390.8255601,-3.403050289,1485,Type II Diabetes,7/7/14 12:28
151,89,Sanofi,Large Pharma,380,Amaryl,glimepiride,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-96,Oct-95,Expired,Expired,10,Sulphonylureas,22,Diabetes,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1485,Type II Diabetes,7/7/14 12:28
151,89,Sanofi,Large Pharma,380,Amaryl,glimepiride,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-96,Oct-95,Expired,Expired,10,Sulphonylureas,22,Diabetes,8,Metabolism,2,ROW,Sales,565.5258499,625.2842703,600.6688002,537.2434143,495.3552148,456.5103355,431.261164,414.8492025,404.1814275,397.2473738,392.7402389,389.8106012,-3.365131801,1485,Type II Diabetes,7/7/14 12:28
151,89,Sanofi,Large Pharma,380,Amaryl,glimepiride,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-96,Oct-95,Expired,Expired,10,Sulphonylureas,22,Diabetes,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1485,Type II Diabetes,7/7/14 12:28
151,89,Sanofi,Large Pharma,380,Amaryl,glimepiride,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-96,Oct-95,Expired,Expired,10,Sulphonylureas,22,Diabetes,8,Metabolism,2,US,Sales,12.50548562,7.94852886,5.56174815,4.171311113,2.656060133,1.829048513,1.415542703,1.208789799,1.105413346,1.05372512,1.027881007,1.01495895,-12.84027406,1485,Type II Diabetes,7/7/14 12:28
152,89,Sanofi,Large Pharma,1110,Ambien,zolpidem,Small Molecule (Chemical),Launched,In-House,Mar-93,May-88,Apr-07,Mar-05,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,2,Global,Alliance Revenue,269.5626901,327.2144381,394.8841187,375.2992272,254.9817728,225.7651113,196.5484499,185.9242093,179.284059,172.6439087,166.0037583,160.6916381,-6.382959869,1683,Insomnia,7/7/14 12:28
152,89,Sanofi,Large Pharma,1110,Ambien,zolpidem,Small Molecule (Chemical),Launched,In-House,Mar-93,May-88,Apr-07,Mar-05,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,2,Global,Sales,943.4694154,757.7597513,286.4300297,263.4806219,264.2779833,251.2632886,241.1490116,234.3594313,229.1529965,225.010065,221.656415,218.9243736,-2.653793854,1683,Insomnia,7/7/14 12:28
152,89,Sanofi,Large Pharma,1110,Ambien,zolpidem,Small Molecule (Chemical),Launched,In-House,Mar-93,May-88,Apr-07,Mar-05,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,2,ROW,Alliance Revenue,269.5626901,327.2144381,394.8841187,375.2992272,254.9817728,225.7651113,196.5484499,185.9242093,179.284059,172.6439087,166.0037583,160.6916381,-6.382959869,1683,Insomnia,7/7/14 12:28
152,89,Sanofi,Large Pharma,1110,Ambien,zolpidem,Small Molecule (Chemical),Launched,In-House,Mar-93,May-88,Apr-07,Mar-05,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,2,ROW,Sales,172.2978019,170.8933705,172.4141927,154.2325592,147.4113374,138.3807329,130.9225161,124.8301516,119.8469918,115.7717276,112.4388846,109.7132165,-4.131605211,1683,Insomnia,7/7/14 12:28
152,89,Sanofi,Large Pharma,1110,Ambien,zolpidem,Small Molecule (Chemical),Launched,In-House,Mar-93,May-88,Apr-07,Mar-05,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1683,Insomnia,7/7/14 12:28
152,89,Sanofi,Large Pharma,1110,Ambien,zolpidem,Small Molecule (Chemical),Launched,In-House,Mar-93,May-88,Apr-07,Mar-05,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,2,US,Sales,771.1716135,586.8663808,114.0158371,109.2480627,116.8666459,112.8825557,110.2264955,109.5292797,109.3060047,109.2383374,109.2175304,109.2111571,-0.963191428,1683,Insomnia,7/7/14 12:28
153,15,Astellas Pharma,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Licensed (Marketed),Aug-97,Jan-97,N/A,Expired,93,Polyenes,25,Fungal Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1344,,7/7/14 12:28
153,15,Astellas Pharma,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Licensed (Marketed),Aug-97,Jan-97,N/A,Expired,93,Polyenes,25,Fungal Infection,7,Anti-infectives,7,Global,Sales,66.79421009,72.37156965,69.63913213,75.84406621,73.91506855,78.11043581,79.78858271,80.45984147,80.72834498,80.83574638,80.87870694,80.89589117,1.297578306,1344,,7/7/14 12:28
153,15,Astellas Pharma,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Licensed (Marketed),Aug-97,Jan-97,N/A,Expired,93,Polyenes,25,Fungal Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1344,,7/7/14 12:28
153,15,Astellas Pharma,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Licensed (Marketed),Aug-97,Jan-97,N/A,Expired,93,Polyenes,25,Fungal Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1344,,7/7/14 12:28
153,15,Astellas Pharma,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Licensed (Marketed),Aug-97,Jan-97,N/A,Expired,93,Polyenes,25,Fungal Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1344,,7/7/14 12:28
153,15,Astellas Pharma,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Licensed (Marketed),Aug-97,Jan-97,N/A,Expired,93,Polyenes,25,Fungal Infection,7,Anti-infectives,7,US,Sales,66.79421009,72.37156965,69.63913213,75.84406621,73.91506855,78.11043581,79.78858271,80.45984147,80.72834498,80.83574638,80.87870694,80.89589117,1.297578306,1344,,7/7/14 12:28
154,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-06,N/A,Nov-13,93,Polyenes,25,Fungal Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1344,,7/7/14 12:28
154,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-06,N/A,Nov-13,93,Polyenes,25,Fungal Infection,7,Anti-infectives,7,Global,Sales,45.96652639,53.64208622,56.97747174,55.37820707,47.01762215,47.24905254,47.51350232,47.68493929,47.79060904,47.869187,47.92182565,47.95733898,0.283105041,1344,,7/7/14 12:28
154,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-06,N/A,Nov-13,93,Polyenes,25,Fungal Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1344,,7/7/14 12:28
154,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-06,N/A,Nov-13,93,Polyenes,25,Fungal Infection,7,Anti-infectives,7,ROW,Sales,45.96652639,53.64208622,56.97747174,55.37820707,47.01762215,47.24905254,47.51350232,47.68493929,47.79060904,47.869187,47.92182565,47.95733898,0.283105041,1344,,7/7/14 12:28
154,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-06,N/A,Nov-13,93,Polyenes,25,Fungal Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1344,,7/7/14 12:28
154,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-06,N/A,Nov-13,93,Polyenes,25,Fungal Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1344,,7/7/14 12:28
155,45,Gilead,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-97,Jan-97,N/A,Jul-08,93,Polyenes,25,Fungal Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1344,,7/7/14 12:28
155,45,Gilead,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-97,Jan-97,N/A,Jul-08,93,Polyenes,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,298.6,305.86,330.16,346.65,352,358.8651,363.4496525,366.4316459,368.7633063,370.4008426,371.5639083,372.4104275,0.808469375,1344,,7/7/14 12:28
155,45,Gilead,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-97,Jan-97,N/A,Jul-08,93,Polyenes,25,Fungal Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1344,,7/7/14 12:28
155,45,Gilead,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-97,Jan-97,N/A,Jul-08,93,Polyenes,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,298.6,305.86,330.16,346.65,352,358.8651,363.4496525,366.4316459,368.7633063,370.4008426,371.5639083,372.4104275,0.808469375,1344,,7/7/14 12:28
155,45,Gilead,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-97,Jan-97,N/A,Jul-08,93,Polyenes,25,Fungal Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1344,,7/7/14 12:28
155,45,Gilead,Regional & Specialty Pharma,1079,AmBisome,amphotericin B,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-97,Jan-97,N/A,Jul-08,93,Polyenes,25,Fungal Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1344,,7/7/14 12:28
165,11,Amgen,Large Pharma,949,trebananib,trebananib,Antibody/Antibody Derivative,Phase III,In-House,Jan-15,Jun-15,Sep-25,Dec-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1340,Ovarian Cancer,7/7/14 12:28
165,11,Amgen,Large Pharma,949,trebananib,trebananib,Antibody/Antibody Derivative,Phase III,In-House,Jan-15,Jun-15,Sep-25,Dec-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,65.75,102.8540125,146.6255731,218.8579381,252.8590101,281.3137446,0,1340,Ovarian Cancer,7/7/14 12:28
165,11,Amgen,Large Pharma,949,trebananib,trebananib,Antibody/Antibody Derivative,Phase III,In-House,Jan-15,Jun-15,Sep-25,Dec-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1340,Ovarian Cancer,7/7/14 12:28
165,11,Amgen,Large Pharma,949,trebananib,trebananib,Antibody/Antibody Derivative,Phase III,In-House,Jan-15,Jun-15,Sep-25,Dec-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,30.75,53.8540125,76.62564315,113.8580431,131.8991382,146.7458944,0,1340,Ovarian Cancer,7/7/14 12:28
165,11,Amgen,Large Pharma,949,trebananib,trebananib,Antibody/Antibody Derivative,Phase III,In-House,Jan-15,Jun-15,Sep-25,Dec-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1340,Ovarian Cancer,7/7/14 12:28
165,11,Amgen,Large Pharma,949,trebananib,trebananib,Antibody/Antibody Derivative,Phase III,In-House,Jan-15,Jun-15,Sep-25,Dec-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,35,49,69.99993,104.999895,120.9598719,134.5678503,0,1340,Ovarian Cancer,7/7/14 12:28
169,11,Amgen,Large Pharma,127,AMG 557,B7RP-1 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,110,Systemic Lupus Erythematosus,7/7/14 12:28
169,11,Amgen,Large Pharma,127,AMG 557,B7RP-1 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,110,Systemic Lupus Erythematosus,7/7/14 12:28
169,11,Amgen,Large Pharma,127,AMG 557,B7RP-1 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,110,Systemic Lupus Erythematosus,7/7/14 12:28
169,11,Amgen,Large Pharma,127,AMG 557,B7RP-1 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,110,Systemic Lupus Erythematosus,7/7/14 12:28
169,11,Amgen,Large Pharma,127,AMG 557,B7RP-1 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,110,Systemic Lupus Erythematosus,7/7/14 12:28
169,11,Amgen,Large Pharma,127,AMG 557,B7RP-1 inhibitor,Antibody/Antibody Derivative,Phase I,In-House,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,110,Systemic Lupus Erythematosus,7/7/14 12:28
173,11,Amgen,Large Pharma,257,AMG 785,romosozumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jun-17,Apr-19,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1347,Osteoporosis,7/7/14 12:28
173,11,Amgen,Large Pharma,257,AMG 785,romosozumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jun-17,Apr-19,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,16.333324,84,157,215,0,1347,Osteoporosis,7/7/14 12:28
173,11,Amgen,Large Pharma,257,AMG 785,romosozumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jun-17,Apr-19,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1347,Osteoporosis,7/7/14 12:28
173,11,Amgen,Large Pharma,257,AMG 785,romosozumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jun-17,Apr-19,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,7,20,0,1347,Osteoporosis,7/7/14 12:28
173,11,Amgen,Large Pharma,257,AMG 785,romosozumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jun-17,Apr-19,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1347,Osteoporosis,7/7/14 12:28
173,11,Amgen,Large Pharma,257,AMG 785,romosozumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jun-17,Apr-19,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,16.333324,84,150,195,0,1347,Osteoporosis,7/7/14 12:28
174,11,Amgen,Large Pharma,397,AMG 811,AMG 811,Antibody/Antibody Derivative,Phase I,In-House,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,113,Systemic Lupus Erythematosus,7/7/14 12:28
174,11,Amgen,Large Pharma,397,AMG 811,AMG 811,Antibody/Antibody Derivative,Phase I,In-House,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,113,Systemic Lupus Erythematosus,7/7/14 12:28
174,11,Amgen,Large Pharma,397,AMG 811,AMG 811,Antibody/Antibody Derivative,Phase I,In-House,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,113,Systemic Lupus Erythematosus,7/7/14 12:28
174,11,Amgen,Large Pharma,397,AMG 811,AMG 811,Antibody/Antibody Derivative,Phase I,In-House,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,113,Systemic Lupus Erythematosus,7/7/14 12:28
174,11,Amgen,Large Pharma,397,AMG 811,AMG 811,Antibody/Antibody Derivative,Phase I,In-House,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,113,Systemic Lupus Erythematosus,7/7/14 12:28
174,11,Amgen,Large Pharma,397,AMG 811,AMG 811,Antibody/Antibody Derivative,Phase I,In-House,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,113,Systemic Lupus Erythematosus,7/7/14 12:28
178,11,Amgen,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase III,In-House,Aug-16,Aug-16,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,114,Psoriasis,7/7/14 12:28
178,11,Amgen,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase III,In-House,Aug-16,Aug-16,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,27.083355,110.1390673,218.4729552,326.8071396,406.649288,0,114,Psoriasis,7/7/14 12:28
178,11,Amgen,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase III,In-House,Aug-16,Aug-16,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,114,Psoriasis,7/7/14 12:28
178,11,Amgen,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase III,In-House,Aug-16,Aug-16,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,14.583345,59.30565161,117.6392836,175.9730751,217.6816602,0,114,Psoriasis,7/7/14 12:28
178,11,Amgen,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase III,In-House,Aug-16,Aug-16,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,114,Psoriasis,7/7/14 12:28
178,11,Amgen,Large Pharma,3848,brodalumab,brodalumab,Antibody/Antibody Derivative,Phase III,In-House,Aug-16,Aug-16,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,12.50001,50.83341567,100.8336717,150.8340644,188.9676279,0,114,Psoriasis,7/7/14 12:28
181,19,Bayer,Large Pharma,1198,amikacin inhale,amikacin inhale,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,118,Gram-Negative Pneumonia,7/7/14 12:28
181,19,Bayer,Large Pharma,1198,amikacin inhale,amikacin inhale,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,118,Gram-Negative Pneumonia,7/7/14 12:28
181,19,Bayer,Large Pharma,1198,amikacin inhale,amikacin inhale,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,118,Gram-Negative Pneumonia,7/7/14 12:28
181,19,Bayer,Large Pharma,1198,amikacin inhale,amikacin inhale,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,118,Gram-Negative Pneumonia,7/7/14 12:28
181,19,Bayer,Large Pharma,1198,amikacin inhale,amikacin inhale,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,118,Gram-Negative Pneumonia,7/7/14 12:28
181,19,Bayer,Large Pharma,1198,amikacin inhale,amikacin inhale,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,118,Gram-Negative Pneumonia,7/7/14 12:28
182,99,Sucampo,Small Biotech,907,Amitiza,lubiprostone,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-12,N/A,Oct-20,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,5.1,8,16.66527665,30.6854944,50.33838403,62.71539339,74.6765962,83.24929918,87.80885677,40.81059315,1532,IBS-C,7/7/14 12:28
182,99,Sucampo,Small Biotech,907,Amitiza,lubiprostone,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-12,N/A,Oct-20,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,5.1,8,16.66527665,30.6854944,50.33838403,62.71539339,74.6765962,83.24929918,87.80885677,40.81059315,1532,IBS-C,7/7/14 12:28
182,99,Sucampo,Small Biotech,907,Amitiza,lubiprostone,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-12,N/A,Oct-20,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1532,IBS-C,7/7/14 12:28
183,100,Takeda,Large Pharma,907,Amitiza,lubiprostone,Small Molecule (Chemical),Launched,Licensed (Development),Apr-06,,Jul-15,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1532,IBS-C,7/7/14 12:28
183,100,Takeda,Large Pharma,907,Amitiza,lubiprostone,Small Molecule (Chemical),Launched,Licensed (Development),Apr-06,,Jul-15,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,Global,Sales,210.8843144,222.4459684,236.7730492,268.4639169,274.3970353,302.4756557,222.090897,40.43151642,29.24330888,27.96737574,25.01528899,21.60669114,-30.44702553,1532,IBS-C,7/7/14 12:28
183,100,Takeda,Large Pharma,907,Amitiza,lubiprostone,Small Molecule (Chemical),Launched,Licensed (Development),Apr-06,,Jul-15,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1532,IBS-C,7/7/14 12:28
183,100,Takeda,Large Pharma,907,Amitiza,lubiprostone,Small Molecule (Chemical),Launched,Licensed (Development),Apr-06,,Jul-15,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1532,IBS-C,7/7/14 12:28
183,100,Takeda,Large Pharma,907,Amitiza,lubiprostone,Small Molecule (Chemical),Launched,Licensed (Development),Apr-06,,Jul-15,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1532,IBS-C,7/7/14 12:28
183,100,Takeda,Large Pharma,907,Amitiza,lubiprostone,Small Molecule (Chemical),Launched,Licensed (Development),Apr-06,,Jul-15,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,US,Sales,210.8843144,222.4459684,236.7730492,268.4639169,274.3970353,302.4756557,222.090897,40.43151642,29.24330888,27.96737574,25.01528899,21.60669114,-30.44702553,1532,IBS-C,7/7/14 12:28
184,35,Dainippon-Sumitomo,Regional & Specialty Pharma,451,Amlodin,amlodipine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-93,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1343,,7/7/14 12:28
184,35,Dainippon-Sumitomo,Regional & Specialty Pharma,451,Amlodin,amlodipine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-93,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,560.209504,483.2553199,450.1388456,351.5312275,270.8217284,247.8168919,232.8343176,221.5313032,213.4668297,207.5934064,203.3484265,200.2716431,-4.219613812,1343,,7/7/14 12:28
184,35,Dainippon-Sumitomo,Regional & Specialty Pharma,451,Amlodin,amlodipine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-93,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1343,,7/7/14 12:28
184,35,Dainippon-Sumitomo,Regional & Specialty Pharma,451,Amlodin,amlodipine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-93,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,560.209504,483.2553199,450.1388456,351.5312275,270.8217284,247.8168919,232.8343176,221.5313032,213.4668297,207.5934064,203.3484265,200.2716431,-4.219613812,1343,,7/7/14 12:28
184,35,Dainippon-Sumitomo,Regional & Specialty Pharma,451,Amlodin,amlodipine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-93,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1343,,7/7/14 12:28
184,35,Dainippon-Sumitomo,Regional & Specialty Pharma,451,Amlodin,amlodipine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-93,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1343,,7/7/14 12:28
186,102,Cephalon,Regional & Specialty Pharma,929,Amrix,cyclobenzaprine ER,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-07,,May-11,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,Global,Proforma,114,109.2,72,0,0,0,0,0,0,0,0,0,0,120,Muscle Spasms,7/7/14 12:28
186,102,Cephalon,Regional & Specialty Pharma,929,Amrix,cyclobenzaprine ER,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-07,,May-11,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,US,Proforma,114,109.2,72,0,0,0,0,0,0,0,0,0,0,120,Muscle Spasms,7/7/14 12:28
186,102,Teva,Regional & Specialty Pharma,929,Amrix,cyclobenzaprine ER,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-07,,May-11,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,120,Muscle Spasms,7/7/14 12:28
186,102,Teva,Regional & Specialty Pharma,929,Amrix,cyclobenzaprine ER,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-07,,May-11,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,Global,Sales,0,4.00E-02,24,12,6,5,4,3.5,3,2.5,3,2,-14.52484659,120,Muscle Spasms,7/7/14 12:28
186,102,Teva,Regional & Specialty Pharma,929,Amrix,cyclobenzaprine ER,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-07,,May-11,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,120,Muscle Spasms,7/7/14 12:28
186,102,Teva,Regional & Specialty Pharma,929,Amrix,cyclobenzaprine ER,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-07,,May-11,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,120,Muscle Spasms,7/7/14 12:28
186,102,Teva,Regional & Specialty Pharma,929,Amrix,cyclobenzaprine ER,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-07,,May-11,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,120,Muscle Spasms,7/7/14 12:28
186,102,Teva,Regional & Specialty Pharma,929,Amrix,cyclobenzaprine ER,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-07,,May-11,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,US,Sales,0,4.00E-02,24,12,6,5,4,3.5,3,2.5,3,2,-14.52484659,120,Muscle Spasms,7/7/14 12:28
187,61,Merck & Co,Large Pharma,674,anacetrapib,anacetrapib,Small Molecule (Chemical),Phase III,In-House,Jun-18,Oct-18,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,122,Secondary prevention of cardiac events,7/7/14 12:28
187,61,Merck & Co,Large Pharma,674,anacetrapib,anacetrapib,Small Molecule (Chemical),Phase III,In-House,Jun-18,Oct-18,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,86.24996,328.7497523,637.08274,0,122,Secondary prevention of cardiac events,7/7/14 12:28
187,61,Merck & Co,Large Pharma,674,anacetrapib,anacetrapib,Small Molecule (Chemical),Phase III,In-House,Jun-18,Oct-18,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,122,Secondary prevention of cardiac events,7/7/14 12:28
187,61,Merck & Co,Large Pharma,674,anacetrapib,anacetrapib,Small Molecule (Chemical),Phase III,In-House,Jun-18,Oct-18,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,16.25,92.0833875,200.4167304,0,122,Secondary prevention of cardiac events,7/7/14 12:28
187,61,Merck & Co,Large Pharma,674,anacetrapib,anacetrapib,Small Molecule (Chemical),Phase III,In-House,Jun-18,Oct-18,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,122,Secondary prevention of cardiac events,7/7/14 12:28
187,61,Merck & Co,Large Pharma,674,anacetrapib,anacetrapib,Small Molecule (Chemical),Phase III,In-House,Jun-18,Oct-18,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,69.99996,236.6663648,436.6660096,0,122,Secondary prevention of cardiac events,7/7/14 12:28
188,19,Bayer,Large Pharma,90,Androcur,cyproterone,Small Molecule (Chemical),Launched,In-House,,,N/A,Expired,107,Anti-androgens,55,Hormonals,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1407,Prostate Cancer,7/7/14 12:28
188,19,Bayer,Large Pharma,90,Androcur,cyproterone,Small Molecule (Chemical),Launched,In-House,,,N/A,Expired,107,Anti-androgens,55,Hormonals,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1407,Prostate Cancer,7/7/14 12:28
188,19,Bayer,Large Pharma,90,Androcur,cyproterone,Small Molecule (Chemical),Launched,In-House,,,N/A,Expired,107,Anti-androgens,55,Hormonals,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1407,Prostate Cancer,7/7/14 12:28
188,19,Bayer,Large Pharma,90,Androcur,cyproterone,Small Molecule (Chemical),Launched,In-House,,,N/A,Expired,107,Anti-androgens,55,Hormonals,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1407,Prostate Cancer,7/7/14 12:28
188,19,Bayer,Large Pharma,90,Androcur,cyproterone,Small Molecule (Chemical),Launched,In-House,,,N/A,Expired,107,Anti-androgens,55,Hormonals,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1407,Prostate Cancer,7/7/14 12:28
188,19,Bayer,Large Pharma,90,Androcur,cyproterone,Small Molecule (Chemical),Launched,In-House,,,N/A,Expired,107,Anti-androgens,55,Hormonals,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1407,Prostate Cancer,7/7/14 12:28
189,1,Abbott,Regional & Specialty Pharma,122,Androgel,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-00,Mar-06,Aug-15,Aug-21,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1658,Hypogonadism,7/7/14 12:28
189,1,Abbott,Regional & Specialty Pharma,122,Androgel,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-00,Mar-06,Aug-15,Aug-21,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,Global,Sales,0,592.4,904,1185,34.64,35.488,36.0944,36.44864,36.660096,36.793408,36.87378432,36.9227735,0.91587414,1658,Hypogonadism,7/7/14 12:28
189,1,Abbott,Regional & Specialty Pharma,122,Androgel,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-00,Mar-06,Aug-15,Aug-21,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1658,Hypogonadism,7/7/14 12:28
189,1,Abbott,Regional & Specialty Pharma,122,Androgel,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-00,Mar-06,Aug-15,Aug-21,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,ROW,Sales,0,24.5,30,33,34.64,35.488,36.0944,36.44864,36.660096,36.793408,36.87378432,36.9227735,0.91587414,1658,Hypogonadism,7/7/14 12:28
189,1,Abbott,Regional & Specialty Pharma,122,Androgel,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-00,Mar-06,Aug-15,Aug-21,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1658,Hypogonadism,7/7/14 12:28
189,1,Abbott,Regional & Specialty Pharma,122,Androgel,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-00,Mar-06,Aug-15,Aug-21,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,US,Sales,0,567.9,874,1152,0,0,0,0,0,0,0,0,0,1658,Hypogonadism,7/7/14 12:28
189,1,Solvay,Regional & Specialty Pharma,122,Androgel,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-00,Mar-06,Aug-15,Aug-21,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,Global,Proforma,578,84.6,0,0,0,0,0,0,0,0,0,0,0,1658,Hypogonadism,7/7/14 12:28
189,1,Solvay,Regional & Specialty Pharma,122,Androgel,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-00,Mar-06,Aug-15,Aug-21,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,ROW,Proforma,18,3.5,0,0,0,0,0,0,0,0,0,0,0,1658,Hypogonadism,7/7/14 12:28
189,1,Solvay,Regional & Specialty Pharma,122,Androgel,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-00,Mar-06,Aug-15,Aug-21,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,US,Proforma,560,81.1,0,0,0,0,0,0,0,0,0,0,0,1658,Hypogonadism,7/7/14 12:28
190,19,Bayer,Large Pharma,312,Angeliq,drospirenone + oestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-06,Sep-03,Aug-17,Sep-11,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1430,Estrogen deficiency,7/7/14 12:28
190,19,Bayer,Large Pharma,312,Angeliq,drospirenone + oestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-06,Sep-03,Aug-17,Sep-11,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,2,Global,Sales,114.9960011,114.3394812,115.1663159,65.32090457,59.67459822,54.28011172,54.61685177,54.66618323,38.83623006,10.85680811,8.494720396,7.091097228,-26.23566886,1430,Estrogen deficiency,7/7/14 12:28
190,19,Bayer,Large Pharma,312,Angeliq,drospirenone + oestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-06,Sep-03,Aug-17,Sep-11,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1430,Estrogen deficiency,7/7/14 12:28
190,19,Bayer,Large Pharma,312,Angeliq,drospirenone + oestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-06,Sep-03,Aug-17,Sep-11,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,2,ROW,Sales,84.65014483,81.23816664,76.47403706,26.41830371,17.99379857,10.62424053,9.296210466,7.9681804,6.70001257,5.312120266,4.642119009,4.139618067,-18.93488405,1430,Estrogen deficiency,7/7/14 12:28
190,19,Bayer,Large Pharma,312,Angeliq,drospirenone + oestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-06,Sep-03,Aug-17,Sep-11,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1430,Estrogen deficiency,7/7/14 12:28
190,19,Bayer,Large Pharma,312,Angeliq,drospirenone + oestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-06,Sep-03,Aug-17,Sep-11,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,2,US,Sales,30.34585625,33.10131456,38.69227888,38.90260085,41.68079966,43.65587118,45.3206413,46.69800283,32.13621749,5.544687848,3.852601387,2.951479161,-31.49389731,1430,Estrogen deficiency,7/7/14 12:28
192,103,The Medicines Company,Small Biotech,1407,Angiomax,bivalirudin,Small Molecule (Chemical),Launched,Licensed (Development),Jan-01,Oct-04,Jun-19,Aug-15,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,400,436.71,483.9,548.2,608.6,657.544,687.333376,689.7829197,706.4371077,720.9951473,521.3224341,254.4562213,-11.71287843,126,,7/7/14 12:28
192,103,The Medicines Company,Small Biotech,1407,Angiomax,bivalirudin,Small Molecule (Chemical),Launched,Licensed (Development),Jan-01,Oct-04,Jun-19,Aug-15,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,18,24.6,31.6,46.5,58.4,68.4,65.505216,40.80585728,34.85528218,30.60244895,27.08854082,24.35131889,-11.74689319,126,,7/7/14 12:28
192,103,The Medicines Company,Small Biotech,1407,Angiomax,bivalirudin,Small Molecule (Chemical),Launched,Licensed (Development),Jan-01,Oct-04,Jun-19,Aug-15,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,382,412.11,452.3,501.7,550.2,589.144,621.82816,648.9770624,671.5818255,690.3926983,494.2338933,230.1049024,-11.7092726,126,,7/7/14 12:28
193,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1416,Anplag,sarpogrelate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-93,N/A,Nov-09,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,127,,7/7/14 12:28
193,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1416,Anplag,sarpogrelate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-93,N/A,Nov-09,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,211.15589,198.1774841,195.0929751,156.5036287,114.7720336,104.1306522,97.08978639,92.43320504,89.35314209,87.31592212,85.96844897,85.07719547,-4.186806222,127,,7/7/14 12:28
193,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1416,Anplag,sarpogrelate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-93,N/A,Nov-09,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,127,,7/7/14 12:28
193,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1416,Anplag,sarpogrelate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-93,N/A,Nov-09,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,211.15589,198.1774841,195.0929751,156.5036287,114.7720336,104.1306522,97.08978639,92.43320504,89.35314209,87.31592212,85.96844897,85.07719547,-4.186806222,127,,7/7/14 12:28
193,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1416,Anplag,sarpogrelate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-93,N/A,Nov-09,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,127,,7/7/14 12:28
193,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1416,Anplag,sarpogrelate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-93,N/A,Nov-09,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,127,,7/7/14 12:28
196,39,Eli Lilly,Large Pharma,4343,ixekizumab,LY-2439821,Antibody/Antibody Derivative,Phase III,In-House,,,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,128,psoriatic arthritis,7/7/14 12:28
196,39,Eli Lilly,Large Pharma,4343,ixekizumab,LY-2439821,Antibody/Antibody Derivative,Phase III,In-House,,,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,128,psoriatic arthritis,7/7/14 12:28
196,39,Eli Lilly,Large Pharma,4343,ixekizumab,LY-2439821,Antibody/Antibody Derivative,Phase III,In-House,,,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,128,psoriatic arthritis,7/7/14 12:28
196,39,Eli Lilly,Large Pharma,4343,ixekizumab,LY-2439821,Antibody/Antibody Derivative,Phase III,In-House,,,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,128,psoriatic arthritis,7/7/14 12:28
196,39,Eli Lilly,Large Pharma,4343,ixekizumab,LY-2439821,Antibody/Antibody Derivative,Phase III,In-House,,,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,128,psoriatic arthritis,7/7/14 12:28
196,39,Eli Lilly,Large Pharma,4343,ixekizumab,LY-2439821,Antibody/Antibody Derivative,Phase III,In-House,,,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,128,psoriatic arthritis,7/7/14 12:28
198,86,Roche,Large Pharma,4594,crenezumab,RG7412,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1001,Alzheimer's Disease,7/7/14 12:28
198,86,Roche,Large Pharma,4594,crenezumab,RG7412,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1001,Alzheimer's Disease,7/7/14 12:28
198,86,Roche,Large Pharma,4594,crenezumab,RG7412,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1001,Alzheimer's Disease,7/7/14 12:28
198,86,Roche,Large Pharma,4594,crenezumab,RG7412,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1001,Alzheimer's Disease,7/7/14 12:28
198,86,Roche,Large Pharma,4594,crenezumab,RG7412,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1001,Alzheimer's Disease,7/7/14 12:28
198,86,Roche,Large Pharma,4594,crenezumab,RG7412,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1001,Alzheimer's Disease,7/7/14 12:28
199,68,Novo Nordisk,Regional & Specialty Pharma,3244,NN-8210,Anti-C5aR-215,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,129,Rheumatoid Arthritis,7/7/14 12:28
199,68,Novo Nordisk,Regional & Specialty Pharma,3244,NN-8210,Anti-C5aR-215,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,129,Rheumatoid Arthritis,7/7/14 12:28
199,68,Novo Nordisk,Regional & Specialty Pharma,3244,NN-8210,Anti-C5aR-215,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,129,Rheumatoid Arthritis,7/7/14 12:28
199,68,Novo Nordisk,Regional & Specialty Pharma,3244,NN-8210,Anti-C5aR-215,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,129,Rheumatoid Arthritis,7/7/14 12:28
199,68,Novo Nordisk,Regional & Specialty Pharma,3244,NN-8210,Anti-C5aR-215,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,129,Rheumatoid Arthritis,7/7/14 12:28
199,68,Novo Nordisk,Regional & Specialty Pharma,3244,NN-8210,Anti-C5aR-215,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,129,Rheumatoid Arthritis,7/7/14 12:28
203,86,Roche,Large Pharma,1827,lebrikizumab,RG3637,Antibody/Antibody Derivative,Phase III,Acquisition (Development),Feb-19,Feb-19,N/A,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,616,Asthma,7/7/14 12:28
203,86,Roche,Large Pharma,1827,lebrikizumab,RG3637,Antibody/Antibody Derivative,Phase III,Acquisition (Development),Feb-19,Feb-19,N/A,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,21.7551218,145.247418,0,616,Asthma,7/7/14 12:28
203,86,Roche,Large Pharma,1827,lebrikizumab,RG3637,Antibody/Antibody Derivative,Phase III,Acquisition (Development),Feb-19,Feb-19,N/A,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,616,Asthma,7/7/14 12:28
203,86,Roche,Large Pharma,1827,lebrikizumab,RG3637,Antibody/Antibody Derivative,Phase III,Acquisition (Development),Feb-19,Feb-19,N/A,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,10.35958181,69.16543715,0,616,Asthma,7/7/14 12:28
203,86,Roche,Large Pharma,1827,lebrikizumab,RG3637,Antibody/Antibody Derivative,Phase III,Acquisition (Development),Feb-19,Feb-19,N/A,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,616,Asthma,7/7/14 12:28
203,86,Roche,Large Pharma,1827,lebrikizumab,RG3637,Antibody/Antibody Derivative,Phase III,Acquisition (Development),Feb-19,Feb-19,N/A,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,US,Sales,0,0,0,0,0,0,0,0,0,0,11.39553999,76.08198087,0,616,Asthma,7/7/14 12:28
204,68,Novo Nordisk,Regional & Specialty Pharma,3243,NN-8226,Anti-IL20,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,132,Rheumatoid Arthritis,7/7/14 12:28
204,68,Novo Nordisk,Regional & Specialty Pharma,3243,NN-8226,Anti-IL20,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,132,Rheumatoid Arthritis,7/7/14 12:28
204,68,Novo Nordisk,Regional & Specialty Pharma,3243,NN-8226,Anti-IL20,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,132,Rheumatoid Arthritis,7/7/14 12:28
204,68,Novo Nordisk,Regional & Specialty Pharma,3243,NN-8226,Anti-IL20,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,132,Rheumatoid Arthritis,7/7/14 12:28
204,68,Novo Nordisk,Regional & Specialty Pharma,3243,NN-8226,Anti-IL20,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,132,Rheumatoid Arthritis,7/7/14 12:28
204,68,Novo Nordisk,Regional & Specialty Pharma,3243,NN-8226,Anti-IL20,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,132,Rheumatoid Arthritis,7/7/14 12:28
208,89,Sanofi,Large Pharma,1569,Apidra,insulin glulisine,Recombinant Protein,Launched,Corporate Acquisition,Feb-06,Dec-04,Jun-18,Sep-19,83,Insulins,22,Diabetes,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,135,Diabetes,7/7/14 12:28
208,89,Sanofi,Large Pharma,1569,Apidra,insulin glulisine,Recombinant Protein,Launched,Corporate Acquisition,Feb-06,Dec-04,Jun-18,Sep-19,83,Insulins,22,Diabetes,8,Metabolism,2,Global,Sales,190.3612812,231.9247856,264.1830371,295.612405,382.4726592,424.9364206,462.5535031,504.9956647,536.9404093,564.9511604,591.7060901,614.1939364,7.000650426,135,Diabetes,7/7/14 12:28
208,89,Sanofi,Large Pharma,1569,Apidra,insulin glulisine,Recombinant Protein,Launched,Corporate Acquisition,Feb-06,Dec-04,Jun-18,Sep-19,83,Insulins,22,Diabetes,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,135,Diabetes,7/7/14 12:28
208,89,Sanofi,Large Pharma,1569,Apidra,insulin glulisine,Recombinant Protein,Launched,Corporate Acquisition,Feb-06,Dec-04,Jun-18,Sep-19,83,Insulins,22,Diabetes,8,Metabolism,2,ROW,Sales,115.3283674,149.7899874,173.8046297,201.7875982,233.7332917,256.6484506,276.3233157,293.322376,307.9990206,320.6715739,331.613592,341.0614028,5.546672901,135,Diabetes,7/7/14 12:28
208,89,Sanofi,Large Pharma,1569,Apidra,insulin glulisine,Recombinant Protein,Launched,Corporate Acquisition,Feb-06,Dec-04,Jun-18,Sep-19,83,Insulins,22,Diabetes,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,135,Diabetes,7/7/14 12:28
208,89,Sanofi,Large Pharma,1569,Apidra,insulin glulisine,Recombinant Protein,Launched,Corporate Acquisition,Feb-06,Dec-04,Jun-18,Sep-19,83,Insulins,22,Diabetes,8,Metabolism,2,US,Sales,75.03291374,82.13479822,90.37840744,93.82480681,148.7393675,168.28797,186.2301875,211.6732887,228.9413887,244.2795865,260.0924981,273.1325335,9.070360463,135,Diabetes,7/7/14 12:28
209,24,Bristol-Myers Squibb,Large Pharma,3460,Eliquis,apixaban,Small Molecule (Chemical),Launched,In-House,Feb-13,Jun-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1348,Venous Thromboembolism,7/7/14 12:28
209,24,Bristol-Myers Squibb,Large Pharma,3460,Eliquis,apixaban,Small Molecule (Chemical),Launched,In-House,Feb-13,Jun-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,1,2,146,814,1158.760286,1464.783477,1752.5,1992.17,2185.18,2304.705123,48.31333055,1348,Venous Thromboembolism,7/7/14 12:28
209,24,Bristol-Myers Squibb,Large Pharma,3460,Eliquis,apixaban,Small Molecule (Chemical),Launched,In-House,Feb-13,Jun-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1348,Venous Thromboembolism,7/7/14 12:28
209,24,Bristol-Myers Squibb,Large Pharma,3460,Eliquis,apixaban,Small Molecule (Chemical),Launched,In-House,Feb-13,Jun-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,1,2,49,331.1,473.8,627.6,791.25,931.25,1021.6,1096.13875,55.8869388,1348,Venous Thromboembolism,7/7/14 12:28
209,24,Bristol-Myers Squibb,Large Pharma,3460,Eliquis,apixaban,Small Molecule (Chemical),Launched,In-House,Feb-13,Jun-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1348,Venous Thromboembolism,7/7/14 12:28
209,24,Bristol-Myers Squibb,Large Pharma,3460,Eliquis,apixaban,Small Molecule (Chemical),Launched,In-House,Feb-13,Jun-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,97,482.9,684.960286,837.1834775,961.25,1060.92,1163.58,1208.566373,43.38366202,1348,Venous Thromboembolism,7/7/14 12:28
210,76,Pfizer,Large Pharma,3460,Eliquis,apixaban,Small Molecule (Chemical),Launched,Licensed (Development),Feb-13,Jun-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1348,Venous Thromboembolism,7/7/14 12:28
210,76,Pfizer,Large Pharma,3460,Eliquis,apixaban,Small Molecule (Chemical),Launched,Licensed (Development),Feb-13,Jun-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,1,2,146,814,1158.760286,1464.783477,1752.5,1992.17,2185.18,2304.705123,48.31333055,1348,Venous Thromboembolism,7/7/14 12:28
210,76,Pfizer,Large Pharma,3460,Eliquis,apixaban,Small Molecule (Chemical),Launched,Licensed (Development),Feb-13,Jun-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1348,Venous Thromboembolism,7/7/14 12:28
210,76,Pfizer,Large Pharma,3460,Eliquis,apixaban,Small Molecule (Chemical),Launched,Licensed (Development),Feb-13,Jun-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,1,2,49,331.1,473.8,627.6,791.25,931.25,1021.6,1096.13875,55.8869388,1348,Venous Thromboembolism,7/7/14 12:28
210,76,Pfizer,Large Pharma,3460,Eliquis,apixaban,Small Molecule (Chemical),Launched,Licensed (Development),Feb-13,Jun-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1348,Venous Thromboembolism,7/7/14 12:28
210,76,Pfizer,Large Pharma,3460,Eliquis,apixaban,Small Molecule (Chemical),Launched,Licensed (Development),Feb-13,Jun-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,97,482.9,684.960286,837.1834775,961.25,1060.92,1163.58,1208.566373,43.38366202,1348,Venous Thromboembolism,7/7/14 12:28
213,26,Celgene,Regional & Specialty Pharma,277,Otezla,apremilast,Small Molecule (Chemical),Approved,In-House,Jun-14,Oct-15,May-20,May-20,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,137,psoriasis,7/7/14 12:28
213,26,Celgene,Regional & Specialty Pharma,277,Otezla,apremilast,Small Molecule (Chemical),Approved,In-House,Jun-14,Oct-15,May-20,May-20,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,14.583325,54.30549266,119.3054353,194.3058061,255.8336668,305.3518204,349.024076,0,137,psoriasis,7/7/14 12:28
213,26,Celgene,Regional & Specialty Pharma,277,Otezla,apremilast,Small Molecule (Chemical),Approved,In-House,Jun-14,Oct-15,May-20,May-20,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,137,psoriasis,7/7/14 12:28
213,26,Celgene,Regional & Specialty Pharma,277,Otezla,apremilast,Small Molecule (Chemical),Approved,In-House,Jun-14,Oct-15,May-20,May-20,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,5,28.33335,61.66668627,94.99999687,120.0666578,143.4266505,0,137,psoriasis,7/7/14 12:28
213,26,Celgene,Regional & Specialty Pharma,277,Otezla,apremilast,Small Molecule (Chemical),Approved,In-House,Jun-14,Oct-15,May-20,May-20,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,137,psoriasis,7/7/14 12:28
213,26,Celgene,Regional & Specialty Pharma,277,Otezla,apremilast,Small Molecule (Chemical),Approved,In-House,Jun-14,Oct-15,May-20,May-20,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,14.583325,49.30549266,90.97208534,132.6391199,160.8336699,185.2851626,205.5974254,0,137,psoriasis,7/7/14 12:28
214,89,Sanofi,Large Pharma,842,Aprovel,irbesartan,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-97,Apr-12,Aug-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1503,,7/7/14 12:28
214,89,Sanofi,Large Pharma,842,Aprovel,irbesartan,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-97,Apr-12,Aug-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,1717.01163,1757.949633,1795.054215,1479.347296,1193.89903,1054.349631,967.0311227,916.8974141,888.9045343,872.8003825,863.5404088,858.2784116,-4.605582196,1503,,7/7/14 12:28
214,89,Sanofi,Large Pharma,842,Aprovel,irbesartan,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-97,Apr-12,Aug-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1503,,7/7/14 12:28
214,89,Sanofi,Large Pharma,842,Aprovel,irbesartan,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-97,Apr-12,Aug-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,1707.693537,1706.284195,1726.922801,1421.510087,1171.322519,1034.269816,949.7008616,902.1680095,874.6979732,858.9566735,849.91315,844.7216106,-4.562378402,1503,,7/7/14 12:28
214,89,Sanofi,Large Pharma,842,Aprovel,irbesartan,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-97,Apr-12,Aug-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1503,,7/7/14 12:28
214,89,Sanofi,Large Pharma,842,Aprovel,irbesartan,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-97,Apr-12,Aug-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,9.318093074,51.66543759,68.13141484,57.83720968,22.57651113,20.07981461,17.33026116,14.72940458,14.20656106,13.84370897,13.6272588,13.55680105,-7.026917368,1503,,7/7/14 12:28
215,23,Boehringer Ingelheim,Large Pharma,261,Aptivus,tipranavir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-05,Oct-05,Dec-19,Jul-18,103,Protease Inhibitors,32,HIV,7,Anti-infectives,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,138,HIV,7/7/14 12:28
215,23,Boehringer Ingelheim,Large Pharma,261,Aptivus,tipranavir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-05,Oct-05,Dec-19,Jul-18,103,Protease Inhibitors,32,HIV,7,Anti-infectives,2,Global,Sales,52.00294214,45.35753758,42.18218,34.70232581,31.80711322,28.29460685,25.20853971,22.48315955,20.09035036,17.9853647,16.1330354,14.50405765,-10.61167476,138,HIV,7/7/14 12:28
215,23,Boehringer Ingelheim,Large Pharma,261,Aptivus,tipranavir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-05,Oct-05,Dec-19,Jul-18,103,Protease Inhibitors,32,HIV,7,Anti-infectives,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,138,HIV,7/7/14 12:28
215,23,Boehringer Ingelheim,Large Pharma,261,Aptivus,tipranavir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-05,Oct-05,Dec-19,Jul-18,103,Protease Inhibitors,32,HIV,7,Anti-infectives,2,ROW,Sales,24.21297409,21.05970253,19.64215386,16.70852724,15.60208254,14.20188549,13.00346636,11.92208209,10.97787626,10.14891464,9.417699108,8.775189175,-7.892221163,138,HIV,7/7/14 12:28
215,23,Boehringer Ingelheim,Large Pharma,261,Aptivus,tipranavir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-05,Oct-05,Dec-19,Jul-18,103,Protease Inhibitors,32,HIV,7,Anti-infectives,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,138,HIV,7/7/14 12:28
215,23,Boehringer Ingelheim,Large Pharma,261,Aptivus,tipranavir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-05,Oct-05,Dec-19,Jul-18,103,Protease Inhibitors,32,HIV,7,Anti-infectives,2,US,Sales,27.78996805,24.29783505,22.54002614,17.99379857,16.20503068,14.09272137,12.20507335,10.56107747,9.1124741,7.836450059,6.715336294,5.728868479,-13.80372614,138,HIV,7/7/14 12:28
217,11,Amgen,Large Pharma,91,Aranesp,darbepoetin alpha,Recombinant Protein,Launched,In-House,Oct-01,Jun-01,May-24,Jun-16,102,ESAs,24,Anemia,14,Hematology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1413,Renal Anemia,7/7/14 12:28
217,11,Amgen,Large Pharma,91,Aranesp,darbepoetin alpha,Recombinant Protein,Launched,In-House,Oct-01,Jun-01,May-24,Jun-16,102,ESAs,24,Anemia,14,Hematology,6,Global,Sales,1610,1541.46,1427.82,1234.5,1108.38,1060.576,1037.445428,999.3031744,868.9000673,811.1696975,726.815546,614.1371476,-8.088863819,1413,Renal Anemia,7/7/14 12:28
217,11,Amgen,Large Pharma,91,Aranesp,darbepoetin alpha,Recombinant Protein,Launched,In-House,Oct-01,Jun-01,May-24,Jun-16,102,ESAs,24,Anemia,14,Hematology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1413,Renal Anemia,7/7/14 12:28
217,11,Amgen,Large Pharma,91,Aranesp,darbepoetin alpha,Recombinant Protein,Launched,In-House,Oct-01,Jun-01,May-24,Jun-16,102,ESAs,24,Anemia,14,Hematology,6,ROW,Sales,899,857.46,816.5,768,675.12,650.576,638.39232,607.5396224,481.6920648,427.3126305,345.6434069,235.3189007,-13.9777299,1413,Renal Anemia,7/7/14 12:28
217,11,Amgen,Large Pharma,91,Aranesp,darbepoetin alpha,Recombinant Protein,Launched,In-House,Oct-01,Jun-01,May-24,Jun-16,102,ESAs,24,Anemia,14,Hematology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1413,Renal Anemia,7/7/14 12:28
217,11,Amgen,Large Pharma,91,Aranesp,darbepoetin alpha,Recombinant Protein,Launched,In-House,Oct-01,Jun-01,May-24,Jun-16,102,ESAs,24,Anemia,14,Hematology,6,US,Sales,711,684,611.32,466.5,433.26,410,399.053108,391.763552,387.2080026,383.857067,381.1721391,378.818247,-1.900022547,1413,Renal Anemia,7/7/14 12:28
218,11,Amgen,Large Pharma,91,Aranesp,darbepoetin alpha,Recombinant Protein,Launched,In-House,Jul-02,Aug-02,May-24,Jun-16,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1413,Chemotherapy-induced Anemia,7/7/14 12:28
218,11,Amgen,Large Pharma,91,Aranesp,darbepoetin alpha,Recombinant Protein,Launched,In-House,Jul-02,Aug-02,May-24,Jun-16,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,Global,Sales,1042.02,944.6,874.68,806,802.5,771.886,753.4758,719.11454,610.419102,560.2022926,478.8863184,377.4226833,-10.21627658,1413,Chemotherapy-induced Anemia,7/7/14 12:28
218,11,Amgen,Large Pharma,91,Aranesp,darbepoetin alpha,Recombinant Protein,Launched,In-House,Jul-02,Aug-02,May-24,Jun-16,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1413,Chemotherapy-induced Anemia,7/7/14 12:28
218,11,Amgen,Large Pharma,91,Aranesp,darbepoetin alpha,Recombinant Protein,Launched,In-House,Jul-02,Aug-02,May-24,Jun-16,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,ROW,Sales,502,525.6,500,490,488.8,476.48,471.98,447.08,344.896,299.871,222.466,124.1332,-17.7822977,1413,Chemotherapy-induced Anemia,7/7/14 12:28
218,11,Amgen,Large Pharma,91,Aranesp,darbepoetin alpha,Recombinant Protein,Launched,In-House,Jul-02,Aug-02,May-24,Jun-16,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1413,Chemotherapy-induced Anemia,7/7/14 12:28
218,11,Amgen,Large Pharma,91,Aranesp,darbepoetin alpha,Recombinant Protein,Launched,In-House,Jul-02,Aug-02,May-24,Jun-16,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,US,Sales,540.02,419,374.68,316,313.7,295.406,281.4958,272.03454,265.523102,260.3312926,256.4203184,253.2894833,-3.009552804,1413,Chemotherapy-induced Anemia,7/7/14 12:28
219,61,Merck & Co,Large Pharma,969,Arcoxia,etoricoxib,Small Molecule (Chemical),Launched,In-House,,Apr-02,,Jul-17,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,141,Pain,7/7/14 12:28
219,61,Merck & Co,Large Pharma,969,Arcoxia,etoricoxib,Small Molecule (Chemical),Launched,In-House,,Apr-02,,Jul-17,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,358,398,431,453,484,493.7017,488.8757,493.914916,374.2838658,156.3223372,104.8947189,77.64795597,-23.00378943,141,Pain,7/7/14 12:28
219,61,Merck & Co,Large Pharma,969,Arcoxia,etoricoxib,Small Molecule (Chemical),Launched,In-House,,Apr-02,,Jul-17,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,141,Pain,7/7/14 12:28
219,61,Merck & Co,Large Pharma,969,Arcoxia,etoricoxib,Small Molecule (Chemical),Launched,In-House,,Apr-02,,Jul-17,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,358,398,431,453,484,493.7017,488.8757,493.914916,374.2838658,156.3223372,104.8947189,77.64795597,-23.00378943,141,Pain,7/7/14 12:28
219,61,Merck & Co,Large Pharma,969,Arcoxia,etoricoxib,Small Molecule (Chemical),Launched,In-House,,Apr-02,,Jul-17,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,141,Pain,7/7/14 12:28
219,61,Merck & Co,Large Pharma,969,Arcoxia,etoricoxib,Small Molecule (Chemical),Launched,In-House,,Apr-02,,Jul-17,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,141,Pain,7/7/14 12:28
220,37,Eisai,Regional & Specialty Pharma,1072,Aricept,donepezil,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-97,Nov-10,Dec-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1423,Alzheimer's Disease,7/7/14 12:28
220,37,Eisai,Regional & Specialty Pharma,1072,Aricept,donepezil,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-97,Nov-10,Dec-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,Global,Sales,3484.107184,3135.323162,1826.482496,1134.651308,819.8653523,675.7789358,622.5717187,578.4857982,550.0318968,532.7263802,517.8350517,507.5149413,-6.622167938,1423,Alzheimer's Disease,7/7/14 12:28
220,37,Eisai,Regional & Specialty Pharma,1072,Aricept,donepezil,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-97,Nov-10,Dec-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1423,Alzheimer's Disease,7/7/14 12:28
220,37,Eisai,Regional & Specialty Pharma,1072,Aricept,donepezil,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-97,Nov-10,Dec-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,ROW,Sales,1383.321544,1599.178232,1718.187314,1002.225161,769.5267411,635.2775283,589.6339492,549.158071,529.7811931,516.314323,503.3861123,497.4472191,-6.042397635,1423,Alzheimer's Disease,7/7/14 12:28
220,37,Eisai,Regional & Specialty Pharma,1072,Aricept,donepezil,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-97,Nov-10,Dec-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1423,Alzheimer's Disease,7/7/14 12:28
220,37,Eisai,Regional & Specialty Pharma,1072,Aricept,donepezil,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-97,Nov-10,Dec-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,US,Sales,2100.78564,1536.14493,108.2951813,132.4261473,50.33861123,40.50140742,32.93776959,29.32772726,20.25070371,16.41205727,14.4489394,10.06772225,-20.54024126,1423,Alzheimer's Disease,7/7/14 12:28
221,76,Pfizer,Large Pharma,1072,Aricept,donepezil,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-97,Nov-10,Jan-12,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Alliance Revenue,710.7,639.5,372.5,230.9,34.7,27.6,22,17.5,15,14.6,12.4,12.2,-13.87142566,1423,Alzheimer's Disease,7/7/14 12:28
221,76,Pfizer,Large Pharma,1072,Aricept,donepezil,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-97,Nov-10,Jan-12,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,432,454,450,326,235,154.99,102,77,56,45,37,31,-25.126555,1423,Alzheimer's Disease,7/7/14 12:28
221,76,Pfizer,Large Pharma,1072,Aricept,donepezil,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-97,Nov-10,Jan-12,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Alliance Revenue,282.1,326.2,350.5,204.6,26.5,19.4,15.8,11.3,10.9,10.5,10.3,10.1,-12.87281097,1423,Alzheimer's Disease,7/7/14 12:28
221,76,Pfizer,Large Pharma,1072,Aricept,donepezil,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-97,Nov-10,Jan-12,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,432,454,450,326,235,154.99,102,77,56,45,37,31,-25.126555,1423,Alzheimer's Disease,7/7/14 12:28
221,76,Pfizer,Large Pharma,1072,Aricept,donepezil,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-97,Nov-10,Jan-12,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,US,Alliance Revenue,428.6,313.3,22,26.3,8.2,8.2,6.2,6.2,4.1,4.1,2.1,2.1,-17.68356069,1423,Alzheimer's Disease,7/7/14 12:28
221,76,Pfizer,Large Pharma,1072,Aricept,donepezil,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-97,Nov-10,Jan-12,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1423,Alzheimer's Disease,7/7/14 12:28
223,16,AstraZeneca,Large Pharma,1567,Arimidex,anastrozole,Small Molecule (Chemical),Launched,In-House,Jul-96,Jan-95,Jun-10,Feb-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,143,Breast Cancer,7/7/14 12:28
223,16,AstraZeneca,Large Pharma,1567,Arimidex,anastrozole,Small Molecule (Chemical),Launched,In-House,Jul-96,Jan-95,Jun-10,Feb-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,Global,Sales,1921,1512,756,543,351,259.47,201.0474,167.0166705,146.3611903,134.0287361,126.6142193,122.1692855,-13.99529777,143,Breast Cancer,7/7/14 12:28
223,16,AstraZeneca,Large Pharma,1567,Arimidex,anastrozole,Small Molecule (Chemical),Launched,In-House,Jul-96,Jan-95,Jun-10,Feb-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,143,Breast Cancer,7/7/14 12:28
223,16,AstraZeneca,Large Pharma,1567,Arimidex,anastrozole,Small Molecule (Chemical),Launched,In-House,Jul-96,Jan-95,Jun-10,Feb-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,ROW,Sales,1043,1018,714,522,345,254.25,195.9375,161.915625,141.2610938,128.9287266,121.5142184,117.0692854,-14.30680518,143,Breast Cancer,7/7/14 12:28
223,16,AstraZeneca,Large Pharma,1567,Arimidex,anastrozole,Small Molecule (Chemical),Launched,In-House,Jul-96,Jan-95,Jun-10,Feb-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,143,Breast Cancer,7/7/14 12:28
223,16,AstraZeneca,Large Pharma,1567,Arimidex,anastrozole,Small Molecule (Chemical),Launched,In-House,Jul-96,Jan-95,Jun-10,Feb-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,US,Sales,878,494,42,21,6,5.22,5.1099,5.1010455,5.100096547,5.100009572,5.100000913,5.100000089,-2.294952422,143,Breast Cancer,7/7/14 12:28
224,46,GlaxoSmithKline,Large Pharma,1389,Arixtra,fondaparinux,Synthetic Peptide,Launched,Licensed (Marketed),Feb-02,Mar-02,Jul-11,Dec-13,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1476,Thrombosis,7/7/14 12:28
224,46,GlaxoSmithKline,Large Pharma,1389,Arixtra,fondaparinux,Synthetic Peptide,Launched,Licensed (Marketed),Feb-02,Mar-02,Jul-11,Dec-13,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,Global,Sales,393.4012402,465.0450174,442.4778761,309.0806304,261.0901427,0,0,0,0,0,0,0,-100,1476,Thrombosis,7/7/14 12:28
224,46,GlaxoSmithKline,Large Pharma,1389,Arixtra,fondaparinux,Synthetic Peptide,Launched,Licensed (Marketed),Feb-02,Mar-02,Jul-11,Dec-13,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1476,Thrombosis,7/7/14 12:28
224,46,GlaxoSmithKline,Large Pharma,1389,Arixtra,fondaparinux,Synthetic Peptide,Launched,Licensed (Marketed),Feb-02,Mar-02,Jul-11,Dec-13,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,ROW,Sales,173.5453419,191.5800072,206.8103117,201.298667,182.9194413,0,0,0,0,0,0,0,-100,1476,Thrombosis,7/7/14 12:28
224,46,GlaxoSmithKline,Large Pharma,1389,Arixtra,fondaparinux,Synthetic Peptide,Launched,Licensed (Marketed),Feb-02,Mar-02,Jul-11,Dec-13,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1476,Thrombosis,7/7/14 12:28
224,46,GlaxoSmithKline,Large Pharma,1389,Arixtra,fondaparinux,Synthetic Peptide,Launched,Licensed (Marketed),Feb-02,Mar-02,Jul-11,Dec-13,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,US,Sales,219.8558982,273.4650103,235.6675644,107.7819634,78.1707014,0,0,0,0,0,0,0,-100,1476,Thrombosis,7/7/14 12:28
226,46,GlaxoSmithKline,Large Pharma,3089,Votrient,pazopanib,Small Molecule (Chemical),Launched,In-House,Nov-09,Jul-10,Oct-23,Jun-25,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1583,Renal Cell Carcinoma,7/7/14 12:28
226,46,GlaxoSmithKline,Large Pharma,3089,Votrient,pazopanib,Small Molecule (Chemical),Launched,In-House,Nov-09,Jul-10,Oct-23,Jun-25,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,Global,Sales,7.796308448,58.84184311,160.3180711,289.4277582,517.4900433,643.3336114,779.6961408,884.5527521,953.0756139,1003.190724,1042.039315,1074.498288,11.00155401,1583,Renal Cell Carcinoma,7/7/14 12:28
226,46,GlaxoSmithKline,Large Pharma,3089,Votrient,pazopanib,Small Molecule (Chemical),Launched,In-House,Nov-09,Jul-10,Oct-23,Jun-25,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1583,Renal Cell Carcinoma,7/7/14 12:28
226,46,GlaxoSmithKline,Large Pharma,3089,Votrient,pazopanib,Small Molecule (Chemical),Launched,In-House,Nov-09,Jul-10,Oct-23,Jun-25,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,ROW,Sales,0,7.72500029,70.53995126,145.8226564,292.3584232,370.0584642,463.9798264,541.7005404,591.3033165,626.8376405,654.5967948,678.7796341,12.78698186,1583,Renal Cell Carcinoma,7/7/14 12:28
226,46,GlaxoSmithKline,Large Pharma,3089,Votrient,pazopanib,Small Molecule (Chemical),Launched,In-House,Nov-09,Jul-10,Oct-23,Jun-25,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1583,Renal Cell Carcinoma,7/7/14 12:28
226,46,GlaxoSmithKline,Large Pharma,3089,Votrient,pazopanib,Small Molecule (Chemical),Launched,In-House,Nov-09,Jul-10,Oct-23,Jun-25,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,US,Sales,7.796308448,51.11684282,89.77811979,143.6051018,225.13162,273.2751472,315.7163144,342.8522117,361.7722974,376.3530839,387.4425205,395.7186542,8.390900902,1583,Renal Cell Carcinoma,7/7/14 12:28
227,76,Pfizer,Large Pharma,340,Aromasin,exemestane,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Jan-00,Apr-11,Jul-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1458,Breast Cancer,7/7/14 12:28
227,76,Pfizer,Large Pharma,340,Aromasin,exemestane,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Jan-00,Apr-11,Jul-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,Global,Sales,483.405,483,361,210,185,140,110.34,95.4422,82.090326,74.47620758,68.9883805,65.26688557,-13.82917905,1458,Breast Cancer,7/7/14 12:28
227,76,Pfizer,Large Pharma,340,Aromasin,exemestane,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Jan-00,Apr-11,Jul-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1458,Breast Cancer,7/7/14 12:28
227,76,Pfizer,Large Pharma,340,Aromasin,exemestane,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Jan-00,Apr-11,Jul-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,ROW,Sales,320,323,303,195,173,130,101,86.32,73.04,65.4496,59.9696,56.250688,-14.82787938,1458,Breast Cancer,7/7/14 12:28
227,76,Pfizer,Large Pharma,340,Aromasin,exemestane,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Jan-00,Apr-11,Jul-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1458,Breast Cancer,7/7/14 12:28
227,76,Pfizer,Large Pharma,340,Aromasin,exemestane,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Jan-00,Apr-11,Jul-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,US,Sales,163.405,160,58,15,12,10,9.34,9.1222,9.050326,9.02660758,9.018780501,9.016197565,-4.001778905,1458,Breast Cancer,7/7/14 12:28
229,46,GlaxoSmithKline,Large Pharma,248,Arranon,nelarabine,Small Molecule (Chemical),Launched,In-House,Jan-06,Nov-07,N/A,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,144,Acute Lymphoblastic Leukemia,7/7/14 12:28
229,46,GlaxoSmithKline,Large Pharma,248,Arranon,nelarabine,Small Molecule (Chemical),Launched,In-House,Jan-06,Nov-07,N/A,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,4,Global,Sales,38.08960947,39.39750148,42.95508138,43.34858666,42.5976407,42.77312892,42.83714121,42.85294861,42.87161011,42.87967274,42.88351012,42.88593105,9.64E-02,144,Acute Lymphoblastic Leukemia,7/7/14 12:28
229,46,GlaxoSmithKline,Large Pharma,248,Arranon,nelarabine,Small Molecule (Chemical),Launched,In-House,Jan-06,Nov-07,N/A,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,144,Acute Lymphoblastic Leukemia,7/7/14 12:28
229,46,GlaxoSmithKline,Large Pharma,248,Arranon,nelarabine,Small Molecule (Chemical),Launched,In-House,Jan-06,Nov-07,N/A,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,4,ROW,Sales,15.84480144,16.99500064,18.99652371,19.46455565,19.2397127,19.38610963,19.45215067,19.47766812,19.49622325,19.50526555,19.5098229,19.51243362,0.201278823,144,Acute Lymphoblastic Leukemia,7/7/14 12:28
229,46,GlaxoSmithKline,Large Pharma,248,Arranon,nelarabine,Small Molecule (Chemical),Launched,In-House,Jan-06,Nov-07,N/A,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,144,Acute Lymphoblastic Leukemia,7/7/14 12:28
229,46,GlaxoSmithKline,Large Pharma,248,Arranon,nelarabine,Small Molecule (Chemical),Launched,In-House,Jan-06,Nov-07,N/A,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,4,US,Sales,22.24480803,22.40250084,23.95855767,23.88403101,23.357928,23.38701928,23.38499054,23.37528049,23.37538687,23.3744072,23.37368722,23.37349743,9.52E-03,144,Acute Lymphoblastic Leukemia,7/7/14 12:28
230,34,Daiichi-Sankyo,Regional & Specialty Pharma,1561,Artist,carvedilol,Small Molecule (Chemical),Launched,Licensed (Development),,May-93,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1382,Hypertension,7/7/14 12:28
230,34,Daiichi-Sankyo,Regional & Specialty Pharma,1561,Artist,carvedilol,Small Molecule (Chemical),Launched,Licensed (Development),,May-93,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,Global,Sales,251.0169508,276.6461614,291.6392521,269.667791,223.8351951,221.61946,220.5476423,219.6435653,219.1001942,218.702146,218.4432557,218.2625976,-0.359510862,1382,Hypertension,7/7/14 12:28
230,34,Daiichi-Sankyo,Regional & Specialty Pharma,1561,Artist,carvedilol,Small Molecule (Chemical),Launched,Licensed (Development),,May-93,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1382,Hypertension,7/7/14 12:28
230,34,Daiichi-Sankyo,Regional & Specialty Pharma,1561,Artist,carvedilol,Small Molecule (Chemical),Launched,Licensed (Development),,May-93,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,251.0169508,276.6461614,291.6392521,269.667791,223.8351951,221.61946,220.5476423,219.6435653,219.1001942,218.702146,218.4432557,218.2625976,-0.359510862,1382,Hypertension,7/7/14 12:28
230,34,Daiichi-Sankyo,Regional & Specialty Pharma,1561,Artist,carvedilol,Small Molecule (Chemical),Launched,Licensed (Development),,May-93,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1382,Hypertension,7/7/14 12:28
230,34,Daiichi-Sankyo,Regional & Specialty Pharma,1561,Artist,carvedilol,Small Molecule (Chemical),Launched,Licensed (Development),,May-93,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1382,Hypertension,7/7/14 12:28
232,46,GlaxoSmithKline,Large Pharma,608,Arzerra,ofatumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Nov-12,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1568,Rheumatoid Arthritis,7/7/14 12:28
232,46,GlaxoSmithKline,Large Pharma,608,Arzerra,ofatumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Nov-12,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,Global,Sales,0,0,0,0.792514437,2.991453563,4.218876874,6.137158,6.93335059,7.481929973,7.885491635,8.122008558,8.279077835,15.65303572,1568,Rheumatoid Arthritis,7/7/14 12:28
232,46,GlaxoSmithKline,Large Pharma,608,Arzerra,ofatumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Nov-12,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1568,Rheumatoid Arthritis,7/7/14 12:28
232,46,GlaxoSmithKline,Large Pharma,608,Arzerra,ofatumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Nov-12,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,ROW,Sales,0,0,0,0.792514437,2.991453563,4.218876874,6.137158,6.93335059,7.481929973,7.885491635,8.122008558,8.279077835,15.65303572,1568,Rheumatoid Arthritis,7/7/14 12:28
232,46,GlaxoSmithKline,Large Pharma,608,Arzerra,ofatumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Nov-12,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1568,Rheumatoid Arthritis,7/7/14 12:28
232,46,GlaxoSmithKline,Large Pharma,608,Arzerra,ofatumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Nov-12,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1568,Rheumatoid Arthritis,7/7/14 12:28
233,46,GlaxoSmithKline,Large Pharma,608,Arzerra,ofatumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Dec-09,May-10,Oct-21,Oct-23,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1568,Chronic Lymphocytic Leukemia,7/7/14 12:28
233,46,GlaxoSmithKline,Large Pharma,608,Arzerra,ofatumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Dec-09,May-10,Oct-21,Oct-23,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,4,Global,Sales,6.237046758,47.8950018,70.68281544,95.10173244,114.129224,128.1731705,140.0338396,149.4969035,157.1745794,163.567178,168.8985848,173.4009968,6.157491858,1568,Chronic Lymphocytic Leukemia,7/7/14 12:28
233,46,GlaxoSmithKline,Large Pharma,608,Arzerra,ofatumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Dec-09,May-10,Oct-21,Oct-23,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1568,Chronic Lymphocytic Leukemia,7/7/14 12:28
233,46,GlaxoSmithKline,Large Pharma,608,Arzerra,ofatumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Dec-09,May-10,Oct-21,Oct-23,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,4,ROW,Sales,0,7.72500029,20.98421341,34.87063523,42.21217876,50.70600544,58.20865787,64.49896847,70.17474157,75.15514974,79.51594825,83.36368931,10.20970438,1568,Chronic Lymphocytic Leukemia,7/7/14 12:28
233,46,GlaxoSmithKline,Large Pharma,608,Arzerra,ofatumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Dec-09,May-10,Oct-21,Oct-23,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1568,Chronic Lymphocytic Leukemia,7/7/14 12:28
233,46,GlaxoSmithKline,Large Pharma,608,Arzerra,ofatumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Dec-09,May-10,Oct-21,Oct-23,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,4,US,Sales,6.237046758,40.17000151,49.69860203,60.23109721,71.91704529,77.46716509,81.8251817,84.99793504,86.99983785,88.41202822,89.38263656,90.03730749,3.262232315,1568,Chronic Lymphocytic Leukemia,7/7/14 12:28
235,37,Eisai,Regional & Specialty Pharma,2587,ranirestat,AS-3201,Small Molecule (Chemical),Phase III,Licensed (Development),Mar-15,Sep-15,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1609,Diabetic Neuropathy,7/7/14 12:28
235,37,Eisai,Regional & Specialty Pharma,2587,ranirestat,AS-3201,Small Molecule (Chemical),Phase III,Licensed (Development),Mar-15,Sep-15,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,1.041842784,23.4484471,39.48586787,55.41253685,100.4697051,121.8295534,140.9481114,0,1609,Diabetic Neuropathy,7/7/14 12:28
235,37,Eisai,Regional & Specialty Pharma,2587,ranirestat,AS-3201,Small Molecule (Chemical),Phase III,Licensed (Development),Mar-15,Sep-15,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1609,Diabetic Neuropathy,7/7/14 12:28
235,37,Eisai,Regional & Specialty Pharma,2587,ranirestat,AS-3201,Small Molecule (Chemical),Phase III,Licensed (Development),Mar-15,Sep-15,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,10.2517371,17.95437977,25.54620971,37.95911301,44.97628343,50.33861123,0,1609,Diabetic Neuropathy,7/7/14 12:28
235,37,Eisai,Regional & Specialty Pharma,2587,ranirestat,AS-3201,Small Molecule (Chemical),Phase III,Licensed (Development),Mar-15,Sep-15,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1609,Diabetic Neuropathy,7/7/14 12:28
235,37,Eisai,Regional & Specialty Pharma,2587,ranirestat,AS-3201,Small Molecule (Chemical),Phase III,Licensed (Development),Mar-15,Sep-15,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,1.041842784,13.19671,21.5314881,29.86632714,62.51059207,76.85326993,90.60950021,0,1609,Diabetic Neuropathy,7/7/14 12:28
237,111,Actavis,Regional & Specialty Pharma,709,Asacol,mesalamine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,,Jul-13,Dec-05,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1542,ulcerative colitis,7/7/14 12:28
237,111,Actavis,Regional & Specialty Pharma,709,Asacol,mesalamine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,,Jul-13,Dec-05,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,4.00E-02,5.00E-02,0,124.0422,434.20487,380.3036665,282.387814,251.6204304,228.8030239,211.7006548,198.9302242,6.980455778,1542,ulcerative colitis,7/7/14 12:28
237,111,Actavis,Regional & Specialty Pharma,709,Asacol,mesalamine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,,Jul-13,Dec-05,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1542,ulcerative colitis,7/7/14 12:28
237,111,Actavis,Regional & Specialty Pharma,709,Asacol,mesalamine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,,Jul-13,Dec-05,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,4.00E-02,5.00E-02,0,21.0422,88.60487,92.6536665,96.38581397,99.08308666,101.3777146,103.2697623,104.791469,25.77805354,1542,ulcerative colitis,7/7/14 12:28
237,111,Actavis,Regional & Specialty Pharma,709,Asacol,mesalamine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,,Jul-13,Dec-05,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1542,ulcerative colitis,7/7/14 12:28
237,111,Actavis,Regional & Specialty Pharma,709,Asacol,mesalamine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,,Jul-13,Dec-05,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,103,345.6,287.65,186.002,152.5373438,127.4253094,108.4308926,94.13875523,-1.276907252,1542,ulcerative colitis,7/7/14 12:28
237,111,Warner Chilcott ,Regional & Specialty Pharma,709,Asacol,mesalamine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,,Jul-13,Dec-05,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Proforma,459.6,713.8,742.8,793,372.7,0,0,0,0,0,0,0,-100,1542,ulcerative colitis,7/7/14 12:28
237,111,Warner Chilcott ,Regional & Specialty Pharma,709,Asacol,mesalamine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,,Jul-13,Dec-05,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Proforma,0,74.8,70.8,74,63.7,0,0,0,0,0,0,0,-100,1542,ulcerative colitis,7/7/14 12:28
237,111,Warner Chilcott ,Regional & Specialty Pharma,709,Asacol,mesalamine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,,Jul-13,Dec-05,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Proforma,459.6,639,672,719,309,0,0,0,0,0,0,0,-100,1542,ulcerative colitis,7/7/14 12:28
239,15,Astellas Pharma,Regional & Specialty Pharma,415,ASKP1240,ASKP1240,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1351,Transplant Rejection,7/7/14 12:28
239,15,Astellas Pharma,Regional & Specialty Pharma,415,ASKP1240,ASKP1240,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1351,Transplant Rejection,7/7/14 12:28
239,15,Astellas Pharma,Regional & Specialty Pharma,415,ASKP1240,ASKP1240,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1351,Transplant Rejection,7/7/14 12:28
239,15,Astellas Pharma,Regional & Specialty Pharma,415,ASKP1240,ASKP1240,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1351,Transplant Rejection,7/7/14 12:28
239,15,Astellas Pharma,Regional & Specialty Pharma,415,ASKP1240,ASKP1240,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1351,Transplant Rejection,7/7/14 12:28
239,15,Astellas Pharma,Regional & Specialty Pharma,415,ASKP1240,ASKP1240,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1351,Transplant Rejection,7/7/14 12:28
240,61,Merck & Co,Large Pharma,344,Asmanex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,Jan-03,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1549,Asthma,7/7/14 12:28
240,61,Merck & Co,Large Pharma,344,Asmanex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,Jan-03,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,Global,Sales,37.2,208,206,185,184,180.9,178.15,177.21875,176.503625,176.1001844,175.9608547,175.9241993,-0.639127354,1549,Asthma,7/7/14 12:28
240,61,Merck & Co,Large Pharma,344,Asmanex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,Jan-03,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1549,Asthma,7/7/14 12:28
240,61,Merck & Co,Large Pharma,344,Asmanex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,Jan-03,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,1.7,13,21,19,22,23.75,24.7125,25.836875,26.67753125,27.34262969,27.90936445,28.36508417,3.696929724,1549,Asthma,7/7/14 12:28
240,61,Merck & Co,Large Pharma,344,Asmanex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,Jan-03,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1549,Asthma,7/7/14 12:28
240,61,Merck & Co,Large Pharma,344,Asmanex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,Jan-03,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,US,Sales,35.5,195,185,166,162,157.15,153.4375,151.381875,149.8260938,148.7575547,148.0514902,147.5591151,-1.324963557,1549,Asthma,7/7/14 12:28
240,61,Schering-Plough,Large Pharma,344,Asmanex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,Jan-03,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,Global,Proforma,176.8,0,0,0,0,0,0,0,0,0,0,0,0,1549,Asthma,7/7/14 12:28
240,61,Schering-Plough,Large Pharma,344,Asmanex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,Jan-03,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,ROW,Proforma,8.3,0,0,0,0,0,0,0,0,0,0,0,0,1549,Asthma,7/7/14 12:28
240,61,Schering-Plough,Large Pharma,344,Asmanex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,Jan-03,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,US,Proforma,168.5,0,0,0,0,0,0,0,0,0,0,0,0,1549,Asthma,7/7/14 12:28
242,61,Merck & Co,Large Pharma,2211,Dulera,formoterol + mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-10,Oct-11,Jan-20,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,390,Asthma,7/7/14 12:28
242,61,Merck & Co,Large Pharma,2211,Dulera,formoterol + mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-10,Oct-11,Jan-20,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,8,96,207,324,392.09345,451.66602,499.2821053,534.9649136,563.5957568,589.2104381,610.9086604,9.483150235,390,Asthma,7/7/14 12:28
242,61,Merck & Co,Large Pharma,2211,Dulera,formoterol + mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-10,Oct-11,Jan-20,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,390,Asthma,7/7/14 12:28
242,61,Merck & Co,Large Pharma,2211,Dulera,formoterol + mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-10,Oct-11,Jan-20,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,2,8,15,21.95115,24.66138,26.597564,27.8661204,28.56899216,29.016688,29.29205629,10.03291431,390,Asthma,7/7/14 12:28
242,61,Merck & Co,Large Pharma,2211,Dulera,formoterol + mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-10,Oct-11,Jan-20,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,390,Asthma,7/7/14 12:28
242,61,Merck & Co,Large Pharma,2211,Dulera,formoterol + mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-10,Oct-11,Jan-20,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,8,94,199,309,370.1423,427.00464,472.6845413,507.0987932,535.0267646,560.1937501,581.6166041,9.45603711,390,Asthma,7/7/14 12:28
243,67,Novartis,Large Pharma,2677,Onbrez + Asmanex,indacaterol + mometasone furoate,Small Molecule (Chemical),Phase II,Licensed (Development),,Jul-17,N/A,Jun-25,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,149,Asthma,7/7/14 12:28
243,67,Novartis,Large Pharma,2677,Onbrez + Asmanex,indacaterol + mometasone furoate,Small Molecule (Chemical),Phase II,Licensed (Development),,Jul-17,N/A,Jun-25,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,37.5,100.000125,150.0001875,199.99975,0,149,Asthma,7/7/14 12:28
243,67,Novartis,Large Pharma,2677,Onbrez + Asmanex,indacaterol + mometasone furoate,Small Molecule (Chemical),Phase II,Licensed (Development),,Jul-17,N/A,Jun-25,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,149,Asthma,7/7/14 12:28
243,67,Novartis,Large Pharma,2677,Onbrez + Asmanex,indacaterol + mometasone furoate,Small Molecule (Chemical),Phase II,Licensed (Development),,Jul-17,N/A,Jun-25,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,37.5,100.000125,150.0001875,199.99975,0,149,Asthma,7/7/14 12:28
243,67,Novartis,Large Pharma,2677,Onbrez + Asmanex,indacaterol + mometasone furoate,Small Molecule (Chemical),Phase II,Licensed (Development),,Jul-17,N/A,Jun-25,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,149,Asthma,7/7/14 12:28
243,67,Novartis,Large Pharma,2677,Onbrez + Asmanex,indacaterol + mometasone furoate,Small Molecule (Chemical),Phase II,Licensed (Development),,Jul-17,N/A,Jun-25,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,149,Asthma,7/7/14 12:28
246,1307,Janssen,Small Biotech,2191,ASP015K,peficitinib,Small Molecule (Chemical),Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,152,Transplant Rejection,7/7/14 12:28
246,1307,Janssen,Small Biotech,2191,ASP015K,peficitinib,Small Molecule (Chemical),Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,152,Transplant Rejection,7/7/14 12:28
246,1307,Janssen,Small Biotech,2191,ASP015K,peficitinib,Small Molecule (Chemical),Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,152,Transplant Rejection,7/7/14 12:28
246,1307,Janssen,Small Biotech,2191,ASP015K,peficitinib,Small Molecule (Chemical),Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,152,Transplant Rejection,7/7/14 12:28
246,1307,Janssen,Small Biotech,2191,ASP015K,peficitinib,Small Molecule (Chemical),Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,152,Transplant Rejection,7/7/14 12:28
246,1307,Janssen,Small Biotech,2191,ASP015K,peficitinib,Small Molecule (Chemical),Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,152,Transplant Rejection,7/7/14 12:28
248,15,Astellas Pharma,Regional & Specialty Pharma,1915,Kiklin,bixalomer,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-12,,Jun-25,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1365,Hyperphosphatemia,7/7/14 12:28
248,15,Astellas Pharma,Regional & Specialty Pharma,1915,Kiklin,bixalomer,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-12,,Jun-25,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,Global,Sales,0,0,0,6.019370334,15.20963953,21.70096159,32.45682619,39.94521386,46.56058797,52.72488899,57.97644121,62.6149542,22.40356756,1365,Hyperphosphatemia,7/7/14 12:28
248,15,Astellas Pharma,Regional & Specialty Pharma,1915,Kiklin,bixalomer,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-12,,Jun-25,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1365,Hyperphosphatemia,7/7/14 12:28
248,15,Astellas Pharma,Regional & Specialty Pharma,1915,Kiklin,bixalomer,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-12,,Jun-25,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,ROW,Sales,0,0,0,6.019370334,15.20963953,21.70096159,32.45682619,39.94521386,46.56058797,52.72488899,57.97644121,62.6149542,22.40356756,1365,Hyperphosphatemia,7/7/14 12:28
248,15,Astellas Pharma,Regional & Specialty Pharma,1915,Kiklin,bixalomer,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-12,,Jun-25,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1365,Hyperphosphatemia,7/7/14 12:28
248,15,Astellas Pharma,Regional & Specialty Pharma,1915,Kiklin,bixalomer,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-12,,Jun-25,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1365,Hyperphosphatemia,7/7/14 12:28
249,15,Astellas Pharma,Regional & Specialty Pharma,4327,Suglat,ipragliflozin,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,155,Type II Diabetes,7/7/14 12:28
249,15,Astellas Pharma,Regional & Specialty Pharma,4327,Suglat,ipragliflozin,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,0,0,30.37605557,65.69702922,116.2062192,162.0056297,198.0989553,231.6096144,246.659195,0,155,Type II Diabetes,7/7/14 12:28
249,15,Astellas Pharma,Regional & Specialty Pharma,4327,Suglat,ipragliflozin,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,155,Type II Diabetes,7/7/14 12:28
249,15,Astellas Pharma,Regional & Specialty Pharma,4327,Suglat,ipragliflozin,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,0,0,30.37605557,65.69702922,116.2062192,162.0056297,198.0989553,231.6096144,246.659195,0,155,Type II Diabetes,7/7/14 12:28
249,15,Astellas Pharma,Regional & Specialty Pharma,4327,Suglat,ipragliflozin,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,155,Type II Diabetes,7/7/14 12:28
249,15,Astellas Pharma,Regional & Specialty Pharma,4327,Suglat,ipragliflozin,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,155,Type II Diabetes,7/7/14 12:28
258,16,AstraZeneca,Large Pharma,951,Atacand,candesartan cilexitil,Small Molecule (Chemical),Launched,Licensed (Development),Oct-98,Dec-97,Dec-12,May-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1375,Hypertension,7/7/14 12:28
258,16,AstraZeneca,Large Pharma,951,Atacand,candesartan cilexitil,Small Molecule (Chemical),Launched,Licensed (Development),Oct-98,Dec-97,Dec-12,May-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,1436,1483,1450,1009,611,512.5,457.325,432.22375,419.1573125,412.9196594,409.7677958,408.2312433,-5.598098218,1375,Hypertension,7/7/14 12:28
258,16,AstraZeneca,Large Pharma,951,Atacand,candesartan cilexitil,Small Molecule (Chemical),Launched,Licensed (Development),Oct-98,Dec-97,Dec-12,May-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1375,Hypertension,7/7/14 12:28
258,16,AstraZeneca,Large Pharma,951,Atacand,candesartan cilexitil,Small Molecule (Chemical),Launched,Licensed (Development),Oct-98,Dec-97,Dec-12,May-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,1173,1267,1268,859,539,457,416,395.5,385.25,380.125,377.5625,376.28125,-5.004414435,1375,Hypertension,7/7/14 12:28
258,16,AstraZeneca,Large Pharma,951,Atacand,candesartan cilexitil,Small Molecule (Chemical),Launched,Licensed (Development),Oct-98,Dec-97,Dec-12,May-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1375,Hypertension,7/7/14 12:28
258,16,AstraZeneca,Large Pharma,951,Atacand,candesartan cilexitil,Small Molecule (Chemical),Launched,Licensed (Development),Oct-98,Dec-97,Dec-12,May-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,263,216,182,150,72,55.5,41.325,36.72375,33.9073125,32.79465938,32.20529578,31.94999327,-10.95875322,1375,Hypertension,7/7/14 12:28
260,67,Novartis,Large Pharma,1575,ATI355,ATI355,Antibody/Antibody Derivative,Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,166,Spinal cord injury,7/7/14 12:28
260,67,Novartis,Large Pharma,1575,ATI355,ATI355,Antibody/Antibody Derivative,Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,166,Spinal cord injury,7/7/14 12:28
260,67,Novartis,Large Pharma,1575,ATI355,ATI355,Antibody/Antibody Derivative,Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,166,Spinal cord injury,7/7/14 12:28
260,67,Novartis,Large Pharma,1575,ATI355,ATI355,Antibody/Antibody Derivative,Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,166,Spinal cord injury,7/7/14 12:28
260,67,Novartis,Large Pharma,1575,ATI355,ATI355,Antibody/Antibody Derivative,Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,166,Spinal cord injury,7/7/14 12:28
260,67,Novartis,Large Pharma,1575,ATI355,ATI355,Antibody/Antibody Derivative,Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,166,Spinal cord injury,7/7/14 12:28
261,45,Gilead,Regional & Specialty Pharma,1192,Atripla,emtricitabine + tenofovir + efavirenz,Small Molecule (Chemical),Launched,In-House,Jul-06,Dec-07,May-21,Jan-18,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,168,HIV,7/7/14 12:28
261,45,Gilead,Regional & Specialty Pharma,1192,Atripla,emtricitabine + tenofovir + efavirenz,Small Molecule (Chemical),Launched,In-House,Jul-06,Dec-07,May-21,Jan-18,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,Global,Sales,2382.2,2926.58,3224.52,3574.83,3649,3255.948195,3143.146301,3026.044415,2899.059197,2540.45909,2131.152559,1794.628356,-9.640968532,168,HIV,7/7/14 12:28
261,45,Gilead,Regional & Specialty Pharma,1192,Atripla,emtricitabine + tenofovir + efavirenz,Small Molecule (Chemical),Launched,In-House,Jul-06,Dec-07,May-21,Jan-18,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,168,HIV,7/7/14 12:28
261,45,Gilead,Regional & Specialty Pharma,1192,Atripla,emtricitabine + tenofovir + efavirenz,Small Molecule (Chemical),Launched,In-House,Jul-06,Dec-07,May-21,Jan-18,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,ROW,Sales,736.2,1017.7,1202.47,1321.83,1293,1197.832995,1163.705821,1145.77313,1128.985455,887.0261856,598.9323221,360.8272664,-16.66748628,168,HIV,7/7/14 12:28
261,45,Gilead,Regional & Specialty Pharma,1192,Atripla,emtricitabine + tenofovir + efavirenz,Small Molecule (Chemical),Launched,In-House,Jul-06,Dec-07,May-21,Jan-18,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,168,HIV,7/7/14 12:28
261,45,Gilead,Regional & Specialty Pharma,1192,Atripla,emtricitabine + tenofovir + efavirenz,Small Molecule (Chemical),Launched,In-House,Jul-06,Dec-07,May-21,Jan-18,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,US,Sales,1646,1908.88,2022.05,2253,2356,2058.1152,1979.44048,1880.271285,1770.073742,1653.432905,1532.220237,1433.80109,-6.848963689,168,HIV,7/7/14 12:28
262,23,Boehringer Ingelheim,Large Pharma,788,Atrovent,ipratropium bromide,Small Molecule (Chemical),Launched,In-House,Mar-87,Jan-75,Expired,Expired,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,169,COPD,7/7/14 12:28
262,23,Boehringer Ingelheim,Large Pharma,788,Atrovent,ipratropium bromide,Small Molecule (Chemical),Launched,In-House,Mar-87,Jan-75,Expired,Expired,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,Global,Sales,304.430451,277.1316558,282.4604098,254.1580064,255.9519086,251.8026585,248.5594358,246.3416939,244.7034046,243.5465952,242.7080656,242.1094639,-0.791133365,169,COPD,7/7/14 12:28
262,23,Boehringer Ingelheim,Large Pharma,788,Atrovent,ipratropium bromide,Small Molecule (Chemical),Launched,In-House,Mar-87,Jan-75,Expired,Expired,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,169,COPD,7/7/14 12:28
262,23,Boehringer Ingelheim,Large Pharma,788,Atrovent,ipratropium bromide,Small Molecule (Chemical),Launched,In-House,Mar-87,Jan-75,Expired,Expired,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,121.9571044,111.0454958,113.2050826,101.8766964,102.6076835,100.9527585,99.658799,98.77413366,98.12054621,97.65907038,97.32455139,97.08575295,-0.787144568,169,COPD,7/7/14 12:28
262,23,Boehringer Ingelheim,Large Pharma,788,Atrovent,ipratropium bromide,Small Molecule (Chemical),Launched,In-House,Mar-87,Jan-75,Expired,Expired,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,169,COPD,7/7/14 12:28
262,23,Boehringer Ingelheim,Large Pharma,788,Atrovent,ipratropium bromide,Small Molecule (Chemical),Launched,In-House,Mar-87,Jan-75,Expired,Expired,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,US,Sales,182.4733466,166.08616,169.2553271,152.28131,153.3442251,150.8499,148.9006368,147.5675603,146.5828584,145.8875248,145.3835142,145.023711,-0.793802938,169,COPD,7/7/14 12:28
263,46,GlaxoSmithKline,Large Pharma,1012,Augmentin,amoxicillin  +  clavulanic acid,Small Molecule (Chemical),Launched,In-House,Jul-84,Jul-81,Apr-01,Expired,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,170,bacterial infection,7/7/14 12:28
263,46,GlaxoSmithKline,Large Pharma,1012,Augmentin,amoxicillin  +  clavulanic acid,Small Molecule (Chemical),Launched,In-House,Jul-84,Jul-81,Apr-01,Expired,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,4,Global,Sales,1040.027547,965.6250362,1027.638835,963.6975554,984.9508377,970.8801114,969.6293802,697.0735968,586.5425388,487.6537462,416.8808823,387.7961646,-12.46738387,170,bacterial infection,7/7/14 12:28
263,46,GlaxoSmithKline,Large Pharma,1012,Augmentin,amoxicillin  +  clavulanic acid,Small Molecule (Chemical),Launched,In-House,Jul-84,Jul-81,Apr-01,Expired,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,170,bacterial infection,7/7/14 12:28
263,46,GlaxoSmithKline,Large Pharma,1012,Augmentin,amoxicillin  +  clavulanic acid,Small Molecule (Chemical),Launched,In-House,Jul-84,Jul-81,Apr-01,Expired,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,4,ROW,Sales,969.8607709,948.6300356,1027.638835,962.1125265,983.3874236,970.8801114,969.6293802,697.0735968,586.5425388,487.6537462,416.8808823,387.7961646,-12.4475172,170,bacterial infection,7/7/14 12:28
263,46,GlaxoSmithKline,Large Pharma,1012,Augmentin,amoxicillin  +  clavulanic acid,Small Molecule (Chemical),Launched,In-House,Jul-84,Jul-81,Apr-01,Expired,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,170,bacterial infection,7/7/14 12:28
263,46,GlaxoSmithKline,Large Pharma,1012,Augmentin,amoxicillin  +  clavulanic acid,Small Molecule (Chemical),Launched,In-House,Jul-84,Jul-81,Apr-01,Expired,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,4,US,Sales,70.16677603,16.99500064,0,1.585028874,1.563414028,0,0,0,0,0,0,0,-100,170,bacterial infection,7/7/14 12:28
265,110,Vivus,Small Biotech,4535,Stendra / Spedra,avanafil,Small Molecule (Chemical),Launched,Licensed (Development),Dec-13,Dec-13,Sep-20,Sep-20,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,Global,Sales,0,0,0,0,1,34.25,57.17793,76.85495598,93.15710755,91.41634262,90.74289227,88.01173807,89.57944004,172,Erectile dysfunction,7/7/14 12:28
265,110,Vivus,Small Biotech,4535,Stendra / Spedra,avanafil,Small Molecule (Chemical),Launched,Licensed (Development),Dec-13,Dec-13,Sep-20,Sep-20,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,14.25,22.02633,27.15797542,28.94693586,28.82886154,27.93210967,28.67173807,0,172,Erectile dysfunction,7/7/14 12:28
265,110,Vivus,Small Biotech,4535,Stendra / Spedra,avanafil,Small Molecule (Chemical),Launched,Licensed (Development),Dec-13,Dec-13,Sep-20,Sep-20,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,US,Sales,0,0,0,0,1,20,35.1516,49.69698056,64.21017169,62.58748108,62.81078259,59.34,79.19880524,172,Erectile dysfunction,7/7/14 12:28
268,46,GlaxoSmithKline,Large Pharma,3138,Avandia products,rosiglitazone / rosiglitazone + metformin / rosiglitazone + glimepiride,Small Molecule (Chemical),Launched,In-House,Jul-99,Jul-99,N/A,N/A,48,PPAR Modulators,22,Diabetes,8,Metabolism,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,175,Type II Diabetes,7/7/14 12:28
268,46,GlaxoSmithKline,Large Pharma,3138,Avandia products,rosiglitazone / rosiglitazone + metformin / rosiglitazone + glimepiride,Small Molecule (Chemical),Launched,In-House,Jul-99,Jul-99,N/A,N/A,48,PPAR Modulators,22,Diabetes,8,Metabolism,4,Global,Sales,1182.699992,679.8000255,197.1912274,28.53051973,20.51501454,18.93693649,17.35885845,15.1495492,13.25585555,11.33060034,9.510173244,8.598777154,-11.68139972,175,Type II Diabetes,7/7/14 12:28
268,46,GlaxoSmithKline,Large Pharma,3138,Avandia products,rosiglitazone / rosiglitazone + metformin / rosiglitazone + glimepiride,Small Molecule (Chemical),Launched,In-House,Jul-99,Jul-99,N/A,N/A,48,PPAR Modulators,22,Diabetes,8,Metabolism,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,175,Type II Diabetes,7/7/14 12:28
268,46,GlaxoSmithKline,Large Pharma,3138,Avandia products,rosiglitazone / rosiglitazone + metformin / rosiglitazone + glimepiride,Small Molecule (Chemical),Launched,In-House,Jul-99,Jul-99,N/A,N/A,48,PPAR Modulators,22,Diabetes,8,Metabolism,4,ROW,Sales,532.487867,313.6350118,51.30178274,28.53051973,20.51501454,18.93693649,17.35885845,15.1495492,13.25585555,11.33060034,9.510173244,8.598777154,-11.68139972,175,Type II Diabetes,7/7/14 12:28
268,46,GlaxoSmithKline,Large Pharma,3138,Avandia products,rosiglitazone / rosiglitazone + metformin / rosiglitazone + glimepiride,Small Molecule (Chemical),Launched,In-House,Jul-99,Jul-99,N/A,N/A,48,PPAR Modulators,22,Diabetes,8,Metabolism,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,175,Type II Diabetes,7/7/14 12:28
268,46,GlaxoSmithKline,Large Pharma,3138,Avandia products,rosiglitazone / rosiglitazone + metformin / rosiglitazone + glimepiride,Small Molecule (Chemical),Launched,In-House,Jul-99,Jul-99,N/A,N/A,48,PPAR Modulators,22,Diabetes,8,Metabolism,4,US,Sales,650.2121246,366.1650137,145.8894447,0,0,0,0,0,0,0,0,0,0,175,Type II Diabetes,7/7/14 12:28
270,24,Bristol-Myers Squibb,Large Pharma,573,Avapro,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),Jul-97,Jul-97,Mar-12,Aug-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1503,Hypertension,7/7/14 12:28
270,24,Bristol-Myers Squibb,Large Pharma,573,Avapro,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),Jul-97,Jul-97,Mar-12,Aug-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,1286,1176,952,503,231,143,119.25,113.3125,111.828125,111.4570313,111.3642578,111.3410645,-9.900884108,1503,Hypertension,7/7/14 12:28
270,24,Bristol-Myers Squibb,Large Pharma,573,Avapro,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),Jul-97,Jul-97,Mar-12,Aug-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1503,Hypertension,7/7/14 12:28
270,24,Bristol-Myers Squibb,Large Pharma,573,Avapro,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),Jul-97,Jul-97,Mar-12,Aug-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,564,534,403,348,238,143,119.25,113.3125,111.828125,111.4570313,111.3642578,111.3410645,-10.28431205,1503,Hypertension,7/7/14 12:28
270,24,Bristol-Myers Squibb,Large Pharma,573,Avapro,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),Jul-97,Jul-97,Mar-12,Aug-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1503,Hypertension,7/7/14 12:28
270,24,Bristol-Myers Squibb,Large Pharma,573,Avapro,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),Jul-97,Jul-97,Mar-12,Aug-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,722,642,549,155,-7,0,0,0,0,0,0,0,0,1503,Hypertension,7/7/14 12:28
271,35,Dainippon-Sumitomo,Regional & Specialty Pharma,573,Avapro,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-08,N/A,Jun-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1503,Hypertension,7/7/14 12:28
271,35,Dainippon-Sumitomo,Regional & Specialty Pharma,573,Avapro,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-08,N/A,Jun-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,39.86106086,96.88452066,135.4797661,140.8532658,127.9941865,133.2532355,132.6141855,130.6999937,117.7647365,109.0934093,103.244375,97.47761633,-3.81616023,1503,Hypertension,7/7/14 12:28
271,35,Dainippon-Sumitomo,Regional & Specialty Pharma,573,Avapro,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-08,N/A,Jun-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1503,Hypertension,7/7/14 12:28
271,35,Dainippon-Sumitomo,Regional & Specialty Pharma,573,Avapro,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-08,N/A,Jun-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,39.86106086,96.88452066,135.4797661,140.8532658,127.9941865,133.2532355,132.6141855,130.6999937,117.7647365,109.0934093,103.244375,97.47761633,-3.81616023,1503,Hypertension,7/7/14 12:28
271,35,Dainippon-Sumitomo,Regional & Specialty Pharma,573,Avapro,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-08,N/A,Jun-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1503,Hypertension,7/7/14 12:28
271,35,Dainippon-Sumitomo,Regional & Specialty Pharma,573,Avapro,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-08,N/A,Jun-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1503,Hypertension,7/7/14 12:28
272,29,Chugai,Regional & Specialty Pharma,727,Avastin,bevacizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-07,N/A,Jan-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,3,Global,Alliance Revenue,372.9837902,599.3903539,707.4399308,820.5963418,772.7719205,844.3932366,900.7946129,945.4966399,982.4676724,1030.926559,1019.510275,986.2446857,3.545998305,1362,Colorectal Cancer,7/7/14 12:28
272,29,Chugai,Regional & Specialty Pharma,727,Avastin,bevacizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-07,N/A,Jan-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,3,ROW,Alliance Revenue,372.9837902,599.3903539,707.4399308,820.5963418,772.7719205,844.3932366,900.7946129,945.4966399,982.4676724,1030.926559,1019.510275,986.2446857,3.545998305,1362,Colorectal Cancer,7/7/14 12:28
272,29,Chugai,Regional & Specialty Pharma,727,Avastin,bevacizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-07,N/A,Jan-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1362,Colorectal Cancer,7/7/14 12:28
273,86,Roche,Large Pharma,727,Avastin,bevacizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-04,Nov-04,Jul-19,Dec-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1362,Colorectal Cancer,7/7/14 12:28
273,86,Roche,Large Pharma,727,Avastin,bevacizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-04,Nov-04,Jul-19,Jan-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,5,Global,Sales,5730.175976,6196.313133,5961.868603,6147.710857,6747.876553,6743.489679,7023.994413,7262.92397,7414.154037,7521.170896,7277.653328,5854.70929,-2.007873749,1362,Colorectal Cancer,7/7/14 12:28
273,86,Roche,Large Pharma,727,Avastin,bevacizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-04,Nov-04,Jul-19,Dec-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1362,Colorectal Cancer,7/7/14 12:28
273,86,Roche,Large Pharma,727,Avastin,bevacizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-04,Nov-04,Jul-19,Jan-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,5,ROW,Sales,2677.736633,3136.994479,3322.827579,3508.149611,3969.134557,4168.967596,4391.443425,4540.47337,4647.970769,4741.610228,4723.317749,3862.269338,-0.38914267,1362,Colorectal Cancer,7/7/14 12:28
273,86,Roche,Large Pharma,727,Avastin,bevacizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-04,Nov-04,Jul-19,Dec-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1362,Colorectal Cancer,7/7/14 12:28
273,86,Roche,Large Pharma,727,Avastin,bevacizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-04,Nov-04,Jul-19,Dec-19,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,5,US,Sales,3052.439343,3059.318654,2639.041025,2639.561246,2778.741995,2574.522083,2632.550988,2722.4506,2766.183268,2779.560668,2554.335579,1992.439952,-4.640832354,1362,Colorectal Cancer,7/7/14 12:28
275,89,Sanofi,Large Pharma,3862,Lyxumia,lixisenatide,Synthetic Peptide,Launched,Corporate Acquisition,Feb-16,Mar-13,N/A,N/A,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,629,Type II Diabetes,7/7/14 12:28
275,89,Sanofi,Large Pharma,3862,Lyxumia,lixisenatide,Synthetic Peptide,Launched,Corporate Acquisition,Feb-16,Mar-13,N/A,N/A,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,2,Global,Sales,0,0,0,0,10.62424053,42.49696213,72.1458177,133.4462577,205.9049581,282.2211063,357.1452643,424.5090615,69.35507279,629,Type II Diabetes,7/7/14 12:28
275,89,Sanofi,Large Pharma,3862,Lyxumia,lixisenatide,Synthetic Peptide,Launched,Corporate Acquisition,Feb-16,Mar-13,N/A,N/A,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,629,Type II Diabetes,7/7/14 12:28
275,89,Sanofi,Large Pharma,3862,Lyxumia,lixisenatide,Synthetic Peptide,Launched,Corporate Acquisition,Feb-16,Mar-13,N/A,N/A,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,2,ROW,Sales,0,0,0,0,10.62424053,42.49696213,72.1458177,101.7948629,128.8792142,154.4092085,178.5473089,201.1777357,52.21893452,629,Type II Diabetes,7/7/14 12:28
275,89,Sanofi,Large Pharma,3862,Lyxumia,lixisenatide,Synthetic Peptide,Launched,Corporate Acquisition,Feb-16,Mar-13,N/A,N/A,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,629,Type II Diabetes,7/7/14 12:28
275,89,Sanofi,Large Pharma,3862,Lyxumia,lixisenatide,Synthetic Peptide,Launched,Corporate Acquisition,Feb-16,Mar-13,N/A,N/A,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,31.65139476,77.02574386,127.8118978,178.5979554,223.3313257,0,629,Type II Diabetes,7/7/14 12:28
282,19,Bayer,Large Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,In-House,Jun-99,Jul-99,Sep-14,Jul-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,Global,Alliance Revenue,176.4662971,172.2181253,122.3584593,70.68992294,31.8727216,17.26439087,14.42240652,11.9522706,10.62424053,9.296210466,9.140565342,9.066381583,-16.43927515,1555,Bacterial infections,7/7/14 12:28
282,19,Bayer,Large Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,In-House,Jun-99,Jul-99,Sep-14,Jul-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,462.7029681,486.1850153,553.3939409,553.9519416,533.8680868,427.9444087,245.5487752,201.334471,179.7821201,168.8952915,158.0995776,147.4332045,-16.79182703,1555,Bacterial infections,7/7/14 12:28
282,19,Bayer,Large Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,In-House,Jun-99,Jul-99,Sep-14,Jul-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
282,19,Bayer,Large Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,In-House,Jun-99,Jul-99,Sep-14,Jul-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,462.7029681,486.1850153,553.3939409,553.9519416,533.8680868,427.9444087,245.5487752,201.334471,179.7821201,168.8952915,158.0995776,147.4332045,-16.79182703,1555,Bacterial infections,7/7/14 12:28
282,19,Bayer,Large Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,In-House,Jun-99,Jul-99,Sep-14,Jul-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,US,Alliance Revenue,176.4662971,172.2181253,122.3584593,70.68992294,31.8727216,17.26439087,14.42240652,11.9522706,10.62424053,9.296210466,9.140565342,9.066381583,-16.43927515,1555,Bacterial infections,7/7/14 12:28
282,19,Bayer,Large Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,In-House,Jun-99,Jul-99,Sep-14,Jul-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
283,61,Merck & Co,Large Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-99,,Feb-14,Jan-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
283,61,Merck & Co,Large Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-99,,Feb-14,Jan-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,90.50002,316,322,201,130,28.12328502,9.006424939,5.015820243,3.88359843,2.175160978,1.611811,1.382718566,-47.74676267,1555,Bacterial infections,7/7/14 12:28
283,61,Merck & Co,Large Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-99,,Feb-14,Jan-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
283,61,Merck & Co,Large Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-99,,Feb-14,Jan-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
283,61,Merck & Co,Large Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-99,,Feb-14,Jan-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
283,61,Merck & Co,Large Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-99,,Feb-14,Jan-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,90.50002,316,322,201,130,28.12328502,9.006424939,5.015820243,3.88359843,2.175160978,1.611811,1.382718566,-47.74676267,1555,Bacterial infections,7/7/14 12:28
283,61,Schering-Plough,Large Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-99,,Feb-14,Jan-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,Global,Proforma,277.49998,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
283,61,Schering-Plough,Large Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-99,,Feb-14,Jan-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,US,Proforma,277.49998,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
284,95,Shionogi,Regional & Specialty Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-05,N/A,Jul-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
284,95,Shionogi,Regional & Specialty Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-05,N/A,Jul-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,13.89685682,4.608778699,2.661179373,0.278953963,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
284,95,Shionogi,Regional & Specialty Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-05,N/A,Jul-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
284,95,Shionogi,Regional & Specialty Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-05,N/A,Jul-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,13.89685682,4.608778699,2.661179373,0.278953963,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
284,95,Shionogi,Regional & Specialty Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-05,N/A,Jul-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
284,95,Shionogi,Regional & Specialty Pharma,1414,Avelox,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-05,N/A,Jul-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
285,76,King,Large Pharma,1014,Avinza,morphine - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,,Nov-17,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Proforma,131,104,16.3,0,0,0,0,0,0,0,0,0,0,1552,Pain,7/7/14 12:28
285,76,King,Large Pharma,1014,Avinza,morphine - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,,Nov-17,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Proforma,131,104,16.3,0,0,0,0,0,0,0,0,0,0,1552,Pain,7/7/14 12:28
285,76,Pfizer,Large Pharma,1014,Avinza,morphine - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,,Nov-17,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1552,Pain,7/7/14 12:28
285,76,Pfizer,Large Pharma,1014,Avinza,morphine - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,,Nov-17,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,81.7,88.19,82.4156,77.726744,74.28049856,71.70027885,59.44047961,3.484356243,2.084400742,1.461448088,-43.78850928,1552,Pain,7/7/14 12:28
285,76,Pfizer,Large Pharma,1014,Avinza,morphine - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,,Nov-17,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1552,Pain,7/7/14 12:28
285,76,Pfizer,Large Pharma,1014,Avinza,morphine - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,,Nov-17,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1552,Pain,7/7/14 12:28
285,76,Pfizer,Large Pharma,1014,Avinza,morphine - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,,Nov-17,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1552,Pain,7/7/14 12:28
285,76,Pfizer,Large Pharma,1014,Avinza,morphine - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,,Nov-17,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,81.7,88.19,82.4156,77.726744,74.28049856,71.70027885,59.44047961,3.484356243,2.084400742,1.461448088,-43.78850928,1552,Pain,7/7/14 12:28
287,46,GlaxoSmithKline,Large Pharma,1132,Avodart / Jalyn / Duodart,dutasteride / dutasteride + tamsulosin ,Small Molecule (Chemical),Launched,In-House,Jan-03,Mar-03,Nov-15,Sep-17,52,5-Alpha Reductase Inhibitors,11,Benign Prostatic Hyperplasia,2,Genitourinary,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1433,Symptoms associated with BPH,7/7/14 12:28
287,46,GlaxoSmithKline,Large Pharma,1132,Avodart / Jalyn / Duodart,dutasteride / dutasteride + tamsulosin ,Small Molecule (Chemical),Launched,In-House,Jan-03,Mar-03,Nov-15,Sep-17,52,5-Alpha Reductase Inhibitors,11,Benign Prostatic Hyperplasia,2,Genitourinary,4,Global,Sales,826.4086955,971.8050364,1199.179171,1252.17281,1339.845822,1405.509211,1386.262959,1051.261855,891.6243256,346.2797589,238.1821281,181.8727762,-24.82006214,1433,Symptoms associated with BPH,7/7/14 12:28
287,46,GlaxoSmithKline,Large Pharma,1132,Avodart / Jalyn / Duodart,dutasteride / dutasteride + tamsulosin ,Small Molecule (Chemical),Launched,In-House,Jan-03,Mar-03,Nov-15,Sep-17,52,5-Alpha Reductase Inhibitors,11,Benign Prostatic Hyperplasia,2,Genitourinary,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1433,Symptoms associated with BPH,7/7/14 12:28
287,46,GlaxoSmithKline,Large Pharma,1132,Avodart / Jalyn / Duodart,dutasteride / dutasteride + tamsulosin ,Small Molecule (Chemical),Launched,In-House,Jan-03,Mar-03,Nov-15,Sep-17,52,5-Alpha Reductase Inhibitors,11,Benign Prostatic Hyperplasia,2,Genitourinary,4,ROW,Sales,329.0042165,451.1400169,668.5263563,749.7186574,852.0606453,923.9776906,980.2605956,1027.163016,877.0752697,336.0109753,230.7467091,175.8528099,-20.18269313,1433,Symptoms associated with BPH,7/7/14 12:28
287,46,GlaxoSmithKline,Large Pharma,1132,Avodart / Jalyn / Duodart,dutasteride / dutasteride + tamsulosin ,Small Molecule (Chemical),Launched,In-House,Jan-03,Mar-03,Nov-15,Sep-17,52,5-Alpha Reductase Inhibitors,11,Benign Prostatic Hyperplasia,2,Genitourinary,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1433,Symptoms associated with BPH,7/7/14 12:28
287,46,GlaxoSmithKline,Large Pharma,1132,Avodart / Jalyn / Duodart,dutasteride / dutasteride + tamsulosin ,Small Molecule (Chemical),Launched,In-House,Jan-03,Mar-03,Nov-15,Sep-17,52,5-Alpha Reductase Inhibitors,11,Benign Prostatic Hyperplasia,2,Genitourinary,4,US,Sales,497.404479,520.6650195,530.6528152,502.454153,487.7851767,481.5315208,406.0023639,24.09883907,14.54905592,10.26878352,7.435419026,6.019966299,-46.62496218,1433,Symptoms associated with BPH,7/7/14 12:28
289,21,Biogen Idec,Regional & Specialty Pharma,287,Avonex,interferon-beta 1a,Recombinant Protein,Launched,In-House,Jul-96,Jan-97,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1719,Multiple Sclerosis,7/7/14 12:28
289,21,Biogen Idec,Regional & Specialty Pharma,287,Avonex,interferon-beta 1a,Recombinant Protein,Launched,In-House,Jul-96,Jan-97,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,2323,2518,2686.6,2913.1,3005,3083.409838,3169.180044,3237.860158,3285.785868,3305.44264,3244.787179,3240.986091,1.085852895,1719,Multiple Sclerosis,7/7/14 12:28
289,21,Biogen Idec,Regional & Specialty Pharma,287,Avonex,interferon-beta 1a,Recombinant Protein,Launched,In-House,Jul-96,Jan-97,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1719,Multiple Sclerosis,7/7/14 12:28
289,21,Biogen Idec,Regional & Specialty Pharma,287,Avonex,interferon-beta 1a,Recombinant Protein,Launched,In-House,Jul-96,Jan-97,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,917,1027,1058.3,1119.4,1103,1084.1415,1093.56975,1111.622831,1118.900531,1115.009715,1108.818644,1106.543332,0.045829031,1719,Multiple Sclerosis,7/7/14 12:28
289,21,Biogen Idec,Regional & Specialty Pharma,287,Avonex,interferon-beta 1a,Recombinant Protein,Launched,In-House,Jul-96,Jan-97,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1719,Multiple Sclerosis,7/7/14 12:28
289,21,Biogen Idec,Regional & Specialty Pharma,287,Avonex,interferon-beta 1a,Recombinant Protein,Launched,In-House,Jul-96,Jan-97,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,1406,1491,1628.3,1793.7,1902,1999.268338,2075.610294,2126.237328,2166.885336,2190.432924,2135.968535,2134.44276,1.660776228,1719,Multiple Sclerosis,7/7/14 12:28
290,53,Johnson & Johnson,Large Pharma,1300,Axert,almotriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-03,Jan-04,Nov-15,Jan-14,117,Triptans,8,Migraine,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1337,Migraine,7/7/14 12:28
290,53,Johnson & Johnson,Large Pharma,1300,Axert,almotriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-03,Jan-04,Nov-15,Jan-14,117,Triptans,8,Migraine,12,Central Nervous System,6,Global,Sales,62.30552,63.7164,62.9660128,62.06922432,61.0361568,48.34662834,38.39922673,12.27749501,9.237854862,7.433745296,6.205849025,4.083794029,-32.0466115,1337,Migraine,7/7/14 12:28
290,53,Johnson & Johnson,Large Pharma,1300,Axert,almotriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-03,Jan-04,Nov-15,Jan-14,117,Triptans,8,Migraine,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1337,Migraine,7/7/14 12:28
290,53,Johnson & Johnson,Large Pharma,1300,Axert,almotriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-03,Jan-04,Nov-15,Jan-14,117,Triptans,8,Migraine,12,Central Nervous System,6,ROW,Sales,18.30552,19.7164,20.9660128,22.06922432,23.0361568,11.34662834,7.514226734,5.134995014,3.933011112,3.218951546,2.710157619,2.341579869,-27.86315654,1337,Migraine,7/7/14 12:28
290,53,Johnson & Johnson,Large Pharma,1300,Axert,almotriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-03,Jan-04,Nov-15,Jan-14,117,Triptans,8,Migraine,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1337,Migraine,7/7/14 12:28
290,53,Johnson & Johnson,Large Pharma,1300,Axert,almotriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-03,Jan-04,Nov-15,Jan-14,117,Triptans,8,Migraine,12,Central Nervous System,6,US,Sales,44,44,42,40,38,37,30.885,7.1425,5.30484375,4.21479375,3.495691406,1.74221416,-35.61867694,1337,Migraine,7/7/14 12:28
291,76,Pfizer,Large Pharma,4177,Inlyta,axitinib,Small Molecule (Chemical),Launched,In-House,Feb-12,Sep-12,Jun-20,Dec-21,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,181,Renal Cell Carcinoma,7/7/14 12:28
291,76,Pfizer,Large Pharma,4177,Inlyta,axitinib,Small Molecule (Chemical),Launched,In-House,Feb-12,Sep-12,Jun-20,Dec-21,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,75,319,500.03168,612.5910005,708.2244991,778.8990279,830.8225348,870.5970219,900.3565427,15.97777433,181,Renal Cell Carcinoma,7/7/14 12:28
291,76,Pfizer,Large Pharma,4177,Inlyta,axitinib,Small Molecule (Chemical),Launched,In-House,Feb-12,Sep-12,Jun-20,Dec-21,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,181,Renal Cell Carcinoma,7/7/14 12:28
291,76,Pfizer,Large Pharma,4177,Inlyta,axitinib,Small Molecule (Chemical),Launched,In-House,Feb-12,Sep-12,Jun-20,Dec-21,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,25,164,289.73388,366.2670844,428.5391441,476.0848044,510.7414578,537.1693198,557.0413553,19.08670919,181,Renal Cell Carcinoma,7/7/14 12:28
291,76,Pfizer,Large Pharma,4177,Inlyta,axitinib,Small Molecule (Chemical),Launched,In-House,Feb-12,Sep-12,Jun-20,Dec-21,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,181,Renal Cell Carcinoma,7/7/14 12:28
291,76,Pfizer,Large Pharma,4177,Inlyta,axitinib,Small Molecule (Chemical),Launched,In-House,Feb-12,Sep-12,Jun-20,Dec-21,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,50,155,210.2978,246.3239161,279.685355,302.8142235,320.081077,333.427702,343.3151874,12.0307599,181,Renal Cell Carcinoma,7/7/14 12:28
292,2409,Elan,Regional & Specialty Pharma,232,Azactam,aztreonam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,,Oct-05,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Proforma,81.4,27.2,0,-0.5,0,0,0,0,0,0,0,0,0,183,Bacterial Infections,7/7/14 12:28
292,2409,Elan,Regional & Specialty Pharma,232,Azactam,aztreonam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,,Oct-05,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Proforma,81.4,27.2,0,-0.5,0,0,0,0,0,0,0,0,0,183,Bacterial Infections,7/7/14 12:28
292,2409,Perrigo ,Regional & Specialty Pharma,232,Azactam,aztreonam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,,Oct-05,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,183,Bacterial Infections,7/7/14 12:28
292,2409,Perrigo ,Regional & Specialty Pharma,232,Azactam,aztreonam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,,Oct-05,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,183,Bacterial Infections,7/7/14 12:28
292,2409,Perrigo ,Regional & Specialty Pharma,232,Azactam,aztreonam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,,Oct-05,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,183,Bacterial Infections,7/7/14 12:28
292,2409,Perrigo ,Regional & Specialty Pharma,232,Azactam,aztreonam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,,Oct-05,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,183,Bacterial Infections,7/7/14 12:28
292,2409,Perrigo ,Regional & Specialty Pharma,232,Azactam,aztreonam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,,Oct-05,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,183,Bacterial Infections,7/7/14 12:28
292,2409,Perrigo ,Regional & Specialty Pharma,232,Azactam,aztreonam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,,Oct-05,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,183,Bacterial Infections,7/7/14 12:28
306,16,AstraZeneca,Large Pharma,1764,olaparib,AZD2281,Small Molecule (Chemical),Filed,Corporate Acquisition,Oct-14,Sep-14,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,810,Ovarian Cancer,7/7/14 12:28
306,16,AstraZeneca,Large Pharma,1764,olaparib,AZD2281,Small Molecule (Chemical),Filed,Corporate Acquisition,Oct-14,Sep-14,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,4.333329,15.88888744,28.3054811,50.7221051,66.26877457,80.5328633,90.30048531,0,810,Ovarian Cancer,7/7/14 12:28
306,16,AstraZeneca,Large Pharma,1764,olaparib,AZD2281,Small Molecule (Chemical),Filed,Corporate Acquisition,Oct-14,Sep-14,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,810,Ovarian Cancer,7/7/14 12:28
306,16,AstraZeneca,Large Pharma,1764,olaparib,AZD2281,Small Molecule (Chemical),Filed,Corporate Acquisition,Oct-14,Sep-14,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,4.333329,15.88888744,24.5554811,33.2220926,38.76872992,43.03270243,46.35028228,0,810,Ovarian Cancer,7/7/14 12:28
306,16,AstraZeneca,Large Pharma,1764,olaparib,AZD2281,Small Molecule (Chemical),Filed,Corporate Acquisition,Oct-14,Sep-14,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,810,Ovarian Cancer,7/7/14 12:28
306,16,AstraZeneca,Large Pharma,1764,olaparib,AZD2281,Small Molecule (Chemical),Filed,Corporate Acquisition,Oct-14,Sep-14,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,3.75,17.5000125,27.50004464,37.50016088,43.95020303,0,810,Ovarian Cancer,7/7/14 12:28
311,16,AstraZeneca,Large Pharma,1311,AZD3241,AZD3241,Small Molecule (Chemical),Phase II,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,198,Parkinson's disease,7/7/14 12:28
311,16,AstraZeneca,Large Pharma,1311,AZD3241,AZD3241,Small Molecule (Chemical),Phase II,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,198,Parkinson's disease,7/7/14 12:28
311,16,AstraZeneca,Large Pharma,1311,AZD3241,AZD3241,Small Molecule (Chemical),Phase II,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,198,Parkinson's disease,7/7/14 12:28
311,16,AstraZeneca,Large Pharma,1311,AZD3241,AZD3241,Small Molecule (Chemical),Phase II,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,198,Parkinson's disease,7/7/14 12:28
311,16,AstraZeneca,Large Pharma,1311,AZD3241,AZD3241,Small Molecule (Chemical),Phase II,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,198,Parkinson's disease,7/7/14 12:28
311,16,AstraZeneca,Large Pharma,1311,AZD3241,AZD3241,Small Molecule (Chemical),Phase II,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,198,Parkinson's disease,7/7/14 12:28
320,16,AstraZeneca,Large Pharma,85,selumetinib,selumetinib,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-17,Dec-17,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,204,Non-small-cell Lung Cancer,7/7/14 12:28
320,16,AstraZeneca,Large Pharma,85,selumetinib,selumetinib,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-17,Dec-17,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,5.9999996,36.00004493,57.33345231,78.6670303,0,204,Non-small-cell Lung Cancer,7/7/14 12:28
320,16,AstraZeneca,Large Pharma,85,selumetinib,selumetinib,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-17,Dec-17,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,204,Non-small-cell Lung Cancer,7/7/14 12:28
320,16,AstraZeneca,Large Pharma,85,selumetinib,selumetinib,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-17,Dec-17,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0.9999996,12.66669493,20.66672612,28.6668158,0,204,Non-small-cell Lung Cancer,7/7/14 12:28
320,16,AstraZeneca,Large Pharma,85,selumetinib,selumetinib,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-17,Dec-17,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,204,Non-small-cell Lung Cancer,7/7/14 12:28
320,16,AstraZeneca,Large Pharma,85,selumetinib,selumetinib,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-17,Dec-17,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,5,23.33335,36.66672619,50.0002145,0,204,Non-small-cell Lung Cancer,7/7/14 12:28
335,16,AstraZeneca,Large Pharma,1299,AZD8848,TLR-7 agonist,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,219,Asthma,7/7/14 12:28
335,16,AstraZeneca,Large Pharma,1299,AZD8848,TLR-7 agonist,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,219,Asthma,7/7/14 12:28
335,16,AstraZeneca,Large Pharma,1299,AZD8848,TLR-7 agonist,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,219,Asthma,7/7/14 12:28
335,16,AstraZeneca,Large Pharma,1299,AZD8848,TLR-7 agonist,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,219,Asthma,7/7/14 12:28
335,16,AstraZeneca,Large Pharma,1299,AZD8848,TLR-7 agonist,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,219,Asthma,7/7/14 12:28
335,16,AstraZeneca,Large Pharma,1299,AZD8848,TLR-7 agonist,Small Molecule (Chemical),Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,219,Asthma,7/7/14 12:28
340,58,Lundbeck,Regional & Specialty Pharma,120,Azilect,rasagiline,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-05,N/A,Oct-19,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1611,Parkinson's Disease,7/7/14 12:28
340,58,Lundbeck,Regional & Specialty Pharma,120,Azilect,rasagiline,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-05,N/A,Oct-19,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,1,Global,Sales,143.4969211,182.8555166,221.5244503,211.3408663,247.8775926,261.4360696,271.6791837,280.7825951,286.9843963,291.7127245,256.6504222,90.8971496,-13.35189651,1611,Parkinson's Disease,7/7/14 12:28
340,58,Lundbeck,Regional & Specialty Pharma,120,Azilect,rasagiline,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-05,N/A,Oct-19,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1611,Parkinson's Disease,7/7/14 12:28
340,58,Lundbeck,Regional & Specialty Pharma,120,Azilect,rasagiline,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-05,N/A,Oct-19,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,1,ROW,Sales,143.4969211,182.8555166,221.5244503,211.3408663,247.8775926,261.4360696,271.6791837,280.7825951,286.9843963,291.7127245,256.6504222,90.8971496,-13.35189651,1611,Parkinson's Disease,7/7/14 12:28
340,58,Lundbeck,Regional & Specialty Pharma,120,Azilect,rasagiline,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-05,N/A,Oct-19,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1611,Parkinson's Disease,7/7/14 12:28
340,58,Lundbeck,Regional & Specialty Pharma,120,Azilect,rasagiline,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-05,N/A,Oct-19,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1611,Parkinson's Disease,7/7/14 12:28
341,102,Teva,Regional & Specialty Pharma,120,Azilect,rasagiline,Small Molecule (Chemical),Launched,In-House,Jul-06,Jan-06,Feb-17,Oct-19,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1611,Parkinson's Disease,7/7/14 12:28
341,102,Teva,Regional & Specialty Pharma,120,Azilect,rasagiline,Small Molecule (Chemical),Launched,In-House,Jul-06,Jan-06,Feb-17,Oct-19,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,179,244,290,330.05,371,398.811,421.3601,441.46797,114.3572465,58.64299179,46.12129587,21.44225349,-33.45303543,1611,Parkinson's Disease,7/7/14 12:28
341,102,Teva,Regional & Specialty Pharma,120,Azilect,rasagiline,Small Molecule (Chemical),Launched,In-House,Jul-06,Jan-06,Feb-17,Oct-19,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1611,Parkinson's Disease,7/7/14 12:28
341,102,Teva,Regional & Specialty Pharma,120,Azilect,rasagiline,Small Molecule (Chemical),Launched,In-House,Jul-06,Jan-06,Feb-17,Oct-19,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,8.95,12.2,14,24.75,28,30.275,31.8675,34,35.49275,36.537675,32.38686745,11.5232464,-11.91200129,1611,Parkinson's Disease,7/7/14 12:28
341,102,Teva,Regional & Specialty Pharma,120,Azilect,rasagiline,Small Molecule (Chemical),Launched,In-House,Jul-06,Jan-06,Feb-17,Oct-19,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1611,Parkinson's Disease,7/7/14 12:28
341,102,Teva,Regional & Specialty Pharma,120,Azilect,rasagiline,Small Molecule (Chemical),Launched,In-House,Jul-06,Jan-06,Feb-17,Oct-19,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,170.05,231.8,276,305.3,343,368.536,389.4926,407.46797,78.86449652,22.10531679,13.73442842,9.919007089,-39.72073536,1611,Parkinson's Disease,7/7/14 12:28
345,67,Alcon,Large Pharma,3573,Azopt / Azarga,brinzolamide / brinzolamide + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Apr-00,Apr-14,Dec-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Proforma,300,231.332,0,0,0,0,0,0,0,0,0,0,0,225,Glaucoma,7/7/14 12:28
345,67,Alcon,Large Pharma,3573,Azopt / Azarga,brinzolamide / brinzolamide + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Apr-00,Apr-14,Dec-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Proforma,180,139.999,0,0,0,0,0,0,0,0,0,0,0,225,Glaucoma,7/7/14 12:28
345,67,Alcon,Large Pharma,3573,Azopt / Azarga,brinzolamide / brinzolamide + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Apr-00,Apr-14,Dec-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Proforma,120,91.333,0,0,0,0,0,0,0,0,0,0,0,225,Glaucoma,7/7/14 12:28
345,67,Novartis,Large Pharma,3573,Azopt / Azarga,brinzolamide / brinzolamide + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Apr-00,Apr-14,Dec-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,225,Glaucoma,7/7/14 12:28
345,67,Novartis,Large Pharma,3573,Azopt / Azarga,brinzolamide / brinzolamide + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Apr-00,Apr-14,Dec-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Sales,0,115.668,395,418.5,425,354.6321,236.622408,205.191409,185.8312707,169.5741877,155.4559649,144.0786369,-14.31845197,225,Glaucoma,7/7/14 12:28
345,67,Novartis,Large Pharma,3573,Azopt / Azarga,brinzolamide / brinzolamide + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Apr-00,Apr-14,Dec-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,225,Glaucoma,7/7/14 12:28
345,67,Novartis,Large Pharma,3573,Azopt / Azarga,brinzolamide / brinzolamide + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Apr-00,Apr-14,Dec-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Sales,0,70.001,250,274.5,285,267.9809,192.26324,173.4947005,161.1144983,149.0444061,137.7056661,129.086156,-10.69779866,225,Glaucoma,7/7/14 12:28
345,67,Novartis,Large Pharma,3573,Azopt / Azarga,brinzolamide / brinzolamide + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Apr-00,Apr-14,Dec-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,225,Glaucoma,7/7/14 12:28
345,67,Novartis,Large Pharma,3573,Azopt / Azarga,brinzolamide / brinzolamide + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Apr-00,Apr-14,Dec-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Sales,0,45.667,145,144,140,86.6512,44.359168,31.69670848,24.7167724,20.52978162,17.75029883,14.99248094,-27.32377704,225,Glaucoma,7/7/14 12:28
346,34,Daiichi-Sankyo,Regional & Specialty Pharma,3356,Azor / Sevikar,olmesartan + amlodipine,Small Molecule (Chemical),Launched,In-House,Oct-07,Jan-09,Oct-16,Jan-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,226,Hypertension,7/7/14 12:28
346,34,Daiichi-Sankyo,Regional & Specialty Pharma,3356,Azor / Sevikar,olmesartan + amlodipine,Small Molecule (Chemical),Launched,In-House,Oct-07,Jan-09,Oct-16,Jan-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,205.7692601,283.6498617,392.511472,446.6372788,412.7766121,435.4934198,459.2772754,418.8290954,237.4664435,230.7131705,129.9882473,86.99871631,-19.94291423,226,Hypertension,7/7/14 12:28
346,34,Daiichi-Sankyo,Regional & Specialty Pharma,3356,Azor / Sevikar,olmesartan + amlodipine,Small Molecule (Chemical),Launched,In-House,Oct-07,Jan-09,Oct-16,Jan-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,226,Hypertension,7/7/14 12:28
346,34,Daiichi-Sankyo,Regional & Specialty Pharma,3356,Azor / Sevikar,olmesartan + amlodipine,Small Molecule (Chemical),Launched,In-House,Oct-07,Jan-09,Oct-16,Jan-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,67.87153606,110.8919212,182.3279096,186.6004803,181.2190004,200.0959792,214.2537132,224.8720137,221.1939522,219.7038506,121.6440644,81.39378238,-10.80487446,226,Hypertension,7/7/14 12:28
346,34,Daiichi-Sankyo,Regional & Specialty Pharma,3356,Azor / Sevikar,olmesartan + amlodipine,Small Molecule (Chemical),Launched,In-House,Oct-07,Jan-09,Oct-16,Jan-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,226,Hypertension,7/7/14 12:28
346,34,Daiichi-Sankyo,Regional & Specialty Pharma,3356,Azor / Sevikar,olmesartan + amlodipine,Small Molecule (Chemical),Launched,In-House,Oct-07,Jan-09,Oct-16,Jan-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,137.8977241,172.7579404,210.1835624,260.0367984,231.5576116,235.3974407,245.0235622,193.9570817,16.27249128,11.00931996,8.344182939,5.604933923,-41.23341745,226,Hypertension,7/7/14 12:28
347,45,Gilead,Regional & Specialty Pharma,2225,Cayston,aztreonam lysine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-10,Feb-10,Dec-21,Dec-21,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,292,Cystic fibrosis,7/7/14 12:28
347,45,Gilead,Regional & Specialty Pharma,2225,Cayston,aztreonam lysine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-10,Feb-10,Dec-21,Dec-21,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,48,77.5,34,38,47.797,100,121.8,137.78421,151.9621035,160,165,23.33886811,292,Cystic fibrosis,7/7/14 12:28
347,45,Gilead,Regional & Specialty Pharma,2225,Cayston,aztreonam lysine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-10,Feb-10,Dec-21,Dec-21,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,292,Cystic fibrosis,7/7/14 12:28
347,45,Gilead,Regional & Specialty Pharma,2225,Cayston,aztreonam lysine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-10,Feb-10,Dec-21,Dec-21,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,8,12.9,7,8,7.797,20,30,36.03421,41.9546035,48,51,30.29436282,292,Cystic fibrosis,7/7/14 12:28
347,45,Gilead,Regional & Specialty Pharma,2225,Cayston,aztreonam lysine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-10,Feb-10,Dec-21,Dec-21,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,292,Cystic fibrosis,7/7/14 12:28
347,45,Gilead,Regional & Specialty Pharma,2225,Cayston,aztreonam lysine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-10,Feb-10,Dec-21,Dec-21,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,40,64.6,27,30,40,80,91.8,101.75,110.0075,112,114,21.01136095,292,Cystic fibrosis,7/7/14 12:28
349,67,Novartis,Large Pharma,4530,siponimod,BAF312,Small Molecule (Chemical),Phase III,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,227,Multiple Sclerosis,7/7/14 12:28
349,67,Novartis,Large Pharma,4530,siponimod,BAF312,Small Molecule (Chemical),Phase III,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,227,Multiple Sclerosis,7/7/14 12:28
349,67,Novartis,Large Pharma,4530,siponimod,BAF312,Small Molecule (Chemical),Phase III,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,227,Multiple Sclerosis,7/7/14 12:28
349,67,Novartis,Large Pharma,4530,siponimod,BAF312,Small Molecule (Chemical),Phase III,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,227,Multiple Sclerosis,7/7/14 12:28
349,67,Novartis,Large Pharma,4530,siponimod,BAF312,Small Molecule (Chemical),Phase III,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,227,Multiple Sclerosis,7/7/14 12:28
349,67,Novartis,Large Pharma,4530,siponimod,BAF312,Small Molecule (Chemical),Phase III,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,227,Multiple Sclerosis,7/7/14 12:28
352,24,Bristol-Myers Squibb,Large Pharma,634,Baraclude,entecavir,Small Molecule (Chemical),Launched,In-House,Apr-05,Feb-06,Jan-14,Oct-16,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,228,Hepatitis B,7/7/14 12:28
352,24,Bristol-Myers Squibb,Large Pharma,634,Baraclude,entecavir,Small Molecule (Chemical),Launched,In-House,Apr-05,Feb-06,Jan-14,Oct-16,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,Global,Sales,734,931,1196,1388,1527,1498.36772,1539.861897,1458.715129,834.3503975,692.6032127,595.5709042,520.0659431,-14.26181935,228,Hepatitis B,7/7/14 12:28
352,24,Bristol-Myers Squibb,Large Pharma,634,Baraclude,entecavir,Small Molecule (Chemical),Launched,In-House,Apr-05,Feb-06,Jan-14,Oct-16,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,228,Hepatitis B,7/7/14 12:28
352,24,Bristol-Myers Squibb,Large Pharma,634,Baraclude,entecavir,Small Molecule (Chemical),Launched,In-House,Apr-05,Feb-06,Jan-14,Oct-16,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,574,752,988,1147,1238,1350.32,1442.528,1387.086336,777.0858906,645.2717107,555.4571776,485.0071123,-12.52959765,228,Hepatitis B,7/7/14 12:28
352,24,Bristol-Myers Squibb,Large Pharma,634,Baraclude,entecavir,Small Molecule (Chemical),Launched,In-House,Apr-05,Feb-06,Jan-14,Oct-16,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,228,Hepatitis B,7/7/14 12:28
352,24,Bristol-Myers Squibb,Large Pharma,634,Baraclude,entecavir,Small Molecule (Chemical),Launched,In-House,Apr-05,Feb-06,Jan-14,Oct-16,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,US,Sales,160,179,208,241,289,148.04772,97.3338975,71.6287935,57.26450692,47.33150203,40.11372664,35.05883082,-26.01756127,228,Hepatitis B,7/7/14 12:28
353,39,Eli Lilly,Large Pharma,942,insulin peglispro,insulin peglispro,Recombinant Protein,Phase III,In-House,Oct-15,Dec-15,,,83,Insulins,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,229,Diabetes,7/7/14 12:28
353,39,Eli Lilly,Large Pharma,942,insulin peglispro,insulin peglispro,Recombinant Protein,Phase III,In-House,Oct-15,Dec-15,,,83,Insulins,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,11.666666,102.7778562,322.7777634,542.7785497,698.1566324,848.3080394,0,229,Diabetes,7/7/14 12:28
353,39,Eli Lilly,Large Pharma,942,insulin peglispro,insulin peglispro,Recombinant Protein,Phase III,In-House,Oct-15,Dec-15,,,83,Insulins,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,229,Diabetes,7/7/14 12:28
353,39,Eli Lilly,Large Pharma,942,insulin peglispro,insulin peglispro,Recombinant Protein,Phase III,In-House,Oct-15,Dec-15,,,83,Insulins,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,1.666666,26.11115622,99.44459958,172.7780307,223.6225479,273.2937292,0,229,Diabetes,7/7/14 12:28
353,39,Eli Lilly,Large Pharma,942,insulin peglispro,insulin peglispro,Recombinant Protein,Phase III,In-House,Oct-15,Dec-15,,,83,Insulins,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,229,Diabetes,7/7/14 12:28
353,39,Eli Lilly,Large Pharma,942,insulin peglispro,insulin peglispro,Recombinant Protein,Phase III,In-House,Oct-15,Dec-15,,,83,Insulins,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,10,76.6667,223.3331638,370.0005191,474.5340845,575.0143102,0,229,Diabetes,7/7/14 12:28
354,100,Takeda,Large Pharma,914,Basen,voglibose,Small Molecule (Chemical),Launched,In-House,,Nov-94,N/A,Expired,133,AGIs,22,Diabetes,8,Metabolism,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,230,Type II Diabetes,7/7/14 12:28
354,100,Takeda,Large Pharma,914,Basen,voglibose,Small Molecule (Chemical),Launched,In-House,,Nov-94,N/A,Expired,133,AGIs,22,Diabetes,8,Metabolism,7,Global,Sales,491.7349335,375.8652488,326.5073757,232.3476949,172.1309816,143.9013113,125.7377968,113.537619,103.542272,96.7681657,91.76189166,88.06843563,-9.129467003,230,Type II Diabetes,7/7/14 12:28
354,100,Takeda,Large Pharma,914,Basen,voglibose,Small Molecule (Chemical),Launched,In-House,,Nov-94,N/A,Expired,133,AGIs,22,Diabetes,8,Metabolism,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,230,Type II Diabetes,7/7/14 12:28
354,100,Takeda,Large Pharma,914,Basen,voglibose,Small Molecule (Chemical),Launched,In-House,,Nov-94,N/A,Expired,133,AGIs,22,Diabetes,8,Metabolism,7,ROW,Sales,491.7349335,375.8652488,326.5073757,232.3476949,172.1309816,143.9013113,125.7377968,113.537619,103.542272,96.7681657,91.76189166,88.06843563,-9.129467003,230,Type II Diabetes,7/7/14 12:28
354,100,Takeda,Large Pharma,914,Basen,voglibose,Small Molecule (Chemical),Launched,In-House,,Nov-94,N/A,Expired,133,AGIs,22,Diabetes,8,Metabolism,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,230,Type II Diabetes,7/7/14 12:28
354,100,Takeda,Large Pharma,914,Basen,voglibose,Small Molecule (Chemical),Launched,In-House,,Nov-94,N/A,Expired,133,AGIs,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,230,Type II Diabetes,7/7/14 12:28
356,19,Bayer,Large Pharma,2326,Stivarga,regorafenib,Small Molecule (Chemical),Launched,Licensed (Development),Oct-12,May-13,Jul-24,Jul-24,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,961,Colorectal Cancer,7/7/14 12:28
356,19,Bayer,Large Pharma,2326,Stivarga,regorafenib,Small Molecule (Chemical),Launched,Licensed (Development),Oct-12,May-13,Jul-24,Jul-24,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,Global,Sales,0,0,0,41.12868244,261.6219231,417.0017065,523.2438462,634.3283383,713.2264615,769.7210954,808.6319268,834.1750118,18.01585652,961,Colorectal Cancer,7/7/14 12:28
356,19,Bayer,Large Pharma,2326,Stivarga,regorafenib,Small Molecule (Chemical),Launched,Licensed (Development),Oct-12,May-13,Jul-24,Jul-24,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,961,Colorectal Cancer,7/7/14 12:28
356,19,Bayer,Large Pharma,2326,Stivarga,regorafenib,Small Molecule (Chemical),Launched,Licensed (Development),Oct-12,May-13,Jul-24,Jul-24,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,0,0,0,0,79.681804,172.6441743,237.7173819,320.1351963,375.0404043,416.8022016,446.4895748,465.3042907,28.67152481,961,Colorectal Cancer,7/7/14 12:28
356,19,Bayer,Large Pharma,2326,Stivarga,regorafenib,Small Molecule (Chemical),Launched,Licensed (Development),Oct-12,May-13,Jul-24,Jul-24,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,961,Colorectal Cancer,7/7/14 12:28
356,19,Bayer,Large Pharma,2326,Stivarga,regorafenib,Small Molecule (Chemical),Launched,Licensed (Development),Oct-12,May-13,Jul-24,Jul-24,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,US,Sales,0,0,0,41.12868244,181.9401191,244.3575323,285.5264643,314.1931421,338.1860572,352.9188938,362.1423519,368.8707211,10.62399629,961,Colorectal Cancer,7/7/14 12:28
358,24,Bristol-Myers Squibb,Large Pharma,3604,Nulojix,belatacept,Recombinant Protein,Launched,In-House,Jun-11,Jul-11,Dec-23,Dec-21,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,232,Transplant Rejection,7/7/14 12:28
358,24,Bristol-Myers Squibb,Large Pharma,3604,Nulojix,belatacept,Recombinant Protein,Launched,In-House,Jun-11,Jul-11,Dec-23,Dec-21,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Sales,0,0,3.25,11,25.51326,39.41121422,49.69357831,59.46415456,68.06382512,75.49380989,82.09301694,87.89184339,19.32743279,232,Transplant Rejection,7/7/14 12:28
358,24,Bristol-Myers Squibb,Large Pharma,3604,Nulojix,belatacept,Recombinant Protein,Launched,In-House,Jun-11,Jul-11,Dec-23,Dec-21,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,232,Transplant Rejection,7/7/14 12:28
358,24,Bristol-Myers Squibb,Large Pharma,3604,Nulojix,belatacept,Recombinant Protein,Launched,In-House,Jun-11,Jul-11,Dec-23,Dec-21,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Sales,0,0,0.25,2,6,9.3846,11.97844,14.46828,16.6282736,18.50484704,20.17224928,21.63518678,20.10820917,232,Transplant Rejection,7/7/14 12:28
358,24,Bristol-Myers Squibb,Large Pharma,3604,Nulojix,belatacept,Recombinant Protein,Launched,In-House,Jun-11,Jul-11,Dec-23,Dec-21,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,232,Transplant Rejection,7/7/14 12:28
358,24,Bristol-Myers Squibb,Large Pharma,3604,Nulojix,belatacept,Recombinant Protein,Launched,In-House,Jun-11,Jul-11,Dec-23,Dec-21,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Sales,0,0,3,9,19.51326,30.02661422,37.71513831,44.99587456,51.43555152,56.98896285,61.92076766,66.25665661,19.08107222,232,Transplant Rejection,7/7/14 12:28
359,46,GlaxoSmithKline,Large Pharma,1910,Benlysta,belimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-11,Aug-11,N/A,Jun-21,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,234,Systemic Lupus Erythematosus,7/7/14 12:28
359,46,GlaxoSmithKline,Large Pharma,1910,Benlysta,belimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-11,Aug-11,N/A,Jun-21,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,Global,Sales,0,0,1.660093626,193.8173307,437.7559278,650.4160378,782.9620485,893.280862,986.770846,1060.518397,1121.823376,1173.043454,15.12099101,234,Systemic Lupus Erythematosus,7/7/14 12:28
359,46,GlaxoSmithKline,Large Pharma,1910,Benlysta,belimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-11,Aug-11,N/A,Jun-21,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,234,Systemic Lupus Erythematosus,7/7/14 12:28
359,46,GlaxoSmithKline,Large Pharma,1910,Benlysta,belimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-11,Aug-11,N/A,Jun-21,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,ROW,Sales,0,0,1.603180711,110.9520212,228.2584481,341.4449647,404.0427812,453.0030973,489.2463407,514.1774447,532.3992682,545.5106586,13.25404298,234,Systemic Lupus Erythematosus,7/7/14 12:28
359,46,GlaxoSmithKline,Large Pharma,1910,Benlysta,belimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-11,Aug-11,N/A,Jun-21,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,234,Systemic Lupus Erythematosus,7/7/14 12:28
359,46,GlaxoSmithKline,Large Pharma,1910,Benlysta,belimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-11,Aug-11,N/A,Jun-21,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,US,Sales,0,0,5.69E-02,82.86530953,209.4974798,308.9710731,378.9192673,440.2777647,497.5245052,546.3409519,589.4241079,627.5327959,16.96752674,234,Systemic Lupus Erythematosus,7/7/14 12:28
359,46,Human Genome Sciences,Large Pharma,1910,Benlysta,belimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-11,Aug-11,N/A,Jun-21,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,Global,Proforma,0,0,51.94305502,69.29746237,0,0,0,0,0,0,0,0,0,234,Systemic Lupus Erythematosus,7/7/14 12:28
359,46,Human Genome Sciences,Large Pharma,1910,Benlysta,belimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-11,Aug-11,N/A,Jun-21,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,US,Proforma,0,0,51.94305502,69.29746237,0,0,0,0,0,0,0,0,0,234,Systemic Lupus Erythematosus,7/7/14 12:28
362,76,Pfizer,Large Pharma,249,BeneFIX,nonacog alfa,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jan-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1563,Hemophilia B,7/7/14 12:28
362,76,Pfizer,Large Pharma,249,BeneFIX,nonacog alfa,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jan-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,98,643,693,775,832,867.790761,854.6470936,829.3279812,796.0039,759.01207,731.904791,711.5750583,-2.208831176,1563,Hemophilia B,7/7/14 12:28
362,76,Pfizer,Large Pharma,249,BeneFIX,nonacog alfa,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jan-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1563,Hemophilia B,7/7/14 12:28
362,76,Pfizer,Large Pharma,249,BeneFIX,nonacog alfa,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jan-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,42,357,392,417,437,450.5,438.55,427.5894506,410.7495,391.40935,373.047655,355.9371015,-2.888587042,1563,Hemophilia B,7/7/14 12:28
362,76,Pfizer,Large Pharma,249,BeneFIX,nonacog alfa,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jan-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1563,Hemophilia B,7/7/14 12:28
362,76,Pfizer,Large Pharma,249,BeneFIX,nonacog alfa,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jan-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,56,286,301,358,395,417.290761,416.0970936,401.7385306,385.2544,367.60272,358.857136,355.6379568,-1.488417931,1563,Hemophilia B,7/7/14 12:28
362,76,Wyeth,Large Pharma,249,BeneFIX,nonacog alfa,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jan-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Proforma,504,0,0,0,0,0,0,0,0,0,0,0,0,1563,Hemophilia B,7/7/14 12:28
362,76,Wyeth,Large Pharma,249,BeneFIX,nonacog alfa,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jan-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Proforma,294,0,0,0,0,0,0,0,0,0,0,0,0,1563,Hemophilia B,7/7/14 12:28
362,76,Wyeth,Large Pharma,249,BeneFIX,nonacog alfa,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jan-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Proforma,210,0,0,0,0,0,0,0,0,0,0,0,0,1563,Hemophilia B,7/7/14 12:28
363,100,Takeda,Large Pharma,424,Benet,risedronate,Small Molecule (Chemical),Launched,Licensed (Development),,May-02,N/A,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
363,100,Takeda,Large Pharma,424,Benet,risedronate,Small Molecule (Chemical),Launched,Licensed (Development),,May-02,N/A,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,200.9699293,219.4792089,208.9173964,160.1152509,121.1022365,108.6818982,98.78606682,92.04584013,86.75208188,82.76321384,79.80484974,77.56409327,-6.166396945,1618,Osteoporosis,7/7/14 12:28
363,100,Takeda,Large Pharma,424,Benet,risedronate,Small Molecule (Chemical),Launched,Licensed (Development),,May-02,N/A,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
363,100,Takeda,Large Pharma,424,Benet,risedronate,Small Molecule (Chemical),Launched,Licensed (Development),,May-02,N/A,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,200.9699293,219.4792089,208.9173964,160.1152509,121.1022365,108.6818982,98.78606682,92.04584013,86.75208188,82.76321384,79.80484974,77.56409327,-6.166396945,1618,Osteoporosis,7/7/14 12:28
363,100,Takeda,Large Pharma,424,Benet,risedronate,Small Molecule (Chemical),Launched,Licensed (Development),,May-02,N/A,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
363,100,Takeda,Large Pharma,424,Benet,risedronate,Small Molecule (Chemical),Launched,Licensed (Development),,May-02,N/A,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
364,34,Daiichi-Sankyo,Regional & Specialty Pharma,2195,Benicar / Olmetec,olmesartan,Small Molecule (Chemical),Launched,In-House,May-02,Oct-02,Oct-16,Feb-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1569,Hypertension,7/7/14 12:28
364,34,Daiichi-Sankyo,Regional & Specialty Pharma,2195,Benicar / Olmetec,olmesartan,Small Molecule (Chemical),Launched,In-House,May-02,Oct-02,Oct-16,Feb-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,2219.291497,2319.392079,2352.5365,2216.332157,2043.747616,1922.104815,1876.017159,1776.282983,1140.780082,933.6353629,797.9116251,699.8182759,-14.19583792,1569,Hypertension,7/7/14 12:28
364,34,Daiichi-Sankyo,Regional & Specialty Pharma,2195,Benicar / Olmetec,olmesartan,Small Molecule (Chemical),Launched,In-House,May-02,Oct-02,Oct-16,Feb-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1569,Hypertension,7/7/14 12:28
364,34,Daiichi-Sankyo,Regional & Specialty Pharma,2195,Benicar / Olmetec,olmesartan,Small Molecule (Chemical),Launched,In-House,May-02,Oct-02,Oct-16,Feb-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,1261.54871,1389.067224,1449.760114,1335.09634,1248.397558,1244.315802,1203.185451,1216.284854,1091.04701,900.2603887,772.7538542,682.9920721,-8.255417103,1569,Hypertension,7/7/14 12:28
364,34,Daiichi-Sankyo,Regional & Specialty Pharma,2195,Benicar / Olmetec,olmesartan,Small Molecule (Chemical),Launched,In-House,May-02,Oct-02,Oct-16,Feb-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1569,Hypertension,7/7/14 12:28
364,34,Daiichi-Sankyo,Regional & Specialty Pharma,2195,Benicar / Olmetec,olmesartan,Small Molecule (Chemical),Launched,In-House,May-02,Oct-02,Oct-16,Feb-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,957.7427866,930.324855,902.7763856,881.2358169,795.3500574,677.7890129,672.8317077,559.998129,49.73307195,33.3749742,25.15777089,16.82620388,-42.35314171,1569,Hypertension,7/7/14 12:28
365,15,Astellas Pharma,Regional & Specialty Pharma,2521,YM533,beraprost,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2170,Nephorosclerosis,7/7/14 12:28
365,15,Astellas Pharma,Regional & Specialty Pharma,2521,YM533,beraprost,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2170,Nephorosclerosis,7/7/14 12:28
365,15,Astellas Pharma,Regional & Specialty Pharma,2521,YM533,beraprost,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2170,Nephorosclerosis,7/7/14 12:28
365,15,Astellas Pharma,Regional & Specialty Pharma,2521,YM533,beraprost,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2170,Nephorosclerosis,7/7/14 12:28
365,15,Astellas Pharma,Regional & Specialty Pharma,2521,YM533,beraprost,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2170,Nephorosclerosis,7/7/14 12:28
365,15,Astellas Pharma,Regional & Specialty Pharma,2521,YM533,beraprost,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2170,Nephorosclerosis,7/7/14 12:28
366,19,Bayer,Large Pharma,3045,Betaseron / Betaferon,interferon-beta 1b,Recombinant Protein,Launched,Licensed (Development),Jul-93,Jan-96,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1501,Multiple Sclerosis,7/7/14 12:28
366,19,Bayer,Large Pharma,3045,Betaseron / Betaferon,interferon-beta 1b,Recombinant Protein,Launched,Licensed (Development),Jul-93,Jan-96,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Sales,1686.851061,1597.654301,1553.118171,1562.889933,1378.495209,1283.484286,1205.956381,1170.860897,1145.097634,1127.512032,1083.015467,1059.054304,-3.69591127,1501,Multiple Sclerosis,7/7/14 12:28
366,19,Bayer,Large Pharma,3045,Betaseron / Betaferon,interferon-beta 1b,Recombinant Protein,Launched,Licensed (Development),Jul-93,Jan-96,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1501,Multiple Sclerosis,7/7/14 12:28
366,19,Bayer,Large Pharma,3045,Betaseron / Betaferon,interferon-beta 1b,Recombinant Protein,Launched,Licensed (Development),Jul-93,Jan-96,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Sales,1021.281326,971.0452757,931.5928151,820.0031061,715.8082059,638.0271449,589.6016907,564.2909732,546.0985435,531.3614812,522.0960194,510.8117112,-4.705830092,1501,Multiple Sclerosis,7/7/14 12:28
366,19,Bayer,Large Pharma,3045,Betaseron / Betaferon,interferon-beta 1b,Recombinant Protein,Launched,Licensed (Development),Jul-93,Jan-96,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1501,Multiple Sclerosis,7/7/14 12:28
366,19,Bayer,Large Pharma,3045,Betaseron / Betaferon,interferon-beta 1b,Recombinant Protein,Launched,Licensed (Development),Jul-93,Jan-96,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,US,Sales,665.5697349,626.6090251,621.5253558,742.8868265,662.6870032,645.4571411,616.3546903,606.5699242,598.9990904,596.1505509,560.9194479,548.2425926,-2.672006151,1501,Multiple Sclerosis,7/7/14 12:28
368,21,Biogen Idec,Regional & Specialty Pharma,365,Tecfidera,dimethyl fumarate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,May-13,Apr-19,N/A,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1363,Multiple Sclerosis,7/7/14 12:28
368,21,Biogen Idec,Regional & Specialty Pharma,365,Tecfidera,dimethyl fumarate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,May-13,Apr-19,N/A,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,876,2544.00288,3920.404248,4798.605688,5160.086115,5419.706344,2903.770271,1697.311648,9.909882255,1363,Multiple Sclerosis,7/7/14 12:28
368,21,Biogen Idec,Regional & Specialty Pharma,365,Tecfidera,dimethyl fumarate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,May-13,Apr-19,N/A,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1363,Multiple Sclerosis,7/7/14 12:28
368,21,Biogen Idec,Regional & Specialty Pharma,365,Tecfidera,dimethyl fumarate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,May-13,Apr-19,N/A,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,12,240,522,709,830,953,1062,1181.2,92.6346083,1363,Multiple Sclerosis,7/7/14 12:28
368,21,Biogen Idec,Regional & Specialty Pharma,365,Tecfidera,dimethyl fumarate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,May-13,Apr-19,N/A,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1363,Multiple Sclerosis,7/7/14 12:28
368,21,Biogen Idec,Regional & Specialty Pharma,365,Tecfidera,dimethyl fumarate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,May-13,Apr-19,N/A,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,864,2304.00288,3398.404248,4089.605688,4330.086115,4466.706344,1841.770271,516.1116483,-7.096328487,1363,Multiple Sclerosis,7/7/14 12:28
371,67,Novartis,Large Pharma,226,BHQ880,BHQ880,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,240,Multiple Myeloma,7/7/14 12:28
371,67,Novartis,Large Pharma,226,BHQ880,BHQ880,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,240,Multiple Myeloma,7/7/14 12:28
371,67,Novartis,Large Pharma,226,BHQ880,BHQ880,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,240,Multiple Myeloma,7/7/14 12:28
371,67,Novartis,Large Pharma,226,BHQ880,BHQ880,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,240,Multiple Myeloma,7/7/14 12:28
371,67,Novartis,Large Pharma,226,BHQ880,BHQ880,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,240,Multiple Myeloma,7/7/14 12:28
371,67,Novartis,Large Pharma,226,BHQ880,BHQ880,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,240,Multiple Myeloma,7/7/14 12:28
372,23,Boehringer Ingelheim,Large Pharma,3766,Jardiance,empagliflozin,Small Molecule (Chemical),Filed,In-House,Nov-14,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,241,Diabetes,7/7/14 12:28
372,23,Boehringer Ingelheim,Large Pharma,3766,Jardiance,empagliflozin,Small Molecule (Chemical),Filed,In-House,Nov-14,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,2,Global,Sales,0,0,0,0,0,17.2644068,113.7680888,255.4249615,397.0820476,503.1831206,602.28635,690.0570331,0,241,Diabetes,7/7/14 12:28
372,23,Boehringer Ingelheim,Large Pharma,3766,Jardiance,empagliflozin,Small Molecule (Chemical),Filed,In-House,Nov-14,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,241,Diabetes,7/7/14 12:28
372,23,Boehringer Ingelheim,Large Pharma,3766,Jardiance,empagliflozin,Small Molecule (Chemical),Filed,In-House,Nov-14,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,2,ROW,Sales,0,0,0,0,0,9.296210466,52.67855696,114.6532989,176.627993,223.2329842,266.664866,305.1387676,0,241,Diabetes,7/7/14 12:28
372,23,Boehringer Ingelheim,Large Pharma,3766,Jardiance,empagliflozin,Small Molecule (Chemical),Filed,In-House,Nov-14,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,241,Diabetes,7/7/14 12:28
372,23,Boehringer Ingelheim,Large Pharma,3766,Jardiance,empagliflozin,Small Molecule (Chemical),Filed,In-House,Nov-14,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,2,US,Sales,0,0,0,0,0,7.968196336,61.0895318,140.7716626,220.4540545,279.9501363,335.6214841,384.9182655,0,241,Diabetes,7/7/14 12:28
373,23,Boehringer Ingelheim,Large Pharma,2478,Striverdi,olodaterol,Small Molecule (Chemical),Approved,In-House,May-14,Jan-14,N/A,Nov-23,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,242,COPD,7/7/14 12:28
373,23,Boehringer Ingelheim,Large Pharma,2478,Striverdi,olodaterol,Small Molecule (Chemical),Approved,In-House,May-14,Jan-14,N/A,Nov-23,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,28.77399053,49.10765152,70.97590725,99.74992952,120.9506358,140.9462857,159.6876774,0,242,COPD,7/7/14 12:28
373,23,Boehringer Ingelheim,Large Pharma,2478,Striverdi,olodaterol,Small Molecule (Chemical),Approved,In-House,May-14,Jan-14,N/A,Nov-23,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,242,COPD,7/7/14 12:28
373,23,Boehringer Ingelheim,Large Pharma,2478,Striverdi,olodaterol,Small Molecule (Chemical),Approved,In-House,May-14,Jan-14,N/A,Nov-23,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,17.26439087,24.17014721,34.5287472,51.7931208,62.28985526,72.2893747,81.57069853,0,242,COPD,7/7/14 12:28
373,23,Boehringer Ingelheim,Large Pharma,2478,Striverdi,olodaterol,Small Molecule (Chemical),Approved,In-House,May-14,Jan-14,N/A,Nov-23,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,242,COPD,7/7/14 12:28
373,23,Boehringer Ingelheim,Large Pharma,2478,Striverdi,olodaterol,Small Molecule (Chemical),Approved,In-House,May-14,Jan-14,N/A,Nov-23,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,11.50959967,24.93750431,36.44716004,47.95680872,58.6607805,68.65691098,78.11697884,0,242,COPD,7/7/14 12:28
374,23,Boehringer Ingelheim,Large Pharma,4636,faldaprevir,faldaprevir,Small Molecule (Chemical),Filed,In-House,Jul-14,Dec-14,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,243,Hepatitis C,7/7/14 12:28
374,23,Boehringer Ingelheim,Large Pharma,4636,faldaprevir,faldaprevir,Small Molecule (Chemical),Filed,In-House,Jul-14,Dec-14,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,7.9681804,126.6940684,260.2938931,358.568118,420.1887131,252.3257127,152.7234577,0,243,Hepatitis C,7/7/14 12:28
374,23,Boehringer Ingelheim,Large Pharma,4636,faldaprevir,faldaprevir,Small Molecule (Chemical),Filed,In-House,Jul-14,Dec-14,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,243,Hepatitis C,7/7/14 12:28
374,23,Boehringer Ingelheim,Large Pharma,4636,faldaprevir,faldaprevir,Small Molecule (Chemical),Filed,In-House,Jul-14,Dec-14,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,1.328030067,3.18727216,46.48105233,115.5386158,138.1151269,106.2424053,79.681804,0,243,Hepatitis C,7/7/14 12:28
374,23,Boehringer Ingelheim,Large Pharma,4636,faldaprevir,faldaprevir,Small Molecule (Chemical),Filed,In-House,Jul-14,Dec-14,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,243,Hepatitis C,7/7/14 12:28
374,23,Boehringer Ingelheim,Large Pharma,4636,faldaprevir,faldaprevir,Small Molecule (Chemical),Filed,In-House,Jul-14,Dec-14,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,2,US,Sales,0,0,0,0,0,6.640150333,123.5067962,213.8128407,243.0295022,282.0735861,146.0833073,73.04165366,0,243,Hepatitis C,7/7/14 12:28
378,23,Boehringer Ingelheim,Large Pharma,3765,volasertib,volasertib,Small Molecule (Chemical),Phase III,In-House,Jul-16,Oct-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,247,Acute Myeloid Leukemia,7/7/14 12:28
378,23,Boehringer Ingelheim,Large Pharma,3765,volasertib,volasertib,Small Molecule (Chemical),Phase III,In-House,Jul-16,Oct-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,17.8620044,79.83953147,180.3561972,259.654266,317.8311589,0,247,Acute Myeloid Leukemia,7/7/14 12:28
378,23,Boehringer Ingelheim,Large Pharma,3765,volasertib,volasertib,Small Molecule (Chemical),Phase III,In-House,Jul-16,Oct-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,247,Acute Myeloid Leukemia,7/7/14 12:28
378,23,Boehringer Ingelheim,Large Pharma,3765,volasertib,volasertib,Small Molecule (Chemical),Phase III,In-House,Jul-16,Oct-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,7.436968373,60.55819229,110.7046146,141.0897101,0,247,Acute Myeloid Leukemia,7/7/14 12:28
378,23,Boehringer Ingelheim,Large Pharma,3765,volasertib,volasertib,Small Molecule (Chemical),Phase III,In-House,Jul-16,Oct-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,247,Acute Myeloid Leukemia,7/7/14 12:28
378,23,Boehringer Ingelheim,Large Pharma,3765,volasertib,volasertib,Small Molecule (Chemical),Phase III,In-House,Jul-16,Oct-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,17.8620044,72.4025631,119.7980049,148.9496514,176.7414487,0,247,Acute Myeloid Leukemia,7/7/14 12:28
379,1,Abbott,Regional & Specialty Pharma,230,Biaxin,clarithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-91,Jul-91,May-05,Jun-08,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1396,Bacterial infections,7/7/14 12:28
379,1,Abbott,Regional & Specialty Pharma,230,Biaxin,clarithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-91,Jul-91,May-05,Jun-08,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,616,524,553,503,456,415.5,379.05,346.245,316.7205,290.14845,266.233605,244.7102445,-8.507827569,1396,Bacterial infections,7/7/14 12:28
379,1,Abbott,Regional & Specialty Pharma,230,Biaxin,clarithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-91,Jul-91,May-05,Jun-08,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1396,Bacterial infections,7/7/14 12:28
379,1,Abbott,Regional & Specialty Pharma,230,Biaxin,clarithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-91,Jul-91,May-05,Jun-08,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,600,521,551,501,456,415.5,379.05,346.245,316.7205,290.14845,266.233605,244.7102445,-8.507827569,1396,Bacterial infections,7/7/14 12:28
379,1,Abbott,Regional & Specialty Pharma,230,Biaxin,clarithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-91,Jul-91,May-05,Jun-08,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1396,Bacterial infections,7/7/14 12:28
379,1,Abbott,Regional & Specialty Pharma,230,Biaxin,clarithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-91,Jul-91,May-05,Jun-08,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,16,3,2,2,0,0,0,0,0,0,0,0,0,1396,Bacterial infections,7/7/14 12:28
384,100,Takeda,Large Pharma,499,Blopress,candesartan cilexitil,Small Molecule (Chemical),Launched,In-House,,Jul-99,N/A,May-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1375,hypertension,7/7/14 12:28
384,100,Takeda,Large Pharma,499,Blopress,candesartan cilexitil,Small Molecule (Chemical),Launched,In-House,,Jul-99,N/A,May-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,2344.261309,2368.417981,2350.004168,1624.026116,1209.908669,1115.684624,889.3440677,803.8668738,756.0306561,711.0077959,677.926338,656.0802102,-8.371784041,1375,hypertension,7/7/14 12:28
384,100,Takeda,Large Pharma,499,Blopress,candesartan cilexitil,Small Molecule (Chemical),Launched,In-House,,Jul-99,N/A,May-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1375,hypertension,7/7/14 12:28
384,100,Takeda,Large Pharma,499,Blopress,candesartan cilexitil,Small Molecule (Chemical),Launched,In-House,,Jul-99,N/A,May-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,2344.261309,2368.417981,2350.004168,1624.026116,1209.908669,1115.684624,889.3440677,803.8668738,756.0306561,711.0077959,677.926338,656.0802102,-8.371784041,1375,hypertension,7/7/14 12:28
384,100,Takeda,Large Pharma,499,Blopress,candesartan cilexitil,Small Molecule (Chemical),Launched,In-House,,Jul-99,N/A,May-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1375,hypertension,7/7/14 12:28
384,100,Takeda,Large Pharma,499,Blopress,candesartan cilexitil,Small Molecule (Chemical),Launched,In-House,,Jul-99,N/A,May-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1375,hypertension,7/7/14 12:28
385,76,Pfizer,Large Pharma,4228,InFuse,rhBMP-2,Recombinant Protein,Launched,Corporate Acquisition,Jul-02,Jul-03,N/A,N/A,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1421,Bone Synthesis,7/7/14 12:28
385,76,Pfizer,Large Pharma,4228,InFuse,rhBMP-2,Recombinant Protein,Launched,Corporate Acquisition,Jul-02,Jul-03,N/A,N/A,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Sales,84.9125,399.904,340,279,224.048,191.832,166.767,148.074625,134.8209069,124.8982575,117.4913467,111.9234788,-9.439239379,1421,Bone Synthesis,7/7/14 12:28
385,76,Pfizer,Large Pharma,4228,InFuse,rhBMP-2,Recombinant Protein,Launched,Corporate Acquisition,Jul-02,Jul-03,N/A,N/A,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1421,Bone Synthesis,7/7/14 12:28
385,76,Pfizer,Large Pharma,4228,InFuse,rhBMP-2,Recombinant Protein,Launched,Corporate Acquisition,Jul-02,Jul-03,N/A,N/A,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Sales,2.14,17.904,17,16,15.048,14.072,13.108,12.138,11.171,10.2025,9.23475,8.266625,-8.20148125,1421,Bone Synthesis,7/7/14 12:28
385,76,Pfizer,Large Pharma,4228,InFuse,rhBMP-2,Recombinant Protein,Launched,Corporate Acquisition,Jul-02,Jul-03,N/A,N/A,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1421,Bone Synthesis,7/7/14 12:28
385,76,Pfizer,Large Pharma,4228,InFuse,rhBMP-2,Recombinant Protein,Launched,Corporate Acquisition,Jul-02,Jul-03,N/A,N/A,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Sales,82.7725,382,323,263,209,177.76,153.659,135.936625,123.6499069,114.6957575,108.2565967,103.6568538,-9.532383408,1421,Bone Synthesis,7/7/14 12:28
385,76,Wyeth,Large Pharma,4228,InFuse,rhBMP-2,Recombinant Protein,Launched,Corporate Acquisition,Jul-02,Jul-03,N/A,N/A,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Proforma,327,0,0,0,0,0,0,0,0,0,0,0,0,1421,Bone Synthesis,7/7/14 12:28
385,76,Wyeth,Large Pharma,4228,InFuse,rhBMP-2,Recombinant Protein,Launched,Corporate Acquisition,Jul-02,Jul-03,N/A,N/A,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Proforma,14,0,0,0,0,0,0,0,0,0,0,0,0,1421,Bone Synthesis,7/7/14 12:28
385,76,Wyeth,Large Pharma,4228,InFuse,rhBMP-2,Recombinant Protein,Launched,Corporate Acquisition,Jul-02,Jul-03,N/A,N/A,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Proforma,313,0,0,0,0,0,0,0,0,0,0,0,0,1421,Bone Synthesis,7/7/14 12:28
395,24,Bristol-Myers Squibb,Large Pharma,3847,daclatasvir,BMS-790052,Small Molecule (Chemical),Filed,In-House,Jun-15,Jul-14,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,262,Hepatitis C,7/7/14 12:28
395,24,Bristol-Myers Squibb,Large Pharma,3847,daclatasvir,BMS-790052,Small Molecule (Chemical),Filed,In-House,Jun-15,Jul-14,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,211,898,1056,1210,1164.31,1028,837,0,262,Hepatitis C,7/7/14 12:28
395,24,Bristol-Myers Squibb,Large Pharma,3847,daclatasvir,BMS-790052,Small Molecule (Chemical),Filed,In-House,Jun-15,Jul-14,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,262,Hepatitis C,7/7/14 12:28
395,24,Bristol-Myers Squibb,Large Pharma,3847,daclatasvir,BMS-790052,Small Molecule (Chemical),Filed,In-House,Jun-15,Jul-14,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,211,512,555,575,583.31,513,413,0,262,Hepatitis C,7/7/14 12:28
395,24,Bristol-Myers Squibb,Large Pharma,3847,daclatasvir,BMS-790052,Small Molecule (Chemical),Filed,In-House,Jun-15,Jul-14,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,262,Hepatitis C,7/7/14 12:28
395,24,Bristol-Myers Squibb,Large Pharma,3847,daclatasvir,BMS-790052,Small Molecule (Chemical),Filed,In-House,Jun-15,Jul-14,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,386,501,635,581,515,424,0,262,Hepatitis C,7/7/14 12:28
396,61,Merck & Co,Large Pharma,3500,Victrelis,boceprevir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-11,Aug-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,265,Hepatitis C,7/7/14 12:28
396,61,Merck & Co,Large Pharma,3500,Victrelis,boceprevir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-11,Aug-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,141,501,428,217,71,32,12.875,5.921875,2.912109375,2,-53.53947857,265,Hepatitis C,7/7/14 12:28
396,61,Merck & Co,Large Pharma,3500,Victrelis,boceprevir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-11,Aug-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,265,Hepatitis C,7/7/14 12:28
396,61,Merck & Co,Large Pharma,3500,Victrelis,boceprevir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-11,Aug-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,43,234,270,178,54,29,10.375,4.921875,1.912109375,1,-55.05693708,265,Hepatitis C,7/7/14 12:28
396,61,Merck & Co,Large Pharma,3500,Victrelis,boceprevir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-11,Aug-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,265,Hepatitis C,7/7/14 12:28
396,61,Merck & Co,Large Pharma,3500,Victrelis,boceprevir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-11,Aug-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,98,267,158,39,17,3,2.5,1,1,1,-51.48160292,265,Hepatitis C,7/7/14 12:28
397,86,Roche,Large Pharma,1257,Bondronat,ibandronic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-96,N/A,Jun-11,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1706,Hypercalcemia of Malignancy,7/7/14 12:28
397,86,Roche,Large Pharma,1257,Bondronat,ibandronic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-96,N/A,Jun-11,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,5,Global,Sales,124.3074845,130.4286323,101.3716143,74.47768093,59.41642044,44.75959885,34.88138158,27.36646507,21.57509242,17.29960959,14.07272768,11.64011147,-20.77459272,1706,Hypercalcemia of Malignancy,7/7/14 12:28
397,86,Roche,Large Pharma,1257,Bondronat,ibandronic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-96,N/A,Jun-11,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1706,Hypercalcemia of Malignancy,7/7/14 12:28
397,86,Roche,Large Pharma,1257,Bondronat,ibandronic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-96,N/A,Jun-11,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,5,ROW,Sales,124.3074845,130.4286323,101.3716143,74.47768093,59.41642044,44.75959885,34.88138158,27.36646507,21.57509242,17.29960959,14.07272768,11.64011147,-20.77459272,1706,Hypercalcemia of Malignancy,7/7/14 12:28
397,86,Roche,Large Pharma,1257,Bondronat,ibandronic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-96,N/A,Jun-11,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1706,Hypercalcemia of Malignancy,7/7/14 12:28
397,86,Roche,Large Pharma,1257,Bondronat,ibandronic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-96,N/A,Jun-11,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1706,Hypercalcemia of Malignancy,7/7/14 12:28
398,29,Chugai,Regional & Specialty Pharma,1983,Bonviva,ibandronate,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-13,N/A,,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,3,Global,Alliance Revenue,0,0,0,0,5.124482231,26.45276409,40.25422922,54.05579425,64.28041179,72.6895617,79.71215296,85.36742783,49.45833521,1493,Osteoporosis,7/7/14 12:28
398,29,Chugai,Regional & Specialty Pharma,1983,Bonviva,ibandronate,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-13,N/A,,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,3,ROW,Alliance Revenue,0,0,0,0,5.124482231,26.45276409,40.25422922,54.05579425,64.28041179,72.6895617,79.71215296,85.36742783,49.45833521,1493,Osteoporosis,7/7/14 12:28
398,29,Chugai,Regional & Specialty Pharma,1983,Bonviva,ibandronate,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-13,N/A,,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1493,Osteoporosis,7/7/14 12:28
398,86,Roche,Large Pharma,1983,Bonviva,ibandronate,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-13,N/A,,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,5,Global,Sales,0,0,0,0,5.124482231,26.45276409,40.25422922,54.05579425,64.28041179,72.6895617,79.71215296,85.36742783,49.45833521,1493,Osteoporosis,7/7/14 12:28
398,86,Roche,Large Pharma,1983,Bonviva,ibandronate,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-13,N/A,,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,5,ROW,Sales,0,0,0,0,5.124482231,26.45276409,40.25422922,54.05579425,64.28041179,72.6895617,79.71215296,85.36742783,49.45833521,1493,Osteoporosis,7/7/14 12:28
399,46,GlaxoSmithKline,Large Pharma,1137,Boniva / Bonviva,ibandronate,Small Molecule (Chemical),Launched,Licensed (Development),Apr-05,Oct-05,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,4,Global,Alliance Revenue,397.6117308,120.5100045,104.9210671,96.03139656,83.30462238,77.70326422,74.02919768,71.25438798,69.44943976,67.22680321,66.12292086,64.09997515,-3.674500922,1493,Osteoporosis,7/7/14 12:28
399,46,GlaxoSmithKline,Large Pharma,1137,Boniva / Bonviva,ibandronate,Small Molecule (Chemical),Launched,Licensed (Development),Apr-05,Oct-05,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1493,Osteoporosis,7/7/14 12:28
399,46,GlaxoSmithKline,Large Pharma,1137,Boniva / Bonviva,ibandronate,Small Molecule (Chemical),Launched,Licensed (Development),Apr-05,Oct-05,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,4,ROW,Alliance Revenue,155.926169,120.5100045,104.9210671,96.03139656,83.30462238,77.70326422,74.02919768,71.25438798,69.44943976,67.22680321,66.12292086,64.09997515,-3.674500922,1493,Osteoporosis,7/7/14 12:28
399,46,GlaxoSmithKline,Large Pharma,1137,Boniva / Bonviva,ibandronate,Small Molecule (Chemical),Launched,Licensed (Development),Apr-05,Oct-05,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1493,Osteoporosis,7/7/14 12:28
399,46,GlaxoSmithKline,Large Pharma,1137,Boniva / Bonviva,ibandronate,Small Molecule (Chemical),Launched,Licensed (Development),Apr-05,Oct-05,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,4,US,Alliance Revenue,241.6855619,0,0,0,0,0,0,0,0,0,0,0,0,1493,Osteoporosis,7/7/14 12:28
399,46,GlaxoSmithKline,Large Pharma,1137,Boniva / Bonviva,ibandronate,Small Molecule (Chemical),Launched,Licensed (Development),Apr-05,Oct-05,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1493,Osteoporosis,7/7/14 12:28
400,86,Roche,Large Pharma,1137,Boniva / Bonviva,ibandronate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,Oct-05,Mar-12,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1493,Osteoporosis,7/7/14 12:28
400,86,Roche,Large Pharma,1137,Boniva / Bonviva,ibandronate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,Oct-05,Mar-12,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,5,Global,Sales,974.2023603,974.3786059,783.9404836,344.4760738,224.4576058,163.5339972,131.7883016,113.2492304,102.9238702,96.01054781,91.34616736,89.24685313,-12.34436199,1493,Osteoporosis,7/7/14 12:28
400,86,Roche,Large Pharma,1137,Boniva / Bonviva,ibandronate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,Oct-05,Mar-12,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1493,Osteoporosis,7/7/14 12:28
400,86,Roche,Large Pharma,1137,Boniva / Bonviva,ibandronate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,Oct-05,Mar-12,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,5,ROW,Sales,448.4277405,469.9266898,431.3925362,264.4893693,170.5014506,121.9409109,97.66064107,85.52050615,79.45043869,76.41540496,74.8978881,74.13912966,-11.21667712,1493,Osteoporosis,7/7/14 12:28
400,86,Roche,Large Pharma,1137,Boniva / Bonviva,ibandronate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,Oct-05,Mar-12,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1493,Osteoporosis,7/7/14 12:28
400,86,Roche,Large Pharma,1137,Boniva / Bonviva,ibandronate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,Oct-05,Mar-12,Jun-11,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,5,US,Sales,525.7746198,504.451916,352.5479474,79.98670443,53.95615525,41.5930863,34.12766056,27.7287242,23.47343153,19.59514285,16.44827926,15.10772347,-16.62753254,1493,Osteoporosis,7/7/14 12:28
401,46,GlaxoSmithKline,Large Pharma,1363,Boostrix,DTaP booster vaccine,Vaccine,Launched,In-House,May-05,Jul-04,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,266,DTaP prophylaxis,7/7/14 12:28
401,46,GlaxoSmithKline,Large Pharma,1363,Boostrix,DTaP booster vaccine,Vaccine,Launched,In-House,May-05,Jul-04,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,216.7373749,279.6450105,307.8106964,377.8852897,450.2632401,415.8681315,443.3177735,442.463075,448.4425841,450.9124656,453.1700689,454.718836,0.140768781,266,DTaP prophylaxis,7/7/14 12:28
401,46,GlaxoSmithKline,Large Pharma,1363,Boostrix,DTaP booster vaccine,Vaccine,Launched,In-House,May-05,Jul-04,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,266,DTaP prophylaxis,7/7/14 12:28
401,46,GlaxoSmithKline,Large Pharma,1363,Boostrix,DTaP booster vaccine,Vaccine,Launched,In-House,May-05,Jul-04,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,102.9112715,109.6950041,134.6671797,144.8860452,164.1584729,157.9048168,160.9652,163.1122564,163.519758,164.3227274,164.8469579,165.1684364,8.77E-02,266,DTaP prophylaxis,7/7/14 12:28
401,46,GlaxoSmithKline,Large Pharma,1363,Boostrix,DTaP booster vaccine,Vaccine,Launched,In-House,May-05,Jul-04,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,266,DTaP prophylaxis,7/7/14 12:28
401,46,GlaxoSmithKline,Large Pharma,1363,Boostrix,DTaP booster vaccine,Vaccine,Launched,In-House,May-05,Jul-04,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,113.8261033,169.9500064,173.1435167,232.9992445,286.1047671,257.9633146,282.3525735,279.3508186,284.9228262,286.5897382,288.323111,289.5503996,0.171164884,266,DTaP prophylaxis,7/7/14 12:28
403,76,Pfizer,Large Pharma,1379,Bosulif,bosutinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-12,Apr-13,Sep-19,,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,268,Chronic Myeloid Leukemia,7/7/14 12:28
403,76,Pfizer,Large Pharma,1379,Bosulif,bosutinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-12,Apr-13,Sep-19,,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,6.66666,35.69444222,60.27766323,83.61081169,103.5662088,118.8922099,131.7135845,142.2132814,150.7263042,22.84845226,268,Chronic Myeloid Leukemia,7/7/14 12:28
403,76,Pfizer,Large Pharma,1379,Bosulif,bosutinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-12,Apr-13,Sep-19,,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,268,Chronic Myeloid Leukemia,7/7/14 12:28
403,76,Pfizer,Large Pharma,1379,Bosulif,bosutinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-12,Apr-13,Sep-19,,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,11.25,22.5,32.4999,42.49979423,49.67473621,55.68592969,60.69657042,64.71713718,28.39623468,268,Chronic Myeloid Leukemia,7/7/14 12:28
403,76,Pfizer,Large Pharma,1379,Bosulif,bosutinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-12,Apr-13,Sep-19,,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,268,Chronic Myeloid Leukemia,7/7/14 12:28
403,76,Pfizer,Large Pharma,1379,Bosulif,bosutinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-12,Apr-13,Sep-19,,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,6.66666,24.44444222,37.77766323,51.11091169,61.06641458,69.21747371,76.02765479,81.51671099,86.00916697,19.68838558,268,Chronic Myeloid Leukemia,7/7/14 12:28
404,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Oct-10,Jun-10,N/A,N/A,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1367,Migraine,7/7/14 12:28
404,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Oct-10,Jun-10,N/A,N/A,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,Global,Sales,34,39.74050078,105.7,150,204,300,379.94,430,470,490.003,500,509,13.95325772,1367,Migraine,7/7/14 12:28
404,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Oct-10,Jun-10,N/A,N/A,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1367,Migraine,7/7/14 12:28
404,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Oct-10,Jun-10,N/A,N/A,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,ROW,Sales,7,7.74050078,10.6,20,31,60,69.94,80,90,95.003,100,103,18.71249423,1367,Migraine,7/7/14 12:28
404,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Oct-10,Jun-10,N/A,N/A,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1367,Migraine,7/7/14 12:28
404,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Oct-10,Jun-10,N/A,N/A,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,US,Sales,27,32,95.1,130,173,240,310,350,380,395,400,406,12.9602517,1367,Migraine,7/7/14 12:28
405,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Jan-07,Jan-07,N/A,N/A,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1367,Overactive bladder,7/7/14 12:28
405,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Jan-07,Jan-07,N/A,N/A,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,Global,Sales,82,91,97.6,110.2,159,237,304,339,366,387,405.2,420.24,14.8946952,1367,Overactive bladder,7/7/14 12:28
405,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Jan-07,Jan-07,N/A,N/A,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1367,Overactive bladder,7/7/14 12:28
405,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Jan-07,Jan-07,N/A,N/A,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,ROW,Sales,20,23,25.6,27.55,39,69,94,104,114,122,129.2,134,19.28259911,1367,Overactive bladder,7/7/14 12:28
405,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Jan-07,Jan-07,N/A,N/A,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1367,Overactive bladder,7/7/14 12:28
405,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Jan-07,Jan-07,N/A,N/A,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,US,Sales,62,68,72,82.65,120,168,210,235,252,265,276,286.24,13.22322697,1367,Overactive bladder,7/7/14 12:28
406,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Feb-90,Dec-97,N/A,N/A,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1367,Muscle Spasms,7/7/14 12:28
406,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Feb-90,Dec-97,N/A,N/A,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,Global,Sales,565,593.6,610.1,659,687,697.5342,713.73443,725.1396025,734.3622778,741.7230377,747.435894,752,1.299831617,1367,Muscle Spasms,7/7/14 12:28
406,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Feb-90,Dec-97,N/A,N/A,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1367,Muscle Spasms,7/7/14 12:28
406,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Feb-90,Dec-97,N/A,N/A,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,ROW,Sales,200,222,242.8,263,278,285.3092,292.93268,298.48874,302.7116084,305.8933773,308.2747515,310,1.568619602,1367,Muscle Spasms,7/7/14 12:28
406,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Feb-90,Dec-97,N/A,N/A,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1367,Muscle Spasms,7/7/14 12:28
406,8,Allergan,Regional & Specialty Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Corporate Acquisition,Feb-90,Dec-97,N/A,N/A,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,US,Sales,365,371.6,367.3,396,409,412.225,420.80175,426.6508625,431.6506694,435.8296604,439.1611425,442,1.114661548,1367,Muscle Spasms,7/7/14 12:28
407,61,Merck & Co,Large Pharma,1328,Bridion,sugammadex sodium,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-15,Sep-08,Mar-22,Jul-23,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1644,Neuromuscular Blocking Agent Reversal,7/7/14 12:28
407,61,Merck & Co,Large Pharma,1328,Bridion,sugammadex sodium,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-15,Sep-08,Mar-22,Jul-23,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Sales,5.311148889,103,201,261,288,323.77,353.2761655,407.9020519,449.0363799,486.6484064,515.349838,539.0526825,9.368235984,1644,Neuromuscular Blocking Agent Reversal,7/7/14 12:28
407,61,Merck & Co,Large Pharma,1328,Bridion,sugammadex sodium,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-15,Sep-08,Mar-22,Jul-23,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1644,Neuromuscular Blocking Agent Reversal,7/7/14 12:28
407,61,Merck & Co,Large Pharma,1328,Bridion,sugammadex sodium,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-15,Sep-08,Mar-22,Jul-23,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Sales,5.311148889,103,201,261,288,323.77,350.3595,370.957525,388.7584287,403.0368603,414.6562246,424.2135993,5.688423233,1644,Neuromuscular Blocking Agent Reversal,7/7/14 12:28
407,61,Merck & Co,Large Pharma,1328,Bridion,sugammadex sodium,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-15,Sep-08,Mar-22,Jul-23,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1644,Neuromuscular Blocking Agent Reversal,7/7/14 12:28
407,61,Merck & Co,Large Pharma,1328,Bridion,sugammadex sodium,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-15,Sep-08,Mar-22,Jul-23,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,2.9166655,36.94452689,60.27795118,83.61154608,100.6936134,114.8390832,0,1644,Neuromuscular Blocking Agent Reversal,7/7/14 12:28
407,61,Schering-Plough,Large Pharma,1328,Bridion,sugammadex sodium,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-15,Sep-08,Mar-22,Jul-23,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Proforma,25.8,0,0,0,0,0,0,0,0,0,0,0,0,1644,Neuromuscular Blocking Agent Reversal,7/7/14 12:28
407,61,Schering-Plough,Large Pharma,1328,Bridion,sugammadex sodium,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-15,Sep-08,Mar-22,Jul-23,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Proforma,25.8,0,0,0,0,0,0,0,0,0,0,0,0,1644,Neuromuscular Blocking Agent Reversal,7/7/14 12:28
408,16,AstraZeneca,Large Pharma,201,Brilinta,ticagrelor,Small Molecule (Chemical),Launched,In-House,Aug-11,Jan-11,Jul-18,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,271,Arterial Thrombosis,7/7/14 12:28
408,16,AstraZeneca,Large Pharma,201,Brilinta,ticagrelor,Small Molecule (Chemical),Launched,In-House,Aug-11,Jan-11,Jul-18,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,21,89,283,516,743.84,938.0327,1115.84946,1069.588836,851.3861399,862.46,17.25625143,271,Arterial Thrombosis,7/7/14 12:28
408,16,AstraZeneca,Large Pharma,201,Brilinta,ticagrelor,Small Molecule (Chemical),Launched,In-House,Aug-11,Jan-11,Jul-18,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,271,Arterial Thrombosis,7/7/14 12:28
408,16,AstraZeneca,Large Pharma,201,Brilinta,ticagrelor,Small Molecule (Chemical),Launched,In-House,Aug-11,Jan-11,Jul-18,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,10,70,210,334,457.49,559.2327,662.3319,738.7044056,788.3515544,817.96,21.43919592,271,Arterial Thrombosis,7/7/14 12:28
408,16,AstraZeneca,Large Pharma,201,Brilinta,ticagrelor,Small Molecule (Chemical),Launched,In-House,Aug-11,Jan-11,Jul-18,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,271,Arterial Thrombosis,7/7/14 12:28
408,16,AstraZeneca,Large Pharma,201,Brilinta,ticagrelor,Small Molecule (Chemical),Launched,In-House,Aug-11,Jan-11,Jul-18,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,11,19,73,182,286.35,378.8,453.51756,330.88443,63.0345855,44.5,-6.826791241,271,Arterial Thrombosis,7/7/14 12:28
410,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1200,Brovana,arformoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-07,,Jan-22,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1349,COPD,7/7/14 12:28
410,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1200,Brovana,arformoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-07,,Jan-22,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,Global,Sales,18.31454148,108.5573545,129.1489359,152.8920065,170.3479628,182.5907334,192.1513788,198.9316716,202.4144292,204.6894675,206.1048295,206.9395271,2.818756284,1349,COPD,7/7/14 12:28
410,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1200,Brovana,arformoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-07,,Jan-22,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1349,COPD,7/7/14 12:28
410,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1200,Brovana,arformoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-07,,Jan-22,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1349,COPD,7/7/14 12:28
410,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1200,Brovana,arformoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-07,,Jan-22,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1349,COPD,7/7/14 12:28
410,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1200,Brovana,arformoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-07,,Jan-22,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,US,Sales,18.31454148,108.5573545,129.1489359,152.8920065,170.3479628,182.5907334,192.1513788,198.9316716,202.4144292,204.6894675,206.1048295,206.9395271,2.818756284,1349,COPD,7/7/14 12:28
410,35,Sepracor,Regional & Specialty Pharma,1200,Brovana,arformoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-07,,Jan-22,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,Global,Proforma,59.25292831,0,0,0,0,0,0,0,0,0,0,0,0,1349,COPD,7/7/14 12:28
410,35,Sepracor,Regional & Specialty Pharma,1200,Brovana,arformoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-07,,Jan-22,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,US,Proforma,59.25292831,0,0,0,0,0,0,0,0,0,0,0,0,1349,COPD,7/7/14 12:28
411,24,Amylin,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Corporate Acquisition,Apr-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,Global,Proforma,667,570,517.7,277,0,0,0,0,0,0,0,0,0,1459,Type II Diabetes,7/7/14 12:28
411,24,Amylin,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Corporate Acquisition,Apr-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,US,Proforma,667,570,517.7,277,0,0,0,0,0,0,0,0,0,1459,Type II Diabetes,7/7/14 12:28
411,24,Bristol-Myers Squibb,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Corporate Acquisition,Apr-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1459,Type II Diabetes,7/7/14 12:28
411,24,Bristol-Myers Squibb,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Corporate Acquisition,Apr-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,227,698,65,0,0,0,0,0,0,-100,1459,Type II Diabetes,7/7/14 12:28
411,24,Bristol-Myers Squibb,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Corporate Acquisition,Apr-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1459,Type II Diabetes,7/7/14 12:28
411,24,Bristol-Myers Squibb,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Corporate Acquisition,Apr-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,5,131,15,0,0,0,0,0,0,-100,1459,Type II Diabetes,7/7/14 12:28
411,24,Bristol-Myers Squibb,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Corporate Acquisition,Apr-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1459,Type II Diabetes,7/7/14 12:28
411,24,Bristol-Myers Squibb,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Corporate Acquisition,Apr-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,222,567,50,0,0,0,0,0,0,-100,1459,Type II Diabetes,7/7/14 12:28
412,39,Eli Lilly,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Licensed (Development),Jun-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,155,140,127,54,0,0,0,0,0,0,0,0,0,1459,Type II Diabetes,7/7/14 12:28
412,39,Eli Lilly,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Licensed (Development),Jun-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,Global,Sales,128.9,150.9,167.1,159,61.9,0,0,0,0,0,0,0,-100,1459,Type II Diabetes,7/7/14 12:28
412,39,Eli Lilly,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Licensed (Development),Jun-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1459,Type II Diabetes,7/7/14 12:28
412,39,Eli Lilly,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Licensed (Development),Jun-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,ROW,Sales,128.9,150.9,167.1,159,61.9,0,0,0,0,0,0,0,-100,1459,Type II Diabetes,7/7/14 12:28
412,39,Eli Lilly,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Licensed (Development),Jun-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,155,140,127,54,0,0,0,0,0,0,0,0,0,1459,Type II Diabetes,7/7/14 12:28
412,39,Eli Lilly,Large Pharma,2488,Byetta / Bydureon,exenatide / exenatide LAR,Synthetic Peptide,Launched,Licensed (Development),Jun-05,Jun-07,Dec-16,May-23,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1459,Type II Diabetes,7/7/14 12:28
414,42,Forest,Regional & Specialty Pharma,520,Bystolic,nebivolol,Small Molecule (Chemical),Launched,Licensed (Development),Jan-08,,Sep-20,N/A,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,274,Hypertension,7/7/14 12:28
414,42,Forest,Regional & Specialty Pharma,520,Bystolic,nebivolol,Small Molecule (Chemical),Launched,Licensed (Development),Jan-08,,Sep-20,N/A,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,Global,Sales,178.9,264.4,347.8,455.1,528.537,582.31331,621.3329753,649.6797061,670.2695231,685.225379,696.0888554,492.7858288,-0.995555309,274,Hypertension,7/7/14 12:28
414,42,Forest,Regional & Specialty Pharma,520,Bystolic,nebivolol,Small Molecule (Chemical),Launched,Licensed (Development),Jan-08,,Sep-20,N/A,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,274,Hypertension,7/7/14 12:28
414,42,Forest,Regional & Specialty Pharma,520,Bystolic,nebivolol,Small Molecule (Chemical),Launched,Licensed (Development),Jan-08,,Sep-20,N/A,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,274,Hypertension,7/7/14 12:28
414,42,Forest,Regional & Specialty Pharma,520,Bystolic,nebivolol,Small Molecule (Chemical),Launched,Licensed (Development),Jan-08,,Sep-20,N/A,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,274,Hypertension,7/7/14 12:28
414,42,Forest,Regional & Specialty Pharma,520,Bystolic,nebivolol,Small Molecule (Chemical),Launched,Licensed (Development),Jan-08,,Sep-20,N/A,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,US,Sales,178.9,264.4,347.8,455.1,528.537,582.31331,621.3329753,649.6797061,670.2695231,685.225379,696.0888554,492.7858288,-0.995555309,274,Hypertension,7/7/14 12:28
415,67,Novartis,Large Pharma,2,CAD106,CAD106,Vaccine,Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,275,Alzheimer's Disease,7/7/14 12:28
415,67,Novartis,Large Pharma,2,CAD106,CAD106,Vaccine,Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,275,Alzheimer's Disease,7/7/14 12:28
415,67,Novartis,Large Pharma,2,CAD106,CAD106,Vaccine,Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,275,Alzheimer's Disease,7/7/14 12:28
415,67,Novartis,Large Pharma,2,CAD106,CAD106,Vaccine,Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,275,Alzheimer's Disease,7/7/14 12:28
415,67,Novartis,Large Pharma,2,CAD106,CAD106,Vaccine,Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,275,Alzheimer's Disease,7/7/14 12:28
415,67,Novartis,Large Pharma,2,CAD106,CAD106,Vaccine,Phase II,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,275,Alzheimer's Disease,7/7/14 12:28
416,76,Pfizer,Large Pharma,597,Caduet,atorvastatin + amlodipine,Small Molecule (Chemical),Launched,In-House,Jun-04,Jul-05,Nov-11,Jul-15,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,276,hypertension - hypercholesterolemia,7/7/14 12:28
416,76,Pfizer,Large Pharma,597,Caduet,atorvastatin + amlodipine,Small Molecule (Chemical),Launched,In-House,Jun-04,Jul-05,Nov-11,Jul-15,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,548,527,538,258,223,195.544,177.087764,161.8041158,149.5216624,139.4344777,131.2137581,124.4888111,-7.990590349,276,hypertension - hypercholesterolemia,7/7/14 12:28
416,76,Pfizer,Large Pharma,597,Caduet,atorvastatin + amlodipine,Small Molecule (Chemical),Launched,In-House,Jun-04,Jul-05,Nov-11,Jul-15,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,276,hypertension - hypercholesterolemia,7/7/14 12:28
416,76,Pfizer,Large Pharma,597,Caduet,atorvastatin + amlodipine,Small Molecule (Chemical),Launched,In-House,Jun-04,Jul-05,Nov-11,Jul-15,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,154,188,266,225,200,176.45,158.3525,143.143625,130.8703812,120.7847591,112.564256,105.8393429,-8.690329906,276,hypertension - hypercholesterolemia,7/7/14 12:28
416,76,Pfizer,Large Pharma,597,Caduet,atorvastatin + amlodipine,Small Molecule (Chemical),Launched,In-House,Jun-04,Jul-05,Nov-11,Jul-15,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,276,hypertension - hypercholesterolemia,7/7/14 12:28
416,76,Pfizer,Large Pharma,597,Caduet,atorvastatin + amlodipine,Small Molecule (Chemical),Launched,In-House,Jun-04,Jul-05,Nov-11,Jul-15,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,394,339,272,33,23,19.094,18.735264,18.66049078,18.65128118,18.64971862,18.64950218,18.64946818,-2.950959981,276,hypertension - hypercholesterolemia,7/7/14 12:28
417,61,Merck & Co,Large Pharma,1295,Caelyx,doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-97,N/A,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1427,Ovarian Cancer,7/7/14 12:28
417,61,Merck & Co,Large Pharma,1295,Caelyx,doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-97,N/A,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,46.5,284,0,0,0,0,0,0,0,0,0,0,0,1427,Ovarian Cancer,7/7/14 12:28
417,61,Merck & Co,Large Pharma,1295,Caelyx,doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-97,N/A,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1427,Ovarian Cancer,7/7/14 12:28
417,61,Merck & Co,Large Pharma,1295,Caelyx,doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-97,N/A,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,46.5,284,0,0,0,0,0,0,0,0,0,0,0,1427,Ovarian Cancer,7/7/14 12:28
417,61,Merck & Co,Large Pharma,1295,Caelyx,doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-97,N/A,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1427,Ovarian Cancer,7/7/14 12:28
417,61,Merck & Co,Large Pharma,1295,Caelyx,doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-97,N/A,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1427,Ovarian Cancer,7/7/14 12:28
417,61,Schering-Plough,Large Pharma,1295,Caelyx,doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-97,N/A,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Proforma,218.5,0,0,0,0,0,0,0,0,0,0,0,0,1427,Ovarian Cancer,7/7/14 12:28
417,61,Schering-Plough,Large Pharma,1295,Caelyx,doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-97,N/A,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Proforma,218.5,0,0,0,0,0,0,0,0,0,0,0,0,1427,Ovarian Cancer,7/7/14 12:28
418,34,Daiichi-Sankyo,Regional & Specialty Pharma,1576,Calblock,azelnidipine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-03,N/A,Dec-13,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,277,Hypertension,7/7/14 12:28
418,34,Daiichi-Sankyo,Regional & Specialty Pharma,1576,Calblock,azelnidipine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-03,N/A,Dec-13,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,147.5936578,157.7311511,164.8395773,131.2222733,89.93297867,68.46963798,57.82157008,51.62661943,46.88903774,43.22959547,40.15150946,38.68408384,-11.35400877,277,Hypertension,7/7/14 12:28
418,34,Daiichi-Sankyo,Regional & Specialty Pharma,1576,Calblock,azelnidipine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-03,N/A,Dec-13,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,277,Hypertension,7/7/14 12:28
418,34,Daiichi-Sankyo,Regional & Specialty Pharma,1576,Calblock,azelnidipine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-03,N/A,Dec-13,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,147.5936578,157.7311511,164.8395773,131.2222733,89.93297867,68.46963798,57.82157008,51.62661943,46.88903774,43.22959547,40.15150946,38.68408384,-11.35400877,277,Hypertension,7/7/14 12:28
418,34,Daiichi-Sankyo,Regional & Specialty Pharma,1576,Calblock,azelnidipine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-03,N/A,Dec-13,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,277,Hypertension,7/7/14 12:28
418,34,Daiichi-Sankyo,Regional & Specialty Pharma,1576,Calblock,azelnidipine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-03,N/A,Dec-13,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,277,Hypertension,7/7/14 12:28
419,16,AstraZeneca,Large Pharma,3227,mavrilimumab,CAM-3001,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,279,Rheumatoid Arthritis,7/7/14 12:28
419,16,AstraZeneca,Large Pharma,3227,mavrilimumab,CAM-3001,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,279,Rheumatoid Arthritis,7/7/14 12:28
419,16,AstraZeneca,Large Pharma,3227,mavrilimumab,CAM-3001,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,279,Rheumatoid Arthritis,7/7/14 12:28
419,16,AstraZeneca,Large Pharma,3227,mavrilimumab,CAM-3001,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,279,Rheumatoid Arthritis,7/7/14 12:28
419,16,AstraZeneca,Large Pharma,3227,mavrilimumab,CAM-3001,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,279,Rheumatoid Arthritis,7/7/14 12:28
419,16,AstraZeneca,Large Pharma,3227,mavrilimumab,CAM-3001,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,279,Rheumatoid Arthritis,7/7/14 12:28
420,19,Bayer,Large Pharma,1647,Campath,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-01,Aug-01,N/A,N/A,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1334,Chronic Lymphocytic Leukemia,7/7/14 12:28
420,19,Bayer,Large Pharma,1647,Campath,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-01,Aug-01,N/A,N/A,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,Global,Sales,59.74843131,0,0,0,0,0,0,0,0,0,0,0,0,1334,Chronic Lymphocytic Leukemia,7/7/14 12:28
420,19,Bayer,Large Pharma,1647,Campath,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-01,Aug-01,N/A,N/A,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1334,Chronic Lymphocytic Leukemia,7/7/14 12:28
420,19,Bayer,Large Pharma,1647,Campath,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-01,Aug-01,N/A,N/A,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,ROW,Sales,28.90156678,0,0,0,0,0,0,0,0,0,0,0,0,1334,Chronic Lymphocytic Leukemia,7/7/14 12:28
420,19,Bayer,Large Pharma,1647,Campath,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-01,Aug-01,N/A,N/A,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1334,Chronic Lymphocytic Leukemia,7/7/14 12:28
420,19,Bayer,Large Pharma,1647,Campath,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-01,Aug-01,N/A,N/A,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,US,Sales,30.84686454,0,0,0,0,0,0,0,0,0,0,0,0,1334,Chronic Lymphocytic Leukemia,7/7/14 12:28
421,42,Forest,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Marketed),Dec-04,,Jul-13,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,280,Alcohol Addiction,7/7/14 12:28
421,42,Forest,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Marketed),Dec-04,,Jul-13,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,Global,Sales,14,13,12,11,7,5,3,1.6,0.62,1,1.266,1.4522,-20.12360805,280,Alcohol Addiction,7/7/14 12:28
421,42,Forest,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Marketed),Dec-04,,Jul-13,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,280,Alcohol Addiction,7/7/14 12:28
421,42,Forest,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Marketed),Dec-04,,Jul-13,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,280,Alcohol Addiction,7/7/14 12:28
421,42,Forest,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Marketed),Dec-04,,Jul-13,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,280,Alcohol Addiction,7/7/14 12:28
421,42,Forest,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Marketed),Dec-04,,Jul-13,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,US,Sales,14,13,12,11,7,5,3,1.6,0.62,1,1.266,1.4522,-20.12360805,280,Alcohol Addiction,7/7/14 12:28
422,76,Pfizer,Large Pharma,1143,Camptosar,irinotecan,Small Molecule (Chemical),Launched,Licensed (Marketed),Nov-96,Nov-96,Feb-08,Jul-09,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1504,Colorectal Cancer,7/7/14 12:28
422,76,Pfizer,Large Pharma,1143,Camptosar,irinotecan,Small Molecule (Chemical),Launched,Licensed (Marketed),Nov-96,Nov-96,Feb-08,Jul-09,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,332,120,85,71,65.4,63.16,62.264,61.9056,61.76224,61.704896,61.6819584,61.67278336,-0.834774512,1504,Colorectal Cancer,7/7/14 12:28
422,76,Pfizer,Large Pharma,1143,Camptosar,irinotecan,Small Molecule (Chemical),Launched,Licensed (Marketed),Nov-96,Nov-96,Feb-08,Jul-09,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1504,Colorectal Cancer,7/7/14 12:28
422,76,Pfizer,Large Pharma,1143,Camptosar,irinotecan,Small Molecule (Chemical),Launched,Licensed (Marketed),Nov-96,Nov-96,Feb-08,Jul-09,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,332,120,85,71,65.4,63.16,62.264,61.9056,61.76224,61.704896,61.6819584,61.67278336,-0.834774512,1504,Colorectal Cancer,7/7/14 12:28
422,76,Pfizer,Large Pharma,1143,Camptosar,irinotecan,Small Molecule (Chemical),Launched,Licensed (Marketed),Nov-96,Nov-96,Feb-08,Jul-09,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1504,Colorectal Cancer,7/7/14 12:28
422,76,Pfizer,Large Pharma,1143,Camptosar,irinotecan,Small Molecule (Chemical),Launched,Licensed (Marketed),Nov-96,Nov-96,Feb-08,Jul-09,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1504,Colorectal Cancer,7/7/14 12:28
424,61,Merck & Co,Large Pharma,1021,Cancidas,caspofungin,Small Molecule (Chemical),Launched,In-House,Feb-01,Feb-01,Sep-13,May-17,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,281,fungal infection,7/7/14 12:28
424,61,Merck & Co,Large Pharma,1021,Cancidas,caspofungin,Small Molecule (Chemical),Launched,In-House,Feb-01,Feb-01,Sep-13,May-17,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,616,611,639,619,661,668.88,671.5504,675.299832,524.3118284,341.6414266,277.120738,234.1451098,-13.7792072,281,fungal infection,7/7/14 12:28
424,61,Merck & Co,Large Pharma,1021,Cancidas,caspofungin,Small Molecule (Chemical),Launched,In-House,Feb-01,Feb-01,Sep-13,May-17,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,281,fungal infection,7/7/14 12:28
424,61,Merck & Co,Large Pharma,1021,Cancidas,caspofungin,Small Molecule (Chemical),Launched,In-House,Feb-01,Feb-01,Sep-13,May-17,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,543,550,595,587,630,641,646,651.28,501.4940528,319.7209846,255.864337,213.3856344,-14.32933125,281,fungal infection,7/7/14 12:28
424,61,Merck & Co,Large Pharma,1021,Cancidas,caspofungin,Small Molecule (Chemical),Launched,In-House,Feb-01,Feb-01,Sep-13,May-17,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,281,fungal infection,7/7/14 12:28
424,61,Merck & Co,Large Pharma,1021,Cancidas,caspofungin,Small Molecule (Chemical),Launched,In-House,Feb-01,Feb-01,Sep-13,May-17,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,6,US,Sales,73,61,44,32,31,27.88,25.5504,24.019832,22.81777556,21.92044204,21.25640103,20.75947535,-5.567362006,281,fungal infection,7/7/14 12:28
425,103,The Medicines Company,Small Biotech,517,cangrelor,cangrelor,Small Molecule (Chemical),Filed,Acquisition (Development),Aug-15,May-16,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,14.75,81.0807125,165.511362,234.9992888,286.3900249,329.1301501,0,282,Arterial Thrombosis,7/7/14 12:28
425,103,The Medicines Company,Small Biotech,517,cangrelor,cangrelor,Small Molecule (Chemical),Filed,Acquisition (Development),Aug-15,May-16,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,9.6,43.2,81.600048,105.6002541,126.7683363,0,282,Arterial Thrombosis,7/7/14 12:28
425,103,The Medicines Company,Small Biotech,517,cangrelor,cangrelor,Small Molecule (Chemical),Filed,Acquisition (Development),Aug-15,May-16,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,14.75,71.4807125,122.311362,153.3992408,180.7897707,202.3618138,0,282,Arterial Thrombosis,7/7/14 12:28
427,96,Shire,Regional & Specialty Pharma,161,Carbatrol,extended-release carbamazepine ,Small Molecule (Chemical),Launched,In-House,Jun-98,,Jul-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1378,Epilepsy,7/7/14 12:28
427,96,Shire,Regional & Specialty Pharma,161,Carbatrol,extended-release carbamazepine ,Small Molecule (Chemical),Launched,In-House,Jun-98,,Jul-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,82.4,82.3,52.3,26,7,6,5.6,5.44,5.376,5.3504,5.34016,5.336064,-3.803240193,1378,Epilepsy,7/7/14 12:28
427,96,Shire,Regional & Specialty Pharma,161,Carbatrol,extended-release carbamazepine ,Small Molecule (Chemical),Launched,In-House,Jun-98,,Jul-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1378,Epilepsy,7/7/14 12:28
427,96,Shire,Regional & Specialty Pharma,161,Carbatrol,extended-release carbamazepine ,Small Molecule (Chemical),Launched,In-House,Jun-98,,Jul-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1378,Epilepsy,7/7/14 12:28
427,96,Shire,Regional & Specialty Pharma,161,Carbatrol,extended-release carbamazepine ,Small Molecule (Chemical),Launched,In-House,Jun-98,,Jul-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1378,Epilepsy,7/7/14 12:28
427,96,Shire,Regional & Specialty Pharma,161,Carbatrol,extended-release carbamazepine ,Small Molecule (Chemical),Launched,In-House,Jun-98,,Jul-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,82.4,82.3,52.3,26,7,6,5.6,5.44,5.376,5.3504,5.34016,5.336064,-3.803240193,1378,Epilepsy,7/7/14 12:28
428,89,Sanofi,Large Pharma,2423,Jevtana,cabazitaxel,Small Molecule (Chemical),Launched,In-House,Jul-10,Apr-11,Mar-16,Mar-21,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,580,Prostate Cancer,7/7/14 12:28
428,89,Sanofi,Large Pharma,2423,Jevtana,cabazitaxel,Small Molecule (Chemical),Launched,In-House,Jul-10,Apr-11,Mar-16,Mar-21,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,Global,Sales,0,108.6298944,261.4021631,300.7534903,306.7749454,329.4776194,331.4120612,299.099449,291.2913654,285.9178897,282.8829711,279.5518643,-1.318748338,580,Prostate Cancer,7/7/14 12:28
428,89,Sanofi,Large Pharma,2423,Jevtana,cabazitaxel,Small Molecule (Chemical),Launched,In-House,Jul-10,Apr-11,Mar-16,Mar-21,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,580,Prostate Cancer,7/7/14 12:28
428,89,Sanofi,Large Pharma,2423,Jevtana,cabazitaxel,Small Molecule (Chemical),Launched,In-House,Jul-10,Apr-11,Mar-16,Mar-21,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,ROW,Sales,0,0,79.25491114,160.6589158,192.5643597,219.124961,226.986899,229.6812064,231.2780722,231.8699971,232.0925762,232.1994504,2.709867962,580,Prostate Cancer,7/7/14 12:28
428,89,Sanofi,Large Pharma,2423,Jevtana,cabazitaxel,Small Molecule (Chemical),Launched,In-House,Jul-10,Apr-11,Mar-16,Mar-21,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,580,Prostate Cancer,7/7/14 12:28
428,89,Sanofi,Large Pharma,2423,Jevtana,cabazitaxel,Small Molecule (Chemical),Launched,In-House,Jul-10,Apr-11,Mar-16,Mar-21,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,US,Sales,0,108.6298944,182.1472519,140.0945745,114.2105857,110.3526584,104.4251622,69.41824266,60.01329315,54.04789261,50.79039484,47.35241388,-11.81868065,580,Prostate Cancer,7/7/14 12:28
429,34,Daiichi-Sankyo,Regional & Specialty Pharma,1672,Carbenin,panipenem,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,283,,7/7/14 12:28
429,34,Daiichi-Sankyo,Regional & Specialty Pharma,1672,Carbenin,panipenem,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,21.75857176,19.15619472,16.56881865,14.6081889,11.39925057,10.85303901,10.56909199,10.38137782,10.26606442,10.19776028,10.15524471,10.12932002,-1.673177196,283,,7/7/14 12:28
429,34,Daiichi-Sankyo,Regional & Specialty Pharma,1672,Carbenin,panipenem,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,283,,7/7/14 12:28
429,34,Daiichi-Sankyo,Regional & Specialty Pharma,1672,Carbenin,panipenem,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,21.75857176,19.15619472,16.56881865,14.6081889,11.39925057,10.85303901,10.56909199,10.38137782,10.26606442,10.19776028,10.15524471,10.12932002,-1.673177196,283,,7/7/14 12:28
429,34,Daiichi-Sankyo,Regional & Specialty Pharma,1672,Carbenin,panipenem,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,283,,7/7/14 12:28
429,34,Daiichi-Sankyo,Regional & Specialty Pharma,1672,Carbenin,panipenem,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,283,,7/7/14 12:28
430,76,Pfizer,Large Pharma,1177,Cardura,doxazosin,Small Molecule (Chemical),Launched,In-House,Jun-88,Jun-88,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1425,,7/7/14 12:28
430,76,Pfizer,Large Pharma,1177,Cardura,doxazosin,Small Molecule (Chemical),Launched,In-House,Jun-88,Jun-88,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Sales,135.6165,120.556375,111.4503187,101,94.39669937,89.42268078,85.46995316,82.58686641,80.40657204,78.75423069,77.51685818,76.58433295,-2.94315412,1425,,7/7/14 12:28
430,76,Pfizer,Large Pharma,1177,Cardura,doxazosin,Small Molecule (Chemical),Launched,In-House,Jun-88,Jun-88,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1425,,7/7/14 12:28
430,76,Pfizer,Large Pharma,1177,Cardura,doxazosin,Small Molecule (Chemical),Launched,In-House,Jun-88,Jun-88,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,135,120,110.94,100,93.2872,88.21696,84.174784,81.243952,79.02868192,77.35149002,76.09788399,75.15407523,-3.040563781,1425,,7/7/14 12:28
430,76,Pfizer,Large Pharma,1177,Cardura,doxazosin,Small Molecule (Chemical),Launched,In-House,Jun-88,Jun-88,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1425,,7/7/14 12:28
430,76,Pfizer,Large Pharma,1177,Cardura,doxazosin,Small Molecule (Chemical),Launched,In-House,Jun-88,Jun-88,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Sales,0.6165,0.556375,0.51031875,1,1.109499375,1.205720781,1.295169164,1.342914408,1.377890117,1.402740669,1.418974188,1.430257722,3.694400266,1425,,7/7/14 12:28
431,76,Pfizer,Large Pharma,1177,Cardura,doxazosin,Small Molecule (Chemical),Launched,In-House,May-97,May-97,Expired,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1425,Symptoms associated with BPH,7/7/14 12:28
431,76,Pfizer,Large Pharma,1177,Cardura,doxazosin,Small Molecule (Chemical),Launched,In-House,May-97,May-97,Expired,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,Global,Sales,318.78,292,264,236.5,206.8,185.56,164.704,146.686,131.19646,117.455839,105.4239648,94.8809468,-10.53333285,1425,Symptoms associated with BPH,7/7/14 12:28
431,76,Pfizer,Large Pharma,1177,Cardura,doxazosin,Small Molecule (Chemical),Launched,In-House,May-97,May-97,Expired,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1425,Symptoms associated with BPH,7/7/14 12:28
431,76,Pfizer,Large Pharma,1177,Cardura,doxazosin,Small Molecule (Chemical),Launched,In-House,May-97,May-97,Expired,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,ROW,Sales,315,281,260,233,204,182.56,162.704,144.976,129.68896,116.142464,104.218496,93.75182336,-10.51210952,1425,Symptoms associated with BPH,7/7/14 12:28
431,76,Pfizer,Large Pharma,1177,Cardura,doxazosin,Small Molecule (Chemical),Launched,In-House,May-97,May-97,Expired,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1425,Symptoms associated with BPH,7/7/14 12:28
431,76,Pfizer,Large Pharma,1177,Cardura,doxazosin,Small Molecule (Chemical),Launched,In-House,May-97,May-97,Expired,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,US,Sales,3.78,11,4,3.5,2.8,3,2,1.71,1.5075,1.313375,1.20546875,1.129123438,-12.16758452,1425,Symptoms associated with BPH,7/7/14 12:28
432,11,Amgen,Large Pharma,1735,Kyprolis,carfilzomib,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-12,Aug-15,Apr-25,Aug-25,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,73,440.04416,535.9760411,644.8943644,804.8292286,987.1308934,1030.917597,1080.483451,46.95517013,285,Multiple Myeloma,7/7/14 12:28
432,11,Amgen,Large Pharma,1735,Kyprolis,carfilzomib,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-12,Aug-15,Apr-25,Aug-25,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,2,2,19,73.10188,133.9542082,275.1079648,314.9079706,333.9903609,107.7441564,285,Multiple Myeloma,7/7/14 12:28
432,11,Amgen,Large Pharma,1735,Kyprolis,carfilzomib,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-12,Aug-15,Apr-25,Aug-25,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,71,438.04416,516.9760411,571.7924844,670.8750204,712.0229286,716.0096263,746.4930902,39.94797916,285,Multiple Myeloma,7/7/14 12:28
432,11,Onyx Pharmaceuticals,Large Pharma,1735,Kyprolis,carfilzomib,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-12,Aug-15,Apr-25,Aug-25,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Proforma,0,0,0,64,190,0,,,,,,,0,285,Multiple Myeloma,7/7/14 12:28
432,11,Onyx Pharmaceuticals,Large Pharma,1735,Kyprolis,carfilzomib,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-12,Aug-15,Apr-25,Aug-25,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Proforma,0,0,0,64,190,0,,,,,,,0,285,Multiple Myeloma,7/7/14 12:28
433,42,Forest,Regional & Specialty Pharma,1368,cariprazine,cariprazine,Small Molecule (Chemical),Filed,Licensed (Development),Feb-15,,,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1380,Schizophrenia,7/7/14 12:28
433,42,Forest,Regional & Specialty Pharma,1368,cariprazine,cariprazine,Small Molecule (Chemical),Filed,Licensed (Development),Feb-15,,,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,11.66669,73.88907361,111.3780562,151.4337119,174.2498807,192.6596158,208.0950745,0,1380,Schizophrenia,7/7/14 12:28
433,42,Forest,Regional & Specialty Pharma,1368,cariprazine,cariprazine,Small Molecule (Chemical),Filed,Licensed (Development),Feb-15,,,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1380,Schizophrenia,7/7/14 12:28
433,42,Forest,Regional & Specialty Pharma,1368,cariprazine,cariprazine,Small Molecule (Chemical),Filed,Licensed (Development),Feb-15,,,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1380,Schizophrenia,7/7/14 12:28
433,42,Forest,Regional & Specialty Pharma,1368,cariprazine,cariprazine,Small Molecule (Chemical),Filed,Licensed (Development),Feb-15,,,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1380,Schizophrenia,7/7/14 12:28
433,42,Forest,Regional & Specialty Pharma,1368,cariprazine,cariprazine,Small Molecule (Chemical),Filed,Licensed (Development),Feb-15,,,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,0,0,0,0,11.66669,73.88907361,111.3780562,151.4337119,174.2498807,192.6596158,208.0950745,0,1380,Schizophrenia,7/7/14 12:28
437,16,AstraZeneca,Large Pharma,311,Casodex,bicalutamide,Small Molecule (Chemical),Launched,In-House,Jun-97,May-95,Jul-09,Expired,107,Anti-androgens,55,Hormonals,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,288,Prostate Cancer,7/7/14 12:28
437,16,AstraZeneca,Large Pharma,311,Casodex,bicalutamide,Small Molecule (Chemical),Launched,In-House,Jun-97,May-95,Jul-09,Expired,107,Anti-androgens,55,Hormonals,3,Oncology,6,Global,Sales,844,579,550,454,376,345.85,307.7775,280.544125,264.1832438,250.2896053,239.5632524,232.8370774,-6.617314868,288,Prostate Cancer,7/7/14 12:28
437,16,AstraZeneca,Large Pharma,311,Casodex,bicalutamide,Small Molecule (Chemical),Launched,In-House,Jun-97,May-95,Jul-09,Expired,107,Anti-androgens,55,Hormonals,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,288,Prostate Cancer,7/7/14 12:28
437,16,AstraZeneca,Large Pharma,311,Casodex,bicalutamide,Small Molecule (Chemical),Launched,In-House,Jun-97,May-95,Jul-09,Expired,107,Anti-androgens,55,Hormonals,3,Oncology,6,ROW,Sales,696,563,556,457,371,341.85,304.7775,277.644125,262.1832438,248.3796053,238.5632524,231.9280774,-6.490823628,288,Prostate Cancer,7/7/14 12:28
437,16,AstraZeneca,Large Pharma,311,Casodex,bicalutamide,Small Molecule (Chemical),Launched,In-House,Jun-97,May-95,Jul-09,Expired,107,Anti-androgens,55,Hormonals,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,288,Prostate Cancer,7/7/14 12:28
437,16,AstraZeneca,Large Pharma,311,Casodex,bicalutamide,Small Molecule (Chemical),Launched,In-House,Jun-97,May-95,Jul-09,Expired,107,Anti-androgens,55,Hormonals,3,Oncology,6,US,Sales,148,16,-6,-3,5,4,3,2.9,2,1.91,1,0.909,-21.6159313,288,Prostate Cancer,7/7/14 12:28
438,16,AstraZeneca,Large Pharma,562,tralokinumab,CAT-354,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,289,Asthma,7/7/14 12:28
438,16,AstraZeneca,Large Pharma,562,tralokinumab,CAT-354,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,289,Asthma,7/7/14 12:28
438,16,AstraZeneca,Large Pharma,562,tralokinumab,CAT-354,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,289,Asthma,7/7/14 12:28
438,16,AstraZeneca,Large Pharma,562,tralokinumab,CAT-354,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,289,Asthma,7/7/14 12:28
438,16,AstraZeneca,Large Pharma,562,tralokinumab,CAT-354,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,289,Asthma,7/7/14 12:28
438,16,AstraZeneca,Large Pharma,562,tralokinumab,CAT-354,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,289,Asthma,7/7/14 12:28
439,16,AstraZeneca,Large Pharma,1503,moxetumomab pasudotox,moxetumomab pasudotox,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,290,Hairy Cell Leukemia,7/7/14 12:28
439,16,AstraZeneca,Large Pharma,1503,moxetumomab pasudotox,moxetumomab pasudotox,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,290,Hairy Cell Leukemia,7/7/14 12:28
439,16,AstraZeneca,Large Pharma,1503,moxetumomab pasudotox,moxetumomab pasudotox,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,290,Hairy Cell Leukemia,7/7/14 12:28
439,16,AstraZeneca,Large Pharma,1503,moxetumomab pasudotox,moxetumomab pasudotox,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,290,Hairy Cell Leukemia,7/7/14 12:28
439,16,AstraZeneca,Large Pharma,1503,moxetumomab pasudotox,moxetumomab pasudotox,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,290,Hairy Cell Leukemia,7/7/14 12:28
439,16,AstraZeneca,Large Pharma,1503,moxetumomab pasudotox,moxetumomab pasudotox,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,290,Hairy Cell Leukemia,7/7/14 12:28
440,23,Boehringer Ingelheim,Large Pharma,1435,Catapres,clonidine,Small Molecule (Chemical),Launched,In-House,Apr-76,Aug-66,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,291,Hypertension,7/7/14 12:28
440,23,Boehringer Ingelheim,Large Pharma,1435,Catapres,clonidine,Small Molecule (Chemical),Launched,In-House,Apr-76,Aug-66,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,Global,Sales,261.2256997,166.0205033,112.7907085,72.38868974,59.39731578,53.77238502,50.81289625,48.87481653,47.43838367,46.32839657,45.45758552,44.77126236,-3.957864908,291,Hypertension,7/7/14 12:28
440,23,Boehringer Ingelheim,Large Pharma,1435,Catapres,clonidine,Small Molecule (Chemical),Launched,In-House,Apr-76,Aug-66,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,291,Hypertension,7/7/14 12:28
440,23,Boehringer Ingelheim,Large Pharma,1435,Catapres,clonidine,Small Molecule (Chemical),Launched,In-House,Apr-76,Aug-66,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,62.52742812,54.33498632,53.00191587,46.40226538,44.02178991,41.26571456,39.02343963,37.26466338,35.87305638,34.77427575,33.90626632,33.22064357,-3.94182032,291,Hypertension,7/7/14 12:28
440,23,Boehringer Ingelheim,Large Pharma,1435,Catapres,clonidine,Small Molecule (Chemical),Launched,In-House,Apr-76,Aug-66,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,291,Hypertension,7/7/14 12:28
440,23,Boehringer Ingelheim,Large Pharma,1435,Catapres,clonidine,Small Molecule (Chemical),Launched,In-House,Apr-76,Aug-66,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,US,Sales,198.6982716,111.6855169,59.78879261,25.98642436,15.37552586,12.50667046,11.78945661,11.61015315,11.56532728,11.55412082,11.5513192,11.5506188,-4.003891444,291,Hypertension,7/7/14 12:28
445,39,Eli Lilly,Large Pharma,1419,Ceclor,cefaclor,Small Molecule (Chemical),Launched,In-House,Jul-79,Jul-79,Expired,Jun-98,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,296,Bacterial infections,7/7/14 12:28
445,39,Eli Lilly,Large Pharma,1419,Ceclor,cefaclor,Small Molecule (Chemical),Launched,In-House,Jul-79,Jul-79,Expired,Jun-98,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,56.3,53.4,52.6,55.4,55.458,55.5289,55.590185,55.59653625,55.60011036,55.60170531,55.6020193,55.60215433,3.71E-02,296,Bacterial infections,7/7/14 12:28
445,39,Eli Lilly,Large Pharma,1419,Ceclor,cefaclor,Small Molecule (Chemical),Launched,In-House,Jul-79,Jul-79,Expired,Jun-98,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,296,Bacterial infections,7/7/14 12:28
445,39,Eli Lilly,Large Pharma,1419,Ceclor,cefaclor,Small Molecule (Chemical),Launched,In-House,Jul-79,Jul-79,Expired,Jun-98,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,56.3,53.4,52.6,55.4,55.458,55.5289,55.590185,55.59653625,55.60011036,55.60170531,55.6020193,55.60215433,3.71E-02,296,Bacterial infections,7/7/14 12:28
445,39,Eli Lilly,Large Pharma,1419,Ceclor,cefaclor,Small Molecule (Chemical),Launched,In-House,Jul-79,Jul-79,Expired,Jun-98,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,296,Bacterial infections,7/7/14 12:28
445,39,Eli Lilly,Large Pharma,1419,Ceclor,cefaclor,Small Molecule (Chemical),Launched,In-House,Jul-79,Jul-79,Expired,Jun-98,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,296,Bacterial infections,7/7/14 12:28
446,15,Astellas Pharma,Regional & Specialty Pharma,330,Cefamezin,cefazolin,Small Molecule (Chemical),Launched,In-House,,Aug-71,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,297,,7/7/14 12:28
446,15,Astellas Pharma,Regional & Specialty Pharma,330,Cefamezin,cefazolin,Small Molecule (Chemical),Launched,In-House,,Aug-71,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,53.99571603,51.83131241,46.79438657,41.05371431,31.16728316,28.4061946,26.37258761,24.63789725,23.21714576,22.07089279,21.12848979,20.3590304,-5.902136832,297,,7/7/14 12:28
446,15,Astellas Pharma,Regional & Specialty Pharma,330,Cefamezin,cefazolin,Small Molecule (Chemical),Launched,In-House,,Aug-71,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,297,,7/7/14 12:28
446,15,Astellas Pharma,Regional & Specialty Pharma,330,Cefamezin,cefazolin,Small Molecule (Chemical),Launched,In-House,,Aug-71,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,53.99571603,51.83131241,46.79438657,41.05371431,31.16728316,28.4061946,26.37258761,24.63789725,23.21714576,22.07089279,21.12848979,20.3590304,-5.902136832,297,,7/7/14 12:28
446,15,Astellas Pharma,Regional & Specialty Pharma,330,Cefamezin,cefazolin,Small Molecule (Chemical),Launched,In-House,,Aug-71,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,297,,7/7/14 12:28
446,15,Astellas Pharma,Regional & Specialty Pharma,330,Cefamezin,cefazolin,Small Molecule (Chemical),Launched,In-House,,Aug-71,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,297,,7/7/14 12:28
447,42,Forest,Regional & Specialty Pharma,3326,Teflaro,ceftaroline,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1385,Bacterial infections,7/7/14 12:28
447,42,Forest,Regional & Specialty Pharma,3326,Teflaro,ceftaroline,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,2.7,22.4,44,68,77.273,88.294725,97.06502063,103.7900931,109.1187735,113.3021222,116,7.928352876,1385,Bacterial infections,7/7/14 12:28
447,42,Forest,Regional & Specialty Pharma,3326,Teflaro,ceftaroline,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1385,Bacterial infections,7/7/14 12:28
447,42,Forest,Regional & Specialty Pharma,3326,Teflaro,ceftaroline,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1385,Bacterial infections,7/7/14 12:28
447,42,Forest,Regional & Specialty Pharma,3326,Teflaro,ceftaroline,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1385,Bacterial infections,7/7/14 12:28
447,42,Forest,Regional & Specialty Pharma,3326,Teflaro,ceftaroline,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,2.7,22.4,44,68,77.273,88.294725,97.06502063,103.7900931,109.1187735,113.3021222,116,7.928352876,1385,Bacterial infections,7/7/14 12:28
448,24,Bristol-Myers Squibb,Large Pharma,1160,Cefzil,cefprozil,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-93,Aug-05,Dec-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,298,bacterial infection,7/7/14 12:28
448,24,Bristol-Myers Squibb,Large Pharma,1160,Cefzil,cefprozil,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-93,Aug-05,Dec-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,71.845,63.71475,56.4081125,50.20246187,45.85987903,42.82082597,40.69390403,39.20528704,38.16338075,37.43411543,36.92366769,36.56637518,-3.183389964,298,bacterial infection,7/7/14 12:28
448,24,Bristol-Myers Squibb,Large Pharma,1160,Cefzil,cefprozil,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-93,Aug-05,Dec-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,298,bacterial infection,7/7/14 12:28
448,24,Bristol-Myers Squibb,Large Pharma,1160,Cefzil,cefprozil,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-93,Aug-05,Dec-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,70,61.9,54.61,48.4135,44.07595,41.039665,38.9142655,37.42648585,36.3850401,35.65602807,35.14571965,34.78850375,-3.323889969,298,bacterial infection,7/7/14 12:28
448,24,Bristol-Myers Squibb,Large Pharma,1160,Cefzil,cefprozil,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-93,Aug-05,Dec-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,298,bacterial infection,7/7/14 12:28
448,24,Bristol-Myers Squibb,Large Pharma,1160,Cefzil,cefprozil,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-93,Aug-05,Dec-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,1.845,1.81475,1.7981125,1.788961875,1.783929031,1.781160967,1.779638532,1.778801193,1.778340656,1.778087361,1.777948048,1.777871427,-4.86E-02,298,bacterial infection,7/7/14 12:28
449,15,Astellas Pharma,Regional & Specialty Pharma,212,Cefzon,cefdinir,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-91,N/A,Aug-08,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1383,Bacterial infections,7/7/14 12:28
449,15,Astellas Pharma,Regional & Specialty Pharma,212,Cefzon,cefdinir,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-91,N/A,Aug-08,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,114.1965527,128.401172,103.8256152,85.47505874,70.47405572,60.40633347,57.63770978,54.4286233,52.93419576,51.75831725,51.09074074,50.62987698,-4.614461522,1383,Bacterial infections,7/7/14 12:28
449,15,Astellas Pharma,Regional & Specialty Pharma,212,Cefzon,cefdinir,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-91,N/A,Aug-08,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1383,Bacterial infections,7/7/14 12:28
449,15,Astellas Pharma,Regional & Specialty Pharma,212,Cefzon,cefdinir,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-91,N/A,Aug-08,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,114.1965527,128.401172,103.8256152,85.47505874,70.47405572,60.40633347,57.63770978,54.4286233,52.93419576,51.75831725,51.09074074,50.62987698,-4.614461522,1383,Bacterial infections,7/7/14 12:28
449,15,Astellas Pharma,Regional & Specialty Pharma,212,Cefzon,cefdinir,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-91,N/A,Aug-08,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1383,Bacterial infections,7/7/14 12:28
449,15,Astellas Pharma,Regional & Specialty Pharma,212,Cefzon,cefdinir,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-91,N/A,Aug-08,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1383,Bacterial infections,7/7/14 12:28
450,76,Pfizer,Large Pharma,1287,Celebrex,celecoxib,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Jan-99,May-14,Nov-14,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1387,Pain,7/7/14 12:28
450,76,Pfizer,Large Pharma,1287,Celebrex,celecoxib,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Jan-99,May-14,Nov-14,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,2383,2374,2523,2719,2918,1734.679615,418.029554,275.5800265,205.8466896,162.9143795,135.043749,115.2877897,-36.97273094,1387,Pain,7/7/14 12:28
450,76,Pfizer,Large Pharma,1287,Celebrex,celecoxib,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Jan-99,May-14,Nov-14,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1387,Pain,7/7/14 12:28
450,76,Pfizer,Large Pharma,1287,Celebrex,celecoxib,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Jan-99,May-14,Nov-14,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,686,794,926,974,985,927.97824,315.624614,212.6363191,160.9704321,130.1785953,108.4015661,92.72504432,-28.64990605,1387,Pain,7/7/14 12:28
450,76,Pfizer,Large Pharma,1287,Celebrex,celecoxib,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Jan-99,May-14,Nov-14,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1387,Pain,7/7/14 12:28
450,76,Pfizer,Large Pharma,1287,Celebrex,celecoxib,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Jan-99,May-14,Nov-14,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,1697,1580,1597,1745,1933,806.701375,102.40494,62.94370742,44.87625749,32.73578424,26.64218288,22.56274534,-47.04825354,1387,Pain,7/7/14 12:28
451,15,Astellas Pharma,Regional & Specialty Pharma,682,Celecox,celecoxib,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-07,N/A,Jun-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1387,Pain,7/7/14 12:28
451,15,Astellas Pharma,Regional & Specialty Pharma,682,Celecox,celecoxib,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-07,N/A,Jun-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,191.7640225,292.9881287,417.8347928,450.248901,418.9698004,451.7394779,476.4235729,496.3527991,511.9032542,524.0522836,533.6238563,521.1036036,3.165494919,1387,Pain,7/7/14 12:28
451,15,Astellas Pharma,Regional & Specialty Pharma,682,Celecox,celecoxib,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-07,N/A,Jun-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1387,Pain,7/7/14 12:28
451,15,Astellas Pharma,Regional & Specialty Pharma,682,Celecox,celecoxib,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-07,N/A,Jun-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,191.7640225,292.9881287,417.8347928,450.248901,418.9698004,451.7394779,476.4235729,496.3527991,511.9032542,524.0522836,533.6238563,521.1036036,3.165494919,1387,Pain,7/7/14 12:28
451,15,Astellas Pharma,Regional & Specialty Pharma,682,Celecox,celecoxib,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-07,N/A,Jun-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1387,Pain,7/7/14 12:28
451,15,Astellas Pharma,Regional & Specialty Pharma,682,Celecox,celecoxib,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-07,N/A,Jun-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1387,Pain,7/7/14 12:28
454,86,Roche,Large Pharma,1424,CellCept,mycophenolate mofetil,Small Molecule (Chemical),Launched,In-House,Aug-95,Apr-96,May-09,Feb-08,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1557,Transplant Rejection,7/7/14 12:28
454,86,Roche,Large Pharma,1424,CellCept,mycophenolate mofetil,Small Molecule (Chemical),Launched,In-House,Aug-95,Apr-96,May-09,Feb-08,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,5,Global,Sales,1451.237922,1240.785283,1115.624216,968.7523993,943.5657667,884.1692882,855.4788831,834.7337068,820.011447,810.67471,803.7485994,799.4992387,-2.339071252,1557,Transplant Rejection,7/7/14 12:28
454,86,Roche,Large Pharma,1424,CellCept,mycophenolate mofetil,Small Molecule (Chemical),Launched,In-House,Aug-95,Apr-96,May-09,Feb-08,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1557,Transplant Rejection,7/7/14 12:28
454,86,Roche,Large Pharma,1424,CellCept,mycophenolate mofetil,Small Molecule (Chemical),Launched,In-House,Aug-95,Apr-96,May-09,Feb-08,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,5,ROW,Sales,945.7208177,977.0509164,886.9749079,786.3827132,723.4246533,673.7402827,650.4454931,634.0168093,622.7261609,615.8433499,610.7890862,607.9547797,-2.453621668,1557,Transplant Rejection,7/7/14 12:28
454,86,Roche,Large Pharma,1424,CellCept,mycophenolate mofetil,Small Molecule (Chemical),Launched,In-House,Aug-95,Apr-96,May-09,Feb-08,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1557,Transplant Rejection,7/7/14 12:28
454,86,Roche,Large Pharma,1424,CellCept,mycophenolate mofetil,Small Molecule (Chemical),Launched,In-House,Aug-95,Apr-96,May-09,Feb-08,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,5,US,Sales,505.5171038,263.7343667,228.6493077,182.3696861,220.1411134,210.4290055,205.0333899,200.7168975,197.285286,194.8313601,192.9595132,191.544459,-1.968211082,1557,Transplant Rejection,7/7/14 12:28
457,61,Merck & Co,Large Pharma,158,Cerazette,desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-00,N/A,Dec-12,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1417,Female contraception,7/7/14 12:28
457,61,Merck & Co,Large Pharma,158,Cerazette,desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-00,N/A,Dec-12,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,30.76668,209,268,271,208,93,62,41.85,28.7525,20.239125,14.70543125,11.10853031,-34.19971242,1417,Female contraception,7/7/14 12:28
457,61,Merck & Co,Large Pharma,158,Cerazette,desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-00,N/A,Dec-12,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1417,Female contraception,7/7/14 12:28
457,61,Merck & Co,Large Pharma,158,Cerazette,desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-00,N/A,Dec-12,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,30.76668,209,268,271,208,93,62,41.85,28.7525,20.239125,14.70543125,11.10853031,-34.19971242,1417,Female contraception,7/7/14 12:28
457,61,Merck & Co,Large Pharma,158,Cerazette,desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-00,N/A,Dec-12,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1417,Female contraception,7/7/14 12:28
457,61,Merck & Co,Large Pharma,158,Cerazette,desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-00,N/A,Dec-12,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1417,Female contraception,7/7/14 12:28
457,61,Schering-Plough,Large Pharma,158,Cerazette,desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-00,N/A,Dec-12,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Proforma,155.83332,0,0,0,0,0,0,0,0,0,0,0,0,1417,Female contraception,7/7/14 12:28
457,61,Schering-Plough,Large Pharma,158,Cerazette,desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-00,N/A,Dec-12,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Proforma,155.83332,0,0,0,0,0,0,0,0,0,0,0,0,1417,Female contraception,7/7/14 12:28
458,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,214,Ceredist,taltirelin,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Jun-12,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,309,Spinocerebellar Degeneration,7/7/14 12:28
458,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,214,Ceredist,taltirelin,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Jun-12,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,7,Global,Sales,182.0680888,210.1110086,225.7034212,230.0389788,192.3816853,194.4781069,191.2867227,181.2190004,177.318606,173.3924524,169.7897348,167.1582361,-1.987698345,309,Spinocerebellar Degeneration,7/7/14 12:28
458,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,214,Ceredist,taltirelin,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Jun-12,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,309,Spinocerebellar Degeneration,7/7/14 12:28
458,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,214,Ceredist,taltirelin,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Jun-12,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,7,ROW,Sales,182.0680888,210.1110086,225.7034212,230.0389788,192.3816853,194.4781069,191.2867227,181.2190004,177.318606,173.3924524,169.7897348,167.1582361,-1.987698345,309,Spinocerebellar Degeneration,7/7/14 12:28
458,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,214,Ceredist,taltirelin,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Jun-12,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,309,Spinocerebellar Degeneration,7/7/14 12:28
458,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,214,Ceredist,taltirelin,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Jun-12,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,309,Spinocerebellar Degeneration,7/7/14 12:28
459,89,Genzyme,Large Pharma,1512,Cerezyme,imiglucerase,Recombinant Protein,Launched,Corporate Acquisition,Oct-94,Oct-96,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Proforma,792.9867384,720.0042392,218.9050919,0,0,0,0,0,0,0,0,0,0,310,Gaucher's Disease,7/7/14 12:28
459,89,Genzyme,Large Pharma,1512,Cerezyme,imiglucerase,Recombinant Protein,Launched,Corporate Acquisition,Oct-94,Oct-96,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Proforma,549.9634678,510.0306018,158.8203877,0,0,0,0,0,0,0,0,0,0,310,Gaucher's Disease,7/7/14 12:28
459,89,Genzyme,Large Pharma,1512,Cerezyme,imiglucerase,Recombinant Protein,Launched,Corporate Acquisition,Oct-94,Oct-96,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Proforma,243.0232706,209.9736374,60.08470421,0,0,0,0,0,0,0,0,0,0,310,Gaucher's Disease,7/7/14 12:28
459,89,Sanofi,Large Pharma,1512,Cerezyme,imiglucerase,Recombinant Protein,Launched,Corporate Acquisition,Oct-94,Oct-96,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,310,Gaucher's Disease,7/7/14 12:28
459,89,Sanofi,Large Pharma,1512,Cerezyme,imiglucerase,Recombinant Protein,Launched,Corporate Acquisition,Oct-94,Oct-96,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Sales,-2.33E-02,2.64E-02,577.8153306,813.5767494,913.6846858,940.1093128,1000.54701,1044.906342,1062.093828,1103.347973,1133.035699,1144.311223,3.267570329,310,Gaucher's Disease,7/7/14 12:28
459,89,Sanofi,Large Pharma,1512,Cerezyme,imiglucerase,Recombinant Protein,Launched,Corporate Acquisition,Oct-94,Oct-96,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,310,Gaucher's Disease,7/7/14 12:28
459,89,Sanofi,Large Pharma,1512,Cerezyme,imiglucerase,Recombinant Protein,Launched,Corporate Acquisition,Oct-94,Oct-96,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Sales,0,0,407.0874865,600.2217093,677.295334,697.746997,753.5242596,793.4979648,807.8141289,846.8582127,874.8398064,884.8611212,3.892757508,310,Gaucher's Disease,7/7/14 12:28
459,89,Sanofi,Large Pharma,1512,Cerezyme,imiglucerase,Recombinant Protein,Launched,Corporate Acquisition,Oct-94,Oct-96,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,310,Gaucher's Disease,7/7/14 12:28
459,89,Sanofi,Large Pharma,1512,Cerezyme,imiglucerase,Recombinant Protein,Launched,Corporate Acquisition,Oct-94,Oct-96,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Sales,-2.33E-02,2.64E-02,170.727844,213.3550401,236.3893519,242.3623158,247.02275,251.408377,254.279699,256.4897605,258.1958922,259.4501014,1.338653107,310,Gaucher's Disease,7/7/14 12:28
460,67,Novartis,Large Pharma,323,Zortress / Certican,everolimus,Small Molecule (Chemical),Launched,In-House,Apr-10,May-04,Jan-20,Jan-19,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1697,Transplant Rejection,7/7/14 12:28
460,67,Novartis,Large Pharma,323,Zortress / Certican,everolimus,Small Molecule (Chemical),Launched,In-House,Apr-10,May-04,Jan-20,Jan-19,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Sales,118,144.45769,186.6740305,210,249,276.9528472,301.2261411,323.8841421,343.2453885,360.3115344,363.4932078,369.1688254,5.786978883,1697,Transplant Rejection,7/7/14 12:28
460,67,Novartis,Large Pharma,323,Zortress / Certican,everolimus,Small Molecule (Chemical),Launched,In-House,Apr-10,May-04,Jan-20,Jan-19,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1697,Transplant Rejection,7/7/14 12:28
460,67,Novartis,Large Pharma,323,Zortress / Certican,everolimus,Small Molecule (Chemical),Launched,In-House,Apr-10,May-04,Jan-20,Jan-19,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Sales,118,140.45769,166.6740305,176,189,200.6328472,209.8981411,218.4761421,225.9922685,232.5398864,226.4185198,223.9532554,2.453766474,1697,Transplant Rejection,7/7/14 12:28
460,67,Novartis,Large Pharma,323,Zortress / Certican,everolimus,Small Molecule (Chemical),Launched,In-House,Apr-10,May-04,Jan-20,Jan-19,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1697,Transplant Rejection,7/7/14 12:28
460,67,Novartis,Large Pharma,323,Zortress / Certican,everolimus,Small Molecule (Chemical),Launched,In-House,Apr-10,May-04,Jan-20,Jan-19,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Sales,0,4,20,34,60,76.32,91.328,105.408,117.25312,127.771648,137.074688,145.2155699,13.45858533,1697,Transplant Rejection,7/7/14 12:28
461,46,GlaxoSmithKline,Large Pharma,1344,Cervarix,HPV vaccine,Vaccine,Launched,Licensed (Development),Nov-09,Jul-07,Jul-26,Jul-19,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1704,HPV,7/7/14 12:28
461,46,GlaxoSmithKline,Large Pharma,1344,Cervarix,HPV vaccine,Vaccine,Launched,Licensed (Development),Nov-09,Jul-07,Jul-26,Jul-19,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,291.581936,373.890014,811.2094395,427.957796,268.4756779,314.587531,303.9584184,303.8109205,305.2470323,303.8240114,301.8718696,299.7978949,1.588892601,1704,HPV,7/7/14 12:28
461,46,GlaxoSmithKline,Large Pharma,1344,Cervarix,HPV vaccine,Vaccine,Launched,Licensed (Development),Nov-09,Jul-07,Jul-26,Jul-19,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1704,HPV,7/7/14 12:28
461,46,GlaxoSmithKline,Large Pharma,1344,Cervarix,HPV vaccine,Vaccine,Launched,Licensed (Development),Nov-09,Jul-07,Jul-26,Jul-19,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,285.3448892,353.8050133,798.3839938,418.4476227,259.5267287,306.4291495,296.1333041,296.1264218,297.6610541,296.2854627,294.3577391,291.9808247,1.697508325,1704,HPV,7/7/14 12:28
461,46,GlaxoSmithKline,Large Pharma,1344,Cervarix,HPV vaccine,Vaccine,Launched,Licensed (Development),Nov-09,Jul-07,Jul-26,Jul-19,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1704,HPV,7/7/14 12:28
461,46,GlaxoSmithKline,Large Pharma,1344,Cervarix,HPV vaccine,Vaccine,Launched,Licensed (Development),Nov-09,Jul-07,Jul-26,Jul-19,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,6.237046758,20.08500075,12.82544568,9.510173244,8.948949263,8.158381465,7.825114249,7.684498667,7.585978212,7.538548709,7.514130508,7.81707014,-1.913262665,1704,HPV,7/7/14 12:28
462,100,Takeda,Large Pharma,968,Oblean,cetilistat,Small Molecule (Chemical),Approved,Licensed (Development),,Aug-14,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,311,Obesity,7/7/14 12:28
462,100,Takeda,Large Pharma,968,Oblean,cetilistat,Small Molecule (Chemical),Approved,Licensed (Development),,Aug-14,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,7,Global,Sales,0,0,0,0,0,5.033861123,8.305870852,11.8295535,17.6184638,21.30323332,24.73026882,27.91165335,0,311,Obesity,7/7/14 12:28
462,100,Takeda,Large Pharma,968,Oblean,cetilistat,Small Molecule (Chemical),Approved,Licensed (Development),,Aug-14,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,311,Obesity,7/7/14 12:28
462,100,Takeda,Large Pharma,968,Oblean,cetilistat,Small Molecule (Chemical),Approved,Licensed (Development),,Aug-14,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,7,ROW,Sales,0,0,0,0,0,5.033861123,8.305870852,11.8295535,17.6184638,21.30323332,24.73026882,27.91165335,0,311,Obesity,7/7/14 12:28
462,100,Takeda,Large Pharma,968,Oblean,cetilistat,Small Molecule (Chemical),Approved,Licensed (Development),,Aug-14,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,311,Obesity,7/7/14 12:28
462,100,Takeda,Large Pharma,968,Oblean,cetilistat,Small Molecule (Chemical),Approved,Licensed (Development),,Aug-14,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,311,Obesity,7/7/14 12:28
464,76,Pfizer,Large Pharma,3074,Chantix / Champix,varenicline,Small Molecule (Chemical),Launched,In-House,Aug-06,Dec-06,May-20,Apr-22,71,Smoking Cessation Agents,16,Addictions,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,312,Smoking Cessation,7/7/14 12:28
464,76,Pfizer,Large Pharma,3074,Chantix / Champix,varenicline,Small Molecule (Chemical),Launched,In-House,Aug-06,Dec-06,May-20,Apr-22,71,Smoking Cessation Agents,16,Addictions,12,Central Nervous System,6,Global,Sales,700,755,720,670,648,619,589,574.2,561.36,550.808,543.3344,537.40672,-2.637943558,312,Smoking Cessation,7/7/14 12:28
464,76,Pfizer,Large Pharma,3074,Chantix / Champix,varenicline,Small Molecule (Chemical),Launched,In-House,Aug-06,Dec-06,May-20,Apr-22,71,Smoking Cessation Agents,16,Addictions,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,312,Smoking Cessation,7/7/14 12:28
464,76,Pfizer,Large Pharma,3074,Chantix / Champix,varenicline,Small Molecule (Chemical),Launched,In-House,Aug-06,Dec-06,May-20,Apr-22,71,Smoking Cessation Agents,16,Addictions,12,Central Nervous System,6,ROW,Sales,314,425,394,357,305,285,269,256.2,245.96,237.768,231.2144,225.97152,-4.193841176,312,Smoking Cessation,7/7/14 12:28
464,76,Pfizer,Large Pharma,3074,Chantix / Champix,varenicline,Small Molecule (Chemical),Launched,In-House,Aug-06,Dec-06,May-20,Apr-22,71,Smoking Cessation Agents,16,Addictions,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,312,Smoking Cessation,7/7/14 12:28
464,76,Pfizer,Large Pharma,3074,Chantix / Champix,varenicline,Small Molecule (Chemical),Launched,In-House,Aug-06,Dec-06,May-20,Apr-22,71,Smoking Cessation Agents,16,Addictions,12,Central Nervous System,6,US,Sales,386,330,326,313,343,334,320,318,315.4,313.04,312.12,311.4352,-1.369663003,312,Smoking Cessation,7/7/14 12:28
465,39,Eli Lilly,Large Pharma,1957,Adcirca,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Mar-10,Nov-17,Mar-20,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1646,Pulmonary Hypertension,7/7/14 12:28
465,39,Eli Lilly,Large Pharma,1957,Adcirca,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Mar-10,Nov-17,Mar-20,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,11,23,49.5,59.9,65.5739,67.492883,71.7516237,72.65120131,55.123583,56.44797213,43.03070915,-4.615274968,1646,Pulmonary Hypertension,7/7/14 12:28
465,39,Eli Lilly,Large Pharma,1957,Adcirca,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Mar-10,Nov-17,Mar-20,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1646,Pulmonary Hypertension,7/7/14 12:28
465,39,Eli Lilly,Large Pharma,1957,Adcirca,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Mar-10,Nov-17,Mar-20,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,7,14,30.1,39.9,42.9219,42.689283,45.7531837,49.16102075,51.97598188,54.25905373,41.35627109,0.513423654,1646,Pulmonary Hypertension,7/7/14 12:28
465,39,Eli Lilly,Large Pharma,1957,Adcirca,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Mar-10,Nov-17,Mar-20,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1646,Pulmonary Hypertension,7/7/14 12:28
465,39,Eli Lilly,Large Pharma,1957,Adcirca,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Mar-10,Nov-17,Mar-20,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,4,9,19.4,20,22.652,24.8036,25.99844,23.49018056,3.147601124,2.18891839,1.674438062,-29.83508165,1646,Pulmonary Hypertension,7/7/14 12:28
466,39,Eli Lilly,Large Pharma,624,Cialis,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Nov-03,Feb-03,Oct-16,Nov-17,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1744,Erectile dysfunction,7/7/14 12:28
466,39,Eli Lilly,Large Pharma,624,Cialis,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Nov-03,Feb-03,Oct-16,Nov-17,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,Global,Sales,1559.1,1699.5,1876,1926.8,2160,2123.735399,2124.397041,2113.6719,1959.182191,555.6155069,253.2016094,174.2488374,-30.20621563,1744,Erectile dysfunction,7/7/14 12:28
466,39,Eli Lilly,Large Pharma,624,Cialis,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Nov-03,Feb-03,Oct-16,Nov-17,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1744,Erectile dysfunction,7/7/14 12:28
466,39,Eli Lilly,Large Pharma,624,Cialis,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Nov-03,Feb-03,Oct-16,Nov-17,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,ROW,Sales,935.8,1041.4,1171,1144.6,1217,1124.265399,1078.969541,1032.204525,901.7025637,233.9518581,33.02881175,26.53949429,-42.10278479,1744,Erectile dysfunction,7/7/14 12:28
466,39,Eli Lilly,Large Pharma,624,Cialis,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Nov-03,Feb-03,Oct-16,Nov-17,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1744,Erectile dysfunction,7/7/14 12:28
466,39,Eli Lilly,Large Pharma,624,Cialis,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Nov-03,Feb-03,Oct-16,Nov-17,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,US,Sales,623.3,658.1,705,782.2,943,999.47,1045.4275,1081.467375,1057.479627,321.6636488,220.1727976,147.7093432,-23.26644891,1744,Erectile dysfunction,7/7/14 12:28
468,86,Roche,Large Pharma,1868,RG7167,MEK inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1392,Solid Tumors,7/7/14 12:28
468,86,Roche,Large Pharma,1868,RG7167,MEK inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1392,Solid Tumors,7/7/14 12:28
468,86,Roche,Large Pharma,1868,RG7167,MEK inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1392,Solid Tumors,7/7/14 12:28
468,86,Roche,Large Pharma,1868,RG7167,MEK inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1392,Solid Tumors,7/7/14 12:28
468,86,Roche,Large Pharma,1868,RG7167,MEK inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1392,Solid Tumors,7/7/14 12:28
468,86,Roche,Large Pharma,1868,RG7167,MEK inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1392,Solid Tumors,7/7/14 12:28
473,105,UCB,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-08,Jan-08,Jun-21,Jun-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1388,Crohn's disease,7/7/14 12:28
473,105,UCB,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-08,Jan-08,Jun-21,Jun-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,2,Global,Sales,44.46394888,64.10200771,90.37840744,116.4949088,142.5932615,163.1838527,182.2013199,194.5621744,206.5865311,216.7320538,225.1458234,232.108281,7.208037433,1388,Crohn's disease,7/7/14 12:28
473,105,UCB,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-08,Jan-08,Jun-21,Jun-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1388,Crohn's disease,7/7/14 12:28
473,105,UCB,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-08,Jan-08,Jun-21,Jun-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,2,ROW,Sales,2.778996805,3.890595527,5.56174815,5.961574722,7.9681804,9.120863678,10.15156857,11.12981842,11.95291687,12.68184899,13.32748544,13.89237948,8.26502411,1388,Crohn's disease,7/7/14 12:28
473,105,UCB,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-08,Jan-08,Jun-21,Jun-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1388,Crohn's disease,7/7/14 12:28
473,105,UCB,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-08,Jan-08,Jun-21,Jun-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,2,US,Sales,41.68495208,60.21141218,84.81665929,110.533334,134.6250811,154.062989,172.0497514,183.432356,194.6336142,204.0502048,211.8183379,218.2159015,7.143478953,1388,Crohn's disease,7/7/14 12:28
474,105,UCB,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-09,Oct-09,Jun-21,Jun-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1388,Rheumatoid Arthritis,7/7/14 12:28
474,105,UCB,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-09,Oct-09,Jun-21,Jun-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Sales,59.74843131,198.7132215,343.4379483,483.2620186,646.7506424,761.5920424,855.6091011,931.5040896,993.4458683,1044.137359,1085.789133,1120.176895,8.162944251,1388,Rheumatoid Arthritis,7/7/14 12:28
474,105,UCB,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-09,Oct-09,Jun-21,Jun-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1388,Rheumatoid Arthritis,7/7/14 12:28
474,105,UCB,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-09,Oct-09,Jun-21,Jun-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Sales,4.168495208,38.41788949,114.0158371,181.223257,277.5582839,332.3727249,379.5368827,412.6799274,438.7797682,458.0337059,472.7736839,483.8217066,8.261949894,1388,Rheumatoid Arthritis,7/7/14 12:28
474,105,UCB,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-09,Oct-09,Jun-21,Jun-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1388,Rheumatoid Arthritis,7/7/14 12:28
474,105,UCB,Regional & Specialty Pharma,1268,Cimzia,certolizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-09,Oct-09,Jun-21,Jun-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Sales,55.57993611,160.295332,229.4221112,302.0387616,369.1923585,429.2193175,476.0722183,518.8241623,554.6661001,586.1036529,613.0154491,636.3551887,8.088152275,1388,Rheumatoid Arthritis,7/7/14 12:28
476,58,Lundbeck,Regional & Specialty Pharma,881,Cipralex,escitalopram,Small Molecule (Chemical),Launched,In-House,,Jun-02,N/A,Jun-14,127,Serotonergics,49,Depression,12,Central Nervous System,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
476,58,Lundbeck,Regional & Specialty Pharma,881,Cipralex,escitalopram,Small Molecule (Chemical),Launched,In-House,,Jun-02,N/A,Jun-14,127,Serotonergics,49,Depression,12,Central Nervous System,1,Global,Sales,992.7225229,1033.098094,1111.728012,1006.113748,1056.507009,739.765745,326.5524625,217.8237255,163.2788578,131.1247312,108.583869,96.7711751,-28.92835273,1450,Depression,7/7/14 12:28
476,58,Lundbeck,Regional & Specialty Pharma,881,Cipralex,escitalopram,Small Molecule (Chemical),Launched,In-House,,Jun-02,N/A,Jun-14,127,Serotonergics,49,Depression,12,Central Nervous System,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
476,58,Lundbeck,Regional & Specialty Pharma,881,Cipralex,escitalopram,Small Molecule (Chemical),Launched,In-House,,Jun-02,N/A,Jun-14,127,Serotonergics,49,Depression,12,Central Nervous System,1,ROW,Sales,992.7225229,1033.098094,1111.728012,1006.113748,1056.507009,739.765745,326.5524625,217.8237255,163.2788578,131.1247312,108.583869,96.7711751,-28.92835273,1450,Depression,7/7/14 12:28
476,58,Lundbeck,Regional & Specialty Pharma,881,Cipralex,escitalopram,Small Molecule (Chemical),Launched,In-House,,Jun-02,N/A,Jun-14,127,Serotonergics,49,Depression,12,Central Nervous System,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
476,58,Lundbeck,Regional & Specialty Pharma,881,Cipralex,escitalopram,Small Molecule (Chemical),Launched,In-House,,Jun-02,N/A,Jun-14,127,Serotonergics,49,Depression,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
477,61,Merck & Co,Large Pharma,1136,Cipro,ciprofloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-87,,Jun-04,N/A,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1394,bacterial infection,7/7/14 12:28
477,61,Merck & Co,Large Pharma,1136,Cipro,ciprofloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-87,,Jun-04,N/A,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,39,75,24,24,52,27,26.59,26.3795,25.856675,25.81601875,25.79409119,26,-9.427624605,1394,bacterial infection,7/7/14 12:28
477,61,Merck & Co,Large Pharma,1136,Cipro,ciprofloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-87,,Jun-04,N/A,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1394,bacterial infection,7/7/14 12:28
477,61,Merck & Co,Large Pharma,1136,Cipro,ciprofloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-87,,Jun-04,N/A,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1394,bacterial infection,7/7/14 12:28
477,61,Merck & Co,Large Pharma,1136,Cipro,ciprofloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-87,,Jun-04,N/A,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1394,bacterial infection,7/7/14 12:28
477,61,Merck & Co,Large Pharma,1136,Cipro,ciprofloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-87,,Jun-04,N/A,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,39,75,24,24,52,27,26.59,26.3795,25.856675,25.81601875,25.79409119,26,-9.427624605,1394,bacterial infection,7/7/14 12:28
477,61,Schering-Plough,Large Pharma,1136,Cipro,ciprofloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-87,,Jun-04,N/A,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,Global,Proforma,157,0,0,0,0,0,0,0,0,0,0,0,0,1394,bacterial infection,7/7/14 12:28
477,61,Schering-Plough,Large Pharma,1136,Cipro,ciprofloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-87,,Jun-04,N/A,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,US,Proforma,157,0,0,0,0,0,0,0,0,0,0,0,0,1394,bacterial infection,7/7/14 12:28
478,19,Bayer,Large Pharma,901,Cipro DPI,ciprofloxacin,Small Molecule (Chemical),Phase III,,,,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1692,Pulmonary Infections In Cystic Fibrosis Patients,7/7/14 12:28
478,19,Bayer,Large Pharma,901,Cipro DPI,ciprofloxacin,Small Molecule (Chemical),Phase III,,,,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1692,Pulmonary Infections In Cystic Fibrosis Patients,7/7/14 12:28
478,19,Bayer,Large Pharma,901,Cipro DPI,ciprofloxacin,Small Molecule (Chemical),Phase III,,,,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1692,Pulmonary Infections In Cystic Fibrosis Patients,7/7/14 12:28
478,19,Bayer,Large Pharma,901,Cipro DPI,ciprofloxacin,Small Molecule (Chemical),Phase III,,,,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1692,Pulmonary Infections In Cystic Fibrosis Patients,7/7/14 12:28
478,19,Bayer,Large Pharma,901,Cipro DPI,ciprofloxacin,Small Molecule (Chemical),Phase III,,,,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1692,Pulmonary Infections In Cystic Fibrosis Patients,7/7/14 12:28
478,19,Bayer,Large Pharma,901,Cipro DPI,ciprofloxacin,Small Molecule (Chemical),Phase III,,,,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1692,Pulmonary Infections In Cystic Fibrosis Patients,7/7/14 12:28
479,19,Bayer,Large Pharma,896,Ciprobay,ciprofloxacin,Small Molecule (Chemical),Launched,In-House,Jul-87,Jul-87,N/A,Sep-04,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,Global,Alliance Revenue,113.938869,43.71690873,13.90437038,14.13798459,17.26439087,16.60701598,16.71707647,16.77543095,16.76503901,16.77018738,16.7718565,16.77190161,-0.412590172,1693,Bacterial infections,7/7/14 12:28
479,19,Bayer,Large Pharma,896,Ciprobay,ciprofloxacin,Small Molecule (Chemical),Launched,In-House,Jul-87,Jul-87,N/A,Sep-04,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,345.9851023,303.3688515,309.2078345,280.1891491,244.3575323,228.4211715,213.8128407,201.8605701,195.2204198,187.8498529,181.7990159,176.875552,-4.511979958,1693,Bacterial infections,7/7/14 12:28
479,19,Bayer,Large Pharma,896,Ciprobay,ciprofloxacin,Small Molecule (Chemical),Launched,In-House,Jul-87,Jul-87,N/A,Sep-04,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1693,Bacterial infections,7/7/14 12:28
479,19,Bayer,Large Pharma,896,Ciprobay,ciprofloxacin,Small Molecule (Chemical),Launched,In-House,Jul-87,Jul-87,N/A,Sep-04,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,345.9851023,303.3688515,309.2078345,280.1891491,244.3575323,228.4211715,213.8128407,201.8605701,195.2204198,187.8498529,181.7990159,176.875552,-4.511979958,1693,Bacterial infections,7/7/14 12:28
479,19,Bayer,Large Pharma,896,Ciprobay,ciprofloxacin,Small Molecule (Chemical),Launched,In-House,Jul-87,Jul-87,N/A,Sep-04,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,US,Alliance Revenue,113.938869,43.71690873,13.90437038,14.13798459,17.26439087,16.60701598,16.71707647,16.77543095,16.76503901,16.77018738,16.7718565,16.77190161,-0.412590172,1693,Bacterial infections,7/7/14 12:28
479,19,Bayer,Large Pharma,896,Ciprobay,ciprofloxacin,Small Molecule (Chemical),Launched,In-House,Jul-87,Jul-87,N/A,Sep-04,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1693,Bacterial infections,7/7/14 12:28
480,58,Lundbeck,Regional & Specialty Pharma,889,Circadin,prolonged-release melatonin,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-08,N/A,Apr-17,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1600,Insomnia,7/7/14 12:28
480,58,Lundbeck,Regional & Specialty Pharma,889,Circadin,prolonged-release melatonin,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-08,N/A,Apr-17,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,1,Global,Sales,29.29651054,49.27137947,63.63929026,66.17697719,71.46574858,73.61661576,74.85756769,75.5256751,46.00961346,23.22577558,15.48449051,11.60555766,-22.86985953,1600,Insomnia,7/7/14 12:28
480,58,Lundbeck,Regional & Specialty Pharma,889,Circadin,prolonged-release melatonin,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-08,N/A,Apr-17,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1600,Insomnia,7/7/14 12:28
480,58,Lundbeck,Regional & Specialty Pharma,889,Circadin,prolonged-release melatonin,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-08,N/A,Apr-17,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,1,ROW,Sales,29.29651054,49.27137947,63.63929026,66.17697719,71.46574858,73.61661576,74.85756769,75.5256751,46.00961346,23.22577558,15.48449051,11.60555766,-22.86985953,1600,Insomnia,7/7/14 12:28
480,58,Lundbeck,Regional & Specialty Pharma,889,Circadin,prolonged-release melatonin,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-08,N/A,Apr-17,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1600,Insomnia,7/7/14 12:28
480,58,Lundbeck,Regional & Specialty Pharma,889,Circadin,prolonged-release melatonin,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-08,N/A,Apr-17,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1600,Insomnia,7/7/14 12:28
481,100,Nycomed,Large Pharma,889,Circadin,prolonged-release melatonin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-07,N/A,Apr-17,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,Global,Proforma,24.02436911,37.00276646,38.94017682,0,0,0,0,0,0,0,0,0,0,1600,Insomnia,7/7/14 12:28
481,100,Nycomed,Large Pharma,889,Circadin,prolonged-release melatonin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-07,N/A,Apr-17,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,ROW,Proforma,24.02436911,37.00276646,38.94017682,0,0,0,0,0,0,0,0,0,0,1600,Insomnia,7/7/14 12:28
481,100,Takeda,Large Pharma,889,Circadin,prolonged-release melatonin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-07,N/A,Apr-17,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1600,Insomnia,7/7/14 12:28
481,100,Takeda,Large Pharma,889,Circadin,prolonged-release melatonin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-07,N/A,Apr-17,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,Global,Sales,0,1.17E-04,8.034583215,51.20815365,54.60234795,58.91148425,62.30278543,64.9747957,40.34893869,20.65589368,13.90916272,10.4953765,-20.98966245,1600,Insomnia,7/7/14 12:28
481,100,Takeda,Large Pharma,889,Circadin,prolonged-release melatonin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-07,N/A,Apr-17,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1600,Insomnia,7/7/14 12:28
481,100,Takeda,Large Pharma,889,Circadin,prolonged-release melatonin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-07,N/A,Apr-17,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,ROW,Sales,0,1.17E-04,8.034583215,51.20815365,54.60234795,58.91148425,62.30278543,64.9747957,40.34893869,20.65589368,13.90916272,10.4953765,-20.98966245,1600,Insomnia,7/7/14 12:28
481,100,Takeda,Large Pharma,889,Circadin,prolonged-release melatonin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-07,N/A,Apr-17,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1600,Insomnia,7/7/14 12:28
481,100,Takeda,Large Pharma,889,Circadin,prolonged-release melatonin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-07,N/A,Apr-17,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1600,Insomnia,7/7/14 12:28
483,61,Merck & Co,Large Pharma,210,Clarinex,desloratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-02,Mar-01,Jul-12,Jan-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1416,Allergic Rhinitis,7/7/14 12:28
483,61,Merck & Co,Large Pharma,210,Clarinex,desloratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-02,Mar-01,Jul-12,Jan-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,Global,Sales,100.6,623,621,393,235,190.5925,165.657475,150.538337,142.6772346,136.9949346,134.0174094,131.5277405,-7.95656427,1416,Allergic Rhinitis,7/7/14 12:28
483,61,Merck & Co,Large Pharma,210,Clarinex,desloratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-02,Mar-01,Jul-12,Jan-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1416,Allergic Rhinitis,7/7/14 12:28
483,61,Merck & Co,Large Pharma,210,Clarinex,desloratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-02,Mar-01,Jul-12,Jan-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,ROW,Sales,65,420,424,267,216,177.5925,155.657475,142.538337,134.6772346,129.9949346,127.1974094,125.5277405,-7.46061702,1416,Allergic Rhinitis,7/7/14 12:28
483,61,Merck & Co,Large Pharma,210,Clarinex,desloratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-02,Mar-01,Jul-12,Jan-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1416,Allergic Rhinitis,7/7/14 12:28
483,61,Merck & Co,Large Pharma,210,Clarinex,desloratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-02,Mar-01,Jul-12,Jan-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,US,Sales,35.6,203,197,126,19,13,10,8,8,7,6.82,6,-15.18250341,1416,Allergic Rhinitis,7/7/14 12:28
483,61,Schering-Plough,Large Pharma,210,Clarinex,desloratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-02,Mar-01,Jul-12,Jan-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,Global,Proforma,618.4,0,0,0,0,0,0,0,0,0,0,0,0,1416,Allergic Rhinitis,7/7/14 12:28
483,61,Schering-Plough,Large Pharma,210,Clarinex,desloratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-02,Mar-01,Jul-12,Jan-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,ROW,Proforma,405,0,0,0,0,0,0,0,0,0,0,0,0,1416,Allergic Rhinitis,7/7/14 12:28
483,61,Schering-Plough,Large Pharma,210,Clarinex,desloratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-02,Mar-01,Jul-12,Jan-12,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,US,Proforma,213.4,0,0,0,0,0,0,0,0,0,0,0,0,1416,Allergic Rhinitis,7/7/14 12:28
484,61,Merck & Co,Large Pharma,282,Claritin,loratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-93,Jan-88,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1529,Allergic Rhinitis,7/7/14 12:28
484,61,Merck & Co,Large Pharma,282,Claritin,loratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-93,Jan-88,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,Global,Sales,71.1,296,314,244,204,193,187,181.28,178.536,176.8208,175.69088,175.039552,-2.163508461,1529,Allergic Rhinitis,7/7/14 12:28
484,61,Merck & Co,Large Pharma,282,Claritin,loratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-93,Jan-88,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1529,Allergic Rhinitis,7/7/14 12:28
484,61,Merck & Co,Large Pharma,282,Claritin,loratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-93,Jan-88,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,ROW,Sales,71.1,296,314,244,204,193,187,181.28,178.536,176.8208,175.69088,175.039552,-2.163508461,1529,Allergic Rhinitis,7/7/14 12:28
484,61,Merck & Co,Large Pharma,282,Claritin,loratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-93,Jan-88,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1529,Allergic Rhinitis,7/7/14 12:28
484,61,Merck & Co,Large Pharma,282,Claritin,loratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-93,Jan-88,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1529,Allergic Rhinitis,7/7/14 12:28
484,61,Schering-Plough,Large Pharma,282,Claritin,loratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-93,Jan-88,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,Global,Proforma,361.9,0,0,0,0,0,0,0,0,0,0,0,0,1529,Allergic Rhinitis,7/7/14 12:28
484,61,Schering-Plough,Large Pharma,282,Claritin,loratadine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-93,Jan-88,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,6,ROW,Proforma,361.9,0,0,0,0,0,0,0,0,0,0,0,0,1529,Allergic Rhinitis,7/7/14 12:28
485,95,Shionogi,Regional & Specialty Pharma,282,Claritin,loratadine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-88,N/A,Nov-11,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1529,Allergic Rhinitis,7/7/14 12:28
485,95,Shionogi,Regional & Specialty Pharma,282,Claritin,loratadine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-88,N/A,Nov-11,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,Global,Sales,96.95933723,116.7283381,98.76095102,75.84406621,54.67690002,51.0992,49.25008244,40.27088898,38.64664233,37.05612631,36.57391191,36.26300235,-5.697574163,1529,Allergic Rhinitis,7/7/14 12:28
485,95,Shionogi,Regional & Specialty Pharma,282,Claritin,loratadine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-88,N/A,Nov-11,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1529,Allergic Rhinitis,7/7/14 12:28
485,95,Shionogi,Regional & Specialty Pharma,282,Claritin,loratadine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-88,N/A,Nov-11,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,ROW,Sales,96.95933723,116.7283381,98.76095102,75.84406621,54.67690002,51.0992,49.25008244,40.27088898,38.64664233,37.05612631,36.57391191,36.26300235,-5.697574163,1529,Allergic Rhinitis,7/7/14 12:28
485,95,Shionogi,Regional & Specialty Pharma,282,Claritin,loratadine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-88,N/A,Nov-11,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1529,Allergic Rhinitis,7/7/14 12:28
485,95,Shionogi,Regional & Specialty Pharma,282,Claritin,loratadine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-88,N/A,Nov-11,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1529,Allergic Rhinitis,7/7/14 12:28
486,76,Pfizer,Large Pharma,846,Cleocin,clindamycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-92,Expired,Expired,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1397,,7/7/14 12:28
486,76,Pfizer,Large Pharma,846,Cleocin,clindamycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-92,Expired,Expired,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,229,214,192,232,198.85,193.7225,190.654625,185.4746562,182.4575941,179.867587,177.5107627,175.4903882,-1.769393008,1397,,7/7/14 12:28
486,76,Pfizer,Large Pharma,846,Cleocin,clindamycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-92,Expired,Expired,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1397,,7/7/14 12:28
486,76,Pfizer,Large Pharma,846,Cleocin,clindamycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-92,Expired,Expired,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,155,149,143,142,138.85,136.0825,133.806625,131.4682562,129.3033541,127.288131,125.3758507,123.5815319,-1.650414383,1397,,7/7/14 12:28
486,76,Pfizer,Large Pharma,846,Cleocin,clindamycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-92,Expired,Expired,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1397,,7/7/14 12:28
486,76,Pfizer,Large Pharma,846,Cleocin,clindamycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-92,Expired,Expired,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,74,65,49,90,60,57.64,56.848,54.0064,53.15424,52.579456,52.134912,51.90885632,-2.048092875,1397,,7/7/14 12:28
487,103,The Medicines Company,Small Biotech,1217,Cleviprex,clevidipine,Small Molecule (Chemical),Launched,Licensed (Development),Sep-08,Sep-13,Jan-21,N/A,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,3,0.77,0.826,3,4.7,7.7134,10.9149,13.89299,16.86182423,19.53830444,22.06802391,25.13725218,27.06657284,317,Hypertension,7/7/14 12:28
487,103,The Medicines Company,Small Biotech,1217,Cleviprex,clevidipine,Small Molecule (Chemical),Launched,Licensed (Development),Sep-08,Sep-13,Jan-21,N/A,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0.3,1.5,3,4.33332,5.666639231,6.691630942,7.575997661,9,62.56128032,317,Hypertension,7/7/14 12:28
487,103,The Medicines Company,Small Biotech,1217,Cleviprex,clevidipine,Small Molecule (Chemical),Launched,Licensed (Development),Sep-08,Sep-13,Jan-21,N/A,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,3,0.77,0.826,3,4.4,6.2134,7.9149,9.55967,11.195185,12.8466735,14.49202625,16.13725218,20.39964104,317,Hypertension,7/7/14 12:28
488,89,Genzyme,Large Pharma,868,Clolar,clofarabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-05,Sep-06,N/A,Sep-16,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,Global,Proforma,81.98040576,103.9932526,56.62881412,0,0,0,0,0,0,0,0,0,0,1398,Acute Lymphoblastic Leukemia,7/7/14 12:28
488,89,Genzyme,Large Pharma,868,Clolar,clofarabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-05,Sep-06,N/A,Sep-16,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,ROW,Proforma,57.94208339,74.05379388,29.51529189,0,0,0,0,0,0,0,0,0,0,1398,Acute Lymphoblastic Leukemia,7/7/14 12:28
488,89,Genzyme,Large Pharma,868,Clolar,clofarabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-05,Sep-06,N/A,Sep-16,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,US,Proforma,24.03832237,29.93945871,27.11352223,0,0,0,0,0,0,0,0,0,0,1398,Acute Lymphoblastic Leukemia,7/7/14 12:28
488,89,Sanofi,Large Pharma,868,Clolar,clofarabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-05,Sep-06,N/A,Sep-16,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1398,Acute Lymphoblastic Leukemia,7/7/14 12:28
488,89,Sanofi,Large Pharma,868,Clolar,clofarabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-05,Sep-06,N/A,Sep-16,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,Global,Sales,0,0,68.23493143,129.1258336,141.4527163,147.0857224,151.1148514,153.7701936,143.1205462,101.8576315,91.87313556,85.20619377,-6.985331625,1398,Acute Lymphoblastic Leukemia,7/7/14 12:28
488,89,Sanofi,Large Pharma,868,Clolar,clofarabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-05,Sep-06,N/A,Sep-16,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1398,Acute Lymphoblastic Leukemia,7/7/14 12:28
488,89,Sanofi,Large Pharma,868,Clolar,clofarabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-05,Sep-06,N/A,Sep-16,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,ROW,Sales,0,0,59.62792132,90.56769383,98.11311546,101.602524,103.9985873,105.5742536,94.19536764,52.42488526,42.09614409,35.19408197,-13.6242443,1398,Acute Lymphoblastic Leukemia,7/7/14 12:28
488,89,Sanofi,Large Pharma,868,Clolar,clofarabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-05,Sep-06,N/A,Sep-16,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1398,Acute Lymphoblastic Leukemia,7/7/14 12:28
488,89,Sanofi,Large Pharma,868,Clolar,clofarabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-05,Sep-06,N/A,Sep-16,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,US,Sales,0,0,8.607010112,38.55813978,43.33960079,45.48319844,47.11626407,48.19594,48.92517859,49.43274619,49.77699147,50.01211179,2.066757415,1398,Acute Lymphoblastic Leukemia,7/7/14 12:28
491,53,Johnson & Johnson,Large Pharma,4340,sirukumab,sirukumab,Antibody/Antibody Derivative,Phase III,In-House,Sep-16,Sep-16,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,320,Rheumatoid arthritis,7/7/14 12:28
491,53,Johnson & Johnson,Large Pharma,4340,sirukumab,sirukumab,Antibody/Antibody Derivative,Phase III,In-House,Sep-16,Sep-16,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,7.333326,34.22221244,70.88891752,107.5555012,133.5888117,0,320,Rheumatoid arthritis,7/7/14 12:28
491,53,Johnson & Johnson,Large Pharma,4340,sirukumab,sirukumab,Antibody/Antibody Derivative,Phase III,In-House,Sep-16,Sep-16,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,320,Rheumatoid arthritis,7/7/14 12:28
491,53,Johnson & Johnson,Large Pharma,4340,sirukumab,sirukumab,Antibody/Antibody Derivative,Phase III,In-House,Sep-16,Sep-16,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,3.999996,18.66666133,38.66668229,58.66663703,72.86662457,0,320,Rheumatoid arthritis,7/7/14 12:28
491,53,Johnson & Johnson,Large Pharma,4340,sirukumab,sirukumab,Antibody/Antibody Derivative,Phase III,In-House,Sep-16,Sep-16,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,320,Rheumatoid arthritis,7/7/14 12:28
491,53,Johnson & Johnson,Large Pharma,4340,sirukumab,sirukumab,Antibody/Antibody Derivative,Phase III,In-House,Sep-16,Sep-16,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,3.33333,15.55555111,32.22223524,48.88886419,60.72218715,0,320,Rheumatoid arthritis,7/7/14 12:28
492,53,Johnson & Johnson,Large Pharma,3448,Sylvant,siltuximab,Antibody/Antibody Derivative,Approved,Corporate Acquisition,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,321,Multicentric Castlemans Disease,7/7/14 12:28
492,53,Johnson & Johnson,Large Pharma,3448,Sylvant,siltuximab,Antibody/Antibody Derivative,Approved,Corporate Acquisition,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,321,Multicentric Castlemans Disease,7/7/14 12:28
492,53,Johnson & Johnson,Large Pharma,3448,Sylvant,siltuximab,Antibody/Antibody Derivative,Approved,Corporate Acquisition,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,321,Multicentric Castlemans Disease,7/7/14 12:28
492,53,Johnson & Johnson,Large Pharma,3448,Sylvant,siltuximab,Antibody/Antibody Derivative,Approved,Corporate Acquisition,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,321,Multicentric Castlemans Disease,7/7/14 12:28
492,53,Johnson & Johnson,Large Pharma,3448,Sylvant,siltuximab,Antibody/Antibody Derivative,Approved,Corporate Acquisition,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,321,Multicentric Castlemans Disease,7/7/14 12:28
492,53,Johnson & Johnson,Large Pharma,3448,Sylvant,siltuximab,Antibody/Antibody Derivative,Approved,Corporate Acquisition,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,321,Multicentric Castlemans Disease,7/7/14 12:28
494,2023,AnGes MG,Regional & Specialty Pharma,15,Collategene,beperminogene perplasmid,Gene Therapy,Phase III,In-House,Jan-19,Jan-19,N/A,N/A,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,325,Peripheral Arterial Disease,7/7/14 12:28
494,2023,AnGes MG,Regional & Specialty Pharma,15,Collategene,beperminogene perplasmid,Gene Therapy,Phase III,In-House,Jan-19,Jan-19,N/A,N/A,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,71.74275124,119.5714912,0,325,Peripheral Arterial Disease,7/7/14 12:28
494,2023,AnGes MG,Regional & Specialty Pharma,15,Collategene,beperminogene perplasmid,Gene Therapy,Phase III,In-House,Jan-19,Jan-19,N/A,N/A,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,325,Peripheral Arterial Disease,7/7/14 12:28
494,2023,AnGes MG,Regional & Specialty Pharma,15,Collategene,beperminogene perplasmid,Gene Therapy,Phase III,In-House,Jan-19,Jan-19,N/A,N/A,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,20.49792893,34.1632832,0,325,Peripheral Arterial Disease,7/7/14 12:28
494,2023,AnGes MG,Regional & Specialty Pharma,15,Collategene,beperminogene perplasmid,Gene Therapy,Phase III,In-House,Jan-19,Jan-19,N/A,N/A,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,325,Peripheral Arterial Disease,7/7/14 12:28
494,2023,AnGes MG,Regional & Specialty Pharma,15,Collategene,beperminogene perplasmid,Gene Therapy,Phase III,In-House,Jan-19,Jan-19,N/A,N/A,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,US,Sales,0,0,0,0,0,0,0,0,0,0,51.24482231,85.408208,0,325,Peripheral Arterial Disease,7/7/14 12:28
495,23,Boehringer Ingelheim,Large Pharma,967,Combivent,salbutamol + ipratropium bromide,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-94,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,326,COPD,7/7/14 12:28
495,23,Boehringer Ingelheim,Large Pharma,967,Combivent,salbutamol + ipratropium bromide,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-94,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,Global,Sales,908.7319553,963.0967468,1065.074771,1134.894581,1230.561167,1307.220142,1359.989667,1389.041402,1412.344018,1430.393405,1444.661255,1456.189196,2.434188737,326,COPD,7/7/14 12:28
495,23,Boehringer Ingelheim,Large Pharma,967,Combivent,salbutamol + ipratropium bromide,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-94,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,326,COPD,7/7/14 12:28
495,23,Boehringer Ingelheim,Large Pharma,967,Combivent,salbutamol + ipratropium bromide,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-94,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,250.1097125,254.3529235,279.4778445,284.0449631,325.3673663,374.0619792,407.8856302,427.3486949,443.8486348,457.7597367,469.5099393,479.4287173,5.693914648,326,COPD,7/7/14 12:28
495,23,Boehringer Ingelheim,Large Pharma,967,Combivent,salbutamol + ipratropium bromide,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-94,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,326,COPD,7/7/14 12:28
495,23,Boehringer Ingelheim,Large Pharma,967,Combivent,salbutamol + ipratropium bromide,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-94,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,US,Sales,658.6222429,708.7438233,785.5969262,850.8496179,905.1938002,933.1581624,952.1040371,961.6927067,968.4953828,972.633668,975.1513154,976.7604787,1.092962833,326,COPD,7/7/14 12:28
496,46,GlaxoSmithKline,Large Pharma,368,Combivir,zidovudine  +  lamivudine,Small Molecule (Chemical),Launched,Acquisition (Development),Jul-97,Jul-98,Dec-11,Jul-13,104,NRTIs,32,HIV,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,327,HIV,7/7/14 12:28
496,46,GlaxoSmithKline,Large Pharma,368,Combivir,zidovudine  +  lamivudine,Small Molecule (Chemical),Launched,Acquisition (Development),Jul-97,Jul-98,Dec-11,Jul-13,104,NRTIs,32,HIV,7,Anti-infectives,4,Global,Sales,662.6862181,560.835021,516.2241888,283.7201684,181.3560273,105.1802421,85.73293506,73.8049459,67.48974991,63.21817193,60.2110694,59.63244577,-14.6913605,327,HIV,7/7/14 12:28
496,46,GlaxoSmithKline,Large Pharma,368,Combivir,zidovudine  +  lamivudine,Small Molecule (Chemical),Launched,Acquisition (Development),Jul-97,Jul-98,Dec-11,Jul-13,104,NRTIs,32,HIV,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,327,HIV,7/7/14 12:28
496,46,GlaxoSmithKline,Large Pharma,368,Combivir,zidovudine  +  lamivudine,Small Molecule (Chemical),Launched,Acquisition (Development),Jul-97,Jul-98,Dec-11,Jul-13,104,NRTIs,32,HIV,7,Anti-infectives,4,ROW,Sales,371.1042821,339.9000127,312.6202386,245.6794755,126.6365363,54.93211529,38.41308267,26.42169708,20.28060678,16.07439768,13.07451884,12.50169957,-28.16362079,327,HIV,7/7/14 12:28
496,46,GlaxoSmithKline,Large Pharma,368,Combivir,zidovudine  +  lamivudine,Small Molecule (Chemical),Launched,Acquisition (Development),Jul-97,Jul-98,Dec-11,Jul-13,104,NRTIs,32,HIV,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,327,HIV,7/7/14 12:28
496,46,GlaxoSmithKline,Large Pharma,368,Combivir,zidovudine  +  lamivudine,Small Molecule (Chemical),Launched,Acquisition (Development),Jul-97,Jul-98,Dec-11,Jul-13,104,NRTIs,32,HIV,7,Anti-infectives,4,US,Sales,291.581936,220.9350083,203.6039502,38.04069297,54.71949098,50.24812686,47.31985239,47.38324883,47.20914313,47.14377425,47.13655056,47.1307462,-2.11019216,327,HIV,7/7/14 12:28
499,67,Novartis,Large Pharma,1174,Comtan / Stalevo,entacapone,Small Molecule (Chemical),Launched,Licensed (Development),Jan-99,Jul-98,Apr-12,Jun-16,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1443,Parkinson's Disease,7/7/14 12:28
499,67,Novartis,Large Pharma,1174,Comtan / Stalevo,entacapone,Small Molecule (Chemical),Launched,Licensed (Development),Jan-99,Jul-98,Apr-12,Jun-16,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,554.3825,600,614,530,401,309,119.2,75.7435,51.2196,37.0316,29.3424,23.8474,-33.18104205,1443,Parkinson's Disease,7/7/14 12:28
499,67,Novartis,Large Pharma,1174,Comtan / Stalevo,entacapone,Small Molecule (Chemical),Launched,Licensed (Development),Jan-99,Jul-98,Apr-12,Jun-16,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1443,Parkinson's Disease,7/7/14 12:28
499,67,Novartis,Large Pharma,1174,Comtan / Stalevo,entacapone,Small Molecule (Chemical),Launched,Licensed (Development),Jan-99,Jul-98,Apr-12,Jun-16,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,337.2625,369,400,383,368,296,112.2,71.7435,48.2196,35.0316,27.3424,21.8474,-33.19740863,1443,Parkinson's Disease,7/7/14 12:28
499,67,Novartis,Large Pharma,1174,Comtan / Stalevo,entacapone,Small Molecule (Chemical),Launched,Licensed (Development),Jan-99,Jul-98,Apr-12,Jun-16,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1443,Parkinson's Disease,7/7/14 12:28
499,67,Novartis,Large Pharma,1174,Comtan / Stalevo,entacapone,Small Molecule (Chemical),Launched,Licensed (Development),Jan-99,Jul-98,Apr-12,Jun-16,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,217.12,231,214,147,33,13,7,4,3,2,2,2,-33.00013985,1443,Parkinson's Disease,7/7/14 12:28
500,72,Orion,Regional & Specialty Pharma,1174,Comtan / Stalevo,entacapone,Small Molecule (Chemical),Launched,In-House,,Jul-98,N/A,Nov-13,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,2,Global,Sales,134.9202949,132.475481,133.4819556,125.95659,122.1787661,102.9223302,39.04408396,25.8965863,19.25643597,15.40514877,12.74908864,10.35863452,-29.70877355,1443,Parkinson's Disease,7/7/14 12:28
500,72,Orion,Regional & Specialty Pharma,1174,Comtan / Stalevo,entacapone,Small Molecule (Chemical),Launched,In-House,,Jul-98,N/A,Nov-13,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,2,ROW,Sales,134.9202949,132.475481,133.4819556,125.95659,122.1787661,102.9223302,39.04408396,25.8965863,19.25643597,15.40514877,12.74908864,10.35863452,-29.70877355,1443,Parkinson's Disease,7/7/14 12:28
500,72,Orion,Regional & Specialty Pharma,1174,Comtan / Stalevo,entacapone,Small Molecule (Chemical),Launched,In-House,,Jul-98,N/A,Nov-13,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1443,Parkinson's Disease,7/7/14 12:28
501,53,Johnson & Johnson,Large Pharma,1392,Concerta,methylphenidate CR,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-00,Feb-02,May-11,May-19,121,Stimulants,37,ADHD,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1726,ADHD,7/7/14 12:28
501,53,Johnson & Johnson,Large Pharma,1392,Concerta,methylphenidate CR,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-00,Feb-02,May-11,May-19,121,Stimulants,37,ADHD,12,Central Nervous System,6,Global,Sales,1326,1319,1268,1073,782,674.56,634.248,620.8712,617.8996,618.239016,440.5886229,261.6807373,-14.47742227,1726,ADHD,7/7/14 12:28
501,53,Johnson & Johnson,Large Pharma,1392,Concerta,methylphenidate CR,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-00,Feb-02,May-11,May-19,121,Stimulants,37,ADHD,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1726,ADHD,7/7/14 12:28
501,53,Johnson & Johnson,Large Pharma,1392,Concerta,methylphenidate CR,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-00,Feb-02,May-11,May-19,121,Stimulants,37,ADHD,12,Central Nervous System,6,ROW,Sales,340,390,446,464,474,486.96,494.808,500.6952,505.4292,508.850856,332.4333589,154.0186317,-14.8359146,1726,ADHD,7/7/14 12:28
501,53,Johnson & Johnson,Large Pharma,1392,Concerta,methylphenidate CR,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-00,Feb-02,May-11,May-19,121,Stimulants,37,ADHD,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1726,ADHD,7/7/14 12:28
501,53,Johnson & Johnson,Large Pharma,1392,Concerta,methylphenidate CR,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-00,Feb-02,May-11,May-19,121,Stimulants,37,ADHD,12,Central Nervous System,6,US,Sales,986,929,822,609,308,187.6,139.44,120.176,112.4704,109.38816,108.155264,107.6621056,-13.94273975,1726,ADHD,7/7/14 12:28
502,63,Merck KGaA,Regional & Specialty Pharma,1608,Concor,bisoprolol,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-86,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1364,Hypertension,7/7/14 12:28
502,63,Merck KGaA,Regional & Specialty Pharma,1608,Concor,bisoprolol,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-86,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,Global,Sales,573.8628403,494.7959215,552.420635,488.4031039,533.1775111,535.9775297,536.5346012,538.4587332,538.8140891,538.9913898,539.1423431,539.1863788,0.160226453,1364,Hypertension,7/7/14 12:28
502,63,Merck KGaA,Regional & Specialty Pharma,1608,Concor,bisoprolol,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-86,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1364,Hypertension,7/7/14 12:28
502,63,Merck KGaA,Regional & Specialty Pharma,1608,Concor,bisoprolol,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-86,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,573.8628403,494.7959215,552.420635,488.4031039,533.1775111,535.9775297,536.5346012,538.4587332,538.8140891,538.9913898,539.1423431,539.1863788,0.160226453,1364,Hypertension,7/7/14 12:28
502,63,Merck KGaA,Regional & Specialty Pharma,1608,Concor,bisoprolol,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-86,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1364,Hypertension,7/7/14 12:28
502,63,Merck KGaA,Regional & Specialty Pharma,1608,Concor,bisoprolol,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-86,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1364,Hypertension,7/7/14 12:28
503,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,703,Coniel,benidipine,Small Molecule (Chemical),Launched,In-House,,Nov-91,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,329,Hypertension,7/7/14 12:28
503,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,703,Coniel,benidipine,Small Molecule (Chemical),Launched,In-House,,Nov-91,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,3,Global,Sales,238.324886,234.6488151,247.1022453,214.232022,158.8589492,146.5601918,137.3361238,130.4180728,125.2295345,121.3381308,118.4195781,116.2306635,-4.365278979,329,Hypertension,7/7/14 12:28
503,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,703,Coniel,benidipine,Small Molecule (Chemical),Launched,In-House,,Nov-91,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,329,Hypertension,7/7/14 12:28
503,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,703,Coniel,benidipine,Small Molecule (Chemical),Launched,In-House,,Nov-91,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,3,ROW,Sales,238.324886,234.6488151,247.1022453,214.232022,158.8589492,146.5601918,137.3361238,130.4180728,125.2295345,121.3381308,118.4195781,116.2306635,-4.365278979,329,Hypertension,7/7/14 12:28
503,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,703,Coniel,benidipine,Small Molecule (Chemical),Launched,In-House,,Nov-91,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,329,Hypertension,7/7/14 12:28
503,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,703,Coniel,benidipine,Small Molecule (Chemical),Launched,In-House,,Nov-91,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,329,Hypertension,7/7/14 12:28
504,53,Johnson & Johnson,Large Pharma,3291,Contraceptive brands - J&J,contraceptives,Small Molecule (Chemical),Launched,In-House,Jan-63,Jan-63,Dec-03,Dec-03,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1404,Female contraception,7/7/14 12:28
504,53,Johnson & Johnson,Large Pharma,3291,Contraceptive brands - J&J,contraceptives,Small Molecule (Chemical),Launched,In-House,Jan-63,Jan-63,Dec-03,Dec-03,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,561.98,489.5245,426.463125,365.9101562,314.9613587,269.9593072,230.0423002,161.9226455,132.3911693,109.1177627,92.35512223,76.63615367,-18.28326511,1404,Female contraception,7/7/14 12:28
504,53,Johnson & Johnson,Large Pharma,3291,Contraceptive brands - J&J,contraceptives,Small Molecule (Chemical),Launched,In-House,Jan-63,Jan-63,Dec-03,Dec-03,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1404,Female contraception,7/7/14 12:28
504,53,Johnson & Johnson,Large Pharma,3291,Contraceptive brands - J&J,contraceptives,Small Molecule (Chemical),Launched,In-House,Jan-63,Jan-63,Dec-03,Dec-03,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,220.33,213.662,202,170,153.33424,137.122016,121.517344,108.7180198,97.25921306,87.10710502,78.24825632,70.43480182,-10.51803788,1404,Female contraception,7/7/14 12:28
504,53,Johnson & Johnson,Large Pharma,3291,Contraceptive brands - J&J,contraceptives,Small Molecule (Chemical),Launched,In-House,Jan-63,Jan-63,Dec-03,Dec-03,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1404,Female contraception,7/7/14 12:28
504,53,Johnson & Johnson,Large Pharma,3291,Contraceptive brands - J&J,contraceptives,Small Molecule (Chemical),Launched,In-House,Jan-63,Jan-63,Dec-03,Dec-03,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,341.65,275.8625,224.463125,195.9101562,161.6271187,132.8372912,108.5249562,53.20462563,35.13195624,22.01065771,14.10686592,6.201351848,-37.23601524,1404,Female contraception,7/7/14 12:28
505,76,Pfizer,Large Pharma,3292,Contraceptive brands - Pfizer,contraceptives,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-75,Jan-75,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3348,Female contraception,7/7/14 12:28
505,76,Pfizer,Large Pharma,3292,Contraceptive brands - Pfizer,contraceptives,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-75,Jan-75,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,47.14438,326.513794,301.5647306,271.1781357,247.0116901,227.3459445,210.5714161,196.4639059,184.6235846,174.6550308,166.2607191,159.1908742,-6.08326657,3348,Female contraception,7/7/14 12:28
505,76,Pfizer,Large Pharma,3292,Contraceptive brands - Pfizer,contraceptives,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-75,Jan-75,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3348,Female contraception,7/7/14 12:28
505,76,Pfizer,Large Pharma,3292,Contraceptive brands - Pfizer,contraceptives,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-75,Jan-75,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,39.649,295.88084,274.593336,247,224.8721039,206.7997832,191.2557994,178.0916324,166.9772612,157.5674116,149.6028247,142.8635515,-6.275064362,3348,Female contraception,7/7/14 12:28
505,76,Pfizer,Large Pharma,3292,Contraceptive brands - Pfizer,contraceptives,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-75,Jan-75,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3348,Female contraception,7/7/14 12:28
505,76,Pfizer,Large Pharma,3292,Contraceptive brands - Pfizer,contraceptives,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-75,Jan-75,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,7.49538,30.632954,26.9713946,24.1781357,22.13958622,20.54616123,19.31561665,18.37227347,17.64632342,17.08761925,16.65789438,16.32732266,-4.257113771,3348,Female contraception,7/7/14 12:28
505,76,Wyeth,Large Pharma,3292,Contraceptive brands - Pfizer,contraceptives,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-75,Jan-75,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Proforma,305.9,0,0,0,0,0,0,0,0,0,0,0,0,3348,Female contraception,7/7/14 12:28
505,76,Wyeth,Large Pharma,3292,Contraceptive brands - Pfizer,contraceptives,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-75,Jan-75,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Proforma,278.25,0,0,0,0,0,0,0,0,0,0,0,0,3348,Female contraception,7/7/14 12:28
505,76,Wyeth,Large Pharma,3292,Contraceptive brands - Pfizer,contraceptives,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-75,Jan-75,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Proforma,27.65,0,0,0,0,0,0,0,0,0,0,0,0,3348,Female contraception,7/7/14 12:28
506,100,Takeda,Large Pharma,141,Contrave,naltrexone + bupropion,Small Molecule (Chemical),Filed,In-House,Nov-14,Mar-15,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,330,Obesity,7/7/14 12:28
506,100,Takeda,Large Pharma,141,Contrave,naltrexone + bupropion,Small Molecule (Chemical),Filed,In-House,Nov-14,Mar-15,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,7,Global,Sales,0,0,0,0,0,23.49136768,117.1773099,221.2109478,325.2449624,382.8215093,428.882215,464.4913131,0,330,Obesity,7/7/14 12:28
506,100,Takeda,Large Pharma,141,Contrave,naltrexone + bupropion,Small Molecule (Chemical),Filed,In-House,Nov-14,Mar-15,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,330,Obesity,7/7/14 12:28
506,100,Takeda,Large Pharma,141,Contrave,naltrexone + bupropion,Small Molecule (Chemical),Filed,In-House,Nov-14,Mar-15,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,7,ROW,Sales,0,0,0,0,0,2.516929555,31.88119159,52.01671457,72.15238478,89.73746031,104.825735,118.3031703,0,330,Obesity,7/7/14 12:28
506,100,Takeda,Large Pharma,141,Contrave,naltrexone + bupropion,Small Molecule (Chemical),Filed,In-House,Nov-14,Mar-15,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,330,Obesity,7/7/14 12:28
506,100,Takeda,Large Pharma,141,Contrave,naltrexone + bupropion,Small Molecule (Chemical),Filed,In-House,Nov-14,Mar-15,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,7,US,Sales,0,0,0,0,0,20.97443812,85.29611828,169.1942332,253.0925776,293.084049,324.0564799,346.1881428,0,330,Obesity,7/7/14 12:28
507,89,Sanofi,Large Pharma,398,Copaxone,glatiramer acetate,Synthetic Peptide,Launched,Corporate Acquisition,Mar-97,Dec-96,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1484,Multiple Sclerosis,7/7/14 12:28
507,89,Sanofi,Large Pharma,398,Copaxone,glatiramer acetate,Synthetic Peptide,Launched,Corporate Acquisition,Mar-97,Dec-96,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Sales,648.895754,679.5992175,606.2305484,31.12208068,0,0,0,0,0,0,0,0,0,1484,Multiple Sclerosis,7/7/14 12:28
507,89,Sanofi,Large Pharma,398,Copaxone,glatiramer acetate,Synthetic Peptide,Launched,Corporate Acquisition,Mar-97,Dec-96,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1484,Multiple Sclerosis,7/7/14 12:28
507,89,Sanofi,Large Pharma,398,Copaxone,glatiramer acetate,Synthetic Peptide,Launched,Corporate Acquisition,Mar-97,Dec-96,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Sales,648.895754,679.5992175,606.2305484,31.12208068,0,0,0,0,0,0,0,0,0,1484,Multiple Sclerosis,7/7/14 12:28
507,89,Sanofi,Large Pharma,398,Copaxone,glatiramer acetate,Synthetic Peptide,Launched,Corporate Acquisition,Mar-97,Dec-96,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1484,Multiple Sclerosis,7/7/14 12:28
507,89,Sanofi,Large Pharma,398,Copaxone,glatiramer acetate,Synthetic Peptide,Launched,Corporate Acquisition,Mar-97,Dec-96,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1484,Multiple Sclerosis,7/7/14 12:28
508,102,Teva,Regional & Specialty Pharma,398,Copaxone,glatiramer acetate,Synthetic Peptide,Launched,In-House,Mar-97,Dec-96,May-15,May-15,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Alliance Revenue,309,322,287,15,0,0,0,0,0,0,0,0,0,1484,Multiple Sclerosis,7/7/14 12:28
508,102,Teva,Regional & Specialty Pharma,398,Copaxone,glatiramer acetate,Synthetic Peptide,Launched,In-House,Mar-97,Dec-96,May-15,May-15,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,2177,2636,3283,3981,4328,4598.1909,4252.079448,3887.104237,3734.179778,3621.670672,3451.849273,3337.49406,-3.644569832,1484,Multiple Sclerosis,7/7/14 12:28
508,102,Teva,Regional & Specialty Pharma,398,Copaxone,glatiramer acetate,Synthetic Peptide,Launched,In-House,Mar-97,Dec-96,May-15,May-15,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Alliance Revenue,309,322,287,15,0,0,0,0,0,0,0,0,0,1484,Multiple Sclerosis,7/7/14 12:28
508,102,Teva,Regional & Specialty Pharma,398,Copaxone,glatiramer acetate,Synthetic Peptide,Launched,In-House,Mar-97,Dec-96,May-15,May-15,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,260,595,713,1104,1102,1123.7589,1052.542173,966.5654878,918.2437933,867.7294604,833.4443979,804.498916,-4.395636368,1484,Multiple Sclerosis,7/7/14 12:28
508,102,Teva,Regional & Specialty Pharma,398,Copaxone,glatiramer acetate,Synthetic Peptide,Launched,In-House,Mar-97,Dec-96,May-15,May-15,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1484,Multiple Sclerosis,7/7/14 12:28
508,102,Teva,Regional & Specialty Pharma,398,Copaxone,glatiramer acetate,Synthetic Peptide,Launched,In-House,Mar-97,Dec-96,May-15,May-15,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,1917,2041,2570,2877,3226,3474.432,3199.537275,2920.538749,2815.935984,2753.941212,2618.404875,2532.995144,-3.395862263,1484,Multiple Sclerosis,7/7/14 12:28
509,86,Roche,Large Pharma,1510,Copegus,ribavirin,Small Molecule (Chemical),Launched,In-House,Jan-03,Jul-03,Expired,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1617,Hepatitis C,7/7/14 12:28
509,86,Roche,Large Pharma,1510,Copegus,ribavirin,Small Molecule (Chemical),Launched,In-House,Jan-03,Jul-03,Expired,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,5,Global,Sales,218.0361193,194.2875968,163.1034919,127.4222949,98.0210564,83.58093431,73.87624175,66.55711863,61.12721384,57.12835254,54.09986562,51.83035977,-8.700910612,1617,Hepatitis C,7/7/14 12:28
509,86,Roche,Large Pharma,1510,Copegus,ribavirin,Small Molecule (Chemical),Launched,In-House,Jan-03,Jul-03,Expired,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1617,Hepatitis C,7/7/14 12:28
509,86,Roche,Large Pharma,1510,Copegus,ribavirin,Small Molecule (Chemical),Launched,In-House,Jan-03,Jul-03,Expired,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,5,ROW,Sales,212.6187265,189.1107719,158.1001688,122.4554036,93.06889682,78.63744631,68.93175213,61.61346973,56.18365765,52.18480127,49.15632427,46.88681967,-9.329964296,1617,Hepatitis C,7/7/14 12:28
509,86,Roche,Large Pharma,1510,Copegus,ribavirin,Small Molecule (Chemical),Launched,In-House,Jan-03,Jul-03,Expired,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1617,Hepatitis C,7/7/14 12:28
509,86,Roche,Large Pharma,1510,Copegus,ribavirin,Small Molecule (Chemical),Launched,In-House,Jan-03,Jul-03,Expired,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,5,US,Sales,5.417392748,5.176824875,5.0033231,4.966891348,4.952159572,4.943487999,4.944489629,4.943648897,4.943556187,4.943551275,4.943541354,4.943540105,-2.49E-02,1617,Hepatitis C,7/7/14 12:28
510,89,Sanofi,Large Pharma,55,Cordarone ,amiodarone,Small Molecule (Chemical),Launched,In-House,,Jul-67,N/A,Expired,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,331,Atrial fibrillation,7/7/14 12:28
510,89,Sanofi,Large Pharma,55,Cordarone ,amiodarone,Small Molecule (Chemical),Launched,In-House,,Jul-67,N/A,Expired,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,Global,Sales,181.9690462,193.4142023,177.9759408,181.2232571,187.2522394,187.2522394,187.2522394,187.2522394,187.2522394,187.2522394,187.2522394,187.2522394,0,331,Atrial fibrillation,7/7/14 12:28
510,89,Sanofi,Large Pharma,55,Cordarone ,amiodarone,Small Molecule (Chemical),Launched,In-House,,Jul-67,N/A,Expired,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,331,Atrial fibrillation,7/7/14 12:28
510,89,Sanofi,Large Pharma,55,Cordarone ,amiodarone,Small Molecule (Chemical),Launched,In-House,,Jul-67,N/A,Expired,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,ROW,Sales,181.9690462,193.4142023,177.9759408,181.2232571,187.2522394,187.2522394,187.2522394,187.2522394,187.2522394,187.2522394,187.2522394,187.2522394,0,331,Atrial fibrillation,7/7/14 12:28
510,89,Sanofi,Large Pharma,55,Cordarone ,amiodarone,Small Molecule (Chemical),Launched,In-House,,Jul-67,N/A,Expired,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,331,Atrial fibrillation,7/7/14 12:28
510,89,Sanofi,Large Pharma,55,Cordarone ,amiodarone,Small Molecule (Chemical),Launched,In-House,,Jul-67,N/A,Expired,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,331,Atrial fibrillation,7/7/14 12:28
511,46,GlaxoSmithKline,Large Pharma,1165,Coreg,carvedilol,Small Molecule (Chemical),Launched,Licensed (Development),Mar-97,Jan-96,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1382,Hypertension,7/7/14 12:28
511,46,GlaxoSmithKline,Large Pharma,1165,Coreg,carvedilol,Small Molecule (Chemical),Launched,Licensed (Development),Mar-97,Jan-96,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,4,Global,Sales,268.1930106,263.8393695,247.9888827,210.3046764,204.3215579,194.9418892,186.8124337,72.02036214,14.60080169,13.93361317,13.26658351,12.59952158,-32.83411759,1382,Hypertension,7/7/14 12:28
511,46,GlaxoSmithKline,Large Pharma,1165,Coreg,carvedilol,Small Molecule (Chemical),Launched,Licensed (Development),Mar-97,Jan-96,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1382,Hypertension,7/7/14 12:28
511,46,GlaxoSmithKline,Large Pharma,1165,Coreg,carvedilol,Small Molecule (Chemical),Launched,Licensed (Development),Mar-97,Jan-96,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,4,ROW,Sales,1.55926169,1.189359697,1.099053297,1.080865074,1.07773423,1.078549613,1.078847019,1.078887119,1.078896275,1.07889781,1.078898115,1.078898171,1.54E-02,1382,Hypertension,7/7/14 12:28
511,46,GlaxoSmithKline,Large Pharma,1165,Coreg,carvedilol,Small Molecule (Chemical),Launched,Licensed (Development),Mar-97,Jan-96,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1382,Hypertension,7/7/14 12:28
511,46,GlaxoSmithKline,Large Pharma,1165,Coreg,carvedilol,Small Molecule (Chemical),Launched,Licensed (Development),Mar-97,Jan-96,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,4,US,Sales,266.6337489,262.6500098,246.8898294,209.2238114,203.2438236,193.8633395,185.7335867,70.94147502,13.52190541,12.85471536,12.18768539,11.52062341,-33.63748468,1382,Hypertension,7/7/14 12:28
512,61,Merck & Co,Large Pharma,3072,Elonva,corifollitropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Oct-14,Mar-10,N/A,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,332,Female infertility,7/7/14 12:28
512,61,Merck & Co,Large Pharma,3072,Elonva,corifollitropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Oct-14,Mar-10,N/A,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,Global,Sales,0,18,51.60006,87.59987386,123.599918,155.9639028,204.7663057,242.4836452,276.6393812,303.3468665,325.1476185,335,15.30838367,332,Female infertility,7/7/14 12:28
512,61,Merck & Co,Large Pharma,3072,Elonva,corifollitropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Oct-14,Mar-10,N/A,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,332,Female infertility,7/7/14 12:28
512,61,Merck & Co,Large Pharma,3072,Elonva,corifollitropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Oct-14,Mar-10,N/A,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,ROW,Sales,0,18,51.60006,87.59987386,123.599918,148.4639028,169.7662807,187.4835559,201.6390595,213.2964464,222.8296061,226,9.003747178,332,Female infertility,7/7/14 12:28
512,61,Merck & Co,Large Pharma,3072,Elonva,corifollitropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Oct-14,Mar-10,N/A,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,332,Female infertility,7/7/14 12:28
512,61,Merck & Co,Large Pharma,3072,Elonva,corifollitropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Oct-14,Mar-10,N/A,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,US,Sales,0,0,0,0,0,7.5,35.000025,55.00008929,75.00032175,90.05042012,102.3180124,109,0,332,Female infertility,7/7/14 12:28
513,24,Bristol-Myers Squibb,Large Pharma,357,Coumadin,warfarin,Synthetic Peptide,Launched,Corporate Acquisition,Jan-54,Jan-54,Expired,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,333,Thrombosis,7/7/14 12:28
513,24,Bristol-Myers Squibb,Large Pharma,357,Coumadin,warfarin,Synthetic Peptide,Launched,Corporate Acquisition,Jan-54,Jan-54,Expired,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,189.08,181.552,174.676,168.13106,161.7384705,155.7860878,150.2408244,145.0938691,140.3533828,135.9966189,132.0018412,128.3466249,-3.249541552,333,Thrombosis,7/7/14 12:28
513,24,Bristol-Myers Squibb,Large Pharma,357,Coumadin,warfarin,Synthetic Peptide,Launched,Corporate Acquisition,Jan-54,Jan-54,Expired,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,333,Thrombosis,7/7/14 12:28
513,24,Bristol-Myers Squibb,Large Pharma,357,Coumadin,warfarin,Synthetic Peptide,Launched,Corporate Acquisition,Jan-54,Jan-54,Expired,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,46.2,48.72,50.48,51.718,52.5435,53.111575,53.50121875,53.76639094,53.94793805,54.07206503,54.15684606,54.21481507,0.448327461,333,Thrombosis,7/7/14 12:28
513,24,Bristol-Myers Squibb,Large Pharma,357,Coumadin,warfarin,Synthetic Peptide,Launched,Corporate Acquisition,Jan-54,Jan-54,Expired,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,333,Thrombosis,7/7/14 12:28
513,24,Bristol-Myers Squibb,Large Pharma,357,Coumadin,warfarin,Synthetic Peptide,Launched,Corporate Acquisition,Jan-54,Jan-54,Expired,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,142.88,132.832,124.196,116.41306,109.1949705,102.6745128,96.7396056,91.32747812,86.4054448,81.92455391,77.84499512,74.13180979,-5.382442309,333,Thrombosis,7/7/14 12:28
515,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,963,Coversyl ,perindopril,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Apr-98,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,334,Hypertension,7/7/14 12:28
515,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,963,Coversyl ,perindopril,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Apr-98,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,3,Global,Sales,49.16118724,47.86006628,48.91871862,43.84865948,34.84647917,33.43212208,32.33138329,31.62358981,31.04339593,30.60984628,30.29041127,30.04691857,-2.094774635,334,Hypertension,7/7/14 12:28
515,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,963,Coversyl ,perindopril,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Apr-98,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,334,Hypertension,7/7/14 12:28
515,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,963,Coversyl ,perindopril,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Apr-98,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,3,ROW,Sales,49.16118724,47.86006628,48.91871862,43.84865948,34.84647917,33.43212208,32.33138329,31.62358981,31.04339593,30.60984628,30.29041127,30.04691857,-2.094774635,334,Hypertension,7/7/14 12:28
515,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,963,Coversyl ,perindopril,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Apr-98,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,334,Hypertension,7/7/14 12:28
515,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,963,Coversyl ,perindopril,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Apr-98,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,334,Hypertension,7/7/14 12:28
516,61,Merck & Co,Large Pharma,1112,Cozaar / Hyzaar,losartan,Small Molecule (Chemical),Launched,In-House,Dec-95,Oct-95,Apr-10,Mar-10,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,335,,7/7/14 12:28
516,61,Merck & Co,Large Pharma,1112,Cozaar / Hyzaar,losartan,Small Molecule (Chemical),Launched,In-House,Dec-95,Oct-95,Apr-10,Mar-10,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,3561,2105,1662,1284,1006,916.63,821.1789,750.624467,693.975212,649.4049607,614.1655171,586.3363654,-7.422166755,335,,7/7/14 12:28
516,61,Merck & Co,Large Pharma,1112,Cozaar / Hyzaar,losartan,Small Molecule (Chemical),Launched,In-House,Dec-95,Oct-95,Apr-10,Mar-10,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,335,,7/7/14 12:28
516,61,Merck & Co,Large Pharma,1112,Cozaar / Hyzaar,losartan,Small Molecule (Chemical),Launched,In-House,Dec-95,Oct-95,Apr-10,Mar-10,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,2240,1705,1555,1256,971,883,787.45,716.92,660.2695,615.6997,580.460245,552.631102,-7.736291808,335,,7/7/14 12:28
516,61,Merck & Co,Large Pharma,1112,Cozaar / Hyzaar,losartan,Small Molecule (Chemical),Launched,In-House,Dec-95,Oct-95,Apr-10,Mar-10,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,335,,7/7/14 12:28
516,61,Merck & Co,Large Pharma,1112,Cozaar / Hyzaar,losartan,Small Molecule (Chemical),Launched,In-House,Dec-95,Oct-95,Apr-10,Mar-10,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,1321,400,107,28,35,33.63,33.7289,33.704467,33.70571201,33.7052607,33.70527206,33.70526338,-0.537038697,335,,7/7/14 12:28
518,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Phase III,In-House,Oct-15,Oct-15,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1168,Psoriasis,7/7/14 12:28
518,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Phase III,In-House,Oct-15,Oct-15,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,11.25,76.2500375,201.2499136,326.2503213,416.6504606,502.8105944,0,1168,Psoriasis,7/7/14 12:28
518,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Phase III,In-House,Oct-15,Oct-15,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1168,Psoriasis,7/7/14 12:28
518,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Phase III,In-House,Oct-15,Oct-15,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,5,28.33335,61.66668627,94.99999687,120.0666578,143.4266505,0,1168,Psoriasis,7/7/14 12:28
518,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Phase III,In-House,Oct-15,Oct-15,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1168,Psoriasis,7/7/14 12:28
518,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Phase III,In-House,Oct-15,Oct-15,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,6.25,47.9166875,139.5832274,231.2503244,296.5838028,359.3839438,0,1168,Psoriasis,7/7/14 12:28
520,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Launched,In-House,Dec-12,Jul-13,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1168,Rheumatoid Arthritis,7/7/14 12:28
520,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Launched,In-House,Dec-12,Jul-13,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,6,114,280.8759,448.7521559,554.2222266,643.6823554,715.8584835,771.1304202,815.3525668,32.45331116,1168,Rheumatoid Arthritis,7/7/14 12:28
520,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Launched,In-House,Dec-12,Jul-13,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1168,Rheumatoid Arthritis,7/7/14 12:28
520,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Launched,In-House,Dec-12,Jul-13,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,2,4.97398,8.947941321,15.40889183,19.42285955,23.21490857,26.72883252,29.6867287,47.01498252,1168,Rheumatoid Arthritis,7/7/14 12:28
520,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Launched,In-House,Dec-12,Jul-13,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1168,Rheumatoid Arthritis,7/7/14 12:28
520,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Launched,In-House,Dec-12,Jul-13,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,6,112,275.90192,439.8042146,538.8133347,624.2594958,692.6435749,744.4015876,785.6658381,32.08693334,1168,Rheumatoid Arthritis,7/7/14 12:28
525,34,Daiichi-Sankyo,Regional & Specialty Pharma,1551,Cravit,levofloxacin,Small Molecule (Chemical),Launched,In-House,,Dec-93,N/A,May-09,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,387.8373489,326.8393468,102.5594491,51.76658487,40.55903875,40.55903875,40.55903875,40.55903875,40.55903875,40.55903875,40.55903875,40.27088898,-0.101802465,1522,,7/7/14 12:28
525,34,Daiichi-Sankyo,Regional & Specialty Pharma,1551,Cravit,levofloxacin,Small Molecule (Chemical),Launched,In-House,,Dec-93,N/A,May-09,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,552.6682222,479.7534697,559.6453891,432.19079,354.387315,340.9781563,325.6600528,317.8057034,311.083041,305.8142869,302.0810595,299.2059961,-2.388972273,1522,,7/7/14 12:28
525,34,Daiichi-Sankyo,Regional & Specialty Pharma,1551,Cravit,levofloxacin,Small Molecule (Chemical),Launched,In-House,,Dec-93,N/A,May-09,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1522,,7/7/14 12:28
525,34,Daiichi-Sankyo,Regional & Specialty Pharma,1551,Cravit,levofloxacin,Small Molecule (Chemical),Launched,In-House,,Dec-93,N/A,May-09,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,552.6682222,479.7534697,559.6453891,432.19079,354.387315,340.9781563,325.6600528,317.8057034,311.083041,305.8142869,302.0810595,299.2059961,-2.388972273,1522,,7/7/14 12:28
525,34,Daiichi-Sankyo,Regional & Specialty Pharma,1551,Cravit,levofloxacin,Small Molecule (Chemical),Launched,In-House,,Dec-93,N/A,May-09,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,387.8373489,326.8393468,102.5594491,51.76658487,40.55903875,40.55903875,40.55903875,40.55903875,40.55903875,40.55903875,40.55903875,40.27088898,-0.101802465,1522,,7/7/14 12:28
525,34,Daiichi-Sankyo,Regional & Specialty Pharma,1551,Cravit,levofloxacin,Small Molecule (Chemical),Launched,In-House,,Dec-93,N/A,May-09,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1522,,7/7/14 12:28
526,91,Santen,Regional & Specialty Pharma,1551,Cravit,levofloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-00,Apr-00,N/A,Jul-11,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1522,Bacterial Conjunctivitis,7/7/14 12:28
526,91,Santen,Regional & Specialty Pharma,1551,Cravit,levofloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-00,Apr-00,N/A,Jul-11,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,Global,Sales,135.7379222,143.7912683,160.3420015,134.3707887,125.4856204,131.7427096,134.8712541,136.4355264,137.2176626,137.6087307,137.8042647,134.2358505,0.96760979,1522,Bacterial Conjunctivitis,7/7/14 12:28
526,91,Santen,Regional & Specialty Pharma,1551,Cravit,levofloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-00,Apr-00,N/A,Jul-11,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1522,Bacterial Conjunctivitis,7/7/14 12:28
526,91,Santen,Regional & Specialty Pharma,1551,Cravit,levofloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-00,Apr-00,N/A,Jul-11,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,ROW,Sales,131.8646986,140.0740058,156.624739,130.7046074,121.8194392,128.0765283,131.2050729,132.7693452,133.5514813,133.9425494,134.1380834,134.2358505,1.396204177,1522,Bacterial Conjunctivitis,7/7/14 12:28
526,91,Santen,Regional & Specialty Pharma,1551,Cravit,levofloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-00,Apr-00,N/A,Jul-11,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1522,Bacterial Conjunctivitis,7/7/14 12:28
526,91,Santen,Regional & Specialty Pharma,1551,Cravit,levofloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-00,Apr-00,N/A,Jul-11,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,US,Sales,3.873223519,3.717262521,3.717262521,3.666181244,3.666181244,3.666181244,3.666181244,3.666181244,3.666181244,3.666181244,3.666181244,0,-100,1522,Bacterial Conjunctivitis,7/7/14 12:28
527,1,Abbott,Regional & Specialty Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,Jul-83,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1579,Pancreatic Insufficiency,7/7/14 12:28
527,1,Abbott,Regional & Specialty Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,Jul-83,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,Global,Sales,0,433.39,628,659,316.3259,330.8436175,338.8754262,345.6590859,351.3172813,355.5231436,358.8752727,361.5204232,1.92610592,1579,Pancreatic Insufficiency,7/7/14 12:28
527,1,Abbott,Regional & Specialty Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,Jul-83,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1579,Pancreatic Insufficiency,7/7/14 12:28
527,1,Abbott,Regional & Specialty Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,Jul-83,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,ROW,Sales,0,187.39,296,306,316.3259,330.8436175,338.8754262,345.6590859,351.3172813,355.5231436,358.8752727,361.5204232,1.92610592,1579,Pancreatic Insufficiency,7/7/14 12:28
527,1,Abbott,Regional & Specialty Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,Jul-83,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1579,Pancreatic Insufficiency,7/7/14 12:28
527,1,Abbott,Regional & Specialty Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,Jul-83,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,US,Sales,0,246,332,353,0,0,0,0,0,0,0,0,0,1579,Pancreatic Insufficiency,7/7/14 12:28
527,1,Solvay,Regional & Specialty Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,Jul-83,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,Global,Proforma,372.4,51.45,0,0,0,0,0,0,0,0,0,0,0,1579,Pancreatic Insufficiency,7/7/14 12:28
527,1,Solvay,Regional & Specialty Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,Jul-83,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,ROW,Proforma,277,37.75,0,0,0,0,0,0,0,0,0,0,0,1579,Pancreatic Insufficiency,7/7/14 12:28
527,1,Solvay,Regional & Specialty Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,Jul-83,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,US,Proforma,95.4,13.7,0,0,0,0,0,0,0,0,0,0,0,1579,Pancreatic Insufficiency,7/7/14 12:28
528,16,AstraZeneca,Large Pharma,83,Crestor,rosuvastatin,Small Molecule (Chemical),Launched,Licensed (Development),Sep-03,Mar-03,Jul-16,Apr-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1624,Dyslipidemia,7/7/14 12:28
528,16,AstraZeneca,Large Pharma,83,Crestor,rosuvastatin,Small Molecule (Chemical),Launched,Licensed (Development),Sep-03,Mar-03,Jul-16,Apr-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,4502,5691,6622,6253,5622,5256,5043.33,3751.23236,1930.073115,1416.203982,1136.262481,953.7750665,-22.38662728,1624,Dyslipidemia,7/7/14 12:28
528,16,AstraZeneca,Large Pharma,83,Crestor,rosuvastatin,Small Molecule (Chemical),Launched,Licensed (Development),Sep-03,Mar-03,Jul-16,Apr-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1624,Dyslipidemia,7/7/14 12:28
528,16,AstraZeneca,Large Pharma,83,Crestor,rosuvastatin,Small Molecule (Chemical),Launched,Licensed (Development),Sep-03,Mar-03,Jul-16,Apr-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,2402,3051,3548,3089,2710,2482.6,2346.16,2264.296,1772.14208,1311.423936,1084.011968,927.6881755,-14.19937399,1624,Dyslipidemia,7/7/14 12:28
528,16,AstraZeneca,Large Pharma,83,Crestor,rosuvastatin,Small Molecule (Chemical),Launched,Licensed (Development),Sep-03,Mar-03,Jul-16,Apr-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1624,Dyslipidemia,7/7/14 12:28
528,16,AstraZeneca,Large Pharma,83,Crestor,rosuvastatin,Small Molecule (Chemical),Launched,Licensed (Development),Sep-03,Mar-03,Jul-16,Apr-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,2100,2640,3074,3164,2912,2773.4,2697.17,1486.93636,157.9310355,104.7800463,52.25051275,26.08689101,-49.01271849,1624,Dyslipidemia,7/7/14 12:28
529,95,Shionogi,Regional & Specialty Pharma,83,Crestor,rosuvastatin,Small Molecule (Chemical),Launched,In-House,,Apr-05,N/A,Jun-17,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1624,Dyslipidemia,7/7/14 12:28
529,95,Shionogi,Regional & Specialty Pharma,83,Crestor,rosuvastatin,Small Molecule (Chemical),Launched,In-House,,Apr-05,N/A,Jun-17,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,Global,Sales,260.7128845,335.2886504,452.0212758,462.5783813,422.5282229,444.905961,464.7620228,479.4555941,470.2384856,429.4991432,400.7185074,380.059907,-1.501854364,1624,Dyslipidemia,7/7/14 12:28
529,95,Shionogi,Regional & Specialty Pharma,83,Crestor,rosuvastatin,Small Molecule (Chemical),Launched,In-House,,Apr-05,N/A,Jun-17,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1624,Dyslipidemia,7/7/14 12:28
529,95,Shionogi,Regional & Specialty Pharma,83,Crestor,rosuvastatin,Small Molecule (Chemical),Launched,In-House,,Apr-05,N/A,Jun-17,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Sales,260.7128845,335.2886504,452.0212758,462.5783813,422.5282229,444.905961,464.7620228,479.4555941,470.2384856,429.4991432,400.7185074,380.059907,-1.501854364,1624,Dyslipidemia,7/7/14 12:28
529,95,Shionogi,Regional & Specialty Pharma,83,Crestor,rosuvastatin,Small Molecule (Chemical),Launched,In-House,,Apr-05,N/A,Jun-17,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1624,Dyslipidemia,7/7/14 12:28
529,95,Shionogi,Regional & Specialty Pharma,83,Crestor,rosuvastatin,Small Molecule (Chemical),Launched,In-House,,Apr-05,N/A,Jun-17,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1624,Dyslipidemia,7/7/14 12:28
531,34,Daiichi-Sankyo,Regional & Specialty Pharma,665,CS-0777,CS-0777,Small Molecule (Chemical),Phase I,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,339,Multiple Sclerosis,7/7/14 12:28
531,34,Daiichi-Sankyo,Regional & Specialty Pharma,665,CS-0777,CS-0777,Small Molecule (Chemical),Phase I,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,339,Multiple Sclerosis,7/7/14 12:28
531,34,Daiichi-Sankyo,Regional & Specialty Pharma,665,CS-0777,CS-0777,Small Molecule (Chemical),Phase I,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,339,Multiple Sclerosis,7/7/14 12:28
531,34,Daiichi-Sankyo,Regional & Specialty Pharma,665,CS-0777,CS-0777,Small Molecule (Chemical),Phase I,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,339,Multiple Sclerosis,7/7/14 12:28
531,34,Daiichi-Sankyo,Regional & Specialty Pharma,665,CS-0777,CS-0777,Small Molecule (Chemical),Phase I,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,339,Multiple Sclerosis,7/7/14 12:28
531,34,Daiichi-Sankyo,Regional & Specialty Pharma,665,CS-0777,CS-0777,Small Molecule (Chemical),Phase I,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,339,Multiple Sclerosis,7/7/14 12:28
536,34,Daiichi-Sankyo,Regional & Specialty Pharma,3274,Inavir,laninamivir,Small Molecule (Chemical),Launched,In-House,,Oct-10,,May-21,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,342,Influenza,7/7/14 12:28
536,34,Daiichi-Sankyo,Regional & Specialty Pharma,3274,Inavir,laninamivir,Small Molecule (Chemical),Launched,In-House,,Oct-10,,May-21,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,7,Global,Sales,0,77.04070317,135.4797661,132.4261473,113.4039408,141.754926,146.8176019,147.9617667,148.7378749,148.9122588,148.9671445,151.0158337,4.176701378,342,Influenza,7/7/14 12:28
536,34,Daiichi-Sankyo,Regional & Specialty Pharma,3274,Inavir,laninamivir,Small Molecule (Chemical),Launched,In-House,,Oct-10,,May-21,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,342,Influenza,7/7/14 12:28
536,34,Daiichi-Sankyo,Regional & Specialty Pharma,3274,Inavir,laninamivir,Small Molecule (Chemical),Launched,In-House,,Oct-10,,May-21,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,7,ROW,Sales,0,77.04070317,135.4797661,132.4261473,113.4039408,141.754926,146.8176019,147.9617667,148.7378749,148.9122588,148.9671445,151.0158337,4.176701378,342,Influenza,7/7/14 12:28
536,34,Daiichi-Sankyo,Regional & Specialty Pharma,3274,Inavir,laninamivir,Small Molecule (Chemical),Launched,In-House,,Oct-10,,May-21,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,342,Influenza,7/7/14 12:28
536,34,Daiichi-Sankyo,Regional & Specialty Pharma,3274,Inavir,laninamivir,Small Molecule (Chemical),Launched,In-House,,Oct-10,,May-21,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,342,Influenza,7/7/14 12:28
538,32,Cubist Pharmaceuticals,Small Biotech,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Licensed (Development),Nov-03,,Jul-18,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,14,25.3,36.7,50.5,61,69,74,75,77,79,80,81,4.134246791,1412,gram-positive cSSSI and BSI including MRSA,7/7/14 12:28
538,32,Cubist Pharmaceuticals,Small Biotech,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Licensed (Development),Nov-03,,Jul-18,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,524,599.6,698,809.2,908,964.342,978.1189485,988.6100841,999.2005246,740.3929193,267.2976863,173.7024478,-21.04335486,1412,gram-positive cSSSI and BSI including MRSA,7/7/14 12:28
538,32,Cubist Pharmaceuticals,Small Biotech,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Licensed (Development),Nov-03,,Jul-18,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,14,25.3,36.7,50.5,61,69,74,75,77,79,80,81,4.134246791,1412,gram-positive cSSSI and BSI including MRSA,7/7/14 12:28
538,32,Cubist Pharmaceuticals,Small Biotech,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Licensed (Development),Nov-03,,Jul-18,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1412,gram-positive cSSSI and BSI including MRSA,7/7/14 12:28
538,32,Cubist Pharmaceuticals,Small Biotech,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Licensed (Development),Nov-03,,Jul-18,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1412,gram-positive cSSSI and BSI including MRSA,7/7/14 12:28
538,32,Cubist Pharmaceuticals,Small Biotech,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Licensed (Development),Nov-03,,Jul-18,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,524,599.6,698,809.2,908,964.342,978.1189485,988.6100841,999.2005246,740.3929193,267.2976863,173.7024478,-21.04335486,1412,gram-positive cSSSI and BSI including MRSA,7/7/14 12:28
539,67,Novartis,Large Pharma,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-06,N/A,Sep-19,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1412,Gram-positive cSSSI and S aureus BSI,7/7/14 12:28
539,67,Novartis,Large Pharma,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-06,N/A,Sep-19,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,65,81,97,112,118.975,124.009375,127.4337344,125.6262577,125.6587288,125.2046491,123.1045984,123.4538879,0.529314303,1412,Gram-positive cSSSI and S aureus BSI,7/7/14 12:28
539,67,Novartis,Large Pharma,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-06,N/A,Sep-19,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1412,Gram-positive cSSSI and S aureus BSI,7/7/14 12:28
539,67,Novartis,Large Pharma,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-06,N/A,Sep-19,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,65,81,97,112,118.975,124.009375,127.4337344,125.6262577,125.6587288,125.2046491,123.1045984,123.4538879,0.529314303,1412,Gram-positive cSSSI and S aureus BSI,7/7/14 12:28
539,67,Novartis,Large Pharma,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-06,N/A,Sep-19,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1412,Gram-positive cSSSI and S aureus BSI,7/7/14 12:28
539,67,Novartis,Large Pharma,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-06,N/A,Sep-19,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1412,Gram-positive cSSSI and S aureus BSI,7/7/14 12:28
540,23,Boehringer Ingelheim,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),Aug-04,Jan-05,Dec-13,Aug-14,66,Noradrenergics,49,Depression,12,Central Nervous System,2,Global,Alliance Revenue,125.0548562,37.09313468,0,0,0,0,0,0,0,0,0,0,0,1432,Depression,7/7/14 12:28
540,23,Boehringer Ingelheim,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),Aug-04,Jan-05,Dec-13,Aug-14,66,Noradrenergics,49,Depression,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Depression,7/7/14 12:28
540,23,Boehringer Ingelheim,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),Aug-04,Jan-05,Dec-13,Aug-14,66,Noradrenergics,49,Depression,12,Central Nervous System,2,ROW,Alliance Revenue,125.0548562,37.09313468,0,0,0,0,0,0,0,0,0,0,0,1432,Depression,7/7/14 12:28
540,23,Boehringer Ingelheim,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),Aug-04,Jan-05,Dec-13,Aug-14,66,Noradrenergics,49,Depression,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Depression,7/7/14 12:28
540,23,Boehringer Ingelheim,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),Aug-04,Jan-05,Dec-13,Aug-14,66,Noradrenergics,49,Depression,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Depression,7/7/14 12:28
540,23,Boehringer Ingelheim,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),Aug-04,Jan-05,Dec-13,Aug-14,66,Noradrenergics,49,Depression,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Depression,7/7/14 12:28
541,23,Boehringer Ingelheim,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),Aug-04,Jan-05,Dec-13,Aug-14,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,2,Global,Alliance Revenue,30.56896486,9.27328367,0,0,0,0,0,0,0,0,0,0,0,1432,Neuropathic pain,7/7/14 12:28
541,23,Boehringer Ingelheim,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),Aug-04,Jan-05,Dec-13,Aug-14,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Neuropathic pain,7/7/14 12:28
541,23,Boehringer Ingelheim,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),Aug-04,Jan-05,Dec-13,Aug-14,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,2,ROW,Alliance Revenue,30.56896486,9.27328367,0,0,0,0,0,0,0,0,0,0,0,1432,Neuropathic pain,7/7/14 12:28
541,23,Boehringer Ingelheim,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),Aug-04,Jan-05,Dec-13,Aug-14,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Neuropathic pain,7/7/14 12:28
541,23,Boehringer Ingelheim,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),Aug-04,Jan-05,Dec-13,Aug-14,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Neuropathic pain,7/7/14 12:28
541,23,Boehringer Ingelheim,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),Aug-04,Jan-05,Dec-13,Aug-14,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Neuropathic pain,7/7/14 12:28
542,39,Eli Lilly,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Dec-13,Aug-14,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Depression,7/7/14 12:28
542,39,Eli Lilly,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Dec-13,Aug-14,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Sales,2563,2895,3170.72,3799.8,3870,905.14276,402.540816,276.3969352,206.4175354,166.9329535,139.4656135,129.2135625,-38.47019822,1432,Depression,7/7/14 12:28
542,39,Eli Lilly,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Dec-13,Aug-14,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Depression,7/7/14 12:28
542,39,Eli Lilly,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Dec-13,Aug-14,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Sales,419,567,790.72,861.4,899,716.8018,282.796,189.1757,142.006,114.12185,94.5372625,84.2675625,-28.69354861,1432,Depression,7/7/14 12:28
542,39,Eli Lilly,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Dec-13,Aug-14,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Depression,7/7/14 12:28
542,39,Eli Lilly,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Dec-13,Aug-14,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Sales,2144,2328,2380,2938.4,2971,188.34096,119.744816,87.2212352,64.41153536,52.81110349,44.928351,44.946,-45.04970468,1432,Depression,7/7/14 12:28
543,39,Eli Lilly,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Dec-13,Aug-14,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Neuropathic Pain,7/7/14 12:28
543,39,Eli Lilly,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Dec-13,Aug-14,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,512,586,991.1,1193.624,1214,239.2591165,108.9956247,75.04899723,55.95755044,45.26970212,37.85423959,34.35501519,-39.90688522,1432,Neuropathic Pain,7/7/14 12:28
543,39,Eli Lilly,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Dec-13,Aug-14,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Neuropathic Pain,7/7/14 12:28
543,39,Eli Lilly,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Dec-13,Aug-14,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,104,142,197.7,214.624,224,177.7259845,70.47742848,47.32201143,35.65124464,28.71394661,23.82166119,20.31060671,-29.03111391,1432,Neuropathic Pain,7/7/14 12:28
543,39,Eli Lilly,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Dec-13,Aug-14,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Neuropathic Pain,7/7/14 12:28
543,39,Eli Lilly,Large Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Dec-13,Aug-14,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,408,444,793.4,979,990,61.533132,38.51819626,27.7269858,20.30630581,16.55575551,14.0325784,14.04440848,-45.55206119,1432,Neuropathic Pain,7/7/14 12:28
544,95,Shionogi,Regional & Specialty Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-10,N/A,Dec-21,66,Noradrenergics,49,Depression,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Depression,7/7/14 12:28
544,95,Shionogi,Regional & Specialty Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-10,N/A,Dec-21,66,Noradrenergics,49,Depression,12,Central Nervous System,7,Global,Sales,0,31.5166513,82.30079251,93.42062758,84.0404204,93.40985564,99.25741965,103.7538542,107.573497,110.451869,112.7167067,114.5106151,4.518679423,1432,Depression,7/7/14 12:28
544,95,Shionogi,Regional & Specialty Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-10,N/A,Dec-21,66,Noradrenergics,49,Depression,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Depression,7/7/14 12:28
544,95,Shionogi,Regional & Specialty Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-10,N/A,Dec-21,66,Noradrenergics,49,Depression,12,Central Nervous System,7,ROW,Sales,0,31.5166513,82.30079251,93.42062758,84.0404204,93.40985564,99.25741965,103.7538542,107.573497,110.451869,112.7167067,114.5106151,4.518679423,1432,Depression,7/7/14 12:28
544,95,Shionogi,Regional & Specialty Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-10,N/A,Dec-21,66,Noradrenergics,49,Depression,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Depression,7/7/14 12:28
544,95,Shionogi,Regional & Specialty Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-10,N/A,Dec-21,66,Noradrenergics,49,Depression,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Depression,7/7/14 12:28
545,95,Shionogi,Regional & Specialty Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-12,N/A,Jun-19,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Painful Diabetic Neuropathy,7/7/14 12:28
545,95,Shionogi,Regional & Specialty Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-12,N/A,Jun-19,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,1.266166039,23.35515689,28.3509852,49.19519653,62.61352346,74.39460159,85.66250511,95.14405758,99.69548784,95.20122715,18.89221258,1432,Painful Diabetic Neuropathy,7/7/14 12:28
545,95,Shionogi,Regional & Specialty Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-12,N/A,Jun-19,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Painful Diabetic Neuropathy,7/7/14 12:28
545,95,Shionogi,Regional & Specialty Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-12,N/A,Jun-19,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,1.266166039,23.35515689,28.3509852,49.19519653,62.61352346,74.39460159,85.66250511,95.14405758,99.69548784,95.20122715,18.89221258,1432,Painful Diabetic Neuropathy,7/7/14 12:28
545,95,Shionogi,Regional & Specialty Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-12,N/A,Jun-19,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Painful Diabetic Neuropathy,7/7/14 12:28
545,95,Shionogi,Regional & Specialty Pharma,1490,Cymbalta,duloxetine,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-12,N/A,Jun-19,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1432,Painful Diabetic Neuropathy,7/7/14 12:28
551,21,Biogen Idec,Regional & Specialty Pharma,1130,daclizumab,daclizumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Nov-15,May-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,348,Multiple Sclerosis,7/7/14 12:28
551,21,Biogen Idec,Regional & Specialty Pharma,1130,daclizumab,daclizumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Nov-15,May-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,10.2,65.678252,131.2565272,229.6741511,327.9565389,401.3822477,0,348,Multiple Sclerosis,7/7/14 12:28
551,21,Biogen Idec,Regional & Specialty Pharma,1130,daclizumab,daclizumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Nov-15,May-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,348,Multiple Sclerosis,7/7/14 12:28
551,21,Biogen Idec,Regional & Specialty Pharma,1130,daclizumab,daclizumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Nov-15,May-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,20,45,80.0001,137.5001719,172.9002246,0,348,Multiple Sclerosis,7/7/14 12:28
551,21,Biogen Idec,Regional & Specialty Pharma,1130,daclizumab,daclizumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Nov-15,May-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,348,Multiple Sclerosis,7/7/14 12:28
551,21,Biogen Idec,Regional & Specialty Pharma,1130,daclizumab,daclizumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Nov-15,May-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,10.2,45.678252,86.25652716,149.6740511,190.456367,228.4820231,0,348,Multiple Sclerosis,7/7/14 12:28
552,37,Eisai,Regional & Specialty Pharma,429,Dacogen,decitabine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-06,,May-13,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1414,Myelodysplastic Syndrome,7/7/14 12:28
552,37,Eisai,Regional & Specialty Pharma,429,Dacogen,decitabine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-06,,May-13,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,Global,Sales,165.9081993,189.0999078,219.0467247,232.3476949,122.8262114,40.27088898,30.20316674,24.16253339,19.63205838,16.23420212,13.68580993,11.77451578,-28.46446002,1414,Myelodysplastic Syndrome,7/7/14 12:28
552,37,Eisai,Regional & Specialty Pharma,429,Dacogen,decitabine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-06,,May-13,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1414,Myelodysplastic Syndrome,7/7/14 12:28
552,37,Eisai,Regional & Specialty Pharma,429,Dacogen,decitabine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-06,,May-13,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1414,Myelodysplastic Syndrome,7/7/14 12:28
552,37,Eisai,Regional & Specialty Pharma,429,Dacogen,decitabine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-06,,May-13,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1414,Myelodysplastic Syndrome,7/7/14 12:28
552,37,Eisai,Regional & Specialty Pharma,429,Dacogen,decitabine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-06,,May-13,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,US,Sales,165.9081993,189.0999078,219.0467247,232.3476949,122.8262114,40.27088898,30.20316674,24.16253339,19.63205838,16.23420212,13.68580993,11.77451578,-28.46446002,1414,Myelodysplastic Syndrome,7/7/14 12:28
553,53,Johnson & Johnson,Large Pharma,429,Dacogen,decitabine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-12,N/A,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1414,Acute Myeloid Leukemia,7/7/14 12:28
553,53,Johnson & Johnson,Large Pharma,429,Dacogen,decitabine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-12,N/A,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,3.75,17.5000125,27.50004464,37.50016088,43.95020303,48.88524046,52.72677322,55.54154485,57.66965672,18.57330552,1414,Acute Myeloid Leukemia,7/7/14 12:28
553,53,Johnson & Johnson,Large Pharma,429,Dacogen,decitabine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-12,N/A,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1414,Acute Myeloid Leukemia,7/7/14 12:28
553,53,Johnson & Johnson,Large Pharma,429,Dacogen,decitabine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-12,N/A,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,3.75,17.5000125,27.50004464,37.50016088,43.95020303,48.88524046,52.72677322,55.54154485,57.66965672,18.57330552,1414,Acute Myeloid Leukemia,7/7/14 12:28
553,53,Johnson & Johnson,Large Pharma,429,Dacogen,decitabine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-12,N/A,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1414,Acute Myeloid Leukemia,7/7/14 12:28
553,53,Johnson & Johnson,Large Pharma,429,Dacogen,decitabine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-12,N/A,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1414,Acute Myeloid Leukemia,7/7/14 12:28
555,24,Bristol-Myers Squibb,Large Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,In-House,Apr-14,Nov-12,Oct-20,N/A,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1411,Type II Diabetes,7/7/14 12:28
555,24,Bristol-Myers Squibb,Large Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,In-House,Apr-14,Nov-12,Oct-20,N/A,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,6.66668,23,4.935,0,0,0,0,0,0,-100,1411,Type II Diabetes,7/7/14 12:28
555,24,Bristol-Myers Squibb,Large Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,In-House,Apr-14,Nov-12,Oct-20,N/A,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1411,Type II Diabetes,7/7/14 12:28
555,24,Bristol-Myers Squibb,Large Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,In-House,Apr-14,Nov-12,Oct-20,N/A,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,6.66668,23,4.935,0,0,0,0,0,0,-100,1411,Type II Diabetes,7/7/14 12:28
555,24,Bristol-Myers Squibb,Large Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,In-House,Apr-14,Nov-12,Oct-20,N/A,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1411,Type II Diabetes,7/7/14 12:28
555,24,Bristol-Myers Squibb,Large Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,In-House,Apr-14,Nov-12,Oct-20,N/A,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1411,Type II Diabetes,7/7/14 12:28
556,60,Menarini,Regional & Specialty Pharma,1879,Priligy,dapoxetine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-09,N/A,Aug-20,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,2,Global,Sales,0,0,0,12.96753362,30.84651183,34.52878173,38.51287193,41.16893206,43.45072984,45.36490432,46.88589134,48.13966512,6.56481373,926,Premature ejaculation,7/7/14 12:28
556,60,Menarini,Regional & Specialty Pharma,1879,Priligy,dapoxetine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-09,N/A,Aug-20,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,2,ROW,Sales,0,0,0,12.96753362,30.84651183,34.52878173,38.51287193,41.16893206,43.45072984,45.36490432,46.88589134,48.13966512,6.56481373,926,Premature ejaculation,7/7/14 12:28
556,60,Menarini,Regional & Specialty Pharma,1879,Priligy,dapoxetine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-09,N/A,Aug-20,73,Other Mens Health,4,Other Men's Health Disorders,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,926,Premature ejaculation,7/7/14 12:28
557,46,GlaxoSmithKline,Large Pharma,1898,Tyrisa,darapladib,Small Molecule (Chemical),Phase III,In-House,Sep-15,Jan-16,N/A,N/A,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1219,Atherosclerosis / Secondary Prevention,7/7/14 12:28
557,46,GlaxoSmithKline,Large Pharma,1898,Tyrisa,darapladib,Small Molecule (Chemical),Phase III,In-House,Sep-15,Jan-16,N/A,N/A,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,Global,Sales,0,0,0,0,0,0,31.78938678,196.8164125,436.5402248,676.2634505,854.8462709,998.873511,0,1219,Atherosclerosis / Secondary Prevention,7/7/14 12:28
557,46,GlaxoSmithKline,Large Pharma,1898,Tyrisa,darapladib,Small Molecule (Chemical),Phase III,In-House,Sep-15,Jan-16,N/A,N/A,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1219,Atherosclerosis / Secondary Prevention,7/7/14 12:28
557,46,GlaxoSmithKline,Large Pharma,1898,Tyrisa,darapladib,Small Molecule (Chemical),Phase III,In-House,Sep-15,Jan-16,N/A,N/A,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,ROW,Sales,0,0,0,0,0,0,0,48.46583487,129.2423879,210.0188803,290.796342,351.3790839,0,1219,Atherosclerosis / Secondary Prevention,7/7/14 12:28
557,46,GlaxoSmithKline,Large Pharma,1898,Tyrisa,darapladib,Small Molecule (Chemical),Phase III,In-House,Sep-15,Jan-16,N/A,N/A,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1219,Atherosclerosis / Secondary Prevention,7/7/14 12:28
557,46,GlaxoSmithKline,Large Pharma,1898,Tyrisa,darapladib,Small Molecule (Chemical),Phase III,In-House,Sep-15,Jan-16,N/A,N/A,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,US,Sales,0,0,0,0,0,0,31.78938678,148.3505776,307.297837,466.2445702,564.0499288,647.4944271,0,1219,Atherosclerosis / Secondary Prevention,7/7/14 12:28
559,46,GlaxoSmithKline,Large Pharma,4683,Anoro,vilanterol + umeclidinium,Small Molecule (Chemical),Approved,Licensed (Development),Mar-14,Jun-14,N/A,Sep-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,352,COPD,7/7/14 12:28
559,46,GlaxoSmithKline,Large Pharma,4683,Anoro,vilanterol + umeclidinium,Small Molecule (Chemical),Approved,Licensed (Development),Mar-14,Jun-14,N/A,Sep-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,176.4155873,481.2815923,827.0607957,1228.609032,1498.802389,1739.790754,1949.906796,0,352,COPD,7/7/14 12:28
559,46,GlaxoSmithKline,Large Pharma,4683,Anoro,vilanterol + umeclidinium,Small Molecule (Chemical),Approved,Licensed (Development),Mar-14,Jun-14,N/A,Sep-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,352,COPD,7/7/14 12:28
559,46,GlaxoSmithKline,Large Pharma,4683,Anoro,vilanterol + umeclidinium,Small Molecule (Chemical),Approved,Licensed (Development),Mar-14,Jun-14,N/A,Sep-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,47.43398161,111.5338927,199.3512184,342.9359269,409.5104475,465.8661302,511.9864138,0,352,COPD,7/7/14 12:28
559,46,GlaxoSmithKline,Large Pharma,4683,Anoro,vilanterol + umeclidinium,Small Molecule (Chemical),Approved,Licensed (Development),Mar-14,Jun-14,N/A,Sep-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,352,COPD,7/7/14 12:28
559,46,GlaxoSmithKline,Large Pharma,4683,Anoro,vilanterol + umeclidinium,Small Molecule (Chemical),Approved,Licensed (Development),Mar-14,Jun-14,N/A,Sep-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,128.9816057,369.7476997,627.7095773,885.6731052,1089.291942,1273.924624,1437.920382,0,352,COPD,7/7/14 12:28
561,100,Takeda,Large Pharma,4629,Dasen / Aniflazym,serrapeptase,Synthetic Peptide,Launched,In-House,,Jul-68,N/A,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,353,Pain,7/7/14 12:28
561,100,Takeda,Large Pharma,4629,Dasen / Aniflazym,serrapeptase,Synthetic Peptide,Launched,In-House,,Jul-68,N/A,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,72.46622104,72.04806609,12.67996748,7.408087806,6.999119244,6.966401759,6.96378436,6.963574968,6.963558217,6.963556877,6.96355677,10.06772225,5.330799858,353,Pain,7/7/14 12:28
561,100,Takeda,Large Pharma,4629,Dasen / Aniflazym,serrapeptase,Synthetic Peptide,Launched,In-House,,Jul-68,N/A,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,353,Pain,7/7/14 12:28
561,100,Takeda,Large Pharma,4629,Dasen / Aniflazym,serrapeptase,Synthetic Peptide,Launched,In-House,,Jul-68,N/A,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,72.46622104,72.04806609,12.67996748,7.408087806,6.999119244,6.966401759,6.96378436,6.963574968,6.963558217,6.963556877,6.96355677,10.06772225,5.330799858,353,Pain,7/7/14 12:28
561,100,Takeda,Large Pharma,4629,Dasen / Aniflazym,serrapeptase,Synthetic Peptide,Launched,In-House,,Jul-68,N/A,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,353,Pain,7/7/14 12:28
561,100,Takeda,Large Pharma,4629,Dasen / Aniflazym,serrapeptase,Synthetic Peptide,Launched,In-House,,Jul-68,N/A,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,353,Pain,7/7/14 12:28
562,100,Nycomed,Large Pharma,1067,Daxas,roflumilast,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-10,N/A,Jul-19,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,7,Global,Proforma,0,5.299008976,8.338496057,0,0,0,0,0,0,0,0,0,0,1622,COPD,7/7/14 12:28
562,100,Nycomed,Large Pharma,1067,Daxas,roflumilast,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-10,N/A,Jul-19,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,7,ROW,Proforma,0,5.299008976,8.338496057,0,0,0,0,0,0,0,0,0,0,1622,COPD,7/7/14 12:28
562,100,Takeda,Large Pharma,1067,Daxas,roflumilast,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-10,N/A,Jul-19,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1622,COPD,7/7/14 12:28
562,100,Takeda,Large Pharma,1067,Daxas,roflumilast,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-10,N/A,Jul-19,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,7,Global,Sales,0,0,8.121662446,36.116222,40.27088898,49.76843856,65.44019459,75.59914445,90.60950021,101.5592714,100.0503876,105.0398297,14.67806052,1622,COPD,7/7/14 12:28
562,100,Takeda,Large Pharma,1067,Daxas,roflumilast,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-10,N/A,Jul-19,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1622,COPD,7/7/14 12:28
562,100,Takeda,Large Pharma,1067,Daxas,roflumilast,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-10,N/A,Jul-19,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,7,ROW,Sales,0,0,8.121662446,36.116222,40.27088898,49.76843856,65.44019459,75.59914445,90.60950021,101.5592714,100.0503876,105.0398297,14.67806052,1622,COPD,7/7/14 12:28
562,100,Takeda,Large Pharma,1067,Daxas,roflumilast,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-10,N/A,Jul-19,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1622,COPD,7/7/14 12:28
562,100,Takeda,Large Pharma,1067,Daxas,roflumilast,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-10,N/A,Jul-19,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1622,COPD,7/7/14 12:28
563,96,Shire,Regional & Specialty Pharma,970,Daytrana,methylphenidate patch,Small Molecule (Chemical),Launched,Licensed (Development),Jun-06,,,,121,Stimulants,37,ADHD,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1727,ADHD,7/7/14 12:28
563,96,Shire,Regional & Specialty Pharma,970,Daytrana,methylphenidate patch,Small Molecule (Chemical),Launched,Licensed (Development),Jun-06,,,,121,Stimulants,37,ADHD,12,Central Nervous System,6,Global,Sales,71,49,0,0,0,0,0,0,0,0,0,0,0,1727,ADHD,7/7/14 12:28
563,96,Shire,Regional & Specialty Pharma,970,Daytrana,methylphenidate patch,Small Molecule (Chemical),Launched,Licensed (Development),Jun-06,,,,121,Stimulants,37,ADHD,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1727,ADHD,7/7/14 12:28
563,96,Shire,Regional & Specialty Pharma,970,Daytrana,methylphenidate patch,Small Molecule (Chemical),Launched,Licensed (Development),Jun-06,,,,121,Stimulants,37,ADHD,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1727,ADHD,7/7/14 12:28
563,96,Shire,Regional & Specialty Pharma,970,Daytrana,methylphenidate patch,Small Molecule (Chemical),Launched,Licensed (Development),Jun-06,,,,121,Stimulants,37,ADHD,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1727,ADHD,7/7/14 12:28
563,96,Shire,Regional & Specialty Pharma,970,Daytrana,methylphenidate patch,Small Molecule (Chemical),Launched,Licensed (Development),Jun-06,,,,121,Stimulants,37,ADHD,12,Central Nervous System,6,US,Sales,71,49,0,0,0,0,0,0,0,0,0,0,0,1727,ADHD,7/7/14 12:28
565,51,Ipsen,Regional & Specialty Pharma,1466,Decapeptyl,triptorelin,Synthetic Peptide,Launched,Licensed (Marketed),,Jun-86,N/A,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,356,Prostate cancer,7/7/14 12:28
565,51,Ipsen,Regional & Specialty Pharma,1466,Decapeptyl,triptorelin,Synthetic Peptide,Launched,Licensed (Marketed),,Jun-86,N/A,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,2,Global,Sales,348.0832448,357.6837987,394.3279438,393.8071343,396.5497779,400.308103,402.7217977,402.8531066,403.6238206,404.0775649,404.319739,404.5254155,0.284876005,356,Prostate cancer,7/7/14 12:28
565,51,Ipsen,Regional & Specialty Pharma,1466,Decapeptyl,triptorelin,Synthetic Peptide,Launched,Licensed (Marketed),,Jun-86,N/A,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,356,Prostate cancer,7/7/14 12:28
565,51,Ipsen,Regional & Specialty Pharma,1466,Decapeptyl,triptorelin,Synthetic Peptide,Launched,Licensed (Marketed),,Jun-86,N/A,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,2,ROW,Sales,348.0832448,357.6837987,394.3279438,393.8071343,396.5497779,400.308103,402.7217977,402.8531066,403.6238206,404.0775649,404.319739,404.5254155,0.284876005,356,Prostate cancer,7/7/14 12:28
565,51,Ipsen,Regional & Specialty Pharma,1466,Decapeptyl,triptorelin,Synthetic Peptide,Launched,Licensed (Marketed),,Jun-86,N/A,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,356,Prostate cancer,7/7/14 12:28
565,51,Ipsen,Regional & Specialty Pharma,1466,Decapeptyl,triptorelin,Synthetic Peptide,Launched,Licensed (Marketed),,Jun-86,N/A,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,356,Prostate cancer,7/7/14 12:28
567,15,Astellas Pharma,Regional & Specialty Pharma,961,degarelix,degarelix,Synthetic Peptide,Launched,Licensed (Development),,,,,33,LHRH Analogs,55,Hormonals,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,357,Prostate Cancer,7/7/14 12:28
567,15,Astellas Pharma,Regional & Specialty Pharma,961,degarelix,degarelix,Synthetic Peptide,Launched,Licensed (Development),,,,,33,LHRH Analogs,55,Hormonals,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,357,Prostate Cancer,7/7/14 12:28
567,15,Astellas Pharma,Regional & Specialty Pharma,961,degarelix,degarelix,Synthetic Peptide,Launched,Licensed (Development),,,,,33,LHRH Analogs,55,Hormonals,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,357,Prostate Cancer,7/7/14 12:28
567,15,Astellas Pharma,Regional & Specialty Pharma,961,degarelix,degarelix,Synthetic Peptide,Launched,Licensed (Development),,,,,33,LHRH Analogs,55,Hormonals,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,357,Prostate Cancer,7/7/14 12:28
567,15,Astellas Pharma,Regional & Specialty Pharma,961,degarelix,degarelix,Synthetic Peptide,Launched,Licensed (Development),,,,,33,LHRH Analogs,55,Hormonals,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,357,Prostate Cancer,7/7/14 12:28
567,15,Astellas Pharma,Regional & Specialty Pharma,961,degarelix,degarelix,Synthetic Peptide,Launched,Licensed (Development),,,,,33,LHRH Analogs,55,Hormonals,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,357,Prostate Cancer,7/7/14 12:28
569,89,Sanofi,Large Pharma,4001,Dengue fever vaccine - Sanofi,Dengue fever vaccine,Vaccine,Phase III,In-House,,Jul-15,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,361,Dengue Fever,7/7/14 12:28
569,89,Sanofi,Large Pharma,4001,Dengue fever vaccine - Sanofi,Dengue fever vaccine,Vaccine,Phase III,In-House,,Jul-15,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,0,0,0,0,0,0,42.49696213,113.325374,169.988061,226.6501814,268.2970655,302.7052963,0,361,Dengue Fever,7/7/14 12:28
569,89,Sanofi,Large Pharma,4001,Dengue fever vaccine - Sanofi,Dengue fever vaccine,Vaccine,Phase III,In-House,,Jul-15,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,361,Dengue Fever,7/7/14 12:28
569,89,Sanofi,Large Pharma,4001,Dengue fever vaccine - Sanofi,Dengue fever vaccine,Vaccine,Phase III,In-House,,Jul-15,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,0,0,0,0,0,0,42.49696213,113.325374,169.988061,226.6501814,268.2970655,302.7052963,0,361,Dengue Fever,7/7/14 12:28
569,89,Sanofi,Large Pharma,4001,Dengue fever vaccine - Sanofi,Dengue fever vaccine,Vaccine,Phase III,In-House,,Jul-15,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,361,Dengue Fever,7/7/14 12:28
569,89,Sanofi,Large Pharma,4001,Dengue fever vaccine - Sanofi,Dengue fever vaccine,Vaccine,Phase III,In-House,,Jul-15,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,361,Dengue Fever,7/7/14 12:28
571,34,Daiichi-Sankyo,Regional & Specialty Pharma,4350,Ranmark,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-12,N/A,Jun-21,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Prevention Of Bone Metastases,7/7/14 12:28
571,34,Daiichi-Sankyo,Regional & Specialty Pharma,4350,Ranmark,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-12,N/A,Jun-21,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,7,Global,Sales,0,0,0,63.01766385,80.54177796,110.7449447,127.7830544,145.1442911,160.0188045,172.0587418,182.5246693,191.389555,13.16171498,1415,Prevention Of Bone Metastases,7/7/14 12:28
571,34,Daiichi-Sankyo,Regional & Specialty Pharma,4350,Ranmark,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-12,N/A,Jun-21,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Prevention Of Bone Metastases,7/7/14 12:28
571,34,Daiichi-Sankyo,Regional & Specialty Pharma,4350,Ranmark,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-12,N/A,Jun-21,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,7,ROW,Sales,0,0,0,63.01766385,80.54177796,110.7449447,127.7830544,145.1442911,160.0188045,172.0587418,182.5246693,191.389555,13.16171498,1415,Prevention Of Bone Metastases,7/7/14 12:28
571,34,Daiichi-Sankyo,Regional & Specialty Pharma,4350,Ranmark,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-12,N/A,Jun-21,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Prevention Of Bone Metastases,7/7/14 12:28
571,34,Daiichi-Sankyo,Regional & Specialty Pharma,4350,Ranmark,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-12,N/A,Jun-21,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Prevention Of Bone Metastases,7/7/14 12:28
572,11,Amgen,Large Pharma,1917,Prolia,denosumab,Antibody/Antibody Derivative,Launched,In-House,Jun-10,Jul-10,Feb-25,May-25,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Osteoporosis,7/7/14 12:28
572,11,Amgen,Large Pharma,1917,Prolia,denosumab,Antibody/Antibody Derivative,Launched,In-House,Jun-10,Jul-10,Feb-25,May-25,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,0,33,192.85,448.4,707,849.761,969.8033,1062.54497,1129.106405,1180.173412,1218.603573,1247.312055,8.448165136,1415,Osteoporosis,7/7/14 12:28
572,11,Amgen,Large Pharma,1917,Prolia,denosumab,Antibody/Antibody Derivative,Launched,In-House,Jun-10,Jul-10,Feb-25,May-25,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Osteoporosis,7/7/14 12:28
572,11,Amgen,Large Pharma,1917,Prolia,denosumab,Antibody/Antibody Derivative,Launched,In-House,Jun-10,Jul-10,Feb-25,May-25,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,0,7,69.35,171,268,322.879,369.0007,404.35543,429.849235,449.3958319,464.0912635,475.077537,8.522176016,1415,Osteoporosis,7/7/14 12:28
572,11,Amgen,Large Pharma,1917,Prolia,denosumab,Antibody/Antibody Derivative,Launched,In-House,Jun-10,Jul-10,Feb-25,May-25,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Osteoporosis,7/7/14 12:28
572,11,Amgen,Large Pharma,1917,Prolia,denosumab,Antibody/Antibody Derivative,Launched,In-House,Jun-10,Jul-10,Feb-25,May-25,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,0,26,123.5,277.4,439,526.882,600.8026,658.18954,699.25717,730.7775802,754.5123095,772.2345177,8.402833679,1415,Osteoporosis,7/7/14 12:28
573,11,Amgen,Large Pharma,3358,Prolia/Xgeva,denosumab,Antibody/Antibody Derivative,Launched,In-House,Nov-10,Sep-10,Feb-25,May-25,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Prevention of Chemotherapy-induced Bone Loss,7/7/14 12:28
573,11,Amgen,Large Pharma,3358,Prolia/Xgeva,denosumab,Antibody/Antibody Derivative,Launched,In-House,Nov-10,Sep-10,Feb-25,May-25,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,6,Global,Sales,0,8.35,361.15,771.6,1056,1233.134,1351.78856,1423.987597,1470.929144,1500.973295,1520.081935,1532.375868,5.46301306,1415,Prevention of Chemotherapy-induced Bone Loss,7/7/14 12:28
573,11,Amgen,Large Pharma,3358,Prolia/Xgeva,denosumab,Antibody/Antibody Derivative,Launched,In-House,Nov-10,Sep-10,Feb-25,May-25,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Prevention of Chemotherapy-induced Bone Loss,7/7/14 12:28
573,11,Amgen,Large Pharma,3358,Prolia/Xgeva,denosumab,Antibody/Antibody Derivative,Launched,In-House,Nov-10,Sep-10,Feb-25,May-25,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,6,ROW,Sales,0,0.35,11.65,113,269,356.042,416.54216,456.0272768,482.2401521,499.5605462,511.0198804,518.5988081,9.831158402,1415,Prevention of Chemotherapy-induced Bone Loss,7/7/14 12:28
573,11,Amgen,Large Pharma,3358,Prolia/Xgeva,denosumab,Antibody/Antibody Derivative,Launched,In-House,Nov-10,Sep-10,Feb-25,May-25,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Prevention of Chemotherapy-induced Bone Loss,7/7/14 12:28
573,11,Amgen,Large Pharma,3358,Prolia/Xgeva,denosumab,Antibody/Antibody Derivative,Launched,In-House,Nov-10,Sep-10,Feb-25,May-25,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,6,US,Sales,0,8,349.5,658.6,787,877.092,935.2464,967.96032,988.688992,1001.412749,1009.062054,1013.77706,3.683502521,1415,Prevention of Chemotherapy-induced Bone Loss,7/7/14 12:28
574,34,Daiichi-Sankyo,Regional & Specialty Pharma,1048,Pralia,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-13,N/A,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Osteoporosis,7/7/14 12:28
574,34,Daiichi-Sankyo,Regional & Specialty Pharma,1048,Pralia,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-13,N/A,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,13.92236386,39.91082282,67.75540658,95.60016846,110.7449447,126.8659948,140.4956775,151.5057612,40.63783157,1415,Osteoporosis,7/7/14 12:28
574,34,Daiichi-Sankyo,Regional & Specialty Pharma,1048,Pralia,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-13,N/A,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Osteoporosis,7/7/14 12:28
574,34,Daiichi-Sankyo,Regional & Specialty Pharma,1048,Pralia,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-13,N/A,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,13.92236386,39.91082282,67.75540658,95.60016846,110.7449447,126.8659948,140.4956775,151.5057612,40.63783157,1415,Osteoporosis,7/7/14 12:28
574,34,Daiichi-Sankyo,Regional & Specialty Pharma,1048,Pralia,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-13,N/A,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Osteoporosis,7/7/14 12:28
574,34,Daiichi-Sankyo,Regional & Specialty Pharma,1048,Pralia,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-13,N/A,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Osteoporosis,7/7/14 12:28
576,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,441,Depakene,sodium valproate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-75,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1639,Epilepsy,7/7/14 12:28
576,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,441,Depakene,sodium valproate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-75,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,Global,Sales,119.6968037,120.4977535,140.4845253,134.0516161,107.6141269,106.5892304,106.0767822,105.8205581,105.692446,105.62839,105.596362,105.580348,-0.272195379,1639,Epilepsy,7/7/14 12:28
576,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,441,Depakene,sodium valproate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-75,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1639,Epilepsy,7/7/14 12:28
576,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,441,Depakene,sodium valproate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-75,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,ROW,Sales,119.6968037,120.4977535,140.4845253,134.0516161,107.6141269,106.5892304,106.0767822,105.8205581,105.692446,105.62839,105.596362,105.580348,-0.272195379,1639,Epilepsy,7/7/14 12:28
576,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,441,Depakene,sodium valproate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-75,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1639,Epilepsy,7/7/14 12:28
576,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,441,Depakene,sodium valproate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-75,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1639,Epilepsy,7/7/14 12:28
577,89,Sanofi,Large Pharma,688,Depakine,sodium valproate,Small Molecule (Chemical),Launched,In-House,,Jul-67,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1639,Epilepsy,7/7/14 12:28
577,89,Sanofi,Large Pharma,688,Depakine,sodium valproate,Small Molecule (Chemical),Launched,In-House,,Jul-67,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,Global,Sales,457.1449745,492.8087893,539.4895706,526.9612437,537.852177,544.0939183,548.7287432,549.5959469,551.4008726,552.587162,553.2252393,553.801537,0.418338294,1639,Epilepsy,7/7/14 12:28
577,89,Sanofi,Large Pharma,688,Depakine,sodium valproate,Small Molecule (Chemical),Launched,In-House,,Jul-67,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1639,Epilepsy,7/7/14 12:28
577,89,Sanofi,Large Pharma,688,Depakine,sodium valproate,Small Molecule (Chemical),Launched,In-House,,Jul-67,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,ROW,Sales,457.1449745,492.8087893,539.4895706,526.9612437,537.852177,544.0939183,548.7287432,549.5959469,551.4008726,552.587162,553.2252393,553.801537,0.418338294,1639,Epilepsy,7/7/14 12:28
577,89,Sanofi,Large Pharma,688,Depakine,sodium valproate,Small Molecule (Chemical),Launched,In-House,,Jul-67,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1639,Epilepsy,7/7/14 12:28
577,89,Sanofi,Large Pharma,688,Depakine,sodium valproate,Small Molecule (Chemical),Launched,In-House,,Jul-67,N/A,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1639,Epilepsy,7/7/14 12:28
578,1,Abbott,Regional & Specialty Pharma,1024,Depakote,valproate semi-sodium,Small Molecule (Chemical),Launched,Licensed (Development),Jul-83,Jul-83,Jul-08,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,364,Epilepsy,7/7/14 12:28
578,1,Abbott,Regional & Specialty Pharma,1024,Depakote,valproate semi-sodium,Small Molecule (Chemical),Launched,Licensed (Development),Jul-83,Jul-83,Jul-08,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,325,255.6,211.9,156.93,81.96,80.99,80.02,79.05,78.08,77.11,76.14,75.17,-1.227814679,364,Epilepsy,7/7/14 12:28
578,1,Abbott,Regional & Specialty Pharma,1024,Depakote,valproate semi-sodium,Small Molecule (Chemical),Launched,Licensed (Development),Jul-83,Jul-83,Jul-08,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,364,Epilepsy,7/7/14 12:28
578,1,Abbott,Regional & Specialty Pharma,1024,Depakote,valproate semi-sodium,Small Molecule (Chemical),Launched,Licensed (Development),Jul-83,Jul-83,Jul-08,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,94,85,83.9,82.93,81.96,80.99,80.02,79.05,78.08,77.11,76.14,75.17,-1.227814679,364,Epilepsy,7/7/14 12:28
578,1,Abbott,Regional & Specialty Pharma,1024,Depakote,valproate semi-sodium,Small Molecule (Chemical),Launched,Licensed (Development),Jul-83,Jul-83,Jul-08,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,364,Epilepsy,7/7/14 12:28
578,1,Abbott,Regional & Specialty Pharma,1024,Depakote,valproate semi-sodium,Small Molecule (Chemical),Launched,Licensed (Development),Jul-83,Jul-83,Jul-08,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,231,170.6,128,74,0,0,0,0,0,0,0,0,0,364,Epilepsy,7/7/14 12:28
579,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,804,Depas,etizolam,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-84,N/A,Expired,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,365,Anxiety,7/7/14 12:28
579,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,804,Depas,etizolam,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-84,N/A,Expired,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,7,Global,Sales,125.0717113,133.0703055,143.2836326,125.2029029,102.2585069,99.76311247,97.46719656,96.03575421,94.89360931,94.0177963,93.37769324,92.89095859,-1.363160454,365,Anxiety,7/7/14 12:28
579,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,804,Depas,etizolam,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-84,N/A,Expired,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,365,Anxiety,7/7/14 12:28
579,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,804,Depas,etizolam,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-84,N/A,Expired,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,7,ROW,Sales,125.0717113,133.0703055,143.2836326,125.2029029,102.2585069,99.76311247,97.46719656,96.03575421,94.89360931,94.0177963,93.37769324,92.89095859,-1.363160454,365,Anxiety,7/7/14 12:28
579,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,804,Depas,etizolam,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-84,N/A,Expired,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,365,Anxiety,7/7/14 12:28
579,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,804,Depas,etizolam,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-84,N/A,Expired,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,365,Anxiety,7/7/14 12:28
580,76,Pfizer,Large Pharma,1316,Depo-Provera,medroxyprogesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-92,Jul-69,Aug-04,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1536,Female contraception,7/7/14 12:28
580,76,Pfizer,Large Pharma,1316,Depo-Provera,medroxyprogesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-92,Jul-69,Aug-04,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,121,130,139,148,191,207.66,222.649,236.60325,246.7887225,255.4139121,262.7012634,268.7605879,5.00024085,1536,Female contraception,7/7/14 12:28
580,76,Pfizer,Large Pharma,1316,Depo-Provera,medroxyprogesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-92,Jul-69,Aug-04,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1536,Female contraception,7/7/14 12:28
580,76,Pfizer,Large Pharma,1316,Depo-Provera,medroxyprogesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-92,Jul-69,Aug-04,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,97,104,110,115,134,143.76,153.024,162.112,169.53216,176.163584,182.051072,187.1848346,4.890935663,1536,Female contraception,7/7/14 12:28
580,76,Pfizer,Large Pharma,1316,Depo-Provera,medroxyprogesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-92,Jul-69,Aug-04,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1536,Female contraception,7/7/14 12:28
580,76,Pfizer,Large Pharma,1316,Depo-Provera,medroxyprogesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-92,Jul-69,Aug-04,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,24,26,29,33,57,63.9,69.625,74.49125,77.2565625,79.25032813,80.65019141,81.57575332,5.254547572,1536,Female contraception,7/7/14 12:28
581,76,Pfizer,Large Pharma,4383,Detrol / Detrol LA,tolterodine ,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-98,Oct-97,Mar-14,Sep-12,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1666,Overactive bladder,7/7/14 12:28
581,76,Pfizer,Large Pharma,4383,Detrol / Detrol LA,tolterodine ,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-98,Oct-97,Mar-14,Sep-12,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Sales,1154,1013,883,761,562,58.605,22.105,11.344,6.83,4.111,2.688,2.516,-53.8230506,1666,Overactive bladder,7/7/14 12:28
581,76,Pfizer,Large Pharma,4383,Detrol / Detrol LA,tolterodine ,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-98,Oct-97,Mar-14,Sep-12,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1666,Overactive bladder,7/7/14 12:28
581,76,Pfizer,Large Pharma,4383,Detrol / Detrol LA,tolterodine ,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-98,Oct-97,Mar-14,Sep-12,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,ROW,Sales,343,324,326,275,187,18.605,7.105,3.344,1.83,1.111,0.688,0.516,-56.9075167,1666,Overactive bladder,7/7/14 12:28
581,76,Pfizer,Large Pharma,4383,Detrol / Detrol LA,tolterodine ,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-98,Oct-97,Mar-14,Sep-12,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1666,Overactive bladder,7/7/14 12:28
581,76,Pfizer,Large Pharma,4383,Detrol / Detrol LA,tolterodine ,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-98,Oct-97,Mar-14,Sep-12,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Sales,811,689,557,486,375,40,15,8,5,3,2,2,-52.65372053,1666,Overactive bladder,7/7/14 12:28
583,39,Eli Lilly,Large Pharma,235,Diabetes compound 1,Diabetes compound,Recombinant Protein,Phase I,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1420,Diabetes,7/7/14 12:28
583,39,Eli Lilly,Large Pharma,235,Diabetes compound 1,Diabetes compound,Recombinant Protein,Phase I,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1420,Diabetes,7/7/14 12:28
583,39,Eli Lilly,Large Pharma,235,Diabetes compound 1,Diabetes compound,Recombinant Protein,Phase I,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1420,Diabetes,7/7/14 12:28
583,39,Eli Lilly,Large Pharma,235,Diabetes compound 1,Diabetes compound,Recombinant Protein,Phase I,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1420,Diabetes,7/7/14 12:28
583,39,Eli Lilly,Large Pharma,235,Diabetes compound 1,Diabetes compound,Recombinant Protein,Phase I,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1420,Diabetes,7/7/14 12:28
583,39,Eli Lilly,Large Pharma,235,Diabetes compound 1,Diabetes compound,Recombinant Protein,Phase I,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1420,Diabetes,7/7/14 12:28
586,19,Bayer,Large Pharma,1484,Diane,cyproterone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-78,Jan-78,N/A,Nov-08,160,Acne Treatments,73,Acne,6,Dermatology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1408,Acne associated with hyperandrogenism,7/7/14 12:28
586,19,Bayer,Large Pharma,1484,Diane,cyproterone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-78,Jan-78,N/A,Nov-08,160,Acne Treatments,73,Acne,6,Dermatology,2,Global,Sales,209.2340113,226.5330725,253.0595408,249.3426373,267.2609328,276.0208199,283.3387218,289.0867978,293.861768,297.7646098,300.9380788,303.5368856,1.834881568,1408,Acne associated with hyperandrogenism,7/7/14 12:28
586,19,Bayer,Large Pharma,1484,Diane,cyproterone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-78,Jan-78,N/A,Nov-08,160,Acne Treatments,73,Acne,6,Dermatology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1408,Acne associated with hyperandrogenism,7/7/14 12:28
586,19,Bayer,Large Pharma,1484,Diane,cyproterone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-78,Jan-78,N/A,Nov-08,160,Acne Treatments,73,Acne,6,Dermatology,2,ROW,Sales,209.2340113,226.5330725,253.0595408,249.3426373,267.2609328,276.0208199,283.3387218,289.0867978,293.861768,297.7646098,300.9380788,303.5368856,1.834881568,1408,Acne associated with hyperandrogenism,7/7/14 12:28
586,19,Bayer,Large Pharma,1484,Diane,cyproterone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-78,Jan-78,N/A,Nov-08,160,Acne Treatments,73,Acne,6,Dermatology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1408,Acne associated with hyperandrogenism,7/7/14 12:28
586,19,Bayer,Large Pharma,1484,Diane,cyproterone + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-78,Jan-78,N/A,Nov-08,160,Acne Treatments,73,Acne,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1408,Acne associated with hyperandrogenism,7/7/14 12:28
588,76,Pfizer,Large Pharma,917,Diflucan,fluconazole,Small Molecule (Chemical),Launched,In-House,Jul-88,Jul-88,Jul-04,Mar-03,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,372,,7/7/14 12:28
588,76,Pfizer,Large Pharma,917,Diflucan,fluconazole,Small Molecule (Chemical),Launched,In-House,Jul-88,Jul-88,Jul-04,Mar-03,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,336,278,265,259,242.43,231.8135,221.922175,211.8280238,202.7435279,194.1666005,186.0433748,178.4385499,-4.28366407,372,,7/7/14 12:28
588,76,Pfizer,Large Pharma,917,Diflucan,fluconazole,Small Molecule (Chemical),Launched,In-House,Jul-88,Jul-88,Jul-04,Mar-03,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,372,,7/7/14 12:28
588,76,Pfizer,Large Pharma,917,Diflucan,fluconazole,Small Molecule (Chemical),Launched,In-House,Jul-88,Jul-88,Jul-04,Mar-03,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,328,272,260,255,239.43,228.9135,219.077175,209.0087738,199.9292154,191.3544074,183.2319508,175.6273266,-4.330527373,372,,7/7/14 12:28
588,76,Pfizer,Large Pharma,917,Diflucan,fluconazole,Small Molecule (Chemical),Launched,In-House,Jul-88,Jul-88,Jul-04,Mar-03,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,372,,7/7/14 12:28
588,76,Pfizer,Large Pharma,917,Diflucan,fluconazole,Small Molecule (Chemical),Launched,In-House,Jul-88,Jul-88,Jul-04,Mar-03,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Sales,8,6,5,4,3,2.9,2.845,2.81925,2.8143125,2.812193125,2.811424031,2.811223245,-0.924167597,372,,7/7/14 12:28
589,86,Roche,Large Pharma,1026,Dilatrend,carvedilol,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Apr-91,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1382,Hypertension ,7/7/14 12:28
589,86,Roche,Large Pharma,1026,Dilatrend,carvedilol,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Apr-91,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,5,Global,Sales,195.2087905,171.6792096,167.8789103,133.8642895,114.8577513,99.43569488,87.55450329,78.49408757,71.55943363,66.25876589,62.20516138,59.10575494,-9.054462808,1382,Hypertension ,7/7/14 12:28
589,86,Roche,Large Pharma,1026,Dilatrend,carvedilol,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Apr-91,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1382,Hypertension ,7/7/14 12:28
589,86,Roche,Large Pharma,1026,Dilatrend,carvedilol,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Apr-91,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,5,ROW,Sales,195.2087905,171.6792096,167.8789103,133.8642895,114.8577513,99.43569488,87.55450329,78.49408757,71.55943363,66.25876589,62.20516138,59.10575494,-9.054462808,1382,Hypertension ,7/7/14 12:28
589,86,Roche,Large Pharma,1026,Dilatrend,carvedilol,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Apr-91,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1382,Hypertension ,7/7/14 12:28
589,86,Roche,Large Pharma,1026,Dilatrend,carvedilol,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Apr-91,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1382,Hypertension ,7/7/14 12:28
591,67,Novartis,Large Pharma,950,Diovan,valsartan,Small Molecule (Chemical),Launched,In-House,Jul-98,Jan-96,Sep-12,Nov-11,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,374,Hypertension,7/7/14 12:28
591,67,Novartis,Large Pharma,950,Diovan,valsartan,Small Molecule (Chemical),Launched,In-House,Jul-98,Jan-96,Sep-12,Nov-11,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,6013,6053,5665,4417,3524,2194.136,1643.562724,1459.192197,1252.281708,1145.54827,1042.683319,1010.835769,-16.33944351,374,Hypertension,7/7/14 12:28
591,67,Novartis,Large Pharma,950,Diovan,valsartan,Small Molecule (Chemical),Launched,In-House,Jul-98,Jan-96,Sep-12,Nov-11,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,374,Hypertension,7/7/14 12:28
591,67,Novartis,Large Pharma,950,Diovan,valsartan,Small Molecule (Chemical),Launched,In-House,Jul-98,Jan-96,Sep-12,Nov-11,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,3521,3533,3332,2330,1845,1605.168,1469.7989,1333.774206,1168.074502,1086.980659,1008.129001,976.6437064,-8.686646104,374,Hypertension,7/7/14 12:28
591,67,Novartis,Large Pharma,950,Diovan,valsartan,Small Molecule (Chemical),Launched,In-House,Jul-98,Jan-96,Sep-12,Nov-11,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,374,Hypertension,7/7/14 12:28
591,67,Novartis,Large Pharma,950,Diovan,valsartan,Small Molecule (Chemical),Launched,In-House,Jul-98,Jan-96,Sep-12,Nov-11,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,2492,2520,2333,2087,1679,588.968,173.763824,125.4179912,84.20720625,58.56761148,34.55431773,34.19206216,-42.66617738,374,Hypertension,7/7/14 12:28
593,16,AstraZeneca,Large Pharma,1357,Diprivan,propofol,Small Molecule (Chemical),Launched,In-House,Apr-96,Dec-86,Expired,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,375,Anesthesia,7/7/14 12:28
593,16,AstraZeneca,Large Pharma,1357,Diprivan,propofol,Small Molecule (Chemical),Launched,In-House,Apr-96,Dec-86,Expired,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,290,322,294,291,289,288.325,287.719375,287.2599531,286.9044215,286.629981,286.4180688,286.254445,-0.136272713,375,Anesthesia,7/7/14 12:28
593,16,AstraZeneca,Large Pharma,1357,Diprivan,propofol,Small Molecule (Chemical),Launched,In-House,Apr-96,Dec-86,Expired,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,375,Anesthesia,7/7/14 12:28
593,16,AstraZeneca,Large Pharma,1357,Diprivan,propofol,Small Molecule (Chemical),Launched,In-House,Apr-96,Dec-86,Expired,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,245,277,282,291,289,288.325,287.719375,287.2599531,286.9044215,286.629981,286.4180688,286.254445,-0.136272713,375,Anesthesia,7/7/14 12:28
593,16,AstraZeneca,Large Pharma,1357,Diprivan,propofol,Small Molecule (Chemical),Launched,In-House,Apr-96,Dec-86,Expired,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,375,Anesthesia,7/7/14 12:28
593,16,AstraZeneca,Large Pharma,1357,Diprivan,propofol,Small Molecule (Chemical),Launched,In-House,Apr-96,Dec-86,Expired,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,45,45,12,0,0,0,0,0,0,0,0,0,0,375,Anesthesia,7/7/14 12:28
595,53,Johnson & Johnson,Large Pharma,178,Ditropan XL,oxybutynin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Jun-00,Expired,May-16,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,376,Overactive bladder,7/7/14 12:28
595,53,Johnson & Johnson,Large Pharma,178,Ditropan XL,oxybutynin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Jun-00,Expired,May-16,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Sales,57.831,48.57465,44.9018125,41.76602312,39.88906153,38.53394002,37.48907161,25.11418112,13.48619775,10.0703375,8.379132992,7.393201607,-21.3994405,376,Overactive bladder,7/7/14 12:28
595,53,Johnson & Johnson,Large Pharma,178,Ditropan XL,oxybutynin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Jun-00,Expired,May-16,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,376,Overactive bladder,7/7/14 12:28
595,53,Johnson & Johnson,Large Pharma,178,Ditropan XL,oxybutynin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Jun-00,Expired,May-16,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,ROW,Sales,46.866,43.2954,40.7349,38,36.290168,34.9776764,33.94797116,21.57846032,9.952053423,6.536736654,4.845714203,3.859839756,-27.39462836,376,Overactive bladder,7/7/14 12:28
595,53,Johnson & Johnson,Large Pharma,178,Ditropan XL,oxybutynin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Jun-00,Expired,May-16,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,376,Overactive bladder,7/7/14 12:28
595,53,Johnson & Johnson,Large Pharma,178,Ditropan XL,oxybutynin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Jun-00,Expired,May-16,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Sales,10.965,5.27925,4.1669125,3.766023125,3.598893531,3.55626362,3.541100449,3.535720802,3.534144326,3.533600849,3.533418788,3.533361851,-0.262179192,376,Overactive bladder,7/7/14 12:28
596,10,Almirall,Regional & Specialty Pharma,1252,Dobupal,venlafaxine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-99,N/A,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1681,Depression,7/7/14 12:28
596,10,Almirall,Regional & Specialty Pharma,1252,Dobupal,venlafaxine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-99,N/A,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,2,Global,Sales,47.93769489,40.53749718,20.85655556,10.28217061,6.651279113,4.992632627,4.288681639,3.993356955,3.868447496,3.815918228,3.793738387,3.784399749,-7.740062968,1681,Depression,7/7/14 12:28
596,10,Almirall,Regional & Specialty Pharma,1252,Dobupal,venlafaxine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-99,N/A,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1681,Depression,7/7/14 12:28
596,10,Almirall,Regional & Specialty Pharma,1252,Dobupal,venlafaxine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-99,N/A,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,2,ROW,Sales,47.93769489,40.53749718,20.85655556,10.28217061,6.651279113,4.992632627,4.288681639,3.993356955,3.868447496,3.815918228,3.793738387,3.784399749,-7.740062968,1681,Depression,7/7/14 12:28
596,10,Almirall,Regional & Specialty Pharma,1252,Dobupal,venlafaxine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-99,N/A,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1681,Depression,7/7/14 12:28
596,10,Almirall,Regional & Specialty Pharma,1252,Dobupal,venlafaxine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-99,N/A,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1681,Depression,7/7/14 12:28
598,53,Johnson & Johnson,Large Pharma,1355,Doribax,doripenem,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-07,Sep-08,Jun-15,Jul-18,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1424,Bacterial infections,7/7/14 12:28
598,53,Johnson & Johnson,Large Pharma,1355,Doribax,doripenem,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-07,Sep-08,Jun-15,Jul-18,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,138,196.2271,232.1209107,247.5420887,258.2276679,264.2710395,215.9585569,149.5459273,134.8248678,110.2180225,72.69891285,59.36873877,-18.94241325,1424,Bacterial infections,7/7/14 12:28
598,53,Johnson & Johnson,Large Pharma,1355,Doribax,doripenem,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-07,Sep-08,Jun-15,Jul-18,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1424,Bacterial infections,7/7/14 12:28
598,53,Johnson & Johnson,Large Pharma,1355,Doribax,doripenem,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-07,Sep-08,Jun-15,Jul-18,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,38,58.7271,79.45424267,86.00875108,90.10099618,92.54836726,93.67704548,94.31214532,94.6558336,78.23661988,46.32475147,37.04165208,-11.92521501,1424,Bacterial infections,7/7/14 12:28
598,53,Johnson & Johnson,Large Pharma,1355,Doribax,doripenem,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-07,Sep-08,Jun-15,Jul-18,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1424,Bacterial infections,7/7/14 12:28
598,53,Johnson & Johnson,Large Pharma,1355,Doribax,doripenem,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-07,Sep-08,Jun-15,Jul-18,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,100,137.5,152.666668,161.5333376,168.1266717,171.7226723,122.2815115,55.23378198,40.16903417,31.98140262,26.37416138,22.32708669,-25.05505738,1424,Bacterial infections,7/7/14 12:28
599,15,Astellas Pharma,Regional & Specialty Pharma,1701,Dorner,beraprost,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-92,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1360,,7/7/14 12:28
599,15,Astellas Pharma,Regional & Specialty Pharma,1701,Dorner,beraprost,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-92,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,70.026188,64.90095601,63.30830193,51.76658466,38.25734453,34.59269363,31.94367456,30.02376395,28.63364591,27.62675963,26.89755335,26.36942167,-5.177308633,1360,,7/7/14 12:28
599,15,Astellas Pharma,Regional & Specialty Pharma,1701,Dorner,beraprost,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-92,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1360,,7/7/14 12:28
599,15,Astellas Pharma,Regional & Specialty Pharma,1701,Dorner,beraprost,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-92,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,70.026188,64.90095601,63.30830193,51.76658466,38.25734453,34.59269363,31.94367456,30.02376395,28.63364591,27.62675963,26.89755335,26.36942167,-5.177308633,1360,,7/7/14 12:28
599,15,Astellas Pharma,Regional & Specialty Pharma,1701,Dorner,beraprost,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-92,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1360,,7/7/14 12:28
599,15,Astellas Pharma,Regional & Specialty Pharma,1701,Dorner,beraprost,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-92,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1360,,7/7/14 12:28
600,67,Novartis,Large Pharma,1018,dovitinib,TKI258,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,378,Solid Tumors,7/7/14 12:28
600,67,Novartis,Large Pharma,1018,dovitinib,TKI258,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,378,Solid Tumors,7/7/14 12:28
600,67,Novartis,Large Pharma,1018,dovitinib,TKI258,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,378,Solid Tumors,7/7/14 12:28
600,67,Novartis,Large Pharma,1018,dovitinib,TKI258,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,378,Solid Tumors,7/7/14 12:28
600,67,Novartis,Large Pharma,1018,dovitinib,TKI258,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,378,Solid Tumors,7/7/14 12:28
600,67,Novartis,Large Pharma,1018,dovitinib,TKI258,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,378,Solid Tumors,7/7/14 12:28
601,53,Johnson & Johnson,Large Pharma,3910,Doxil / Caelyx,doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-95,Apr-07,Feb-13,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1427,Ovarian Cancer,7/7/14 12:28
601,53,Johnson & Johnson,Large Pharma,3910,Doxil / Caelyx,doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-95,Apr-07,Feb-13,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,302,340,402,83,434,423.951573,411.2302158,403.3333333,392.7933716,381.8979283,372.4542333,364.2043478,-2.473596178,1427,Ovarian Cancer,7/7/14 12:28
601,53,Johnson & Johnson,Large Pharma,3910,Doxil / Caelyx,doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-95,Apr-07,Feb-13,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1427,Ovarian Cancer,7/7/14 12:28
601,53,Johnson & Johnson,Large Pharma,3910,Doxil / Caelyx,doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-95,Apr-07,Feb-13,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,22,35,262,40,289,311,314,320,320.87,321.38,321.6209,323,1.601626771,1427,Ovarian Cancer,7/7/14 12:28
601,53,Johnson & Johnson,Large Pharma,3910,Doxil / Caelyx,doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-95,Apr-07,Feb-13,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1427,Ovarian Cancer,7/7/14 12:28
601,53,Johnson & Johnson,Large Pharma,3910,Doxil / Caelyx,doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-95,Apr-07,Feb-13,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,280,305,140,43,145,112.951573,97.23021583,83.33333333,71.92337165,60.51792829,50.83333333,41.20434783,-16.45136289,1427,Ovarian Cancer,7/7/14 12:28
603,34,Daiichi-Sankyo,Regional & Specialty Pharma,3539,Lixiana,edoxaban,Small Molecule (Chemical),Launched,In-House,Dec-14,Jul-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,389,Venous Thromboembolism,7/7/14 12:28
603,34,Daiichi-Sankyo,Regional & Specialty Pharma,3539,Lixiana,edoxaban,Small Molecule (Chemical),Launched,In-House,Dec-14,Jul-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,0,0,13.78834175,18.75317762,22.78260803,80.13114959,289.7417063,465.1575215,651.9277313,803.3961107,928.5078082,1028.998406,72.34606525,389,Venous Thromboembolism,7/7/14 12:28
603,34,Daiichi-Sankyo,Regional & Specialty Pharma,3539,Lixiana,edoxaban,Small Molecule (Chemical),Launched,In-House,Dec-14,Jul-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,389,Venous Thromboembolism,7/7/14 12:28
603,34,Daiichi-Sankyo,Regional & Specialty Pharma,3539,Lixiana,edoxaban,Small Molecule (Chemical),Launched,In-House,Dec-14,Jul-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,0,0,13.78834175,18.75317762,22.78260803,29.7925887,105.1668153,179.9062561,265.9998843,360.7403264,437.2198869,489.3735616,54.98541086,389,Venous Thromboembolism,7/7/14 12:28
603,34,Daiichi-Sankyo,Regional & Specialty Pharma,3539,Lixiana,edoxaban,Small Molecule (Chemical),Launched,In-House,Dec-14,Jul-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,389,Venous Thromboembolism,7/7/14 12:28
603,34,Daiichi-Sankyo,Regional & Specialty Pharma,3539,Lixiana,edoxaban,Small Molecule (Chemical),Launched,In-House,Dec-14,Jul-11,N/A,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,50.33856089,184.574891,285.2512654,385.927847,442.6557843,491.2879213,539.6248445,0,389,Venous Thromboembolism,7/7/14 12:28
605,1,Abbott,Regional & Specialty Pharma,184,Duodopa / Duopa,levodopa + carbidopa,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-05,N/A,Jan-14,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2177,Parkinson's Disease,7/7/14 12:28
605,1,Abbott,Regional & Specialty Pharma,184,Duodopa / Duopa,levodopa + carbidopa,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-05,N/A,Jan-14,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,87.75,121,141,0,0,0,0,0,0,0,0,0,2177,Parkinson's Disease,7/7/14 12:28
605,1,Abbott,Regional & Specialty Pharma,184,Duodopa / Duopa,levodopa + carbidopa,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-05,N/A,Jan-14,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2177,Parkinson's Disease,7/7/14 12:28
605,1,Abbott,Regional & Specialty Pharma,184,Duodopa / Duopa,levodopa + carbidopa,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-05,N/A,Jan-14,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,87.75,121,141,0,0,0,0,0,0,0,0,0,2177,Parkinson's Disease,7/7/14 12:28
605,1,Abbott,Regional & Specialty Pharma,184,Duodopa / Duopa,levodopa + carbidopa,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-05,N/A,Jan-14,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2177,Parkinson's Disease,7/7/14 12:28
605,1,Abbott,Regional & Specialty Pharma,184,Duodopa / Duopa,levodopa + carbidopa,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-05,N/A,Jan-14,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2177,Parkinson's Disease,7/7/14 12:28
605,1,Solvay,Regional & Specialty Pharma,184,Duodopa / Duopa,levodopa + carbidopa,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-05,N/A,Jan-14,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,Global,Proforma,82,11.25,0,0,0,0,0,0,0,0,0,0,0,2177,Parkinson's Disease,7/7/14 12:28
605,1,Solvay,Regional & Specialty Pharma,184,Duodopa / Duopa,levodopa + carbidopa,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-05,N/A,Jan-14,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Proforma,82,11.25,0,0,0,0,0,0,0,0,0,0,0,2177,Parkinson's Disease,7/7/14 12:28
606,1,Abbott,Regional & Specialty Pharma,539,Duphalac,lactulose,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-50,Expired,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1507,Constipation,7/7/14 12:28
606,1,Abbott,Regional & Specialty Pharma,539,Duphalac,lactulose,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-50,Expired,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,119.75,133.1,128.54,124.46,120.8696,117.72464,114.95216,112.5139136,110.3700262,108.4836954,106.8245106,-2.159160861,1507,Constipation,7/7/14 12:28
606,1,Abbott,Regional & Specialty Pharma,539,Duphalac,lactulose,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-50,Expired,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1507,Constipation,7/7/14 12:28
606,1,Abbott,Regional & Specialty Pharma,539,Duphalac,lactulose,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-50,Expired,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,119.75,133.1,128.54,124.46,120.8696,117.72464,114.95216,112.5139136,110.3700262,108.4836954,106.8245106,-2.159160861,1507,Constipation,7/7/14 12:28
606,1,Abbott,Regional & Specialty Pharma,539,Duphalac,lactulose,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-50,Expired,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1507,Constipation,7/7/14 12:28
606,1,Abbott,Regional & Specialty Pharma,539,Duphalac,lactulose,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-50,Expired,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1507,Constipation,7/7/14 12:28
606,1,Solvay,Regional & Specialty Pharma,539,Duphalac,lactulose,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-50,Expired,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Proforma,144.5,18.75,0,0,0,0,0,0,0,0,0,0,0,1507,Constipation,7/7/14 12:28
606,1,Solvay,Regional & Specialty Pharma,539,Duphalac,lactulose,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-50,Expired,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Proforma,144.5,18.75,0,0,0,0,0,0,0,0,0,0,0,1507,Constipation,7/7/14 12:28
607,1,Abbott,Regional & Specialty Pharma,1284,Duphaston,dydrogesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-61,N/A,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1434,Estrogen deficiency,7/7/14 12:28
607,1,Abbott,Regional & Specialty Pharma,1284,Duphaston,dydrogesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-61,N/A,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Sales,0,118.875,223,259,271.66,281.899,286.73425,289.1406475,290.5511196,291.2693812,291.6484468,291.8545785,1.029611586,1434,Estrogen deficiency,7/7/14 12:28
607,1,Abbott,Regional & Specialty Pharma,1284,Duphaston,dydrogesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-61,N/A,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1434,Estrogen deficiency,7/7/14 12:28
607,1,Abbott,Regional & Specialty Pharma,1284,Duphaston,dydrogesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-61,N/A,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Sales,0,118.875,223,259,271.66,281.899,286.73425,289.1406475,290.5511196,291.2693812,291.6484468,291.8545785,1.029611586,1434,Estrogen deficiency,7/7/14 12:28
607,1,Abbott,Regional & Specialty Pharma,1284,Duphaston,dydrogesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-61,N/A,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1434,Estrogen deficiency,7/7/14 12:28
607,1,Abbott,Regional & Specialty Pharma,1284,Duphaston,dydrogesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-61,N/A,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1434,Estrogen deficiency,7/7/14 12:28
607,1,Solvay,Regional & Specialty Pharma,1284,Duphaston,dydrogesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-61,N/A,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Proforma,144.5,19.125,0,0,0,0,0,0,0,0,0,0,0,1434,Estrogen deficiency,7/7/14 12:28
607,1,Solvay,Regional & Specialty Pharma,1284,Duphaston,dydrogesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-61,N/A,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Proforma,144.5,19.125,0,0,0,0,0,0,0,0,0,0,0,1434,Estrogen deficiency,7/7/14 12:28
608,53,Johnson & Johnson,Large Pharma,4680,Duragesic / Durogesic,fentanyl - transdermal,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-91,Mar-94,Jan-05,Jan-05,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1669,Chronic Pain,7/7/14 12:28
608,53,Johnson & Johnson,Large Pharma,4680,Duragesic / Durogesic,fentanyl - transdermal,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-91,Mar-94,Jan-05,Jan-05,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,888,748,589,486.1,407.965,350.56675,307.0643125,273.8744819,248.2492835,228.3152759,212.7052226,200.4201061,-9.655302084,1669,Chronic Pain,7/7/14 12:28
608,53,Johnson & Johnson,Large Pharma,4680,Duragesic / Durogesic,fentanyl - transdermal,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-91,Mar-94,Jan-05,Jan-05,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1669,Chronic Pain,7/7/14 12:28
608,53,Johnson & Johnson,Large Pharma,4680,Duragesic / Durogesic,fentanyl - transdermal,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-91,Mar-94,Jan-05,Jan-05,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,672,586,499,429.4,373.72,329.176,293.5408,265.03264,242.226112,223.9808896,209.3847117,197.7077693,-8.694527059,1669,Chronic Pain,7/7/14 12:28
608,53,Johnson & Johnson,Large Pharma,4680,Duragesic / Durogesic,fentanyl - transdermal,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-91,Mar-94,Jan-05,Jan-05,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1669,Chronic Pain,7/7/14 12:28
608,53,Johnson & Johnson,Large Pharma,4680,Duragesic / Durogesic,fentanyl - transdermal,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-91,Mar-94,Jan-05,Jan-05,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,216,162,90,56.7,34.245,21.39075,13.5235125,8.841841875,6.023171531,4.334386317,3.320510941,2.712336777,-30.38894425,1669,Chronic Pain,7/7/14 12:28
610,1,Abbott,Regional & Specialty Pharma,1390,Duspatal,mebeverine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-65,N/A,Expired,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1534,IBS,7/7/14 12:28
610,1,Abbott,Regional & Specialty Pharma,1390,Duspatal,mebeverine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-65,N/A,Expired,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,71.28,76.342,71.3188,66.83432,63.031248,59.7162272,56.86899008,54.40408691,52.2792308,50.44332708,48.85902315,-4.376722301,1534,IBS,7/7/14 12:28
610,1,Abbott,Regional & Specialty Pharma,1390,Duspatal,mebeverine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-65,N/A,Expired,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1534,IBS,7/7/14 12:28
610,1,Abbott,Regional & Specialty Pharma,1390,Duspatal,mebeverine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-65,N/A,Expired,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,71.28,76.342,71.3188,66.83432,63.031248,59.7162272,56.86899008,54.40408691,52.2792308,50.44332708,48.85902315,-4.376722301,1534,IBS,7/7/14 12:28
610,1,Abbott,Regional & Specialty Pharma,1390,Duspatal,mebeverine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-65,N/A,Expired,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1534,IBS,7/7/14 12:28
610,1,Abbott,Regional & Specialty Pharma,1390,Duspatal,mebeverine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-65,N/A,Expired,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1534,IBS,7/7/14 12:28
610,1,Solvay,Regional & Specialty Pharma,1390,Duspatal,mebeverine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-65,N/A,Expired,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Proforma,88.9,11.25,0,0,0,0,0,0,0,0,0,0,0,1534,IBS,7/7/14 12:28
610,1,Solvay,Regional & Specialty Pharma,1390,Duspatal,mebeverine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-65,N/A,Expired,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Proforma,88.9,11.25,0,0,0,0,0,0,0,0,0,0,0,1534,IBS,7/7/14 12:28
612,37,Eisai,Regional & Specialty Pharma,1462,eritoran,E-5564,Small Molecule (Chemical),Phase III,In-House,Feb-17,Sep-17,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,398,Severe sepsis,7/7/14 12:28
612,37,Eisai,Regional & Specialty Pharma,1462,eritoran,E-5564,Small Molecule (Chemical),Phase III,In-House,Feb-17,Sep-17,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,2.08369057,16.80843671,29.17165428,40.84031374,50.33861123,0,398,Severe sepsis,7/7/14 12:28
612,37,Eisai,Regional & Specialty Pharma,1462,eritoran,E-5564,Small Molecule (Chemical),Phase III,In-House,Feb-17,Sep-17,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,398,Severe sepsis,7/7/14 12:28
612,37,Eisai,Regional & Specialty Pharma,1462,eritoran,E-5564,Small Molecule (Chemical),Phase III,In-House,Feb-17,Sep-17,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,2.917159296,6.945610427,10.27950343,20.13544449,0,398,Severe sepsis,7/7/14 12:28
612,37,Eisai,Regional & Specialty Pharma,1462,eritoran,E-5564,Small Molecule (Chemical),Phase III,In-House,Feb-17,Sep-17,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,398,Severe sepsis,7/7/14 12:28
612,37,Eisai,Regional & Specialty Pharma,1462,eritoran,E-5564,Small Molecule (Chemical),Phase III,In-House,Feb-17,Sep-17,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,2.08369057,13.89127741,22.22604386,30.5608103,30.20316674,0,398,Severe sepsis,7/7/14 12:28
613,10,Almirall,Regional & Specialty Pharma,1364,Ebastel,ebastine,Small Molecule (Chemical),Launched,In-House,,Jan-90,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1436,Allergic Rhinitis,7/7/14 12:28
613,10,Almirall,Regional & Specialty Pharma,1364,Ebastel,ebastine,Small Molecule (Chemical),Launched,In-House,,Jan-90,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,Global,Sales,158.9586173,155.6586902,161.5687838,116.8311635,100.7974821,92.00592302,85.44279843,81.70412819,79.51006316,78.15404885,77.35135667,76.86933232,-3.7975305,1436,Allergic Rhinitis,7/7/14 12:28
613,10,Almirall,Regional & Specialty Pharma,1364,Ebastel,ebastine,Small Molecule (Chemical),Launched,In-House,,Jan-90,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1436,Allergic Rhinitis,7/7/14 12:28
613,10,Almirall,Regional & Specialty Pharma,1364,Ebastel,ebastine,Small Molecule (Chemical),Launched,In-House,,Jan-90,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,ROW,Sales,158.9586173,155.6586902,161.5687838,116.8311635,100.7974821,92.00592302,85.44279843,81.70412819,79.51006316,78.15404885,77.35135667,76.86933232,-3.7975305,1436,Allergic Rhinitis,7/7/14 12:28
613,10,Almirall,Regional & Specialty Pharma,1364,Ebastel,ebastine,Small Molecule (Chemical),Launched,In-House,,Jan-90,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1436,Allergic Rhinitis,7/7/14 12:28
613,10,Almirall,Regional & Specialty Pharma,1364,Ebastel,ebastine,Small Molecule (Chemical),Launched,In-House,,Jan-90,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1436,Allergic Rhinitis,7/7/14 12:28
614,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1364,Ebastel,ebastine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-96,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1436,Allergic rhinitis,7/7/14 12:28
614,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1364,Ebastel,ebastine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-96,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,Global,Sales,99.11398917,100.3863708,83.56695855,72.5122868,50.33861123,53.76575461,52.18094816,40.27088898,37.97287184,35.9572768,34.325591,33.57354106,-5.621978053,1436,Allergic rhinitis,7/7/14 12:28
614,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1364,Ebastel,ebastine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-96,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1436,Allergic rhinitis,7/7/14 12:28
614,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1364,Ebastel,ebastine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-96,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,ROW,Sales,99.11398917,100.3863708,83.56695855,72.5122868,50.33861123,53.76575461,52.18094816,40.27088898,37.97287184,35.9572768,34.325591,33.57354106,-5.621978053,1436,Allergic rhinitis,7/7/14 12:28
614,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1364,Ebastel,ebastine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-96,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1436,Allergic rhinitis,7/7/14 12:28
614,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1364,Ebastel,ebastine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-96,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1436,Allergic rhinitis,7/7/14 12:28
615,58,Lundbeck,Regional & Specialty Pharma,826,Ebixa,memantine,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-02,N/A,Apr-13,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1539,Alzheimer's Disease,7/7/14 12:28
615,58,Lundbeck,Regional & Specialty Pharma,826,Ebixa,memantine,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-02,N/A,Apr-13,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,1,Global,Sales,403.4334764,427.4336637,513.4067083,483.9774904,373.2409728,203.295846,98.86297729,65.11055981,48.59772932,38.96874861,32.25174348,27.45951268,-31.11880646,1539,Alzheimer's Disease,7/7/14 12:28
615,58,Lundbeck,Regional & Specialty Pharma,826,Ebixa,memantine,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-02,N/A,Apr-13,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1539,Alzheimer's Disease,7/7/14 12:28
615,58,Lundbeck,Regional & Specialty Pharma,826,Ebixa,memantine,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-02,N/A,Apr-13,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,1,ROW,Sales,403.4334764,427.4336637,513.4067083,483.9774904,373.2409728,203.295846,98.86297729,65.11055981,48.59772932,38.96874861,32.25174348,27.45951268,-31.11880646,1539,Alzheimer's Disease,7/7/14 12:28
615,58,Lundbeck,Regional & Specialty Pharma,826,Ebixa,memantine,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-02,N/A,Apr-13,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1539,Alzheimer's Disease,7/7/14 12:28
615,58,Lundbeck,Regional & Specialty Pharma,826,Ebixa,memantine,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-02,N/A,Apr-13,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1539,Alzheimer's Disease,7/7/14 12:28
618,29,Chugai,Regional & Specialty Pharma,3364,Edirol,eldecalcitol,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-11,N/A,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,3,Global,Alliance Revenue,0,0,16.30623954,98.97268855,153.7344669,184.4813603,215.2282537,246.5490891,271.3761806,293.7435207,313.6602923,330.9674972,11.57666986,1440,Osteoporosis,7/7/14 12:28
618,29,Chugai,Regional & Specialty Pharma,3364,Edirol,eldecalcitol,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-11,N/A,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,3,ROW,Alliance Revenue,0,0,16.30623954,98.97268855,153.7344669,184.4813603,215.2282537,246.5490891,271.3761806,293.7435207,313.6602923,330.9674972,11.57666986,1440,Osteoporosis,7/7/14 12:28
618,29,Chugai,Regional & Specialty Pharma,3364,Edirol,eldecalcitol,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-11,N/A,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1440,Osteoporosis,7/7/14 12:28
618,86,Roche,Large Pharma,3364,Edirol,eldecalcitol,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-11,N/A,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,5,Global,Sales,0,0,16.30623954,98.97268855,153.7344669,184.4813603,215.2282537,246.5490891,271.3761806,293.7435207,313.6602923,330.9674972,11.57666986,1440,Osteoporosis,7/7/14 12:28
618,86,Roche,Large Pharma,3364,Edirol,eldecalcitol,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-11,N/A,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,5,ROW,Sales,0,0,16.30623954,98.97268855,153.7344669,184.4813603,215.2282537,246.5490891,271.3761806,293.7435207,313.6602923,330.9674972,11.57666986,1440,Osteoporosis,7/7/14 12:28
619,76,Pfizer,Large Pharma,1732,Effexor,venlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-94,Jul-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1681,Depression,7/7/14 12:28
619,76,Pfizer,Large Pharma,1732,Effexor,venlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-94,Jul-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Sales,520,1718,678,425,440,377.6,339.96,319.376,308.0256,301.71536,298.179216,296.1825296,-5.497380321,1681,Depression,7/7/14 12:28
619,76,Pfizer,Large Pharma,1732,Effexor,venlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-94,Jul-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1681,Depression,7/7/14 12:28
619,76,Pfizer,Large Pharma,1732,Effexor,venlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-94,Jul-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Sales,65,492,436,316,267,237.6,219.96,209.376,203.0256,199.21536,196.929216,195.5575296,-4.350988074,1681,Depression,7/7/14 12:28
619,76,Pfizer,Large Pharma,1732,Effexor,venlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-94,Jul-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1681,Depression,7/7/14 12:28
619,76,Pfizer,Large Pharma,1732,Effexor,venlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-94,Jul-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Sales,455,1226,242,109,173,140,120,110,105,102.5,101.25,100.625,-7.449236963,1681,Depression,7/7/14 12:28
619,76,Wyeth,Large Pharma,1732,Effexor,venlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-94,Jul-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Proforma,2410,0,0,0,0,0,0,0,0,0,0,0,0,1681,Depression,7/7/14 12:28
619,76,Wyeth,Large Pharma,1732,Effexor,venlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-94,Jul-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Proforma,515,0,0,0,0,0,0,0,0,0,0,0,0,1681,Depression,7/7/14 12:28
619,76,Wyeth,Large Pharma,1732,Effexor,venlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-94,Jul-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Proforma,1895,0,0,0,0,0,0,0,0,0,0,0,0,1681,Depression,7/7/14 12:28
620,96,Shire,Regional & Specialty Pharma,300,Elaprase,idonurate sulfatase,Recombinant Protein,Launched,Corporate Acquisition,Aug-06,Jan-07,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,405,Hunter Syndrome,7/7/14 12:28
620,96,Shire,Regional & Specialty Pharma,300,Elaprase,idonurate sulfatase,Recombinant Protein,Launched,Corporate Acquisition,Aug-06,Jan-07,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Sales,353.1,403.6,464.9,498,546,580.568,613.36032,642.7376768,668.4360504,691.601374,712.1407782,730.4481045,4.245341587,405,Hunter Syndrome,7/7/14 12:28
620,96,Shire,Regional & Specialty Pharma,300,Elaprase,idonurate sulfatase,Recombinant Protein,Launched,Corporate Acquisition,Aug-06,Jan-07,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,405,Hunter Syndrome,7/7/14 12:28
620,96,Shire,Regional & Specialty Pharma,300,Elaprase,idonurate sulfatase,Recombinant Protein,Launched,Corporate Acquisition,Aug-06,Jan-07,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Sales,202.1,232,270,292,320,341.6,361.504,379.40096,395.1138304,409.2283433,421.7644882,432.9330273,4.412608113,405,Hunter Syndrome,7/7/14 12:28
620,96,Shire,Regional & Specialty Pharma,300,Elaprase,idonurate sulfatase,Recombinant Protein,Launched,Corporate Acquisition,Aug-06,Jan-07,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,405,Hunter Syndrome,7/7/14 12:28
620,96,Shire,Regional & Specialty Pharma,300,Elaprase,idonurate sulfatase,Recombinant Protein,Launched,Corporate Acquisition,Aug-06,Jan-07,Sep-19,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Sales,151,171.6,194.9,206,226,238.968,251.85632,263.3367168,273.32222,282.3730307,290.3762901,297.5150771,4.005714761,405,Hunter Syndrome,7/7/14 12:28
622,14,Asahi Kasei Pharma,Regional & Specialty Pharma,436,Elcitonin,elcatonin,Synthetic Peptide,Launched,In-House,,Jul-81,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,150.8256,156.416,157.0046,125.0211841,81.00281485,69.07809192,58.82726928,50.7796288,45.08922182,40.70342573,37.39769679,34.93368597,-11.3210246,406,Osteoporosis,7/7/14 12:28
622,14,Asahi Kasei Pharma,Regional & Specialty Pharma,436,Elcitonin,elcatonin,Synthetic Peptide,Launched,In-House,,Jul-81,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,150.8256,156.416,157.0046,125.0211841,81.00281485,69.07809192,58.82726928,50.7796288,45.08922182,40.70342573,37.39769679,34.93368597,-11.3210246,406,Osteoporosis,7/7/14 12:28
622,14,Asahi Kasei Pharma,Regional & Specialty Pharma,436,Elcitonin,elcatonin,Synthetic Peptide,Launched,In-House,,Jul-81,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,406,Osteoporosis,7/7/14 12:28
625,67,Novartis,Large Pharma,278,Elidel,pimecrolimus,Small Molecule (Chemical),Launched,In-House,Feb-02,Aug-02,N/A,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,407,Atopic dermatitis,7/7/14 12:28
625,67,Novartis,Large Pharma,278,Elidel,pimecrolimus,Small Molecule (Chemical),Launched,In-House,Feb-02,Aug-02,N/A,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,Global,Sales,133.16,117.928,25,0,0,0,0,0,0,0,0,0,0,407,Atopic dermatitis,7/7/14 12:28
625,67,Novartis,Large Pharma,278,Elidel,pimecrolimus,Small Molecule (Chemical),Launched,In-House,Feb-02,Aug-02,N/A,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,407,Atopic dermatitis,7/7/14 12:28
625,67,Novartis,Large Pharma,278,Elidel,pimecrolimus,Small Molecule (Chemical),Launched,In-House,Feb-02,Aug-02,N/A,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,ROW,Sales,52.64,46.112,10,0,0,0,0,0,0,0,0,0,0,407,Atopic dermatitis,7/7/14 12:28
625,67,Novartis,Large Pharma,278,Elidel,pimecrolimus,Small Molecule (Chemical),Launched,In-House,Feb-02,Aug-02,N/A,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,407,Atopic dermatitis,7/7/14 12:28
625,67,Novartis,Large Pharma,278,Elidel,pimecrolimus,Small Molecule (Chemical),Launched,In-House,Feb-02,Aug-02,N/A,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,US,Sales,80.52,71.816,15,0,0,0,0,0,0,0,0,0,0,407,Atopic dermatitis,7/7/14 12:28
626,15,Astellas Pharma,Regional & Specialty Pharma,600,Eligard,leuprolide,Synthetic Peptide,Launched,Licensed (Development),,Dec-04,N/A,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2178,Prostate Cancer,7/7/14 12:28
626,15,Astellas Pharma,Regional & Specialty Pharma,600,Eligard,leuprolide,Synthetic Peptide,Launched,Licensed (Development),,Dec-04,N/A,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,7,Global,Sales,150.727447,165.428218,174.7309133,186.2815644,176.1851393,185.8531543,192.2972815,196.0029282,198.2665237,199.6146291,200.4260053,200.9122028,1.893889527,2178,Prostate Cancer,7/7/14 12:28
626,15,Astellas Pharma,Regional & Specialty Pharma,600,Eligard,leuprolide,Synthetic Peptide,Launched,Licensed (Development),,Dec-04,N/A,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2178,Prostate Cancer,7/7/14 12:28
626,15,Astellas Pharma,Regional & Specialty Pharma,600,Eligard,leuprolide,Synthetic Peptide,Launched,Licensed (Development),,Dec-04,N/A,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,7,ROW,Sales,150.727447,165.428218,174.7309133,186.2815644,176.1851393,185.8531543,192.2972815,196.0029282,198.2665237,199.6146291,200.4260053,200.9122028,1.893889527,2178,Prostate Cancer,7/7/14 12:28
626,15,Astellas Pharma,Regional & Specialty Pharma,600,Eligard,leuprolide,Synthetic Peptide,Launched,Licensed (Development),,Dec-04,N/A,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2178,Prostate Cancer,7/7/14 12:28
626,15,Astellas Pharma,Regional & Specialty Pharma,600,Eligard,leuprolide,Synthetic Peptide,Launched,Licensed (Development),,Dec-04,N/A,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2178,Prostate Cancer,7/7/14 12:28
627,89,Sanofi,Large Pharma,600,Eligard,leuprolide,Synthetic Peptide,Launched,Licensed (Development),May-02,,N/A,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2178,Prostate Cancer,7/7/14 12:28
627,89,Sanofi,Large Pharma,600,Eligard,leuprolide,Synthetic Peptide,Launched,Licensed (Development),May-02,,N/A,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,2,Global,Sales,94.48589138,90.51913192,96.53676346,90.16562524,90.79869598,90.40695164,89.94312969,89.40834166,89.09316351,88.8261501,88.60838855,88.44457527,-0.374565462,2178,Prostate Cancer,7/7/14 12:28
627,89,Sanofi,Large Pharma,600,Eligard,leuprolide,Synthetic Peptide,Launched,Licensed (Development),May-02,,N/A,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2178,Prostate Cancer,7/7/14 12:28
627,89,Sanofi,Large Pharma,600,Eligard,leuprolide,Synthetic Peptide,Launched,Licensed (Development),May-02,,N/A,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2178,Prostate Cancer,7/7/14 12:28
627,89,Sanofi,Large Pharma,600,Eligard,leuprolide,Synthetic Peptide,Launched,Licensed (Development),May-02,,N/A,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2178,Prostate Cancer,7/7/14 12:28
627,89,Sanofi,Large Pharma,600,Eligard,leuprolide,Synthetic Peptide,Launched,Licensed (Development),May-02,,N/A,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,2,US,Sales,94.48589138,90.51913192,96.53676346,90.16562524,90.79869598,90.40695164,89.94312969,89.40834166,89.09316351,88.8261501,88.60838855,88.44457527,-0.374565462,2178,Prostate Cancer,7/7/14 12:28
628,76,Pfizer,Large Pharma,1108,Ellence,epirubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,Sep-06,Expired,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1444,Breast Cancer,7/7/14 12:28
628,76,Pfizer,Large Pharma,1108,Ellence,epirubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,Sep-06,Expired,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1444,Breast Cancer,7/7/14 12:28
628,76,Pfizer,Large Pharma,1108,Ellence,epirubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,Sep-06,Expired,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1444,Breast Cancer,7/7/14 12:28
628,76,Pfizer,Large Pharma,1108,Ellence,epirubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,Sep-06,Expired,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1444,Breast Cancer,7/7/14 12:28
628,76,Pfizer,Large Pharma,1108,Ellence,epirubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,Sep-06,Expired,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1444,Breast Cancer,7/7/14 12:28
628,76,Pfizer,Large Pharma,1108,Ellence,epirubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,Sep-06,Expired,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1444,Breast Cancer,7/7/14 12:28
629,61,Merck & Co,Large Pharma,153,Elocon / Fulmeta,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-88,Jul-90,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1729,Atopic dermatitis,7/7/14 12:28
629,61,Merck & Co,Large Pharma,153,Elocon / Fulmeta,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-88,Jul-90,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,Global,Sales,35,221.513,233.59865,243.4683225,250.3713856,255.669817,259.6864814,262.6735015,264.9284363,266.6245835,267.8977577,268.855609,1.022752392,1729,Atopic dermatitis,7/7/14 12:28
629,61,Merck & Co,Large Pharma,153,Elocon / Fulmeta,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-88,Jul-90,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1729,Atopic dermatitis,7/7/14 12:28
629,61,Merck & Co,Large Pharma,153,Elocon / Fulmeta,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-88,Jul-90,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,ROW,Sales,35,220.7,232.79,242.663,249.5651,254.86367,258.880379,261.8673863,264.1223245,265.8184724,267.0916465,268.0494979,1.025967072,1729,Atopic dermatitis,7/7/14 12:28
629,61,Merck & Co,Large Pharma,153,Elocon / Fulmeta,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-88,Jul-90,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1729,Atopic dermatitis,7/7/14 12:28
629,61,Merck & Co,Large Pharma,153,Elocon / Fulmeta,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-88,Jul-90,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,US,Sales,0,0.813,0.80865,0.8053225,0.806285625,0.806146956,0.806102367,0.80611524,0.806111772,0.806111093,0.806111213,0.806111129,-3.09E-03,1729,Atopic dermatitis,7/7/14 12:28
629,61,Schering-Plough,Large Pharma,153,Elocon / Fulmeta,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-88,Jul-90,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,Global,Proforma,171.75,0,0,0,0,0,0,0,0,0,0,0,0,1729,Atopic dermatitis,7/7/14 12:28
629,61,Schering-Plough,Large Pharma,153,Elocon / Fulmeta,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-88,Jul-90,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,ROW,Proforma,171,0,0,0,0,0,0,0,0,0,0,0,0,1729,Atopic dermatitis,7/7/14 12:28
629,61,Schering-Plough,Large Pharma,153,Elocon / Fulmeta,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-88,Jul-90,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,US,Proforma,0.75,0,0,0,0,0,0,0,0,0,0,0,0,1729,Atopic dermatitis,7/7/14 12:28
630,24,Bristol-Myers Squibb,Large Pharma,422,elotuzumab,elotuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jun-15,Oct-15,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,413,Multiple Myeloma,7/7/14 12:28
630,24,Bristol-Myers Squibb,Large Pharma,422,elotuzumab,elotuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jun-15,Oct-15,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,14.66666,56.44440413,109.77768,163.111294,198.826931,229.9941215,0,413,Multiple Myeloma,7/7/14 12:28
630,24,Bristol-Myers Squibb,Large Pharma,422,elotuzumab,elotuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jun-15,Oct-15,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,413,Multiple Myeloma,7/7/14 12:28
630,24,Bristol-Myers Squibb,Large Pharma,422,elotuzumab,elotuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jun-15,Oct-15,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,3,17.00001,37.00001176,56.99999812,70.15999512,81.76599145,0,413,Multiple Myeloma,7/7/14 12:28
630,24,Bristol-Myers Squibb,Large Pharma,422,elotuzumab,elotuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jun-15,Oct-15,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,413,Multiple Myeloma,7/7/14 12:28
630,24,Bristol-Myers Squibb,Large Pharma,422,elotuzumab,elotuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jun-15,Oct-15,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,11.66666,39.44439413,72.77766827,106.1112959,128.6669359,148.2281301,0,413,Multiple Myeloma,7/7/14 12:28
631,89,Sanofi,Large Pharma,722,Eloxatin,oxaliplatin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-02,Oct-96,Aug-12,Apr-06,84,Alkylating Agents,51,Cytotoxics,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1573,Colorectal Cancer,7/7/14 12:28
631,89,Sanofi,Large Pharma,722,Eloxatin,oxaliplatin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-02,Oct-96,Aug-12,Apr-06,84,Alkylating Agents,51,Cytotoxics,3,Oncology,2,Global,Sales,1329.749971,565.6703039,1489.158067,1228.719388,293.4946447,267.5671722,255.8788866,250.9259408,248.6470974,247.6696825,247.2137133,246.8869756,-2.440143385,1573,Colorectal Cancer,7/7/14 12:28
631,89,Sanofi,Large Pharma,722,Eloxatin,oxaliplatin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-02,Oct-96,Aug-12,Apr-06,84,Alkylating Agents,51,Cytotoxics,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1573,Colorectal Cancer,7/7/14 12:28
631,89,Sanofi,Large Pharma,722,Eloxatin,oxaliplatin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-02,Oct-96,Aug-12,Apr-06,84,Alkylating Agents,51,Cytotoxics,3,Oncology,2,ROW,Sales,389.0595527,337.8124765,368.4658149,305.8945756,268.2620735,255.7121893,246.6583444,243.417785,241.5736244,240.8109164,240.4198861,240.2468253,-1.563328924,1573,Colorectal Cancer,7/7/14 12:28
631,89,Sanofi,Large Pharma,722,Eloxatin,oxaliplatin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-02,Oct-96,Aug-12,Apr-06,84,Alkylating Agents,51,Cytotoxics,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1573,Colorectal Cancer,7/7/14 12:28
631,89,Sanofi,Large Pharma,722,Eloxatin,oxaliplatin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-02,Oct-96,Aug-12,Apr-06,84,Alkylating Agents,51,Cytotoxics,3,Oncology,2,US,Sales,940.6904186,227.8578273,1120.692252,922.8248122,25.23257127,11.85498283,9.220542203,7.508155794,7.07347309,6.858766178,6.793827217,6.640150333,-17.36313086,1573,Colorectal Cancer,7/7/14 12:28
632,45,Gilead,Regional & Specialty Pharma,218,Vitekta,elvitegravir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-14,Dec-13,N/A,Jan-23,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,414,HIV,7/7/14 12:28
632,45,Gilead,Regional & Specialty Pharma,218,Vitekta,elvitegravir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-14,Dec-13,N/A,Jan-23,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0.9999996,25.50669453,74.38466878,118.5267994,144.6054915,166.2400396,182.7216243,194.6897614,112.3482635,414,HIV,7/7/14 12:28
632,45,Gilead,Regional & Specialty Pharma,218,Vitekta,elvitegravir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-14,Dec-13,N/A,Jan-23,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,414,HIV,7/7/14 12:28
632,45,Gilead,Regional & Specialty Pharma,218,Vitekta,elvitegravir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-14,Dec-13,N/A,Jan-23,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0.9999996,13.66669453,33.66667198,53.66669514,64.78670142,74.12270476,81.32510967,86.5007125,89.11102385,414,HIV,7/7/14 12:28
632,45,Gilead,Regional & Specialty Pharma,218,Vitekta,elvitegravir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-14,Dec-13,N/A,Jan-23,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,414,HIV,7/7/14 12:28
632,45,Gilead,Regional & Specialty Pharma,218,Vitekta,elvitegravir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-14,Dec-13,N/A,Jan-23,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,11.84,40.7179968,64.86010428,79.81879013,92.11733485,101.3965146,108.1890489,0,414,HIV,7/7/14 12:28
633,61,Merck & Co,Large Pharma,1902,Emend / Ivemend,aprepitant / fosaprepitant,Small Molecule (Chemical),Launched,In-House,Apr-03,Feb-04,Apr-15,Jul-18,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,418,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
633,61,Merck & Co,Large Pharma,1902,Emend / Ivemend,aprepitant / fosaprepitant,Small Molecule (Chemical),Launched,In-House,Apr-03,Feb-04,Apr-15,Jul-18,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,Global,Sales,313,377,419,481,507,530.72,363.89275,280.3948712,275.7612603,207.661013,94.4591292,67.67597868,-25.00003413,418,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
633,61,Merck & Co,Large Pharma,1902,Emend / Ivemend,aprepitant / fosaprepitant,Small Molecule (Chemical),Launched,In-House,Apr-03,Feb-04,Apr-15,Jul-18,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,418,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
633,61,Merck & Co,Large Pharma,1902,Emend / Ivemend,aprepitant / fosaprepitant,Small Molecule (Chemical),Launched,In-House,Apr-03,Feb-04,Apr-15,Jul-18,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,ROW,Sales,115,147,180,205,214,227.02,236.967,244.44265,250.9707975,188.8327512,79.44401458,53.58732665,-17.94733279,418,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
633,61,Merck & Co,Large Pharma,1902,Emend / Ivemend,aprepitant / fosaprepitant,Small Molecule (Chemical),Launched,In-House,Apr-03,Feb-04,Apr-15,Jul-18,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,418,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
633,61,Merck & Co,Large Pharma,1902,Emend / Ivemend,aprepitant / fosaprepitant,Small Molecule (Chemical),Launched,In-House,Apr-03,Feb-04,Apr-15,Jul-18,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,US,Sales,198,230,239,276,293,303.7,126.92575,35.95222125,24.79046281,18.82826178,15.01511462,14.08865203,-35.17914811,418,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
636,71,Orexigen Therapeutics,Small Biotech,1386,Empatic,bupropion + zonisamide,Small Molecule (Chemical),Phase II,In-House,Jan-15,,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,420,Obesity,7/7/14 12:28
636,71,Orexigen Therapeutics,Small Biotech,1386,Empatic,bupropion + zonisamide,Small Molecule (Chemical),Phase II,In-House,Jan-15,,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,420,Obesity,7/7/14 12:28
636,71,Orexigen Therapeutics,Small Biotech,1386,Empatic,bupropion + zonisamide,Small Molecule (Chemical),Phase II,In-House,Jan-15,,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,420,Obesity,7/7/14 12:28
636,71,Orexigen Therapeutics,Small Biotech,1386,Empatic,bupropion + zonisamide,Small Molecule (Chemical),Phase II,In-House,Jan-15,,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,420,Obesity,7/7/14 12:28
636,71,Orexigen Therapeutics,Small Biotech,1386,Empatic,bupropion + zonisamide,Small Molecule (Chemical),Phase II,In-House,Jan-15,,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,420,Obesity,7/7/14 12:28
636,71,Orexigen Therapeutics,Small Biotech,1386,Empatic,bupropion + zonisamide,Small Molecule (Chemical),Phase II,In-House,Jan-15,,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,420,Obesity,7/7/14 12:28
637,67,Novartis,Large Pharma,758,Enablex,darifenacin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-05,Jan-05,N/A,Mar-16,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,421,Overactive bladder,7/7/14 12:28
637,67,Novartis,Large Pharma,758,Enablex,darifenacin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-05,Jan-05,N/A,Mar-16,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Sales,222.98,245.422,66.07285,69,46,33.41186843,26.03656774,10.68542753,4.520443422,2.129403498,1.073024396,0.714055319,-44.84714781,421,Overactive bladder,7/7/14 12:28
637,67,Novartis,Large Pharma,758,Enablex,darifenacin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-05,Jan-05,N/A,Mar-16,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,421,Overactive bladder,7/7/14 12:28
637,67,Novartis,Large Pharma,758,Enablex,darifenacin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-05,Jan-05,N/A,Mar-16,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,ROW,Sales,53.98,60.763,66.07285,69,46,33.41186843,26.03656774,10.68542753,4.520443422,2.129403498,1.073024396,0.714055319,-44.84714781,421,Overactive bladder,7/7/14 12:28
637,67,Novartis,Large Pharma,758,Enablex,darifenacin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-05,Jan-05,N/A,Mar-16,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,421,Overactive bladder,7/7/14 12:28
637,67,Novartis,Large Pharma,758,Enablex,darifenacin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-05,Jan-05,N/A,Mar-16,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Sales,169,184.659,0,0,0,0,0,0,0,0,0,0,0,421,Overactive bladder,7/7/14 12:28
638,11,Amgen,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-04,Feb-06,Jun-28,Oct-16,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1453,Psoriasis,7/7/14 12:28
638,11,Amgen,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-04,Feb-06,Jun-28,Oct-16,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,923,858,852,904,975.56,1005.668,1033.8212,1052.2738,1061.690116,1071.734863,1077.817536,1083.232183,1.506852292,1453,Psoriasis,7/7/14 12:28
638,11,Amgen,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-04,Feb-06,Jun-28,Oct-16,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1453,Psoriasis,7/7/14 12:28
638,11,Amgen,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-04,Feb-06,Jun-28,Oct-16,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,30,35,37,49,53.56,57.328,60.7192,58.962,54.697416,54.0286888,52.00958152,51.42356183,-0.579826926,1453,Psoriasis,7/7/14 12:28
638,11,Amgen,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-04,Feb-06,Jun-28,Oct-16,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1453,Psoriasis,7/7/14 12:28
638,11,Amgen,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-04,Feb-06,Jun-28,Oct-16,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,893,823,815,855,922,948.34,973.102,993.3118,1006.9927,1017.706174,1025.807954,1031.808622,1.620462914,1453,Psoriasis,7/7/14 12:28
639,11,Amgen,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Nov-98,Jun-00,Jun-28,Oct-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1453,Rheumatoid Arthritis,7/7/14 12:28
639,11,Amgen,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Nov-98,Jun-00,Jun-28,Oct-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,2570,2675.8,2848,3332,3575,3730.67,3859.2675,3910.8413,3931.73373,3947.195394,3949.856305,3963.384334,1.484235714,1453,Rheumatoid Arthritis,7/7/14 12:28
639,11,Amgen,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Nov-98,Jun-00,Jun-28,Oct-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1453,Rheumatoid Arthritis,7/7/14 12:28
639,11,Amgen,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Nov-98,Jun-00,Jun-28,Oct-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,180,195,205,220,241,254.6,267.48,246.6139248,217.8317617,198.4370459,177.6886854,175.1684803,-4.455524708,1453,Rheumatoid Arthritis,7/7/14 12:28
639,11,Amgen,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Nov-98,Jun-00,Jun-28,Oct-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1453,Rheumatoid Arthritis,7/7/14 12:28
639,11,Amgen,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Nov-98,Jun-00,Jun-28,Oct-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,2390,2480.8,2643,3112,3334,3476.07,3591.7875,3664.227375,3713.901969,3748.758348,3772.16762,3788.215854,1.841351098,1453,Rheumatoid Arthritis,7/7/14 12:28
640,100,Takeda,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-05,N/A,Jan-17,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1453,Rheumatoid Arthritis,7/7/14 12:28
640,100,Takeda,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-05,N/A,Jan-17,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,347.9762881,448.2368185,524.19274,520.0735968,461.8780503,481.8407924,499.1939809,515.238706,529.0154001,541.1533219,551.8820532,561.290918,2.823971079,1453,Rheumatoid Arthritis,7/7/14 12:28
640,100,Takeda,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-05,N/A,Jan-17,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1453,Rheumatoid Arthritis,7/7/14 12:28
640,100,Takeda,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-05,N/A,Jan-17,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,347.9762881,448.2368185,524.19274,520.0735968,461.8780503,481.8407924,499.1939809,515.238706,529.0154001,541.1533219,551.8820532,561.290918,2.823971079,1453,Rheumatoid Arthritis,7/7/14 12:28
640,100,Takeda,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-05,N/A,Jan-17,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1453,Rheumatoid Arthritis,7/7/14 12:28
640,100,Takeda,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-05,N/A,Jan-17,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1453,Rheumatoid Arthritis,7/7/14 12:28
641,76,Pfizer,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Sep-04,N/A,Oct-16,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Alliance Revenue,67.7,195,178,164,158,0,0,0,0,0,0,0,-100,1453,Psoriasis,7/7/14 12:28
641,76,Pfizer,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Sep-04,N/A,Oct-16,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,103.2,563,623,640,645,652.65,656.4125,644.7205911,593.8487456,566.4323322,519.5278588,495.6021932,-3.693993553,1453,Psoriasis,7/7/14 12:28
641,76,Pfizer,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Sep-04,N/A,Oct-16,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1453,Psoriasis,7/7/14 12:28
641,76,Pfizer,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Sep-04,N/A,Oct-16,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,103.2,563,623,640,645,652.65,656.4125,644.7205911,593.8487456,566.4323322,519.5278588,495.6021932,-3.693993553,1453,Psoriasis,7/7/14 12:28
641,76,Pfizer,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Sep-04,N/A,Oct-16,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Alliance Revenue,67.7,195,178,164,158,0,0,0,0,0,0,0,-100,1453,Psoriasis,7/7/14 12:28
641,76,Pfizer,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Sep-04,N/A,Oct-16,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1453,Psoriasis,7/7/14 12:28
641,76,Wyeth,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Sep-04,N/A,Oct-16,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Proforma,364.6,0,0,0,0,0,0,0,0,0,0,0,0,1453,Psoriasis,7/7/14 12:28
641,76,Wyeth,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Sep-04,N/A,Oct-16,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Proforma,364.6,0,0,0,0,0,0,0,0,0,0,0,0,1453,Psoriasis,7/7/14 12:28
642,76,Pfizer,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jan-00,N/A,Oct-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,161.3,620.3,693.3,731.5,568,0,0,0,0,0,0,0,-100,1453,Rheumatoid Arthritis,7/7/14 12:28
642,76,Pfizer,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jan-00,N/A,Oct-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,526.4,2711,3043,3097,3129,3198.02,3236.457,2981.617208,2676.956211,2656.270824,2604.276163,2549.079596,-2.88583948,1453,Rheumatoid Arthritis,7/7/14 12:28
642,76,Pfizer,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jan-00,N/A,Oct-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1453,Rheumatoid Arthritis,7/7/14 12:28
642,76,Pfizer,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jan-00,N/A,Oct-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,526.4,2711,3043,3097,3129,3198.02,3236.457,2981.617208,2676.956211,2656.270824,2604.276163,2549.079596,-2.88583948,1453,Rheumatoid Arthritis,7/7/14 12:28
642,76,Pfizer,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jan-00,N/A,Oct-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,161.3,620.3,693.3,731.5,568,0,0,0,0,0,0,0,-100,1453,Rheumatoid Arthritis,7/7/14 12:28
642,76,Pfizer,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jan-00,N/A,Oct-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1453,Rheumatoid Arthritis,7/7/14 12:28
642,76,Wyeth,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jan-00,N/A,Oct-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Proforma,1819.6,0,0,0,0,0,0,0,0,0,0,0,0,1453,Rheumatoid Arthritis,7/7/14 12:28
642,76,Wyeth,Large Pharma,1062,Enbrel,etanercept,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jan-00,N/A,Oct-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Proforma,1819.6,0,0,0,0,0,0,0,0,0,0,0,0,1453,Rheumatoid Arthritis,7/7/14 12:28
643,32,Adolor,Small Biotech,1301,Entereg,alvimopan,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-08,,Nov-20,Nov-20,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Proforma,14.6,25.4,28.75,0,0,0,0,0,0,0,0,0,0,422,Post-operative Ileus,7/7/14 12:28
643,32,Adolor,Small Biotech,1301,Entereg,alvimopan,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-08,,Nov-20,Nov-20,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Proforma,14.6,25.4,28.75,0,0,0,0,0,0,0,0,0,0,422,Post-operative Ileus,7/7/14 12:28
643,32,Cubist Pharmaceuticals,Small Biotech,1301,Entereg,alvimopan,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-08,,Nov-20,Nov-20,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,0,2.508002,40.17,51.02,58.43615984,65.43254346,71.74697526,77.13846563,81.92994679,86.15080603,89.85174366,8.420712877,422,Post-operative Ileus,7/7/14 12:28
643,32,Cubist Pharmaceuticals,Small Biotech,1301,Entereg,alvimopan,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-08,,Nov-20,Nov-20,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,422,Post-operative Ileus,7/7/14 12:28
643,32,Cubist Pharmaceuticals,Small Biotech,1301,Entereg,alvimopan,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-08,,Nov-20,Nov-20,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,2.508002,40.17,51.02,58.43615984,65.43254346,71.74697526,77.13846563,81.92994679,86.15080603,89.85174366,8.420712877,422,Post-operative Ileus,7/7/14 12:28
645,46,GlaxoSmithKline,Large Pharma,1684,Epivir,lamivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-95,Jul-96,Dec-11,Dec-11,104,NRTIs,32,HIV,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1508,HIV,7/7/14 12:28
645,46,GlaxoSmithKline,Large Pharma,1684,Epivir,lamivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-95,Jul-96,Dec-11,Dec-11,104,NRTIs,32,HIV,7,Anti-infectives,4,Global,Sales,201.144758,177.6750067,176.3498782,77.59957294,67.22680321,52.29036008,43.77559278,37.52193667,33.21614751,26.57803848,23.52674023,21.13234839,-15.2380715,1508,HIV,7/7/14 12:28
645,46,GlaxoSmithKline,Large Pharma,1684,Epivir,lamivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-95,Jul-96,Dec-11,Dec-11,104,NRTIs,32,HIV,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1508,HIV,7/7/14 12:28
645,46,GlaxoSmithKline,Large Pharma,1684,Epivir,lamivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-95,Jul-96,Dec-11,Dec-11,104,NRTIs,32,HIV,7,Anti-infectives,4,ROW,Sales,126.3001969,115.8750043,113.8258304,64.98618383,51.59266292,38.64759478,32.83169459,28.1414525,24.13410967,18.76096834,15.86487518,13.54800065,-17.38838341,1508,HIV,7/7/14 12:28
645,46,GlaxoSmithKline,Large Pharma,1684,Epivir,lamivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-95,Jul-96,Dec-11,Dec-11,104,NRTIs,32,HIV,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1508,HIV,7/7/14 12:28
645,46,GlaxoSmithKline,Large Pharma,1684,Epivir,lamivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-95,Jul-96,Dec-11,Dec-11,104,NRTIs,32,HIV,7,Anti-infectives,4,US,Sales,74.8445611,61.80000232,62.52404771,12.61338911,15.63414028,13.64276531,10.9438982,9.380484168,9.082037847,7.81707014,7.661865057,7.584347739,-9.817836589,1508,HIV,7/7/14 12:28
646,11,Amgen,Large Pharma,1064,Epogen,epoetin alfa,Recombinant Protein,Launched,In-House,Jan-89,,Jul-15,N/A,102,ESAs,24,Anemia,14,Hematology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1752,Renal Anemia,7/7/14 12:28
646,11,Amgen,Large Pharma,1064,Epogen,epoetin alfa,Recombinant Protein,Launched,In-House,Jan-89,,Jul-15,N/A,102,ESAs,24,Anemia,14,Hematology,6,Global,Sales,2569,2524,2040,1941,1953,1903.5,1806.5,1642.75,1499.75,1255.375,800.875,654.1875,-14.46518414,1752,Renal Anemia,7/7/14 12:28
646,11,Amgen,Large Pharma,1064,Epogen,epoetin alfa,Recombinant Protein,Launched,In-House,Jan-89,,Jul-15,N/A,102,ESAs,24,Anemia,14,Hematology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1752,Renal Anemia,7/7/14 12:28
646,11,Amgen,Large Pharma,1064,Epogen,epoetin alfa,Recombinant Protein,Launched,In-House,Jan-89,,Jul-15,N/A,102,ESAs,24,Anemia,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1752,Renal Anemia,7/7/14 12:28
646,11,Amgen,Large Pharma,1064,Epogen,epoetin alfa,Recombinant Protein,Launched,In-House,Jan-89,,Jul-15,N/A,102,ESAs,24,Anemia,14,Hematology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1752,Renal Anemia,7/7/14 12:28
646,11,Amgen,Large Pharma,1064,Epogen,epoetin alfa,Recombinant Protein,Launched,In-House,Jan-89,,Jul-15,N/A,102,ESAs,24,Anemia,14,Hematology,6,US,Sales,2569,2524,2040,1941,1953,1903.5,1806.5,1642.75,1499.75,1255.375,800.875,654.1875,-14.46518414,1752,Renal Anemia,7/7/14 12:28
647,29,Chugai,Regional & Specialty Pharma,1227,Epogin,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jan-90,N/A,Apr-17,102,ESAs,24,Anemia,14,Hematology,3,Global,Alliance Revenue,474.512329,455.8101551,361.2459221,181.6587321,107.6141269,81.9917157,71.74275124,67.64316545,66.00333114,65.34739741,65.08502392,64.98007453,-6.953168002,1449,Renal Anemia,7/7/14 12:28
647,29,Chugai,Regional & Specialty Pharma,1227,Epogin,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jan-90,N/A,Apr-17,102,ESAs,24,Anemia,14,Hematology,3,ROW,Alliance Revenue,474.512329,455.8101551,361.2459221,181.6587321,107.6141269,81.9917157,71.74275124,67.64316545,66.00333114,65.34739741,65.08502392,64.98007453,-6.953168002,1449,Renal Anemia,7/7/14 12:28
647,29,Chugai,Regional & Specialty Pharma,1227,Epogin,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jan-90,N/A,Apr-17,102,ESAs,24,Anemia,14,Hematology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1449,Renal Anemia,7/7/14 12:28
647,86,Roche,Large Pharma,1227,Epogin,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jan-90,N/A,Apr-17,102,ESAs,24,Anemia,14,Hematology,5,Global,Sales,474.512329,455.8101551,361.2459221,181.6587321,107.6141269,81.9917157,71.74275124,67.64316545,66.00333114,65.34739741,65.08502392,64.98007453,-6.953168002,1449,Renal Anemia,7/7/14 12:28
647,86,Roche,Large Pharma,1227,Epogin,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jan-90,N/A,Apr-17,102,ESAs,24,Anemia,14,Hematology,5,ROW,Sales,474.512329,455.8101551,361.2459221,181.6587321,107.6141269,81.9917157,71.74275124,67.64316545,66.00333114,65.34739741,65.08502392,64.98007453,-6.953168002,1449,Renal Anemia,7/7/14 12:28
649,105,UCB,Regional & Specialty Pharma,642,epratuzumab,epratuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),May-15,May-16,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,424,Systemic Lupus Erythematosus,7/7/14 12:28
649,105,UCB,Regional & Specialty Pharma,642,epratuzumab,epratuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),May-15,May-16,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,22.13384551,92.22443007,195.5155829,306.1849975,404.6073361,487.0635155,0,424,Systemic Lupus Erythematosus,7/7/14 12:28
649,105,UCB,Regional & Specialty Pharma,642,epratuzumab,epratuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),May-15,May-16,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,424,Systemic Lupus Erythematosus,7/7/14 12:28
649,105,UCB,Regional & Specialty Pharma,642,epratuzumab,epratuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),May-15,May-16,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,22.13384551,70.09058456,125.4249984,180.7599991,223.847337,0,424,Systemic Lupus Erythematosus,7/7/14 12:28
649,105,UCB,Regional & Specialty Pharma,642,epratuzumab,epratuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),May-15,May-16,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,424,Systemic Lupus Erythematosus,7/7/14 12:28
649,105,UCB,Regional & Specialty Pharma,642,epratuzumab,epratuzumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),May-15,May-16,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,22.13384551,70.09058456,125.4249984,180.7599991,223.847337,263.2161785,0,424,Systemic Lupus Erythematosus,7/7/14 12:28
651,46,GlaxoSmithKline,Large Pharma,4679,Epzicom / Kivexa,abacavir + lamivudine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Nov-16,Nov-19,104,NRTIs,32,HIV,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,426,HIV,7/7/14 12:28
651,46,GlaxoSmithKline,Large Pharma,4679,Epzicom / Kivexa,abacavir + lamivudine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Nov-16,Nov-19,104,NRTIs,32,HIV,7,Anti-infectives,4,Global,Sales,851.3568825,857.4750322,989.1624984,1054.044201,1192.884903,1216.58626,1231.151025,1203.318533,945.4921564,908.8278802,859.2468883,460.2710132,-12.71964592,426,HIV,7/7/14 12:28
651,46,GlaxoSmithKline,Large Pharma,4679,Epzicom / Kivexa,abacavir + lamivudine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Nov-16,Nov-19,104,NRTIs,32,HIV,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,426,HIV,7/7/14 12:28
651,46,GlaxoSmithKline,Large Pharma,4679,Epzicom / Kivexa,abacavir + lamivudine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Nov-16,Nov-19,104,NRTIs,32,HIV,7,Anti-infectives,4,ROW,Sales,503.6415257,533.02502,620.430935,668.8821848,772.3265298,789.4928159,800.1521727,806.750718,808.7367854,809.7576791,780.5668392,395.49086,-9.11827928,426,HIV,7/7/14 12:28
651,46,GlaxoSmithKline,Large Pharma,4679,Epzicom / Kivexa,abacavir + lamivudine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Nov-16,Nov-19,104,NRTIs,32,HIV,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,426,HIV,7/7/14 12:28
651,46,GlaxoSmithKline,Large Pharma,4679,Epzicom / Kivexa,abacavir + lamivudine,Small Molecule (Chemical),Launched,In-House,Aug-04,Jan-05,Nov-16,Nov-19,104,NRTIs,32,HIV,7,Anti-infectives,4,US,Sales,347.7153568,324.4500122,368.7315634,385.1620164,420.5583735,427.0934442,430.9988524,396.567815,136.755371,99.07020107,78.6800491,64.78015316,-23.44999665,426,HIV,7/7/14 12:28
652,96,Shire,Regional & Specialty Pharma,420,Equasym XL,methylphenidate CR,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-05,N/A,Oct-20,121,Stimulants,37,ADHD,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1545,ADHD,7/7/14 12:28
652,96,Shire,Regional & Specialty Pharma,420,Equasym XL,methylphenidate CR,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-05,N/A,Oct-20,121,Stimulants,37,ADHD,12,Central Nervous System,6,Global,Sales,22.8,22,19.9,29.2,34.78,38.128,40.1368,41.34208,42.065248,42.4991488,42.75948928,42.91569357,3.048321887,1545,ADHD,7/7/14 12:28
652,96,Shire,Regional & Specialty Pharma,420,Equasym XL,methylphenidate CR,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-05,N/A,Oct-20,121,Stimulants,37,ADHD,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1545,ADHD,7/7/14 12:28
652,96,Shire,Regional & Specialty Pharma,420,Equasym XL,methylphenidate CR,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-05,N/A,Oct-20,121,Stimulants,37,ADHD,12,Central Nervous System,6,ROW,Sales,22.8,22,19.9,29.2,34.78,38.128,40.1368,41.34208,42.065248,42.4991488,42.75948928,42.91569357,3.048321887,1545,ADHD,7/7/14 12:28
652,96,Shire,Regional & Specialty Pharma,420,Equasym XL,methylphenidate CR,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-05,N/A,Oct-20,121,Stimulants,37,ADHD,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1545,ADHD,7/7/14 12:28
652,96,Shire,Regional & Specialty Pharma,420,Equasym XL,methylphenidate CR,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-05,N/A,Oct-20,121,Stimulants,37,ADHD,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1545,ADHD,7/7/14 12:28
653,76,Pfizer,Large Pharma,211,Eraxis,anidulafungin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,Jan-08,Mar-12,Mar-18,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,427,,7/7/14 12:28
653,76,Pfizer,Large Pharma,211,Eraxis,anidulafungin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,Jan-08,Mar-12,Mar-18,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,227.419109,263.7077648,294.559729,220.333168,174.3330952,166.6488863,160.4982493,160.0030101,162.7886042,124.8879859,94.80803076,81.38390248,-10.31145055,427,,7/7/14 12:28
653,76,Pfizer,Large Pharma,211,Eraxis,anidulafungin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,Jan-08,Mar-12,Mar-18,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,427,,7/7/14 12:28
653,76,Pfizer,Large Pharma,211,Eraxis,anidulafungin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,Jan-08,Mar-12,Mar-18,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,41.66675,58.33345,74.9999,88.333168,100.3330952,110.9996824,120.2796227,128.4715681,135.6821859,100.5482415,72.02518471,59.47376606,-7.198607293,427,,7/7/14 12:28
653,76,Pfizer,Large Pharma,211,Eraxis,anidulafungin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,Jan-08,Mar-12,Mar-18,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,427,,7/7/14 12:28
653,76,Pfizer,Large Pharma,211,Eraxis,anidulafungin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,Jan-08,Mar-12,Mar-18,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,6,US,Sales,185.752359,205.3743148,219.559829,132,74,55.64920395,40.21862661,31.53144199,27.10641833,24.33974439,22.78284605,21.91013642,-15.95967976,427,,7/7/14 12:28
655,24,Bristol-Myers Squibb,Large Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Licensed (Development),Feb-04,Sep-05,Feb-17,Feb-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1390,Colorectal Cancer,7/7/14 12:28
655,24,Bristol-Myers Squibb,Large Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Licensed (Development),Feb-04,Sep-05,Feb-17,Feb-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,683,662,691,702,696,696.4,696.1408,695.675712,674.0206509,425.9752207,0,0,-100,1390,Colorectal Cancer,7/7/14 12:28
655,24,Bristol-Myers Squibb,Large Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Licensed (Development),Feb-04,Sep-05,Feb-17,Feb-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1390,Colorectal Cancer,7/7/14 12:28
655,24,Bristol-Myers Squibb,Large Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Licensed (Development),Feb-04,Sep-05,Feb-17,Feb-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,12,16,19,14,14,13.28,12.192,11.584,10.66448,6.697504,0,0,-100,1390,Colorectal Cancer,7/7/14 12:28
655,24,Bristol-Myers Squibb,Large Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Licensed (Development),Feb-04,Sep-05,Feb-17,Feb-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1390,Colorectal Cancer,7/7/14 12:28
655,24,Bristol-Myers Squibb,Large Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Licensed (Development),Feb-04,Sep-05,Feb-17,Feb-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,671,646,672,688,682,683.12,683.9488,684.091712,663.3561709,419.2777167,0,0,-100,1390,Colorectal Cancer,7/7/14 12:28
656,63,Merck KGaA,Regional & Specialty Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Dec-03,N/A,Jun-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1390,Colorectal Cancer,7/7/14 12:28
656,63,Merck KGaA,Regional & Specialty Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Dec-03,N/A,Jun-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,2,Global,Sales,968.4803867,1086.298944,1189.379842,1140.035666,1171.588125,1167.763398,1165.468563,1164.091661,1128.56552,990.2698358,816.4724251,622.4939787,-8.637961482,1390,Colorectal Cancer,7/7/14 12:28
656,63,Merck KGaA,Regional & Specialty Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Dec-03,N/A,Jun-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1390,Colorectal Cancer,7/7/14 12:28
656,63,Merck KGaA,Regional & Specialty Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Dec-03,N/A,Jun-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,2,ROW,Sales,968.4803867,1086.298944,1189.379842,1140.035666,1171.588125,1167.763398,1165.468563,1164.091661,1128.56552,990.2698358,816.4724251,622.4939787,-8.637961482,1390,Colorectal Cancer,7/7/14 12:28
656,63,Merck KGaA,Regional & Specialty Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Dec-03,N/A,Jun-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1390,Colorectal Cancer,7/7/14 12:28
656,63,Merck KGaA,Regional & Specialty Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Dec-03,N/A,Jun-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1390,Colorectal Cancer,7/7/14 12:28
658,37,Eisai,Regional & Specialty Pharma,3339,Halaven,eribulin,Small Molecule (Chemical),Launched,In-House,Dec-10,Apr-11,Jun-17,Oct-23,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,428,Breast Cancer,7/7/14 12:28
658,37,Eisai,Regional & Specialty Pharma,3339,Halaven,eribulin,Small Molecule (Chemical),Launched,In-House,Dec-10,Apr-11,Jun-17,Oct-23,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,7,Global,Sales,0,25.68023439,202.5865662,271.9864858,302.0316674,336.3283699,356.10506,369.1721526,376.4460081,392.4913286,307.300394,269.7824357,-1.600143996,428,Breast Cancer,7/7/14 12:28
658,37,Eisai,Regional & Specialty Pharma,3339,Halaven,eribulin,Small Molecule (Chemical),Launched,In-House,Dec-10,Apr-11,Jun-17,Oct-23,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,428,Breast Cancer,7/7/14 12:28
658,37,Eisai,Regional & Specialty Pharma,3339,Halaven,eribulin,Small Molecule (Chemical),Launched,In-House,Dec-10,Apr-11,Jun-17,Oct-23,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,0,64.57446797,132.3370941,161.0835559,185.866261,201.6183792,211.7757741,217.6801237,221.3400505,223.5931494,224.9553083,4.886766977,428,Breast Cancer,7/7/14 12:28
658,37,Eisai,Regional & Specialty Pharma,3339,Halaven,eribulin,Small Molecule (Chemical),Launched,In-House,Dec-10,Apr-11,Jun-17,Oct-23,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,428,Breast Cancer,7/7/14 12:28
658,37,Eisai,Regional & Specialty Pharma,3339,Halaven,eribulin,Small Molecule (Chemical),Launched,In-House,Dec-10,Apr-11,Jun-17,Oct-23,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,7,US,Sales,0,25.68023439,138.0120982,139.6493917,140.9481114,150.4621089,154.4866809,157.3963784,158.7658844,171.1512782,83.70724459,44.82712739,-15.09641649,428,Breast Cancer,7/7/14 12:28
659,1,Abbott,Regional & Specialty Pharma,152,Erythromycin brands,erythromycin,Small Molecule (Chemical),Launched,In-House,Jul-52,Jul-52,Expired,Expired,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,429,,7/7/14 12:28
659,1,Abbott,Regional & Specialty Pharma,152,Erythromycin brands,erythromycin,Small Molecule (Chemical),Launched,In-House,Jul-52,Jul-52,Expired,Expired,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,70,45.35,35.26625,28.75834375,22.44016641,21.35229271,20.69395276,20.34424412,20.13776825,20.01883177,19.95185831,19.91319632,-1.692228676,429,,7/7/14 12:28
659,1,Abbott,Regional & Specialty Pharma,152,Erythromycin brands,erythromycin,Small Molecule (Chemical),Launched,In-House,Jul-52,Jul-52,Expired,Expired,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,429,,7/7/14 12:28
659,1,Abbott,Regional & Specialty Pharma,152,Erythromycin brands,erythromycin,Small Molecule (Chemical),Launched,In-House,Jul-52,Jul-52,Expired,Expired,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,40,33.35,28.26625,24.15834375,22.44016641,21.35229271,20.69395276,20.34424412,20.13776825,20.01883177,19.95185831,19.91319632,-1.692228676,429,,7/7/14 12:28
659,1,Abbott,Regional & Specialty Pharma,152,Erythromycin brands,erythromycin,Small Molecule (Chemical),Launched,In-House,Jul-52,Jul-52,Expired,Expired,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,429,,7/7/14 12:28
659,1,Abbott,Regional & Specialty Pharma,152,Erythromycin brands,erythromycin,Small Molecule (Chemical),Launched,In-House,Jul-52,Jul-52,Expired,Expired,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,30,12,7,4.6,0,0,0,0,0,0,0,0,0,429,,7/7/14 12:28
664,29,Chugai,Regional & Specialty Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-04,N/A,Jul-18,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,3,Global,Alliance Revenue,191.3011417,213.0912475,232.0503319,201.7038336,0,0,0,0,0,0,0,0,0,1605,Osteoporosis,7/7/14 12:28
664,29,Chugai,Regional & Specialty Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-04,N/A,Jul-18,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,3,ROW,Alliance Revenue,191.3011417,213.0912475,232.0503319,201.7038336,0,0,0,0,0,0,0,0,0,1605,Osteoporosis,7/7/14 12:28
664,29,Chugai,Regional & Specialty Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-04,N/A,Jul-18,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1605,Osteoporosis,7/7/14 12:28
664,86,Roche,Large Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-04,N/A,Jul-18,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,5,Global,Sales,191.3011417,213.0912475,232.0503319,201.7038336,0,0,0,0,0,0,0,0,0,1605,Osteoporosis,7/7/14 12:28
664,86,Roche,Large Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-04,N/A,Jul-18,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,5,ROW,Sales,191.3011417,213.0912475,232.0503319,201.7038336,0,0,0,0,0,0,0,0,0,1605,Osteoporosis,7/7/14 12:28
665,39,Eli Lilly,Large Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,In-House,Jan-98,Jan-98,Mar-14,Aug-13,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1605,Osteoporosis,7/7/14 12:28
665,39,Eli Lilly,Large Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,In-House,Jan-98,Jan-98,Mar-14,Aug-13,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,1030.3,1024.4,1066.9,1011,1050,792.251608,352.194744,265.1056608,183.1804883,117.1774284,89.42220275,62.3222964,-33.19955751,1605,Osteoporosis,7/7/14 12:28
665,39,Eli Lilly,Large Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,In-House,Jan-98,Jan-98,Mar-14,Aug-13,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1605,Osteoporosis,7/7/14 12:28
665,39,Eli Lilly,Large Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,In-House,Jan-98,Jan-98,Mar-14,Aug-13,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,348.1,342.6,359.4,311,278,124.865536,90.229152,68.562,50.27805952,35.50526976,24.5553984,15.15557304,-34.00605074,1605,Osteoporosis,7/7/14 12:28
665,39,Eli Lilly,Large Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,In-House,Jan-98,Jan-98,Mar-14,Aug-13,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1605,Osteoporosis,7/7/14 12:28
665,39,Eli Lilly,Large Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,In-House,Jan-98,Jan-98,Mar-14,Aug-13,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,682.2,681.8,707.5,700,772,667.386072,261.965592,196.5436608,132.9024288,81.67215859,64.86680435,47.16672335,-32.9229072,1605,Osteoporosis,7/7/14 12:28
667,67,Novartis,Large Pharma,1473,Exelon / Exelon Patch,rivastigmine,Small Molecule (Chemical),Launched,In-House,Jun-00,Nov-97,Jan-19,Oct-13,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,432,Alzheimer's Disease,7/7/14 12:28
667,67,Novartis,Large Pharma,1473,Exelon / Exelon Patch,rivastigmine,Small Molecule (Chemical),Launched,In-House,Jun-00,Nov-97,Jan-19,Oct-13,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,954,1003,1067,1050,1032,820.98,774.8574,739.398762,716.7812381,692.8700933,418.44408,315.4792007,-15.57516484,432,Alzheimer's Disease,7/7/14 12:28
667,67,Novartis,Large Pharma,1473,Exelon / Exelon Patch,rivastigmine,Small Molecule (Chemical),Launched,In-House,Jun-00,Nov-97,Jan-19,Oct-13,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,432,Alzheimer's Disease,7/7/14 12:28
667,67,Novartis,Large Pharma,1473,Exelon / Exelon Patch,rivastigmine,Small Molecule (Chemical),Launched,In-House,Jun-00,Nov-97,Jan-19,Oct-13,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,592,624,692,622,575,342,280,233,202,172,160,149,-17.54499897,432,Alzheimer's Disease,7/7/14 12:28
667,67,Novartis,Large Pharma,1473,Exelon / Exelon Patch,rivastigmine,Small Molecule (Chemical),Launched,In-House,Jun-00,Nov-97,Jan-19,Oct-13,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,432,Alzheimer's Disease,7/7/14 12:28
667,67,Novartis,Large Pharma,1473,Exelon / Exelon Patch,rivastigmine,Small Molecule (Chemical),Launched,In-House,Jun-00,Nov-97,Jan-19,Oct-13,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,362,379,375,428,457,478.98,494.8574,506.398762,514.7812381,520.8700933,258.44408,166.4792007,-13.43363642,432,Alzheimer's Disease,7/7/14 12:28
668,67,Novartis,Large Pharma,1251,Exforge,valsartan + amlodipine,Small Molecule (Chemical),Launched,In-House,Jul-07,Feb-07,Oct-14,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,433,Hypertension,7/7/14 12:28
668,67,Novartis,Large Pharma,1251,Exforge,valsartan + amlodipine,Small Molecule (Chemical),Launched,In-House,Jul-07,Feb-07,Oct-14,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,671,904,1209,1352,1456,1482.261,1246.8328,1284.783155,732.7758254,457.435132,344.9555004,257.3290996,-21.93156591,433,Hypertension,7/7/14 12:28
668,67,Novartis,Large Pharma,1251,Exforge,valsartan + amlodipine,Small Molecule (Chemical),Launched,In-House,Jul-07,Feb-07,Oct-14,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,433,Hypertension,7/7/14 12:28
668,67,Novartis,Large Pharma,1251,Exforge,valsartan + amlodipine,Small Molecule (Chemical),Launched,In-House,Jul-07,Feb-07,Oct-14,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,442,620,884,994,1100,1176.686,1192.6558,1248.522075,707.320518,435.5694537,326.7049865,239.056816,-19.59162207,433,Hypertension,7/7/14 12:28
668,67,Novartis,Large Pharma,1251,Exforge,valsartan + amlodipine,Small Molecule (Chemical),Launched,In-House,Jul-07,Feb-07,Oct-14,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,433,Hypertension,7/7/14 12:28
668,67,Novartis,Large Pharma,1251,Exforge,valsartan + amlodipine,Small Molecule (Chemical),Launched,In-House,Jul-07,Feb-07,Oct-14,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,229,284,325,358,356,305.575,54.177,36.26108,25.45530736,21.86567825,18.25051392,18.27228359,-34.57203005,433,Hypertension,7/7/14 12:28
669,67,Novartis,Large Pharma,1264,Exjade,deferasirox,Small Molecule (Chemical),Launched,In-House,Dec-05,Sep-06,Apr-19,Aug-21,56,Iron Chelators,59,Iron Overload,14,Hematology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,434,Iron Overload,7/7/14 12:28
669,67,Novartis,Large Pharma,1264,Exjade,deferasirox,Small Molecule (Chemical),Launched,In-House,Dec-05,Sep-06,Apr-19,Aug-21,56,Iron Chelators,59,Iron Overload,14,Hematology,6,Global,Sales,652,762,850,870,893,919.025,940.669375,956.5756406,972.1918246,984.6180996,995.42643,1004.615308,1.696708616,434,Iron Overload,7/7/14 12:28
669,67,Novartis,Large Pharma,1264,Exjade,deferasirox,Small Molecule (Chemical),Launched,In-House,Dec-05,Sep-06,Apr-19,Aug-21,56,Iron Chelators,59,Iron Overload,14,Hematology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,434,Iron Overload,7/7/14 12:28
669,67,Novartis,Large Pharma,1264,Exjade,deferasirox,Small Molecule (Chemical),Launched,In-House,Dec-05,Sep-06,Apr-19,Aug-21,56,Iron Chelators,59,Iron Overload,14,Hematology,6,ROW,Sales,405,498,591,619,628,651.625,666.709375,679.0316406,690.5902246,699.9598596,707.922494,714.7504374,1.865663558,434,Iron Overload,7/7/14 12:28
669,67,Novartis,Large Pharma,1264,Exjade,deferasirox,Small Molecule (Chemical),Launched,In-House,Dec-05,Sep-06,Apr-19,Aug-21,56,Iron Chelators,59,Iron Overload,14,Hematology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,434,Iron Overload,7/7/14 12:28
669,67,Novartis,Large Pharma,1264,Exjade,deferasirox,Small Molecule (Chemical),Launched,In-House,Dec-05,Sep-06,Apr-19,Aug-21,56,Iron Chelators,59,Iron Overload,14,Hematology,6,US,Sales,247,264,259,251,265,267.4,273.96,277.544,281.6016,284.65824,287.503936,289.8648704,1.289456054,434,Iron Overload,7/7/14 12:28
670,67,Novartis,Large Pharma,739,Extavia,interferon-beta 1b,Recombinant Protein,Launched,Licensed (Marketed),Sep-09,Jan-09,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1720,Multiple Sclerosis,7/7/14 12:28
670,67,Novartis,Large Pharma,739,Extavia,interferon-beta 1b,Recombinant Protein,Launched,Licensed (Marketed),Sep-09,Jan-09,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,49.166665,124,154,159,159,156.71154,155.8598564,155.2547532,154.5855925,151.9372145,150.8173428,148.9311857,-0.930214749,1720,Multiple Sclerosis,7/7/14 12:28
670,67,Novartis,Large Pharma,739,Extavia,interferon-beta 1b,Recombinant Protein,Launched,Licensed (Marketed),Sep-09,Jan-09,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1720,Multiple Sclerosis,7/7/14 12:28
670,67,Novartis,Large Pharma,739,Extavia,interferon-beta 1b,Recombinant Protein,Launched,Licensed (Marketed),Sep-09,Jan-09,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,45,112,138,142,143,140.95074,140.5385124,140.4038668,140.3355925,138.0579242,138.0395178,136.8199618,-0.62913648,1720,Multiple Sclerosis,7/7/14 12:28
670,67,Novartis,Large Pharma,739,Extavia,interferon-beta 1b,Recombinant Protein,Launched,Licensed (Marketed),Sep-09,Jan-09,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1720,Multiple Sclerosis,7/7/14 12:28
670,67,Novartis,Large Pharma,739,Extavia,interferon-beta 1b,Recombinant Protein,Launched,Licensed (Marketed),Sep-09,Jan-09,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,4.166665,12,16,17,16,15.7608,15.321344,14.8508864,14.25,13.87929024,12.777825,12.11122387,-3.899859119,1720,Multiple Sclerosis,7/7/14 12:28
672,89,Genzyme,Large Pharma,1259,Fabrazyme,agalsidase beta,Recombinant Protein,Launched,Corporate Acquisition,Jul-03,Dec-01,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Proforma,430.0497556,161.3551359,47.43529279,0,0,0,0,0,0,0,0,0,0,436,Fabry's Disease,7/7/14 12:28
672,89,Genzyme,Large Pharma,1259,Fabrazyme,agalsidase beta,Recombinant Protein,Launched,Corporate Acquisition,Jul-03,Dec-01,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Proforma,167.9903569,58.02426068,14.40627411,0,0,0,0,0,0,0,0,0,0,436,Fabry's Disease,7/7/14 12:28
672,89,Genzyme,Large Pharma,1259,Fabrazyme,agalsidase beta,Recombinant Protein,Launched,Corporate Acquisition,Jul-03,Dec-01,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Proforma,262.0593987,103.3308752,33.02901869,0,0,0,0,0,0,0,0,0,0,436,Fabry's Disease,7/7/14 12:28
672,89,Sanofi,Large Pharma,1259,Fabrazyme,agalsidase beta,Recombinant Protein,Launched,Corporate Acquisition,Jul-03,Dec-01,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,436,Fabry's Disease,7/7/14 12:28
672,89,Sanofi,Large Pharma,1259,Fabrazyme,agalsidase beta,Recombinant Protein,Launched,Corporate Acquisition,Jul-03,Dec-01,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Sales,9.64E-03,26.76004716,144.4450184,375.2992272,508.6355155,593.1380687,676.7249451,740.6449911,792.4006087,835.6404472,870.5918768,899.1510297,8.4792143,436,Fabry's Disease,7/7/14 12:28
672,89,Sanofi,Large Pharma,1259,Fabrazyme,agalsidase beta,Recombinant Protein,Launched,Corporate Acquisition,Jul-03,Dec-01,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,436,Fabry's Disease,7/7/14 12:28
672,89,Sanofi,Large Pharma,1259,Fabrazyme,agalsidase beta,Recombinant Protein,Launched,Corporate Acquisition,Jul-03,Dec-01,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Sales,9.64E-03,26.76004716,73.19125926,179.9379857,248.3416225,291.476039,333.9969057,366.6758744,393.0817137,415.1392623,432.9796861,447.5527372,8.778249061,436,Fabry's Disease,7/7/14 12:28
672,89,Sanofi,Large Pharma,1259,Fabrazyme,agalsidase beta,Recombinant Protein,Launched,Corporate Acquisition,Jul-03,Dec-01,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,436,Fabry's Disease,7/7/14 12:28
672,89,Sanofi,Large Pharma,1259,Fabrazyme,agalsidase beta,Recombinant Protein,Launched,Corporate Acquisition,Jul-03,Dec-01,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Sales,0,-3.77E-14,71.25375913,195.3612416,260.2938931,301.6620296,342.7280394,373.9691167,399.3188949,420.5011849,437.6121907,451.5982925,8.189225158,436,Fabry's Disease,7/7/14 12:28
673,3,Acorda Therapeutics,Small Biotech,2367,Ampyra,dalfampridine,Small Molecule (Chemical),Launched,In-House,Mar-10,,Jul-18,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,133.1,210.5,266.1,302.6,340.4075,371.1378125,396.6433672,418.7933955,326.3361728,142.7746954,106.4075257,-13.86935561,1409,Multiple Sclerosis adjunctive therapy,7/7/14 12:28
673,3,Acorda Therapeutics,Small Biotech,2367,Ampyra,dalfampridine,Small Molecule (Chemical),Launched,In-House,Mar-10,,Jul-18,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1409,Multiple Sclerosis adjunctive therapy,7/7/14 12:28
673,3,Acorda Therapeutics,Small Biotech,2367,Ampyra,dalfampridine,Small Molecule (Chemical),Launched,In-House,Mar-10,,Jul-18,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,133.1,210.5,266.1,302.6,340.4075,371.1378125,396.6433672,418.7933955,326.3361728,142.7746954,106.4075257,-13.86935561,1409,Multiple Sclerosis adjunctive therapy,7/7/14 12:28
674,67,Novartis,Large Pharma,1096,Famvir,famciclovir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-94,Jul-94,Sep-07,Dec-08,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,437,Herpes zoster and H simplex,7/7/14 12:28
674,67,Novartis,Large Pharma,1096,Famvir,famciclovir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-94,Jul-94,Sep-07,Dec-08,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,6,Global,Sales,65,51,35.93,29.08275,25.81213125,23.75416172,22.75516333,22.20962991,21.90817906,21.74992064,21.66310106,21.6158544,-2.502684083,437,Herpes zoster and H simplex,7/7/14 12:28
674,67,Novartis,Large Pharma,1096,Famvir,famciclovir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-94,Jul-94,Sep-07,Dec-08,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,437,Herpes zoster and H simplex,7/7/14 12:28
674,67,Novartis,Large Pharma,1096,Famvir,famciclovir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-94,Jul-94,Sep-07,Dec-08,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,6,ROW,Sales,40,31,21.6,16.62,14.6215,13.3791125,12.78712094,12.48749813,12.3289081,12.24996142,12.20923553,12.18838325,-2.566624119,437,Herpes zoster and H simplex,7/7/14 12:28
674,67,Novartis,Large Pharma,1096,Famvir,famciclovir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-94,Jul-94,Sep-07,Dec-08,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,437,Herpes zoster and H simplex,7/7/14 12:28
674,67,Novartis,Large Pharma,1096,Famvir,famciclovir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-94,Jul-94,Sep-07,Dec-08,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,6,US,Sales,25,20,14.33,12.46275,11.19063125,10.37504922,9.968042395,9.722131775,9.579270957,9.499959221,9.453865538,9.427471154,-2.419518367,437,Herpes zoster and H simplex,7/7/14 12:28
676,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1882,Farmorubicin / Adriacin,epirubicin / doxorubicin,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jan-99,N/A,Expired,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,441,Breast Cancer,7/7/14 12:28
676,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1882,Farmorubicin / Adriacin,epirubicin / doxorubicin,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jan-99,N/A,Expired,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,441,Breast Cancer,7/7/14 12:28
676,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1882,Farmorubicin / Adriacin,epirubicin / doxorubicin,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jan-99,N/A,Expired,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,441,Breast Cancer,7/7/14 12:28
676,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1882,Farmorubicin / Adriacin,epirubicin / doxorubicin,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jan-99,N/A,Expired,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,441,Breast Cancer,7/7/14 12:28
676,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1882,Farmorubicin / Adriacin,epirubicin / doxorubicin,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jan-99,N/A,Expired,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,441,Breast Cancer,7/7/14 12:28
676,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1882,Farmorubicin / Adriacin,epirubicin / doxorubicin,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jan-99,N/A,Expired,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,441,Breast Cancer,7/7/14 12:28
677,16,AstraZeneca,Large Pharma,320,Faslodex,fulvestrant,Small Molecule (Chemical),Launched,In-House,May-02,May-04,Jan-21,Jan-21,53,Anti-estrogens,55,Hormonals,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,442,Breast Cancer,7/7/14 12:28
677,16,AstraZeneca,Large Pharma,320,Faslodex,fulvestrant,Small Molecule (Chemical),Launched,In-House,May-02,May-04,Jan-21,Jan-21,53,Anti-estrogens,55,Hormonals,3,Oncology,6,Global,Sales,270.04,345,546,654,681,720,744.27,756.0246,766.060608,772.5530798,776.4078798,779.2173873,1.943321741,442,Breast Cancer,7/7/14 12:28
677,16,AstraZeneca,Large Pharma,320,Faslodex,fulvestrant,Small Molecule (Chemical),Launched,In-House,May-02,May-04,Jan-21,Jan-21,53,Anti-estrogens,55,Hormonals,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,442,Breast Cancer,7/7/14 12:28
677,16,AstraZeneca,Large Pharma,320,Faslodex,fulvestrant,Small Molecule (Chemical),Launched,In-House,May-02,May-04,Jan-21,Jan-21,53,Anti-estrogens,55,Hormonals,3,Oncology,6,ROW,Sales,160.04,200,282,344,357,378,394.11,401.2398,407.753064,412.4669335,415.1849878,417.2708733,2.253584465,442,Breast Cancer,7/7/14 12:28
677,16,AstraZeneca,Large Pharma,320,Faslodex,fulvestrant,Small Molecule (Chemical),Launched,In-House,May-02,May-04,Jan-21,Jan-21,53,Anti-estrogens,55,Hormonals,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,442,Breast Cancer,7/7/14 12:28
677,16,AstraZeneca,Large Pharma,320,Faslodex,fulvestrant,Small Molecule (Chemical),Launched,In-House,May-02,May-04,Jan-21,Jan-21,53,Anti-estrogens,55,Hormonals,3,Oncology,6,US,Sales,110,145,264,310,324,342,350.16,354.7848,358.307544,360.0861463,361.222892,361.946514,1.594765976,442,Breast Cancer,7/7/14 12:28
678,34,Daiichi-Sankyo,Regional & Specialty Pharma,1145,Fastic,nateglinide,Small Molecule (Chemical),Launched,Licensed (Marketed),Feb-01,Aug-99,N/A,Dec-11,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1560,Type II Diabetes,7/7/14 12:28
678,34,Daiichi-Sankyo,Regional & Specialty Pharma,1145,Fastic,nateglinide,Small Molecule (Chemical),Launched,Licensed (Marketed),Feb-01,Aug-99,N/A,Dec-11,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,Global,Sales,52.9015655,54.49275129,50.23190396,47.16096573,38.47633705,36.84131407,35.87587648,34.94316869,34.07677687,33.35190026,32.70478234,32.13334209,-2.54072433,1560,Type II Diabetes,7/7/14 12:28
678,34,Daiichi-Sankyo,Regional & Specialty Pharma,1145,Fastic,nateglinide,Small Molecule (Chemical),Launched,Licensed (Marketed),Feb-01,Aug-99,N/A,Dec-11,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1560,Type II Diabetes,7/7/14 12:28
678,34,Daiichi-Sankyo,Regional & Specialty Pharma,1145,Fastic,nateglinide,Small Molecule (Chemical),Launched,Licensed (Marketed),Feb-01,Aug-99,N/A,Dec-11,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,ROW,Sales,52.9015655,54.49275129,50.23190396,47.16096573,38.47633705,36.84131407,35.87587648,34.94316869,34.07677687,33.35190026,32.70478234,32.13334209,-2.54072433,1560,Type II Diabetes,7/7/14 12:28
678,34,Daiichi-Sankyo,Regional & Specialty Pharma,1145,Fastic,nateglinide,Small Molecule (Chemical),Launched,Licensed (Marketed),Feb-01,Aug-99,N/A,Dec-11,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1560,Type II Diabetes,7/7/14 12:28
678,34,Daiichi-Sankyo,Regional & Specialty Pharma,1145,Fastic,nateglinide,Small Molecule (Chemical),Launched,Licensed (Marketed),Feb-01,Aug-99,N/A,Dec-11,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1560,Type II Diabetes,7/7/14 12:28
679,89,Sanofi,Large Pharma,769,Fasturtec,rasburicase,Recombinant Protein,Launched,In-House,Oct-02,Jul-01,N/A,N/A,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,443,Chemotherapy-Induced Hyperuricemia,7/7/14 12:28
679,89,Sanofi,Large Pharma,769,Fasturtec,rasburicase,Recombinant Protein,Launched,In-House,Oct-02,Jul-01,N/A,N/A,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,Global,Sales,70.1864752,67.24233014,71.90707736,67.0139163,69.02555184,69.29565335,69.46205887,69.57367173,69.69956755,69.79953339,69.8822787,69.95322224,0.190896248,443,Chemotherapy-Induced Hyperuricemia,7/7/14 12:28
679,89,Sanofi,Large Pharma,769,Fasturtec,rasburicase,Recombinant Protein,Launched,In-House,Oct-02,Jul-01,N/A,N/A,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,443,Chemotherapy-Induced Hyperuricemia,7/7/14 12:28
679,89,Sanofi,Large Pharma,769,Fasturtec,rasburicase,Recombinant Protein,Launched,In-House,Oct-02,Jul-01,N/A,N/A,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,ROW,Sales,54.1904377,52.29707705,56.28394731,52.71096935,54.47014515,54.80692073,55.02491689,55.17271872,55.31737714,55.42956543,55.51990186,55.59533133,0.292519179,443,Chemotherapy-Induced Hyperuricemia,7/7/14 12:28
679,89,Sanofi,Large Pharma,769,Fasturtec,rasburicase,Recombinant Protein,Launched,In-House,Oct-02,Jul-01,N/A,N/A,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,443,Chemotherapy-Induced Hyperuricemia,7/7/14 12:28
679,89,Sanofi,Large Pharma,769,Fasturtec,rasburicase,Recombinant Protein,Launched,In-House,Oct-02,Jul-01,N/A,N/A,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,US,Sales,15.9960375,14.94525309,15.62313005,14.30294695,14.55540669,14.48873261,14.43714197,14.400953,14.38219041,14.36996796,14.36237684,14.35789092,-0.194992843,443,Chemotherapy-Induced Hyperuricemia,7/7/14 12:28
680,67,Novartis,Large Pharma,806,Femara,letrozole,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-97,May-97,Apr-11,Jul-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1516,Breast Cancer,7/7/14 12:28
680,67,Novartis,Large Pharma,806,Femara,letrozole,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-97,May-97,Apr-11,Jul-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,Global,Sales,1266,1376,911,438,384,332.8,307.16,291.848,283.1376,278.10928,275.219136,273.5555808,-4.729331064,1516,Breast Cancer,7/7/14 12:28
680,67,Novartis,Large Pharma,806,Femara,letrozole,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-97,May-97,Apr-11,Jul-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1516,Breast Cancer,7/7/14 12:28
680,67,Novartis,Large Pharma,806,Femara,letrozole,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-97,May-97,Apr-11,Jul-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,ROW,Sales,694,726,692,416,365,315.6,291.04,276.376,268.0544,263.25936,260.509184,258.9296096,-4.786522177,1516,Breast Cancer,7/7/14 12:28
680,67,Novartis,Large Pharma,806,Femara,letrozole,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-97,May-97,Apr-11,Jul-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1516,Breast Cancer,7/7/14 12:28
680,67,Novartis,Large Pharma,806,Femara,letrozole,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-97,May-97,Apr-11,Jul-11,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,6,US,Sales,572,650,219,22,19,17.2,16.12,15.472,15.0832,14.84992,14.709952,14.6259712,-3.668722866,1516,Breast Cancer,7/7/14 12:28
682,102,Cephalon,Regional & Specialty Pharma,3720,Fentora / Effentora,fentanyl - buccal,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-06,Jan-09,Oct-18,Mar-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Proforma,141,181.6,153,0,0,0,0,0,0,0,0,0,0,444,Cancer Pain,7/7/14 12:28
682,102,Cephalon,Regional & Specialty Pharma,3720,Fentora / Effentora,fentanyl - buccal,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-06,Jan-09,Oct-18,Mar-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Proforma,4,22,27,0,0,0,0,0,0,0,0,0,0,444,Cancer Pain,7/7/14 12:28
682,102,Cephalon,Regional & Specialty Pharma,3720,Fentora / Effentora,fentanyl - buccal,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-06,Jan-09,Oct-18,Mar-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Proforma,137,159.6,126,0,0,0,0,0,0,0,0,0,0,444,Cancer Pain,7/7/14 12:28
682,102,Teva,Regional & Specialty Pharma,3720,Fentora / Effentora,fentanyl - buccal,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-06,Jan-09,Oct-18,Mar-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,444,Cancer Pain,7/7/14 12:28
682,102,Teva,Regional & Specialty Pharma,3720,Fentora / Effentora,fentanyl - buccal,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-06,Jan-09,Oct-18,Mar-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,3.00E-02,51.2925,224.8903403,247.5916434,267.4478967,286.2201738,304.1151214,320.8104883,308.6389028,196.8954094,102.2609842,-11.86686969,444,Cancer Pain,7/7/14 12:28
682,102,Teva,Regional & Specialty Pharma,3720,Fentora / Effentora,fentanyl - buccal,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-06,Jan-09,Oct-18,Mar-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,444,Cancer Pain,7/7/14 12:28
682,102,Teva,Regional & Specialty Pharma,3720,Fentora / Effentora,fentanyl - buccal,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-06,Jan-09,Oct-18,Mar-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,4.00E-02,8.815,49.5901653,62.75543968,74.87860779,86.36818727,97.18150282,107.3318515,116.887228,125.8741383,95.10228575,6.118558648,444,Cancer Pain,7/7/14 12:28
682,102,Teva,Regional & Specialty Pharma,3720,Fentora / Effentora,fentanyl - buccal,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-06,Jan-09,Oct-18,Mar-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,444,Cancer Pain,7/7/14 12:28
682,102,Teva,Regional & Specialty Pharma,3720,Fentora / Effentora,fentanyl - buccal,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-06,Jan-09,Oct-18,Mar-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,-1.00E-02,42.4775,175.300175,184.8362038,192.5692889,199.8519865,206.9336186,213.4786368,191.7516749,71.02127113,7.158698408,-37.15183036,444,Cancer Pain,7/7/14 12:28
683,111,Actavis,Regional & Specialty Pharma,1274,Ferrlecit,ferric gluconate complex,Small Molecule (Chemical),Launched,Licensed (Development),Jun-99,,,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,446,Iron-deficiency Anemia,7/7/14 12:28
683,111,Actavis,Regional & Specialty Pharma,1274,Ferrlecit,ferric gluconate complex,Small Molecule (Chemical),Launched,Licensed (Development),Jun-99,,,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,Global,Sales,113.8,0,0,0,0,0,0,0,0,0,0,0,0,446,Iron-deficiency Anemia,7/7/14 12:28
683,111,Actavis,Regional & Specialty Pharma,1274,Ferrlecit,ferric gluconate complex,Small Molecule (Chemical),Launched,Licensed (Development),Jun-99,,,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,446,Iron-deficiency Anemia,7/7/14 12:28
683,111,Actavis,Regional & Specialty Pharma,1274,Ferrlecit,ferric gluconate complex,Small Molecule (Chemical),Launched,Licensed (Development),Jun-99,,,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,446,Iron-deficiency Anemia,7/7/14 12:28
683,111,Actavis,Regional & Specialty Pharma,1274,Ferrlecit,ferric gluconate complex,Small Molecule (Chemical),Launched,Licensed (Development),Jun-99,,,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,446,Iron-deficiency Anemia,7/7/14 12:28
683,111,Actavis,Regional & Specialty Pharma,1274,Ferrlecit,ferric gluconate complex,Small Molecule (Chemical),Launched,Licensed (Development),Jun-99,,,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,US,Sales,113.8,0,0,0,0,0,0,0,0,0,0,0,0,446,Iron-deficiency Anemia,7/7/14 12:28
684,89,Sanofi,Large Pharma,383,ferroquine,ferroquine,Small Molecule (Chemical),Phase II,,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,447,Malaria,7/7/14 12:28
684,89,Sanofi,Large Pharma,383,ferroquine,ferroquine,Small Molecule (Chemical),Phase II,,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,447,Malaria,7/7/14 12:28
684,89,Sanofi,Large Pharma,383,ferroquine,ferroquine,Small Molecule (Chemical),Phase II,,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,447,Malaria,7/7/14 12:28
684,89,Sanofi,Large Pharma,383,ferroquine,ferroquine,Small Molecule (Chemical),Phase II,,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,447,Malaria,7/7/14 12:28
684,89,Sanofi,Large Pharma,383,ferroquine,ferroquine,Small Molecule (Chemical),Phase II,,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,447,Malaria,7/7/14 12:28
684,89,Sanofi,Large Pharma,383,ferroquine,ferroquine,Small Molecule (Chemical),Phase II,,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,447,Malaria,7/7/14 12:28
685,67,Novartis,Large Pharma,3300,Gilenya,fingolimod,Small Molecule (Chemical),Launched,Licensed (Development),Oct-10,Dec-10,Feb-19,Mar-21,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1469,Multiple Sclerosis,7/7/14 12:28
685,67,Novartis,Large Pharma,3300,Gilenya,fingolimod,Small Molecule (Chemical),Launched,Licensed (Development),Oct-10,Dec-10,Feb-19,Mar-21,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,15,494,1195,1934,2206.4392,2431.49588,2584.171852,2699.817013,2779.448269,1606.771856,1343.208058,-5.074290065,1469,Multiple Sclerosis,7/7/14 12:28
685,67,Novartis,Large Pharma,3300,Gilenya,fingolimod,Small Molecule (Chemical),Launched,Licensed (Development),Oct-10,Dec-10,Feb-19,Mar-21,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1469,Multiple Sclerosis,7/7/14 12:28
685,67,Novartis,Large Pharma,3300,Gilenya,fingolimod,Small Molecule (Chemical),Launched,Licensed (Development),Oct-10,Dec-10,Feb-19,Mar-21,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,2,111,468,911,988.3192,1060.27988,1096.385452,1126.087813,1140.582037,1144.296711,1148.32791,3.362717888,1469,Multiple Sclerosis,7/7/14 12:28
685,67,Novartis,Large Pharma,3300,Gilenya,fingolimod,Small Molecule (Chemical),Launched,Licensed (Development),Oct-10,Dec-10,Feb-19,Mar-21,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1469,Multiple Sclerosis,7/7/14 12:28
685,67,Novartis,Large Pharma,3300,Gilenya,fingolimod,Small Molecule (Chemical),Launched,Licensed (Development),Oct-10,Dec-10,Feb-19,Mar-21,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,13,383,727,1023,1218.12,1371.216,1487.7864,1573.7292,1638.866232,462.4751452,194.8801473,-21.09082069,1469,Multiple Sclerosis,7/7/14 12:28
686,95,Shionogi,Regional & Specialty Pharma,1215,Finibax,doripenem,Small Molecule (Chemical),Launched,In-House,,Sep-05,N/A,Nov-23,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1424,Bacterial infections,7/7/14 12:28
686,95,Shionogi,Regional & Specialty Pharma,1215,Finibax,doripenem,Small Molecule (Chemical),Launched,In-House,,Sep-05,N/A,Nov-23,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,36.62908295,42.97686137,59.50980382,63.88923228,48.60168891,49.48354389,49.6124632,49.23058387,49.24504814,49.19611946,49.13821891,49.11377729,0.149845013,1424,Bacterial infections,7/7/14 12:28
686,95,Shionogi,Regional & Specialty Pharma,1215,Finibax,doripenem,Small Molecule (Chemical),Launched,In-House,,Sep-05,N/A,Nov-23,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1424,Bacterial infections,7/7/14 12:28
686,95,Shionogi,Regional & Specialty Pharma,1215,Finibax,doripenem,Small Molecule (Chemical),Launched,In-House,,Sep-05,N/A,Nov-23,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,36.62908295,42.97686137,59.50980382,63.88923228,48.60168891,49.48354389,49.6124632,49.23058387,49.24504814,49.19611946,49.13821891,49.11377729,0.149845013,1424,Bacterial infections,7/7/14 12:28
686,95,Shionogi,Regional & Specialty Pharma,1215,Finibax,doripenem,Small Molecule (Chemical),Launched,In-House,,Sep-05,N/A,Nov-23,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1424,Bacterial infections,7/7/14 12:28
686,95,Shionogi,Regional & Specialty Pharma,1215,Finibax,doripenem,Small Molecule (Chemical),Launched,In-House,,Sep-05,N/A,Nov-23,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1424,Bacterial infections,7/7/14 12:28
688,100,Takeda,Large Pharma,262,Firstcin,cefozopran,Small Molecule (Chemical),Launched,In-House,,Aug-95,N/A,Jul-12,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,452,bacterial infection,7/7/14 12:28
688,100,Takeda,Large Pharma,262,Firstcin,cefozopran,Small Molecule (Chemical),Launched,In-House,,Aug-95,N/A,Jul-12,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,57.09827637,55.59141718,51.49719364,46.13726019,35.14717624,30.82120676,28.95419372,26.59632633,23.87804179,22.47718386,20.86843814,19.13552655,-8.3191553,452,bacterial infection,7/7/14 12:28
688,100,Takeda,Large Pharma,262,Firstcin,cefozopran,Small Molecule (Chemical),Launched,In-House,,Aug-95,N/A,Jul-12,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,452,bacterial infection,7/7/14 12:28
688,100,Takeda,Large Pharma,262,Firstcin,cefozopran,Small Molecule (Chemical),Launched,In-House,,Aug-95,N/A,Jul-12,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,57.09827637,55.59141718,51.49719364,46.13726019,35.14717624,30.82120676,28.95419372,26.59632633,23.87804179,22.47718386,20.86843814,19.13552655,-8.3191553,452,bacterial infection,7/7/14 12:28
688,100,Takeda,Large Pharma,262,Firstcin,cefozopran,Small Molecule (Chemical),Launched,In-House,,Aug-95,N/A,Jul-12,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,452,bacterial infection,7/7/14 12:28
688,100,Takeda,Large Pharma,262,Firstcin,cefozopran,Small Molecule (Chemical),Launched,In-House,,Aug-95,N/A,Jul-12,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,452,bacterial infection,7/7/14 12:28
689,76,King,Large Pharma,195,Flector,diclofenac,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,,Apr-14,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Proforma,139,151,14.5,0,0,0,0,0,0,0,0,0,0,1668,Pain,7/7/14 12:28
689,76,King,Large Pharma,195,Flector,diclofenac,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,,Apr-14,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Proforma,139,151,14.5,0,0,0,0,0,0,0,0,0,0,1668,Pain,7/7/14 12:28
689,76,Pfizer,Large Pharma,195,Flector,diclofenac,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,,Apr-14,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1668,Pain,7/7/14 12:28
689,76,Pfizer,Large Pharma,195,Flector,diclofenac,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,,Apr-14,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,159.73135,182.3384038,188.3787231,119.4193795,61.57954669,44.96740028,35.90522058,29.66508081,25.14557297,21.98628754,-26.42477995,1668,Pain,7/7/14 12:28
689,76,Pfizer,Large Pharma,195,Flector,diclofenac,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,,Apr-14,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1668,Pain,7/7/14 12:28
689,76,Pfizer,Large Pharma,195,Flector,diclofenac,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,,Apr-14,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1668,Pain,7/7/14 12:28
689,76,Pfizer,Large Pharma,195,Flector,diclofenac,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,,Apr-14,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1668,Pain,7/7/14 12:28
689,76,Pfizer,Large Pharma,195,Flector,diclofenac,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,,Apr-14,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,159.73135,182.3384038,188.3787231,119.4193795,61.57954669,44.96740028,35.90522058,29.66508081,25.14557297,21.98628754,-26.42477995,1668,Pain,7/7/14 12:28
691,46,GlaxoSmithKline,Large Pharma,630,Flonase / Flixonase,fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Apr-95,Mar-92,Expired,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1471,Allergic Rhinitis,7/7/14 12:28
691,46,GlaxoSmithKline,Large Pharma,630,Flonase / Flixonase,fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Apr-95,Mar-92,Expired,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,4,Global,Sales,266.6337489,253.3800095,221.2389381,210.8088402,171.9755431,165.2626078,158.2777068,154.5345085,153.2763377,150.6998438,149.8786602,149.1991533,-2.009115945,1471,Allergic Rhinitis,7/7/14 12:28
691,46,GlaxoSmithKline,Large Pharma,630,Flonase / Flixonase,fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Apr-95,Mar-92,Expired,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1471,Allergic Rhinitis,7/7/14 12:28
691,46,GlaxoSmithKline,Large Pharma,630,Flonase / Flixonase,fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Apr-95,Mar-92,Expired,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,4,ROW,Sales,224.5336833,196.2150074,210.0166731,188.618436,161.0316449,156.2279433,150.9358531,148.5243327,147.0226816,146.0096018,145.433866,145.0770172,-1.479461652,1471,Allergic Rhinitis,7/7/14 12:28
691,46,GlaxoSmithKline,Large Pharma,630,Flonase / Flixonase,fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Apr-95,Mar-92,Expired,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1471,Allergic Rhinitis,7/7/14 12:28
691,46,GlaxoSmithKline,Large Pharma,630,Flonase / Flixonase,fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Apr-95,Mar-92,Expired,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,4,US,Sales,42.10006562,57.16500214,11.22226497,22.19040424,10.9438982,9.034664581,7.341853744,6.010175885,6.253656112,4.690242084,4.444794217,4.122136086,-13.01957422,1471,Allergic Rhinitis,7/7/14 12:28
692,46,GlaxoSmithKline,Large Pharma,4668,Flovent / Flixotide,fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Jan-96,Jan-93,Jul-15,Jan-14,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1699,Asthma,7/7/14 12:28
692,46,GlaxoSmithKline,Large Pharma,4668,Flovent / Flixotide,fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Jan-96,Jan-93,Jul-15,Jan-14,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,Global,Sales,1208.427809,1242.180047,1303.385918,1234.737493,1244.477566,1241.699067,1197.632402,1161.521862,1131.060073,1114.517893,1104.597405,1094.162359,-1.822145695,1699,Asthma,7/7/14 12:28
692,46,GlaxoSmithKline,Large Pharma,4668,Flovent / Flixotide,fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Jan-96,Jan-93,Jul-15,Jan-14,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1699,Asthma,7/7/14 12:28
692,46,GlaxoSmithKline,Large Pharma,4668,Flovent / Flixotide,fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Jan-96,Jan-93,Jul-15,Jan-14,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,590.9601804,576.2850216,586.7641401,524.6445573,490.9120048,473.5402862,446.7235746,429.0591046,413.8153827,402.555149,395.0344661,389.2149416,-3.261802017,1699,Asthma,7/7/14 12:28
692,46,GlaxoSmithKline,Large Pharma,4668,Flovent / Flixotide,fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Jan-96,Jan-93,Jul-15,Jan-14,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1699,Asthma,7/7/14 12:28
692,46,GlaxoSmithKline,Large Pharma,4668,Flovent / Flixotide,fluticasone propionate,Small Molecule (Chemical),Launched,In-House,Jan-96,Jan-93,Jul-15,Jan-14,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,US,Sales,617.4676291,665.895025,716.6217776,710.0929355,753.5655615,768.1587808,750.9088272,732.4627577,717.2446902,711.9627437,709.5629389,704.9474174,-0.948229143,1699,Asthma,7/7/14 12:28
693,46,GlaxoSmithKline,Large Pharma,1694,Flolan,epoprostenol,Small Molecule (Chemical),Launched,In-House,Jan-95,Jan-95,Expired,Expired,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,454,Pulmonary Hypertension,7/7/14 12:28
693,46,GlaxoSmithKline,Large Pharma,1694,Flolan,epoprostenol,Small Molecule (Chemical),Launched,In-House,Jan-95,Jan-95,Expired,Expired,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,4,Global,Sales,336.800525,293.8229146,258.1120944,213.6232743,161.0316449,136.2665018,116.6883916,101.3724726,90.95623548,83.166044,77.40872426,73.22268953,-10.64785761,454,Pulmonary Hypertension,7/7/14 12:28
693,46,GlaxoSmithKline,Large Pharma,1694,Flolan,epoprostenol,Small Molecule (Chemical),Launched,In-House,Jan-95,Jan-95,Expired,Expired,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,454,Pulmonary Hypertension,7/7/14 12:28
693,46,GlaxoSmithKline,Large Pharma,1694,Flolan,epoprostenol,Small Molecule (Chemical),Launched,In-House,Jan-95,Jan-95,Expired,Expired,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,4,ROW,Sales,193.3484495,190.3079107,184.3657817,161.6729451,121.9462942,105.4973082,91.36973788,79.66801692,71.64065966,65.43083428,60.71875584,57.22408087,-10.24500034,454,Pulmonary Hypertension,7/7/14 12:28
693,46,GlaxoSmithKline,Large Pharma,1694,Flolan,epoprostenol,Small Molecule (Chemical),Launched,In-House,Jan-95,Jan-95,Expired,Expired,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,454,Pulmonary Hypertension,7/7/14 12:28
693,46,GlaxoSmithKline,Large Pharma,1694,Flolan,epoprostenol,Small Molecule (Chemical),Launched,In-House,Jan-95,Jan-95,Expired,Expired,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,4,US,Sales,143.4520754,103.5150039,73.74631268,51.95032912,39.0853507,30.76919364,25.31865369,21.70445566,19.31557582,17.73520973,16.68996842,15.99860867,-11.98002778,454,Pulmonary Hypertension,7/7/14 12:28
695,23,Boehringer Ingelheim,Large Pharma,850,Flomax / Omnic,tamsulosin,Small Molecule (Chemical),Launched,Licensed (Development),Oct-97,Nov-93,Mar-10,Feb-06,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1649,Symptoms associated with BPH,7/7/14 12:28
695,23,Boehringer Ingelheim,Large Pharma,850,Flomax / Omnic,tamsulosin,Small Molecule (Chemical),Launched,Licensed (Development),Oct-97,Nov-93,Mar-10,Feb-06,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,Global,Sales,1964.472842,1087.623699,1042.793583,878.7208557,780.363296,732.8970351,696.6615935,670.8440894,655.9967748,645.9392189,639.4019702,635.2662594,-2.896025444,1649,Symptoms associated with BPH,7/7/14 12:28
695,23,Boehringer Ingelheim,Large Pharma,850,Flomax / Omnic,tamsulosin,Small Molecule (Chemical),Launched,Licensed (Development),Oct-97,Nov-93,Mar-10,Feb-06,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1649,Symptoms associated with BPH,7/7/14 12:28
695,23,Boehringer Ingelheim,Large Pharma,850,Flomax / Omnic,tamsulosin,Small Molecule (Chemical),Launched,Licensed (Development),Oct-97,Nov-93,Mar-10,Feb-06,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,ROW,Sales,532.1778882,533.8761884,591.570807,563.8308942,575.5747468,580.6681504,582.0409897,582.6328563,583.5351379,583.9712515,584.2981171,584.5409411,0.221068376,1649,Symptoms associated with BPH,7/7/14 12:28
695,23,Boehringer Ingelheim,Large Pharma,850,Flomax / Omnic,tamsulosin,Small Molecule (Chemical),Launched,Licensed (Development),Oct-97,Nov-93,Mar-10,Feb-06,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1649,Symptoms associated with BPH,7/7/14 12:28
695,23,Boehringer Ingelheim,Large Pharma,850,Flomax / Omnic,tamsulosin,Small Molecule (Chemical),Launched,Licensed (Development),Oct-97,Nov-93,Mar-10,Feb-06,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,US,Sales,1432.294953,553.7475106,451.2227764,314.8899615,204.7885492,152.2288847,114.6206038,88.21123307,72.46163694,61.96796748,55.10385301,50.72531822,-18.07487693,1649,Symptoms associated with BPH,7/7/14 12:28
696,95,Shionogi,Regional & Specialty Pharma,78,Flomox,cefcapene pivoxil,Small Molecule (Chemical),Launched,In-House,,Jul-97,N/A,Oct-08,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,455,,7/7/14 12:28
696,95,Shionogi,Regional & Specialty Pharma,78,Flomox,cefcapene pivoxil,Small Molecule (Chemical),Launched,In-House,,Jul-97,N/A,Oct-08,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,258.5582326,255.6350605,262.09637,219.7829643,167.0683056,152.53827,138.7743974,127.1046576,116.8086265,107.687257,99.70050331,92.66930818,-8.074799254,455,,7/7/14 12:28
696,95,Shionogi,Regional & Specialty Pharma,78,Flomox,cefcapene pivoxil,Small Molecule (Chemical),Launched,In-House,,Jul-97,N/A,Oct-08,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,455,,7/7/14 12:28
696,95,Shionogi,Regional & Specialty Pharma,78,Flomox,cefcapene pivoxil,Small Molecule (Chemical),Launched,In-House,,Jul-97,N/A,Oct-08,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,258.5582326,255.6350605,262.09637,219.7829643,167.0683056,152.53827,138.7743974,127.1046576,116.8086265,107.687257,99.70050331,92.66930818,-8.074799254,455,,7/7/14 12:28
696,95,Shionogi,Regional & Specialty Pharma,78,Flomox,cefcapene pivoxil,Small Molecule (Chemical),Launched,In-House,,Jul-97,N/A,Oct-08,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,455,,7/7/14 12:28
696,95,Shionogi,Regional & Specialty Pharma,78,Flomox,cefcapene pivoxil,Small Molecule (Chemical),Launched,In-House,,Jul-97,N/A,Oct-08,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,455,,7/7/14 12:28
700,46,GlaxoSmithKline,Large Pharma,2240,H1N1 pandemic influenza vaccine,H1N1 pandemic influenza,Vaccine,Launched,In-House,Nov-09,Sep-09,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,511,Pandemic Influenza,7/7/14 12:28
700,46,GlaxoSmithKline,Large Pharma,2240,H1N1 pandemic influenza vaccine,H1N1 pandemic influenza,Vaccine,Launched,In-House,Nov-09,Sep-09,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,1376.828072,1841.628574,28.85725279,0,0,0,0,0,0,0,0,0,0,511,Pandemic Influenza,7/7/14 12:28
700,46,GlaxoSmithKline,Large Pharma,2240,H1N1 pandemic influenza vaccine,H1N1 pandemic influenza,Vaccine,Launched,In-House,Nov-09,Sep-09,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,511,Pandemic Influenza,7/7/14 12:28
700,46,GlaxoSmithKline,Large Pharma,2240,H1N1 pandemic influenza vaccine,H1N1 pandemic influenza,Vaccine,Launched,In-House,Nov-09,Sep-09,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,1085.246136,1840.095069,28.85725279,0,0,0,0,0,0,0,0,0,0,511,Pandemic Influenza,7/7/14 12:28
700,46,GlaxoSmithKline,Large Pharma,2240,H1N1 pandemic influenza vaccine,H1N1 pandemic influenza,Vaccine,Launched,In-House,Nov-09,Sep-09,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,511,Pandemic Influenza,7/7/14 12:28
700,46,GlaxoSmithKline,Large Pharma,2240,H1N1 pandemic influenza vaccine,H1N1 pandemic influenza,Vaccine,Launched,In-House,Nov-09,Sep-09,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,291.581936,1.533504518,0,0,0,0,0,0,0,0,0,0,0,511,Pandemic Influenza,7/7/14 12:28
704,19,Bayer,Large Pharma,1547,Fludara,fludarabine phosphate,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-91,Dec-94,Expired,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1470,Chronic Lymphocytic Leukemia,7/7/14 12:28
704,19,Bayer,Large Pharma,1547,Fludara,fludarabine phosphate,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-91,Dec-94,Expired,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,Global,Sales,59.74843131,0,0,0,0,0,0,0,0,0,0,0,0,1470,Chronic Lymphocytic Leukemia,7/7/14 12:28
704,19,Bayer,Large Pharma,1547,Fludara,fludarabine phosphate,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-91,Dec-94,Expired,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1470,Chronic Lymphocytic Leukemia,7/7/14 12:28
704,19,Bayer,Large Pharma,1547,Fludara,fludarabine phosphate,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-91,Dec-94,Expired,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,ROW,Sales,59.74843131,0,0,0,0,0,0,0,0,0,0,0,0,1470,Chronic Lymphocytic Leukemia,7/7/14 12:28
704,19,Bayer,Large Pharma,1547,Fludara,fludarabine phosphate,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-91,Dec-94,Expired,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1470,Chronic Lymphocytic Leukemia,7/7/14 12:28
704,19,Bayer,Large Pharma,1547,Fludara,fludarabine phosphate,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-91,Dec-94,Expired,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1470,Chronic Lymphocytic Leukemia,7/7/14 12:28
705,46,GlaxoSmithKline,Large Pharma,168,Flulaval / Fluarix,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-05,Jul-96,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1708,Influenza,7/7/14 12:28
705,46,GlaxoSmithKline,Large Pharma,168,Flulaval / Fluarix,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-05,Jul-96,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,329.0042165,372.345014,368.7315634,317.0057748,392.416921,434.8167095,454.9784968,477.4219306,492.0094433,502.3803026,510.4844601,516.2954919,3.997164483,1708,Influenza,7/7/14 12:28
705,46,GlaxoSmithKline,Large Pharma,168,Flulaval / Fluarix,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-05,Jul-96,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1708,Influenza,7/7/14 12:28
705,46,GlaxoSmithKline,Large Pharma,168,Flulaval / Fluarix,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-05,Jul-96,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,215.1781132,202.3950076,157.1117096,177.5232339,164.1584729,187.6096834,194.0196809,198.045472,202.3585405,204.681676,206.3119993,207.4993573,3.403727128,1708,Influenza,7/7/14 12:28
705,46,GlaxoSmithKline,Large Pharma,168,Flulaval / Fluarix,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-05,Jul-96,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1708,Influenza,7/7/14 12:28
705,46,GlaxoSmithKline,Large Pharma,168,Flulaval / Fluarix,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-05,Jul-96,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,113.8261033,169.9500064,211.6198538,139.4825409,228.2584481,247.2070261,260.9588159,279.3764585,289.6509029,297.6986266,304.1724608,308.7961347,4.411723901,1708,Influenza,7/7/14 12:28
706,95,Shionogi,Regional & Specialty Pharma,1730,Flumarin,flomoxef,Small Molecule (Chemical),Launched,In-House,,Jul-88,N/A,Dec-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,459,,7/7/14 12:28
706,95,Shionogi,Regional & Specialty Pharma,1730,Flumarin,flomoxef,Small Molecule (Chemical),Launched,In-House,,Jul-88,N/A,Dec-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,93.72735932,87.5462536,87.36545667,72.232444,55.08931438,50.58117546,47.25561333,44.67937871,42.71865569,41.21689215,40.06927618,39.19157401,-4.747788088,459,,7/7/14 12:28
706,95,Shionogi,Regional & Specialty Pharma,1730,Flumarin,flomoxef,Small Molecule (Chemical),Launched,In-House,,Jul-88,N/A,Dec-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,459,,7/7/14 12:28
706,95,Shionogi,Regional & Specialty Pharma,1730,Flumarin,flomoxef,Small Molecule (Chemical),Launched,In-House,,Jul-88,N/A,Dec-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,93.72735932,87.5462536,87.36545667,72.232444,55.08931438,50.58117546,47.25561333,44.67937871,42.71865569,41.21689215,40.06927618,39.19157401,-4.747788088,459,,7/7/14 12:28
706,95,Shionogi,Regional & Specialty Pharma,1730,Flumarin,flomoxef,Small Molecule (Chemical),Launched,In-House,,Jul-88,N/A,Dec-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,459,,7/7/14 12:28
706,95,Shionogi,Regional & Specialty Pharma,1730,Flumarin,flomoxef,Small Molecule (Chemical),Launched,In-House,,Jul-88,N/A,Dec-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,459,,7/7/14 12:28
708,16,AstraZeneca,Large Pharma,3955,Flumist / CAIV-T / Fluenz,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Sep-07,Oct-10,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1710,seasonal influenza,7/7/14 12:28
708,16,AstraZeneca,Large Pharma,3955,Flumist / CAIV-T / Fluenz,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Sep-07,Oct-10,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,533,174,161,181,245,271.205,298.014625,323.3797281,342.8290335,359.8973121,374.5934926,387.0172132,6.749607162,1710,seasonal influenza,7/7/14 12:28
708,16,AstraZeneca,Large Pharma,3955,Flumist / CAIV-T / Fluenz,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Sep-07,Oct-10,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1710,seasonal influenza,7/7/14 12:28
708,16,AstraZeneca,Large Pharma,3955,Flumist / CAIV-T / Fluenz,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Sep-07,Oct-10,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,1,1,7,46,63.04,80.176,97.36,111.07264,123.423616,134.40448,143.9550822,17.70129448,1710,seasonal influenza,7/7/14 12:28
708,16,AstraZeneca,Large Pharma,3955,Flumist / CAIV-T / Fluenz,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Sep-07,Oct-10,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1710,seasonal influenza,7/7/14 12:28
708,16,AstraZeneca,Large Pharma,3955,Flumist / CAIV-T / Fluenz,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Sep-07,Oct-10,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,533,173,160,174,199,208.165,217.838625,226.0197281,231.7563935,236.4736961,240.1890126,243.062131,2.898528116,1710,seasonal influenza,7/7/14 12:28
709,46,GlaxoSmithKline,Large Pharma,1413,fluticasone furoate,fluticasone furoate,Small Molecule (Chemical),Filed,In-House,Oct-14,Oct-14,N/A,Jan-23,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1473,Asthma,7/7/14 12:28
709,46,GlaxoSmithKline,Large Pharma,1413,fluticasone furoate,fluticasone furoate,Small Molecule (Chemical),Filed,In-House,Oct-14,Oct-14,N/A,Jan-23,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,19.62084605,139.3895867,247.7923116,319.6376384,363.3192543,395.1651783,417.7143601,0,1473,Asthma,7/7/14 12:28
709,46,GlaxoSmithKline,Large Pharma,1413,fluticasone furoate,fluticasone furoate,Small Molecule (Chemical),Filed,In-House,Oct-14,Oct-14,N/A,Jan-23,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1473,Asthma,7/7/14 12:28
709,46,GlaxoSmithKline,Large Pharma,1413,fluticasone furoate,fluticasone furoate,Small Molecule (Chemical),Filed,In-House,Oct-14,Oct-14,N/A,Jan-23,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,5.862802605,27.35976503,42.99395557,58.62827757,72.07372609,83.70561326,94.08676729,0,1473,Asthma,7/7/14 12:28
709,46,GlaxoSmithKline,Large Pharma,1413,fluticasone furoate,fluticasone furoate,Small Molecule (Chemical),Filed,In-House,Oct-14,Oct-14,N/A,Jan-23,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1473,Asthma,7/7/14 12:28
709,46,GlaxoSmithKline,Large Pharma,1413,fluticasone furoate,fluticasone furoate,Small Molecule (Chemical),Filed,In-House,Oct-14,Oct-14,N/A,Jan-23,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,13.75804345,112.0298217,204.7983561,261.0093609,291.2455282,311.459565,323.6275928,0,1473,Asthma,7/7/14 12:28
711,46,GlaxoSmithKline,Large Pharma,4619,Breo / Relvar,vilanterol + fluticasone furoate ,Small Molecule (Chemical),Launched,In-House,Oct-13,Dec-13,N/A,Sep-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,461,COPD,7/7/14 12:28
711,46,GlaxoSmithKline,Large Pharma,4619,Breo / Relvar,vilanterol + fluticasone furoate ,Small Molecule (Chemical),Launched,In-House,Oct-13,Dec-13,N/A,Sep-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,12.50731222,218.8779639,604.724575,1048.027095,1339.900066,1610.141581,1843.398998,2045.43144,107.1243917,461,COPD,7/7/14 12:28
711,46,GlaxoSmithKline,Large Pharma,4619,Breo / Relvar,vilanterol + fluticasone furoate ,Small Molecule (Chemical),Launched,In-House,Oct-13,Dec-13,N/A,Sep-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,461,COPD,7/7/14 12:28
711,46,GlaxoSmithKline,Large Pharma,4619,Breo / Relvar,vilanterol + fluticasone furoate ,Small Molecule (Chemical),Launched,In-House,Oct-13,Dec-13,N/A,Sep-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,4.690242084,54.71949098,208.3997286,362.0799405,468.439962,572.4560596,664.1777376,742.8478757,106.1784184,461,COPD,7/7/14 12:28
711,46,GlaxoSmithKline,Large Pharma,4619,Breo / Relvar,vilanterol + fluticasone furoate ,Small Molecule (Chemical),Launched,In-House,Oct-13,Dec-13,N/A,Sep-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,461,COPD,7/7/14 12:28
711,46,GlaxoSmithKline,Large Pharma,4619,Breo / Relvar,vilanterol + fluticasone furoate ,Small Molecule (Chemical),Launched,In-House,Oct-13,Dec-13,N/A,Sep-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,7.81707014,164.1584729,396.3248464,685.9471544,871.4601042,1037.685521,1179.22126,1302.583565,107.6797703,461,COPD,7/7/14 12:28
714,65,Mundipharma,Regional & Specialty Pharma,735,Flutiform,formoterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,N/A,Nov-19,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,5,Global,Sales,0,0,0,2.452925603,17.22592472,35.68229723,54.13860865,61.22415097,66.3325266,69.68097172,71.5305092,72.71090017,22.84152322,1472,Asthma,7/7/14 12:28
714,65,Mundipharma,Regional & Specialty Pharma,735,Flutiform,formoterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,N/A,Nov-19,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,5,ROW,Sales,0,0,0,2.452925603,17.22592472,35.68229723,54.13860865,61.22415097,66.3325266,69.68097172,71.5305092,72.71090017,22.84152322,1472,Asthma,7/7/14 12:28
714,65,Mundipharma,Regional & Specialty Pharma,735,Flutiform,formoterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,N/A,Nov-19,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1472,Asthma,7/7/14 12:28
715,67,Novartis,Large Pharma,1052,Fluvirin,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-89,Jul-91,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1711,seasonal influenza,7/7/14 12:28
715,67,Novartis,Large Pharma,1052,Fluvirin,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-89,Jul-91,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,295,410.221332,410.2434652,358.5,344.343339,324.2157843,302.2407093,284.5401254,267.1729464,250.7607229,235.6194198,221.3539501,-6.117399311,1711,seasonal influenza,7/7/14 12:28
715,67,Novartis,Large Pharma,1052,Fluvirin,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-89,Jul-91,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1711,seasonal influenza,7/7/14 12:28
715,67,Novartis,Large Pharma,1052,Fluvirin,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-89,Jul-91,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,60,60.221332,60.2434652,56,54.34333901,52.66578428,50.91820931,49.55150043,48.31699013,47.21556389,46.2600375,45.41596299,-2.53110537,1711,seasonal influenza,7/7/14 12:28
715,67,Novartis,Large Pharma,1052,Fluvirin,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-89,Jul-91,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1711,seasonal influenza,7/7/14 12:28
715,67,Novartis,Large Pharma,1052,Fluvirin,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-89,Jul-91,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,235,350,350,302.5,290,271.55,251.3225,234.988625,218.8559563,203.5451591,189.3593823,175.9379871,-6.890381268,1711,seasonal influenza,7/7/14 12:28
716,89,Sanofi,Large Pharma,351,Influenza Vaccines - Sanofi,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1712,influenza,7/7/14 12:28
716,89,Sanofi,Large Pharma,351,Influenza Vaccines - Sanofi,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,1475.647304,1718.206989,1148.500993,1136.179852,1233.739932,1218.533988,1234.845517,1246.180752,1252.036177,1257.673158,1261.622814,1264.322084,0.350411092,1712,influenza,7/7/14 12:28
716,89,Sanofi,Large Pharma,351,Influenza Vaccines - Sanofi,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1712,influenza,7/7/14 12:28
716,89,Sanofi,Large Pharma,351,Influenza Vaccines - Sanofi,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,616.9372908,1018.736449,543.6608817,537.2434143,525.8999064,494.6247983,489.4554413,484.1122783,480.9690553,479.7065257,478.9136665,478.4925165,-1.34050888,1712,influenza,7/7/14 12:28
716,89,Sanofi,Large Pharma,351,Influenza Vaccines - Sanofi,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1712,influenza,7/7/14 12:28
716,89,Sanofi,Large Pharma,351,Influenza Vaccines - Sanofi,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,858.7100128,699.4705397,604.8401113,598.936438,707.8400255,723.9091893,745.3900757,762.0684733,771.0671221,777.9666325,782.7091472,785.8295673,1.504370771,1712,influenza,7/7/14 12:28
717,61,Merck & Co,Large Pharma,2188,Follistim / Puregon,follitropin-beta,Recombinant Protein,Launched,Acquisition (Marketed),Sep-97,Jun-96,Jun-15,Expired,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1475,Female infertility,7/7/14 12:28
717,61,Merck & Co,Large Pharma,2188,Follistim / Puregon,follitropin-beta,Recombinant Protein,Launched,Acquisition (Marketed),Sep-97,Jun-96,Jun-15,Expired,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,Global,Sales,96.5,517.8,530,468,481,469.14,400.7646766,366.5912535,337.4553509,303.7117938,272.3318992,248.678281,-8.993913682,1475,Female infertility,7/7/14 12:28
717,61,Merck & Co,Large Pharma,2188,Follistim / Puregon,follitropin-beta,Recombinant Protein,Launched,Acquisition (Marketed),Sep-97,Jun-96,Jun-15,Expired,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1475,Female infertility,7/7/14 12:28
717,61,Merck & Co,Large Pharma,2188,Follistim / Puregon,follitropin-beta,Recombinant Protein,Launched,Acquisition (Marketed),Sep-97,Jun-96,Jun-15,Expired,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,ROW,Sales,64,350.8,367,303,300,287.84,222.2324125,199.0455597,182.1947466,167.0079887,153.2932509,143.902537,-9.962988077,1475,Female infertility,7/7/14 12:28
717,61,Merck & Co,Large Pharma,2188,Follistim / Puregon,follitropin-beta,Recombinant Protein,Launched,Acquisition (Marketed),Sep-97,Jun-96,Jun-15,Expired,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1475,Female infertility,7/7/14 12:28
717,61,Merck & Co,Large Pharma,2188,Follistim / Puregon,follitropin-beta,Recombinant Protein,Launched,Acquisition (Marketed),Sep-97,Jun-96,Jun-15,Expired,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,US,Sales,32.5,167,163,165,181,181.3,178.5322641,167.5456938,155.2606044,136.7038052,119.0386483,104.775744,-7.512465512,1475,Female infertility,7/7/14 12:28
717,61,Schering-Plough,Large Pharma,2188,Follistim / Puregon,follitropin-beta,Recombinant Protein,Launched,Acquisition (Marketed),Sep-97,Jun-96,Jun-15,Expired,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,Global,Proforma,450.5,0,0,0,0,0,0,0,0,0,0,0,0,1475,Female infertility,7/7/14 12:28
717,61,Schering-Plough,Large Pharma,2188,Follistim / Puregon,follitropin-beta,Recombinant Protein,Launched,Acquisition (Marketed),Sep-97,Jun-96,Jun-15,Expired,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,ROW,Proforma,304,0,0,0,0,0,0,0,0,0,0,0,0,1475,Female infertility,7/7/14 12:28
717,61,Schering-Plough,Large Pharma,2188,Follistim / Puregon,follitropin-beta,Recombinant Protein,Launched,Acquisition (Marketed),Sep-97,Jun-96,Jun-15,Expired,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,US,Proforma,146.5,0,0,0,0,0,0,0,0,0,0,0,0,1475,Female infertility,7/7/14 12:28
718,67,Novartis,Large Pharma,1472,Foradil,formoterol,Small Molecule (Chemical),Launched,Licensed (Development),May-01,Jan-86,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1477,COPD,7/7/14 12:28
718,67,Novartis,Large Pharma,1472,Foradil,formoterol,Small Molecule (Chemical),Launched,Licensed (Development),May-01,Jan-86,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Sales,357,353,312,240,205,170,150,135,117,100.98,86.3892,72.386568,-13.81832322,1477,COPD,7/7/14 12:28
718,67,Novartis,Large Pharma,1472,Foradil,formoterol,Small Molecule (Chemical),Launched,Licensed (Development),May-01,Jan-86,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1477,COPD,7/7/14 12:28
718,67,Novartis,Large Pharma,1472,Foradil,formoterol,Small Molecule (Chemical),Launched,Licensed (Development),May-01,Jan-86,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,357,353,312,240,205,170,150,135,117,100.98,86.3892,72.386568,-13.81832322,1477,COPD,7/7/14 12:28
718,67,Novartis,Large Pharma,1472,Foradil,formoterol,Small Molecule (Chemical),Launched,Licensed (Development),May-01,Jan-86,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1477,COPD,7/7/14 12:28
718,67,Novartis,Large Pharma,1472,Foradil,formoterol,Small Molecule (Chemical),Launched,Licensed (Development),May-01,Jan-86,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1477,COPD,7/7/14 12:28
719,61,Merck & Co,Large Pharma,1472,Foradil,formoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-01,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1477,COPD,7/7/14 12:28
719,61,Merck & Co,Large Pharma,1472,Foradil,formoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-01,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Sales,16.4,94.8,91.92,89.328,86.736,84.144,81.552,78.96,76.368,73.776,71.184,68.592,-3.297173463,1477,COPD,7/7/14 12:28
719,61,Merck & Co,Large Pharma,1472,Foradil,formoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-01,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1477,COPD,7/7/14 12:28
719,61,Merck & Co,Large Pharma,1472,Foradil,formoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-01,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1477,COPD,7/7/14 12:28
719,61,Merck & Co,Large Pharma,1472,Foradil,formoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-01,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1477,COPD,7/7/14 12:28
719,61,Merck & Co,Large Pharma,1472,Foradil,formoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-01,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Sales,16.4,94.8,91.92,89.328,86.736,84.144,81.552,78.96,76.368,73.776,71.184,68.592,-3.297173463,1477,COPD,7/7/14 12:28
719,61,Schering-Plough,Large Pharma,1472,Foradil,formoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-01,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Proforma,81.6,0,0,0,0,0,0,0,0,0,0,0,0,1477,COPD,7/7/14 12:28
719,61,Schering-Plough,Large Pharma,1472,Foradil,formoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-01,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Proforma,81.6,0,0,0,0,0,0,0,0,0,0,0,0,1477,COPD,7/7/14 12:28
720,39,Eli Lilly,Large Pharma,1322,Forteo,teriparatide,Synthetic Peptide,Launched,In-House,Jan-03,Oct-03,Aug-18,Dec-18,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,466,Osteoporosis,7/7/14 12:28
720,39,Eli Lilly,Large Pharma,1322,Forteo,teriparatide,Synthetic Peptide,Launched,In-House,Jan-03,Oct-03,Aug-18,Dec-18,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,816.7,830,949.8,1151,1245,1332.714,1401.30668,1450.97149,1490.569905,1521.072369,1544.524932,1562.817937,3.301246589,466,Osteoporosis,7/7/14 12:28
720,39,Eli Lilly,Large Pharma,1322,Forteo,teriparatide,Synthetic Peptide,Launched,In-House,Jan-03,Oct-03,Aug-18,Dec-18,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,466,Osteoporosis,7/7/14 12:28
720,39,Eli Lilly,Large Pharma,1322,Forteo,teriparatide,Synthetic Peptide,Launched,In-House,Jan-03,Oct-03,Aug-18,Dec-18,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,298.4,331,496.7,663,734,805.118,859.1894,896.73206,926.26187,948.3670598,964.8191017,977.2772257,4.174212881,466,Osteoporosis,7/7/14 12:28
720,39,Eli Lilly,Large Pharma,1322,Forteo,teriparatide,Synthetic Peptide,Launched,In-House,Jan-03,Oct-03,Aug-18,Dec-18,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,466,Osteoporosis,7/7/14 12:28
720,39,Eli Lilly,Large Pharma,1322,Forteo,teriparatide,Synthetic Peptide,Launched,In-House,Jan-03,Oct-03,Aug-18,Dec-18,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,518.3,499,453.1,488,511,527.596,542.11728,554.2394304,564.3080351,572.7053095,579.7058305,585.5407109,1.964271215,466,Osteoporosis,7/7/14 12:28
721,46,GlaxoSmithKline,Large Pharma,489,Fortum,ceftazidime,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-83,Sep-03,Sep-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,468,,7/7/14 12:28
721,46,GlaxoSmithKline,Large Pharma,489,Fortum,ceftazidime,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-83,Sep-03,Sep-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,4,Global,Sales,188.6706644,169.9639328,157.2082711,141.1655995,126.7517653,116.944835,109.0194142,102.5101165,97.25020872,92.9743766,89.49316309,86.6639646,-5.286453206,468,,7/7/14 12:28
721,46,GlaxoSmithKline,Large Pharma,489,Fortum,ceftazidime,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-83,Sep-03,Sep-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,468,,7/7/14 12:28
721,46,GlaxoSmithKline,Large Pharma,489,Fortum,ceftazidime,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-83,Sep-03,Sep-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,4,ROW,Sales,171.5187859,154.9939959,143.7531145,129.4390111,116.1172431,107.1130439,99.78279723,93.70840173,88.78242362,84.7564737,81.46252045,78.7745504,-5.392175705,468,,7/7/14 12:28
721,46,GlaxoSmithKline,Large Pharma,489,Fortum,ceftazidime,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-83,Sep-03,Sep-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,468,,7/7/14 12:28
721,46,GlaxoSmithKline,Large Pharma,489,Fortum,ceftazidime,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-83,Sep-03,Sep-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,4,US,Sales,17.15187859,14.96993692,13.45515666,11.72658846,10.63452219,9.831791116,9.236616929,8.801714815,8.467785099,8.217902901,8.030642639,7.889414199,-4.175784551,468,,7/7/14 12:28
722,61,Merck & Co,Large Pharma,335,Fosamax,alendronate,Small Molecule (Chemical),Launched,Licensed (Development),Oct-95,Jul-93,Expired,Expired,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1335,Osteoporosis,7/7/14 12:28
722,61,Merck & Co,Large Pharma,335,Fosamax,alendronate,Small Molecule (Chemical),Launched,Licensed (Development),Oct-95,Jul-93,Expired,Expired,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,1100,925,855,676,560,477.88,398.51275,334.4965687,280.7704789,234.4735085,195.4754383,162.3920182,-16.20912196,1335,Osteoporosis,7/7/14 12:28
722,61,Merck & Co,Large Pharma,335,Fosamax,alendronate,Small Molecule (Chemical),Launched,Licensed (Development),Oct-95,Jul-93,Expired,Expired,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1335,Osteoporosis,7/7/14 12:28
722,61,Merck & Co,Large Pharma,335,Fosamax,alendronate,Small Molecule (Chemical),Launched,Licensed (Development),Oct-95,Jul-93,Expired,Expired,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,939,832,810,648,540,459.75,381.05625,317.2898437,263.6338477,217.3613452,178.3715967,145.2907286,-17.101009,1335,Osteoporosis,7/7/14 12:28
722,61,Merck & Co,Large Pharma,335,Fosamax,alendronate,Small Molecule (Chemical),Launched,Licensed (Development),Oct-95,Jul-93,Expired,Expired,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1335,Osteoporosis,7/7/14 12:28
722,61,Merck & Co,Large Pharma,335,Fosamax,alendronate,Small Molecule (Chemical),Launched,Licensed (Development),Oct-95,Jul-93,Expired,Expired,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,161,93,45,28,20,18.13,17.4565,17.206725,17.13663125,17.11216331,17.1038416,17.1012896,-2.212000416,1335,Osteoporosis,7/7/14 12:28
723,96,Shire,Regional & Specialty Pharma,196,Fosrenol,lanthanum carbonate,Small Molecule (Chemical),Launched,Licensed (Development),Jan-05,Jan-06,Oct-18,Mar-16,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,469,Hyperphosphatemia,7/7/14 12:28
723,96,Shire,Regional & Specialty Pharma,196,Fosrenol,lanthanum carbonate,Small Molecule (Chemical),Launched,Licensed (Development),Jan-05,Jan-06,Oct-18,Mar-16,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,6,Global,Sales,184.4,182.1,166.9,172,183,189.2728,186.48592,168.463512,146.9438424,107.0816151,54.45711656,35.10480413,-21.01230246,469,Hyperphosphatemia,7/7/14 12:28
723,96,Shire,Regional & Specialty Pharma,196,Fosrenol,lanthanum carbonate,Small Molecule (Chemical),Launched,Licensed (Development),Jan-05,Jan-06,Oct-18,Mar-16,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,469,Hyperphosphatemia,7/7/14 12:28
723,96,Shire,Regional & Specialty Pharma,196,Fosrenol,lanthanum carbonate,Small Molecule (Chemical),Launched,Licensed (Development),Jan-05,Jan-06,Oct-18,Mar-16,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,6,ROW,Sales,95,99.33,100,107,119,127.4,126.616,109.642008,89.4968536,62.32478952,37.36351528,33.27963831,-16.64196746,469,Hyperphosphatemia,7/7/14 12:28
723,96,Shire,Regional & Specialty Pharma,196,Fosrenol,lanthanum carbonate,Small Molecule (Chemical),Launched,Licensed (Development),Jan-05,Jan-06,Oct-18,Mar-16,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,469,Hyperphosphatemia,7/7/14 12:28
723,96,Shire,Regional & Specialty Pharma,196,Fosrenol,lanthanum carbonate,Small Molecule (Chemical),Launched,Licensed (Development),Jan-05,Jan-06,Oct-18,Mar-16,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,6,US,Sales,89.4,82.77,66.9,65,64,61.8728,59.86992,58.821504,57.4469888,44.7568256,17.09360128,1.825165824,-39.84061136,469,Hyperphosphatemia,7/7/14 12:28
724,37,Eisai,Regional & Specialty Pharma,670,Fragmin,dalteparin sodium,Synthetic Peptide,Launched,Licensed (Marketed),Jul-95,,Expired,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1410,Thrombosis,7/7/14 12:28
724,37,Eisai,Regional & Specialty Pharma,670,Fragmin,dalteparin sodium,Synthetic Peptide,Launched,Licensed (Marketed),Jul-95,,Expired,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,145.4390058,191.4344745,181.323535,116.7757845,70.47405572,55.63130084,47.28614824,42.65365327,40.06782175,38.627898,37.82523476,37.37800614,-8.661199104,1410,Thrombosis,7/7/14 12:28
724,37,Eisai,Regional & Specialty Pharma,670,Fragmin,dalteparin sodium,Synthetic Peptide,Launched,Licensed (Marketed),Jul-95,,Expired,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1410,Thrombosis,7/7/14 12:28
724,37,Eisai,Regional & Specialty Pharma,670,Fragmin,dalteparin sodium,Synthetic Peptide,Launched,Licensed (Marketed),Jul-95,,Expired,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1410,Thrombosis,7/7/14 12:28
724,37,Eisai,Regional & Specialty Pharma,670,Fragmin,dalteparin sodium,Synthetic Peptide,Launched,Licensed (Marketed),Jul-95,,Expired,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1410,Thrombosis,7/7/14 12:28
724,37,Eisai,Regional & Specialty Pharma,670,Fragmin,dalteparin sodium,Synthetic Peptide,Launched,Licensed (Marketed),Jul-95,,Expired,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,US,Sales,145.4390058,191.4344745,181.323535,116.7757845,70.47405572,55.63130084,47.28614824,42.65365327,40.06782175,38.627898,37.82523476,37.37800614,-8.661199104,1410,Thrombosis,7/7/14 12:28
725,76,Pfizer,Large Pharma,670,Fragmin,dalteparin sodium,Synthetic Peptide,Launched,Corporate Acquisition,Jul-95,Jul-82,Expired,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1410,,7/7/14 12:28
725,76,Pfizer,Large Pharma,670,Fragmin,dalteparin sodium,Synthetic Peptide,Launched,Corporate Acquisition,Jul-95,Jul-82,Expired,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,359,341,382,380.95,359,356.4025,354.6115625,353.2686328,352.8538963,352.6135201,352.4853946,352.4306312,-0.2634888,1410,,7/7/14 12:28
725,76,Pfizer,Large Pharma,670,Fragmin,dalteparin sodium,Synthetic Peptide,Launched,Corporate Acquisition,Jul-95,Jul-82,Expired,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1410,,7/7/14 12:28
725,76,Pfizer,Large Pharma,670,Fragmin,dalteparin sodium,Synthetic Peptide,Launched,Corporate Acquisition,Jul-95,Jul-82,Expired,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,277,301,339,339,336,335.7,335.67,335.667,335.6667,335.66667,335.666667,335.6666667,-1.42E-02,1410,,7/7/14 12:28
725,76,Pfizer,Large Pharma,670,Fragmin,dalteparin sodium,Synthetic Peptide,Launched,Corporate Acquisition,Jul-95,Jul-82,Expired,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1410,,7/7/14 12:28
725,76,Pfizer,Large Pharma,670,Fragmin,dalteparin sodium,Synthetic Peptide,Launched,Corporate Acquisition,Jul-95,Jul-82,Expired,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,82,40,43,41.95,23,20.7025,18.9415625,17.60163281,17.18719629,16.94685012,16.81872763,16.76396453,-4.417489432,1410,,7/7/14 12:28
726,15,Astellas Pharma,Regional & Specialty Pharma,1321,Frandol,isosorbide dinitrate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-81,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,473,Angina,7/7/14 12:28
726,15,Astellas Pharma,Regional & Specialty Pharma,1321,Frandol,isosorbide dinitrate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-81,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,117.5887884,117.8956215,119.0196076,107.5182184,81.54855019,76.96773656,72.43618866,69.24686213,66.54455608,64.48248467,62.81495256,61.50959133,-3.948573948,473,Angina,7/7/14 12:28
726,15,Astellas Pharma,Regional & Specialty Pharma,1321,Frandol,isosorbide dinitrate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-81,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,473,Angina,7/7/14 12:28
726,15,Astellas Pharma,Regional & Specialty Pharma,1321,Frandol,isosorbide dinitrate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-81,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,117.5887884,117.8956215,119.0196076,107.5182184,81.54855019,76.96773656,72.43618866,69.24686213,66.54455608,64.48248467,62.81495256,61.50959133,-3.948573948,473,Angina,7/7/14 12:28
726,15,Astellas Pharma,Regional & Specialty Pharma,1321,Frandol,isosorbide dinitrate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-81,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,473,Angina,7/7/14 12:28
726,15,Astellas Pharma,Regional & Specialty Pharma,1321,Frandol,isosorbide dinitrate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-81,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,473,Angina,7/7/14 12:28
727,46,GlaxoSmithKline,Large Pharma,811,Fraxiparine,nadroparin,Synthetic Peptide,Launched,Acquisition (Marketed),,Jan-88,N/A,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1558,Thrombosis,7/7/14 12:28
727,46,GlaxoSmithKline,Large Pharma,811,Fraxiparine,nadroparin,Synthetic Peptide,Launched,Acquisition (Marketed),,Jan-88,N/A,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,Global,Sales,357.0709269,342.9900129,375.1442863,369.3117276,345.5145002,0,0,0,0,0,0,0,-100,1558,Thrombosis,7/7/14 12:28
727,46,GlaxoSmithKline,Large Pharma,811,Fraxiparine,nadroparin,Synthetic Peptide,Launched,Acquisition (Marketed),,Jan-88,N/A,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1558,Thrombosis,7/7/14 12:28
727,46,GlaxoSmithKline,Large Pharma,811,Fraxiparine,nadroparin,Synthetic Peptide,Launched,Acquisition (Marketed),,Jan-88,N/A,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,ROW,Sales,357.0709269,342.9900129,375.1442863,369.3117276,345.5145002,0,0,0,0,0,0,0,-100,1558,Thrombosis,7/7/14 12:28
727,46,GlaxoSmithKline,Large Pharma,811,Fraxiparine,nadroparin,Synthetic Peptide,Launched,Acquisition (Marketed),,Jan-88,N/A,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1558,Thrombosis,7/7/14 12:28
727,46,GlaxoSmithKline,Large Pharma,811,Fraxiparine,nadroparin,Synthetic Peptide,Launched,Acquisition (Marketed),,Jan-88,N/A,Expired,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1558,Thrombosis,7/7/14 12:28
729,40,Endo Health Solutions,Regional & Specialty Pharma,1366,Frova,frovatriptan,Small Molecule (Chemical),Launched,Licensed (Development),Jun-02,,Nov-15,,117,Triptans,8,Migraine,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,474,Migraine,7/7/14 12:28
729,40,Endo Health Solutions,Regional & Specialty Pharma,1366,Frova,frovatriptan,Small Molecule (Chemical),Launched,Licensed (Development),Jun-02,,Nov-15,,117,Triptans,8,Migraine,12,Central Nervous System,6,Global,Sales,57.924,59.299,58.18,61,61,60,50.15,5.9,4.64,4.06,3.42,2.822,-35.53583547,474,Migraine,7/7/14 12:28
729,40,Endo Health Solutions,Regional & Specialty Pharma,1366,Frova,frovatriptan,Small Molecule (Chemical),Launched,Licensed (Development),Jun-02,,Nov-15,,117,Triptans,8,Migraine,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,474,Migraine,7/7/14 12:28
729,40,Endo Health Solutions,Regional & Specialty Pharma,1366,Frova,frovatriptan,Small Molecule (Chemical),Launched,Licensed (Development),Jun-02,,Nov-15,,117,Triptans,8,Migraine,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,474,Migraine,7/7/14 12:28
729,40,Endo Health Solutions,Regional & Specialty Pharma,1366,Frova,frovatriptan,Small Molecule (Chemical),Launched,Licensed (Development),Jun-02,,Nov-15,,117,Triptans,8,Migraine,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,474,Migraine,7/7/14 12:28
729,40,Endo Health Solutions,Regional & Specialty Pharma,1366,Frova,frovatriptan,Small Molecule (Chemical),Launched,Licensed (Development),Jun-02,,Nov-15,,117,Triptans,8,Migraine,12,Central Nervous System,6,US,Sales,57.924,59.299,58.18,61,61,60,50.15,5.9,4.64,4.06,3.42,2.822,-35.53583547,474,Migraine,7/7/14 12:28
730,15,Astellas Pharma,Regional & Specialty Pharma,4353,Funguard / Mycamine,micafungin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-05,Jan-03,Mar-19,Dec-17,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,476,,7/7/14 12:28
730,15,Astellas Pharma,Regional & Specialty Pharma,4353,Funguard / Mycamine,micafungin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-05,Jan-03,Mar-19,Dec-17,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,7,Global,Sales,230.4579057,290.3530581,329.2031701,361.2833772,377.5602501,398.4314037,412.641295,427.1450631,425.904358,412.6721514,356.4603912,319.280036,-2.366706725,476,,7/7/14 12:28
730,15,Astellas Pharma,Regional & Specialty Pharma,4353,Funguard / Mycamine,micafungin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-05,Jan-03,Mar-19,Dec-17,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,476,,7/7/14 12:28
730,15,Astellas Pharma,Regional & Specialty Pharma,4353,Funguard / Mycamine,micafungin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-05,Jan-03,Mar-19,Dec-17,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,7,ROW,Sales,149.658458,196.679631,225.3775549,252.0706554,266.2207791,281.8962229,291.9639451,303.4152038,300.6512797,286.4167547,283.3758711,279.1961369,0.682152212,476,,7/7/14 12:28
730,15,Astellas Pharma,Regional & Specialty Pharma,4353,Funguard / Mycamine,micafungin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-05,Jan-03,Mar-19,Dec-17,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,476,,7/7/14 12:28
730,15,Astellas Pharma,Regional & Specialty Pharma,4353,Funguard / Mycamine,micafungin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-05,Jan-03,Mar-19,Dec-17,95,Echinocandins,25,Fungal Infection,7,Anti-infectives,7,US,Sales,80.79944769,93.67342706,103.8256152,109.2127218,111.339471,116.5351808,120.6773499,123.7298593,125.2530783,126.2553967,73.08452012,40.08389909,-13.57939119,476,,7/7/14 12:28
731,86,Roche,Large Pharma,855,Fuzeon,enfuvirtide,Synthetic Peptide,Launched,Licensed (Development),Mar-03,Jul-03,Jun-15,Apr-18,26,Other HIV Treatments,32,HIV,7,Anti-infectives,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,477,HIV,7/7/14 12:28
731,86,Roche,Large Pharma,855,Fuzeon,enfuvirtide,Synthetic Peptide,Launched,Licensed (Development),Mar-03,Jul-03,Jun-15,Apr-18,26,Other HIV Treatments,32,HIV,7,Anti-infectives,5,Global,Sales,112.2450546,88.42294041,50.68580713,35.49498478,28.15030504,23.35298598,21.36094089,20.25617387,19.66607721,19.37579247,19.22080599,19.13956224,-5.362305489,477,HIV,7/7/14 12:28
731,86,Roche,Large Pharma,855,Fuzeon,enfuvirtide,Synthetic Peptide,Launched,Licensed (Development),Mar-03,Jul-03,Jun-15,Apr-18,26,Other HIV Treatments,32,HIV,7,Anti-infectives,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,477,HIV,7/7/14 12:28
731,86,Roche,Large Pharma,855,Fuzeon,enfuvirtide,Synthetic Peptide,Launched,Licensed (Development),Mar-03,Jul-03,Jun-15,Apr-18,26,Other HIV Treatments,32,HIV,7,Anti-infectives,5,ROW,Sales,73.11121683,57.25433344,32.77682194,21.98260382,16.45287439,12.77873143,11.1569294,10.23557801,9.730964543,9.475042775,9.335958215,9.261785763,-7.880736534,477,HIV,7/7/14 12:28
731,86,Roche,Large Pharma,855,Fuzeon,enfuvirtide,Synthetic Peptide,Launched,Licensed (Development),Mar-03,Jul-03,Jun-15,Apr-18,26,Other HIV Treatments,32,HIV,7,Anti-infectives,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,477,HIV,7/7/14 12:28
731,86,Roche,Large Pharma,855,Fuzeon,enfuvirtide,Synthetic Peptide,Launched,Licensed (Development),Mar-03,Jul-03,Jun-15,Apr-18,26,Other HIV Treatments,32,HIV,7,Anti-infectives,5,US,Sales,39.13383773,31.16860698,17.90898519,13.51238096,11.69743065,10.57425455,10.20401149,10.02059586,9.935112671,9.900749692,9.884847777,9.877776479,-2.386513045,477,HIV,7/7/14 12:28
732,688,Depomed,Small Biotech,3449,Gralise,gabapentin GR,Small Molecule (Chemical),Launched,In-House,Oct-11,,Jun-20,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0.5,7.6,33,45.00012,55.528162,65.2890019,72.59620148,78.6774236,83.70688084,87.76725546,14.99747578,478,Post-herpetic Neuralgia,7/7/14 12:28
732,688,Depomed,Small Biotech,3449,Gralise,gabapentin GR,Small Molecule (Chemical),Launched,In-House,Oct-11,,Jun-20,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,478,Post-herpetic Neuralgia,7/7/14 12:28
732,688,Depomed,Small Biotech,3449,Gralise,gabapentin GR,Small Molecule (Chemical),Launched,In-House,Oct-11,,Jun-20,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0.5,7.6,33,45.00012,55.528162,65.2890019,72.59620148,78.6774236,83.70688084,87.76725546,14.99747578,478,Post-herpetic Neuralgia,7/7/14 12:28
733,102,Cephalon,Regional & Specialty Pharma,1187,Gabitril,tiagabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-00,Jun-02,Nov-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Proforma,56.5,44.5,30.75,0,0,0,0,0,0,0,0,0,0,479,Epilepsy,7/7/14 12:28
733,102,Cephalon,Regional & Specialty Pharma,1187,Gabitril,tiagabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-00,Jun-02,Nov-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Proforma,5.4,4.8,3,0,0,0,0,0,0,0,0,0,0,479,Epilepsy,7/7/14 12:28
733,102,Cephalon,Regional & Specialty Pharma,1187,Gabitril,tiagabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-00,Jun-02,Nov-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Proforma,51.1,39.7,27.75,0,0,0,0,0,0,0,0,0,0,479,Epilepsy,7/7/14 12:28
733,102,Teva,Regional & Specialty Pharma,1187,Gabitril,tiagabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-00,Jun-02,Nov-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,479,Epilepsy,7/7/14 12:28
733,102,Teva,Regional & Specialty Pharma,1187,Gabitril,tiagabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-00,Jun-02,Nov-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,0,-1.00E-02,6.8782,30.83425,27.437275,24.987382,23.19997786,21.99121179,21.15676625,20.57646218,20.17532353,19.897892,-4.48609423,479,Epilepsy,7/7/14 12:28
733,102,Teva,Regional & Specialty Pharma,1187,Gabitril,tiagabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-00,Jun-02,Nov-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,479,Epilepsy,7/7/14 12:28
733,102,Teva,Regional & Specialty Pharma,1187,Gabitril,tiagabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-00,Jun-02,Nov-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,0,-4.00E-02,1.3282,3.83425,3.587275,3.413182,3.28516186,3.198448113,3.138698726,3.097134987,3.068396604,3.048523393,-2.297975778,479,Epilepsy,7/7/14 12:28
733,102,Teva,Regional & Specialty Pharma,1187,Gabitril,tiagabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-00,Jun-02,Nov-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,479,Epilepsy,7/7/14 12:28
733,102,Teva,Regional & Specialty Pharma,1187,Gabitril,tiagabine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-00,Jun-02,Nov-11,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,0,3.00E-02,5.55,27,23.85,21.5742,19.914816,18.79276368,18.01806753,17.47932719,17.10692693,16.84936861,-4.842680501,479,Epilepsy,7/7/14 12:28
735,67,Novartis,Large Pharma,1280,Galvus / Eucreas,vildagliptin / vildagliptin + metformin,Small Molecule (Chemical),Launched,In-House,,May-07,N/A,Sep-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,481,Type II Diabetes,7/7/14 12:28
735,67,Novartis,Large Pharma,1280,Galvus / Eucreas,vildagliptin / vildagliptin + metformin,Small Molecule (Chemical),Launched,In-House,,May-07,N/A,Sep-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,Global,Sales,181,391,677,910,1200,1408.8,1578.4875,1716.131719,1826.839717,1896.961651,1958.290829,1994.996944,7.531883429,481,Type II Diabetes,7/7/14 12:28
735,67,Novartis,Large Pharma,1280,Galvus / Eucreas,vildagliptin / vildagliptin + metformin,Small Molecule (Chemical),Launched,In-House,,May-07,N/A,Sep-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,481,Type II Diabetes,7/7/14 12:28
735,67,Novartis,Large Pharma,1280,Galvus / Eucreas,vildagliptin / vildagliptin + metformin,Small Molecule (Chemical),Launched,In-House,,May-07,N/A,Sep-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Sales,181,391,677,910,1200,1408.8,1578.4875,1716.131719,1826.839717,1896.961651,1958.290829,1994.996944,7.531883429,481,Type II Diabetes,7/7/14 12:28
735,67,Novartis,Large Pharma,1280,Galvus / Eucreas,vildagliptin / vildagliptin + metformin,Small Molecule (Chemical),Launched,In-House,,May-07,N/A,Sep-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,481,Type II Diabetes,7/7/14 12:28
735,67,Novartis,Large Pharma,1280,Galvus / Eucreas,vildagliptin / vildagliptin + metformin,Small Molecule (Chemical),Launched,In-House,,May-07,N/A,Sep-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,481,Type II Diabetes,7/7/14 12:28
738,61,Merck & Co,Large Pharma,461,Gardasil,HPV vaccine,Vaccine,Launched,Licensed (Development),Jun-06,Oct-06,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1491,Prevention of cervical cancer,7/7/14 12:28
738,61,Merck & Co,Large Pharma,461,Gardasil,HPV vaccine,Vaccine,Launched,Licensed (Development),Jun-06,Oct-06,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,1119,988,1209,1630,1831,1993.6,1495.5715,594.14069,463.215842,389.0801785,309.3492967,260.9783912,-24.29387677,1491,Prevention of cervical cancer,7/7/14 12:28
738,61,Merck & Co,Large Pharma,461,Gardasil,HPV vaccine,Vaccine,Launched,Licensed (Development),Jun-06,Oct-06,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1491,Prevention of cervical cancer,7/7/14 12:28
738,61,Merck & Co,Large Pharma,461,Gardasil,HPV vaccine,Vaccine,Launched,Licensed (Development),Jun-06,Oct-06,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,317,266,329,517,536,583.1,592.0495,452.2007,332.85505,272.215364,207.3808383,174.880741,-14.78597145,1491,Prevention of cervical cancer,7/7/14 12:28
738,61,Merck & Co,Large Pharma,461,Gardasil,HPV vaccine,Vaccine,Launched,Licensed (Development),Jun-06,Oct-06,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1491,Prevention of cervical cancer,7/7/14 12:28
738,61,Merck & Co,Large Pharma,461,Gardasil,HPV vaccine,Vaccine,Launched,Licensed (Development),Jun-06,Oct-06,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,802,722,880,1113,1295,1410.5,903.522,141.93999,130.360792,116.8648145,101.9684584,86.09765016,-32.10816773,1491,Prevention of cervical cancer,7/7/14 12:28
739,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,461,Gardasil,HPV vaccine,Vaccine,Launched,Licensed (Development),,Sep-06,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,549.1992436,349.7352698,252.9882282,263.9947304,290.8385846,294.8386112,269.7398437,182.0239969,30.56636169,24.58200308,21.58839771,18.55094958,-32.50912706,1491,prophylaxis of HPV,7/7/14 12:28
739,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,461,Gardasil,HPV vaccine,Vaccine,Launched,Licensed (Development),,Sep-06,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,549.1992436,349.7352698,252.9882282,263.9947304,290.8385846,294.8386112,269.7398437,182.0239969,30.56636169,24.58200308,21.58839771,18.55094958,-32.50912706,1491,prophylaxis of HPV,7/7/14 12:28
739,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,461,Gardasil,HPV vaccine,Vaccine,Launched,Licensed (Development),,Sep-06,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1491,prophylaxis of HPV,7/7/14 12:28
740,35,Dainippon-Sumitomo,Regional & Specialty Pharma,205,Gasmotin,mosapride,Small Molecule (Chemical),Launched,In-House,,Oct-98,Expired,Dec-12,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,482,Gastritis,7/7/14 12:28
740,35,Dainippon-Sumitomo,Regional & Specialty Pharma,205,Gasmotin,mosapride,Small Molecule (Chemical),Launched,In-House,,Oct-98,Expired,Dec-12,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,223.0064756,245.1295101,268.4272002,244.3864355,165.2780829,154.3461251,144.8425388,136.9171806,132.4171073,129.1529267,126.8693347,125.3588023,-3.872305428,482,Gastritis,7/7/14 12:28
740,35,Dainippon-Sumitomo,Regional & Specialty Pharma,205,Gasmotin,mosapride,Small Molecule (Chemical),Launched,In-House,,Oct-98,Expired,Dec-12,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,482,Gastritis,7/7/14 12:28
740,35,Dainippon-Sumitomo,Regional & Specialty Pharma,205,Gasmotin,mosapride,Small Molecule (Chemical),Launched,In-House,,Oct-98,Expired,Dec-12,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,223.0064756,245.1295101,268.4272002,244.3864355,165.2780829,154.3461251,144.8425388,136.9171806,132.4171073,129.1529267,126.8693347,125.3588023,-3.872305428,482,Gastritis,7/7/14 12:28
740,35,Dainippon-Sumitomo,Regional & Specialty Pharma,205,Gasmotin,mosapride,Small Molecule (Chemical),Launched,In-House,,Oct-98,Expired,Dec-12,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,482,Gastritis,7/7/14 12:28
740,35,Dainippon-Sumitomo,Regional & Specialty Pharma,205,Gasmotin,mosapride,Small Molecule (Chemical),Launched,In-House,,Oct-98,Expired,Dec-12,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,482,Gastritis,7/7/14 12:28
741,15,Astellas Pharma,Regional & Specialty Pharma,841,Gaster,famotidine,Small Molecule (Chemical),Launched,In-House,,Jul-85,N/A,Jul-05,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,483,Gastric Ulcers,7/7/14 12:28
741,15,Astellas Pharma,Regional & Specialty Pharma,841,Gaster,famotidine,Small Molecule (Chemical),Launched,In-House,,Jul-85,N/A,Jul-05,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,537.5856586,486.75717,474.8122645,363.5699682,270.3468946,237.1988445,208.2311681,186.4136263,168.0535476,152.9903615,140.808174,130.8107283,-9.851121614,483,Gastric Ulcers,7/7/14 12:28
741,15,Astellas Pharma,Regional & Specialty Pharma,841,Gaster,famotidine,Small Molecule (Chemical),Launched,In-House,,Jul-85,N/A,Jul-05,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,483,Gastric Ulcers,7/7/14 12:28
741,15,Astellas Pharma,Regional & Specialty Pharma,841,Gaster,famotidine,Small Molecule (Chemical),Launched,In-House,,Jul-85,N/A,Jul-05,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,537.5856586,486.75717,474.8122645,363.5699682,270.3468946,237.1988445,208.2311681,186.4136263,168.0535476,152.9903615,140.808174,130.8107283,-9.851121614,483,Gastric Ulcers,7/7/14 12:28
741,15,Astellas Pharma,Regional & Specialty Pharma,841,Gaster,famotidine,Small Molecule (Chemical),Launched,In-House,,Jul-85,N/A,Jul-05,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,483,Gastric Ulcers,7/7/14 12:28
741,15,Astellas Pharma,Regional & Specialty Pharma,841,Gaster,famotidine,Small Molecule (Chemical),Launched,In-House,,Jul-85,N/A,Jul-05,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,483,Gastric Ulcers,7/7/14 12:28
744,29,Chugai,Regional & Specialty Pharma,3749,RG7686,GC33,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,487,Hepatocellular Carcinoma,7/7/14 12:28
744,29,Chugai,Regional & Specialty Pharma,3749,RG7686,GC33,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,487,Hepatocellular Carcinoma,7/7/14 12:28
744,29,Chugai,Regional & Specialty Pharma,3749,RG7686,GC33,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,487,Hepatocellular Carcinoma,7/7/14 12:28
745,39,Eli Lilly,Large Pharma,839,Gemzar,gemcitabine,Small Molecule (Chemical),Launched,In-House,Mar-95,Jun-95,Nov-10,Mar-09,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,489,Non-small-cell Lung Cancer,7/7/14 12:28
745,39,Eli Lilly,Large Pharma,839,Gemzar,gemcitabine,Small Molecule (Chemical),Launched,In-House,Mar-95,Jun-95,Nov-10,Mar-09,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,Global,Sales,1363.2,1149.4,452.1,289.9,193,161.02,148.348,143.2792,141.25168,140.440672,140.1162688,139.9865075,-4.484121875,489,Non-small-cell Lung Cancer,7/7/14 12:28
745,39,Eli Lilly,Large Pharma,839,Gemzar,gemcitabine,Small Molecule (Chemical),Launched,In-House,Mar-95,Jun-95,Nov-10,Mar-09,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,489,Non-small-cell Lung Cancer,7/7/14 12:28
745,39,Eli Lilly,Large Pharma,839,Gemzar,gemcitabine,Small Molecule (Chemical),Launched,In-House,Mar-95,Jun-95,Nov-10,Mar-09,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,ROW,Sales,615.8,426.1,381.5,271.9,192.7,161.02,148.348,143.2792,141.25168,140.440672,140.1162688,139.9865075,-4.462892997,489,Non-small-cell Lung Cancer,7/7/14 12:28
745,39,Eli Lilly,Large Pharma,839,Gemzar,gemcitabine,Small Molecule (Chemical),Launched,In-House,Mar-95,Jun-95,Nov-10,Mar-09,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,489,Non-small-cell Lung Cancer,7/7/14 12:28
745,39,Eli Lilly,Large Pharma,839,Gemzar,gemcitabine,Small Molecule (Chemical),Launched,In-House,Mar-95,Jun-95,Nov-10,Mar-09,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,US,Sales,747.4,723.3,70.6,18,0.3,0,0,0,0,0,0,0,-100,489,Non-small-cell Lung Cancer,7/7/14 12:28
746,15,Astellas Pharma,Regional & Specialty Pharma,861,Geninax,garenoxacin,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-07,N/A,Feb-22,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1481,,7/7/14 12:28
746,15,Astellas Pharma,Regional & Specialty Pharma,861,Geninax,garenoxacin,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-07,N/A,Feb-22,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,87.26340351,119.0629049,150.6737586,148.0765102,136.6922501,143.3287213,148.1175812,152.2919159,155.2025877,157.4018327,159.0864472,160.3369763,2.305394058,1481,,7/7/14 12:28
746,15,Astellas Pharma,Regional & Specialty Pharma,861,Geninax,garenoxacin,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-07,N/A,Feb-22,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1481,,7/7/14 12:28
746,15,Astellas Pharma,Regional & Specialty Pharma,861,Geninax,garenoxacin,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-07,N/A,Feb-22,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,87.26340351,119.0629049,150.6737586,148.0765102,136.6922501,143.3287213,148.1175812,152.2919159,155.2025877,157.4018327,159.0864472,160.3369763,2.305394058,1481,,7/7/14 12:28
746,15,Astellas Pharma,Regional & Specialty Pharma,861,Geninax,garenoxacin,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-07,N/A,Feb-22,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1481,,7/7/14 12:28
746,15,Astellas Pharma,Regional & Specialty Pharma,861,Geninax,garenoxacin,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-07,N/A,Feb-22,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1481,,7/7/14 12:28
747,76,Pfizer,Large Pharma,1069,Genotropin,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Apr-95,Jul-87,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3350,Growth Hormone Disorders,7/7/14 12:28
747,76,Pfizer,Large Pharma,1069,Genotropin,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Apr-95,Jul-87,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Sales,887,885,889,832,772,730.08,693.7024,662.009216,635.4284902,612.8657422,593.672248,577.3897389,-4.064610961,3350,Growth Hormone Disorders,7/7/14 12:28
747,76,Pfizer,Large Pharma,1069,Genotropin,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Apr-95,Jul-87,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3350,Growth Hormone Disorders,7/7/14 12:28
747,76,Pfizer,Large Pharma,1069,Genotropin,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Apr-95,Jul-87,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Sales,666,676,684,628,573,533.96,500.0944,470.897216,446.3785702,425.6416142,408.072696,393.2081402,-5.237111167,3350,Growth Hormone Disorders,7/7/14 12:28
747,76,Pfizer,Large Pharma,1069,Genotropin,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Apr-95,Jul-87,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3350,Growth Hormone Disorders,7/7/14 12:28
747,76,Pfizer,Large Pharma,1069,Genotropin,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Apr-95,Jul-87,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Sales,221,209,205,204,199,196.12,193.608,191.112,189.04992,187.224128,185.599552,184.1815987,-1.099376863,3350,Growth Hormone Disorders,7/7/14 12:28
748,76,Pfizer,Large Pharma,452,Geodon,ziprasidone,Small Molecule (Chemical),Launched,In-House,Feb-01,Sep-00,Mar-12,Feb-13,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,490,Schizophrenia,7/7/14 12:28
748,76,Pfizer,Large Pharma,452,Geodon,ziprasidone,Small Molecule (Chemical),Launched,In-House,Feb-01,Sep-00,Mar-12,Feb-13,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,1002,1027,1022,353,194,107.5,77.575,62.00125,54.0504375,48.36765313,43.12867859,40.54503751,-20.03928568,490,Schizophrenia,7/7/14 12:28
748,76,Pfizer,Large Pharma,452,Geodon,ziprasidone,Small Molecule (Chemical),Launched,In-House,Feb-01,Sep-00,Mar-12,Feb-13,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,490,Schizophrenia,7/7/14 12:28
748,76,Pfizer,Large Pharma,452,Geodon,ziprasidone,Small Molecule (Chemical),Launched,In-House,Feb-01,Sep-00,Mar-12,Feb-13,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,166,163,163,139,110,69,55,45,39,34,29,26.5,-18.39939081,490,Schizophrenia,7/7/14 12:28
748,76,Pfizer,Large Pharma,452,Geodon,ziprasidone,Small Molecule (Chemical),Launched,In-House,Feb-01,Sep-00,Mar-12,Feb-13,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,490,Schizophrenia,7/7/14 12:28
748,76,Pfizer,Large Pharma,452,Geodon,ziprasidone,Small Molecule (Chemical),Launched,In-House,Feb-01,Sep-00,Mar-12,Feb-13,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,836,864,859,214,84,38.5,22.575,17.00125,15.0504375,14.36765313,14.12867859,14.04503751,-22.54759398,490,Schizophrenia,7/7/14 12:28
750,37,Eisai,Regional & Specialty Pharma,110,Glakay,menatetrenone,Small Molecule (Chemical),Launched,In-House,,Oct-95,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,491,Osteoporosis,7/7/14 12:28
750,37,Eisai,Regional & Specialty Pharma,110,Glakay,menatetrenone,Small Molecule (Chemical),Launched,In-House,,Oct-95,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,56.65641625,46.08778699,41.5515199,34.10444925,27.63696534,25.43921594,23.85184641,22.7110074,21.67068122,20.84475914,20.17750045,19.6248706,-4.77312912,491,Osteoporosis,7/7/14 12:28
750,37,Eisai,Regional & Specialty Pharma,110,Glakay,menatetrenone,Small Molecule (Chemical),Launched,In-House,,Oct-95,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,491,Osteoporosis,7/7/14 12:28
750,37,Eisai,Regional & Specialty Pharma,110,Glakay,menatetrenone,Small Molecule (Chemical),Launched,In-House,,Oct-95,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,56.65641625,46.08778699,41.5515199,34.10444925,27.63696534,25.43921594,23.85184641,22.7110074,21.67068122,20.84475914,20.17750045,19.6248706,-4.77312912,491,Osteoporosis,7/7/14 12:28
750,37,Eisai,Regional & Specialty Pharma,110,Glakay,menatetrenone,Small Molecule (Chemical),Launched,In-House,,Oct-95,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,491,Osteoporosis,7/7/14 12:28
750,37,Eisai,Regional & Specialty Pharma,110,Glakay,menatetrenone,Small Molecule (Chemical),Launched,In-House,,Oct-95,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,491,Osteoporosis,7/7/14 12:28
751,67,Novartis,Large Pharma,3220,Glivec / Gleevec,imatinib,Small Molecule (Chemical),Launched,In-House,May-01,Sep-01,Jul-15,Dec-16,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1494,Chronic Myeloid Leukemia,7/7/14 12:28
751,67,Novartis,Large Pharma,3220,Glivec / Gleevec,imatinib,Small Molecule (Chemical),Launched,In-House,May-01,Sep-01,Jul-15,Dec-16,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,3944,4265,4659,4675,4693,4736.2,3859.669,2616.864967,1326.323714,1026.272344,831.5108081,692.8277478,-23.91294184,1494,Chronic Myeloid Leukemia,7/7/14 12:28
751,67,Novartis,Large Pharma,3220,Glivec / Gleevec,imatinib,Small Molecule (Chemical),Launched,In-House,May-01,Sep-01,Jul-15,Dec-16,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1494,Chronic Myeloid Leukemia,7/7/14 12:28
751,67,Novartis,Large Pharma,3220,Glivec / Gleevec,imatinib,Small Molecule (Chemical),Launched,In-House,May-01,Sep-01,Jul-15,Dec-16,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,2856,2980,3200,2977,2754,2653.2,2531.775,2359.637417,1146.578379,888.5158768,720.8927704,598.2193858,-19.59722651,1494,Chronic Myeloid Leukemia,7/7/14 12:28
751,67,Novartis,Large Pharma,3220,Glivec / Gleevec,imatinib,Small Molecule (Chemical),Launched,In-House,May-01,Sep-01,Jul-15,Dec-16,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1494,Chronic Myeloid Leukemia,7/7/14 12:28
751,67,Novartis,Large Pharma,3220,Glivec / Gleevec,imatinib,Small Molecule (Chemical),Launched,In-House,May-01,Sep-01,Jul-15,Dec-16,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,1088,1285,1459,1698,1939,2083,1327.894,257.22755,179.745335,137.756467,110.6180377,94.60836196,-35.04361297,1494,Chronic Myeloid Leukemia,7/7/14 12:28
752,39,Eli Lilly,Large Pharma,3328,Dulaglutide,GLP-1 Fc,Recombinant Protein,Filed,In-House,Oct-14,Oct-14,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,492,Type II Diabetes,7/7/14 12:28
752,39,Eli Lilly,Large Pharma,3328,Dulaglutide,GLP-1 Fc,Recombinant Protein,Filed,In-House,Oct-14,Oct-14,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,12.5,95.833375,279.1664547,462.5006488,593.1676056,718.7678877,829.7015412,0,492,Type II Diabetes,7/7/14 12:28
752,39,Eli Lilly,Large Pharma,3328,Dulaglutide,GLP-1 Fc,Recombinant Protein,Filed,In-House,Oct-14,Oct-14,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,492,Type II Diabetes,7/7/14 12:28
752,39,Eli Lilly,Large Pharma,3328,Dulaglutide,GLP-1 Fc,Recombinant Protein,Filed,In-House,Oct-14,Oct-14,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,5,38.33335,111.6665819,185.0002595,237.2670423,287.5071551,331.8806165,0,492,Type II Diabetes,7/7/14 12:28
752,39,Eli Lilly,Large Pharma,3328,Dulaglutide,GLP-1 Fc,Recombinant Protein,Filed,In-House,Oct-14,Oct-14,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,492,Type II Diabetes,7/7/14 12:28
752,39,Eli Lilly,Large Pharma,3328,Dulaglutide,GLP-1 Fc,Recombinant Protein,Filed,In-House,Oct-14,Oct-14,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,7.5,57.500025,167.4998728,277.5003893,355.9005634,431.2607326,497.8209247,0,492,Type II Diabetes,7/7/14 12:28
754,19,Bayer,Large Pharma,434,Glucobay,acarbose,Small Molecule (Chemical),Launched,In-House,Jan-96,Nov-90,Expired,Expired,133,AGIs,22,Diabetes,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,494,Type II Diabetes,7/7/14 12:28
754,19,Bayer,Large Pharma,434,Glucobay,acarbose,Small Molecule (Chemical),Launched,In-House,Jan-96,Nov-90,Expired,Expired,133,AGIs,22,Diabetes,8,Metabolism,2,Global,Sales,437.6919968,459.6897202,504.7406199,525.7931134,561.8311005,579.6134231,594.0922046,604.2002595,611.837517,617.5676371,621.8247088,625.0030138,1.533860334,494,Type II Diabetes,7/7/14 12:28
754,19,Bayer,Large Pharma,434,Glucobay,acarbose,Small Molecule (Chemical),Launched,In-House,Jan-96,Nov-90,Expired,Expired,133,AGIs,22,Diabetes,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,494,Type II Diabetes,7/7/14 12:28
754,19,Bayer,Large Pharma,434,Glucobay,acarbose,Small Molecule (Chemical),Launched,In-House,Jan-96,Nov-90,Expired,Expired,133,AGIs,22,Diabetes,8,Metabolism,2,ROW,Sales,436.3024984,458.3651642,503.3382076,524.3907011,560.4286881,578.2110108,592.6897922,602.7978471,610.4351046,616.1652247,620.4222964,623.6006014,1.537528615,494,Type II Diabetes,7/7/14 12:28
754,19,Bayer,Large Pharma,434,Glucobay,acarbose,Small Molecule (Chemical),Launched,In-House,Jan-96,Nov-90,Expired,Expired,133,AGIs,22,Diabetes,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,494,Type II Diabetes,7/7/14 12:28
754,19,Bayer,Large Pharma,434,Glucobay,acarbose,Small Molecule (Chemical),Launched,In-House,Jan-96,Nov-90,Expired,Expired,133,AGIs,22,Diabetes,8,Metabolism,2,US,Sales,1.389498403,1.324555943,1.402412348,1.402412348,1.402412348,1.402412348,1.402412348,1.402412348,1.402412348,1.402412348,1.402412348,1.402412348,0,494,Type II Diabetes,7/7/14 12:28
756,24,Bristol-Myers Squibb,Large Pharma,100,Glucophage / Glucovance,metformin / metformin + glyburide,Small Molecule (Chemical),Launched,Licensed (Development),May-95,,Expired,N/A,110,Biguanides,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1543,Type II Diabetes,7/7/14 12:28
756,24,Bristol-Myers Squibb,Large Pharma,100,Glucophage / Glucovance,metformin / metformin + glyburide,Small Molecule (Chemical),Launched,Licensed (Development),May-95,,Expired,N/A,110,Biguanides,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1543,Type II Diabetes,7/7/14 12:28
756,24,Bristol-Myers Squibb,Large Pharma,100,Glucophage / Glucovance,metformin / metformin + glyburide,Small Molecule (Chemical),Launched,Licensed (Development),May-95,,Expired,N/A,110,Biguanides,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1543,Type II Diabetes,7/7/14 12:28
756,24,Bristol-Myers Squibb,Large Pharma,100,Glucophage / Glucovance,metformin / metformin + glyburide,Small Molecule (Chemical),Launched,Licensed (Development),May-95,,Expired,N/A,110,Biguanides,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1543,Type II Diabetes,7/7/14 12:28
756,24,Bristol-Myers Squibb,Large Pharma,100,Glucophage / Glucovance,metformin / metformin + glyburide,Small Molecule (Chemical),Launched,Licensed (Development),May-95,,Expired,N/A,110,Biguanides,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1543,Type II Diabetes,7/7/14 12:28
756,24,Bristol-Myers Squibb,Large Pharma,100,Glucophage / Glucovance,metformin / metformin + glyburide,Small Molecule (Chemical),Launched,Licensed (Development),May-95,,Expired,N/A,110,Biguanides,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1543,Type II Diabetes,7/7/14 12:28
757,63,Merck KGaA,Regional & Specialty Pharma,100,Glucophage / Glucovance,metformin / metformin + glyburide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-58,N/A,Expired,110,Biguanides,22,Diabetes,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1543,Type II Diabetes,7/7/14 12:28
757,63,Merck KGaA,Regional & Specialty Pharma,100,Glucophage / Glucovance,metformin / metformin + glyburide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-58,N/A,Expired,110,Biguanides,22,Diabetes,8,Metabolism,2,Global,Sales,423.7970128,418.2250935,480.9521713,513.5944219,523.2438462,535.3196237,538.4674136,542.2309649,544.3597858,545.9803717,547.0594526,547.8206172,0.657872335,1543,Type II Diabetes,7/7/14 12:28
757,63,Merck KGaA,Regional & Specialty Pharma,100,Glucophage / Glucovance,metformin / metformin + glyburide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-58,N/A,Expired,110,Biguanides,22,Diabetes,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1543,Type II Diabetes,7/7/14 12:28
757,63,Merck KGaA,Regional & Specialty Pharma,100,Glucophage / Glucovance,metformin / metformin + glyburide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-58,N/A,Expired,110,Biguanides,22,Diabetes,8,Metabolism,2,ROW,Sales,423.7970128,418.2250935,480.9521713,513.5944219,523.2438462,535.3196237,538.4674136,542.2309649,544.3597858,545.9803717,547.0594526,547.8206172,0.657872335,1543,Type II Diabetes,7/7/14 12:28
757,63,Merck KGaA,Regional & Specialty Pharma,100,Glucophage / Glucovance,metformin / metformin + glyburide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-58,N/A,Expired,110,Biguanides,22,Diabetes,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1543,Type II Diabetes,7/7/14 12:28
757,63,Merck KGaA,Regional & Specialty Pharma,100,Glucophage / Glucovance,metformin / metformin + glyburide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-58,N/A,Expired,110,Biguanides,22,Diabetes,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1543,Type II Diabetes,7/7/14 12:28
759,67,Novartis,Large Pharma,3998,Seebri,glycopyrronium,Small Molecule (Chemical),Launched,Licensed (Development),Sep-15,Nov-12,N/A,Apr-21,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,498,COPD,7/7/14 12:28
759,67,Novartis,Large Pharma,3998,Seebri,glycopyrronium,Small Molecule (Chemical),Launched,Licensed (Development),Sep-15,Nov-12,N/A,Apr-21,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,4.166675,58,109.63856,154.8033067,208.8728947,248.090764,282.835737,310.7630465,334.0339358,28.41717729,498,COPD,7/7/14 12:28
759,67,Novartis,Large Pharma,3998,Seebri,glycopyrronium,Small Molecule (Chemical),Launched,Licensed (Development),Sep-15,Nov-12,N/A,Apr-21,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,498,COPD,7/7/14 12:28
759,67,Novartis,Large Pharma,3998,Seebri,glycopyrronium,Small Molecule (Chemical),Launched,Licensed (Development),Sep-15,Nov-12,N/A,Apr-21,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,4.166675,58,109.63856,140.8033207,157.539566,168.7576712,175.5028225,179.536925,182.0506121,17.75144251,498,COPD,7/7/14 12:28
759,67,Novartis,Large Pharma,3998,Seebri,glycopyrronium,Small Molecule (Chemical),Launched,Licensed (Development),Sep-15,Nov-12,N/A,Apr-21,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,498,COPD,7/7/14 12:28
759,67,Novartis,Large Pharma,3998,Seebri,glycopyrronium,Small Molecule (Chemical),Launched,Licensed (Development),Sep-15,Nov-12,N/A,Apr-21,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,13.999986,51.33332867,79.33309279,107.3329146,131.2261215,151.9833237,0,498,COPD,7/7/14 12:28
761,63,Merck KGaA,Regional & Specialty Pharma,1040,Gonal F,follitropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Jul-99,Jan-96,Jun-15,Oct-15,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1612,Female infertility,7/7/14 12:28
761,63,Merck KGaA,Regional & Specialty Pharma,1040,Gonal F,follitropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Jul-99,Jan-96,Jun-15,Oct-15,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,Global,Sales,675.2962237,667.3275274,731.7803776,787.8713229,778.225619,767.4685755,748.6073329,712.4613046,688.552106,660.774832,640.8935572,624.0598125,-3.104642415,1612,Female infertility,7/7/14 12:28
761,63,Merck KGaA,Regional & Specialty Pharma,1040,Gonal F,follitropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Jul-99,Jan-96,Jun-15,Oct-15,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1612,Female infertility,7/7/14 12:28
761,63,Merck KGaA,Regional & Specialty Pharma,1040,Gonal F,follitropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Jul-99,Jan-96,Jun-15,Oct-15,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,ROW,Sales,536.3463834,537.9829283,596.4974891,646.491477,637.454432,630.8142816,619.1807383,597.6940086,588.4480628,576.9297491,570.3628001,563.9734391,-1.73443273,1612,Female infertility,7/7/14 12:28
761,63,Merck KGaA,Regional & Specialty Pharma,1040,Gonal F,follitropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Jul-99,Jan-96,Jun-15,Oct-15,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1612,Female infertility,7/7/14 12:28
761,63,Merck KGaA,Regional & Specialty Pharma,1040,Gonal F,follitropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Jul-99,Jan-96,Jun-15,Oct-15,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,US,Sales,138.9498403,129.344599,135.2828885,141.3798459,140.7711871,136.6542939,129.4265947,114.7672959,100.1040432,83.84508291,70.53075704,60.08637334,-11.45167104,1612,Female infertility,7/7/14 12:28
762,34,Daiichi-Sankyo,Regional & Specialty Pharma,1081,Gracevit,sitafloxacin,Small Molecule (Chemical),Launched,In-House,,Jun-08,N/A,Sep-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,499,Respiratory and urinary tract infections,7/7/14 12:28
762,34,Daiichi-Sankyo,Regional & Specialty Pharma,1081,Gracevit,sitafloxacin,Small Molecule (Chemical),Launched,In-House,,Jun-08,N/A,Sep-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,19.04093841,28.39578462,29.16392521,30.08951103,25.92812141,26.14240465,26.36182858,26.45992493,26.50724453,26.53633658,26.55084493,26.55847864,0.343744748,499,Respiratory and urinary tract infections,7/7/14 12:28
762,34,Daiichi-Sankyo,Regional & Specialty Pharma,1081,Gracevit,sitafloxacin,Small Molecule (Chemical),Launched,In-House,,Jun-08,N/A,Sep-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,499,Respiratory and urinary tract infections,7/7/14 12:28
762,34,Daiichi-Sankyo,Regional & Specialty Pharma,1081,Gracevit,sitafloxacin,Small Molecule (Chemical),Launched,In-House,,Jun-08,N/A,Sep-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,19.04093841,28.39578462,29.16392521,30.08951103,25.92812141,26.14240465,26.36182858,26.45992493,26.50724453,26.53633658,26.55084493,26.55847864,0.343744748,499,Respiratory and urinary tract infections,7/7/14 12:28
762,34,Daiichi-Sankyo,Regional & Specialty Pharma,1081,Gracevit,sitafloxacin,Small Molecule (Chemical),Launched,In-House,,Jun-08,N/A,Sep-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,499,Respiratory and urinary tract infections,7/7/14 12:28
762,34,Daiichi-Sankyo,Regional & Specialty Pharma,1081,Gracevit,sitafloxacin,Small Molecule (Chemical),Launched,In-House,,Jun-08,N/A,Sep-14,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,499,Respiratory and urinary tract infections,7/7/14 12:28
763,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,442,Gran,filgrastim,Recombinant Protein,Launched,Corporate Acquisition,,Jan-91,N/A,Jun-13,118,G-CSFs,78,Neutropenia,3,Oncology,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1467,Neutropenia,7/7/14 12:28
763,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,442,Gran,filgrastim,Recombinant Protein,Launched,Corporate Acquisition,,Jan-91,N/A,Jun-13,118,G-CSFs,78,Neutropenia,3,Oncology,3,Global,Sales,163.5143837,161.812605,185.6402655,169.1305437,127.0871593,116.1054219,102.7329604,93.71479319,86.16897581,78.48486056,67.97264366,59.89303911,-10.18993707,1467,Neutropenia,7/7/14 12:28
763,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,442,Gran,filgrastim,Recombinant Protein,Launched,Corporate Acquisition,,Jan-91,N/A,Jun-13,118,G-CSFs,78,Neutropenia,3,Oncology,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1467,Neutropenia,7/7/14 12:28
763,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,442,Gran,filgrastim,Recombinant Protein,Launched,Corporate Acquisition,,Jan-91,N/A,Jun-13,118,G-CSFs,78,Neutropenia,3,Oncology,3,ROW,Sales,163.5143837,161.812605,185.6402655,169.1305437,127.0871593,116.1054219,102.7329604,93.71479319,86.16897581,78.48486056,67.97264366,59.89303911,-10.18993707,1467,Neutropenia,7/7/14 12:28
763,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,442,Gran,filgrastim,Recombinant Protein,Launched,Corporate Acquisition,,Jan-91,N/A,Jun-13,118,G-CSFs,78,Neutropenia,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1467,Neutropenia,7/7/14 12:28
763,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,442,Gran,filgrastim,Recombinant Protein,Launched,Corporate Acquisition,,Jan-91,N/A,Jun-13,118,G-CSFs,78,Neutropenia,3,Oncology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1467,Neutropenia,7/7/14 12:28
767,34,Daiichi-Sankyo,Regional & Specialty Pharma,51,Hanp,carperitide,Small Molecule (Chemical),Launched,In-House,,May-95,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,512,Heart failure - Acute ,7/7/14 12:28
767,34,Daiichi-Sankyo,Regional & Specialty Pharma,51,Hanp,carperitide,Small Molecule (Chemical),Launched,In-House,,May-95,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,101.2686411,109.7246379,117.7534416,102.3292953,81.54855019,79.28331268,77.68506177,76.69779576,76.07916569,75.68400602,75.43447383,75.27669009,-1.136746006,512,Heart failure - Acute ,7/7/14 12:28
767,34,Daiichi-Sankyo,Regional & Specialty Pharma,51,Hanp,carperitide,Small Molecule (Chemical),Launched,In-House,,May-95,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,512,Heart failure - Acute ,7/7/14 12:28
767,34,Daiichi-Sankyo,Regional & Specialty Pharma,51,Hanp,carperitide,Small Molecule (Chemical),Launched,In-House,,May-95,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,101.2686411,109.7246379,117.7534416,102.3292953,81.54855019,79.28331268,77.68506177,76.69779576,76.07916569,75.68400602,75.43447383,75.27669009,-1.136746006,512,Heart failure - Acute ,7/7/14 12:28
767,34,Daiichi-Sankyo,Regional & Specialty Pharma,51,Hanp,carperitide,Small Molecule (Chemical),Launched,In-House,,May-95,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,512,Heart failure - Acute ,7/7/14 12:28
767,34,Daiichi-Sankyo,Regional & Specialty Pharma,51,Hanp,carperitide,Small Molecule (Chemical),Launched,In-House,,May-95,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,512,Heart failure - Acute ,7/7/14 12:28
768,15,Astellas Pharma,Regional & Specialty Pharma,425,Harnal / Omnic,tamsulosin,Small Molecule (Chemical),Launched,In-House,Jul-97,Aug-93,N/A,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,Global,Alliance Revenue,491.260642,60.69873583,59.50980382,46.9510886,37.81059831,34.49077046,31.52532643,29.30982716,20.13544449,15.45950055,11.03279126,6.671979767,-21.94918941,1649,Symptoms associated with BPH,7/7/14 12:28
768,15,Astellas Pharma,Regional & Specialty Pharma,425,Harnal / Omnic,tamsulosin,Small Molecule (Chemical),Launched,In-House,Jul-97,Aug-93,N/A,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,Global,Sales,734.736311,714.3774294,710.3191477,601.9370334,556.8943521,555.343241,557.738677,566.8859028,570.87152,575.0443708,579.1336154,582.4084962,0.642001931,1649,Symptoms associated with BPH,7/7/14 12:28
768,15,Astellas Pharma,Regional & Specialty Pharma,425,Harnal / Omnic,tamsulosin,Small Molecule (Chemical),Launched,In-House,Jul-97,Aug-93,N/A,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1649,Symptoms associated with BPH,7/7/14 12:28
768,15,Astellas Pharma,Regional & Specialty Pharma,425,Harnal / Omnic,tamsulosin,Small Molecule (Chemical),Launched,In-House,Jul-97,Aug-93,N/A,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,ROW,Sales,734.736311,714.3774294,710.3191477,601.9370334,556.8943521,555.343241,557.738677,566.8859028,570.87152,575.0443708,579.1336154,582.4084962,0.642001931,1649,Symptoms associated with BPH,7/7/14 12:28
768,15,Astellas Pharma,Regional & Specialty Pharma,425,Harnal / Omnic,tamsulosin,Small Molecule (Chemical),Launched,In-House,Jul-97,Aug-93,N/A,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,US,Alliance Revenue,491.260642,60.69873583,59.50980382,46.9510886,37.81059831,34.49077046,31.52532643,29.30982716,20.13544449,15.45950055,11.03279126,6.671979767,-21.94918941,1649,Symptoms associated with BPH,7/7/14 12:28
768,15,Astellas Pharma,Regional & Specialty Pharma,425,Harnal / Omnic,tamsulosin,Small Molecule (Chemical),Launched,In-House,Jul-97,Aug-93,N/A,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1649,Symptoms associated with BPH,7/7/14 12:28
769,89,Genzyme,Large Pharma,223,Hectorol,doxecalciferol,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Mar-10,Feb-14,Nov-22,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,2,Global,Proforma,131.0296994,184.9357715,52.59835893,0,0,0,0,0,0,0,0,0,0,1426,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
769,89,Genzyme,Large Pharma,223,Hectorol,doxecalciferol,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Mar-10,Feb-14,Nov-22,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,2,US,Proforma,131.0296994,184.9357715,52.59835893,0,0,0,0,0,0,0,0,0,0,1426,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
769,89,Sanofi,Large Pharma,223,Hectorol,doxecalciferol,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Mar-10,Feb-14,Nov-22,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1426,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
769,89,Sanofi,Large Pharma,223,Hectorol,doxecalciferol,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Mar-10,Feb-14,Nov-22,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,2,Global,Sales,0,0,156.8196744,206.718037,214.7234977,115.8215361,68.69256245,49.9085738,39.71770569,32.74900112,28.60362434,24.22023756,-26.78260833,1426,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
769,89,Sanofi,Large Pharma,223,Hectorol,doxecalciferol,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Mar-10,Feb-14,Nov-22,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1426,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
769,89,Sanofi,Large Pharma,223,Hectorol,doxecalciferol,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Mar-10,Feb-14,Nov-22,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1426,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
769,89,Sanofi,Large Pharma,223,Hectorol,doxecalciferol,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Mar-10,Feb-14,Nov-22,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1426,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
769,89,Sanofi,Large Pharma,223,Hectorol,doxecalciferol,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Mar-10,Feb-14,Nov-22,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,2,US,Sales,0,0,156.8196744,206.718037,214.7234977,115.8215361,68.69256245,49.9085738,39.71770569,32.74900112,28.60362434,24.22023756,-26.78260833,1426,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
771,100,Takeda,Large Pharma,4456,Omontys,peginesatide,Synthetic Peptide,Launched,Licensed (Development),Apr-12,,,,102,ESAs,24,Anemia,14,Hematology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,514,Anemia,7/7/14 12:28
771,100,Takeda,Large Pharma,4456,Omontys,peginesatide,Synthetic Peptide,Launched,Licensed (Development),Apr-12,,,,102,ESAs,24,Anemia,14,Hematology,7,Global,Sales,0,0,0,37.32009607,0,0,0,0,0,0,0,0,0,514,Anemia,7/7/14 12:28
771,100,Takeda,Large Pharma,4456,Omontys,peginesatide,Synthetic Peptide,Launched,Licensed (Development),Apr-12,,,,102,ESAs,24,Anemia,14,Hematology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,514,Anemia,7/7/14 12:28
771,100,Takeda,Large Pharma,4456,Omontys,peginesatide,Synthetic Peptide,Launched,Licensed (Development),Apr-12,,,,102,ESAs,24,Anemia,14,Hematology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,514,Anemia,7/7/14 12:28
771,100,Takeda,Large Pharma,4456,Omontys,peginesatide,Synthetic Peptide,Launched,Licensed (Development),Apr-12,,,,102,ESAs,24,Anemia,14,Hematology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,514,Anemia,7/7/14 12:28
771,100,Takeda,Large Pharma,4456,Omontys,peginesatide,Synthetic Peptide,Launched,Licensed (Development),Apr-12,,,,102,ESAs,24,Anemia,14,Hematology,7,US,Sales,0,0,0,37.32009607,0,0,0,0,0,0,0,0,0,514,Anemia,7/7/14 12:28
774,46,GlaxoSmithKline,Large Pharma,3115,Hepatitis vaccines - GSK,Hepatitis vaccine,Vaccine,Launched,In-House,Jul-89,Jul-87,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1489,,7/7/14 12:28
774,46,GlaxoSmithKline,Large Pharma,3115,Hepatitis vaccines - GSK,Hepatitis vaccine,Vaccine,Launched,In-House,Jul-89,Jul-87,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,1036.909024,1112.400042,1102.988329,1023.928653,983.3874236,964.3294068,949.9541276,940.0503438,933.1855199,928.3392338,924.8914765,922.4440951,-0.909783761,1489,,7/7/14 12:28
774,46,GlaxoSmithKline,Large Pharma,3115,Hepatitis vaccines - GSK,Hepatitis vaccine,Vaccine,Launched,In-House,Jul-89,Jul-87,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1489,,7/7/14 12:28
774,46,GlaxoSmithKline,Large Pharma,3115,Hepatitis vaccines - GSK,Hepatitis vaccine,Vaccine,Launched,In-House,Jul-89,Jul-87,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,636.1787694,638.0850239,633.2563807,602.3109721,572.2095343,558.232613,548.234893,540.5706998,535.0746449,531.1067238,528.1907305,526.0684114,-1.193871757,1489,,7/7/14 12:28
774,46,GlaxoSmithKline,Large Pharma,3115,Hepatitis vaccines - GSK,Hepatitis vaccine,Vaccine,Launched,In-House,Jul-89,Jul-87,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1489,,7/7/14 12:28
774,46,GlaxoSmithKline,Large Pharma,3115,Hepatitis vaccines - GSK,Hepatitis vaccine,Vaccine,Launched,In-House,Jul-89,Jul-87,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,400.7302542,474.3150178,469.7319482,421.6176805,411.1778894,406.0967939,401.7192346,399.479644,398.1108751,397.23251,396.700746,396.3756837,-0.522394284,1489,,7/7/14 12:28
775,61,Merck & Co,Large Pharma,3116,Hepatitis vaccines - Merck,Hepatitis vaccine,Vaccine,Launched,In-House,Jul-82,Jul-83,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2171,,7/7/14 12:28
775,61,Merck & Co,Large Pharma,3116,Hepatitis vaccines - Merck,Hepatitis vaccine,Vaccine,Launched,In-House,Jul-82,Jul-83,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,117,112.67,106.1905,100.815,97.97196,95.692332,94.0554016,92.92822896,92.09488014,91.49030367,91.05061045,90.72647608,-1.091598571,2171,,7/7/14 12:28
775,61,Merck & Co,Large Pharma,3116,Hepatitis vaccines - Merck,Hepatitis vaccine,Vaccine,Launched,In-House,Jul-82,Jul-83,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2171,,7/7/14 12:28
775,61,Merck & Co,Large Pharma,3116,Hepatitis vaccines - Merck,Hepatitis vaccine,Vaccine,Launched,In-House,Jul-82,Jul-83,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,19,16.67,14.1905,12.055,11.14396,10.507132,10.0996016,9.86879296,9.722781344,9.633279552,9.579393108,9.546194675,-2.186525277,2171,,7/7/14 12:28
775,61,Merck & Co,Large Pharma,3116,Hepatitis vaccines - Merck,Hepatitis vaccine,Vaccine,Launched,In-House,Jul-82,Jul-83,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2171,,7/7/14 12:28
775,61,Merck & Co,Large Pharma,3116,Hepatitis vaccines - Merck,Hepatitis vaccine,Vaccine,Launched,In-House,Jul-82,Jul-83,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,98,96,92,88.76,86.828,85.1852,83.9558,83.059436,82.3720988,81.85702412,81.47121734,81.1802814,-0.956209043,2171,,7/7/14 12:28
776,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,3148,Hepatitis Vaccines - SPMSD,Hepatitis vaccine,Vaccine,Launched,Licensed (Marketed),,Jul-00,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,44.19994419,25.17034139,38.93223705,30.84651183,29.9472673,30.01637029,29.45394905,29.17045985,29.06295698,28.96948345,28.91577044,28.88680121,-0.513722439,2172,,7/7/14 12:28
776,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,3148,Hepatitis Vaccines - SPMSD,Hepatitis vaccine,Vaccine,Launched,Licensed (Marketed),,Jul-00,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,44.19994419,25.17034139,38.93223705,30.84651183,29.9472673,30.01637029,29.45394905,29.17045985,29.06295698,28.96948345,28.91577044,28.88680121,-0.513722439,2172,,7/7/14 12:28
776,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,3148,Hepatitis Vaccines - SPMSD,Hepatitis vaccine,Vaccine,Launched,Licensed (Marketed),,Jul-00,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2172,,7/7/14 12:28
777,45,Gilead,Regional & Specialty Pharma,181,Hepsera,adefovir,Small Molecule (Chemical),Launched,Licensed (Development),Sep-02,Apr-03,Sep-14,Jul-18,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,517,Hepatitis B,7/7/14 12:28
777,45,Gilead,Regional & Specialty Pharma,181,Hepsera,adefovir,Small Molecule (Chemical),Launched,Licensed (Development),Sep-02,Apr-03,Sep-14,Jul-18,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,Global,Sales,271.6,200.59,144.68,108.31,81,62.325,48.83315,39.33434938,32.52478059,27.66946057,24.1828772,21.67784512,-17.16405922,517,Hepatitis B,7/7/14 12:28
777,45,Gilead,Regional & Specialty Pharma,181,Hepsera,adefovir,Small Molecule (Chemical),Launched,Licensed (Development),Sep-02,Apr-03,Sep-14,Jul-18,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,517,Hepatitis B,7/7/14 12:28
777,45,Gilead,Regional & Specialty Pharma,181,Hepsera,adefovir,Small Molecule (Chemical),Launched,Licensed (Development),Sep-02,Apr-03,Sep-14,Jul-18,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,173.95,124.04,87.42,64.95,47,35.8845,27.8914875,22.63664656,18.99348687,16.54653669,14.87175648,13.73828062,-16.11376113,517,Hepatitis B,7/7/14 12:28
777,45,Gilead,Regional & Specialty Pharma,181,Hepsera,adefovir,Small Molecule (Chemical),Launched,Licensed (Development),Sep-02,Apr-03,Sep-14,Jul-18,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,517,Hepatitis B,7/7/14 12:28
777,45,Gilead,Regional & Specialty Pharma,181,Hepsera,adefovir,Small Molecule (Chemical),Launched,Licensed (Development),Sep-02,Apr-03,Sep-14,Jul-18,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,US,Sales,97.65,76.55,57.26,43.36,34,26.4405,20.9416625,16.69770281,13.53129373,11.12292388,9.311120721,7.939564494,-18.76189752,517,Hepatitis B,7/7/14 12:28
778,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,873,Herbesser,diltiazem,Small Molecule (Chemical),Launched,In-House,,Feb-74,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,518,,7/7/14 12:28
778,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,873,Herbesser,diltiazem,Small Molecule (Chemical),Launched,In-House,,Feb-74,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,166.9855252,165.7542402,167.3349478,162.522999,125.8465281,121.8442861,118.9522127,115.9230477,113.8543233,112.2153312,110.8854661,109.8647222,-1.921487858,518,,7/7/14 12:28
778,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,873,Herbesser,diltiazem,Small Molecule (Chemical),Launched,In-House,,Feb-74,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,518,,7/7/14 12:28
778,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,873,Herbesser,diltiazem,Small Molecule (Chemical),Launched,In-House,,Feb-74,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,166.9855252,165.7542402,167.3349478,162.522999,125.8465281,121.8442861,118.9522127,115.9230477,113.8543233,112.2153312,110.8854661,109.8647222,-1.921487858,518,,7/7/14 12:28
778,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,873,Herbesser,diltiazem,Small Molecule (Chemical),Launched,In-House,,Feb-74,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,518,,7/7/14 12:28
778,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,873,Herbesser,diltiazem,Small Molecule (Chemical),Launched,In-House,,Feb-74,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,518,,7/7/14 12:28
779,29,Chugai,Regional & Specialty Pharma,307,Herceptin,trastuzumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-01,N/A,Jun-14,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,3,Global,Alliance Revenue,317.4102742,284.8813469,326.1247908,359.5590078,316.6930019,332.4764072,335.5535186,327.8964783,309.2629127,270.1617426,248.2625514,218.4739413,-5.165599,1670,Breast Cancer,7/7/14 12:28
779,29,Chugai,Regional & Specialty Pharma,307,Herceptin,trastuzumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-01,N/A,Jun-14,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,3,ROW,Alliance Revenue,317.4102742,284.8813469,326.1247908,359.5590078,316.6930019,332.4764072,335.5535186,327.8964783,309.2629127,270.1617426,248.2625514,218.4739413,-5.165599,1670,Breast Cancer,7/7/14 12:28
779,29,Chugai,Regional & Specialty Pharma,307,Herceptin,trastuzumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-01,N/A,Jun-14,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1670,Breast Cancer,7/7/14 12:28
780,86,Roche,Large Pharma,307,Herceptin,trastuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-99,Aug-99,Jun-19,Mar-15,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1670,Breast Cancer,7/7/14 12:28
780,86,Roche,Large Pharma,307,Herceptin,trastuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-99,Aug-99,Jun-19,Jun-14,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,Global,Sales,4848.648285,5203.767045,5918.458844,6280.708115,6559.420164,6418.870784,6122.572587,5677.218155,4896.869766,4126.805165,3157.276538,2383.612315,-13.46420231,1670,Breast Cancer,7/7/14 12:28
780,86,Roche,Large Pharma,307,Herceptin,trastuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-99,Aug-99,Jun-19,Mar-15,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1670,Breast Cancer,7/7/14 12:28
780,86,Roche,Large Pharma,307,Herceptin,trastuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-99,Aug-99,Jun-19,Jun-14,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,ROW,Sales,3406.681464,3677.943854,4316.787339,4507.136255,4631.027175,4594.936911,4390.644901,3970.375362,3225.377284,2597.101362,1917.611895,1515.633637,-14.74841063,1670,Breast Cancer,7/7/14 12:28
780,86,Roche,Large Pharma,307,Herceptin,trastuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-99,Aug-99,Jun-19,Mar-15,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1670,Breast Cancer,7/7/14 12:28
780,86,Roche,Large Pharma,307,Herceptin,trastuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-99,Aug-99,Jun-19,Mar-15,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,US,Sales,1441.966821,1525.823191,1601.671505,1773.57186,1928.392989,1823.933872,1731.927686,1706.842793,1671.492481,1529.703803,1239.664642,867.9786777,-10.77770122,1670,Breast Cancer,7/7/14 12:28
781,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,653,Hexyon,DTaP-HepB-Polio-Hib,Vaccine,Launched,In-House,,May-14,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,519,diphtheria tetanus pertussis polio Hib HBV,7/7/14 12:28
781,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,653,Hexyon,DTaP-HepB-Polio-Hib,Vaccine,Launched,In-House,,May-14,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,0,0,0,0,0,17.70707641,38.36539124,56.07255391,73.77970572,84.75813832,93.36381494,100.046494,0,519,diphtheria tetanus pertussis polio Hib HBV,7/7/14 12:28
781,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,653,Hexyon,DTaP-HepB-Polio-Hib,Vaccine,Launched,In-House,,May-14,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,519,diphtheria tetanus pertussis polio Hib HBV,7/7/14 12:28
781,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,653,Hexyon,DTaP-HepB-Polio-Hib,Vaccine,Launched,In-House,,May-14,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,0,0,0,0,0,17.70707641,38.36539124,56.07255391,73.77970572,84.75813832,93.36381494,100.046494,0,519,diphtheria tetanus pertussis polio Hib HBV,7/7/14 12:28
781,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,653,Hexyon,DTaP-HepB-Polio-Hib,Vaccine,Launched,In-House,,May-14,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,519,diphtheria tetanus pertussis polio Hib HBV,7/7/14 12:28
781,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,653,Hexyon,DTaP-HepB-Polio-Hib,Vaccine,Launched,In-House,,May-14,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,519,diphtheria tetanus pertussis polio Hib HBV,7/7/14 12:28
782,61,Merck & Co,Large Pharma,2848,V419,Hib+HepB+DTaP+IPV,Vaccine,Filed,In-House,Oct-15,May-14,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,521,diphtheria tetanus pertussus polio Hib HBV,7/7/14 12:28
782,61,Merck & Co,Large Pharma,2848,V419,Hib+HepB+DTaP+IPV,Vaccine,Filed,In-House,Oct-15,May-14,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,20.00001,69.58343167,148.7499635,240.4170085,311.2837417,358.5438136,396.4778926,0,521,diphtheria tetanus pertussus polio Hib HBV,7/7/14 12:28
782,61,Merck & Co,Large Pharma,2848,V419,Hib+HepB+DTaP+IPV,Vaccine,Filed,In-House,Oct-15,May-14,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,521,diphtheria tetanus pertussus polio Hib HBV,7/7/14 12:28
782,61,Merck & Co,Large Pharma,2848,V419,Hib+HepB+DTaP+IPV,Vaccine,Filed,In-House,Oct-15,May-14,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,20.00001,63.33343167,113.333276,163.3336507,192.5337456,216.2938229,234.6779081,0,521,diphtheria tetanus pertussus polio Hib HBV,7/7/14 12:28
782,61,Merck & Co,Large Pharma,2848,V419,Hib+HepB+DTaP+IPV,Vaccine,Filed,In-House,Oct-15,May-14,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,521,diphtheria tetanus pertussus polio Hib HBV,7/7/14 12:28
782,61,Merck & Co,Large Pharma,2848,V419,Hib+HepB+DTaP+IPV,Vaccine,Filed,In-House,Oct-15,May-14,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,6.25,35.4166875,77.08335784,118.7499961,142.2499907,161.7999844,0,521,diphtheria tetanus pertussus polio Hib HBV,7/7/14 12:28
783,46,GlaxoSmithKline,Large Pharma,1972,Menhibrix,Hib-MenCY-TT,Vaccine,Launched,In-House,May-14,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,688,meningococcus CY and Hib,7/7/14 12:28
783,46,GlaxoSmithKline,Large Pharma,1972,Menhibrix,Hib-MenCY-TT,Vaccine,Launched,In-House,May-14,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,0,0,0,0,0,10.4227654,22.58269311,33.00550928,43.42831906,48.8134367,52.76541919,55.60346344,0,688,meningococcus CY and Hib,7/7/14 12:28
783,46,GlaxoSmithKline,Large Pharma,1972,Menhibrix,Hib-MenCY-TT,Vaccine,Launched,In-House,May-14,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,688,meningococcus CY and Hib,7/7/14 12:28
783,46,GlaxoSmithKline,Large Pharma,1972,Menhibrix,Hib-MenCY-TT,Vaccine,Launched,In-House,May-14,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,688,meningococcus CY and Hib,7/7/14 12:28
783,46,GlaxoSmithKline,Large Pharma,1972,Menhibrix,Hib-MenCY-TT,Vaccine,Launched,In-House,May-14,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,688,meningococcus CY and Hib,7/7/14 12:28
783,46,GlaxoSmithKline,Large Pharma,1972,Menhibrix,Hib-MenCY-TT,Vaccine,Launched,In-House,May-14,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,0,0,0,0,0,10.4227654,22.58269311,33.00550928,43.42831906,48.8134367,52.76541919,55.60346344,0,688,meningococcus CY and Hib,7/7/14 12:28
784,46,GlaxoSmithKline,Large Pharma,4689,HIV vaccine,HIV vaccine,Vaccine,Phase I,Licensed (Development),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,522,HIV prophylaxis,7/7/14 12:28
784,46,GlaxoSmithKline,Large Pharma,4689,HIV vaccine,HIV vaccine,Vaccine,Phase I,Licensed (Development),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,522,HIV prophylaxis,7/7/14 12:28
784,46,GlaxoSmithKline,Large Pharma,4689,HIV vaccine,HIV vaccine,Vaccine,Phase I,Licensed (Development),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,522,HIV prophylaxis,7/7/14 12:28
784,46,GlaxoSmithKline,Large Pharma,4689,HIV vaccine,HIV vaccine,Vaccine,Phase I,Licensed (Development),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,522,HIV prophylaxis,7/7/14 12:28
784,46,GlaxoSmithKline,Large Pharma,4689,HIV vaccine,HIV vaccine,Vaccine,Phase I,Licensed (Development),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,522,HIV prophylaxis,7/7/14 12:28
784,46,GlaxoSmithKline,Large Pharma,4689,HIV vaccine,HIV vaccine,Vaccine,Phase I,Licensed (Development),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,522,HIV prophylaxis,7/7/14 12:28
785,24,Bristol-Myers Squibb,Large Pharma,847,HIV attachment inhibitor,HIV attachment inhibitor,Small Molecule (Chemical),Phase I,,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,523,HIV,7/7/14 12:28
785,24,Bristol-Myers Squibb,Large Pharma,847,HIV attachment inhibitor,HIV attachment inhibitor,Small Molecule (Chemical),Phase I,,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,523,HIV,7/7/14 12:28
785,24,Bristol-Myers Squibb,Large Pharma,847,HIV attachment inhibitor,HIV attachment inhibitor,Small Molecule (Chemical),Phase I,,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,523,HIV,7/7/14 12:28
785,24,Bristol-Myers Squibb,Large Pharma,847,HIV attachment inhibitor,HIV attachment inhibitor,Small Molecule (Chemical),Phase I,,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,523,HIV,7/7/14 12:28
785,24,Bristol-Myers Squibb,Large Pharma,847,HIV attachment inhibitor,HIV attachment inhibitor,Small Molecule (Chemical),Phase I,,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,523,HIV,7/7/14 12:28
785,24,Bristol-Myers Squibb,Large Pharma,847,HIV attachment inhibitor,HIV attachment inhibitor,Small Molecule (Chemical),Phase I,,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,523,HIV,7/7/14 12:28
787,67,Novartis,Large Pharma,3121,HIV vaccine - Novartis,HIV vaccine,Vaccine,Phase I,Licensed (Development),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,525,HIV,7/7/14 12:28
787,67,Novartis,Large Pharma,3121,HIV vaccine - Novartis,HIV vaccine,Vaccine,Phase I,Licensed (Development),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,525,HIV,7/7/14 12:28
787,67,Novartis,Large Pharma,3121,HIV vaccine - Novartis,HIV vaccine,Vaccine,Phase I,Licensed (Development),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,525,HIV,7/7/14 12:28
787,67,Novartis,Large Pharma,3121,HIV vaccine - Novartis,HIV vaccine,Vaccine,Phase I,Licensed (Development),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,525,HIV,7/7/14 12:28
787,67,Novartis,Large Pharma,3121,HIV vaccine - Novartis,HIV vaccine,Vaccine,Phase I,Licensed (Development),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,525,HIV,7/7/14 12:28
787,67,Novartis,Large Pharma,3121,HIV vaccine - Novartis,HIV vaccine,Vaccine,Phase I,Licensed (Development),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,525,HIV,7/7/14 12:28
789,61,Merck & Co,Large Pharma,2520,V503,HPV 9-valent vaccine,Vaccine,Phase III,Licensed (Development),Jan-15,Jan-15,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,527,HPV,7/7/14 12:28
789,61,Merck & Co,Large Pharma,2520,V503,HPV 9-valent vaccine,Vaccine,Phase III,Licensed (Development),Jan-15,Jan-15,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,135,697.5,1034.998575,1259.998412,1504.685531,1697.69295,0,527,HPV,7/7/14 12:28
789,61,Merck & Co,Large Pharma,2520,V503,HPV 9-valent vaccine,Vaccine,Phase III,Licensed (Development),Jan-15,Jan-15,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,527,HPV,7/7/14 12:28
789,61,Merck & Co,Large Pharma,2520,V503,HPV 9-valent vaccine,Vaccine,Phase III,Licensed (Development),Jan-15,Jan-15,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,60,210,299.9997,359.99964,425.24955,476.7182077,0,527,HPV,7/7/14 12:28
789,61,Merck & Co,Large Pharma,2520,V503,HPV 9-valent vaccine,Vaccine,Phase III,Licensed (Development),Jan-15,Jan-15,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,527,HPV,7/7/14 12:28
789,61,Merck & Co,Large Pharma,2520,V503,HPV 9-valent vaccine,Vaccine,Phase III,Licensed (Development),Jan-15,Jan-15,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,75,487.5,734.998875,899.9987724,1079.435981,1220.974742,0,527,HPV,7/7/14 12:28
791,68,Novo Nordisk,Regional & Specialty Pharma,3109,HRT range - Novo Nordisk,HRT range,Small Molecule (Chemical),Launched,In-House,Jan-80,Jan-77,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1490,Estrogen deficiency,7/7/14 12:28
791,68,Novo Nordisk,Regional & Specialty Pharma,3109,HRT range - Novo Nordisk,HRT range,Small Molecule (Chemical),Launched,In-House,Jan-80,Jan-77,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,1,Global,Sales,392.4239597,397.194911,471.6025997,433.041579,455.1594344,464.7717445,469.4583814,474.3146244,478.3442266,481.4305275,484.0368233,486.1612944,0.945767546,1490,Estrogen deficiency,7/7/14 12:28
791,68,Novo Nordisk,Regional & Specialty Pharma,3109,HRT range - Novo Nordisk,HRT range,Small Molecule (Chemical),Launched,In-House,Jan-80,Jan-77,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1490,Estrogen deficiency,7/7/14 12:28
791,68,Novo Nordisk,Regional & Specialty Pharma,3109,HRT range - Novo Nordisk,HRT range,Small Molecule (Chemical),Launched,In-House,Jan-80,Jan-77,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,1,ROW,Sales,206.3817876,201.5323933,236.6411145,202.707661,202.5747096,200.1560879,195.6047055,192.596195,190.2488189,188.1582566,186.5124193,185.1687255,-1.275245036,1490,Estrogen deficiency,7/7/14 12:28
791,68,Novo Nordisk,Regional & Specialty Pharma,3109,HRT range - Novo Nordisk,HRT range,Small Molecule (Chemical),Launched,In-House,Jan-80,Jan-77,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1490,Estrogen deficiency,7/7/14 12:28
791,68,Novo Nordisk,Regional & Specialty Pharma,3109,HRT range - Novo Nordisk,HRT range,Small Molecule (Chemical),Launched,In-House,Jan-80,Jan-77,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,1,US,Sales,186.042172,195.6625177,234.9614852,230.333918,252.5847248,264.6156567,273.8536759,281.7184294,288.0954076,293.272271,297.524404,300.9925689,2.536472717,1490,Estrogen deficiency,7/7/14 12:28
794,39,Eli Lilly,Large Pharma,805,Humalog / Humalog Mix,insulin lispro / insulin lispro + protamine suspension,Recombinant Protein,Launched,In-House,Oct-96,May-96,Sep-16,Jan-11,83,Insulins,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,530,Diabetes,7/7/14 12:28
794,39,Eli Lilly,Large Pharma,805,Humalog / Humalog Mix,insulin lispro / insulin lispro + protamine suspension,Recombinant Protein,Launched,In-House,Oct-96,May-96,Sep-16,Jan-11,83,Insulins,22,Diabetes,8,Metabolism,6,Global,Sales,1958.6,2054.2,2368,2396,2611,2738.65112,2852.359939,2927.999608,2930.677301,2906.543125,2912.807488,2927.508647,1.647979908,530,Diabetes,7/7/14 12:28
794,39,Eli Lilly,Large Pharma,805,Humalog / Humalog Mix,insulin lispro / insulin lispro + protamine suspension,Recombinant Protein,Launched,In-House,Oct-96,May-96,Sep-16,Jan-11,83,Insulins,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,530,Diabetes,7/7/14 12:28
794,39,Eli Lilly,Large Pharma,805,Humalog / Humalog Mix,insulin lispro / insulin lispro + protamine suspension,Recombinant Protein,Launched,In-House,Oct-96,May-96,Sep-16,Jan-11,83,Insulins,22,Diabetes,8,Metabolism,6,ROW,Sales,750.6,831.8,969,1025,1090,1128.31712,1155.805579,1165.073409,1166.042948,1170.031588,1175.752787,1177.175701,1.105210287,530,Diabetes,7/7/14 12:28
794,39,Eli Lilly,Large Pharma,805,Humalog / Humalog Mix,insulin lispro / insulin lispro + protamine suspension,Recombinant Protein,Launched,In-House,Oct-96,May-96,Sep-16,Jan-11,83,Insulins,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,530,Diabetes,7/7/14 12:28
794,39,Eli Lilly,Large Pharma,805,Humalog / Humalog Mix,insulin lispro / insulin lispro + protamine suspension,Recombinant Protein,Launched,In-House,Oct-96,May-96,Sep-16,Jan-11,83,Insulins,22,Diabetes,8,Metabolism,6,US,Sales,1208,1222.4,1399,1371,1521,1610.334,1696.55436,1762.926199,1764.634353,1736.511537,1737.054701,1750.332946,2.026515867,530,Diabetes,7/7/14 12:28
796,39,Eli Lilly,Large Pharma,1041,Humatrope,somatropin,Recombinant Protein,Launched,In-House,Mar-87,May-87,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1740,Growth Hormone Disorders,7/7/14 12:28
796,39,Eli Lilly,Large Pharma,1041,Humatrope,somatropin,Recombinant Protein,Launched,In-House,Mar-87,May-87,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Sales,448.9,426.8,436.7,392,358,336.646,319.26204,306.8487096,297.5968311,290.6895578,285.5087997,281.6140925,-3.370393987,1740,Growth Hormone Disorders,7/7/14 12:28
796,39,Eli Lilly,Large Pharma,1041,Humatrope,somatropin,Recombinant Protein,Launched,In-House,Mar-87,May-87,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1740,Growth Hormone Disorders,7/7/14 12:28
796,39,Eli Lilly,Large Pharma,1041,Humatrope,somatropin,Recombinant Protein,Launched,In-House,Mar-87,May-87,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Sales,246,251,251.3,226,219,214.95,211.715,209.8685,208.76565,208.070435,207.6448815,207.3847568,-0.775489991,1740,Growth Hormone Disorders,7/7/14 12:28
796,39,Eli Lilly,Large Pharma,1041,Humatrope,somatropin,Recombinant Protein,Launched,In-House,Mar-87,May-87,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1740,Growth Hormone Disorders,7/7/14 12:28
796,39,Eli Lilly,Large Pharma,1041,Humatrope,somatropin,Recombinant Protein,Launched,In-House,Mar-87,May-87,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Sales,202.9,175.8,185.4,166,139,121.696,107.54704,96.9802096,88.8311811,82.61912276,77.86391818,74.22933569,-8.571804254,1740,Growth Hormone Disorders,7/7/14 12:28
797,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,Mar-08,N/A,N/A,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,Psoriasis,7/7/14 12:28
797,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,Mar-08,N/A,N/A,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,938,1501,2061,2397,0,0,0,0,0,0,0,0,0,1327,Psoriasis,7/7/14 12:28
797,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,Mar-08,N/A,N/A,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,Psoriasis,7/7/14 12:28
797,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,Mar-08,N/A,N/A,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,611,910,1256,1335,0,0,0,0,0,0,0,0,0,1327,Psoriasis,7/7/14 12:28
797,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,Mar-08,N/A,N/A,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,Psoriasis,7/7/14 12:28
797,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,Mar-08,N/A,N/A,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,327,591,805,1062,0,0,0,0,0,0,0,0,0,1327,Psoriasis,7/7/14 12:28
798,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-07,Sep-07,N/A,N/A,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,Crohn's disease,7/7/14 12:28
798,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-07,Sep-07,N/A,N/A,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,796,967,1228,1492,0,0,0,0,0,0,0,0,0,1327,Crohn's disease,7/7/14 12:28
798,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-07,Sep-07,N/A,N/A,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,Crohn's disease,7/7/14 12:28
798,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-07,Sep-07,N/A,N/A,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,383,511,716,803,0,0,0,0,0,0,0,0,0,1327,Crohn's disease,7/7/14 12:28
798,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-07,Sep-07,N/A,N/A,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,Crohn's disease,7/7/14 12:28
798,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-07,Sep-07,N/A,N/A,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,413,456,512,689,0,0,0,0,0,0,0,0,0,1327,Crohn's disease,7/7/14 12:28
799,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-03,Sep-03,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,,7/7/14 12:28
799,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-03,Sep-03,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,3775,4080,4643,5376,0,0,0,0,0,0,0,0,0,1327,,7/7/14 12:28
799,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-03,Sep-03,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,,7/7/14 12:28
799,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-03,Sep-03,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,1996,2255,2533,2751,0,0,0,0,0,0,0,0,0,1327,,7/7/14 12:28
799,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-03,Sep-03,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,,7/7/14 12:28
799,1,Abbott,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jan-03,Sep-03,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,1779,1825,2110,2625,0,0,0,0,0,0,0,0,0,1327,,7/7/14 12:28
800,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-10,N/A,Jun-19,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,psoriasis,7/7/14 12:28
800,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-10,N/A,Jun-19,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,7,Global,Sales,0,22.49267582,48.3965569,60.19370334,86.78894717,107.2678473,126.1045827,144.3862666,159.4963806,172.9419081,184.8716158,195.2880438,12.28347384,1327,psoriasis,7/7/14 12:28
800,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-10,N/A,Jun-19,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,psoriasis,7/7/14 12:28
800,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-10,N/A,Jun-19,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,7,ROW,Sales,0,22.49267582,48.3965569,60.19370334,86.78894717,107.2678473,126.1045827,144.3862666,159.4963806,172.9419081,184.8716158,195.2880438,12.28347384,1327,psoriasis,7/7/14 12:28
800,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-10,N/A,Jun-19,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,psoriasis,7/7/14 12:28
800,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-10,N/A,Jun-19,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,psoriasis,7/7/14 12:28
801,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Oct-10,N/A,Jun-19,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,Crohn's disease,7/7/14 12:28
801,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Oct-10,N/A,Jun-19,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,Global,Sales,0,11.24632666,21.22170595,30.02182754,37.41687424,44.45869263,50.66103783,56.03408383,60.202997,63.6587846,66.49600847,68.79840006,9.090573345,1327,Crohn's disease,7/7/14 12:28
801,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Oct-10,N/A,Jun-19,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,Crohn's disease,7/7/14 12:28
801,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Oct-10,N/A,Jun-19,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,ROW,Sales,0,11.24632666,21.22170595,30.02182754,37.41687424,44.45869263,50.66103783,56.03408383,60.202997,63.6587846,66.49600847,68.79840006,9.090573345,1327,Crohn's disease,7/7/14 12:28
801,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Oct-10,N/A,Jun-19,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,Crohn's disease,7/7/14 12:28
801,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Oct-10,N/A,Jun-19,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,Crohn's disease,7/7/14 12:28
802,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-08,N/A,Jun-19,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,Rheumatoid Arthritis,7/7/14 12:28
802,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-08,N/A,Jun-19,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,72.69125104,161.0851066,227.909887,270.1043166,261.8245706,289.7035159,313.261904,332.3938733,347.9403764,360.6975403,358.6666318,360.6239815,4.679933445,1327,Rheumatoid Arthritis,7/7/14 12:28
802,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-08,N/A,Jun-19,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,Rheumatoid Arthritis,7/7/14 12:28
802,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-08,N/A,Jun-19,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,72.69125104,161.0851066,227.909887,270.1043166,261.8245706,289.7035159,313.261904,332.3938733,347.9403764,360.6975403,358.6666318,360.6239815,4.679933445,1327,Rheumatoid Arthritis,7/7/14 12:28
802,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-08,N/A,Jun-19,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,Rheumatoid Arthritis,7/7/14 12:28
802,37,Eisai,Regional & Specialty Pharma,1225,Humira,adalimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-08,N/A,Jun-19,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1327,Rheumatoid Arthritis,7/7/14 12:28
803,39,Eli Lilly,Large Pharma,940,Humulin,human insulin,Recombinant Protein,Launched,Licensed (Development),Feb-83,Mar-83,Expired,Expired,83,Insulins,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,532,Diabetes,7/7/14 12:28
803,39,Eli Lilly,Large Pharma,940,Humulin,human insulin,Recombinant Protein,Launched,Licensed (Development),Feb-83,Mar-83,Expired,Expired,83,Insulins,22,Diabetes,8,Metabolism,6,Global,Sales,1022,1088.8,1248.7,1239,1316,1356.998,1387.3573,1417.952635,1441.211175,1460.353237,1476.465286,1489.564047,1.785561536,532,Diabetes,7/7/14 12:28
803,39,Eli Lilly,Large Pharma,940,Humulin,human insulin,Recombinant Protein,Launched,Licensed (Development),Feb-83,Mar-83,Expired,Expired,83,Insulins,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,532,Diabetes,7/7/14 12:28
803,39,Eli Lilly,Large Pharma,940,Humulin,human insulin,Recombinant Protein,Launched,Licensed (Development),Feb-83,Mar-83,Expired,Expired,83,Insulins,22,Diabetes,8,Metabolism,6,ROW,Sales,619.6,618,660.7,647,639,633,628.5,625.125,622.59375,620.6953125,619.2714844,618.2036133,-0.471549651,532,Diabetes,7/7/14 12:28
803,39,Eli Lilly,Large Pharma,940,Humulin,human insulin,Recombinant Protein,Launched,Licensed (Development),Feb-83,Mar-83,Expired,Expired,83,Insulins,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,532,Diabetes,7/7/14 12:28
803,39,Eli Lilly,Large Pharma,940,Humulin,human insulin,Recombinant Protein,Launched,Licensed (Development),Feb-83,Mar-83,Expired,Expired,83,Insulins,22,Diabetes,8,Metabolism,6,US,Sales,402.4,470.8,588,592,677,723.998,758.8573,792.827635,818.6174253,839.6579242,857.1938017,871.3604342,3.671274306,532,Diabetes,7/7/14 12:28
804,91,Santen,Regional & Specialty Pharma,533,Hyalein,hyaluronic acid,Small Molecule (Chemical),Launched,In-House,,Jul-95,N/A,Aug-06,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1492,Dry Eye,7/7/14 12:28
804,91,Santen,Regional & Specialty Pharma,533,Hyalein,hyaluronic acid,Small Molecule (Chemical),Launched,In-House,,Jul-95,N/A,Aug-06,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,Global,Sales,228.6085707,245.1295101,281.3420938,254.7277138,218.4695727,222.2822185,224.9510706,226.8192671,228.1270046,229.0424208,229.6832122,230.1317662,0.745698583,1492,Dry Eye,7/7/14 12:28
804,91,Santen,Regional & Specialty Pharma,533,Hyalein,hyaluronic acid,Small Molecule (Chemical),Launched,In-House,,Jul-95,N/A,Aug-06,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1492,Dry Eye,7/7/14 12:28
804,91,Santen,Regional & Specialty Pharma,533,Hyalein,hyaluronic acid,Small Molecule (Chemical),Launched,In-House,,Jul-95,N/A,Aug-06,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,ROW,Sales,228.6085707,245.1295101,281.3420938,254.7277138,218.4695727,222.2822185,224.9510706,226.8192671,228.1270046,229.0424208,229.6832122,230.1317662,0.745698583,1492,Dry Eye,7/7/14 12:28
804,91,Santen,Regional & Specialty Pharma,533,Hyalein,hyaluronic acid,Small Molecule (Chemical),Launched,In-House,,Jul-95,N/A,Aug-06,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1492,Dry Eye,7/7/14 12:28
804,91,Santen,Regional & Specialty Pharma,533,Hyalein,hyaluronic acid,Small Molecule (Chemical),Launched,In-House,,Jul-95,N/A,Aug-06,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1492,Dry Eye,7/7/14 12:28
805,46,GlaxoSmithKline,Large Pharma,186,Hycamtin,topotecan,Small Molecule (Chemical),Launched,In-House,Jul-96,Jan-98,Nov-10,Jan-10,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,534,Ovarian Cancer,7/7/14 12:28
805,46,GlaxoSmithKline,Large Pharma,186,Hycamtin,topotecan,Small Molecule (Chemical),Launched,In-House,Jul-96,Jan-98,Nov-10,Jan-10,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,534,Ovarian Cancer,7/7/14 12:28
805,46,GlaxoSmithKline,Large Pharma,186,Hycamtin,topotecan,Small Molecule (Chemical),Launched,In-House,Jul-96,Jan-98,Nov-10,Jan-10,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,534,Ovarian Cancer,7/7/14 12:28
805,46,GlaxoSmithKline,Large Pharma,186,Hycamtin,topotecan,Small Molecule (Chemical),Launched,In-House,Jul-96,Jan-98,Nov-10,Jan-10,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,534,Ovarian Cancer,7/7/14 12:28
805,46,GlaxoSmithKline,Large Pharma,186,Hycamtin,topotecan,Small Molecule (Chemical),Launched,In-House,Jul-96,Jan-98,Nov-10,Jan-10,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,534,Ovarian Cancer,7/7/14 12:28
805,46,GlaxoSmithKline,Large Pharma,186,Hycamtin,topotecan,Small Molecule (Chemical),Launched,In-House,Jul-96,Jan-98,Nov-10,Jan-10,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,534,Ovarian Cancer,7/7/14 12:28
806,263,Horizon Pharma,Small Biotech,3921,Duexis,ibuprofen + famotidine,Small Molecule (Chemical),Launched,In-House,Dec-11,,Apr-14,N/A,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0.1,11,60,80,91,101.65,107.9625,112,115.02125,117.0134375,10.01213665,536,Pain,7/7/14 12:28
806,263,Horizon Pharma,Small Biotech,3921,Duexis,ibuprofen + famotidine,Small Molecule (Chemical),Launched,In-House,Dec-11,,Apr-14,N/A,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,536,Pain,7/7/14 12:28
806,263,Horizon Pharma,Small Biotech,3921,Duexis,ibuprofen + famotidine,Small Molecule (Chemical),Launched,In-House,Dec-11,,Apr-14,N/A,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0.1,11,60,80,91,101.65,107.9625,112,115.02125,117.0134375,10.01213665,536,Pain,7/7/14 12:28
817,39,Eli Lilly,Large Pharma,3086,Cyramza,ramucirumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Aug-14,Apr-15,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,543,Gastric Cancer,7/7/14 12:28
817,39,Eli Lilly,Large Pharma,3086,Cyramza,ramucirumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Aug-14,Apr-15,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,20.416683,128.4945197,390.9502636,570.4600394,698.7327872,784.5611054,848.29429,0,543,Gastric Cancer,7/7/14 12:28
817,39,Eli Lilly,Large Pharma,3086,Cyramza,ramucirumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Aug-14,Apr-15,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,543,Gastric Cancer,7/7/14 12:28
817,39,Eli Lilly,Large Pharma,3086,Cyramza,ramucirumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Aug-14,Apr-15,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,52.75,191.996696,299.1734013,384.8165111,441.0754757,483.3954646,0,543,Gastric Cancer,7/7/14 12:28
817,39,Eli Lilly,Large Pharma,3086,Cyramza,ramucirumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Aug-14,Apr-15,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,543,Gastric Cancer,7/7/14 12:28
817,39,Eli Lilly,Large Pharma,3086,Cyramza,ramucirumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Aug-14,Apr-15,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,20.416683,75.74451968,198.9535676,271.2866381,313.9162761,343.4856297,364.8988254,0,543,Gastric Cancer,7/7/14 12:28
818,39,Eli Lilly,Large Pharma,2353,necitumumab,necitumumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Mar-15,Jun-15,Jun-25,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,763,Non-small-cell Lung Cancer,7/7/14 12:28
818,39,Eli Lilly,Large Pharma,2353,necitumumab,necitumumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Mar-15,Jun-15,Jun-25,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,39.583315,81.38889899,118.0555005,154.7219265,169.7996506,180.1484946,0,763,Non-small-cell Lung Cancer,7/7/14 12:28
818,39,Eli Lilly,Large Pharma,2353,necitumumab,necitumumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Mar-15,Jun-15,Jun-25,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,763,Non-small-cell Lung Cancer,7/7/14 12:28
818,39,Eli Lilly,Large Pharma,2353,necitumumab,necitumumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Mar-15,Jun-15,Jun-25,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,14.583325,34.72216766,51.38880813,68.05522639,74.99961431,79.72179332,0,763,Non-small-cell Lung Cancer,7/7/14 12:28
818,39,Eli Lilly,Large Pharma,2353,necitumumab,necitumumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Mar-15,Jun-15,Jun-25,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,763,Non-small-cell Lung Cancer,7/7/14 12:28
818,39,Eli Lilly,Large Pharma,2353,necitumumab,necitumumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Mar-15,Jun-15,Jun-25,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,24.99999,46.66673133,66.66669238,86.6667001,94.80003627,100.4267013,0,763,Non-small-cell Lung Cancer,7/7/14 12:28
819,39,Eli Lilly,Large Pharma,1538,IMC-18F1,Icrucumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,544,Various Malignancies,7/7/14 12:28
819,39,Eli Lilly,Large Pharma,1538,IMC-18F1,Icrucumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,544,Various Malignancies,7/7/14 12:28
819,39,Eli Lilly,Large Pharma,1538,IMC-18F1,Icrucumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,544,Various Malignancies,7/7/14 12:28
819,39,Eli Lilly,Large Pharma,1538,IMC-18F1,Icrucumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,544,Various Malignancies,7/7/14 12:28
819,39,Eli Lilly,Large Pharma,1538,IMC-18F1,Icrucumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,544,Various Malignancies,7/7/14 12:28
819,39,Eli Lilly,Large Pharma,1538,IMC-18F1,Icrucumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,544,Various Malignancies,7/7/14 12:28
820,39,Eli Lilly,Large Pharma,822,LY3012207,olaratumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,545,Various Malignancies,7/7/14 12:28
820,39,Eli Lilly,Large Pharma,822,LY3012207,olaratumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,545,Various Malignancies,7/7/14 12:28
820,39,Eli Lilly,Large Pharma,822,LY3012207,olaratumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,545,Various Malignancies,7/7/14 12:28
820,39,Eli Lilly,Large Pharma,822,LY3012207,olaratumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,545,Various Malignancies,7/7/14 12:28
820,39,Eli Lilly,Large Pharma,822,LY3012207,olaratumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,545,Various Malignancies,7/7/14 12:28
820,39,Eli Lilly,Large Pharma,822,LY3012207,olaratumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,545,Various Malignancies,7/7/14 12:28
822,46,GlaxoSmithKline,Large Pharma,2649,Imitrex / Imigran,sumatriptan,Small Molecule (Chemical),Launched,In-House,Mar-93,Sep-91,Nov-08,May-06,117,Triptans,8,Migraine,12,Central Nervous System,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,548,Migraine,7/7/14 12:28
822,46,GlaxoSmithKline,Large Pharma,2649,Imitrex / Imigran,sumatriptan,Small Molecule (Chemical),Launched,In-House,Mar-93,Sep-91,Nov-08,May-06,117,Triptans,8,Migraine,12,Central Nervous System,4,Global,Sales,414.7636094,327.4986278,336.4604416,301.5471195,293.9218373,276.9355116,257.9478262,240.1481806,227.9109772,217.4180895,208.6566979,201.4535964,-5.253465574,548,Migraine,7/7/14 12:28
822,46,GlaxoSmithKline,Large Pharma,2649,Imitrex / Imigran,sumatriptan,Small Molecule (Chemical),Launched,In-House,Mar-93,Sep-91,Nov-08,May-06,117,Triptans,8,Migraine,12,Central Nervous System,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,548,Migraine,7/7/14 12:28
822,46,GlaxoSmithKline,Large Pharma,2649,Imitrex / Imigran,sumatriptan,Small Molecule (Chemical),Launched,In-House,Mar-93,Sep-91,Nov-08,May-06,117,Triptans,8,Migraine,12,Central Nervous System,4,ROW,Sales,222.9744216,211.6236235,204.9996234,187.4250406,168.848715,156.5526315,145.3820162,135.3994408,126.7580896,119.1184325,112.3914334,106.4844998,-6.373582691,548,Migraine,7/7/14 12:28
822,46,GlaxoSmithKline,Large Pharma,2649,Imitrex / Imigran,sumatriptan,Small Molecule (Chemical),Launched,In-House,Mar-93,Sep-91,Nov-08,May-06,117,Triptans,8,Migraine,12,Central Nervous System,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,548,Migraine,7/7/14 12:28
822,46,GlaxoSmithKline,Large Pharma,2649,Imitrex / Imigran,sumatriptan,Small Molecule (Chemical),Launched,In-House,Mar-93,Sep-91,Nov-08,May-06,117,Triptans,8,Migraine,12,Central Nervous System,4,US,Sales,191.7891878,115.8750043,131.4608183,114.1220789,125.0731222,120.3828802,112.56581,104.7487399,101.1528876,98.29965701,96.26526451,94.96909657,-3.857166092,548,Migraine,7/7/14 12:28
825,61,Merck & Co,Large Pharma,965,Implanon,etonogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-07,Jul-99,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1455,Female contraception,7/7/14 12:28
825,61,Merck & Co,Large Pharma,965,Implanon,etonogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-07,Jul-99,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,35.03,236,295,348,402,427.595,446.123375,458.7243969,466.6214984,471.9350295,475.4322252,477.7310466,2.496300706,1455,Female contraception,7/7/14 12:28
825,61,Merck & Co,Large Pharma,965,Implanon,etonogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-07,Jul-99,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1455,Female contraception,7/7/14 12:28
825,61,Merck & Co,Large Pharma,965,Implanon,etonogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-07,Jul-99,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,21.33,150,169,209,197,202.39,206.29225,206.9347188,208.3481689,209.2721225,209.8301006,210.2914765,0.937088544,1455,Female contraception,7/7/14 12:28
825,61,Merck & Co,Large Pharma,965,Implanon,etonogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-07,Jul-99,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1455,Female contraception,7/7/14 12:28
825,61,Merck & Co,Large Pharma,965,Implanon,etonogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-07,Jul-99,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,13.7,86,126,139,205,225.205,239.831125,251.7896781,258.2733295,262.6629069,265.6021246,267.4395701,3.87139292,1455,Female contraception,7/7/14 12:28
825,61,Schering-Plough,Large Pharma,965,Implanon,etonogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-07,Jul-99,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Proforma,143.97,0,0,0,0,0,0,0,0,0,0,0,0,1455,Female contraception,7/7/14 12:28
825,61,Schering-Plough,Large Pharma,965,Implanon,etonogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-07,Jul-99,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Proforma,90.67,0,0,0,0,0,0,0,0,0,0,0,0,1455,Female contraception,7/7/14 12:28
825,61,Schering-Plough,Large Pharma,965,Implanon,etonogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-07,Jul-99,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Proforma,53.3,0,0,0,0,0,0,0,0,0,0,0,0,1455,Female contraception,7/7/14 12:28
826,95,Shionogi,Regional & Specialty Pharma,909,Imunace,teceleukin,Recombinant Protein,Launched,Licensed (Development),,Jan-99,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,551,Renal Cancer,7/7/14 12:28
826,95,Shionogi,Regional & Specialty Pharma,909,Imunace,teceleukin,Recombinant Protein,Launched,Licensed (Development),,Jan-99,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,Global,Sales,49.55699458,36.18578482,26.58948681,20.00338946,14.34064261,12.52740222,11.2179195,10.26601855,9.574657169,9.07246643,8.707690968,8.442729075,-7.289133818,551,Renal Cancer,7/7/14 12:28
826,95,Shionogi,Regional & Specialty Pharma,909,Imunace,teceleukin,Recombinant Protein,Launched,Licensed (Development),,Jan-99,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,551,Renal Cancer,7/7/14 12:28
826,95,Shionogi,Regional & Specialty Pharma,909,Imunace,teceleukin,Recombinant Protein,Launched,Licensed (Development),,Jan-99,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,ROW,Sales,49.55699458,36.18578482,26.58948681,20.00338946,14.34064261,12.52740222,11.2179195,10.26601855,9.574657169,9.07246643,8.707690968,8.442729075,-7.289133818,551,Renal Cancer,7/7/14 12:28
826,95,Shionogi,Regional & Specialty Pharma,909,Imunace,teceleukin,Recombinant Protein,Launched,Licensed (Development),,Jan-99,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,551,Renal Cancer,7/7/14 12:28
826,95,Shionogi,Regional & Specialty Pharma,909,Imunace,teceleukin,Recombinant Protein,Launched,Licensed (Development),,Jan-99,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,551,Renal Cancer,7/7/14 12:28
827,67,Novartis,Large Pharma,2215,Arcapta / Onbrez,indacaterol,Small Molecule (Chemical),Launched,In-House,Mar-12,Dec-09,Jan-25,Nov-24,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,811,COPD,7/7/14 12:28
827,67,Novartis,Large Pharma,2215,Arcapta / Onbrez,indacaterol,Small Molecule (Chemical),Launched,In-House,Mar-12,Dec-09,Jan-25,Nov-24,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,33,103,134,192,252.347,289.9526463,327.6324798,360.4195525,387.8436535,412.0877845,433.1021704,12.32329253,811,COPD,7/7/14 12:28
827,67,Novartis,Large Pharma,2215,Arcapta / Onbrez,indacaterol,Small Molecule (Chemical),Launched,In-House,Mar-12,Dec-09,Jan-25,Nov-24,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,811,COPD,7/7/14 12:28
827,67,Novartis,Large Pharma,2215,Arcapta / Onbrez,indacaterol,Small Molecule (Chemical),Launched,In-House,Mar-12,Dec-09,Jan-25,Nov-24,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,33,103,110.8,122,137.358,146.1773,154.057235,160.8173853,166.0729262,170.435188,174.0120642,5.203778722,811,COPD,7/7/14 12:28
827,67,Novartis,Large Pharma,2215,Arcapta / Onbrez,indacaterol,Small Molecule (Chemical),Launched,In-House,Mar-12,Dec-09,Jan-25,Nov-24,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,811,COPD,7/7/14 12:28
827,67,Novartis,Large Pharma,2215,Arcapta / Onbrez,indacaterol,Small Molecule (Chemical),Launched,In-House,Mar-12,Dec-09,Jan-25,Nov-24,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,23.2,70,114.989,143.7753463,173.5752448,199.6021673,221.7707273,241.6525965,259.0901062,20.55720601,811,COPD,7/7/14 12:28
828,67,Novartis,Large Pharma,4025,Ultibro,indacaterol + glycopyrronium,Small Molecule (Chemical),Launched,Licensed (Development),Dec-15,Nov-13,N/A,Jun-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,812,COPD,7/7/14 12:28
828,67,Novartis,Large Pharma,4025,Ultibro,indacaterol + glycopyrronium,Small Molecule (Chemical),Launched,Licensed (Development),Dec-15,Nov-13,N/A,Jun-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,6,53.091731,140.6246706,411.0170673,619.3075958,765.8062943,909.9513581,1030.172543,108.5695607,812,COPD,7/7/14 12:28
828,67,Novartis,Large Pharma,4025,Ultibro,indacaterol + glycopyrronium,Small Molecule (Chemical),Launched,Licensed (Development),Dec-15,Nov-13,N/A,Jun-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,812,COPD,7/7/14 12:28
828,67,Novartis,Large Pharma,4025,Ultibro,indacaterol + glycopyrronium,Small Molecule (Chemical),Launched,Licensed (Development),Dec-15,Nov-13,N/A,Jun-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,6,53.091731,134.9246706,262.8170673,330.8881658,393.0270652,446.9755462,488.4366372,87.47817813,812,COPD,7/7/14 12:28
828,67,Novartis,Large Pharma,4025,Ultibro,indacaterol + glycopyrronium,Small Molecule (Chemical),Launched,Licensed (Development),Dec-15,Nov-13,N/A,Jun-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,812,COPD,7/7/14 12:28
828,67,Novartis,Large Pharma,4025,Ultibro,indacaterol + glycopyrronium,Small Molecule (Chemical),Launched,Licensed (Development),Dec-15,Nov-13,N/A,Jun-22,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,5.7,148.2,288.41943,372.7792291,462.9758119,541.7359056,0,812,COPD,7/7/14 12:28
829,46,GlaxoSmithKline,Large Pharma,571,Infanrix / Pediarix,DTaP vaccine,Vaccine,Launched,In-House,Jul-94,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,553,DTaP,7/7/14 12:28
829,46,GlaxoSmithKline,Large Pharma,571,Infanrix / Pediarix,DTaP vaccine,Vaccine,Launched,In-House,Jul-94,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,1011.960837,1081.500041,1106.19469,1228.397377,1347.662892,1333.592166,1364.07874,1376.976906,1384.989403,1388.83931,1391.045678,1392.173876,0.465286706,553,DTaP,7/7/14 12:28
829,46,GlaxoSmithKline,Large Pharma,571,Infanrix / Pediarix,DTaP vaccine,Vaccine,Launched,In-House,Jul-94,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,553,DTaP,7/7/14 12:28
829,46,GlaxoSmithKline,Large Pharma,571,Infanrix / Pediarix,DTaP vaccine,Vaccine,Launched,In-House,Jul-94,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,803.0197701,855.9300321,844.8762344,882.8610828,923.9776906,950.5557293,963.8447486,970.4892583,973.8115131,975.4726406,976.3032043,976.7184861,0.796159585,553,DTaP,7/7/14 12:28
829,46,GlaxoSmithKline,Large Pharma,571,Infanrix / Pediarix,DTaP vaccine,Vaccine,Launched,In-House,Jul-94,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,553,DTaP,7/7/14 12:28
829,46,GlaxoSmithKline,Large Pharma,571,Infanrix / Pediarix,DTaP vaccine,Vaccine,Launched,In-House,Jul-94,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,208.9410664,225.5700085,261.3184558,345.5362945,423.6852016,383.0364369,400.2339912,406.4876473,411.1778894,413.366669,414.7424734,415.4553902,-0.279828698,553,DTaP,7/7/14 12:28
831,67,Novartis,Large Pharma,3135,Influenza Vaccines - Novartis,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-87,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1713,seasonal influenza,7/7/14 12:28
831,67,Novartis,Large Pharma,3135,Influenza Vaccines - Novartis,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-87,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,1189,1324,734.475,329.97,335,322,311,308.4,304.9,304.591,304.5319,304.5195437,-1.3535442,1713,seasonal influenza,7/7/14 12:28
831,67,Novartis,Large Pharma,3135,Influenza Vaccines - Novartis,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-87,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1713,seasonal influenza,7/7/14 12:28
831,67,Novartis,Large Pharma,3135,Influenza Vaccines - Novartis,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-87,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,504,530,577.475,200,210,220,226,228.4,229.9,230.701,231.10015,231.3221125,1.391065634,1713,seasonal influenza,7/7/14 12:28
831,67,Novartis,Large Pharma,3135,Influenza Vaccines - Novartis,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-87,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1713,seasonal influenza,7/7/14 12:28
831,67,Novartis,Large Pharma,3135,Influenza Vaccines - Novartis,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-87,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,685,794,157,129.97,125,102,85,80,75,73.89,73.43175,73.19743125,-7.360114726,1713,seasonal influenza,7/7/14 12:28
832,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,167,Influenza Vaccines - Sanofi Pasteur MSD,influenza vaccine,Vaccine,Launched,Licensed (Marketed),,Jul-86,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,248.7202,219.9093,182.7034,160.6589158,162.0196681,155.1537538,151.989725,149.7704217,148.0544001,146.9760963,146.2271868,145.7066117,-1.504602298,1714,seasonal influenza,7/7/14 12:28
832,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,167,Influenza Vaccines - Sanofi Pasteur MSD,influenza vaccine,Vaccine,Launched,Licensed (Marketed),,Jul-86,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,248.7202,219.9093,182.7034,160.6589158,162.0196681,155.1537538,151.989725,149.7704217,148.0544001,146.9760963,146.2271868,145.7066117,-1.504602298,1714,seasonal influenza,7/7/14 12:28
832,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,167,Influenza Vaccines - Sanofi Pasteur MSD,influenza vaccine,Vaccine,Launched,Licensed (Marketed),,Jul-86,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1714,seasonal influenza,7/7/14 12:28
833,1,Abbott,Regional & Specialty Pharma,1636,Influvac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-85,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1715,seasonal influenza,7/7/14 12:28
833,1,Abbott,Regional & Specialty Pharma,1636,Influvac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-85,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,210.75,252.68375,263.5121875,269.5681094,273.8872305,276.9582428,278.9794562,280.3773235,281.3370736,281.9888125,282.4354965,0.668353057,1715,seasonal influenza,7/7/14 12:28
833,1,Abbott,Regional & Specialty Pharma,1636,Influvac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-85,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1715,seasonal influenza,7/7/14 12:28
833,1,Abbott,Regional & Specialty Pharma,1636,Influvac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-85,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,210.75,252.68375,263.5121875,269.5681094,273.8872305,276.9582428,278.9794562,280.3773235,281.3370736,281.9888125,282.4354965,0.668353057,1715,seasonal influenza,7/7/14 12:28
833,1,Abbott,Regional & Specialty Pharma,1636,Influvac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-85,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1715,seasonal influenza,7/7/14 12:28
833,1,Abbott,Regional & Specialty Pharma,1636,Influvac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-85,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1715,seasonal influenza,7/7/14 12:28
833,1,Solvay,Regional & Specialty Pharma,1636,Influvac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-85,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Proforma,225.1,30.125,0,0,0,0,0,0,0,0,0,0,0,1715,seasonal influenza,7/7/14 12:28
833,1,Solvay,Regional & Specialty Pharma,1636,Influvac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-85,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Proforma,225.1,30.125,0,0,0,0,0,0,0,0,0,0,0,1715,seasonal influenza,7/7/14 12:28
834,86,Roche,Large Pharma,118,Inhibace,cilazapril,Small Molecule (Chemical),Launched,In-House,,Oct-90,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,555,Hypertension ,7/7/14 12:28
834,86,Roche,Large Pharma,118,Inhibace,cilazapril,Small Molecule (Chemical),Launched,In-House,,Oct-90,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,5,Global,Sales,71.32896598,64.48682078,65.17322246,54.21251926,48.96464718,44.84159287,41.95545486,39.93515825,38.52095062,37.53100528,36.83804354,36.35297033,-4.165366578,555,Hypertension ,7/7/14 12:28
834,86,Roche,Large Pharma,118,Inhibace,cilazapril,Small Molecule (Chemical),Launched,In-House,,Oct-90,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,555,Hypertension ,7/7/14 12:28
834,86,Roche,Large Pharma,118,Inhibace,cilazapril,Small Molecule (Chemical),Launched,In-House,,Oct-90,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,5,ROW,Sales,71.32896598,64.48682078,65.17322246,54.21251926,48.96464718,44.84159287,41.95545486,39.93515825,38.52095062,37.53100528,36.83804354,36.35297033,-4.165366578,555,Hypertension ,7/7/14 12:28
834,86,Roche,Large Pharma,118,Inhibace,cilazapril,Small Molecule (Chemical),Launched,In-House,,Oct-90,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,555,Hypertension ,7/7/14 12:28
834,86,Roche,Large Pharma,118,Inhibace,cilazapril,Small Molecule (Chemical),Launched,In-House,,Oct-90,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,555,Hypertension ,7/7/14 12:28
835,76,Pfizer,Large Pharma,1580,inotuzumab ozogamicin,inotuzumab ozogamicin,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,556,Acute Lymphoblastic Leukemia,7/7/14 12:28
835,76,Pfizer,Large Pharma,1580,inotuzumab ozogamicin,inotuzumab ozogamicin,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,556,Acute Lymphoblastic Leukemia,7/7/14 12:28
835,76,Pfizer,Large Pharma,1580,inotuzumab ozogamicin,inotuzumab ozogamicin,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,556,Acute Lymphoblastic Leukemia,7/7/14 12:28
835,76,Pfizer,Large Pharma,1580,inotuzumab ozogamicin,inotuzumab ozogamicin,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,556,Acute Lymphoblastic Leukemia,7/7/14 12:28
835,76,Pfizer,Large Pharma,1580,inotuzumab ozogamicin,inotuzumab ozogamicin,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,556,Acute Lymphoblastic Leukemia,7/7/14 12:28
835,76,Pfizer,Large Pharma,1580,inotuzumab ozogamicin,inotuzumab ozogamicin,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,556,Acute Lymphoblastic Leukemia,7/7/14 12:28
836,37,Eisai,Regional & Specialty Pharma,3555,Inovelon / Banzel,rufinamide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-09,Jun-07,Nov-22,Jan-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,557,Epilepsy,7/7/14 12:28
836,37,Eisai,Regional & Specialty Pharma,3555,Inovelon / Banzel,rufinamide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-09,Jun-07,Nov-22,Jan-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,Global,Sales,27.38282682,48.0168833,68.47182441,82.03108916,100.9426637,114.5575197,126.849766,138.0600818,147.6727242,156.1750164,163.676618,171.1512782,7.834537383,557,Epilepsy,7/7/14 12:28
836,37,Eisai,Regional & Specialty Pharma,3555,Inovelon / Banzel,rufinamide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-09,Jun-07,Nov-22,Jan-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,557,Epilepsy,7/7/14 12:28
836,37,Eisai,Regional & Specialty Pharma,3555,Inovelon / Banzel,rufinamide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-09,Jun-07,Nov-22,Jan-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,ROW,Sales,12.92791163,15.17468396,17.75195448,18.13871639,25.00423683,28.10103449,31.08514943,34.12051012,36.54632961,38.72260236,40.66096585,40.27088898,7.045447207,557,Epilepsy,7/7/14 12:28
836,37,Eisai,Regional & Specialty Pharma,3555,Inovelon / Banzel,rufinamide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-09,Jun-07,Nov-22,Jan-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,557,Epilepsy,7/7/14 12:28
836,37,Eisai,Regional & Specialty Pharma,3555,Inovelon / Banzel,rufinamide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-09,Jun-07,Nov-22,Jan-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,US,Sales,14.45491519,32.84219934,50.71986993,63.89237277,75.93842688,86.45648525,95.76461653,103.9395717,111.1263946,117.452414,123.0156521,130.8803892,8.086946821,557,Epilepsy,7/7/14 12:28
837,76,Pfizer,Large Pharma,880,Inspra,eplerenone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-04,Mar-04,Expired,Mar-14,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,558,,7/7/14 12:28
837,76,Pfizer,Large Pharma,880,Inspra,eplerenone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-04,Mar-04,Expired,Mar-14,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Sales,124,157,194.679625,214,233,195.0740281,163.599483,153.5875523,117.7469923,105.8805208,98.7007765,93.87142836,-12.17931043,558,,7/7/14 12:28
837,76,Pfizer,Large Pharma,880,Inspra,eplerenone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-04,Mar-04,Expired,Mar-14,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,558,,7/7/14 12:28
837,76,Pfizer,Large Pharma,880,Inspra,eplerenone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-04,Mar-04,Expired,Mar-14,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,111,152,191,209,227,188.8,157.2025,147.1485,111.2913563,99.4188275,92.23677934,87.40657373,-12.74539052,558,,7/7/14 12:28
837,76,Pfizer,Large Pharma,880,Inspra,eplerenone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-04,Mar-04,Expired,Mar-14,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,558,,7/7/14 12:28
837,76,Pfizer,Large Pharma,880,Inspra,eplerenone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-04,Mar-04,Expired,Mar-14,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Sales,13,5,3.679625,5,6,6.274028125,6.396983047,6.439052268,6.455636,6.461693345,6.46399716,6.464854629,1.071716206,558,,7/7/14 12:28
838,100,Nycomed,Large Pharma,702,Instanyl,fentanyl - nasal,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-09,N/A,Jul-19,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Proforma,2.778962338,7.948499457,10.42312007,0,0,0,0,0,0,0,0,0,0,559,Cancer Pain,7/7/14 12:28
838,100,Nycomed,Large Pharma,702,Instanyl,fentanyl - nasal,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-09,N/A,Jul-19,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Proforma,2.778962338,7.948499457,10.42312007,0,0,0,0,0,0,0,0,0,0,559,Cancer Pain,7/7/14 12:28
838,100,Takeda,Large Pharma,702,Instanyl,fentanyl - nasal,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-09,N/A,Jul-19,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,559,Cancer Pain,7/7/14 12:28
838,100,Takeda,Large Pharma,702,Instanyl,fentanyl - nasal,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-09,N/A,Jul-19,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,3.45E-05,1.39E-05,2.232719738,16.6834376,19.72572967,23.01226813,25.91948836,28.43551408,30.38675471,40.27088898,36.70618059,19.65219382,-0.053341162,559,Cancer Pain,7/7/14 12:28
838,100,Takeda,Large Pharma,702,Instanyl,fentanyl - nasal,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-09,N/A,Jul-19,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,559,Cancer Pain,7/7/14 12:28
838,100,Takeda,Large Pharma,702,Instanyl,fentanyl - nasal,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-09,N/A,Jul-19,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,3.45E-05,1.39E-05,2.232719738,16.6834376,19.72572967,23.01226813,25.91948836,28.43551408,30.38675471,40.27088898,36.70618059,19.65219382,-0.053341162,559,Cancer Pain,7/7/14 12:28
838,100,Takeda,Large Pharma,702,Instanyl,fentanyl - nasal,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-09,N/A,Jul-19,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,559,Cancer Pain,7/7/14 12:28
838,100,Takeda,Large Pharma,702,Instanyl,fentanyl - nasal,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-09,N/A,Jul-19,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,559,Cancer Pain,7/7/14 12:28
839,68,Novo Nordisk,Regional & Specialty Pharma,3122,Human Insulins - Novo Nordisk,Human insulins,Recombinant Protein,Launched,In-House,Jul-50,Jul-50,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,560,Diabetes,7/7/14 12:28
839,68,Novo Nordisk,Regional & Specialty Pharma,3122,Human Insulins - Novo Nordisk,Human insulins,Recombinant Protein,Launched,In-House,Jul-50,Jul-50,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Sales,2111.401381,2103.727816,2012.755852,1951.449731,1935.475255,1897.039982,1877.890725,1848.669661,1826.23577,1807.185278,1789.505576,1774.272155,-1.234636947,560,Diabetes,7/7/14 12:28
839,68,Novo Nordisk,Regional & Specialty Pharma,3122,Human Insulins - Novo Nordisk,Human insulins,Recombinant Protein,Launched,In-House,Jul-50,Jul-50,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,560,Diabetes,7/7/14 12:28
839,68,Novo Nordisk,Regional & Specialty Pharma,3122,Human Insulins - Novo Nordisk,Human insulins,Recombinant Protein,Launched,In-House,Jul-50,Jul-50,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Sales,1718.044411,1739.439783,1700.344791,1630.121829,1601.232265,1564.321297,1539.770019,1508.298112,1483.911288,1462.675096,1443.292276,1426.54057,-1.636757874,560,Diabetes,7/7/14 12:28
839,68,Novo Nordisk,Regional & Specialty Pharma,3122,Human Insulins - Novo Nordisk,Human insulins,Recombinant Protein,Launched,In-House,Jul-50,Jul-50,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,560,Diabetes,7/7/14 12:28
839,68,Novo Nordisk,Regional & Specialty Pharma,3122,Human Insulins - Novo Nordisk,Human insulins,Recombinant Protein,Launched,In-House,Jul-50,Jul-50,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,1,US,Sales,393.3569696,364.288033,312.4110613,321.3279021,334.2429895,332.7186847,338.1207068,340.3715493,342.3244828,344.5101819,346.2133004,347.731585,0.566780057,560,Diabetes,7/7/14 12:28
841,46,GlaxoSmithKline,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-99,N/A,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1447,,7/7/14 12:28
841,46,GlaxoSmithKline,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-99,N/A,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,4,Global,Sales,85.75939293,78.79500295,76.63091936,71.66676716,67.71620415,64.75208165,62.08190643,59.59938297,57.31444588,55.20465417,53.25855239,51.4628645,-3.84505174,1447,,7/7/14 12:28
841,46,GlaxoSmithKline,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-99,N/A,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1447,,7/7/14 12:28
841,46,GlaxoSmithKline,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-99,N/A,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,4,ROW,Sales,85.75939293,78.79500295,76.63091936,71.66676716,67.71620415,64.75208165,62.08190643,59.59938297,57.31444588,55.20465417,53.25855239,51.4628645,-3.84505174,1447,,7/7/14 12:28
841,46,GlaxoSmithKline,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-99,N/A,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1447,,7/7/14 12:28
841,46,GlaxoSmithKline,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-99,N/A,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1447,,7/7/14 12:28
842,61,Merck & Co,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-98,,Jun-15,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1447,Acute Coronary Syndrome,7/7/14 12:28
842,61,Merck & Co,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-98,,Jun-15,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,45.9,265,230,211,196.87,186.76895,131.0958126,66.32153455,51.72110244,43.97880391,38.84357822,35.81861053,-21.60728518,1447,Acute Coronary Syndrome,7/7/14 12:28
842,61,Merck & Co,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-98,,Jun-15,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1447,Acute Coronary Syndrome,7/7/14 12:28
842,61,Merck & Co,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-98,,Jun-15,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,3,20,22,18,17.45,17.05375,16.94315625,16.89408359,16.87720135,16.87056651,16.86813924,16.86721685,-0.484077518,1447,Acute Coronary Syndrome,7/7/14 12:28
842,61,Merck & Co,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-98,,Jun-15,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1447,Acute Coronary Syndrome,7/7/14 12:28
842,61,Merck & Co,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-98,,Jun-15,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Sales,42.9,245,208,193,179.42,169.7152,114.1526563,49.42745096,34.84390109,27.10823741,21.97543898,18.95139367,-27.46648002,1447,Acute Coronary Syndrome,7/7/14 12:28
842,61,Schering-Plough,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-98,,Jun-15,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Proforma,248.1,0,0,0,0,0,0,0,0,0,0,0,0,1447,Acute Coronary Syndrome,7/7/14 12:28
842,61,Schering-Plough,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-98,,Jun-15,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Proforma,16,0,0,0,0,0,0,0,0,0,0,0,0,1447,Acute Coronary Syndrome,7/7/14 12:28
842,61,Schering-Plough,Large Pharma,1555,Integrilin,eptifibatide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-98,,Jun-15,Jul-10,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Proforma,232.1,0,0,0,0,0,0,0,0,0,0,0,0,1447,Acute Coronary Syndrome,7/7/14 12:28
843,53,Johnson & Johnson,Large Pharma,1524,Intelence,etravirine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,Aug-08,Nov-19,Nov-19,91,NNRTIs,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,562,HIV,7/7/14 12:28
843,53,Johnson & Johnson,Large Pharma,1524,Intelence,etravirine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,Aug-08,Nov-19,Nov-19,91,NNRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,160.00025,243,314,349,379,399.5,413.406,423.6606,430.97174,436.241582,405.8207005,147.917065,-12.57701322,562,HIV,7/7/14 12:28
843,53,Johnson & Johnson,Large Pharma,1524,Intelence,etravirine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,Aug-08,Nov-19,Nov-19,91,NNRTIs,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,562,HIV,7/7/14 12:28
843,53,Johnson & Johnson,Large Pharma,1524,Intelence,etravirine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,Aug-08,Nov-19,Nov-19,91,NNRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,76.66675,116,151,173,192,205.86,216.078,223.9182,229.7727,234.166446,223.2970436,83.9882559,-11.14077368,562,HIV,7/7/14 12:28
843,53,Johnson & Johnson,Large Pharma,1524,Intelence,etravirine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,Aug-08,Nov-19,Nov-19,91,NNRTIs,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,562,HIV,7/7/14 12:28
843,53,Johnson & Johnson,Large Pharma,1524,Intelence,etravirine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,Aug-08,Nov-19,Nov-19,91,NNRTIs,32,HIV,7,Anti-infectives,6,US,Sales,83.3335,127,163,176,187,193.64,197.328,199.7424,201.19904,202.075136,182.5236569,63.9288091,-14.21567767,562,HIV,7/7/14 12:28
845,61,Merck & Co,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,,Jul-86,N/A,N/A,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1499,Hepatitis C,7/7/14 12:28
845,61,Merck & Co,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,,Jul-86,N/A,N/A,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,Global,Sales,3.490909091,17.92,17.612,16.7174,15.67727,14.9122295,14.12609818,13.37855474,12.69219745,12.03999631,11.4266315,10.85097872,-5.12075211,1499,Hepatitis C,7/7/14 12:28
845,61,Merck & Co,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,,Jul-86,N/A,N/A,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1499,Hepatitis C,7/7/14 12:28
845,61,Merck & Co,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,,Jul-86,N/A,N/A,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,3.490909091,17.92,17.612,16.7174,15.67727,14.9122295,14.12609818,13.37855474,12.69219745,12.03999631,11.4266315,10.85097872,-5.12075211,1499,Hepatitis C,7/7/14 12:28
845,61,Merck & Co,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,,Jul-86,N/A,N/A,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1499,Hepatitis C,7/7/14 12:28
845,61,Merck & Co,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,,Jul-86,N/A,N/A,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1499,Hepatitis C,7/7/14 12:28
845,61,Schering-Plough,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,,Jul-86,N/A,N/A,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,Global,Proforma,17.50909091,0,0,0,0,0,0,0,0,0,0,0,0,1499,Hepatitis C,7/7/14 12:28
845,61,Schering-Plough,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,,Jul-86,N/A,N/A,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,ROW,Proforma,17.50909091,0,0,0,0,0,0,0,0,0,0,0,0,1499,Hepatitis C,7/7/14 12:28
846,96,Shire,Regional & Specialty Pharma,1702,Intuniv / Intuniv XR,guanfacine ER,Small Molecule (Chemical),Launched,In-House,Nov-09,Nov-13,Dec-14,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,563,ADHD,7/7/14 12:28
846,96,Shire,Regional & Specialty Pharma,1702,Intuniv / Intuniv XR,guanfacine ER,Small Molecule (Chemical),Launched,In-House,Nov-09,Nov-13,Dec-14,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,Global,Sales,5.4,165.9,223,287.8,335,338.47579,183.394968,170.163629,155.6350323,137.5593628,113.1504881,120.7385929,-13.56573092,563,ADHD,7/7/14 12:28
846,96,Shire,Regional & Specialty Pharma,1702,Intuniv / Intuniv XR,guanfacine ER,Small Molecule (Chemical),Launched,In-House,Nov-09,Nov-13,Dec-14,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,563,ADHD,7/7/14 12:28
846,96,Shire,Regional & Specialty Pharma,1702,Intuniv / Intuniv XR,guanfacine ER,Small Molecule (Chemical),Launched,In-House,Nov-09,Nov-13,Dec-14,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,ROW,Sales,0,0,0,0,1,6.66667,16.000008,36.666685,58.9166963,79.01253977,93.53004712,101.0547384,93.35925049,563,ADHD,7/7/14 12:28
846,96,Shire,Regional & Specialty Pharma,1702,Intuniv / Intuniv XR,guanfacine ER,Small Molecule (Chemical),Launched,In-House,Nov-09,Nov-13,Dec-14,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,563,ADHD,7/7/14 12:28
846,96,Shire,Regional & Specialty Pharma,1702,Intuniv / Intuniv XR,guanfacine ER,Small Molecule (Chemical),Launched,In-House,Nov-09,Nov-13,Dec-14,,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,US,Sales,5.4,165.9,223,287.8,334,331.80912,167.39496,133.496944,96.718336,58.54682304,19.62044096,19.68385449,-33.26743101,563,ADHD,7/7/14 12:28
847,61,Merck & Co,Large Pharma,177,Invanz,ertapenem,Small Molecule (Chemical),Launched,Licensed (Development),Mar-02,Mar-02,Jun-16,Jul-17,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,564,bacterial infection,7/7/14 12:28
847,61,Merck & Co,Large Pharma,177,Invanz,ertapenem,Small Molecule (Chemical),Launched,Licensed (Development),Mar-02,Mar-02,Jun-16,Jul-17,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,293,362,405,445,488,518.37,544.417,478.9555678,310.718007,211.4256723,172.1542158,145.3524546,-15.88807314,564,bacterial infection,7/7/14 12:28
847,61,Merck & Co,Large Pharma,177,Invanz,ertapenem,Small Molecule (Chemical),Launched,Licensed (Development),Mar-02,Mar-02,Jun-16,Jul-17,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,564,bacterial infection,7/7/14 12:28
847,61,Merck & Co,Large Pharma,177,Invanz,ertapenem,Small Molecule (Chemical),Launched,Licensed (Development),Mar-02,Mar-02,Jun-16,Jul-17,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,141,182,200,218,236,249.5,261.3125,271.4796875,214.7409748,140.1636054,114.4158837,97.04050369,-11.92288905,564,bacterial infection,7/7/14 12:28
847,61,Merck & Co,Large Pharma,177,Invanz,ertapenem,Small Molecule (Chemical),Launched,Licensed (Development),Mar-02,Mar-02,Jun-16,Jul-17,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,564,bacterial infection,7/7/14 12:28
847,61,Merck & Co,Large Pharma,177,Invanz,ertapenem,Small Molecule (Chemical),Launched,Licensed (Development),Mar-02,Mar-02,Jun-16,Jul-17,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,152,180,205,227,252,268.87,283.1045,207.4758803,95.97703224,71.26206683,57.73833216,48.31195095,-21.01909469,564,bacterial infection,7/7/14 12:28
848,53,Johnson & Johnson,Large Pharma,3503,Invega / Invega Sustena / Xeplion,paliperidone / paliperidone palmitate,Small Molecule (Chemical),Launched,In-House,Jan-07,Jul-07,Oct-14,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,565,Schizophrenia,7/7/14 12:28
848,53,Johnson & Johnson,Large Pharma,3503,Invega / Invega Sustena / Xeplion,paliperidone / paliperidone palmitate,Small Molecule (Chemical),Launched,In-House,Jan-07,Jul-07,Oct-14,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,393,576,877,1346,1831,1971.6811,1965.579475,2157.059944,2430.213069,2579.261463,2612.862442,2670.1459,5.537460709,565,Schizophrenia,7/7/14 12:28
848,53,Johnson & Johnson,Large Pharma,3503,Invega / Invega Sustena / Xeplion,paliperidone / paliperidone palmitate,Small Molecule (Chemical),Launched,In-House,Jan-07,Jul-07,Oct-14,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,565,Schizophrenia,7/7/14 12:28
848,53,Johnson & Johnson,Large Pharma,3503,Invega / Invega Sustena / Xeplion,paliperidone / paliperidone palmitate,Small Molecule (Chemical),Launched,In-House,Jan-07,Jul-07,Oct-14,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,127,154,273,565,825,964.3111,947.597475,1072.234694,1233.617344,1332.045557,1370.991766,1418.999133,8.055493072,565,Schizophrenia,7/7/14 12:28
848,53,Johnson & Johnson,Large Pharma,3503,Invega / Invega Sustena / Xeplion,paliperidone / paliperidone palmitate,Small Molecule (Chemical),Launched,In-House,Jan-07,Jul-07,Oct-14,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,565,Schizophrenia,7/7/14 12:28
848,53,Johnson & Johnson,Large Pharma,3503,Invega / Invega Sustena / Xeplion,paliperidone / paliperidone palmitate,Small Molecule (Chemical),Launched,In-House,Jan-07,Jul-07,Oct-14,Oct-14,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,266,422,604,781,1006,1007.37,1017.982,1084.82525,1196.595725,1247.215906,1241.870676,1251.146767,3.164440237,565,Schizophrenia,7/7/14 12:28
849,86,Roche,Large Pharma,731,Invirase / Fortovase,saquinavir,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-96,Nov-10,Jan-11,103,Protease Inhibitors,32,HIV,7,Anti-infectives,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,566,HIV,7/7/14 12:28
849,86,Roche,Large Pharma,731,Invirase / Fortovase,saquinavir,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-96,Nov-10,Jan-11,103,Protease Inhibitors,32,HIV,7,Anti-infectives,5,Global,Sales,135.9147555,128.1180996,116.0213935,95.87374217,79.80521535,65.59290924,51.4431989,39.32783983,29.81858679,20.62298966,13.37421516,8.647427004,-27.20151006,566,HIV,7/7/14 12:28
849,86,Roche,Large Pharma,731,Invirase / Fortovase,saquinavir,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-96,Nov-10,Jan-11,103,Protease Inhibitors,32,HIV,7,Anti-infectives,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,566,HIV,7/7/14 12:28
849,86,Roche,Large Pharma,731,Invirase / Fortovase,saquinavir,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-96,Nov-10,Jan-11,103,Protease Inhibitors,32,HIV,7,Anti-infectives,5,ROW,Sales,89.87494642,85.17210348,77.58053372,64.54184701,54.0764067,45.32317041,35.61106246,27.53680053,21.5824621,15.48871051,10.13684585,5.410057689,-28.02681458,566,HIV,7/7/14 12:28
849,86,Roche,Large Pharma,731,Invirase / Fortovase,saquinavir,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-96,Nov-10,Jan-11,103,Protease Inhibitors,32,HIV,7,Anti-infectives,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,566,HIV,7/7/14 12:28
849,86,Roche,Large Pharma,731,Invirase / Fortovase,saquinavir,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-96,Nov-10,Jan-11,103,Protease Inhibitors,32,HIV,7,Anti-infectives,5,US,Sales,46.03980909,42.94599608,38.44085982,31.33189516,25.72880865,20.26973883,15.83213644,11.79103929,8.236124691,5.134279152,3.237369315,3.237369315,-25.63026913,566,HIV,7/7/14 12:28
850,1,Abbott,Regional & Specialty Pharma,1601,Invivac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-04,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1716,seasonal influenza,7/7/14 12:28
850,1,Abbott,Regional & Specialty Pharma,1601,Invivac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-04,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,45.55,54.0125,57.31025,59.018825,60.3604925,61.46626625,62.24452752,62.83804528,63.28888049,63.6243556,63.8773706,1.136533174,1716,seasonal influenza,7/7/14 12:28
850,1,Abbott,Regional & Specialty Pharma,1601,Invivac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-04,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1716,seasonal influenza,7/7/14 12:28
850,1,Abbott,Regional & Specialty Pharma,1601,Invivac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-04,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,45.55,54.0125,57.31025,59.018825,60.3604925,61.46626625,62.24452752,62.83804528,63.28888049,63.6243556,63.8773706,1.136533174,1716,seasonal influenza,7/7/14 12:28
850,1,Abbott,Regional & Specialty Pharma,1601,Invivac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-04,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1716,seasonal influenza,7/7/14 12:28
850,1,Abbott,Regional & Specialty Pharma,1601,Invivac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-04,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1716,seasonal influenza,7/7/14 12:28
850,1,Solvay,Regional & Specialty Pharma,1601,Invivac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-04,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Proforma,49,6.5,0,0,0,0,0,0,0,0,0,0,0,1716,seasonal influenza,7/7/14 12:28
850,1,Solvay,Regional & Specialty Pharma,1601,Invivac,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-04,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Proforma,49,6.5,0,0,0,0,0,0,0,0,0,0,0,1716,seasonal influenza,7/7/14 12:28
852,46,GlaxoSmithKline,Large Pharma,254,losmapimod,losmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,636,Atherosclerosis,7/7/14 12:28
852,46,GlaxoSmithKline,Large Pharma,254,losmapimod,losmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,636,Atherosclerosis,7/7/14 12:28
852,46,GlaxoSmithKline,Large Pharma,254,losmapimod,losmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,636,Atherosclerosis,7/7/14 12:28
852,46,GlaxoSmithKline,Large Pharma,254,losmapimod,losmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,636,Atherosclerosis,7/7/14 12:28
852,46,GlaxoSmithKline,Large Pharma,254,losmapimod,losmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,636,Atherosclerosis,7/7/14 12:28
852,46,GlaxoSmithKline,Large Pharma,254,losmapimod,losmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,636,Atherosclerosis,7/7/14 12:28
855,24,Bristol-Myers Squibb,Large Pharma,3341,Yervoy,ipilimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Apr-11,Jul-11,May-23,Jul-21,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,568,Melanoma,7/7/14 12:28
855,24,Bristol-Myers Squibb,Large Pharma,3341,Yervoy,ipilimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Apr-11,Jul-11,May-23,Jul-21,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,360,706,960,1095.325236,1147.56074,976.5523986,905.798512,827.3820449,972.0092141,1065.188818,1.496428423,568,Melanoma,7/7/14 12:28
855,24,Bristol-Myers Squibb,Large Pharma,3341,Yervoy,ipilimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Apr-11,Jul-11,May-23,Jul-21,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,568,Melanoma,7/7/14 12:28
855,24,Bristol-Myers Squibb,Large Pharma,3341,Yervoy,ipilimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Apr-11,Jul-11,May-23,Jul-21,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,38,203,383,466.6752356,521.2810125,515.5172512,475.565324,424.9069368,474.1932902,505.2621785,4.037107901,568,Melanoma,7/7/14 12:28
855,24,Bristol-Myers Squibb,Large Pharma,3341,Yervoy,ipilimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Apr-11,Jul-11,May-23,Jul-21,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,568,Melanoma,7/7/14 12:28
855,24,Bristol-Myers Squibb,Large Pharma,3341,Yervoy,ipilimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Apr-11,Jul-11,May-23,Jul-21,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,322,503,577,628.65,626.2797273,461.0351473,430.2331879,402.4751082,497.8159239,559.926639,-0.428173044,568,Melanoma,7/7/14 12:28
856,95,Shionogi,Regional & Specialty Pharma,518,Irbetan,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-08,N/A,Jun-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1503,Hypertension,7/7/14 12:28
856,95,Shionogi,Regional & Specialty Pharma,518,Irbetan,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-08,N/A,Jun-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,40.93838683,84.11021126,112.6887774,124.8766843,118.8483652,128.1025167,131.2822972,132.8449243,122.3204323,115.4410704,110.9913466,106.1967144,-1.595072607,1503,Hypertension,7/7/14 12:28
856,95,Shionogi,Regional & Specialty Pharma,518,Irbetan,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-08,N/A,Jun-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1503,Hypertension,7/7/14 12:28
856,95,Shionogi,Regional & Specialty Pharma,518,Irbetan,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-08,N/A,Jun-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,40.93838683,84.11021126,112.6887774,124.8766843,118.8483652,128.1025167,131.2822972,132.8449243,122.3204323,115.4410704,110.9913466,106.1967144,-1.595072607,1503,Hypertension,7/7/14 12:28
856,95,Shionogi,Regional & Specialty Pharma,518,Irbetan,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-08,N/A,Jun-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1503,Hypertension,7/7/14 12:28
856,95,Shionogi,Regional & Specialty Pharma,518,Irbetan,irbesartan,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-08,N/A,Jun-16,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1503,Hypertension,7/7/14 12:28
857,16,AstraZeneca,Large Pharma,1147,Iressa,gefitinib,Small Molecule (Chemical),Launched,In-House,Oct-03,Jul-02,N/A,Jun-19,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,569,Non-small-cell Lung Cancer,7/7/14 12:28
857,16,AstraZeneca,Large Pharma,1147,Iressa,gefitinib,Small Molecule (Chemical),Launched,In-House,Oct-03,Jul-02,N/A,Jun-19,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,297.035,393,554,611,647,678.98,700.2716,715.211672,725.9602942,733.5450202,711.5769209,617.2607052,-0.669956801,569,Non-small-cell Lung Cancer,7/7/14 12:28
857,16,AstraZeneca,Large Pharma,1147,Iressa,gefitinib,Small Molecule (Chemical),Launched,In-House,Oct-03,Jul-02,N/A,Jun-19,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,569,Non-small-cell Lung Cancer,7/7/14 12:28
857,16,AstraZeneca,Large Pharma,1147,Iressa,gefitinib,Small Molecule (Chemical),Launched,In-House,Oct-03,Jul-02,N/A,Jun-19,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,292,389,552,611,647,678.98,700.2716,715.211672,725.9602942,733.5450202,711.5769209,617.2607052,-0.669956801,569,Non-small-cell Lung Cancer,7/7/14 12:28
857,16,AstraZeneca,Large Pharma,1147,Iressa,gefitinib,Small Molecule (Chemical),Launched,In-House,Oct-03,Jul-02,N/A,Jun-19,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,569,Non-small-cell Lung Cancer,7/7/14 12:28
857,16,AstraZeneca,Large Pharma,1147,Iressa,gefitinib,Small Molecule (Chemical),Launched,In-House,Oct-03,Jul-02,N/A,Jun-19,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,5.035,4,2,0,0,0,0,0,0,0,0,0,0,569,Non-small-cell Lung Cancer,7/7/14 12:28
858,15,Astellas Pharma,Regional & Specialty Pharma,1651,Irribow,ramosetron,Small Molecule (Chemical),Launched,In-House,,Oct-08,,Jun-15,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1607,IBS-D,7/7/14 12:28
858,15,Astellas Pharma,Regional & Specialty Pharma,1651,Irribow,ramosetron,Small Molecule (Chemical),Launched,In-House,,Oct-08,,Jun-15,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,Global,Sales,10.47970866,18.6765341,29.77425782,32.95347659,36.65205025,40.98720212,41.28333059,37.82664475,36.96295365,35.56925261,33.78650022,31.70662876,-2.049330631,1607,IBS-D,7/7/14 12:28
858,15,Astellas Pharma,Regional & Specialty Pharma,1651,Irribow,ramosetron,Small Molecule (Chemical),Launched,In-House,,Oct-08,,Jun-15,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1607,IBS-D,7/7/14 12:28
858,15,Astellas Pharma,Regional & Specialty Pharma,1651,Irribow,ramosetron,Small Molecule (Chemical),Launched,In-House,,Oct-08,,Jun-15,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,ROW,Sales,10.47970866,18.6765341,29.77425782,32.95347659,36.65205025,40.98720212,41.28333059,37.82664475,36.96295365,35.56925261,33.78650022,31.70662876,-2.049330631,1607,IBS-D,7/7/14 12:28
858,15,Astellas Pharma,Regional & Specialty Pharma,1651,Irribow,ramosetron,Small Molecule (Chemical),Launched,In-House,,Oct-08,,Jun-15,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1607,IBS-D,7/7/14 12:28
858,15,Astellas Pharma,Regional & Specialty Pharma,1651,Irribow,ramosetron,Small Molecule (Chemical),Launched,In-House,,Oct-08,,Jun-15,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1607,IBS-D,7/7/14 12:28
859,15,Astellas Pharma,Regional & Specialty Pharma,635,isavuconazole,isavuconazole,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,Apr-16,N/A,N/A,131,Azoles,25,Fungal Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,571,invasive fungal infections,7/7/14 12:28
859,15,Astellas Pharma,Regional & Specialty Pharma,635,isavuconazole,isavuconazole,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,Apr-16,N/A,N/A,131,Azoles,25,Fungal Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,50.33861123,114.1010199,167.7957063,221.489829,255.0485756,280.5533329,0,571,invasive fungal infections,7/7/14 12:28
859,15,Astellas Pharma,Regional & Specialty Pharma,635,isavuconazole,isavuconazole,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,Apr-16,N/A,N/A,131,Azoles,25,Fungal Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,571,invasive fungal infections,7/7/14 12:28
859,15,Astellas Pharma,Regional & Specialty Pharma,635,isavuconazole,isavuconazole,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,Apr-16,N/A,N/A,131,Azoles,25,Fungal Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,30.20316674,50.3387119,70.47419666,90.60937939,106.7176561,0,571,invasive fungal infections,7/7/14 12:28
859,15,Astellas Pharma,Regional & Specialty Pharma,635,isavuconazole,isavuconazole,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,Apr-16,N/A,N/A,131,Azoles,25,Fungal Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,571,invasive fungal infections,7/7/14 12:28
859,15,Astellas Pharma,Regional & Specialty Pharma,635,isavuconazole,isavuconazole,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,Apr-16,N/A,N/A,131,Azoles,25,Fungal Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,50.33861123,83.89785317,117.4569944,151.0156323,164.4391962,173.8356768,0,571,invasive fungal infections,7/7/14 12:28
860,61,Merck & Co,Large Pharma,1585,Isentress,raltegravir,Small Molecule (Chemical),Launched,In-House,Oct-07,Nov-07,Oct-23,Oct-22,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,572,HIV,7/7/14 12:28
860,61,Merck & Co,Large Pharma,1585,Isentress,raltegravir,Small Molecule (Chemical),Launched,In-House,Oct-07,Nov-07,Oct-23,Oct-22,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,Global,Sales,752,1090,1359,1514,1643,1427,910,668,357,258,197,105.2,-32.47217417,572,HIV,7/7/14 12:28
860,61,Merck & Co,Large Pharma,1585,Isentress,raltegravir,Small Molecule (Chemical),Launched,In-House,Oct-07,Nov-07,Oct-23,Oct-22,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,572,HIV,7/7/14 12:28
860,61,Merck & Co,Large Pharma,1585,Isentress,raltegravir,Small Molecule (Chemical),Launched,In-House,Oct-07,Nov-07,Oct-23,Oct-22,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Sales,382,536,678,692,761,648,467,318,198,117,78,27.15,-37.8847712,572,HIV,7/7/14 12:28
860,61,Merck & Co,Large Pharma,1585,Isentress,raltegravir,Small Molecule (Chemical),Launched,In-House,Oct-07,Nov-07,Oct-23,Oct-22,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,572,HIV,7/7/14 12:28
860,61,Merck & Co,Large Pharma,1585,Isentress,raltegravir,Small Molecule (Chemical),Launched,In-House,Oct-07,Nov-07,Oct-23,Oct-22,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,US,Sales,370,554,681,822,882,779,443,350,159,141,119,78.05,-29.2774501,572,HIV,7/7/14 12:28
861,1,Abbott,Regional & Specialty Pharma,292,Isoptin,verapamil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-97,Aug-93,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,573,Hypertension,7/7/14 12:28
861,1,Abbott,Regional & Specialty Pharma,292,Isoptin,verapamil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-97,Aug-93,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,122,117.128,110.2412,105.43156,99.32206,94.88229,90.435243,85.9931205,81.54999115,77.10638033,72.66321161,68.21991813,-5.224716715,573,Hypertension,7/7/14 12:28
861,1,Abbott,Regional & Specialty Pharma,292,Isoptin,verapamil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-97,Aug-93,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,573,Hypertension,7/7/14 12:28
861,1,Abbott,Regional & Specialty Pharma,292,Isoptin,verapamil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-97,Aug-93,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,117,112.628,108.2412,103.7554,99.32206,94.88229,90.435243,85.9931205,81.54999115,77.10638033,72.66321161,68.21991813,-5.224716715,573,Hypertension,7/7/14 12:28
861,1,Abbott,Regional & Specialty Pharma,292,Isoptin,verapamil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-97,Aug-93,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,573,Hypertension,7/7/14 12:28
861,1,Abbott,Regional & Specialty Pharma,292,Isoptin,verapamil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-97,Aug-93,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,5,4.5,2,1.67616,0,0,0,0,0,0,0,0,0,573,Hypertension,7/7/14 12:28
862,24,Bristol-Myers Squibb,Large Pharma,1661,Ixempra,ixabepilone,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,Jul-08,Mar-21,Jun-18,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,576,Breast Cancer,7/7/14 12:28
862,24,Bristol-Myers Squibb,Large Pharma,1661,Ixempra,ixabepilone,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,Jul-08,Mar-21,Jun-18,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Sales,109,116.5,114,110.5,106.5,102.25,97.875,93.4375,88.96875,84.484375,79.9921875,75.49609375,-4.796355338,576,Breast Cancer,7/7/14 12:28
862,24,Bristol-Myers Squibb,Large Pharma,1661,Ixempra,ixabepilone,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,Jul-08,Mar-21,Jun-18,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,576,Breast Cancer,7/7/14 12:28
862,24,Bristol-Myers Squibb,Large Pharma,1661,Ixempra,ixabepilone,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,Jul-08,Mar-21,Jun-18,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Sales,10,18,20,21,21.5,21.75,21.875,21.9375,21.96875,21.984375,21.9921875,21.99609375,0.326416193,576,Breast Cancer,7/7/14 12:28
862,24,Bristol-Myers Squibb,Large Pharma,1661,Ixempra,ixabepilone,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,Jul-08,Mar-21,Jun-18,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,576,Breast Cancer,7/7/14 12:28
862,24,Bristol-Myers Squibb,Large Pharma,1661,Ixempra,ixabepilone,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,Jul-08,Mar-21,Jun-18,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Sales,99,98.5,94,89.5,85,80.5,76,71.5,67,62.5,58,53.5,-6.399873267,576,Breast Cancer,7/7/14 12:28
863,67,Novartis,Large Pharma,770,Ixiaro,Japanese Encephalitis Virus vaccine,Vaccine,Launched,Licensed (Development),May-09,May-09,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,577,Japanese Encephalitis,7/7/14 12:28
863,67,Novartis,Large Pharma,770,Ixiaro,Japanese Encephalitis Virus vaccine,Vaccine,Launched,Licensed (Development),May-09,May-09,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,9.5,30.083365,53.83327917,77.58344527,85.67430087,91.62352558,95.42209252,97.41052318,98.65993761,99.40604926,99.83850279,100.099509,2.24791785,577,Japanese Encephalitis,7/7/14 12:28
863,67,Novartis,Large Pharma,770,Ixiaro,Japanese Encephalitis Virus vaccine,Vaccine,Launched,Licensed (Development),May-09,May-09,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,577,Japanese Encephalitis,7/7/14 12:28
863,67,Novartis,Large Pharma,770,Ixiaro,Japanese Encephalitis Virus vaccine,Vaccine,Launched,Licensed (Development),May-09,May-09,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,5,15.83335,28.33330482,40.83339225,45.0917373,48.0244537,49.85981142,50.7870184,51.34728233,51.67116029,51.85157114,51.9563687,2.044988256,577,Japanese Encephalitis,7/7/14 12:28
863,67,Novartis,Large Pharma,770,Ixiaro,Japanese Encephalitis Virus vaccine,Vaccine,Launched,Licensed (Development),May-09,May-09,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,577,Japanese Encephalitis,7/7/14 12:28
863,67,Novartis,Large Pharma,770,Ixiaro,Japanese Encephalitis Virus vaccine,Vaccine,Launched,Licensed (Development),May-09,May-09,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,4.5,14.250015,25.49997434,36.75005302,40.58256357,43.59907187,45.56228109,46.62350478,47.31265528,47.73488896,47.98693166,48.14314028,2.470596935,577,Japanese Encephalitis,7/7/14 12:28
864,61,Merck & Co,Large Pharma,1478,Janumet / Janumet XR,sitagliptin + metformin / sitagliptin + metformin XR,Small Molecule (Chemical),Launched,In-House,Apr-07,Jul-08,Jul-22,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,578,Type II Diabetes,7/7/14 12:28
864,61,Merck & Co,Large Pharma,1478,Janumet / Janumet XR,sitagliptin + metformin / sitagliptin + metformin XR,Small Molecule (Chemical),Launched,In-House,Apr-07,Jul-08,Jul-22,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,Global,Sales,659,954,1363,1660,1829,1975.475,2093.36,2180.439125,2247.029225,2298.242313,2337.410397,2367.432766,3.75502025,578,Type II Diabetes,7/7/14 12:28
864,61,Merck & Co,Large Pharma,1478,Janumet / Janumet XR,sitagliptin + metformin / sitagliptin + metformin XR,Small Molecule (Chemical),Launched,In-House,Apr-07,Jul-08,Jul-22,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,578,Type II Diabetes,7/7/14 12:28
864,61,Merck & Co,Large Pharma,1478,Janumet / Janumet XR,sitagliptin + metformin / sitagliptin + metformin XR,Small Molecule (Chemical),Launched,In-House,Apr-07,Jul-08,Jul-22,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Sales,187,378,651,795,951,1068,1155.75,1221.5625,1270.921875,1307.941406,1335.706055,1356.529541,5.204789584,578,Type II Diabetes,7/7/14 12:28
864,61,Merck & Co,Large Pharma,1478,Janumet / Janumet XR,sitagliptin + metformin / sitagliptin + metformin XR,Small Molecule (Chemical),Launched,In-House,Apr-07,Jul-08,Jul-22,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,578,Type II Diabetes,7/7/14 12:28
864,61,Merck & Co,Large Pharma,1478,Janumet / Janumet XR,sitagliptin + metformin / sitagliptin + metformin XR,Small Molecule (Chemical),Launched,In-House,Apr-07,Jul-08,Jul-22,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,US,Sales,472,576,712,865,878,907.475,937.61,958.876625,976.10735,990.3009069,1001.704342,1010.903225,2.034020725,578,Type II Diabetes,7/7/14 12:28
865,61,Merck & Co,Large Pharma,1290,Januvia,sitagliptin,Small Molecule (Chemical),Launched,In-House,Oct-06,Apr-07,Jul-22,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1636,Type II Diabetes,7/7/14 12:28
865,61,Merck & Co,Large Pharma,1290,Januvia,sitagliptin,Small Molecule (Chemical),Launched,In-House,Oct-06,Apr-07,Jul-22,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,Global,Sales,1922,2385,3323,4086,4003,3977.71,3961.924025,3952.896333,3947.726386,3865.166965,3743.852123,3604.650353,-1.486261583,1636,Type II Diabetes,7/7/14 12:28
865,61,Merck & Co,Large Pharma,1290,Januvia,sitagliptin,Small Molecule (Chemical),Launched,In-House,Oct-06,Apr-07,Jul-22,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1636,Type II Diabetes,7/7/14 12:28
865,61,Merck & Co,Large Pharma,1290,Januvia,sitagliptin,Small Molecule (Chemical),Launched,In-House,Oct-06,Apr-07,Jul-22,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Sales,518,822,1499,1950,1935,1936.66,1936.8254,1936.873426,1936.884205,1917.517866,1898.149575,1840.043085,-0.716255274,1636,Type II Diabetes,7/7/14 12:28
865,61,Merck & Co,Large Pharma,1290,Januvia,sitagliptin,Small Molecule (Chemical),Launched,In-House,Oct-06,Apr-07,Jul-22,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1636,Type II Diabetes,7/7/14 12:28
865,61,Merck & Co,Large Pharma,1290,Januvia,sitagliptin,Small Molecule (Chemical),Launched,In-House,Oct-06,Apr-07,Jul-22,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,US,Sales,1404,1563,1824,2136,2068,2041.05,2025.098625,2016.022907,2010.842181,1947.649099,1845.702548,1764.607268,-2.240988902,1636,Type II Diabetes,7/7/14 12:28
866,78,Pierre Fabre,Regional & Specialty Pharma,391,Javlor,vinflunine,Small Molecule (Chemical),Launched,In-House,,Dec-09,N/A,Sep-19,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,Global,Sales,3.461005999,14.45342,19.67686,26.47971,30.91989275,33.52520098,35.56710939,36.82430761,37.70542425,38.31847399,38.72962374,39.0124803,3.376932296,579,Bladder Cancer,7/7/14 12:28
866,78,Pierre Fabre,Regional & Specialty Pharma,391,Javlor,vinflunine,Small Molecule (Chemical),Launched,In-House,,Dec-09,N/A,Sep-19,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,ROW,Sales,3.461005999,14.45342,19.67686,26.47971,30.91989275,33.52520098,35.56710939,36.82430761,37.70542425,38.31847399,38.72962374,39.0124803,3.376932296,579,Bladder Cancer,7/7/14 12:28
866,78,Pierre Fabre,Regional & Specialty Pharma,391,Javlor,vinflunine,Small Molecule (Chemical),Launched,In-House,,Dec-09,N/A,Sep-19,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,579,Bladder Cancer,7/7/14 12:28
872,53,Johnson & Johnson,Large Pharma,2108,Invokana / Vokanamet,canagliflozin / canagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),May-13,Sep-13,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1373,Type II Diabetes,7/7/14 12:28
872,53,Johnson & Johnson,Large Pharma,2108,Invokana / Vokanamet,canagliflozin / canagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),May-13,Sep-13,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,54.999995,232.2583147,586.4494924,1029.3,1341.666086,1596.160019,1839.815565,2059.621436,67.79334812,1373,Type II Diabetes,7/7/14 12:28
872,53,Johnson & Johnson,Large Pharma,2108,Invokana / Vokanamet,canagliflozin / canagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),May-13,Sep-13,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1373,Type II Diabetes,7/7/14 12:28
872,53,Johnson & Johnson,Large Pharma,2108,Invokana / Vokanamet,canagliflozin / canagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),May-13,Sep-13,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,4.999995,37.33331467,119.2499404,191.4,243.2000092,289.5600191,329.338699,364.4885748,84.54478786,1373,Type II Diabetes,7/7/14 12:28
872,53,Johnson & Johnson,Large Pharma,2108,Invokana / Vokanamet,canagliflozin / canagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),May-13,Sep-13,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1373,Type II Diabetes,7/7/14 12:28
872,53,Johnson & Johnson,Large Pharma,2108,Invokana / Vokanamet,canagliflozin / canagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),May-13,Sep-13,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,50,194.925,467.199552,837.9,1098.466077,1306.6,1510.476866,1695.132861,65.42631714,1373,Type II Diabetes,7/7/14 12:28
874,53,Johnson & Johnson,Large Pharma,1529,JNJ-37822681,JNJ-37822681,Small Molecule (Chemical),Phase II,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,584,Schizophrenia,7/7/14 12:28
874,53,Johnson & Johnson,Large Pharma,1529,JNJ-37822681,JNJ-37822681,Small Molecule (Chemical),Phase II,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,584,Schizophrenia,7/7/14 12:28
874,53,Johnson & Johnson,Large Pharma,1529,JNJ-37822681,JNJ-37822681,Small Molecule (Chemical),Phase II,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,584,Schizophrenia,7/7/14 12:28
874,53,Johnson & Johnson,Large Pharma,1529,JNJ-37822681,JNJ-37822681,Small Molecule (Chemical),Phase II,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,584,Schizophrenia,7/7/14 12:28
874,53,Johnson & Johnson,Large Pharma,1529,JNJ-37822681,JNJ-37822681,Small Molecule (Chemical),Phase II,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,584,Schizophrenia,7/7/14 12:28
874,53,Johnson & Johnson,Large Pharma,1529,JNJ-37822681,JNJ-37822681,Small Molecule (Chemical),Phase II,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,584,Schizophrenia,7/7/14 12:28
876,111,Actavis,Regional & Specialty Pharma,1720,Kadian,morphine - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-96,,Nov-11,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,6.5,23,18,13,10,8,7,6,5.85,-17.76414122,1551,Pain,7/7/14 12:28
876,111,Actavis,Regional & Specialty Pharma,1720,Kadian,morphine - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-96,,Nov-11,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1551,Pain,7/7/14 12:28
876,111,Actavis,Regional & Specialty Pharma,1720,Kadian,morphine - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-96,,Nov-11,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,6.5,23,18,13,10,8,7,6,5.85,-17.76414122,1551,Pain,7/7/14 12:28
876,111,Actavis (legacy),Regional & Specialty Pharma,1720,Kadian,morphine - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-96,,Nov-11,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Proforma,218,224,217,32.5,0,0,0,0,0,0,0,0,0,1551,Pain,7/7/14 12:28
876,111,Actavis (legacy),Regional & Specialty Pharma,1720,Kadian,morphine - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-96,,Nov-11,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Proforma,218,224,217,32.5,0,0,0,0,0,0,0,0,0,1551,Pain,7/7/14 12:28
877,2221,AbbVie,Large Pharma,82,Kaletra,lopinavir  +  ritonavir,Small Molecule (Chemical),Launched,In-House,Sep-00,Feb-02,Jun-16,Dec-16,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,589,HIV,7/7/14 12:28
877,2221,AbbVie,Large Pharma,82,Kaletra,lopinavir  +  ritonavir,Small Molecule (Chemical),Launched,In-House,Sep-00,Feb-02,Jun-16,Dec-16,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,962,833,754,633.81,291.369,215.65326,168.8442566,135.8424338,-24.39481079,589,HIV,7/7/14 12:28
877,2221,AbbVie,Large Pharma,82,Kaletra,lopinavir  +  ritonavir,Small Molecule (Chemical),Launched,In-House,Sep-00,Feb-02,Jun-16,Dec-16,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,589,HIV,7/7/14 12:28
877,2221,AbbVie,Large Pharma,82,Kaletra,lopinavir  +  ritonavir,Small Molecule (Chemical),Launched,In-House,Sep-00,Feb-02,Jun-16,Dec-16,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,718,632,588,538.905,257.664,197.1294,158.366325,130.3837662,-21.62868807,589,HIV,7/7/14 12:28
877,2221,AbbVie,Large Pharma,82,Kaletra,lopinavir  +  ritonavir,Small Molecule (Chemical),Launched,In-House,Sep-00,Feb-02,Jun-16,Dec-16,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,589,HIV,7/7/14 12:28
877,2221,AbbVie,Large Pharma,82,Kaletra,lopinavir  +  ritonavir,Small Molecule (Chemical),Launched,In-House,Sep-00,Feb-02,Jun-16,Dec-16,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,244,201,166,94.905,33.705,18.52386,10.47793162,5.458667616,-41.89110202,589,HIV,7/7/14 12:28
878,100,Takeda,Large Pharma,2438,Dexilant,dexlansoprazole,Small Molecule (Chemical),Launched,Licensed (Development),Feb-09,Nov-13,Dec-20,Jun-20,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,367,GERD,7/7/14 12:28
878,100,Takeda,Large Pharma,2438,Dexilant,dexlansoprazole,Small Molecule (Chemical),Launched,Licensed (Development),Feb-09,Nov-13,Dec-20,Jun-20,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,91.57270738,211.278292,305.1460153,393.6668198,485.3418724,567.1682041,645.7188199,713.8315884,754.0426373,784.8202358,807.4076298,823.1708715,7.83939161,367,GERD,7/7/14 12:28
878,100,Takeda,Large Pharma,2438,Dexilant,dexlansoprazole,Small Molecule (Chemical),Launched,Licensed (Development),Feb-09,Nov-13,Dec-20,Jun-20,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,367,GERD,7/7/14 12:28
878,100,Takeda,Large Pharma,2438,Dexilant,dexlansoprazole,Small Molecule (Chemical),Launched,Licensed (Development),Feb-09,Nov-13,Dec-20,Jun-20,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,8.437799964,34.31374798,68.06509363,101.8165316,121.122319,137.0394755,149.3398367,158.2117278,52.00515296,367,GERD,7/7/14 12:28
878,100,Takeda,Large Pharma,2438,Dexilant,dexlansoprazole,Small Molecule (Chemical),Launched,Licensed (Development),Feb-09,Nov-13,Dec-20,Jun-20,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,367,GERD,7/7/14 12:28
878,100,Takeda,Large Pharma,2438,Dexilant,dexlansoprazole,Small Molecule (Chemical),Launched,Licensed (Development),Feb-09,Nov-13,Dec-20,Jun-20,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,91.57270738,211.278292,305.1460153,393.6668198,476.9040724,532.8544561,577.6537263,612.0150568,632.9203183,647.7807603,658.067793,664.9591437,4.863270418,367,GERD,7/7/14 12:28
881,73,Otsuka,Regional & Specialty Pharma,3564,E Keppra,levetiracetam,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-10,N/A,Dec-19,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1519,Epilepsy,7/7/14 12:28
881,73,Otsuka,Regional & Specialty Pharma,3564,E Keppra,levetiracetam,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-10,N/A,Dec-19,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,Global,Sales,0,9.338267051,60.77596986,126.406777,161.0835559,181.2190004,200.297334,213.6244813,221.8315626,227.7902384,230.6844659,210.6452566,3.906545995,1519,Epilepsy,7/7/14 12:28
881,73,Otsuka,Regional & Specialty Pharma,3564,E Keppra,levetiracetam,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-10,N/A,Dec-19,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1519,Epilepsy,7/7/14 12:28
881,73,Otsuka,Regional & Specialty Pharma,3564,E Keppra,levetiracetam,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-10,N/A,Dec-19,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,ROW,Sales,0,9.338267051,60.77596986,126.406777,161.0835559,181.2190004,200.297334,213.6244813,221.8315626,227.7902384,230.6844659,210.6452566,3.906545995,1519,Epilepsy,7/7/14 12:28
881,73,Otsuka,Regional & Specialty Pharma,3564,E Keppra,levetiracetam,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-10,N/A,Dec-19,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1519,Epilepsy,7/7/14 12:28
881,73,Otsuka,Regional & Specialty Pharma,3564,E Keppra,levetiracetam,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-10,N/A,Dec-19,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1519,Epilepsy,7/7/14 12:28
882,105,UCB,Regional & Specialty Pharma,1088,Keppra,levetiracetam,Small Molecule (Chemical),Launched,In-House,Apr-00,May-00,Nov-08,Sep-10,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1519,Epilepsy,7/7/14 12:28
882,105,UCB,Regional & Specialty Pharma,1088,Keppra,levetiracetam,Small Molecule (Chemical),Launched,In-House,Apr-00,May-00,Nov-08,Sep-10,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,Global,Sales,1268.612042,1247.919031,1343.162178,1077.057371,945.5574074,880.5702562,838.3008189,811.056696,794.5823647,783.7761643,776.4296266,771.2814221,-2.868359777,1519,Epilepsy,7/7/14 12:28
882,105,UCB,Regional & Specialty Pharma,1088,Keppra,levetiracetam,Small Molecule (Chemical),Launched,In-House,Apr-00,May-00,Nov-08,Sep-10,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1519,Epilepsy,7/7/14 12:28
882,105,UCB,Regional & Specialty Pharma,1088,Keppra,levetiracetam,Small Molecule (Chemical),Launched,In-House,Apr-00,May-00,Nov-08,Sep-10,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,ROW,Sales,823.9725528,879.6371938,1026.142534,773.7333383,649.4067026,596.8698332,562.9296344,543.2207333,532.8855504,527.0573791,523.8103204,522.021483,-3.071140968,1519,Epilepsy,7/7/14 12:28
882,105,UCB,Regional & Specialty Pharma,1088,Keppra,levetiracetam,Small Molecule (Chemical),Launched,In-House,Apr-00,May-00,Nov-08,Sep-10,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1519,Epilepsy,7/7/14 12:28
882,105,UCB,Regional & Specialty Pharma,1088,Keppra,levetiracetam,Small Molecule (Chemical),Launched,In-House,Apr-00,May-00,Nov-08,Sep-10,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,US,Sales,444.6394888,368.2818372,317.0196446,303.324033,296.1507049,283.700423,275.3711845,267.8359627,261.6968143,256.7187853,252.6193061,249.2599391,-2.432386092,1519,Epilepsy,7/7/14 12:28
884,19,Bayer,Large Pharma,291,Kogenate,octocog alfa,Recombinant Protein,Launched,Licensed (Development),Jun-93,Jun-93,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,591,Hemophilia A,7/7/14 12:28
884,19,Bayer,Large Pharma,291,Kogenate,octocog alfa,Recombinant Protein,Launched,Licensed (Development),Jun-93,Jun-93,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,Global,Sales,1233.874582,1330.053829,1494.719815,1519.65371,1596.29214,1594.588351,1596.383964,1591.699627,1575.159151,1555.448885,1537.166976,1522.922541,-0.669921202,591,Hemophilia A,7/7/14 12:28
884,19,Bayer,Large Pharma,291,Kogenate,octocog alfa,Recombinant Protein,Launched,Licensed (Development),Jun-93,Jun-93,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,591,Hemophilia A,7/7/14 12:28
884,19,Bayer,Large Pharma,291,Kogenate,octocog alfa,Recombinant Protein,Launched,Licensed (Development),Jun-93,Jun-93,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,ROW,Sales,886.4999809,933.952141,1091.493074,1092.94363,1158.042218,1155.026308,1155.013105,1154.348669,1143.871121,1128.806258,1116.931685,1107.433175,-0.636336881,591,Hemophilia A,7/7/14 12:28
884,19,Bayer,Large Pharma,291,Kogenate,octocog alfa,Recombinant Protein,Launched,Licensed (Development),Jun-93,Jun-93,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,591,Hemophilia A,7/7/14 12:28
884,19,Bayer,Large Pharma,291,Kogenate,octocog alfa,Recombinant Protein,Launched,Licensed (Development),Jun-93,Jun-93,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,US,Sales,347.3746007,396.1016882,403.2267409,426.7100803,438.249922,439.5620422,441.370859,437.3509585,431.2880298,426.6426272,420.2352911,415.4893664,-0.758994561,591,Hemophilia A,7/7/14 12:28
886,34,Daiichi-Sankyo,Regional & Specialty Pharma,1422,Kremezin,carbonaceous absorbent,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-92,N/A,Expired,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1379,Chronic Renal Failure,7/7/14 12:28
886,34,Daiichi-Sankyo,Regional & Specialty Pharma,1422,Kremezin,carbonaceous absorbent,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-92,N/A,Expired,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,7,Global,Sales,143.2843539,163.4196734,0,0,0,0,0,0,0,0,0,0,0,1379,Chronic Renal Failure,7/7/14 12:28
886,34,Daiichi-Sankyo,Regional & Specialty Pharma,1422,Kremezin,carbonaceous absorbent,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-92,N/A,Expired,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1379,Chronic Renal Failure,7/7/14 12:28
886,34,Daiichi-Sankyo,Regional & Specialty Pharma,1422,Kremezin,carbonaceous absorbent,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-92,N/A,Expired,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,7,ROW,Sales,143.2843539,163.4196734,0,0,0,0,0,0,0,0,0,0,0,1379,Chronic Renal Failure,7/7/14 12:28
886,34,Daiichi-Sankyo,Regional & Specialty Pharma,1422,Kremezin,carbonaceous absorbent,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-92,N/A,Expired,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1379,Chronic Renal Failure,7/7/14 12:28
886,34,Daiichi-Sankyo,Regional & Specialty Pharma,1422,Kremezin,carbonaceous absorbent,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-92,N/A,Expired,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1379,Chronic Renal Failure,7/7/14 12:28
888,63,Merck KGaA,Regional & Specialty Pharma,93,Kuvan,sapropterin,Small Molecule (Chemical),Launched,Licensed (Development),Dec-07,Apr-09,Nov-24,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1629,Phenylketonuria,7/7/14 12:28
888,63,Merck KGaA,Regional & Specialty Pharma,93,Kuvan,sapropterin,Small Molecule (Chemical),Launched,Licensed (Development),Dec-07,Apr-09,Nov-24,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,Global,Sales,7.781191055,26.4950962,47.27485928,62.10177459,76.74257118,89.31081486,99.602255,108.7471741,116.8860064,123.9829503,130.2382347,135.7458281,8.488641538,1629,Phenylketonuria,7/7/14 12:28
888,63,Merck KGaA,Regional & Specialty Pharma,93,Kuvan,sapropterin,Small Molecule (Chemical),Launched,Licensed (Development),Dec-07,Apr-09,Nov-24,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1629,Phenylketonuria,7/7/14 12:28
888,63,Merck KGaA,Regional & Specialty Pharma,93,Kuvan,sapropterin,Small Molecule (Chemical),Launched,Licensed (Development),Dec-07,Apr-09,Nov-24,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,ROW,Sales,7.781191055,26.4950962,47.27485928,62.10177459,76.74257118,89.31081486,99.602255,108.7471741,116.8860064,123.9829503,130.2382347,135.7458281,8.488641538,1629,Phenylketonuria,7/7/14 12:28
888,63,Merck KGaA,Regional & Specialty Pharma,93,Kuvan,sapropterin,Small Molecule (Chemical),Launched,Licensed (Development),Dec-07,Apr-09,Nov-24,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1629,Phenylketonuria,7/7/14 12:28
888,63,Merck KGaA,Regional & Specialty Pharma,93,Kuvan,sapropterin,Small Molecule (Chemical),Launched,Licensed (Development),Dec-07,Apr-09,Nov-24,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1629,Phenylketonuria,7/7/14 12:28
890,25,Cardiome,Regional & Specialty Pharma,2612,Brinavess,vernakalant hydrochloride,Small Molecule (Chemical),Launched,In-House,,Oct-10,N/A,N/A,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,8,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1682,Atrial Fibrillation,7/7/14 12:28
890,25,Cardiome,Regional & Specialty Pharma,2612,Brinavess,vernakalant hydrochloride,Small Molecule (Chemical),Launched,In-House,,Oct-10,N/A,N/A,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,8,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1682,Atrial Fibrillation,7/7/14 12:28
890,25,Cardiome,Regional & Specialty Pharma,2612,Brinavess,vernakalant hydrochloride,Small Molecule (Chemical),Launched,In-House,,Oct-10,N/A,N/A,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,8,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1682,Atrial Fibrillation,7/7/14 12:28
890,25,Cardiome,Regional & Specialty Pharma,2612,Brinavess,vernakalant hydrochloride,Small Molecule (Chemical),Launched,In-House,,Oct-10,N/A,N/A,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,8,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1682,Atrial Fibrillation,7/7/14 12:28
890,25,Cardiome,Regional & Specialty Pharma,2612,Brinavess,vernakalant hydrochloride,Small Molecule (Chemical),Launched,In-House,,Oct-10,N/A,N/A,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,8,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1682,Atrial Fibrillation,7/7/14 12:28
890,25,Cardiome,Regional & Specialty Pharma,2612,Brinavess,vernakalant hydrochloride,Small Molecule (Chemical),Launched,In-House,,Oct-10,N/A,N/A,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,8,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1682,Atrial Fibrillation,7/7/14 12:28
891,29,Chugai,Regional & Specialty Pharma,1550,Kytril,granisetron,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-92,N/A,Jul-07,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,Global,Alliance Revenue,91.91004571,62.67389632,42.64708803,30.06765222,22.85141569,20.79251761,20.01900622,19.5039398,19.25656203,19.11478074,19.04117279,17.42323959,-3.800303416,1488,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
891,29,Chugai,Regional & Specialty Pharma,1550,Kytril,granisetron,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-92,N/A,Jul-07,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,ROW,Alliance Revenue,91.91004571,62.67389632,42.64708803,30.06765222,22.85141569,20.79251761,20.01900622,19.5039398,19.25656203,19.11478074,19.04117279,17.42323959,-3.800303416,1488,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
891,29,Chugai,Regional & Specialty Pharma,1550,Kytril,granisetron,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-92,N/A,Jul-07,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1488,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
892,86,Roche,Large Pharma,1550,Kytril,granisetron,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-91,Feb-91,Dec-07,Expired,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1488,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
892,86,Roche,Large Pharma,1550,Kytril,granisetron,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-91,Feb-91,Dec-07,Jul-07,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,5,Global,Sales,172.4560976,123.3417892,95.18543336,68.7147518,54.42699985,47.36013372,43.16991855,40.3343999,38.50516865,37.28165417,36.46956699,34.34696781,-6.364793527,1488,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
892,86,Roche,Large Pharma,1550,Kytril,granisetron,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-91,Feb-91,Dec-07,Expired,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1488,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
892,86,Roche,Large Pharma,1550,Kytril,granisetron,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-91,Feb-91,Dec-07,Jul-07,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,5,ROW,Sales,160.1410428,115.6440661,89.2880347,63.57278485,49.51048831,42.53158782,38.36330677,35.53725114,33.71091038,32.48826299,31.67649514,29.55399575,-7.105829694,1488,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
892,86,Roche,Large Pharma,1550,Kytril,granisetron,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-91,Feb-91,Dec-07,Expired,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1488,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
892,86,Roche,Large Pharma,1550,Kytril,granisetron,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-91,Feb-91,Dec-07,Expired,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,5,US,Sales,12.31505478,7.697723039,5.897398655,5.141966944,4.916511543,4.8285459,4.806611785,4.79714876,4.794258272,4.793391175,4.793071845,4.792972056,-0.362890351,1488,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
896,46,GlaxoSmithKline,Large Pharma,9,Lamictal,lamotrigine,Small Molecule (Chemical),Launched,In-House,May-95,Sep-97,Jul-08,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,605,Epilepsy,7/7/14 12:28
896,46,GlaxoSmithKline,Large Pharma,9,Lamictal,lamotrigine,Small Molecule (Chemical),Launched,In-House,May-95,Sep-97,Jul-08,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,4,Global,Sales,779.6308448,778.6800292,859.3048608,966.8676131,870.8216136,812.1623193,776.2563274,766.1397129,761.8434772,752.1731713,745.6123845,740.7547864,-2.284463782,605,Epilepsy,7/7/14 12:28
896,46,GlaxoSmithKline,Large Pharma,9,Lamictal,lamotrigine,Small Molecule (Chemical),Launched,In-House,May-95,Sep-97,Jul-08,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,605,Epilepsy,7/7/14 12:28
896,46,GlaxoSmithKline,Large Pharma,9,Lamictal,lamotrigine,Small Molecule (Chemical),Launched,In-House,May-95,Sep-97,Jul-08,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,4,ROW,Sales,363.3079737,381.6150143,415.223804,440.638027,439.3193419,443.1966087,444.8125535,445.6398372,446.0338435,437.3015861,432.9295789,428.5097368,-0.355268754,605,Epilepsy,7/7/14 12:28
896,46,GlaxoSmithKline,Large Pharma,9,Lamictal,lamotrigine,Small Molecule (Chemical),Launched,In-House,May-95,Sep-97,Jul-08,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,605,Epilepsy,7/7/14 12:28
896,46,GlaxoSmithKline,Large Pharma,9,Lamictal,lamotrigine,Small Molecule (Chemical),Launched,In-House,May-95,Sep-97,Jul-08,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,4,US,Sales,416.3228711,397.0650149,444.0810568,526.2295861,431.5022717,368.9657106,331.4437739,320.4998757,315.8096337,314.8715852,312.6828056,312.2450497,-4.516050661,605,Epilepsy,7/7/14 12:28
897,67,Novartis,Large Pharma,1573,Lamisil,terbinafine,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-91,Jun-07,Aug-05,60,Other Anti-fungals,25,Fungal Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,606,,7/7/14 12:28
897,67,Novartis,Large Pharma,1573,Lamisil,terbinafine,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-91,Jun-07,Aug-05,60,Other Anti-fungals,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,221.43,166.4366,165.699668,159.1386863,152.3468812,149.6773445,146.6680896,144.2450221,142.4408703,140.8910295,139.6364557,138.6213797,-1.339710765,606,,7/7/14 12:28
897,67,Novartis,Large Pharma,1573,Lamisil,terbinafine,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-91,Jun-07,Aug-05,60,Other Anti-fungals,25,Fungal Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,606,,7/7/14 12:28
897,67,Novartis,Large Pharma,1573,Lamisil,terbinafine,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-91,Jun-07,Aug-05,60,Other Anti-fungals,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,192.71,151.223,160,153.60532,147.402172,145.1169674,142.1192295,139.7216876,137.9330943,136.3839195,135.1304479,134.1160031,-1.340357563,606,,7/7/14 12:28
897,67,Novartis,Large Pharma,1573,Lamisil,terbinafine,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-91,Jun-07,Aug-05,60,Other Anti-fungals,25,Fungal Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,606,,7/7/14 12:28
897,67,Novartis,Large Pharma,1573,Lamisil,terbinafine,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-91,Jun-07,Aug-05,60,Other Anti-fungals,25,Fungal Infection,7,Anti-infectives,6,US,Sales,28.72,15.2136,5.699668,5.53336634,4.944709172,4.560377098,4.548860085,4.523334553,4.507776057,4.507109956,4.506007812,4.505376631,-1.320441337,606,,7/7/14 12:28
898,89,Sanofi,Large Pharma,305,Lantus,insulin glargine,Recombinant Protein,Launched,Corporate Acquisition,May-01,Jun-00,Jul-16,Dec-14,83,Insulins,22,Diabetes,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1498,Diabetes,7/7/14 12:28
898,89,Sanofi,Large Pharma,305,Lantus,insulin glargine,Recombinant Protein,Launched,Corporate Acquisition,May-01,Jun-00,Jul-16,Dec-14,83,Insulins,22,Diabetes,8,Metabolism,2,Global,Sales,4279.65508,4649.889383,5444.951439,6375.480161,7589.691831,8243.852671,8853.886491,9078.079961,9224.124545,9306.619772,9219.56749,9225.039903,2.826792621,1498,Diabetes,7/7/14 12:28
898,89,Sanofi,Large Pharma,305,Lantus,insulin glargine,Recombinant Protein,Launched,Corporate Acquisition,May-01,Jun-00,Jul-16,Dec-14,83,Insulins,22,Diabetes,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1498,Diabetes,7/7/14 12:28
898,89,Sanofi,Large Pharma,305,Lantus,insulin glargine,Recombinant Protein,Launched,Corporate Acquisition,May-01,Jun-00,Jul-16,Dec-14,83,Insulins,22,Diabetes,8,Metabolism,2,ROW,Sales,1627.10263,1822.862619,2196.890519,2407.313194,2613.563171,2714.026056,2806.610195,2830.674989,2845.27346,2865.873516,2865.47314,2898.133783,1.487416605,1498,Diabetes,7/7/14 12:28
898,89,Sanofi,Large Pharma,305,Lantus,insulin glargine,Recombinant Protein,Launched,Corporate Acquisition,May-01,Jun-00,Jul-16,Dec-14,83,Insulins,22,Diabetes,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1498,Diabetes,7/7/14 12:28
898,89,Sanofi,Large Pharma,305,Lantus,insulin glargine,Recombinant Protein,Launched,Corporate Acquisition,May-01,Jun-00,Jul-16,Dec-14,83,Insulins,22,Diabetes,8,Metabolism,2,US,Sales,2652.552451,2827.026764,3248.06092,3968.166967,4976.12866,5529.826615,6047.276296,6247.404972,6378.851085,6440.746256,6354.09435,6326.906121,3.490373674,1498,Diabetes,7/7/14 12:28
899,102,Teva,Regional & Specialty Pharma,417,Nerventra,laquinimod,Small Molecule (Chemical),Filed,Licensed (Development),Jan-18,Jul-18,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1511,Multiple Sclerosis,7/7/14 12:28
899,102,Teva,Regional & Specialty Pharma,417,Nerventra,laquinimod,Small Molecule (Chemical),Filed,Licensed (Development),Jan-18,Jul-18,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,103.1,145.679569,207.0312796,0,1511,Multiple Sclerosis,7/7/14 12:28
899,102,Teva,Regional & Specialty Pharma,417,Nerventra,laquinimod,Small Molecule (Chemical),Filed,Licensed (Development),Jan-18,Jul-18,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1511,Multiple Sclerosis,7/7/14 12:28
899,102,Teva,Regional & Specialty Pharma,417,Nerventra,laquinimod,Small Molecule (Chemical),Filed,Licensed (Development),Jan-18,Jul-18,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,13.1,24.719569,35.13145146,0,1511,Multiple Sclerosis,7/7/14 12:28
899,102,Teva,Regional & Specialty Pharma,417,Nerventra,laquinimod,Small Molecule (Chemical),Filed,Licensed (Development),Jan-18,Jul-18,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1511,Multiple Sclerosis,7/7/14 12:28
899,102,Teva,Regional & Specialty Pharma,417,Nerventra,laquinimod,Small Molecule (Chemical),Filed,Licensed (Development),Jan-18,Jul-18,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,90,120.96,171.8998281,0,1511,Multiple Sclerosis,7/7/14 12:28
901,60,Menarini,Regional & Specialty Pharma,102,Latixa,ranolazine,Small Molecule (Chemical),Launched,Licensed (Development),,Mar-09,N/A,Aug-19,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,Global,Sales,6.947492,15.89706,26.4183,37.27517,46.01593601,53.6914469,60.68704506,66.52751669,71.77073065,76.38902513,68.36481127,50.39553629,1.30725285,1610,Angina,7/7/14 12:28
901,60,Menarini,Regional & Specialty Pharma,102,Latixa,ranolazine,Small Molecule (Chemical),Launched,Licensed (Development),,Mar-09,N/A,Aug-19,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,6.947492,15.89706,26.4183,37.27517,46.01593601,53.6914469,60.68704506,66.52751669,71.77073065,76.38902513,68.36481127,50.39553629,1.30725285,1610,Angina,7/7/14 12:28
901,60,Menarini,Regional & Specialty Pharma,102,Latixa,ranolazine,Small Molecule (Chemical),Launched,Licensed (Development),,Mar-09,N/A,Aug-19,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1610,Angina,7/7/14 12:28
903,67,Novartis,Large Pharma,1036,LCZ696,LCZ696,Small Molecule (Chemical),Phase III,In-House,Dec-15,May-15,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,614,Heart failure,7/7/14 12:28
903,67,Novartis,Large Pharma,1036,LCZ696,LCZ696,Small Molecule (Chemical),Phase III,In-House,Dec-15,May-15,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,24.5833305,157.1807529,366.2221374,618.5765719,807.7301186,995.152601,0,614,Heart failure,7/7/14 12:28
903,67,Novartis,Large Pharma,1036,LCZ696,LCZ696,Small Molecule (Chemical),Phase III,In-House,Dec-15,May-15,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,614,Heart failure,7/7/14 12:28
903,67,Novartis,Large Pharma,1036,LCZ696,LCZ696,Small Molecule (Chemical),Phase III,In-House,Dec-15,May-15,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,17.5,60.375,127.7498775,238.4374814,322.5687465,411.3156358,0,614,Heart failure,7/7/14 12:28
903,67,Novartis,Large Pharma,1036,LCZ696,LCZ696,Small Molecule (Chemical),Phase III,In-House,Dec-15,May-15,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,614,Heart failure,7/7/14 12:28
903,67,Novartis,Large Pharma,1036,LCZ696,LCZ696,Small Molecule (Chemical),Phase III,In-House,Dec-15,May-15,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,7.0833305,96.80575294,238.4722599,380.1390906,485.1613721,583.8369652,0,614,Heart failure,7/7/14 12:28
904,67,Novartis,Large Pharma,2819,Lescol / Lochol,fluvastatin,Small Molecule (Chemical),Launched,In-House,Jan-94,Jan-94,Apr-12,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,617,Lipid disorders,7/7/14 12:28
904,67,Novartis,Large Pharma,2819,Lescol / Lochol,fluvastatin,Small Molecule (Chemical),Launched,In-House,Jan-94,Jan-94,Apr-12,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,563,436,353.71,261.5775,204.96705,165.146361,136.8907456,115.6015942,99.43977835,86.9673333,77.31418992,69.81182189,-14.26109894,617,Lipid disorders,7/7/14 12:28
904,67,Novartis,Large Pharma,2819,Lescol / Lochol,fluvastatin,Small Molecule (Chemical),Launched,In-House,Jan-94,Jan-94,Apr-12,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,617,Lipid disorders,7/7/14 12:28
904,67,Novartis,Large Pharma,2819,Lescol / Lochol,fluvastatin,Small Molecule (Chemical),Launched,In-House,Jan-94,Jan-94,Apr-12,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,442,339,277.95,219.5775,177.96705,144.146361,118.2907456,97.96159424,82.18377835,69.8649333,60.27322992,52.79543789,-15.93636045,617,Lipid disorders,7/7/14 12:28
904,67,Novartis,Large Pharma,2819,Lescol / Lochol,fluvastatin,Small Molecule (Chemical),Launched,In-House,Jan-94,Jan-94,Apr-12,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,617,Lipid disorders,7/7/14 12:28
904,67,Novartis,Large Pharma,2819,Lescol / Lochol,fluvastatin,Small Molecule (Chemical),Launched,In-House,Jan-94,Jan-94,Apr-12,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,121,97,75.76,42,27,21,18.6,17.64,17.256,17.1024,17.04096,17.016384,-6.382363325,617,Lipid disorders,7/7/14 12:28
905,45,Gilead,Regional & Specialty Pharma,129,Letairis,ambrisentan,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,,Oct-15,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1339,Pulmonary Hypertension,7/7/14 12:28
905,45,Gilead,Regional & Specialty Pharma,129,Letairis,ambrisentan,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,,Oct-15,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Sales,183.95,240.28,293,410.05,519.97,569.38616,566.34656,118.209732,86.0183392,74.00720422,59.01036285,51.80402214,-28.06962681,1339,Pulmonary Hypertension,7/7/14 12:28
905,45,Gilead,Regional & Specialty Pharma,129,Letairis,ambrisentan,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,,Oct-15,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1339,Pulmonary Hypertension,7/7/14 12:28
905,45,Gilead,Regional & Specialty Pharma,129,Letairis,ambrisentan,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,,Oct-15,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1339,Pulmonary Hypertension,7/7/14 12:28
905,45,Gilead,Regional & Specialty Pharma,129,Letairis,ambrisentan,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,,Oct-15,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1339,Pulmonary Hypertension,7/7/14 12:28
905,45,Gilead,Regional & Specialty Pharma,129,Letairis,ambrisentan,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,,Oct-15,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Sales,183.95,240.28,293,410.05,519.97,569.38616,566.34656,118.209732,86.0183392,74.00720422,59.01036285,51.80402214,-28.06962681,1339,Pulmonary Hypertension,7/7/14 12:28
906,100,Takeda,Large Pharma,1642,Leuplin,leuprolide,Synthetic Peptide,Launched,In-House,,Jul-90,N/A,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Endometriosis,7/7/14 12:28
906,100,Takeda,Large Pharma,1642,Leuplin,leuprolide,Synthetic Peptide,Launched,In-House,,Jul-90,N/A,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,Global,Sales,66.27731712,64.33005883,79.12299709,72.88735036,73.58933748,70.47405572,73.29943394,70.47405572,69.95241835,69.60119513,68.67188682,68.21126843,-1.078291317,1517,Endometriosis,7/7/14 12:28
906,100,Takeda,Large Pharma,1642,Leuplin,leuprolide,Synthetic Peptide,Launched,In-House,,Jul-90,N/A,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Endometriosis,7/7/14 12:28
906,100,Takeda,Large Pharma,1642,Leuplin,leuprolide,Synthetic Peptide,Launched,In-House,,Jul-90,N/A,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,ROW,Sales,66.27731712,64.33005883,79.12299709,72.88735036,73.58933748,70.47405572,73.29943394,70.47405572,69.95241835,69.60119513,68.67188682,68.21126843,-1.078291317,1517,Endometriosis,7/7/14 12:28
906,100,Takeda,Large Pharma,1642,Leuplin,leuprolide,Synthetic Peptide,Launched,In-House,,Jul-90,N/A,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Endometriosis,7/7/14 12:28
906,100,Takeda,Large Pharma,1642,Leuplin,leuprolide,Synthetic Peptide,Launched,In-House,,Jul-90,N/A,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Endometriosis,7/7/14 12:28
907,100,Takeda,Large Pharma,1642,Leuplin,leuprolide,Synthetic Peptide,Launched,In-House,,Jul-99,N/A,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Prostate Cancer,7/7/14 12:28
907,100,Takeda,Large Pharma,1642,Leuplin,leuprolide,Synthetic Peptide,Launched,In-House,,Jul-99,N/A,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,7,Global,Sales,1249.698124,1284.01172,1452.292446,1383.609445,1238.329836,1253.23223,1265.664545,1269.69065,1271.907226,1272.789342,1273.214113,1273.396425,0.399712269,1517,Prostate Cancer,7/7/14 12:28
907,100,Takeda,Large Pharma,1642,Leuplin,leuprolide,Synthetic Peptide,Launched,In-House,,Jul-99,N/A,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Prostate Cancer,7/7/14 12:28
907,100,Takeda,Large Pharma,1642,Leuplin,leuprolide,Synthetic Peptide,Launched,In-House,,Jul-99,N/A,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,7,ROW,Sales,1249.698124,1284.01172,1452.292446,1383.609445,1238.329836,1253.23223,1265.664545,1269.69065,1271.907226,1272.789342,1273.214113,1273.396425,0.399712269,1517,Prostate Cancer,7/7/14 12:28
907,100,Takeda,Large Pharma,1642,Leuplin,leuprolide,Synthetic Peptide,Launched,In-House,,Jul-99,N/A,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Prostate Cancer,7/7/14 12:28
907,100,Takeda,Large Pharma,1642,Leuplin,leuprolide,Synthetic Peptide,Launched,In-House,,Jul-99,N/A,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Prostate Cancer,7/7/14 12:28
908,53,Johnson & Johnson,Large Pharma,1496,Levaquin / Floxin,levofloxacin / ofloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-97,Jul-97,Jun-11,N/A,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,620,,7/7/14 12:28
908,53,Johnson & Johnson,Large Pharma,1496,Levaquin / Floxin,levofloxacin / ofloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-97,Jul-97,Jun-11,N/A,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,1550,1357,623,75,60.648,52.68448,48.9893328,47.90384221,47.24291484,46.79075766,46.48812284,46.2840455,-3.787675689,620,,7/7/14 12:28
908,53,Johnson & Johnson,Large Pharma,1496,Levaquin / Floxin,levofloxacin / ofloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-97,Jul-97,Jun-11,N/A,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,620,,7/7/14 12:28
908,53,Johnson & Johnson,Large Pharma,1496,Levaquin / Floxin,levofloxacin / ofloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-97,Jul-97,Jun-11,N/A,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,72,45,44,40,36.15,34.4875,33.094375,32.11171875,31.49083594,31.0489043,30.74702334,30.54317507,-2.378897621,620,,7/7/14 12:28
908,53,Johnson & Johnson,Large Pharma,1496,Levaquin / Floxin,levofloxacin / ofloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-97,Jul-97,Jun-11,N/A,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,620,,7/7/14 12:28
908,53,Johnson & Johnson,Large Pharma,1496,Levaquin / Floxin,levofloxacin / ofloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-97,Jul-97,Jun-11,N/A,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,1478,1312,579,35,24.498,18.19698,15.8949578,15.79212346,15.7520789,15.74185336,15.7410995,15.74087043,-6.123497531,620,,7/7/14 12:28
909,68,Novo Nordisk,Regional & Specialty Pharma,328,Levemir,insulin detemir,Recombinant Protein,Launched,In-House,Mar-06,Mar-04,Jun-19,Sep-18,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,621,Diabetes,7/7/14 12:28
909,68,Novo Nordisk,Regional & Specialty Pharma,328,Levemir,insulin detemir,Recombinant Protein,Launched,In-House,Mar-06,Mar-04,Jun-19,Sep-18,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Sales,974.622131,1223.780111,1433.843599,1689.86361,2056.030664,2258.656608,2435.138723,2539.580675,2612.990439,2607.631431,2573.906232,2523.566395,2.970341075,621,Diabetes,7/7/14 12:28
909,68,Novo Nordisk,Regional & Specialty Pharma,328,Levemir,insulin detemir,Recombinant Protein,Launched,In-House,Mar-06,Mar-04,Jun-19,Sep-18,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,621,Diabetes,7/7/14 12:28
909,68,Novo Nordisk,Regional & Specialty Pharma,328,Levemir,insulin detemir,Recombinant Protein,Launched,In-House,Mar-06,Mar-04,Jun-19,Sep-18,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Sales,529.3898115,678.0595614,775.9887651,822.0538108,901.93966,933.9182645,965.6081681,972.6921923,979.9848706,970.5483711,942.581579,923.1505438,0.33261879,621,Diabetes,7/7/14 12:28
909,68,Novo Nordisk,Regional & Specialty Pharma,328,Levemir,insulin detemir,Recombinant Protein,Launched,In-House,Mar-06,Mar-04,Jun-19,Sep-18,83,Insulins,22,Diabetes,8,Metabolism,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,621,Diabetes,7/7/14 12:28
909,68,Novo Nordisk,Regional & Specialty Pharma,328,Levemir,insulin detemir,Recombinant Protein,Launched,In-House,Mar-06,Mar-04,Jun-19,Sep-18,83,Insulins,22,Diabetes,8,Metabolism,1,US,Sales,445.2323195,545.7205495,657.8548334,867.809799,1154.091004,1324.738344,1469.530555,1566.888483,1633.005568,1637.083059,1631.324653,1600.415851,4.781512659,621,Diabetes,7/7/14 12:28
910,19,Bayer,Large Pharma,76,Levitra,vardenafil,Small Molecule (Chemical),Launched,In-House,Aug-03,Mar-03,Oct-18,Oct-18,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,622,Erectile dysfunction,7/7/14 12:28
910,19,Bayer,Large Pharma,76,Levitra,vardenafil,Small Molecule (Chemical),Launched,In-House,Aug-03,Mar-03,Oct-18,Oct-18,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,2,Global,Sales,500.219425,568.3198135,461.6250965,394.5782971,384.6959251,338.6949862,312.0336135,288.5281699,257.3952106,193.4648779,66.50988068,31.22710492,-30.1442475,622,Erectile dysfunction,7/7/14 12:28
910,19,Bayer,Large Pharma,76,Levitra,vardenafil,Small Molecule (Chemical),Launched,In-House,Aug-03,Mar-03,Oct-18,Oct-18,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,622,Erectile dysfunction,7/7/14 12:28
910,19,Bayer,Large Pharma,76,Levitra,vardenafil,Small Molecule (Chemical),Launched,In-House,Aug-03,Mar-03,Oct-18,Oct-18,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,2,ROW,Sales,283.4576741,278.1985101,315.6292075,296.8976763,275.7974596,248.7209492,229.4467437,209.8299382,183.043284,135.3193488,56.59132705,27.04442234,-28.232648,622,Erectile dysfunction,7/7/14 12:28
910,19,Bayer,Large Pharma,76,Levitra,vardenafil,Small Molecule (Chemical),Launched,In-House,Aug-03,Mar-03,Oct-18,Oct-18,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,622,Erectile dysfunction,7/7/14 12:28
910,19,Bayer,Large Pharma,76,Levitra,vardenafil,Small Molecule (Chemical),Launched,In-House,Aug-03,Mar-03,Oct-18,Oct-18,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,2,US,Sales,216.7617508,290.1213034,145.9958889,97.68062079,108.8984655,89.97403702,82.58686977,78.69823174,74.35192653,58.14552913,9.918553631,4.182682585,-37.22649676,622,Erectile dysfunction,7/7/14 12:28
911,76,King,Large Pharma,941,Levoxyl,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-50,,Expired,Expired,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,Global,Proforma,70.8,62,8.9,0,0,0,0,0,0,0,0,0,0,1525,Hypothyroidism,7/7/14 12:28
911,76,King,Large Pharma,941,Levoxyl,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-50,,Expired,Expired,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,US,Proforma,70.8,62,8.9,0,0,0,0,0,0,0,0,0,0,1525,Hypothyroidism,7/7/14 12:28
911,76,Pfizer,Large Pharma,941,Levoxyl,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-50,,Expired,Expired,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1525,Hypothyroidism,7/7/14 12:28
911,76,Pfizer,Large Pharma,941,Levoxyl,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-50,,Expired,Expired,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,Global,Sales,0,0,44.74,45.698,38.1531,30.985445,26,22,19,18,17.05,16,-11.67485454,1525,Hypothyroidism,7/7/14 12:28
911,76,Pfizer,Large Pharma,941,Levoxyl,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-50,,Expired,Expired,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1525,Hypothyroidism,7/7/14 12:28
911,76,Pfizer,Large Pharma,941,Levoxyl,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-50,,Expired,Expired,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1525,Hypothyroidism,7/7/14 12:28
911,76,Pfizer,Large Pharma,941,Levoxyl,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-50,,Expired,Expired,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1525,Hypothyroidism,7/7/14 12:28
911,76,Pfizer,Large Pharma,941,Levoxyl,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-50,,Expired,Expired,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,US,Sales,0,0,44.74,45.698,38.1531,30.985445,26,22,19,18,17.05,16,-11.67485454,1525,Hypothyroidism,7/7/14 12:28
912,42,Forest,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Development),Sep-02,,Feb-12,,127,Serotonergics,49,Depression,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
912,42,Forest,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Development),Sep-02,,Feb-12,,127,Serotonergics,49,Depression,12,Central Nervous System,6,Global,Sales,2300,2315.8,2130.6,195,52,20,11,9,8.7,8,7.895,7.87925,-23.62942668,1450,Depression,7/7/14 12:28
912,42,Forest,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Development),Sep-02,,Feb-12,,127,Serotonergics,49,Depression,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
912,42,Forest,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Development),Sep-02,,Feb-12,,127,Serotonergics,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
912,42,Forest,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Development),Sep-02,,Feb-12,,127,Serotonergics,49,Depression,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
912,42,Forest,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Development),Sep-02,,Feb-12,,127,Serotonergics,49,Depression,12,Central Nervous System,6,US,Sales,2300,2315.8,2130.6,195,52,20,11,9,8.7,8,7.895,7.87925,-23.62942668,1450,Depression,7/7/14 12:28
913,58,Lundbeck,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,In-House,Sep-02,Sep-12,Feb-12,,127,Serotonergics,49,Depression,12,Central Nervous System,1,Global,Alliance Revenue,457.361448,434.5486644,473.0956036,99.2818612,11.39667093,4.45182458,2.493021765,1.958802815,1.916065299,1.780729832,1.769902995,1.769036848,-23.36576765,1450,Depression,7/7/14 12:28
913,58,Lundbeck,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,In-House,Sep-02,Sep-12,Feb-12,,127,Serotonergics,49,Depression,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
913,58,Lundbeck,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,In-House,Sep-02,Sep-12,Feb-12,,127,Serotonergics,49,Depression,12,Central Nervous System,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
913,58,Lundbeck,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,In-House,Sep-02,Sep-12,Feb-12,,127,Serotonergics,49,Depression,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
913,58,Lundbeck,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,In-House,Sep-02,Sep-12,Feb-12,,127,Serotonergics,49,Depression,12,Central Nervous System,1,US,Alliance Revenue,457.361448,434.5486644,473.0956036,99.2818612,11.39667093,4.45182458,2.493021765,1.958802815,1.916065299,1.780729832,1.769902995,1.769036848,-23.36576765,1450,Depression,7/7/14 12:28
913,58,Lundbeck,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,In-House,Sep-02,Sep-12,Feb-12,,127,Serotonergics,49,Depression,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
914,46,GlaxoSmithKline,Large Pharma,835,Lexiva,fosamprenavir,Small Molecule (Chemical),Launched,Licensed (Development),Dec-03,Sep-04,Jul-18,Dec-15,103,Protease Inhibitors,32,HIV,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,624,HIV,7/7/14 12:28
914,46,GlaxoSmithKline,Large Pharma,835,Lexiva,fosamprenavir,Small Molecule (Chemical),Launched,Licensed (Development),Dec-03,Sep-04,Jul-18,Dec-15,103,Protease Inhibitors,32,HIV,7,Anti-infectives,4,Global,Sales,277.5485807,239.475009,227.6516609,201.5188754,173.84193,152.66003,132.9602069,114.7564582,97.11175564,79.23210033,62.59926114,46.48257298,-17.17483419,624,HIV,7/7/14 12:28
914,46,GlaxoSmithKline,Large Pharma,835,Lexiva,fosamprenavir,Small Molecule (Chemical),Launched,Licensed (Development),Dec-03,Sep-04,Jul-18,Dec-15,103,Protease Inhibitors,32,HIV,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,624,HIV,7/7/14 12:28
914,46,GlaxoSmithKline,Large Pharma,835,Lexiva,fosamprenavir,Small Molecule (Chemical),Launched,Licensed (Development),Dec-03,Sep-04,Jul-18,Dec-15,103,Protease Inhibitors,32,HIV,7,Anti-infectives,4,ROW,Sales,123.1816735,115.8750043,109.0162883,93.51670356,81.88535844,72.61493275,64.16998967,56.9101392,50.49614457,44.83699171,39.87239578,35.50212158,-11.25379848,624,HIV,7/7/14 12:28
914,46,GlaxoSmithKline,Large Pharma,835,Lexiva,fosamprenavir,Small Molecule (Chemical),Launched,Licensed (Development),Dec-03,Sep-04,Jul-18,Dec-15,103,Protease Inhibitors,32,HIV,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,624,HIV,7/7/14 12:28
914,46,GlaxoSmithKline,Large Pharma,835,Lexiva,fosamprenavir,Small Molecule (Chemical),Launched,Licensed (Development),Dec-03,Sep-04,Jul-18,Dec-15,103,Protease Inhibitors,32,HIV,7,Anti-infectives,4,US,Sales,154.3669073,123.6000046,118.6353726,108.0021719,91.95657157,80.04509723,68.79021723,57.84631904,46.61561107,34.39510862,22.72686536,10.9804514,-26.18436924,624,HIV,7/7/14 12:28
915,40,Endo Health Solutions,Regional & Specialty Pharma,477,Lidoderm,transdermal lidocaine,Small Molecule (Chemical),Launched,Licensed (Development),Sep-99,,Jan-13,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,625,Post-herpetic Neuralgia,7/7/14 12:28
915,40,Endo Health Solutions,Regional & Specialty Pharma,477,Lidoderm,transdermal lidocaine,Small Molecule (Chemical),Launched,Licensed (Development),Sep-99,,Jan-13,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,763.7,782.6,825.18,947.68,603,491,388,335,281,225,203,170,-16.54594354,625,Post-herpetic Neuralgia,7/7/14 12:28
915,40,Endo Health Solutions,Regional & Specialty Pharma,477,Lidoderm,transdermal lidocaine,Small Molecule (Chemical),Launched,Licensed (Development),Sep-99,,Jan-13,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,625,Post-herpetic Neuralgia,7/7/14 12:28
915,40,Endo Health Solutions,Regional & Specialty Pharma,477,Lidoderm,transdermal lidocaine,Small Molecule (Chemical),Launched,Licensed (Development),Sep-99,,Jan-13,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,625,Post-herpetic Neuralgia,7/7/14 12:28
915,40,Endo Health Solutions,Regional & Specialty Pharma,477,Lidoderm,transdermal lidocaine,Small Molecule (Chemical),Launched,Licensed (Development),Sep-99,,Jan-13,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,625,Post-herpetic Neuralgia,7/7/14 12:28
915,40,Endo Health Solutions,Regional & Specialty Pharma,477,Lidoderm,transdermal lidocaine,Small Molecule (Chemical),Launched,Licensed (Development),Sep-99,,Jan-13,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,763.7,782.6,825.18,947.68,603,491,388,335,281,225,203,170,-16.54594354,625,Post-herpetic Neuralgia,7/7/14 12:28
916,42,Forest,Regional & Specialty Pharma,396,Linzess,linaclotide,Small Molecule (Chemical),Launched,Licensed (Development),Dec-12,,Jan-25,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1527,IBS-C,7/7/14 12:28
916,42,Forest,Regional & Specialty Pharma,396,Linzess,linaclotide,Small Molecule (Chemical),Launched,Licensed (Development),Dec-12,,Jan-25,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,23.7,151.2,313.200216,470.4478968,582.6519519,681.9787001,765.8713938,838.5450464,896.1017019,28.94386297,1527,IBS-C,7/7/14 12:28
916,42,Forest,Regional & Specialty Pharma,396,Linzess,linaclotide,Small Molecule (Chemical),Launched,Licensed (Development),Dec-12,,Jan-25,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1527,IBS-C,7/7/14 12:28
916,42,Forest,Regional & Specialty Pharma,396,Linzess,linaclotide,Small Molecule (Chemical),Launched,Licensed (Development),Dec-12,,Jan-25,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1527,IBS-C,7/7/14 12:28
916,42,Forest,Regional & Specialty Pharma,396,Linzess,linaclotide,Small Molecule (Chemical),Launched,Licensed (Development),Dec-12,,Jan-25,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1527,IBS-C,7/7/14 12:28
916,42,Forest,Regional & Specialty Pharma,396,Linzess,linaclotide,Small Molecule (Chemical),Launched,Licensed (Development),Dec-12,,Jan-25,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,23.7,151.2,313.200216,470.4478968,582.6519519,681.9787001,765.8713938,838.5450464,896.1017019,28.94386297,1527,IBS-C,7/7/14 12:28
917,1,Abbott,Regional & Specialty Pharma,740,Lipanthyl,fenofibrate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-00,N/A,Jan-18,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1461,Dyslipidemia,7/7/14 12:28
917,1,Abbott,Regional & Specialty Pharma,740,Lipanthyl,fenofibrate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-00,N/A,Jan-18,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,171.75,308,292,296.08,294.9136,295.158112,295.050855,295.0498193,250.7755663,221.2662002,206.5101403,-5.016647296,1461,Dyslipidemia,7/7/14 12:28
917,1,Abbott,Regional & Specialty Pharma,740,Lipanthyl,fenofibrate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-00,N/A,Jan-18,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1461,Dyslipidemia,7/7/14 12:28
917,1,Abbott,Regional & Specialty Pharma,740,Lipanthyl,fenofibrate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-00,N/A,Jan-18,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,171.75,308,292,296.08,294.9136,295.158112,295.050855,295.0498193,250.7755663,221.2662002,206.5101403,-5.016647296,1461,Dyslipidemia,7/7/14 12:28
917,1,Abbott,Regional & Specialty Pharma,740,Lipanthyl,fenofibrate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-00,N/A,Jan-18,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1461,Dyslipidemia,7/7/14 12:28
917,1,Abbott,Regional & Specialty Pharma,740,Lipanthyl,fenofibrate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-00,N/A,Jan-18,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1461,Dyslipidemia,7/7/14 12:28
917,1,Solvay,Regional & Specialty Pharma,740,Lipanthyl,fenofibrate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-00,N/A,Jan-18,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,Global,Proforma,232,76.25,0,0,0,0,0,0,0,0,0,0,0,1461,Dyslipidemia,7/7/14 12:28
917,1,Solvay,Regional & Specialty Pharma,740,Lipanthyl,fenofibrate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-00,N/A,Jan-18,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Proforma,232,76.25,0,0,0,0,0,0,0,0,0,0,0,1461,Dyslipidemia,7/7/14 12:28
918,15,Astellas Pharma,Regional & Specialty Pharma,1209,Lipitor,atorvastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-00,N/A,Nov-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1353,Dyslipidemia,7/7/14 12:28
918,15,Astellas Pharma,Regional & Specialty Pharma,1209,Lipitor,atorvastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-00,N/A,Nov-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,Global,Sales,1076.248643,1134.599447,1158.949028,734.3631807,523.5215568,458.010888,392.4891391,359.6190011,336.0129999,318.481015,307.7009789,300.2069443,-7.63699416,1353,Dyslipidemia,7/7/14 12:28
918,15,Astellas Pharma,Regional & Specialty Pharma,1209,Lipitor,atorvastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-00,N/A,Nov-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1353,Dyslipidemia,7/7/14 12:28
918,15,Astellas Pharma,Regional & Specialty Pharma,1209,Lipitor,atorvastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-00,N/A,Nov-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Sales,1076.248643,1134.599447,1158.949028,734.3631807,523.5215568,458.010888,392.4891391,359.6190011,336.0129999,318.481015,307.7009789,300.2069443,-7.63699416,1353,Dyslipidemia,7/7/14 12:28
918,15,Astellas Pharma,Regional & Specialty Pharma,1209,Lipitor,atorvastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-00,N/A,Nov-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1353,Dyslipidemia,7/7/14 12:28
918,15,Astellas Pharma,Regional & Specialty Pharma,1209,Lipitor,atorvastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-00,N/A,Nov-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1353,Dyslipidemia,7/7/14 12:28
919,76,Pfizer,Large Pharma,1209,Lipitor,atorvastatin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-97,Jul-97,Nov-11,Nov-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1353,Dyslipidemia,7/7/14 12:28
919,76,Pfizer,Large Pharma,1209,Lipitor,atorvastatin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-97,Jul-97,Nov-11,Nov-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,11434,10733,9577,3948,2315,1677,1468,1349.78,1291.9608,1261.426088,1243.009864,1231.421899,-8.623063663,1353,Dyslipidemia,7/7/14 12:28
919,76,Pfizer,Large Pharma,1209,Lipitor,atorvastatin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-97,Jul-97,Nov-11,Nov-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1353,Dyslipidemia,7/7/14 12:28
919,76,Pfizer,Large Pharma,1209,Lipitor,atorvastatin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-97,Jul-97,Nov-11,Nov-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,5767,5404,4574,3016,1883,1493,1351,1264.78,1220.9608,1197.426088,1185.009864,1178.421899,-6.476333005,1353,Dyslipidemia,7/7/14 12:28
919,76,Pfizer,Large Pharma,1209,Lipitor,atorvastatin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-97,Jul-97,Nov-11,Nov-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1353,Dyslipidemia,7/7/14 12:28
919,76,Pfizer,Large Pharma,1209,Lipitor,atorvastatin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-97,Jul-97,Nov-11,Nov-11,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,5667,5329,5003,932,432,184,117,85,71,64,58,53,-25.89840155,1353,Dyslipidemia,7/7/14 12:28
922,34,Daiichi-Sankyo,Regional & Specialty Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-03,N/A,Dec-14,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1592,,7/7/14 12:28
922,34,Daiichi-Sankyo,Regional & Specialty Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-03,N/A,Dec-14,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,Global,Sales,78.64479575,88.71353699,101.2932831,96.30992495,56.25953287,0,0,0,0,0,0,0,-100,1592,,7/7/14 12:28
922,34,Daiichi-Sankyo,Regional & Specialty Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-03,N/A,Dec-14,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1592,,7/7/14 12:28
922,34,Daiichi-Sankyo,Regional & Specialty Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-03,N/A,Dec-14,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Sales,78.64479575,88.71353699,101.2932831,96.30992495,56.25953287,0,0,0,0,0,0,0,-100,1592,,7/7/14 12:28
922,34,Daiichi-Sankyo,Regional & Specialty Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-03,N/A,Dec-14,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1592,,7/7/14 12:28
922,34,Daiichi-Sankyo,Regional & Specialty Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-03,N/A,Dec-14,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1592,,7/7/14 12:28
923,55,Kowa,Regional & Specialty Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,In-House,Feb-10,Sep-03,Jan-16,Dec-13,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,Global,Sales,299.7857641,408.3038925,547.30452,605.7796903,708.0136411,741.5480878,747.493609,563.714662,524.0124703,504.4581782,483.8556667,459.4908433,-5.989472596,1592,Lipid disorders,7/7/14 12:28
923,55,Kowa,Regional & Specialty Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,In-House,Feb-10,Sep-03,Jan-16,Dec-13,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Sales,290.8780117,346.3111153,443.1581135,462.5783813,543.842151,562.5953287,557.7945152,522.8010857,501.2384321,488.6828046,471.9636516,449.423121,-2.687428943,1592,Lipid disorders,7/7/14 12:28
923,55,Kowa,Regional & Specialty Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,In-House,Feb-10,Sep-03,Jan-16,Dec-13,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,US,Sales,8.907752364,61.99277722,104.1464065,143.2013089,164.1714901,178.9527592,189.6990939,40.91357629,22.77403821,15.77537363,11.89201504,10.06772225,-32.88726204,1592,Lipid disorders,7/7/14 12:28
924,61,Merck & Co,Large Pharma,1704,Livial,tibolone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-90,N/A,Mar-10,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1660,Estrogen deficiency,7/7/14 12:28
924,61,Merck & Co,Large Pharma,1704,Livial,tibolone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-90,N/A,Mar-10,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Sales,24.4,118,103.06,89.098,78.8602,71.4829,65.751466,61.4755858,58.27588762,55.85854765,54.04429436,52.6809334,-5.60025456,1660,Estrogen deficiency,7/7/14 12:28
924,61,Merck & Co,Large Pharma,1704,Livial,tibolone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-90,N/A,Mar-10,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1660,Estrogen deficiency,7/7/14 12:28
924,61,Merck & Co,Large Pharma,1704,Livial,tibolone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-90,N/A,Mar-10,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Sales,24.4,118,103.06,89.098,78.8602,71.4829,65.751466,61.4755858,58.27588762,55.85854765,54.04429436,52.6809334,-5.60025456,1660,Estrogen deficiency,7/7/14 12:28
924,61,Merck & Co,Large Pharma,1704,Livial,tibolone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-90,N/A,Mar-10,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1660,Estrogen deficiency,7/7/14 12:28
924,61,Merck & Co,Large Pharma,1704,Livial,tibolone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-90,N/A,Mar-10,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1660,Estrogen deficiency,7/7/14 12:28
924,61,Schering-Plough,Large Pharma,1704,Livial,tibolone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-90,N/A,Mar-10,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Proforma,121.6,0,0,0,0,0,0,0,0,0,0,0,0,1660,Estrogen deficiency,7/7/14 12:28
924,61,Schering-Plough,Large Pharma,1704,Livial,tibolone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-90,N/A,Mar-10,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Proforma,121.6,0,0,0,0,0,0,0,0,0,0,0,0,1660,Estrogen deficiency,7/7/14 12:28
925,16,AstraZeneca,Large Pharma,3012,Local anesthetics,Local anesthetics,Small Molecule (Chemical),Launched,In-House,Jul-48,Jul-48,Expired,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,631,Anesthesia,7/7/14 12:28
925,16,AstraZeneca,Large Pharma,3012,Local anesthetics,Local anesthetics,Small Molecule (Chemical),Launched,In-House,Jul-48,Jul-48,Expired,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,599,605,602,540,510,489,474.3,464.01,456.807,451.7649,448.23543,445.764801,-1.904756253,631,Anesthesia,7/7/14 12:28
925,16,AstraZeneca,Large Pharma,3012,Local anesthetics,Local anesthetics,Small Molecule (Chemical),Launched,In-House,Jul-48,Jul-48,Expired,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,631,Anesthesia,7/7/14 12:28
925,16,AstraZeneca,Large Pharma,3012,Local anesthetics,Local anesthetics,Small Molecule (Chemical),Launched,In-House,Jul-48,Jul-48,Expired,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,559,576,592,540,510,489,474.3,464.01,456.807,451.7649,448.23543,445.764801,-1.904756253,631,Anesthesia,7/7/14 12:28
925,16,AstraZeneca,Large Pharma,3012,Local anesthetics,Local anesthetics,Small Molecule (Chemical),Launched,In-House,Jul-48,Jul-48,Expired,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,631,Anesthesia,7/7/14 12:28
925,16,AstraZeneca,Large Pharma,3012,Local anesthetics,Local anesthetics,Small Molecule (Chemical),Launched,In-House,Jul-48,Jul-48,Expired,Expired,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,40,29,10,0,0,0,0,0,0,0,0,0,0,631,Anesthesia,7/7/14 12:28
927,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1641,Lonasen,blonanserin,Small Molecule (Chemical),Launched,In-House,,Apr-08,N/A,Jun-17,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,633,Schizophrenia,7/7/14 12:28
927,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1641,Lonasen,blonanserin,Small Molecule (Chemical),Launched,In-House,,Apr-08,N/A,Jun-17,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Sales,59.38513453,107.1541048,124.0842718,132.4261473,120.8126669,127.747617,133.3105463,136.2472049,136.3496237,124.1665852,116.1888471,112.0182057,-1.073901402,633,Schizophrenia,7/7/14 12:28
927,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1641,Lonasen,blonanserin,Small Molecule (Chemical),Launched,In-House,,Apr-08,N/A,Jun-17,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,633,Schizophrenia,7/7/14 12:28
927,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1641,Lonasen,blonanserin,Small Molecule (Chemical),Launched,In-House,,Apr-08,N/A,Jun-17,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Sales,59.38513453,107.1541048,124.0842718,132.4261473,120.8126669,127.747617,133.3105463,136.2472049,136.3496237,124.1665852,116.1888471,112.0182057,-1.073901402,633,Schizophrenia,7/7/14 12:28
927,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1641,Lonasen,blonanserin,Small Molecule (Chemical),Launched,In-House,,Apr-08,N/A,Jun-17,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,633,Schizophrenia,7/7/14 12:28
927,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1641,Lonasen,blonanserin,Small Molecule (Chemical),Launched,In-House,,Apr-08,N/A,Jun-17,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,633,Schizophrenia,7/7/14 12:28
929,37,Eisai,Regional & Specialty Pharma,4611,Belviq,lorcaserin,Small Molecule (Chemical),Launched,In-House,Apr-13,Aug-13,N/A,Apr-23,80,Obesity Treatments,38,Obesity,8,Metabolism,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,635,Obesity,7/7/14 12:28
929,37,Eisai,Regional & Specialty Pharma,4611,Belviq,lorcaserin,Small Molecule (Chemical),Launched,In-House,Apr-13,Aug-13,N/A,Apr-23,80,Obesity Treatments,38,Obesity,8,Metabolism,7,Global,Sales,0,0,0,0,20.25070472,68.17737811,97.54081824,117.7915134,135.1126002,147.6521586,157.107424,164.3965261,34.87195572,635,Obesity,7/7/14 12:28
929,37,Eisai,Regional & Specialty Pharma,4611,Belviq,lorcaserin,Small Molecule (Chemical),Launched,In-House,Apr-13,Aug-13,N/A,Apr-23,80,Obesity Treatments,38,Obesity,8,Metabolism,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,635,Obesity,7/7/14 12:28
929,37,Eisai,Regional & Specialty Pharma,4611,Belviq,lorcaserin,Small Molecule (Chemical),Launched,In-House,Apr-13,Aug-13,N/A,Apr-23,80,Obesity Treatments,38,Obesity,8,Metabolism,7,ROW,Sales,0,0,0,0,2.025071384,4.387661415,6.412742664,8.43782267,9.902630339,11.1240912,12.14272331,12.96082441,30.36776256,635,Obesity,7/7/14 12:28
929,37,Eisai,Regional & Specialty Pharma,4611,Belviq,lorcaserin,Small Molecule (Chemical),Launched,In-House,Apr-13,Aug-13,N/A,Apr-23,80,Obesity Treatments,38,Obesity,8,Metabolism,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,635,Obesity,7/7/14 12:28
929,37,Eisai,Regional & Specialty Pharma,4611,Belviq,lorcaserin,Small Molecule (Chemical),Launched,In-House,Apr-13,Aug-13,N/A,Apr-23,80,Obesity Treatments,38,Obesity,8,Metabolism,7,US,Sales,0,0,0,0,18.22563334,63.78971669,91.12807558,109.3536907,125.2099698,136.5280674,144.9647007,151.4357017,35.32048082,635,Obesity,7/7/14 12:28
930,46,GlaxoSmithKline,Large Pharma,254,losmapimod,losmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,636,COPD,7/7/14 12:28
930,46,GlaxoSmithKline,Large Pharma,254,losmapimod,losmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,636,COPD,7/7/14 12:28
930,46,GlaxoSmithKline,Large Pharma,254,losmapimod,losmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,636,COPD,7/7/14 12:28
930,46,GlaxoSmithKline,Large Pharma,254,losmapimod,losmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,636,COPD,7/7/14 12:28
930,46,GlaxoSmithKline,Large Pharma,254,losmapimod,losmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,636,COPD,7/7/14 12:28
930,46,GlaxoSmithKline,Large Pharma,254,losmapimod,losmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,636,COPD,7/7/14 12:28
931,67,Novartis,Large Pharma,290,Lotrel,benazepril + amlodipine,Small Molecule (Chemical),Launched,In-House,Jan-91,,Expired,N/A,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,637,Hypertension,7/7/14 12:28
931,67,Novartis,Large Pharma,290,Lotrel,benazepril + amlodipine,Small Molecule (Chemical),Launched,In-House,Jan-91,,Expired,N/A,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Sales,322,266,60,42.4,34.108,32.58496,32.1534352,32.05596102,32.03131838,32.02543704,32.023992,32.02364215,-0.896775489,637,Hypertension,7/7/14 12:28
931,67,Novartis,Large Pharma,290,Lotrel,benazepril + amlodipine,Small Molecule (Chemical),Launched,In-House,Jan-91,,Expired,N/A,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,637,Hypertension,7/7/14 12:28
931,67,Novartis,Large Pharma,290,Lotrel,benazepril + amlodipine,Small Molecule (Chemical),Launched,In-House,Jan-91,,Expired,N/A,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,637,Hypertension,7/7/14 12:28
931,67,Novartis,Large Pharma,290,Lotrel,benazepril + amlodipine,Small Molecule (Chemical),Launched,In-House,Jan-91,,Expired,N/A,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,637,Hypertension,7/7/14 12:28
931,67,Novartis,Large Pharma,290,Lotrel,benazepril + amlodipine,Small Molecule (Chemical),Launched,In-House,Jan-91,,Expired,N/A,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Sales,322,266,60,42.4,34.108,32.58496,32.1534352,32.05596102,32.03131838,32.02543704,32.023992,32.02364215,-0.896775489,637,Hypertension,7/7/14 12:28
932,46,GlaxoSmithKline,Large Pharma,213,Lovaza,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Jan-08,Apr-14,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,638,Hypertriglyceridemia,7/7/14 12:28
932,46,GlaxoSmithKline,Large Pharma,213,Lovaza,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Jan-08,Apr-14,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,4,Global,Sales,701.6208359,818.8500307,912.2098243,962.1125265,913.3618969,618.8789417,470.6766983,285.1149719,192.2110747,145.7653476,99.24963345,80.54709072,-29.31227521,638,Hypertriglyceridemia,7/7/14 12:28
932,46,GlaxoSmithKline,Large Pharma,213,Lovaza,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Jan-08,Apr-14,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,638,Hypertriglyceridemia,7/7/14 12:28
932,46,GlaxoSmithKline,Large Pharma,213,Lovaza,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Jan-08,Apr-14,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,4,ROW,Sales,3.071598972,3.090000116,3.206361421,4.755086622,5.018346659,5.347326408,5.642385977,5.80452904,5.922221716,6.005472302,6.060153156,6.253656112,3.193732302,638,Hypertriglyceridemia,7/7/14 12:28
932,46,GlaxoSmithKline,Large Pharma,213,Lovaza,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Jan-08,Apr-14,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,638,Hypertriglyceridemia,7/7/14 12:28
932,46,GlaxoSmithKline,Large Pharma,213,Lovaza,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Jan-08,Apr-14,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,4,US,Sales,698.5492369,815.7600306,909.0034629,957.3574399,908.3435503,613.5316153,465.0343123,279.3104429,186.2888529,139.7598753,93.18948029,74.29343461,-30.06869598,638,Hypertriglyceridemia,7/7/14 12:28
933,89,Sanofi,Large Pharma,1380,Lovenox,enoxaparin,Synthetic Peptide,Launched,Corporate Acquisition,May-93,Nov-87,Jul-10,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1442,,7/7/14 12:28
933,89,Sanofi,Large Pharma,1380,Lovenox,enoxaparin,Synthetic Peptide,Launched,Corporate Acquisition,May-93,Nov-87,Jul-10,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,Global,Sales,4228.243639,3717.261997,2935.212586,2433.01862,2261.635203,2242.684215,2222.591319,2211.640275,2202.833768,2196.696071,2192.186386,2188.93764,-0.465651469,1442,,7/7/14 12:28
933,89,Sanofi,Large Pharma,1380,Lovenox,enoxaparin,Synthetic Peptide,Launched,Corporate Acquisition,May-93,Nov-87,Jul-10,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1442,,7/7/14 12:28
933,89,Sanofi,Large Pharma,1380,Lovenox,enoxaparin,Synthetic Peptide,Launched,Corporate Acquisition,May-93,Nov-87,Jul-10,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,ROW,Sales,1696.57755,1810.939825,2055.065941,2023.017067,2013.293581,2003.107591,1983.452945,1972.523813,1963.718402,1957.58076,1953.071077,1949.822331,-0.456578642,1442,,7/7/14 12:28
933,89,Sanofi,Large Pharma,1380,Lovenox,enoxaparin,Synthetic Peptide,Launched,Corporate Acquisition,May-93,Nov-87,Jul-10,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1442,,7/7/14 12:28
933,89,Sanofi,Large Pharma,1380,Lovenox,enoxaparin,Synthetic Peptide,Launched,Corporate Acquisition,May-93,Nov-87,Jul-10,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,US,Sales,2531.66609,1906.322172,880.1466448,410.001553,248.3416225,239.576624,239.1383741,239.1164616,239.115366,239.1153112,239.1153085,239.1153083,-0.539388237,1442,,7/7/14 12:28
934,34,Daiichi-Sankyo,Regional & Specialty Pharma,1094,Loxonin,loxoprofen,Small Molecule (Chemical),Launched,In-House,,Jan-86,N/A,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,639,Pain,7/7/14 12:28
934,34,Daiichi-Sankyo,Regional & Specialty Pharma,1094,Loxonin,loxoprofen,Small Molecule (Chemical),Launched,In-House,,Jan-86,N/A,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,506.3432055,632.6675927,772.3612836,717.5089438,624.1987792,639.904425,650.717158,660.5618796,668.5301918,675.0012189,680.3321091,684.6991039,1.330350175,639,Pain,7/7/14 12:28
934,34,Daiichi-Sankyo,Regional & Specialty Pharma,1094,Loxonin,loxoprofen,Small Molecule (Chemical),Launched,In-House,,Jan-86,N/A,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,639,Pain,7/7/14 12:28
934,34,Daiichi-Sankyo,Regional & Specialty Pharma,1094,Loxonin,loxoprofen,Small Molecule (Chemical),Launched,In-House,,Jan-86,N/A,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,506.3432055,632.6675927,772.3612836,717.5089438,624.1987792,639.904425,650.717158,660.5618796,668.5301918,675.0012189,680.3321091,684.6991039,1.330350175,639,Pain,7/7/14 12:28
934,34,Daiichi-Sankyo,Regional & Specialty Pharma,1094,Loxonin,loxoprofen,Small Molecule (Chemical),Launched,In-House,,Jan-86,N/A,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,639,Pain,7/7/14 12:28
934,34,Daiichi-Sankyo,Regional & Specialty Pharma,1094,Loxonin,loxoprofen,Small Molecule (Chemical),Launched,In-House,,Jan-86,N/A,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,639,Pain,7/7/14 12:28
935,58,Lundbeck,Regional & Specialty Pharma,2274,Brintellix,vortioxetine,Small Molecule (Chemical),Launched,In-House,Jan-14,Jul-14,N/A,,127,Serotonergics,49,Depression,12,Central Nervous System,1,Global,Alliance Revenue,0,0,0,0,0,6.944846345,42.38137,105.775352,146.3759922,179.4975671,208.5234633,250.7267604,0,1530,Depression,7/7/14 12:28
935,58,Lundbeck,Regional & Specialty Pharma,2274,Brintellix,vortioxetine,Small Molecule (Chemical),Launched,In-House,Jan-14,Jul-14,N/A,,127,Serotonergics,49,Depression,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,26.17672853,95.98142521,183.237179,270.4928913,329.1287565,380.1908144,422.5918661,0,1530,Depression,7/7/14 12:28
935,58,Lundbeck,Regional & Specialty Pharma,2274,Brintellix,vortioxetine,Small Molecule (Chemical),Launched,In-House,Jan-14,Jul-14,N/A,,127,Serotonergics,49,Depression,12,Central Nervous System,1,ROW,Alliance Revenue,0,0,0,0,0,3.917605631,6.054481429,9.081722144,13.53354672,16.38271446,18.16344429,21.190685,0,1530,Depression,7/7/14 12:28
935,58,Lundbeck,Regional & Specialty Pharma,2274,Brintellix,vortioxetine,Small Molecule (Chemical),Launched,In-House,Jan-14,Jul-14,N/A,,127,Serotonergics,49,Depression,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,26.17672853,95.98142521,183.237179,270.4928913,329.1287565,380.1908144,422.5918661,0,1530,Depression,7/7/14 12:28
935,58,Lundbeck,Regional & Specialty Pharma,2274,Brintellix,vortioxetine,Small Molecule (Chemical),Launched,In-House,Jan-14,Jul-14,N/A,,127,Serotonergics,49,Depression,12,Central Nervous System,1,US,Alliance Revenue,0,0,0,0,0,3.027240715,36.32688858,96.69362988,132.8424455,163.1148526,190.3600191,229.5360754,0,1530,Depression,7/7/14 12:28
935,58,Lundbeck,Regional & Specialty Pharma,2274,Brintellix,vortioxetine,Small Molecule (Chemical),Launched,In-House,Jan-14,Jul-14,N/A,,127,Serotonergics,49,Depression,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1530,Depression,7/7/14 12:28
936,100,Takeda,Large Pharma,2274,Brintellix,vortioxetine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-14,Jun-14,N/A,,127,Serotonergics,49,Depression,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1530,Depression,7/7/14 12:28
936,100,Takeda,Large Pharma,2274,Brintellix,vortioxetine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-14,Jun-14,N/A,,127,Serotonergics,49,Depression,12,Central Nervous System,7,Global,Sales,0,0,0,0,12.15042223,131.5113247,343.4043975,476.6518185,592.9498377,691.301133,768.8013093,832.8618658,82.9291113,1530,Depression,7/7/14 12:28
936,100,Takeda,Large Pharma,2274,Brintellix,vortioxetine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-14,Jun-14,N/A,,127,Serotonergics,49,Depression,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1530,Depression,7/7/14 12:28
936,100,Takeda,Large Pharma,2274,Brintellix,vortioxetine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-14,Jun-14,N/A,,127,Serotonergics,49,Depression,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,14.3465042,21.41789612,30.55884,45.70502346,53.91578076,61.24997648,67.6616697,0,1530,Depression,7/7/14 12:28
936,100,Takeda,Large Pharma,2274,Brintellix,vortioxetine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-14,Jun-14,N/A,,127,Serotonergics,49,Depression,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1530,Depression,7/7/14 12:28
936,100,Takeda,Large Pharma,2274,Brintellix,vortioxetine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-14,Jun-14,N/A,,127,Serotonergics,49,Depression,12,Central Nervous System,7,US,Sales,0,0,0,0,12.15042223,117.1648205,321.9865014,446.0929785,547.2448142,637.3853523,707.5513329,765.2001961,80.72822624,1530,Depression,7/7/14 12:28
937,100,Takeda,Large Pharma,2079,tedatioxetine,Lu AA24530,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,127,Serotonergics,49,Depression,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1531,Depression,7/7/14 12:28
937,100,Takeda,Large Pharma,2079,tedatioxetine,Lu AA24530,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,127,Serotonergics,49,Depression,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1531,Depression,7/7/14 12:28
937,100,Takeda,Large Pharma,2079,tedatioxetine,Lu AA24530,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,127,Serotonergics,49,Depression,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1531,Depression,7/7/14 12:28
937,100,Takeda,Large Pharma,2079,tedatioxetine,Lu AA24530,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,127,Serotonergics,49,Depression,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1531,Depression,7/7/14 12:28
937,100,Takeda,Large Pharma,2079,tedatioxetine,Lu AA24530,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,127,Serotonergics,49,Depression,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1531,Depression,7/7/14 12:28
937,100,Takeda,Large Pharma,2079,tedatioxetine,Lu AA24530,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,127,Serotonergics,49,Depression,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1531,Depression,7/7/14 12:28
939,67,Novartis,Large Pharma,1663,Lucentis,ranibizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-06,N/A,Apr-18,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1608,AMD,7/7/14 12:28
939,67,Novartis,Large Pharma,1663,Lucentis,ranibizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-06,N/A,Apr-18,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Sales,1232,1533,2050,2413,2383,2074.716785,1990.800111,1924.466457,1871.456327,1693.906487,1401.862636,1260.34,-8.697942422,1608,AMD,7/7/14 12:28
939,67,Novartis,Large Pharma,1663,Lucentis,ranibizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-06,N/A,Apr-18,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1608,AMD,7/7/14 12:28
939,67,Novartis,Large Pharma,1663,Lucentis,ranibizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-06,N/A,Apr-18,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Sales,1232,1533,2050,2413,2383,2074.716785,1990.800111,1924.466457,1871.456327,1693.906487,1401.862636,1260.34,-8.697942422,1608,AMD,7/7/14 12:28
939,67,Novartis,Large Pharma,1663,Lucentis,ranibizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-06,N/A,Apr-18,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1608,AMD,7/7/14 12:28
939,67,Novartis,Large Pharma,1663,Lucentis,ranibizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-06,N/A,Apr-18,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1608,AMD,7/7/14 12:28
940,86,Roche,Large Pharma,1663,Lucentis,ranibizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-06,,Jun-20,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1608,AMD,7/7/14 12:28
940,86,Roche,Large Pharma,1663,Lucentis,ranibizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-06,,Jun-20,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,5,Global,Sales,1103.113826,1398.271661,1715.432984,1579.47079,1822.638924,1780.418233,1719.69058,1691.525467,1689.003556,1687.521165,1686.811544,1686.550762,-1.102447404,1608,AMD,7/7/14 12:28
940,86,Roche,Large Pharma,1663,Lucentis,ranibizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-06,,Jun-20,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1608,AMD,7/7/14 12:28
940,86,Roche,Large Pharma,1663,Lucentis,ranibizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-06,,Jun-20,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1608,AMD,7/7/14 12:28
940,86,Roche,Large Pharma,1663,Lucentis,ranibizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-06,,Jun-20,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1608,AMD,7/7/14 12:28
940,86,Roche,Large Pharma,1663,Lucentis,ranibizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-06,,Jun-20,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,5,US,Sales,1103.113826,1398.271661,1715.432984,1579.47079,1822.638924,1780.418233,1719.69058,1691.525467,1689.003556,1687.521165,1686.811544,1686.550762,-1.102447404,1608,AMD,7/7/14 12:28
941,8,Allergan,Regional & Specialty Pharma,3051,Lumigan / Lumigan X / Ganfort,bimatoprost / bimatoprost + timolol,Small Molecule (Chemical),Launched,In-House,Mar-01,Apr-02,Jan-24,Jun-17,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,646,Glaucoma,7/7/14 12:28
941,8,Allergan,Regional & Specialty Pharma,3051,Lumigan / Lumigan X / Ganfort,bimatoprost / bimatoprost + timolol,Small Molecule (Chemical),Launched,In-House,Mar-01,Apr-02,Jan-24,Jun-17,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Sales,456.5,527,612.7,622.6,625,635.687632,643.2679488,651.0341072,613.2436376,584.7883965,576.5208122,564.1632139,-1.452321313,646,Glaucoma,7/7/14 12:28
941,8,Allergan,Regional & Specialty Pharma,3051,Lumigan / Lumigan X / Ganfort,bimatoprost / bimatoprost + timolol,Small Molecule (Chemical),Launched,In-House,Mar-01,Apr-02,Jan-24,Jun-17,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,646,Glaucoma,7/7/14 12:28
941,8,Allergan,Regional & Specialty Pharma,3051,Lumigan / Lumigan X / Ganfort,bimatoprost / bimatoprost + timolol,Small Molecule (Chemical),Launched,In-House,Mar-01,Apr-02,Jan-24,Jun-17,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Sales,152.9,191.8,243.8546,252.6,262,276.187632,285.5179488,294.1591072,256.8061376,228.5696465,220.4114372,208.1085264,-3.236254856,646,Glaucoma,7/7/14 12:28
941,8,Allergan,Regional & Specialty Pharma,3051,Lumigan / Lumigan X / Ganfort,bimatoprost / bimatoprost + timolol,Small Molecule (Chemical),Launched,In-House,Mar-01,Apr-02,Jan-24,Jun-17,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,646,Glaucoma,7/7/14 12:28
941,8,Allergan,Regional & Specialty Pharma,3051,Lumigan / Lumigan X / Ganfort,bimatoprost / bimatoprost + timolol,Small Molecule (Chemical),Launched,In-House,Mar-01,Apr-02,Jan-24,Jun-17,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Sales,303.6,335.2,368.8454,370,363,359.5,357.75,356.875,356.4375,356.21875,356.109375,356.0546875,-0.275597806,646,Glaucoma,7/7/14 12:28
942,35,Dainippon-Sumitomo,Regional & Specialty Pharma,42,Lunesta,eszopiclone,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,,May-14,N/A,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1452,Insomnia,7/7/14 12:28
942,35,Dainippon-Sumitomo,Regional & Specialty Pharma,42,Lunesta,eszopiclone,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,,May-14,N/A,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,Global,Sales,113.1192268,629.1657426,533.0559023,539.3355819,565.8059902,243.3765637,32.29303708,20.73147111,15.25277704,11.43533932,9.520329993,8.210761594,-45.37540268,1452,Insomnia,7/7/14 12:28
942,35,Dainippon-Sumitomo,Regional & Specialty Pharma,42,Lunesta,eszopiclone,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,,May-14,N/A,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1452,Insomnia,7/7/14 12:28
942,35,Dainippon-Sumitomo,Regional & Specialty Pharma,42,Lunesta,eszopiclone,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,,May-14,N/A,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1452,Insomnia,7/7/14 12:28
942,35,Dainippon-Sumitomo,Regional & Specialty Pharma,42,Lunesta,eszopiclone,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,,May-14,N/A,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1452,Insomnia,7/7/14 12:28
942,35,Dainippon-Sumitomo,Regional & Specialty Pharma,42,Lunesta,eszopiclone,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,,May-14,N/A,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,US,Sales,113.1192268,629.1657426,533.0559023,539.3355819,565.8059902,243.3765637,32.29303708,20.73147111,15.25277704,11.43533932,9.520329993,8.210761594,-45.37540268,1452,Insomnia,7/7/14 12:28
942,35,Sepracor,Regional & Specialty Pharma,42,Lunesta,eszopiclone,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,,May-14,N/A,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,Global,Proforma,511.7298354,0,0,0,0,0,0,0,0,0,0,0,0,1452,Insomnia,7/7/14 12:28
942,35,Sepracor,Regional & Specialty Pharma,42,Lunesta,eszopiclone,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,,May-14,N/A,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,US,Proforma,511.7298354,0,0,0,0,0,0,0,0,0,0,0,0,1452,Insomnia,7/7/14 12:28
944,1,Abbott,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jan-90,Jan-90,Expired,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Endometriosis,7/7/14 12:28
944,1,Abbott,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jan-90,Jan-90,Expired,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,Global,Sales,48,44.840768,48.6,47.76,0,0,0,0,0,0,0,0,0,1517,Endometriosis,7/7/14 12:28
944,1,Abbott,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jan-90,Jan-90,Expired,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Endometriosis,7/7/14 12:28
944,1,Abbott,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jan-90,Jan-90,Expired,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,ROW,Sales,15.6,15.840768,16.2,14,0,0,0,0,0,0,0,0,0,1517,Endometriosis,7/7/14 12:28
944,1,Abbott,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jan-90,Jan-90,Expired,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Endometriosis,7/7/14 12:28
944,1,Abbott,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jan-90,Jan-90,Expired,Expired,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,US,Sales,32.4,29,32.4,33.76,0,0,0,0,0,0,0,0,0,1517,Endometriosis,7/7/14 12:28
945,1,Abbott,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Feb-99,Jan-99,Expired,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Prostate Cancer,7/7/14 12:28
945,1,Abbott,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Feb-99,Jan-99,Expired,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,6,Global,Sales,752,703,761.4,751.8,0,0,0,0,0,0,0,0,0,1517,Prostate Cancer,7/7/14 12:28
945,1,Abbott,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Feb-99,Jan-99,Expired,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Prostate Cancer,7/7/14 12:28
945,1,Abbott,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Feb-99,Jan-99,Expired,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,6,ROW,Sales,244.4,249,253.8,217,0,0,0,0,0,0,0,0,0,1517,Prostate Cancer,7/7/14 12:28
945,1,Abbott,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Feb-99,Jan-99,Expired,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Prostate Cancer,7/7/14 12:28
945,1,Abbott,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Feb-99,Jan-99,Expired,Expired,33,LHRH Analogs,55,Hormonals,3,Oncology,6,US,Sales,507.6,454,507.6,534.8,0,0,0,0,0,0,0,0,0,1517,Prostate Cancer,7/7/14 12:28
946,893,ImmuPharma,Small Biotech,1093,Lupuzor,forigerimod,Synthetic Peptide,Phase II,In-House,Apr-17,Nov-17,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,Global,Sales,0,0,0,0,0,0,0,0,22.79979833,92.71923477,183.9185611,275.1179047,0,648,Systemic Lupus Erythematosus,7/7/14 12:28
946,893,ImmuPharma,Small Biotech,1093,Lupuzor,forigerimod,Synthetic Peptide,Phase II,In-House,Apr-17,Nov-17,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,ROW,Sales,0,0,0,0,0,0,0,0,5.211390516,39.95401133,92.06802601,144.1822114,0,648,Systemic Lupus Erythematosus,7/7/14 12:28
946,893,ImmuPharma,Small Biotech,1093,Lupuzor,forigerimod,Synthetic Peptide,Phase II,In-House,Apr-17,Nov-17,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,US,Sales,0,0,0,0,0,0,0,0,17.58840782,52.76522345,91.85053506,130.9356932,0,648,Systemic Lupus Erythematosus,7/7/14 12:28
947,35,Dainippon-Sumitomo,Regional & Specialty Pharma,3311,Latuda,lurasidone,Small Molecule (Chemical),Launched,In-House,Feb-11,Sep-12,Jul-18,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,649,Schizophrenia,7/7/14 12:28
947,35,Dainippon-Sumitomo,Regional & Specialty Pharma,3311,Latuda,lurasidone,Small Molecule (Chemical),Launched,In-House,Feb-11,Sep-12,Jul-18,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Sales,0,5.836416907,87.36545667,206.3721809,396.5908667,547.7231402,583.7046226,601.8900068,629.547596,397.0232873,166.4963935,110.7682287,-16.65729739,649,Schizophrenia,7/7/14 12:28
947,35,Dainippon-Sumitomo,Regional & Specialty Pharma,3311,Latuda,lurasidone,Small Molecule (Chemical),Launched,In-House,Feb-11,Sep-12,Jul-18,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,649,Schizophrenia,7/7/14 12:28
947,35,Dainippon-Sumitomo,Regional & Specialty Pharma,3311,Latuda,lurasidone,Small Molecule (Chemical),Launched,In-House,Feb-11,Sep-12,Jul-18,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Sales,0,0,0,13.75233026,24.08514359,34.26930571,50.92076136,60.64925887,68.97682139,76.26565654,81.92752662,86.60569528,20.06032715,649,Schizophrenia,7/7/14 12:28
947,35,Dainippon-Sumitomo,Regional & Specialty Pharma,3311,Latuda,lurasidone,Small Molecule (Chemical),Launched,In-House,Feb-11,Sep-12,Jul-18,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,649,Schizophrenia,7/7/14 12:28
947,35,Dainippon-Sumitomo,Regional & Specialty Pharma,3311,Latuda,lurasidone,Small Molecule (Chemical),Launched,In-House,Feb-11,Sep-12,Jul-18,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Sales,0,5.836416907,87.36545667,192.6198507,372.5057231,513.4538345,532.7838612,541.2407479,560.5707746,320.7576307,84.56886686,24.16253339,-32.34697134,649,Schizophrenia,7/7/14 12:28
948,15,Astellas Pharma,Regional & Specialty Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-99,N/A,May-07,127,Serotonergics,49,Depression,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
948,15,Astellas Pharma,Regional & Specialty Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-99,N/A,May-07,127,Serotonergics,49,Depression,12,Central Nervous System,7,Global,Sales,101.2686411,95.71723727,77.23612836,0,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
948,15,Astellas Pharma,Regional & Specialty Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-99,N/A,May-07,127,Serotonergics,49,Depression,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
948,15,Astellas Pharma,Regional & Specialty Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-99,N/A,May-07,127,Serotonergics,49,Depression,12,Central Nervous System,7,ROW,Sales,101.2686411,95.71723727,77.23612836,0,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
948,15,Astellas Pharma,Regional & Specialty Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-99,N/A,May-07,127,Serotonergics,49,Depression,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
948,15,Astellas Pharma,Regional & Specialty Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-99,N/A,May-07,127,Serotonergics,49,Depression,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
949,1,Abbott,Regional & Specialty Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-83,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
949,1,Abbott,Regional & Specialty Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-83,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,Global,Sales,0,108.86,121.54,118.72,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
949,1,Abbott,Regional & Specialty Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-83,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
949,1,Abbott,Regional & Specialty Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-83,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,ROW,Sales,0,108.86,121.54,118.72,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
949,1,Abbott,Regional & Specialty Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-83,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
949,1,Abbott,Regional & Specialty Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-83,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
949,1,Solvay,Regional & Specialty Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-83,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,Global,Proforma,125,15.5,0,0,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
949,1,Solvay,Regional & Specialty Pharma,471,Luvox,fluvoxamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Sep-83,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,ROW,Proforma,125,15.5,0,0,0,0,0,0,0,0,0,0,0,1474,Depression,7/7/14 12:28
950,52,Jazz Pharmaceuticals,Small Biotech,1028,Luvox CR,fluvoxamine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-08,,Mar-13,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,Global,Sales,18.3,27.4,33.17,42.219,17,6,5,4.4,3,3,3,3,-21.94838934,1474,Obsessive Compulsive Disorder,7/7/14 12:28
950,52,Jazz Pharmaceuticals,Small Biotech,1028,Luvox CR,fluvoxamine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-08,,Mar-13,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1474,Obsessive Compulsive Disorder,7/7/14 12:28
950,52,Jazz Pharmaceuticals,Small Biotech,1028,Luvox CR,fluvoxamine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-08,,Mar-13,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,US,Sales,18.3,27.4,33.17,42.219,17,6,5,4.4,3,3,3,3,-21.94838934,1474,Obsessive Compulsive Disorder,7/7/14 12:28
951,24,Bristol-Myers Squibb,Large Pharma,1189,LXR Agonist,,Small Molecule (Chemical),Phase I,Licensed (Marketed),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,650,Atherosclerosis / Secondary Prevention,7/7/14 12:28
951,24,Bristol-Myers Squibb,Large Pharma,1189,LXR Agonist,,Small Molecule (Chemical),Phase I,Licensed (Marketed),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,650,Atherosclerosis / Secondary Prevention,7/7/14 12:28
951,24,Bristol-Myers Squibb,Large Pharma,1189,LXR Agonist,,Small Molecule (Chemical),Phase I,Licensed (Marketed),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,650,Atherosclerosis / Secondary Prevention,7/7/14 12:28
951,24,Bristol-Myers Squibb,Large Pharma,1189,LXR Agonist,,Small Molecule (Chemical),Phase I,Licensed (Marketed),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,650,Atherosclerosis / Secondary Prevention,7/7/14 12:28
951,24,Bristol-Myers Squibb,Large Pharma,1189,LXR Agonist,,Small Molecule (Chemical),Phase I,Licensed (Marketed),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,650,Atherosclerosis / Secondary Prevention,7/7/14 12:28
951,24,Bristol-Myers Squibb,Large Pharma,1189,LXR Agonist,,Small Molecule (Chemical),Phase I,Licensed (Marketed),,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,650,Atherosclerosis / Secondary Prevention,7/7/14 12:28
952,39,Eli Lilly,Large Pharma,4342,tabalumab,LY-2127399,Antibody/Antibody Derivative,Phase III,In-House,Nov-15,Nov-15,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,651,Systemic Lupus Erythematosus,7/7/14 12:28
952,39,Eli Lilly,Large Pharma,4342,tabalumab,LY-2127399,Antibody/Antibody Derivative,Phase III,In-House,Nov-15,Nov-15,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,8.33335,63.88904444,147.2227196,230.5566677,292.7792402,351.0018047,0,651,Systemic Lupus Erythematosus,7/7/14 12:28
952,39,Eli Lilly,Large Pharma,4342,tabalumab,LY-2127399,Antibody/Antibody Derivative,Phase III,In-House,Nov-15,Nov-15,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,651,Systemic Lupus Erythematosus,7/7/14 12:28
952,39,Eli Lilly,Large Pharma,4342,tabalumab,LY-2127399,Antibody/Antibody Derivative,Phase III,In-House,Nov-15,Nov-15,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,3.33334,25.55561778,58.88908783,92.2226671,117.1116961,140.4007219,0,651,Systemic Lupus Erythematosus,7/7/14 12:28
952,39,Eli Lilly,Large Pharma,4342,tabalumab,LY-2127399,Antibody/Antibody Derivative,Phase III,In-House,Nov-15,Nov-15,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,651,Systemic Lupus Erythematosus,7/7/14 12:28
952,39,Eli Lilly,Large Pharma,4342,tabalumab,LY-2127399,Antibody/Antibody Derivative,Phase III,In-House,Nov-15,Nov-15,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,5.00001,38.33342667,88.33363174,138.3340006,175.6675441,210.6010828,0,651,Systemic Lupus Erythematosus,7/7/14 12:28
954,39,Eli Lilly,Large Pharma,407,LY2157299,galunisertib,Small Molecule (Chemical),Phase II,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,653,Solid Tumors,7/7/14 12:28
954,39,Eli Lilly,Large Pharma,407,LY2157299,galunisertib,Small Molecule (Chemical),Phase II,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,653,Solid Tumors,7/7/14 12:28
954,39,Eli Lilly,Large Pharma,407,LY2157299,galunisertib,Small Molecule (Chemical),Phase II,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,653,Solid Tumors,7/7/14 12:28
954,39,Eli Lilly,Large Pharma,407,LY2157299,galunisertib,Small Molecule (Chemical),Phase II,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,653,Solid Tumors,7/7/14 12:28
954,39,Eli Lilly,Large Pharma,407,LY2157299,galunisertib,Small Molecule (Chemical),Phase II,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,653,Solid Tumors,7/7/14 12:28
954,39,Eli Lilly,Large Pharma,407,LY2157299,galunisertib,Small Molecule (Chemical),Phase II,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,653,Solid Tumors,7/7/14 12:28
966,76,Pfizer,Large Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Sep-04,Dec-18,May-18,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1598,Epilepsy,7/7/14 12:28
966,76,Pfizer,Large Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Sep-04,Dec-18,May-18,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,284.8,289,329,349.36,388,415.666,437.2813,453.632665,471.1417559,420.5168046,209.8505594,169.6881521,-11.14362466,1598,Epilepsy,7/7/14 12:28
966,76,Pfizer,Large Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Sep-04,Dec-18,May-18,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1598,Epilepsy,7/7/14 12:28
966,76,Pfizer,Large Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Sep-04,Dec-18,May-18,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,126.9,147,185.2,198.88,211,217.45,222.0925,224.865625,226.7195312,174.7811137,111.5709301,89.3514613,-11.55189938,1598,Epilepsy,7/7/14 12:28
966,76,Pfizer,Large Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Sep-04,Dec-18,May-18,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1598,Epilepsy,7/7/14 12:28
966,76,Pfizer,Large Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Sep-04,Dec-18,May-18,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,157.9,142,143.8,150.48,177,198.216,215.1888,228.76704,244.4222246,245.7356909,98.27962932,80.33669077,-10.67118485,1598,Epilepsy,7/7/14 12:28
967,76,Pfizer,Large Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Sep-04,Dec-18,May-18,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1598,Neuropathic Pain,7/7/14 12:28
967,76,Pfizer,Large Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Sep-04,Dec-18,May-18,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,2555.2,2773,3364,3808.6,4207,4525.4325,4731.481375,4869.531669,5122.255075,4263.597905,1607.396099,1334.717819,-15.12614651,1598,Neuropathic Pain,7/7/14 12:28
967,76,Pfizer,Large Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Sep-04,Dec-18,May-18,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1598,Neuropathic Pain,7/7/14 12:28
967,76,Pfizer,Large Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Sep-04,Dec-18,May-18,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,1209.1,1491,1993.8,2287.1,2421,2607.1825,2747.106375,2852.094169,2945.908512,1964.041998,940.2803963,636.2019632,-17.37987875,1598,Neuropathic Pain,7/7/14 12:28
967,76,Pfizer,Large Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Sep-04,Dec-18,May-18,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1598,Neuropathic Pain,7/7/14 12:28
967,76,Pfizer,Large Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-05,Sep-04,Dec-18,May-18,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,1346.1,1282,1370.2,1521.5,1786,1918.25,1984.375,2017.4375,2176.346562,2299.555906,667.1157031,698.5158555,-12.55067528,1598,Neuropathic Pain,7/7/14 12:28
968,111,Actavis,Regional & Specialty Pharma,1115,Macrobid,nitrofurantoin monohydrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-92,Jul-00,Jun-06,Jun-07,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,2.7,0,0,0,0,0,0,0,-100,1533,,7/7/14 12:28
968,111,Actavis,Regional & Specialty Pharma,1115,Macrobid,nitrofurantoin monohydrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-92,Jul-00,Jun-06,Jun-07,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,2.20E-04,-1.85E-02,3.25E-02,0,7.62635044,25.84937368,21.55639573,17.78365824,14.42908505,11.44387739,8.790542372,8,0.685655357,1533,,7/7/14 12:28
968,111,Actavis,Regional & Specialty Pharma,1115,Macrobid,nitrofurantoin monohydrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-92,Jul-00,Jun-06,Jun-07,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,2.7,0,0,0,0,0,0,0,-100,1533,,7/7/14 12:28
968,111,Actavis,Regional & Specialty Pharma,1115,Macrobid,nitrofurantoin monohydrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-92,Jul-00,Jun-06,Jun-07,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,-5.00E-04,8.60E-03,2.77E-02,0,5.4751382,18.98775204,16.33005736,13.93302714,11.74572151,9.753065811,7.940929067,7,3.572214937,1533,,7/7/14 12:28
968,111,Actavis,Regional & Specialty Pharma,1115,Macrobid,nitrofurantoin monohydrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-92,Jul-00,Jun-06,Jun-07,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1533,,7/7/14 12:28
968,111,Actavis,Regional & Specialty Pharma,1115,Macrobid,nitrofurantoin monohydrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-92,Jul-00,Jun-06,Jun-07,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,7.20E-04,-2.71E-02,4.73E-03,0,2.15121224,6.86162165,5.226338373,3.850631097,2.683363543,1.690811581,0.849613305,1,-10.36577507,1533,,7/7/14 12:28
968,111,Warner Chilcott ,Regional & Specialty Pharma,1115,Macrobid,nitrofurantoin monohydrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-92,Jul-00,Jun-06,Jun-07,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Proforma,56.4,48.9,42.5,36,20.3,0,0,0,0,0,0,0,-100,1533,,7/7/14 12:28
968,111,Warner Chilcott ,Regional & Specialty Pharma,1115,Macrobid,nitrofurantoin monohydrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-92,Jul-00,Jun-06,Jun-07,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Proforma,36,32.3,28.7,25,13.7,0,0,0,0,0,0,0,-100,1533,,7/7/14 12:28
968,111,Warner Chilcott ,Regional & Specialty Pharma,1115,Macrobid,nitrofurantoin monohydrate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-92,Jul-00,Jun-06,Jun-07,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Proforma,20.4,16.6,13.8,11,6.6,0,0,0,0,0,0,0,-100,1533,,7/7/14 12:28
970,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1084,Maintate,bisoprolol,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-90,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1364,Hypertension,7/7/14 12:28
970,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1084,Maintate,bisoprolol,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-90,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,Global,Sales,115.2767953,143.5758559,173.4647473,169.7462434,161.0835559,168.9363792,176.3542768,180.9093975,184.3295364,186.6540154,188.3116611,189.4662886,2.345479966,1364,Hypertension,7/7/14 12:28
970,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1084,Maintate,bisoprolol,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-90,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1364,Hypertension,7/7/14 12:28
970,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1084,Maintate,bisoprolol,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-90,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,115.2767953,143.5758559,173.4647473,169.7462434,161.0835559,168.9363792,176.3542768,180.9093975,184.3295364,186.6540154,188.3116611,189.4662886,2.345479966,1364,Hypertension,7/7/14 12:28
970,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1084,Maintate,bisoprolol,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-90,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1364,Hypertension,7/7/14 12:28
970,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1084,Maintate,bisoprolol,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-90,N/A,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1364,Hypertension,7/7/14 12:28
971,1,Abbott,Regional & Specialty Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-86,,Jun-08,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1428,Appetite Stimulant,7/7/14 12:28
971,1,Abbott,Regional & Specialty Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-86,,Jun-08,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,Global,Sales,0,6.5,4,2.12,0,0,0,0,0,0,0,0,0,1428,Appetite Stimulant,7/7/14 12:28
971,1,Abbott,Regional & Specialty Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-86,,Jun-08,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1428,Appetite Stimulant,7/7/14 12:28
971,1,Abbott,Regional & Specialty Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-86,,Jun-08,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1428,Appetite Stimulant,7/7/14 12:28
971,1,Abbott,Regional & Specialty Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-86,,Jun-08,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1428,Appetite Stimulant,7/7/14 12:28
971,1,Abbott,Regional & Specialty Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-86,,Jun-08,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,US,Sales,0,6.5,4,2.12,0,0,0,0,0,0,0,0,0,1428,Appetite Stimulant,7/7/14 12:28
971,1,Solvay,Regional & Specialty Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-86,,Jun-08,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,Global,Proforma,26,1.5,0,0,0,0,0,0,0,0,0,0,0,1428,Appetite Stimulant,7/7/14 12:28
971,1,Solvay,Regional & Specialty Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-86,,Jun-08,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,US,Proforma,26,1.5,0,0,0,0,0,0,0,0,0,0,0,1428,Appetite Stimulant,7/7/14 12:28
973,61,Merck & Co,Large Pharma,1142,Marvelon,ethinyloestradiol + desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-91,Expired,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1418,Female contraception,7/7/14 12:28
973,61,Merck & Co,Large Pharma,1142,Marvelon,ethinyloestradiol + desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-91,Expired,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,21.572305,118.2651901,109.7680968,103.5662858,98.625313,94.19195058,90.20943182,86.62581788,83.40082941,80.49843125,77.88628569,75.53535902,-3.738701215,1418,Female contraception,7/7/14 12:28
973,61,Merck & Co,Large Pharma,1142,Marvelon,ethinyloestradiol + desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-91,Expired,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1418,Female contraception,7/7/14 12:28
973,61,Merck & Co,Large Pharma,1142,Marvelon,ethinyloestradiol + desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-91,Expired,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,21,116.4,108.72,102.576,97.6608,93.23712,89.255808,85.6726272,82.44776448,79.54538803,76.93324923,74.58232431,-3.778155213,1418,Female contraception,7/7/14 12:28
973,61,Merck & Co,Large Pharma,1142,Marvelon,ethinyloestradiol + desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-91,Expired,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1418,Female contraception,7/7/14 12:28
973,61,Merck & Co,Large Pharma,1142,Marvelon,ethinyloestradiol + desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-91,Expired,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0.572305,1.865190125,1.048096828,0.990285823,0.964512999,0.954830581,0.953623818,0.953190684,0.95306493,0.953043222,0.953036461,0.953034709,-0.170882031,1418,Female contraception,7/7/14 12:28
973,61,Schering-Plough,Large Pharma,1142,Marvelon,ethinyloestradiol + desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-91,Expired,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Proforma,107.5,0,0,0,0,0,0,0,0,0,0,0,0,1418,Female contraception,7/7/14 12:28
973,61,Schering-Plough,Large Pharma,1142,Marvelon,ethinyloestradiol + desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-91,Expired,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Proforma,105,0,0,0,0,0,0,0,0,0,0,0,0,1418,Female contraception,7/7/14 12:28
973,61,Schering-Plough,Large Pharma,1142,Marvelon,ethinyloestradiol + desogestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-92,Jul-91,Expired,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Proforma,2.5,0,0,0,0,0,0,0,0,0,0,0,0,1418,Female contraception,7/7/14 12:28
975,100,Nycomed,Large Pharma,693,Matrifen,fentanyl - transdermal,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-06,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Proforma,51.41139577,46.36624683,35.16233277,0,0,0,0,0,0,0,0,0,0,1746,Chronic Pain,7/7/14 12:28
975,100,Nycomed,Large Pharma,693,Matrifen,fentanyl - transdermal,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-06,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Proforma,51.41139577,46.36624683,35.16233277,0,0,0,0,0,0,0,0,0,0,1746,Chronic Pain,7/7/14 12:28
975,100,Takeda,Large Pharma,693,Matrifen,fentanyl - transdermal,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-06,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1746,Chronic Pain,7/7/14 12:28
975,100,Takeda,Large Pharma,693,Matrifen,fentanyl - transdermal,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-06,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,4.51E-05,8.14E-05,15.55738612,49.69649198,47.73353066,46.77149279,45.68209456,44.51748696,43.47103266,42.43506803,30.20316674,30.20316674,-6.32921495,1746,Chronic Pain,7/7/14 12:28
975,100,Takeda,Large Pharma,693,Matrifen,fentanyl - transdermal,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-06,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1746,Chronic Pain,7/7/14 12:28
975,100,Takeda,Large Pharma,693,Matrifen,fentanyl - transdermal,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-06,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,4.51E-05,8.14E-05,15.55738612,49.69649198,47.73353066,46.77149279,45.68209456,44.51748696,43.47103266,42.43506803,30.20316674,30.20316674,-6.32921495,1746,Chronic Pain,7/7/14 12:28
975,100,Takeda,Large Pharma,693,Matrifen,fentanyl - transdermal,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-06,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1746,Chronic Pain,7/7/14 12:28
975,100,Takeda,Large Pharma,693,Matrifen,fentanyl - transdermal,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-06,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1746,Chronic Pain,7/7/14 12:28
976,1,Abbott,Regional & Specialty Pharma,650,Mavik / Tarka,trandolapril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Jan-93,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,666,Hypertension,7/7/14 12:28
976,1,Abbott,Regional & Specialty Pharma,650,Mavik / Tarka,trandolapril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Jan-93,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Sales,96,64,43.743,36.87875,30.4741375,28.86764688,27.71890734,26.95028762,26.42517269,26.06372705,25.81773643,25.64951043,-2.432131151,666,Hypertension,7/7/14 12:28
976,1,Abbott,Regional & Specialty Pharma,650,Mavik / Tarka,trandolapril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Jan-93,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,666,Hypertension,7/7/14 12:28
976,1,Abbott,Regional & Specialty Pharma,650,Mavik / Tarka,trandolapril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Jan-93,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,49,41,36.743,32.87875,30.4741375,28.86764688,27.71890734,26.95028762,26.42517269,26.06372705,25.81773643,25.64951043,-2.432131151,666,Hypertension,7/7/14 12:28
976,1,Abbott,Regional & Specialty Pharma,650,Mavik / Tarka,trandolapril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Jan-93,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,666,Hypertension,7/7/14 12:28
976,1,Abbott,Regional & Specialty Pharma,650,Mavik / Tarka,trandolapril,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-97,Jan-93,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Sales,47,23,7,4,0,0,0,0,0,0,0,0,0,666,Hypertension,7/7/14 12:28
977,61,Merck & Co,Large Pharma,692,Maxalt,rizatriptan,Small Molecule (Chemical),Launched,In-House,Jul-98,Mar-98,Jan-13,Jan-13,117,Triptans,8,Migraine,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,667,Migraine,7/7/14 12:28
977,61,Merck & Co,Large Pharma,692,Maxalt,rizatriptan,Small Molecule (Chemical),Launched,In-House,Jul-98,Mar-98,Jan-13,Jan-13,117,Triptans,8,Migraine,12,Central Nervous System,6,Global,Sales,574,551,638,637,149,113.25,93.4625,82.53137188,75.02687719,69.73876073,66.93869447,65.20865141,-11.13488037,667,Migraine,7/7/14 12:28
977,61,Merck & Co,Large Pharma,692,Maxalt,rizatriptan,Small Molecule (Chemical),Launched,In-House,Jul-98,Mar-98,Jan-13,Jan-13,117,Triptans,8,Migraine,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,667,Migraine,7/7/14 12:28
977,61,Merck & Co,Large Pharma,692,Maxalt,rizatriptan,Small Molecule (Chemical),Launched,In-House,Jul-98,Mar-98,Jan-13,Jan-13,117,Triptans,8,Migraine,12,Central Nervous System,6,ROW,Sales,176,173,187,146,111,88.25,73.4625,63.53137188,57.02687719,52.73876073,50.13869447,48.44865141,-11.16878915,667,Migraine,7/7/14 12:28
977,61,Merck & Co,Large Pharma,692,Maxalt,rizatriptan,Small Molecule (Chemical),Launched,In-House,Jul-98,Mar-98,Jan-13,Jan-13,117,Triptans,8,Migraine,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,667,Migraine,7/7/14 12:28
977,61,Merck & Co,Large Pharma,692,Maxalt,rizatriptan,Small Molecule (Chemical),Launched,In-House,Jul-98,Mar-98,Jan-13,Jan-13,117,Triptans,8,Migraine,12,Central Nervous System,6,US,Sales,398,378,451,491,38,25,20,19,18,17,16.8,16.76,-11.03627323,667,Migraine,7/7/14 12:28
978,24,Bristol-Myers Squibb,Large Pharma,1002,Maxipime,cefepime,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Jun-09,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1384,,7/7/14 12:28
978,24,Bristol-Myers Squibb,Large Pharma,1002,Maxipime,cefepime,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Jun-09,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,120,104.52624,90.996432,78.6936528,70.7106024,64.47761006,59.69442979,56.17957104,53.51618188,51.51050892,50.00761394,48.87611761,-5.139048847,1384,,7/7/14 12:28
978,24,Bristol-Myers Squibb,Large Pharma,1002,Maxipime,cefepime,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Jun-09,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1384,,7/7/14 12:28
978,24,Bristol-Myers Squibb,Large Pharma,1002,Maxipime,cefepime,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Jun-09,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,120,104.52624,90.996432,78.6936528,70.7106024,64.47761006,59.69442979,56.17957104,53.51618188,51.51050892,50.00761394,48.87611761,-5.139048847,1384,,7/7/14 12:28
978,24,Bristol-Myers Squibb,Large Pharma,1002,Maxipime,cefepime,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Jun-09,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1384,,7/7/14 12:28
978,24,Bristol-Myers Squibb,Large Pharma,1002,Maxipime,cefepime,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Jun-09,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1384,,7/7/14 12:28
979,2409,Elan,Regional & Specialty Pharma,1002,Maxipime,cefepime,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-96,,Mar-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Proforma,13.2,8.2,0,0,0,0,0,0,0,0,0,0,0,1384,Bacterial Infections,7/7/14 12:28
979,2409,Elan,Regional & Specialty Pharma,1002,Maxipime,cefepime,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-96,,Mar-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Proforma,13.2,8.2,0,0,0,0,0,0,0,0,0,0,0,1384,Bacterial Infections,7/7/14 12:28
979,2409,Perrigo ,Regional & Specialty Pharma,1002,Maxipime,cefepime,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-96,,Mar-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1384,Bacterial Infections,7/7/14 12:28
979,2409,Perrigo ,Regional & Specialty Pharma,1002,Maxipime,cefepime,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-96,,Mar-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1384,Bacterial Infections,7/7/14 12:28
979,2409,Perrigo ,Regional & Specialty Pharma,1002,Maxipime,cefepime,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-96,,Mar-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1384,Bacterial Infections,7/7/14 12:28
979,2409,Perrigo ,Regional & Specialty Pharma,1002,Maxipime,cefepime,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-96,,Mar-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1384,Bacterial Infections,7/7/14 12:28
979,2409,Perrigo ,Regional & Specialty Pharma,1002,Maxipime,cefepime,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-96,,Mar-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1384,Bacterial Infections,7/7/14 12:28
979,2409,Perrigo ,Regional & Specialty Pharma,1002,Maxipime,cefepime,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-96,,Mar-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1384,Bacterial Infections,7/7/14 12:28
984,16,AstraZeneca,Large Pharma,2239,sifalimumab,sifalimumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1087,Systemic lupus erythematosus,7/7/14 12:28
984,16,AstraZeneca,Large Pharma,2239,sifalimumab,sifalimumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1087,Systemic lupus erythematosus,7/7/14 12:28
984,16,AstraZeneca,Large Pharma,2239,sifalimumab,sifalimumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1087,Systemic lupus erythematosus,7/7/14 12:28
984,16,AstraZeneca,Large Pharma,2239,sifalimumab,sifalimumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1087,Systemic lupus erythematosus,7/7/14 12:28
984,16,AstraZeneca,Large Pharma,2239,sifalimumab,sifalimumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1087,Systemic lupus erythematosus,7/7/14 12:28
984,16,AstraZeneca,Large Pharma,2239,sifalimumab,sifalimumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1087,Systemic lupus erythematosus,7/7/14 12:28
986,16,AstraZeneca,Large Pharma,1616,MEDI-559,RSV vaccine,Vaccine,Phase I,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,682,LRT disease caused by RSV,7/7/14 12:28
986,16,AstraZeneca,Large Pharma,1616,MEDI-559,RSV vaccine,Vaccine,Phase I,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,682,LRT disease caused by RSV,7/7/14 12:28
986,16,AstraZeneca,Large Pharma,1616,MEDI-559,RSV vaccine,Vaccine,Phase I,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,682,LRT disease caused by RSV,7/7/14 12:28
986,16,AstraZeneca,Large Pharma,1616,MEDI-559,RSV vaccine,Vaccine,Phase I,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,682,LRT disease caused by RSV,7/7/14 12:28
986,16,AstraZeneca,Large Pharma,1616,MEDI-559,RSV vaccine,Vaccine,Phase I,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,682,LRT disease caused by RSV,7/7/14 12:28
986,16,AstraZeneca,Large Pharma,1616,MEDI-559,RSV vaccine,Vaccine,Phase I,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,682,LRT disease caused by RSV,7/7/14 12:28
988,16,AstraZeneca,Large Pharma,3035,benralizumab,KHK-4563,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jul-17,Jul-17,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,684,Asthma,7/7/14 12:28
988,16,AstraZeneca,Large Pharma,3035,benralizumab,KHK-4563,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jul-17,Jul-17,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,14.1225,57.2447064,94.71766366,117.7662599,0,684,Asthma,7/7/14 12:28
988,16,AstraZeneca,Large Pharma,3035,benralizumab,KHK-4563,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jul-17,Jul-17,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,684,Asthma,7/7/14 12:28
988,16,AstraZeneca,Large Pharma,3035,benralizumab,KHK-4563,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jul-17,Jul-17,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,4.7075,19.0815688,31.57255455,39.25541998,0,684,Asthma,7/7/14 12:28
988,16,AstraZeneca,Large Pharma,3035,benralizumab,KHK-4563,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jul-17,Jul-17,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,684,Asthma,7/7/14 12:28
988,16,AstraZeneca,Large Pharma,3035,benralizumab,KHK-4563,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jul-17,Jul-17,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,9.415,38.1631376,63.1451091,78.51083995,0,684,Asthma,7/7/14 12:28
989,76,Pfizer,Large Pharma,58,Medrol / Solu-Medrol,methylprednisolone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-57,Jun-70,Expired,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3830,Endocrine Disorders,7/7/14 12:28
989,76,Pfizer,Large Pharma,58,Medrol / Solu-Medrol,methylprednisolone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-57,Jun-70,Expired,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Sales,457,455,510,523,464,429,408.26,395.985,388.72985,384.4481625,381.9255616,380.4421687,-2.796582027,3830,Endocrine Disorders,7/7/14 12:28
989,76,Pfizer,Large Pharma,58,Medrol / Solu-Medrol,methylprednisolone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-57,Jun-70,Expired,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3830,Endocrine Disorders,7/7/14 12:28
989,76,Pfizer,Large Pharma,58,Medrol / Solu-Medrol,methylprednisolone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-57,Jun-70,Expired,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,ROW,Sales,317,342,358,383,316,275.8,251.68,237.208,228.5248,223.31488,220.188928,218.3133568,-5.145880295,3830,Endocrine Disorders,7/7/14 12:28
989,76,Pfizer,Large Pharma,58,Medrol / Solu-Medrol,methylprednisolone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-57,Jun-70,Expired,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3830,Endocrine Disorders,7/7/14 12:28
989,76,Pfizer,Large Pharma,58,Medrol / Solu-Medrol,methylprednisolone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-57,Jun-70,Expired,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Sales,140,113,152,140,148,153.2,156.58,158.777,160.20505,161.1332825,161.7366336,162.1288119,1.311074322,3830,Endocrine Disorders,7/7/14 12:28
991,19,Bayer,Large Pharma,512,Meliane,gestodene + ethinyloestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jun-95,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1483,Female contraception,7/7/14 12:28
991,19,Bayer,Large Pharma,512,Meliane,gestodene + ethinyloestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jun-95,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,2,Global,Sales,118.9434852,99.29972409,92.1119551,74.64388042,69.60602552,63.21306767,57.77905351,53.16014146,49.23406623,45.89690228,43.06031292,40.64921196,-7.39608213,1483,Female contraception,7/7/14 12:28
991,19,Bayer,Large Pharma,512,Meliane,gestodene + ethinyloestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jun-95,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1483,Female contraception,7/7/14 12:28
991,19,Bayer,Large Pharma,512,Meliane,gestodene + ethinyloestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jun-95,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,2,ROW,Sales,118.9434852,99.29972409,92.1119551,74.64388042,69.60602552,63.21306767,57.77905351,53.16014146,49.23406623,45.89690228,43.06031292,40.64921196,-7.39608213,1483,Female contraception,7/7/14 12:28
991,19,Bayer,Large Pharma,512,Meliane,gestodene + ethinyloestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jun-95,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1483,Female contraception,7/7/14 12:28
991,19,Bayer,Large Pharma,512,Meliane,gestodene + ethinyloestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jun-95,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1483,Female contraception,7/7/14 12:28
992,34,Daiichi-Sankyo,Regional & Specialty Pharma,3445,Memary,memantine,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-11,N/A,Jun-20,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1539,Alzheimer's Disease,7/7/14 12:28
992,34,Daiichi-Sankyo,Regional & Specialty Pharma,3445,Memary,memantine,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-11,N/A,Jun-20,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,7,Global,Sales,0,0,124.0842718,286.5220279,342.3025563,444.9933232,522.2328882,585.2085043,637.8469859,680.3088729,715.0412008,715.974995,11.11787135,1539,Alzheimer's Disease,7/7/14 12:28
992,34,Daiichi-Sankyo,Regional & Specialty Pharma,3445,Memary,memantine,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-11,N/A,Jun-20,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1539,Alzheimer's Disease,7/7/14 12:28
992,34,Daiichi-Sankyo,Regional & Specialty Pharma,3445,Memary,memantine,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-11,N/A,Jun-20,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,7,ROW,Sales,0,0,124.0842718,286.5220279,342.3025563,444.9933232,522.2328882,585.2085043,637.8469859,680.3088729,715.0412008,715.974995,11.11787135,1539,Alzheimer's Disease,7/7/14 12:28
992,34,Daiichi-Sankyo,Regional & Specialty Pharma,3445,Memary,memantine,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-11,N/A,Jun-20,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1539,Alzheimer's Disease,7/7/14 12:28
992,34,Daiichi-Sankyo,Regional & Specialty Pharma,3445,Memary,memantine,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-11,N/A,Jun-20,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1539,Alzheimer's Disease,7/7/14 12:28
994,46,GlaxoSmithKline,Large Pharma,2472,Nimenrix,MenACWY-TT,Vaccine,Launched,In-House,May-19,Jun-12,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,777,meningococcus ACYW135,7/7/14 12:28
994,46,GlaxoSmithKline,Large Pharma,2472,Nimenrix,MenACWY-TT,Vaccine,Launched,In-House,May-19,Jun-12,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,0,0,0,1.585028875,18.76096834,27.76623314,36.77137787,41.02884294,43.6813745,45.4431882,57.91949387,71.92128727,21.16345803,777,meningococcus ACYW135,7/7/14 12:28
994,46,GlaxoSmithKline,Large Pharma,2472,Nimenrix,MenACWY-TT,Vaccine,Launched,In-House,May-19,Jun-12,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,777,meningococcus ACYW135,7/7/14 12:28
994,46,GlaxoSmithKline,Large Pharma,2472,Nimenrix,MenACWY-TT,Vaccine,Launched,In-House,May-19,Jun-12,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,0,0,0,1.585028875,18.76096834,27.76623314,36.77137787,41.02884294,43.6813745,45.4431882,46.45445193,47.08032485,14.04687774,777,meningococcus ACYW135,7/7/14 12:28
994,46,GlaxoSmithKline,Large Pharma,2472,Nimenrix,MenACWY-TT,Vaccine,Launched,In-House,May-19,Jun-12,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,777,meningococcus ACYW135,7/7/14 12:28
994,46,GlaxoSmithKline,Large Pharma,2472,Nimenrix,MenACWY-TT,Vaccine,Launched,In-House,May-19,Jun-12,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,0,0,0,0,0,0,0,0,0,0,11.46504194,24.84096242,0,777,meningococcus ACYW135,7/7/14 12:28
995,67,Novartis,Large Pharma,3435,Bexsero,MenB vaccine,Vaccine,Launched,In-House,Sep-14,Feb-14,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1540,Meningococcal B,7/7/14 12:28
995,67,Novartis,Large Pharma,3435,Bexsero,MenB vaccine,Vaccine,Launched,In-House,Sep-14,Feb-14,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,75,225.0002818,365.0000351,504.9996809,588.7995158,655.8693265,709.1266594,0,1540,Meningococcal B,7/7/14 12:28
995,67,Novartis,Large Pharma,3435,Bexsero,MenB vaccine,Vaccine,Launched,In-House,Sep-14,Feb-14,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1540,Meningococcal B,7/7/14 12:28
995,67,Novartis,Large Pharma,3435,Bexsero,MenB vaccine,Vaccine,Launched,In-House,Sep-14,Feb-14,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,55.00002,151.6669552,251.6670454,351.6669458,401.333628,438.7502926,465.5544512,0,1540,Meningococcal B,7/7/14 12:28
995,67,Novartis,Large Pharma,3435,Bexsero,MenB vaccine,Vaccine,Launched,In-House,Sep-14,Feb-14,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1540,Meningococcal B,7/7/14 12:28
995,67,Novartis,Large Pharma,3435,Bexsero,MenB vaccine,Vaccine,Launched,In-House,Sep-14,Feb-14,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,19.99998,73.33332667,113.3329897,153.3327351,187.4658878,217.1190339,243.5722083,0,1540,Meningococcal B,7/7/14 12:28
996,89,Sanofi,Large Pharma,1250,Meninge ACYW-conj,Meninge ACYW-conj,Vaccine,Phase II,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,689,Paediatric Meningitis,7/7/14 12:28
996,89,Sanofi,Large Pharma,1250,Meninge ACYW-conj,Meninge ACYW-conj,Vaccine,Phase II,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,689,Paediatric Meningitis,7/7/14 12:28
996,89,Sanofi,Large Pharma,1250,Meninge ACYW-conj,Meninge ACYW-conj,Vaccine,Phase II,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,689,Paediatric Meningitis,7/7/14 12:28
996,89,Sanofi,Large Pharma,1250,Meninge ACYW-conj,Meninge ACYW-conj,Vaccine,Phase II,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,689,Paediatric Meningitis,7/7/14 12:28
996,89,Sanofi,Large Pharma,1250,Meninge ACYW-conj,Meninge ACYW-conj,Vaccine,Phase II,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,689,Paediatric Meningitis,7/7/14 12:28
996,89,Sanofi,Large Pharma,1250,Meninge ACYW-conj,Meninge ACYW-conj,Vaccine,Phase II,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,689,Paediatric Meningitis,7/7/14 12:28
997,67,Novartis,Large Pharma,381,Menveo,Men ACWY vaccine,Vaccine,Launched,In-House,Apr-10,May-10,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,690,meningococcus ACYW135,7/7/14 12:28
997,67,Novartis,Large Pharma,381,Menveo,Men ACWY vaccine,Vaccine,Launched,In-House,Apr-10,May-10,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,41,142,164,209.04316,230.583962,243.2616461,252.8193116,258.5457445,262.2402455,264.6968758,266.2713862,3.517227836,690,meningococcus ACYW135,7/7/14 12:28
997,67,Novartis,Large Pharma,381,Menveo,Men ACWY vaccine,Vaccine,Launched,In-House,Apr-10,May-10,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,690,meningococcus ACYW135,7/7/14 12:28
997,67,Novartis,Large Pharma,381,Menveo,Men ACWY vaccine,Vaccine,Launched,In-House,Apr-10,May-10,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,11,42,60,73.0434,82.10425,88.1259725,92.29487062,95.14643853,97.08683748,98.41656221,99.32521003,4.488462731,690,meningococcus ACYW135,7/7/14 12:28
997,67,Novartis,Large Pharma,381,Menveo,Men ACWY vaccine,Vaccine,Launched,In-House,Apr-10,May-10,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,690,meningococcus ACYW135,7/7/14 12:28
997,67,Novartis,Large Pharma,381,Menveo,Men ACWY vaccine,Vaccine,Launched,In-House,Apr-10,May-10,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,30,100,104,135.99976,148.479712,155.1356736,160.524441,163.399306,165.153408,166.2803136,166.9461762,2.972142566,690,meningococcus ACYW135,7/7/14 12:28
998,61,Merck & Co,Large Pharma,1624,Mercilon,desogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-88,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4280,Female contraception,7/7/14 12:28
998,61,Merck & Co,Large Pharma,1624,Mercilon,desogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-88,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,22.7,121.05,105.87,93.818,82.9252,74.118224,66.90577728,61.00825756,56.18504763,52.2405349,49.01462894,46.37641563,-7.966822852,4280,Female contraception,7/7/14 12:28
998,61,Merck & Co,Large Pharma,1624,Mercilon,desogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-88,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4280,Female contraception,7/7/14 12:28
998,61,Merck & Co,Large Pharma,1624,Mercilon,desogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-88,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,22.7,121.05,105.87,93.818,82.9252,74.118224,66.90577728,61.00825756,56.18504763,52.2405349,49.01462894,46.37641563,-7.966822852,4280,Female contraception,7/7/14 12:28
998,61,Merck & Co,Large Pharma,1624,Mercilon,desogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-88,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4280,Female contraception,7/7/14 12:28
998,61,Merck & Co,Large Pharma,1624,Mercilon,desogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-88,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4280,Female contraception,7/7/14 12:28
998,61,Schering-Plough,Large Pharma,1624,Mercilon,desogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-88,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Proforma,113.3,0,0,0,0,0,0,0,0,0,0,0,0,4280,Female contraception,7/7/14 12:28
998,61,Schering-Plough,Large Pharma,1624,Mercilon,desogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-88,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Proforma,113.3,0,0,0,0,0,0,0,0,0,0,0,0,4280,Female contraception,7/7/14 12:28
1000,35,Dainippon-Sumitomo,Regional & Specialty Pharma,108,Meropen,meropenem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-95,N/A,May-11,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1541,Bacterial infections,7/7/14 12:28
1000,35,Dainippon-Sumitomo,Regional & Specialty Pharma,108,Meropen,meropenem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-95,N/A,May-11,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,368.4454815,370.200149,374.7851475,264.8522947,231.5576116,211.4221671,200.2469954,195.4396579,190.5480034,187.4864719,185.5066071,184.0632458,-3.22608696,1541,Bacterial infections,7/7/14 12:28
1000,35,Dainippon-Sumitomo,Regional & Specialty Pharma,108,Meropen,meropenem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-95,N/A,May-11,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1541,Bacterial infections,7/7/14 12:28
1000,35,Dainippon-Sumitomo,Regional & Specialty Pharma,108,Meropen,meropenem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-95,N/A,May-11,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,368.4454815,370.200149,374.7851475,264.8522947,231.5576116,211.4221671,200.2469954,195.4396579,190.5480034,187.4864719,185.5066071,184.0632458,-3.22608696,1541,Bacterial infections,7/7/14 12:28
1000,35,Dainippon-Sumitomo,Regional & Specialty Pharma,108,Meropen,meropenem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-95,N/A,May-11,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1541,Bacterial infections,7/7/14 12:28
1000,35,Dainippon-Sumitomo,Regional & Specialty Pharma,108,Meropen,meropenem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-95,N/A,May-11,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1541,Bacterial infections,7/7/14 12:28
1001,16,AstraZeneca,Large Pharma,1275,Merrem,meropenem,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-96,Jul-94,Jun-10,Jan-10,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1541,Bacterial infections,7/7/14 12:28
1001,16,AstraZeneca,Large Pharma,1275,Merrem,meropenem,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-96,Jul-94,Jun-10,Jan-10,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,872,817,583,396,293,244.26,215.5995,197.4516625,189.1486522,183.0244587,176.9670736,173.6480907,-7.201013878,1541,Bacterial infections,7/7/14 12:28
1001,16,AstraZeneca,Large Pharma,1275,Merrem,meropenem,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-96,Jul-94,Jun-10,Jan-10,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1541,Bacterial infections,7/7/14 12:28
1001,16,AstraZeneca,Large Pharma,1275,Merrem,meropenem,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-96,Jul-94,Jun-10,Jan-10,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,695,690,542,358,282,238,211,194,186,180,174,170.7,-6.920305917,1541,Bacterial infections,7/7/14 12:28
1001,16,AstraZeneca,Large Pharma,1275,Merrem,meropenem,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-96,Jul-94,Jun-10,Jan-10,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1541,Bacterial infections,7/7/14 12:28
1001,16,AstraZeneca,Large Pharma,1275,Merrem,meropenem,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-96,Jul-94,Jun-10,Jan-10,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,177,127,41,38,11,6.26,4.5995,3.4516625,3.148652187,3.024458727,2.967073628,2.94809073,-17.14724354,1541,Bacterial infections,7/7/14 12:28
1002,96,Shire,Regional & Specialty Pharma,2605,Lialda / Mezavant,mesalazine,Small Molecule (Chemical),Launched,Licensed (Development),Mar-07,Nov-07,Jun-20,Jun-20,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1724,Ulcerative colitis,7/7/14 12:28
1002,96,Shire,Regional & Specialty Pharma,2605,Lialda / Mezavant,mesalazine,Small Molecule (Chemical),Launched,Licensed (Development),Mar-07,Nov-07,Jun-20,Jun-20,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,235.897736,293.4,372.1,399.9,528.9,576.2545,562.4158163,583.3324838,599.1770086,610.7535603,619.113138,284.0341623,-8.498506442,1724,Ulcerative colitis,7/7/14 12:28
1002,96,Shire,Regional & Specialty Pharma,2605,Lialda / Mezavant,mesalazine,Small Molecule (Chemical),Launched,Licensed (Development),Mar-07,Nov-07,Jun-20,Jun-20,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1724,Ulcerative colitis,7/7/14 12:28
1002,96,Shire,Regional & Specialty Pharma,2605,Lialda / Mezavant,mesalazine,Small Molecule (Chemical),Launched,Licensed (Development),Mar-07,Nov-07,Jun-20,Jun-20,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,7.897736,13.4,29.1,35,68,85.128,100.8432,116.52,129.302848,140.6928512,150.825024,95.79404974,5.017422066,1724,Ulcerative colitis,7/7/14 12:28
1002,96,Shire,Regional & Specialty Pharma,2605,Lialda / Mezavant,mesalazine,Small Molecule (Chemical),Launched,Licensed (Development),Mar-07,Nov-07,Jun-20,Jun-20,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1724,Ulcerative colitis,7/7/14 12:28
1002,96,Shire,Regional & Specialty Pharma,2605,Lialda / Mezavant,mesalazine,Small Molecule (Chemical),Launched,Licensed (Development),Mar-07,Nov-07,Jun-20,Jun-20,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,228,280,343,364.9,460.9,491.1265,461.5726163,466.8124838,469.8741606,470.0607091,468.288114,188.2401126,-12.00789779,1724,Ulcerative colitis,7/7/14 12:28
1003,105,UCB,Regional & Specialty Pharma,1098,Metadate CD,methylphenidate CR,Small Molecule (Chemical),Launched,Corporate Acquisition,May-01,Feb-05,Oct-20,N/A,121,Stimulants,37,ADHD,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1545,ADHD,7/7/14 12:28
1003,105,UCB,Regional & Specialty Pharma,1098,Metadate CD,methylphenidate CR,Small Molecule (Chemical),Launched,Corporate Acquisition,May-01,Feb-05,Oct-20,N/A,121,Stimulants,37,ADHD,12,Central Nervous System,2,Global,Sales,100.043885,71.53675974,86.20709633,83.5426362,87.6499844,89.6420295,90.73765431,91.44317028,91.98309751,92.33346919,92.5726028,92.73893467,0.809500334,1545,ADHD,7/7/14 12:28
1003,105,UCB,Regional & Specialty Pharma,1098,Metadate CD,methylphenidate CR,Small Molecule (Chemical),Launched,Corporate Acquisition,May-01,Feb-05,Oct-20,N/A,121,Stimulants,37,ADHD,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1545,ADHD,7/7/14 12:28
1003,105,UCB,Regional & Specialty Pharma,1098,Metadate CD,methylphenidate CR,Small Molecule (Chemical),Launched,Corporate Acquisition,May-01,Feb-05,Oct-20,N/A,121,Stimulants,37,ADHD,12,Central Nervous System,2,ROW,Sales,4.168495208,0,0,0,0,0,0,0,0,0,0,0,0,1545,ADHD,7/7/14 12:28
1003,105,UCB,Regional & Specialty Pharma,1098,Metadate CD,methylphenidate CR,Small Molecule (Chemical),Launched,Corporate Acquisition,May-01,Feb-05,Oct-20,N/A,121,Stimulants,37,ADHD,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1545,ADHD,7/7/14 12:28
1003,105,UCB,Regional & Specialty Pharma,1098,Metadate CD,methylphenidate CR,Small Molecule (Chemical),Launched,Corporate Acquisition,May-01,Feb-05,Oct-20,N/A,121,Stimulants,37,ADHD,12,Central Nervous System,2,US,Sales,95.87538978,71.53675974,86.20709633,83.5426362,87.6499844,89.6420295,90.73765431,91.44317028,91.98309751,92.33346919,92.5726028,92.73893467,0.809500334,1545,ADHD,7/7/14 12:28
1004,23,Boehringer Ingelheim,Large Pharma,1016,Metalyse,tenecteplase,Recombinant Protein,Launched,Licensed (Development),,Feb-01,N/A,N/A,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,692,Thrombosis,7/7/14 12:28
1004,23,Boehringer Ingelheim,Large Pharma,1016,Metalyse,tenecteplase,Recombinant Protein,Launched,Licensed (Development),,Feb-01,N/A,N/A,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,Global,Sales,111.1598722,96.97975549,93.91215907,81.85591235,77.7919589,72.95196691,69.02989814,65.95065808,63.51480373,61.59140511,60.07198779,58.8718276,-3.902869692,692,Thrombosis,7/7/14 12:28
1004,23,Boehringer Ingelheim,Large Pharma,1016,Metalyse,tenecteplase,Recombinant Protein,Launched,Licensed (Development),,Feb-01,N/A,N/A,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,692,Thrombosis,7/7/14 12:28
1004,23,Boehringer Ingelheim,Large Pharma,1016,Metalyse,tenecteplase,Recombinant Protein,Launched,Licensed (Development),,Feb-01,N/A,N/A,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,ROW,Sales,111.1598722,96.97975549,93.91215907,81.85591235,77.7919589,72.95196691,69.02989814,65.95065808,63.51480373,61.59140511,60.07198779,58.8718276,-3.902869692,692,Thrombosis,7/7/14 12:28
1004,23,Boehringer Ingelheim,Large Pharma,1016,Metalyse,tenecteplase,Recombinant Protein,Launched,Licensed (Development),,Feb-01,N/A,N/A,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,692,Thrombosis,7/7/14 12:28
1004,23,Boehringer Ingelheim,Large Pharma,1016,Metalyse,tenecteplase,Recombinant Protein,Launched,Licensed (Development),,Feb-01,N/A,N/A,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,692,Thrombosis,7/7/14 12:28
1005,37,Eisai,Regional & Specialty Pharma,660,Methycobal,mecobalamin,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Expired,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1535,Peripheral Neuropathy,7/7/14 12:28
1005,37,Eisai,Regional & Specialty Pharma,660,Methycobal,mecobalamin,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Expired,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,415.8478241,438.8985514,490.006257,435.8024122,405.0140742,384.7633705,371.6004131,363.0444908,357.4831413,353.8682641,351.5185939,342.3025563,-2.374589849,1535,Peripheral Neuropathy,7/7/14 12:28
1005,37,Eisai,Regional & Specialty Pharma,660,Methycobal,mecobalamin,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Expired,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1535,Peripheral Neuropathy,7/7/14 12:28
1005,37,Eisai,Regional & Specialty Pharma,660,Methycobal,mecobalamin,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Expired,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,415.8478241,438.8985514,490.006257,435.8024122,405.0140742,384.7633705,371.6004131,363.0444908,357.4831413,353.8682641,351.5185939,342.3025563,-2.374589849,1535,Peripheral Neuropathy,7/7/14 12:28
1005,37,Eisai,Regional & Specialty Pharma,660,Methycobal,mecobalamin,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Expired,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1535,Peripheral Neuropathy,7/7/14 12:28
1005,37,Eisai,Regional & Specialty Pharma,660,Methycobal,mecobalamin,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Expired,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1535,Peripheral Neuropathy,7/7/14 12:28
1006,86,Roche,Large Pharma,4006,onartuzumab,MetMAb / anti-cMet,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Sep-17,Nov-17,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,981,Gastric Cancer,7/7/14 12:28
1006,86,Roche,Large Pharma,4006,onartuzumab,MetMAb / anti-cMet,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Sep-17,Nov-17,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,20.12564591,60.50501776,85.51202069,125.0351942,0,981,Gastric Cancer,7/7/14 12:28
1006,86,Roche,Large Pharma,4006,onartuzumab,MetMAb / anti-cMet,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Sep-17,Nov-17,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,981,Gastric Cancer,7/7/14 12:28
1006,86,Roche,Large Pharma,4006,onartuzumab,MetMAb / anti-cMet,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Sep-17,Nov-17,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,8.255291753,32.01616779,45.1527216,65.68321259,0,981,Gastric Cancer,7/7/14 12:28
1006,86,Roche,Large Pharma,4006,onartuzumab,MetMAb / anti-cMet,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Sep-17,Nov-17,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,981,Gastric Cancer,7/7/14 12:28
1006,86,Roche,Large Pharma,4006,onartuzumab,MetMAb / anti-cMet,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Sep-17,Nov-17,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,11.87035415,28.48884997,40.35929909,59.35198165,0,981,Gastric Cancer,7/7/14 12:28
1007,34,Daiichi-Sankyo,Regional & Specialty Pharma,163,Mevalotin,pravastatin,Small Molecule (Chemical),Launched,In-House,,Oct-89,N/A,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1597,,7/7/14 12:28
1007,34,Daiichi-Sankyo,Regional & Specialty Pharma,163,Mevalotin,pravastatin,Small Molecule (Chemical),Launched,In-House,,Oct-89,N/A,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,Global,Sales,592.5292831,524.1102382,496.3370872,310.5995092,221.4898894,191.2263161,176.5285489,167.8131698,163.0836269,160.4172446,158.9388459,158.1131888,-4.701127486,1597,,7/7/14 12:28
1007,34,Daiichi-Sankyo,Regional & Specialty Pharma,163,Mevalotin,pravastatin,Small Molecule (Chemical),Launched,In-House,,Oct-89,N/A,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1597,,7/7/14 12:28
1007,34,Daiichi-Sankyo,Regional & Specialty Pharma,163,Mevalotin,pravastatin,Small Molecule (Chemical),Launched,In-House,,Oct-89,N/A,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Sales,592.5292831,524.1102382,496.3370872,310.5995092,221.4898894,191.2263161,176.5285489,167.8131698,163.0836269,160.4172446,158.9388459,158.1131888,-4.701127486,1597,,7/7/14 12:28
1007,34,Daiichi-Sankyo,Regional & Specialty Pharma,163,Mevalotin,pravastatin,Small Molecule (Chemical),Launched,In-House,,Oct-89,N/A,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1597,,7/7/14 12:28
1007,34,Daiichi-Sankyo,Regional & Specialty Pharma,163,Mevalotin,pravastatin,Small Molecule (Chemical),Launched,In-House,,Oct-89,N/A,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1597,,7/7/14 12:28
1008,67,Novartis,Large Pharma,610,Miacalcic ,salmon calcitonin,Synthetic Peptide,Launched,In-House,Jul-91,Jul-76,Expired,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1628,Osteoporosis,7/7/14 12:28
1008,67,Novartis,Large Pharma,610,Miacalcic ,salmon calcitonin,Synthetic Peptide,Launched,In-House,Jul-91,Jul-76,Expired,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,127.33,105.5985,96.150395,86.61515245,77.41022822,72.29046464,67.60248647,63.51359211,60.88021851,58.60930645,56.73236961,55.41604901,-4.66278098,1628,Osteoporosis,7/7/14 12:28
1008,67,Novartis,Large Pharma,610,Miacalcic ,salmon calcitonin,Synthetic Peptide,Launched,In-House,Jul-91,Jul-76,Expired,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1628,Osteoporosis,7/7/14 12:28
1008,67,Novartis,Large Pharma,610,Miacalcic ,salmon calcitonin,Synthetic Peptide,Launched,In-House,Jul-91,Jul-76,Expired,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,10.38,9.114,8.0826,7.3509,6.793818,6.3712194,6.05636106,5.81898597,5.64038711,5.506296935,5.405437077,5.329611024,-3.408203309,1628,Osteoporosis,7/7/14 12:28
1008,67,Novartis,Large Pharma,610,Miacalcic ,salmon calcitonin,Synthetic Peptide,Launched,In-House,Jul-91,Jul-76,Expired,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1628,Osteoporosis,7/7/14 12:28
1008,67,Novartis,Large Pharma,610,Miacalcic ,salmon calcitonin,Synthetic Peptide,Launched,In-House,Jul-91,Jul-76,Expired,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,116.95,96.4845,88.067795,79.26425245,70.61641022,65.91924524,61.54612541,57.69460614,55.2398314,53.10300952,51.32693253,50.08643799,-4.788850495,1628,Osteoporosis,7/7/14 12:28
1009,1,Abbott,Regional & Specialty Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,,N/A,N/A,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1655,Hypertension,7/7/14 12:28
1009,1,Abbott,Regional & Specialty Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,,N/A,N/A,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1655,Hypertension,7/7/14 12:28
1009,1,Abbott,Regional & Specialty Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,,N/A,N/A,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1655,Hypertension,7/7/14 12:28
1009,1,Abbott,Regional & Specialty Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,,N/A,N/A,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1655,Hypertension,7/7/14 12:28
1009,1,Abbott,Regional & Specialty Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,,N/A,N/A,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1655,Hypertension,7/7/14 12:28
1009,1,Abbott,Regional & Specialty Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,,N/A,N/A,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1655,Hypertension,7/7/14 12:28
1010,15,Astellas Pharma,Regional & Specialty Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-02,N/A,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1655,Hypertension,7/7/14 12:28
1010,15,Astellas Pharma,Regional & Specialty Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-02,N/A,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,754.1281784,786.7489991,814.1447629,752.4212887,634.2665014,624.9935252,599.8992644,599.1782894,575.5933737,509.1329191,465.4972291,440.8042538,-5.06532237,1655,Hypertension,7/7/14 12:28
1010,15,Astellas Pharma,Regional & Specialty Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-02,N/A,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1655,Hypertension,7/7/14 12:28
1010,15,Astellas Pharma,Regional & Specialty Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-02,N/A,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,754.1281784,786.7489991,814.1447629,752.4212887,634.2665014,624.9935252,599.8992644,599.1782894,575.5933737,509.1329191,465.4972291,440.8042538,-5.06532237,1655,Hypertension,7/7/14 12:28
1010,15,Astellas Pharma,Regional & Specialty Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-02,N/A,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1655,Hypertension,7/7/14 12:28
1010,15,Astellas Pharma,Regional & Specialty Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-02,N/A,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1655,Hypertension,7/7/14 12:28
1011,23,Boehringer Ingelheim,Large Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,In-House,Feb-99,Jun-00,Jan-14,Dec-13,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1655,Hypertension,7/7/14 12:28
1011,23,Boehringer Ingelheim,Large Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,In-House,Feb-99,Jun-00,Jan-14,Dec-13,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,1935.571275,2059.993729,2214.966201,2085.995362,2153.846827,1510.413333,1366.543847,1331.902252,1223.84549,984.3678841,812.4546412,697.4261628,-14.87824707,1655,Hypertension,7/7/14 12:28
1011,23,Boehringer Ingelheim,Large Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,In-House,Feb-99,Jun-00,Jan-14,Dec-13,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1655,Hypertension,7/7/14 12:28
1011,23,Boehringer Ingelheim,Large Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,In-House,Feb-99,Jun-00,Jan-14,Dec-13,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,1483.984294,1661.242532,1838.157764,1776.244973,1857.036228,1468.257451,1344.841031,1313.358982,1208.193289,971.4545732,802.1903688,689.7599326,-13.19314893,1655,Hypertension,7/7/14 12:28
1011,23,Boehringer Ingelheim,Large Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,In-House,Feb-99,Jun-00,Jan-14,Dec-13,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1655,Hypertension,7/7/14 12:28
1011,23,Boehringer Ingelheim,Large Pharma,792,Micardis,telmisartan,Small Molecule (Chemical),Launched,In-House,Feb-99,Jun-00,Jan-14,Dec-13,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,451.5869809,398.7511978,376.8084372,309.7503896,296.8105994,42.15588183,21.7028163,18.54326984,15.65220093,12.91331092,10.26427238,7.666230236,-40.68593073,1655,Hypertension,7/7/14 12:28
1012,19,Bayer,Large Pharma,795,Microgynon,levonorgestrol + ethinyloestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-73,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1524,Female contraception,7/7/14 12:28
1012,19,Bayer,Large Pharma,795,Microgynon,levonorgestrol + ethinyloestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-73,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,2,Global,Sales,140.8304918,116.6553793,108.1749671,98.96589215,94.29013473,88.79997031,85.09340509,82.07564442,79.74192738,77.96434302,76.59429234,75.53927286,-3.117841602,1524,Female contraception,7/7/14 12:28
1012,19,Bayer,Large Pharma,795,Microgynon,levonorgestrol + ethinyloestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-73,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1524,Female contraception,7/7/14 12:28
1012,19,Bayer,Large Pharma,795,Microgynon,levonorgestrol + ethinyloestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-73,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,2,ROW,Sales,140.8304918,116.6553793,108.1749671,98.96589215,94.29013473,88.79997031,85.09340509,82.07564442,79.74192738,77.96434302,76.59429234,75.53927286,-3.117841602,1524,Female contraception,7/7/14 12:28
1012,19,Bayer,Large Pharma,795,Microgynon,levonorgestrol + ethinyloestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-73,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1524,Female contraception,7/7/14 12:28
1012,19,Bayer,Large Pharma,795,Microgynon,levonorgestrol + ethinyloestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-73,N/A,Expired,89,Contraceptives,3,Contraception,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1524,Female contraception,7/7/14 12:28
1013,67,Novartis,Large Pharma,715,midostaurin,PKC412,Small Molecule (Chemical),Phase III,In-House,Aug-16,Nov-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,693,Acute Myeloid Leukemia,7/7/14 12:28
1013,67,Novartis,Large Pharma,715,midostaurin,PKC412,Small Molecule (Chemical),Phase III,In-House,Aug-16,Nov-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,8.75001,35.83341117,55.8334717,75.83360462,91.90867608,0,693,Acute Myeloid Leukemia,7/7/14 12:28
1013,67,Novartis,Large Pharma,715,midostaurin,PKC412,Small Molecule (Chemical),Phase III,In-House,Aug-16,Nov-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,693,Acute Myeloid Leukemia,7/7/14 12:28
1013,67,Novartis,Large Pharma,715,midostaurin,PKC412,Small Molecule (Chemical),Phase III,In-House,Aug-16,Nov-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,2.500005,16.66670833,26.66673333,36.66675833,45.33344687,0,693,Acute Myeloid Leukemia,7/7/14 12:28
1013,67,Novartis,Large Pharma,715,midostaurin,PKC412,Small Molecule (Chemical),Phase III,In-House,Aug-16,Nov-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,693,Acute Myeloid Leukemia,7/7/14 12:28
1013,67,Novartis,Large Pharma,715,midostaurin,PKC412,Small Molecule (Chemical),Phase III,In-House,Aug-16,Nov-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,6.250005,19.16670283,29.16673837,39.16684629,46.57522922,0,693,Acute Myeloid Leukemia,7/7/14 12:28
1016,89,Sanofi,Large Pharma,3915,Kynamro,mipomersen,DNA/RNA Therapy,Launched,Corporate Acquisition,Mar-13,Dec-16,N/A,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,695,Lipid disorders,7/7/14 12:28
1016,89,Sanofi,Large Pharma,3915,Kynamro,mipomersen,DNA/RNA Therapy,Launched,Corporate Acquisition,Mar-13,Dec-16,N/A,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,10.94433926,53.26248753,101.4176351,157.7154093,213.6978336,288.1197129,355.5374261,364.9561317,65.0359333,695,Lipid disorders,7/7/14 12:28
1016,89,Sanofi,Large Pharma,3915,Kynamro,mipomersen,DNA/RNA Therapy,Launched,Corporate Acquisition,Mar-13,Dec-16,N/A,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,695,Lipid disorders,7/7/14 12:28
1016,89,Sanofi,Large Pharma,3915,Kynamro,mipomersen,DNA/RNA Therapy,Launched,Corporate Acquisition,Mar-13,Dec-16,N/A,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0.664014768,10.40292016,39.61962546,68.83632587,91.62535445,0,695,Lipid disorders,7/7/14 12:28
1016,89,Sanofi,Large Pharma,3915,Kynamro,mipomersen,DNA/RNA Therapy,Launched,Corporate Acquisition,Mar-13,Dec-16,N/A,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,695,Lipid disorders,7/7/14 12:28
1016,89,Sanofi,Large Pharma,3915,Kynamro,mipomersen,DNA/RNA Therapy,Launched,Corporate Acquisition,Mar-13,Dec-16,N/A,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,10.94433926,53.26248753,101.4176351,157.0513945,203.2949134,248.5000874,286.7011002,273.3307772,58.3589134,695,Lipid disorders,7/7/14 12:28
1017,15,Astellas Pharma,Regional & Specialty Pharma,4104,Myrbetriq / Betmiga / Betanis,mirabegron,Small Molecule (Chemical),Launched,In-House,Oct-12,Sep-11,Dec-23,Dec-22,187,Beta-3 Agonists,60,Incontinence,2,Genitourinary,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,696,Overactive bladder,7/7/14 12:28
1017,15,Astellas Pharma,Regional & Specialty Pharma,4104,Myrbetriq / Betmiga / Betanis,mirabegron,Small Molecule (Chemical),Launched,In-House,Oct-12,Sep-11,Dec-23,Dec-22,187,Beta-3 Agonists,60,Incontinence,2,Genitourinary,7,Global,Sales,0,0,11.39549435,83.06731061,271.8285006,654.4019459,875.459628,996.7045023,1083.812205,1128.837667,1148.888291,1170.683627,23.1946899,696,Overactive bladder,7/7/14 12:28
1017,15,Astellas Pharma,Regional & Specialty Pharma,4104,Myrbetriq / Betmiga / Betanis,mirabegron,Small Molecule (Chemical),Launched,In-House,Oct-12,Sep-11,Dec-23,Dec-22,187,Beta-3 Agonists,60,Incontinence,2,Genitourinary,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,696,Overactive bladder,7/7/14 12:28
1017,15,Astellas Pharma,Regional & Specialty Pharma,4104,Myrbetriq / Betmiga / Betanis,mirabegron,Small Molecule (Chemical),Launched,In-House,Oct-12,Sep-11,Dec-23,Dec-22,187,Beta-3 Agonists,60,Incontinence,2,Genitourinary,7,ROW,Sales,0,0,11.39549435,63.80532554,130.8803892,322.1671118,414.3874476,483.2506678,539.4285579,579.1718982,604.667398,628.4294374,25.1238734,696,Overactive bladder,7/7/14 12:28
1017,15,Astellas Pharma,Regional & Specialty Pharma,4104,Myrbetriq / Betmiga / Betanis,mirabegron,Small Molecule (Chemical),Launched,In-House,Oct-12,Sep-11,Dec-23,Dec-22,187,Beta-3 Agonists,60,Incontinence,2,Genitourinary,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,696,Overactive bladder,7/7/14 12:28
1017,15,Astellas Pharma,Regional & Specialty Pharma,4104,Myrbetriq / Betmiga / Betanis,mirabegron,Small Molecule (Chemical),Launched,In-House,Oct-12,Sep-11,Dec-23,Dec-22,187,Beta-3 Agonists,60,Incontinence,2,Genitourinary,7,US,Sales,0,0,0,19.26198507,140.9481114,332.2348341,461.0721804,513.4538345,544.3836471,549.6657685,544.2208933,542.2541899,21.22490911,696,Overactive bladder,7/7/14 12:28
1018,23,Boehringer Ingelheim,Large Pharma,3347,Mirapex / Sifrol,pramipexole,Small Molecule (Chemical),Launched,In-House,Jul-97,Jan-98,Mar-13,Dec-16,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1594,Parkinson's Disease,7/7/14 12:28
1018,23,Boehringer Ingelheim,Large Pharma,3347,Mirapex / Sifrol,pramipexole,Small Molecule (Chemical),Launched,In-House,Jul-97,Jan-98,Mar-13,Dec-16,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,Global,Sales,1111.706108,884.9362131,305.6468965,138.0926245,101.9834576,23.9045412,17.26439087,14.87891686,10.3002012,8.986364451,6.261661764,5.401471789,-34.27782146,1594,Parkinson's Disease,7/7/14 12:28
1018,23,Boehringer Ingelheim,Large Pharma,3347,Mirapex / Sifrol,pramipexole,Small Molecule (Chemical),Launched,In-House,Jul-97,Jan-98,Mar-13,Dec-16,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1594,Parkinson's Disease,7/7/14 12:28
1018,23,Boehringer Ingelheim,Large Pharma,3347,Mirapex / Sifrol,pramipexole,Small Molecule (Chemical),Launched,In-House,Jul-97,Jan-98,Mar-13,Dec-16,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,ROW,Sales,377.3562024,362.9828179,124.5529139,55.70144308,40.84371541,17.26439087,13.28030067,12.22285673,7.97614858,6.745313714,4.933631697,4.30169689,-27.49643471,1594,Parkinson's Disease,7/7/14 12:28
1018,23,Boehringer Ingelheim,Large Pharma,3347,Mirapex / Sifrol,pramipexole,Small Molecule (Chemical),Launched,In-House,Jul-97,Jan-98,Mar-13,Dec-16,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1594,Parkinson's Disease,7/7/14 12:28
1018,23,Boehringer Ingelheim,Large Pharma,3347,Mirapex / Sifrol,pramipexole,Small Molecule (Chemical),Launched,In-House,Jul-97,Jan-98,Mar-13,Dec-16,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,US,Sales,734.3499058,521.9533951,181.0939825,82.39118143,61.1397422,6.640150333,3.9840902,2.656060133,2.324052617,2.241050737,1.328030067,1.099774899,-43.67363742,1594,Parkinson's Disease,7/7/14 12:28
1019,76,Pfizer,Large Pharma,1399,Mirapex,pramipexole,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-97,Jan-98,Jan-10,N/A,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,Global,Alliance Revenue,147,104.4,36.2,16.4,3.2,0.6,1,1,0.76,0.736,0.6856,0.63736,-20.58714871,1594,Parkinson's Disease,7/7/14 12:28
1019,76,Pfizer,Large Pharma,1399,Mirapex,pramipexole,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-97,Jan-98,Jan-10,N/A,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1594,Parkinson's Disease,7/7/14 12:28
1019,76,Pfizer,Large Pharma,1399,Mirapex,pramipexole,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-97,Jan-98,Jan-10,N/A,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1594,Parkinson's Disease,7/7/14 12:28
1019,76,Pfizer,Large Pharma,1399,Mirapex,pramipexole,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-97,Jan-98,Jan-10,N/A,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1594,Parkinson's Disease,7/7/14 12:28
1019,76,Pfizer,Large Pharma,1399,Mirapex,pramipexole,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-97,Jan-98,Jan-10,N/A,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,US,Alliance Revenue,147,104.4,36.2,16.4,3.2,0.6,1,1,0.76,0.736,0.6856,0.63736,-20.58714871,1594,Parkinson's Disease,7/7/14 12:28
1019,76,Pfizer,Large Pharma,1399,Mirapex,pramipexole,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-97,Jan-98,Jan-10,N/A,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1594,Parkinson's Disease,7/7/14 12:28
1021,86,Roche,Large Pharma,894,Mircera,PEG-epoetin beta,Recombinant Protein,Launched,In-House,Jul-14,Sep-07,Nov-19,Jul-22,102,ESAs,24,Anemia,14,Hematology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1584,Renal Anemia,7/7/14 12:28
1021,86,Roche,Large Pharma,894,Mircera,PEG-epoetin beta,Recombinant Protein,Launched,In-House,Jul-14,Sep-07,Nov-19,Jul-20,102,ESAs,24,Anemia,14,Hematology,5,Global,Sales,164.8225165,244.5536855,388.2572452,400.9156558,458.2966756,544.9947495,649.2905998,750.5979752,842.6523856,908.4692246,963.7006522,1009.004373,11.93443568,1584,Renal Anemia,7/7/14 12:28
1021,86,Roche,Large Pharma,894,Mircera,PEG-epoetin beta,Recombinant Protein,Launched,In-House,Jul-14,Sep-07,Nov-19,Jul-22,102,ESAs,24,Anemia,14,Hematology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1584,Renal Anemia,7/7/14 12:28
1021,86,Roche,Large Pharma,894,Mircera,PEG-epoetin beta,Recombinant Protein,Launched,In-House,Jul-14,Sep-07,Nov-19,Jul-20,102,ESAs,24,Anemia,14,Hematology,5,ROW,Sales,164.8225165,244.5536855,388.2572452,400.9156558,458.2966756,527.1892182,584.0035926,625.9592026,658.6618759,684.5943296,705.0931104,721.5554406,6.699012545,1584,Renal Anemia,7/7/14 12:28
1021,86,Roche,Large Pharma,894,Mircera,PEG-epoetin beta,Recombinant Protein,Launched,In-House,Jul-14,Sep-07,Nov-19,Jul-22,102,ESAs,24,Anemia,14,Hematology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1584,Renal Anemia,7/7/14 12:28
1021,86,Roche,Large Pharma,894,Mircera,PEG-epoetin beta,Recombinant Protein,Launched,In-House,Jul-14,Sep-07,Nov-19,Jul-22,102,ESAs,24,Anemia,14,Hematology,5,US,Sales,0,0,0,0,0,17.80553123,65.2870072,124.6387726,183.9905097,223.874895,258.6075419,287.4489324,0,1584,Renal Anemia,7/7/14 12:28
1023,19,Bayer,Large Pharma,913,Mirena,levonorgestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-01,Jan-90,Dec-15,Dec-15,89,Contraceptives,3,Contraception,2,Genitourinary,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1523,Female contraception,7/7/14 12:28
1023,19,Bayer,Large Pharma,913,Mirena,levonorgestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-01,Jan-90,Dec-15,Dec-15,89,Contraceptives,3,Contraception,2,Genitourinary,2,Global,Sales,680.8542173,714.0428426,807.8439188,870.1286878,948.9882166,991.7170518,963.8365353,161.9414564,107.4857981,80.59006924,64.13848677,53.27465112,-33.72907897,1523,Female contraception,7/7/14 12:28
1023,19,Bayer,Large Pharma,913,Mirena,levonorgestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-01,Jan-90,Dec-15,Dec-15,89,Contraceptives,3,Contraception,2,Genitourinary,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1523,Female contraception,7/7/14 12:28
1023,19,Bayer,Large Pharma,913,Mirena,levonorgestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-01,Jan-90,Dec-15,Dec-15,89,Contraceptives,3,Contraception,2,Genitourinary,2,ROW,Sales,302.9106518,336.4877217,372.6371261,375.2992272,397.855739,409.7609963,401.2690461,130.1162355,87.76450652,66.3990572,53.71759257,44.7488881,-26.81251966,1523,Female contraception,7/7/14 12:28
1023,19,Bayer,Large Pharma,913,Mirena,levonorgestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-01,Jan-90,Dec-15,Dec-15,89,Contraceptives,3,Contraception,2,Genitourinary,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1523,Female contraception,7/7/14 12:28
1023,19,Bayer,Large Pharma,913,Mirena,levonorgestrel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-01,Jan-90,Dec-15,Dec-15,89,Contraceptives,3,Contraception,2,Genitourinary,2,US,Sales,377.9435655,377.5551208,435.2067927,494.8294606,551.1324776,581.9560555,562.5674892,31.82522091,19.72129157,14.19101204,10.4208942,8.525763025,-44.87429561,1523,Female contraception,7/7/14 12:28
1029,61,Merck & Co,Large Pharma,2585,dalotuzumab,dalotuzumab,Antibody/Antibody Derivative,Phase II,,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,699,Cancer,7/7/14 12:28
1029,61,Merck & Co,Large Pharma,2585,dalotuzumab,dalotuzumab,Antibody/Antibody Derivative,Phase II,,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,699,Cancer,7/7/14 12:28
1029,61,Merck & Co,Large Pharma,2585,dalotuzumab,dalotuzumab,Antibody/Antibody Derivative,Phase II,,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,699,Cancer,7/7/14 12:28
1029,61,Merck & Co,Large Pharma,2585,dalotuzumab,dalotuzumab,Antibody/Antibody Derivative,Phase II,,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,699,Cancer,7/7/14 12:28
1029,61,Merck & Co,Large Pharma,2585,dalotuzumab,dalotuzumab,Antibody/Antibody Derivative,Phase II,,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,699,Cancer,7/7/14 12:28
1029,61,Merck & Co,Large Pharma,2585,dalotuzumab,dalotuzumab,Antibody/Antibody Derivative,Phase II,,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,699,Cancer,7/7/14 12:28
1030,61,Merck & Co,Large Pharma,1431,Liptruzet,ezetimibe + atorvastatin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-13,Sep-15,Apr-17,May-22,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,700,Lipid disorders,7/7/14 12:28
1030,61,Merck & Co,Large Pharma,1431,Liptruzet,ezetimibe + atorvastatin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-13,Sep-15,Apr-17,May-22,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,22,376.3061398,849.7773628,1406.44674,1073.457547,778.3866255,805.7728435,845.6993145,68.4219984,700,Lipid disorders,7/7/14 12:28
1030,61,Merck & Co,Large Pharma,1431,Liptruzet,ezetimibe + atorvastatin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-13,Sep-15,Apr-17,May-22,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,700,Lipid disorders,7/7/14 12:28
1030,61,Merck & Co,Large Pharma,1431,Liptruzet,ezetimibe + atorvastatin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-13,Sep-15,Apr-17,May-22,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,30,225,552.8992725,701.9985363,747.1483922,808.8582067,0,700,Lipid disorders,7/7/14 12:28
1030,61,Merck & Co,Large Pharma,1431,Liptruzet,ezetimibe + atorvastatin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-13,Sep-15,Apr-17,May-22,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,700,Lipid disorders,7/7/14 12:28
1030,61,Merck & Co,Large Pharma,1431,Liptruzet,ezetimibe + atorvastatin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-13,Sep-15,Apr-17,May-22,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,22,376.3061398,819.7773628,1181.44674,520.558274,76.38808913,58.62445133,36.8411078,7.643326643,700,Lipid disorders,7/7/14 12:28
1032,61,Merck & Co,Large Pharma,863,MK-0752,MK-0752,Small Molecule (Chemical),Phase I,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,702,Solid Tumors,7/7/14 12:28
1032,61,Merck & Co,Large Pharma,863,MK-0752,MK-0752,Small Molecule (Chemical),Phase I,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,702,Solid Tumors,7/7/14 12:28
1032,61,Merck & Co,Large Pharma,863,MK-0752,MK-0752,Small Molecule (Chemical),Phase I,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,702,Solid Tumors,7/7/14 12:28
1032,61,Merck & Co,Large Pharma,863,MK-0752,MK-0752,Small Molecule (Chemical),Phase I,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,702,Solid Tumors,7/7/14 12:28
1032,61,Merck & Co,Large Pharma,863,MK-0752,MK-0752,Small Molecule (Chemical),Phase I,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,702,Solid Tumors,7/7/14 12:28
1032,61,Merck & Co,Large Pharma,863,MK-0752,MK-0752,Small Molecule (Chemical),Phase I,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,702,Solid Tumors,7/7/14 12:28
1051,61,Merck & Co,Large Pharma,3814,suvorexant,MK-4305,Small Molecule (Chemical),Filed,In-House,Feb-15,Jun-14,N/A,N/A,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,716,Insomnia,7/7/14 12:28
1051,61,Merck & Co,Large Pharma,3814,suvorexant,MK-4305,Small Molecule (Chemical),Filed,In-House,Feb-15,Jun-14,N/A,N/A,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,10.25,60.7680175,144.18907,241.882989,325.3333439,383.4245264,432.2153857,0,716,Insomnia,7/7/14 12:28
1051,61,Merck & Co,Large Pharma,3814,suvorexant,MK-4305,Small Molecule (Chemical),Filed,In-House,Feb-15,Jun-14,N/A,N/A,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,716,Insomnia,7/7/14 12:28
1051,61,Merck & Co,Large Pharma,3814,suvorexant,MK-4305,Small Molecule (Chemical),Filed,In-House,Feb-15,Jun-14,N/A,N/A,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,10.25,24.1013375,43.07776659,74.10495876,90.88871338,105.9354379,119.0701869,0,716,Insomnia,7/7/14 12:28
1051,61,Merck & Co,Large Pharma,3814,suvorexant,MK-4305,Small Molecule (Chemical),Filed,In-House,Feb-15,Jun-14,N/A,N/A,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,716,Insomnia,7/7/14 12:28
1051,61,Merck & Co,Large Pharma,3814,suvorexant,MK-4305,Small Molecule (Chemical),Filed,In-House,Feb-15,Jun-14,N/A,N/A,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,36.66668,101.1113034,167.7780302,234.4446306,277.4890884,313.1451988,0,716,Insomnia,7/7/14 12:28
1052,920,Tesaro,Regional & Specialty Pharma,629,niraparib,MK-4827,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,719,Solid Tumors,7/7/14 12:28
1052,920,Tesaro,Regional & Specialty Pharma,629,niraparib,MK-4827,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,719,Solid Tumors,7/7/14 12:28
1052,920,Tesaro,Regional & Specialty Pharma,629,niraparib,MK-4827,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,719,Solid Tumors,7/7/14 12:28
1052,920,Tesaro,Regional & Specialty Pharma,629,niraparib,MK-4827,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,719,Solid Tumors,7/7/14 12:28
1052,920,Tesaro,Regional & Specialty Pharma,629,niraparib,MK-4827,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,719,Solid Tumors,7/7/14 12:28
1052,920,Tesaro,Regional & Specialty Pharma,629,niraparib,MK-4827,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,719,Solid Tumors,7/7/14 12:28
1062,61,Merck & Co,Large Pharma,2978,vaniprevir,vaniprevir,Small Molecule (Chemical),Phase III,,,Jun-15,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,727,Hepatitis C,7/7/14 12:28
1062,61,Merck & Co,Large Pharma,2978,vaniprevir,vaniprevir,Small Molecule (Chemical),Phase III,,,Jun-15,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,20.5,35.902675,30,22,9,1,0,727,Hepatitis C,7/7/14 12:28
1062,61,Merck & Co,Large Pharma,2978,vaniprevir,vaniprevir,Small Molecule (Chemical),Phase III,,,Jun-15,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,727,Hepatitis C,7/7/14 12:28
1062,61,Merck & Co,Large Pharma,2978,vaniprevir,vaniprevir,Small Molecule (Chemical),Phase III,,,Jun-15,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,20.5,35.902675,30,22,9,1,0,727,Hepatitis C,7/7/14 12:28
1062,61,Merck & Co,Large Pharma,2978,vaniprevir,vaniprevir,Small Molecule (Chemical),Phase III,,,Jun-15,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,727,Hepatitis C,7/7/14 12:28
1062,61,Merck & Co,Large Pharma,2978,vaniprevir,vaniprevir,Small Molecule (Chemical),Phase III,,,Jun-15,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,727,Hepatitis C,7/7/14 12:28
1069,100,Takeda,Large Pharma,666,MLN4924,MLN4924,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,734,Cancer,7/7/14 12:28
1069,100,Takeda,Large Pharma,666,MLN4924,MLN4924,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,734,Cancer,7/7/14 12:28
1069,100,Takeda,Large Pharma,666,MLN4924,MLN4924,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,734,Cancer,7/7/14 12:28
1069,100,Takeda,Large Pharma,666,MLN4924,MLN4924,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,734,Cancer,7/7/14 12:28
1069,100,Takeda,Large Pharma,666,MLN4924,MLN4924,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,734,Cancer,7/7/14 12:28
1069,100,Takeda,Large Pharma,666,MLN4924,MLN4924,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,734,Cancer,7/7/14 12:28
1070,100,Takeda,Large Pharma,3935,alisertib,alisertib,Small Molecule (Chemical),Phase III,Corporate Acquisition,Nov-17,Feb-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,735,Peripheral T-cell Lymphoma,7/7/14 12:28
1070,100,Takeda,Large Pharma,3935,alisertib,alisertib,Small Molecule (Chemical),Phase III,Corporate Acquisition,Nov-17,Feb-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,16.00768844,51.86839122,77.45092971,106.0994821,0,735,Peripheral T-cell Lymphoma,7/7/14 12:28
1070,100,Takeda,Large Pharma,3935,alisertib,alisertib,Small Molecule (Chemical),Phase III,Corporate Acquisition,Nov-17,Feb-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,735,Peripheral T-cell Lymphoma,7/7/14 12:28
1070,100,Takeda,Large Pharma,3935,alisertib,alisertib,Small Molecule (Chemical),Phase III,Corporate Acquisition,Nov-17,Feb-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,3.423025563,13.27538312,18.72240557,27.23529616,0,735,Peripheral T-cell Lymphoma,7/7/14 12:28
1070,100,Takeda,Large Pharma,3935,alisertib,alisertib,Small Molecule (Chemical),Phase III,Corporate Acquisition,Nov-17,Feb-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,735,Peripheral T-cell Lymphoma,7/7/14 12:28
1070,100,Takeda,Large Pharma,3935,alisertib,alisertib,Small Molecule (Chemical),Phase III,Corporate Acquisition,Nov-17,Feb-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,12.58466287,38.5930081,58.72852414,78.86418593,0,735,Peripheral T-cell Lymphoma,7/7/14 12:28
1074,34,Daiichi-Sankyo,Regional & Specialty Pharma,523,Mobic,meloxicam,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-01,N/A,Jul-09,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1538,Rheumatoid & Osteoarthritis,7/7/14 12:28
1074,34,Daiichi-Sankyo,Regional & Specialty Pharma,523,Mobic,meloxicam,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-01,N/A,Jul-09,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,77.56746978,71.2074716,0,0,0,0,0,0,0,0,0,0,0,1538,Rheumatoid & Osteoarthritis,7/7/14 12:28
1074,34,Daiichi-Sankyo,Regional & Specialty Pharma,523,Mobic,meloxicam,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-01,N/A,Jul-09,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1538,Rheumatoid & Osteoarthritis,7/7/14 12:28
1074,34,Daiichi-Sankyo,Regional & Specialty Pharma,523,Mobic,meloxicam,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-01,N/A,Jul-09,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,77.56746978,71.2074716,0,0,0,0,0,0,0,0,0,0,0,1538,Rheumatoid & Osteoarthritis,7/7/14 12:28
1074,34,Daiichi-Sankyo,Regional & Specialty Pharma,523,Mobic,meloxicam,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-01,N/A,Jul-09,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1538,Rheumatoid & Osteoarthritis,7/7/14 12:28
1074,34,Daiichi-Sankyo,Regional & Specialty Pharma,523,Mobic,meloxicam,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-01,N/A,Jul-09,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1538,Rheumatoid & Osteoarthritis,7/7/14 12:28
1075,23,Boehringer Ingelheim,Large Pharma,523,Mobic,meloxicam,Small Molecule (Chemical),Launched,Licensed (Development),Apr-00,Oct-96,Oct-06,Oct-03,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1538,Rheumatoid & Osteoarthritis,7/7/14 12:28
1075,23,Boehringer Ingelheim,Large Pharma,523,Mobic,meloxicam,Small Molecule (Chemical),Launched,Licensed (Development),Apr-00,Oct-96,Oct-06,Oct-03,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,Global,Sales,137.1558757,93.15311452,73.88838531,53.70537281,43.70520451,36.13733093,29.9139942,24.48489588,19.56878827,15.01925394,11.9522706,10.21023133,-18.75696276,1538,Rheumatoid & Osteoarthritis,7/7/14 12:28
1075,23,Boehringer Ingelheim,Large Pharma,523,Mobic,meloxicam,Small Molecule (Chemical),Launched,Licensed (Development),Apr-00,Oct-96,Oct-06,Oct-03,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1538,Rheumatoid & Osteoarthritis,7/7/14 12:28
1075,23,Boehringer Ingelheim,Large Pharma,523,Mobic,meloxicam,Small Molecule (Chemical),Launched,Licensed (Development),Apr-00,Oct-96,Oct-06,Oct-03,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,ROW,Sales,67.16599229,55.97213246,51.68311955,41.76754163,36.06134292,30.64045415,25.49060981,20.5982577,15.95052319,11.5351754,9.296210466,7.9681804,-19.40072577,1538,Rheumatoid & Osteoarthritis,7/7/14 12:28
1075,23,Boehringer Ingelheim,Large Pharma,523,Mobic,meloxicam,Small Molecule (Chemical),Launched,Licensed (Development),Apr-00,Oct-96,Oct-06,Oct-03,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1538,Rheumatoid & Osteoarthritis,7/7/14 12:28
1075,23,Boehringer Ingelheim,Large Pharma,523,Mobic,meloxicam,Small Molecule (Chemical),Launched,Licensed (Development),Apr-00,Oct-96,Oct-06,Oct-03,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,US,Sales,69.98988337,37.18098206,22.20526576,11.93783119,7.643861588,5.496876788,4.423384388,3.886638188,3.618265088,3.484078538,2.656060133,2.242050931,-16.07241207,1538,Rheumatoid & Osteoarthritis,7/7/14 12:28
1077,24,Bristol-Myers Squibb,Large Pharma,622,Monopril,fosinopril,Small Molecule (Chemical),Launched,In-House,,Jan-91,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,741,,7/7/14 12:28
1077,24,Bristol-Myers Squibb,Large Pharma,622,Monopril,fosinopril,Small Molecule (Chemical),Launched,In-House,,Jan-91,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Sales,26,20.81,17.132,15.1336,13.87736,13.092064,12.624384,12.33611328,12.15951386,12.05218708,11.98646814,11.94631719,-2.117761428,741,,7/7/14 12:28
1077,24,Bristol-Myers Squibb,Large Pharma,622,Monopril,fosinopril,Small Molecule (Chemical),Launched,In-House,,Jan-91,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,741,,7/7/14 12:28
1077,24,Bristol-Myers Squibb,Large Pharma,622,Monopril,fosinopril,Small Molecule (Chemical),Launched,In-House,,Jan-91,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,26,20.81,17.132,15.1336,13.87736,13.092064,12.624384,12.33611328,12.15951386,12.05218708,11.98646814,11.94631719,-2.117761428,741,,7/7/14 12:28
1077,24,Bristol-Myers Squibb,Large Pharma,622,Monopril,fosinopril,Small Molecule (Chemical),Launched,In-House,,Jan-91,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,741,,7/7/14 12:28
1077,24,Bristol-Myers Squibb,Large Pharma,622,Monopril,fosinopril,Small Molecule (Chemical),Launched,In-House,,Jan-91,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,741,,7/7/14 12:28
1078,46,GlaxoSmithKline,Large Pharma,505,Mosquirix,malaria vaccine,Vaccine,Phase III,Licensed (Development),,Nov-15,,,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,743,Malaria,7/7/14 12:28
1078,46,GlaxoSmithKline,Large Pharma,505,Mosquirix,malaria vaccine,Vaccine,Phase III,Licensed (Development),,Nov-15,,,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,0,0,0,0,0,0,4.916937118,22.01932282,41.58018824,72.15077425,86.89519211,99.1685268,0,743,Malaria,7/7/14 12:28
1078,46,GlaxoSmithKline,Large Pharma,505,Mosquirix,malaria vaccine,Vaccine,Phase III,Licensed (Development),,Nov-15,,,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,743,Malaria,7/7/14 12:28
1078,46,GlaxoSmithKline,Large Pharma,505,Mosquirix,malaria vaccine,Vaccine,Phase III,Licensed (Development),,Nov-15,,,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,0,0,0,0,0,0,4.916937118,22.01932282,41.58018824,72.15077425,86.89519211,99.1685268,0,743,Malaria,7/7/14 12:28
1078,46,GlaxoSmithKline,Large Pharma,505,Mosquirix,malaria vaccine,Vaccine,Phase III,Licensed (Development),,Nov-15,,,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,743,Malaria,7/7/14 12:28
1078,46,GlaxoSmithKline,Large Pharma,505,Mosquirix,malaria vaccine,Vaccine,Phase III,Licensed (Development),,Nov-15,,,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,743,Malaria,7/7/14 12:28
1083,89,Genzyme,Large Pharma,553,Mozobil,plerixafor,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-09,Aug-09,Jul-23,Oct-19,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,Global,Proforma,54.8851869,91.93798381,34.30655733,0,0,0,0,0,0,0,0,0,0,745,Stem Cell Mobilization,7/7/14 12:28
1083,89,Genzyme,Large Pharma,553,Mozobil,plerixafor,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-09,Aug-09,Jul-23,Oct-19,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,ROW,Proforma,15.97923163,30.99926255,11.81871482,0,0,0,0,0,0,0,0,0,0,745,Stem Cell Mobilization,7/7/14 12:28
1083,89,Genzyme,Large Pharma,553,Mozobil,plerixafor,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-09,Aug-09,Jul-23,Oct-19,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,US,Proforma,38.90595527,60.93872126,22.48784251,0,0,0,0,0,0,0,0,0,0,745,Stem Cell Mobilization,7/7/14 12:28
1083,89,Sanofi,Large Pharma,553,Mozobil,plerixafor,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-09,Aug-09,Jul-23,Oct-19,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,745,Stem Cell Mobilization,7/7/14 12:28
1083,89,Sanofi,Large Pharma,553,Mozobil,plerixafor,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-09,Aug-09,Jul-23,Oct-19,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,Global,Sales,2.08E-02,7.37E-04,47.72922789,123.3860473,133.4691394,143.7990956,157.2277968,166.0349873,174.4335448,182.0552857,188.5287863,194.2911736,5.510579156,745,Stem Cell Mobilization,7/7/14 12:28
1083,89,Sanofi,Large Pharma,553,Mozobil,plerixafor,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-09,Aug-09,Jul-23,Oct-19,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,745,Stem Cell Mobilization,7/7/14 12:28
1083,89,Sanofi,Large Pharma,553,Mozobil,plerixafor,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-09,Aug-09,Jul-23,Oct-19,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,ROW,Sales,2.08E-02,7.37E-04,21.55177408,51.41085305,59.09945563,65.07347326,72.297618,77.57756061,82.37917521,86.72287043,90.45752684,93.7621346,6.81563565,745,Stem Cell Mobilization,7/7/14 12:28
1083,89,Sanofi,Large Pharma,553,Mozobil,plerixafor,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-09,Aug-09,Jul-23,Oct-19,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,745,Stem Cell Mobilization,7/7/14 12:28
1083,89,Sanofi,Large Pharma,553,Mozobil,plerixafor,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-09,Aug-09,Jul-23,Oct-19,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,US,Sales,0,0,26.1774538,71.97519426,74.36968373,78.72562235,84.93017883,88.45742669,92.05436957,95.33241525,98.07125947,100.529039,4.399724402,745,Stem Cell Mobilization,7/7/14 12:28
1084,89,Sanofi,Large Pharma,748,Multaq,dronedarone,Small Molecule (Chemical),Launched,In-House,Jul-09,Jan-10,Jul-16,Nov-19,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,752,Atrial Fibrillation,7/7/14 12:28
1084,89,Sanofi,Large Pharma,748,Multaq,dronedarone,Small Molecule (Chemical),Launched,In-House,Jul-09,Jan-10,Jul-16,Nov-19,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,Global,Sales,34.73746007,227.8578273,362.8628604,327.5254254,357.2400879,367.9437457,376.2899587,242.2236668,83.22082699,76.84965817,70.61836051,39.91557681,-26.88168616,752,Atrial Fibrillation,7/7/14 12:28
1084,89,Sanofi,Large Pharma,748,Multaq,dronedarone,Small Molecule (Chemical),Launched,In-House,Jul-09,Jan-10,Jul-16,Nov-19,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,752,Atrial Fibrillation,7/7/14 12:28
1084,89,Sanofi,Large Pharma,748,Multaq,dronedarone,Small Molecule (Chemical),Launched,In-House,Jul-09,Jan-10,Jul-16,Nov-19,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,ROW,Sales,0,58.28921164,107.0636519,70.47116021,70.38559353,68.33307842,67.4969722,67.11387335,66.94251352,66.86550003,63.48937474,33.40769585,-10.09866253,752,Atrial Fibrillation,7/7/14 12:28
1084,89,Sanofi,Large Pharma,748,Multaq,dronedarone,Small Molecule (Chemical),Launched,In-House,Jul-09,Jan-10,Jul-16,Nov-19,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,752,Atrial Fibrillation,7/7/14 12:28
1084,89,Sanofi,Large Pharma,748,Multaq,dronedarone,Small Molecule (Chemical),Launched,In-House,Jul-09,Jan-10,Jul-16,Nov-19,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,US,Sales,34.73746007,169.5686157,255.7992086,257.0542652,286.8544944,299.6106673,308.7929865,175.1097935,16.27831347,9.984158137,7.128985767,6.507880952,-41.77474901,752,Atrial Fibrillation,7/7/14 12:28
1086,67,Novartis,Large Pharma,1116,Myfortic,mycophenolic acid,Small Molecule (Chemical),Launched,In-House,Mar-04,Apr-03,Jan-14,Apr-17,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,754,Transplant Rejection,7/7/14 12:28
1086,67,Novartis,Large Pharma,1116,Myfortic,mycophenolic acid,Small Molecule (Chemical),Launched,In-House,Mar-04,Apr-03,Jan-14,Apr-17,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Sales,353,444,518,579,637,686.784,713.49576,732.802008,708.163908,696.4511016,688.8001602,683.0373436,1.001839552,754,Transplant Rejection,7/7/14 12:28
1086,67,Novartis,Large Pharma,1116,Myfortic,mycophenolic acid,Small Molecule (Chemical),Launched,In-House,Mar-04,Apr-03,Jan-14,Apr-17,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,754,Transplant Rejection,7/7/14 12:28
1086,67,Novartis,Large Pharma,1116,Myfortic,mycophenolic acid,Small Molecule (Chemical),Launched,In-House,Mar-04,Apr-03,Jan-14,Apr-17,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Sales,218,281,318,340,367,425.1,446.19,464.295,438.522324,427.8140328,419.3890982,413.975499,1.735528606,754,Transplant Rejection,7/7/14 12:28
1086,67,Novartis,Large Pharma,1116,Myfortic,mycophenolic acid,Small Molecule (Chemical),Launched,In-House,Mar-04,Apr-03,Jan-14,Apr-17,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,754,Transplant Rejection,7/7/14 12:28
1086,67,Novartis,Large Pharma,1116,Myfortic,mycophenolic acid,Small Molecule (Chemical),Launched,In-House,Mar-04,Apr-03,Jan-14,Apr-17,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Sales,135,163,200,239,270,261.684,267.30576,268.507008,269.641584,268.6370688,269.411062,269.0618445,-4.97E-02,754,Transplant Rejection,7/7/14 12:28
1087,37,Eisai,Regional & Specialty Pharma,1588,Myonal,eperisone,Small Molecule (Chemical),Launched,In-House,,Oct-95,N/A,Expired,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,755,Muscle Spasms,7/7/14 12:28
1087,37,Eisai,Regional & Specialty Pharma,1588,Myonal,eperisone,Small Molecule (Chemical),Launched,In-House,,Oct-95,N/A,Expired,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,7,Global,Sales,78.86128586,77.04070317,78.04782077,72.59017593,69.010807,66.14731186,63.85651574,62.02387885,60.55776934,50.33861123,50.33861123,50.33861123,-4.406949008,755,Muscle Spasms,7/7/14 12:28
1087,37,Eisai,Regional & Specialty Pharma,1588,Myonal,eperisone,Small Molecule (Chemical),Launched,In-House,,Oct-95,N/A,Expired,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,755,Muscle Spasms,7/7/14 12:28
1087,37,Eisai,Regional & Specialty Pharma,1588,Myonal,eperisone,Small Molecule (Chemical),Launched,In-House,,Oct-95,N/A,Expired,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,7,ROW,Sales,78.86128586,77.04070317,78.04782077,72.59017593,69.010807,66.14731186,63.85651574,62.02387885,60.55776934,50.33861123,50.33861123,50.33861123,-4.406949008,755,Muscle Spasms,7/7/14 12:28
1087,37,Eisai,Regional & Specialty Pharma,1588,Myonal,eperisone,Small Molecule (Chemical),Launched,In-House,,Oct-95,N/A,Expired,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,755,Muscle Spasms,7/7/14 12:28
1087,37,Eisai,Regional & Specialty Pharma,1588,Myonal,eperisone,Small Molecule (Chemical),Launched,In-House,,Oct-95,N/A,Expired,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,755,Muscle Spasms,7/7/14 12:28
1088,89,Genzyme,Large Pharma,2453,Myozyme / Lumizyme,alpha-glucosidase,Recombinant Protein,Launched,Corporate Acquisition,May-06,Jul-06,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Proforma,325.0036764,411.9987459,123.3317613,0,0,0,0,0,0,0,0,0,0,756,Pompe Disease,7/7/14 12:28
1088,89,Genzyme,Large Pharma,2453,Myozyme / Lumizyme,alpha-glucosidase,Recombinant Protein,Launched,Corporate Acquisition,May-06,Jul-06,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Proforma,230.9346345,300.0569645,92.05960528,0,0,0,0,0,0,0,0,0,0,756,Pompe Disease,7/7/14 12:28
1088,89,Genzyme,Large Pharma,2453,Myozyme / Lumizyme,alpha-glucosidase,Recombinant Protein,Launched,Corporate Acquisition,May-06,Jul-06,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Proforma,94.06904186,111.9417814,31.27215599,0,0,0,0,0,0,0,0,0,0,756,Pompe Disease,7/7/14 12:28
1088,89,Sanofi,Large Pharma,2453,Myozyme / Lumizyme,alpha-glucosidase,Recombinant Protein,Launched,Corporate Acquisition,May-06,Jul-06,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,756,Pompe Disease,7/7/14 12:28
1088,89,Sanofi,Large Pharma,2453,Myozyme / Lumizyme,alpha-glucosidase,Recombinant Protein,Launched,Corporate Acquisition,May-06,Jul-06,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Sales,0,0,431.4526167,593.7953527,664.0150333,720.2903075,771.4782305,817.6507251,860.3711895,899.6509297,935.7699161,969.0354131,5.548399744,756,Pompe Disease,7/7/14 12:28
1088,89,Sanofi,Large Pharma,2453,Myozyme / Lumizyme,alpha-glucosidase,Recombinant Protein,Launched,Corporate Acquisition,May-06,Jul-06,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,756,Pompe Disease,7/7/14 12:28
1088,89,Sanofi,Large Pharma,2453,Myozyme / Lumizyme,alpha-glucosidase,Recombinant Protein,Launched,Corporate Acquisition,May-06,Jul-06,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Sales,0,0,311.1671356,443.4186075,500.6673351,548.1776108,592.3322866,632.5263085,670.0723088,704.9351337,737.2744555,767.3026767,6.288965819,756,Pompe Disease,7/7/14 12:28
1088,89,Sanofi,Large Pharma,2453,Myozyme / Lumizyme,alpha-glucosidase,Recombinant Protein,Launched,Corporate Acquisition,May-06,Jul-06,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,756,Pompe Disease,7/7/14 12:28
1088,89,Sanofi,Large Pharma,2453,Myozyme / Lumizyme,alpha-glucosidase,Recombinant Protein,Launched,Corporate Acquisition,May-06,Jul-06,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Sales,0,0,120.2854811,150.3767452,163.3476982,172.1126967,179.1459439,185.1244166,190.2988807,194.715796,198.4954607,201.7327364,3.061095066,756,Pompe Disease,7/7/14 12:28
1089,15,Astellas Pharma,Regional & Specialty Pharma,541,Myslee,zolpidem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-00,N/A,Jun-12,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1683,Insomnia,7/7/14 12:28
1089,15,Astellas Pharma,Regional & Specialty Pharma,541,Myslee,zolpidem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-00,N/A,Jun-12,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,Global,Sales,312.4245311,381.7016657,445.6904456,387.6474495,291.9639451,266.1905751,245.5718791,229.0769223,215.8809569,205.3241846,196.8787667,190.1224324,-5.944037481,1683,Insomnia,7/7/14 12:28
1089,15,Astellas Pharma,Regional & Specialty Pharma,541,Myslee,zolpidem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-00,N/A,Jun-12,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1683,Insomnia,7/7/14 12:28
1089,15,Astellas Pharma,Regional & Specialty Pharma,541,Myslee,zolpidem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-00,N/A,Jun-12,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,ROW,Sales,312.4245311,381.7016657,445.6904456,387.6474495,291.9639451,266.1905751,245.5718791,229.0769223,215.8809569,205.3241846,196.8787667,190.1224324,-5.944037481,1683,Insomnia,7/7/14 12:28
1089,15,Astellas Pharma,Regional & Specialty Pharma,541,Myslee,zolpidem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-00,N/A,Jun-12,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1683,Insomnia,7/7/14 12:28
1089,15,Astellas Pharma,Regional & Specialty Pharma,541,Myslee,zolpidem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-00,N/A,Jun-12,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1683,Insomnia,7/7/14 12:28
1091,58,Lundbeck,Regional & Specialty Pharma,4216,Selincro,nalmefene,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-13,,Feb-23,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,759,Alcohol Addiction,7/7/14 12:28
1091,58,Lundbeck,Regional & Specialty Pharma,4216,Selincro,nalmefene,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-13,,Feb-23,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,1,Global,Sales,0,0,0,0,17.09374654,51.28123961,89.26730504,127.2532214,157.0342425,184.1410413,208.2089525,229.1067121,44.88668949,759,Alcohol Addiction,7/7/14 12:28
1091,58,Lundbeck,Regional & Specialty Pharma,4216,Selincro,nalmefene,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-13,,Feb-23,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,759,Alcohol Addiction,7/7/14 12:28
1091,58,Lundbeck,Regional & Specialty Pharma,4216,Selincro,nalmefene,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-13,,Feb-23,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,1,ROW,Sales,0,0,0,0,17.09374654,51.28123961,89.26730504,127.2532214,157.0342425,184.1410413,208.2089525,229.1067121,44.88668949,759,Alcohol Addiction,7/7/14 12:28
1091,58,Lundbeck,Regional & Specialty Pharma,4216,Selincro,nalmefene,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-13,,Feb-23,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,759,Alcohol Addiction,7/7/14 12:28
1091,58,Lundbeck,Regional & Specialty Pharma,4216,Selincro,nalmefene,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-13,,Feb-23,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,759,Alcohol Addiction,7/7/14 12:28
1092,42,Forest,Regional & Specialty Pharma,1446,Namenda,memantine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-04,,Jan-15,,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1539,Alzheimer's Disease,7/7/14 12:28
1092,42,Forest,Regional & Specialty Pharma,1446,Namenda,memantine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-04,,Jan-15,,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,1114.9,1266.7,1390.2,1520.6,1611.397,922.9,0,0,0,2.27E-13,0,0,-100,1539,Alzheimer's Disease,7/7/14 12:28
1092,42,Forest,Regional & Specialty Pharma,1446,Namenda,memantine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-04,,Jan-15,,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1539,Alzheimer's Disease,7/7/14 12:28
1092,42,Forest,Regional & Specialty Pharma,1446,Namenda,memantine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-04,,Jan-15,,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1539,Alzheimer's Disease,7/7/14 12:28
1092,42,Forest,Regional & Specialty Pharma,1446,Namenda,memantine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-04,,Jan-15,,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1539,Alzheimer's Disease,7/7/14 12:28
1092,42,Forest,Regional & Specialty Pharma,1446,Namenda,memantine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-04,,Jan-15,,28,NMDA Antagonists,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,1114.9,1266.7,1390.2,1520.6,1611.397,922.9,0,0,0,2.27E-13,0,0,-100,1539,Alzheimer's Disease,7/7/14 12:28
1093,89,Sanofi,Large Pharma,364,Nasacort,triamcinolone acetonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-91,Jan-97,Jun-11,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1747,Allergic Rhinitis,7/7/14 12:28
1093,89,Sanofi,Large Pharma,364,Nasacort,triamcinolone acetonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-91,Jan-97,Jun-11,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,2,Global,Sales,305.6896486,250.6355196,147.386326,91.25426416,83.24492421,75.91276334,71.90590272,67.98460586,64.79485895,62.22547292,59.97836527,58.03491391,-5.022918587,1747,Allergic Rhinitis,7/7/14 12:28
1093,89,Sanofi,Large Pharma,364,Nasacort,triamcinolone acetonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-91,Jan-97,Jun-11,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1747,Allergic Rhinitis,7/7/14 12:28
1093,89,Sanofi,Large Pharma,364,Nasacort,triamcinolone acetonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-91,Jan-97,Jun-11,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,2,ROW,Sales,86.14890096,78.41739429,72.30272595,64.26356631,61.39531167,58.96260509,57.40804216,56.15959555,55.21331544,54.51816347,53.98947387,53.12120266,-2.046724128,1747,Allergic Rhinitis,7/7/14 12:28
1093,89,Sanofi,Large Pharma,364,Nasacort,triamcinolone acetonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-91,Jan-97,Jun-11,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1747,Allergic Rhinitis,7/7/14 12:28
1093,89,Sanofi,Large Pharma,364,Nasacort,triamcinolone acetonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-91,Jan-97,Jun-11,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,2,US,Sales,219.5407476,172.2181253,75.08360003,26.99069785,21.84961254,16.95015825,14.49786056,11.82501031,9.581543504,7.707309445,5.9888914,4.913711246,-19.19768727,1747,Allergic Rhinitis,7/7/14 12:28
1094,15,Astellas Pharma,Regional & Specialty Pharma,1080,Nasea,ramosetron,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-96,N/A,N/A,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1607,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1094,15,Astellas Pharma,Regional & Specialty Pharma,1080,Nasea,ramosetron,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-96,N/A,N/A,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,Global,Sales,41.0028074,39.85008641,34.2359122,29.77770133,22.60675236,20.64271574,19.36191737,18.34867264,17.57847112,17.01133081,16.58096307,16.25734332,-4.600849778,1607,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1094,15,Astellas Pharma,Regional & Specialty Pharma,1080,Nasea,ramosetron,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-96,N/A,N/A,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1607,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1094,15,Astellas Pharma,Regional & Specialty Pharma,1080,Nasea,ramosetron,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-96,N/A,N/A,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,ROW,Sales,41.0028074,39.85008641,34.2359122,29.77770133,22.60675236,20.64271574,19.36191737,18.34867264,17.57847112,17.01133081,16.58096307,16.25734332,-4.600849778,1607,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1094,15,Astellas Pharma,Regional & Specialty Pharma,1080,Nasea,ramosetron,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-96,N/A,N/A,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1607,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1094,15,Astellas Pharma,Regional & Specialty Pharma,1080,Nasea,ramosetron,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-96,N/A,N/A,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1607,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1095,61,Merck & Co,Large Pharma,566,Nasonex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-98,Jan-98,Jul-14,Jan-15,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1730,Allergic Rhinitis,7/7/14 12:28
1095,61,Merck & Co,Large Pharma,566,Nasonex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-98,Jan-98,Jul-14,Jan-15,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,Global,Sales,164.9,1220,1286,1268,1335,1031.52176,380.8501226,311.1397066,206.1069811,189.4923948,173.0977229,140.8398564,-27.4790287,1730,Allergic Rhinitis,7/7/14 12:28
1095,61,Merck & Co,Large Pharma,566,Nasonex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-98,Jan-98,Jul-14,Jan-15,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1730,Allergic Rhinitis,7/7/14 12:28
1095,61,Merck & Co,Large Pharma,566,Nasonex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-98,Jan-98,Jul-14,Jan-15,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,ROW,Sales,78.3,581,682,671,654,650.775,355.4228906,288.911417,191.6730099,174.9946015,158.5588212,132.8306282,-20.36517604,1730,Allergic Rhinitis,7/7/14 12:28
1095,61,Merck & Co,Large Pharma,566,Nasonex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-98,Jan-98,Jul-14,Jan-15,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1730,Allergic Rhinitis,7/7/14 12:28
1095,61,Merck & Co,Large Pharma,566,Nasonex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-98,Jan-98,Jul-14,Jan-15,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,US,Sales,86.6,639,604,597,681,380.74676,25.427232,22.2282896,14.4339712,14.49779328,14.53890176,8.009228283,-46.99103122,1730,Allergic Rhinitis,7/7/14 12:28
1095,61,Schering-Plough,Large Pharma,566,Nasonex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-98,Jan-98,Jul-14,Jan-15,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,Global,Proforma,1013.1,0,0,0,0,0,0,0,0,0,0,0,0,1730,Allergic Rhinitis,7/7/14 12:28
1095,61,Schering-Plough,Large Pharma,566,Nasonex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-98,Jan-98,Jul-14,Jan-15,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,ROW,Proforma,451.7,0,0,0,0,0,0,0,0,0,0,0,0,1730,Allergic Rhinitis,7/7/14 12:28
1095,61,Schering-Plough,Large Pharma,566,Nasonex,mometasone furoate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-98,Jan-98,Jul-14,Jan-15,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,US,Proforma,561.4,0,0,0,0,0,0,0,0,0,0,0,0,1730,Allergic Rhinitis,7/7/14 12:28
1096,53,Johnson & Johnson,Large Pharma,17,Natrecor,nesiritide,Small Molecule (Chemical),Launched,In-House,Aug-01,,N/A,N/A,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,760,Heart Failure,7/7/14 12:28
1096,53,Johnson & Johnson,Large Pharma,17,Natrecor,nesiritide,Small Molecule (Chemical),Launched,In-House,Aug-01,,N/A,N/A,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,97.748,78,61,49.59352,40.741816,33.9931384,29.0064508,25.23347807,22.39414117,20.2648025,18.66216353,17.45737045,-11.40283394,760,Heart Failure,7/7/14 12:28
1096,53,Johnson & Johnson,Large Pharma,17,Natrecor,nesiritide,Small Molecule (Chemical),Launched,In-House,Aug-01,,N/A,N/A,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,760,Heart Failure,7/7/14 12:28
1096,53,Johnson & Johnson,Large Pharma,17,Natrecor,nesiritide,Small Molecule (Chemical),Launched,In-House,Aug-01,,N/A,N/A,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,760,Heart Failure,7/7/14 12:28
1096,53,Johnson & Johnson,Large Pharma,17,Natrecor,nesiritide,Small Molecule (Chemical),Launched,In-House,Aug-01,,N/A,N/A,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,760,Heart Failure,7/7/14 12:28
1096,53,Johnson & Johnson,Large Pharma,17,Natrecor,nesiritide,Small Molecule (Chemical),Launched,In-House,Aug-01,,N/A,N/A,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,97.748,78,61,49.59352,40.741816,33.9931384,29.0064508,25.23347807,22.39414117,20.2648025,18.66216353,17.45737045,-11.40283394,760,Heart Failure,7/7/14 12:28
1097,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,544,Nauzelin,domperidone,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-82,N/A,Expired,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,761,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1097,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,544,Nauzelin,domperidone,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-82,N/A,Expired,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,Global,Sales,54.50479455,60.39484555,60.20765369,61.38812328,46.12034008,45.09544364,42.3077253,41.20575664,39.24530192,38.22636923,36.80864897,35.92969681,-3.504127538,761,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1097,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,544,Nauzelin,domperidone,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-82,N/A,Expired,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,761,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1097,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,544,Nauzelin,domperidone,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-82,N/A,Expired,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,ROW,Sales,54.50479455,60.39484555,60.20765369,61.38812328,46.12034008,45.09544364,42.3077253,41.20575664,39.24530192,38.22636923,36.80864897,35.92969681,-3.504127538,761,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1097,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,544,Nauzelin,domperidone,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-82,N/A,Expired,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,761,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1097,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,544,Nauzelin,domperidone,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-82,N/A,Expired,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,761,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1098,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,996,Navelbine,vinorelbine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-99,N/A,Oct-09,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,762,Breast Cancer,7/7/14 12:28
1098,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,996,Navelbine,vinorelbine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-99,N/A,Oct-09,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,3,Global,Sales,30.99292239,22.79050775,21.32354401,15.05649322,11.27386091,9.672797253,8.391946327,7.594286818,6.93230816,6.43643374,6.072796114,5.021992587,-10.90996971,762,Breast Cancer,7/7/14 12:28
1098,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,996,Navelbine,vinorelbine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-99,N/A,Oct-09,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,762,Breast Cancer,7/7/14 12:28
1098,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,996,Navelbine,vinorelbine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-99,N/A,Oct-09,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,3,ROW,Sales,30.99292239,22.79050775,21.32354401,15.05649322,11.27386091,9.672797253,8.391946327,7.594286818,6.93230816,6.43643374,6.072796114,5.021992587,-10.90996971,762,Breast Cancer,7/7/14 12:28
1098,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,996,Navelbine,vinorelbine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-99,N/A,Oct-09,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,762,Breast Cancer,7/7/14 12:28
1098,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,996,Navelbine,vinorelbine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-99,N/A,Oct-09,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,762,Breast Cancer,7/7/14 12:28
1100,86,Roche,Large Pharma,1639,NeoRecormon,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-90,N/A,Expired,102,ESAs,24,Anemia,14,Hematology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1449,Renal Anemia,7/7/14 12:28
1100,86,Roche,Large Pharma,1639,NeoRecormon,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-90,N/A,Expired,102,ESAs,24,Anemia,14,Hematology,5,Global,Sales,553.3985052,457.459247,397.6019981,348.6353824,294.6006077,262.205332,244.9393623,226.8273602,216.8951111,209.8195167,204.2106665,200.8090978,-5.328029598,1449,Renal Anemia,7/7/14 12:28
1100,86,Roche,Large Pharma,1639,NeoRecormon,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-90,N/A,Expired,102,ESAs,24,Anemia,14,Hematology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1449,Renal Anemia,7/7/14 12:28
1100,86,Roche,Large Pharma,1639,NeoRecormon,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-90,N/A,Expired,102,ESAs,24,Anemia,14,Hematology,5,ROW,Sales,553.3985052,457.459247,397.6019981,348.6353824,294.6006077,262.205332,244.9393623,226.8273602,216.8951111,209.8195167,204.2106665,200.8090978,-5.328029598,1449,Renal Anemia,7/7/14 12:28
1100,86,Roche,Large Pharma,1639,NeoRecormon,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-90,N/A,Expired,102,ESAs,24,Anemia,14,Hematology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1449,Renal Anemia,7/7/14 12:28
1100,86,Roche,Large Pharma,1639,NeoRecormon,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-90,N/A,Expired,102,ESAs,24,Anemia,14,Hematology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1449,Renal Anemia,7/7/14 12:28
1101,86,Roche,Large Pharma,1639,NeoRecormon,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-97,N/A,Expired,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1449,Chemotherapy-induced Anemia,7/7/14 12:28
1101,86,Roche,Large Pharma,1639,NeoRecormon,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-97,N/A,Expired,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,5,Global,Sales,408.8335047,319.3583423,250.0499818,187.7021331,158.6310964,125.6315119,106.2139866,89.74579316,77.89655424,69.02270635,62.32483296,57.35628081,-13.5261633,1449,Chemotherapy-induced Anemia,7/7/14 12:28
1101,86,Roche,Large Pharma,1639,NeoRecormon,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-97,N/A,Expired,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1449,Chemotherapy-induced Anemia,7/7/14 12:28
1101,86,Roche,Large Pharma,1639,NeoRecormon,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-97,N/A,Expired,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,5,ROW,Sales,408.8335047,319.3583423,250.0499818,187.7021331,158.6310964,125.6315119,106.2139866,89.74579316,77.89655424,69.02270635,62.32483296,57.35628081,-13.5261633,1449,Chemotherapy-induced Anemia,7/7/14 12:28
1101,86,Roche,Large Pharma,1639,NeoRecormon,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-97,N/A,Expired,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1449,Chemotherapy-induced Anemia,7/7/14 12:28
1101,86,Roche,Large Pharma,1639,NeoRecormon,epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-97,N/A,Expired,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1449,Chemotherapy-induced Anemia,7/7/14 12:28
1102,963,Puma Biotechnology,Small Biotech,865,neratinib,neratinib,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,764,Breast Cancer,7/7/14 12:28
1102,963,Puma Biotechnology,Small Biotech,865,neratinib,neratinib,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,764,Breast Cancer,7/7/14 12:28
1102,963,Puma Biotechnology,Small Biotech,865,neratinib,neratinib,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,764,Breast Cancer,7/7/14 12:28
1102,963,Puma Biotechnology,Small Biotech,865,neratinib,neratinib,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,764,Breast Cancer,7/7/14 12:28
1102,963,Puma Biotechnology,Small Biotech,865,neratinib,neratinib,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,764,Breast Cancer,7/7/14 12:28
1102,963,Puma Biotechnology,Small Biotech,865,neratinib,neratinib,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,764,Breast Cancer,7/7/14 12:28
1105,11,Amgen,Large Pharma,1317,Neulasta,pegfilgrastim,Recombinant Protein,Launched,In-House,Apr-02,Jan-03,Oct-15,Aug-17,118,G-CSFs,78,Neutropenia,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1585,Neutropenia,7/7/14 12:28
1105,11,Amgen,Large Pharma,1317,Neulasta,pegfilgrastim,Recombinant Protein,Launched,In-House,Apr-02,Jan-03,Oct-15,Aug-17,118,G-CSFs,78,Neutropenia,3,Oncology,6,Global,Sales,3355,3558,3952,4092,4392,4603.526754,4573.207383,4228.798578,3398.021002,2347.697399,1721.759148,1309.625424,-15.87473017,1585,Neutropenia,7/7/14 12:28
1105,11,Amgen,Large Pharma,1317,Neulasta,pegfilgrastim,Recombinant Protein,Launched,In-House,Apr-02,Jan-03,Oct-15,Aug-17,118,G-CSFs,78,Neutropenia,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1585,Neutropenia,7/7/14 12:28
1105,11,Amgen,Large Pharma,1317,Neulasta,pegfilgrastim,Recombinant Protein,Launched,In-House,Apr-02,Jan-03,Oct-15,Aug-17,118,G-CSFs,78,Neutropenia,3,Oncology,6,ROW,Sales,828,904,946,885,893,1021.516754,977.3930292,921.3874528,682.1665981,429.6941472,337.2770968,284.8715591,-15.0596554,1585,Neutropenia,7/7/14 12:28
1105,11,Amgen,Large Pharma,1317,Neulasta,pegfilgrastim,Recombinant Protein,Launched,In-House,Apr-02,Jan-03,Oct-15,Aug-17,118,G-CSFs,78,Neutropenia,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1585,Neutropenia,7/7/14 12:28
1105,11,Amgen,Large Pharma,1317,Neulasta,pegfilgrastim,Recombinant Protein,Launched,In-House,Apr-02,Jan-03,Oct-15,Aug-17,118,G-CSFs,78,Neutropenia,3,Oncology,6,US,Sales,2527,2654,3006,3207,3499,3582.01,3595.814354,3307.411125,2715.854404,1918.003252,1384.482052,1024.753865,-16.09054904,1585,Neutropenia,7/7/14 12:28
1106,11,Amgen,Large Pharma,19,Neupogen,filgrastim,Recombinant Protein,Launched,In-House,Jul-92,Jul-92,Nov-13,Sep-08,118,G-CSFs,78,Neutropenia,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1467,Neutropenia,7/7/14 12:28
1106,11,Amgen,Large Pharma,19,Neupogen,filgrastim,Recombinant Protein,Launched,In-House,Jul-92,Jul-92,Nov-13,Sep-08,118,G-CSFs,78,Neutropenia,3,Oncology,6,Global,Sales,1288,1286,1260,1260,1398,1209.742,1059.2857,862.971505,681.5229352,516.519681,439.6692566,412.859638,-15.99058328,1467,Neutropenia,7/7/14 12:28
1106,11,Amgen,Large Pharma,19,Neupogen,filgrastim,Recombinant Protein,Launched,In-House,Jul-92,Jul-92,Nov-13,Sep-08,118,G-CSFs,78,Neutropenia,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1467,Neutropenia,7/7/14 12:28
1106,11,Amgen,Large Pharma,19,Neupogen,filgrastim,Recombinant Protein,Launched,In-House,Jul-92,Jul-92,Nov-13,Sep-08,118,G-CSFs,78,Neutropenia,3,Oncology,6,ROW,Sales,387,354,301,253,229,246.092,231.8732,220.92088,212.833404,207.3484544,203.8679578,200.9146762,-1.851804463,1467,Neutropenia,7/7/14 12:28
1106,11,Amgen,Large Pharma,19,Neupogen,filgrastim,Recombinant Protein,Launched,In-House,Jul-92,Jul-92,Nov-13,Sep-08,118,G-CSFs,78,Neutropenia,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1467,Neutropenia,7/7/14 12:28
1106,11,Amgen,Large Pharma,19,Neupogen,filgrastim,Recombinant Protein,Launched,In-House,Jul-92,Jul-92,Nov-13,Sep-08,118,G-CSFs,78,Neutropenia,3,Oncology,6,US,Sales,901,932,959,1007,1169,963.65,827.4125,642.050625,468.6895312,309.1712266,235.8012988,211.9449618,-21.64648656,1467,Neutropenia,7/7/14 12:28
1107,105,UCB,Regional & Specialty Pharma,1123,Neupro,rotigotine patch,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-07,Mar-06,Mar-21,Feb-21,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1626,Parkinson's Disease,7/7/14 12:28
1107,105,UCB,Regional & Specialty Pharma,1123,Neupro,rotigotine patch,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-07,Mar-06,Mar-21,Feb-21,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,Global,Sales,84.75940256,108.6298944,133.4819556,170.9410864,229.7492015,263.514366,295.4991401,323.0587728,345.654984,365.1271966,381.6473688,395.6131128,8.072857121,1626,Parkinson's Disease,7/7/14 12:28
1107,105,UCB,Regional & Specialty Pharma,1123,Neupro,rotigotine patch,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-07,Mar-06,Mar-21,Feb-21,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1626,Parkinson's Disease,7/7/14 12:28
1107,105,UCB,Regional & Specialty Pharma,1123,Neupro,rotigotine patch,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-07,Mar-06,Mar-21,Feb-21,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,ROW,Sales,84.75940256,108.6298944,133.4819556,151.6620165,176.6279989,193.46078,208.6376736,221.1044521,231.7192123,240.7813065,248.4379297,254.9403486,5.382478759,1626,Parkinson's Disease,7/7/14 12:28
1107,105,UCB,Regional & Specialty Pharma,1123,Neupro,rotigotine patch,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-07,Mar-06,Mar-21,Feb-21,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1626,Parkinson's Disease,7/7/14 12:28
1107,105,UCB,Regional & Specialty Pharma,1123,Neupro,rotigotine patch,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-07,Mar-06,Mar-21,Feb-21,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,US,Sales,0,0,0,19.27906989,53.12120266,70.05358601,86.86146655,101.9543208,113.9357717,124.3458901,133.2094391,140.6727642,14.92651641,1626,Parkinson's Disease,7/7/14 12:28
1108,63,Merck KGaA,Regional & Specialty Pharma,418,Neurobion,vitamin B,Small Molecule (Chemical),Launched,In-House,,Jul-82,N/A,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,769,Vitamin B Deficiency,7/7/14 12:28
1108,63,Merck KGaA,Regional & Specialty Pharma,418,Neurobion,vitamin B,Small Molecule (Chemical),Launched,In-House,,Jul-82,N/A,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,769,Vitamin B Deficiency,7/7/14 12:28
1108,63,Merck KGaA,Regional & Specialty Pharma,418,Neurobion,vitamin B,Small Molecule (Chemical),Launched,In-House,,Jul-82,N/A,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,769,Vitamin B Deficiency,7/7/14 12:28
1108,63,Merck KGaA,Regional & Specialty Pharma,418,Neurobion,vitamin B,Small Molecule (Chemical),Launched,In-House,,Jul-82,N/A,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,769,Vitamin B Deficiency,7/7/14 12:28
1108,63,Merck KGaA,Regional & Specialty Pharma,418,Neurobion,vitamin B,Small Molecule (Chemical),Launched,In-House,,Jul-82,N/A,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,769,Vitamin B Deficiency,7/7/14 12:28
1108,63,Merck KGaA,Regional & Specialty Pharma,418,Neurobion,vitamin B,Small Molecule (Chemical),Launched,In-House,,Jul-82,N/A,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,769,Vitamin B Deficiency,7/7/14 12:28
1109,76,Pfizer,Large Pharma,1592,Neurontin,gabapentin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-94,Jul-93,Expired,Dec-15,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1478,Epilepsy,7/7/14 12:28
1109,76,Pfizer,Large Pharma,1592,Neurontin,gabapentin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-94,Jul-93,Expired,Dec-15,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,70.95,67.6,62.8,51.55,47.25,41.8075,38.19391798,34.68491048,32.19749496,30.2889942,28.84527335,27.60555478,-7.390313448,1478,Epilepsy,7/7/14 12:28
1109,76,Pfizer,Large Pharma,1592,Neurontin,gabapentin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-94,Jul-93,Expired,Dec-15,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1478,Epilepsy,7/7/14 12:28
1109,76,Pfizer,Large Pharma,1592,Neurontin,gabapentin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-94,Jul-93,Expired,Dec-15,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,64.25,60,56.5,46.75,42.75,37.9375,34.64941798,31.47483548,29.21839371,27.50778251,26.21416382,25.09624235,-7.326992175,1478,Epilepsy,7/7/14 12:28
1109,76,Pfizer,Large Pharma,1592,Neurontin,gabapentin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-94,Jul-93,Expired,Dec-15,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1478,Epilepsy,7/7/14 12:28
1109,76,Pfizer,Large Pharma,1592,Neurontin,gabapentin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-94,Jul-93,Expired,Dec-15,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,6.7,7.6,6.3,4.8,4.5,3.87,3.5445,3.210075,2.97910125,2.781211688,2.631109528,2.509312425,-8.005214525,1478,Epilepsy,7/7/14 12:28
1110,76,Pfizer,Large Pharma,1592,Neurontin,gabapentin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-94,Jul-93,Expired,Dec-15,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1478,Neuropathic pain,7/7/14 12:28
1110,76,Pfizer,Large Pharma,1592,Neurontin,gabapentin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-94,Jul-93,Expired,Dec-15,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,253.05,248.4,226.2,183.5,168.8,150.42,138.7721999,127.4503565,119.6278277,113.6320012,108.7532604,104.6692875,-6.599419346,1478,Neuropathic pain,7/7/14 12:28
1110,76,Pfizer,Large Pharma,1592,Neurontin,gabapentin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-94,Jul-93,Expired,Dec-15,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1478,Neuropathic pain,7/7/14 12:28
1110,76,Pfizer,Large Pharma,1592,Neurontin,gabapentin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-94,Jul-93,Expired,Dec-15,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,192.75,180,169.5,140.3,128.3,113.88,104.4371999,94.59360655,87.7796402,82.44185432,78.00324872,74.21134583,-7.522763915,1478,Neuropathic pain,7/7/14 12:28
1110,76,Pfizer,Large Pharma,1592,Neurontin,gabapentin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-94,Jul-93,Expired,Dec-15,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1478,Neuropathic pain,7/7/14 12:28
1110,76,Pfizer,Large Pharma,1592,Neurontin,gabapentin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-94,Jul-93,Expired,Dec-15,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,60.3,68.4,56.7,43.2,40.5,36.54,34.335,32.85675,31.8481875,31.19014687,30.75001172,30.45794168,-3.989041069,1478,Neuropathic pain,7/7/14 12:28
1111,29,Chugai,Regional & Specialty Pharma,604,Neutrogin,lenograstim,Recombinant Protein,Launched,Licensed (Development),,Dec-91,N/A,Sep-08,118,G-CSFs,78,Neutropenia,3,Oncology,3,Global,Alliance Revenue,348.4031965,312.2299562,313.5815296,284.3898772,233.6763897,209.078875,199.0553878,191.7437765,184.7943637,180.1906314,176.681224,173.9658004,-4.127789904,770,Neutropenia,7/7/14 12:28
1111,29,Chugai,Regional & Specialty Pharma,604,Neutrogin,lenograstim,Recombinant Protein,Launched,Licensed (Development),,Dec-91,N/A,Sep-08,118,G-CSFs,78,Neutropenia,3,Oncology,3,ROW,Alliance Revenue,348.4031965,312.2299562,313.5815296,284.3898772,233.6763897,209.078875,199.0553878,191.7437765,184.7943637,180.1906314,176.681224,173.9658004,-4.127789904,770,Neutropenia,7/7/14 12:28
1111,29,Chugai,Regional & Specialty Pharma,604,Neutrogin,lenograstim,Recombinant Protein,Launched,Licensed (Development),,Dec-91,N/A,Sep-08,118,G-CSFs,78,Neutropenia,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,770,Neutropenia,7/7/14 12:28
1111,86,Roche,Large Pharma,604,Neutrogin,lenograstim,Recombinant Protein,Launched,Licensed (Development),,Dec-91,N/A,Sep-08,118,G-CSFs,78,Neutropenia,3,Oncology,5,Global,Sales,348.4031965,312.2299562,313.5815296,284.3898772,233.6763897,209.078875,199.0553878,191.7437765,184.7943637,180.1906314,176.681224,173.9658004,-4.127789904,770,Neutropenia,7/7/14 12:28
1111,86,Roche,Large Pharma,604,Neutrogin,lenograstim,Recombinant Protein,Launched,Licensed (Development),,Dec-91,N/A,Sep-08,118,G-CSFs,78,Neutropenia,3,Oncology,5,ROW,Sales,348.4031965,312.2299562,313.5815296,284.3898772,233.6763897,209.078875,199.0553878,191.7437765,184.7943637,180.1906314,176.681224,173.9658004,-4.127789904,770,Neutropenia,7/7/14 12:28
1112,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,356,Neu-Up,nartograstim,Recombinant Protein,Launched,In-House,,Jun-94,N/A,N/A,118,G-CSFs,78,Neutropenia,3,Oncology,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,771,Neutropenia,7/7/14 12:28
1112,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,356,Neu-Up,nartograstim,Recombinant Protein,Launched,In-House,,Jun-94,N/A,N/A,118,G-CSFs,78,Neutropenia,3,Oncology,3,Global,Sales,16.03082193,2.279050775,0,0,0,0,0,0,0,0,0,0,0,771,Neutropenia,7/7/14 12:28
1112,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,356,Neu-Up,nartograstim,Recombinant Protein,Launched,In-House,,Jun-94,N/A,N/A,118,G-CSFs,78,Neutropenia,3,Oncology,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,771,Neutropenia,7/7/14 12:28
1112,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,356,Neu-Up,nartograstim,Recombinant Protein,Launched,In-House,,Jun-94,N/A,N/A,118,G-CSFs,78,Neutropenia,3,Oncology,3,ROW,Sales,16.03082193,2.279050775,0,0,0,0,0,0,0,0,0,0,0,771,Neutropenia,7/7/14 12:28
1112,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,356,Neu-Up,nartograstim,Recombinant Protein,Launched,In-House,,Jun-94,N/A,N/A,118,G-CSFs,78,Neutropenia,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,771,Neutropenia,7/7/14 12:28
1112,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,356,Neu-Up,nartograstim,Recombinant Protein,Launched,In-House,,Jun-94,N/A,N/A,118,G-CSFs,78,Neutropenia,3,Oncology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,771,Neutropenia,7/7/14 12:28
1114,19,Bayer,Large Pharma,972,Nexavar,sorafenib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-06,Aug-06,Jan-20,Jul-20,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,772,Renal Cell Carcinoma,7/7/14 12:28
1114,19,Bayer,Large Pharma,972,Nexavar,sorafenib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-06,Aug-06,Jan-20,Jul-20,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,Global,Sales,839.2570352,933.952141,1008.066852,1017.93489,1023.911181,1043.740837,1079.536804,1103.320815,1085.526541,1060.501791,1048.355212,842.1842688,-2.752634165,772,Renal Cell Carcinoma,7/7/14 12:28
1114,19,Bayer,Large Pharma,972,Nexavar,sorafenib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-06,Aug-06,Jan-20,Jul-20,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,772,Renal Cell Carcinoma,7/7/14 12:28
1114,19,Bayer,Large Pharma,972,Nexavar,sorafenib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-06,Aug-06,Jan-20,Jul-20,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,625.2742812,703.4448041,766.1308077,755.7395398,733.0725968,728.2900495,727.1326751,720.3692277,699.566142,678.0509315,666.8778553,633.287095,-2.068600817,772,Renal Cell Carcinoma,7/7/14 12:28
1114,19,Bayer,Large Pharma,972,Nexavar,sorafenib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-06,Aug-06,Jan-20,Jul-20,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,772,Renal Cell Carcinoma,7/7/14 12:28
1114,19,Bayer,Large Pharma,972,Nexavar,sorafenib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-06,Aug-06,Jan-20,Jul-20,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,US,Sales,213.982754,230.5073369,241.9360445,262.1953505,290.8385846,315.4507876,352.4041287,382.9515873,385.9603994,382.4508591,381.4773568,208.8971738,-4.617506992,772,Renal Cell Carcinoma,7/7/14 12:28
1115,16,AstraZeneca,Large Pharma,888,Nexium,esomeprazole,Small Molecule (Chemical),Launched,In-House,Mar-01,Aug-00,May-13,Oct-10,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,773,GERD,7/7/14 12:28
1115,16,AstraZeneca,Large Pharma,888,Nexium,esomeprazole,Small Molecule (Chemical),Launched,In-House,Mar-01,Aug-00,May-13,Oct-10,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,Global,Sales,4959,4969,4429,3944,3872,2462.4959,1635.277821,1569.843475,1513.01141,1464.764362,1423.880019,1404.692454,-13.48481626,773,GERD,7/7/14 12:28
1115,16,AstraZeneca,Large Pharma,888,Nexium,esomeprazole,Small Molecule (Chemical),Launched,In-House,Mar-01,Aug-00,May-13,Oct-10,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,773,GERD,7/7/14 12:28
1115,16,AstraZeneca,Large Pharma,888,Nexium,esomeprazole,Small Molecule (Chemical),Launched,In-House,Mar-01,Aug-00,May-13,Oct-10,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,ROW,Sales,2124,2274,2032,1672,1749,1654.68,1577.832,1536.776,1486.81888,1444.686912,1409.275456,1377.006062,-3.358483737,773,GERD,7/7/14 12:28
1115,16,AstraZeneca,Large Pharma,888,Nexium,esomeprazole,Small Molecule (Chemical),Launched,In-House,Mar-01,Aug-00,May-13,Oct-10,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,773,GERD,7/7/14 12:28
1115,16,AstraZeneca,Large Pharma,888,Nexium,esomeprazole,Small Molecule (Chemical),Launched,In-House,Mar-01,Aug-00,May-13,Oct-10,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,US,Sales,2835,2695,2397,2272,2123,807.8159,57.445821,33.06747479,26.19252975,20.07745006,14.60456318,27.68639242,-46.2027902,773,GERD,7/7/14 12:28
1116,2221,AbbVie,Large Pharma,501,Niaspan,Extended-release niacin,Small Molecule (Chemical),Launched,In-House,Aug-97,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1561,Dyslipidemia,7/7/14 12:28
1116,2221,AbbVie,Large Pharma,501,Niaspan,Extended-release niacin,Small Molecule (Chemical),Launched,In-House,Aug-97,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,650,157,115,96,79.48,67.5688,58.585728,51.88763968,-30.31095351,1561,Dyslipidemia,7/7/14 12:28
1116,2221,AbbVie,Large Pharma,501,Niaspan,Extended-release niacin,Small Molecule (Chemical),Launched,In-House,Aug-97,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1561,Dyslipidemia,7/7/14 12:28
1116,2221,AbbVie,Large Pharma,501,Niaspan,Extended-release niacin,Small Molecule (Chemical),Launched,In-House,Aug-97,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1561,Dyslipidemia,7/7/14 12:28
1116,2221,AbbVie,Large Pharma,501,Niaspan,Extended-release niacin,Small Molecule (Chemical),Launched,In-House,Aug-97,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1561,Dyslipidemia,7/7/14 12:28
1116,2221,AbbVie,Large Pharma,501,Niaspan,Extended-release niacin,Small Molecule (Chemical),Launched,In-House,Aug-97,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,650,157,115,96,79.48,67.5688,58.585728,51.88763968,-30.31095351,1561,Dyslipidemia,7/7/14 12:28
1119,34,Daiichi-Sankyo,Regional & Specialty Pharma,345,nimotuzumab,nimotuzumab,Antibody/Antibody Derivative,Phase III,,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,778,Gastric Cancer,7/7/14 12:28
1119,34,Daiichi-Sankyo,Regional & Specialty Pharma,345,nimotuzumab,nimotuzumab,Antibody/Antibody Derivative,Phase III,,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,778,Gastric Cancer,7/7/14 12:28
1119,34,Daiichi-Sankyo,Regional & Specialty Pharma,345,nimotuzumab,nimotuzumab,Antibody/Antibody Derivative,Phase III,,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,778,Gastric Cancer,7/7/14 12:28
1119,34,Daiichi-Sankyo,Regional & Specialty Pharma,345,nimotuzumab,nimotuzumab,Antibody/Antibody Derivative,Phase III,,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,778,Gastric Cancer,7/7/14 12:28
1119,34,Daiichi-Sankyo,Regional & Specialty Pharma,345,nimotuzumab,nimotuzumab,Antibody/Antibody Derivative,Phase III,,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,778,Gastric Cancer,7/7/14 12:28
1119,34,Daiichi-Sankyo,Regional & Specialty Pharma,345,nimotuzumab,nimotuzumab,Antibody/Antibody Derivative,Phase III,,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,778,Gastric Cancer,7/7/14 12:28
1120,53,Johnson & Johnson,Large Pharma,190,Nizoral,ketoconazole,Small Molecule (Chemical),Launched,In-House,Jul-81,Jul-81,May-00,Dec-97,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,780,,7/7/14 12:28
1120,53,Johnson & Johnson,Large Pharma,190,Nizoral,ketoconazole,Small Molecule (Chemical),Launched,In-House,Jul-81,Jul-81,May-00,Dec-97,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,155,139.1536,123.83784,108.642,96.3524576,85.33911744,75.5529568,67.02896412,59.50855407,52.88884611,47.07222568,41.95358199,-11.19953699,780,,7/7/14 12:28
1120,53,Johnson & Johnson,Large Pharma,190,Nizoral,ketoconazole,Small Molecule (Chemical),Launched,In-House,Jul-81,Jul-81,May-00,Dec-97,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,780,,7/7/14 12:28
1120,53,Johnson & Johnson,Large Pharma,190,Nizoral,ketoconazole,Small Molecule (Chemical),Launched,In-House,Jul-81,Jul-81,May-00,Dec-97,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,65,59.9536,55.11784,50.386,46.5252576,43.07159744,40.0064608,37.33380892,34.97652975,32.90175977,31.07848048,29.4740593,-6.313122102,780,,7/7/14 12:28
1120,53,Johnson & Johnson,Large Pharma,190,Nizoral,ketoconazole,Small Molecule (Chemical),Launched,In-House,Jul-81,Jul-81,May-00,Dec-97,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,780,,7/7/14 12:28
1120,53,Johnson & Johnson,Large Pharma,190,Nizoral,ketoconazole,Small Molecule (Chemical),Launched,In-House,Jul-81,Jul-81,May-00,Dec-97,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Sales,90,79.2,68.72,58.256,49.8272,42.26752,35.546496,29.6951552,24.53202432,19.98708634,15.9937452,12.47952269,-17.94508787,780,,7/7/14 12:28
1122,68,Novo Nordisk,Regional & Specialty Pharma,4543,Tresiba,insulin degludec,Recombinant Protein,Launched,In-House,Sep-16,Mar-13,Jun-25,Jun-24,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,358,Diabetes,7/7/14 12:28
1122,68,Novo Nordisk,Regional & Specialty Pharma,4543,Tresiba,insulin degludec,Recombinant Protein,Launched,In-House,Sep-16,Mar-13,Jun-25,Jun-24,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,50.04590447,143.465093,243.5563844,366.6790656,549.8824147,764.4608311,978.9721933,1187.242069,57.20008105,358,Diabetes,7/7/14 12:28
1122,68,Novo Nordisk,Regional & Specialty Pharma,4543,Tresiba,insulin degludec,Recombinant Protein,Launched,In-House,Sep-16,Mar-13,Jun-25,Jun-24,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,358,Diabetes,7/7/14 12:28
1122,68,Novo Nordisk,Regional & Specialty Pharma,4543,Tresiba,insulin degludec,Recombinant Protein,Launched,In-House,Sep-16,Mar-13,Jun-25,Jun-24,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,50.04590447,143.465093,243.5563844,343.6483161,442.4055071,541.8299404,641.1877007,740.4453491,46.94691434,358,Diabetes,7/7/14 12:28
1122,68,Novo Nordisk,Regional & Specialty Pharma,4543,Tresiba,insulin degludec,Recombinant Protein,Launched,In-House,Sep-16,Mar-13,Jun-25,Jun-24,83,Insulins,22,Diabetes,8,Metabolism,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,358,Diabetes,7/7/14 12:28
1122,68,Novo Nordisk,Regional & Specialty Pharma,4543,Tresiba,insulin degludec,Recombinant Protein,Launched,In-House,Sep-16,Mar-13,Jun-25,Jun-24,83,Insulins,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,23.03074946,107.4769076,222.6308907,337.7844926,446.7967202,0,358,Diabetes,7/7/14 12:28
1123,68,Novo Nordisk,Regional & Specialty Pharma,4544,Ryzodeg,insulin degludec + insulin aspart,Recombinant Protein,Approved,In-House,Jan-17,Jan-14,Jun-25,Jun-24,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,359,Diabetes,7/7/14 12:28
1123,68,Novo Nordisk,Regional & Specialty Pharma,4544,Ryzodeg,insulin degludec + insulin aspart,Recombinant Protein,Approved,In-House,Jan-17,Jan-14,Jun-25,Jun-24,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,0,26.88902047,71.7041442,116.5192343,191.6072694,286.8767479,382.1462122,477.4163226,0,359,Diabetes,7/7/14 12:28
1123,68,Novo Nordisk,Regional & Specialty Pharma,4544,Ryzodeg,insulin degludec + insulin aspart,Recombinant Protein,Approved,In-House,Jan-17,Jan-14,Jun-25,Jun-24,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,359,Diabetes,7/7/14 12:28
1123,68,Novo Nordisk,Regional & Specialty Pharma,4544,Ryzodeg,insulin degludec + insulin aspart,Recombinant Protein,Approved,In-House,Jan-17,Jan-14,Jun-25,Jun-24,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,0,26.88902047,71.7041442,116.5192343,161.3348622,206.150228,250.9656172,295.7810472,0,359,Diabetes,7/7/14 12:28
1123,68,Novo Nordisk,Regional & Specialty Pharma,4544,Ryzodeg,insulin degludec + insulin aspart,Recombinant Protein,Approved,In-House,Jan-17,Jan-14,Jun-25,Jun-24,83,Insulins,22,Diabetes,8,Metabolism,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,359,Diabetes,7/7/14 12:28
1123,68,Novo Nordisk,Regional & Specialty Pharma,4544,Ryzodeg,insulin degludec + insulin aspart,Recombinant Protein,Approved,In-House,Jan-17,Jan-14,Jun-25,Jun-24,83,Insulins,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,0,30.27240715,80.72651996,131.1805949,181.6352754,0,359,Diabetes,7/7/14 12:28
1124,68,Novo Nordisk,Regional & Specialty Pharma,2242,semaglutide,semaglutide,Synthetic Peptide,Phase III,In-House,Jun-17,Mar-17,Jan-17,Jan-13,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1078,Type II Diabetes,7/7/14 12:28
1124,68,Novo Nordisk,Regional & Specialty Pharma,2242,semaglutide,semaglutide,Synthetic Peptide,Phase III,In-House,Jun-17,Mar-17,Jan-17,Jan-13,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,0,0,0,0,57.13172059,311.7759891,639.3467559,1052.766727,0,1078,Type II Diabetes,7/7/14 12:28
1124,68,Novo Nordisk,Regional & Specialty Pharma,2242,semaglutide,semaglutide,Synthetic Peptide,Phase III,In-House,Jun-17,Mar-17,Jan-17,Jan-13,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1078,Type II Diabetes,7/7/14 12:28
1124,68,Novo Nordisk,Regional & Specialty Pharma,2242,semaglutide,semaglutide,Synthetic Peptide,Phase III,In-House,Jun-17,Mar-17,Jan-17,Jan-13,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,0,0,0,0,25.96896633,107.2000177,185.7817176,303.3201172,0,1078,Type II Diabetes,7/7/14 12:28
1124,68,Novo Nordisk,Regional & Specialty Pharma,2242,semaglutide,semaglutide,Synthetic Peptide,Phase III,In-House,Jun-17,Mar-17,Jan-17,Jan-13,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1078,Type II Diabetes,7/7/14 12:28
1124,68,Novo Nordisk,Regional & Specialty Pharma,2242,semaglutide,semaglutide,Synthetic Peptide,Phase III,In-House,Jun-17,Mar-17,Jan-17,Jan-13,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,0,31.16275425,204.5759715,453.5650383,749.4466097,0,1078,Type II Diabetes,7/7/14 12:28
1125,16,AstraZeneca,Large Pharma,10,Nolvadex,tamoxifen,Small Molecule (Chemical),Launched,In-House,,Jan-73,Expired,Expired,53,Anti-estrogens,55,Hormonals,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,795,Breast Cancer,7/7/14 12:28
1125,16,AstraZeneca,Large Pharma,10,Nolvadex,tamoxifen,Small Molecule (Chemical),Launched,In-House,,Jan-73,Expired,Expired,53,Anti-estrogens,55,Hormonals,3,Oncology,6,Global,Sales,88,89,99,98.96,99.6168,100.266944,100.3559635,100.4415017,100.4926946,100.5072635,100.5166329,100.5213281,0.129213279,795,Breast Cancer,7/7/14 12:28
1125,16,AstraZeneca,Large Pharma,10,Nolvadex,tamoxifen,Small Molecule (Chemical),Launched,In-House,,Jan-73,Expired,Expired,53,Anti-estrogens,55,Hormonals,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,795,Breast Cancer,7/7/14 12:28
1125,16,AstraZeneca,Large Pharma,10,Nolvadex,tamoxifen,Small Molecule (Chemical),Launched,In-House,,Jan-73,Expired,Expired,53,Anti-estrogens,55,Hormonals,3,Oncology,6,ROW,Sales,88,89,99,98.96,99.6168,100.266944,100.3559635,100.4415017,100.4926946,100.5072635,100.5166329,100.5213281,0.129213279,795,Breast Cancer,7/7/14 12:28
1125,16,AstraZeneca,Large Pharma,10,Nolvadex,tamoxifen,Small Molecule (Chemical),Launched,In-House,,Jan-73,Expired,Expired,53,Anti-estrogens,55,Hormonals,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,795,Breast Cancer,7/7/14 12:28
1125,16,AstraZeneca,Large Pharma,10,Nolvadex,tamoxifen,Small Molecule (Chemical),Launched,In-House,,Jan-73,Expired,Expired,53,Anti-estrogens,55,Hormonals,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,795,Breast Cancer,7/7/14 12:28
1126,61,Merck & Co,Large Pharma,3960,Zoely,nomegestrol + estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-12,Oct-17,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,796,Female contraception,7/7/14 12:28
1126,61,Merck & Co,Large Pharma,3960,Zoely,nomegestrol + estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-12,Oct-17,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,0,27.50001,48.33346758,68.33337312,88.33318477,100.4331262,110.0630634,117.5300114,122.9554774,127.0827603,14.80925403,796,Female contraception,7/7/14 12:28
1126,61,Merck & Co,Large Pharma,3960,Zoely,nomegestrol + estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-12,Oct-17,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,796,Female contraception,7/7/14 12:28
1126,61,Merck & Co,Large Pharma,3960,Zoely,nomegestrol + estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-12,Oct-17,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,27.50001,48.33346758,68.33337312,88.33318477,100.4331262,110.0630634,117.5300114,122.9554774,127.0827603,14.80925403,796,Female contraception,7/7/14 12:28
1126,61,Merck & Co,Large Pharma,3960,Zoely,nomegestrol + estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-12,Oct-17,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,796,Female contraception,7/7/14 12:28
1126,61,Merck & Co,Large Pharma,3960,Zoely,nomegestrol + estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-12,Oct-17,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,796,Female contraception,7/7/14 12:28
1127,105,UCB,Regional & Specialty Pharma,752,Nootropil,piracetam,Small Molecule (Chemical),Launched,In-House,,Jul-71,N/A,Expired,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,797,Dementia,7/7/14 12:28
1127,105,UCB,Regional & Specialty Pharma,752,Nootropil,piracetam,Small Molecule (Chemical),Launched,In-House,,Jul-71,N/A,Expired,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,Global,Sales,97.26488819,87.43381746,95.94015559,80.97209355,77.02574386,71.71362363,67.46392743,64.06417048,61.34436492,59.16852047,57.42784491,56.03530446,-4.44336379,797,Dementia,7/7/14 12:28
1127,105,UCB,Regional & Specialty Pharma,752,Nootropil,piracetam,Small Molecule (Chemical),Launched,In-House,,Jul-71,N/A,Expired,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,797,Dementia,7/7/14 12:28
1127,105,UCB,Regional & Specialty Pharma,752,Nootropil,piracetam,Small Molecule (Chemical),Launched,In-House,,Jul-71,N/A,Expired,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,ROW,Sales,97.26488819,87.43381746,95.94015559,80.97209355,77.02574386,71.71362363,67.46392743,64.06417048,61.34436492,59.16852047,57.42784491,56.03530446,-4.44336379,797,Dementia,7/7/14 12:28
1127,105,UCB,Regional & Specialty Pharma,752,Nootropil,piracetam,Small Molecule (Chemical),Launched,In-House,,Jul-71,N/A,Expired,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,797,Dementia,7/7/14 12:28
1127,105,UCB,Regional & Specialty Pharma,752,Nootropil,piracetam,Small Molecule (Chemical),Launched,In-House,,Jul-71,N/A,Expired,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,797,Dementia,7/7/14 12:28
1128,68,Novo Nordisk,Regional & Specialty Pharma,1673,Norditropin,somatropin,Recombinant Protein,Launched,In-House,Feb-97,Jan-88,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1749,Growth Hormone Disorders,7/7/14 12:28
1128,68,Novo Nordisk,Regional & Specialty Pharma,1673,Norditropin,somatropin,Recombinant Protein,Launched,In-House,Feb-97,Jan-88,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,1,Global,Sales,821.2353051,854.3337024,941.898821,983.8400785,1088.738219,1146.135594,1199.969616,1240.542107,1273.605459,1300.32842,1321.857841,1339.197563,3.002050453,1749,Growth Hormone Disorders,7/7/14 12:28
1128,68,Novo Nordisk,Regional & Specialty Pharma,1673,Norditropin,somatropin,Recombinant Protein,Launched,In-House,Feb-97,Jan-88,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1749,Growth Hormone Disorders,7/7/14 12:28
1128,68,Novo Nordisk,Regional & Specialty Pharma,1673,Norditropin,somatropin,Recombinant Protein,Launched,In-House,Feb-97,Jan-88,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,1,ROW,Sales,629.0352678,631.2784322,694.8066793,701.5342645,704.2786486,700.2274882,700.8062254,699.593771,698.7375872,698.25118,697.8637867,697.5750738,-0.136534355,1749,Growth Hormone Disorders,7/7/14 12:28
1128,68,Novo Nordisk,Regional & Specialty Pharma,1673,Norditropin,somatropin,Recombinant Protein,Launched,In-House,Feb-97,Jan-88,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1749,Growth Hormone Disorders,7/7/14 12:28
1128,68,Novo Nordisk,Regional & Specialty Pharma,1673,Norditropin,somatropin,Recombinant Protein,Launched,In-House,Feb-97,Jan-88,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,1,US,Sales,192.2000373,223.0552702,247.0921417,282.305814,384.4595708,445.9081054,499.1633909,540.948336,574.8678714,602.0772402,623.9940542,641.6224896,7.590896321,1749,Growth Hormone Disorders,7/7/14 12:28
1129,76,Pfizer,Large Pharma,47,Norvasc,amlodipine,Small Molecule (Chemical),Launched,In-House,Jan-90,Jan-90,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1343,,7/7/14 12:28
1129,76,Pfizer,Large Pharma,47,Norvasc,amlodipine,Small Molecule (Chemical),Launched,In-House,Jan-90,Jan-90,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,1973,1506,1445,1349,1229,1138.86,1063.6881,1000.584503,948.2714259,904.729546,868.4802678,838.3178447,-5.318466164,1343,,7/7/14 12:28
1129,76,Pfizer,Large Pharma,47,Norvasc,amlodipine,Small Molecule (Chemical),Launched,In-House,Jan-90,Jan-90,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1343,,7/7/14 12:28
1129,76,Pfizer,Large Pharma,47,Norvasc,amlodipine,Small Molecule (Chemical),Launched,In-House,Jan-90,Jan-90,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,1909,1473,1422,1301,1190,1099.6,1023.984,961.12576,908.7979264,865.2507945,829.0081767,798.8453602,-5.534396353,1343,,7/7/14 12:28
1129,76,Pfizer,Large Pharma,47,Norvasc,amlodipine,Small Molecule (Chemical),Launched,In-House,Jan-90,Jan-90,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1343,,7/7/14 12:28
1129,76,Pfizer,Large Pharma,47,Norvasc,amlodipine,Small Molecule (Chemical),Launched,In-House,Jan-90,Jan-90,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,64,33,23,48,39,39.26,39.7041,39.4587435,39.47349952,39.47875151,39.47209109,39.47248448,0.172179136,1343,,7/7/14 12:28
1130,2221,AbbVie,Large Pharma,1175,Norvir,ritonavir,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-96,Jan-14,Dec-13,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,798,HIV,7/7/14 12:28
1130,2221,AbbVie,Large Pharma,1175,Norvir,ritonavir,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-96,Jan-14,Dec-13,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,309.436,150.176,102.345,77.13,62.4864384,52.167687,44.47784533,41.05014562,-25.06618908,798,HIV,7/7/14 12:28
1130,2221,AbbVie,Large Pharma,1175,Norvir,ritonavir,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-96,Jan-14,Dec-13,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,798,HIV,7/7/14 12:28
1130,2221,AbbVie,Large Pharma,1175,Norvir,ritonavir,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-96,Jan-14,Dec-13,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,94.86,45.872,35.88,29.25,24.595464,21.037415,18.19099958,18.12369482,-21.05780619,798,HIV,7/7/14 12:28
1130,2221,AbbVie,Large Pharma,1175,Norvir,ritonavir,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-96,Jan-14,Dec-13,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,798,HIV,7/7/14 12:28
1130,2221,AbbVie,Large Pharma,1175,Norvir,ritonavir,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-96,Jan-14,Dec-13,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,214.576,104.304,66.465,47.88,37.8909744,31.130272,26.28684576,22.9264508,-27.34743519,798,HIV,7/7/14 12:28
1131,68,Novo Nordisk,Regional & Specialty Pharma,1087,NovoNorm / Prandin,repaglinide,Small Molecule (Chemical),Launched,Licensed (Development),Jul-98,Dec-98,Aug-13,Jan-10,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1613,Type II Diabetes,7/7/14 12:28
1131,68,Novo Nordisk,Regional & Specialty Pharma,1087,NovoNorm / Prandin,repaglinide,Small Molecule (Chemical),Launched,Licensed (Development),Jul-98,Dec-98,Aug-13,Jan-10,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,1,Global,Sales,494.8684456,489.3341693,480.560623,476.2076056,399.9825397,341.4372342,311.6830279,280.9964345,275.3135167,270.6069361,266.5622388,263.0357244,-5.811849458,1613,Type II Diabetes,7/7/14 12:28
1131,68,Novo Nordisk,Regional & Specialty Pharma,1087,NovoNorm / Prandin,repaglinide,Small Molecule (Chemical),Launched,Licensed (Development),Jul-98,Dec-98,Aug-13,Jan-10,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1613,Type II Diabetes,7/7/14 12:28
1131,68,Novo Nordisk,Regional & Specialty Pharma,1087,NovoNorm / Prandin,repaglinide,Small Molecule (Chemical),Launched,Licensed (Development),Jul-98,Dec-98,Aug-13,Jan-10,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,1,ROW,Sales,301.8697518,298.4938433,293.3752619,288.694386,280.139422,270.2080409,264.661076,259.6276765,255.7254886,252.7996378,250.5356703,248.7898858,-1.681117237,1613,Type II Diabetes,7/7/14 12:28
1131,68,Novo Nordisk,Regional & Specialty Pharma,1087,NovoNorm / Prandin,repaglinide,Small Molecule (Chemical),Launched,Licensed (Development),Jul-98,Dec-98,Aug-13,Jan-10,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1613,Type II Diabetes,7/7/14 12:28
1131,68,Novo Nordisk,Regional & Specialty Pharma,1087,NovoNorm / Prandin,repaglinide,Small Molecule (Chemical),Launched,Licensed (Development),Jul-98,Dec-98,Aug-13,Jan-10,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,1,US,Sales,192.9986938,190.840326,187.1853611,187.5132196,119.8431177,71.22919328,47.02195195,21.36875799,19.58802815,17.80729832,16.02656849,14.24583866,-26.23200523,1613,Type II Diabetes,7/7/14 12:28
1132,68,Novo Nordisk,Regional & Specialty Pharma,2405,NovoRapid / NovoLog,insulin aspart,Recombinant Protein,Launched,In-House,Sep-01,Sep-99,Dec-17,Dec-17,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,802,Diabetes,7/7/14 12:28
1132,68,Novo Nordisk,Regional & Specialty Pharma,2405,NovoRapid / NovoLog,insulin aspart,Recombinant Protein,Launched,In-House,Sep-01,Sep-99,Dec-17,Dec-17,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Sales,1819.182683,2116.712692,2389.552705,2709.617822,3000.173621,3227.149007,3426.790958,3572.381646,3628.773105,3642.086511,3686.017431,3709.219505,3.077124211,802,Diabetes,7/7/14 12:28
1132,68,Novo Nordisk,Regional & Specialty Pharma,2405,NovoRapid / NovoLog,insulin aspart,Recombinant Protein,Launched,In-House,Sep-01,Sep-99,Dec-17,Dec-17,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,802,Diabetes,7/7/14 12:28
1132,68,Novo Nordisk,Regional & Specialty Pharma,2405,NovoRapid / NovoLog,insulin aspart,Recombinant Protein,Launched,In-House,Sep-01,Sep-99,Dec-17,Dec-17,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Sales,799.9626796,1018.156592,1160.250638,1227.987125,1316.493565,1384.28595,1426.089706,1456.074181,1477.615673,1487.557233,1499.163503,1506.278629,1.942485126,802,Diabetes,7/7/14 12:28
1132,68,Novo Nordisk,Regional & Specialty Pharma,2405,NovoRapid / NovoLog,insulin aspart,Recombinant Protein,Launched,In-House,Sep-01,Sep-99,Dec-17,Dec-17,83,Insulins,22,Diabetes,8,Metabolism,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,802,Diabetes,7/7/14 12:28
1132,68,Novo Nordisk,Regional & Specialty Pharma,2405,NovoRapid / NovoLog,insulin aspart,Recombinant Protein,Launched,In-House,Sep-01,Sep-99,Dec-17,Dec-17,83,Insulins,22,Diabetes,8,Metabolism,1,US,Sales,1019.220004,1098.5561,1229.302067,1481.630697,1683.680056,1842.863057,2000.701251,2116.307464,2151.157432,2154.529279,2186.853928,2202.940875,3.914844929,802,Diabetes,7/7/14 12:28
1133,68,Novo Nordisk,Regional & Specialty Pharma,1506,NovoSeven,eptacog alfa,Recombinant Protein,Launched,In-House,Apr-99,May-96,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,803,Hemophilia with Inhibitors,7/7/14 12:28
1133,68,Novo Nordisk,Regional & Specialty Pharma,1506,NovoSeven,eptacog alfa,Recombinant Protein,Launched,In-House,Apr-99,May-96,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,Global,Sales,1319.649188,1428.336379,1557.76292,1542.408463,1648.243533,1711.074804,1753.387438,1783.956123,1808.649859,1827.254249,1841.533808,1852.745403,1.684868301,803,Hemophilia with Inhibitors,7/7/14 12:28
1133,68,Novo Nordisk,Regional & Specialty Pharma,1506,NovoSeven,eptacog alfa,Recombinant Protein,Launched,In-House,Apr-99,May-96,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,803,Hemophilia with Inhibitors,7/7/14 12:28
1133,68,Novo Nordisk,Regional & Specialty Pharma,1506,NovoSeven,eptacog alfa,Recombinant Protein,Launched,In-House,Apr-99,May-96,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,ROW,Sales,675.6484419,714.1681897,778.9747729,817.4782119,854.2161005,883.0354321,909.432793,926.2820676,941.7574659,954.4078335,964.4441943,972.7800535,1.874111813,803,Hemophilia with Inhibitors,7/7/14 12:28
1133,68,Novo Nordisk,Regional & Specialty Pharma,1506,NovoSeven,eptacog alfa,Recombinant Protein,Launched,In-House,Apr-99,May-96,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,803,Hemophilia with Inhibitors,7/7/14 12:28
1133,68,Novo Nordisk,Regional & Specialty Pharma,1506,NovoSeven,eptacog alfa,Recombinant Protein,Launched,In-House,Apr-99,May-96,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,US,Sales,644.0007464,714.1681897,778.7881474,724.9302509,794.0274321,828.0393719,843.9546448,857.6740552,866.8923927,872.8464159,877.0896134,879.96535,1.478892102,803,Hemophilia with Inhibitors,7/7/14 12:28
1134,61,Merck & Co,Large Pharma,33,Noxafil,posaconazole,Small Molecule (Chemical),Launched,In-House,Sep-06,Dec-05,Sep-14,Dec-19,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1593,fungal infection,7/7/14 12:28
1134,61,Merck & Co,Large Pharma,33,Noxafil,posaconazole,Small Molecule (Chemical),Launched,In-House,Sep-06,Dec-05,Sep-14,Dec-19,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,30.95537,198,230,259,301.4144,305.2118,277.5797784,291.0783064,303.6739015,317.0321801,322.6943254,328.5461025,1.23891203,1593,fungal infection,7/7/14 12:28
1134,61,Merck & Co,Large Pharma,33,Noxafil,posaconazole,Small Molecule (Chemical),Launched,In-House,Sep-06,Dec-05,Sep-14,Dec-19,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1593,fungal infection,7/7/14 12:28
1134,61,Merck & Co,Large Pharma,33,Noxafil,posaconazole,Small Molecule (Chemical),Launched,In-House,Sep-06,Dec-05,Sep-14,Dec-19,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,20.38,147,169,184,195.4144,204.17872,221.1957384,237.110588,252.1278858,266.4075832,273.3854087,279.8065635,5.261995017,1593,fungal infection,7/7/14 12:28
1134,61,Merck & Co,Large Pharma,33,Noxafil,posaconazole,Small Molecule (Chemical),Launched,In-House,Sep-06,Dec-05,Sep-14,Dec-19,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1593,fungal infection,7/7/14 12:28
1134,61,Merck & Co,Large Pharma,33,Noxafil,posaconazole,Small Molecule (Chemical),Launched,In-House,Sep-06,Dec-05,Sep-14,Dec-19,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Sales,10.57537,51,61,75,106,101.03308,56.38404,53.9677184,51.54601568,50.62459693,49.30891674,48.73953902,-10.5054568,1593,fungal infection,7/7/14 12:28
1134,61,Schering-Plough,Large Pharma,33,Noxafil,posaconazole,Small Molecule (Chemical),Launched,In-House,Sep-06,Dec-05,Sep-14,Dec-19,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Proforma,154.66,0,0,0,0,0,0,0,0,0,0,0,0,1593,fungal infection,7/7/14 12:28
1134,61,Schering-Plough,Large Pharma,33,Noxafil,posaconazole,Small Molecule (Chemical),Launched,In-House,Sep-06,Dec-05,Sep-14,Dec-19,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Proforma,102,0,0,0,0,0,0,0,0,0,0,0,0,1593,fungal infection,7/7/14 12:28
1134,61,Schering-Plough,Large Pharma,33,Noxafil,posaconazole,Small Molecule (Chemical),Launched,In-House,Sep-06,Dec-05,Sep-14,Dec-19,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Proforma,52.66,0,0,0,0,0,0,0,0,0,0,0,0,1593,fungal infection,7/7/14 12:28
1135,11,Amgen,Large Pharma,971,Nplate,romiplostim,Antibody/Antibody Derivative,Launched,In-House,Dec-08,Feb-09,Oct-19,May-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1623,Immune Thrombocytopenic Purpura,7/7/14 12:28
1135,11,Amgen,Large Pharma,971,Nplate,romiplostim,Antibody/Antibody Derivative,Launched,In-House,Dec-08,Feb-09,Oct-19,May-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,6,Global,Sales,110,229,297,368,427,456.54,485.382,506.8518,522.8691,534.999894,544.0986222,550.9338596,3.707510998,1623,Immune Thrombocytopenic Purpura,7/7/14 12:28
1135,11,Amgen,Large Pharma,971,Nplate,romiplostim,Antibody/Antibody Derivative,Launched,In-House,Dec-08,Feb-09,Oct-19,May-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1623,Immune Thrombocytopenic Purpura,7/7/14 12:28
1135,11,Amgen,Large Pharma,971,Nplate,romiplostim,Antibody/Antibody Derivative,Launched,In-House,Dec-08,Feb-09,Oct-19,May-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,6,ROW,Sales,32,100,134,154,186,195.48,207.204,216.6276,223.4226,228.564228,232.4606484,235.3704676,3.420244582,1623,Immune Thrombocytopenic Purpura,7/7/14 12:28
1135,11,Amgen,Large Pharma,971,Nplate,romiplostim,Antibody/Antibody Derivative,Launched,In-House,Dec-08,Feb-09,Oct-19,May-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1623,Immune Thrombocytopenic Purpura,7/7/14 12:28
1135,11,Amgen,Large Pharma,971,Nplate,romiplostim,Antibody/Antibody Derivative,Launched,In-House,Dec-08,Feb-09,Oct-19,May-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,6,US,Sales,78,129,163,214,241,261.06,278.178,290.2242,299.4465,306.435666,311.6379738,315.563392,3.925999025,1623,Immune Thrombocytopenic Purpura,7/7/14 12:28
1136,76,Pfizer,Large Pharma,4239,PF-05212377,PF-05212377,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,904,Alzheimer's Disease,7/7/14 12:28
1136,76,Pfizer,Large Pharma,4239,PF-05212377,PF-05212377,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,904,Alzheimer's Disease,7/7/14 12:28
1136,76,Pfizer,Large Pharma,4239,PF-05212377,PF-05212377,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,904,Alzheimer's Disease,7/7/14 12:28
1136,76,Pfizer,Large Pharma,4239,PF-05212377,PF-05212377,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,904,Alzheimer's Disease,7/7/14 12:28
1136,76,Pfizer,Large Pharma,4239,PF-05212377,PF-05212377,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,904,Alzheimer's Disease,7/7/14 12:28
1136,76,Pfizer,Large Pharma,4239,PF-05212377,PF-05212377,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,904,Alzheimer's Disease,7/7/14 12:28
1137,86,Roche,Large Pharma,558,Nutropin,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Jan-94,Jan-97,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1750,Growth Hormone Disorders,7/7/14 12:28
1137,86,Roche,Large Pharma,558,Nutropin,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Jan-94,Jan-97,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,Global,Sales,368.3184727,388.4087947,357.0533524,323.7307274,295.2592476,272.3682468,255.1664237,241.005853,229.9233131,221.1385905,214.1591087,208.6243617,-4.840606334,1750,Growth Hormone Disorders,7/7/14 12:28
1137,86,Roche,Large Pharma,558,Nutropin,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Jan-94,Jan-97,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1750,Growth Hormone Disorders,7/7/14 12:28
1137,86,Roche,Large Pharma,558,Nutropin,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Jan-94,Jan-97,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,ROW,Sales,9.207961818,10.54937467,9.010810156,6.983377871,6.05425551,5.447146727,5.082881458,4.864322296,4.733186799,4.654505501,4.607296722,4.578971454,-3.911265635,1750,Growth Hormone Disorders,7/7/14 12:28
1137,86,Roche,Large Pharma,558,Nutropin,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Jan-94,Jan-97,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1750,Growth Hormone Disorders,7/7/14 12:28
1137,86,Roche,Large Pharma,558,Nutropin,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Jan-94,Jan-97,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,5,US,Sales,359.1105109,377.85942,348.0425423,316.7473496,289.2049921,266.9211,250.0835423,236.1415308,225.1901263,216.484085,209.5518119,204.0453903,-4.860653309,1750,Growth Hormone Disorders,7/7/14 12:28
1138,61,Merck & Co,Large Pharma,1170,Nuvaring,etonogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Feb-03,Apr-18,May-24,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1456,Female contraception,7/7/14 12:28
1138,61,Merck & Co,Large Pharma,1170,Nuvaring,etonogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Feb-03,Apr-18,May-24,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,88.3,559,623,623,686,698.45,709.1042494,703.8119087,686.2046066,480.719335,330.0442531,284.1339405,-11.83134873,1456,Female contraception,7/7/14 12:28
1138,61,Merck & Co,Large Pharma,1170,Nuvaring,etonogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Feb-03,Apr-18,May-24,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1456,Female contraception,7/7/14 12:28
1138,61,Merck & Co,Large Pharma,1170,Nuvaring,etonogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Feb-03,Apr-18,May-24,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,33,217,254,257,260,265.88,268.006912,265.346368,258.9814,246.4973712,241.8832613,239.7834118,-1.149703882,1456,Female contraception,7/7/14 12:28
1138,61,Merck & Co,Large Pharma,1170,Nuvaring,etonogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Feb-03,Apr-18,May-24,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1456,Female contraception,7/7/14 12:28
1138,61,Merck & Co,Large Pharma,1170,Nuvaring,etonogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Feb-03,Apr-18,May-24,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,55.3,342,369,366,426,432.57,441.0973374,438.4655407,427.2232066,234.2219638,88.16099181,44.35052877,-27.61618731,1456,Female contraception,7/7/14 12:28
1138,61,Schering-Plough,Large Pharma,1170,Nuvaring,etonogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Feb-03,Apr-18,May-24,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Proforma,422.7,0,0,0,0,0,0,0,0,0,0,0,0,1456,Female contraception,7/7/14 12:28
1138,61,Schering-Plough,Large Pharma,1170,Nuvaring,etonogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Feb-03,Apr-18,May-24,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Proforma,165,0,0,0,0,0,0,0,0,0,0,0,0,1456,Female contraception,7/7/14 12:28
1138,61,Schering-Plough,Large Pharma,1170,Nuvaring,etonogestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Feb-03,Apr-18,May-24,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Proforma,257.7,0,0,0,0,0,0,0,0,0,0,0,0,1456,Female contraception,7/7/14 12:28
1139,102,Cephalon,Regional & Specialty Pharma,1578,Nuvigil,armodafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-09,,Jun-16,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,Global,Proforma,73.4,186.2,180,0,0,0,0,0,0,0,0,0,0,805,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1139,102,Cephalon,Regional & Specialty Pharma,1578,Nuvigil,armodafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-09,,Jun-16,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,US,Proforma,73.4,186.2,180,0,0,0,0,0,0,0,0,0,0,805,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1139,102,Teva,Regional & Specialty Pharma,1578,Nuvigil,armodafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-09,,Jun-16,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,805,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1139,102,Teva,Regional & Specialty Pharma,1578,Nuvigil,armodafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-09,,Jun-16,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,Global,Sales,0,-1.00E-02,86,347,320,307.04,295.5488,201.2255502,87.76388436,62.1031487,48.37848489,39.20419166,-25.913259,805,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1139,102,Teva,Regional & Specialty Pharma,1578,Nuvigil,armodafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-09,,Jun-16,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,805,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1139,102,Teva,Regional & Specialty Pharma,1578,Nuvigil,armodafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-09,,Jun-16,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,805,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1139,102,Teva,Regional & Specialty Pharma,1578,Nuvigil,armodafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-09,,Jun-16,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,805,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1139,102,Teva,Regional & Specialty Pharma,1578,Nuvigil,armodafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-09,,Jun-16,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,US,Sales,0,-1.00E-02,86,347,320,307.04,295.5488,201.2255502,87.76388436,62.1031487,48.37848489,39.20419166,-25.913259,805,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1145,86,Roche,Large Pharma,1148,ocrelizumab,ocrelizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Dec-16,Dec-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,807,Multiple Sclerosis,7/7/14 12:28
1145,86,Roche,Large Pharma,1148,ocrelizumab,ocrelizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Dec-16,Dec-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,5,Global,Sales,0,0,0,0,0,0,0,21.5824621,165.4656147,320.139562,557.545457,712.6508668,0,807,Multiple Sclerosis,7/7/14 12:28
1145,86,Roche,Large Pharma,1148,ocrelizumab,ocrelizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Dec-16,Dec-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,807,Multiple Sclerosis,7/7/14 12:28
1145,86,Roche,Large Pharma,1148,ocrelizumab,ocrelizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Dec-16,Dec-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,5,ROW,Sales,0,0,0,0,0,0,0,6.47473863,49.63968441,96.0418686,167.2636371,213.79526,0,807,Multiple Sclerosis,7/7/14 12:28
1145,86,Roche,Large Pharma,1148,ocrelizumab,ocrelizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Dec-16,Dec-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,807,Multiple Sclerosis,7/7/14 12:28
1145,86,Roche,Large Pharma,1148,ocrelizumab,ocrelizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Dec-16,Dec-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,5,US,Sales,0,0,0,0,0,0,0,15.10772347,115.8259303,224.0976934,390.2818199,498.8556067,0,807,Multiple Sclerosis,7/7/14 12:28
1147,61,Merck & Co,Large Pharma,564,odanacatib,odanacatib,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-15,Nov-15,Jul-24,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,808,Osteoporosis,7/7/14 12:28
1147,61,Merck & Co,Large Pharma,564,odanacatib,odanacatib,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-15,Nov-15,Jul-24,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,15.00001,125.0001467,381.6667684,638.3348121,865.6688479,1107.669603,0,808,Osteoporosis,7/7/14 12:28
1147,61,Merck & Co,Large Pharma,564,odanacatib,odanacatib,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-15,Nov-15,Jul-24,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,808,Osteoporosis,7/7/14 12:28
1147,61,Merck & Co,Large Pharma,564,odanacatib,odanacatib,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-15,Nov-15,Jul-24,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,5.00001,48.33344667,158.3336046,268.3342931,365.001372,468.3351496,0,808,Osteoporosis,7/7/14 12:28
1147,61,Merck & Co,Large Pharma,564,odanacatib,odanacatib,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-15,Nov-15,Jul-24,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,808,Osteoporosis,7/7/14 12:28
1147,61,Merck & Co,Large Pharma,564,odanacatib,odanacatib,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-15,Nov-15,Jul-24,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,10,76.6667,223.3331638,370.0005191,500.6674759,639.3344536,0,808,Osteoporosis,7/7/14 12:28
1150,76,Pfizer,Large Pharma,1514,Olmetec,olmesartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-06,Apr-16,Feb-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,107,107,106,104,102,100,97,93,44,22,9,8,-30.48634382,1569,,7/7/14 12:28
1150,76,Pfizer,Large Pharma,1514,Olmetec,olmesartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-06,Apr-16,Feb-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1569,,7/7/14 12:28
1150,76,Pfizer,Large Pharma,1514,Olmetec,olmesartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-06,Apr-16,Feb-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,107,107,106,104,102,100,97,93,44,22,9,8,-30.48634382,1569,,7/7/14 12:28
1150,76,Pfizer,Large Pharma,1514,Olmetec,olmesartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-06,Apr-16,Feb-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1569,,7/7/14 12:28
1150,76,Pfizer,Large Pharma,1514,Olmetec,olmesartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-06,Apr-16,Feb-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1569,,7/7/14 12:28
1150,76,Pfizer,Large Pharma,1514,Olmetec,olmesartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-06,Apr-16,Feb-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1569,,7/7/14 12:28
1151,100,Nycomed,Large Pharma,48,Omnaris,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-08,N/A,Apr-19,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,Global,Proforma,19.45297768,35.76831024,41.44132076,0,0,0,0,0,0,0,0,0,0,1691,Allergic Rhinitis,7/7/14 12:28
1151,100,Nycomed,Large Pharma,48,Omnaris,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-08,N/A,Apr-19,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,ROW,Proforma,19.45297768,35.76831024,41.44132076,0,0,0,0,0,0,0,0,0,0,1691,Allergic Rhinitis,7/7/14 12:28
1151,100,Takeda,Large Pharma,48,Omnaris,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-08,N/A,Apr-19,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1691,Allergic Rhinitis,7/7/14 12:28
1151,100,Takeda,Large Pharma,48,Omnaris,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-08,N/A,Apr-19,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,Global,Sales,-2.63E-14,-2.59E-14,8.033564007,55.8133511,62.06840688,67.86601995,72.35799459,75.88992856,78.02646955,79.53959236,80.5915476,81.29515894,3.930255645,1691,Allergic Rhinitis,7/7/14 12:28
1151,100,Takeda,Large Pharma,48,Omnaris,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-08,N/A,Apr-19,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1691,Allergic Rhinitis,7/7/14 12:28
1151,100,Takeda,Large Pharma,48,Omnaris,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-08,N/A,Apr-19,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,ROW,Sales,-2.63E-14,-2.59E-14,8.033564007,55.8133511,62.06840688,67.86601995,72.35799459,75.88992856,78.02646955,79.53959236,80.5915476,81.29515894,3.930255645,1691,Allergic Rhinitis,7/7/14 12:28
1151,100,Takeda,Large Pharma,48,Omnaris,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-08,N/A,Apr-19,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1691,Allergic Rhinitis,7/7/14 12:28
1151,100,Takeda,Large Pharma,48,Omnaris,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-08,N/A,Apr-19,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1691,Allergic Rhinitis,7/7/14 12:28
1152,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4743,Omnaris / Zetonna,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-19,N/A,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1691,Allergic Rhinitis,7/7/14 12:28
1152,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4743,Omnaris / Zetonna,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-19,N/A,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,Global,Sales,6.463955815,56.02960231,64.57446797,28.75487235,40.27088898,39.94872187,39.49173778,40.30118442,40.34260157,40.43417909,40.51470039,40.54243038,0.096049422,1691,Allergic Rhinitis,7/7/14 12:28
1152,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4743,Omnaris / Zetonna,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-19,N/A,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1691,Allergic Rhinitis,7/7/14 12:28
1152,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4743,Omnaris / Zetonna,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-19,N/A,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1691,Allergic Rhinitis,7/7/14 12:28
1152,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4743,Omnaris / Zetonna,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-19,N/A,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1691,Allergic Rhinitis,7/7/14 12:28
1152,35,Dainippon-Sumitomo,Regional & Specialty Pharma,4743,Omnaris / Zetonna,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-19,N/A,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,US,Sales,6.463955815,56.02960231,64.57446797,28.75487235,40.27088898,39.94872187,39.49173778,40.30118442,40.34260157,40.43417909,40.51470039,40.54243038,0.096049422,1691,Allergic Rhinitis,7/7/14 12:28
1152,35,Sepracor,Regional & Specialty Pharma,4743,Omnaris / Zetonna,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-19,N/A,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,Global,Proforma,24.77849729,0,0,0,0,0,0,0,0,0,0,0,0,1691,Allergic Rhinitis,7/7/14 12:28
1152,35,Sepracor,Regional & Specialty Pharma,4743,Omnaris / Zetonna,ciclesonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-19,N/A,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,7,US,Proforma,24.77849729,0,0,0,0,0,0,0,0,0,0,0,0,1691,Allergic Rhinitis,7/7/14 12:28
1153,1,Abbott,Regional & Specialty Pharma,1007,Omnicef,cefdinir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-98,,May-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1383,Bacterial infections,7/7/14 12:28
1153,1,Abbott,Regional & Specialty Pharma,1007,Omnicef,cefdinir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-98,,May-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,60.3,23,5,4,0,0,0,0,0,0,0,0,0,1383,Bacterial infections,7/7/14 12:28
1153,1,Abbott,Regional & Specialty Pharma,1007,Omnicef,cefdinir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-98,,May-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1383,Bacterial infections,7/7/14 12:28
1153,1,Abbott,Regional & Specialty Pharma,1007,Omnicef,cefdinir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-98,,May-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1383,Bacterial infections,7/7/14 12:28
1153,1,Abbott,Regional & Specialty Pharma,1007,Omnicef,cefdinir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-98,,May-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1383,Bacterial infections,7/7/14 12:28
1153,1,Abbott,Regional & Specialty Pharma,1007,Omnicef,cefdinir,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-98,,May-07,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,60.3,23,5,4,0,0,0,0,0,0,0,0,0,1383,Bacterial infections,7/7/14 12:28
1154,67,Novartis,Large Pharma,346,Omnitrope,somatropin,Recombinant Protein,Launched,In-House,Apr-06,Sep-04,N/A,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1751,Growth Hormone Disorders,7/7/14 12:28
1154,67,Novartis,Large Pharma,346,Omnitrope,somatropin,Recombinant Protein,Launched,In-House,Apr-06,Sep-04,N/A,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Sales,77,109,127,155,177.68,199.316,219.8099,238.95182,256.9020883,273.7576516,289.5657829,304.3936782,7.993980736,1751,Growth Hormone Disorders,7/7/14 12:28
1154,67,Novartis,Large Pharma,346,Omnitrope,somatropin,Recombinant Protein,Launched,In-House,Apr-06,Sep-04,N/A,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1751,Growth Hormone Disorders,7/7/14 12:28
1154,67,Novartis,Large Pharma,346,Omnitrope,somatropin,Recombinant Protein,Launched,In-House,Apr-06,Sep-04,N/A,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Sales,39,53,59,68,76.19,83.3855,90.454775,97.05293375,103.2259994,109.0578514,114.536581,119.6877612,6.664930176,1751,Growth Hormone Disorders,7/7/14 12:28
1154,67,Novartis,Large Pharma,346,Omnitrope,somatropin,Recombinant Protein,Launched,In-House,Apr-06,Sep-04,N/A,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1751,Growth Hormone Disorders,7/7/14 12:28
1154,67,Novartis,Large Pharma,346,Omnitrope,somatropin,Recombinant Protein,Launched,In-House,Apr-06,Sep-04,N/A,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Sales,38,56,68,87,101.49,115.9305,129.355125,141.8988863,153.6760888,164.6998003,175.0292019,184.7059169,8.93088755,1751,Growth Hormone Disorders,7/7/14 12:28
1155,23,Boehringer Ingelheim,Large Pharma,3703,Tradjenta / Trajenta / Jentadueto,linagliptin / linagliptin + metformin,Small Molecule (Chemical),Launched,In-House,May-11,Sep-11,Aug-23,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,813,Type II Diabetes,7/7/14 12:28
1155,23,Boehringer Ingelheim,Large Pharma,3703,Tradjenta / Trajenta / Jentadueto,linagliptin / linagliptin + metformin,Small Molecule (Chemical),Launched,In-House,May-11,Sep-11,Aug-23,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,2,Global,Sales,0,0,34.76092594,177.367443,496.6832449,925.6236761,1131.654261,1332.845504,1502.634679,1648.411875,1773.941281,1863.267359,20.78913475,813,Type II Diabetes,7/7/14 12:28
1155,23,Boehringer Ingelheim,Large Pharma,3703,Tradjenta / Trajenta / Jentadueto,linagliptin / linagliptin + metformin,Small Molecule (Chemical),Launched,In-House,May-11,Sep-11,Aug-23,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,813,Type II Diabetes,7/7/14 12:28
1155,23,Boehringer Ingelheim,Large Pharma,3703,Tradjenta / Trajenta / Jentadueto,linagliptin / linagliptin + metformin,Small Molecule (Chemical),Launched,In-House,May-11,Sep-11,Aug-23,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,2,ROW,Sales,0,0,8.342622225,65.54883763,261.6219231,502.9913877,631.6775012,752.7274417,853.8702116,948.0636658,1035.710463,1101.790543,22.80144266,813,Type II Diabetes,7/7/14 12:28
1155,23,Boehringer Ingelheim,Large Pharma,3703,Tradjenta / Trajenta / Jentadueto,linagliptin / linagliptin + metformin,Small Molecule (Chemical),Launched,In-House,May-11,Sep-11,Aug-23,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,813,Type II Diabetes,7/7/14 12:28
1155,23,Boehringer Ingelheim,Large Pharma,3703,Tradjenta / Trajenta / Jentadueto,linagliptin / linagliptin + metformin,Small Molecule (Chemical),Launched,In-House,May-11,Sep-11,Aug-23,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,2,US,Sales,0,0,26.41830371,111.8186054,235.0613218,422.6322884,499.9767595,580.1180619,648.7644672,700.3482095,738.2308183,761.4768159,18.28372697,813,Type II Diabetes,7/7/14 12:28
1157,24,Bristol-Myers Squibb,Large Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,In-House,Aug-09,Sep-09,Mar-21,Mar-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1630,Type II Diabetes,7/7/14 12:28
1157,24,Bristol-Myers Squibb,Large Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,In-House,Aug-09,Sep-09,Mar-21,Mar-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,Global,Sales,24,158,473,709,877,87,0,0,0,0,0,0,-100,1630,Type II Diabetes,7/7/14 12:28
1157,24,Bristol-Myers Squibb,Large Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,In-House,Aug-09,Sep-09,Mar-21,Mar-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1630,Type II Diabetes,7/7/14 12:28
1157,24,Bristol-Myers Squibb,Large Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,In-House,Aug-09,Sep-09,Mar-21,Mar-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Sales,2,39,127,193,286,29,0,0,0,0,0,0,-100,1630,Type II Diabetes,7/7/14 12:28
1157,24,Bristol-Myers Squibb,Large Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,In-House,Aug-09,Sep-09,Mar-21,Mar-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1630,Type II Diabetes,7/7/14 12:28
1157,24,Bristol-Myers Squibb,Large Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,In-House,Aug-09,Sep-09,Mar-21,Mar-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,US,Sales,22,119,346,516,591,58,0,0,0,0,0,0,-100,1630,Type II Diabetes,7/7/14 12:28
1158,70,Ono,Regional & Specialty Pharma,2275,Rivastach,rivastigmine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-11,N/A,Dec-20,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,432,Alzheimer's Disease,7/7/14 12:28
1158,70,Ono,Regional & Specialty Pharma,2275,Rivastach,rivastigmine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-11,N/A,Dec-20,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,Global,Sales,0,0,15.19399246,46.9510886,73.76249865,88.76505325,108.5593108,126.6622466,141.9539643,156.4342167,169.5652111,181.4379401,13.72127704,432,Alzheimer's Disease,7/7/14 12:28
1158,70,Ono,Regional & Specialty Pharma,2275,Rivastach,rivastigmine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-11,N/A,Dec-20,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,432,Alzheimer's Disease,7/7/14 12:28
1158,70,Ono,Regional & Specialty Pharma,2275,Rivastach,rivastigmine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-11,N/A,Dec-20,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,ROW,Sales,0,0,15.19399246,46.9510886,73.76249865,88.76505325,108.5593108,126.6622466,141.9539643,156.4342167,169.5652111,181.4379401,13.72127704,432,Alzheimer's Disease,7/7/14 12:28
1158,70,Ono,Regional & Specialty Pharma,2275,Rivastach,rivastigmine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-11,N/A,Dec-20,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,432,Alzheimer's Disease,7/7/14 12:28
1158,70,Ono,Regional & Specialty Pharma,2275,Rivastach,rivastigmine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-11,N/A,Dec-20,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,432,Alzheimer's Disease,7/7/14 12:28
1159,70,Ono,Regional & Specialty Pharma,686,Onon,pranlukast,Small Molecule (Chemical),Launched,In-House,,Jun-95,N/A,Expired,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,822,Asthma,7/7/14 12:28
1159,70,Ono,Regional & Specialty Pharma,686,Onon,pranlukast,Small Molecule (Chemical),Launched,In-House,,Jun-95,N/A,Expired,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,7,Global,Sales,368.4454815,352.5715705,338.0663323,281.7065316,197.4443612,174.560157,160.8296345,152.591321,147.6483329,144.68254,142.9030643,141.8353789,-4.615646553,822,Asthma,7/7/14 12:28
1159,70,Ono,Regional & Specialty Pharma,686,Onon,pranlukast,Small Molecule (Chemical),Launched,In-House,,Jun-95,N/A,Expired,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,822,Asthma,7/7/14 12:28
1159,70,Ono,Regional & Specialty Pharma,686,Onon,pranlukast,Small Molecule (Chemical),Launched,In-House,,Jun-95,N/A,Expired,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,7,ROW,Sales,368.4454815,352.5715705,338.0663323,281.7065316,197.4443612,174.560157,160.8296345,152.591321,147.6483329,144.68254,142.9030643,141.8353789,-4.615646553,822,Asthma,7/7/14 12:28
1159,70,Ono,Regional & Specialty Pharma,686,Onon,pranlukast,Small Molecule (Chemical),Launched,In-House,,Jun-95,N/A,Expired,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,822,Asthma,7/7/14 12:28
1159,70,Ono,Regional & Specialty Pharma,686,Onon,pranlukast,Small Molecule (Chemical),Launched,In-House,,Jun-95,N/A,Expired,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,822,Asthma,7/7/14 12:28
1161,70,Ono,Regional & Specialty Pharma,399,Opalmon,limaprost,Small Molecule (Chemical),Launched,In-House,,Apr-88,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1526,Thromboangiitis obliterans ,7/7/14 12:28
1161,70,Ono,Regional & Specialty Pharma,399,Opalmon,limaprost,Small Molecule (Chemical),Launched,In-House,,Apr-88,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,480.4873823,468.0806359,500.8587156,408.1133086,314.3325503,288.3024331,271.671807,258.873584,250.0449293,243.556866,238.9618506,233.5711561,-4.153620635,1526,Thromboangiitis obliterans ,7/7/14 12:28
1161,70,Ono,Regional & Specialty Pharma,399,Opalmon,limaprost,Small Molecule (Chemical),Launched,In-House,,Apr-88,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1526,Thromboangiitis obliterans ,7/7/14 12:28
1161,70,Ono,Regional & Specialty Pharma,399,Opalmon,limaprost,Small Molecule (Chemical),Launched,In-House,,Apr-88,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,480.4873823,468.0806359,500.8587156,408.1133086,314.3325503,288.3024331,271.671807,258.873584,250.0449293,243.556866,238.9618506,233.5711561,-4.153620635,1526,Thromboangiitis obliterans ,7/7/14 12:28
1161,70,Ono,Regional & Specialty Pharma,399,Opalmon,limaprost,Small Molecule (Chemical),Launched,In-House,,Apr-88,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1526,Thromboangiitis obliterans ,7/7/14 12:28
1161,70,Ono,Regional & Specialty Pharma,399,Opalmon,limaprost,Small Molecule (Chemical),Launched,In-House,,Apr-88,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1526,Thromboangiitis obliterans ,7/7/14 12:28
1162,40,Endo Health Solutions,Regional & Specialty Pharma,994,Opana / Opana ER,oxymorphone,Small Molecule (Chemical),Launched,Licensed (Development),Jul-06,,Jan-13,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,823,Pain,7/7/14 12:28
1162,40,Endo Health Solutions,Regional & Specialty Pharma,994,Opana / Opana ER,oxymorphone,Small Molecule (Chemical),Launched,Licensed (Development),Jul-06,,Jan-13,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,231,299.08,384.3,299.29,227.8,19,13,10,7.3,6,6,6,-40.51995322,823,Pain,7/7/14 12:28
1162,40,Endo Health Solutions,Regional & Specialty Pharma,994,Opana / Opana ER,oxymorphone,Small Molecule (Chemical),Launched,Licensed (Development),Jul-06,,Jan-13,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,823,Pain,7/7/14 12:28
1162,40,Endo Health Solutions,Regional & Specialty Pharma,994,Opana / Opana ER,oxymorphone,Small Molecule (Chemical),Launched,Licensed (Development),Jul-06,,Jan-13,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,823,Pain,7/7/14 12:28
1162,40,Endo Health Solutions,Regional & Specialty Pharma,994,Opana / Opana ER,oxymorphone,Small Molecule (Chemical),Launched,Licensed (Development),Jul-06,,Jan-13,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,823,Pain,7/7/14 12:28
1162,40,Endo Health Solutions,Regional & Specialty Pharma,994,Opana / Opana ER,oxymorphone,Small Molecule (Chemical),Launched,Licensed (Development),Jul-06,,Jan-13,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,231,299.08,384.3,299.29,227.8,19,13,10,7.3,6,6,6,-40.51995322,823,Pain,7/7/14 12:28
1164,73,Otsuka,Regional & Specialty Pharma,4109,Mucosta Ophthalmic Suspension,rebamipide,Small Molecule (Chemical),Launched,In-House,,Jan-12,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,824,Dry Eye,7/7/14 12:28
1164,73,Otsuka,Regional & Specialty Pharma,4109,Mucosta Ophthalmic Suspension,rebamipide,Small Molecule (Chemical),Launched,In-House,,Jan-12,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,Global,Sales,0,0,6.339983741,18.05811093,20.13544449,29.46641082,31.92272991,33.43299641,34.44046308,34.87488621,35.12133767,35.25785147,8.331894952,824,Dry Eye,7/7/14 12:28
1164,73,Otsuka,Regional & Specialty Pharma,4109,Mucosta Ophthalmic Suspension,rebamipide,Small Molecule (Chemical),Launched,In-House,,Jan-12,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,824,Dry Eye,7/7/14 12:28
1164,73,Otsuka,Regional & Specialty Pharma,4109,Mucosta Ophthalmic Suspension,rebamipide,Small Molecule (Chemical),Launched,In-House,,Jan-12,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,ROW,Sales,0,0,6.339983741,18.05811093,20.13544449,29.46641082,31.92272991,33.43299641,34.44046308,34.87488621,35.12133767,35.25785147,8.331894952,824,Dry Eye,7/7/14 12:28
1164,73,Otsuka,Regional & Specialty Pharma,4109,Mucosta Ophthalmic Suspension,rebamipide,Small Molecule (Chemical),Launched,In-House,,Jan-12,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,824,Dry Eye,7/7/14 12:28
1164,73,Otsuka,Regional & Specialty Pharma,4109,Mucosta Ophthalmic Suspension,rebamipide,Small Molecule (Chemical),Launched,In-House,,Jan-12,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,824,Dry Eye,7/7/14 12:28
1165,67,Novartis,Large Pharma,1258,Flucelvax / Optaflu,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Sep-13,Nov-07,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1718,seasonal influenza,7/7/14 12:28
1165,67,Novartis,Large Pharma,1258,Flucelvax / Optaflu,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Sep-13,Nov-07,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,4,5,6,6.5,14.875,44.47711,84.6506294,124.7717508,147.5749372,166.4472542,181.0203227,191.5203558,44.057772,1718,seasonal influenza,7/7/14 12:28
1165,67,Novartis,Large Pharma,1258,Flucelvax / Optaflu,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Sep-13,Nov-07,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1718,seasonal influenza,7/7/14 12:28
1165,67,Novartis,Large Pharma,1258,Flucelvax / Optaflu,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Sep-13,Nov-07,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,4,5,6,6.5,6.875,7.14375,7.3171875,7.438359375,7.521542969,7.577858398,7.616531982,7.642966052,1.524271808,1718,seasonal influenza,7/7/14 12:28
1165,67,Novartis,Large Pharma,1258,Flucelvax / Optaflu,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Sep-13,Nov-07,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1718,seasonal influenza,7/7/14 12:28
1165,67,Novartis,Large Pharma,1258,Flucelvax / Optaflu,influenza vaccine,Vaccine,Launched,Corporate Acquisition,Sep-13,Nov-07,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,8,37.33336,77.3334419,117.3333914,140.0533942,158.8693958,173.4037907,183.8773898,56.49158793,1718,seasonal influenza,7/7/14 12:28
1167,24,Bristol-Myers Squibb,Large Pharma,251,Orencia,abatacept,Antibody/Antibody Derivative,Launched,In-House,Feb-06,Sep-06,Oct-19,Jun-18,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,826,Rheumatoid arthritis,7/7/14 12:28
1167,24,Bristol-Myers Squibb,Large Pharma,251,Orencia,abatacept,Antibody/Antibody Derivative,Launched,In-House,Feb-06,Sep-06,Oct-19,Jun-18,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,602,733,917,1176,1444,1615.765,1766.348625,1874.263141,1958.013277,2005.025185,1949.801968,1967.953558,4.521777855,826,Rheumatoid arthritis,7/7/14 12:28
1167,24,Bristol-Myers Squibb,Large Pharma,251,Orencia,abatacept,Antibody/Antibody Derivative,Launched,In-House,Feb-06,Sep-06,Oct-19,Jun-18,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,826,Rheumatoid arthritis,7/7/14 12:28
1167,24,Bristol-Myers Squibb,Large Pharma,251,Orencia,abatacept,Antibody/Antibody Derivative,Launched,In-House,Feb-06,Sep-06,Oct-19,Jun-18,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,135,186,296,379,490,566.8,633.025,682.503104,723.9563932,736.6644373,713.6080987,723.8105292,5.731426695,826,Rheumatoid arthritis,7/7/14 12:28
1167,24,Bristol-Myers Squibb,Large Pharma,251,Orencia,abatacept,Antibody/Antibody Derivative,Launched,In-House,Feb-06,Sep-06,Oct-19,Jun-18,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,826,Rheumatoid arthritis,7/7/14 12:28
1167,24,Bristol-Myers Squibb,Large Pharma,251,Orencia,abatacept,Antibody/Antibody Derivative,Launched,In-House,Feb-06,Sep-06,Oct-19,Jun-18,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,467,547,621,797,954,1048.965,1133.323625,1191.760037,1234.056884,1268.360748,1236.19387,1244.143029,3.866272405,826,Rheumatoid arthritis,7/7/14 12:28
1171,61,Merck & Co,Large Pharma,607,Org 43902,Org 43902,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,827,Female infertility,7/7/14 12:28
1171,61,Merck & Co,Large Pharma,607,Org 43902,Org 43902,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,827,Female infertility,7/7/14 12:28
1171,61,Merck & Co,Large Pharma,607,Org 43902,Org 43902,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,827,Female infertility,7/7/14 12:28
1171,61,Merck & Co,Large Pharma,607,Org 43902,Org 43902,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,827,Female infertility,7/7/14 12:28
1171,61,Merck & Co,Large Pharma,607,Org 43902,Org 43902,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,827,Female infertility,7/7/14 12:28
1171,61,Merck & Co,Large Pharma,607,Org 43902,Org 43902,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,827,Female infertility,7/7/14 12:28
1304,61,Merck & Co,Large Pharma,3133,Other Vaccines - Merck,other vaccines,Vaccine,Launched,In-House,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1572,,7/7/14 12:28
1304,61,Merck & Co,Large Pharma,3133,Other Vaccines - Merck,other vaccines,Vaccine,Launched,In-House,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,71,169,177,219,270,287.43,301.8745,311.917875,317.8421863,321.9786067,324.7397603,326.5616748,2.754345049,1572,,7/7/14 12:28
1304,61,Merck & Co,Large Pharma,3133,Other Vaccines - Merck,other vaccines,Vaccine,Launched,In-House,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1572,,7/7/14 12:28
1304,61,Merck & Co,Large Pharma,3133,Other Vaccines - Merck,other vaccines,Vaccine,Launched,In-House,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,26,51,54,59,79,82.63,85.2745,87.197875,87.94218625,88.38560669,88.63451027,88.75641232,1.677452542,1572,,7/7/14 12:28
1304,61,Merck & Co,Large Pharma,3133,Other Vaccines - Merck,other vaccines,Vaccine,Launched,In-House,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1572,,7/7/14 12:28
1304,61,Merck & Co,Large Pharma,3133,Other Vaccines - Merck,other vaccines,Vaccine,Launched,In-House,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,45,118,123,160,191,204.8,216.6,224.72,229.9,233.593,236.10525,237.8052625,3.180656196,1572,,7/7/14 12:28
1305,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,3144,Other Vaccines - SPMSD,other vaccines,Vaccine,Launched,Licensed (Marketed),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,480.7664473,411.0051798,417.1311113,401.0046538,386.4567494,382.7382652,378.3185811,367.4971547,363.1615126,357.5906546,351.8490554,347.7603194,-1.495931628,2297,,7/7/14 12:28
1305,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,3144,Other Vaccines - SPMSD,other vaccines,Vaccine,Launched,Licensed (Marketed),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,480.7664473,411.0051798,417.1311113,401.0046538,386.4567494,382.7382652,378.3185811,367.4971547,363.1615126,357.5906546,351.8490554,347.7603194,-1.495931628,2297,,7/7/14 12:28
1305,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,3144,Other Vaccines - SPMSD,other vaccines,Vaccine,Launched,Licensed (Marketed),,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2297,,7/7/14 12:28
1306,89,Sanofi,Large Pharma,4002,Other Vaccines - Sanofi,other vaccines,Vaccine,Launched,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2296,,7/7/14 12:28
1306,89,Sanofi,Large Pharma,4002,Other Vaccines - Sanofi,other vaccines,Vaccine,Launched,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,272.3416869,223.8835629,310.0674594,410.001553,491.3711246,517.7325215,539.6067703,552.0803777,558.1371506,562.1056161,564.3329453,565.5286041,2.028311081,2296,,7/7/14 12:28
1306,89,Sanofi,Large Pharma,4002,Other Vaccines - Sanofi,other vaccines,Vaccine,Launched,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2296,,7/7/14 12:28
1306,89,Sanofi,Large Pharma,4002,Other Vaccines - Sanofi,other vaccines,Vaccine,Launched,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,84.75940256,54.31494721,65.35054076,53.9813957,30.54469153,27.9417526,25.90189842,24.53243382,24.16897855,23.96887098,23.87227432,23.83606999,-3.480704089,2296,,7/7/14 12:28
1306,89,Sanofi,Large Pharma,4002,Other Vaccines - Sanofi,other vaccines,Vaccine,Launched,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2296,,7/7/14 12:28
1306,89,Sanofi,Large Pharma,4002,Other Vaccines - Sanofi,other vaccines,Vaccine,Launched,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,187.5822844,169.5686157,244.7169186,356.0201573,460.8264331,489.7907689,513.7048719,527.5479439,533.968172,538.1367452,540.4606709,541.6925342,2.336549821,2296,,7/7/14 12:28
1308,16,AstraZeneca,Large Pharma,588,Oxis Turbuhaler,formoterol,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-97,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1702,COPD,7/7/14 12:28
1308,16,AstraZeneca,Large Pharma,588,Oxis Turbuhaler,formoterol,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-97,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Sales,63,63,56,51.92,49.022,46.1709,43.993235,42.22660125,40.75181579,39.55977469,38.58552663,37.78774122,-3.6500638,1702,COPD,7/7/14 12:28
1308,16,AstraZeneca,Large Pharma,588,Oxis Turbuhaler,formoterol,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-97,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1702,COPD,7/7/14 12:28
1308,16,AstraZeneca,Large Pharma,588,Oxis Turbuhaler,formoterol,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-97,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,63,63,56,51.92,49.022,46.1709,43.993235,42.22660125,40.75181579,39.55977469,38.58552663,37.78774122,-3.6500638,1702,COPD,7/7/14 12:28
1308,16,AstraZeneca,Large Pharma,588,Oxis Turbuhaler,formoterol,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-97,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1702,COPD,7/7/14 12:28
1308,16,AstraZeneca,Large Pharma,588,Oxis Turbuhaler,formoterol,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-97,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1702,COPD,7/7/14 12:28
1309,82,Purdue Pharma,Regional & Specialty Pharma,837,OxyContin,oxycodone,Small Molecule (Chemical),Launched,In-House,Jan-95,,Jan-14,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,2292,2452,2594,2636.6,2670.68,2564.944,2630.7552,2655.088035,2682.384245,2707.084049,2726.924297,2736.73545,0.349647306,1574,Pain,7/7/14 12:28
1309,82,Purdue Pharma,Regional & Specialty Pharma,837,OxyContin,oxycodone,Small Molecule (Chemical),Launched,In-House,Jan-95,,Jan-14,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1574,Pain,7/7/14 12:28
1309,82,Purdue Pharma,Regional & Specialty Pharma,837,OxyContin,oxycodone,Small Molecule (Chemical),Launched,In-House,Jan-95,,Jan-14,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,2292,2452,2594,2636.6,2670.68,2564.944,2630.7552,2655.088035,2682.384245,2707.084049,2726.924297,2736.73545,0.349647306,1574,Pain,7/7/14 12:28
1310,95,Shionogi,Regional & Specialty Pharma,837,OxyContin,oxycodone,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-03,Jan-12,Dec-16,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1574,Pain,7/7/14 12:28
1310,95,Shionogi,Regional & Specialty Pharma,837,OxyContin,oxycodone,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-03,Jan-12,Dec-16,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,91.57270738,112.0592046,112.6887774,122.7951548,108.1101178,111.7687419,116.0196495,118.4393148,104.2423483,97.50766032,93.06357046,88.38176265,-2.837319719,1574,Pain,7/7/14 12:28
1310,95,Shionogi,Regional & Specialty Pharma,837,OxyContin,oxycodone,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-03,Jan-12,Dec-16,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1574,Pain,7/7/14 12:28
1310,95,Shionogi,Regional & Specialty Pharma,837,OxyContin,oxycodone,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-03,Jan-12,Dec-16,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,91.57270738,112.0592046,112.6887774,122.7951548,108.1101178,111.7687419,116.0196495,118.4393148,104.2423483,97.50766032,93.06357046,88.38176265,-2.837319719,1574,Pain,7/7/14 12:28
1310,95,Shionogi,Regional & Specialty Pharma,837,OxyContin,oxycodone,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-03,Jan-12,Dec-16,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1574,Pain,7/7/14 12:28
1310,95,Shionogi,Regional & Specialty Pharma,837,OxyContin,oxycodone,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-03,Jan-12,Dec-16,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1574,Pain,7/7/14 12:28
1313,61,Merck & Co,Large Pharma,3111,Pediatric Vaccines - Merck,pediatric vaccine,Vaccine,Launched,In-House,Jul-79,Jul-79,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1575,,7/7/14 12:28
1313,61,Merck & Co,Large Pharma,3111,Pediatric Vaccines - Merck,pediatric vaccine,Vaccine,Launched,In-House,Jul-79,Jul-79,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,1369,1378,1202,1273,1306,1339.02,1357.4335,1376.448962,1389.707886,1401.594726,1411.185136,1419.466863,1.197285594,1575,,7/7/14 12:28
1313,61,Merck & Co,Large Pharma,3111,Pediatric Vaccines - Merck,pediatric vaccine,Vaccine,Launched,In-House,Jul-79,Jul-79,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1575,,7/7/14 12:28
1313,61,Merck & Co,Large Pharma,3111,Pediatric Vaccines - Merck,pediatric vaccine,Vaccine,Launched,In-House,Jul-79,Jul-79,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,81,73,94,109,134,141.42,146.3935,149.7929625,151.4294859,152.4209661,153.0042725,153.3250131,1.943210725,1575,,7/7/14 12:28
1313,61,Merck & Co,Large Pharma,3111,Pediatric Vaccines - Merck,pediatric vaccine,Vaccine,Launched,In-House,Jul-79,Jul-79,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1575,,7/7/14 12:28
1313,61,Merck & Co,Large Pharma,3111,Pediatric Vaccines - Merck,pediatric vaccine,Vaccine,Launched,In-House,Jul-79,Jul-79,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,1288,1305,1108,1164,1172,1197.6,1211.04,1226.656,1238.2784,1249.17376,1258.180864,1266.14185,1.109865159,1575,,7/7/14 12:28
1314,67,Novartis,Large Pharma,3112,Pediatric Vaccines - Novartis,pediatric vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2174,,7/7/14 12:28
1314,67,Novartis,Large Pharma,3112,Pediatric Vaccines - Novartis,pediatric vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,268,294.822025,321.5641094,349.2074966,366.8931672,381.5079416,393.3000894,402.2815556,409.3999216,414.9977557,419.3727238,422.8115536,2.047183564,2174,,7/7/14 12:28
1314,67,Novartis,Large Pharma,3112,Pediatric Vaccines - Novartis,pediatric vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2174,,7/7/14 12:28
1314,67,Novartis,Large Pharma,3112,Pediatric Vaccines - Novartis,pediatric vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,268,294.822025,321.5641094,349.2074966,366.8931672,381.5079416,393.3000894,402.2815556,409.3999216,414.9977557,419.3727238,422.8115536,2.047183564,2174,,7/7/14 12:28
1314,67,Novartis,Large Pharma,3112,Pediatric Vaccines - Novartis,pediatric vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2174,,7/7/14 12:28
1314,67,Novartis,Large Pharma,3112,Pediatric Vaccines - Novartis,pediatric vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2174,,7/7/14 12:28
1315,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,3113,Pediatric Vaccines - Sanofi Pasteur MSD,pediatric vaccine,Vaccine,Launched,Licensed (Marketed),,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,111.9935713,92.99778766,105.0058051,106.6775201,103.5863452,104.4447838,104.7839096,104.0631611,103.9936021,103.847059,103.6564278,103.5338756,-7.24E-03,2175,,7/7/14 12:28
1315,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,3113,Pediatric Vaccines - Sanofi Pasteur MSD,pediatric vaccine,Vaccine,Launched,Licensed (Marketed),,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,111.9935713,92.99778766,105.0058051,106.6775201,103.5863452,104.4447838,104.7839096,104.0631611,103.9936021,103.847059,103.6564278,103.5338756,-7.24E-03,2175,,7/7/14 12:28
1315,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,3113,Pediatric Vaccines - Sanofi Pasteur MSD,pediatric vaccine,Vaccine,Launched,Licensed (Marketed),,Jul-94,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2175,,7/7/14 12:28
1316,89,Sanofi,Large Pharma,4003,Pediatric Vaccines - Sanofi,pediatric vaccine,Vaccine,Launched,Corporate Acquisition,Jul-80,Jul-80,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2176,,7/7/14 12:28
1316,89,Sanofi,Large Pharma,4003,Pediatric Vaccines - Sanofi,pediatric vaccine,Vaccine,Launched,Corporate Acquisition,Jul-80,Jul-80,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,1345.034454,1303.558733,1494.719815,1521.76125,1524.578516,1565.674407,1585.207903,1597.426299,1608.263001,1615.162601,1619.822548,1622.979487,0.897512239,2176,,7/7/14 12:28
1316,89,Sanofi,Large Pharma,4003,Pediatric Vaccines - Sanofi,pediatric vaccine,Vaccine,Launched,Corporate Acquisition,Jul-80,Jul-80,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2176,,7/7/14 12:28
1316,89,Sanofi,Large Pharma,4003,Pediatric Vaccines - Sanofi,pediatric vaccine,Vaccine,Launched,Corporate Acquisition,Jul-80,Jul-80,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,609.9897988,680.9239723,850.947467,1041.069774,1159.370248,1231.382679,1274.478084,1300.901753,1317.844811,1328.352553,1334.95561,1339.095129,2.080154021,2176,,7/7/14 12:28
1316,89,Sanofi,Large Pharma,4003,Pediatric Vaccines - Sanofi,pediatric vaccine,Vaccine,Launched,Corporate Acquisition,Jul-80,Jul-80,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2176,,7/7/14 12:28
1316,89,Sanofi,Large Pharma,4003,Pediatric Vaccines - Sanofi,pediatric vaccine,Vaccine,Launched,Corporate Acquisition,Jul-80,Jul-80,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,735.044655,622.6347607,643.7723484,480.691476,365.2082683,334.2917284,310.7298189,296.5245454,290.4181901,286.8100476,284.8669378,283.8843572,-3.534600505,2176,,7/7/14 12:28
1319,34,Daiichi-Sankyo,Regional & Specialty Pharma,2796,Panaldine / Ticlid ,ticlopidine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-81,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,839,,7/7/14 12:28
1319,34,Daiichi-Sankyo,Regional & Specialty Pharma,2796,Panaldine / Ticlid ,ticlopidine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-81,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,839,,7/7/14 12:28
1319,34,Daiichi-Sankyo,Regional & Specialty Pharma,2796,Panaldine / Ticlid ,ticlopidine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-81,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,839,,7/7/14 12:28
1319,34,Daiichi-Sankyo,Regional & Specialty Pharma,2796,Panaldine / Ticlid ,ticlopidine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-81,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,839,,7/7/14 12:28
1319,34,Daiichi-Sankyo,Regional & Specialty Pharma,2796,Panaldine / Ticlid ,ticlopidine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-81,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,839,,7/7/14 12:28
1319,34,Daiichi-Sankyo,Regional & Specialty Pharma,2796,Panaldine / Ticlid ,ticlopidine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-81,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,839,,7/7/14 12:28
1321,67,Novartis,Large Pharma,878,panobinostat,LBH589,Small Molecule (Chemical),Phase III,In-House,Dec-15,Feb-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,840,Multiple Myeloma,7/7/14 12:28
1321,67,Novartis,Large Pharma,878,panobinostat,LBH589,Small Molecule (Chemical),Phase III,In-House,Dec-15,Feb-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,1.2,13.580004,19.27251942,27.69752364,35.48908808,40.47232186,0,840,Multiple Myeloma,7/7/14 12:28
1321,67,Novartis,Large Pharma,878,panobinostat,LBH589,Small Molecule (Chemical),Phase III,In-House,Dec-15,Feb-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,840,Multiple Myeloma,7/7/14 12:28
1321,67,Novartis,Large Pharma,878,panobinostat,LBH589,Small Molecule (Chemical),Phase III,In-House,Dec-15,Feb-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,5.1,7.352517,10.49755615,15.72512916,18.93137048,0,840,Multiple Myeloma,7/7/14 12:28
1321,67,Novartis,Large Pharma,878,panobinostat,LBH589,Small Molecule (Chemical),Phase III,In-House,Dec-15,Feb-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,840,Multiple Myeloma,7/7/14 12:28
1321,67,Novartis,Large Pharma,878,panobinostat,LBH589,Small Molecule (Chemical),Phase III,In-House,Dec-15,Feb-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,1.2,8.480004,11.92000242,17.1999675,19.76395893,21.54095139,0,840,Multiple Myeloma,7/7/14 12:28
1322,100,Takeda,Large Pharma,337,Pansporin,cefotiam,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Mar-06,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,841,bacterial infection,7/7/14 12:28
1322,100,Takeda,Large Pharma,337,Pansporin,cefotiam,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Mar-06,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,56.0209504,46.364212,38.13763142,30.2092189,21.46448069,18.78917128,17.04439781,15.82702852,14.99343924,14.42795918,14.03981384,13.77459657,-6.140159132,841,bacterial infection,7/7/14 12:28
1322,100,Takeda,Large Pharma,337,Pansporin,cefotiam,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Mar-06,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,841,bacterial infection,7/7/14 12:28
1322,100,Takeda,Large Pharma,337,Pansporin,cefotiam,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Mar-06,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,56.0209504,46.364212,38.13763142,30.2092189,21.46448069,18.78917128,17.04439781,15.82702852,14.99343924,14.42795918,14.03981384,13.77459657,-6.140159132,841,bacterial infection,7/7/14 12:28
1322,100,Takeda,Large Pharma,337,Pansporin,cefotiam,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Mar-06,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,841,bacterial infection,7/7/14 12:28
1322,100,Takeda,Large Pharma,337,Pansporin,cefotiam,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Mar-06,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,841,bacterial infection,7/7/14 12:28
1324,100,Nycomed,Large Pharma,1338,Pantozol,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,Oct-94,Expired,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,Global,Proforma,1689.907951,1202.872684,525.3056929,0,0,0,0,0,0,0,0,0,0,1581,GERD / PUD,7/7/14 12:28
1324,100,Nycomed,Large Pharma,1338,Pantozol,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,Oct-94,Expired,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,ROW,Proforma,1689.907951,1202.872684,525.3056929,0,0,0,0,0,0,0,0,0,0,1581,GERD / PUD,7/7/14 12:28
1324,100,Takeda,Large Pharma,1338,Pantozol,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,Oct-94,Expired,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1581,GERD / PUD,7/7/14 12:28
1324,100,Takeda,Large Pharma,1338,Pantozol,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,Oct-94,Expired,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,5.82E-06,2.34E-03,490.1594701,939.0217721,1006.772225,1041.627765,1089.294728,1136.447601,1163.356181,1185.636308,1202.822235,1215.217465,2.724650135,1581,GERD / PUD,7/7/14 12:28
1324,100,Takeda,Large Pharma,1338,Pantozol,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,Oct-94,Expired,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1581,GERD / PUD,7/7/14 12:28
1324,100,Takeda,Large Pharma,1338,Pantozol,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,Oct-94,Expired,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,5.82E-06,2.34E-03,490.1594701,939.0217721,1006.772225,1041.627765,1089.294728,1136.447601,1163.356181,1185.636308,1202.822235,1215.217465,2.724650135,1581,GERD / PUD,7/7/14 12:28
1324,100,Takeda,Large Pharma,1338,Pantozol,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,Oct-94,Expired,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1581,GERD / PUD,7/7/14 12:28
1324,100,Takeda,Large Pharma,1338,Pantozol,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,Oct-94,Expired,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1581,GERD / PUD,7/7/14 12:28
1326,37,Eisai,Regional & Specialty Pharma,995,Aciphex / Pariet,rabeprazole,Small Molecule (Chemical),Launched,In-House,Aug-99,Dec-97,Nov-13,Jan-11,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1604,GERD / PUD,7/7/14 12:28
1326,37,Eisai,Regional & Specialty Pharma,995,Aciphex / Pariet,rabeprazole,Small Molecule (Chemical),Launched,In-House,Aug-99,Dec-97,Nov-13,Jan-11,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,1589.76076,1598.010949,1600.433873,1304.999488,858.5802418,852.1339945,703.7277834,559.0613273,448.8088627,357.6193984,268.078162,203.0757289,-18.61320146,1604,GERD / PUD,7/7/14 12:28
1326,37,Eisai,Regional & Specialty Pharma,995,Aciphex / Pariet,rabeprazole,Small Molecule (Chemical),Launched,In-House,Aug-99,Dec-97,Nov-13,Jan-11,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1604,GERD / PUD,7/7/14 12:28
1326,37,Eisai,Regional & Specialty Pharma,995,Aciphex / Pariet,rabeprazole,Small Molecule (Chemical),Launched,In-House,Aug-99,Dec-97,Nov-13,Jan-11,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,713.1897916,832.2730509,892.6470573,686.208218,496.1422409,511.1469812,439.7502946,366.157889,306.9864804,258.9922697,216.4986625,178.4751837,-13.58931664,1604,GERD / PUD,7/7/14 12:28
1326,37,Eisai,Regional & Specialty Pharma,995,Aciphex / Pariet,rabeprazole,Small Molecule (Chemical),Launched,In-House,Aug-99,Dec-97,Nov-13,Jan-11,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1604,GERD / PUD,7/7/14 12:28
1326,37,Eisai,Regional & Specialty Pharma,995,Aciphex / Pariet,rabeprazole,Small Molecule (Chemical),Launched,In-House,Aug-99,Dec-97,Nov-13,Jan-11,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,876.5709684,765.7378982,707.7868156,618.7912703,362.4380008,340.9870133,263.9774888,192.9034384,141.8223823,98.62712866,51.57949956,24.60054528,-31.90711432,1604,GERD / PUD,7/7/14 12:28
1327,53,Johnson & Johnson,Large Pharma,995,Aciphex / Pariet,rabeprazole,Small Molecule (Chemical),Launched,Licensed (Development),Aug-99,May-98,Nov-13,Jan-11,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1604,GERD,7/7/14 12:28
1327,53,Johnson & Johnson,Large Pharma,995,Aciphex / Pariet,rabeprazole,Small Molecule (Chemical),Launched,Licensed (Development),Aug-99,May-98,Nov-13,Jan-11,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,Global,Sales,1096,1006,975,835,470,0,2.84E-14,0,0.105805,0.24020575,0.485563313,8.58E-02,-70.76424861,1604,GERD,7/7/14 12:28
1327,53,Johnson & Johnson,Large Pharma,995,Aciphex / Pariet,rabeprazole,Small Molecule (Chemical),Launched,Licensed (Development),Aug-99,May-98,Nov-13,Jan-11,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1604,GERD,7/7/14 12:28
1327,53,Johnson & Johnson,Large Pharma,995,Aciphex / Pariet,rabeprazole,Small Molecule (Chemical),Launched,Licensed (Development),Aug-99,May-98,Nov-13,Jan-11,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,ROW,Sales,541,531,561,463,205,0,0,0,0.105805,0.24020575,0.485563313,8.58E-02,-67.08514679,1604,GERD,7/7/14 12:28
1327,53,Johnson & Johnson,Large Pharma,995,Aciphex / Pariet,rabeprazole,Small Molecule (Chemical),Launched,Licensed (Development),Aug-99,May-98,Nov-13,Jan-11,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1604,GERD,7/7/14 12:28
1327,53,Johnson & Johnson,Large Pharma,995,Aciphex / Pariet,rabeprazole,Small Molecule (Chemical),Launched,Licensed (Development),Aug-99,May-98,Nov-13,Jan-11,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,US,Sales,555,475,414,372,265,0,2.84E-14,0,0,0,0,0,-100,1604,GERD,7/7/14 12:28
1328,67,Novartis,Large Pharma,4251,Signifor / Signifor LAR,pasireotide / pasireotide LAR,Synthetic Peptide,Launched,In-House,Oct-13,Oct-12,Jun-26,Jun-26,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1582,Cushing's Disease,7/7/14 12:28
1328,67,Novartis,Large Pharma,4251,Signifor / Signifor LAR,pasireotide / pasireotide LAR,Synthetic Peptide,Launched,In-House,Oct-13,Oct-12,Jun-26,Jun-26,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Sales,0,0,0,2,13.58334,71.09169582,130.6250142,208.428122,254.6699125,299.4798641,334.3305464,357.7397833,59.56477911,1582,Cushing's Disease,7/7/14 12:28
1328,67,Novartis,Large Pharma,4251,Signifor / Signifor LAR,pasireotide / pasireotide LAR,Synthetic Peptide,Launched,In-House,Oct-13,Oct-12,Jun-26,Jun-26,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1582,Cushing's Disease,7/7/14 12:28
1328,67,Novartis,Large Pharma,4251,Signifor / Signifor LAR,pasireotide / pasireotide LAR,Synthetic Peptide,Launched,In-House,Oct-13,Oct-12,Jun-26,Jun-26,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Sales,0,0,0,2,11.33334,46.86668157,77.89999744,104.1181255,127.6994218,145.8699214,162.2507516,173.4502335,47.65882155,1582,Cushing's Disease,7/7/14 12:28
1328,67,Novartis,Large Pharma,4251,Signifor / Signifor LAR,pasireotide / pasireotide LAR,Synthetic Peptide,Launched,In-House,Oct-13,Oct-12,Jun-26,Jun-26,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1582,Cushing's Disease,7/7/14 12:28
1328,67,Novartis,Large Pharma,4251,Signifor / Signifor LAR,pasireotide / pasireotide LAR,Synthetic Peptide,Launched,In-House,Oct-13,Oct-12,Jun-26,Jun-26,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Sales,0,0,0,0,2.25,24.22501425,52.72501676,104.3099966,126.9704906,153.6099427,172.0797948,184.2895498,87.64236446,1582,Cushing's Disease,7/7/14 12:28
1330,67,Alcon,Large Pharma,3062,Patanol / Pataday,olopatadine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Mar-97,Apr-99,Dec-15,May-17,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Proforma,431,148.83,0,0,0,0,0,0,0,0,0,0,0,844,Allergic conjunctivitis,7/7/14 12:28
1330,67,Alcon,Large Pharma,3062,Patanol / Pataday,olopatadine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Mar-97,Apr-99,Dec-15,May-17,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Proforma,91,73.33,0,0,0,0,0,0,0,0,0,0,0,844,Allergic conjunctivitis,7/7/14 12:28
1330,67,Alcon,Large Pharma,3062,Patanol / Pataday,olopatadine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Mar-97,Apr-99,Dec-15,May-17,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Proforma,340,75.5,0,0,0,0,0,0,0,0,0,0,0,844,Allergic conjunctivitis,7/7/14 12:28
1330,67,Novartis,Large Pharma,3062,Patanol / Pataday,olopatadine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Mar-97,Apr-99,Dec-15,May-17,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,844,Allergic conjunctivitis,7/7/14 12:28
1330,67,Novartis,Large Pharma,3062,Patanol / Pataday,olopatadine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Mar-97,Apr-99,Dec-15,May-17,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Sales,0,323.17,491.6,511,523.76,533.416,525.4004864,292.1783504,200.6514601,123.3818646,90.39047454,69.70521867,-25.03194161,844,Allergic conjunctivitis,7/7/14 12:28
1330,67,Novartis,Large Pharma,3062,Patanol / Pataday,olopatadine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Mar-97,Apr-99,Dec-15,May-17,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,844,Allergic conjunctivitis,7/7/14 12:28
1330,67,Novartis,Large Pharma,3062,Patanol / Pataday,olopatadine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Mar-97,Apr-99,Dec-15,May-17,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Sales,0,36.67,125.2,140,151.84,161.312,168.8896,174.95168,115.801344,56.02272794,37.91732661,28.768719,-21.15199277,844,Allergic conjunctivitis,7/7/14 12:28
1330,67,Novartis,Large Pharma,3062,Patanol / Pataday,olopatadine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Mar-97,Apr-99,Dec-15,May-17,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,844,Allergic conjunctivitis,7/7/14 12:28
1330,67,Novartis,Large Pharma,3062,Patanol / Pataday,olopatadine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Mar-97,Apr-99,Dec-15,May-17,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Sales,0,286.5,366.4,371,371.92,372.104,356.5108864,117.2266704,84.8501161,67.35913668,52.47314792,40.93649968,-27.03835954,844,Allergic conjunctivitis,7/7/14 12:28
1332,46,GlaxoSmithKline,Large Pharma,3056,Paxil / Seroxat,paroxetine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-93,Feb-91,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,846,Depression,7/7/14 12:28
1332,46,GlaxoSmithKline,Large Pharma,3056,Paxil / Seroxat,paroxetine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-93,Feb-91,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,4,Global,Sales,815.4938637,744.6900279,692.5740669,592.8007989,445.572998,347.0779144,278.131356,229.868765,195.7483299,171.223606,154.323391,142.8514214,-14.99905731,846,Depression,7/7/14 12:28
1332,46,GlaxoSmithKline,Large Pharma,3056,Paxil / Seroxat,paroxetine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-93,Feb-91,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,846,Depression,7/7/14 12:28
1332,46,GlaxoSmithKline,Large Pharma,3056,Paxil / Seroxat,paroxetine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-93,Feb-91,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,4,ROW,Sales,750.0048727,702.9750264,697.3836091,594.3858277,445.572998,347.0779144,278.131356,229.868765,195.7483299,171.223606,154.323391,142.8514214,-14.99905731,846,Depression,7/7/14 12:28
1332,46,GlaxoSmithKline,Large Pharma,3056,Paxil / Seroxat,paroxetine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-93,Feb-91,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,846,Depression,7/7/14 12:28
1332,46,GlaxoSmithKline,Large Pharma,3056,Paxil / Seroxat,paroxetine,Small Molecule (Chemical),Launched,Licensed (Development),Jan-93,Feb-91,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,4,US,Sales,65.48899096,41.71500156,-4.809542132,-1.585028874,0,0,0,0,0,0,0,0,0,846,Depression,7/7/14 12:28
1339,86,Roche,Large Pharma,1278,Pegasys,peg-interferon alpha 2a,Recombinant Protein,Launched,In-House,Jan-03,Jun-02,Apr-16,May-17,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1586,Hepatitis C and Hepatitis B,7/7/14 12:28
1339,86,Roche,Large Pharma,1278,Pegasys,peg-interferon alpha 2a,Recombinant Protein,Launched,In-House,Jan-03,Jun-02,Apr-16,May-17,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,5,Global,Sales,1523.763056,1592.726483,1619.051525,1758.699867,1416.064417,1122.263497,989.7096883,803.0855047,596.0018456,427.7893697,225.6179,152.2428724,-27.28292216,1586,Hepatitis C and Hepatitis B,7/7/14 12:28
1339,86,Roche,Large Pharma,1278,Pegasys,peg-interferon alpha 2a,Recombinant Protein,Launched,In-House,Jan-03,Jun-02,Apr-16,May-17,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1586,Hepatitis C and Hepatitis B,7/7/14 12:28
1339,86,Roche,Large Pharma,1278,Pegasys,peg-interferon alpha 2a,Recombinant Protein,Launched,In-House,Jan-03,Jun-02,Apr-16,May-17,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,5,ROW,Sales,1151.761398,1219.662234,1232.71304,1181.729106,1084.773624,871.9069363,776.4264022,607.4514119,478.2447913,329.2673525,160.0110292,119.4561937,-27.03335815,1586,Hepatitis C and Hepatitis B,7/7/14 12:28
1339,86,Roche,Large Pharma,1278,Pegasys,peg-interferon alpha 2a,Recombinant Protein,Launched,In-House,Jan-03,Jun-02,Apr-16,May-17,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1586,Hepatitis C and Hepatitis B,7/7/14 12:28
1339,86,Roche,Large Pharma,1278,Pegasys,peg-interferon alpha 2a,Recombinant Protein,Launched,In-House,Jan-03,Jun-02,Apr-16,May-17,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,5,US,Sales,372.0016574,373.0642497,386.3384855,576.9707613,331.2907932,250.3565603,213.2832861,195.6340928,117.7570543,98.52201723,65.60687074,32.7866787,-28.13814271,1586,Hepatitis C and Hepatitis B,7/7/14 12:28
1340,24,Bristol-Myers Squibb,Large Pharma,580,peg-interferon lambda,peg-interferon lambda,Recombinant Protein,Phase III,Corporate Acquisition,Mar-16,Nov-16,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,853,Hepatitis C and Hepatitis B,7/7/14 12:28
1340,24,Bristol-Myers Squibb,Large Pharma,580,peg-interferon lambda,peg-interferon lambda,Recombinant Protein,Phase III,Corporate Acquisition,Mar-16,Nov-16,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,14.5,44,63.08407,63,48,0,853,Hepatitis C and Hepatitis B,7/7/14 12:28
1340,24,Bristol-Myers Squibb,Large Pharma,580,peg-interferon lambda,peg-interferon lambda,Recombinant Protein,Phase III,Corporate Acquisition,Mar-16,Nov-16,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,853,Hepatitis C and Hepatitis B,7/7/14 12:28
1340,24,Bristol-Myers Squibb,Large Pharma,580,peg-interferon lambda,peg-interferon lambda,Recombinant Protein,Phase III,Corporate Acquisition,Mar-16,Nov-16,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,2,11,16,17,14,0,853,Hepatitis C and Hepatitis B,7/7/14 12:28
1340,24,Bristol-Myers Squibb,Large Pharma,580,peg-interferon lambda,peg-interferon lambda,Recombinant Protein,Phase III,Corporate Acquisition,Mar-16,Nov-16,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,853,Hepatitis C and Hepatitis B,7/7/14 12:28
1340,24,Bristol-Myers Squibb,Large Pharma,580,peg-interferon lambda,peg-interferon lambda,Recombinant Protein,Phase III,Corporate Acquisition,Mar-16,Nov-16,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,12.5,33,47.08407,46,34,0,853,Hepatitis C and Hepatitis B,7/7/14 12:28
1342,61,Merck & Co,Large Pharma,843,Peg-Intron,peg-interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Feb-01,Jul-00,Nov-16,Oct-16,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1587,Hepatitis C,7/7/14 12:28
1342,61,Merck & Co,Large Pharma,843,Peg-Intron,peg-interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Feb-01,Jul-00,Nov-16,Oct-16,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,Global,Sales,151.91,737,657,652.6,496,386.8562,349.348383,278.5871701,223.3042393,156.3428038,80.56467895,64.47709305,-25.2832783,1587,Hepatitis C,7/7/14 12:28
1342,61,Merck & Co,Large Pharma,843,Peg-Intron,peg-interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Feb-01,Jul-00,Nov-16,Oct-16,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1587,Hepatitis C,7/7/14 12:28
1342,61,Merck & Co,Large Pharma,843,Peg-Intron,peg-interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Feb-01,Jul-00,Nov-16,Oct-16,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,129.61,639,586,565.3,453,353.6,322.5,258.999376,207.1651827,142.5587251,68.30650206,53.07440122,-26.3844281,1587,Hepatitis C,7/7/14 12:28
1342,61,Merck & Co,Large Pharma,843,Peg-Intron,peg-interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Feb-01,Jul-00,Nov-16,Oct-16,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1587,Hepatitis C,7/7/14 12:28
1342,61,Merck & Co,Large Pharma,843,Peg-Intron,peg-interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Feb-01,Jul-00,Nov-16,Oct-16,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,US,Sales,22.3,98,71,87.3,43,33.2562,26.848383,19.58779406,16.13905662,13.78407869,12.25817689,11.40269182,-17.27276652,1587,Hepatitis C,7/7/14 12:28
1342,61,Schering-Plough,Large Pharma,843,Peg-Intron,peg-interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Feb-01,Jul-00,Nov-16,Oct-16,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,Global,Proforma,693.09,0,0,0,0,0,0,0,0,0,0,0,0,1587,Hepatitis C,7/7/14 12:28
1342,61,Schering-Plough,Large Pharma,843,Peg-Intron,peg-interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Feb-01,Jul-00,Nov-16,Oct-16,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,ROW,Proforma,605.39,0,0,0,0,0,0,0,0,0,0,0,0,1587,Hepatitis C,7/7/14 12:28
1342,61,Schering-Plough,Large Pharma,843,Peg-Intron,peg-interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Feb-01,Jul-00,Nov-16,Oct-16,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,US,Proforma,87.7,0,0,0,0,0,0,0,0,0,0,0,0,1587,Hepatitis C,7/7/14 12:28
1343,96,Shire,Regional & Specialty Pharma,419,Pentasa,mesalazine,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-86,,Expired,N/A,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1725,Ulcerative colitis,7/7/14 12:28
1343,96,Shire,Regional & Specialty Pharma,419,Pentasa,mesalazine,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-86,,Expired,N/A,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,215,235.9,251.4,265.8,280.6,291.715,256.1671563,253.9669534,253.3477016,251.6465314,252.3061463,252.2777513,-1.508497769,1725,Ulcerative colitis,7/7/14 12:28
1343,96,Shire,Regional & Specialty Pharma,419,Pentasa,mesalazine,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-86,,Expired,N/A,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1725,Ulcerative colitis,7/7/14 12:28
1343,96,Shire,Regional & Specialty Pharma,419,Pentasa,mesalazine,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-86,,Expired,N/A,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1725,Ulcerative colitis,7/7/14 12:28
1343,96,Shire,Regional & Specialty Pharma,419,Pentasa,mesalazine,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-86,,Expired,N/A,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1725,Ulcerative colitis,7/7/14 12:28
1343,96,Shire,Regional & Specialty Pharma,419,Pentasa,mesalazine,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-86,,Expired,N/A,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,215,235.9,251.4,265.8,280.6,291.715,256.1671563,253.9669534,253.3477016,251.6465314,252.3061463,252.2777513,-1.508497769,1725,Ulcerative colitis,7/7/14 12:28
1344,40,Endo Health Solutions,Regional & Specialty Pharma,54,Percocet,oxycodone + acetaminophen,Small Molecule (Chemical),Launched,In-House,Jan-99,,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,856,Pain,7/7/14 12:28
1344,40,Endo Health Solutions,Regional & Specialty Pharma,54,Percocet,oxycodone + acetaminophen,Small Molecule (Chemical),Launched,In-House,Jan-99,,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,127,121.35,104.6,103.41,105.8,103.497,102.90095,102.7075575,102.1325364,101.7931265,101.5398607,101.2911923,-0.620225972,856,Pain,7/7/14 12:28
1344,40,Endo Health Solutions,Regional & Specialty Pharma,54,Percocet,oxycodone + acetaminophen,Small Molecule (Chemical),Launched,In-House,Jan-99,,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,856,Pain,7/7/14 12:28
1344,40,Endo Health Solutions,Regional & Specialty Pharma,54,Percocet,oxycodone + acetaminophen,Small Molecule (Chemical),Launched,In-House,Jan-99,,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,856,Pain,7/7/14 12:28
1344,40,Endo Health Solutions,Regional & Specialty Pharma,54,Percocet,oxycodone + acetaminophen,Small Molecule (Chemical),Launched,In-House,Jan-99,,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,856,Pain,7/7/14 12:28
1344,40,Endo Health Solutions,Regional & Specialty Pharma,54,Percocet,oxycodone + acetaminophen,Small Molecule (Chemical),Launched,In-House,Jan-99,,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,127,121.35,104.6,103.41,105.8,103.497,102.90095,102.7075575,102.1325364,101.7931265,101.5398607,101.2911923,-0.620225972,856,Pain,7/7/14 12:28
1345,15,Astellas Pharma,Regional & Specialty Pharma,502,Perdipine / Perdipine LA,nicardipine,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,857,,7/7/14 12:28
1345,15,Astellas Pharma,Regional & Specialty Pharma,502,Perdipine / Perdipine LA,nicardipine,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,48.47966861,44.35676849,40.51731324,33.70847373,25.16930561,22.75305227,20.85025277,19.34613507,18.15824452,17.21989253,16.47869776,15.8932281,-6.356573311,857,,7/7/14 12:28
1345,15,Astellas Pharma,Regional & Specialty Pharma,502,Perdipine / Perdipine LA,nicardipine,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,857,,7/7/14 12:28
1345,15,Astellas Pharma,Regional & Specialty Pharma,502,Perdipine / Perdipine LA,nicardipine,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,48.47966861,44.35676849,40.51731324,33.70847373,25.16930561,22.75305227,20.85025277,19.34613507,18.15824452,17.21989253,16.47869776,15.8932281,-6.356573311,857,,7/7/14 12:28
1345,15,Astellas Pharma,Regional & Specialty Pharma,502,Perdipine / Perdipine LA,nicardipine,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,857,,7/7/14 12:28
1345,15,Astellas Pharma,Regional & Specialty Pharma,502,Perdipine / Perdipine LA,nicardipine,Small Molecule (Chemical),Launched,In-House,,Jul-81,N/A,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,857,,7/7/14 12:28
1346,63,Merck KGaA,Regional & Specialty Pharma,1171,Pergoveris,recombinant follitropin alfa + recombinant human luteinizing hormone,Recombinant Protein,Launched,In-House,,Jan-08,N/A,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,858,Female infertility,7/7/14 12:28
1346,63,Merck KGaA,Regional & Specialty Pharma,1171,Pergoveris,recombinant follitropin alfa + recombinant human luteinizing hormone,Recombinant Protein,Launched,In-House,,Jan-08,N/A,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,Global,Sales,40.29545368,42.39215392,40.32267409,42.41395376,43.54499253,44.81414393,45.65717423,46.37811482,47.03779286,47.5998075,48.09338557,48.52343572,1.558477675,858,Female infertility,7/7/14 12:28
1346,63,Merck KGaA,Regional & Specialty Pharma,1171,Pergoveris,recombinant follitropin alfa + recombinant human luteinizing hormone,Recombinant Protein,Launched,In-House,,Jan-08,N/A,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,858,Female infertility,7/7/14 12:28
1346,63,Merck KGaA,Regional & Specialty Pharma,1171,Pergoveris,recombinant follitropin alfa + recombinant human luteinizing hormone,Recombinant Protein,Launched,In-House,,Jan-08,N/A,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,ROW,Sales,40.29545368,42.39215392,40.32267409,42.41395376,43.54499253,44.81414393,45.65717423,46.37811482,47.03779286,47.5998075,48.09338557,48.52343572,1.558477675,858,Female infertility,7/7/14 12:28
1346,63,Merck KGaA,Regional & Specialty Pharma,1171,Pergoveris,recombinant follitropin alfa + recombinant human luteinizing hormone,Recombinant Protein,Launched,In-House,,Jan-08,N/A,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,858,Female infertility,7/7/14 12:28
1346,63,Merck KGaA,Regional & Specialty Pharma,1171,Pergoveris,recombinant follitropin alfa + recombinant human luteinizing hormone,Recombinant Protein,Launched,In-House,,Jan-08,N/A,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,858,Female infertility,7/7/14 12:28
1347,86,Roche,Large Pharma,1703,Perjeta,pertuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-12,Aug-12,Jun-24,Jun-23,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1589,Breast Cancer,7/7/14 12:28
1347,86,Roche,Large Pharma,1703,Perjeta,pertuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-12,Aug-12,Jun-24,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,Global,Sales,0,0,0,59.72340598,351.5718155,717.869655,845.6155064,1093.435249,1421.541878,1949.919572,2295.578482,2572.816414,32.88771697,1589,Breast Cancer,7/7/14 12:28
1347,86,Roche,Large Pharma,1703,Perjeta,pertuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-12,Aug-12,Jun-24,Jun-23,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1589,Breast Cancer,7/7/14 12:28
1347,86,Roche,Large Pharma,1703,Perjeta,pertuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-12,Aug-12,Jun-24,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,2.132978785,115.2438555,341.4204842,484.2651849,640.5796795,841.0213089,1186.307832,1427.3887,1588.747994,45.4710539,1589,Breast Cancer,7/7/14 12:28
1347,86,Roche,Large Pharma,1703,Perjeta,pertuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-12,Aug-12,Jun-24,Jun-23,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1589,Breast Cancer,7/7/14 12:28
1347,86,Roche,Large Pharma,1703,Perjeta,pertuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-12,Aug-12,Jun-24,Jun-23,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,US,Sales,0,0,0,57.59042719,236.32796,376.4491707,361.3503215,452.8555695,580.5205686,763.6117404,868.1897821,984.0684197,22.60307619,1589,Breast Cancer,7/7/14 12:28
1357,76,Pfizer,Large Pharma,570,dacomitinib,dacomitinib,Small Molecule (Chemical),Phase III,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,865,Non-small-cell Lung Cancer,7/7/14 12:28
1357,76,Pfizer,Large Pharma,570,dacomitinib,dacomitinib,Small Molecule (Chemical),Phase III,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,865,Non-small-cell Lung Cancer,7/7/14 12:28
1357,76,Pfizer,Large Pharma,570,dacomitinib,dacomitinib,Small Molecule (Chemical),Phase III,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,865,Non-small-cell Lung Cancer,7/7/14 12:28
1357,76,Pfizer,Large Pharma,570,dacomitinib,dacomitinib,Small Molecule (Chemical),Phase III,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,865,Non-small-cell Lung Cancer,7/7/14 12:28
1357,76,Pfizer,Large Pharma,570,dacomitinib,dacomitinib,Small Molecule (Chemical),Phase III,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,865,Non-small-cell Lung Cancer,7/7/14 12:28
1357,76,Pfizer,Large Pharma,570,dacomitinib,dacomitinib,Small Molecule (Chemical),Phase III,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,865,Non-small-cell Lung Cancer,7/7/14 12:28
1373,76,Pfizer,Large Pharma,1305,PF-4171327,fosdagrocorat,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,875,Rheumatoid Arthritis,7/7/14 12:28
1373,76,Pfizer,Large Pharma,1305,PF-4171327,fosdagrocorat,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,875,Rheumatoid Arthritis,7/7/14 12:28
1373,76,Pfizer,Large Pharma,1305,PF-4171327,fosdagrocorat,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,875,Rheumatoid Arthritis,7/7/14 12:28
1373,76,Pfizer,Large Pharma,1305,PF-4171327,fosdagrocorat,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,875,Rheumatoid Arthritis,7/7/14 12:28
1373,76,Pfizer,Large Pharma,1305,PF-4171327,fosdagrocorat,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,875,Rheumatoid Arthritis,7/7/14 12:28
1373,76,Pfizer,Large Pharma,1305,PF-4171327,fosdagrocorat,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,875,Rheumatoid Arthritis,7/7/14 12:28
1377,76,Pfizer,Large Pharma,387,PF-4236921,anti-IL6,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,878,Systemic lupus erthymatosis,7/7/14 12:28
1377,76,Pfizer,Large Pharma,387,PF-4236921,anti-IL6,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,878,Systemic lupus erthymatosis,7/7/14 12:28
1377,76,Pfizer,Large Pharma,387,PF-4236921,anti-IL6,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,878,Systemic lupus erthymatosis,7/7/14 12:28
1377,76,Pfizer,Large Pharma,387,PF-4236921,anti-IL6,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,878,Systemic lupus erthymatosis,7/7/14 12:28
1377,76,Pfizer,Large Pharma,387,PF-4236921,anti-IL6,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,878,Systemic lupus erthymatosis,7/7/14 12:28
1377,76,Pfizer,Large Pharma,387,PF-4236921,anti-IL6,Small Molecule (Chemical),Phase II,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,878,Systemic lupus erthymatosis,7/7/14 12:28
1398,76,Pfizer,Large Pharma,1388,PH-797804,PH-797804,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,910,COPD,7/7/14 12:28
1398,76,Pfizer,Large Pharma,1388,PH-797804,PH-797804,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,910,COPD,7/7/14 12:28
1398,76,Pfizer,Large Pharma,1388,PH-797804,PH-797804,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,910,COPD,7/7/14 12:28
1398,76,Pfizer,Large Pharma,1388,PH-797804,PH-797804,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,910,COPD,7/7/14 12:28
1398,76,Pfizer,Large Pharma,1388,PH-797804,PH-797804,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,910,COPD,7/7/14 12:28
1398,76,Pfizer,Large Pharma,1388,PH-797804,PH-797804,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,910,COPD,7/7/14 12:28
1399,1,Abbott,Regional & Specialty Pharma,675,Physiotens,moxonidine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-91,N/A,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1556,Hypertension,7/7/14 12:28
1399,1,Abbott,Regional & Specialty Pharma,675,Physiotens,moxonidine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-91,N/A,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,54.92,56,51.888,48.58112,45.8067968,43.50212915,41.58325015,39.98642076,38.65742931,37.55138208,36.63087322,-3.953213544,1556,Hypertension,7/7/14 12:28
1399,1,Abbott,Regional & Specialty Pharma,675,Physiotens,moxonidine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-91,N/A,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1556,Hypertension,7/7/14 12:28
1399,1,Abbott,Regional & Specialty Pharma,675,Physiotens,moxonidine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-91,N/A,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,54.92,56,51.888,48.58112,45.8067968,43.50212915,41.58325015,39.98642076,38.65742931,37.55138208,36.63087322,-3.953213544,1556,Hypertension,7/7/14 12:28
1399,1,Abbott,Regional & Specialty Pharma,675,Physiotens,moxonidine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-91,N/A,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1556,Hypertension,7/7/14 12:28
1399,1,Abbott,Regional & Specialty Pharma,675,Physiotens,moxonidine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-91,N/A,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1556,Hypertension,7/7/14 12:28
1399,1,Solvay,Regional & Specialty Pharma,675,Physiotens,moxonidine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-91,N/A,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Proforma,63.9,5.3,0,0,0,0,0,0,0,0,0,0,0,1556,Hypertension,7/7/14 12:28
1399,1,Solvay,Regional & Specialty Pharma,675,Physiotens,moxonidine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-91,N/A,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Proforma,63.9,5.3,0,0,0,0,0,0,0,0,0,0,0,1556,Hypertension,7/7/14 12:28
1402,95,Shionogi,Regional & Specialty Pharma,1352,Pirespa,pirfenidone,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-08,N/A,Oct-22,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,911,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
1402,95,Shionogi,Regional & Specialty Pharma,1352,Pirespa,pirfenidone,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-08,N/A,Oct-22,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,7,Global,Sales,16.15988954,32.68393468,43.04964532,54.174333,53.65960827,60.62593151,67.18954587,72.82368647,77.76722187,82.14700808,85.98683355,89.36487809,7.558711898,911,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
1402,95,Shionogi,Regional & Specialty Pharma,1352,Pirespa,pirfenidone,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-08,N/A,Oct-22,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,911,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
1402,95,Shionogi,Regional & Specialty Pharma,1352,Pirespa,pirfenidone,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-08,N/A,Oct-22,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,7,ROW,Sales,16.15988954,32.68393468,43.04964532,54.174333,53.65960827,60.62593151,67.18954587,72.82368647,77.76722187,82.14700808,85.98683355,89.36487809,7.558711898,911,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
1402,95,Shionogi,Regional & Specialty Pharma,1352,Pirespa,pirfenidone,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-08,N/A,Oct-22,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,911,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
1402,95,Shionogi,Regional & Specialty Pharma,1352,Pirespa,pirfenidone,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-08,N/A,Oct-22,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,911,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
1403,84,Recordati,Regional & Specialty Pharma,3317,Livazo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),,May-11,N/A,N/A,113,Statins,20,Lipid Disorders,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1592,Lipid disorders,7/7/14 12:28
1403,84,Recordati,Regional & Specialty Pharma,3317,Livazo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),,May-11,N/A,N/A,113,Statins,20,Lipid Disorders,10,Cardiovasculars,2,Global,Sales,0,0,9.454971855,20.94992262,29.8806765,39.31669533,46.60024718,52.68975132,58.02751737,62.49185085,66.28039888,69.50624433,12.81741571,1592,Lipid disorders,7/7/14 12:28
1403,84,Recordati,Regional & Specialty Pharma,3317,Livazo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),,May-11,N/A,N/A,113,Statins,20,Lipid Disorders,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1592,Lipid disorders,7/7/14 12:28
1403,84,Recordati,Regional & Specialty Pharma,3317,Livazo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),,May-11,N/A,N/A,113,Statins,20,Lipid Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,9.454971855,20.94992262,29.8806765,39.31669533,46.60024718,52.68975132,58.02751737,62.49185085,66.28039888,69.50624433,12.81741571,1592,Lipid disorders,7/7/14 12:28
1403,84,Recordati,Regional & Specialty Pharma,3317,Livazo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),,May-11,N/A,N/A,113,Statins,20,Lipid Disorders,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1592,Lipid disorders,7/7/14 12:28
1403,84,Recordati,Regional & Specialty Pharma,3317,Livazo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),,May-11,N/A,N/A,113,Statins,20,Lipid Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1592,Lipid disorders,7/7/14 12:28
1404,24,Bristol-Myers Squibb,Large Pharma,641,Plavix,clopidogrel bisulfate ,Small Molecule (Chemical),Launched,Licensed (Development),Jan-97,Jan-98,May-12,Aug-08,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1399,,7/7/14 12:28
1404,24,Bristol-Myers Squibb,Large Pharma,641,Plavix,clopidogrel bisulfate ,Small Molecule (Chemical),Launched,Licensed (Development),Jan-97,Jan-98,May-12,Aug-08,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,6146,6666,7087,2547,258,172.4,148,133.63,128.37925,125.8335362,43.72931863,0,-100,1399,,7/7/14 12:28
1404,24,Bristol-Myers Squibb,Large Pharma,641,Plavix,clopidogrel bisulfate ,Small Molecule (Chemical),Launched,Licensed (Development),Jan-97,Jan-98,May-12,Aug-08,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1399,,7/7/14 12:28
1404,24,Bristol-Myers Squibb,Large Pharma,641,Plavix,clopidogrel bisulfate ,Small Molecule (Chemical),Launched,Licensed (Development),Jan-97,Jan-98,May-12,Aug-08,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,590,512,378,123,105,94.4,85,82.18,81.334,81.0802,0,0,-100,1399,,7/7/14 12:28
1404,24,Bristol-Myers Squibb,Large Pharma,641,Plavix,clopidogrel bisulfate ,Small Molecule (Chemical),Launched,Licensed (Development),Jan-97,Jan-98,May-12,Aug-08,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1399,,7/7/14 12:28
1404,24,Bristol-Myers Squibb,Large Pharma,641,Plavix,clopidogrel bisulfate ,Small Molecule (Chemical),Launched,Licensed (Development),Jan-97,Jan-98,May-12,Aug-08,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Sales,5556,6154,6709,2424,153,78,63,51.45,47.04525,44.75333625,43.72931863,0,-100,1399,,7/7/14 12:28
1405,89,Sanofi,Large Pharma,641,Plavix,clopidogrel bisulfate ,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-98,May-12,Aug-08,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1399,,7/7/14 12:28
1405,89,Sanofi,Large Pharma,641,Plavix,clopidogrel bisulfate ,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-98,May-12,Aug-08,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,Global,Sales,3644.65431,2759.464269,2836.491557,2655.37056,2466.151834,2365.354352,2240.81747,1961.23469,1788.891343,1691.733077,1620.676814,1573.889365,-6.214355074,1399,,7/7/14 12:28
1405,89,Sanofi,Large Pharma,641,Plavix,clopidogrel bisulfate ,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-98,May-12,Aug-08,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1399,,7/7/14 12:28
1405,89,Sanofi,Large Pharma,641,Plavix,clopidogrel bisulfate ,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-98,May-12,Aug-08,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,ROW,Sales,3336.185665,2477.291495,2563.965897,2557.689939,2459.511683,2358.714202,2234.17732,1954.59454,1782.251193,1685.092926,1614.036664,1567.249215,-6.234874745,1399,,7/7/14 12:28
1405,89,Sanofi,Large Pharma,641,Plavix,clopidogrel bisulfate ,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-98,May-12,Aug-08,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1399,,7/7/14 12:28
1405,89,Sanofi,Large Pharma,641,Plavix,clopidogrel bisulfate ,Small Molecule (Chemical),Launched,In-House,Jan-97,Jan-98,May-12,Aug-08,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,US,Sales,308.4686454,282.1727745,272.5256594,97.68062079,6.640150333,6.640150333,6.640150333,6.640150333,6.640150333,6.640150333,6.640150333,6.640150333,0,1399,,7/7/14 12:28
1407,16,AstraZeneca,Large Pharma,56,Plendil,felodipine,Small Molecule (Chemical),Launched,In-House,Jan-89,Jan-89,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,914,,7/7/14 12:28
1407,16,AstraZeneca,Large Pharma,56,Plendil,felodipine,Small Molecule (Chemical),Launched,In-House,Jan-89,Jan-89,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,241,255,256,252,260,261.8,262.88,264.023,264.3533,264.553055,264.683528,264.7363294,0.258228527,914,,7/7/14 12:28
1407,16,AstraZeneca,Large Pharma,56,Plendil,felodipine,Small Molecule (Chemical),Launched,In-House,Jan-89,Jan-89,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,914,,7/7/14 12:28
1407,16,AstraZeneca,Large Pharma,56,Plendil,felodipine,Small Molecule (Chemical),Launched,In-House,Jan-89,Jan-89,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,227,240,248,248,260,261.8,262.88,264.023,264.3533,264.553055,264.683528,264.7363294,0.258228527,914,,7/7/14 12:28
1407,16,AstraZeneca,Large Pharma,56,Plendil,felodipine,Small Molecule (Chemical),Launched,In-House,Jan-89,Jan-89,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,914,,7/7/14 12:28
1407,16,AstraZeneca,Large Pharma,56,Plendil,felodipine,Small Molecule (Chemical),Launched,In-House,Jan-89,Jan-89,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,14,15,8,4,0,0,0,0,0,0,0,0,0,914,,7/7/14 12:28
1408,10,Almirall,Regional & Specialty Pharma,856,Plusvent,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-04,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1627,Asthma,7/7/14 12:28
1408,10,Almirall,Regional & Specialty Pharma,856,Plusvent,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-04,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,Global,Sales,83.508854,75.51102417,75.50073114,63.36387638,58.03491391,54.07725151,51.11731685,49.6231821,48.9615639,48.5347822,48.2719113,48.11519385,-2.642273149,1627,Asthma,7/7/14 12:28
1408,10,Almirall,Regional & Specialty Pharma,856,Plusvent,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-04,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1627,Asthma,7/7/14 12:28
1408,10,Almirall,Regional & Specialty Pharma,856,Plusvent,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-04,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,83.508854,75.51102417,75.50073114,63.36387638,58.03491391,54.07725151,51.11731685,49.6231821,48.9615639,48.5347822,48.2719113,48.11519385,-2.642273149,1627,Asthma,7/7/14 12:28
1408,10,Almirall,Regional & Specialty Pharma,856,Plusvent,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-04,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1627,Asthma,7/7/14 12:28
1408,10,Almirall,Regional & Specialty Pharma,856,Plusvent,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-04,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1627,Asthma,7/7/14 12:28
1409,16,AstraZeneca,Large Pharma,1876,Vimovo,naproxen + esomeprazole,Small Molecule (Chemical),Launched,Licensed (Development),Sep-10,Jan-11,Aug-15,Nov-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1259,Rheumatoid Arthritis,7/7/14 12:28
1409,16,AstraZeneca,Large Pharma,1876,Vimovo,naproxen + esomeprazole,Small Molecule (Chemical),Launched,Licensed (Development),Sep-10,Jan-11,Aug-15,Nov-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,5,34,65,91,91.28541,104.7995953,113.7220666,119.639603,123.5553336,126.1493828,127.8668797,4.978982973,1259,Rheumatoid Arthritis,7/7/14 12:28
1409,16,AstraZeneca,Large Pharma,1876,Vimovo,naproxen + esomeprazole,Small Molecule (Chemical),Launched,Licensed (Development),Sep-10,Jan-11,Aug-15,Nov-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1259,Rheumatoid Arthritis,7/7/14 12:28
1409,16,AstraZeneca,Large Pharma,1876,Vimovo,naproxen + esomeprazole,Small Molecule (Chemical),Launched,Licensed (Development),Sep-10,Jan-11,Aug-15,Nov-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,13,40,71,91.28541,104.7995953,113.7220666,119.639603,123.5553336,126.1493828,127.8668797,8.767694556,1259,Rheumatoid Arthritis,7/7/14 12:28
1409,16,AstraZeneca,Large Pharma,1876,Vimovo,naproxen + esomeprazole,Small Molecule (Chemical),Launched,Licensed (Development),Sep-10,Jan-11,Aug-15,Nov-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1259,Rheumatoid Arthritis,7/7/14 12:28
1409,16,AstraZeneca,Large Pharma,1876,Vimovo,naproxen + esomeprazole,Small Molecule (Chemical),Launched,Licensed (Development),Sep-10,Jan-11,Aug-15,Nov-20,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,5,21,25,20,0,0,0,0,0,0,0,-100,1259,Rheumatoid Arthritis,7/7/14 12:28
1410,89,Sanofi,Large Pharma,63,Streptococcus pneumonia vaccine,Streptococcus pneumonia,Vaccine,Phase I,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,916,Paediatric Meningitis & Pneumonia,7/7/14 12:28
1410,89,Sanofi,Large Pharma,63,Streptococcus pneumonia vaccine,Streptococcus pneumonia,Vaccine,Phase I,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,916,Paediatric Meningitis & Pneumonia,7/7/14 12:28
1410,89,Sanofi,Large Pharma,63,Streptococcus pneumonia vaccine,Streptococcus pneumonia,Vaccine,Phase I,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,916,Paediatric Meningitis & Pneumonia,7/7/14 12:28
1410,89,Sanofi,Large Pharma,63,Streptococcus pneumonia vaccine,Streptococcus pneumonia,Vaccine,Phase I,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,916,Paediatric Meningitis & Pneumonia,7/7/14 12:28
1410,89,Sanofi,Large Pharma,63,Streptococcus pneumonia vaccine,Streptococcus pneumonia,Vaccine,Phase I,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,916,Paediatric Meningitis & Pneumonia,7/7/14 12:28
1410,89,Sanofi,Large Pharma,63,Streptococcus pneumonia vaccine,Streptococcus pneumonia,Vaccine,Phase I,In-House,,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,916,Paediatric Meningitis & Pneumonia,7/7/14 12:28
1414,8,Allergan,Regional & Specialty Pharma,1781,Ozurdex,dexamethasone,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,Dec-10,Oct-20,Jul-25,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,835,Macular Edema,7/7/14 12:28
1414,8,Allergan,Regional & Specialty Pharma,1781,Ozurdex,dexamethasone,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,Dec-10,Oct-20,Jul-25,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,Global,Sales,13,40.7,74.499893,83,108,121.7076488,133.523769,136.5706043,139.4646726,142.4400867,143.4538238,141.4512239,3.929875073,835,Macular Edema,7/7/14 12:28
1414,8,Allergan,Regional & Specialty Pharma,1781,Ozurdex,dexamethasone,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,Dec-10,Oct-20,Jul-25,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,835,Macular Edema,7/7/14 12:28
1414,8,Allergan,Regional & Specialty Pharma,1781,Ozurdex,dexamethasone,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,Dec-10,Oct-20,Jul-25,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,ROW,Sales,0,3,21.20001,28,38,37.36779475,36.24668453,32.60330809,31.20247945,30.04682856,28.98660062,28.48138222,-4.03539404,835,Macular Edema,7/7/14 12:28
1414,8,Allergan,Regional & Specialty Pharma,1781,Ozurdex,dexamethasone,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,Dec-10,Oct-20,Jul-25,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,835,Macular Edema,7/7/14 12:28
1414,8,Allergan,Regional & Specialty Pharma,1781,Ozurdex,dexamethasone,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,Dec-10,Oct-20,Jul-25,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,6,US,Sales,13,37.7,53.299883,55,70,84.33985404,97.27708448,103.9672962,108.2621931,112.3932582,114.4672232,112.9698416,7.07667974,835,Macular Edema,7/7/14 12:28
1416,23,Boehringer Ingelheim,Large Pharma,954,Pradaxa,dabigatran etexilate,Small Molecule (Chemical),Launched,In-House,Nov-10,Apr-08,Feb-18,Sep-23,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,921,Venous Thromboembolism,7/7/14 12:28
1416,23,Boehringer Ingelheim,Large Pharma,954,Pradaxa,dabigatran etexilate,Small Molecule (Chemical),Launched,In-House,Nov-10,Apr-08,Feb-18,Sep-23,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,Global,Sales,51.20849566,166.9191061,878.7562077,1424.080629,1970.796619,2423.082491,2741.390177,2942.73825,3081.999722,2021.414703,1897.962014,1927.818699,-0.314485288,921,Venous Thromboembolism,7/7/14 12:28
1416,23,Boehringer Ingelheim,Large Pharma,954,Pradaxa,dabigatran etexilate,Small Molecule (Chemical),Launched,In-House,Nov-10,Apr-08,Feb-18,Sep-23,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,921,Venous Thromboembolism,7/7/14 12:28
1416,23,Boehringer Ingelheim,Large Pharma,954,Pradaxa,dabigatran etexilate,Small Molecule (Chemical),Launched,In-House,Nov-10,Apr-08,Feb-18,Sep-23,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,ROW,Sales,51.20849566,111.279404,431.0354816,744.1720978,1066.408143,1330.991574,1513.662508,1626.478981,1709.772491,1756.514797,1820.702713,1875.552611,8.400020593,921,Venous Thromboembolism,7/7/14 12:28
1416,23,Boehringer Ingelheim,Large Pharma,954,Pradaxa,dabigatran etexilate,Small Molecule (Chemical),Launched,In-House,Nov-10,Apr-08,Feb-18,Sep-23,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,921,Venous Thromboembolism,7/7/14 12:28
1416,23,Boehringer Ingelheim,Large Pharma,954,Pradaxa,dabigatran etexilate,Small Molecule (Chemical),Launched,In-House,Nov-10,Apr-08,Feb-18,Sep-23,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,US,Sales,0,55.63970202,447.7207261,679.9085315,904.3884754,1092.090917,1227.727669,1316.259269,1372.227231,264.8999058,77.25930167,52.26608764,-33.45372591,921,Venous Thromboembolism,7/7/14 12:28
1417,178,Allos Therapeutics,Regional & Specialty Pharma,2154,Folotyn,pralatrexate,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,,Jul-22,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,Global,Proforma,3.6,35.2,50.5,39.6,0,0,0,0,0,0,0,0,0,464,Peripheral T-cell Lymphoma,7/7/14 12:28
1417,178,Allos Therapeutics,Regional & Specialty Pharma,2154,Folotyn,pralatrexate,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,,Jul-22,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,US,Proforma,3.6,35.2,50.5,39.6,0,0,0,0,0,0,0,0,0,464,Peripheral T-cell Lymphoma,7/7/14 12:28
1417,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,2154,Folotyn,pralatrexate,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,,Jul-22,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,20.4,44.4,40.2805,37.5009925,35.11973711,33.67063546,30.48868221,28.42933611,27.59038227,-6.570906238,464,Peripheral T-cell Lymphoma,7/7/14 12:28
1417,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,2154,Folotyn,pralatrexate,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,,Jul-22,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,464,Peripheral T-cell Lymphoma,7/7/14 12:28
1417,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,2154,Folotyn,pralatrexate,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,,Jul-22,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,20.4,44.4,40.2805,37.5009925,35.11973711,33.67063546,30.48868221,28.42933611,27.59038227,-6.570906238,464,Peripheral T-cell Lymphoma,7/7/14 12:28
1419,34,Daiichi-Sankyo,Regional & Specialty Pharma,1932,Effient,prasugrel,Small Molecule (Chemical),Launched,In-House,Aug-09,Apr-09,Apr-17,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Alliance Revenue,10.68988986,60.69873583,136.7459322,173.3578656,211.1106581,268.4629952,334.3654617,393.753322,296.2038401,268.6364977,278.0670905,308.8601,5.586247313,1596,Acute Coronary Syndrome,7/7/14 12:28
1419,34,Daiichi-Sankyo,Regional & Specialty Pharma,1932,Effient,prasugrel,Small Molecule (Chemical),Launched,In-House,Aug-09,Apr-09,Apr-17,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1596,Acute Coronary Syndrome,7/7/14 12:28
1419,34,Daiichi-Sankyo,Regional & Specialty Pharma,1932,Effient,prasugrel,Small Molecule (Chemical),Launched,In-House,Aug-09,Apr-09,Apr-17,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Alliance Revenue,10.68988986,21.01110086,36.71881512,46.9510886,53.3589279,80.54177796,120.8126669,156.0496948,191.1860454,227.3795069,263.0645484,298.7923777,27.90285499,1596,Acute Coronary Syndrome,7/7/14 12:28
1419,34,Daiichi-Sankyo,Regional & Specialty Pharma,1932,Effient,prasugrel,Small Molecule (Chemical),Launched,In-House,Aug-09,Apr-09,Apr-17,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1596,Acute Coronary Syndrome,7/7/14 12:28
1419,34,Daiichi-Sankyo,Regional & Specialty Pharma,1932,Effient,prasugrel,Small Molecule (Chemical),Launched,In-House,Aug-09,Apr-09,Apr-17,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Alliance Revenue,0,39.68763497,100.0271171,126.406777,157.7517302,187.9212172,213.5527947,237.7036272,105.0177947,41.25699077,15.0025421,10.06772225,-32.50373276,1596,Acute Coronary Syndrome,7/7/14 12:28
1419,34,Daiichi-Sankyo,Regional & Specialty Pharma,1932,Effient,prasugrel,Small Molecule (Chemical),Launched,In-House,Aug-09,Apr-09,Apr-17,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1596,Acute Coronary Syndrome,7/7/14 12:28
1420,39,Eli Lilly,Large Pharma,1932,Effient,prasugrel,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Apr-09,Apr-17,Apr-19,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1596,Acute Coronary Syndrome,7/7/14 12:28
1420,39,Eli Lilly,Large Pharma,1932,Effient,prasugrel,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Apr-09,Apr-17,Apr-19,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,27,115,302.5,457.2,508.7,606.5049,690.2641825,763.1169909,502.5560051,403.4469176,263.426638,175.3183366,-14.11655869,1596,Acute Coronary Syndrome,7/7/14 12:28
1420,39,Eli Lilly,Large Pharma,1932,Effient,prasugrel,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Apr-09,Apr-17,Apr-19,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1596,Acute Coronary Syndrome,7/7/14 12:28
1420,39,Eli Lilly,Large Pharma,1932,Effient,prasugrel,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Apr-09,Apr-17,Apr-19,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,4.5,30.4,80.1,118.2,131.8,168.4874,203.31012,238.37528,278.9198328,315.2748317,232.8275471,156.3385404,2.469103919,1596,Acute Coronary Syndrome,7/7/14 12:28
1420,39,Eli Lilly,Large Pharma,1932,Effient,prasugrel,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Apr-09,Apr-17,Apr-19,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1596,Acute Coronary Syndrome,7/7/14 12:28
1420,39,Eli Lilly,Large Pharma,1932,Effient,prasugrel,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Apr-09,Apr-17,Apr-19,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Sales,22.5,84.6,222.4,339,376.9,438.0175,486.9540625,524.7417109,223.6361723,88.17208588,30.59909091,18.97979626,-34.74993358,1596,Acute Coronary Syndrome,7/7/14 12:28
1421,24,Bristol-Myers Squibb,Large Pharma,985,Pravachol,pravastatin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-91,Jan-91,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1597,,7/7/14 12:28
1421,24,Bristol-Myers Squibb,Large Pharma,985,Pravachol,pravastatin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-91,Jan-91,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,112.5,80.3571,57.85707,42.107049,34.2320385,30.29453325,28.32578063,27.34140431,26.84921616,26.60312208,26.48007504,26.41855152,-3.63369805,1597,,7/7/14 12:28
1421,24,Bristol-Myers Squibb,Large Pharma,985,Pravachol,pravastatin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-91,Jan-91,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1597,,7/7/14 12:28
1421,24,Bristol-Myers Squibb,Large Pharma,985,Pravachol,pravastatin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-91,Jan-91,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,112.5,80.3571,57.85707,42.107049,34.2320385,30.29453325,28.32578063,27.34140431,26.84921616,26.60312208,26.48007504,26.41855152,-3.63369805,1597,,7/7/14 12:28
1421,24,Bristol-Myers Squibb,Large Pharma,985,Pravachol,pravastatin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-91,Jan-91,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1597,,7/7/14 12:28
1421,24,Bristol-Myers Squibb,Large Pharma,985,Pravachol,pravastatin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-91,Jan-91,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1597,,7/7/14 12:28
1423,76,Pfizer,Large Pharma,2840,Premarin Family,conjugated estrogens,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-42,Jul-42,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1403,Estrogen deficiency,7/7/14 12:28
1423,76,Pfizer,Large Pharma,2840,Premarin Family,conjugated estrogens,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-42,Jul-42,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Sales,212.94645,1040,1013,1073,1092,1098.98,1100.534,1101.7166,1082.5623,1073.271998,1063.807269,1054.209752,-0.501870766,1403,Estrogen deficiency,7/7/14 12:28
1423,76,Pfizer,Large Pharma,2840,Premarin Family,conjugated estrogens,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-42,Jul-42,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1403,Estrogen deficiency,7/7/14 12:28
1423,76,Pfizer,Large Pharma,2840,Premarin Family,conjugated estrogens,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-42,Jul-42,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Sales,12.96975,91,98,96,91,89.98,88.534,87.3166,86.5687,85.951678,85.4858614,85.14530446,-0.945504285,1403,Estrogen deficiency,7/7/14 12:28
1423,76,Pfizer,Large Pharma,2840,Premarin Family,conjugated estrogens,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-42,Jul-42,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1403,Estrogen deficiency,7/7/14 12:28
1423,76,Pfizer,Large Pharma,2840,Premarin Family,conjugated estrogens,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-42,Jul-42,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Sales,199.9767,949,915,977,1001,1009,1012,1014.4,995.9936,987.32032,978.321408,969.064448,-0.462123585,1403,Estrogen deficiency,7/7/14 12:28
1423,76,Wyeth,Large Pharma,2840,Premarin Family,conjugated estrogens,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-42,Jul-42,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Proforma,880.5,0,0,0,0,0,0,0,0,0,0,0,0,1403,Estrogen deficiency,7/7/14 12:28
1423,76,Wyeth,Large Pharma,2840,Premarin Family,conjugated estrogens,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-42,Jul-42,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Proforma,88,0,0,0,0,0,0,0,0,0,0,0,0,1403,Estrogen deficiency,7/7/14 12:28
1423,76,Wyeth,Large Pharma,2840,Premarin Family,conjugated estrogens,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-42,Jul-42,Expired,Expired,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Proforma,792.5,0,0,0,0,0,0,0,0,0,0,0,0,1403,Estrogen deficiency,7/7/14 12:28
1424,46,GlaxoSmithKline,Large Pharma,74,Prepandrix,H5N1 pandemic influenza vaccine,Vaccine,Launched,In-House,,May-07,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,923,H5N1 pandemic influenza,7/7/14 12:28
1424,46,GlaxoSmithKline,Large Pharma,74,Prepandrix,H5N1 pandemic influenza vaccine,Vaccine,Launched,In-House,,May-07,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,53.85514008,47.69780484,45.25130772,41.02740014,38.6396773,59.97811535,62.79468328,65.02793366,66.89671862,67.54702297,67.94675429,69.57249677,8.764273504,923,H5N1 pandemic influenza,7/7/14 12:28
1424,46,GlaxoSmithKline,Large Pharma,74,Prepandrix,H5N1 pandemic influenza vaccine,Vaccine,Launched,In-House,,May-07,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,923,H5N1 pandemic influenza,7/7/14 12:28
1424,46,GlaxoSmithKline,Large Pharma,74,Prepandrix,H5N1 pandemic influenza vaccine,Vaccine,Launched,In-House,,May-07,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,36.85918766,47.69780484,45.25130772,41.02740014,38.6396773,37.78771112,37.27571841,37.01254832,36.87587549,36.80096969,36.76164306,36.74080218,-0.717296404,923,H5N1 pandemic influenza,7/7/14 12:28
1424,46,GlaxoSmithKline,Large Pharma,74,Prepandrix,H5N1 pandemic influenza vaccine,Vaccine,Launched,In-House,,May-07,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,923,H5N1 pandemic influenza,7/7/14 12:28
1424,46,GlaxoSmithKline,Large Pharma,74,Prepandrix,H5N1 pandemic influenza vaccine,Vaccine,Launched,In-House,,May-07,N/A,N/A,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,16.99595242,0,0,0,0,22.19040424,25.51896487,28.01538535,30.02084313,30.74605328,31.18511123,32.83169459,0,923,H5N1 pandemic influenza,7/7/14 12:28
1426,100,Takeda,Large Pharma,1681,Prevacid / Takepron,lansoprazole,Small Molecule (Chemical),Launched,In-House,Jun-95,Dec-91,Nov-09,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1510,GERD / PUD,7/7/14 12:28
1426,100,Takeda,Large Pharma,1681,Prevacid / Takepron,lansoprazole,Small Molecule (Chemical),Launched,In-House,Jun-95,Dec-91,Nov-09,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,2350.725265,1560.657881,1545.988733,1326.669222,1165.427999,1060.899582,1013.350873,978.1989699,936.0019718,903.0789225,874.1581187,847.9367457,-4.441723831,1510,GERD / PUD,7/7/14 12:28
1426,100,Takeda,Large Pharma,1681,Prevacid / Takepron,lansoprazole,Small Molecule (Chemical),Launched,In-House,Jun-95,Dec-91,Nov-09,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1510,GERD / PUD,7/7/14 12:28
1426,100,Takeda,Large Pharma,1681,Prevacid / Takepron,lansoprazole,Small Molecule (Chemical),Launched,In-House,Jun-95,Dec-91,Nov-09,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,1068.707361,1061.060594,1238.310386,1031.720075,927.48223,855.7563908,823.0977687,803.1686673,775.8828231,754.9601215,736.8537821,720.2240629,-3.548524219,1510,GERD / PUD,7/7/14 12:28
1426,100,Takeda,Large Pharma,1681,Prevacid / Takepron,lansoprazole,Small Molecule (Chemical),Launched,In-House,Jun-95,Dec-91,Nov-09,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1510,GERD / PUD,7/7/14 12:28
1426,100,Takeda,Large Pharma,1681,Prevacid / Takepron,lansoprazole,Small Molecule (Chemical),Launched,In-House,Jun-95,Dec-91,Nov-09,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,1282.017903,499.5972872,307.6783474,294.9491464,237.9457686,205.1431907,190.2531043,175.0303026,160.1191487,148.1188009,137.3043366,127.7126828,-8.505758974,1510,GERD / PUD,7/7/14 12:28
1427,10,Almirall,Regional & Specialty Pharma,959,Prevencor,atorvastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Nov-97,N/A,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1353,Dyslipidemia,7/7/14 12:28
1427,10,Almirall,Regional & Specialty Pharma,959,Prevencor,atorvastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Nov-97,N/A,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,2,Global,Sales,156.7354198,96.57462565,42.40832964,17.99379857,11.15545256,8.490096218,7.547340954,7.212836343,7.09423744,7.052180598,7.037267284,7.031978983,-6.379688555,1353,Dyslipidemia,7/7/14 12:28
1427,10,Almirall,Regional & Specialty Pharma,959,Prevencor,atorvastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Nov-97,N/A,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1353,Dyslipidemia,7/7/14 12:28
1427,10,Almirall,Regional & Specialty Pharma,959,Prevencor,atorvastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Nov-97,N/A,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,2,ROW,Sales,156.7354198,96.57462565,42.40832964,17.99379857,11.15545256,8.490096218,7.547340954,7.212836343,7.09423744,7.052180598,7.037267284,7.031978983,-6.379688555,1353,Dyslipidemia,7/7/14 12:28
1427,10,Almirall,Regional & Specialty Pharma,959,Prevencor,atorvastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Nov-97,N/A,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1353,Dyslipidemia,7/7/14 12:28
1427,10,Almirall,Regional & Specialty Pharma,959,Prevencor,atorvastatin,Small Molecule (Chemical),Launched,Licensed (Development),,Nov-97,N/A,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1353,Dyslipidemia,7/7/14 12:28
1429,76,Pfizer,Large Pharma,1395,Prevnar family,pneumococcal vaccine,Vaccine,Launched,Corporate Acquisition,Mar-10,Feb-10,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1742,prevention of otitis media and invasive disease caused by Strep pneumoniae,7/7/14 12:28
1429,76,Pfizer,Large Pharma,1395,Prevnar family,pneumococcal vaccine,Vaccine,Launched,Corporate Acquisition,Mar-10,Feb-10,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,382,3669,4145,4117,3974,3925.18,3893.5412,3877.125988,3867.524264,3862.033722,3858.804901,3856.903124,-0.426353555,1742,prevention of otitis media and invasive disease caused by Strep pneumoniae,7/7/14 12:28
1429,76,Pfizer,Large Pharma,1395,Prevnar family,pneumococcal vaccine,Vaccine,Launched,Corporate Acquisition,Mar-10,Feb-10,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1742,prevention of otitis media and invasive disease caused by Strep pneumoniae,7/7/14 12:28
1429,76,Pfizer,Large Pharma,1395,Prevnar family,pneumococcal vaccine,Vaccine,Launched,Corporate Acquisition,Mar-10,Feb-10,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,238,1694,2217,2230,2170,2156.38,2149.5112,2147.045488,2146.041589,2145.652711,2145.499146,2145.438958,-0.16248189,1742,prevention of otitis media and invasive disease caused by Strep pneumoniae,7/7/14 12:28
1429,76,Pfizer,Large Pharma,1395,Prevnar family,pneumococcal vaccine,Vaccine,Launched,Corporate Acquisition,Mar-10,Feb-10,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1742,prevention of otitis media and invasive disease caused by Strep pneumoniae,7/7/14 12:28
1429,76,Pfizer,Large Pharma,1395,Prevnar family,pneumococcal vaccine,Vaccine,Launched,Corporate Acquisition,Mar-10,Feb-10,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,144,1975,1928,1887,1804,1768.8,1744.03,1730.0805,1721.482675,1716.381011,1713.305755,1711.464166,-0.749422398,1742,prevention of otitis media and invasive disease caused by Strep pneumoniae,7/7/14 12:28
1429,76,Wyeth,Large Pharma,1395,Prevnar family,pneumococcal vaccine,Vaccine,Launched,Corporate Acquisition,Mar-10,Feb-10,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Proforma,2425,0,0,0,0,0,0,0,0,0,0,0,0,1742,prevention of otitis media and invasive disease caused by Strep pneumoniae,7/7/14 12:28
1429,76,Wyeth,Large Pharma,1395,Prevnar family,pneumococcal vaccine,Vaccine,Launched,Corporate Acquisition,Mar-10,Feb-10,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Proforma,1369,0,0,0,0,0,0,0,0,0,0,0,0,1742,prevention of otitis media and invasive disease caused by Strep pneumoniae,7/7/14 12:28
1429,76,Wyeth,Large Pharma,1395,Prevnar family,pneumococcal vaccine,Vaccine,Launched,Corporate Acquisition,Mar-10,Feb-10,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,US,Proforma,1056,0,0,0,0,0,0,0,0,0,0,0,0,1742,prevention of otitis media and invasive disease caused by Strep pneumoniae,7/7/14 12:28
1431,53,Johnson & Johnson,Large Pharma,1126,Prezista,darunavir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,Feb-07,Aug-14,Dec-17,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,925,HIV,7/7/14 12:28
1431,53,Johnson & Johnson,Large Pharma,1126,Prezista,darunavir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,Feb-07,Aug-14,Dec-17,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Sales,592,857,1187,1414,1673,1299.403133,1022.09158,925.6839697,673.8845709,516.5584703,465.926432,439.9290079,-17.3720937,925,HIV,7/7/14 12:28
1431,53,Johnson & Johnson,Large Pharma,1126,Prezista,darunavir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,Feb-07,Aug-14,Dec-17,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,925,HIV,7/7/14 12:28
1431,53,Johnson & Johnson,Large Pharma,1126,Prezista,darunavir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,Feb-07,Aug-14,Dec-17,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Sales,289,456,679,742,866,887,881.2868473,840.1916149,624.9670061,484.068161,434.5306378,410.0400079,-10.12983818,925,HIV,7/7/14 12:28
1431,53,Johnson & Johnson,Large Pharma,1126,Prezista,darunavir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,Feb-07,Aug-14,Dec-17,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,925,HIV,7/7/14 12:28
1431,53,Johnson & Johnson,Large Pharma,1126,Prezista,darunavir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,Feb-07,Aug-14,Dec-17,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Sales,303,401,508,672,807,412.4031331,140.8047323,85.49235477,48.91756484,32.49030936,31.39579419,29.889,-37.55180395,925,HIV,7/7/14 12:28
1432,16,AstraZeneca,Large Pharma,919,Prilosec,omeprazole,Small Molecule (Chemical),Launched,In-House,Dec-89,Dec-89,Expired,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,927,GERD / PUD,7/7/14 12:28
1432,16,AstraZeneca,Large Pharma,919,Prilosec,omeprazole,Small Molecule (Chemical),Launched,In-House,Dec-89,Dec-89,Expired,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,Global,Sales,946,986,946,710,486,408,345.328,304.5856,281.7216,266.43136,256.666752,250.4202035,-9.037599717,927,GERD / PUD,7/7/14 12:28
1432,16,AstraZeneca,Large Pharma,919,Prilosec,omeprazole,Small Molecule (Chemical),Launched,In-House,Dec-89,Dec-89,Expired,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,927,GERD / PUD,7/7/14 12:28
1432,16,AstraZeneca,Large Pharma,919,Prilosec,omeprazole,Small Molecule (Chemical),Launched,In-House,Dec-89,Dec-89,Expired,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,ROW,Sales,882,939,908,680,456,381.36,321.312,282.4256,261.47136,247.810304,239.452672,234.4654797,-9.065093957,927,GERD / PUD,7/7/14 12:28
1432,16,AstraZeneca,Large Pharma,919,Prilosec,omeprazole,Small Molecule (Chemical),Launched,In-House,Dec-89,Dec-89,Expired,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,927,GERD / PUD,7/7/14 12:28
1432,16,AstraZeneca,Large Pharma,919,Prilosec,omeprazole,Small Molecule (Chemical),Launched,In-House,Dec-89,Dec-89,Expired,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,US,Sales,64,47,38,30,30,26.64,24.016,22.16,20.25024,18.621056,17.21408,15.95472384,-8.625703897,927,GERD / PUD,7/7/14 12:28
1433,61,Merck & Co,Large Pharma,1487,Primaxin,imipenem + cilastin,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-85,Nov-09,Aug-10,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,928,bacterial infection,7/7/14 12:28
1433,61,Merck & Co,Large Pharma,1487,Primaxin,imipenem + cilastin,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-85,Nov-09,Aug-10,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,689,610,515.5,384,335,289.24,249.1088,215.597312,185.8858317,159.7716248,136.8800371,116.7199816,-13.98269386,928,bacterial infection,7/7/14 12:28
1433,61,Merck & Co,Large Pharma,1487,Primaxin,imipenem + cilastin,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-85,Nov-09,Aug-10,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,928,bacterial infection,7/7/14 12:28
1433,61,Merck & Co,Large Pharma,1487,Primaxin,imipenem + cilastin,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-85,Nov-09,Aug-10,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,553,487,428.5,363,317,273.52,234.608,201.248,171.60832,145.520128,122.633728,102.4756531,-14.89846031,928,bacterial infection,7/7/14 12:28
1433,61,Merck & Co,Large Pharma,1487,Primaxin,imipenem + cilastin,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-85,Nov-09,Aug-10,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,928,bacterial infection,7/7/14 12:28
1433,61,Merck & Co,Large Pharma,1487,Primaxin,imipenem + cilastin,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-85,Nov-09,Aug-10,141,Penems,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,136,123,87,21,18,15.72,14.5008,14.349312,14.27751168,14.25149676,14.24630914,14.24432847,-3.287776534,928,bacterial infection,7/7/14 12:28
1434,76,Pfizer,Large Pharma,1542,Pristiq,desvenlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-08,Feb-09,Dec-14,Feb-17,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1419,Depression,7/7/14 12:28
1434,76,Pfizer,Large Pharma,1542,Pristiq,desvenlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-08,Feb-09,Dec-14,Feb-17,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Sales,37,466,577,630,698,679.96905,217.6615144,216.5539144,118.404807,71.65455809,48.62162214,39.01229871,-33.77078242,1419,Depression,7/7/14 12:28
1434,76,Pfizer,Large Pharma,1542,Pristiq,desvenlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-08,Feb-09,Dec-14,Feb-17,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1419,Depression,7/7/14 12:28
1434,76,Pfizer,Large Pharma,1542,Pristiq,desvenlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-08,Feb-09,Dec-14,Feb-17,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Sales,1.8,61,103,137,158,175.14585,188.7037144,198.7058504,105.6452294,62.33248705,41.02568179,31.9887633,-20.4013201,1419,Depression,7/7/14 12:28
1434,76,Pfizer,Large Pharma,1542,Pristiq,desvenlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-08,Feb-09,Dec-14,Feb-17,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1419,Depression,7/7/14 12:28
1434,76,Pfizer,Large Pharma,1542,Pristiq,desvenlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-08,Feb-09,Dec-14,Feb-17,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Sales,35.2,405,474,493,540,504.8232,28.9578,17.848064,12.7595776,9.32207104,7.595940352,7.023535411,-46.22321395,1419,Depression,7/7/14 12:28
1434,76,Wyeth,Large Pharma,1542,Pristiq,desvenlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-08,Feb-09,Dec-14,Feb-17,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Proforma,185,0,0,0,0,0,0,0,0,0,0,0,0,1419,Depression,7/7/14 12:28
1434,76,Wyeth,Large Pharma,1542,Pristiq,desvenlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-08,Feb-09,Dec-14,Feb-17,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Proforma,9.2,0,0,0,0,0,0,0,0,0,0,0,0,1419,Depression,7/7/14 12:28
1434,76,Wyeth,Large Pharma,1542,Pristiq,desvenlafaxine,Small Molecule (Chemical),Launched,Corporate Acquisition,May-08,Feb-09,Dec-14,Feb-17,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Proforma,175.8,0,0,0,0,0,0,0,0,0,0,0,0,1419,Depression,7/7/14 12:28
1437,102,Teva,Regional & Specialty Pharma,124,ProAir,albuterol,Small Molecule (Chemical),Launched,Acquisition (Marketed),Dec-04,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1332,Asthma,7/7/14 12:28
1437,102,Teva,Regional & Specialty Pharma,124,ProAir,albuterol,Small Molecule (Chemical),Launched,Acquisition (Marketed),Dec-04,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Sales,455,396,436,406,429,430.04,430.7632,431.824256,432.0085965,432.1371562,432.2046305,432.2276868,0.107137004,1332,Asthma,7/7/14 12:28
1437,102,Teva,Regional & Specialty Pharma,124,ProAir,albuterol,Small Molecule (Chemical),Launched,Acquisition (Marketed),Dec-04,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1332,Asthma,7/7/14 12:28
1437,102,Teva,Regional & Specialty Pharma,124,ProAir,albuterol,Small Molecule (Chemical),Launched,Acquisition (Marketed),Dec-04,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1332,Asthma,7/7/14 12:28
1437,102,Teva,Regional & Specialty Pharma,124,ProAir,albuterol,Small Molecule (Chemical),Launched,Acquisition (Marketed),Dec-04,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1332,Asthma,7/7/14 12:28
1437,102,Teva,Regional & Specialty Pharma,124,ProAir,albuterol,Small Molecule (Chemical),Launched,Acquisition (Marketed),Dec-04,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Sales,455,396,436,406,429,430.04,430.7632,431.824256,432.0085965,432.1371562,432.2046305,432.2276868,0.107137004,1332,Asthma,7/7/14 12:28
1438,94,Servier,Regional & Specialty Pharma,882,Procoralan,ivabradine,Small Molecule (Chemical),Launched,In-House,,Feb-06,N/A,Sep-17,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,Global,Sales,60.03717305,91.97630807,136.2628297,189.0994371,228.5619566,263.5599192,295.9592267,322.6259023,286.0011663,112.1999971,78.43634559,61.21461173,-17.15533763,931,Angina,7/7/14 12:28
1438,94,Servier,Regional & Specialty Pharma,882,Procoralan,ivabradine,Small Molecule (Chemical),Launched,In-House,,Feb-06,N/A,Sep-17,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,60.03717305,91.97630807,136.2628297,189.0994371,228.5619566,263.5599192,295.9592267,322.6259023,286.0011663,112.1999971,78.43634559,61.21461173,-17.15533763,931,Angina,7/7/14 12:28
1438,94,Servier,Regional & Specialty Pharma,882,Procoralan,ivabradine,Small Molecule (Chemical),Launched,In-House,,Feb-06,N/A,Sep-17,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,931,Angina,7/7/14 12:28
1439,53,Johnson & Johnson,Large Pharma,1481,Procrit / Eprex,epoetin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-91,Jan-91,Jul-15,Expired,102,ESAs,24,Anemia,14,Hematology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1752,Renal Anemia,7/7/14 12:28
1439,53,Johnson & Johnson,Large Pharma,1481,Procrit / Eprex,epoetin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-91,Jan-91,Jul-15,Expired,102,ESAs,24,Anemia,14,Hematology,6,Global,Sales,1073.15,941.4475,770.9,696,641.6,562.477,517.3665,448.8004275,386.1678722,307.7509534,229.9110529,183.4453599,-16.37802568,1752,Renal Anemia,7/7/14 12:28
1439,53,Johnson & Johnson,Large Pharma,1481,Procrit / Eprex,epoetin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-91,Jan-91,Jul-15,Expired,102,ESAs,24,Anemia,14,Hematology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1752,Renal Anemia,7/7/14 12:28
1439,53,Johnson & Johnson,Large Pharma,1481,Procrit / Eprex,epoetin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-91,Jan-91,Jul-15,Expired,102,ESAs,24,Anemia,14,Hematology,6,ROW,Sales,444.15,406.4475,380.2,309,268,229.54,200.3035,176.4358375,157.3271022,141.9247921,129.5391138,119.571113,-10.88980295,1752,Renal Anemia,7/7/14 12:28
1439,53,Johnson & Johnson,Large Pharma,1481,Procrit / Eprex,epoetin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-91,Jan-91,Jul-15,Expired,102,ESAs,24,Anemia,14,Hematology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1752,Renal Anemia,7/7/14 12:28
1439,53,Johnson & Johnson,Large Pharma,1481,Procrit / Eprex,epoetin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-91,Jan-91,Jul-15,Expired,102,ESAs,24,Anemia,14,Hematology,6,US,Sales,629,535,390.7,387,373.6,332.937,317.063,272.36459,228.84077,165.8261613,100.3719391,63.87424689,-22.30070131,1752,Renal Anemia,7/7/14 12:28
1440,53,Johnson & Johnson,Large Pharma,1481,Procrit / Eprex,epoetin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-93,Mar-93,Jul-15,Expired,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1752,Chemotherapy-induced Anemia,7/7/14 12:28
1440,53,Johnson & Johnson,Large Pharma,1481,Procrit / Eprex,epoetin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-93,Mar-93,Jul-15,Expired,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,Global,Sales,1171.85,993,851.97,766,722,638.2602,579.252776,505.4153357,435.282478,345.4118694,258.6108657,212.8227204,-16.01308722,1752,Chemotherapy-induced Anemia,7/7/14 12:28
1440,53,Johnson & Johnson,Large Pharma,1481,Procrit / Eprex,epoetin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-93,Mar-93,Jul-15,Expired,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1752,Chemotherapy-induced Anemia,7/7/14 12:28
1440,53,Johnson & Johnson,Large Pharma,1481,Procrit / Eprex,epoetin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-93,Mar-93,Jul-15,Expired,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,ROW,Sales,542.85,458,428.77,348,301,261.1322,225.501416,197.7818125,174.462212,155.1829251,139.3744921,126.2851865,-11.66916673,1752,Chemotherapy-induced Anemia,7/7/14 12:28
1440,53,Johnson & Johnson,Large Pharma,1481,Procrit / Eprex,epoetin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-93,Mar-93,Jul-15,Expired,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1752,Chemotherapy-induced Anemia,7/7/14 12:28
1440,53,Johnson & Johnson,Large Pharma,1481,Procrit / Eprex,epoetin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-93,Mar-93,Jul-15,Expired,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,US,Sales,629,535,423.2,418,421,377.128,353.75136,307.6335232,260.820266,190.2289443,119.2363736,86.5375339,-20.22879398,1752,Chemotherapy-induced Anemia,7/7/14 12:28
1441,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-05,N/A,May-10,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1645,Rheumatoid Arthritis,7/7/14 12:28
1441,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-05,N/A,May-10,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,102.1305019,99.21908742,102.5594491,110.7564141,94.10097001,95.40332727,96.72710931,97.26638259,97.63727967,97.88207444,98.01868291,98.10505174,0.597067738,1645,Rheumatoid Arthritis,7/7/14 12:28
1441,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-05,N/A,May-10,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1645,Rheumatoid Arthritis,7/7/14 12:28
1441,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-05,N/A,May-10,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,102.1305019,99.21908742,102.5594491,110.7564141,94.10097001,95.40332727,96.72710931,97.26638259,97.63727967,97.88207444,98.01868291,98.10505174,0.597067738,1645,Rheumatoid Arthritis,7/7/14 12:28
1441,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-05,N/A,May-10,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1645,Rheumatoid Arthritis,7/7/14 12:28
1441,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-05,N/A,May-10,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1645,Rheumatoid Arthritis,7/7/14 12:28
1442,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-94,Jul-93,Aug-09,May-10,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1645,Transplant Rejection,7/7/14 12:28
1442,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-94,Jul-93,Aug-09,May-10,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,Global,Sales,1896.093706,1769.601606,1806.818937,1774.510374,1730.641454,1652.012543,1551.234644,1459.493783,1425.518839,1397.077366,1377.24923,1364.65756,-3.337165368,1645,Transplant Rejection,7/7/14 12:28
1442,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-94,Jul-93,Aug-09,May-10,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1645,Transplant Rejection,7/7/14 12:28
1442,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-94,Jul-93,Aug-09,May-10,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,ROW,Sales,1162.434721,1291.01542,1437.098454,1396.493917,1419.548837,1369.210225,1308.803892,1248.397558,1238.329836,1227.758728,1221.642587,1219.169702,-2.150383684,1645,Transplant Rejection,7/7/14 12:28
1442,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-94,Jul-93,Aug-09,May-10,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1645,Transplant Rejection,7/7/14 12:28
1442,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-94,Jul-93,Aug-09,May-10,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,US,Sales,733.658985,478.5861864,369.7204833,378.016457,311.0926174,282.8023179,242.4307517,211.0962246,187.1890024,169.3186381,155.6066432,145.4878578,-10.28848387,1645,Transplant Rejection,7/7/14 12:28
1443,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-09,N/A,May-10,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1645,Ulcerative Colitis,7/7/14 12:28
1443,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-09,N/A,May-10,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,Global,Sales,12.76631274,28.94862786,50.64664155,60.19370334,59.23837103,66.6099199,72.46839267,77.31284974,81.27070584,84.49347765,87.13082155,89.28477385,6.036026577,1645,Ulcerative Colitis,7/7/14 12:28
1443,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-09,N/A,May-10,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1645,Ulcerative Colitis,7/7/14 12:28
1443,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-09,N/A,May-10,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,ROW,Sales,12.76631274,28.94862786,50.64664155,60.19370334,59.23837103,66.6099199,72.46839267,77.31284974,81.27070584,84.49347765,87.13082155,89.28477385,6.036026577,1645,Ulcerative Colitis,7/7/14 12:28
1443,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-09,N/A,May-10,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1645,Ulcerative Colitis,7/7/14 12:28
1443,15,Astellas Pharma,Regional & Specialty Pharma,1372,Prograf,tacrolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-09,N/A,May-10,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1645,Ulcerative Colitis,7/7/14 12:28
1444,46,GlaxoSmithKline,Large Pharma,966,Promacta / Revolade,eltrombopag ,Small Molecule (Chemical),Launched,Licensed (Development),Jan-09,Apr-10,Sep-21,May-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1441,Immune Thrombocytopenic Purpura,7/7/14 12:28
1444,46,GlaxoSmithKline,Large Pharma,966,Promacta / Revolade,eltrombopag ,Small Molecule (Chemical),Launched,Licensed (Development),Jan-09,Apr-10,Sep-21,May-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,4,Global,Sales,20.27040196,47.8950018,120.590219,206.0537536,290.7950092,365.8388826,424.9885845,461.9791218,489.2694406,508.7885284,522.39361,532.1534212,9.016643582,1441,Immune Thrombocytopenic Purpura,7/7/14 12:28
1444,46,GlaxoSmithKline,Large Pharma,966,Promacta / Revolade,eltrombopag ,Small Molecule (Chemical),Launched,Licensed (Development),Jan-09,Apr-10,Sep-21,May-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1441,Immune Thrombocytopenic Purpura,7/7/14 12:28
1444,46,GlaxoSmithKline,Large Pharma,966,Promacta / Revolade,eltrombopag ,Small Molecule (Chemical),Launched,Licensed (Development),Jan-09,Apr-10,Sep-21,May-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,4,ROW,Sales,0,9.270000348,68.93677055,120.4621944,176.6657852,226.6950341,268.9072128,292.7492768,310.0445444,322.1658888,330.1747215,335.7246581,9.605647113,1441,Immune Thrombocytopenic Purpura,7/7/14 12:28
1444,46,GlaxoSmithKline,Large Pharma,966,Promacta / Revolade,eltrombopag ,Small Molecule (Chemical),Launched,Licensed (Development),Jan-09,Apr-10,Sep-21,May-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1441,Immune Thrombocytopenic Purpura,7/7/14 12:28
1444,46,GlaxoSmithKline,Large Pharma,966,Promacta / Revolade,eltrombopag ,Small Molecule (Chemical),Launched,Licensed (Development),Jan-09,Apr-10,Sep-21,May-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,4,US,Sales,20.27040196,38.62500145,51.65344841,85.59155919,114.129224,139.1438485,156.0813717,169.2298451,179.2248962,186.6226395,192.2188885,196.4287632,8.06544708,1441,Immune Thrombocytopenic Purpura,7/7/14 12:28
1445,1,Abbott,Regional & Specialty Pharma,111,Prometrium,progesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1599,Estrogen deficiency,7/7/14 12:28
1445,1,Abbott,Regional & Specialty Pharma,111,Prometrium,progesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Sales,0,67.5,86,51,0,0,0,0,0,0,0,0,0,1599,Estrogen deficiency,7/7/14 12:28
1445,1,Abbott,Regional & Specialty Pharma,111,Prometrium,progesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1599,Estrogen deficiency,7/7/14 12:28
1445,1,Abbott,Regional & Specialty Pharma,111,Prometrium,progesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1599,Estrogen deficiency,7/7/14 12:28
1445,1,Abbott,Regional & Specialty Pharma,111,Prometrium,progesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1599,Estrogen deficiency,7/7/14 12:28
1445,1,Abbott,Regional & Specialty Pharma,111,Prometrium,progesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Sales,0,67.5,86,51,0,0,0,0,0,0,0,0,0,1599,Estrogen deficiency,7/7/14 12:28
1445,1,Solvay,Regional & Specialty Pharma,111,Prometrium,progesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Proforma,80,14.5,0,0,0,0,0,0,0,0,0,0,0,1599,Estrogen deficiency,7/7/14 12:28
1445,1,Solvay,Regional & Specialty Pharma,111,Prometrium,progesterone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,,Expired,N/A,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Proforma,80,14.5,0,0,0,0,0,0,0,0,0,0,0,1599,Estrogen deficiency,7/7/14 12:28
1447,61,Merck & Co,Large Pharma,587,Propecia,finasteride,Small Molecule (Chemical),Launched,In-House,Jun-98,Jun-98,Jan-13,Oct-13,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1698,Alopecia (androgenic),7/7/14 12:28
1447,61,Merck & Co,Large Pharma,587,Propecia,finasteride,Small Molecule (Chemical),Launched,In-House,Jun-98,Jun-98,Jan-13,Oct-13,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,Global,Sales,441,445.52,447,424,282,153,120,99,85,72,60.72,50.9056,-21.69523855,1698,Alopecia (androgenic),7/7/14 12:28
1447,61,Merck & Co,Large Pharma,587,Propecia,finasteride,Small Molecule (Chemical),Launched,In-House,Jun-98,Jun-98,Jan-13,Oct-13,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1698,Alopecia (androgenic),7/7/14 12:28
1447,61,Merck & Co,Large Pharma,587,Propecia,finasteride,Small Molecule (Chemical),Launched,In-House,Jun-98,Jun-98,Jan-13,Oct-13,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,ROW,Sales,293,298,313,300,258,141,112,93,79,68,58,49.12,-21.09739553,1698,Alopecia (androgenic),7/7/14 12:28
1447,61,Merck & Co,Large Pharma,587,Propecia,finasteride,Small Molecule (Chemical),Launched,In-House,Jun-98,Jun-98,Jan-13,Oct-13,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1698,Alopecia (androgenic),7/7/14 12:28
1447,61,Merck & Co,Large Pharma,587,Propecia,finasteride,Small Molecule (Chemical),Launched,In-House,Jun-98,Jun-98,Jan-13,Oct-13,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,US,Sales,148,147.52,134,124,24,12,8,6,6,4,2.72,1.7856,-31.00838761,1698,Alopecia (androgenic),7/7/14 12:28
1449,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1351,Prorenal,limaprost,Small Molecule (Chemical),Launched,In-House,,Apr-88,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1526,Thromboangiitis obliterans ,7/7/14 12:28
1449,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1351,Prorenal,limaprost,Small Molecule (Chemical),Launched,In-House,,Apr-88,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,165.9081993,178.5901746,196.539496,170.9501175,133.9007059,126.6649703,121.2166602,117.0274838,113.8306423,111.3844629,109.5144982,108.0845179,-3.013445536,1526,Thromboangiitis obliterans ,7/7/14 12:28
1449,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1351,Prorenal,limaprost,Small Molecule (Chemical),Launched,In-House,,Apr-88,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1526,Thromboangiitis obliterans ,7/7/14 12:28
1449,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1351,Prorenal,limaprost,Small Molecule (Chemical),Launched,In-House,,Apr-88,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,165.9081993,178.5901746,196.539496,170.9501175,133.9007059,126.6649703,121.2166602,117.0274838,113.8306423,111.3844629,109.5144982,108.0845179,-3.013445536,1526,Thromboangiitis obliterans ,7/7/14 12:28
1449,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1351,Prorenal,limaprost,Small Molecule (Chemical),Launched,In-House,,Apr-88,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1526,Thromboangiitis obliterans ,7/7/14 12:28
1449,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1351,Prorenal,limaprost,Small Molecule (Chemical),Launched,In-House,,Apr-88,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1526,Thromboangiitis obliterans ,7/7/14 12:28
1450,61,Merck & Co,Large Pharma,114,Proscar,finasteride,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-92,Expired,Expired,52,5-Alpha Reductase Inhibitors,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1468,Symptoms associated with BPH,7/7/14 12:28
1450,61,Merck & Co,Large Pharma,114,Proscar,finasteride,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-92,Expired,Expired,52,5-Alpha Reductase Inhibitors,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,Global,Sales,291,216,223,217,178,170,162.73,155.6785,151.932425,149.1116862,147.0455186,145.6454439,-2.825155247,1468,Symptoms associated with BPH,7/7/14 12:28
1450,61,Merck & Co,Large Pharma,114,Proscar,finasteride,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-92,Expired,Expired,52,5-Alpha Reductase Inhibitors,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1468,Symptoms associated with BPH,7/7/14 12:28
1450,61,Merck & Co,Large Pharma,114,Proscar,finasteride,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-92,Expired,Expired,52,5-Alpha Reductase Inhibitors,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,ROW,Sales,285,210,218,212,174,166,159,152.25,148.7125,146.115625,144.2607812,143.0537891,-2.758862852,1468,Symptoms associated with BPH,7/7/14 12:28
1450,61,Merck & Co,Large Pharma,114,Proscar,finasteride,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-92,Expired,Expired,52,5-Alpha Reductase Inhibitors,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1468,Symptoms associated with BPH,7/7/14 12:28
1450,61,Merck & Co,Large Pharma,114,Proscar,finasteride,Small Molecule (Chemical),Launched,In-House,Jul-92,Jul-92,Expired,Expired,52,5-Alpha Reductase Inhibitors,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,US,Sales,6,6,5,5,4,4,3.73,3.4285,3.219925,2.99606125,2.784737312,2.591654828,-6.011675413,1468,Symptoms associated with BPH,7/7/14 12:28
1451,94,Servier,Regional & Specialty Pharma,524,Protelos,strontium ranelate,Small Molecule (Chemical),Launched,In-House,,Jan-05,N/A,Aug-15,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,2,Global,Sales,215.8597567,224.3645145,251.4560507,236.6440523,225.7651113,172.6439087,98.53319079,34.55183034,21.10842675,14.99315169,8.660499595,7.586162929,-38.41414531,935,Osteoporosis,7/7/14 12:28
1451,94,Servier,Regional & Specialty Pharma,524,Protelos,strontium ranelate,Small Molecule (Chemical),Launched,In-House,,Jan-05,N/A,Aug-15,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,2,ROW,Sales,215.8597567,224.3645145,251.4560507,236.6440523,225.7651113,172.6439087,98.53319079,34.55183034,21.10842675,14.99315169,8.660499595,7.586162929,-38.41414531,935,Osteoporosis,7/7/14 12:28
1451,94,Servier,Regional & Specialty Pharma,524,Protelos,strontium ranelate,Small Molecule (Chemical),Launched,In-House,,Jan-05,N/A,Aug-15,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,935,Osteoporosis,7/7/14 12:28
1452,76,Pfizer,Large Pharma,1572,Protonix,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,,Expired,N/A,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1581,GERD / PUD,7/7/14 12:28
1452,76,Pfizer,Large Pharma,1572,Protonix,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,,Expired,N/A,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,Global,Sales,68,690,168,117.16,107.5392,83.471104,78.16450048,76.18015222,74.76704245,74.3058312,74.11458753,74.01666545,-5.196740787,1581,GERD / PUD,7/7/14 12:28
1452,76,Pfizer,Large Pharma,1572,Protonix,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,,Expired,N/A,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1581,GERD / PUD,7/7/14 12:28
1452,76,Pfizer,Large Pharma,1572,Protonix,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,,Expired,N/A,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1581,GERD / PUD,7/7/14 12:28
1452,76,Pfizer,Large Pharma,1572,Protonix,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,,Expired,N/A,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1581,GERD / PUD,7/7/14 12:28
1452,76,Pfizer,Large Pharma,1572,Protonix,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,,Expired,N/A,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,US,Sales,68,690,168,117.16,107.5392,83.471104,78.16450048,76.18015222,74.76704245,74.3058312,74.11458753,74.01666545,-5.196740787,1581,GERD / PUD,7/7/14 12:28
1452,76,Wyeth,Large Pharma,1572,Protonix,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,,Expired,N/A,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,Global,Proforma,188,0,0,0,0,0,0,0,0,0,0,0,0,1581,GERD / PUD,7/7/14 12:28
1452,76,Wyeth,Large Pharma,1572,Protonix,pantoprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,May-00,,Expired,N/A,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,6,US,Proforma,188,0,0,0,0,0,0,0,0,0,0,0,0,1581,GERD / PUD,7/7/14 12:28
1453,15,Astellas Pharma,Regional & Specialty Pharma,672,Protopic,tacrolimus,Small Molecule (Chemical),Launched,In-House,Feb-01,Nov-99,Sep-14,Jun-12,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1743,Atopic dermatitis,7/7/14 12:28
1453,15,Astellas Pharma,Regional & Specialty Pharma,672,Protopic,tacrolimus,Small Molecule (Chemical),Launched,In-House,Feb-01,Nov-99,Sep-14,Jun-12,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,7,Global,Sales,175.604133,189.0999078,212.7158945,218.5341975,223.0747131,202.6632488,135.0081553,124.437047,113.1455916,108.7314002,96.38033389,93.95080109,-11.62079833,1743,Atopic dermatitis,7/7/14 12:28
1453,15,Astellas Pharma,Regional & Specialty Pharma,672,Protopic,tacrolimus,Small Molecule (Chemical),Launched,In-House,Feb-01,Nov-99,Sep-14,Jun-12,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1743,Atopic dermatitis,7/7/14 12:28
1453,15,Astellas Pharma,Regional & Specialty Pharma,672,Protopic,tacrolimus,Small Molecule (Chemical),Launched,In-House,Feb-01,Nov-99,Sep-14,Jun-12,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,7,ROW,Sales,96.95933723,106.2227877,119.0196076,118.6328501,111.5373566,110.7449447,100.6772225,90.60950021,90.60950021,90.60950021,80.54177796,80.54177796,-4.544678709,1743,Atopic dermatitis,7/7/14 12:28
1453,15,Astellas Pharma,Regional & Specialty Pharma,672,Protopic,tacrolimus,Small Molecule (Chemical),Launched,In-House,Feb-01,Nov-99,Sep-14,Jun-12,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1743,Atopic dermatitis,7/7/14 12:28
1453,15,Astellas Pharma,Regional & Specialty Pharma,672,Protopic,tacrolimus,Small Molecule (Chemical),Launched,In-House,Feb-01,Nov-99,Sep-14,Jun-12,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,7,US,Sales,78.64479575,82.87712008,93.69628686,99.90134742,111.5373566,91.9183041,34.33093286,33.82754674,22.53609141,18.12190004,15.83855593,13.40902313,-26.11296407,1743,Atopic dermatitis,7/7/14 12:28
1454,36,Dendreon,Small Biotech,24,Provenge,sipuleucel-T,Cell Therapy,Launched,In-House,May-10,Jan-14,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,48,213.5,325.3,283.7,306.0737331,320.9496434,330.1294667,265.399885,173.8316468,119.6334255,102.6371882,-13.51897349,936,Prostate Cancer,7/7/14 12:28
1454,36,Dendreon,Small Biotech,24,Provenge,sipuleucel-T,Cell Therapy,Launched,In-House,May-10,Jan-14,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,30,50.0001,70.00014,66.55686188,37.37289581,24.16924953,23,0,936,Prostate Cancer,7/7/14 12:28
1454,36,Dendreon,Small Biotech,24,Provenge,sipuleucel-T,Cell Therapy,Launched,In-House,May-10,Jan-14,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,48,213.5,325.3,283.7,276.0737331,270.9495434,260.1293267,198.8430231,136.458751,95.46417602,79.63718821,-16.59739982,936,Prostate Cancer,7/7/14 12:28
1455,102,Cephalon,Regional & Specialty Pharma,683,Provigil,modafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Mar-98,Mar-12,Oct-12,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,Global,Proforma,1024.7,1124.5,808.5,0,0,0,0,0,0,0,0,0,0,937,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1455,102,Cephalon,Regional & Specialty Pharma,683,Provigil,modafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Mar-98,Mar-12,Oct-12,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,ROW,Proforma,63.6,64.8,52.5,0,0,0,0,0,0,0,0,0,0,937,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1455,102,Cephalon,Regional & Specialty Pharma,683,Provigil,modafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Mar-98,Mar-12,Oct-12,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,US,Proforma,961.1,1059.7,756,0,0,0,0,0,0,0,0,0,0,937,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1455,102,Teva,Regional & Specialty Pharma,683,Provigil,modafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Mar-98,Mar-12,Oct-12,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,937,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1455,102,Teva,Regional & Specialty Pharma,683,Provigil,modafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Mar-98,Mar-12,Oct-12,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,Global,Sales,0,0,350,417,91,71,44,31,28,23.47,22.6835,21.051425,-18.87078964,937,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1455,102,Teva,Regional & Specialty Pharma,683,Provigil,modafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Mar-98,Mar-12,Oct-12,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,937,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1455,102,Teva,Regional & Specialty Pharma,683,Provigil,modafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Mar-98,Mar-12,Oct-12,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,ROW,Sales,0,0,17,50,31,27,22,20,17,14.78,15,13.7268,-10.98600746,937,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1455,102,Teva,Regional & Specialty Pharma,683,Provigil,modafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Mar-98,Mar-12,Oct-12,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,937,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1455,102,Teva,Regional & Specialty Pharma,683,Provigil,modafinil,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-99,Mar-98,Mar-12,Oct-12,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,US,Sales,0,0,333,367,60,44,22,11,11,8.69,7.6835,7.324625,-25.95098362,937,Excessive Sleepiness Associated with Narcolepsy,7/7/14 12:28
1456,39,Eli Lilly,Large Pharma,224,Prozac,fluoxetine,Small Molecule (Chemical),Launched,In-House,Jan-88,Oct-88,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,938,Depression,7/7/14 12:28
1456,39,Eli Lilly,Large Pharma,224,Prozac,fluoxetine,Small Molecule (Chemical),Launched,In-House,Jan-88,Oct-88,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,Global,Sales,229.5,206.2,188.7,180,174.9,169.87,165.6546,161.946276,159.2109422,156.6552484,154.4282686,152.6492385,-1.925107296,938,Depression,7/7/14 12:28
1456,39,Eli Lilly,Large Pharma,224,Prozac,fluoxetine,Small Molecule (Chemical),Launched,In-House,Jan-88,Oct-88,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,938,Depression,7/7/14 12:28
1456,39,Eli Lilly,Large Pharma,224,Prozac,fluoxetine,Small Molecule (Chemical),Launched,In-House,Jan-88,Oct-88,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,ROW,Sales,107.4,106.9,106,103.4,99.3,97.66,95.3736,92.974176,91.38553216,89.64092739,88.0207465,86.70735488,-1.918595026,938,Depression,7/7/14 12:28
1456,39,Eli Lilly,Large Pharma,224,Prozac,fluoxetine,Small Molecule (Chemical),Launched,In-House,Jan-88,Oct-88,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,938,Depression,7/7/14 12:28
1456,39,Eli Lilly,Large Pharma,224,Prozac,fluoxetine,Small Molecule (Chemical),Launched,In-House,Jan-88,Oct-88,Expired,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,6,US,Sales,122.1,99.3,82.7,76.6,75.6,72.21,70.281,68.9721,67.82541,67.014321,66.4075221,65.94188361,-1.933665055,938,Depression,7/7/14 12:28
1458,67,Novartis,Large Pharma,2599,Pseudomonas aeruginosa vaccine,IC-43,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,941,Pseudmonas aeruginosa,7/7/14 12:28
1458,67,Novartis,Large Pharma,2599,Pseudomonas aeruginosa vaccine,IC-43,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,941,Pseudmonas aeruginosa,7/7/14 12:28
1458,67,Novartis,Large Pharma,2599,Pseudomonas aeruginosa vaccine,IC-43,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,941,Pseudmonas aeruginosa,7/7/14 12:28
1458,67,Novartis,Large Pharma,2599,Pseudomonas aeruginosa vaccine,IC-43,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,941,Pseudmonas aeruginosa,7/7/14 12:28
1458,67,Novartis,Large Pharma,2599,Pseudomonas aeruginosa vaccine,IC-43,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,941,Pseudmonas aeruginosa,7/7/14 12:28
1458,67,Novartis,Large Pharma,2599,Pseudomonas aeruginosa vaccine,IC-43,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,941,Pseudmonas aeruginosa,7/7/14 12:28
1460,16,AstraZeneca,Large Pharma,23,Pulmicort,budesonide,Small Molecule (Chemical),Launched,In-House,Jan-83,Jan-81,Dec-09,Expired,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1369,Asthma,7/7/14 12:28
1460,16,AstraZeneca,Large Pharma,23,Pulmicort,budesonide,Small Molecule (Chemical),Launched,In-House,Jan-83,Jan-81,Dec-09,Expired,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,Global,Sales,1310,872,892,866,867,871.41,874.5865,880.006125,885.8794662,891.5699793,897.1346753,902.3725357,0.572898088,1369,Asthma,7/7/14 12:28
1460,16,AstraZeneca,Large Pharma,23,Pulmicort,budesonide,Small Molecule (Chemical),Launched,In-House,Jan-83,Jan-81,Dec-09,Expired,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1369,Asthma,7/7/14 12:28
1460,16,AstraZeneca,Large Pharma,23,Pulmicort,budesonide,Small Molecule (Chemical),Launched,In-House,Jan-83,Jan-81,Dec-09,Expired,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,506,567,613,633,643,659.16,671.224,681.528,691.13056,699.374784,706.625728,713.041129,1.488023533,1369,Asthma,7/7/14 12:28
1460,16,AstraZeneca,Large Pharma,23,Pulmicort,budesonide,Small Molecule (Chemical),Launched,In-House,Jan-83,Jan-81,Dec-09,Expired,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1369,Asthma,7/7/14 12:28
1460,16,AstraZeneca,Large Pharma,23,Pulmicort,budesonide,Small Molecule (Chemical),Launched,In-House,Jan-83,Jan-81,Dec-09,Expired,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,US,Sales,804,305,279,233,224,212.25,203.3625,198.478125,194.7489063,192.1951953,190.5089473,189.3314067,-2.373478218,1369,Asthma,7/7/14 12:28
1461,86,Roche,Large Pharma,1591,Pulmozyme,dornase alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-94,May-94,N/A,N/A,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,943,Cystic Fibrosis,7/7/14 12:28
1461,86,Roche,Large Pharma,1591,Pulmozyme,dornase alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-94,May-94,N/A,N/A,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,5,Global,Sales,461.3188871,495.8206095,553.7300373,577.7160791,625.4575876,640.808061,655.9412137,664.8918684,670.9728613,675.6447321,679.0322955,681.645234,1.23652148,943,Cystic Fibrosis,7/7/14 12:28
1461,86,Roche,Large Pharma,1591,Pulmozyme,dornase alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-94,May-94,N/A,N/A,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,943,Cystic Fibrosis,7/7/14 12:28
1461,86,Roche,Large Pharma,1591,Pulmozyme,dornase alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-94,May-94,N/A,N/A,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,5,ROW,Sales,184.1592364,208.1103912,237.6601179,235.3729841,242.3688853,249.5486913,257.5392384,262.481731,266.8284251,270.4508601,273.2844316,275.6157641,1.853346934,943,Cystic Fibrosis,7/7/14 12:28
1461,86,Roche,Large Pharma,1591,Pulmozyme,dornase alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-94,May-94,N/A,N/A,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,943,Cystic Fibrosis,7/7/14 12:28
1461,86,Roche,Large Pharma,1591,Pulmozyme,dornase alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-94,May-94,N/A,N/A,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,5,US,Sales,277.1596507,287.7102183,316.0699194,342.343095,383.0887023,391.2593696,398.4019753,402.4101374,404.1444362,405.193872,405.7478639,406.0294699,0.834305719,943,Cystic Fibrosis,7/7/14 12:28
1462,1,Abbott,Regional & Specialty Pharma,1562,Pulzium,tedisamil,Small Molecule (Chemical),Approved,Corporate Acquisition,,,N/A,N/A,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1652,Atrial Fibrillation,7/7/14 12:28
1462,1,Abbott,Regional & Specialty Pharma,1562,Pulzium,tedisamil,Small Molecule (Chemical),Approved,Corporate Acquisition,,,N/A,N/A,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1652,Atrial Fibrillation,7/7/14 12:28
1462,1,Abbott,Regional & Specialty Pharma,1562,Pulzium,tedisamil,Small Molecule (Chemical),Approved,Corporate Acquisition,,,N/A,N/A,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1652,Atrial Fibrillation,7/7/14 12:28
1462,1,Abbott,Regional & Specialty Pharma,1562,Pulzium,tedisamil,Small Molecule (Chemical),Approved,Corporate Acquisition,,,N/A,N/A,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1652,Atrial Fibrillation,7/7/14 12:28
1462,1,Abbott,Regional & Specialty Pharma,1562,Pulzium,tedisamil,Small Molecule (Chemical),Approved,Corporate Acquisition,,,N/A,N/A,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1652,Atrial Fibrillation,7/7/14 12:28
1462,1,Abbott,Regional & Specialty Pharma,1562,Pulzium,tedisamil,Small Molecule (Chemical),Approved,Corporate Acquisition,,,N/A,N/A,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1652,Atrial Fibrillation,7/7/14 12:28
1467,67,Novartis,Large Pharma,831,QAX576,QAX576,Antibody/Antibody Derivative,Phase II,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,946,Perianal Fistula,7/7/14 12:28
1467,67,Novartis,Large Pharma,831,QAX576,QAX576,Antibody/Antibody Derivative,Phase II,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,946,Perianal Fistula,7/7/14 12:28
1467,67,Novartis,Large Pharma,831,QAX576,QAX576,Antibody/Antibody Derivative,Phase II,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,946,Perianal Fistula,7/7/14 12:28
1467,67,Novartis,Large Pharma,831,QAX576,QAX576,Antibody/Antibody Derivative,Phase II,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,946,Perianal Fistula,7/7/14 12:28
1467,67,Novartis,Large Pharma,831,QAX576,QAX576,Antibody/Antibody Derivative,Phase II,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,946,Perianal Fistula,7/7/14 12:28
1467,67,Novartis,Large Pharma,831,QAX576,QAX576,Antibody/Antibody Derivative,Phase II,In-House,,,,,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,946,Perianal Fistula,7/7/14 12:28
1468,19,Bayer,Large Pharma,347,Natazia / Qlaira,oestradiol valerate + dienogest,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-10,May-09,Oct-16,May-19,89,Contraceptives,3,Contraception,2,Genitourinary,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,948,Female contraception,7/7/14 12:28
1468,19,Bayer,Large Pharma,347,Natazia / Qlaira,oestradiol valerate + dienogest,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-10,May-09,Oct-16,May-19,89,Contraceptives,3,Contraception,2,Genitourinary,2,Global,Sales,13.31156153,43.65186404,108.4061645,178.0982128,244.0536317,287.5642689,324.5276414,310.0386902,180.484868,186.7933841,127.5277239,63.39638244,-17.51622269,948,Female contraception,7/7/14 12:28
1468,19,Bayer,Large Pharma,347,Natazia / Qlaira,oestradiol valerate + dienogest,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-10,May-09,Oct-16,May-19,89,Contraceptives,3,Contraception,2,Genitourinary,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,948,Female contraception,7/7/14 12:28
1468,19,Bayer,Large Pharma,347,Natazia / Qlaira,oestradiol valerate + dienogest,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-10,May-09,Oct-16,May-19,89,Contraceptives,3,Contraception,2,Genitourinary,2,ROW,Sales,13.31156153,28.32248812,53.41973421,84.60807974,107.7431479,126.9478679,144.1818184,158.0136576,169.9589441,180.135683,122.6643765,59.78396897,-8.07016575,948,Female contraception,7/7/14 12:28
1468,19,Bayer,Large Pharma,347,Natazia / Qlaira,oestradiol valerate + dienogest,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-10,May-09,Oct-16,May-19,89,Contraceptives,3,Contraception,2,Genitourinary,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,948,Female contraception,7/7/14 12:28
1468,19,Bayer,Large Pharma,347,Natazia / Qlaira,oestradiol valerate + dienogest,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-10,May-09,Oct-16,May-19,89,Contraceptives,3,Contraception,2,Genitourinary,2,US,Sales,0,15.32937592,54.98643026,93.49013306,136.3104838,160.616401,180.345823,152.0250326,10.52592383,6.657701162,4.863347407,3.612413474,-40.46767768,948,Female contraception,7/7/14 12:28
1469,110,Vivus,Small Biotech,4620,Qsymia,phentermine + topiramate,Small Molecule (Chemical),Launched,In-House,Sep-12,,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,6,Global,Sales,0,0,0,2,23.7,75,107.26275,139.5379875,172.0067869,201.1393557,228.8251303,254.9939063,40.40972975,949,Obesity,7/7/14 12:28
1469,110,Vivus,Small Biotech,4620,Qsymia,phentermine + topiramate,Small Molecule (Chemical),Launched,In-House,Sep-12,,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,949,Obesity,7/7/14 12:28
1469,110,Vivus,Small Biotech,4620,Qsymia,phentermine + topiramate,Small Molecule (Chemical),Launched,In-House,Sep-12,,N/A,N/A,80,Obesity Treatments,38,Obesity,8,Metabolism,6,US,Sales,0,0,0,2,23.7,75,107.26275,139.5379875,172.0067869,201.1393557,228.8251303,254.9939063,40.40972975,949,Obesity,7/7/14 12:28
1470,66,NeurogesX,Small Biotech,266,Qutenza,capsaicin,Small Molecule (Chemical),Launched,In-House,Apr-10,,N/A,N/A,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0.688,2.6,2.8,1.2,0.4,5.55E-17,0,0,0,0,0,-100,1377,Post-herpetic Neuralgia,7/7/14 12:28
1470,66,NeurogesX,Small Biotech,266,Qutenza,capsaicin,Small Molecule (Chemical),Launched,In-House,Apr-10,,N/A,N/A,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1377,Post-herpetic Neuralgia,7/7/14 12:28
1470,66,NeurogesX,Small Biotech,266,Qutenza,capsaicin,Small Molecule (Chemical),Launched,In-House,Apr-10,,N/A,N/A,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0.688,2.6,2.8,1.2,0.4,5.55E-17,0,0,0,0,0,-100,1377,Post-herpetic Neuralgia,7/7/14 12:28
1471,102,Teva,Regional & Specialty Pharma,1707,QVAR,beclomethasone,Small Molecule (Chemical),Launched,Acquisition (Marketed),Oct-00,Jun-98,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1358,Asthma,7/7/14 12:28
1471,102,Teva,Regional & Specialty Pharma,1707,QVAR,beclomethasone,Small Molecule (Chemical),Launched,Acquisition (Marketed),Oct-00,Jun-98,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,Global,Sales,202,250,305,297,328,344.35,355.1785,365.695675,373.0835163,378.6733302,383.0345671,386.2850877,2.364110815,1358,Asthma,7/7/14 12:28
1471,102,Teva,Regional & Specialty Pharma,1707,QVAR,beclomethasone,Small Molecule (Chemical),Launched,Acquisition (Marketed),Oct-00,Jun-98,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1358,Asthma,7/7/14 12:28
1471,102,Teva,Regional & Specialty Pharma,1707,QVAR,beclomethasone,Small Molecule (Chemical),Launched,Acquisition (Marketed),Oct-00,Jun-98,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,65,57,52,41,37,35.11,33.8065,33.200875,32.87931625,32.69836619,32.60594589,32.55650382,-1.811121665,1358,Asthma,7/7/14 12:28
1471,102,Teva,Regional & Specialty Pharma,1707,QVAR,beclomethasone,Small Molecule (Chemical),Launched,Acquisition (Marketed),Oct-00,Jun-98,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1358,Asthma,7/7/14 12:28
1471,102,Teva,Regional & Specialty Pharma,1707,QVAR,beclomethasone,Small Molecule (Chemical),Launched,Acquisition (Marketed),Oct-00,Jun-98,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,US,Sales,137,193,253,256,291,309.24,321.372,332.4948,340.2042,345.974964,350.4286212,353.7285839,2.827910688,1358,Asthma,7/7/14 12:28
1472,86,Roche,Large Pharma,2645,gantenerumab,RG1450,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1480,Alzheimer's Disease,7/7/14 12:28
1472,86,Roche,Large Pharma,2645,gantenerumab,RG1450,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1480,Alzheimer's Disease,7/7/14 12:28
1472,86,Roche,Large Pharma,2645,gantenerumab,RG1450,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1480,Alzheimer's Disease,7/7/14 12:28
1472,86,Roche,Large Pharma,2645,gantenerumab,RG1450,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1480,Alzheimer's Disease,7/7/14 12:28
1472,86,Roche,Large Pharma,2645,gantenerumab,RG1450,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1480,Alzheimer's Disease,7/7/14 12:28
1472,86,Roche,Large Pharma,2645,gantenerumab,RG1450,Antibody/Antibody Derivative,Phase III,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1480,Alzheimer's Disease,7/7/14 12:28
1476,86,Roche,Large Pharma,1836,RG1512,Inclacumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,975,CV Disease - P selectin huMAb,7/7/14 12:28
1476,86,Roche,Large Pharma,1836,RG1512,Inclacumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,975,CV Disease - P selectin huMAb,7/7/14 12:28
1476,86,Roche,Large Pharma,1836,RG1512,Inclacumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,975,CV Disease - P selectin huMAb,7/7/14 12:28
1476,86,Roche,Large Pharma,1836,RG1512,Inclacumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,975,CV Disease - P selectin huMAb,7/7/14 12:28
1476,86,Roche,Large Pharma,1836,RG1512,Inclacumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,975,CV Disease - P selectin huMAb,7/7/14 12:28
1476,86,Roche,Large Pharma,1836,RG1512,Inclacumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,975,CV Disease - P selectin huMAb,7/7/14 12:28
1477,86,Roche,Large Pharma,1857,RG1578,RG1578,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,976,Depression,7/7/14 12:28
1477,86,Roche,Large Pharma,1857,RG1578,RG1578,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,976,Depression,7/7/14 12:28
1477,86,Roche,Large Pharma,1857,RG1578,RG1578,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,976,Depression,7/7/14 12:28
1477,86,Roche,Large Pharma,1857,RG1578,RG1578,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,976,Depression,7/7/14 12:28
1477,86,Roche,Large Pharma,1857,RG1578,RG1578,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,976,Depression,7/7/14 12:28
1477,86,Roche,Large Pharma,1857,RG1578,RG1578,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,976,Depression,7/7/14 12:28
1480,29,Chugai,Regional & Specialty Pharma,4301,bitopertin,bitopertin,Small Molecule (Chemical),Phase III,Licensed (Development),,Jan-17,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,30.74689339,51.24482231,61.49378678,71.74275124,0,1486,Schizophrenia,7/7/14 12:28
1480,29,Chugai,Regional & Specialty Pharma,4301,bitopertin,bitopertin,Small Molecule (Chemical),Phase III,Licensed (Development),,Jan-17,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,30.74689339,51.24482231,61.49378678,71.74275124,0,1486,Schizophrenia,7/7/14 12:28
1480,29,Chugai,Regional & Specialty Pharma,4301,bitopertin,bitopertin,Small Molecule (Chemical),Phase III,Licensed (Development),,Jan-17,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1486,Schizophrenia,7/7/14 12:28
1481,86,Roche,Large Pharma,4301,bitopertin,bitopertin,Small Molecule (Chemical),Phase III,In-House,May-16,Oct-16,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1486,Schizophrenia,7/7/14 12:28
1481,86,Roche,Large Pharma,4301,bitopertin,bitopertin,Small Molecule (Chemical),Phase III,In-House,May-16,Oct-16,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,5,Global,Sales,0,0,0,0,0,0,0,134.1710263,388.896425,588.5295964,777.9143425,923.1791064,0,1486,Schizophrenia,7/7/14 12:28
1481,86,Roche,Large Pharma,4301,bitopertin,bitopertin,Small Molecule (Chemical),Phase III,In-House,May-16,Oct-16,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1486,Schizophrenia,7/7/14 12:28
1481,86,Roche,Large Pharma,4301,bitopertin,bitopertin,Small Molecule (Chemical),Phase III,In-House,May-16,Oct-16,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,5,ROW,Sales,0,0,0,0,0,0,0,26.97807762,156.6446789,249.0843794,331.2757204,387.9272816,0,1486,Schizophrenia,7/7/14 12:28
1481,86,Roche,Large Pharma,4301,bitopertin,bitopertin,Small Molecule (Chemical),Phase III,In-House,May-16,Oct-16,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1486,Schizophrenia,7/7/14 12:28
1481,86,Roche,Large Pharma,4301,bitopertin,bitopertin,Small Molecule (Chemical),Phase III,In-House,May-16,Oct-16,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,5,US,Sales,0,0,0,0,0,0,0,107.1929487,232.2517461,339.445217,446.6386221,535.2518248,0,1486,Schizophrenia,7/7/14 12:28
1483,690,Transgene,Small Biotech,3469,TG4001,MVA-HPV-IL2,Vaccine,Phase II,In-House,,,N/A,N/A,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,978,Cervical Intraepithelial Neoplasia,7/7/14 12:28
1483,690,Transgene,Small Biotech,3469,TG4001,MVA-HPV-IL2,Vaccine,Phase II,In-House,,,N/A,N/A,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,978,Cervical Intraepithelial Neoplasia,7/7/14 12:28
1483,690,Transgene,Small Biotech,3469,TG4001,MVA-HPV-IL2,Vaccine,Phase II,In-House,,,N/A,N/A,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,978,Cervical Intraepithelial Neoplasia,7/7/14 12:28
1483,690,Transgene,Small Biotech,3469,TG4001,MVA-HPV-IL2,Vaccine,Phase II,In-House,,,N/A,N/A,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,978,Cervical Intraepithelial Neoplasia,7/7/14 12:28
1483,690,Transgene,Small Biotech,3469,TG4001,MVA-HPV-IL2,Vaccine,Phase II,In-House,,,N/A,N/A,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,978,Cervical Intraepithelial Neoplasia,7/7/14 12:28
1483,690,Transgene,Small Biotech,3469,TG4001,MVA-HPV-IL2,Vaccine,Phase II,In-House,,,N/A,N/A,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,978,Cervical Intraepithelial Neoplasia,7/7/14 12:28
1485,86,Roche,Large Pharma,4268,Erivedge,vismodegib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-12,Jul-13,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,980,Basal Cell Carcinoma,7/7/14 12:28
1485,86,Roche,Large Pharma,4268,Erivedge,vismodegib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-12,Jul-13,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,Global,Sales,0,0,0,30.92819238,80.93423287,125.6099618,167.0478779,192.3077927,208.6257651,220.3463386,228.3100931,233.8132194,16.3642241,980,Basal Cell Carcinoma,7/7/14 12:28
1485,86,Roche,Large Pharma,4268,Erivedge,vismodegib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-12,Jul-13,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,980,Basal Cell Carcinoma,7/7/14 12:28
1485,86,Roche,Large Pharma,4268,Erivedge,vismodegib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-12,Jul-13,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,ROW,Sales,0,0,0,0,9.712107945,25.89898689,38.84848034,51.79784429,59.95598777,66.28825554,71.21032537,74.80573173,33.86285082,980,Basal Cell Carcinoma,7/7/14 12:28
1485,86,Roche,Large Pharma,4268,Erivedge,vismodegib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-12,Jul-13,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,980,Basal Cell Carcinoma,7/7/14 12:28
1485,86,Roche,Large Pharma,4268,Erivedge,vismodegib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-12,Jul-13,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,US,Sales,0,0,0,30.92819238,71.22212493,99.7109749,128.1993975,140.5099485,148.6697773,154.058083,157.0997677,159.0074877,12.15764972,980,Basal Cell Carcinoma,7/7/14 12:28
1492,86,Roche,Large Pharma,3508,mericitabine,RG7128,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,989,Hepatitis C,7/7/14 12:28
1492,86,Roche,Large Pharma,3508,mericitabine,RG7128,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,989,Hepatitis C,7/7/14 12:28
1492,86,Roche,Large Pharma,3508,mericitabine,RG7128,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,989,Hepatitis C,7/7/14 12:28
1492,86,Roche,Large Pharma,3508,mericitabine,RG7128,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,989,Hepatitis C,7/7/14 12:28
1492,86,Roche,Large Pharma,3508,mericitabine,RG7128,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,989,Hepatitis C,7/7/14 12:28
1492,86,Roche,Large Pharma,3508,mericitabine,RG7128,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,989,Hepatitis C,7/7/14 12:28
1496,86,Roche,Large Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Launched,Licensed (Development),Sep-11,Jan-12,Jun-29,Jun-26,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,992,Melanoma,7/7/14 12:28
1496,86,Roche,Large Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Launched,Licensed (Development),Sep-11,Jan-12,Jun-29,Jun-26,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,Global,Sales,0,0,33.79053809,249.5585178,382.0095792,459.5298554,474.2749302,447.5192089,412.1139683,391.3311425,374.8743122,352.5322052,-1.14063944,992,Melanoma,7/7/14 12:28
1496,86,Roche,Large Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Launched,Licensed (Development),Sep-11,Jan-12,Jun-29,Jun-26,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,992,Melanoma,7/7/14 12:28
1496,86,Roche,Large Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Launched,Licensed (Development),Sep-11,Jan-12,Jun-29,Jun-26,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,ROW,Sales,0,0,0,130.1117059,249.2774372,289.4835547,307.6637773,299.2989308,279.7358617,264.7269228,250.6480436,237.0532377,-0.715736095,992,Melanoma,7/7/14 12:28
1496,86,Roche,Large Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Launched,Licensed (Development),Sep-11,Jan-12,Jun-29,Jun-26,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,992,Melanoma,7/7/14 12:28
1496,86,Roche,Large Pharma,3737,Zelboraf,vemurafenib,Small Molecule (Chemical),Launched,Licensed (Development),Sep-11,Jan-12,Jun-29,Jun-26,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,US,Sales,0,0,33.79053809,119.446812,132.7321419,170.0463007,166.6111529,148.220278,132.3781066,126.6042198,124.2262686,115.4789675,-1.969553983,992,Melanoma,7/7/14 12:28
1497,86,Roche,Large Pharma,3101,danoprevir,danoprevir,Small Molecule (Chemical),Phase II,Licensed (Development),,Nov-17,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,993,Hepatitis C,7/7/14 12:28
1497,86,Roche,Large Pharma,3101,danoprevir,danoprevir,Small Molecule (Chemical),Phase II,Licensed (Development),,Nov-17,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,5,Global,Sales,0,0,0,0,0,0,0,0,6.329057011,24.54572864,34.61708656,41.00667799,0,993,Hepatitis C,7/7/14 12:28
1497,86,Roche,Large Pharma,3101,danoprevir,danoprevir,Small Molecule (Chemical),Phase II,Licensed (Development),,Nov-17,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,993,Hepatitis C,7/7/14 12:28
1497,86,Roche,Large Pharma,3101,danoprevir,danoprevir,Small Molecule (Chemical),Phase II,Licensed (Development),,Nov-17,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,5,ROW,Sales,0,0,0,0,0,0,0,0,6.329057011,24.54572864,34.61708656,41.00667799,0,993,Hepatitis C,7/7/14 12:28
1497,86,Roche,Large Pharma,3101,danoprevir,danoprevir,Small Molecule (Chemical),Phase II,Licensed (Development),,Nov-17,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,993,Hepatitis C,7/7/14 12:28
1497,86,Roche,Large Pharma,3101,danoprevir,danoprevir,Small Molecule (Chemical),Phase II,Licensed (Development),,Nov-17,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,993,Hepatitis C,7/7/14 12:28
1500,29,Chugai,Regional & Specialty Pharma,1870,RG7304,CKI27,Small Molecule (Chemical),Phase I,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1395,Solid Tumors,7/7/14 12:28
1500,29,Chugai,Regional & Specialty Pharma,1870,RG7304,CKI27,Small Molecule (Chemical),Phase I,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1395,Solid Tumors,7/7/14 12:28
1500,29,Chugai,Regional & Specialty Pharma,1870,RG7304,CKI27,Small Molecule (Chemical),Phase I,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1395,Solid Tumors,7/7/14 12:28
1501,86,Roche,Large Pharma,1870,RG7304,CKI27,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1395,Solid Tumors,7/7/14 12:28
1501,86,Roche,Large Pharma,1870,RG7304,CKI27,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1395,Solid Tumors,7/7/14 12:28
1501,86,Roche,Large Pharma,1870,RG7304,CKI27,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1395,Solid Tumors,7/7/14 12:28
1501,86,Roche,Large Pharma,1870,RG7304,CKI27,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1395,Solid Tumors,7/7/14 12:28
1501,86,Roche,Large Pharma,1870,RG7304,CKI27,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1395,Solid Tumors,7/7/14 12:28
1501,86,Roche,Large Pharma,1870,RG7304,CKI27,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1395,Solid Tumors,7/7/14 12:28
1506,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1543,Radicut,edaravone,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-01,N/A,Jun-11,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1437,Stroke recovery,7/7/14 12:28
1506,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1543,Radicut,edaravone,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-01,N/A,Jun-11,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,Global,Sales,301.6512714,335.0103305,283.6211927,166.2781749,121.5042223,93.06468066,70.9982637,57.15317361,45.61494653,37.01339216,30.69463416,25.86613973,-19.82847742,1437,Stroke recovery,7/7/14 12:28
1506,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1543,Radicut,edaravone,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-01,N/A,Jun-11,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1437,Stroke recovery,7/7/14 12:28
1506,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1543,Radicut,edaravone,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-01,N/A,Jun-11,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,ROW,Sales,301.6512714,335.0103305,283.6211927,166.2781749,121.5042223,93.06468066,70.9982637,57.15317361,45.61494653,37.01339216,30.69463416,25.86613973,-19.82847742,1437,Stroke recovery,7/7/14 12:28
1506,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1543,Radicut,edaravone,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-01,N/A,Jun-11,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1437,Stroke recovery,7/7/14 12:28
1506,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1543,Radicut,edaravone,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-01,N/A,Jun-11,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1437,Stroke recovery,7/7/14 12:28
1507,67,Novartis,Large Pharma,934,RAF265,RAF265,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,953,Melanoma,7/7/14 12:28
1507,67,Novartis,Large Pharma,934,RAF265,RAF265,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,953,Melanoma,7/7/14 12:28
1507,67,Novartis,Large Pharma,934,RAF265,RAF265,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,953,Melanoma,7/7/14 12:28
1507,67,Novartis,Large Pharma,934,RAF265,RAF265,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,953,Melanoma,7/7/14 12:28
1507,67,Novartis,Large Pharma,934,RAF265,RAF265,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,953,Melanoma,7/7/14 12:28
1507,67,Novartis,Large Pharma,934,RAF265,RAF265,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,953,Melanoma,7/7/14 12:28
1508,61,Merck & Co,Large Pharma,2473,Grastek,SCH-900237,Vaccine,Approved,Licensed (Development),Jul-14,,Dec-24,N/A,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,500,Grass Pollen Allergy,7/7/14 12:28
1508,61,Merck & Co,Large Pharma,2473,Grastek,SCH-900237,Vaccine,Approved,Licensed (Development),Jul-14,,Dec-24,N/A,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,Global,Sales,0,0,0,0,0,10,26.6667,40.00005,53.33326667,64.53322933,74.3465224,83.09314533,0,500,Grass Pollen Allergy,7/7/14 12:28
1508,61,Merck & Co,Large Pharma,2473,Grastek,SCH-900237,Vaccine,Approved,Licensed (Development),Jul-14,,Dec-24,N/A,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,500,Grass Pollen Allergy,7/7/14 12:28
1508,61,Merck & Co,Large Pharma,2473,Grastek,SCH-900237,Vaccine,Approved,Licensed (Development),Jul-14,,Dec-24,N/A,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,500,Grass Pollen Allergy,7/7/14 12:28
1508,61,Merck & Co,Large Pharma,2473,Grastek,SCH-900237,Vaccine,Approved,Licensed (Development),Jul-14,,Dec-24,N/A,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,500,Grass Pollen Allergy,7/7/14 12:28
1508,61,Merck & Co,Large Pharma,2473,Grastek,SCH-900237,Vaccine,Approved,Licensed (Development),Jul-14,,Dec-24,N/A,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,US,Sales,0,0,0,0,0,10,26.6667,40.00005,53.33326667,64.53322933,74.3465224,83.09314533,0,500,Grass Pollen Allergy,7/7/14 12:28
1509,45,CV Therapeutics,Regional & Specialty Pharma,1655,Ranexa,ranolazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-06,,May-19,N/A,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Proforma,35.5,0,0,0,0,0,0,0,0,0,0,0,0,1610,Angina,7/7/14 12:28
1509,45,CV Therapeutics,Regional & Specialty Pharma,1655,Ranexa,ranolazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-06,,May-19,N/A,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Proforma,35.5,0,0,0,0,0,0,0,0,0,0,0,0,1610,Angina,7/7/14 12:28
1509,45,Gilead,Regional & Specialty Pharma,1655,Ranexa,ranolazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-06,,May-19,N/A,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1610,Angina,7/7/14 12:28
1509,45,Gilead,Regional & Specialty Pharma,1655,Ranexa,ranolazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-06,,May-19,N/A,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Sales,95.9,239.83,320,372.95,448.62,509.0771,591.2044194,658.834938,722.7818378,783.2994372,461.303682,226.0471119,-9.327753577,1610,Angina,7/7/14 12:28
1509,45,Gilead,Regional & Specialty Pharma,1655,Ranexa,ranolazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-06,,May-19,N/A,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1610,Angina,7/7/14 12:28
1509,45,Gilead,Regional & Specialty Pharma,1655,Ranexa,ranolazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-06,,May-19,N/A,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1610,Angina,7/7/14 12:28
1509,45,Gilead,Regional & Specialty Pharma,1655,Ranexa,ranolazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-06,,May-19,N/A,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1610,Angina,7/7/14 12:28
1509,45,Gilead,Regional & Specialty Pharma,1655,Ranexa,ranolazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-06,,May-19,N/A,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Sales,95.9,239.83,320,372.95,448.62,509.0771,591.2044194,658.834938,722.7818378,783.2994372,461.303682,226.0471119,-9.327753577,1610,Angina,7/7/14 12:28
1510,111,Actavis,Regional & Specialty Pharma,29,Rapaflo,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,Mar-12,Dec-18,,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1633,Symptoms associated with BPH,7/7/14 12:28
1510,111,Actavis,Regional & Specialty Pharma,29,Rapaflo,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,Mar-12,Dec-18,,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,Global,Sales,15,34,49.11096,99,131.5944656,156.8176014,180.4378603,198.5650346,213.4010389,211.4199733,45.13833586,43.15452084,-14.7239604,1633,Symptoms associated with BPH,7/7/14 12:28
1510,111,Actavis,Regional & Specialty Pharma,29,Rapaflo,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,Mar-12,Dec-18,,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1633,Symptoms associated with BPH,7/7/14 12:28
1510,111,Actavis,Regional & Specialty Pharma,29,Rapaflo,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,Mar-12,Dec-18,,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,ROW,Sales,0,0,0,2,12,17.14284,22.285692,26.5656866,29.86368123,32.6367775,34.89913931,36.7350354,17.33135993,1633,Symptoms associated with BPH,7/7/14 12:28
1510,111,Actavis,Regional & Specialty Pharma,29,Rapaflo,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,Mar-12,Dec-18,,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1633,Symptoms associated with BPH,7/7/14 12:28
1510,111,Actavis,Regional & Specialty Pharma,29,Rapaflo,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,Mar-12,Dec-18,,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,US,Sales,15,34,49.11096,97,119.5944656,139.6747614,158.1521683,171.999348,183.5373577,178.7831958,10.23919655,6.419485433,-34.15216712,1633,Symptoms associated with BPH,7/7/14 12:28
1511,76,Pfizer,Large Pharma,1474,Rapamune,sirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Apr-01,Jan-14,Sep-14,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1635,Transplant Rejection,7/7/14 12:28
1511,76,Pfizer,Large Pharma,1474,Rapamune,sirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Apr-01,Jan-14,Sep-14,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Sales,63.13,388,372,346,349.8,273.948,244.3036,216.0276,198.221376,187.41848,187.1800461,187.0272143,-8.556037081,1635,Transplant Rejection,7/7/14 12:28
1511,76,Pfizer,Large Pharma,1474,Rapamune,sirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Apr-01,Jan-14,Sep-14,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1635,Transplant Rejection,7/7/14 12:28
1511,76,Pfizer,Large Pharma,1474,Rapamune,sirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Apr-01,Jan-14,Sep-14,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Sales,23.03,191,184,161,149,121.788,111.0848,102.2436,94.381056,93.7114304,93.3102016,93.06589645,-6.502361263,1635,Transplant Rejection,7/7/14 12:28
1511,76,Pfizer,Large Pharma,1474,Rapamune,sirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Apr-01,Jan-14,Sep-14,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1635,Transplant Rejection,7/7/14 12:28
1511,76,Pfizer,Large Pharma,1474,Rapamune,sirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Apr-01,Jan-14,Sep-14,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Sales,40.1,197,188,185,200.8,152.16,133.2188,113.784,103.84032,93.7070496,93.86984448,93.96131789,-10.28115492,1635,Transplant Rejection,7/7/14 12:28
1511,76,Wyeth,Large Pharma,1474,Rapamune,sirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Apr-01,Jan-14,Sep-14,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Proforma,314.5,0,0,0,0,0,0,0,0,0,0,0,0,1635,Transplant Rejection,7/7/14 12:28
1511,76,Wyeth,Large Pharma,1474,Rapamune,sirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Apr-01,Jan-14,Sep-14,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Proforma,162.8,0,0,0,0,0,0,0,0,0,0,0,0,1635,Transplant Rejection,7/7/14 12:28
1511,76,Wyeth,Large Pharma,1474,Rapamune,sirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Apr-01,Jan-14,Sep-14,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Proforma,151.7,0,0,0,0,0,0,0,0,0,0,0,0,1635,Transplant Rejection,7/7/14 12:28
1512,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2193,Abstral,fentanyl - sublingual,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Aug-08,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,596,Cancer Pain,7/7/14 12:28
1512,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2193,Abstral,fentanyl - sublingual,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Aug-08,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,3,Global,Sales,1.19E-15,0,21.95070707,55.07038898,68.09027723,92.24068016,106.7063247,119.5188626,128.8644884,135.7103102,140.983774,144.9195361,11.39432652,596,Cancer Pain,7/7/14 12:28
1512,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2193,Abstral,fentanyl - sublingual,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Aug-08,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,596,Cancer Pain,7/7/14 12:28
1512,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2193,Abstral,fentanyl - sublingual,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Aug-08,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,3,ROW,Sales,1.19E-15,0,15.67907648,41.20521173,68.09027723,92.24068016,106.7063247,119.5188626,128.8644884,135.7103102,140.983774,144.9195361,11.39432652,596,Cancer Pain,7/7/14 12:28
1512,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2193,Abstral,fentanyl - sublingual,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Aug-08,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,596,Cancer Pain,7/7/14 12:28
1512,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2193,Abstral,fentanyl - sublingual,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Aug-08,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,3,US,Sales,0,0,6.271630593,13.86517726,0,0,0,0,0,0,0,0,0,596,Cancer Pain,7/7/14 12:28
1512,56,Prostrakan,Regional & Specialty Pharma,2193,Abstral,fentanyl - sublingual,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Aug-08,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,3,Global,Proforma,8.54977169,26.20908392,21.32354401,0,0,0,0,0,0,0,0,0,0,596,Cancer Pain,7/7/14 12:28
1512,56,Prostrakan,Regional & Specialty Pharma,2193,Abstral,fentanyl - sublingual,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Aug-08,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,3,ROW,Proforma,8.54977169,26.20908392,15.05191342,0,0,0,0,0,0,0,0,0,0,596,Cancer Pain,7/7/14 12:28
1512,56,Prostrakan,Regional & Specialty Pharma,2193,Abstral,fentanyl - sublingual,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Aug-08,N/A,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,3,US,Proforma,0,0,6.271630593,0,0,0,0,0,0,0,0,0,0,596,Cancer Pain,7/7/14 12:28
1515,53,Johnson & Johnson,Large Pharma,617,Razadyne / Reminyl,galantamine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-01,Nov-00,Sep-08,Aug-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,956,Alzheimer's Disease,7/7/14 12:28
1515,53,Johnson & Johnson,Large Pharma,617,Razadyne / Reminyl,galantamine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-01,Nov-00,Sep-08,Aug-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,415,414,421.71,197,126.6368,84.324288,68.49175808,55.48205281,51.47919877,47.39835392,44.47410458,42.78883089,-14.35903224,956,Alzheimer's Disease,7/7/14 12:28
1515,53,Johnson & Johnson,Large Pharma,617,Razadyne / Reminyl,galantamine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-01,Nov-00,Sep-08,Aug-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,956,Alzheimer's Disease,7/7/14 12:28
1515,53,Johnson & Johnson,Large Pharma,617,Razadyne / Reminyl,galantamine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-01,Nov-00,Sep-08,Aug-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,379,399,410.35,187,117,74.8,59,46,42,37.92,34.996,33.3108,-16.42870986,956,Alzheimer's Disease,7/7/14 12:28
1515,53,Johnson & Johnson,Large Pharma,617,Razadyne / Reminyl,galantamine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-01,Nov-00,Sep-08,Aug-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,956,Alzheimer's Disease,7/7/14 12:28
1515,53,Johnson & Johnson,Large Pharma,617,Razadyne / Reminyl,galantamine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-01,Nov-00,Sep-08,Aug-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,36,15,11.36,10,9.6368,9.524288,9.49175808,9.482052813,9.479198773,9.478353916,9.478104578,9.478030889,-0.237040103,956,Alzheimer's Disease,7/7/14 12:28
1516,61,Merck & Co,Large Pharma,1444,Rebetol,ribavirin,Small Molecule (Chemical),Launched,In-House,Oct-01,Oct-98,Apr-04,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1735,Hepatitis C,7/7/14 12:28
1516,61,Merck & Co,Large Pharma,1444,Rebetol,ribavirin,Small Molecule (Chemical),Launched,In-House,Oct-01,Oct-98,Apr-04,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,Global,Sales,35.9,220.83625,173.7610625,143.7338906,114.8550014,92.77436304,73.66615538,58.22138283,45.26429863,34.61368016,25.76082495,18.44703199,-22.9913294,1735,Hepatitis C,7/7/14 12:28
1516,61,Merck & Co,Large Pharma,1444,Rebetol,ribavirin,Small Molecule (Chemical),Launched,In-House,Oct-01,Oct-98,Apr-04,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1735,Hepatitis C,7/7/14 12:28
1516,61,Merck & Co,Large Pharma,1444,Rebetol,ribavirin,Small Molecule (Chemical),Launched,In-House,Oct-01,Oct-98,Apr-04,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,35.9,220,173,143,114.125,92.046875,72.93945313,57.49487305,44.53787231,33.88727951,25.03443193,17.72064179,-23.36224384,1735,Hepatitis C,7/7/14 12:28
1516,61,Merck & Co,Large Pharma,1444,Rebetol,ribavirin,Small Molecule (Chemical),Launched,In-House,Oct-01,Oct-98,Apr-04,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1735,Hepatitis C,7/7/14 12:28
1516,61,Merck & Co,Large Pharma,1444,Rebetol,ribavirin,Small Molecule (Chemical),Launched,In-House,Oct-01,Oct-98,Apr-04,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0.83625,0.7610625,0.733890625,0.730001406,0.727488039,0.726702257,0.726509782,0.726426318,0.726400654,0.726393018,0.726390197,-7.08E-02,1735,Hepatitis C,7/7/14 12:28
1516,61,Schering-Plough,Large Pharma,1444,Rebetol,ribavirin,Small Molecule (Chemical),Launched,In-House,Oct-01,Oct-98,Apr-04,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,Global,Proforma,217.95,0,0,0,0,0,0,0,0,0,0,0,0,1735,Hepatitis C,7/7/14 12:28
1516,61,Schering-Plough,Large Pharma,1444,Rebetol,ribavirin,Small Molecule (Chemical),Launched,In-House,Oct-01,Oct-98,Apr-04,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,ROW,Proforma,217.1,0,0,0,0,0,0,0,0,0,0,0,0,1735,Hepatitis C,7/7/14 12:28
1516,61,Schering-Plough,Large Pharma,1444,Rebetol,ribavirin,Small Molecule (Chemical),Launched,In-House,Oct-01,Oct-98,Apr-04,Jul-09,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,US,Proforma,0.85,0,0,0,0,0,0,0,0,0,0,0,0,1735,Hepatitis C,7/7/14 12:28
1517,63,Merck KGaA,Regional & Specialty Pharma,1037,Rebif,interferon-beta 1a,Recombinant Protein,Launched,Corporate Acquisition,Mar-02,May-98,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1500,Multiple Sclerosis,7/7/14 12:28
1517,63,Merck KGaA,Regional & Specialty Pharma,1037,Rebif,interferon-beta 1a,Recombinant Protein,Launched,Corporate Acquisition,Mar-02,May-98,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Sales,2135.659045,2210.220925,2351.507118,2432.504512,2476.417506,2361.932018,2319.217883,2280.630432,2252.19963,2223.591197,2162.5824,2119.228292,-2.200580293,1500,Multiple Sclerosis,7/7/14 12:28
1517,63,Merck KGaA,Regional & Specialty Pharma,1037,Rebif,interferon-beta 1a,Recombinant Protein,Launched,Corporate Acquisition,Mar-02,May-98,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1500,Multiple Sclerosis,7/7/14 12:28
1517,63,Merck KGaA,Regional & Specialty Pharma,1037,Rebif,interferon-beta 1a,Recombinant Protein,Launched,Corporate Acquisition,Mar-02,May-98,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Sales,1174.68195,1215.330063,1276.699288,1169.46838,1205.8513,1144.019549,1128.645569,1112.430046,1101.217729,1083.701985,1073.419471,1055.760163,-1.881007133,1500,Multiple Sclerosis,7/7/14 12:28
1517,63,Merck KGaA,Regional & Specialty Pharma,1037,Rebif,interferon-beta 1a,Recombinant Protein,Launched,Corporate Acquisition,Mar-02,May-98,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1500,Multiple Sclerosis,7/7/14 12:28
1517,63,Merck KGaA,Regional & Specialty Pharma,1037,Rebif,interferon-beta 1a,Recombinant Protein,Launched,Corporate Acquisition,Mar-02,May-98,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,US,Sales,960.9770953,994.8908623,1074.80783,1263.036132,1270.566206,1217.91247,1190.572315,1168.200387,1150.9819,1139.889212,1089.162929,1063.468128,-2.509783103,1500,Multiple Sclerosis,7/7/14 12:28
1518,76,Pfizer,Large Pharma,1037,Rebif,interferon-beta 1a,Recombinant Protein,Launched,Licensed (Marketed),Mar-02,Jul-95,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Alliance Revenue,307.5,318,344,404.2,406,351,339,0,0,0,0,0,-100,1500,Multiple Sclerosis,7/7/14 12:28
1518,76,Pfizer,Large Pharma,1037,Rebif,interferon-beta 1a,Recombinant Protein,Launched,Licensed (Marketed),Mar-02,Jul-95,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1500,Multiple Sclerosis,7/7/14 12:28
1518,76,Pfizer,Large Pharma,1037,Rebif,interferon-beta 1a,Recombinant Protein,Launched,Licensed (Marketed),Mar-02,Jul-95,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1500,Multiple Sclerosis,7/7/14 12:28
1518,76,Pfizer,Large Pharma,1037,Rebif,interferon-beta 1a,Recombinant Protein,Launched,Licensed (Marketed),Mar-02,Jul-95,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1500,Multiple Sclerosis,7/7/14 12:28
1518,76,Pfizer,Large Pharma,1037,Rebif,interferon-beta 1a,Recombinant Protein,Launched,Licensed (Marketed),Mar-02,Jul-95,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Alliance Revenue,307.5,318,344,404.2,406,351,339,0,0,0,0,0,-100,1500,Multiple Sclerosis,7/7/14 12:28
1518,76,Pfizer,Large Pharma,1037,Rebif,interferon-beta 1a,Recombinant Protein,Launched,Licensed (Marketed),Mar-02,Jul-95,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1500,Multiple Sclerosis,7/7/14 12:28
1519,70,Ono,Regional & Specialty Pharma,1695,Recalbon,minodronate,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-09,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1547,Osteoporosis,7/7/14 12:28
1519,70,Ono,Regional & Specialty Pharma,1695,Recalbon,minodronate,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-09,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,11.75887884,24.55047566,44.37988619,92.69830314,105.7110836,126.4223585,145.5038133,160.4782373,172.6259697,182.6937088,190.8648606,197.5396715,9.342878938,1547,Osteoporosis,7/7/14 12:28
1519,70,Ono,Regional & Specialty Pharma,1695,Recalbon,minodronate,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-09,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1547,Osteoporosis,7/7/14 12:28
1519,70,Ono,Regional & Specialty Pharma,1695,Recalbon,minodronate,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-09,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,11.75887884,24.55047566,44.37988619,92.69830314,105.7110836,126.4223585,145.5038133,160.4782373,172.6259697,182.6937088,190.8648606,197.5396715,9.342878938,1547,Osteoporosis,7/7/14 12:28
1519,70,Ono,Regional & Specialty Pharma,1695,Recalbon,minodronate,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-09,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1547,Osteoporosis,7/7/14 12:28
1519,70,Ono,Regional & Specialty Pharma,1695,Recalbon,minodronate,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-09,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1547,Osteoporosis,7/7/14 12:28
1522,24,Bristol-Myers Squibb,Large Pharma,255,Recothrom,thrombin alfa,Recombinant Protein,Launched,Licensed (Development),Feb-08,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,960,Surgical Hemostasis,7/7/14 12:28
1522,24,Bristol-Myers Squibb,Large Pharma,255,Recothrom,thrombin alfa,Recombinant Protein,Launched,Licensed (Development),Feb-08,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,0,15.016464,65,66,0,0,0,0,0,0,0,0,0,960,Surgical Hemostasis,7/7/14 12:28
1522,24,Bristol-Myers Squibb,Large Pharma,255,Recothrom,thrombin alfa,Recombinant Protein,Launched,Licensed (Development),Feb-08,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,960,Surgical Hemostasis,7/7/14 12:28
1522,24,Bristol-Myers Squibb,Large Pharma,255,Recothrom,thrombin alfa,Recombinant Protein,Launched,Licensed (Development),Feb-08,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,960,Surgical Hemostasis,7/7/14 12:28
1522,24,Bristol-Myers Squibb,Large Pharma,255,Recothrom,thrombin alfa,Recombinant Protein,Launched,Licensed (Development),Feb-08,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,960,Surgical Hemostasis,7/7/14 12:28
1522,24,Bristol-Myers Squibb,Large Pharma,255,Recothrom,thrombin alfa,Recombinant Protein,Launched,Licensed (Development),Feb-08,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,0,15.016464,65,66,0,0,0,0,0,0,0,0,0,960,Surgical Hemostasis,7/7/14 12:28
1522,24,ZymoGenetics,Large Pharma,255,Recothrom,thrombin alfa,Recombinant Protein,Launched,Licensed (Development),Feb-08,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Proforma,29.6,34.1,0,0,0,0,0,0,0,0,0,0,0,960,Surgical Hemostasis,7/7/14 12:28
1522,24,ZymoGenetics,Large Pharma,255,Recothrom,thrombin alfa,Recombinant Protein,Launched,Licensed (Development),Feb-08,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Proforma,29.6,34.1,0,0,0,0,0,0,0,0,0,0,0,960,Surgical Hemostasis,7/7/14 12:28
1523,76,Pfizer,Large Pharma,3948,ReFacto AF / Xyntha,moroctocog alfa,Recombinant Protein,Launched,Corporate Acquisition,Jan-01,May-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1550,Hemophilia A,7/7/14 12:28
1523,76,Pfizer,Large Pharma,3948,ReFacto AF / Xyntha,moroctocog alfa,Recombinant Protein,Launched,Corporate Acquisition,Jan-01,May-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,47.35,404,506,584,602,600.2938859,569.0723074,539.3790183,503.1326282,479.4589242,459.0847508,448.179298,-4.127592632,1550,Hemophilia A,7/7/14 12:28
1523,76,Pfizer,Large Pharma,3948,ReFacto AF / Xyntha,moroctocog alfa,Recombinant Protein,Launched,Corporate Acquisition,Jan-01,May-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1550,Hemophilia A,7/7/14 12:28
1523,76,Pfizer,Large Pharma,3948,ReFacto AF / Xyntha,moroctocog alfa,Recombinant Protein,Launched,Corporate Acquisition,Jan-01,May-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,30.4,324,409,478,479,476.5823592,459.3056354,445.6551982,426.9861672,415.8939216,405.92412,399.3256313,-2.565422227,1550,Hemophilia A,7/7/14 12:28
1523,76,Pfizer,Large Pharma,3948,ReFacto AF / Xyntha,moroctocog alfa,Recombinant Protein,Launched,Corporate Acquisition,Jan-01,May-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1550,Hemophilia A,7/7/14 12:28
1523,76,Pfizer,Large Pharma,3948,ReFacto AF / Xyntha,moroctocog alfa,Recombinant Protein,Launched,Corporate Acquisition,Jan-01,May-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,16.95,80,97,106,123,123.7115267,109.766672,93.72382011,76.14646091,63.56500265,53.16063081,48.85366666,-12.3578127,1550,Hemophilia A,7/7/14 12:28
1523,76,Wyeth,Large Pharma,3948,ReFacto AF / Xyntha,moroctocog alfa,Recombinant Protein,Launched,Corporate Acquisition,Jan-01,May-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Proforma,328.6,0,0,0,0,0,0,0,0,0,0,0,0,1550,Hemophilia A,7/7/14 12:28
1523,76,Wyeth,Large Pharma,3948,ReFacto AF / Xyntha,moroctocog alfa,Recombinant Protein,Launched,Corporate Acquisition,Jan-01,May-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Proforma,264.6,0,0,0,0,0,0,0,0,0,0,0,0,1550,Hemophilia A,7/7/14 12:28
1523,76,Wyeth,Large Pharma,3948,ReFacto AF / Xyntha,moroctocog alfa,Recombinant Protein,Launched,Corporate Acquisition,Jan-01,May-99,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Proforma,64,0,0,0,0,0,0,0,0,0,0,0,0,1550,Hemophilia A,7/7/14 12:28
1524,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,644,Regpara,cinacalcet,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-08,N/A,Oct-19,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1393,Secondary Hyperparathyroidism,7/7/14 12:28
1524,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,644,Regpara,cinacalcet,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-08,N/A,Oct-19,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,Global,Sales,58.7796804,108.2549118,144.2475036,162.5225422,154.7593634,166.4769438,175.7280206,183.229008,188.5506077,192.6073946,195.6824371,197.9737635,3.580655909,1393,Secondary Hyperparathyroidism,7/7/14 12:28
1524,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,644,Regpara,cinacalcet,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-08,N/A,Oct-19,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1393,Secondary Hyperparathyroidism,7/7/14 12:28
1524,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,644,Regpara,cinacalcet,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-08,N/A,Oct-19,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,ROW,Sales,58.7796804,108.2549118,144.2475036,162.5225422,154.7593634,166.4769438,175.7280206,183.229008,188.5506077,192.6073946,195.6824371,197.9737635,3.580655909,1393,Secondary Hyperparathyroidism,7/7/14 12:28
1524,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,644,Regpara,cinacalcet,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-08,N/A,Oct-19,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1393,Secondary Hyperparathyroidism,7/7/14 12:28
1524,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,644,Regpara,cinacalcet,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-08,N/A,Oct-19,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1393,Secondary Hyperparathyroidism,7/7/14 12:28
1525,76,Pfizer,Large Pharma,1202,Relistor,methylnaltrexone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-08,Jul-08,N/A,N/A,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1544,Post-operative Ileus,7/7/14 12:28
1525,76,Pfizer,Large Pharma,1202,Relistor,methylnaltrexone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-08,Jul-08,N/A,N/A,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,16,0,0,0,0,0,0,0,0,0,0,0,1544,Post-operative Ileus,7/7/14 12:28
1525,76,Pfizer,Large Pharma,1202,Relistor,methylnaltrexone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-08,Jul-08,N/A,N/A,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1544,Post-operative Ileus,7/7/14 12:28
1525,76,Pfizer,Large Pharma,1202,Relistor,methylnaltrexone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-08,Jul-08,N/A,N/A,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,6,0,0,0,0,0,0,0,0,0,0,0,1544,Post-operative Ileus,7/7/14 12:28
1525,76,Pfizer,Large Pharma,1202,Relistor,methylnaltrexone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-08,Jul-08,N/A,N/A,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1544,Post-operative Ileus,7/7/14 12:28
1525,76,Pfizer,Large Pharma,1202,Relistor,methylnaltrexone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-08,Jul-08,N/A,N/A,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,10,0,0,0,0,0,0,0,0,0,0,0,1544,Post-operative Ileus,7/7/14 12:28
1525,76,Wyeth,Large Pharma,1202,Relistor,methylnaltrexone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-08,Jul-08,N/A,N/A,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Proforma,12.3,0,0,0,0,0,0,0,0,0,0,0,0,1544,Post-operative Ileus,7/7/14 12:28
1525,76,Wyeth,Large Pharma,1202,Relistor,methylnaltrexone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-08,Jul-08,N/A,N/A,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Proforma,5.2,0,0,0,0,0,0,0,0,0,0,0,0,1544,Post-operative Ileus,7/7/14 12:28
1525,76,Wyeth,Large Pharma,1202,Relistor,methylnaltrexone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-08,Jul-08,N/A,N/A,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Proforma,7.1,0,0,0,0,0,0,0,0,0,0,0,0,1544,Post-operative Ileus,7/7/14 12:28
1526,76,Pfizer,Large Pharma,810,Relpax,eletriptan,Small Molecule (Chemical),Launched,In-House,Mar-03,Apr-01,Dec-16,Dec-15,117,Triptans,8,Migraine,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,963,Migraine,7/7/14 12:28
1526,76,Pfizer,Large Pharma,810,Relpax,eletriptan,Small Molecule (Chemical),Launched,In-House,Mar-03,Apr-01,Dec-16,Dec-15,117,Triptans,8,Migraine,12,Central Nervous System,6,Global,Sales,314,323,341,368,359,351.127,337.4004,245.6482,74.018272,53.93062112,39.34300986,25.86542534,-31.32419485,963,Migraine,7/7/14 12:28
1526,76,Pfizer,Large Pharma,810,Relpax,eletriptan,Small Molecule (Chemical),Launched,In-House,Mar-03,Apr-01,Dec-16,Dec-15,117,Triptans,8,Migraine,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,963,Migraine,7/7/14 12:28
1526,76,Pfizer,Large Pharma,810,Relpax,eletriptan,Small Molecule (Chemical),Launched,In-House,Mar-03,Apr-01,Dec-16,Dec-15,117,Triptans,8,Migraine,12,Central Nervous System,6,ROW,Sales,121,134,148,149,141,133.927,123.006,38.24212,24.42144,15.17469152,11.38669498,8.67831648,-32.85230901,963,Migraine,7/7/14 12:28
1526,76,Pfizer,Large Pharma,810,Relpax,eletriptan,Small Molecule (Chemical),Launched,In-House,Mar-03,Apr-01,Dec-16,Dec-15,117,Triptans,8,Migraine,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,963,Migraine,7/7/14 12:28
1526,76,Pfizer,Large Pharma,810,Relpax,eletriptan,Small Molecule (Chemical),Launched,In-House,Mar-03,Apr-01,Dec-16,Dec-15,117,Triptans,8,Migraine,12,Central Nervous System,6,US,Sales,193,189,193,219,218,217.2,214.3944,207.40608,49.596832,38.7559296,27.95631488,17.18710886,-30.43472744,963,Migraine,7/7/14 12:28
1527,61,Merck & Co,Large Pharma,316,Remeron,mirtazapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-96,Dec-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1548,Depression,7/7/14 12:28
1527,61,Merck & Co,Large Pharma,316,Remeron,mirtazapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-96,Dec-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Sales,39.1,223,240,232,206,187.45,175.5425,167.877625,162.9329562,158.9592957,136.1606709,124.3446804,-6.957787343,1548,Depression,7/7/14 12:28
1527,61,Merck & Co,Large Pharma,316,Remeron,mirtazapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-96,Dec-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1548,Depression,7/7/14 12:28
1527,61,Merck & Co,Large Pharma,316,Remeron,mirtazapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-96,Dec-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Sales,37.4,216,234,227,200,182.45,171.0425,163.627625,158.8079562,154.8967957,132.1294209,120.3290554,-7.001220821,1548,Depression,7/7/14 12:28
1527,61,Merck & Co,Large Pharma,316,Remeron,mirtazapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-96,Dec-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1548,Depression,7/7/14 12:28
1527,61,Merck & Co,Large Pharma,316,Remeron,mirtazapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-96,Dec-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Sales,1.7,7,6,5,6,5,4.5,4.25,4.125,4.0625,4.03125,4.015625,-5.575213729,1548,Depression,7/7/14 12:28
1527,61,Schering-Plough,Large Pharma,316,Remeron,mirtazapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-96,Dec-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Proforma,194.9,0,0,0,0,0,0,0,0,0,0,0,0,1548,Depression,7/7/14 12:28
1527,61,Schering-Plough,Large Pharma,316,Remeron,mirtazapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-96,Dec-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Proforma,186.6,0,0,0,0,0,0,0,0,0,0,0,0,1548,Depression,7/7/14 12:28
1527,61,Schering-Plough,Large Pharma,316,Remeron,mirtazapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-96,Dec-94,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Proforma,8.3,0,0,0,0,0,0,0,0,0,0,0,0,1548,Depression,7/7/14 12:28
1528,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Sep-06,Oct-05,Aug-15,Feb-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Alliance Revenue,78,116.6,191,114,110,100.935,98.294075,96.69522338,96.0262076,95.69441932,95.54288453,95.47092074,-2.003353876,1496,Psoriasis,7/7/14 12:28
1528,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Sep-06,Oct-05,Aug-15,Feb-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,141,149,195,334,374,401.615,411.1252118,403.153763,375.8318864,349.6078067,335.165356,328.0108186,-1.856957439,1496,Psoriasis,7/7/14 12:28
1528,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Sep-06,Oct-05,Aug-15,Feb-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Alliance Revenue,78,116.6,191,114,110,100.935,98.294075,96.69522338,96.0262076,95.69441932,95.54288453,95.47092074,-2.003353876,1496,Psoriasis,7/7/14 12:28
1528,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Sep-06,Oct-05,Aug-15,Feb-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,3,4,42,156,189,209.055,216.9299485,214.5412489,203.343565,189.1335693,182.5012073,179.5582119,-0.729433881,1496,Psoriasis,7/7/14 12:28
1528,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Sep-06,Oct-05,Aug-15,Feb-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,Psoriasis,7/7/14 12:28
1528,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Sep-06,Oct-05,Aug-15,Feb-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,138,145,153,178,185,192.56,194.1952633,188.6125142,172.4883214,160.4742374,152.6641487,148.4526067,-3.09522652,1496,Psoriasis,7/7/14 12:28
1529,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-98,Jul-00,Aug-15,Feb-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Alliance Revenue,386,402,540,385,333,318.505,288.008875,271.0707656,258.9064749,249.4119332,242.9306342,238.2436056,-4.670940297,1496,inflammatory bowel disease,7/7/14 12:28
1529,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-98,Jul-00,Aug-15,Feb-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,827,830,999,1294,1541,1691.145,1788.622288,1730.721474,1616.893492,1512.618485,1359.27483,1329.021949,-2.091925131,1496,inflammatory bowel disease,7/7/14 12:28
1529,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-98,Jul-00,Aug-15,Feb-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Alliance Revenue,386,402,540,385,333,318.505,288.008875,271.0707656,258.9064749,249.4119332,242.9306342,238.2436056,-4.670940297,1496,inflammatory bowel disease,7/7/14 12:28
1529,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-98,Jul-00,Aug-15,Feb-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,7,8,126,336,455,535.355,592.3644095,598.492011,575.4997082,571.92087,527.5209381,519.4067721,1.909280693,1496,inflammatory bowel disease,7/7/14 12:28
1529,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-98,Jul-00,Aug-15,Feb-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,inflammatory bowel disease,7/7/14 12:28
1529,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-98,Jul-00,Aug-15,Feb-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,820,822,873,958,1086,1155.79,1196.257879,1132.229463,1041.393784,940.6976149,831.7538922,809.6151767,-4.108873542,1496,inflammatory bowel disease,7/7/14 12:28
1530,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-98,Jul-00,Aug-15,Feb-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,732,968,1066,971,898,875.3,849.175,831.93875,821.4409375,813.6185469,808.3646523,804.8280389,-1.552695442,1496,Rheumatoid Arthritis,7/7/14 12:28
1530,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-98,Jul-00,Aug-15,Feb-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,2140,2144,2501,3041,3419,3672.5,3714.747006,3537.020666,3208.918375,2774.915969,2355.804391,2202.353934,-6.089835635,1496,Rheumatoid Arthritis,7/7/14 12:28
1530,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-98,Jul-00,Aug-15,Feb-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,732,968,1066,971,898,875.3,849.175,831.93875,821.4409375,813.6185469,808.3646523,804.8280389,-1.552695442,1496,Rheumatoid Arthritis,7/7/14 12:28
1530,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-98,Jul-00,Aug-15,Feb-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,10,12,251,594,799,925.6,1008.678717,1024.133954,1014.16676,993.2093211,947.4891709,916.4165382,1.978021709,1496,Rheumatoid Arthritis,7/7/14 12:28
1530,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-98,Jul-00,Aug-15,Feb-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,Rheumatoid Arthritis,7/7/14 12:28
1530,53,Johnson & Johnson,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-98,Jul-00,Aug-15,Feb-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,2130,2132,2250,2447,2620,2746.9,2706.068289,2512.886713,2194.751614,1781.706648,1408.31522,1285.937396,-9.667183971,1496,Rheumatoid Arthritis,7/7/14 12:28
1531,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-10,N/A,Jun-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,psoriasis,7/7/14 12:28
1531,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-10,N/A,Jun-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,7,Global,Sales,0,30.34936792,54.44513966,75.17576393,81.29239833,92.39738441,99.36661135,105.3013972,108.323204,110.1502237,111.0288768,111.2011313,4.577202256,1496,psoriasis,7/7/14 12:28
1531,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-10,N/A,Jun-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,psoriasis,7/7/14 12:28
1531,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-10,N/A,Jun-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,7,ROW,Sales,0,30.34936792,54.44513966,75.17576393,81.29239833,92.39738441,99.36661135,105.3013972,108.323204,110.1502237,111.0288768,111.2011313,4.577202256,1496,psoriasis,7/7/14 12:28
1531,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-10,N/A,Jun-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,psoriasis,7/7/14 12:28
1531,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-10,N/A,Jun-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,psoriasis,7/7/14 12:28
1532,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,May-02,N/A,Jun-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,inflammatory bowel disease,7/7/14 12:28
1532,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,May-02,N/A,Jun-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,Global,Sales,120.6605086,164.5869568,190.1995122,205.9453774,188.5965438,201.6672631,213.181127,220.931389,224.2995219,225.5972788,224.8500018,225.1548316,2.563420199,1496,inflammatory bowel disease,7/7/14 12:28
1532,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,May-02,N/A,Jun-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,inflammatory bowel disease,7/7/14 12:28
1532,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,May-02,N/A,Jun-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,ROW,Sales,120.6605086,164.5869568,190.1995122,205.9453774,188.5965438,201.6672631,213.181127,220.931389,224.2995219,225.5972788,224.8500018,225.1548316,2.563420199,1496,inflammatory bowel disease,7/7/14 12:28
1532,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,May-02,N/A,Jun-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,inflammatory bowel disease,7/7/14 12:28
1532,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,May-02,N/A,Jun-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,inflammatory bowel disease,7/7/14 12:28
1533,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-03,N/A,Jun-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,Rheumatoid Arthritis,7/7/14 12:28
1533,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-03,N/A,Jun-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,387.8373489,510.1028377,595.9584717,607.9564037,543.7294367,569.8310269,587.023244,602.212275,618.7483895,633.4105279,641.9035024,645.167069,2.473779192,1496,Rheumatoid Arthritis,7/7/14 12:28
1533,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-03,N/A,Jun-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,Rheumatoid Arthritis,7/7/14 12:28
1533,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-03,N/A,Jun-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,387.8373489,510.1028377,595.9584717,607.9564037,543.7294367,569.8310269,587.023244,602.212275,618.7483895,633.4105279,641.9035024,645.167069,2.473779192,1496,Rheumatoid Arthritis,7/7/14 12:28
1533,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-03,N/A,Jun-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,Rheumatoid Arthritis,7/7/14 12:28
1533,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-03,N/A,Jun-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,Rheumatoid Arthritis,7/7/14 12:28
1534,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-05,N/A,Feb-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,psoriasis,7/7/14 12:28
1534,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-05,N/A,Feb-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,36.3,258,267,208,212,215,209.9905022,205.6428763,200.7891192,195.8628055,188.682584,185.6957553,-1.874726133,1496,psoriasis,7/7/14 12:28
1534,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-05,N/A,Feb-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,psoriasis,7/7/14 12:28
1534,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-05,N/A,Feb-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,36.3,258,267,208,212,215,209.9905022,205.6428763,200.7891192,195.8628055,188.682584,185.6957553,-1.874726133,1496,psoriasis,7/7/14 12:28
1534,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-05,N/A,Feb-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,psoriasis,7/7/14 12:28
1534,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-05,N/A,Feb-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,psoriasis,7/7/14 12:28
1534,61,Schering-Plough,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-05,N/A,Feb-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Proforma,159.7,0,0,0,0,0,0,0,0,0,0,0,0,1496,psoriasis,7/7/14 12:28
1534,61,Schering-Plough,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-05,N/A,Feb-15,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Proforma,159.7,0,0,0,0,0,0,0,0,0,0,0,0,1496,psoriasis,7/7/14 12:28
1535,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-00,N/A,Feb-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,inflammatory bowel disease,7/7/14 12:28
1535,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-00,N/A,Feb-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,112.9,789,800,688,771,777.565,777.077301,760.0426757,724.8361822,736.468102,705.1502126,687.1819053,-1.630689626,1496,inflammatory bowel disease,7/7/14 12:28
1535,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-00,N/A,Feb-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,inflammatory bowel disease,7/7/14 12:28
1535,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-00,N/A,Feb-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,112.9,789,800,688,771,777.565,777.077301,760.0426757,724.8361822,736.468102,705.1502126,687.1819053,-1.630689626,1496,inflammatory bowel disease,7/7/14 12:28
1535,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-00,N/A,Feb-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,inflammatory bowel disease,7/7/14 12:28
1535,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-00,N/A,Feb-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,inflammatory bowel disease,7/7/14 12:28
1535,61,Schering-Plough,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-00,N/A,Feb-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Proforma,497.1,0,0,0,0,0,0,0,0,0,0,0,0,1496,inflammatory bowel disease,7/7/14 12:28
1535,61,Schering-Plough,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-00,N/A,Feb-15,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Proforma,497.1,0,0,0,0,0,0,0,0,0,0,0,0,1496,inflammatory bowel disease,7/7/14 12:28
1536,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jul-00,N/A,Feb-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,Rheumatoid Arthritis,7/7/14 12:28
1536,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jul-00,N/A,Feb-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,281.5,1667,1600,1180,1288,1299,1293,1259.746694,1169.01981,1084.360125,1043.661344,1020.630982,-3.269214995,1496,Rheumatoid Arthritis,7/7/14 12:28
1536,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jul-00,N/A,Feb-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,Rheumatoid Arthritis,7/7/14 12:28
1536,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jul-00,N/A,Feb-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,281.5,1667,1600,1180,1288,1299,1293,1259.746694,1169.01981,1084.360125,1043.661344,1020.630982,-3.269214995,1496,Rheumatoid Arthritis,7/7/14 12:28
1536,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jul-00,N/A,Feb-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,Rheumatoid Arthritis,7/7/14 12:28
1536,61,Merck & Co,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jul-00,N/A,Feb-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1496,Rheumatoid Arthritis,7/7/14 12:28
1536,61,Schering-Plough,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jul-00,N/A,Feb-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Proforma,1239.5,0,0,0,0,0,0,0,0,0,0,0,0,1496,Rheumatoid Arthritis,7/7/14 12:28
1536,61,Schering-Plough,Large Pharma,1337,Remicade,infliximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Jul-00,N/A,Feb-15,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Proforma,1239.5,0,0,0,0,0,0,0,0,0,0,0,0,1496,Rheumatoid Arthritis,7/7/14 12:28
1537,106,United Therapeutics,Small Biotech,1309,Remodulin,treprostinil,Small Molecule (Chemical),Launched,Licensed (Development),Jul-02,Feb-05,Oct-14,Feb-15,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Sales,299,362,430.13,457.969,490.68,491.413783,344.749612,268.4964437,233.9232536,211.0935172,186.5047234,160.4735781,-14.75715182,1673,Pulmonary Hypertension,7/7/14 12:28
1537,106,United Therapeutics,Small Biotech,1309,Remodulin,treprostinil,Small Molecule (Chemical),Launched,Licensed (Development),Jul-02,Feb-05,Oct-14,Feb-15,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,40,50,66,69,73.18,79.37,71.67115,67.114875,66.355065,64.99104625,63.1249785,60.74123344,-2.626313642,1673,Pulmonary Hypertension,7/7/14 12:28
1537,106,United Therapeutics,Small Biotech,1309,Remodulin,treprostinil,Small Molecule (Chemical),Launched,Licensed (Development),Jul-02,Feb-05,Oct-14,Feb-15,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Sales,259,312,364.13,388.969,417.5,412.043783,273.078462,201.3815687,167.5681886,146.1024709,123.3797449,99.73234466,-18.49793812,1673,Pulmonary Hypertension,7/7/14 12:28
1539,76,Pfizer,Large Pharma,1255,Remoxy,oxycodone - long-acting oral,Small Molecule (Chemical),Filed,Corporate Acquisition,Dec-16,,,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,964,Pain,7/7/14 12:28
1539,76,Pfizer,Large Pharma,1255,Remoxy,oxycodone - long-acting oral,Small Molecule (Chemical),Filed,Corporate Acquisition,Dec-16,,,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,2.499999,34.16673633,84.16667995,134.1667378,171.2334254,0,964,Pain,7/7/14 12:28
1539,76,Pfizer,Large Pharma,1255,Remoxy,oxycodone - long-acting oral,Small Molecule (Chemical),Filed,Corporate Acquisition,Dec-16,,,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,964,Pain,7/7/14 12:28
1539,76,Pfizer,Large Pharma,1255,Remoxy,oxycodone - long-acting oral,Small Molecule (Chemical),Filed,Corporate Acquisition,Dec-16,,,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,964,Pain,7/7/14 12:28
1539,76,Pfizer,Large Pharma,1255,Remoxy,oxycodone - long-acting oral,Small Molecule (Chemical),Filed,Corporate Acquisition,Dec-16,,,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,964,Pain,7/7/14 12:28
1539,76,Pfizer,Large Pharma,1255,Remoxy,oxycodone - long-acting oral,Small Molecule (Chemical),Filed,Corporate Acquisition,Dec-16,,,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,2.499999,34.16673633,84.16667995,134.1667378,171.2334254,0,964,Pain,7/7/14 12:28
1540,89,Genzyme,Large Pharma,1586,Renagel / Renvela,sevelamer hydrochloride / sevelamer carbonate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Sep-00,Sep-14,Jan-15,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,2,Global,Proforma,705.8651885,696.82103,189.7411712,0,0,0,0,0,0,0,0,0,0,966,Hyperphosphatemia,7/7/14 12:28
1540,89,Genzyme,Large Pharma,1586,Renagel / Renvela,sevelamer hydrochloride / sevelamer carbonate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Sep-00,Sep-14,Jan-15,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,2,ROW,Proforma,220.930246,221.2340533,76.95058609,0,0,0,0,0,0,0,0,0,0,966,Hyperphosphatemia,7/7/14 12:28
1540,89,Genzyme,Large Pharma,1586,Renagel / Renvela,sevelamer hydrochloride / sevelamer carbonate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Sep-00,Sep-14,Jan-15,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,2,US,Proforma,484.9349425,475.5869768,112.7905851,0,0,0,0,0,0,0,0,0,0,966,Hyperphosphatemia,7/7/14 12:28
1540,89,Sanofi,Large Pharma,1586,Renagel / Renvela,sevelamer hydrochloride / sevelamer carbonate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Sep-00,Sep-14,Jan-15,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,966,Hyperphosphatemia,7/7/14 12:28
1540,89,Sanofi,Large Pharma,1586,Renagel / Renvela,sevelamer hydrochloride / sevelamer carbonate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Sep-00,Sep-14,Jan-15,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,2,Global,Sales,3.95E-14,3.77E-14,574.9991995,839.282176,996.02255,944.7672694,470.0437022,362.8259151,299.597325,255.3576355,203.8011599,186.7002355,-21.27272795,966,Hyperphosphatemia,7/7/14 12:28
1540,89,Sanofi,Large Pharma,1586,Renagel / Renvela,sevelamer hydrochloride / sevelamer carbonate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Sep-00,Sep-14,Jan-15,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,966,Hyperphosphatemia,7/7/14 12:28
1540,89,Sanofi,Large Pharma,1586,Renagel / Renvela,sevelamer hydrochloride / sevelamer carbonate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Sep-00,Sep-14,Jan-15,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,2,ROW,Sales,3.95E-14,3.77E-14,164.9854584,259.6248079,290.8385846,307.8506498,210.4386816,163.9926303,134.9696147,115.1779617,97.50567095,87.99380431,-15.69979012,966,Hyperphosphatemia,7/7/14 12:28
1540,89,Sanofi,Large Pharma,1586,Renagel / Renvela,sevelamer hydrochloride / sevelamer carbonate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Sep-00,Sep-14,Jan-15,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,966,Hyperphosphatemia,7/7/14 12:28
1540,89,Sanofi,Large Pharma,1586,Renagel / Renvela,sevelamer hydrochloride / sevelamer carbonate,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-99,Sep-00,Sep-14,Jan-15,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,2,US,Sales,0,0,410.013741,579.6573681,705.1839654,636.9166197,259.6050206,198.8332848,164.6277103,140.1796738,106.2954889,98.70643118,-24.48968745,966,Hyperphosphatemia,7/7/14 12:28
1541,39,Eli Lilly,Large Pharma,706,ReoPro,abciximab,Antibody/Antibody Derivative,Launched,In-House,Feb-95,Jul-95,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,967,,7/7/14 12:28
1541,39,Eli Lilly,Large Pharma,706,ReoPro,abciximab,Antibody/Antibody Derivative,Launched,In-House,Feb-95,Jul-95,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,231.6,205.1,173.5,143.2,126.8,114.458,106.32236,100.6838312,96.8512339,94.22660786,92.4343974,91.20923632,-4.597455408,967,,7/7/14 12:28
1541,39,Eli Lilly,Large Pharma,706,ReoPro,abciximab,Antibody/Antibody Derivative,Launched,In-House,Feb-95,Jul-95,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,967,,7/7/14 12:28
1541,39,Eli Lilly,Large Pharma,706,ReoPro,abciximab,Antibody/Antibody Derivative,Launched,In-House,Feb-95,Jul-95,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,155.2,139.4,122.3,98,83.4,72.894,65.85348,61.0053816,57.70188667,55.44176109,53.89787926,52.84262628,-6.311051863,967,,7/7/14 12:28
1541,39,Eli Lilly,Large Pharma,706,ReoPro,abciximab,Antibody/Antibody Derivative,Launched,In-House,Feb-95,Jul-95,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,967,,7/7/14 12:28
1541,39,Eli Lilly,Large Pharma,706,ReoPro,abciximab,Antibody/Antibody Derivative,Launched,In-House,Feb-95,Jul-95,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Sales,76.4,65.7,51.2,45.2,43.4,41.564,40.46888,39.6784496,39.14934723,38.78484677,38.53651814,38.36661004,-1.745609813,967,,7/7/14 12:28
1542,35,Dainippon-Sumitomo,Regional & Specialty Pharma,73,Replagal,agalsidase alfa,Recombinant Protein,Launched,Licensed (Development),,Jun-07,N/A,Mar-20,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1330,Fabry's Disease,7/7/14 12:28
1542,35,Dainippon-Sumitomo,Regional & Specialty Pharma,73,Replagal,agalsidase alfa,Recombinant Protein,Launched,Licensed (Development),,Jun-07,N/A,Mar-20,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,7,Global,Sales,43.39084093,69.13168049,115.2211095,119.1835326,104.2911241,115.8925886,120.532739,124.5640227,129.3634432,132.0570499,134.4535635,136.6658204,3.937724997,1330,Fabry's Disease,7/7/14 12:28
1542,35,Dainippon-Sumitomo,Regional & Specialty Pharma,73,Replagal,agalsidase alfa,Recombinant Protein,Launched,Licensed (Development),,Jun-07,N/A,Mar-20,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1330,Fabry's Disease,7/7/14 12:28
1542,35,Dainippon-Sumitomo,Regional & Specialty Pharma,73,Replagal,agalsidase alfa,Recombinant Protein,Launched,Licensed (Development),,Jun-07,N/A,Mar-20,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,7,ROW,Sales,43.39084093,69.13168049,115.2211095,119.1835326,104.2911241,115.8925886,120.532739,124.5640227,129.3634432,132.0570499,134.4535635,136.6658204,3.937724997,1330,Fabry's Disease,7/7/14 12:28
1542,35,Dainippon-Sumitomo,Regional & Specialty Pharma,73,Replagal,agalsidase alfa,Recombinant Protein,Launched,Licensed (Development),,Jun-07,N/A,Mar-20,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1330,Fabry's Disease,7/7/14 12:28
1542,35,Dainippon-Sumitomo,Regional & Specialty Pharma,73,Replagal,agalsidase alfa,Recombinant Protein,Launched,Licensed (Development),,Jun-07,N/A,Mar-20,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1330,Fabry's Disease,7/7/14 12:28
1543,96,Shire,Regional & Specialty Pharma,73,Replagal,agalsidase alfa,Recombinant Protein,Launched,Corporate Acquisition,Jun-12,Sep-01,N/A,Sep-17,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1330,Fabry's Disease,7/7/14 12:28
1543,96,Shire,Regional & Specialty Pharma,73,Replagal,agalsidase alfa,Recombinant Protein,Launched,Corporate Acquisition,Jun-12,Sep-01,N/A,Sep-17,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Sales,193.8,351.3,475.2,498,468,432,415.5,402.375,394.96875,389.8359375,386.7011719,384.6342773,-2.763596287,1330,Fabry's Disease,7/7/14 12:28
1543,96,Shire,Regional & Specialty Pharma,73,Replagal,agalsidase alfa,Recombinant Protein,Launched,Corporate Acquisition,Jun-12,Sep-01,N/A,Sep-17,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1330,Fabry's Disease,7/7/14 12:28
1543,96,Shire,Regional & Specialty Pharma,73,Replagal,agalsidase alfa,Recombinant Protein,Launched,Corporate Acquisition,Jun-12,Sep-01,N/A,Sep-17,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Sales,193.8,351.3,475.2,498,468,432,415.5,402.375,394.96875,389.8359375,386.7011719,384.6342773,-2.763596287,1330,Fabry's Disease,7/7/14 12:28
1543,96,Shire,Regional & Specialty Pharma,73,Replagal,agalsidase alfa,Recombinant Protein,Launched,Corporate Acquisition,Jun-12,Sep-01,N/A,Sep-17,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1330,Fabry's Disease,7/7/14 12:28
1543,96,Shire,Regional & Specialty Pharma,73,Replagal,agalsidase alfa,Recombinant Protein,Launched,Corporate Acquisition,Jun-12,Sep-01,N/A,Sep-17,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1330,Fabry's Disease,7/7/14 12:28
1544,46,GlaxoSmithKline,Large Pharma,1394,Requip,ropinirole,Small Molecule (Chemical),Launched,In-House,Nov-97,Sep-96,May-08,Jun-16,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,968,Parkinson's Disease,7/7/14 12:28
1544,46,GlaxoSmithKline,Large Pharma,1394,Requip,ropinirole,Small Molecule (Chemical),Launched,In-House,Nov-97,Sep-96,May-08,Jun-16,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,4,Global,Sales,325.8856931,359.4792097,349.4933949,261.9609548,195.5780574,187.12233,179.5497605,170.1255245,150.894184,136.4728474,127.7395198,119.7764028,-6.765045254,968,Parkinson's Disease,7/7/14 12:28
1544,46,GlaxoSmithKline,Large Pharma,1394,Requip,ropinirole,Small Molecule (Chemical),Launched,In-House,Nov-97,Sep-96,May-08,Jun-16,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,968,Parkinson's Disease,7/7/14 12:28
1544,46,GlaxoSmithKline,Large Pharma,1394,Requip,ropinirole,Small Molecule (Chemical),Launched,In-House,Nov-97,Sep-96,May-08,Jun-16,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,4,ROW,Sales,285.3448892,292.005011,282.1598051,230.399394,184.4828553,180.7822145,175.1116797,166.4482575,147.5212426,133.2216362,124.5370006,116.6495747,-6.338512767,968,Parkinson's Disease,7/7/14 12:28
1544,46,GlaxoSmithKline,Large Pharma,1394,Requip,ropinirole,Small Molecule (Chemical),Launched,In-House,Nov-97,Sep-96,May-08,Jun-16,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,968,Parkinson's Disease,7/7/14 12:28
1544,46,GlaxoSmithKline,Large Pharma,1394,Requip,ropinirole,Small Molecule (Chemical),Launched,In-House,Nov-97,Sep-96,May-08,Jun-16,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,4,US,Sales,40.54080393,67.47419879,67.33358984,31.56156082,11.09520212,6.340115496,4.438080847,3.677266988,3.372941444,3.251211226,3.202519139,3.126828056,-16.55041326,968,Parkinson's Disease,7/7/14 12:28
1545,8,Allergan,Regional & Specialty Pharma,1288,Restasis,cyclosporin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-03,Mar-08,May-15,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,969,Dry Eye,7/7/14 12:28
1545,8,Allergan,Regional & Specialty Pharma,1288,Restasis,cyclosporin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-03,Mar-08,May-15,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Sales,523,620.5,697.1,792,940,1021.438,759.432402,444.4615653,370.305821,331.1823836,304.0235999,283.9797166,-15.71755204,969,Dry Eye,7/7/14 12:28
1545,8,Allergan,Regional & Specialty Pharma,1288,Restasis,cyclosporin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-03,Mar-08,May-15,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,969,Dry Eye,7/7/14 12:28
1545,8,Allergan,Regional & Specialty Pharma,1288,Restasis,cyclosporin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-03,Mar-08,May-15,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Sales,20,26,45,60,84,97.195,108.113375,117.3548719,124.2027915,129.649846,133.9568776,137.3090681,7.272531967,969,Dry Eye,7/7/14 12:28
1545,8,Allergan,Regional & Specialty Pharma,1288,Restasis,cyclosporin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-03,Mar-08,May-15,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,969,Dry Eye,7/7/14 12:28
1545,8,Allergan,Regional & Specialty Pharma,1288,Restasis,cyclosporin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-03,Mar-08,May-15,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Sales,503,594.5,652.1,732,856,924.243,651.319027,327.1066935,246.1030295,201.5325376,170.0667222,146.6706485,-22.27640365,969,Dry Eye,7/7/14 12:28
1546,46,GlaxoSmithKline,Large Pharma,3456,Potiga / Trobalt,ezogabine / retigabine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-12,May-11,Jun-16,Mar-21,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,970,Epilepsy,7/7/14 12:28
1546,46,GlaxoSmithKline,Large Pharma,3456,Potiga / Trobalt,ezogabine / retigabine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-12,May-11,Jun-16,Mar-21,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,4,Global,Sales,0,0,1.603180711,11.09520212,17.19755431,22.66950341,27.8287697,25.62982787,18.81490612,19.71777772,20.78089926,20.97319919,2.875980279,970,Epilepsy,7/7/14 12:28
1546,46,GlaxoSmithKline,Large Pharma,3456,Potiga / Trobalt,ezogabine / retigabine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-12,May-11,Jun-16,Mar-21,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,970,Epilepsy,7/7/14 12:28
1546,46,GlaxoSmithKline,Large Pharma,3456,Potiga / Trobalt,ezogabine / retigabine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-12,May-11,Jun-16,Mar-21,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,4,ROW,Sales,0,0,1.603180711,6.340115496,6.253656112,6.722680321,8.286094349,9.693166974,10.78755679,11.88194661,12.97633643,13.60170204,11.73993585,970,Epilepsy,7/7/14 12:28
1546,46,GlaxoSmithKline,Large Pharma,3456,Potiga / Trobalt,ezogabine / retigabine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-12,May-11,Jun-16,Mar-21,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,970,Epilepsy,7/7/14 12:28
1546,46,GlaxoSmithKline,Large Pharma,3456,Potiga / Trobalt,ezogabine / retigabine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-12,May-11,Jun-16,Mar-21,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,4,US,Sales,0,0,0,4.755086622,10.9438982,15.94682309,19.54267535,15.93666089,8.027349327,7.835831108,7.804562828,7.371497142,-5.488772428,970,Epilepsy,7/7/14 12:28
1547,53,Johnson & Johnson,Large Pharma,4043,Retin A,tretinoin,Small Molecule (Chemical),Launched,In-House,Jul-71,Jul-71,Expired,Expired,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,971,Acne,7/7/14 12:28
1547,53,Johnson & Johnson,Large Pharma,4043,Retin A,tretinoin,Small Molecule (Chemical),Launched,In-House,Jul-71,Jul-71,Expired,Expired,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Sales,217.04,213.328,209.7,84.35,83.085,81.7875,80.48925,79.197875,77.9032125,76.60881875,75.31494813,74.02076219,-1.636721188,971,Acne,7/7/14 12:28
1547,53,Johnson & Johnson,Large Pharma,4043,Retin A,tretinoin,Small Molecule (Chemical),Launched,In-House,Jul-71,Jul-71,Expired,Expired,160,Acne Treatments,73,Acne,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,971,Acne,7/7/14 12:28
1547,53,Johnson & Johnson,Large Pharma,4043,Retin A,tretinoin,Small Molecule (Chemical),Launched,In-House,Jul-71,Jul-71,Expired,Expired,160,Acne Treatments,73,Acne,6,Dermatology,6,ROW,Sales,88,87,85.7,84.35,83.085,81.7875,80.48925,79.197875,77.9032125,76.60881875,75.31494813,74.02076219,-1.636721188,971,Acne,7/7/14 12:28
1547,53,Johnson & Johnson,Large Pharma,4043,Retin A,tretinoin,Small Molecule (Chemical),Launched,In-House,Jul-71,Jul-71,Expired,Expired,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,971,Acne,7/7/14 12:28
1547,53,Johnson & Johnson,Large Pharma,4043,Retin A,tretinoin,Small Molecule (Chemical),Launched,In-House,Jul-71,Jul-71,Expired,Expired,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Sales,129.04,126.328,124,0,0,0,0,0,0,0,0,0,0,971,Acne,7/7/14 12:28
1548,46,GlaxoSmithKline,Large Pharma,844,retosiban,retosiban,Small Molecule (Chemical),Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,972,Pre-term labor,7/7/14 12:28
1548,46,GlaxoSmithKline,Large Pharma,844,retosiban,retosiban,Small Molecule (Chemical),Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,972,Pre-term labor,7/7/14 12:28
1548,46,GlaxoSmithKline,Large Pharma,844,retosiban,retosiban,Small Molecule (Chemical),Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,972,Pre-term labor,7/7/14 12:28
1548,46,GlaxoSmithKline,Large Pharma,844,retosiban,retosiban,Small Molecule (Chemical),Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,972,Pre-term labor,7/7/14 12:28
1548,46,GlaxoSmithKline,Large Pharma,844,retosiban,retosiban,Small Molecule (Chemical),Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,972,Pre-term labor,7/7/14 12:28
1548,46,GlaxoSmithKline,Large Pharma,844,retosiban,retosiban,Small Molecule (Chemical),Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,972,Pre-term labor,7/7/14 12:28
1549,76,Pfizer,Large Pharma,1709,Revatio,sildenafil,Small Molecule (Chemical),Launched,In-House,Oct-05,Apr-06,Nov-12,Apr-14,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1739,Pulmonary Hypertension,7/7/14 12:28
1549,76,Pfizer,Large Pharma,1709,Revatio,sildenafil,Small Molecule (Chemical),Launched,In-House,Oct-05,Apr-06,Nov-12,Apr-14,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Sales,450,481,535,534,307,240.6,175.2,151.9,124.96,95.2408,90.150784,91.94607232,-15.82185854,1739,Pulmonary Hypertension,7/7/14 12:28
1549,76,Pfizer,Large Pharma,1709,Revatio,sildenafil,Small Molecule (Chemical),Launched,In-House,Oct-05,Apr-06,Nov-12,Apr-14,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1739,Pulmonary Hypertension,7/7/14 12:28
1549,76,Pfizer,Large Pharma,1709,Revatio,sildenafil,Small Molecule (Chemical),Launched,In-House,Oct-05,Apr-06,Nov-12,Apr-14,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,157,188,223,222,240,180.6,124.2,102.9,78,49.5,45.24,47.58,-20.63994036,1739,Pulmonary Hypertension,7/7/14 12:28
1549,76,Pfizer,Large Pharma,1709,Revatio,sildenafil,Small Molecule (Chemical),Launched,In-House,Oct-05,Apr-06,Nov-12,Apr-14,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1739,Pulmonary Hypertension,7/7/14 12:28
1549,76,Pfizer,Large Pharma,1709,Revatio,sildenafil,Small Molecule (Chemical),Launched,In-House,Oct-05,Apr-06,Nov-12,Apr-14,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Sales,293,293,312,312,67,60,51,49,46.96,45.7408,44.910784,44.36607232,-5.718779892,1739,Pulmonary Hypertension,7/7/14 12:28
1550,26,Celgene,Regional & Specialty Pharma,646,Revlimid,lenalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Dec-05,Jul-07,Apr-27,Jun-22,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,973,Multiple Myeloma,7/7/14 12:28
1550,26,Celgene,Regional & Specialty Pharma,646,Revlimid,lenalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Dec-05,Jul-07,Apr-27,Jun-22,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,1706,2465.78,3208,3767,4280,4866.9529,5483.29565,6057.731035,6525.14452,7224.727073,7978.715992,8635.696827,10.54789397,973,Multiple Myeloma,7/7/14 12:28
1550,26,Celgene,Regional & Specialty Pharma,646,Revlimid,lenalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Dec-05,Jul-07,Apr-27,Jun-22,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,973,Multiple Myeloma,7/7/14 12:28
1550,26,Celgene,Regional & Specialty Pharma,646,Revlimid,lenalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Dec-05,Jul-07,Apr-27,Jun-22,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,668,1036.09,1378,1616,1791,1986.9529,2237.9459,2478.567759,2672.828523,2992.739794,3286.10917,3534.543041,10.19877593,973,Multiple Myeloma,7/7/14 12:28
1550,26,Celgene,Regional & Specialty Pharma,646,Revlimid,lenalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Dec-05,Jul-07,Apr-27,Jun-22,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,973,Multiple Myeloma,7/7/14 12:28
1550,26,Celgene,Regional & Specialty Pharma,646,Revlimid,lenalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Dec-05,Jul-07,Apr-27,Jun-22,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,1038,1429.69,1830,2151,2489,2880,3245.34975,3579.163276,3852.315997,4231.987279,4692.606823,5101.153786,10.79507564,973,Multiple Myeloma,7/7/14 12:28
1551,24,Bristol-Myers Squibb,Large Pharma,1253,Reyataz,atazanavir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-03,Jan-04,Jun-17,Mar-19,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,974,HIV,7/7/14 12:28
1551,24,Bristol-Myers Squibb,Large Pharma,1253,Reyataz,atazanavir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-03,Jan-04,Jun-17,Mar-19,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Sales,1401,1479.44,1569,1521,1551,1516.222649,1360.601034,1279.901525,803.4671897,715.758946,527.7184463,256.5816238,-22.66546034,974,HIV,7/7/14 12:28
1551,24,Bristol-Myers Squibb,Large Pharma,1253,Reyataz,atazanavir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-03,Jan-04,Jun-17,Mar-19,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,974,HIV,7/7/14 12:28
1551,24,Bristol-Myers Squibb,Large Pharma,1253,Reyataz,atazanavir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-03,Jan-04,Jun-17,Mar-19,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Sales,674,725,809,738,782,785.5,726.1813687,704.4103622,669.1017838,609.8307957,449.2860465,187.6139005,-18.44755561,974,HIV,7/7/14 12:28
1551,24,Bristol-Myers Squibb,Large Pharma,1253,Reyataz,atazanavir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-03,Jan-04,Jun-17,Mar-19,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,974,HIV,7/7/14 12:28
1551,24,Bristol-Myers Squibb,Large Pharma,1253,Reyataz,atazanavir,Small Molecule (Chemical),Launched,Licensed (Development),Jun-03,Jan-04,Jun-17,Mar-19,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Sales,727,754.44,760,783,769,730.7226486,634.4196657,575.4911631,134.3654059,105.9281503,78.43239983,68.96772336,-29.14203805,974,HIV,7/7/14 12:28
1555,68,Novo Nordisk,Regional & Specialty Pharma,4591,NovoThirteen/Tretten,catridecacog,Recombinant Protein,Launched,Licensed (Development),Apr-14,Jan-13,Jul-21,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,784,Congenital FXIII Deficiency,7/7/14 12:28
1555,68,Novo Nordisk,Regional & Specialty Pharma,4591,NovoThirteen/Tretten,catridecacog,Recombinant Protein,Launched,Licensed (Development),Apr-14,Jan-13,Jul-21,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,Global,Sales,0,0,0,0,4.579023377,14.97723145,25.37543036,34.95735035,43.01295766,47.50396737,50.7932529,53.09478646,41.91872724,784,Congenital FXIII Deficiency,7/7/14 12:28
1555,68,Novo Nordisk,Regional & Specialty Pharma,4591,NovoThirteen/Tretten,catridecacog,Recombinant Protein,Launched,Licensed (Development),Apr-14,Jan-13,Jul-21,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,784,Congenital FXIII Deficiency,7/7/14 12:28
1555,68,Novo Nordisk,Regional & Specialty Pharma,4591,NovoThirteen/Tretten,catridecacog,Recombinant Protein,Launched,Licensed (Development),Apr-14,Jan-13,Jul-21,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,ROW,Sales,0,0,0,0,4.579023377,7.631720891,10.68440925,13.73705181,15.26338546,16.40813409,17.22853555,17.75798158,21.36363988,784,Congenital FXIII Deficiency,7/7/14 12:28
1555,68,Novo Nordisk,Regional & Specialty Pharma,4591,NovoThirteen/Tretten,catridecacog,Recombinant Protein,Launched,Licensed (Development),Apr-14,Jan-13,Jul-21,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,784,Congenital FXIII Deficiency,7/7/14 12:28
1555,68,Novo Nordisk,Regional & Specialty Pharma,4591,NovoThirteen/Tretten,catridecacog,Recombinant Protein,Launched,Licensed (Development),Apr-14,Jan-13,Jul-21,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,US,Sales,0,0,0,0,0,7.345510558,14.69102112,21.22029854,27.7495722,31.09583328,33.56471734,35.33680489,0,784,Congenital FXIII Deficiency,7/7/14 12:28
1557,16,AstraZeneca,Large Pharma,637,Rhinocort,budesonide,Small Molecule (Chemical),Launched,In-House,Jan-83,Jan-83,Oct-17,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1687,Allergic Rhinitis,7/7/14 12:28
1557,16,AstraZeneca,Large Pharma,637,Rhinocort,budesonide,Small Molecule (Chemical),Launched,In-House,Jan-83,Jan-83,Oct-17,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,Global,Sales,264,227,212,177,142.5,123.050625,105.3536125,91.02507656,79.84379562,70.43106078,62.57136259,54.82,-12.75670028,1687,Allergic Rhinitis,7/7/14 12:28
1557,16,AstraZeneca,Large Pharma,637,Rhinocort,budesonide,Small Molecule (Chemical),Launched,In-House,Jan-83,Jan-83,Oct-17,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1687,Allergic Rhinitis,7/7/14 12:28
1557,16,AstraZeneca,Large Pharma,637,Rhinocort,budesonide,Small Molecule (Chemical),Launched,In-House,Jan-83,Jan-83,Oct-17,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,ROW,Sales,135,134,138,122,104.3,94.02,83.1,73.4328,65.30032,57.98,51.5533248,46,-11.03676762,1687,Allergic Rhinitis,7/7/14 12:28
1557,16,AstraZeneca,Large Pharma,637,Rhinocort,budesonide,Small Molecule (Chemical),Launched,In-House,Jan-83,Jan-83,Oct-17,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1687,Allergic Rhinitis,7/7/14 12:28
1557,16,AstraZeneca,Large Pharma,637,Rhinocort,budesonide,Small Molecule (Chemical),Launched,In-House,Jan-83,Jan-83,Oct-17,Expired,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,US,Sales,129,93,74,55,38.2,29.030625,22.2536125,17.59227656,14.54347563,12.45106078,11.01803779,8.82,-18.89306688,1687,Allergic Rhinitis,7/7/14 12:28
1558,86,Roche,Large Pharma,3004,etrolizumab,RG7413,Antibody/Antibody Derivative,Phase III,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1002,Ulcerative Colitis,7/7/14 12:28
1558,86,Roche,Large Pharma,3004,etrolizumab,RG7413,Antibody/Antibody Derivative,Phase III,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1002,Ulcerative Colitis,7/7/14 12:28
1558,86,Roche,Large Pharma,3004,etrolizumab,RG7413,Antibody/Antibody Derivative,Phase III,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1002,Ulcerative Colitis,7/7/14 12:28
1558,86,Roche,Large Pharma,3004,etrolizumab,RG7413,Antibody/Antibody Derivative,Phase III,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1002,Ulcerative Colitis,7/7/14 12:28
1558,86,Roche,Large Pharma,3004,etrolizumab,RG7413,Antibody/Antibody Derivative,Phase III,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1002,Ulcerative Colitis,7/7/14 12:28
1558,86,Roche,Large Pharma,3004,etrolizumab,RG7413,Antibody/Antibody Derivative,Phase III,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1002,Ulcerative Colitis,7/7/14 12:28
1559,86,Roche,Large Pharma,1877,rontalizumab,RG7415,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1024,Systemic Lupus Erythematosus,7/7/14 12:28
1559,86,Roche,Large Pharma,1877,rontalizumab,RG7415,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1024,Systemic Lupus Erythematosus,7/7/14 12:28
1559,86,Roche,Large Pharma,1877,rontalizumab,RG7415,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1024,Systemic Lupus Erythematosus,7/7/14 12:28
1559,86,Roche,Large Pharma,1877,rontalizumab,RG7415,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1024,Systemic Lupus Erythematosus,7/7/14 12:28
1559,86,Roche,Large Pharma,1877,rontalizumab,RG7415,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1024,Systemic Lupus Erythematosus,7/7/14 12:28
1559,86,Roche,Large Pharma,1877,rontalizumab,RG7415,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1024,Systemic Lupus Erythematosus,7/7/14 12:28
1560,105,UCB,Regional & Specialty Pharma,68,Rikelta,brivaracetam,Small Molecule (Chemical),Phase III,In-House,Dec-15,Feb-16,N/A,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1011,Epilepsy,7/7/14 12:28
1560,105,UCB,Regional & Specialty Pharma,68,Rikelta,brivaracetam,Small Molecule (Chemical),Phase III,In-House,Dec-15,Feb-16,N/A,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,2.988066455,56.10936142,93.84772483,131.0327719,165.1897234,193.8150535,0,1011,Epilepsy,7/7/14 12:28
1560,105,UCB,Regional & Specialty Pharma,68,Rikelta,brivaracetam,Small Molecule (Chemical),Phase III,In-House,Dec-15,Feb-16,N/A,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1011,Epilepsy,7/7/14 12:28
1560,105,UCB,Regional & Specialty Pharma,68,Rikelta,brivaracetam,Small Molecule (Chemical),Phase III,In-House,Dec-15,Feb-16,N/A,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,18.26042006,32.09414908,45.37438703,58.65456263,69.36728662,0,1011,Epilepsy,7/7/14 12:28
1560,105,UCB,Regional & Specialty Pharma,68,Rikelta,brivaracetam,Small Molecule (Chemical),Phase III,In-House,Dec-15,Feb-16,N/A,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1011,Epilepsy,7/7/14 12:28
1560,105,UCB,Regional & Specialty Pharma,68,Rikelta,brivaracetam,Small Molecule (Chemical),Phase III,In-House,Dec-15,Feb-16,N/A,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,2.988066455,37.84894136,61.75357575,85.65838492,106.5351608,124.4477669,0,1011,Epilepsy,7/7/14 12:28
1562,53,Johnson & Johnson,Large Pharma,3685,Edurant,rilpivirine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-11,Dec-11,N/A,N/A,91,NNRTIs,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1013,HIV,7/7/14 12:28
1562,53,Johnson & Johnson,Large Pharma,3685,Edurant,rilpivirine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-11,Dec-11,N/A,N/A,91,NNRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,17.5,27,63,86.51928,91.411208,94.7515576,96.31987944,96.87280972,97.15581604,97.28002537,6.40320393,1013,HIV,7/7/14 12:28
1562,53,Johnson & Johnson,Large Pharma,3685,Edurant,rilpivirine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-11,Dec-11,N/A,N/A,91,NNRTIs,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1013,HIV,7/7/14 12:28
1562,53,Johnson & Johnson,Large Pharma,3685,Edurant,rilpivirine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-11,Dec-11,N/A,N/A,91,NNRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,5,10,26,36.0646,38.23106,39.691582,40.3702058,40.6123579,40.73571142,40.78972085,6.644778983,1013,HIV,7/7/14 12:28
1562,53,Johnson & Johnson,Large Pharma,3685,Edurant,rilpivirine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-11,Dec-11,N/A,N/A,91,NNRTIs,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1013,HIV,7/7/14 12:28
1562,53,Johnson & Johnson,Large Pharma,3685,Edurant,rilpivirine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-11,Dec-11,N/A,N/A,91,NNRTIs,32,HIV,7,Anti-infectives,6,US,Sales,0,0,12.5,17,37,50.45468,53.180148,55.0599756,55.94967364,56.26045182,56.42010462,56.49030452,6.231458465,1013,HIV,7/7/14 12:28
1563,95,Shionogi,Regional & Specialty Pharma,165,Rinderon,betamethasone propionate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-62,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1016,Atopic dermatitis,7/7/14 12:28
1563,95,Shionogi,Regional & Specialty Pharma,165,Rinderon,betamethasone propionate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-62,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,7,Global,Sales,102.3459671,110.8919212,116.4872756,108.348666,89.620266,88.17293373,86.96326021,85.91190935,84.91057201,84.01126467,83.19498838,82.44852024,-1.184462111,1016,Atopic dermatitis,7/7/14 12:28
1563,95,Shionogi,Regional & Specialty Pharma,165,Rinderon,betamethasone propionate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-62,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1016,Atopic dermatitis,7/7/14 12:28
1563,95,Shionogi,Regional & Specialty Pharma,165,Rinderon,betamethasone propionate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-62,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,7,ROW,Sales,102.3459671,110.8919212,116.4872756,108.348666,89.620266,88.17293373,86.96326021,85.91190935,84.91057201,84.01126467,83.19498838,82.44852024,-1.184462111,1016,Atopic dermatitis,7/7/14 12:28
1563,95,Shionogi,Regional & Specialty Pharma,165,Rinderon,betamethasone propionate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-62,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1016,Atopic dermatitis,7/7/14 12:28
1563,95,Shionogi,Regional & Specialty Pharma,165,Rinderon,betamethasone propionate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-62,Expired,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1016,Atopic dermatitis,7/7/14 12:28
1564,19,Bayer,Large Pharma,1055,Adempas,riociguat,Small Molecule (Chemical),Launched,In-House,Oct-13,Apr-14,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1017,Pulmonary Hypertension,7/7/14 12:28
1564,19,Bayer,Large Pharma,1055,Adempas,riociguat,Small Molecule (Chemical),Launched,In-House,Oct-13,Apr-14,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,14.77486391,113.6049546,271.865409,436.7658714,572.6088922,681.1380327,774.3373949,851.755799,78.460213,1017,Pulmonary Hypertension,7/7/14 12:28
1564,19,Bayer,Large Pharma,1055,Adempas,riociguat,Small Molecule (Chemical),Launched,In-House,Oct-13,Apr-14,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1017,Pulmonary Hypertension,7/7/14 12:28
1564,19,Bayer,Large Pharma,1055,Adempas,riociguat,Small Molecule (Chemical),Launched,In-House,Oct-13,Apr-14,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,29.8806765,89.6420295,156.0434664,222.4446427,267.9959456,307.1793497,339.7554795,0,1017,Pulmonary Hypertension,7/7/14 12:28
1564,19,Bayer,Large Pharma,1055,Adempas,riociguat,Small Molecule (Chemical),Launched,In-House,Oct-13,Apr-14,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1017,Pulmonary Hypertension,7/7/14 12:28
1564,19,Bayer,Large Pharma,1055,Adempas,riociguat,Small Molecule (Chemical),Launched,In-House,Oct-13,Apr-14,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,14.77486391,83.72427806,182.2233795,280.722405,350.1642495,413.1420872,467.1580451,512.0003195,65.94478181,1017,Pulmonary Hypertension,7/7/14 12:28
1565,53,Johnson & Johnson,Large Pharma,1234,Risperdal,risperidone,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-94,Jun-08,Dec-07,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1018,Schizophrenia,7/7/14 12:28
1565,53,Johnson & Johnson,Large Pharma,1234,Risperdal,risperidone,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-94,Jun-08,Dec-07,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,2324,2027,2125,1871,1673,1485.58,1322.17,1192.914,1094.7832,1024.16022,957.859888,929.4490684,-8.053999181,1018,Schizophrenia,7/7/14 12:28
1565,53,Johnson & Johnson,Large Pharma,1234,Risperdal,risperidone,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-94,Jun-08,Dec-07,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1018,Schizophrenia,7/7/14 12:28
1565,53,Johnson & Johnson,Large Pharma,1234,Risperdal,risperidone,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-94,Jun-08,Dec-07,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,1558,1594,1648,1409,1208,1057.88,896.35,790.99,707.25,650.715,616.275,597.102,-9.576122086,1018,Schizophrenia,7/7/14 12:28
1565,53,Johnson & Johnson,Large Pharma,1234,Risperdal,risperidone,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-94,Jun-08,Dec-07,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1018,Schizophrenia,7/7/14 12:28
1565,53,Johnson & Johnson,Large Pharma,1234,Risperdal,risperidone,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-94,Jun-08,Dec-07,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,766,433,477,462,465,427.7,425.82,401.924,387.5332,373.44522,341.584888,332.3470684,-4.684677698,1018,Schizophrenia,7/7/14 12:28
1567,29,Chugai,Regional & Specialty Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-01,N/A,Jun-17,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,3,Global,Alliance Revenue,225.5002284,262.0908392,287.2406811,309.4462541,268.5228689,276.3325798,283.6564898,289.1042244,279.2266399,241.725893,201.0282739,174.1791076,-5.996289619,1619,Non-Hodgkin's Lymphoma,7/7/14 12:28
1567,29,Chugai,Regional & Specialty Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-01,N/A,Jun-17,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,3,ROW,Alliance Revenue,225.5002284,262.0908392,287.2406811,309.4462541,268.5228689,276.3325798,283.6564898,289.1042244,279.2266399,241.725893,201.0282739,174.1791076,-5.996289619,1619,Non-Hodgkin's Lymphoma,7/7/14 12:28
1567,29,Chugai,Regional & Specialty Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-01,N/A,Jun-17,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1619,Non-Hodgkin's Lymphoma,7/7/14 12:28
1568,86,Roche,Large Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-06,Jul-06,Jan-17,May-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1619,Rheumatoid Arthritis,7/7/14 12:28
1568,86,Roche,Large Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-06,Jul-06,Jan-17,May-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,Global,Sales,814.9046209,952.3208225,1101.571542,1157.140991,1285.235618,1340.076654,1393.374544,1409.23813,1363.289393,1265.746625,1162.518697,1139.944937,-1.699141548,1619,Rheumatoid Arthritis,7/7/14 12:28
1568,86,Roche,Large Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-06,Jul-06,Jan-17,May-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1619,Rheumatoid Arthritis,7/7/14 12:28
1568,86,Roche,Large Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-06,Jul-06,Jan-17,May-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,ROW,Sales,382.1304154,493.9025414,609.3560368,776.404278,813.6588211,861.7661292,905.4641402,907.6736278,883.2763307,827.3239059,785.401981,774.9909961,-0.693153382,1619,Rheumatoid Arthritis,7/7/14 12:28
1568,86,Roche,Large Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-06,Jul-06,Jan-17,May-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1619,Rheumatoid Arthritis,7/7/14 12:28
1568,86,Roche,Large Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Apr-06,Jul-06,Jan-17,May-16,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,US,Sales,432.7742054,458.4182811,492.2155048,380.7367132,471.5767969,478.310525,487.9104042,501.5645018,480.0130622,438.4227188,377.116716,364.9539413,-3.595354267,1619,Rheumatoid Arthritis,7/7/14 12:28
1569,86,Roche,Large Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Dec-97,Dec-97,Jan-17,May-16,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1619,Non-Hodgkin's Lymphoma,7/7/14 12:28
1569,86,Roche,Large Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Dec-97,Dec-97,Jan-17,May-16,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,Global,Sales,4790.807698,5205.911423,5663.315291,5994.901205,6216.649423,5901.484535,5812.589456,5487.674455,4915.250279,4166.385156,3528.212361,3008.042542,-9.850954999,1619,Non-Hodgkin's Lymphoma,7/7/14 12:28
1569,86,Roche,Large Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Dec-97,Dec-97,Jan-17,May-16,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1619,Non-Hodgkin's Lymphoma,7/7/14 12:28
1569,86,Roche,Large Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Dec-97,Dec-97,Jan-17,May-16,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,ROW,Sales,2447.381415,2762.292636,3089.60264,3056.957557,3094.746281,3032.785716,2968.185151,2750.513289,2415.870583,2020.26399,1727.172679,1509.837464,-9.744805076,1619,Non-Hodgkin's Lymphoma,7/7/14 12:28
1569,86,Roche,Large Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Dec-97,Dec-97,Jan-17,May-16,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1619,Non-Hodgkin's Lymphoma,7/7/14 12:28
1569,86,Roche,Large Pharma,1404,Rituxan / MabThera,rituximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Dec-97,Dec-97,Jan-17,May-16,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,US,Sales,2343.426283,2443.618787,2573.712651,2937.943648,3121.903143,2868.69882,2844.404305,2737.161166,2499.379696,2146.121167,1801.039682,1498.205078,-9.95692697,1619,Non-Hodgkin's Lymphoma,7/7/14 12:28
1571,86,Roche,Large Pharma,53,Roaccutane,isotretinoin,Small Molecule (Chemical),Launched,In-House,Jul-82,Jul-83,Expired,Expired,160,Acne Treatments,73,Acne,6,Dermatology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1021,Acne,7/7/14 12:28
1571,86,Roche,Large Pharma,53,Roaccutane,isotretinoin,Small Molecule (Chemical),Launched,In-House,Jul-82,Jul-83,Expired,Expired,160,Acne Treatments,73,Acne,6,Dermatology,5,Global,Sales,75.04488881,23.34526785,18.70423885,11.64502984,8.532612031,6.47821494,5.186332587,4.42139921,3.949034885,3.659419427,3.483617946,3.375914649,-12.40630689,1021,Acne,7/7/14 12:28
1571,86,Roche,Large Pharma,53,Roaccutane,isotretinoin,Small Molecule (Chemical),Launched,In-House,Jul-82,Jul-83,Expired,Expired,160,Acne Treatments,73,Acne,6,Dermatology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1021,Acne,7/7/14 12:28
1571,86,Roche,Large Pharma,53,Roaccutane,isotretinoin,Small Molecule (Chemical),Launched,In-House,Jul-82,Jul-83,Expired,Expired,160,Acne Treatments,73,Acne,6,Dermatology,5,ROW,Sales,32.22786636,23.34526785,18.70423885,11.64502984,8.532612031,6.47821494,5.186332587,4.42139921,3.949034885,3.659419427,3.483617946,3.375914649,-12.40630689,1021,Acne,7/7/14 12:28
1571,86,Roche,Large Pharma,53,Roaccutane,isotretinoin,Small Molecule (Chemical),Launched,In-House,Jul-82,Jul-83,Expired,Expired,160,Acne Treatments,73,Acne,6,Dermatology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1021,Acne,7/7/14 12:28
1571,86,Roche,Large Pharma,53,Roaccutane,isotretinoin,Small Molecule (Chemical),Launched,In-House,Jul-82,Jul-83,Expired,Expired,160,Acne Treatments,73,Acne,6,Dermatology,5,US,Sales,42.81702245,0,0,0,0,0,0,0,0,0,0,0,0,1021,Acne,7/7/14 12:28
1573,86,Roche,Large Pharma,1619,Rocephin,ceftriaxone,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-82,Jul-05,Jul-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1386,,7/7/14 12:28
1573,86,Roche,Large Pharma,1619,Rocephin,ceftriaxone,Small Molecule (Chemical),Launched,In-House,Jul-85,May-82,Jul-05,Jul-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,5,Global,Sales,283.4539487,300.3338521,297.9580223,284.4806614,291.9147837,292.352186,298.1503836,304.2225776,308.8649154,313.7520882,318.3466867,322.5905684,1.4376926,1386,,7/7/14 12:28
1573,86,Roche,Large Pharma,1619,Rocephin,ceftriaxone,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-82,Jul-05,Jul-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1386,,7/7/14 12:28
1573,86,Roche,Large Pharma,1619,Rocephin,ceftriaxone,Small Molecule (Chemical),Launched,In-House,Jul-85,May-82,Jul-05,Jul-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,5,ROW,Sales,280.6915602,299.374818,297.1253448,283.6861797,291.1355116,291.5749161,297.3733286,303.4456915,308.0880458,312.9752217,317.5698214,321.8137032,1.441488995,1386,,7/7/14 12:28
1573,86,Roche,Large Pharma,1619,Rocephin,ceftriaxone,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-82,Jul-05,Jul-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1386,,7/7/14 12:28
1573,86,Roche,Large Pharma,1619,Rocephin,ceftriaxone,Small Molecule (Chemical),Launched,In-House,Jul-85,Jul-82,Jul-05,Jul-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,5,US,Sales,2.762388545,0.959034061,0.832677413,0.794481761,0.77927217,0.777269865,0.777055022,0.776886052,0.77686957,0.776866513,0.776865305,0.776865161,-4.42E-02,1386,,7/7/14 12:28
1579,46,GlaxoSmithKline,Large Pharma,385,Rotarix,rotavirus vaccine,Vaccine,Launched,Licensed (Development),Aug-08,Jan-05,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1736,Rotavirus,7/7/14 12:28
1579,46,GlaxoSmithKline,Large Pharma,385,Rotarix,rotavirus vaccine,Vaccine,Launched,Licensed (Development),Aug-08,Jan-05,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,439.7117965,363.0750136,480.9542132,570.6103946,595.953881,629.0699206,651.8714828,666.1081868,676.56453,683.7011209,688.5622584,691.9528197,2.156558155,1736,Rotavirus,7/7/14 12:28
1579,46,GlaxoSmithKline,Large Pharma,385,Rotarix,rotavirus vaccine,Vaccine,Launched,Licensed (Development),Aug-08,Jan-05,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1736,Rotavirus,7/7/14 12:28
1579,46,GlaxoSmithKline,Large Pharma,385,Rotarix,rotavirus vaccine,Vaccine,Launched,Licensed (Development),Aug-08,Jan-05,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,321.2079081,248.7450093,304.604335,412.1075072,428.66858,455.1635612,476.0583446,487.4743809,496.1121056,502.0734205,506.0010116,508.7408791,2.47666589,1736,Rotavirus,7/7/14 12:28
1579,46,GlaxoSmithKline,Large Pharma,385,Rotarix,rotavirus vaccine,Vaccine,Launched,Licensed (Development),Aug-08,Jan-05,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1736,Rotavirus,7/7/14 12:28
1579,46,GlaxoSmithKline,Large Pharma,385,Rotarix,rotavirus vaccine,Vaccine,Launched,Licensed (Development),Aug-08,Jan-05,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,118.5038884,114.3300043,176.3498782,158.5028874,167.285301,173.9063594,175.8131383,178.6338059,180.4524244,181.6277003,182.5612467,183.2119405,1.307658801,1736,Rotavirus,7/7/14 12:28
1580,61,Merck & Co,Large Pharma,1099,RotaTeq,rotavirus vaccine,Vaccine,Launched,In-House,Apr-06,Jul-06,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1625,rotavirus gastroenteritis,7/7/14 12:28
1580,61,Merck & Co,Large Pharma,1099,RotaTeq,rotavirus vaccine,Vaccine,Launched,In-House,Apr-06,Jul-06,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,522,520,651,601,637,653.795,665.908375,677.5802469,685.8280634,692.2824575,697.4399531,701.4024452,1.385395625,1625,rotavirus gastroenteritis,7/7/14 12:28
1580,61,Merck & Co,Large Pharma,1099,RotaTeq,rotavirus vaccine,Vaccine,Launched,In-House,Apr-06,Jul-06,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1625,rotavirus gastroenteritis,7/7/14 12:28
1580,61,Merck & Co,Large Pharma,1099,RotaTeq,rotavirus vaccine,Vaccine,Launched,In-House,Apr-06,Jul-06,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,54,81,129,148,166,181.795,192.908375,201.9402469,209.0960634,214.6276575,218.9949531,222.4232412,4.268502368,1625,rotavirus gastroenteritis,7/7/14 12:28
1580,61,Merck & Co,Large Pharma,1099,RotaTeq,rotavirus vaccine,Vaccine,Launched,In-House,Apr-06,Jul-06,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1625,rotavirus gastroenteritis,7/7/14 12:28
1580,61,Merck & Co,Large Pharma,1099,RotaTeq,rotavirus vaccine,Vaccine,Launched,In-House,Apr-06,Jul-06,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,468,439,522,453,471,472,473,475.64,476.732,477.6548,478.445,478.979204,0.240274916,1625,rotavirus gastroenteritis,7/7/14 12:28
1581,100,Takeda,Large Pharma,1409,Rozerem,ramelteon,Small Molecule (Chemical),Launched,In-House,Sep-05,Jul-10,Mar-17,Dec-19,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1025,Insomnia,7/7/14 12:28
1581,100,Takeda,Large Pharma,1409,Rozerem,ramelteon,Small Molecule (Chemical),Launched,In-House,Sep-05,Jul-10,Mar-17,Dec-19,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,Global,Sales,74.33549188,65.36786936,81.03462648,100.0169473,95.59979681,101.5904388,106.8082335,110.4299647,102.3025714,102.5449001,102.6635449,88.50237954,-1.095966872,1025,Insomnia,7/7/14 12:28
1581,100,Takeda,Large Pharma,1409,Rozerem,ramelteon,Small Molecule (Chemical),Launched,In-House,Sep-05,Jul-10,Mar-17,Dec-19,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1025,Insomnia,7/7/14 12:28
1581,100,Takeda,Large Pharma,1409,Rozerem,ramelteon,Small Molecule (Chemical),Launched,In-House,Sep-05,Jul-10,Mar-17,Dec-19,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,ROW,Sales,0,11.67283381,31.65415097,58.75995655,60.40633347,69.91319628,77.66970235,83.05989727,87.21395037,90.36118212,92.23640507,81.05226508,4.289447015,1025,Insomnia,7/7/14 12:28
1581,100,Takeda,Large Pharma,1409,Rozerem,ramelteon,Small Molecule (Chemical),Launched,In-House,Sep-05,Jul-10,Mar-17,Dec-19,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1025,Insomnia,7/7/14 12:28
1581,100,Takeda,Large Pharma,1409,Rozerem,ramelteon,Small Molecule (Chemical),Launched,In-House,Sep-05,Jul-10,Mar-17,Dec-19,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,US,Sales,74.33549188,53.69503554,49.38047551,41.25699077,35.19346334,31.67724253,29.13853111,27.37006739,15.08862106,12.18371798,10.42713987,7.450114461,-19.89278029,1025,Insomnia,7/7/14 12:28
1583,46,GlaxoSmithKline,Large Pharma,3229,Rytmonorm,propafenone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-90,,Expired,N/A,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1601,,7/7/14 12:28
1583,46,GlaxoSmithKline,Large Pharma,3229,Rytmonorm,propafenone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-90,,Expired,N/A,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,4,Global,Sales,74.8445611,79.25977208,26.45248172,12.50448032,8.84941593,7.978280354,7.76049646,7.706050487,7.692438993,7.68903612,7.688185401,7.687972722,-1.989852902,1601,,7/7/14 12:28
1583,46,GlaxoSmithKline,Large Pharma,3229,Rytmonorm,propafenone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-90,,Expired,N/A,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1601,,7/7/14 12:28
1583,46,GlaxoSmithKline,Large Pharma,3229,Rytmonorm,propafenone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-90,,Expired,N/A,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1601,,7/7/14 12:28
1583,46,GlaxoSmithKline,Large Pharma,3229,Rytmonorm,propafenone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-90,,Expired,N/A,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1601,,7/7/14 12:28
1583,46,GlaxoSmithKline,Large Pharma,3229,Rytmonorm,propafenone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-90,,Expired,N/A,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,4,US,Sales,74.8445611,79.25977208,26.45248172,12.50448032,8.84941593,7.978280354,7.76049646,7.706050487,7.692438993,7.68903612,7.688185401,7.687972722,-1.989852902,1601,,7/7/14 12:28
1587,58,Lundbeck,Regional & Specialty Pharma,1237,Sabril,vigabatrin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-09,,Apr-16,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1043,Epilepsy,7/7/14 12:28
1587,58,Lundbeck,Regional & Specialty Pharma,1237,Sabril,vigabatrin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-09,,Apr-16,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,1,Global,Sales,3.73203956,31.76613847,57.66727475,64.92170402,94.3786811,105.3464303,113.3949425,119.7945569,76.5693791,39.82837776,29.26381021,23.46289339,-18.03205668,1043,Epilepsy,7/7/14 12:28
1587,58,Lundbeck,Regional & Specialty Pharma,1237,Sabril,vigabatrin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-09,,Apr-16,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1043,Epilepsy,7/7/14 12:28
1587,58,Lundbeck,Regional & Specialty Pharma,1237,Sabril,vigabatrin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-09,,Apr-16,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1043,Epilepsy,7/7/14 12:28
1587,58,Lundbeck,Regional & Specialty Pharma,1237,Sabril,vigabatrin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-09,,Apr-16,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1043,Epilepsy,7/7/14 12:28
1587,58,Lundbeck,Regional & Specialty Pharma,1237,Sabril,vigabatrin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-09,,Apr-16,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,1,US,Sales,3.73203956,31.76613847,57.66727475,64.92170402,94.3786811,105.3464303,113.3949425,119.7945569,76.5693791,39.82837776,29.26381021,23.46289339,-18.03205668,1043,Epilepsy,7/7/14 12:28
1589,625,Zambon,Small Biotech,1615,safinamide,ME2125,Small Molecule (Chemical),Filed,Licensed (Development),Jul-15,Feb-15,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,19.083337,41.72230144,61.05561515,80.38877442,96.38426772,110.5157535,0,1045,Parkinson's Disease,7/7/14 12:28
1589,625,Zambon,Small Biotech,1615,safinamide,ME2125,Small Molecule (Chemical),Filed,Licensed (Development),Jul-15,Feb-15,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,10.083337,17.72227144,25.05557015,32.38883442,38.30436132,43.6038833,0,1045,Parkinson's Disease,7/7/14 12:28
1589,625,Zambon,Small Biotech,1615,safinamide,ME2125,Small Molecule (Chemical),Filed,Licensed (Development),Jul-15,Feb-15,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,9,24.00003,36.000045,47.99994,58.0799064,66.91187016,0,1045,Parkinson's Disease,7/7/14 12:28
1592,63,Merck KGaA,Regional & Specialty Pharma,200,Saizen,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jun-89,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1641,Growth Hormone Disorders,7/7/14 12:28
1592,63,Merck KGaA,Regional & Specialty Pharma,200,Saizen,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jun-89,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,Global,Sales,265.3941949,299.659538,312.9873771,321.3178316,312.0870657,314.3686463,313.1658114,310.3245867,308.6352068,307.0204513,305.4051397,304.0244125,-0.373218611,1641,Growth Hormone Disorders,7/7/14 12:28
1592,63,Merck KGaA,Regional & Specialty Pharma,200,Saizen,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jun-89,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1641,Growth Hormone Disorders,7/7/14 12:28
1592,63,Merck KGaA,Regional & Specialty Pharma,200,Saizen,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jun-89,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,ROW,Sales,137.5603419,155.2612637,164.2106141,169.655815,172.6439087,178.7502159,180.8833925,183.0568093,184.7858851,186.2757876,187.5251112,188.5823091,1.269466378,1641,Growth Hormone Disorders,7/7/14 12:28
1592,63,Merck KGaA,Regional & Specialty Pharma,200,Saizen,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jun-89,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1641,Growth Hormone Disorders,7/7/14 12:28
1592,63,Merck KGaA,Regional & Specialty Pharma,200,Saizen,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jun-89,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,US,Sales,127.833853,144.3982743,148.776763,151.6620165,139.443157,135.6184304,132.2824189,127.2677773,123.8493217,120.7446636,117.8800284,115.4421035,-2.662314518,1641,Growth Hormone Disorders,7/7/14 12:28
1594,8,Allergan,Regional & Specialty Pharma,1970,Sanctura XR,trospium chloride,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,,Oct-12,N/A,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1048,Overactive bladder,7/7/14 12:28
1594,8,Allergan,Regional & Specialty Pharma,1970,Sanctura XR,trospium chloride,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,,Oct-12,N/A,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Sales,65.6,62.5,56.8,27.7,11,0,0,0,0,0,0,0,-100,1048,Overactive bladder,7/7/14 12:28
1594,8,Allergan,Regional & Specialty Pharma,1970,Sanctura XR,trospium chloride,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,,Oct-12,N/A,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1048,Overactive bladder,7/7/14 12:28
1594,8,Allergan,Regional & Specialty Pharma,1970,Sanctura XR,trospium chloride,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,,Oct-12,N/A,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1048,Overactive bladder,7/7/14 12:28
1594,8,Allergan,Regional & Specialty Pharma,1970,Sanctura XR,trospium chloride,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,,Oct-12,N/A,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1048,Overactive bladder,7/7/14 12:28
1594,8,Allergan,Regional & Specialty Pharma,1970,Sanctura XR,trospium chloride,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-08,,Oct-12,N/A,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Sales,65.6,62.5,56.8,27.7,11,0,0,0,0,0,0,0,-100,1048,Overactive bladder,7/7/14 12:28
1596,67,Novartis,Large Pharma,953,Sandimmune / Neoral,cyclosporine A,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-97,Expired,Expired,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1406,Rheumatoid Arthritis,7/7/14 12:28
1596,67,Novartis,Large Pharma,953,Sandimmune / Neoral,cyclosporine A,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-97,Expired,Expired,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,119.944,115.9664,110.2,106.7,97.4,93.1554832,89.1056428,85.40957327,82.55998377,80.17923997,78.19444524,76.56952666,-3.379113972,1406,Rheumatoid Arthritis,7/7/14 12:28
1596,67,Novartis,Large Pharma,953,Sandimmune / Neoral,cyclosporine A,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-97,Expired,Expired,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1406,Rheumatoid Arthritis,7/7/14 12:28
1596,67,Novartis,Large Pharma,953,Sandimmune / Neoral,cyclosporine A,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-97,Expired,Expired,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,109,105.8,101.5,98.4,90.2,86.077,82.47795,79.2044525,76.72570787,74.66684578,72.96741803,71.59323303,-3.246539865,1406,Rheumatoid Arthritis,7/7/14 12:28
1596,67,Novartis,Large Pharma,953,Sandimmune / Neoral,cyclosporine A,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-97,Expired,Expired,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1406,Rheumatoid Arthritis,7/7/14 12:28
1596,67,Novartis,Large Pharma,953,Sandimmune / Neoral,cyclosporine A,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-97,Expired,Expired,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,10.944,10.1664,8.7,8.3,7.2,7.0784832,6.6276928,6.205120768,5.834275891,5.512394189,5.227027212,4.976293633,-5.140255232,1406,Rheumatoid Arthritis,7/7/14 12:28
1597,67,Novartis,Large Pharma,953,Sandimmune / Neoral,cyclosporine A,Small Molecule (Chemical),Launched,In-House,Jul-83,Jul-83,Expired,Expired,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1406,Transplant rejection,7/7/14 12:28
1597,67,Novartis,Large Pharma,953,Sandimmune / Neoral,cyclosporine A,Small Molecule (Chemical),Launched,In-House,Jul-83,Jul-83,Expired,Expired,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,Global,Sales,799,755,792.8,726.98,652.8,630.1832,608.99888,593.88416,584.5544512,577.4638093,572.20448,568.2256436,-1.962656483,1406,Transplant rejection,7/7/14 12:28
1597,67,Novartis,Large Pharma,953,Sandimmune / Neoral,cyclosporine A,Small Molecule (Chemical),Launched,In-House,Jul-83,Jul-83,Expired,Expired,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1406,Transplant rejection,7/7/14 12:28
1597,67,Novartis,Large Pharma,953,Sandimmune / Neoral,cyclosporine A,Small Molecule (Chemical),Launched,In-House,Jul-83,Jul-83,Expired,Expired,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,ROW,Sales,721,683,730.5,671.3,603.8,586.996,570.7992,560.14336,554.724256,551.0659904,548.8315776,547.5121748,-1.388248295,1406,Transplant rejection,7/7/14 12:28
1597,67,Novartis,Large Pharma,953,Sandimmune / Neoral,cyclosporine A,Small Molecule (Chemical),Launched,In-House,Jul-83,Jul-83,Expired,Expired,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1406,Transplant rejection,7/7/14 12:28
1597,67,Novartis,Large Pharma,953,Sandimmune / Neoral,cyclosporine A,Small Molecule (Chemical),Launched,In-House,Jul-83,Jul-83,Expired,Expired,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,6,US,Sales,78,72,62.3,55.68,49,43.1872,38.19968,33.7408,29.8301952,26.39781888,23.3729024,20.71346872,-11.57407948,1406,Transplant rejection,7/7/14 12:28
1598,67,Novartis,Large Pharma,984,Sandostatin,octreotide,Synthetic Peptide,Launched,In-House,Dec-95,Dec-96,Jan-16,Jan-16,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1567,Acromegaly,7/7/14 12:28
1598,67,Novartis,Large Pharma,984,Sandostatin,octreotide,Synthetic Peptide,Launched,In-House,Dec-95,Dec-96,Jan-16,Jan-16,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Sales,206.2805,210.0693225,233,272,286,274.5760923,260.6508643,234.4941055,179.4262807,131.7598514,108.3739225,91.67561225,-15.00123582,1567,Acromegaly,7/7/14 12:28
1598,67,Novartis,Large Pharma,984,Sandostatin,octreotide,Synthetic Peptide,Launched,In-House,Dec-95,Dec-96,Jan-16,Jan-16,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1567,Acromegaly,7/7/14 12:28
1598,67,Novartis,Large Pharma,984,Sandostatin,octreotide,Synthetic Peptide,Launched,In-House,Dec-95,Dec-96,Jan-16,Jan-16,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Sales,126.616,128.24136,141,155,158,140.8358083,122.7119808,111.7185352,94.06810602,92.53584085,89.32294968,87.71789105,-8.063028636,1567,Acromegaly,7/7/14 12:28
1598,67,Novartis,Large Pharma,984,Sandostatin,octreotide,Synthetic Peptide,Launched,In-House,Dec-95,Dec-96,Jan-16,Jan-16,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1567,Acromegaly,7/7/14 12:28
1598,67,Novartis,Large Pharma,984,Sandostatin,octreotide,Synthetic Peptide,Launched,In-House,Dec-95,Dec-96,Jan-16,Jan-16,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Sales,79.6645,81.8279625,92,117,128,133.7402841,137.9388835,122.7755702,85.35817472,39.22401054,19.05097278,3.957721196,-39.14173964,1567,Acromegaly,7/7/14 12:28
1599,67,Novartis,Large Pharma,984,Sandostatin,octreotide,Synthetic Peptide,Launched,In-House,Mar-98,Jan-99,Jan-17,Jan-17,191,Somatostatin Analogs,55,Hormonals,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1567,Severe Diarrhea Associated With Metastatic Carcinoid Tumors,7/7/14 12:28
1599,67,Novartis,Large Pharma,984,Sandostatin,octreotide,Synthetic Peptide,Launched,In-House,Mar-98,Jan-99,Jan-17,Jan-17,191,Somatostatin Analogs,55,Hormonals,3,Oncology,6,Global,Sales,947.1,1081,1210,1239.78,1302.9,1357.912,1408.28712,1455.146243,1122.099259,1007.936373,944.9252394,919.3139576,-4.85965914,1567,Severe Diarrhea Associated With Metastatic Carcinoid Tumors,7/7/14 12:28
1599,67,Novartis,Large Pharma,984,Sandostatin,octreotide,Synthetic Peptide,Launched,In-House,Mar-98,Jan-99,Jan-17,Jan-17,191,Somatostatin Analogs,55,Hormonals,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1567,Severe Diarrhea Associated With Metastatic Carcinoid Tumors,7/7/14 12:28
1599,67,Novartis,Large Pharma,984,Sandostatin,octreotide,Synthetic Peptide,Launched,In-House,Mar-98,Jan-99,Jan-17,Jan-17,191,Somatostatin Analogs,55,Hormonals,3,Oncology,6,ROW,Sales,571.5,652,722,707.6,720.7,731.18,739.564,746.2712,751.63696,755.929568,759.3636544,762.1109235,0.801323494,1567,Severe Diarrhea Associated With Metastatic Carcinoid Tumors,7/7/14 12:28
1599,67,Novartis,Large Pharma,984,Sandostatin,octreotide,Synthetic Peptide,Launched,In-House,Mar-98,Jan-99,Jan-17,Jan-17,191,Somatostatin Analogs,55,Hormonals,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1567,Severe Diarrhea Associated With Metastatic Carcinoid Tumors,7/7/14 12:28
1599,67,Novartis,Large Pharma,984,Sandostatin,octreotide,Synthetic Peptide,Launched,In-House,Mar-98,Jan-99,Jan-17,Jan-17,191,Somatostatin Analogs,55,Hormonals,3,Oncology,6,US,Sales,375.6,429,488,532.18,582.2,626.732,668.72312,708.8750432,370.4622988,252.0068047,185.561585,157.2030341,-17.05887939,1567,Severe Diarrhea Associated With Metastatic Carcinoid Tumors,7/7/14 12:28
1600,61,Merck & Co,Large Pharma,2631,Saphris / Sycrest,asenapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,Oct-15,Jun-15,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1049,Schizophrenia,7/7/14 12:28
1600,61,Merck & Co,Large Pharma,2631,Saphris / Sycrest,asenapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,Oct-15,Jun-15,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,40,78,120,166,158,0,4.158,12.0582,17.04776258,24.94786623,30.56943472,35.512417,-19.20413901,1049,Schizophrenia,7/7/14 12:28
1600,61,Merck & Co,Large Pharma,2631,Saphris / Sycrest,asenapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,Oct-15,Jun-15,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1049,Schizophrenia,7/7/14 12:28
1600,61,Merck & Co,Large Pharma,2631,Saphris / Sycrest,asenapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,Oct-15,Jun-15,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,4.158,12.0582,17.04776258,24.94786623,30.56943472,35.512417,0,1049,Schizophrenia,7/7/14 12:28
1600,61,Merck & Co,Large Pharma,2631,Saphris / Sycrest,asenapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,Oct-15,Jun-15,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1049,Schizophrenia,7/7/14 12:28
1600,61,Merck & Co,Large Pharma,2631,Saphris / Sycrest,asenapine,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-09,Oct-15,Jun-15,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,40,78,120,166,158,0,0,0,0,0,0,0,-100,1049,Schizophrenia,7/7/14 12:28
1602,89,Sanofi,Large Pharma,4110,sarilumab,sarilumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Nov-16,Oct-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1052,Rheumatoid Arthritis,7/7/14 12:28
1602,89,Sanofi,Large Pharma,4110,sarilumab,sarilumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Nov-16,Oct-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,13.83366423,96.09791307,217.8343686,339.5710886,430.6448057,0,1052,Rheumatoid Arthritis,7/7/14 12:28
1602,89,Sanofi,Large Pharma,4110,sarilumab,sarilumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Nov-16,Oct-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1052,Rheumatoid Arthritis,7/7/14 12:28
1602,89,Sanofi,Large Pharma,4110,sarilumab,sarilumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Nov-16,Oct-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,4.98011275,28.22065552,61.42141011,94.62213913,119.5890987,0,1052,Rheumatoid Arthritis,7/7/14 12:28
1602,89,Sanofi,Large Pharma,4110,sarilumab,sarilumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Nov-16,Oct-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1052,Rheumatoid Arthritis,7/7/14 12:28
1602,89,Sanofi,Large Pharma,4110,sarilumab,sarilumab,Antibody/Antibody Derivative,Phase III,Licensed (Development),Nov-16,Oct-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,8.853551484,67.87725756,156.4129585,244.9489495,311.055707,0,1052,Rheumatoid Arthritis,7/7/14 12:28
1604,89,Sanofi,Large Pharma,986,SAR3419,SAR3419,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1057,B-cell Malignancies,7/7/14 12:28
1604,89,Sanofi,Large Pharma,986,SAR3419,SAR3419,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1057,B-cell Malignancies,7/7/14 12:28
1604,89,Sanofi,Large Pharma,986,SAR3419,SAR3419,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1057,B-cell Malignancies,7/7/14 12:28
1604,89,Sanofi,Large Pharma,986,SAR3419,SAR3419,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1057,B-cell Malignancies,7/7/14 12:28
1604,89,Sanofi,Large Pharma,986,SAR3419,SAR3419,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1057,B-cell Malignancies,7/7/14 12:28
1604,89,Sanofi,Large Pharma,986,SAR3419,SAR3419,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1057,B-cell Malignancies,7/7/14 12:28
1613,42,Forest,Regional & Specialty Pharma,131,Savella,milnacipran,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,,Nov-21,N/A,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1060,Fibromyalgia,7/7/14 12:28
1613,42,Forest,Regional & Specialty Pharma,131,Savella,milnacipran,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,,Nov-21,N/A,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,53,90.2,102.9,104.6,106.84,108.5888,110.027136,111.2026419,112.1640731,112.950344,113.5933735,114.1192564,0.946040604,1060,Fibromyalgia,7/7/14 12:28
1613,42,Forest,Regional & Specialty Pharma,131,Savella,milnacipran,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,,Nov-21,N/A,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1060,Fibromyalgia,7/7/14 12:28
1613,42,Forest,Regional & Specialty Pharma,131,Savella,milnacipran,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,,Nov-21,N/A,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1060,Fibromyalgia,7/7/14 12:28
1613,42,Forest,Regional & Specialty Pharma,131,Savella,milnacipran,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,,Nov-21,N/A,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1060,Fibromyalgia,7/7/14 12:28
1613,42,Forest,Regional & Specialty Pharma,131,Savella,milnacipran,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,,Nov-21,N/A,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,53,90.2,102.9,104.6,106.84,108.5888,110.027136,111.2026419,112.1640731,112.950344,113.5933735,114.1192564,0.946040604,1060,Fibromyalgia,7/7/14 12:28
1617,262,Anacor,Small Biotech,3102,tavaborole,AN2690,Small Molecule (Chemical),Filed,In-House,Oct-14,,,,60,Other Anti-fungals,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,5,23.33335,36.66672619,50.0002145,60.03361341,68.21200824,75.04814857,0,1064,Onychomycosis,7/7/14 12:28
1617,262,Anacor,Small Biotech,3102,tavaborole,AN2690,Small Molecule (Chemical),Filed,In-House,Oct-14,,,,60,Other Anti-fungals,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1064,Onychomycosis,7/7/14 12:28
1617,262,Anacor,Small Biotech,3102,tavaborole,AN2690,Small Molecule (Chemical),Filed,In-House,Oct-14,,,,60,Other Anti-fungals,25,Fungal Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,5,23.33335,36.66672619,50.0002145,60.03361341,68.21200824,75.04814857,0,1064,Onychomycosis,7/7/14 12:28
1620,61,Merck & Co,Large Pharma,3090,Zontivity,vorapaxar,Small Molecule (Chemical),Approved,Corporate Acquisition,Jun-14,Nov-14,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1066,Secondary Prevention of Cardiac Events,7/7/14 12:28
1620,61,Merck & Co,Large Pharma,3090,Zontivity,vorapaxar,Small Molecule (Chemical),Approved,Corporate Acquisition,Jun-14,Nov-14,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,30.41666,120.694409,237.3611134,354.0287496,450.9180746,544.3963127,631.7356945,0,1066,Secondary Prevention of Cardiac Events,7/7/14 12:28
1620,61,Merck & Co,Large Pharma,3090,Zontivity,vorapaxar,Small Molecule (Chemical),Approved,Corporate Acquisition,Jun-14,Nov-14,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1066,Secondary Prevention of Cardiac Events,7/7/14 12:28
1620,61,Merck & Co,Large Pharma,3090,Zontivity,vorapaxar,Small Molecule (Chemical),Approved,Corporate Acquisition,Jun-14,Nov-14,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,4.166675,31.94452222,73.61135978,115.2783339,154.1674416,194.4454553,234.5845892,0,1066,Secondary Prevention of Cardiac Events,7/7/14 12:28
1620,61,Merck & Co,Large Pharma,3090,Zontivity,vorapaxar,Small Molecule (Chemical),Approved,Corporate Acquisition,Jun-14,Nov-14,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1066,Secondary Prevention of Cardiac Events,7/7/14 12:28
1620,61,Merck & Co,Large Pharma,3090,Zontivity,vorapaxar,Small Molecule (Chemical),Approved,Corporate Acquisition,Jun-14,Nov-14,N/A,N/A,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,26.249985,88.74988679,163.7497536,238.7504158,296.7506329,349.9508574,397.1511053,0,1066,Secondary Prevention of Cardiac Events,7/7/14 12:28
1621,2448,FKD Therapies Oy,Small Biotech,507,SCH-721015,SCH-721015,Gene Therapy,Phase II,Licensed (Development),,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1067,Bladder Cancer,7/7/14 12:28
1621,2448,FKD Therapies Oy,Small Biotech,507,SCH-721015,SCH-721015,Gene Therapy,Phase II,Licensed (Development),,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1067,Bladder Cancer,7/7/14 12:28
1621,2448,FKD Therapies Oy,Small Biotech,507,SCH-721015,SCH-721015,Gene Therapy,Phase II,Licensed (Development),,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1067,Bladder Cancer,7/7/14 12:28
1621,2448,FKD Therapies Oy,Small Biotech,507,SCH-721015,SCH-721015,Gene Therapy,Phase II,Licensed (Development),,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1067,Bladder Cancer,7/7/14 12:28
1621,2448,FKD Therapies Oy,Small Biotech,507,SCH-721015,SCH-721015,Gene Therapy,Phase II,Licensed (Development),,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1067,Bladder Cancer,7/7/14 12:28
1621,2448,FKD Therapies Oy,Small Biotech,507,SCH-721015,SCH-721015,Gene Therapy,Phase II,Licensed (Development),,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1067,Bladder Cancer,7/7/14 12:28
1623,170,AVEO Pharmaceuticals,Regional & Specialty Pharma,3581,ficlatuzumab,AV299,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1069,Non-small-cell Lung Cancer,7/7/14 12:28
1623,170,AVEO Pharmaceuticals,Regional & Specialty Pharma,3581,ficlatuzumab,AV299,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1069,Non-small-cell Lung Cancer,7/7/14 12:28
1623,170,AVEO Pharmaceuticals,Regional & Specialty Pharma,3581,ficlatuzumab,AV299,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1069,Non-small-cell Lung Cancer,7/7/14 12:28
1626,67,Novartis,Large Pharma,515,Tyzeka / Sebivo,telbivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-06,Nov-06,Aug-19,May-22,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1071,Hepatitis B,7/7/14 12:28
1626,67,Novartis,Large Pharma,515,Tyzeka / Sebivo,telbivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-06,Nov-06,Aug-19,May-22,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,Global,Sales,84,95,114,117.512,119.42016,120.0601088,119.980714,119.7039191,119.3642738,119.0343441,118.7428847,118.4959788,-0.110924107,1071,Hepatitis B,7/7/14 12:28
1626,67,Novartis,Large Pharma,515,Tyzeka / Sebivo,telbivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-06,Nov-06,Aug-19,May-22,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1071,Hepatitis B,7/7/14 12:28
1626,67,Novartis,Large Pharma,515,Tyzeka / Sebivo,telbivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-06,Nov-06,Aug-19,May-22,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,50.4,63,84,89.112,92.30016,93.9641088,94.70391398,95.08247911,95.26712176,95.35662246,95.40070737,95.422237,0.476355774,1071,Hepatitis B,7/7/14 12:28
1626,67,Novartis,Large Pharma,515,Tyzeka / Sebivo,telbivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-06,Nov-06,Aug-19,May-22,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1071,Hepatitis B,7/7/14 12:28
1626,67,Novartis,Large Pharma,515,Tyzeka / Sebivo,telbivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-06,Nov-06,Aug-19,May-22,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,6,US,Sales,33.6,32,30,28.4,27.12,26.096,25.2768,24.62144,24.097152,23.6777216,23.34217728,23.07374182,-2.281793437,1071,Hepatitis B,7/7/14 12:28
1629,16,AstraZeneca,Large Pharma,2897,Seloken / Toprol XL ,metoprolol,Small Molecule (Chemical),Launched,In-House,Feb-75,Feb-75,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1074,Hypertension,7/7/14 12:28
1629,16,AstraZeneca,Large Pharma,2897,Seloken / Toprol XL ,metoprolol,Small Molecule (Chemical),Launched,In-House,Feb-75,Feb-75,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,Global,Sales,1443,1210,986,918,750,701,693.42,685.6005,679.2313125,673.8629903,669.4008094,665.0418304,-1.702808994,1074,Hypertension,7/7/14 12:28
1629,16,AstraZeneca,Large Pharma,2897,Seloken / Toprol XL ,metoprolol,Small Molecule (Chemical),Launched,In-House,Feb-75,Feb-75,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1074,Hypertension,7/7/14 12:28
1629,16,AstraZeneca,Large Pharma,2897,Seloken / Toprol XL ,metoprolol,Small Molecule (Chemical),Launched,In-House,Feb-75,Feb-75,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,479,521,582,598,619,614,614.42,614.6005,614.6313125,614.6389903,614.6414494,614,-0.115794855,1074,Hypertension,7/7/14 12:28
1629,16,AstraZeneca,Large Pharma,2897,Seloken / Toprol XL ,metoprolol,Small Molecule (Chemical),Launched,In-House,Feb-75,Feb-75,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1074,Hypertension,7/7/14 12:28
1629,16,AstraZeneca,Large Pharma,2897,Seloken / Toprol XL ,metoprolol,Small Molecule (Chemical),Launched,In-House,Feb-75,Feb-75,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,US,Sales,964,689,404,320,131,87,79,71,64.6,59.224,54.75936,51.0418304,-12.59783441,1074,Hypertension,7/7/14 12:28
1630,76,Pfizer,Large Pharma,342,Selzentry,maraviroc,Small Molecule (Chemical),Launched,Licensed (Development),Sep-07,Dec-07,May-21,Sep-22,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1076,HIV,7/7/14 12:28
1630,76,Pfizer,Large Pharma,342,Selzentry,maraviroc,Small Molecule (Chemical),Launched,Licensed (Development),Sep-07,Dec-07,May-21,Sep-22,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,Global,Sales,100,0,0,0,0,0,0,0,0,0,0,0,0,1076,HIV,7/7/14 12:28
1630,76,Pfizer,Large Pharma,342,Selzentry,maraviroc,Small Molecule (Chemical),Launched,Licensed (Development),Sep-07,Dec-07,May-21,Sep-22,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1076,HIV,7/7/14 12:28
1630,76,Pfizer,Large Pharma,342,Selzentry,maraviroc,Small Molecule (Chemical),Launched,Licensed (Development),Sep-07,Dec-07,May-21,Sep-22,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,ROW,Sales,55,0,0,0,0,0,0,0,0,0,0,0,0,1076,HIV,7/7/14 12:28
1630,76,Pfizer,Large Pharma,342,Selzentry,maraviroc,Small Molecule (Chemical),Launched,Licensed (Development),Sep-07,Dec-07,May-21,Sep-22,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1076,HIV,7/7/14 12:28
1630,76,Pfizer,Large Pharma,342,Selzentry,maraviroc,Small Molecule (Chemical),Launched,Licensed (Development),Sep-07,Dec-07,May-21,Sep-22,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,US,Sales,45,0,0,0,0,0,0,0,0,0,0,0,0,1076,HIV,7/7/14 12:28
1632,11,Amgen,Large Pharma,4378,Sensipar / Mimpara,cinacalcet,Small Molecule (Chemical),Launched,Licensed (Development),May-04,Dec-04,Dec-16,Oct-19,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1393,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
1632,11,Amgen,Large Pharma,4378,Sensipar / Mimpara,cinacalcet,Small Molecule (Chemical),Launched,Licensed (Development),May-04,Dec-04,Dec-16,Oct-19,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,Global,Sales,651,714,808,950,1089,1164.24,1214.686,1214.959296,672.3620745,538.853439,463.0325391,283.7025348,-17.4821339,1393,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
1632,11,Amgen,Large Pharma,4378,Sensipar / Mimpara,cinacalcet,Small Molecule (Chemical),Launched,Licensed (Development),May-04,Dec-04,Dec-16,Oct-19,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1393,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
1632,11,Amgen,Large Pharma,4378,Sensipar / Mimpara,cinacalcet,Small Molecule (Chemical),Launched,Licensed (Development),May-04,Dec-04,Dec-16,Oct-19,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,ROW,Sales,222,255,290,311,332,351.04,367.056,381.392,394.01664,405.069696,373.3331328,211.6926131,-6.226286107,1393,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
1632,11,Amgen,Large Pharma,4378,Sensipar / Mimpara,cinacalcet,Small Molecule (Chemical),Launched,Licensed (Development),May-04,Dec-04,Dec-16,Oct-19,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1393,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
1632,11,Amgen,Large Pharma,4378,Sensipar / Mimpara,cinacalcet,Small Molecule (Chemical),Launched,Licensed (Development),May-04,Dec-04,Dec-16,Oct-19,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,US,Sales,429,459,518,639,757,813.2,847.63,833.567296,278.3454345,133.783743,89.6994063,72.0099217,-28.54337545,1393,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
1633,1,Abbott,Regional & Specialty Pharma,762,Serc,betahistine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-70,N/A,Expired,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1361,Mnire's Disease,7/7/14 12:28
1633,1,Abbott,Regional & Specialty Pharma,762,Serc,betahistine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-70,N/A,Expired,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Sales,0,157.5,233,205,185.4,169.72,157.176,147.1408,139.11264,132.690112,127.5520896,123.4416717,-5.645068018,1361,Mnire's Disease,7/7/14 12:28
1633,1,Abbott,Regional & Specialty Pharma,762,Serc,betahistine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-70,N/A,Expired,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1361,Mnire's Disease,7/7/14 12:28
1633,1,Abbott,Regional & Specialty Pharma,762,Serc,betahistine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-70,N/A,Expired,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Sales,0,157.5,233,205,185.4,169.72,157.176,147.1408,139.11264,132.690112,127.5520896,123.4416717,-5.645068018,1361,Mnire's Disease,7/7/14 12:28
1633,1,Abbott,Regional & Specialty Pharma,762,Serc,betahistine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-70,N/A,Expired,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1361,Mnire's Disease,7/7/14 12:28
1633,1,Abbott,Regional & Specialty Pharma,762,Serc,betahistine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-70,N/A,Expired,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1361,Mnire's Disease,7/7/14 12:28
1633,1,Solvay,Regional & Specialty Pharma,762,Serc,betahistine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-70,N/A,Expired,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Proforma,195,22.5,0,0,0,0,0,0,0,0,0,0,0,1361,Mnire's Disease,7/7/14 12:28
1633,1,Solvay,Regional & Specialty Pharma,762,Serc,betahistine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-70,N/A,Expired,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Proforma,195,22.5,0,0,0,0,0,0,0,0,0,0,0,1361,Mnire's Disease,7/7/14 12:28
1634,58,Lundbeck,Regional & Specialty Pharma,1068,Serdolect,sertindole,Small Molecule (Chemical),Launched,In-House,,Jul-96,N/A,Mar-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1084,Schizophrenia,7/7/14 12:28
1634,58,Lundbeck,Regional & Specialty Pharma,1068,Serdolect,sertindole,Small Molecule (Chemical),Launched,In-House,,Jul-96,N/A,Mar-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,Global,Sales,12.39402438,13.01672612,9.517899717,4.650646497,2.988557325,2.265447184,1.976203128,1.860505506,1.814226457,1.795714837,1.788310189,1.78534833,-7.095367299,1084,Schizophrenia,7/7/14 12:28
1634,58,Lundbeck,Regional & Specialty Pharma,1068,Serdolect,sertindole,Small Molecule (Chemical),Launched,In-House,,Jul-96,N/A,Mar-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1084,Schizophrenia,7/7/14 12:28
1634,58,Lundbeck,Regional & Specialty Pharma,1068,Serdolect,sertindole,Small Molecule (Chemical),Launched,In-House,,Jul-96,N/A,Mar-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,ROW,Sales,12.39402438,13.01672612,9.517899717,4.650646497,2.988557325,2.265447184,1.976203128,1.860505506,1.814226457,1.795714837,1.788310189,1.78534833,-7.095367299,1084,Schizophrenia,7/7/14 12:28
1634,58,Lundbeck,Regional & Specialty Pharma,1068,Serdolect,sertindole,Small Molecule (Chemical),Launched,In-House,,Jul-96,N/A,Mar-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1084,Schizophrenia,7/7/14 12:28
1634,58,Lundbeck,Regional & Specialty Pharma,1068,Serdolect,sertindole,Small Molecule (Chemical),Launched,In-House,,Jul-96,N/A,Mar-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1084,Schizophrenia,7/7/14 12:28
1635,46,GlaxoSmithKline,Large Pharma,711,Serevent,salmeterol,Small Molecule (Chemical),Launched,In-House,Mar-94,Dec-90,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1085,COPD,7/7/14 12:28
1635,46,GlaxoSmithKline,Large Pharma,711,Serevent,salmeterol,Small Molecule (Chemical),Launched,In-House,Mar-94,Dec-90,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,Global,Sales,367.9857587,310.5450116,291.7788893,229.8291867,201.6804096,190.9397552,183.6065618,180.0390464,178.1994924,177.1624913,176.6273304,176.3433529,-1.899600319,1085,COPD,7/7/14 12:28
1635,46,GlaxoSmithKline,Large Pharma,711,Serevent,salmeterol,Small Molecule (Chemical),Launched,In-House,Mar-94,Dec-90,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1085,COPD,7/7/14 12:28
1635,46,GlaxoSmithKline,Large Pharma,711,Serevent,salmeterol,Small Molecule (Chemical),Launched,In-House,Mar-94,Dec-90,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,254.1596554,211.6650079,192.3816853,148.9927142,121.9462942,112.9410294,106.8999976,103.6824915,102.1158569,101.2288242,100.7617218,100.5178255,-2.722891801,1085,COPD,7/7/14 12:28
1635,46,GlaxoSmithKline,Large Pharma,711,Serevent,salmeterol,Small Molecule (Chemical),Launched,In-House,Mar-94,Dec-90,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1085,COPD,7/7/14 12:28
1635,46,GlaxoSmithKline,Large Pharma,711,Serevent,salmeterol,Small Molecule (Chemical),Launched,In-House,Mar-94,Dec-90,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,US,Sales,113.8261033,98.88000371,99.39720405,80.83647257,79.73411543,77.99872586,76.70656417,76.35655486,76.08363553,75.93366709,75.86560853,75.82552743,-0.71546375,1085,COPD,7/7/14 12:28
1636,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1408,Sermion,nicergoline,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-88,N/A,Expired,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1086,Stroke recovery,7/7/14 12:28
1636,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1408,Sermion,nicergoline,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-88,N/A,Expired,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,Global,Sales,77.56746978,73.53885303,69.63913213,60.50543126,53.34027085,47.21360252,41.98762089,37.50705184,33.67608639,30.39872879,20.13544449,15.4986071,-16.18539305,1086,Stroke recovery,7/7/14 12:28
1636,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1408,Sermion,nicergoline,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-88,N/A,Expired,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1086,Stroke recovery,7/7/14 12:28
1636,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1408,Sermion,nicergoline,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-88,N/A,Expired,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,ROW,Sales,77.56746978,73.53885303,69.63913213,60.50543126,53.34027085,47.21360252,41.98762089,37.50705184,33.67608639,30.39872879,20.13544449,15.4986071,-16.18539305,1086,Stroke recovery,7/7/14 12:28
1636,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1408,Sermion,nicergoline,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-88,N/A,Expired,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1086,Stroke recovery,7/7/14 12:28
1636,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1408,Sermion,nicergoline,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-88,N/A,Expired,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1086,Stroke recovery,7/7/14 12:28
1637,15,Astellas Pharma,Regional & Specialty Pharma,1038,Seroquel,quetiapine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-01,N/A,Dec-12,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1603,Schizophrenia,7/7/14 12:28
1637,15,Astellas Pharma,Regional & Specialty Pharma,1038,Seroquel,quetiapine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-01,N/A,Dec-12,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Sales,256.5573566,308.1628127,351.9941588,343.104109,211.4221671,201.3544449,191.2867227,190.2799504,184.8433804,180.5142599,175.5060714,173.1275384,-2.814327141,1603,Schizophrenia,7/7/14 12:28
1637,15,Astellas Pharma,Regional & Specialty Pharma,1038,Seroquel,quetiapine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-01,N/A,Dec-12,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1603,Schizophrenia,7/7/14 12:28
1637,15,Astellas Pharma,Regional & Specialty Pharma,1038,Seroquel,quetiapine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-01,N/A,Dec-12,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Sales,256.5573566,308.1628127,351.9941588,343.104109,211.4221671,201.3544449,191.2867227,190.2799504,184.8433804,180.5142599,175.5060714,173.1275384,-2.814327141,1603,Schizophrenia,7/7/14 12:28
1637,15,Astellas Pharma,Regional & Specialty Pharma,1038,Seroquel,quetiapine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-01,N/A,Dec-12,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1603,Schizophrenia,7/7/14 12:28
1637,15,Astellas Pharma,Regional & Specialty Pharma,1038,Seroquel,quetiapine,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-01,N/A,Dec-12,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1603,Schizophrenia,7/7/14 12:28
1638,16,AstraZeneca,Large Pharma,1038,Seroquel,quetiapine,Small Molecule (Chemical),Launched,In-House,Oct-97,Sep-97,Mar-12,Mar-12,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1603,Schizophrenia,7/7/14 12:28
1638,16,AstraZeneca,Large Pharma,1038,Seroquel,quetiapine,Small Molecule (Chemical),Launched,In-House,Oct-97,Sep-97,Mar-12,Mar-12,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,4866,5302,5828,2803,1682,1439.5,1315.505,1181.916692,792.5226533,429.1517374,344.8875793,307.9654772,-21.53642143,1603,Schizophrenia,7/7/14 12:28
1638,16,AstraZeneca,Large Pharma,1038,Seroquel,quetiapine,Small Molecule (Chemical),Launched,In-House,Oct-97,Sep-97,Mar-12,Mar-12,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1603,Schizophrenia,7/7/14 12:28
1638,16,AstraZeneca,Large Pharma,1038,Seroquel,quetiapine,Small Molecule (Chemical),Launched,In-House,Oct-97,Sep-97,Mar-12,Mar-12,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,1450,1555,1705,1295,956,752.6,630.56,557.336,484.3435902,257.9412079,207.9191582,184.6938982,-20.93225763,1603,Schizophrenia,7/7/14 12:28
1638,16,AstraZeneca,Large Pharma,1038,Seroquel,quetiapine,Small Molecule (Chemical),Launched,In-House,Oct-97,Sep-97,Mar-12,Mar-12,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1603,Schizophrenia,7/7/14 12:28
1638,16,AstraZeneca,Large Pharma,1038,Seroquel,quetiapine,Small Molecule (Chemical),Launched,In-House,Oct-97,Sep-97,Mar-12,Mar-12,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,3416,3747,4123,1508,726,686.9,684.945,624.580692,308.1790631,171.2105295,136.9684212,123.271579,-22.37714953,1603,Schizophrenia,7/7/14 12:28
1639,63,Merck KGaA,Regional & Specialty Pharma,1511,Serostim,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jun-89,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1741,AIDS-Associated Cachexia,7/7/14 12:28
1639,63,Merck KGaA,Regional & Specialty Pharma,1511,Serostim,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jun-89,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,Global,Sales,90.92789777,93.27472573,104.8865644,111.5398501,110.942863,110.9957351,112.2379404,112.0950288,112.3290822,112.5707487,112.7000019,112.8444377,0.243078877,1741,AIDS-Associated Cachexia,7/7/14 12:28
1639,63,Merck KGaA,Regional & Specialty Pharma,1511,Serostim,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jun-89,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1741,AIDS-Associated Cachexia,7/7/14 12:28
1639,63,Merck KGaA,Regional & Specialty Pharma,1511,Serostim,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jun-89,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,ROW,Sales,2,1.866643843,1.96307737,1.97227619,2.044397545,2.097269614,2.158242156,2.205891479,2.258582317,2.311417041,2.36317152,2.415437344,2.411138289,1741,AIDS-Associated Cachexia,7/7/14 12:28
1639,63,Merck KGaA,Regional & Specialty Pharma,1511,Serostim,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jun-89,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1741,AIDS-Associated Cachexia,7/7/14 12:28
1639,63,Merck KGaA,Regional & Specialty Pharma,1511,Serostim,somatropin,Recombinant Protein,Launched,Corporate Acquisition,Feb-97,Jun-89,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,US,Sales,88.92789777,91.40808189,102.923487,109.5675739,108.8984655,108.8984655,110.0796982,109.8891373,110.0704999,110.2593316,110.3368303,110.4290003,0.199582199,1741,AIDS-Associated Cachexia,7/7/14 12:28
1640,29,Chugai,Regional & Specialty Pharma,866,Sigmart,nicorandil,Small Molecule (Chemical),Launched,In-House,,Jan-84,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,Global,Alliance Revenue,177.4077627,173.2078589,165.5710476,119.01779,88.14109438,78.4148271,72.15803928,67.64009486,64.47738135,62.24543755,60.67367402,59.56620429,-5.444061758,1088,Angina,7/7/14 12:28
1640,29,Chugai,Regional & Specialty Pharma,866,Sigmart,nicorandil,Small Molecule (Chemical),Launched,In-House,,Jan-84,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,ROW,Alliance Revenue,177.4077627,173.2078589,165.5710476,119.01779,88.14109438,78.4148271,72.15803928,67.64009486,64.47738135,62.24543755,60.67367402,59.56620429,-5.444061758,1088,Angina,7/7/14 12:28
1640,29,Chugai,Regional & Specialty Pharma,866,Sigmart,nicorandil,Small Molecule (Chemical),Launched,In-House,,Jan-84,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1088,Angina,7/7/14 12:28
1640,86,Roche,Large Pharma,866,Sigmart,nicorandil,Small Molecule (Chemical),Launched,In-House,,Jan-84,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,5,Global,Sales,177.4077627,173.2078589,165.5710476,119.01779,88.14109438,78.4148271,72.15803928,67.64009486,64.47738135,62.24543755,60.67367402,59.56620429,-5.444061758,1088,Angina,7/7/14 12:28
1640,86,Roche,Large Pharma,866,Sigmart,nicorandil,Small Molecule (Chemical),Launched,In-House,,Jan-84,N/A,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,5,ROW,Sales,177.4077627,173.2078589,165.5710476,119.01779,88.14109438,78.4148271,72.15803928,67.64009486,64.47738135,62.24543755,60.67367402,59.56620429,-5.444061758,1088,Angina,7/7/14 12:28
1641,2222,Pernix Therapeutics,Regional & Specialty Pharma,1568,Silenor,doxepin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-10,,Jan-20,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1089,Insomnia,7/7/14 12:28
1641,2222,Pernix Therapeutics,Regional & Specialty Pharma,1568,Silenor,doxepin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-10,,Jan-20,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,9.2,10.4153,9.66592,9.307698,9.0894712,8.96635828,8.895290432,8.854552001,-0.545247651,1089,Insomnia,7/7/14 12:28
1641,2222,Pernix Therapeutics,Regional & Specialty Pharma,1568,Silenor,doxepin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-10,,Jan-20,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1089,Insomnia,7/7/14 12:28
1641,2222,Pernix Therapeutics,Regional & Specialty Pharma,1568,Silenor,doxepin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-10,,Jan-20,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1089,Insomnia,7/7/14 12:28
1641,2222,Pernix Therapeutics,Regional & Specialty Pharma,1568,Silenor,doxepin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-10,,Jan-20,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1089,Insomnia,7/7/14 12:28
1641,2222,Pernix Therapeutics,Regional & Specialty Pharma,1568,Silenor,doxepin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-10,,Jan-20,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,9.2,10.4153,9.66592,9.307698,9.0894712,8.96635828,8.895290432,8.854552001,-0.545247651,1089,Insomnia,7/7/14 12:28
1641,2222,Somaxon,Regional & Specialty Pharma,1568,Silenor,doxepin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-10,,Jan-20,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,Global,Proforma,0,0,1.382,16.155,1.8,0,0,0,0,0,0,0,-100,1089,Insomnia,7/7/14 12:28
1641,2222,Somaxon,Regional & Specialty Pharma,1568,Silenor,doxepin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-10,,Jan-20,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,US,Proforma,0,0,1.382,16.155,1.8,0,0,0,0,0,0,0,-100,1089,Insomnia,7/7/14 12:28
1642,2221,AbbVie,Large Pharma,1548,Simcor,Extended-release niacin  +  simvastatin,Small Molecule (Chemical),Launched,In-House,Mar-08,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1090,Dyslipidemia,7/7/14 12:28
1642,2221,AbbVie,Large Pharma,1548,Simcor,Extended-release niacin  +  simvastatin,Small Molecule (Chemical),Launched,In-House,Mar-08,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,98,45,43.46,40.0644,39.496616,39.21339024,39.13967159,39.11235744,-12.29737009,1090,Dyslipidemia,7/7/14 12:28
1642,2221,AbbVie,Large Pharma,1548,Simcor,Extended-release niacin  +  simvastatin,Small Molecule (Chemical),Launched,In-House,Mar-08,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1090,Dyslipidemia,7/7/14 12:28
1642,2221,AbbVie,Large Pharma,1548,Simcor,Extended-release niacin  +  simvastatin,Small Molecule (Chemical),Launched,In-House,Mar-08,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1090,Dyslipidemia,7/7/14 12:28
1642,2221,AbbVie,Large Pharma,1548,Simcor,Extended-release niacin  +  simvastatin,Small Molecule (Chemical),Launched,In-House,Mar-08,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1090,Dyslipidemia,7/7/14 12:28
1642,2221,AbbVie,Large Pharma,1548,Simcor,Extended-release niacin  +  simvastatin,Small Molecule (Chemical),Launched,In-House,Mar-08,,Sep-13,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,98,45,43.46,40.0644,39.496616,39.21339024,39.13967159,39.11235744,-12.29737009,1090,Dyslipidemia,7/7/14 12:28
1644,53,Johnson & Johnson,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-13,Oct-13,Aug-21,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,Ulcerative Colitis,7/7/14 12:28
1644,53,Johnson & Johnson,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-13,Oct-13,Aug-21,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,66,148,229.40592,284.5496473,325.5858311,357.5912676,381.1966589,398.9635969,29.30845903,1487,Ulcerative Colitis,7/7/14 12:28
1644,53,Johnson & Johnson,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-13,Oct-13,Aug-21,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,Ulcerative Colitis,7/7/14 12:28
1644,53,Johnson & Johnson,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-13,Oct-13,Aug-21,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,22,36,51,64.99797,73.577361,80.4708129,85.76289525,89.62086822,22.21959397,1487,Ulcerative Colitis,7/7/14 12:28
1644,53,Johnson & Johnson,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-13,Oct-13,Aug-21,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,Ulcerative Colitis,7/7/14 12:28
1644,53,Johnson & Johnson,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-13,Oct-13,Aug-21,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,44,112,178.40592,219.5516773,252.0084701,277.1204547,295.4337636,309.3427287,32.12897183,1487,Ulcerative Colitis,7/7/14 12:28
1645,53,Johnson & Johnson,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-09,Jun-09,Aug-21,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,Rheumatoid Arthritis,7/7/14 12:28
1645,53,Johnson & Johnson,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-09,Jun-09,Aug-21,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,83,226,410,607,866,1009.465,1129.702625,1228.446378,1301.22511,1358.684521,1403.572233,1438.218518,7.515825768,1487,Rheumatoid Arthritis,7/7/14 12:28
1645,53,Johnson & Johnson,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-09,Jun-09,Aug-21,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,Rheumatoid Arthritis,7/7/14 12:28
1645,53,Johnson & Johnson,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-09,Jun-09,Aug-21,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,15,40,175,315,506,612.925,703.120625,778.1145781,833.9760098,878.4802272,913.5862909,940.9360701,9.266503825,1487,Rheumatoid Arthritis,7/7/14 12:28
1645,53,Johnson & Johnson,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-09,Jun-09,Aug-21,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,Rheumatoid Arthritis,7/7/14 12:28
1645,53,Johnson & Johnson,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-09,Jun-09,Aug-21,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,68,186,235,292,360,396.54,426.582,450.3318,467.2491,480.204294,489.9859422,497.2824476,4.723205466,1487,Rheumatoid Arthritis,7/7/14 12:28
1646,61,Merck & Co,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-13,N/A,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,TNF inhibitor for Ulcerative Colitis,7/7/14 12:28
1646,61,Merck & Co,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-13,N/A,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,25,99.16666833,215.8332786,332.4997991,420.2330622,501.9929901,574.4195876,637.0499314,58.81455208,1487,TNF inhibitor for Ulcerative Colitis,7/7/14 12:28
1646,61,Merck & Co,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-13,N/A,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,TNF inhibitor for Ulcerative Colitis,7/7/14 12:28
1646,61,Merck & Co,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-13,N/A,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,25,99.16666833,215.8332786,332.4997991,420.2330622,501.9929901,574.4195876,637.0499314,58.81455208,1487,TNF inhibitor for Ulcerative Colitis,7/7/14 12:28
1646,61,Merck & Co,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-13,N/A,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,TNF inhibitor for Ulcerative Colitis,7/7/14 12:28
1646,61,Merck & Co,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-13,N/A,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,TNF inhibitor for Ulcerative Colitis,7/7/14 12:28
1647,61,Merck & Co,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-09,N/A,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,Rheumatoid Arthritis,7/7/14 12:28
1647,61,Merck & Co,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-09,N/A,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,3.9,97,264,331,475,544.025,594.136875,635.1467656,662.2856949,682.0278387,696.4459395,706.6536532,5.838746946,1487,Rheumatoid Arthritis,7/7/14 12:28
1647,61,Merck & Co,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-09,N/A,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,Rheumatoid Arthritis,7/7/14 12:28
1647,61,Merck & Co,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-09,N/A,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,3.9,97,264,331,475,544.025,594.136875,635.1467656,662.2856949,682.0278387,696.4459395,706.6536532,5.838746946,1487,Rheumatoid Arthritis,7/7/14 12:28
1647,61,Merck & Co,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-09,N/A,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,Rheumatoid Arthritis,7/7/14 12:28
1647,61,Merck & Co,Large Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,,Oct-09,N/A,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,Rheumatoid Arthritis,7/7/14 12:28
1648,61,Merck & Co,Large Pharma,1637,Singulair,montelukast,Small Molecule (Chemical),Launched,In-House,Feb-98,Feb-98,Aug-12,Feb-13,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1092,Asthma,7/7/14 12:28
1648,61,Merck & Co,Large Pharma,1637,Singulair,montelukast,Small Molecule (Chemical),Launched,In-House,Feb-98,Feb-98,Aug-12,Feb-13,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,Global,Sales,4659,4987,5478,3853,1196,376.4130884,267.5193957,231.742839,208.7231121,187.0856737,166.6940677,153.7784491,-25.40016207,1092,Asthma,7/7/14 12:28
1648,61,Merck & Co,Large Pharma,1637,Singulair,montelukast,Small Molecule (Chemical),Launched,In-House,Feb-98,Feb-98,Aug-12,Feb-13,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1092,Asthma,7/7/14 12:28
1648,61,Merck & Co,Large Pharma,1637,Singulair,montelukast,Small Molecule (Chemical),Launched,In-House,Feb-98,Feb-98,Aug-12,Feb-13,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,1615,1768,1942,1701,1135,331.4130884,237.5193957,210.742839,189.2731121,168.8356737,148.9715677,136.1934491,-26.13280441,1092,Asthma,7/7/14 12:28
1648,61,Merck & Co,Large Pharma,1637,Singulair,montelukast,Small Molecule (Chemical),Launched,In-House,Feb-98,Feb-98,Aug-12,Feb-13,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1092,Asthma,7/7/14 12:28
1648,61,Merck & Co,Large Pharma,1637,Singulair,montelukast,Small Molecule (Chemical),Launched,In-House,Feb-98,Feb-98,Aug-12,Feb-13,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,US,Sales,3044,3219,3536,2152,61,45,30,21,19.45,18.25,17.7225,17.585,-16.27976481,1092,Asthma,7/7/14 12:28
1651,76,King,Large Pharma,779,Skelaxin,metaxalone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-84,,Apr-10,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,Global,Proforma,401,389.9,18.4,0,0,0,0,0,0,0,0,0,0,1095,Muscle Relaxant,7/7/14 12:28
1651,76,King,Large Pharma,779,Skelaxin,metaxalone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-84,,Apr-10,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,US,Proforma,401,389.9,18.4,0,0,0,0,0,0,0,0,0,0,1095,Muscle Relaxant,7/7/14 12:28
1651,76,Pfizer,Large Pharma,779,Skelaxin,metaxalone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-84,,Apr-10,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1095,Muscle Relaxant,7/7/14 12:28
1651,76,Pfizer,Large Pharma,779,Skelaxin,metaxalone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-84,,Apr-10,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,Global,Sales,0,2.00E-02,203,223,211,203.8,199.48,196.888,195.3328,194.39968,193.839808,193.5038848,-1.228963766,1095,Muscle Relaxant,7/7/14 12:28
1651,76,Pfizer,Large Pharma,779,Skelaxin,metaxalone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-84,,Apr-10,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1095,Muscle Relaxant,7/7/14 12:28
1651,76,Pfizer,Large Pharma,779,Skelaxin,metaxalone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-84,,Apr-10,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1095,Muscle Relaxant,7/7/14 12:28
1651,76,Pfizer,Large Pharma,779,Skelaxin,metaxalone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-84,,Apr-10,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1095,Muscle Relaxant,7/7/14 12:28
1651,76,Pfizer,Large Pharma,779,Skelaxin,metaxalone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-84,,Apr-10,N/A,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,6,US,Sales,0,2.00E-02,203,223,211,203.8,199.48,196.888,195.3328,194.39968,193.839808,193.5038848,-1.228963766,1095,Muscle Relaxant,7/7/14 12:28
1653,51,Ipsen,Regional & Specialty Pharma,1436,Smecta,diosmectite,Small Molecule (Chemical),Launched,In-House,,Jul-77,N/A,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1101,Diarrhea,7/7/14 12:28
1653,51,Ipsen,Regional & Specialty Pharma,1436,Smecta,diosmectite,Small Molecule (Chemical),Launched,In-House,,Jul-77,N/A,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,2,Global,Sales,139.612631,134.1976622,142.2417089,145.8782955,160.8244411,165.2228767,168.9137378,171.246343,172.6653046,173.6316501,174.2505722,174.6479928,1.184952075,1101,Diarrhea,7/7/14 12:28
1653,51,Ipsen,Regional & Specialty Pharma,1436,Smecta,diosmectite,Small Molecule (Chemical),Launched,In-House,,Jul-77,N/A,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1101,Diarrhea,7/7/14 12:28
1653,51,Ipsen,Regional & Specialty Pharma,1436,Smecta,diosmectite,Small Molecule (Chemical),Launched,In-House,,Jul-77,N/A,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,2,ROW,Sales,139.612631,134.1976622,142.2417089,145.8782955,160.8244411,165.2228767,168.9137378,171.246343,172.6653046,173.6316501,174.2505722,174.6479928,1.184952075,1101,Diarrhea,7/7/14 12:28
1653,51,Ipsen,Regional & Specialty Pharma,1436,Smecta,diosmectite,Small Molecule (Chemical),Launched,In-House,,Jul-77,N/A,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1101,Diarrhea,7/7/14 12:28
1653,51,Ipsen,Regional & Specialty Pharma,1436,Smecta,diosmectite,Small Molecule (Chemical),Launched,In-House,,Jul-77,N/A,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1101,Diarrhea,7/7/14 12:28
1658,39,Eli Lilly,Large Pharma,125,solanezumab,LY2062430,Antibody/Antibody Derivative,Phase III,In-House,Feb-18,Nov-18,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1107,Alzheimer's Disease,7/7/14 12:28
1658,39,Eli Lilly,Large Pharma,125,solanezumab,LY2062430,Antibody/Antibody Derivative,Phase III,In-House,Feb-18,Nov-18,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,807.5,1803.2036,3354.545245,0,1107,Alzheimer's Disease,7/7/14 12:28
1658,39,Eli Lilly,Large Pharma,125,solanezumab,LY2062430,Antibody/Antibody Derivative,Phase III,In-House,Feb-18,Nov-18,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1107,Alzheimer's Disease,7/7/14 12:28
1658,39,Eli Lilly,Large Pharma,125,solanezumab,LY2062430,Antibody/Antibody Derivative,Phase III,In-House,Feb-18,Nov-18,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,42.5,241.32605,613.2939572,0,1107,Alzheimer's Disease,7/7/14 12:28
1658,39,Eli Lilly,Large Pharma,125,solanezumab,LY2062430,Antibody/Antibody Derivative,Phase III,In-House,Feb-18,Nov-18,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1107,Alzheimer's Disease,7/7/14 12:28
1658,39,Eli Lilly,Large Pharma,125,solanezumab,LY2062430,Antibody/Antibody Derivative,Phase III,In-House,Feb-18,Nov-18,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,765,1561.87755,2741.251288,0,1107,Alzheimer's Disease,7/7/14 12:28
1661,46,GlaxoSmithKline,Large Pharma,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,Licensed (Development),Jun-12,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1479,Post-herpetic Neuralgia,7/7/14 12:28
1661,46,GlaxoSmithKline,Large Pharma,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,Licensed (Development),Jun-12,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,4,Global,Sales,0,0,0,0.789039021,0.836381362,0,0,0,0,0,0,0,-100,1479,Post-herpetic Neuralgia,7/7/14 12:28
1661,46,GlaxoSmithKline,Large Pharma,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,Licensed (Development),Jun-12,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1479,Post-herpetic Neuralgia,7/7/14 12:28
1661,46,GlaxoSmithKline,Large Pharma,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,Licensed (Development),Jun-12,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1479,Post-herpetic Neuralgia,7/7/14 12:28
1661,46,GlaxoSmithKline,Large Pharma,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,Licensed (Development),Jun-12,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1479,Post-herpetic Neuralgia,7/7/14 12:28
1661,46,GlaxoSmithKline,Large Pharma,2395,Horizant,gabapentin enacarbil,Small Molecule (Chemical),Launched,Licensed (Development),Jun-12,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,4,US,Sales,0,0,0,0.789039021,0.836381362,0,0,0,0,0,0,0,-100,1479,Post-herpetic Neuralgia,7/7/14 12:28
1663,51,Ipsen,Regional & Specialty Pharma,603,Somatuline,lanreotide,Small Molecule (Chemical),Launched,In-House,Jan-08,Jul-97,Mar-20,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1509,Acromegaly,7/7/14 12:28
1663,51,Ipsen,Regional & Specialty Pharma,603,Somatuline,lanreotide,Small Molecule (Chemical),Launched,In-House,Jan-08,Jul-97,Mar-20,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,Global,Sales,194.5019864,225.2083177,261.4299718,290.4713197,328.337401,355.2749699,380.5973186,398.5547281,413.0219801,423.9689953,429.1572691,435.0882367,4.103484486,1509,Acromegaly,7/7/14 12:28
1663,51,Ipsen,Regional & Specialty Pharma,603,Somatuline,lanreotide,Small Molecule (Chemical),Launched,In-House,Jan-08,Jul-97,Mar-20,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1509,Acromegaly,7/7/14 12:28
1663,51,Ipsen,Regional & Specialty Pharma,603,Somatuline,lanreotide,Small Molecule (Chemical),Launched,In-House,Jan-08,Jul-97,Mar-20,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,ROW,Sales,164.7945106,183.9554529,205.7846816,230.2435054,257.2967033,275.6947992,293.160828,303.6915782,312.1771566,318.789051,320.2719954,323.6883532,3.333662289,1509,Acromegaly,7/7/14 12:28
1663,51,Ipsen,Regional & Specialty Pharma,603,Somatuline,lanreotide,Small Molecule (Chemical),Launched,In-House,Jan-08,Jul-97,Mar-20,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1509,Acromegaly,7/7/14 12:28
1663,51,Ipsen,Regional & Specialty Pharma,603,Somatuline,lanreotide,Small Molecule (Chemical),Launched,In-House,Jan-08,Jul-97,Mar-20,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,US,Sales,29.70747585,41.25286478,55.64529024,60.22781434,71.04069764,79.58017075,87.43649062,94.86314988,100.8448235,105.1799444,108.8852737,111.3998835,6.637767959,1509,Acromegaly,7/7/14 12:28
1664,51,Ipsen,Regional & Specialty Pharma,603,Somatuline,lanreotide,Small Molecule (Chemical),Phase III,In-House,Apr-15,Apr-15,Mar-20,Expired,68,Other Hormonal Agents,55,Hormonals,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1509,Neuroendocrine Tumors,7/7/14 12:28
1664,51,Ipsen,Regional & Specialty Pharma,603,Somatuline,lanreotide,Small Molecule (Chemical),Phase III,In-House,Apr-15,Apr-15,Mar-20,Expired,68,Other Hormonal Agents,55,Hormonals,3,Oncology,2,Global,Sales,0,0,0,0,0,0,34.19677421,61.31079224,86.98595343,112.6608955,133.4311539,152.0092691,0,1509,Neuroendocrine Tumors,7/7/14 12:28
1664,51,Ipsen,Regional & Specialty Pharma,603,Somatuline,lanreotide,Small Molecule (Chemical),Phase III,In-House,Apr-15,Apr-15,Mar-20,Expired,68,Other Hormonal Agents,55,Hormonals,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1509,Neuroendocrine Tumors,7/7/14 12:28
1664,51,Ipsen,Regional & Specialty Pharma,603,Somatuline,lanreotide,Small Molecule (Chemical),Phase III,In-House,Apr-15,Apr-15,Mar-20,Expired,68,Other Hormonal Agents,55,Hormonals,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,12.94829315,25.8965863,37.40606511,48.91553729,58.35332798,66.73223419,0,1509,Neuroendocrine Tumors,7/7/14 12:28
1664,51,Ipsen,Regional & Specialty Pharma,603,Somatuline,lanreotide,Small Molecule (Chemical),Phase III,In-House,Apr-15,Apr-15,Mar-20,Expired,68,Other Hormonal Agents,55,Hormonals,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1509,Neuroendocrine Tumors,7/7/14 12:28
1664,51,Ipsen,Regional & Specialty Pharma,603,Somatuline,lanreotide,Small Molecule (Chemical),Phase III,In-House,Apr-15,Apr-15,Mar-20,Expired,68,Other Hormonal Agents,55,Hormonals,3,Oncology,2,US,Sales,0,0,0,0,0,0,21.24848107,35.41420594,49.57988831,63.7453582,75.07782591,85.27703494,0,1509,Neuroendocrine Tumors,7/7/14 12:28
1665,76,Pfizer,Large Pharma,1091,Somavert,pegvisomant,Recombinant Protein,Launched,Corporate Acquisition,Apr-03,Jan-04,Sep-15,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1109,Acromegaly,7/7/14 12:28
1665,76,Pfizer,Large Pharma,1091,Somavert,pegvisomant,Recombinant Protein,Launched,Corporate Acquisition,Apr-03,Jan-04,Sep-15,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,Global,Sales,125.7753,157,183,197,217,225.4,231.065,235.259,237.7717625,239.4682275,240.6203304,241.3788644,1.53263029,1109,Acromegaly,7/7/14 12:28
1665,76,Pfizer,Large Pharma,1091,Somavert,pegvisomant,Recombinant Protein,Launched,Corporate Acquisition,Apr-03,Jan-04,Sep-15,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1109,Acromegaly,7/7/14 12:28
1665,76,Pfizer,Large Pharma,1091,Somavert,pegvisomant,Recombinant Protein,Launched,Corporate Acquisition,Apr-03,Jan-04,Sep-15,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,ROW,Sales,95,125,144,151,165,171.45,175.8625,179.333125,181.5076562,183.0131328,184.0627441,184.7684216,1.629674937,1109,Acromegaly,7/7/14 12:28
1665,76,Pfizer,Large Pharma,1091,Somavert,pegvisomant,Recombinant Protein,Launched,Corporate Acquisition,Apr-03,Jan-04,Sep-15,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1109,Acromegaly,7/7/14 12:28
1665,76,Pfizer,Large Pharma,1091,Somavert,pegvisomant,Recombinant Protein,Launched,Corporate Acquisition,Apr-03,Jan-04,Sep-15,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,6,US,Sales,30.7753,32,39,46,52,53.95,55.2025,55.925875,56.26410625,56.45509469,56.55758627,56.61044284,1.220960271,1109,Acromegaly,7/7/14 12:28
1668,23,Boehringer Ingelheim,Large Pharma,732,Spiriva,tiotropium,Small Molecule (Chemical),Launched,In-House,May-04,Jun-02,Jan-18,Sep-15,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1662,COPD,7/7/14 12:28
1668,23,Boehringer Ingelheim,Large Pharma,732,Spiriva,tiotropium,Small Molecule (Chemical),Launched,In-House,May-04,Jun-02,Jan-18,Sep-15,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,Global,Sales,3340.35416,3792.773021,4384.047979,4578.136464,4880.050994,4882.693486,4638.954756,4260.501693,3969.598653,3675.774109,3536.687225,3416.468095,-4.965996882,1662,COPD,7/7/14 12:28
1668,23,Boehringer Ingelheim,Large Pharma,732,Spiriva,tiotropium,Small Molecule (Chemical),Launched,In-House,May-04,Jun-02,Jan-18,Sep-15,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1662,COPD,7/7/14 12:28
1668,23,Boehringer Ingelheim,Large Pharma,732,Spiriva,tiotropium,Small Molecule (Chemical),Launched,In-House,May-04,Jun-02,Jan-18,Sep-15,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,1827.190399,2029.524369,2302.563734,2278.786061,2427.044291,2427.777135,2250.399277,2021.420754,1935.545425,1855.192467,1824.484265,1776.654273,-4.358477757,1662,COPD,7/7/14 12:28
1668,23,Boehringer Ingelheim,Large Pharma,732,Spiriva,tiotropium,Small Molecule (Chemical),Launched,In-House,May-04,Jun-02,Jan-18,Sep-15,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1662,COPD,7/7/14 12:28
1668,23,Boehringer Ingelheim,Large Pharma,732,Spiriva,tiotropium,Small Molecule (Chemical),Launched,In-House,May-04,Jun-02,Jan-18,Sep-15,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,2,US,Sales,1513.16376,1763.248652,2081.484245,2299.350402,2453.006703,2454.916351,2388.555478,2239.080939,2034.053228,1820.581642,1712.20296,1639.813822,-5.590931679,1662,COPD,7/7/14 12:28
1669,76,Pfizer,Large Pharma,732,Spiriva,tiotropium,Small Molecule (Chemical),Launched,Licensed (Development),May-04,Jun-02,N/A,Sep-15,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,992,1027.6,1119.9,1202.5,936.7,854,101,25.752,0,0,0,0,-100,1662,COPD,7/7/14 12:28
1669,76,Pfizer,Large Pharma,732,Spiriva,tiotropium,Small Molecule (Chemical),Launched,Licensed (Development),May-04,Jun-02,N/A,Sep-15,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1662,COPD,7/7/14 12:28
1669,76,Pfizer,Large Pharma,732,Spiriva,tiotropium,Small Molecule (Chemical),Launched,Licensed (Development),May-04,Jun-02,N/A,Sep-15,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,480,475.8,497.9,513.8,208,105,101,25.752,0,0,0,0,-100,1662,COPD,7/7/14 12:28
1669,76,Pfizer,Large Pharma,732,Spiriva,tiotropium,Small Molecule (Chemical),Launched,Licensed (Development),May-04,Jun-02,N/A,Sep-15,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1662,COPD,7/7/14 12:28
1669,76,Pfizer,Large Pharma,732,Spiriva,tiotropium,Small Molecule (Chemical),Launched,Licensed (Development),May-04,Jun-02,N/A,Sep-15,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,512,551.8,622,688.7,728.7,749,0,0,0,0,0,0,-100,1662,COPD,7/7/14 12:28
1669,76,Pfizer,Large Pharma,732,Spiriva,tiotropium,Small Molecule (Chemical),Launched,Licensed (Development),May-04,Jun-02,N/A,Sep-15,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1662,COPD,7/7/14 12:28
1670,23,Boehringer Ingelheim,Large Pharma,2849,Striverdi + Spiriva ,olodaterol + tiotropium,Small Molecule (Chemical),Phase III,In-House,Apr-15,Apr-15,N/A,Oct-26,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1111,COPD,7/7/14 12:28
1670,23,Boehringer Ingelheim,Large Pharma,2849,Striverdi + Spiriva ,olodaterol + tiotropium,Small Molecule (Chemical),Phase III,In-House,Apr-15,Apr-15,N/A,Oct-26,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,183.2283083,685.5959102,1202.79294,1584.081011,1857.660224,2075.255637,0,1111,COPD,7/7/14 12:28
1670,23,Boehringer Ingelheim,Large Pharma,2849,Striverdi + Spiriva ,olodaterol + tiotropium,Small Molecule (Chemical),Phase III,In-House,Apr-15,Apr-15,N/A,Oct-26,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1111,COPD,7/7/14 12:28
1670,23,Boehringer Ingelheim,Large Pharma,2849,Striverdi + Spiriva ,olodaterol + tiotropium,Small Molecule (Chemical),Phase III,In-House,Apr-15,Apr-15,N/A,Oct-26,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,66.73351085,200.2005325,348.497075,496.7930353,589.8044576,667.0228945,0,1111,COPD,7/7/14 12:28
1670,23,Boehringer Ingelheim,Large Pharma,2849,Striverdi + Spiriva ,olodaterol + tiotropium,Small Molecule (Chemical),Phase III,In-House,Apr-15,Apr-15,N/A,Oct-26,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1111,COPD,7/7/14 12:28
1670,23,Boehringer Ingelheim,Large Pharma,2849,Striverdi + Spiriva ,olodaterol + tiotropium,Small Molecule (Chemical),Phase III,In-House,Apr-15,Apr-15,N/A,Oct-26,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,116.4947974,485.3953777,854.2958647,1087.287976,1267.855766,1408.232742,0,1111,COPD,7/7/14 12:28
1672,53,Johnson & Johnson,Large Pharma,1677,Sporanox,itraconazole,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-89,Jun-00,Dec-03,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1112,,7/7/14 12:28
1672,53,Johnson & Johnson,Large Pharma,1677,Sporanox,itraconazole,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-89,Jun-00,Dec-03,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,363.9568,324.5344,289.070656,253.7628032,225.1644314,199.7872911,177.2513342,157.6489785,140.3868754,125.2008927,111.8650531,100.1350381,-10.9309825,1112,,7/7/14 12:28
1672,53,Johnson & Johnson,Large Pharma,1677,Sporanox,itraconazole,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-89,Jun-00,Dec-03,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1112,,7/7/14 12:28
1672,53,Johnson & Johnson,Large Pharma,1677,Sporanox,itraconazole,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-89,Jun-00,Dec-03,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,350,312.08,277.552,242.8,214.54528,189.378432,166.97024,147.4461645,130.2318725,115.0750669,101.7570625,90.03794064,-11.6656604,1112,,7/7/14 12:28
1672,53,Johnson & Johnson,Large Pharma,1677,Sporanox,itraconazole,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-89,Jun-00,Dec-03,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1112,,7/7/14 12:28
1672,53,Johnson & Johnson,Large Pharma,1677,Sporanox,itraconazole,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-89,Jun-00,Dec-03,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Sales,13.9568,12.4544,11.518656,10.9628032,10.61915136,10.40885914,10.28109425,10.20281405,10.15500285,10.1258258,10.10799063,10.09709745,-0.717570953,1112,,7/7/14 12:28
1673,24,Bristol-Myers Squibb,Large Pharma,1294,Sprycel,dasatinib,Small Molecule (Chemical),Launched,In-House,Jul-06,Nov-06,Jun-20,Apr-20,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1113,Chronic Myeloid Leukemia,7/7/14 12:28
1673,24,Bristol-Myers Squibb,Large Pharma,1294,Sprycel,dasatinib,Small Molecule (Chemical),Launched,In-House,Jul-06,Nov-06,Jun-20,Apr-20,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,421,576,803,1012,1280,1428.98,1516.055488,1593.914559,1599.132039,1639.591967,1668.978018,1690.155686,4.050753961,1113,Chronic Myeloid Leukemia,7/7/14 12:28
1673,24,Bristol-Myers Squibb,Large Pharma,1294,Sprycel,dasatinib,Small Molecule (Chemical),Launched,In-House,Jul-06,Nov-06,Jun-20,Apr-20,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1113,Chronic Myeloid Leukemia,7/7/14 12:28
1673,24,Bristol-Myers Squibb,Large Pharma,1294,Sprycel,dasatinib,Small Molecule (Chemical),Launched,In-House,Jul-06,Nov-06,Jun-20,Apr-20,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,298,388,509,608,739,810.64,867.592,909.0467424,889.100128,912.4383578,930.1037582,943.2768472,3.548089415,1113,Chronic Myeloid Leukemia,7/7/14 12:28
1673,24,Bristol-Myers Squibb,Large Pharma,1294,Sprycel,dasatinib,Small Molecule (Chemical),Launched,In-House,Jul-06,Nov-06,Jun-20,Apr-20,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1113,Chronic Myeloid Leukemia,7/7/14 12:28
1673,24,Bristol-Myers Squibb,Large Pharma,1294,Sprycel,dasatinib,Small Molecule (Chemical),Launched,In-House,Jul-06,Nov-06,Jun-20,Apr-20,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,123,188,294,404,541,618.34,648.463488,684.867817,710.031911,727.1536097,738.87426,746.878839,4.71467175,1113,Chronic Myeloid Leukemia,7/7/14 12:28
1683,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1737,Aptiom,eslicarbazepine acetate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-14,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1451,Epilepsy,7/7/14 12:28
1683,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1737,Aptiom,eslicarbazepine acetate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-14,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,55.37249248,97.32158534,137.5922841,177.8627939,198.1659354,213.3093671,224.1677472,0,1451,Epilepsy,7/7/14 12:28
1683,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1737,Aptiom,eslicarbazepine acetate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-14,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1451,Epilepsy,7/7/14 12:28
1683,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1737,Aptiom,eslicarbazepine acetate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-14,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1451,Epilepsy,7/7/14 12:28
1683,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1737,Aptiom,eslicarbazepine acetate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-14,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1451,Epilepsy,7/7/14 12:28
1683,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1737,Aptiom,eslicarbazepine acetate,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-14,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,US,Sales,0,0,0,0,0,55.37249248,97.32158534,137.5922841,177.8627939,198.1659354,213.3093671,224.1677472,0,1451,Epilepsy,7/7/14 12:28
1684,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Launched,In-House,Oct-09,Feb-09,Aug-21,Aug-21,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1676,Psoriasis,7/7/14 12:28
1684,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Launched,In-House,Oct-09,Feb-09,Aug-21,Aug-21,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,39,336,723,1000,1449,1666.06,1835.551,1972.84195,2068.080417,2140.748977,2196.231017,2238.087123,6.407595763,1676,Psoriasis,7/7/14 12:28
1684,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Launched,In-House,Oct-09,Feb-09,Aug-21,Aug-21,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1676,Psoriasis,7/7/14 12:28
1684,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Launched,In-House,Oct-09,Feb-09,Aug-21,Aug-21,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,25,133,280,373,504,589.96,660.576,721.6832,769.93448,809.54118,842.0913018,868.5564306,8.085329902,1676,Psoriasis,7/7/14 12:28
1684,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Launched,In-House,Oct-09,Feb-09,Aug-21,Aug-21,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1676,Psoriasis,7/7/14 12:28
1684,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Launched,In-House,Oct-09,Feb-09,Aug-21,Aug-21,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,14,203,443,627,945,1076.1,1174.975,1251.15875,1298.145937,1331.207797,1354.139715,1369.530692,5.44353844,1676,Psoriasis,7/7/14 12:28
1685,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Phase III,In-House,Oct-16,Oct-16,Aug-21,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1676,Crohn's Disease,7/7/14 12:28
1685,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Phase III,In-House,Oct-16,Oct-16,Aug-21,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,26,250.71436,689.0006684,954.5690861,1201.939465,0,1676,Crohn's Disease,7/7/14 12:28
1685,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Phase III,In-House,Oct-16,Oct-16,Aug-21,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1676,Crohn's Disease,7/7/14 12:28
1685,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Phase III,In-House,Oct-16,Oct-16,Aug-21,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,10,96.4286,265.0002571,367.1419562,462.2844095,0,1676,Crohn's Disease,7/7/14 12:28
1685,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Phase III,In-House,Oct-16,Oct-16,Aug-21,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1676,Crohn's Disease,7/7/14 12:28
1685,53,Johnson & Johnson,Large Pharma,37,Stelara,ustekinumab,Antibody/Antibody Derivative,Phase III,In-House,Oct-16,Oct-16,Aug-21,Aug-21,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,16,154.28576,424.0004113,587.4271299,739.6550552,0,1676,Crohn's Disease,7/7/14 12:28
1688,61,Merck & Co,Large Pharma,1461,Stocrin,efavirenz,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-99,N/A,Nov-13,91,NNRTIs,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1439,HIV,7/7/14 12:28
1688,61,Merck & Co,Large Pharma,1461,Stocrin,efavirenz,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-99,N/A,Nov-13,91,NNRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,196,198,187,171.615,162.611375,75,56,44,36,29,24,18.73,-26.5634033,1439,HIV,7/7/14 12:28
1688,61,Merck & Co,Large Pharma,1461,Stocrin,efavirenz,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-99,N/A,Nov-13,91,NNRTIs,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1439,HIV,7/7/14 12:28
1688,61,Merck & Co,Large Pharma,1461,Stocrin,efavirenz,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-99,N/A,Nov-13,91,NNRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,196,198,187,171.615,162.611375,75,56,44,36,29,24,18.73,-26.5634033,1439,HIV,7/7/14 12:28
1688,61,Merck & Co,Large Pharma,1461,Stocrin,efavirenz,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-99,N/A,Nov-13,91,NNRTIs,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1439,HIV,7/7/14 12:28
1688,61,Merck & Co,Large Pharma,1461,Stocrin,efavirenz,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-99,N/A,Nov-13,91,NNRTIs,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1439,HIV,7/7/14 12:28
1689,39,Eli Lilly,Large Pharma,931,Strattera,atomoxetine,Small Molecule (Chemical),Launched,In-House,Dec-02,Jul-04,May-17,Dec-18,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1120,ADHD,7/7/14 12:28
1689,39,Eli Lilly,Large Pharma,931,Strattera,atomoxetine,Small Molecule (Chemical),Launched,In-House,Dec-02,Jul-04,May-17,Dec-18,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,Global,Sales,609.3,576.7,620.1,621.4,709,736.68,756.182,773.0038,657.228445,482.8702386,350.9990803,216.181851,-15.6062079,1120,ADHD,7/7/14 12:28
1689,39,Eli Lilly,Large Pharma,931,Strattera,atomoxetine,Small Molecule (Chemical),Launched,In-House,Dec-02,Jul-04,May-17,Dec-18,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1120,ADHD,7/7/14 12:28
1689,39,Eli Lilly,Large Pharma,931,Strattera,atomoxetine,Small Molecule (Chemical),Launched,In-House,Dec-02,Jul-04,May-17,Dec-18,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,ROW,Sales,163.7,186.9,227.9,237.3,263,273.28,277.392,279.0368,279.69472,278.5580986,196.0442086,112.0421048,-11.4760386,1120,ADHD,7/7/14 12:28
1689,39,Eli Lilly,Large Pharma,931,Strattera,atomoxetine,Small Molecule (Chemical),Launched,In-House,Dec-02,Jul-04,May-17,Dec-18,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1120,ADHD,7/7/14 12:28
1689,39,Eli Lilly,Large Pharma,931,Strattera,atomoxetine,Small Molecule (Chemical),Launched,In-House,Dec-02,Jul-04,May-17,Dec-18,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,6,US,Sales,445.6,389.8,392.2,384.1,446,463.4,478.79,493.967,377.533725,204.31214,154.9548717,104.1397461,-18.76286241,1120,ADHD,7/7/14 12:28
1691,83,Reckitt Benckiser,Regional & Specialty Pharma,2322,Subutex / Suboxone,buprenorphine / buprenorphine + naloxone,Small Molecule (Chemical),Launched,In-House,Oct-02,Oct-07,Mar-13,Jul-16,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,4,Global,Sales,916.8458735,1138.665043,1221.623701,1325.71815,1213.834651,1145.441542,1088.773005,1000.287625,881.7944483,825.4604274,781.9240055,746.404809,-6.710937253,1372,Opiate Dependence,7/7/14 12:28
1691,83,Reckitt Benckiser,Regional & Specialty Pharma,2322,Subutex / Suboxone,buprenorphine / buprenorphine + naloxone,Small Molecule (Chemical),Launched,In-House,Oct-02,Oct-07,Mar-13,Jul-16,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,4,ROW,Sales,134.0965053,268.8300101,280.5566243,265.3338335,242.95454,238.3487222,235.899384,193.500322,114.1805158,91.14385994,75.91019837,64.44834812,-17.26874335,1372,Opiate Dependence,7/7/14 12:28
1691,83,Reckitt Benckiser,Regional & Specialty Pharma,2322,Subutex / Suboxone,buprenorphine / buprenorphine + naloxone,Small Molecule (Chemical),Launched,In-House,Oct-02,Oct-07,Mar-13,Jul-16,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,4,US,Sales,782.7493682,869.8350326,941.0670771,1060.384317,970.8801114,907.0928195,852.8736214,806.7873031,767.6139324,734.3165674,706.0138071,681.9564609,-4.92103254,1372,Opiate Dependence,7/7/14 12:28
1692,61,Merck & Co,Large Pharma,2322,Subutex / Suboxone,buprenorphine / buprenorphine + naloxone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-96,N/A,N/A,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1372,Opiate Dependence,7/7/14 12:28
1692,61,Merck & Co,Large Pharma,2322,Subutex / Suboxone,buprenorphine / buprenorphine + naloxone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-96,N/A,N/A,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,Global,Sales,36.3,111,0,0,0,0,0,0,0,0,0,0,0,1372,Opiate Dependence,7/7/14 12:28
1692,61,Merck & Co,Large Pharma,2322,Subutex / Suboxone,buprenorphine / buprenorphine + naloxone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-96,N/A,N/A,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1372,Opiate Dependence,7/7/14 12:28
1692,61,Merck & Co,Large Pharma,2322,Subutex / Suboxone,buprenorphine / buprenorphine + naloxone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-96,N/A,N/A,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,ROW,Sales,36.3,111,0,0,0,0,0,0,0,0,0,0,0,1372,Opiate Dependence,7/7/14 12:28
1692,61,Merck & Co,Large Pharma,2322,Subutex / Suboxone,buprenorphine / buprenorphine + naloxone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-96,N/A,N/A,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1372,Opiate Dependence,7/7/14 12:28
1692,61,Merck & Co,Large Pharma,2322,Subutex / Suboxone,buprenorphine / buprenorphine + naloxone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-96,N/A,N/A,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1372,Opiate Dependence,7/7/14 12:28
1692,61,Schering-Plough,Large Pharma,2322,Subutex / Suboxone,buprenorphine / buprenorphine + naloxone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-96,N/A,N/A,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,Global,Proforma,174.7,0,0,0,0,0,0,0,0,0,0,0,0,1372,Opiate Dependence,7/7/14 12:28
1692,61,Schering-Plough,Large Pharma,2322,Subutex / Suboxone,buprenorphine / buprenorphine + naloxone,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-96,N/A,N/A,106,Other Addiction Treatments,16,Addictions,12,Central Nervous System,6,ROW,Proforma,174.7,0,0,0,0,0,0,0,0,0,0,0,0,1372,Opiate Dependence,7/7/14 12:28
1694,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1623,Sumiferon,interferon alpha,Recombinant Protein,Launched,Corporate Acquisition,,Jul-87,N/A,Jul-98,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1124,,7/7/14 12:28
1694,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1623,Sumiferon,interferon alpha,Recombinant Protein,Launched,Corporate Acquisition,,Jul-87,N/A,Jul-98,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,7,Global,Sales,62.48490621,61.06631777,50.71986993,34.9654716,11.13788704,8.218764207,6.116558555,5.614425706,5.353991856,5.277735186,5.244066134,5.233073562,-10.22894337,1124,,7/7/14 12:28
1694,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1623,Sumiferon,interferon alpha,Recombinant Protein,Launched,Corporate Acquisition,,Jul-87,N/A,Jul-98,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1124,,7/7/14 12:28
1694,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1623,Sumiferon,interferon alpha,Recombinant Protein,Launched,Corporate Acquisition,,Jul-87,N/A,Jul-98,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,7,ROW,Sales,62.48490621,61.06631777,50.71986993,34.9654716,11.13788704,8.218764207,6.116558555,5.614425706,5.353991856,5.277735186,5.244066134,5.233073562,-10.22894337,1124,,7/7/14 12:28
1694,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1623,Sumiferon,interferon alpha,Recombinant Protein,Launched,Corporate Acquisition,,Jul-87,N/A,Jul-98,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1124,,7/7/14 12:28
1694,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1623,Sumiferon,interferon alpha,Recombinant Protein,Launched,Corporate Acquisition,,Jul-87,N/A,Jul-98,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1124,,7/7/14 12:28
1696,34,Daiichi-Sankyo,Regional & Specialty Pharma,1086,Sunrythm,pilsicainide,Small Molecule (Chemical),Launched,In-House,,May-91,N/A,Expired,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1126,Arrhythmia,7/7/14 12:28
1696,34,Daiichi-Sankyo,Regional & Specialty Pharma,1086,Sunrythm,pilsicainide,Small Molecule (Chemical),Launched,In-House,,May-91,N/A,Expired,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,7,Global,Sales,123.8924865,120.9804409,120.8254151,111.7415888,105.258722,99.89986674,95.43294068,91.71669117,88.62358332,86.04939437,83.90701618,80.54177796,-3.751327556,1126,Arrhythmia,7/7/14 12:28
1696,34,Daiichi-Sankyo,Regional & Specialty Pharma,1086,Sunrythm,pilsicainide,Small Molecule (Chemical),Launched,In-House,,May-91,N/A,Expired,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1126,Arrhythmia,7/7/14 12:28
1696,34,Daiichi-Sankyo,Regional & Specialty Pharma,1086,Sunrythm,pilsicainide,Small Molecule (Chemical),Launched,In-House,,May-91,N/A,Expired,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,7,ROW,Sales,123.8924865,120.9804409,120.8254151,111.7415888,105.258722,99.89986674,95.43294068,91.71669117,88.62358332,86.04939437,83.90701618,80.54177796,-3.751327556,1126,Arrhythmia,7/7/14 12:28
1696,34,Daiichi-Sankyo,Regional & Specialty Pharma,1086,Sunrythm,pilsicainide,Small Molecule (Chemical),Launched,In-House,,May-91,N/A,Expired,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1126,Arrhythmia,7/7/14 12:28
1696,34,Daiichi-Sankyo,Regional & Specialty Pharma,1086,Sunrythm,pilsicainide,Small Molecule (Chemical),Launched,In-House,,May-91,N/A,Expired,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1126,Arrhythmia,7/7/14 12:28
1697,24,Bristol-Myers Squibb,Large Pharma,236,Sustiva,efavirenz,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,Mar-15,Nov-13,91,NNRTIs,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,869,1053,1204,1267,1369,1377.83488,1389.769975,1397.016081,1399.77562,1401.202691,1401.923215,1402.246766,0.343376945,1439,HIV,7/7/14 12:28
1697,24,Bristol-Myers Squibb,Large Pharma,236,Sustiva,efavirenz,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,Mar-15,Nov-13,91,NNRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,408,315,281,259.53,245,204,118.728336,66.65359359,48.99706599,39.86419849,32.94673806,28.5742588,-26.43231035,1439,HIV,7/7/14 12:28
1697,24,Bristol-Myers Squibb,Large Pharma,236,Sustiva,efavirenz,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,Mar-15,Nov-13,91,NNRTIs,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,268.51,366.23,448.89,468.5307862,485,492.5475924,495.0246514,496.3582391,496.8906406,497.1229784,497.2314998,497.2775882,0.357773944,1439,HIV,7/7/14 12:28
1697,24,Bristol-Myers Squibb,Large Pharma,236,Sustiva,efavirenz,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,Mar-15,Nov-13,91,NNRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,205.49,120.77,96.11,42,37,17,12,9,7.6,7.08,6,5.8048,-23.24904942,1439,HIV,7/7/14 12:28
1697,24,Bristol-Myers Squibb,Large Pharma,236,Sustiva,efavirenz,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,Mar-15,Nov-13,91,NNRTIs,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,600.49,686.77,755.11,798.4692138,884,885.2872877,894.7453239,900.6578422,902.8849797,904.0797125,904.6917154,904.9691776,0.33547287,1439,HIV,7/7/14 12:28
1697,24,Bristol-Myers Squibb,Large Pharma,236,Sustiva,efavirenz,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,Mar-15,Nov-13,91,NNRTIs,32,HIV,7,Anti-infectives,6,US,Sales,202.51,194.23,184.89,217.53,208,187,106.728336,57.65359359,41.39706599,32.78419849,26.94673806,22.7694588,-27.09526059,1439,HIV,7/7/14 12:28
1698,76,Pfizer,Large Pharma,723,Sutent,sunitinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-06,Sep-06,Feb-21,Jul-21,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1128,Renal Cell Carcinoma,7/7/14 12:28
1698,76,Pfizer,Large Pharma,723,Sutent,sunitinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-06,Sep-06,Feb-21,Jul-21,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,964,1066,1187,1236,1204,1188.322696,1172.360197,1153.491672,1141.419241,1133.066871,1127.029229,1122.667308,-0.994194847,1128,Renal Cell Carcinoma,7/7/14 12:28
1698,76,Pfizer,Large Pharma,723,Sutent,sunitinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-06,Sep-06,Feb-21,Jul-21,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1128,Renal Cell Carcinoma,7/7/14 12:28
1698,76,Pfizer,Large Pharma,723,Sutent,sunitinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-06,Sep-06,Feb-21,Jul-21,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,691,796,880,899,853,834.271844,819.3492801,802.5990404,793.5758453,786.6368501,782.2137973,778.9754177,-1.288483727,1128,Renal Cell Carcinoma,7/7/14 12:28
1698,76,Pfizer,Large Pharma,723,Sutent,sunitinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-06,Sep-06,Feb-21,Jul-21,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1128,Renal Cell Carcinoma,7/7/14 12:28
1698,76,Pfizer,Large Pharma,723,Sutent,sunitinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-06,Sep-06,Feb-21,Jul-21,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,273,270,307,337,351,354.0508517,353.0109172,350.8926319,347.843396,346.4300207,344.8154322,343.6918906,-0.300128899,1128,Renal Cell Carcinoma,7/7/14 12:28
1699,16,AstraZeneca,Large Pharma,1418,Symbicort,formoterol + budesonide,Small Molecule (Chemical),Launched,In-House,Jun-07,Jan-00,Jul-15,Jan-14,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1370,Asthma,7/7/14 12:28
1699,16,AstraZeneca,Large Pharma,1418,Symbicort,formoterol + budesonide,Small Molecule (Chemical),Launched,In-House,Jun-07,Jan-00,Jul-15,Jan-14,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Sales,2294,2746,3148,3194,3483,3492.99956,3490.378646,3464.624111,3348.222315,3267.801393,3234.608037,3206.448232,-1.174901405,1370,Asthma,7/7/14 12:28
1699,16,AstraZeneca,Large Pharma,1418,Symbicort,formoterol + budesonide,Small Molecule (Chemical),Launched,In-House,Jun-07,Jan-00,Jul-15,Jan-14,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1370,Asthma,7/7/14 12:28
1699,16,AstraZeneca,Large Pharma,1418,Symbicort,formoterol + budesonide,Small Molecule (Chemical),Launched,In-House,Jun-07,Jan-00,Jul-15,Jan-14,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,1806,2025,2302,2191,2250,2224.39476,2181.929366,2150.134923,2068.729899,2016.713331,1993.752097,1975.927125,-1.838494893,1370,Asthma,7/7/14 12:28
1699,16,AstraZeneca,Large Pharma,1418,Symbicort,formoterol + budesonide,Small Molecule (Chemical),Launched,In-House,Jun-07,Jan-00,Jul-15,Jan-14,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1370,Asthma,7/7/14 12:28
1699,16,AstraZeneca,Large Pharma,1418,Symbicort,formoterol + budesonide,Small Molecule (Chemical),Launched,In-House,Jun-07,Jan-00,Jul-15,Jan-14,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Sales,488,721,846,1003,1233,1268.6048,1308.44928,1314.489187,1279.492416,1251.088062,1240.85594,1230.521106,-2.87E-02,1370,Asthma,7/7/14 12:28
1700,39,Eli Lilly,Large Pharma,1731,Symbyax,olanzapine  +  fluoxetine,Small Molecule (Chemical),Launched,In-House,Jan-04,Jul-04,Jun-12,N/A,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1129,Bipolar Depression,7/7/14 12:28
1700,39,Eli Lilly,Large Pharma,1731,Symbyax,olanzapine  +  fluoxetine,Small Molecule (Chemical),Launched,In-House,Jan-04,Jul-04,Jun-12,N/A,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,Global,Sales,85.3775,77.3,77.5,37,16.945,13.14575,12.5107625,12.50157938,12.58467966,12.67226266,12.74434421,12.80269529,-3.925404339,1129,Bipolar Depression,7/7/14 12:28
1700,39,Eli Lilly,Large Pharma,1731,Symbyax,olanzapine  +  fluoxetine,Small Molecule (Chemical),Launched,In-House,Jan-04,Jul-04,Jun-12,N/A,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1129,Bipolar Depression,7/7/14 12:28
1700,39,Eli Lilly,Large Pharma,1731,Symbyax,olanzapine  +  fluoxetine,Small Molecule (Chemical),Launched,In-House,Jan-04,Jul-04,Jun-12,N/A,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,ROW,Sales,3.3775,4,4.2,4.7,4.945,5.20575,5.3827625,5.535979375,5.651559656,5.745638661,5.819019411,5.877630325,2.498949362,1129,Bipolar Depression,7/7/14 12:28
1700,39,Eli Lilly,Large Pharma,1731,Symbyax,olanzapine  +  fluoxetine,Small Molecule (Chemical),Launched,In-House,Jan-04,Jul-04,Jun-12,N/A,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1129,Bipolar Depression,7/7/14 12:28
1700,39,Eli Lilly,Large Pharma,1731,Symbyax,olanzapine  +  fluoxetine,Small Molecule (Chemical),Launched,In-House,Jan-04,Jul-04,Jun-12,N/A,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,US,Sales,82,73.3,73.3,32.3,12,7.94,7.128,6.9656,6.93312,6.926624,6.9253248,6.92506496,-7.55321021,1129,Bipolar Depression,7/7/14 12:28
1701,24,Amylin,Large Pharma,101,Symlin,pramlintide,Synthetic Peptide,Launched,Corporate Acquisition,Jun-05,,Mar-19,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Proforma,86.4,91.8,103.9,61,0,0,0,0,0,0,0,0,0,1130,Diabetes,7/7/14 12:28
1701,24,Amylin,Large Pharma,101,Symlin,pramlintide,Synthetic Peptide,Launched,Corporate Acquisition,Jun-05,,Mar-19,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Proforma,86.4,91.8,103.9,61,0,0,0,0,0,0,0,0,0,1130,Diabetes,7/7/14 12:28
1701,24,Bristol-Myers Squibb,Large Pharma,101,Symlin,pramlintide,Synthetic Peptide,Launched,Corporate Acquisition,Jun-05,,Mar-19,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1130,Diabetes,7/7/14 12:28
1701,24,Bristol-Myers Squibb,Large Pharma,101,Symlin,pramlintide,Synthetic Peptide,Launched,Corporate Acquisition,Jun-05,,Mar-19,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,49.8525,115,10,0,0,0,0,0,0,-100,1130,Diabetes,7/7/14 12:28
1701,24,Bristol-Myers Squibb,Large Pharma,101,Symlin,pramlintide,Synthetic Peptide,Launched,Corporate Acquisition,Jun-05,,Mar-19,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1130,Diabetes,7/7/14 12:28
1701,24,Bristol-Myers Squibb,Large Pharma,101,Symlin,pramlintide,Synthetic Peptide,Launched,Corporate Acquisition,Jun-05,,Mar-19,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1130,Diabetes,7/7/14 12:28
1701,24,Bristol-Myers Squibb,Large Pharma,101,Symlin,pramlintide,Synthetic Peptide,Launched,Corporate Acquisition,Jun-05,,Mar-19,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1130,Diabetes,7/7/14 12:28
1701,24,Bristol-Myers Squibb,Large Pharma,101,Symlin,pramlintide,Synthetic Peptide,Launched,Corporate Acquisition,Jun-05,,Mar-19,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,49.8525,115,10,0,0,0,0,0,0,-100,1130,Diabetes,7/7/14 12:28
1702,1,Abbott,Regional & Specialty Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Licensed (Marketed),,Jul-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1577,RSV prevention,7/7/14 12:28
1702,1,Abbott,Regional & Specialty Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Licensed (Marketed),,Jul-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,Global,Sales,300,392,405,427,0,0,0,0,0,0,0,0,0,1577,RSV prevention,7/7/14 12:28
1702,1,Abbott,Regional & Specialty Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Licensed (Marketed),,Jul-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1577,RSV prevention,7/7/14 12:28
1702,1,Abbott,Regional & Specialty Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Licensed (Marketed),,Jul-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,ROW,Sales,300,392,405,427,0,0,0,0,0,0,0,0,0,1577,RSV prevention,7/7/14 12:28
1702,1,Abbott,Regional & Specialty Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Licensed (Marketed),,Jul-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1577,RSV prevention,7/7/14 12:28
1702,1,Abbott,Regional & Specialty Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Licensed (Marketed),,Jul-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1577,RSV prevention,7/7/14 12:28
1703,16,AstraZeneca,Large Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Acquisition (Marketed),Jul-98,Jul-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,Global,Alliance Revenue,300,392,405,427,443,443.86,444.3415,444.5264375,444.5468834,444.5549836,444.5573422,444.5577271,0.050157472,1577,RSV prevention,7/7/14 12:28
1703,16,AstraZeneca,Large Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Acquisition (Marketed),Jul-98,Jul-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,Global,Sales,782,646,570,611,617,608,607.1,604.13,602.969,601.7297,601.00961,600.421793,-0.388338296,1577,RSV prevention,7/7/14 12:28
1703,16,AstraZeneca,Large Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Acquisition (Marketed),Jul-98,Jul-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,ROW,Alliance Revenue,300,392,405,427,443,443.86,444.3415,444.5264375,444.5468834,444.5549836,444.5573422,444.5577271,0.050157472,1577,RSV prevention,7/7/14 12:28
1703,16,AstraZeneca,Large Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Acquisition (Marketed),Jul-98,Jul-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1577,RSV prevention,7/7/14 12:28
1703,16,AstraZeneca,Large Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Acquisition (Marketed),Jul-98,Jul-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1577,RSV prevention,7/7/14 12:28
1703,16,AstraZeneca,Large Pharma,1029,Synagis,palivizumab,Antibody/Antibody Derivative,Launched,Acquisition (Marketed),Jul-98,Jul-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,US,Sales,782,646,570,611,617,608,607.1,604.13,602.969,601.7297,601.00961,600.421793,-0.388338296,1577,RSV prevention,7/7/14 12:28
1704,46,GlaxoSmithKline,Large Pharma,577,Tanzeum / Eperzan,albiglutide,Recombinant Protein,Approved,Licensed (Development),Aug-14,Jul-14,N/A,N/A,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1131,Type II Diabetes,7/7/14 12:28
1704,46,GlaxoSmithKline,Large Pharma,577,Tanzeum / Eperzan,albiglutide,Recombinant Protein,Approved,Licensed (Development),Aug-14,Jul-14,N/A,N/A,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,4,Global,Sales,0,0,0,0,0,50.94126178,146.5268723,221.5709379,296.6149897,371.809739,443.1731721,512.7596762,0,1131,Type II Diabetes,7/7/14 12:28
1704,46,GlaxoSmithKline,Large Pharma,577,Tanzeum / Eperzan,albiglutide,Recombinant Protein,Approved,Licensed (Development),Aug-14,Jul-14,N/A,N/A,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1131,Type II Diabetes,7/7/14 12:28
1704,46,GlaxoSmithKline,Large Pharma,577,Tanzeum / Eperzan,albiglutide,Recombinant Protein,Approved,Licensed (Development),Aug-14,Jul-14,N/A,N/A,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,4,ROW,Sales,0,0,0,0,0,24.23291743,64.62119393,96.9317909,129.2420648,161.4717375,192.1282736,222.0145369,0,1131,Type II Diabetes,7/7/14 12:28
1704,46,GlaxoSmithKline,Large Pharma,577,Tanzeum / Eperzan,albiglutide,Recombinant Protein,Approved,Licensed (Development),Aug-14,Jul-14,N/A,N/A,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1131,Type II Diabetes,7/7/14 12:28
1704,46,GlaxoSmithKline,Large Pharma,577,Tanzeum / Eperzan,albiglutide,Recombinant Protein,Approved,Licensed (Development),Aug-14,Jul-14,N/A,N/A,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,4,US,Sales,0,0,0,0,0,26.70834435,81.90567835,124.639147,167.3729249,210.3380014,251.0448986,290.7451393,0,1131,Type II Diabetes,7/7/14 12:28
1705,46,GlaxoSmithKline,Large Pharma,472,Synflorix,pneumococcal vaccine,Vaccine,Launched,In-House,,Dec-09,N/A,Jun-20,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2224,pneumococcal vaccine,7/7/14 12:28
1705,46,GlaxoSmithKline,Large Pharma,472,Synflorix,pneumococcal vaccine,Vaccine,Launched,In-House,,Dec-09,N/A,Jun-20,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,113.8261033,341.4450128,561.1132487,610.2361165,674.6178539,730.4800475,766.891666,796.5947608,818.7632438,835.12974,847.5943872,856.9399686,3.476511912,2224,pneumococcal vaccine,7/7/14 12:28
1705,46,GlaxoSmithKline,Large Pharma,472,Synflorix,pneumococcal vaccine,Vaccine,Launched,In-House,,Dec-09,N/A,Jun-20,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2224,pneumococcal vaccine,7/7/14 12:28
1705,46,GlaxoSmithKline,Large Pharma,472,Synflorix,pneumococcal vaccine,Vaccine,Launched,In-House,,Dec-09,N/A,Jun-20,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,113.8261033,341.4450128,561.1132487,610.2361165,674.6178539,730.4800475,766.891666,796.5947608,818.7632438,835.12974,847.5943872,856.9399686,3.476511912,2224,pneumococcal vaccine,7/7/14 12:28
1705,46,GlaxoSmithKline,Large Pharma,472,Synflorix,pneumococcal vaccine,Vaccine,Launched,In-House,,Dec-09,N/A,Jun-20,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2224,pneumococcal vaccine,7/7/14 12:28
1705,46,GlaxoSmithKline,Large Pharma,472,Synflorix,pneumococcal vaccine,Vaccine,Launched,In-House,,Dec-09,N/A,Jun-20,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2224,pneumococcal vaccine,7/7/14 12:28
1706,1,Abbott,Regional & Specialty Pharma,763,Synthroid,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-57,Jan-57,Expired,N/A,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1525,Hypothyroidism,7/7/14 12:28
1706,1,Abbott,Regional & Specialty Pharma,763,Synthroid,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-57,Jan-57,Expired,N/A,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,Global,Sales,502,555,638,656,105,104,104,103,102.37,101.8165,101.217325,100.6848513,-0.597705935,1525,Hypothyroidism,7/7/14 12:28
1706,1,Abbott,Regional & Specialty Pharma,763,Synthroid,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-57,Jan-57,Expired,N/A,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1525,Hypothyroidism,7/7/14 12:28
1706,1,Abbott,Regional & Specialty Pharma,763,Synthroid,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-57,Jan-57,Expired,N/A,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,ROW,Sales,87,104,116,105,105,104,104,103,102.37,101.8165,101.217325,100.6848513,-0.597705935,1525,Hypothyroidism,7/7/14 12:28
1706,1,Abbott,Regional & Specialty Pharma,763,Synthroid,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-57,Jan-57,Expired,N/A,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1525,Hypothyroidism,7/7/14 12:28
1706,1,Abbott,Regional & Specialty Pharma,763,Synthroid,levothyroxine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-57,Jan-57,Expired,N/A,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,US,Sales,415,451,522,551,0,0,0,0,0,0,0,0,0,1525,Hypothyroidism,7/7/14 12:28
1707,89,Genzyme,Large Pharma,745,Synvisc,hylan G-F 20,Synthetic Peptide,Launched,Corporate Acquisition,Jan-95,Dec-00,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Proforma,327.921623,393.4521786,412.9598001,101.5364348,0,0,0,0,0,0,0,0,0,1132,Osteoarthritis Pain,7/7/14 12:28
1707,89,Genzyme,Large Pharma,745,Synvisc,hylan G-F 20,Synthetic Peptide,Launched,Corporate Acquisition,Jan-95,Dec-00,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Proforma,56.96943451,67.56249531,65.35054076,18.39223268,0,0,0,0,0,0,0,0,0,1132,Osteoarthritis Pain,7/7/14 12:28
1707,89,Genzyme,Large Pharma,745,Synvisc,hylan G-F 20,Synthetic Peptide,Launched,Corporate Acquisition,Jan-95,Dec-00,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Proforma,270.9521885,325.8896833,347.6092594,83.14420209,0,0,0,0,0,0,0,0,0,1132,Osteoarthritis Pain,7/7/14 12:28
1707,89,Sanofi,Large Pharma,745,Synvisc,hylan G-F 20,Synthetic Peptide,Launched,Corporate Acquisition,Jan-95,Dec-00,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1132,Osteoarthritis Pain,7/7/14 12:28
1707,89,Sanofi,Large Pharma,745,Synvisc,hylan G-F 20,Synthetic Peptide,Launched,Corporate Acquisition,Jan-95,Dec-00,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Sales,4.94E-14,-7.53E-14,-3.95E-14,365.0170566,492.6991547,511.6634241,529.7830663,539.9074364,548.4819953,555.0511067,559.7801851,563.4102958,1.934316408,1132,Osteoarthritis Pain,7/7/14 12:28
1707,89,Sanofi,Large Pharma,745,Synvisc,hylan G-F 20,Synthetic Peptide,Launched,Corporate Acquisition,Jan-95,Dec-00,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1132,Osteoarthritis Pain,7/7/14 12:28
1707,89,Sanofi,Large Pharma,745,Synvisc,hylan G-F 20,Synthetic Peptide,Launched,Corporate Acquisition,Jan-95,Dec-00,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Sales,9.87E-15,0,0,60.00931822,100.9302851,109.6156017,118.0379684,124.5184895,129.0209098,132.5488138,135.1952831,137.1645371,4.479589702,1132,Osteoarthritis Pain,7/7/14 12:28
1707,89,Sanofi,Large Pharma,745,Synvisc,hylan G-F 20,Synthetic Peptide,Launched,Corporate Acquisition,Jan-95,Dec-00,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1132,Osteoarthritis Pain,7/7/14 12:28
1707,89,Sanofi,Large Pharma,745,Synvisc,hylan G-F 20,Synthetic Peptide,Launched,Corporate Acquisition,Jan-95,Dec-00,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Sales,3.95E-14,-7.53E-14,-3.95E-14,305.0077384,391.7688696,402.0478224,411.7450979,415.3889469,419.4610855,422.5022929,424.584902,426.2457587,1.212201844,1132,Osteoarthritis Pain,7/7/14 12:28
1709,100,Takeda,Large Pharma,4293,SYR-472,trelagliptin,Small Molecule (Chemical),Filed,In-House,,Jul-15,,,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1133,Type II Diabetes,7/7/14 12:28
1709,100,Takeda,Large Pharma,4293,SYR-472,trelagliptin,Small Molecule (Chemical),Filed,In-House,,Jul-15,,,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,13.06170389,54.42380976,95.78590519,121.9095951,133.7196083,140.9481114,0,1133,Type II Diabetes,7/7/14 12:28
1709,100,Takeda,Large Pharma,4293,SYR-472,trelagliptin,Small Molecule (Chemical),Filed,In-House,,Jul-15,,,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1133,Type II Diabetes,7/7/14 12:28
1709,100,Takeda,Large Pharma,4293,SYR-472,trelagliptin,Small Molecule (Chemical),Filed,In-House,,Jul-15,,,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,13.06170389,54.42380976,95.78590519,121.9095951,133.7196083,140.9481114,0,1133,Type II Diabetes,7/7/14 12:28
1709,100,Takeda,Large Pharma,4293,SYR-472,trelagliptin,Small Molecule (Chemical),Filed,In-House,,Jul-15,,,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1133,Type II Diabetes,7/7/14 12:28
1709,100,Takeda,Large Pharma,4293,SYR-472,trelagliptin,Small Molecule (Chemical),Filed,In-House,,Jul-15,,,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1133,Type II Diabetes,7/7/14 12:28
1710,106,United Therapeutics,Small Biotech,1957,Adcirca,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,,Nov-17,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Sales,6,36.31,70.58,122.54,176.97,230.659,284.5703,338.41491,340.4986294,50.41361003,38.49988892,32.1237891,-21.63312104,1646,Pulmonary Hypertension,7/7/14 12:28
1710,106,United Therapeutics,Small Biotech,1957,Adcirca,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,,Nov-17,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1646,Pulmonary Hypertension,7/7/14 12:28
1710,106,United Therapeutics,Small Biotech,1957,Adcirca,tadalafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,,Nov-17,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Sales,6,36.31,70.58,122.54,176.97,230.659,284.5703,338.41491,340.4986294,50.41361003,38.49988892,32.1237891,-21.63312104,1646,Pulmonary Hypertension,7/7/14 12:28
1711,46,GlaxoSmithKline,Large Pharma,1648,tafenoquine,tafenoquine,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1140,Malaria,7/7/14 12:28
1711,46,GlaxoSmithKline,Large Pharma,1648,tafenoquine,tafenoquine,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1140,Malaria,7/7/14 12:28
1711,46,GlaxoSmithKline,Large Pharma,1648,tafenoquine,tafenoquine,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1140,Malaria,7/7/14 12:28
1711,46,GlaxoSmithKline,Large Pharma,1648,tafenoquine,tafenoquine,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1140,Malaria,7/7/14 12:28
1711,46,GlaxoSmithKline,Large Pharma,1648,tafenoquine,tafenoquine,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1140,Malaria,7/7/14 12:28
1711,46,GlaxoSmithKline,Large Pharma,1648,tafenoquine,tafenoquine,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1140,Malaria,7/7/14 12:28
1712,91,Santen,Regional & Specialty Pharma,2968,Taflotan / Tapros,tafluprost,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-08,,Dec-22,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1647,Glaucoma,7/7/14 12:28
1712,91,Santen,Regional & Specialty Pharma,2968,Taflotan / Tapros,tafluprost,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-08,,Dec-22,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,Global,Sales,50.52658796,86.41460061,93.0758655,94.76896653,86.18795735,89.14967673,90.07758115,92.2288359,93.71047216,92.93142529,90.85478332,89.50230304,0.540510625,1647,Glaucoma,7/7/14 12:28
1712,91,Santen,Regional & Specialty Pharma,2968,Taflotan / Tapros,tafluprost,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-08,,Dec-22,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1647,Glaucoma,7/7/14 12:28
1712,91,Santen,Regional & Specialty Pharma,2968,Taflotan / Tapros,tafluprost,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-08,,Dec-22,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,ROW,Sales,50.52658796,86.41460061,93.0758655,94.76896653,86.18795735,89.14967673,90.07758115,92.2288359,93.71047216,92.93142529,90.85478332,89.50230304,0.540510625,1647,Glaucoma,7/7/14 12:28
1712,91,Santen,Regional & Specialty Pharma,2968,Taflotan / Tapros,tafluprost,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-08,,Dec-22,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1647,Glaucoma,7/7/14 12:28
1712,91,Santen,Regional & Specialty Pharma,2968,Taflotan / Tapros,tafluprost,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-08,,Dec-22,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1647,Glaucoma,7/7/14 12:28
1714,100,Takeda,Large Pharma,240,Lotriga,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-13,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4564,Hypertriglyceridemia,7/7/14 12:28
1714,100,Takeda,Large Pharma,240,Lotriga,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-13,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,Global,Sales,0,0,0,13.24261473,55.37247235,118.1501022,195.7416374,246.7072478,294.9161067,336.1004213,370.0363742,392.6411676,32.29052008,4564,Hypertriglyceridemia,7/7/14 12:28
1714,100,Takeda,Large Pharma,240,Lotriga,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-13,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4564,Hypertriglyceridemia,7/7/14 12:28
1714,100,Takeda,Large Pharma,240,Lotriga,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-13,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,13.24261473,55.37247235,118.1501022,195.7416374,246.7072478,294.9161067,336.1004213,370.0363742,392.6411676,32.29052008,4564,Hypertriglyceridemia,7/7/14 12:28
1714,100,Takeda,Large Pharma,240,Lotriga,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-13,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,4564,Hypertriglyceridemia,7/7/14 12:28
1714,100,Takeda,Large Pharma,240,Lotriga,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-13,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4564,Hypertriglyceridemia,7/7/14 12:28
1719,100,Takeda,Large Pharma,67,relugolix,TAK-385,Small Molecule (Chemical),Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1146,Endometriosis,7/7/14 12:28
1719,100,Takeda,Large Pharma,67,relugolix,TAK-385,Small Molecule (Chemical),Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1146,Endometriosis,7/7/14 12:28
1719,100,Takeda,Large Pharma,67,relugolix,TAK-385,Small Molecule (Chemical),Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1146,Endometriosis,7/7/14 12:28
1719,100,Takeda,Large Pharma,67,relugolix,TAK-385,Small Molecule (Chemical),Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1146,Endometriosis,7/7/14 12:28
1719,100,Takeda,Large Pharma,67,relugolix,TAK-385,Small Molecule (Chemical),Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1146,Endometriosis,7/7/14 12:28
1719,100,Takeda,Large Pharma,67,relugolix,TAK-385,Small Molecule (Chemical),Phase II,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1146,Endometriosis,7/7/14 12:28
1721,100,Takeda,Large Pharma,761,TAK-438,vonoprazan,Small Molecule (Chemical),Filed,In-House,,Jan-15,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1148,GERD,7/7/14 12:28
1721,100,Takeda,Large Pharma,761,TAK-438,vonoprazan,Small Molecule (Chemical),Filed,In-House,,Jan-15,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,0,0,0,0,0,2.516930561,11.74568434,18.45752075,25.16941359,30.94161207,35.93523957,40.39192106,0,1148,GERD,7/7/14 12:28
1721,100,Takeda,Large Pharma,761,TAK-438,vonoprazan,Small Molecule (Chemical),Filed,In-House,,Jan-15,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1148,GERD,7/7/14 12:28
1721,100,Takeda,Large Pharma,761,TAK-438,vonoprazan,Small Molecule (Chemical),Filed,In-House,,Jan-15,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,0,2.516930561,11.74568434,18.45752075,25.16941359,30.94161207,35.93523957,40.39192106,0,1148,GERD,7/7/14 12:28
1721,100,Takeda,Large Pharma,761,TAK-438,vonoprazan,Small Molecule (Chemical),Filed,In-House,,Jan-15,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1148,GERD,7/7/14 12:28
1721,100,Takeda,Large Pharma,761,TAK-438,vonoprazan,Small Molecule (Chemical),Filed,In-House,,Jan-15,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1148,GERD,7/7/14 12:28
1725,100,Takeda,Large Pharma,3484,Edarbi,azilsartan medoxomil ,Small Molecule (Chemical),Launched,In-House,Apr-11,Jan-12,Sep-16,N/A,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,224,Hypertension,7/7/14 12:28
1725,100,Takeda,Large Pharma,3484,Edarbi,azilsartan medoxomil ,Small Molecule (Chemical),Launched,In-House,Apr-11,Jan-12,Sep-16,N/A,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,15.19399246,60.19958968,101.2296603,77.12131688,94.6288751,110.2357552,122.3785541,132.3570367,140.5844566,147.2595267,5.500285981,224,Hypertension,7/7/14 12:28
1725,100,Takeda,Large Pharma,3484,Edarbi,azilsartan medoxomil ,Small Molecule (Chemical),Launched,In-House,Apr-11,Jan-12,Sep-16,N/A,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,224,Hypertension,7/7/14 12:28
1725,100,Takeda,Large Pharma,3484,Edarbi,azilsartan medoxomil ,Small Molecule (Chemical),Launched,In-House,Apr-11,Jan-12,Sep-16,N/A,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,2.532332077,24.08336767,55.66557692,77.12131688,94.6288751,110.2357552,122.3785541,132.3570367,140.5844566,147.2595267,14.90967837,224,Hypertension,7/7/14 12:28
1725,100,Takeda,Large Pharma,3484,Edarbi,azilsartan medoxomil ,Small Molecule (Chemical),Launched,In-House,Apr-11,Jan-12,Sep-16,N/A,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,224,Hypertension,7/7/14 12:28
1725,100,Takeda,Large Pharma,3484,Edarbi,azilsartan medoxomil ,Small Molecule (Chemical),Launched,In-House,Apr-11,Jan-12,Sep-16,N/A,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,12.66166039,36.116222,45.56408335,0,0,0,0,0,0,0,-100,224,Hypertension,7/7/14 12:28
1734,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,625,Talion,bepotastine besilate,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-00,N/A,Jun-18,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1159,Allergic Rhinitis,7/7/14 12:28
1734,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,625,Talion,bepotastine besilate,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-00,N/A,Jun-18,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,Global,Sales,114.1965527,156.4159731,168.4000831,172.1539915,151.0158337,151.0158337,140.9481114,139.4983594,138.0002823,126.8533003,112.9935423,108.98163,-4.553157665,1159,Allergic Rhinitis,7/7/14 12:28
1734,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,625,Talion,bepotastine besilate,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-00,N/A,Jun-18,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1159,Allergic Rhinitis,7/7/14 12:28
1734,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,625,Talion,bepotastine besilate,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-00,N/A,Jun-18,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,ROW,Sales,114.1965527,156.4159731,168.4000831,172.1539915,151.0158337,151.0158337,140.9481114,139.4983594,138.0002823,126.8533003,112.9935423,108.98163,-4.553157665,1159,Allergic Rhinitis,7/7/14 12:28
1734,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,625,Talion,bepotastine besilate,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-00,N/A,Jun-18,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1159,Allergic Rhinitis,7/7/14 12:28
1734,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,625,Talion,bepotastine besilate,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-00,N/A,Jun-18,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1159,Allergic Rhinitis,7/7/14 12:28
1736,29,Chugai,Regional & Specialty Pharma,1232,Tamiflu,oseltamivir,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-99,N/A,May-18,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,3,Global,Alliance Revenue,814.3657539,207.3936206,109.1263723,150.5649322,112.7386091,112.0142028,112.1796468,112.0685728,112.0610336,112.0608334,112.0596046,112.0594955,-8.63E-02,1571,Influenza,7/7/14 12:28
1736,29,Chugai,Regional & Specialty Pharma,1232,Tamiflu,oseltamivir,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-99,N/A,May-18,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,3,ROW,Alliance Revenue,814.3657539,207.3936206,109.1263723,150.5649322,112.7386091,112.0142028,112.1796468,112.0685728,112.0610336,112.0608334,112.0596046,112.0594955,-8.63E-02,1571,Influenza,7/7/14 12:28
1736,29,Chugai,Regional & Specialty Pharma,1232,Tamiflu,oseltamivir,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-99,N/A,May-18,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1571,Influenza,7/7/14 12:28
1737,86,Roche,Large Pharma,1232,Tamiflu,oseltamivir,Small Molecule (Chemical),Launched,Licensed (Development),Jul-99,Oct-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1571,Influenza,7/7/14 12:28
1737,86,Roche,Large Pharma,1232,Tamiflu,oseltamivir,Small Molecule (Chemical),Launched,Licensed (Development),Jul-99,Oct-99,N/A,May-18,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,5,Global,Sales,2946.929711,906.5294509,404.2304049,597.4239876,797.9817807,478.4443465,474.9425017,469.3872643,464.018905,463.3476907,462.9365221,463.0414157,-7.48067778,1571,Influenza,7/7/14 12:28
1737,86,Roche,Large Pharma,1232,Tamiflu,oseltamivir,Small Molecule (Chemical),Launched,Licensed (Development),Jul-99,Oct-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1571,Influenza,7/7/14 12:28
1737,86,Roche,Large Pharma,1232,Tamiflu,oseltamivir,Small Molecule (Chemical),Launched,Licensed (Development),Jul-99,Oct-99,N/A,May-18,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,5,ROW,Sales,2112.68837,673.4841742,224.0142018,225.2191896,336.1170918,222.0847595,220.3293644,219.679808,217.3215609,217.1492541,217.0581291,217.0013478,-6.059439673,1571,Influenza,7/7/14 12:28
1737,86,Roche,Large Pharma,1232,Tamiflu,oseltamivir,Small Molecule (Chemical),Launched,Licensed (Development),Jul-99,Oct-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1571,Influenza,7/7/14 12:28
1737,86,Roche,Large Pharma,1232,Tamiflu,oseltamivir,Small Molecule (Chemical),Launched,Licensed (Development),Jul-99,Oct-99,N/A,N/A,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,5,US,Sales,834.2413407,233.0452768,180.2162031,372.204798,461.8646889,256.359587,254.6131374,249.7074563,246.6973441,246.1984366,245.878393,246.0400679,-8.603969078,1571,Influenza,7/7/14 12:28
1738,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,794,Tanatril,imidapril,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1162,,7/7/14 12:28
1738,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,794,Tanatril,imidapril,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,Global,Sales,138.97505,133.0703055,131.3061969,110.7564141,80.54177796,72.14751988,65.49726733,60.47584939,56.61880156,53.67435036,51.42158922,49.69940151,-6.664434059,1162,,7/7/14 12:28
1738,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,794,Tanatril,imidapril,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1162,,7/7/14 12:28
1738,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,794,Tanatril,imidapril,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,138.97505,133.0703055,131.3061969,110.7564141,80.54177796,72.14751988,65.49726733,60.47584939,56.61880156,53.67435036,51.42158922,49.69940151,-6.664434059,1162,,7/7/14 12:28
1738,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,794,Tanatril,imidapril,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1162,,7/7/14 12:28
1738,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,794,Tanatril,imidapril,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1162,,7/7/14 12:28
1741,76,Pfizer,Large Pharma,662,tanezumab,tanezumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jun-16,Jan-17,N/A,N/A,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1164,Pain,7/7/14 12:28
1741,76,Pfizer,Large Pharma,662,tanezumab,tanezumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jun-16,Jan-17,N/A,N/A,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,204.16655,890.2768972,1806.943195,2723.615428,3508.065978,0,1164,Pain,7/7/14 12:28
1741,76,Pfizer,Large Pharma,662,tanezumab,tanezumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jun-16,Jan-17,N/A,N/A,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1164,Pain,7/7/14 12:28
1741,76,Pfizer,Large Pharma,662,tanezumab,tanezumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jun-16,Jan-17,N/A,N/A,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,200,533.334,866.66775,1200.0055,0,1164,Pain,7/7/14 12:28
1741,76,Pfizer,Large Pharma,662,tanezumab,tanezumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jun-16,Jan-17,N/A,N/A,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1164,Pain,7/7/14 12:28
1741,76,Pfizer,Large Pharma,662,tanezumab,tanezumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jun-16,Jan-17,N/A,N/A,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,204.16655,690.2768972,1273.609195,1856.947678,2308.060478,0,1164,Pain,7/7/14 12:28
1742,47,Grunenthal,Regional & Specialty Pharma,1762,Nucynta / Palexia,tapentadol,Small Molecule (Chemical),Launched,In-House,Jun-09,Oct-10,N/A,Aug-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,Global,Alliance Revenue,3.334796166,10.59803848,20.85655556,25.70542652,32.65179257,38.60291076,43.87672784,48.72114777,53.13653969,57.14495724,60.79801102,63.7454432,10.02869831,1650,Pain,7/7/14 12:28
1742,47,Grunenthal,Regional & Specialty Pharma,1762,Nucynta / Palexia,tapentadol,Small Molecule (Chemical),Launched,In-House,Jun-09,Oct-10,N/A,Aug-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,Global,Sales,0,5.29901924,43.10354816,86.11317885,119.9901238,145.9042231,168.1799723,185.7601407,200.2190809,212.0901502,221.7426254,229.638168,9.716307825,1650,Pain,7/7/14 12:28
1742,47,Grunenthal,Regional & Specialty Pharma,1762,Nucynta / Palexia,tapentadol,Small Molecule (Chemical),Launched,In-House,Jun-09,Oct-10,N/A,Aug-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1650,Pain,7/7/14 12:28
1742,47,Grunenthal,Regional & Specialty Pharma,1762,Nucynta / Palexia,tapentadol,Small Molecule (Chemical),Launched,In-House,Jun-09,Oct-10,N/A,Aug-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,ROW,Sales,0,5.29901924,43.10354816,86.11317885,119.9901238,145.9042231,168.1799723,185.7601407,200.2190809,212.0901502,221.7426254,229.638168,9.716307825,1650,Pain,7/7/14 12:28
1742,47,Grunenthal,Regional & Specialty Pharma,1762,Nucynta / Palexia,tapentadol,Small Molecule (Chemical),Launched,In-House,Jun-09,Oct-10,N/A,Aug-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,US,Alliance Revenue,3.334796166,10.59803848,20.85655556,25.70542652,32.65179257,38.60291076,43.87672784,48.72114777,53.13653969,57.14495724,60.79801102,63.7454432,10.02869831,1650,Pain,7/7/14 12:28
1742,47,Grunenthal,Regional & Specialty Pharma,1762,Nucynta / Palexia,tapentadol,Small Molecule (Chemical),Launched,In-House,Jun-09,Oct-10,N/A,Aug-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1650,Pain,7/7/14 12:28
1743,53,Johnson & Johnson,Large Pharma,1762,Nucynta / Palexia,tapentadol,Small Molecule (Chemical),Launched,Licensed (Development),Jun-09,Mar-12,Aug-22,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1650,Pain,7/7/14 12:28
1743,53,Johnson & Johnson,Large Pharma,1762,Nucynta / Palexia,tapentadol,Small Molecule (Chemical),Launched,Licensed (Development),Jun-09,Mar-12,Aug-22,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,40.83331,138.0553794,259,353.33333,444.4742072,529.2968641,605.1990854,673.5645891,735.539013,791.5016825,842.1398078,887.9975204,10.3920609,1650,Pain,7/7/14 12:28
1743,53,Johnson & Johnson,Large Pharma,1762,Nucynta / Palexia,tapentadol,Small Molecule (Chemical),Launched,Licensed (Development),Jun-09,Mar-12,Aug-22,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1650,Pain,7/7/14 12:28
1743,53,Johnson & Johnson,Large Pharma,1762,Nucynta / Palexia,tapentadol,Small Molecule (Chemical),Launched,Licensed (Development),Jun-09,Mar-12,Aug-22,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,8.33333,15.55557711,22.22223079,28.88890003,33.63334613,37.62723433,40.95476257,43.62233643,45.81391255,16.68521385,1650,Pain,7/7/14 12:28
1743,53,Johnson & Johnson,Large Pharma,1762,Nucynta / Palexia,tapentadol,Small Molecule (Chemical),Launched,Licensed (Development),Jun-09,Mar-12,Aug-22,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1650,Pain,7/7/14 12:28
1743,53,Johnson & Johnson,Large Pharma,1762,Nucynta / Palexia,tapentadol,Small Molecule (Chemical),Launched,Licensed (Development),Jun-09,Mar-12,Aug-22,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,40.83331,138.0553794,259,345,428.91863,507.0746333,576.3101854,639.9312429,697.9117787,750.54692,798.5174714,842.1836079,10.11884673,1650,Pain,7/7/14 12:28
1744,29,Chugai,Regional & Specialty Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-07,N/A,Jun-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,3,Global,Alliance Revenue,61.98584478,93.51436883,104.1090678,119.01779,106.5892304,111.7137126,118.8879878,124.01247,127.0871593,130.1618487,132.2116416,128.1161554,2.662758008,1448,Non-small-cell Lung Cancer,7/7/14 12:28
1744,29,Chugai,Regional & Specialty Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-07,N/A,Jun-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,3,ROW,Alliance Revenue,61.98584478,93.51436883,104.1090678,119.01779,106.5892304,111.7137126,118.8879878,124.01247,127.0871593,130.1618487,132.2116416,128.1161554,2.662758008,1448,Non-small-cell Lung Cancer,7/7/14 12:28
1744,29,Chugai,Regional & Specialty Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-07,N/A,Jun-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1448,Non-small-cell Lung Cancer,7/7/14 12:28
1745,86,Roche,Large Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-04,Sep-05,Nov-20,Mar-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1448,Non-small-cell Lung Cancer,7/7/14 12:28
1745,86,Roche,Large Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-04,Sep-05,Nov-20,Mar-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,5,Global,Sales,1200.899423,1274.085298,1409.550189,1400.93804,1444.701881,1492.289857,1528.155318,1565.555698,1594.016185,1620.507709,1642.697841,1348.619236,-0.978348998,1448,Non-small-cell Lung Cancer,7/7/14 12:28
1745,86,Roche,Large Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-04,Sep-05,Nov-20,Mar-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1448,Non-small-cell Lung Cancer,7/7/14 12:28
1745,86,Roche,Large Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-04,Sep-05,Nov-20,Mar-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,5,ROW,Sales,721.1646124,772.5104839,864.3961748,791.9725967,792.9115252,788.7015926,789.6034647,792.2992455,792.8924575,794.355232,795.3869545,597.1172045,-3.970427224,1448,Non-small-cell Lung Cancer,7/7/14 12:28
1745,86,Roche,Large Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-04,Sep-05,Nov-20,Mar-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1448,Non-small-cell Lung Cancer,7/7/14 12:28
1745,86,Roche,Large Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-04,Sep-05,Nov-20,Mar-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,5,US,Sales,479.7348107,501.5748138,545.1540145,608.9654431,651.7903554,703.5882644,738.5518531,773.2564522,801.1237273,826.152477,847.3108869,751.5020317,2.054401045,1448,Non-small-cell Lung Cancer,7/7/14 12:28
1747,34,Daiichi-Sankyo,Regional & Specialty Pharma,1715,Tarivid,ofloxacin,Small Molecule (Chemical),Launched,In-House,,Jul-84,N/A,May-03,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1165,,7/7/14 12:28
1747,34,Daiichi-Sankyo,Regional & Specialty Pharma,1715,Tarivid,ofloxacin,Small Molecule (Chemical),Launched,In-House,,Jul-84,N/A,May-03,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,22.21740028,20.44958568,17.95447489,15.47479074,11.64340642,10.61039788,9.906689194,9.353898376,8.937432542,8.628545402,8.394580512,8.218815459,-4.854138385,1165,,7/7/14 12:28
1747,34,Daiichi-Sankyo,Regional & Specialty Pharma,1715,Tarivid,ofloxacin,Small Molecule (Chemical),Launched,In-House,,Jul-84,N/A,May-03,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1165,,7/7/14 12:28
1747,34,Daiichi-Sankyo,Regional & Specialty Pharma,1715,Tarivid,ofloxacin,Small Molecule (Chemical),Launched,In-House,,Jul-84,N/A,May-03,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,22.21740028,20.44958568,17.95447489,15.47479074,11.64340642,10.61039788,9.906689194,9.353898376,8.937432542,8.628545402,8.394580512,8.218815459,-4.854138385,1165,,7/7/14 12:28
1747,34,Daiichi-Sankyo,Regional & Specialty Pharma,1715,Tarivid,ofloxacin,Small Molecule (Chemical),Launched,In-House,,Jul-84,N/A,May-03,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1165,,7/7/14 12:28
1747,34,Daiichi-Sankyo,Regional & Specialty Pharma,1715,Tarivid,ofloxacin,Small Molecule (Chemical),Launched,In-House,,Jul-84,N/A,May-03,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1165,,7/7/14 12:28
1748,67,Novartis,Large Pharma,3,Tasigna,nilotinib,Small Molecule (Chemical),Launched,In-House,Nov-07,Dec-07,Jul-23,Apr-23,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1166,Chronic Myeloid Leukemia,7/7/14 12:28
1748,67,Novartis,Large Pharma,3,Tasigna,nilotinib,Small Molecule (Chemical),Launched,In-House,Nov-07,Dec-07,Jul-23,Apr-23,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,212,399,716,998,1266,1463.4,1611.927675,1742.777375,1781.148297,1866.891695,1937.016679,1994.200255,6.706455712,1166,Chronic Myeloid Leukemia,7/7/14 12:28
1748,67,Novartis,Large Pharma,3,Tasigna,nilotinib,Small Molecule (Chemical),Launched,In-House,Nov-07,Dec-07,Jul-23,Apr-23,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1166,Chronic Myeloid Leukemia,7/7/14 12:28
1748,67,Novartis,Large Pharma,3,Tasigna,nilotinib,Small Molecule (Chemical),Launched,In-House,Nov-07,Dec-07,Jul-23,Apr-23,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,125,265,461,647,838,971.35,1084.1725,1173.855278,1178.521786,1236.758251,1284.414513,1323.238962,6.743640166,1166,Chronic Myeloid Leukemia,7/7/14 12:28
1748,67,Novartis,Large Pharma,3,Tasigna,nilotinib,Small Molecule (Chemical),Launched,In-House,Nov-07,Dec-07,Jul-23,Apr-23,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1166,Chronic Myeloid Leukemia,7/7/14 12:28
1748,67,Novartis,Large Pharma,3,Tasigna,nilotinib,Small Molecule (Chemical),Launched,In-House,Nov-07,Dec-07,Jul-23,Apr-23,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,87,134,255,351,428,492.05,527.755175,568.9220962,602.6265104,630.1334434,652.6021658,670.9612926,6.633424702,1166,Chronic Myeloid Leukemia,7/7/14 12:28
1751,24,Bristol-Myers Squibb,Large Pharma,405,Taxol,paclitaxel,Small Molecule (Chemical),Launched,In-House,Jan-93,Jan-95,Jan-02,Sep-03,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1169,Solid Tumors,7/7/14 12:28
1751,24,Bristol-Myers Squibb,Large Pharma,405,Taxol,paclitaxel,Small Molecule (Chemical),Launched,In-House,Jan-93,Jan-95,Jan-02,Sep-03,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Sales,294.475,230.425,187.138125,149.294125,120.29955,97.95238664,80.21291642,66.34774175,55.50872633,46.99793496,40.32610888,35.09840312,-16.13614123,1169,Solid Tumors,7/7/14 12:28
1751,24,Bristol-Myers Squibb,Large Pharma,405,Taxol,paclitaxel,Small Molecule (Chemical),Launched,In-House,Jan-93,Jan-95,Jan-02,Sep-03,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1169,Solid Tumors,7/7/14 12:28
1751,24,Bristol-Myers Squibb,Large Pharma,405,Taxol,paclitaxel,Small Molecule (Chemical),Launched,In-House,Jan-93,Jan-95,Jan-02,Sep-03,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Sales,289,226,184.205,146.636625,118.0868781,96.04902727,78.43563635,64.70243629,53.93961442,45.47398249,38.83858584,33.63211686,-16.42449387,1169,Solid Tumors,7/7/14 12:28
1751,24,Bristol-Myers Squibb,Large Pharma,405,Taxol,paclitaxel,Small Molecule (Chemical),Launched,In-House,Jan-93,Jan-95,Jan-02,Sep-03,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1169,Solid Tumors,7/7/14 12:28
1751,24,Bristol-Myers Squibb,Large Pharma,405,Taxol,paclitaxel,Small Molecule (Chemical),Launched,In-House,Jan-93,Jan-95,Jan-02,Sep-03,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Sales,5.475,4.425,2.933125,2.6575,2.212671875,1.903359375,1.777280078,1.645305469,1.569111904,1.523952471,1.48752304,1.466286266,-5.708682452,1169,Solid Tumors,7/7/14 12:28
1752,89,Sanofi,Large Pharma,170,Taxotere,docetaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-96,Jun-96,Mar-11,Nov-10,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1422,Solid Tumors,7/7/14 12:28
1752,89,Sanofi,Large Pharma,170,Taxotere,docetaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-96,Jun-96,Mar-11,Nov-10,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,Global,Sales,3024.938023,2811.129707,1281.982949,723.6077566,543.1642972,423.4955081,348.538968,301.3662099,271.5165034,252.5975402,240.5978786,232.9848138,-11.3894867,1422,Solid Tumors,7/7/14 12:28
1752,89,Sanofi,Large Pharma,170,Taxotere,docetaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-96,Jun-96,Mar-11,Nov-10,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1422,Solid Tumors,7/7/14 12:28
1752,89,Sanofi,Large Pharma,170,Taxotere,docetaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-96,Jun-96,Mar-11,Nov-10,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,ROW,Sales,1875.822844,1769.872426,944.1067485,655.4883763,487.3870344,371.370328,297.3268085,250.3823056,220.5896629,201.6849656,189.6888706,182.0766974,-13.1216536,1422,Solid Tumors,7/7/14 12:28
1752,89,Sanofi,Large Pharma,170,Taxotere,docetaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-96,Jun-96,Mar-11,Nov-10,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1422,Solid Tumors,7/7/14 12:28
1752,89,Sanofi,Large Pharma,170,Taxotere,docetaxel,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-96,Jun-96,Mar-11,Nov-10,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,2,US,Sales,1149.115179,1041.257281,337.8762001,68.11938029,55.7772628,52.12518012,51.21215945,50.98390429,50.92684049,50.91257455,50.90900806,50.90811644,-1.296435062,1422,Solid Tumors,7/7/14 12:28
1753,8,Allergan,Regional & Specialty Pharma,1318,Tazorac / Zorac,tazarotene,Small Molecule (Chemical),Launched,In-House,Jun-97,Jun-97,N/A,Dec-11,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1170,Acne,7/7/14 12:28
1753,8,Allergan,Regional & Specialty Pharma,1318,Tazorac / Zorac,tazarotene,Small Molecule (Chemical),Launched,In-House,Jun-97,Jun-97,N/A,Dec-11,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Sales,67.4,59.66,51.784,46.3184,43.18916,41.072754,39.7446201,38.89630156,38.34069254,37.98007162,37.74381331,37.587757,-1.964882579,1170,Acne,7/7/14 12:28
1753,8,Allergan,Regional & Specialty Pharma,1318,Tazorac / Zorac,tazarotene,Small Molecule (Chemical),Launched,In-House,Jun-97,Jun-97,N/A,Dec-11,160,Acne Treatments,73,Acne,6,Dermatology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1170,Acne,7/7/14 12:28
1753,8,Allergan,Regional & Specialty Pharma,1318,Tazorac / Zorac,tazarotene,Small Molecule (Chemical),Launched,In-House,Jun-97,Jun-97,N/A,Dec-11,160,Acne Treatments,73,Acne,6,Dermatology,6,ROW,Sales,22.4,18.16,14.624,11.9024,10.46016,9.611104,9.1272576,8.84881344,8.689051136,8.597301798,8.544625833,8.514380513,-2.897438124,1170,Acne,7/7/14 12:28
1753,8,Allergan,Regional & Specialty Pharma,1318,Tazorac / Zorac,tazarotene,Small Molecule (Chemical),Launched,In-House,Jun-97,Jun-97,N/A,Dec-11,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1170,Acne,7/7/14 12:28
1753,8,Allergan,Regional & Specialty Pharma,1318,Tazorac / Zorac,tazarotene,Small Molecule (Chemical),Launched,In-House,Jun-97,Jun-97,N/A,Dec-11,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Sales,45,41.5,37.16,34.416,32.729,31.46165,30.6173625,30.04748812,29.65164141,29.38276982,29.19918748,29.07337648,-1.677745828,1170,Acne,7/7/14 12:28
1754,59,Mannkind,Small Biotech,2372,Afrezza,inhaled insulin,Recombinant Protein,Approved,In-House,Jul-14,Nov-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,19.166675,67.77789722,104.4446306,141.1111639,160.6389294,174.6875242,184.795491,0,80,Diabetes,7/7/14 12:28
1754,59,Mannkind,Small Biotech,2372,Afrezza,inhaled insulin,Recombinant Protein,Approved,In-House,Jul-14,Nov-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,4.166675,27.77784722,44.44455556,61.11126389,70.13906444,76.56269167,81.18943939,0,80,Diabetes,7/7/14 12:28
1754,59,Mannkind,Small Biotech,2372,Afrezza,inhaled insulin,Recombinant Protein,Approved,In-House,Jul-14,Nov-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,15,40.00005,60.000075,79.9999,90.499865,98.1248325,103.6060516,0,80,Diabetes,7/7/14 12:28
1755,67,Novartis,Large Pharma,4616,Tegretol / Tegretol XR,carbamazepine ,Small Molecule (Chemical),Launched,In-House,Jul-74,Jul-65,Expired,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1690,Epilepsy,7/7/14 12:28
1755,67,Novartis,Large Pharma,4616,Tegretol / Tegretol XR,carbamazepine ,Small Molecule (Chemical),Launched,In-House,Jul-74,Jul-65,Expired,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,375,355,364,348,342,338.55,334.6325,332.115625,330.1805812,328.5886591,327.3564145,326.3580894,-0.666561103,1690,Epilepsy,7/7/14 12:28
1755,67,Novartis,Large Pharma,4616,Tegretol / Tegretol XR,carbamazepine ,Small Molecule (Chemical),Launched,In-House,Jul-74,Jul-65,Expired,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1690,Epilepsy,7/7/14 12:28
1755,67,Novartis,Large Pharma,4616,Tegretol / Tegretol XR,carbamazepine ,Small Molecule (Chemical),Launched,In-House,Jul-74,Jul-65,Expired,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,284,266.25,273,261,256.5,254.25,251.8125,250.415625,249.4757813,248.7875391,248.3348145,248.0244126,-0.478870482,1690,Epilepsy,7/7/14 12:28
1755,67,Novartis,Large Pharma,4616,Tegretol / Tegretol XR,carbamazepine ,Small Molecule (Chemical),Launched,In-House,Jul-74,Jul-65,Expired,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1690,Epilepsy,7/7/14 12:28
1755,67,Novartis,Large Pharma,4616,Tegretol / Tegretol XR,carbamazepine ,Small Molecule (Chemical),Launched,In-House,Jul-74,Jul-65,Expired,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,91,88.75,91,87,85.5,84.3,82.82,81.7,80.7048,79.80112,79.0216,78.3336768,-1.242765632,1690,Epilepsy,7/7/14 12:28
1756,67,Novartis,Large Pharma,1107,Tekturna,aliskiren,Small Molecule (Chemical),Launched,Licensed (Development),Mar-07,Sep-07,Jul-18,Apr-20,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1173,,7/7/14 12:28
1756,67,Novartis,Large Pharma,1107,Tekturna,aliskiren,Small Molecule (Chemical),Launched,Licensed (Development),Mar-07,Sep-07,Jul-18,Apr-20,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Sales,290,438,557,383,292.15,241.9975,212.958375,195.5069438,184.7331134,157.5850549,119.4341497,84.15022497,-16.28976491,1173,,7/7/14 12:28
1756,67,Novartis,Large Pharma,1107,Tekturna,aliskiren,Small Molecule (Chemical),Launched,Licensed (Development),Mar-07,Sep-07,Jul-18,Apr-20,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1173,,7/7/14 12:28
1756,67,Novartis,Large Pharma,1107,Tekturna,aliskiren,Small Molecule (Chemical),Launched,Licensed (Development),Mar-07,Sep-07,Jul-18,Apr-20,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,134,231,341,256,200.75,164.8375,141.494375,126.3213438,116.4588734,110.0482677,105.881374,77.37966984,-12.73238547,1173,,7/7/14 12:28
1756,67,Novartis,Large Pharma,1107,Tekturna,aliskiren,Small Molecule (Chemical),Launched,Licensed (Development),Mar-07,Sep-07,Jul-18,Apr-20,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1173,,7/7/14 12:28
1756,67,Novartis,Large Pharma,1107,Tekturna,aliskiren,Small Molecule (Chemical),Launched,Licensed (Development),Mar-07,Sep-07,Jul-18,Apr-20,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Sales,156,207,216,127,91.4,77.16,71.464,69.1856,68.27424,47.5367872,13.55277568,6.770555136,-31.05137623,1173,,7/7/14 12:28
1757,53,Johnson & Johnson,Large Pharma,3699,Incivo,telaprevir,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1653,Hepatitis C,7/7/14 12:28
1757,53,Johnson & Johnson,Large Pharma,3699,Incivo,telaprevir,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,66,443,517,87,31,10,5,2.14,1.2754,1,-59.04010058,1653,Hepatitis C,7/7/14 12:28
1757,53,Johnson & Johnson,Large Pharma,3699,Incivo,telaprevir,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1653,Hepatitis C,7/7/14 12:28
1757,53,Johnson & Johnson,Large Pharma,3699,Incivo,telaprevir,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,66,443,517,87,31,10,5,2.14,1.2754,1,-59.04010058,1653,Hepatitis C,7/7/14 12:28
1757,53,Johnson & Johnson,Large Pharma,3699,Incivo,telaprevir,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1653,Hepatitis C,7/7/14 12:28
1757,53,Johnson & Johnson,Large Pharma,3699,Incivo,telaprevir,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1653,Hepatitis C,7/7/14 12:28
1758,108,Vertex,Regional & Specialty Pharma,3683,Incivek,telaprevir,Small Molecule (Chemical),Launched,In-House,Jun-11,,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1653,Hepatitis C,7/7/14 12:28
1758,108,Vertex,Regional & Specialty Pharma,3683,Incivek,telaprevir,Small Molecule (Chemical),Launched,In-House,Jun-11,,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,950.9,1161.813,466,29,6,2,0,0,0,0,-100,1653,Hepatitis C,7/7/14 12:28
1758,108,Vertex,Regional & Specialty Pharma,3683,Incivek,telaprevir,Small Molecule (Chemical),Launched,In-House,Jun-11,,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1653,Hepatitis C,7/7/14 12:28
1758,108,Vertex,Regional & Specialty Pharma,3683,Incivek,telaprevir,Small Molecule (Chemical),Launched,In-House,Jun-11,,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1653,Hepatitis C,7/7/14 12:28
1758,108,Vertex,Regional & Specialty Pharma,3683,Incivek,telaprevir,Small Molecule (Chemical),Launched,In-House,Jun-11,,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1653,Hepatitis C,7/7/14 12:28
1758,108,Vertex,Regional & Specialty Pharma,3683,Incivek,telaprevir,Small Molecule (Chemical),Launched,In-House,Jun-11,,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,950.9,1161.813,466,29,6,2,0,0,0,0,-100,1653,Hepatitis C,7/7/14 12:28
1760,61,Merck & Co,Large Pharma,1056,Temodar,temozolomide,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,May-99,Aug-13,Jun-11,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1656,Glioma,7/7/14 12:28
1760,61,Merck & Co,Large Pharma,1056,Temodar,temozolomide,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,May-99,Aug-13,Jun-11,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,Global,Sales,188.1,1064.6,934,917,707,408.8,348.74,318.662,297.9206,284.56478,274.902614,268.1673182,-12.93266228,1656,Glioma,7/7/14 12:28
1760,61,Merck & Co,Large Pharma,1056,Temodar,temozolomide,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,May-99,Aug-13,Jun-11,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1656,Glioma,7/7/14 12:28
1760,61,Merck & Co,Large Pharma,1056,Temodar,temozolomide,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,May-99,Aug-13,Jun-11,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,ROW,Sales,120.4,662,538,494,404,363.8,324.74,300.962,282.1106,269.32178,259.829714,253.1454482,-6.459772257,1656,Glioma,7/7/14 12:28
1760,61,Merck & Co,Large Pharma,1056,Temodar,temozolomide,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,May-99,Aug-13,Jun-11,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1656,Glioma,7/7/14 12:28
1760,61,Merck & Co,Large Pharma,1056,Temodar,temozolomide,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,May-99,Aug-13,Jun-11,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,US,Sales,67.7,402.6,396,423,303,45,24,17.7,15.81,15.243,15.0729,15.02187,-34.89537964,1656,Glioma,7/7/14 12:28
1760,61,Schering-Plough,Large Pharma,1056,Temodar,temozolomide,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,May-99,Aug-13,Jun-11,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,Global,Proforma,884.9,0,0,0,0,0,0,0,0,0,0,0,0,1656,Glioma,7/7/14 12:28
1760,61,Schering-Plough,Large Pharma,1056,Temodar,temozolomide,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,May-99,Aug-13,Jun-11,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,ROW,Proforma,565.6,0,0,0,0,0,0,0,0,0,0,0,0,1656,Glioma,7/7/14 12:28
1760,61,Schering-Plough,Large Pharma,1056,Temodar,temozolomide,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,May-99,Aug-13,Jun-11,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,US,Proforma,319.3,0,0,0,0,0,0,0,0,0,0,0,0,1656,Glioma,7/7/14 12:28
1761,16,AstraZeneca,Large Pharma,1724,Tenormin,atenolol,Small Molecule (Chemical),Launched,In-House,Jan-81,Jan-76,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1177,Hypertension,7/7/14 12:28
1761,16,AstraZeneca,Large Pharma,1724,Tenormin,atenolol,Small Molecule (Chemical),Launched,In-House,Jan-81,Jan-76,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,Global,Sales,296,286.7,270,229.395,197,175.945,165.157925,159.3558426,156.1345146,154.3641953,153.3803306,152.5926576,-3.583246704,1177,Hypertension,7/7/14 12:28
1761,16,AstraZeneca,Large Pharma,1724,Tenormin,atenolol,Small Molecule (Chemical),Launched,In-House,Jan-81,Jan-76,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1177,Hypertension,7/7/14 12:28
1761,16,AstraZeneca,Large Pharma,1724,Tenormin,atenolol,Small Molecule (Chemical),Launched,In-House,Jan-81,Jan-76,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,281,273,259,219,182,164.945,154.577675,149.0095426,145.8559921,144.1109258,143.1355005,142.5926576,-3.425862046,1177,Hypertension,7/7/14 12:28
1761,16,AstraZeneca,Large Pharma,1724,Tenormin,atenolol,Small Molecule (Chemical),Launched,In-House,Jan-81,Jan-76,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1177,Hypertension,7/7/14 12:28
1761,16,AstraZeneca,Large Pharma,1724,Tenormin,atenolol,Small Molecule (Chemical),Launched,In-House,Jan-81,Jan-76,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,US,Sales,15,13.7,11,10.395,15,11,10.58025,10.3463,10.2785225,10.2532695,10.24483003,10,-5.62778879,1177,Hypertension,7/7/14 12:28
1763,89,Sanofi,Large Pharma,3818,Aubagio,teriflunomide,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-12,Oct-13,Sep-18,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1179,Multiple Sclerosis,7/7/14 12:28
1763,89,Sanofi,Large Pharma,3818,Aubagio,teriflunomide,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-12,Oct-13,Sep-18,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Sales,0,0,0,8.996899283,220.4529911,366.8143348,499.6412187,582.7628279,640.2054314,538.2609984,219.1257601,218.0539519,-0.156191475,1179,Multiple Sclerosis,7/7/14 12:28
1763,89,Sanofi,Large Pharma,3818,Aubagio,teriflunomide,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-12,Oct-13,Sep-18,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1179,Multiple Sclerosis,7/7/14 12:28
1763,89,Sanofi,Large Pharma,3818,Aubagio,teriflunomide,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-12,Oct-13,Sep-18,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Sales,0,0,0,0,18.59242093,49.60457905,67.08130747,94.82083834,116.5472964,136.4279382,155.9241151,174.3543761,37.67999708,1179,Multiple Sclerosis,7/7/14 12:28
1763,89,Sanofi,Large Pharma,3818,Aubagio,teriflunomide,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-12,Oct-13,Sep-18,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1179,Multiple Sclerosis,7/7/14 12:28
1763,89,Sanofi,Large Pharma,3818,Aubagio,teriflunomide,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-12,Oct-13,Sep-18,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,US,Sales,0,0,0,8.996899283,201.8605701,317.2097557,432.5599113,487.9419895,523.658135,401.8330602,63.20164503,43.69957587,-19.63611695,1179,Multiple Sclerosis,7/7/14 12:28
1765,63,Merck KGaA,Regional & Specialty Pharma,3091,Egrifta,tesamorelin,Recombinant Protein,Launched,Licensed (Development),Dec-10,,Jul-20,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1180,Lipodystrophy in HIV Patients,7/7/14 12:28
1765,63,Merck KGaA,Regional & Specialty Pharma,3091,Egrifta,tesamorelin,Recombinant Protein,Launched,Licensed (Development),Dec-10,,Jul-20,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,Global,Sales,0,2.189911221,9.733059263,18.8313284,31.8727216,7.304165366,0.592009244,0,0,0,0,0,-100,1180,Lipodystrophy in HIV Patients,7/7/14 12:28
1765,63,Merck KGaA,Regional & Specialty Pharma,3091,Egrifta,tesamorelin,Recombinant Protein,Launched,Licensed (Development),Dec-10,,Jul-20,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1180,Lipodystrophy in HIV Patients,7/7/14 12:28
1765,63,Merck KGaA,Regional & Specialty Pharma,3091,Egrifta,tesamorelin,Recombinant Protein,Launched,Licensed (Development),Dec-10,,Jul-20,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1180,Lipodystrophy in HIV Patients,7/7/14 12:28
1765,63,Merck KGaA,Regional & Specialty Pharma,3091,Egrifta,tesamorelin,Recombinant Protein,Launched,Licensed (Development),Dec-10,,Jul-20,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1180,Lipodystrophy in HIV Patients,7/7/14 12:28
1765,63,Merck KGaA,Regional & Specialty Pharma,3091,Egrifta,tesamorelin,Recombinant Protein,Launched,Licensed (Development),Dec-10,,Jul-20,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,US,Sales,0,2.189911221,9.733059263,18.8313284,31.8727216,7.304165366,0.592009244,0,0,0,0,0,-100,1180,Lipodystrophy in HIV Patients,7/7/14 12:28
1767,1,Abbott,Regional & Specialty Pharma,1273,Teveten,eprosartan,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Jul-97,Dec-11,Apr-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1446,Hypertension,7/7/14 12:28
1767,1,Abbott,Regional & Specialty Pharma,1273,Teveten,eprosartan,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Jul-97,Dec-11,Apr-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,17.67,127,129.4375,75,45.78125,33.171875,26.8671875,23.71484375,22.13867188,21.35058594,20.95654297,20.75952148,-10.6832602,1446,Hypertension,7/7/14 12:28
1767,1,Abbott,Regional & Specialty Pharma,1273,Teveten,eprosartan,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Jul-97,Dec-11,Apr-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1446,Hypertension,7/7/14 12:28
1767,1,Abbott,Regional & Specialty Pharma,1273,Teveten,eprosartan,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Jul-97,Dec-11,Apr-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,115,121.4375,71,45.78125,33.171875,26.8671875,23.71484375,22.13867188,21.35058594,20.95654297,20.75952148,-10.6832602,1446,Hypertension,7/7/14 12:28
1767,1,Abbott,Regional & Specialty Pharma,1273,Teveten,eprosartan,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Jul-97,Dec-11,Apr-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1446,Hypertension,7/7/14 12:28
1767,1,Abbott,Regional & Specialty Pharma,1273,Teveten,eprosartan,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Jul-97,Dec-11,Apr-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,17.67,12,8,4,0,0,0,0,0,0,0,0,0,1446,Hypertension,7/7/14 12:28
1767,1,Solvay,Regional & Specialty Pharma,1273,Teveten,eprosartan,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Jul-97,Dec-11,Apr-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Proforma,149,18.25,0,0,0,0,0,0,0,0,0,0,0,1446,Hypertension,7/7/14 12:28
1767,1,Solvay,Regional & Specialty Pharma,1273,Teveten,eprosartan,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-99,Jul-97,Dec-11,Apr-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Proforma,149,18.25,0,0,0,0,0,0,0,0,0,0,0,1446,Hypertension,7/7/14 12:28
1768,26,Celgene,Regional & Specialty Pharma,359,Thalomid,thalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Oct-98,Jun-03,Dec-23,Feb-19,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1659,Multiple Myeloma,7/7/14 12:28
1768,26,Celgene,Regional & Specialty Pharma,359,Thalomid,thalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Oct-98,Jun-03,Dec-23,Feb-19,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,437,387.3,339,302,245,210.8000715,147.2864673,127.384307,113.8669342,104.0533704,60.05600228,33.72943969,-24.66831174,1659,Multiple Myeloma,7/7/14 12:28
1768,26,Celgene,Regional & Specialty Pharma,359,Thalomid,thalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Oct-98,Jun-03,Dec-23,Feb-19,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1659,Multiple Myeloma,7/7/14 12:28
1768,26,Celgene,Regional & Specialty Pharma,359,Thalomid,thalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Oct-98,Jun-03,Dec-23,Feb-19,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,136,147.3,152.55,140,135,128.3531215,86.81841233,81.8164712,79.02410627,76.7564123,38.11379928,15.57485308,-26.54641139,1659,Multiple Myeloma,7/7/14 12:28
1768,26,Celgene,Regional & Specialty Pharma,359,Thalomid,thalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Oct-98,Jun-03,Dec-23,Feb-19,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1659,Multiple Myeloma,7/7/14 12:28
1768,26,Celgene,Regional & Specialty Pharma,359,Thalomid,thalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Oct-98,Jun-03,Dec-23,Feb-19,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,301,240,186.45,162,110,82.44695,60.46805495,45.56783578,34.84282797,27.2969581,21.94220301,18.15458661,-22.69140506,1659,Multiple Myeloma,7/7/14 12:28
1769,76,Pfizer,Large Pharma,1367,Thelin,sitaxentan,Small Molecule (Chemical),Launched,In-House,Jul-12,Nov-06,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1637,Pulmonary Hypertension,7/7/14 12:28
1769,76,Pfizer,Large Pharma,1367,Thelin,sitaxentan,Small Molecule (Chemical),Launched,In-House,Jul-12,Nov-06,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Sales,46,57.366667,0,0,0,0,0,0,0,0,0,0,0,1637,Pulmonary Hypertension,7/7/14 12:28
1769,76,Pfizer,Large Pharma,1367,Thelin,sitaxentan,Small Molecule (Chemical),Launched,In-House,Jul-12,Nov-06,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1637,Pulmonary Hypertension,7/7/14 12:28
1769,76,Pfizer,Large Pharma,1367,Thelin,sitaxentan,Small Molecule (Chemical),Launched,In-House,Jul-12,Nov-06,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,46,57.366667,0,0,0,0,0,0,0,0,0,0,0,1637,Pulmonary Hypertension,7/7/14 12:28
1769,76,Pfizer,Large Pharma,1367,Thelin,sitaxentan,Small Molecule (Chemical),Launched,In-House,Jul-12,Nov-06,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1637,Pulmonary Hypertension,7/7/14 12:28
1769,76,Pfizer,Large Pharma,1367,Thelin,sitaxentan,Small Molecule (Chemical),Launched,In-House,Jul-12,Nov-06,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1637,Pulmonary Hypertension,7/7/14 12:28
1770,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,890,Theodur,theophylline,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-84,N/A,Expired,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3351,Asthma,7/7/14 12:28
1770,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,890,Theodur,theophylline,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-84,N/A,Expired,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,7,Global,Sales,47.40234265,43.00997159,50.64664155,43.3394664,33.21115409,30.78503718,28.84414365,27.29142882,26.04925696,25.05551947,24.26052948,23.62453749,-4.749229089,3351,Asthma,7/7/14 12:28
1770,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,890,Theodur,theophylline,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-84,N/A,Expired,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3351,Asthma,7/7/14 12:28
1770,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,890,Theodur,theophylline,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-84,N/A,Expired,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,7,ROW,Sales,47.40234265,43.00997159,50.64664155,43.3394664,33.21115409,30.78503718,28.84414365,27.29142882,26.04925696,25.05551947,24.26052948,23.62453749,-4.749229089,3351,Asthma,7/7/14 12:28
1770,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,890,Theodur,theophylline,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-84,N/A,Expired,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3351,Asthma,7/7/14 12:28
1770,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,890,Theodur,theophylline,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-84,N/A,Expired,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3351,Asthma,7/7/14 12:28
1771,76,King,Large Pharma,390,Thrombin-JMI,thrombin,Recombinant Protein,Launched,Corporate Acquisition,Jul-95,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Proforma,183.5,139,18.18,0,0,0,0,0,0,0,0,0,0,1183,Hemostasis,7/7/14 12:28
1771,76,King,Large Pharma,390,Thrombin-JMI,thrombin,Recombinant Protein,Launched,Corporate Acquisition,Jul-95,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Proforma,183.5,139,18.18,0,0,0,0,0,0,0,0,0,0,1183,Hemostasis,7/7/14 12:28
1771,76,Pfizer,Large Pharma,390,Thrombin-JMI,thrombin,Recombinant Protein,Launched,Corporate Acquisition,Jul-95,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1183,Hemostasis,7/7/14 12:28
1771,76,Pfizer,Large Pharma,390,Thrombin-JMI,thrombin,Recombinant Protein,Launched,Corporate Acquisition,Jul-95,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,0,0,90.928,89.41984,76.3824832,67.76197274,62.0596449,58.28806628,55.7934292,54.14341397,53.05205021,52.33019378,-5.259218682,1183,Hemostasis,7/7/14 12:28
1771,76,Pfizer,Large Pharma,390,Thrombin-JMI,thrombin,Recombinant Protein,Launched,Corporate Acquisition,Jul-95,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1183,Hemostasis,7/7/14 12:28
1771,76,Pfizer,Large Pharma,390,Thrombin-JMI,thrombin,Recombinant Protein,Launched,Corporate Acquisition,Jul-95,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1183,Hemostasis,7/7/14 12:28
1771,76,Pfizer,Large Pharma,390,Thrombin-JMI,thrombin,Recombinant Protein,Launched,Corporate Acquisition,Jul-95,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1183,Hemostasis,7/7/14 12:28
1771,76,Pfizer,Large Pharma,390,Thrombin-JMI,thrombin,Recombinant Protein,Launched,Corporate Acquisition,Jul-95,,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,0,0,90.928,89.41984,76.3824832,67.76197274,62.0596449,58.28806628,55.7934292,54.14341397,53.05205021,52.33019378,-5.259218682,1183,Hemostasis,7/7/14 12:28
1772,89,Genzyme,Large Pharma,1479,Thymoglobulin,anti-thymocyte globulin rabbit,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-99,Sep-84,N/A,N/A,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,Global,Proforma,215.3722524,230.5073369,65.99340767,0,0,0,0,0,0,0,0,0,0,1184,Transplant rejection,7/7/14 12:28
1772,89,Genzyme,Large Pharma,1479,Thymoglobulin,anti-thymocyte globulin rabbit,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-99,Sep-84,N/A,N/A,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,ROW,Proforma,94.48589138,107.3051396,21.3899993,0,0,0,0,0,0,0,0,0,0,1184,Transplant rejection,7/7/14 12:28
1772,89,Genzyme,Large Pharma,1479,Thymoglobulin,anti-thymocyte globulin rabbit,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-99,Sep-84,N/A,N/A,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,US,Proforma,120.886361,123.2021973,44.60340837,0,0,0,0,0,0,0,0,0,0,1184,Transplant rejection,7/7/14 12:28
1772,89,Sanofi,Large Pharma,1479,Thymoglobulin,anti-thymocyte globulin rabbit,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-99,Sep-84,N/A,N/A,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1184,Transplant rejection,7/7/14 12:28
1772,89,Sanofi,Large Pharma,1479,Thymoglobulin,anti-thymocyte globulin rabbit,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-99,Sep-84,N/A,N/A,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,Global,Sales,0,0,185.6756961,237.7751953,262.9499532,272.6180121,281.4786287,290.105512,297.2297028,303.5675298,309.1927677,314.1038118,2.571941493,1184,Transplant rejection,7/7/14 12:28
1772,89,Sanofi,Large Pharma,1479,Thymoglobulin,anti-thymocyte globulin rabbit,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-99,Sep-84,N/A,N/A,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1184,Transplant rejection,7/7/14 12:28
1772,89,Sanofi,Large Pharma,1479,Thymoglobulin,anti-thymocyte globulin rabbit,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-99,Sep-84,N/A,N/A,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,ROW,Sales,0,0,100.96846,116.9596907,127.4908864,132.5905219,136.8614666,140.856181,144.2950352,147.3126595,149.9841885,152.3272466,2.57525963,1184,Transplant rejection,7/7/14 12:28
1772,89,Sanofi,Large Pharma,1479,Thymoglobulin,anti-thymocyte globulin rabbit,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-99,Sep-84,N/A,N/A,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1184,Transplant rejection,7/7/14 12:28
1772,89,Sanofi,Large Pharma,1479,Thymoglobulin,anti-thymocyte globulin rabbit,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-99,Sep-84,N/A,N/A,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,2,US,Sales,0,0,84.70723612,120.8155047,135.4590668,140.0274902,144.6171621,149.249331,152.9346676,156.2548703,159.2085791,161.7765652,2.568817952,1184,Transplant rejection,7/7/14 12:28
1773,89,Genzyme,Large Pharma,655,Thyrogen,recombinant thyrotropin alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-99,Oct-01,Dec-14,Dec-13,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,Global,Proforma,171.0472534,181.0939825,50.94901819,0,0,0,0,0,0,0,0,0,0,1185,Adjunct to Thyroid Ablation,7/7/14 12:28
1773,89,Genzyme,Large Pharma,655,Thyrogen,recombinant thyrotropin alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-99,Oct-01,Dec-14,Dec-13,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,ROW,Proforma,50.99459138,54.04999625,15.10901919,0,0,0,0,0,0,0,0,0,0,1185,Adjunct to Thyroid Ablation,7/7/14 12:28
1773,89,Genzyme,Large Pharma,655,Thyrogen,recombinant thyrotropin alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-99,Oct-01,Dec-14,Dec-13,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,US,Proforma,120.052662,127.0439863,35.839999,0,0,0,0,0,0,0,0,0,0,1185,Adjunct to Thyroid Ablation,7/7/14 12:28
1773,89,Sanofi,Large Pharma,655,Thyrogen,recombinant thyrotropin alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-99,Oct-01,Dec-14,Dec-13,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1185,Adjunct to Thyroid Ablation,7/7/14 12:28
1773,89,Sanofi,Large Pharma,655,Thyrogen,recombinant thyrotropin alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-99,Oct-01,Dec-14,Dec-13,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,Global,Sales,0,0,153.0578781,210.1321868,223.9848992,223.588907,122.2730264,109.2440908,102.2908654,97.48573512,93.96342734,91.49386048,-12.00593689,1185,Adjunct to Thyroid Ablation,7/7/14 12:28
1773,89,Sanofi,Large Pharma,655,Thyrogen,recombinant thyrotropin alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-99,Oct-01,Dec-14,Dec-13,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1185,Adjunct to Thyroid Ablation,7/7/14 12:28
1773,89,Sanofi,Large Pharma,655,Thyrogen,recombinant thyrotropin alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-99,Oct-01,Dec-14,Dec-13,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,ROW,Sales,0,0,45.76275951,62.78339728,66.94334898,68.86663082,70.33138192,71.19318771,71.82068,72.25329905,72.54175824,72.74151512,1.193718067,1185,Adjunct to Thyroid Ablation,7/7/14 12:28
1773,89,Sanofi,Large Pharma,655,Thyrogen,recombinant thyrotropin alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-99,Oct-01,Dec-14,Dec-13,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1185,Adjunct to Thyroid Ablation,7/7/14 12:28
1773,89,Sanofi,Large Pharma,655,Thyrogen,recombinant thyrotropin alpha,Recombinant Protein,Launched,Corporate Acquisition,Jan-99,Oct-01,Dec-14,Dec-13,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,2,US,Sales,0,0,107.2951186,147.3487895,157.0415503,154.7222762,51.94164446,38.05090307,30.47018542,25.23243607,21.4216691,18.75234535,-26.18428194,1185,Adjunct to Thyroid Ablation,7/7/14 12:28
1774,63,Merck KGaA,Regional & Specialty Pharma,4046,Euthyrox / Thyroid Preparations,levothyroxine,Small Molecule (Chemical),Launched,In-House,,Jul-70,N/A,Expired,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1186,Hypothyroidism,7/7/14 12:28
1774,63,Merck KGaA,Regional & Specialty Pharma,4046,Euthyrox / Thyroid Preparations,levothyroxine,Small Molecule (Chemical),Launched,In-House,,Jul-70,N/A,Expired,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,2,Global,Sales,219.5407476,224.8108913,277.1141016,300.7534903,365.2082683,391.7688696,413.8965066,429.9103182,441.251901,449.5450152,455.5328499,459.8617259,3.347049075,1186,Hypothyroidism,7/7/14 12:28
1774,63,Merck KGaA,Regional & Specialty Pharma,4046,Euthyrox / Thyroid Preparations,levothyroxine,Small Molecule (Chemical),Launched,In-House,,Jul-70,N/A,Expired,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1186,Hypothyroidism,7/7/14 12:28
1774,63,Merck KGaA,Regional & Specialty Pharma,4046,Euthyrox / Thyroid Preparations,levothyroxine,Small Molecule (Chemical),Launched,In-House,,Jul-70,N/A,Expired,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,2,ROW,Sales,219.5407476,224.8108913,277.1141016,300.7534903,365.2082683,391.7688696,413.8965066,429.9103182,441.251901,449.5450152,455.5328499,459.8617259,3.347049075,1186,Hypothyroidism,7/7/14 12:28
1774,63,Merck KGaA,Regional & Specialty Pharma,4046,Euthyrox / Thyroid Preparations,levothyroxine,Small Molecule (Chemical),Launched,In-House,,Jul-70,N/A,Expired,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1186,Hypothyroidism,7/7/14 12:28
1774,63,Merck KGaA,Regional & Specialty Pharma,4046,Euthyrox / Thyroid Preparations,levothyroxine,Small Molecule (Chemical),Launched,In-House,,Jul-70,N/A,Expired,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1186,Hypothyroidism,7/7/14 12:28
1775,61,Merck & Co,Large Pharma,1476,Timoptic / Timoptic XE,timolol,Small Molecule (Chemical),Launched,In-House,Dec-78,Dec-78,Expired,Expired,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1188,Glaucoma,7/7/14 12:28
1775,61,Merck & Co,Large Pharma,1476,Timoptic / Timoptic XE,timolol,Small Molecule (Chemical),Launched,In-House,Dec-78,Dec-78,Expired,Expired,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Sales,110,106.36,95,72,58.2,49.92,44.952,41.9712,40.18272,39.109632,38.4657792,38.07946752,-5.880166041,1188,Glaucoma,7/7/14 12:28
1775,61,Merck & Co,Large Pharma,1476,Timoptic / Timoptic XE,timolol,Small Molecule (Chemical),Launched,In-House,Dec-78,Dec-78,Expired,Expired,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1188,Glaucoma,7/7/14 12:28
1775,61,Merck & Co,Large Pharma,1476,Timoptic / Timoptic XE,timolol,Small Molecule (Chemical),Launched,In-House,Dec-78,Dec-78,Expired,Expired,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Sales,109,106.36,95,72,58.2,49.92,44.952,41.9712,40.18272,39.109632,38.4657792,38.07946752,-5.880166041,1188,Glaucoma,7/7/14 12:28
1775,61,Merck & Co,Large Pharma,1476,Timoptic / Timoptic XE,timolol,Small Molecule (Chemical),Launched,In-House,Dec-78,Dec-78,Expired,Expired,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1188,Glaucoma,7/7/14 12:28
1775,61,Merck & Co,Large Pharma,1476,Timoptic / Timoptic XE,timolol,Small Molecule (Chemical),Launched,In-House,Dec-78,Dec-78,Expired,Expired,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Sales,1,0,0,0,0,0,0,0,0,0,0,0,0,1188,Glaucoma,7/7/14 12:28
1776,53,Johnson & Johnson,Large Pharma,3837,Olysio / Sovriad,simeprevir,Small Molecule (Chemical),Launched,Licensed (Development),Dec-13,Dec-13,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1189,Hepatitis C,7/7/14 12:28
1776,53,Johnson & Johnson,Large Pharma,3837,Olysio / Sovriad,simeprevir,Small Molecule (Chemical),Launched,Licensed (Development),Dec-13,Dec-13,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,73.5,2218,1779,1513,1229,918,664,536.04,32.82282525,1189,Hepatitis C,7/7/14 12:28
1776,53,Johnson & Johnson,Large Pharma,3837,Olysio / Sovriad,simeprevir,Small Molecule (Chemical),Launched,Licensed (Development),Dec-13,Dec-13,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1189,Hepatitis C,7/7/14 12:28
1776,53,Johnson & Johnson,Large Pharma,3837,Olysio / Sovriad,simeprevir,Small Molecule (Chemical),Launched,Licensed (Development),Dec-13,Dec-13,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,43.5,1131,880,637,529,431,338,228,26.70035702,1189,Hepatitis C,7/7/14 12:28
1776,53,Johnson & Johnson,Large Pharma,3837,Olysio / Sovriad,simeprevir,Small Molecule (Chemical),Launched,Licensed (Development),Dec-13,Dec-13,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1189,Hepatitis C,7/7/14 12:28
1776,53,Johnson & Johnson,Large Pharma,3837,Olysio / Sovriad,simeprevir,Small Molecule (Chemical),Launched,Licensed (Development),Dec-13,Dec-13,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,30,1087,899,876,700,487,326,308.04,39.47547062,1189,Hepatitis C,7/7/14 12:28
1777,53,Johnson & Johnson,Large Pharma,4612,Sirturo,bedaquiline,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Dec-13,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1190,Tuberculosis,7/7/14 12:28
1777,53,Johnson & Johnson,Large Pharma,4612,Sirturo,bedaquiline,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Dec-13,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,3.68,15.6641056,22.07692701,32.06410332,37.65265674,41.89645307,45.37399274,48.37199615,44.48432209,1190,Tuberculosis,7/7/14 12:28
1777,53,Johnson & Johnson,Large Pharma,4612,Sirturo,bedaquiline,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Dec-13,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1190,Tuberculosis,7/7/14 12:28
1777,53,Johnson & Johnson,Large Pharma,4612,Sirturo,bedaquiline,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Dec-13,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,1.6,11.306672,15.89333656,22.93328999,27.03567629,30.08398354,32.58169966,34.37199615,54.98784304,1190,Tuberculosis,7/7/14 12:28
1777,53,Johnson & Johnson,Large Pharma,4612,Sirturo,bedaquiline,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Dec-13,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1190,Tuberculosis,7/7/14 12:28
1777,53,Johnson & Johnson,Large Pharma,4612,Sirturo,bedaquiline,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-13,Dec-13,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,2.08,4.3574336,6.183590447,9.130813326,10.61698045,11.81246953,12.79229309,14,31.30910432,1190,Tuberculosis,7/7/14 12:28
1778,67,Novartis,Large Pharma,504,TOBI,tobramycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,Expired,Oct-15,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1664,,7/7/14 12:28
1778,67,Novartis,Large Pharma,504,TOBI,tobramycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,Expired,Oct-15,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,300.0575,279,296,317,387,398.7726,406.903695,412.2666429,414.2191471,415.3131162,415.8798037,416.1450133,1.042670077,1664,,7/7/14 12:28
1778,67,Novartis,Large Pharma,504,TOBI,tobramycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,Expired,Oct-15,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1664,,7/7/14 12:28
1778,67,Novartis,Large Pharma,504,TOBI,tobramycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,Expired,Oct-15,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,106,98.58,108,125,119,120.5936,121.55232,121.455296,121.6784256,121.7881062,121.829056,121.868258,0.340823657,1664,,7/7/14 12:28
1778,67,Novartis,Large Pharma,504,TOBI,tobramycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,Expired,Oct-15,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1664,,7/7/14 12:28
1778,67,Novartis,Large Pharma,504,TOBI,tobramycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,Expired,Oct-15,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,194.0575,180.42,188,192,268,278.179,285.351375,290.8113469,292.5407215,293.52501,294.0507477,294.2767553,1.345161183,1664,,7/7/14 12:28
1779,53,Johnson & Johnson,Large Pharma,59,Topamax,topiramate,Small Molecule (Chemical),Launched,In-House,Dec-96,Oct-95,Mar-09,Sep-09,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1667,Epilepsy,7/7/14 12:28
1779,53,Johnson & Johnson,Large Pharma,59,Topamax,topiramate,Small Molecule (Chemical),Launched,In-House,Dec-96,Oct-95,Mar-09,Sep-09,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,1151,538,488,461,441.4,426.82,415.761,407.24655,400.6180025,395.4158214,391.3094378,388.0547796,-1.823243385,1667,Epilepsy,7/7/14 12:28
1779,53,Johnson & Johnson,Large Pharma,59,Topamax,topiramate,Small Molecule (Chemical),Launched,In-House,Dec-96,Oct-95,Mar-09,Sep-09,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1667,Epilepsy,7/7/14 12:28
1779,53,Johnson & Johnson,Large Pharma,59,Topamax,topiramate,Small Molecule (Chemical),Launched,In-House,Dec-96,Oct-95,Mar-09,Sep-09,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,420,339,312,293,277.8,265.64,255.912,248.1296,241.90368,236.922944,232.9383552,229.7506842,-2.676480078,1667,Epilepsy,7/7/14 12:28
1779,53,Johnson & Johnson,Large Pharma,59,Topamax,topiramate,Small Molecule (Chemical),Launched,In-House,Dec-96,Oct-95,Mar-09,Sep-09,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1667,Epilepsy,7/7/14 12:28
1779,53,Johnson & Johnson,Large Pharma,59,Topamax,topiramate,Small Molecule (Chemical),Launched,In-House,Dec-96,Oct-95,Mar-09,Sep-09,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,731,199,176,168,163.6,161.18,159.849,159.11695,158.7143225,158.4928774,158.3710826,158.3040954,-0.468990411,1667,Epilepsy,7/7/14 12:28
1780,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1195,Topina,topiramate,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-07,,Dec-16,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1667,Epilepsy,7/7/14 12:28
1780,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1195,Topina,topiramate,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-07,,Dec-16,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,Global,Sales,16.03082193,23.93003314,31.58981062,36.13927931,39.89820475,44.90352584,49.35085562,53.24503509,52.50684524,52.51162464,53.15762702,53.6913103,4.332953737,1667,Epilepsy,7/7/14 12:28
1780,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1195,Topina,topiramate,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-07,,Dec-16,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1667,Epilepsy,7/7/14 12:28
1780,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1195,Topina,topiramate,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-07,,Dec-16,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,ROW,Sales,16.03082193,23.93003314,31.58981062,36.13927931,39.89820475,44.90352584,49.35085562,53.24503509,52.50684524,52.51162464,53.15762702,53.6913103,4.332953737,1667,Epilepsy,7/7/14 12:28
1780,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1195,Topina,topiramate,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-07,,Dec-16,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1667,Epilepsy,7/7/14 12:28
1780,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1195,Topina,topiramate,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-07,,Dec-16,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1667,Epilepsy,7/7/14 12:28
1781,34,Daiichi-Sankyo,Regional & Specialty Pharma,691,Topotecin,irinotecan,Small Molecule (Chemical),Launched,In-House,,,N/A,May-09,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1504,Solid Tumors,7/7/14 12:28
1781,34,Daiichi-Sankyo,Regional & Specialty Pharma,691,Topotecin,irinotecan,Small Molecule (Chemical),Launched,In-House,,,N/A,May-09,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1504,Solid Tumors,7/7/14 12:28
1781,34,Daiichi-Sankyo,Regional & Specialty Pharma,691,Topotecin,irinotecan,Small Molecule (Chemical),Launched,In-House,,,N/A,May-09,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1504,Solid Tumors,7/7/14 12:28
1781,34,Daiichi-Sankyo,Regional & Specialty Pharma,691,Topotecin,irinotecan,Small Molecule (Chemical),Launched,In-House,,,N/A,May-09,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1504,Solid Tumors,7/7/14 12:28
1781,34,Daiichi-Sankyo,Regional & Specialty Pharma,691,Topotecin,irinotecan,Small Molecule (Chemical),Launched,In-House,,,N/A,May-09,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1504,Solid Tumors,7/7/14 12:28
1781,34,Daiichi-Sankyo,Regional & Specialty Pharma,691,Topotecin,irinotecan,Small Molecule (Chemical),Launched,In-House,,,N/A,May-09,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1504,Solid Tumors,7/7/14 12:28
1782,76,Pfizer,Large Pharma,1717,Torisel,temsirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,Nov-07,May-13,Apr-20,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1657,Renal Cell Carcinoma,7/7/14 12:28
1782,76,Pfizer,Large Pharma,1717,Torisel,temsirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,Nov-07,May-13,Apr-20,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,28.6102,200.2541623,235.6566912,238,244.5405695,162.6060583,102.2811846,94.89368556,90.40636197,88.30997066,87.06438704,86.23909154,-13.83393826,1657,Renal Cell Carcinoma,7/7/14 12:28
1782,76,Pfizer,Large Pharma,1717,Torisel,temsirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,Nov-07,May-13,Apr-20,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1657,Renal Cell Carcinoma,7/7/14 12:28
1782,76,Pfizer,Large Pharma,1717,Torisel,temsirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,Nov-07,May-13,Apr-20,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,7.5102,77.06809935,93.14150612,90,87.3297198,85.05998162,83.13070417,81.49081834,80.09691539,78.91209788,77.90500299,77.04897234,-1.773365869,1657,Renal Cell Carcinoma,7/7/14 12:28
1782,76,Pfizer,Large Pharma,1717,Torisel,temsirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,Nov-07,May-13,Apr-20,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1657,Renal Cell Carcinoma,7/7/14 12:28
1782,76,Pfizer,Large Pharma,1717,Torisel,temsirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,Nov-07,May-13,Apr-20,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,21.1,123.186063,142.515185,148,157.2108497,77.54607666,19.15048039,13.40286722,10.30944658,9.397872784,9.159384052,9.190119206,-33.34476466,1657,Renal Cell Carcinoma,7/7/14 12:28
1782,76,Wyeth,Large Pharma,1717,Torisel,temsirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,Nov-07,May-13,Apr-20,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Proforma,131.5,0,0,0,0,0,0,0,0,0,0,0,0,1657,Renal Cell Carcinoma,7/7/14 12:28
1782,76,Wyeth,Large Pharma,1717,Torisel,temsirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,Nov-07,May-13,Apr-20,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Proforma,52.5,0,0,0,0,0,0,0,0,0,0,0,0,1657,Renal Cell Carcinoma,7/7/14 12:28
1782,76,Wyeth,Large Pharma,1717,Torisel,temsirolimus,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-07,Nov-07,May-13,Apr-20,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Proforma,79,0,0,0,0,0,0,0,0,0,0,0,0,1657,Renal Cell Carcinoma,7/7/14 12:28
1784,76,Pfizer,Large Pharma,199,Toviaz,fesoterodine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,Jul-08,Oct-19,Nov-20,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1193,Overactive bladder,7/7/14 12:28
1784,76,Pfizer,Large Pharma,199,Toviaz,fesoterodine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,Jul-08,Oct-19,Nov-20,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Sales,59,137,187,207,236,250.0995,261.032325,265.0365356,265.6657135,262.109621,256.0185902,254.4334524,1.080184285,1193,Overactive bladder,7/7/14 12:28
1784,76,Pfizer,Large Pharma,199,Toviaz,fesoterodine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,Jul-08,Oct-19,Nov-20,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1193,Overactive bladder,7/7/14 12:28
1784,76,Pfizer,Large Pharma,199,Toviaz,fesoterodine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,Jul-08,Oct-19,Nov-20,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,ROW,Sales,29,67,88,94,116,123.2385,127.568575,129.1868156,128.3214499,126.0393385,123.6735956,123.2537443,0.870264124,1193,Overactive bladder,7/7/14 12:28
1784,76,Pfizer,Large Pharma,199,Toviaz,fesoterodine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,Jul-08,Oct-19,Nov-20,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1193,Overactive bladder,7/7/14 12:28
1784,76,Pfizer,Large Pharma,199,Toviaz,fesoterodine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-09,Jul-08,Oct-19,Nov-20,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Sales,30,70,99,113,120,126.861,133.46375,135.84972,137.3442636,136.0702825,132.3449946,131.1797081,1.280650532,1193,Overactive bladder,7/7/14 12:28
1785,23,Boehringer Ingelheim,Large Pharma,3331,Gilotrif / Giotrif,afatinib,Small Molecule (Chemical),Launched,In-House,Sep-13,Jan-14,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1194,Non-small-cell Lung Cancer,7/7/14 12:28
1785,23,Boehringer Ingelheim,Large Pharma,3331,Gilotrif / Giotrif,afatinib,Small Molecule (Chemical),Launched,In-House,Sep-13,Jan-14,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,Global,Sales,0,0,0,0,14.00874584,88.55028999,191.8778674,300.3247993,409.3660797,511.1150828,587.1435063,642.0131098,72.70548867,1194,Non-small-cell Lung Cancer,7/7/14 12:28
1785,23,Boehringer Ingelheim,Large Pharma,3331,Gilotrif / Giotrif,afatinib,Small Molecule (Chemical),Launched,In-House,Sep-13,Jan-14,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1194,Non-small-cell Lung Cancer,7/7/14 12:28
1785,23,Boehringer Ingelheim,Large Pharma,3331,Gilotrif / Giotrif,afatinib,Small Molecule (Chemical),Launched,In-House,Sep-13,Jan-14,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,0,0,0,0,0,37.18484186,85.91818909,134.810956,184.3966826,219.1777833,247.8498678,269.0914687,0,1194,Non-small-cell Lung Cancer,7/7/14 12:28
1785,23,Boehringer Ingelheim,Large Pharma,3331,Gilotrif / Giotrif,afatinib,Small Molecule (Chemical),Launched,In-House,Sep-13,Jan-14,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1194,Non-small-cell Lung Cancer,7/7/14 12:28
1785,23,Boehringer Ingelheim,Large Pharma,3331,Gilotrif / Giotrif,afatinib,Small Molecule (Chemical),Launched,In-House,Sep-13,Jan-14,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,US,Sales,0,0,0,0,14.00874584,51.36544812,105.9596784,165.5138433,224.9693972,291.9372994,339.2936385,372.9216411,59.80943463,1194,Non-small-cell Lung Cancer,7/7/14 12:28
1787,5,Actelion,Small Biotech,898,Tracleer,bosentan,Small Molecule (Chemical),Launched,In-House,Dec-01,May-02,Nov-15,Sep-17,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,Global,Sales,1388.560642,1569.075627,1714.419267,1599.947387,1653.216597,1253.340695,918.0521454,697.7299317,361.4953166,240.9487315,187.5847876,187.4410883,-26.72873116,1196,Pulmonary Hypertension,7/7/14 12:28
1787,5,Actelion,Small Biotech,898,Tracleer,bosentan,Small Molecule (Chemical),Launched,In-House,Dec-01,May-02,Nov-15,Sep-17,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,ROW,Sales,825.8897193,921.9961655,1083.775192,1018.95596,1023.008703,835.4504346,659.3648841,535.7646389,231.8545013,130.7365503,90.33411611,90.18902808,-29.31535815,1196,Pulmonary Hypertension,7/7/14 12:28
1787,5,Actelion,Small Biotech,898,Tracleer,bosentan,Small Molecule (Chemical),Launched,In-House,Dec-01,May-02,Nov-15,Sep-17,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,US,Sales,562.6709228,647.0794616,630.6440758,580.9914263,630.2078933,417.8902606,258.6872613,161.9652928,129.6408153,110.2121812,97.25067145,97.25206021,-23.42986767,1196,Pulmonary Hypertension,7/7/14 12:28
1788,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3578,Acref,fentanyl - transmucosal,Small Molecule (Chemical),Approved,Licensed (Development),,Dec-14,N/A,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,70,Cancer Pain,7/7/14 12:28
1788,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3578,Acref,fentanyl - transmucosal,Small Molecule (Chemical),Approved,Licensed (Development),,Dec-14,N/A,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,6.711808118,24.60998547,38.03350205,51.45704626,61.47997005,69.68622998,76.54253114,0,70,Cancer Pain,7/7/14 12:28
1788,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3578,Acref,fentanyl - transmucosal,Small Molecule (Chemical),Approved,Licensed (Development),,Dec-14,N/A,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,70,Cancer Pain,7/7/14 12:28
1788,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3578,Acref,fentanyl - transmucosal,Small Molecule (Chemical),Approved,Licensed (Development),,Dec-14,N/A,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,6.711808118,24.60998547,38.03350205,51.45704626,61.47997005,69.68622998,76.54253114,0,70,Cancer Pain,7/7/14 12:28
1788,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3578,Acref,fentanyl - transmucosal,Small Molecule (Chemical),Approved,Licensed (Development),,Dec-14,N/A,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,70,Cancer Pain,7/7/14 12:28
1788,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3578,Acref,fentanyl - transmucosal,Small Molecule (Chemical),Approved,Licensed (Development),,Dec-14,N/A,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,70,Cancer Pain,7/7/14 12:28
1789,86,Roche,Large Pharma,492,Kadcyla,trastuzumab emtansine,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-13,Dec-13,N/A,N/A,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1671,Breast Cancer,7/7/14 12:28
1789,86,Roche,Large Pharma,492,Kadcyla,trastuzumab emtansine,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-13,Dec-13,N/A,N/A,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,252.5148066,697.1085474,1273.371395,1612.694681,1958.073103,2447.919428,3079.850241,3602.048247,46.18220324,1671,Breast Cancer,7/7/14 12:28
1789,86,Roche,Large Pharma,492,Kadcyla,trastuzumab emtansine,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-13,Dec-13,N/A,N/A,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1671,Breast Cancer,7/7/14 12:28
1789,86,Roche,Large Pharma,492,Kadcyla,trastuzumab emtansine,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-13,Dec-13,N/A,N/A,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,12.94947726,184.5250725,412.7740675,576.0634193,754.3368235,932.4066181,1184.166684,1341.93904,94.05529839,1671,Breast Cancer,7/7/14 12:28
1789,86,Roche,Large Pharma,492,Kadcyla,trastuzumab emtansine,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-13,Dec-13,N/A,N/A,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1671,Breast Cancer,7/7/14 12:28
1789,86,Roche,Large Pharma,492,Kadcyla,trastuzumab emtansine,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-13,Dec-13,N/A,N/A,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,239.5653293,512.5834749,860.5973273,1036.631261,1203.73628,1515.51281,1895.683557,2260.109207,37.79818512,1671,Breast Cancer,7/7/14 12:28
1790,67,Alcon,Large Pharma,3126,Travatan / Travatan Z / DuoTrav,travoprost / travoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-01,Nov-01,Dec-14,Aug-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Proforma,617,461.999996,0,0,0,0,0,0,0,0,0,0,0,1198,Glaucoma,7/7/14 12:28
1790,67,Alcon,Large Pharma,3126,Travatan / Travatan Z / DuoTrav,travoprost / travoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-01,Nov-01,Dec-14,Aug-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Proforma,328,246.666666,0,0,0,0,0,0,0,0,0,0,0,1198,Glaucoma,7/7/14 12:28
1790,67,Alcon,Large Pharma,3126,Travatan / Travatan Z / DuoTrav,travoprost / travoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-01,Nov-01,Dec-14,Aug-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Proforma,289,215.33333,0,0,0,0,0,0,0,0,0,0,0,1198,Glaucoma,7/7/14 12:28
1790,67,Novartis,Large Pharma,3126,Travatan / Travatan Z / DuoTrav,travoprost / travoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-01,Nov-01,Dec-14,Aug-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1198,Glaucoma,7/7/14 12:28
1790,67,Novartis,Large Pharma,3126,Travatan / Travatan Z / DuoTrav,travoprost / travoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-01,Nov-01,Dec-14,Aug-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Sales,0,231.000004,761,784.52,827,763.1223072,385.796988,312.8440305,266.4044653,230.9395211,202.931741,182.1223782,-19.43941018,1198,Glaucoma,7/7/14 12:28
1790,67,Novartis,Large Pharma,3126,Travatan / Travatan Z / DuoTrav,travoprost / travoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-01,Nov-01,Dec-14,Aug-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1198,Glaucoma,7/7/14 12:28
1790,67,Novartis,Large Pharma,3126,Travatan / Travatan Z / DuoTrav,travoprost / travoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-01,Nov-01,Dec-14,Aug-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Sales,0,123.333334,421,471.52,529,489.1343072,298.730988,251.5758705,218.8782093,192.5480619,170.9619323,154.5582579,-16.11922402,1198,Glaucoma,7/7/14 12:28
1790,67,Novartis,Large Pharma,3126,Travatan / Travatan Z / DuoTrav,travoprost / travoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-01,Nov-01,Dec-14,Aug-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1198,Glaucoma,7/7/14 12:28
1790,67,Novartis,Large Pharma,3126,Travatan / Travatan Z / DuoTrav,travoprost / travoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-01,Nov-01,Dec-14,Aug-14,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Sales,0,107.66667,340,313,298,273.988,87.066,61.26816,47.526256,38.3914592,31.96980864,27.56412032,-28.82882604,1198,Glaucoma,7/7/14 12:28
1791,67,Novartis,Large Pharma,3128,Travel Vaccines - Novartis,travel vaccine,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1672,,7/7/14 12:28
1791,67,Novartis,Large Pharma,3128,Travel Vaccines - Novartis,travel vaccine,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,178,178.173716,177.0492462,176.8911322,176.9210858,177.0097187,177.2512983,177.55841,177.9069163,178.2859685,178.6781968,179.0742008,0.172955786,1672,,7/7/14 12:28
1791,67,Novartis,Large Pharma,3128,Travel Vaccines - Novartis,travel vaccine,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1672,,7/7/14 12:28
1791,67,Novartis,Large Pharma,3128,Travel Vaccines - Novartis,travel vaccine,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,20,20.947466,21.8239337,22.64537598,23.42221517,24.15134641,24.83706166,25.48233001,26.0890875,26.65977958,27.19656384,27.70141996,2.426084333,1672,,7/7/14 12:28
1791,67,Novartis,Large Pharma,3128,Travel Vaccines - Novartis,travel vaccine,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1672,,7/7/14 12:28
1791,67,Novartis,Large Pharma,3128,Travel Vaccines - Novartis,travel vaccine,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,158,157.22625,155.2253125,154.2457563,153.4988706,152.8583723,152.4142367,152.07608,151.8178288,151.6261889,151.481633,151.3727808,-0.199053821,1672,,7/7/14 12:28
1792,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,3146,Travel Vaccines - SPMSD,travel vaccine,Vaccine,Launched,Licensed (Marketed),,Jul-94,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,112.5493706,75.51102417,70.13114524,73.26046559,67.0302339,67.0325731,66.60867289,64.85456671,64.66135419,64.12838697,63.70261425,63.5094413,-0.767824752,2226,,7/7/14 12:28
1792,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,3146,Travel Vaccines - SPMSD,travel vaccine,Vaccine,Launched,Licensed (Marketed),,Jul-94,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,112.5493706,75.51102417,70.13114524,73.26046559,67.0302339,67.0325731,66.60867289,64.85456671,64.66135419,64.12838697,63.70261425,63.5094413,-0.767824752,2226,,7/7/14 12:28
1792,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,3146,Travel Vaccines - SPMSD,travel vaccine,Vaccine,Launched,Licensed (Marketed),,Jul-94,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2226,,7/7/14 12:28
1793,89,Sanofi,Large Pharma,4004,Travel Vaccines - Sanofi,travel vaccine,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2225,,7/7/14 12:28
1793,89,Sanofi,Large Pharma,4004,Travel Vaccines - Sanofi,travel vaccine,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,434.913,506.0563374,514.4617039,467.8387627,507.3074854,511.2384545,516.470893,522.8279073,526.8195939,530.461387,533.6589557,536.2709016,0.796326682,2225,,7/7/14 12:28
1793,89,Sanofi,Large Pharma,4004,Travel Vaccines - Sanofi,travel vaccine,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2225,,7/7/14 12:28
1793,89,Sanofi,Large Pharma,4004,Travel Vaccines - Sanofi,travel vaccine,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,339.0376102,400.0759526,390.7128075,344.4527154,378.488569,378.9135386,381.7395866,386.5842404,389.2683485,391.9568763,394.451618,396.5242187,0.667233324,2225,,7/7/14 12:28
1793,89,Sanofi,Large Pharma,4004,Travel Vaccines - Sanofi,travel vaccine,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2225,,7/7/14 12:28
1793,89,Sanofi,Large Pharma,4004,Travel Vaccines - Sanofi,travel vaccine,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,3,Travel Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,95.87538978,105.9803848,123.7488963,123.3860473,128.8189165,132.3249158,134.7313063,136.243667,137.5512454,138.5045107,139.2073377,139.7466829,1.169986054,2225,,7/7/14 12:28
1794,102,Cephalon,Regional & Specialty Pharma,1708,Treanda,bendamustine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-16,N/A,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,Global,Proforma,222.1,393.5,383.5,0,0,0,0,0,0,0,0,0,0,1359,Chronic Lymphocytic Leukemia,7/7/14 12:28
1794,102,Cephalon,Regional & Specialty Pharma,1708,Treanda,bendamustine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-16,N/A,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,US,Proforma,222.1,393.5,383.5,0,0,0,0,0,0,0,0,0,0,1359,Chronic Lymphocytic Leukemia,7/7/14 12:28
1794,102,Teva,Regional & Specialty Pharma,1708,Treanda,bendamustine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-16,N/A,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1359,Chronic Lymphocytic Leukemia,7/7/14 12:28
1794,102,Teva,Regional & Specialty Pharma,1708,Treanda,bendamustine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-16,N/A,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,Global,Sales,1.00E-02,-3.00E-02,131.5,608,709,770.6236,818.45068,565.8233054,278.2341041,206.1039133,166.4449216,138.7587414,-20.78596829,1359,Chronic Lymphocytic Leukemia,7/7/14 12:28
1794,102,Teva,Regional & Specialty Pharma,1708,Treanda,bendamustine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-16,N/A,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1359,Chronic Lymphocytic Leukemia,7/7/14 12:28
1794,102,Teva,Regional & Specialty Pharma,1708,Treanda,bendamustine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-16,N/A,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1359,Chronic Lymphocytic Leukemia,7/7/14 12:28
1794,102,Teva,Regional & Specialty Pharma,1708,Treanda,bendamustine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-16,N/A,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1359,Chronic Lymphocytic Leukemia,7/7/14 12:28
1794,102,Teva,Regional & Specialty Pharma,1708,Treanda,bendamustine,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-08,,Apr-16,N/A,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,US,Sales,1.00E-02,-3.00E-02,131.5,608,709,770.6236,818.45068,565.8233054,278.2341041,206.1039133,166.4449216,138.7587414,-20.78596829,1359,Chronic Lymphocytic Leukemia,7/7/14 12:28
1795,61,Merck & Co,Large Pharma,1302,Tredaptive,Modified-release nicotinic acid + laropiprant,Small Molecule (Chemical),Launched,In-House,,Jun-09,N/A,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1199,Lipid disorders,7/7/14 12:28
1795,61,Merck & Co,Large Pharma,1302,Tredaptive,Modified-release nicotinic acid + laropiprant,Small Molecule (Chemical),Launched,In-House,,Jun-09,N/A,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,5,10,15,20,3,0,0,0,0,0,0,0,-100,1199,Lipid disorders,7/7/14 12:28
1795,61,Merck & Co,Large Pharma,1302,Tredaptive,Modified-release nicotinic acid + laropiprant,Small Molecule (Chemical),Launched,In-House,,Jun-09,N/A,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1199,Lipid disorders,7/7/14 12:28
1795,61,Merck & Co,Large Pharma,1302,Tredaptive,Modified-release nicotinic acid + laropiprant,Small Molecule (Chemical),Launched,In-House,,Jun-09,N/A,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,5,10,15,20,3,0,0,0,0,0,0,0,-100,1199,Lipid disorders,7/7/14 12:28
1795,61,Merck & Co,Large Pharma,1302,Tredaptive,Modified-release nicotinic acid + laropiprant,Small Molecule (Chemical),Launched,In-House,,Jun-09,N/A,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1199,Lipid disorders,7/7/14 12:28
1795,61,Merck & Co,Large Pharma,1302,Tredaptive,Modified-release nicotinic acid + laropiprant,Small Molecule (Chemical),Launched,In-House,,Jun-09,N/A,N/A,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1199,Lipid disorders,7/7/14 12:28
1797,46,GlaxoSmithKline,Large Pharma,301,Treximet,sumatriptan + naproxen,Small Molecule (Chemical),Launched,Licensed (Development),May-08,,Aug-17,N/A,117,Triptans,8,Migraine,12,Central Nervous System,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1201,Migraine,7/7/14 12:28
1797,46,GlaxoSmithKline,Large Pharma,301,Treximet,sumatriptan + naproxen,Small Molecule (Chemical),Launched,Licensed (Development),May-08,,Aug-17,N/A,117,Triptans,8,Migraine,12,Central Nervous System,4,Global,Sales,85.75939293,86.52000324,91.3813005,77.66641482,71.32629933,68.68580532,67.36555832,66.70543482,41.81648504,3.376727452,2.711240897,2.04868364,-39.7791781,1201,Migraine,7/7/14 12:28
1797,46,GlaxoSmithKline,Large Pharma,301,Treximet,sumatriptan + naproxen,Small Molecule (Chemical),Launched,Licensed (Development),May-08,,Aug-17,N/A,117,Triptans,8,Migraine,12,Central Nervous System,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1201,Migraine,7/7/14 12:28
1797,46,GlaxoSmithKline,Large Pharma,301,Treximet,sumatriptan + naproxen,Small Molecule (Chemical),Launched,Licensed (Development),May-08,,Aug-17,N/A,117,Triptans,8,Migraine,12,Central Nervous System,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1201,Migraine,7/7/14 12:28
1797,46,GlaxoSmithKline,Large Pharma,301,Treximet,sumatriptan + naproxen,Small Molecule (Chemical),Launched,Licensed (Development),May-08,,Aug-17,N/A,117,Triptans,8,Migraine,12,Central Nervous System,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1201,Migraine,7/7/14 12:28
1797,46,GlaxoSmithKline,Large Pharma,301,Treximet,sumatriptan + naproxen,Small Molecule (Chemical),Launched,Licensed (Development),May-08,,Aug-17,N/A,117,Triptans,8,Migraine,12,Central Nervous System,4,US,Sales,85.75939293,86.52000324,91.3813005,77.66641482,71.32629933,68.68580532,67.36555832,66.70543482,41.81648504,3.376727452,2.711240897,2.04868364,-39.7791781,1201,Migraine,7/7/14 12:28
1798,1,Abbott,Regional & Specialty Pharma,902,Tricor,fenofibrate,Small Molecule (Chemical),Launched,Licensed (Development),Jun-98,,Nov-12,N/A,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1461,Dyslipidemia,7/7/14 12:28
1798,1,Abbott,Regional & Specialty Pharma,902,Tricor,fenofibrate,Small Molecule (Chemical),Launched,Licensed (Development),Jun-98,,Nov-12,N/A,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,1337,1355,1372,1098,0,0,0,0,0,0,0,0,0,1461,Dyslipidemia,7/7/14 12:28
1798,1,Abbott,Regional & Specialty Pharma,902,Tricor,fenofibrate,Small Molecule (Chemical),Launched,Licensed (Development),Jun-98,,Nov-12,N/A,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1461,Dyslipidemia,7/7/14 12:28
1798,1,Abbott,Regional & Specialty Pharma,902,Tricor,fenofibrate,Small Molecule (Chemical),Launched,Licensed (Development),Jun-98,,Nov-12,N/A,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1461,Dyslipidemia,7/7/14 12:28
1798,1,Abbott,Regional & Specialty Pharma,902,Tricor,fenofibrate,Small Molecule (Chemical),Launched,Licensed (Development),Jun-98,,Nov-12,N/A,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1461,Dyslipidemia,7/7/14 12:28
1798,1,Abbott,Regional & Specialty Pharma,902,Tricor,fenofibrate,Small Molecule (Chemical),Launched,Licensed (Development),Jun-98,,Nov-12,N/A,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,1337,1355,1372,1098,0,0,0,0,0,0,0,0,0,1461,Dyslipidemia,7/7/14 12:28
1799,67,Novartis,Large Pharma,374,Trileptal,oxcarbazepine,Small Molecule (Chemical),Launched,In-House,Jul-00,Jul-90,Oct-07,Jan-09,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1202,Epilepsy,7/7/14 12:28
1799,67,Novartis,Large Pharma,374,Trileptal,oxcarbazepine,Small Molecule (Chemical),Launched,In-House,Jul-00,Jul-90,Oct-07,Jan-09,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,295,253,263,279,256.9,246.0405,240.5545475,237.7847035,236.386201,235.680093,235.323577,235.1435711,-1.256193853,1202,Epilepsy,7/7/14 12:28
1799,67,Novartis,Large Pharma,374,Trileptal,oxcarbazepine,Small Molecule (Chemical),Launched,In-House,Jul-00,Jul-90,Oct-07,Jan-09,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1202,Epilepsy,7/7/14 12:28
1799,67,Novartis,Large Pharma,374,Trileptal,oxcarbazepine,Small Molecule (Chemical),Launched,In-House,Jul-00,Jul-90,Oct-07,Jan-09,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,174,164.4,171,181.3,167,159.973,156.423135,154.6308168,153.72587,153.2689597,153.0382644,152.9217857,-1.250220958,1202,Epilepsy,7/7/14 12:28
1799,67,Novartis,Large Pharma,374,Trileptal,oxcarbazepine,Small Molecule (Chemical),Launched,In-House,Jul-00,Jul-90,Oct-07,Jan-09,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1202,Epilepsy,7/7/14 12:28
1799,67,Novartis,Large Pharma,374,Trileptal,oxcarbazepine,Small Molecule (Chemical),Launched,In-House,Jul-00,Jul-90,Oct-07,Jan-09,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,121,88.6,92,97.7,89.9,86.0675,84.1314125,83.15388669,82.66033097,82.41113326,82.28531262,82.22178541,-1.267294977,1202,Epilepsy,7/7/14 12:28
1800,89,Sanofi,Large Pharma,1283,Tritace,ramipril,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-00,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1606,Hypertension,7/7/14 12:28
1800,89,Sanofi,Large Pharma,1283,Tritace,ramipril,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-00,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,Global,Sales,596.0948147,543.1494721,521.4138891,443.4186075,407.7052304,377.6651904,352.8286377,335.3319718,322.0507684,312.3219659,305.07462,299.7186665,-4.300501222,1606,Hypertension,7/7/14 12:28
1800,89,Sanofi,Large Pharma,1283,Tritace,ramipril,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-00,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1606,Hypertension,7/7/14 12:28
1800,89,Sanofi,Large Pharma,1283,Tritace,ramipril,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-00,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,596.0948147,543.1494721,521.4138891,443.4186075,407.7052304,377.6651904,352.8286377,335.3319718,322.0507684,312.3219659,305.07462,299.7186665,-4.300501222,1606,Hypertension,7/7/14 12:28
1800,89,Sanofi,Large Pharma,1283,Tritace,ramipril,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-00,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1606,Hypertension,7/7/14 12:28
1800,89,Sanofi,Large Pharma,1283,Tritace,ramipril,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-00,N/A,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1606,Hypertension,7/7/14 12:28
1801,46,GlaxoSmithKline,Large Pharma,547,Trizivir,abacavir  +  zidovudine  +  lamivudine,Small Molecule (Chemical),Launched,In-House,Dec-00,Dec-00,Nov-16,Dec-19,104,NRTIs,32,HIV,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1203,HIV,7/7/14 12:28
1801,46,GlaxoSmithKline,Large Pharma,547,Trizivir,abacavir  +  zidovudine  +  lamivudine,Small Molecule (Chemical),Launched,In-House,Dec-00,Dec-00,Nov-16,Dec-19,104,NRTIs,32,HIV,7,Anti-infectives,4,Global,Sales,313.4115996,222.4800083,202.0007695,169.5980895,151.6511607,136.1264594,123.155595,112.8718874,103.9119128,96.24847029,89.6342802,83.80945091,-8.123003868,1203,HIV,7/7/14 12:28
1801,46,GlaxoSmithKline,Large Pharma,547,Trizivir,abacavir  +  zidovudine  +  lamivudine,Small Molecule (Chemical),Launched,In-House,Dec-00,Dec-00,Nov-16,Dec-19,104,NRTIs,32,HIV,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1203,HIV,7/7/14 12:28
1801,46,GlaxoSmithKline,Large Pharma,547,Trizivir,abacavir  +  zidovudine  +  lamivudine,Small Molecule (Chemical),Launched,In-House,Dec-00,Dec-00,Nov-16,Dec-19,104,NRTIs,32,HIV,7,Anti-infectives,4,ROW,Sales,151.2483839,109.6950041,94.58766192,72.9113282,60.97314709,51.78027261,44.61358271,39.49559056,35.56704379,32.60723838,30.39799929,28.73103697,-10.19176833,1203,HIV,7/7/14 12:28
1801,46,GlaxoSmithKline,Large Pharma,547,Trizivir,abacavir  +  zidovudine  +  lamivudine,Small Molecule (Chemical),Launched,In-House,Dec-00,Dec-00,Nov-16,Dec-19,104,NRTIs,32,HIV,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1203,HIV,7/7/14 12:28
1801,46,GlaxoSmithKline,Large Pharma,547,Trizivir,abacavir  +  zidovudine  +  lamivudine,Small Molecule (Chemical),Launched,In-House,Dec-00,Dec-00,Nov-16,Dec-19,104,NRTIs,32,HIV,7,Anti-infectives,4,US,Sales,162.1632157,112.7850042,107.4131076,96.68676131,90.67801363,84.34618682,78.54201225,73.37629689,68.34486902,63.64123191,59.23628092,55.07841394,-6.874520787,1203,HIV,7/7/14 12:28
1804,61,Merck & Co,Large Pharma,3579,Cosopt / Trusopt ,dorzolamide / dorzolamide + timolol,Small Molecule (Chemical),Launched,Licensed (Development),Jun-95,Nov-95,Oct-08,Mar-13,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1205,Glaucoma,7/7/14 12:28
1804,61,Merck & Co,Large Pharma,3579,Cosopt / Trusopt ,dorzolamide / dorzolamide + timolol,Small Molecule (Chemical),Launched,Licensed (Development),Jun-95,Nov-95,Oct-08,Mar-13,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Sales,503,484,477,444,416,206.912,162.24,134.55,113.988,97.76564,84.8594844,84.78158782,-20.32619506,1205,Glaucoma,7/7/14 12:28
1804,61,Merck & Co,Large Pharma,3579,Cosopt / Trusopt ,dorzolamide / dorzolamide + timolol,Small Molecule (Chemical),Launched,Licensed (Development),Jun-95,Nov-95,Oct-08,Mar-13,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1205,Glaucoma,7/7/14 12:28
1804,61,Merck & Co,Large Pharma,3579,Cosopt / Trusopt ,dorzolamide / dorzolamide + timolol,Small Molecule (Chemical),Launched,Licensed (Development),Jun-95,Nov-95,Oct-08,Mar-13,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Sales,464,464,461,430,400,206.912,162.24,134.55,113.988,97.76564,84.8594844,84.78158782,-19.8785335,1205,Glaucoma,7/7/14 12:28
1804,61,Merck & Co,Large Pharma,3579,Cosopt / Trusopt ,dorzolamide / dorzolamide + timolol,Small Molecule (Chemical),Launched,Licensed (Development),Jun-95,Nov-95,Oct-08,Mar-13,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1205,Glaucoma,7/7/14 12:28
1804,61,Merck & Co,Large Pharma,3579,Cosopt / Trusopt ,dorzolamide / dorzolamide + timolol,Small Molecule (Chemical),Launched,Licensed (Development),Jun-95,Nov-95,Oct-08,Mar-13,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Sales,39,20,16,14,16,0,0,0,0,0,0,0,-100,1205,Glaucoma,7/7/14 12:28
1805,45,Gilead,Regional & Specialty Pharma,1535,Truvada,tenofovir disoproxil + emtricitabine,Small Molecule (Chemical),Launched,In-House,Aug-04,Feb-05,May-21,Aug-18,104,NRTIs,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1206,HIV,7/7/14 12:28
1805,45,Gilead,Regional & Specialty Pharma,1535,Truvada,tenofovir disoproxil + emtricitabine,Small Molecule (Chemical),Launched,In-House,Aug-04,Feb-05,May-21,Aug-18,104,NRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,2488,2648.93,2875.14,3181.11,3135,3151.749,3145.3239,3105,3043,2705.30866,2088.238934,1929.787231,-6.696912891,1206,HIV,7/7/14 12:28
1805,45,Gilead,Regional & Specialty Pharma,1535,Truvada,tenofovir disoproxil + emtricitabine,Small Molecule (Chemical),Launched,In-House,Aug-04,Feb-05,May-21,Aug-18,104,NRTIs,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1206,HIV,7/7/14 12:28
1805,45,Gilead,Regional & Specialty Pharma,1535,Truvada,tenofovir disoproxil + emtricitabine,Small Molecule (Chemical),Launched,In-House,Aug-04,Feb-05,May-21,Aug-18,104,NRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,1312,1340,1489.73,1568.6,1565,1586,1580,1576,1574,1342.30866,766.238934,611.8872313,-12.55463809,1206,HIV,7/7/14 12:28
1805,45,Gilead,Regional & Specialty Pharma,1535,Truvada,tenofovir disoproxil + emtricitabine,Small Molecule (Chemical),Launched,In-House,Aug-04,Feb-05,May-21,Aug-18,104,NRTIs,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1206,HIV,7/7/14 12:28
1805,45,Gilead,Regional & Specialty Pharma,1535,Truvada,tenofovir disoproxil + emtricitabine,Small Molecule (Chemical),Launched,In-House,Aug-04,Feb-05,May-21,Aug-18,104,NRTIs,32,HIV,7,Anti-infectives,6,US,Sales,1176,1308.93,1385.41,1612.51,1570,1565.749,1565.3239,1529,1469,1363,1322,1317.9,-2.469508763,1206,HIV,7/7/14 12:28
1807,89,Sanofi,Large Pharma,4005,Tuberculosis vaccine - Sanofi,Tuberculosis vaccine,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1748,Tuberculosis,7/7/14 12:28
1807,89,Sanofi,Large Pharma,4005,Tuberculosis vaccine - Sanofi,Tuberculosis vaccine,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1748,Tuberculosis,7/7/14 12:28
1807,89,Sanofi,Large Pharma,4005,Tuberculosis vaccine - Sanofi,Tuberculosis vaccine,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1748,Tuberculosis,7/7/14 12:28
1807,89,Sanofi,Large Pharma,4005,Tuberculosis vaccine - Sanofi,Tuberculosis vaccine,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1748,Tuberculosis,7/7/14 12:28
1807,89,Sanofi,Large Pharma,4005,Tuberculosis vaccine - Sanofi,Tuberculosis vaccine,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1748,Tuberculosis,7/7/14 12:28
1807,89,Sanofi,Large Pharma,4005,Tuberculosis vaccine - Sanofi,Tuberculosis vaccine,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1748,Tuberculosis,7/7/14 12:28
1808,46,GlaxoSmithKline,Large Pharma,3124,Tuberculosis vaccine - GSK,Tuberculosis vaccine,Vaccine,Phase II,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1675,Tuberculosis ,7/7/14 12:28
1808,46,GlaxoSmithKline,Large Pharma,3124,Tuberculosis vaccine - GSK,Tuberculosis vaccine,Vaccine,Phase II,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1675,Tuberculosis ,7/7/14 12:28
1808,46,GlaxoSmithKline,Large Pharma,3124,Tuberculosis vaccine - GSK,Tuberculosis vaccine,Vaccine,Phase II,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1675,Tuberculosis ,7/7/14 12:28
1808,46,GlaxoSmithKline,Large Pharma,3124,Tuberculosis vaccine - GSK,Tuberculosis vaccine,Vaccine,Phase II,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1675,Tuberculosis ,7/7/14 12:28
1808,46,GlaxoSmithKline,Large Pharma,3124,Tuberculosis vaccine - GSK,Tuberculosis vaccine,Vaccine,Phase II,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1675,Tuberculosis ,7/7/14 12:28
1808,46,GlaxoSmithKline,Large Pharma,3124,Tuberculosis vaccine - GSK,Tuberculosis vaccine,Vaccine,Phase II,Corporate Acquisition,,,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1675,Tuberculosis ,7/7/14 12:28
1809,105,UCB,Regional & Specialty Pharma,454,Tussionex,hydrocodone + chlorpheniramine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-88,,Oct-10,N/A,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1214,Cold and Allergy Symptoms,7/7/14 12:28
1809,105,UCB,Regional & Specialty Pharma,454,Tussionex,hydrocodone + chlorpheniramine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-88,,Oct-10,N/A,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,2,Global,Sales,204.2562652,105.9803848,61.17922965,43.69922509,43.8249922,37.43052743,34.61726174,33.00150151,31.68266276,30.9146025,30.41832729,30.08428174,-5.23243779,1214,Cold and Allergy Symptoms,7/7/14 12:28
1809,105,UCB,Regional & Specialty Pharma,454,Tussionex,hydrocodone + chlorpheniramine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-88,,Oct-10,N/A,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1214,Cold and Allergy Symptoms,7/7/14 12:28
1809,105,UCB,Regional & Specialty Pharma,454,Tussionex,hydrocodone + chlorpheniramine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-88,,Oct-10,N/A,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1214,Cold and Allergy Symptoms,7/7/14 12:28
1809,105,UCB,Regional & Specialty Pharma,454,Tussionex,hydrocodone + chlorpheniramine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-88,,Oct-10,N/A,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1214,Cold and Allergy Symptoms,7/7/14 12:28
1809,105,UCB,Regional & Specialty Pharma,454,Tussionex,hydrocodone + chlorpheniramine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-88,,Oct-10,N/A,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,2,US,Sales,204.2562652,105.9803848,61.17922965,43.69922509,43.8249922,37.43052743,34.61726174,33.00150151,31.68266276,30.9146025,30.41832729,30.08428174,-5.23243779,1214,Cold and Allergy Symptoms,7/7/14 12:28
1811,76,Pfizer,Large Pharma,673,Tygacil,tigecycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,May-06,Apr-16,Aug-17,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1661,cSSSI and cIAI and CAP,7/7/14 12:28
1811,76,Pfizer,Large Pharma,673,Tygacil,tigecycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,May-06,Apr-16,Aug-17,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,45.03412036,324,298,335,358,364.66,369.71775,315.1744898,238.3206663,143.6324186,114.725092,95.38110255,-17.21722438,1661,cSSSI and cIAI and CAP,7/7/14 12:28
1811,76,Pfizer,Large Pharma,673,Tygacil,tigecycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,May-06,Apr-16,Aug-17,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1661,cSSSI and cIAI and CAP,7/7/14 12:28
1811,76,Pfizer,Large Pharma,673,Tygacil,tigecycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,May-06,Apr-16,Aug-17,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,12.25702036,160,150,183,208,215.41,220.5115,222.915925,191.3908527,109.6691752,87.76583144,73.18910659,-13.86143112,1661,cSSSI and cIAI and CAP,7/7/14 12:28
1811,76,Pfizer,Large Pharma,673,Tygacil,tigecycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,May-06,Apr-16,Aug-17,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1661,cSSSI and cIAI and CAP,7/7/14 12:28
1811,76,Pfizer,Large Pharma,673,Tygacil,tigecycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,May-06,Apr-16,Aug-17,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,32.7771,164,148,152,150,149.25,149.20625,92.25856484,46.92981357,33.96324349,26.95926057,22.19199596,-23.88965246,1661,cSSSI and cIAI and CAP,7/7/14 12:28
1811,76,Wyeth,Large Pharma,673,Tygacil,tigecycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,May-06,Apr-16,Aug-17,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Proforma,219,0,0,0,0,0,0,0,0,0,0,0,0,1661,cSSSI and cIAI and CAP,7/7/14 12:28
1811,76,Wyeth,Large Pharma,673,Tygacil,tigecycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,May-06,Apr-16,Aug-17,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Proforma,96,0,0,0,0,0,0,0,0,0,0,0,0,1661,cSSSI and cIAI and CAP,7/7/14 12:28
1811,76,Wyeth,Large Pharma,673,Tygacil,tigecycline,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-05,May-06,Apr-16,Aug-17,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Proforma,123,0,0,0,0,0,0,0,0,0,0,0,0,1661,cSSSI and cIAI and CAP,7/7/14 12:28
1812,46,GlaxoSmithKline,Large Pharma,1242,Tykerb / Tyverb,lapatinib,Small Molecule (Chemical),Launched,In-House,Mar-07,May-07,Nov-21,Jun-23,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1218,Breast Cancer,7/7/14 12:28
1812,46,GlaxoSmithKline,Large Pharma,1242,Tykerb / Tyverb,lapatinib,Small Molecule (Chemical),Launched,In-House,Mar-07,May-07,Nov-21,Jun-23,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,Global,Sales,263.784066,350.7150132,370.3347441,378.8219009,323.6267038,179.7926132,146.2104799,122.575412,95.68375267,84.37691104,76.18046582,70.80501892,-19.51458396,1218,Breast Cancer,7/7/14 12:28
1812,46,GlaxoSmithKline,Large Pharma,1242,Tykerb / Tyverb,lapatinib,Small Molecule (Chemical),Launched,In-House,Mar-07,May-07,Nov-21,Jun-23,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1218,Breast Cancer,7/7/14 12:28
1812,46,GlaxoSmithKline,Large Pharma,1242,Tykerb / Tyverb,lapatinib,Small Molecule (Chemical),Launched,In-House,Mar-07,May-07,Nov-21,Jun-23,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,ROW,Sales,179.3150943,242.5650091,267.7311787,271.0399374,237.6389323,121.9462942,99.71454671,86.98898189,68.79021723,63.41700086,60.59436214,58.67196831,-18.11275896,1218,Breast Cancer,7/7/14 12:28
1812,46,GlaxoSmithKline,Large Pharma,1242,Tykerb / Tyverb,lapatinib,Small Molecule (Chemical),Launched,In-House,Mar-07,May-07,Nov-21,Jun-23,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1218,Breast Cancer,7/7/14 12:28
1812,46,GlaxoSmithKline,Large Pharma,1242,Tykerb / Tyverb,lapatinib,Small Molecule (Chemical),Launched,In-House,Mar-07,May-07,Nov-21,Jun-23,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,4,US,Sales,84.46897173,108.1500041,102.6035655,107.7819634,85.98777154,57.84631904,46.4959332,35.58643012,26.89353544,20.95991018,15.58610368,12.13305061,-24.40294438,1218,Breast Cancer,7/7/14 12:28
1813,21,Biogen Idec,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Nov-04,Jul-06,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Alliance Revenue,227,246,317,372,109,0,0,0,0,0,0,0,-100,1559,Multiple Sclerosis,7/7/14 12:28
1813,21,Biogen Idec,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Nov-04,Jul-06,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,544.291238,647.4,753,752.8,1388,1749.14,1939.517,2097.6776,2195.460605,2265.310788,2316.253827,2363.799914,7.902516546,1559,Multiple Sclerosis,7/7/14 12:28
1813,21,Biogen Idec,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Nov-04,Jul-06,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1559,Multiple Sclerosis,7/7/14 12:28
1813,21,Biogen Idec,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Nov-04,Jul-06,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,544.291238,647.4,753,752.8,712,725,746,764.72,781.7732,797.271092,811.3591725,835,2.302590346,1559,Multiple Sclerosis,7/7/14 12:28
1813,21,Biogen Idec,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Nov-04,Jul-06,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Alliance Revenue,227,246,317,372,109,0,0,0,0,0,0,0,-100,1559,Multiple Sclerosis,7/7/14 12:28
1813,21,Biogen Idec,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Nov-04,Jul-06,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,676,1024.14,1193.517,1332.9576,1413.687405,1468.039696,1504.894655,1528.799914,12.36449017,1559,Multiple Sclerosis,7/7/14 12:28
1814,21,Biogen Idec,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Mar-08,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Alliance Revenue,4.94867,6.8,9.5,11.1,3.5,0,0,0,0,0,0,0,-100,1559,Crohn's disease,7/7/14 12:28
1814,21,Biogen Idec,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Mar-08,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,27.2,28,31,34.24,35.464,36.4468,37.12477,37.52015125,4.702368298,1559,Crohn's disease,7/7/14 12:28
1814,21,Biogen Idec,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Mar-08,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1559,Crohn's disease,7/7/14 12:28
1814,21,Biogen Idec,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Mar-08,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1559,Crohn's disease,7/7/14 12:28
1814,21,Biogen Idec,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Mar-08,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Alliance Revenue,4.94867,6.8,9.5,11.1,3.5,0,0,0,0,0,0,0,-100,1559,Crohn's disease,7/7/14 12:28
1814,21,Biogen Idec,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Mar-08,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,27.2,28,31,34.24,35.464,36.4468,37.12477,37.52015125,4.702368298,1559,Crohn's disease,7/7/14 12:28
1815,2409,Elan,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Nov-04,Jul-06,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Proforma,498.5,577.2,724.5,860.3,146.4,0,0,0,0,0,0,0,-100,1559,Multiple Sclerosis,7/7/14 12:28
1815,2409,Elan,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Nov-04,Jul-06,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Proforma,498.5,577.2,724.5,860.3,146.4,0,0,0,0,0,0,0,-100,1559,Multiple Sclerosis,7/7/14 12:28
1815,2409,Perrigo ,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Nov-04,Jul-06,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Alliance Revenue,216,258,318,317,87,0,0,0,0,0,0,0,-100,1559,Multiple Sclerosis,7/7/14 12:28
1815,2409,Perrigo ,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Nov-04,Jul-06,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1559,Multiple Sclerosis,7/7/14 12:28
1815,2409,Perrigo ,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Nov-04,Jul-06,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Alliance Revenue,216,258,318,317,87,0,0,0,0,0,0,0,-100,1559,Multiple Sclerosis,7/7/14 12:28
1815,2409,Perrigo ,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Nov-04,Jul-06,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1559,Multiple Sclerosis,7/7/14 12:28
1815,2409,Perrigo ,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Nov-04,Jul-06,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1559,Multiple Sclerosis,7/7/14 12:28
1815,2409,Perrigo ,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Nov-04,Jul-06,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1559,Multiple Sclerosis,7/7/14 12:28
1816,2409,Elan,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Proforma,10,16.4,22,25.7,7,0,0,0,0,0,0,0,-100,1559,Crohn's disease,7/7/14 12:28
1816,2409,Elan,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Proforma,10,16.4,22,25.7,7,0,0,0,0,0,0,0,-100,1559,Crohn's disease,7/7/14 12:28
1816,2409,Perrigo ,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1559,Crohn's disease,7/7/14 12:28
1816,2409,Perrigo ,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,2.70E-02,0,0,0,0,0,0,0,0,0,0,0,1559,Crohn's disease,7/7/14 12:28
1816,2409,Perrigo ,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1559,Crohn's disease,7/7/14 12:28
1816,2409,Perrigo ,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1559,Crohn's disease,7/7/14 12:28
1816,2409,Perrigo ,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1559,Crohn's disease,7/7/14 12:28
1816,2409,Perrigo ,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Mar-08,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,2.70E-02,0,0,0,0,0,0,0,0,0,0,0,1559,Crohn's disease,7/7/14 12:28
1817,34,Daiichi-Sankyo,Regional & Specialty Pharma,2666,patritumab,U3-1287,Antibody/Antibody Derivative,Phase II,,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1342,Solid Tumors,7/7/14 12:28
1817,34,Daiichi-Sankyo,Regional & Specialty Pharma,2666,patritumab,U3-1287,Antibody/Antibody Derivative,Phase II,,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1342,Solid Tumors,7/7/14 12:28
1817,34,Daiichi-Sankyo,Regional & Specialty Pharma,2666,patritumab,U3-1287,Antibody/Antibody Derivative,Phase II,,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1342,Solid Tumors,7/7/14 12:28
1817,34,Daiichi-Sankyo,Regional & Specialty Pharma,2666,patritumab,U3-1287,Antibody/Antibody Derivative,Phase II,,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1342,Solid Tumors,7/7/14 12:28
1817,34,Daiichi-Sankyo,Regional & Specialty Pharma,2666,patritumab,U3-1287,Antibody/Antibody Derivative,Phase II,,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1342,Solid Tumors,7/7/14 12:28
1817,34,Daiichi-Sankyo,Regional & Specialty Pharma,2666,patritumab,U3-1287,Antibody/Antibody Derivative,Phase II,,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1342,Solid Tumors,7/7/14 12:28
1820,1,Abbott,Regional & Specialty Pharma,2729,Ultane / Sevorane,sevoflurane,Small Molecule (Chemical),Launched,Licensed (Development),Dec-98,Jul-94,Apr-06,Apr-06,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1222,Anesthetic,7/7/14 12:28
1820,1,Abbott,Regional & Specialty Pharma,2729,Ultane / Sevorane,sevoflurane,Small Molecule (Chemical),Launched,Licensed (Development),Dec-98,Jul-94,Apr-06,Apr-06,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,721,664,665,602,0,0,0,0,0,0,0,0,0,1222,Anesthetic,7/7/14 12:28
1820,1,Abbott,Regional & Specialty Pharma,2729,Ultane / Sevorane,sevoflurane,Small Molecule (Chemical),Launched,Licensed (Development),Dec-98,Jul-94,Apr-06,Apr-06,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1222,Anesthetic,7/7/14 12:28
1820,1,Abbott,Regional & Specialty Pharma,2729,Ultane / Sevorane,sevoflurane,Small Molecule (Chemical),Launched,Licensed (Development),Dec-98,Jul-94,Apr-06,Apr-06,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,561,538,577,520,0,0,0,0,0,0,0,0,0,1222,Anesthetic,7/7/14 12:28
1820,1,Abbott,Regional & Specialty Pharma,2729,Ultane / Sevorane,sevoflurane,Small Molecule (Chemical),Launched,Licensed (Development),Dec-98,Jul-94,Apr-06,Apr-06,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1222,Anesthetic,7/7/14 12:28
1820,1,Abbott,Regional & Specialty Pharma,2729,Ultane / Sevorane,sevoflurane,Small Molecule (Chemical),Launched,Licensed (Development),Dec-98,Jul-94,Apr-06,Apr-06,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,160,126,88,82,0,0,0,0,0,0,0,0,0,1222,Anesthetic,7/7/14 12:28
1821,53,Johnson & Johnson,Large Pharma,828,Ultram / Ultracet,tramadol / tramadol + acetaminophen,Small Molecule (Chemical),Launched,Licensed (Development),Jul-95,Jul-11,Nov-09,Dec-18,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1223,Pain,7/7/14 12:28
1821,53,Johnson & Johnson,Large Pharma,828,Ultram / Ultracet,tramadol / tramadol + acetaminophen,Small Molecule (Chemical),Launched,Licensed (Development),Jul-95,Jul-11,Nov-09,Dec-18,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,400.77,135,68.719,87.598148,105.6530567,0,0,0,0,0,0,0,-100,1223,Pain,7/7/14 12:28
1821,53,Johnson & Johnson,Large Pharma,828,Ultram / Ultracet,tramadol / tramadol + acetaminophen,Small Molecule (Chemical),Launched,Licensed (Development),Jul-95,Jul-11,Nov-09,Dec-18,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1223,Pain,7/7/14 12:28
1821,53,Johnson & Johnson,Large Pharma,828,Ultram / Ultracet,tramadol / tramadol + acetaminophen,Small Molecule (Chemical),Launched,Licensed (Development),Jul-95,Jul-11,Nov-09,Dec-18,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,13.45,54.518768,90.20729872,0,0,0,0,0,0,0,-100,1223,Pain,7/7/14 12:28
1821,53,Johnson & Johnson,Large Pharma,828,Ultram / Ultracet,tramadol / tramadol + acetaminophen,Small Molecule (Chemical),Launched,Licensed (Development),Jul-95,Jul-11,Nov-09,Dec-18,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1223,Pain,7/7/14 12:28
1821,53,Johnson & Johnson,Large Pharma,828,Ultram / Ultracet,tramadol / tramadol + acetaminophen,Small Molecule (Chemical),Launched,Licensed (Development),Jul-95,Jul-11,Nov-09,Dec-18,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,400.77,135,55.269,33.07938,15.445758,0,0,0,0,0,0,0,-100,1223,Pain,7/7/14 12:28
1822,76,Pfizer,Large Pharma,319,Unasyn,ampicillin  +  sulbactam,Small Molecule (Chemical),Launched,In-House,Jul-87,Jul-87,Expired,Jun-05,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1224,,7/7/14 12:28
1822,76,Pfizer,Large Pharma,319,Unasyn,ampicillin  +  sulbactam,Small Molecule (Chemical),Launched,In-House,Jul-87,Jul-87,Expired,Jun-05,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,245,244,231,228,212,205.745,199.560875,193.5055906,188,182.0290692,176.0518392,170.0696874,-3.099212419,1224,,7/7/14 12:28
1822,76,Pfizer,Large Pharma,319,Unasyn,ampicillin  +  sulbactam,Small Molecule (Chemical),Launched,In-House,Jul-87,Jul-87,Expired,Jun-05,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1224,,7/7/14 12:28
1822,76,Pfizer,Large Pharma,319,Unasyn,ampicillin  +  sulbactam,Small Molecule (Chemical),Launched,In-House,Jul-87,Jul-87,Expired,Jun-05,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,239,238,225,226,211,205,199,193,187,181,175,169,-3.121101511,1224,,7/7/14 12:28
1822,76,Pfizer,Large Pharma,319,Unasyn,ampicillin  +  sulbactam,Small Molecule (Chemical),Launched,In-House,Jul-87,Jul-87,Expired,Jun-05,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1224,,7/7/14 12:28
1822,76,Pfizer,Large Pharma,319,Unasyn,ampicillin  +  sulbactam,Small Molecule (Chemical),Launched,In-House,Jul-87,Jul-87,Expired,Jun-05,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,6,6,6,2,1,0.745,0.560875,0.505590625,1,1.029069156,1.051839234,1.069687383,0.967022489,1224,,7/7/14 12:28
1824,34,Daiichi-Sankyo,Regional & Specialty Pharma,484,Urief,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),,May-06,N/A,Jan-18,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1633,Symptoms associated with BPH,7/7/14 12:28
1824,34,Daiichi-Sankyo,Regional & Specialty Pharma,484,Urief,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),,May-06,N/A,Jan-18,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,Global,Sales,99.41597568,117.8956215,136.9436488,132.4261473,121.5042223,127.4061919,132.6462196,137.8801878,142.1756968,136.645196,128.169686,124.9201505,0.396866806,1633,Symptoms associated with BPH,7/7/14 12:28
1824,34,Daiichi-Sankyo,Regional & Specialty Pharma,484,Urief,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),,May-06,N/A,Jan-18,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1633,Symptoms associated with BPH,7/7/14 12:28
1824,34,Daiichi-Sankyo,Regional & Specialty Pharma,484,Urief,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),,May-06,N/A,Jan-18,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,ROW,Sales,99.41597568,117.8956215,136.9436488,132.4261473,121.5042223,127.4061919,132.6462196,137.8801878,142.1756968,136.645196,128.169686,124.9201505,0.396866806,1633,Symptoms associated with BPH,7/7/14 12:28
1824,34,Daiichi-Sankyo,Regional & Specialty Pharma,484,Urief,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),,May-06,N/A,Jan-18,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1633,Symptoms associated with BPH,7/7/14 12:28
1824,34,Daiichi-Sankyo,Regional & Specialty Pharma,484,Urief,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),,May-06,N/A,Jan-18,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1633,Symptoms associated with BPH,7/7/14 12:28
1825,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1057,Urso,ursodesoxycholic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-57,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1229,Liver Biliary Cirrhosis,7/7/14 12:28
1825,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1057,Urso,ursodesoxycholic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-57,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,Global,Sales,175.604133,178.5943574,182.3279096,160.1152509,122.5167575,116.0208499,110.6940275,106.5606436,103.5822914,101.305558,99.59042852,98.30867541,-3.095856035,1229,Liver Biliary Cirrhosis,7/7/14 12:28
1825,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1057,Urso,ursodesoxycholic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-57,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1229,Liver Biliary Cirrhosis,7/7/14 12:28
1825,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1057,Urso,ursodesoxycholic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-57,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,ROW,Sales,175.604133,178.5943574,182.3279096,160.1152509,122.5167575,116.0208499,110.6940275,106.5606436,103.5822914,101.305558,99.59042852,98.30867541,-3.095856035,1229,Liver Biliary Cirrhosis,7/7/14 12:28
1825,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1057,Urso,ursodesoxycholic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-57,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1229,Liver Biliary Cirrhosis,7/7/14 12:28
1825,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1057,Urso,ursodesoxycholic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-57,Expired,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1229,Liver Biliary Cirrhosis,7/7/14 12:28
1828,61,Merck & Co,Large Pharma,1286,V950,V950,Vaccine,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1234,Alzheimer's Disease,7/7/14 12:28
1828,61,Merck & Co,Large Pharma,1286,V950,V950,Vaccine,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1234,Alzheimer's Disease,7/7/14 12:28
1828,61,Merck & Co,Large Pharma,1286,V950,V950,Vaccine,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1234,Alzheimer's Disease,7/7/14 12:28
1828,61,Merck & Co,Large Pharma,1286,V950,V950,Vaccine,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1234,Alzheimer's Disease,7/7/14 12:28
1828,61,Merck & Co,Large Pharma,1286,V950,V950,Vaccine,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1234,Alzheimer's Disease,7/7/14 12:28
1828,61,Merck & Co,Large Pharma,1286,V950,V950,Vaccine,Phase I,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1234,Alzheimer's Disease,7/7/14 12:28
1830,86,Roche,Large Pharma,2522,Valcyte / Cymevene,valganciclovir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-01,May-02,Oct-15,Jan-15,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1236,CMV,7/7/14 12:28
1830,86,Roche,Large Pharma,2522,Valcyte / Cymevene,valganciclovir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-01,May-02,Oct-15,Jan-15,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,5,Global,Sales,519.3290465,580.2156068,640.8938724,680.4202324,747.8323117,755.1703488,580.9765491,304.9000758,234.8975569,192.5149769,161.80623,138.6340505,-21.39719223,1236,CMV,7/7/14 12:28
1830,86,Roche,Large Pharma,2522,Valcyte / Cymevene,valganciclovir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-01,May-02,Oct-15,Jan-15,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1236,CMV,7/7/14 12:28
1830,86,Roche,Large Pharma,2522,Valcyte / Cymevene,valganciclovir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-01,May-02,Oct-15,Jan-15,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,5,ROW,Sales,266.1100965,289.6282864,346.916191,335.9441586,361.5062402,366.6860311,239.8890662,181.5337146,145.5710824,121.5893136,103.4160645,89.25639439,-18.1124768,1236,CMV,7/7/14 12:28
1830,86,Roche,Large Pharma,2522,Valcyte / Cymevene,valganciclovir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-01,May-02,Oct-15,Jan-15,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1236,CMV,7/7/14 12:28
1830,86,Roche,Large Pharma,2522,Valcyte / Cymevene,valganciclovir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-01,May-02,Oct-15,Jan-15,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,5,US,Sales,253.21895,290.5873205,293.9776813,344.4760738,386.3260716,388.4843178,341.0874828,123.3663613,89.32647446,70.92566335,58.39016556,49.3776561,-25.4636379,1236,CMV,7/7/14 12:28
1831,94,Servier,Regional & Specialty Pharma,1043,Valdoxan,agomelatine,Small Molecule (Chemical),Launched,In-House,,Apr-09,N/A,Feb-19,46,Other Anti-depressants,49,Depression,12,Central Nervous System,2,Global,Sales,21.29849846,60.421308,111.5877023,146.5851922,176.587764,201.2483772,221.4395906,237.2028753,250.4126656,261.1731519,140.0886035,84.51269119,-9.992181721,1331,Depression ,7/7/14 12:28
1831,94,Servier,Regional & Specialty Pharma,1043,Valdoxan,agomelatine,Small Molecule (Chemical),Launched,In-House,,Apr-09,N/A,Feb-19,46,Other Anti-depressants,49,Depression,12,Central Nervous System,2,ROW,Sales,21.29849846,60.421308,111.5877023,146.5851922,176.587764,201.2483772,221.4395906,237.2028753,250.4126656,261.1731519,140.0886035,84.51269119,-9.992181721,1331,Depression ,7/7/14 12:28
1831,94,Servier,Regional & Specialty Pharma,1043,Valdoxan,agomelatine,Small Molecule (Chemical),Launched,In-House,,Apr-09,N/A,Feb-19,46,Other Anti-depressants,49,Depression,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1331,Depression ,7/7/14 12:28
1832,46,GlaxoSmithKline,Large Pharma,11,Valtrex,valaciclovir,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-95,Nov-09,Dec-09,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1238,Herpes zoster and H simplex,7/7/14 12:28
1832,46,GlaxoSmithKline,Large Pharma,11,Valtrex,valaciclovir,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-95,Nov-09,Dec-09,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,4,Global,Sales,2017.684626,821.9400308,543.4782609,399.4272762,350.2047423,292.3584232,249.1691108,212.6487362,182.3667501,158.332084,138.5644721,122.2070328,-13.96362762,1238,Herpes zoster and H simplex,7/7/14 12:28
1832,46,GlaxoSmithKline,Large Pharma,11,Valtrex,valaciclovir,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-95,Nov-09,Dec-09,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1238,Herpes zoster and H simplex,7/7/14 12:28
1832,46,GlaxoSmithKline,Large Pharma,11,Valtrex,valaciclovir,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-95,Nov-09,Dec-09,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,4,ROW,Sales,548.8601147,432.6000162,428.0492497,343.9512656,279.851111,228.2584481,186.6325497,151.6755892,122.9570171,99.07869233,79.35485601,63.00404562,-19.18504762,1238,Herpes zoster and H simplex,7/7/14 12:28
1832,46,GlaxoSmithKline,Large Pharma,11,Valtrex,valaciclovir,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-95,Nov-09,Dec-09,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1238,Herpes zoster and H simplex,7/7/14 12:28
1832,46,GlaxoSmithKline,Large Pharma,11,Valtrex,valaciclovir,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-95,Nov-09,Dec-09,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,4,US,Sales,1468.824512,389.3400146,115.4290112,55.47601059,70.35363126,64.09997515,62.53656112,60.97314709,59.40973306,59.25339166,59.20961607,59.20298719,-2.435037391,1238,Herpes zoster and H simplex,7/7/14 12:28
1833,39,Eli Lilly,Large Pharma,1205,Vancocin,vancomycin,Small Molecule (Chemical),Launched,In-House,Jul-58,Jul-58,Expired,Expired,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1677,Bacterial infections,7/7/14 12:28
1833,39,Eli Lilly,Large Pharma,1205,Vancocin,vancomycin,Small Molecule (Chemical),Launched,In-House,Jul-58,Jul-58,Expired,Expired,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,85.9,87.1,88.1,66.2,75,75.88,75.968,75.9768,75.97768,75.977768,75.9777768,75.97777768,0.185210905,1677,Bacterial infections,7/7/14 12:28
1833,39,Eli Lilly,Large Pharma,1205,Vancocin,vancomycin,Small Molecule (Chemical),Launched,In-House,Jul-58,Jul-58,Expired,Expired,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1677,Bacterial infections,7/7/14 12:28
1833,39,Eli Lilly,Large Pharma,1205,Vancocin,vancomycin,Small Molecule (Chemical),Launched,In-House,Jul-58,Jul-58,Expired,Expired,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,85.9,87.1,88.1,66.2,75,75.88,75.968,75.9768,75.97768,75.977768,75.9777768,75.97777768,0.185210905,1677,Bacterial infections,7/7/14 12:28
1833,39,Eli Lilly,Large Pharma,1205,Vancocin,vancomycin,Small Molecule (Chemical),Launched,In-House,Jul-58,Jul-58,Expired,Expired,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1677,Bacterial infections,7/7/14 12:28
1833,39,Eli Lilly,Large Pharma,1205,Vancocin,vancomycin,Small Molecule (Chemical),Launched,In-House,Jul-58,Jul-58,Expired,Expired,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1677,Bacterial infections,7/7/14 12:28
1834,96,Shire,Regional & Specialty Pharma,1205,Vancocin,vancomycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-58,,Apr-12,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,4.00E-02,-3.00E-02,-1.00E-02,-2.00E-02,0,6.05041,6.40110205,6.22944674,6.22474136,6.222904251,6.222537639,6.222520884,0,1677,Bacterial infections,7/7/14 12:28
1834,96,Shire,Regional & Specialty Pharma,1205,Vancocin,vancomycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-58,,Apr-12,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1677,Bacterial infections,7/7/14 12:28
1834,96,Shire,Regional & Specialty Pharma,1205,Vancocin,vancomycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-58,,Apr-12,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,4.00E-02,-3.00E-02,-1.00E-02,-2.00E-02,0,6.05041,6.40110205,6.22944674,6.22474136,6.222904251,6.222537639,6.222520884,0,1677,Bacterial infections,7/7/14 12:28
1835,95,Shionogi,Regional & Specialty Pharma,1596,vancomycin,vancomycin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-82,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1677,Bacterial infections,7/7/14 12:28
1835,95,Shionogi,Regional & Specialty Pharma,1596,vancomycin,vancomycin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-82,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,65.71688412,59.91412309,54.44513966,38.75656708,28.79173611,25.51973379,22.64763895,21.30133294,20.19457662,19.37006042,18.90202717,18.5442913,-6.091245056,1677,Bacterial infections,7/7/14 12:28
1835,95,Shionogi,Regional & Specialty Pharma,1596,vancomycin,vancomycin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-82,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1677,Bacterial infections,7/7/14 12:28
1835,95,Shionogi,Regional & Specialty Pharma,1596,vancomycin,vancomycin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-82,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,65.71688412,59.91412309,54.44513966,38.75656708,28.79173611,25.51973379,22.64763895,21.30133294,20.19457662,19.37006042,18.90202717,18.5442913,-6.091245056,1677,Bacterial infections,7/7/14 12:28
1835,95,Shionogi,Regional & Specialty Pharma,1596,vancomycin,vancomycin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-82,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1677,Bacterial infections,7/7/14 12:28
1835,95,Shionogi,Regional & Specialty Pharma,1596,vancomycin,vancomycin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-82,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1677,Bacterial infections,7/7/14 12:28
1836,23,Boehringer Ingelheim,Large Pharma,481,Vargatef,nintedanib,Small Molecule (Chemical),Filed,In-House,Nov-14,Jan-15,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1241,Non-small-cell Lung Cancer,7/7/14 12:28
1836,23,Boehringer Ingelheim,Large Pharma,481,Vargatef,nintedanib,Small Molecule (Chemical),Filed,In-House,Nov-14,Jan-15,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,Global,Sales,0,0,0,0,0,5.079715005,28.99666598,40.79844407,59.00914478,76.4712889,88.05953542,98.33197007,0,1241,Non-small-cell Lung Cancer,7/7/14 12:28
1836,23,Boehringer Ingelheim,Large Pharma,481,Vargatef,nintedanib,Small Molecule (Chemical),Filed,In-House,Nov-14,Jan-15,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1241,Non-small-cell Lung Cancer,7/7/14 12:28
1836,23,Boehringer Ingelheim,Large Pharma,481,Vargatef,nintedanib,Small Molecule (Chemical),Filed,In-House,Nov-14,Jan-15,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,9.296210466,13.01469465,18.59240234,27.88860351,32.83418032,37.29821353,0,1241,Non-small-cell Lung Cancer,7/7/14 12:28
1836,23,Boehringer Ingelheim,Large Pharma,481,Vargatef,nintedanib,Small Molecule (Chemical),Filed,In-House,Nov-14,Jan-15,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1241,Non-small-cell Lung Cancer,7/7/14 12:28
1836,23,Boehringer Ingelheim,Large Pharma,481,Vargatef,nintedanib,Small Molecule (Chemical),Filed,In-House,Nov-14,Jan-15,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,US,Sales,0,0,0,0,0,5.079715005,19.70045551,27.78374942,40.41674244,48.58268539,55.2253551,61.03375654,0,1241,Non-small-cell Lung Cancer,7/7/14 12:28
1837,46,GlaxoSmithKline,Large Pharma,4134,GSK1437173A,GSK1437173A,Vaccine,Phase III,In-House,Feb-16,Sep-16,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1242,herpes zoster prevention,7/7/14 12:28
1837,46,GlaxoSmithKline,Large Pharma,4134,GSK1437173A,GSK1437173A,Vaccine,Phase III,In-House,Feb-16,Sep-16,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,0,0,0,0,0,0,0,57.97659833,196.6863476,363.4506751,530.2145499,659.1370983,0,1242,herpes zoster prevention,7/7/14 12:28
1837,46,GlaxoSmithKline,Large Pharma,4134,GSK1437173A,GSK1437173A,Vaccine,Phase III,In-House,Feb-16,Sep-16,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1242,herpes zoster prevention,7/7/14 12:28
1837,46,GlaxoSmithKline,Large Pharma,4134,GSK1437173A,GSK1437173A,Vaccine,Phase III,In-House,Feb-16,Sep-16,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,0,0,0,0,0,0,0,19.28208706,89.98313724,186.39377,282.8040835,355.8189289,0,1242,herpes zoster prevention,7/7/14 12:28
1837,46,GlaxoSmithKline,Large Pharma,4134,GSK1437173A,GSK1437173A,Vaccine,Phase III,In-House,Feb-16,Sep-16,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1242,herpes zoster prevention,7/7/14 12:28
1837,46,GlaxoSmithKline,Large Pharma,4134,GSK1437173A,GSK1437173A,Vaccine,Phase III,In-House,Feb-16,Sep-16,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,0,0,0,0,0,0,0,38.69451126,106.7032104,177.0569051,247.4104663,303.3181694,0,1242,herpes zoster prevention,7/7/14 12:28
1838,61,Merck & Co,Large Pharma,1045,Vasotec,enalapril,Small Molecule (Chemical),Launched,In-House,,Jan-84,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1243,Hypertension,7/7/14 12:28
1838,61,Merck & Co,Large Pharma,1045,Vasotec,enalapril,Small Molecule (Chemical),Launched,In-House,,Jan-84,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Sales,311,255,231,192,169.575,151.766625,139.2909394,130.1418693,123.5462837,118.7612236,115.2978821,112.7889749,-5.658948073,1243,Hypertension,7/7/14 12:28
1838,61,Merck & Co,Large Pharma,1045,Vasotec,enalapril,Small Molecule (Chemical),Launched,In-House,,Jan-84,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1243,Hypertension,7/7/14 12:28
1838,61,Merck & Co,Large Pharma,1045,Vasotec,enalapril,Small Molecule (Chemical),Launched,In-House,,Jan-84,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,311,255,231,192,169.575,151.766625,139.2909394,130.1418693,123.5462837,118.7612236,115.2978821,112.7889749,-5.658948073,1243,Hypertension,7/7/14 12:28
1838,61,Merck & Co,Large Pharma,1045,Vasotec,enalapril,Small Molecule (Chemical),Launched,In-House,,Jan-84,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1243,Hypertension,7/7/14 12:28
1838,61,Merck & Co,Large Pharma,1045,Vasotec,enalapril,Small Molecule (Chemical),Launched,In-House,,Jan-84,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1243,Hypertension,7/7/14 12:28
1839,11,Amgen,Large Pharma,1166,Vectibix,panitumumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-06,Jan-08,Apr-20,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1580,Colorectal Cancer,7/7/14 12:28
1839,11,Amgen,Large Pharma,1166,Vectibix,panitumumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-06,Jan-08,Apr-20,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,233,288,322,359,389,405.75,422.6802241,434.6767493,442.9165938,448.9334297,452.842584,455.7129604,2.286953606,1580,Colorectal Cancer,7/7/14 12:28
1839,11,Amgen,Large Pharma,1166,Vectibix,panitumumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-06,Jan-08,Apr-20,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1580,Colorectal Cancer,7/7/14 12:28
1839,11,Amgen,Large Pharma,1166,Vectibix,panitumumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-06,Jan-08,Apr-20,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,136,173,200,237,263,277.75,289.0375,296.671875,301.7485938,305.2916797,307.7023965,309.3442104,2.345665266,1580,Colorectal Cancer,7/7/14 12:28
1839,11,Amgen,Large Pharma,1166,Vectibix,panitumumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-06,Jan-08,Apr-20,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1580,Colorectal Cancer,7/7/14 12:28
1839,11,Amgen,Large Pharma,1166,Vectibix,panitumumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Oct-06,Jan-08,Apr-20,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,97,115,122,122,126,128,133.6427241,138.0048743,141.168,143.64175,145.1401875,146.36875,2.163749129,1580,Colorectal Cancer,7/7/14 12:28
1840,100,Takeda,Large Pharma,1166,Vectibix,panitumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-10,N/A,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1580,Colorectal Cancer,7/7/14 12:28
1840,100,Takeda,Large Pharma,1166,Vectibix,panitumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-10,N/A,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,Global,Sales,0,103.6975207,217.7805587,226.3283245,202.3612171,219.2343214,228.5851023,235.9980599,241.9298602,246.1658264,249.3938952,251.8366058,3.173986492,1580,Colorectal Cancer,7/7/14 12:28
1840,100,Takeda,Large Pharma,1166,Vectibix,panitumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-10,N/A,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1580,Colorectal Cancer,7/7/14 12:28
1840,100,Takeda,Large Pharma,1166,Vectibix,panitumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-10,N/A,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,ROW,Sales,0,103.6975207,217.7805587,226.3283245,202.3612171,219.2343214,228.5851023,235.9980599,241.9298602,246.1658264,249.3938952,251.8366058,3.173986492,1580,Colorectal Cancer,7/7/14 12:28
1840,100,Takeda,Large Pharma,1166,Vectibix,panitumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-10,N/A,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1580,Colorectal Cancer,7/7/14 12:28
1840,100,Takeda,Large Pharma,1166,Vectibix,panitumumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-10,N/A,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1580,Colorectal Cancer,7/7/14 12:28
1841,100,Takeda,Large Pharma,584,Entyvio,vedolizumab,Antibody/Antibody Derivative,Approved,Corporate Acquisition,Aug-14,Aug-14,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1244,Ulcerative Colitis,7/7/14 12:28
1841,100,Takeda,Large Pharma,584,Entyvio,vedolizumab,Antibody/Antibody Derivative,Approved,Corporate Acquisition,Aug-14,Aug-14,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,Global,Sales,0,0,0,0,0,36.24380008,142.9616559,237.5982249,298.004884,361.9551812,417.1747493,464.2757133,0,1244,Ulcerative Colitis,7/7/14 12:28
1841,100,Takeda,Large Pharma,584,Entyvio,vedolizumab,Antibody/Antibody Derivative,Approved,Corporate Acquisition,Aug-14,Aug-14,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1244,Ulcerative Colitis,7/7/14 12:28
1841,100,Takeda,Large Pharma,584,Entyvio,vedolizumab,Antibody/Antibody Derivative,Approved,Corporate Acquisition,Aug-14,Aug-14,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,0,20.13544449,70.47405572,100.6771218,120.8125461,144.1696295,163.1774553,179.6079535,0,1244,Ulcerative Colitis,7/7/14 12:28
1841,100,Takeda,Large Pharma,584,Entyvio,vedolizumab,Antibody/Antibody Derivative,Approved,Corporate Acquisition,Aug-14,Aug-14,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1244,Ulcerative Colitis,7/7/14 12:28
1841,100,Takeda,Large Pharma,584,Entyvio,vedolizumab,Antibody/Antibody Derivative,Approved,Corporate Acquisition,Aug-14,Aug-14,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,16.10835559,72.48760017,136.9211031,177.1923379,217.7855517,253.997294,284.6677598,0,1244,Ulcerative Colitis,7/7/14 12:28
1842,19,Bayer,Large Pharma,3371,Eylea,aflibercept,Recombinant Protein,Launched,Licensed (Development),,Nov-12,N/A,Jul-20,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1328,Age-related macular degeneration,7/7/14 12:28
1842,19,Bayer,Large Pharma,3371,Eylea,aflibercept,Recombinant Protein,Launched,Licensed (Development),,Nov-12,N/A,Jul-20,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,2,Global,Sales,0,0,0,17.99379857,442.2340122,1019.061946,1595.89177,1923.606736,2194.969946,2332.449567,2376.74848,2430.842157,27.56429273,1328,Age-related macular degeneration,7/7/14 12:28
1842,19,Bayer,Large Pharma,3371,Eylea,aflibercept,Recombinant Protein,Launched,Licensed (Development),,Nov-12,N/A,Jul-20,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1328,Age-related macular degeneration,7/7/14 12:28
1842,19,Bayer,Large Pharma,3371,Eylea,aflibercept,Recombinant Protein,Launched,Licensed (Development),,Nov-12,N/A,Jul-20,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,2,ROW,Sales,0,0,0,17.99379857,442.2340122,1019.061946,1595.89177,1923.606736,2194.969946,2332.449567,2376.74848,2430.842157,27.56429273,1328,Age-related macular degeneration,7/7/14 12:28
1842,19,Bayer,Large Pharma,3371,Eylea,aflibercept,Recombinant Protein,Launched,Licensed (Development),,Nov-12,N/A,Jul-20,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1328,Age-related macular degeneration,7/7/14 12:28
1842,19,Bayer,Large Pharma,3371,Eylea,aflibercept,Recombinant Protein,Launched,Licensed (Development),,Nov-12,N/A,Jul-20,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1328,Age-related macular degeneration,7/7/14 12:28
1843,85,Regeneron,Small Biotech,3371,Eylea,aflibercept,Recombinant Protein,Launched,In-House,Dec-11,,Dec-23,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Sales,0,0,24.8,837.9,1409,1875.751962,2112.024048,2224.29272,2281.704547,2309.928675,2325.470542,2333.786704,7.474921248,1328,AMD,7/7/14 12:28
1843,85,Regeneron,Small Biotech,3371,Eylea,aflibercept,Recombinant Protein,Launched,In-House,Dec-11,,Dec-23,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1328,AMD,7/7/14 12:28
1843,85,Regeneron,Small Biotech,3371,Eylea,aflibercept,Recombinant Protein,Launched,In-House,Dec-11,,Dec-23,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Sales,0,0,24.8,837.9,1409,1875.751962,2112.024048,2224.29272,2281.704547,2309.928675,2325.470542,2333.786704,7.474921248,1328,AMD,7/7/14 12:28
1844,89,Sanofi,Large Pharma,3684,Zaltrap,aflibercept,Recombinant Protein,Launched,Licensed (Development),Aug-12,Mar-13,Aug-24,Feb-23,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3784,Colorectal Cancer,7/7/14 12:28
1844,89,Sanofi,Large Pharma,3684,Zaltrap,aflibercept,Recombinant Protein,Launched,Licensed (Development),Aug-12,Mar-13,Aug-24,Feb-23,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,2,Global,Sales,0,0,0,32.13178315,70.38559353,101.5498642,136.4822549,147.0268971,154.8899619,158.6795744,160.2526091,160.7641863,12.5235942,3784,Colorectal Cancer,7/7/14 12:28
1844,89,Sanofi,Large Pharma,3684,Zaltrap,aflibercept,Recombinant Protein,Launched,Licensed (Development),Aug-12,Mar-13,Aug-24,Feb-23,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3784,Colorectal Cancer,7/7/14 12:28
1844,89,Sanofi,Large Pharma,3684,Zaltrap,aflibercept,Recombinant Protein,Launched,Licensed (Development),Aug-12,Mar-13,Aug-24,Feb-23,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,22.57651113,33.70447347,43.28028513,53.94310471,59.30596484,60.91482288,61.39748029,61.25637002,15.32612865,3784,Colorectal Cancer,7/7/14 12:28
1844,89,Sanofi,Large Pharma,3684,Zaltrap,aflibercept,Recombinant Protein,Launched,Licensed (Development),Aug-12,Mar-13,Aug-24,Feb-23,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3784,Colorectal Cancer,7/7/14 12:28
1844,89,Sanofi,Large Pharma,3684,Zaltrap,aflibercept,Recombinant Protein,Launched,Licensed (Development),Aug-12,Mar-13,Aug-24,Feb-23,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,2,US,Sales,0,0,0,32.13178315,47.8090824,67.84539074,93.20196981,93.08379239,95.58399707,97.76475155,98.85512879,99.50781632,11.03964561,3784,Colorectal Cancer,7/7/14 12:28
1845,96,Shire,Regional & Specialty Pharma,2421,Vpriv,velaglucerase alfa,Recombinant Protein,Launched,Corporate Acquisition,Jul-09,Jul-09,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1267,Gaucher's disease,7/7/14 12:28
1845,96,Shire,Regional & Specialty Pharma,2421,Vpriv,velaglucerase alfa,Recombinant Protein,Launched,Corporate Acquisition,Jul-09,Jul-09,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Sales,5,143,256.2,307,343,378.132,402.3769,421.1739325,436.1076336,447.4312357,456.2047187,463.0079625,4.379078519,1267,Gaucher's disease,7/7/14 12:28
1845,96,Shire,Regional & Specialty Pharma,2421,Vpriv,velaglucerase alfa,Recombinant Protein,Launched,Corporate Acquisition,Jul-09,Jul-09,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1267,Gaucher's disease,7/7/14 12:28
1845,96,Shire,Regional & Specialty Pharma,2421,Vpriv,velaglucerase alfa,Recombinant Protein,Launched,Corporate Acquisition,Jul-09,Jul-09,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Sales,3,54,118.2,149,173.6,189.852,204.5329,215.9703325,225.2610336,232.4193277,238.0443263,242.4761093,4.889326893,1267,Gaucher's disease,7/7/14 12:28
1845,96,Shire,Regional & Specialty Pharma,2421,Vpriv,velaglucerase alfa,Recombinant Protein,Launched,Corporate Acquisition,Jul-09,Jul-09,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1267,Gaucher's disease,7/7/14 12:28
1845,96,Shire,Regional & Specialty Pharma,2421,Vpriv,velaglucerase alfa,Recombinant Protein,Launched,Corporate Acquisition,Jul-09,Jul-09,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Sales,2,89,138,158,169.4,188.28,197.844,205.2036,210.8466,215.011908,218.1603924,220.5318532,3.8401725,1267,Gaucher's disease,7/7/14 12:28
1846,53,Johnson & Johnson,Large Pharma,594,Velcade,bortezomib,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-04,,Apr-19,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1366,Multiple Myeloma,7/7/14 12:28
1846,53,Johnson & Johnson,Large Pharma,594,Velcade,bortezomib,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-04,,Apr-19,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,933,1080,1274,1500,1666,1741.84,1731.931428,1715.576942,1667.242071,1610.187959,1073.539493,551.9047531,-14.60043479,1366,Multiple Myeloma,7/7/14 12:28
1846,53,Johnson & Johnson,Large Pharma,594,Velcade,bortezomib,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-04,,Apr-19,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1366,Multiple Myeloma,7/7/14 12:28
1846,53,Johnson & Johnson,Large Pharma,594,Velcade,bortezomib,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-04,,Apr-19,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,933,1080,1274,1500,1666,1741.84,1731.931428,1715.576942,1667.242071,1610.187959,1073.539493,551.9047531,-14.60043479,1366,Multiple Myeloma,7/7/14 12:28
1846,53,Johnson & Johnson,Large Pharma,594,Velcade,bortezomib,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-04,,Apr-19,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1366,Multiple Myeloma,7/7/14 12:28
1846,53,Johnson & Johnson,Large Pharma,594,Velcade,bortezomib,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-04,,Apr-19,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1366,Multiple Myeloma,7/7/14 12:28
1847,100,Takeda,Large Pharma,594,Velcade,bortezomib,Small Molecule (Chemical),Launched,Corporate Acquisition,May-03,,Jan-22,N/A,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1366,Multiple Myeloma,7/7/14 12:28
1847,100,Takeda,Large Pharma,594,Velcade,bortezomib,Small Molecule (Chemical),Launched,Corporate Acquisition,May-03,,Jan-22,N/A,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,497.7245978,592.9799577,735.6424685,877.6241947,963.2771703,1067.718972,1153.36192,1212.570352,1177.662946,1154.622724,1081.498633,1063.304233,1.421367438,1366,Multiple Myeloma,7/7/14 12:28
1847,100,Takeda,Large Pharma,594,Velcade,bortezomib,Small Molecule (Chemical),Launched,Corporate Acquisition,May-03,,Jan-22,N/A,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1366,Multiple Myeloma,7/7/14 12:28
1847,100,Takeda,Large Pharma,594,Velcade,bortezomib,Small Molecule (Chemical),Launched,Corporate Acquisition,May-03,,Jan-22,N/A,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1366,Multiple Myeloma,7/7/14 12:28
1847,100,Takeda,Large Pharma,594,Velcade,bortezomib,Small Molecule (Chemical),Launched,Corporate Acquisition,May-03,,Jan-22,N/A,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1366,Multiple Myeloma,7/7/14 12:28
1847,100,Takeda,Large Pharma,594,Velcade,bortezomib,Small Molecule (Chemical),Launched,Corporate Acquisition,May-03,,Jan-22,N/A,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,US,Sales,497.7245978,592.9799577,735.6424685,877.6241947,963.2771703,1067.718972,1153.36192,1212.570352,1177.662946,1154.622724,1081.498633,1063.304233,1.421367438,1366,Multiple Myeloma,7/7/14 12:28
1848,34,Daiichi-Sankyo,Regional & Specialty Pharma,1525,Venofer,iron sucrose,Small Molecule (Chemical),Launched,Licensed (Development),Jan-01,,N/A,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1246,Iron-deficiency Anemia,7/7/14 12:28
1848,34,Daiichi-Sankyo,Regional & Specialty Pharma,1525,Venofer,iron sucrose,Small Molecule (Chemical),Launched,Licensed (Development),Jan-01,,N/A,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,Global,Sales,346.8989621,358.3559981,314.0091776,284.1142798,232.8830927,229.4205992,227.5014535,226.3103785,225.6056303,225.1803072,224.9257319,224.7728321,-0.505095608,1246,Iron-deficiency Anemia,7/7/14 12:28
1848,34,Daiichi-Sankyo,Regional & Specialty Pharma,1525,Venofer,iron sucrose,Small Molecule (Chemical),Launched,Licensed (Development),Jan-01,,N/A,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1246,Iron-deficiency Anemia,7/7/14 12:28
1848,34,Daiichi-Sankyo,Regional & Specialty Pharma,1525,Venofer,iron sucrose,Small Molecule (Chemical),Launched,Licensed (Development),Jan-01,,N/A,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1246,Iron-deficiency Anemia,7/7/14 12:28
1848,34,Daiichi-Sankyo,Regional & Specialty Pharma,1525,Venofer,iron sucrose,Small Molecule (Chemical),Launched,Licensed (Development),Jan-01,,N/A,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1246,Iron-deficiency Anemia,7/7/14 12:28
1848,34,Daiichi-Sankyo,Regional & Specialty Pharma,1525,Venofer,iron sucrose,Small Molecule (Chemical),Launched,Licensed (Development),Jan-01,,N/A,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,US,Sales,346.8989621,358.3559981,314.0091776,284.1142798,232.8830927,229.4205992,227.5014535,226.3103785,225.6056303,225.1803072,224.9257319,224.7728321,-0.505095608,1246,Iron-deficiency Anemia,7/7/14 12:28
1850,5,Actelion,Small Biotech,455,Ventavis,iloprost,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-05,,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,Global,Sales,126.1490769,113.837343,119.8437751,117.527131,118.7035415,112.2288029,103.5958181,93.88371013,85.89819915,76.96305985,68.09698441,59.55550921,-9.383274102,1248,Pulmonary Hypertension,7/7/14 12:28
1850,5,Actelion,Small Biotech,455,Ventavis,iloprost,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-05,,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1248,Pulmonary Hypertension,7/7/14 12:28
1850,5,Actelion,Small Biotech,455,Ventavis,iloprost,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-05,,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,US,Sales,126.1490769,113.837343,119.8437751,117.527131,118.7035415,112.2288029,103.5958181,93.88371013,85.89819915,76.96305985,68.09698441,59.55550921,-9.383274102,1248,Pulmonary Hypertension,7/7/14 12:28
1851,46,GlaxoSmithKline,Large Pharma,1674,Ventolin range,salbutamol,Small Molecule (Chemical),Launched,In-House,May-81,Jan-69,Expired,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1249,Asthma,7/7/14 12:28
1851,46,GlaxoSmithKline,Large Pharma,1674,Ventolin range,salbutamol,Small Molecule (Chemical),Launched,In-House,May-81,Jan-69,Expired,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,Global,Sales,743.7678259,806.4900302,965.1147877,1000.153219,1003.711806,1027.225553,1038.913636,1046.256992,1051.539284,1054.460176,1056.159053,1057.060825,0.742561472,1249,Asthma,7/7/14 12:28
1851,46,GlaxoSmithKline,Large Pharma,1674,Ventolin range,salbutamol,Small Molecule (Chemical),Launched,In-House,May-81,Jan-69,Expired,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1249,Asthma,7/7/14 12:28
1851,46,GlaxoSmithKline,Large Pharma,1674,Ventolin range,salbutamol,Small Molecule (Chemical),Launched,In-House,May-81,Jan-69,Expired,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,505.2007874,529.9350199,581.9545979,561.1002214,548.7583238,548.5081776,545.0311449,542.829858,541.074832,539.2881875,537.8001176,536.4952908,-0.322341163,1249,Asthma,7/7/14 12:28
1851,46,GlaxoSmithKline,Large Pharma,1674,Ventolin range,salbutamol,Small Molecule (Chemical),Launched,In-House,May-81,Jan-69,Expired,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1249,Asthma,7/7/14 12:28
1851,46,GlaxoSmithKline,Large Pharma,1674,Ventolin range,salbutamol,Small Molecule (Chemical),Launched,In-House,May-81,Jan-69,Expired,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,4,US,Sales,238.5670385,276.5550104,383.1601898,439.0529981,454.9534822,478.7173754,493.8824915,503.4271342,510.4644516,515.1719889,518.3589352,520.5655341,1.9432176,1249,Asthma,7/7/14 12:28
1852,46,GlaxoSmithKline,Large Pharma,20,Veramyst,fluticasone furoate,Small Molecule (Chemical),Launched,In-House,Jun-07,Mar-08,Aug-21,Jun-23,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1700,Allergic Rhinitis,7/7/14 12:28
1852,46,GlaxoSmithKline,Large Pharma,20,Veramyst,fluticasone furoate,Small Molecule (Chemical),Launched,In-House,Jun-07,Mar-08,Aug-21,Jun-23,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,4,Global,Sales,221.4151599,298.9253234,386.3665512,389.917103,389.290093,429.3855274,448.0432532,464.2378921,477.4536557,492.3504166,505.7000754,516.3018486,4.116269969,1700,Allergic Rhinitis,7/7/14 12:28
1852,46,GlaxoSmithKline,Large Pharma,20,Veramyst,fluticasone furoate,Small Molecule (Chemical),Launched,In-House,Jun-07,Mar-08,Aug-21,Jun-23,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1700,Allergic Rhinitis,7/7/14 12:28
1852,46,GlaxoSmithKline,Large Pharma,20,Veramyst,fluticasone furoate,Small Molecule (Chemical),Launched,In-House,Jun-07,Mar-08,Aug-21,Jun-23,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,4,ROW,Sales,115.385365,191.5800072,286.9693472,296.4003994,323.6267038,358.3907349,382.0814939,405.1886391,425.1818591,442.5153835,457.9443092,470.5876224,5.494057934,1700,Allergic Rhinitis,7/7/14 12:28
1852,46,GlaxoSmithKline,Large Pharma,20,Veramyst,fluticasone furoate,Small Molecule (Chemical),Launched,In-House,Jun-07,Mar-08,Aug-21,Jun-23,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1700,Allergic Rhinitis,7/7/14 12:28
1852,46,GlaxoSmithKline,Large Pharma,20,Veramyst,fluticasone furoate,Small Molecule (Chemical),Launched,In-House,Jun-07,Mar-08,Aug-21,Jun-23,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,4,US,Sales,106.0297949,107.3453163,99.39720405,93.51670356,65.66338918,70.99479251,65.96175935,59.049253,52.27179651,49.83503312,47.75576616,45.71422618,-5.041771279,1700,Allergic Rhinitis,7/7/14 12:28
1853,15,Astellas Pharma,Regional & Specialty Pharma,595,Vesicare,solifenacin,Small Molecule (Chemical),Launched,In-House,Jan-05,Aug-04,Dec-18,Dec-15,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1640,Overactive bladder,7/7/14 12:28
1853,15,Astellas Pharma,Regional & Specialty Pharma,595,Vesicare,solifenacin,Small Molecule (Chemical),Launched,In-House,Jan-05,Aug-04,Dec-18,Dec-15,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,Global,Sales,882.3299688,1012.034692,1225.648725,1329.325183,1308.803892,1240.343381,1212.646806,752.8920459,682.3764661,549.4563424,180.8392398,114.6112867,-29.38325499,1640,Overactive bladder,7/7/14 12:28
1853,15,Astellas Pharma,Regional & Specialty Pharma,595,Vesicare,solifenacin,Small Molecule (Chemical),Launched,In-House,Jan-05,Aug-04,Dec-18,Dec-15,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1640,Overactive bladder,7/7/14 12:28
1853,15,Astellas Pharma,Regional & Specialty Pharma,595,Vesicare,solifenacin,Small Molecule (Chemical),Launched,In-House,Jan-05,Aug-04,Dec-18,Dec-15,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,ROW,Sales,504.1885536,594.1472411,733.1101364,763.5043716,755.0791684,684.6051127,641.8069552,216.4177972,171.4450466,125.8740236,87.74285842,76.60928905,-27.8823744,1640,Overactive bladder,7/7/14 12:28
1853,15,Astellas Pharma,Regional & Specialty Pharma,595,Vesicare,solifenacin,Small Molecule (Chemical),Launched,In-House,Jan-05,Aug-04,Dec-18,Dec-15,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1640,Overactive bladder,7/7/14 12:28
1853,15,Astellas Pharma,Regional & Specialty Pharma,595,Vesicare,solifenacin,Small Molecule (Chemical),Launched,In-House,Jan-05,Aug-04,Dec-18,Dec-15,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,US,Sales,378.1414152,417.8874505,492.538589,565.8208114,553.7247235,555.7382679,570.8398513,536.4742487,510.9314195,423.5823187,93.09638143,38.00199765,-31.79948284,1640,Overactive bladder,7/7/14 12:28
1854,46,GlaxoSmithKline,Large Pharma,595,Vesicare,solifenacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-05,,Dec-18,N/A,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,4,Global,Alliance Revenue,162.1632157,176.1300066,202.0007695,277.3800529,0,0,0,0,0,0,0,0,0,1640,Overactive bladder,7/7/14 12:28
1854,46,GlaxoSmithKline,Large Pharma,595,Vesicare,solifenacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-05,,Dec-18,N/A,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1640,Overactive bladder,7/7/14 12:28
1854,46,GlaxoSmithKline,Large Pharma,595,Vesicare,solifenacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-05,,Dec-18,N/A,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,4,ROW,Alliance Revenue,0,1.545000058,0,1.585028874,0,0,0,0,0,0,0,0,0,1640,Overactive bladder,7/7/14 12:28
1854,46,GlaxoSmithKline,Large Pharma,595,Vesicare,solifenacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-05,,Dec-18,N/A,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1640,Overactive bladder,7/7/14 12:28
1854,46,GlaxoSmithKline,Large Pharma,595,Vesicare,solifenacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-05,,Dec-18,N/A,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,4,US,Alliance Revenue,162.1632157,174.5850065,202.0007695,275.7950241,0,0,0,0,0,0,0,0,0,1640,Overactive bladder,7/7/14 12:28
1854,46,GlaxoSmithKline,Large Pharma,595,Vesicare,solifenacin,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-05,,Dec-18,N/A,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1640,Overactive bladder,7/7/14 12:28
1855,76,Pfizer,Large Pharma,1235,Vfend,voriconazole,Small Molecule (Chemical),Launched,In-House,Jul-02,Jul-02,Feb-11,Feb-16,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1251,,7/7/14 12:28
1855,76,Pfizer,Large Pharma,1235,Vfend,voriconazole,Small Molecule (Chemical),Launched,In-House,Jul-02,Jul-02,Feb-11,Feb-16,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,798,825,747,754,775,787,794.8,562.21014,419.72376,346.322642,297.1676355,259.7668527,-14.45724857,1251,,7/7/14 12:28
1855,76,Pfizer,Large Pharma,1235,Vfend,voriconazole,Small Molecule (Chemical),Launched,In-House,Jul-02,Jul-02,Feb-11,Feb-16,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1251,,7/7/14 12:28
1855,76,Pfizer,Large Pharma,1235,Vfend,voriconazole,Small Molecule (Chemical),Launched,In-House,Jul-02,Jul-02,Feb-11,Feb-16,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,548,565,661,665,714,731,745.4,515.13014,374.42776,301.847442,253.2133955,216.0809647,-15.69651167,1251,,7/7/14 12:28
1855,76,Pfizer,Large Pharma,1235,Vfend,voriconazole,Small Molecule (Chemical),Launched,In-House,Jul-02,Jul-02,Feb-11,Feb-16,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1251,,7/7/14 12:28
1855,76,Pfizer,Large Pharma,1235,Vfend,voriconazole,Small Molecule (Chemical),Launched,In-House,Jul-02,Jul-02,Feb-11,Feb-16,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Sales,250,260,86,89,61,56,49.4,47.08,45.296,44.4752,43.95424,43.685888,-4.657320308,1251,,7/7/14 12:28
1857,76,Pfizer,Large Pharma,75,Viagra,sildenafil,Small Molecule (Chemical),Launched,In-House,Apr-98,Apr-98,Dec-17,Jun-13,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1632,Erectile dysfunction,7/7/14 12:28
1857,76,Pfizer,Large Pharma,75,Viagra,sildenafil,Small Molecule (Chemical),Launched,In-House,Apr-98,Apr-98,Dec-17,Jun-13,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,Global,Sales,1892,1928,1981,2051,1881,1588.15,1511.9375,1459.106875,1381.648609,1151.829747,319.429448,177.612593,-28.61882181,1632,Erectile dysfunction,7/7/14 12:28
1857,76,Pfizer,Large Pharma,75,Viagra,sildenafil,Small Molecule (Chemical),Launched,In-House,Apr-98,Apr-98,Dec-17,Jun-13,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1632,Erectile dysfunction,7/7/14 12:28
1857,76,Pfizer,Large Pharma,75,Viagra,sildenafil,Small Molecule (Chemical),Launched,In-House,Apr-98,Apr-98,Dec-17,Jun-13,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,ROW,Sales,930,936,978,916,749,436,342,282,215.82,165.29332,99.12,58.324392,-30.55768094,1632,Erectile dysfunction,7/7/14 12:28
1857,76,Pfizer,Large Pharma,75,Viagra,sildenafil,Small Molecule (Chemical),Launched,In-House,Apr-98,Apr-98,Dec-17,Jun-13,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1632,Erectile dysfunction,7/7/14 12:28
1857,76,Pfizer,Large Pharma,75,Viagra,sildenafil,Small Molecule (Chemical),Launched,In-House,Apr-98,Apr-98,Dec-17,Jun-13,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,US,Sales,962,992,1003,1135,1132,1152.15,1169.9375,1177.106875,1165.828609,986.5364273,220.309448,119.288201,-27.49079417,1632,Erectile dysfunction,7/7/14 12:28
1858,20,Biodel,Small Biotech,3139,Linjeta,recombinant insulin,Recombinant Protein,Phase III,In-House,,,Jan-26,Mar-25,83,Insulins,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1253,Diabetes,7/7/14 12:28
1858,20,Biodel,Small Biotech,3139,Linjeta,recombinant insulin,Recombinant Protein,Phase III,In-House,,,Jan-26,Mar-25,83,Insulins,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1253,Diabetes,7/7/14 12:28
1858,20,Biodel,Small Biotech,3139,Linjeta,recombinant insulin,Recombinant Protein,Phase III,In-House,,,Jan-26,Mar-25,83,Insulins,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1253,Diabetes,7/7/14 12:28
1858,20,Biodel,Small Biotech,3139,Linjeta,recombinant insulin,Recombinant Protein,Phase III,In-House,,,Jan-26,Mar-25,83,Insulins,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1253,Diabetes,7/7/14 12:28
1858,20,Biodel,Small Biotech,3139,Linjeta,recombinant insulin,Recombinant Protein,Phase III,In-House,,,Jan-26,Mar-25,83,Insulins,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1253,Diabetes,7/7/14 12:28
1858,20,Biodel,Small Biotech,3139,Linjeta,recombinant insulin,Recombinant Protein,Phase III,In-House,,,Jan-26,Mar-25,83,Insulins,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1253,Diabetes,7/7/14 12:28
1859,15,Astellas Pharma,Regional & Specialty Pharma,1296,Vibativ,telavancin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-09,Nov-11,Aug-22,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1254,cSSSIs HAP,7/7/14 12:28
1859,15,Astellas Pharma,Regional & Specialty Pharma,1296,Vibativ,telavancin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-09,Nov-11,Aug-22,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,4.309303877,13.79552283,18.80005939,1.255797599,0,0,0,0,0,0,0,0,0,1254,cSSSIs HAP,7/7/14 12:28
1859,15,Astellas Pharma,Regional & Specialty Pharma,1296,Vibativ,telavancin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-09,Nov-11,Aug-22,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1254,cSSSIs HAP,7/7/14 12:28
1859,15,Astellas Pharma,Regional & Specialty Pharma,1296,Vibativ,telavancin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-09,Nov-11,Aug-22,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,5.232494181,0,0,0,0,0,0,0,0,0,0,1254,cSSSIs HAP,7/7/14 12:28
1859,15,Astellas Pharma,Regional & Specialty Pharma,1296,Vibativ,telavancin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-09,Nov-11,Aug-22,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1254,cSSSIs HAP,7/7/14 12:28
1859,15,Astellas Pharma,Regional & Specialty Pharma,1296,Vibativ,telavancin,Small Molecule (Chemical),Launched,Licensed (Development),Nov-09,Nov-11,Aug-22,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,4.309303877,13.79552283,13.56756521,1.255797599,0,0,0,0,0,0,0,0,0,1254,cSSSIs HAP,7/7/14 12:28
1860,1,Abbott,Regional & Specialty Pharma,1254,Vicodin / Vicoprofen,hydrocodone  +  acetaminophen / hydrocodone  +  ibuprofen,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-78,Aug-78,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1255,Pain,7/7/14 12:28
1860,1,Abbott,Regional & Specialty Pharma,1254,Vicodin / Vicoprofen,hydrocodone  +  acetaminophen / hydrocodone  +  ibuprofen,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-78,Aug-78,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,88.72,82.768,79.32,81.2872,0,0,0,0,0,0,0,0,0,1255,Pain,7/7/14 12:28
1860,1,Abbott,Regional & Specialty Pharma,1254,Vicodin / Vicoprofen,hydrocodone  +  acetaminophen / hydrocodone  +  ibuprofen,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-78,Aug-78,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1255,Pain,7/7/14 12:28
1860,1,Abbott,Regional & Specialty Pharma,1254,Vicodin / Vicoprofen,hydrocodone  +  acetaminophen / hydrocodone  +  ibuprofen,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-78,Aug-78,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,68.72,72.768,76.32,78.2872,0,0,0,0,0,0,0,0,0,1255,Pain,7/7/14 12:28
1860,1,Abbott,Regional & Specialty Pharma,1254,Vicodin / Vicoprofen,hydrocodone  +  acetaminophen / hydrocodone  +  ibuprofen,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-78,Aug-78,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1255,Pain,7/7/14 12:28
1860,1,Abbott,Regional & Specialty Pharma,1254,Vicodin / Vicoprofen,hydrocodone  +  acetaminophen / hydrocodone  +  ibuprofen,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-78,Aug-78,Expired,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,20,10,3,3,0,0,0,0,0,0,0,0,0,1255,Pain,7/7/14 12:28
1863,68,Novo Nordisk,Regional & Specialty Pharma,1556,Victoza,liraglutide,Synthetic Peptide,Launched,Licensed (Development),Jan-10,Jul-09,Jul-22,Jul-17,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1257,Type II Diabetes,7/7/14 12:28
1863,68,Novo Nordisk,Regional & Specialty Pharma,1556,Victoza,liraglutide,Synthetic Peptide,Launched,Licensed (Development),Jan-10,Jul-09,Jul-22,Jul-17,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,Global,Sales,9.330098899,412.1364123,1118.073278,1639.618355,2071.523014,2353.254061,2564.516866,2713.216289,2823.055497,2816.799153,2815.076581,2706.581451,3.893929996,1257,Type II Diabetes,7/7/14 12:28
1863,68,Novo Nordisk,Regional & Specialty Pharma,1556,Victoza,liraglutide,Synthetic Peptide,Launched,Licensed (Development),Jan-10,Jul-09,Jul-22,Jul-17,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1257,Type II Diabetes,7/7/14 12:28
1863,68,Novo Nordisk,Regional & Specialty Pharma,1556,Victoza,liraglutide,Synthetic Peptide,Launched,Licensed (Development),Jan-10,Jul-09,Jul-22,Jul-17,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,ROW,Sales,9.330098899,165.95739,459.2853177,666.8287791,796.5204539,915.9023626,1008.350421,1075.819849,1131.294433,1139.263505,1147.72192,1111.225075,4.871589572,1257,Type II Diabetes,7/7/14 12:28
1863,68,Novo Nordisk,Regional & Specialty Pharma,1556,Victoza,liraglutide,Synthetic Peptide,Launched,Licensed (Development),Jan-10,Jul-09,Jul-22,Jul-17,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1257,Type II Diabetes,7/7/14 12:28
1863,68,Novo Nordisk,Regional & Specialty Pharma,1556,Victoza,liraglutide,Synthetic Peptide,Launched,Licensed (Development),Jan-10,Jul-09,Jul-22,Jul-17,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,US,Sales,0,246.1790223,658.7879608,972.7895757,1275.00256,1437.351699,1556.166445,1637.396439,1691.761064,1677.535648,1667.354661,1595.356376,3.253944416,1257,Type II Diabetes,7/7/14 12:28
1864,26,Celgene,Regional & Specialty Pharma,217,Vidaza,azacitidine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Jan-09,Oct-13,Dec-18,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1354,Myelodysplastic Syndrome,7/7/14 12:28
1864,26,Celgene,Regional & Specialty Pharma,217,Vidaza,azacitidine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Jan-09,Oct-13,Dec-18,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,Global,Sales,387,533.7,705.9,823,803,650.72275,681.0520062,707.4018055,734.08183,743.5563595,449.8655823,398.0791968,-9.538269435,1354,Myelodysplastic Syndrome,7/7/14 12:28
1864,26,Celgene,Regional & Specialty Pharma,217,Vidaza,azacitidine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Jan-09,Oct-13,Dec-18,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1354,Myelodysplastic Syndrome,7/7/14 12:28
1864,26,Celgene,Regional & Specialty Pharma,217,Vidaza,azacitidine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Jan-09,Oct-13,Dec-18,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,ROW,Sales,127,271.25,401.45,496,528,566.72275,623.0520062,670.2018055,713.52183,724.5563595,432.1135823,381.3255968,-4.542757969,1354,Myelodysplastic Syndrome,7/7/14 12:28
1864,26,Celgene,Regional & Specialty Pharma,217,Vidaza,azacitidine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Jan-09,Oct-13,Dec-18,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1354,Myelodysplastic Syndrome,7/7/14 12:28
1864,26,Celgene,Regional & Specialty Pharma,217,Vidaza,azacitidine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Jan-09,Oct-13,Dec-18,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,US,Sales,260,262.45,304.45,327,275,84,58,37.2,20.56,19,17.752,16.7536,-32.95032668,1354,Myelodysplastic Syndrome,7/7/14 12:28
1865,42,Forest,Regional & Specialty Pharma,3446,Viibryd,vilazodone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-11,,Jan-16,,127,Serotonergics,49,Depression,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1258,Depression,7/7/14 12:28
1865,42,Forest,Regional & Specialty Pharma,3446,Viibryd,vilazodone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-11,,Jan-16,,127,Serotonergics,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,56.4,162.5,201,260,291.135,311.61875,327.3099375,337.4187969,344.3480648,349.1658295,8.208706466,1258,Depression,7/7/14 12:28
1865,42,Forest,Regional & Specialty Pharma,3446,Viibryd,vilazodone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-11,,Jan-16,,127,Serotonergics,49,Depression,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1258,Depression,7/7/14 12:28
1865,42,Forest,Regional & Specialty Pharma,3446,Viibryd,vilazodone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-11,,Jan-16,,127,Serotonergics,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1258,Depression,7/7/14 12:28
1865,42,Forest,Regional & Specialty Pharma,3446,Viibryd,vilazodone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-11,,Jan-16,,127,Serotonergics,49,Depression,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1258,Depression,7/7/14 12:28
1865,42,Forest,Regional & Specialty Pharma,3446,Viibryd,vilazodone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-11,,Jan-16,,127,Serotonergics,49,Depression,12,Central Nervous System,6,US,Sales,0,0,56.4,162.5,201,260,291.135,311.61875,327.3099375,337.4187969,344.3480648,349.1658295,8.208706466,1258,Depression,7/7/14 12:28
1866,105,UCB,Regional & Specialty Pharma,247,Vimpat,lacosamide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-09,Sep-08,Mar-22,Mar-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1506,Epilepsy,7/7/14 12:28
1866,105,UCB,Regional & Specialty Pharma,247,Vimpat,lacosamide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-09,Sep-08,Mar-22,Mar-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,Global,Sales,63.91692652,176.1923897,303.1152742,429.2806229,545.8203574,641.7572494,729.3222399,803.7344207,869.8647934,928.1862644,979.2920911,1024.312434,9.409399545,1506,Epilepsy,7/7/14 12:28
1866,105,UCB,Regional & Specialty Pharma,247,Vimpat,lacosamide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-09,Sep-08,Mar-22,Mar-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1506,Epilepsy,7/7/14 12:28
1866,105,UCB,Regional & Specialty Pharma,247,Vimpat,lacosamide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-09,Sep-08,Mar-22,Mar-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,ROW,Sales,22.23197444,49.01592797,83.42622225,106.6775201,128.8189165,148.4737615,165.6850311,180.2614891,193.3675523,204.8621306,214.9376504,223.8235272,8.211924776,1506,Epilepsy,7/7/14 12:28
1866,105,UCB,Regional & Specialty Pharma,247,Vimpat,lacosamide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-09,Sep-08,Mar-22,Mar-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1506,Epilepsy,7/7/14 12:28
1866,105,UCB,Regional & Specialty Pharma,247,Vimpat,lacosamide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-09,Sep-08,Mar-22,Mar-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,2,US,Sales,41.68495208,127.1764618,219.6890519,322.6031029,417.0014409,493.283488,563.6372088,623.4729315,676.4972411,723.3241338,764.3544407,800.4889073,9.763927908,1506,Epilepsy,7/7/14 12:28
1869,23,Boehringer Ingelheim,Large Pharma,1127,Viramune,nevirapine,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-98,May-12,Dec-12,91,NNRTIs,32,HIV,7,Anti-infectives,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1260,HIV,7/7/14 12:28
1869,23,Boehringer Ingelheim,Large Pharma,1127,Viramune,nevirapine,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-98,May-12,Dec-12,91,NNRTIs,32,HIV,7,Anti-infectives,2,Global,Sales,289.0156678,244.2887612,230.1548715,122.0043806,78.30546539,54.42657107,42.48712391,36.51740033,33.53253854,32.04010765,31.2938922,30.92078448,-12.43082428,1260,HIV,7/7/14 12:28
1869,23,Boehringer Ingelheim,Large Pharma,1127,Viramune,nevirapine,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-98,May-12,Dec-12,91,NNRTIs,32,HIV,7,Anti-infectives,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1260,HIV,7/7/14 12:28
1869,23,Boehringer Ingelheim,Large Pharma,1127,Viramune,nevirapine,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-98,May-12,Dec-12,91,NNRTIs,32,HIV,7,Anti-infectives,2,ROW,Sales,147.2868307,127.1764618,125.1393334,70.68992294,49.24954636,37.35349272,31.4054659,28.43145249,26.94444579,26.20094243,25.82919076,25.64331492,-8.901690815,1260,HIV,7/7/14 12:28
1869,23,Boehringer Ingelheim,Large Pharma,1127,Viramune,nevirapine,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-98,May-12,Dec-12,91,NNRTIs,32,HIV,7,Anti-infectives,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1260,HIV,7/7/14 12:28
1869,23,Boehringer Ingelheim,Large Pharma,1127,Viramune,nevirapine,Small Molecule (Chemical),Launched,In-House,Jul-96,Jul-98,May-12,Dec-12,91,NNRTIs,32,HIV,7,Anti-infectives,2,US,Sales,141.7288371,117.1122995,105.0155381,51.3144577,29.05591903,17.07307835,11.08165801,8.085947842,6.588092757,5.839165215,5.464701444,5.277469558,-21.62631521,1260,HIV,7/7/14 12:28
1870,45,Gilead,Regional & Specialty Pharma,1515,Viread,tenofovir,Small Molecule (Chemical),Launched,Licensed (Development),Nov-01,Nov-01,Dec-17,Jul-18,104,NRTIs,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1261,HIV and Hepatitis B,7/7/14 12:28
1870,45,Gilead,Regional & Specialty Pharma,1515,Viread,tenofovir,Small Molecule (Chemical),Launched,Licensed (Development),Nov-01,Nov-01,Dec-17,Jul-18,104,NRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,668,732.24,737.87,848.7,959,972,979,981,963.6183075,593.1254093,370.2845647,293.047089,-15.57994766,1261,HIV and Hepatitis B,7/7/14 12:28
1870,45,Gilead,Regional & Specialty Pharma,1515,Viread,tenofovir,Small Molecule (Chemical),Launched,Licensed (Development),Nov-01,Nov-01,Dec-17,Jul-18,104,NRTIs,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1261,HIV and Hepatitis B,7/7/14 12:28
1870,45,Gilead,Regional & Specialty Pharma,1515,Viread,tenofovir,Small Molecule (Chemical),Launched,Licensed (Development),Nov-01,Nov-01,Dec-17,Jul-18,104,NRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,378,412.45,413.13,460.77,531,541,547,550,551.59,455.7782625,269.820995,215.729844,-12.07414793,1261,HIV and Hepatitis B,7/7/14 12:28
1870,45,Gilead,Regional & Specialty Pharma,1515,Viread,tenofovir,Small Molecule (Chemical),Launched,Licensed (Development),Nov-01,Nov-01,Dec-17,Jul-18,104,NRTIs,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1261,HIV and Hepatitis B,7/7/14 12:28
1870,45,Gilead,Regional & Specialty Pharma,1515,Viread,tenofovir,Small Molecule (Chemical),Launched,Licensed (Development),Nov-01,Nov-01,Dec-17,Jul-18,104,NRTIs,32,HIV,7,Anti-infectives,6,US,Sales,290,319.79,324.74,387.93,428,431,432,431,412.0283075,137.3471468,100.4635697,77.317245,-21.68709488,1261,HIV and Hepatitis B,7/7/14 12:28
1871,19,Bayer,Large Pharma,704,Visanne,progestogen dienogest,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-10,N/A,Mar-27,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1262,Endometriosis,7/7/14 12:28
1871,19,Bayer,Large Pharma,704,Visanne,progestogen dienogest,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-10,N/A,Mar-27,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,2,Global,Sales,0,21.19289508,67.45340015,95.30965193,116.0290172,129.842404,139.3334924,145.5331304,149.8880419,152.8558243,154.8709704,156.2554154,4.343861548,1262,Endometriosis,7/7/14 12:28
1871,19,Bayer,Large Pharma,704,Visanne,progestogen dienogest,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-10,N/A,Mar-27,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1262,Endometriosis,7/7/14 12:28
1871,19,Bayer,Large Pharma,704,Visanne,progestogen dienogest,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-10,N/A,Mar-27,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,2,ROW,Sales,0,21.19289508,67.45340015,95.30965193,116.0290172,129.842404,139.3334924,145.5331304,149.8880419,152.8558243,154.8709704,156.2554154,4.343861548,1262,Endometriosis,7/7/14 12:28
1871,19,Bayer,Large Pharma,704,Visanne,progestogen dienogest,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-10,N/A,Mar-27,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1262,Endometriosis,7/7/14 12:28
1871,19,Bayer,Large Pharma,704,Visanne,progestogen dienogest,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-10,N/A,Mar-27,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1262,Endometriosis,7/7/14 12:28
1872,67,Novartis,Large Pharma,559,Visudyne,verteporfin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-00,Mar-00,N/A,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1263,AMD,7/7/14 12:28
1872,67,Novartis,Large Pharma,559,Visudyne,verteporfin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-00,Mar-00,N/A,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Sales,105.657,68,69.3,68,67.09,66.453,66.0071,65.69497,65.476479,65.3235353,65.21647471,65.1415323,-0.420152727,1263,AMD,7/7/14 12:28
1872,67,Novartis,Large Pharma,559,Visudyne,verteporfin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-00,Mar-00,N/A,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1263,AMD,7/7/14 12:28
1872,67,Novartis,Large Pharma,559,Visudyne,verteporfin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-00,Mar-00,N/A,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Sales,74.848,68,69.3,68,67.09,66.453,66.0071,65.69497,65.476479,65.3235353,65.21647471,65.1415323,-0.420152727,1263,AMD,7/7/14 12:28
1872,67,Novartis,Large Pharma,559,Visudyne,verteporfin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-00,Mar-00,N/A,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1263,AMD,7/7/14 12:28
1872,67,Novartis,Large Pharma,559,Visudyne,verteporfin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-00,Mar-00,N/A,N/A,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Sales,30.809,0,0,0,0,0,0,0,0,0,0,0,0,1263,AMD,7/7/14 12:28
1873,76,Pfizer,Large Pharma,3664,Viviant,bazedoxifene,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Feb-10,N/A,N/A,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,328,Osteoporosis ,7/7/14 12:28
1873,76,Pfizer,Large Pharma,3664,Viviant,bazedoxifene,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Feb-10,N/A,N/A,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,328,Osteoporosis ,7/7/14 12:28
1873,76,Pfizer,Large Pharma,3664,Viviant,bazedoxifene,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Feb-10,N/A,N/A,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,328,Osteoporosis ,7/7/14 12:28
1873,76,Pfizer,Large Pharma,3664,Viviant,bazedoxifene,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Feb-10,N/A,N/A,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,328,Osteoporosis ,7/7/14 12:28
1873,76,Pfizer,Large Pharma,3664,Viviant,bazedoxifene,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Feb-10,N/A,N/A,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,328,Osteoporosis ,7/7/14 12:28
1873,76,Pfizer,Large Pharma,3664,Viviant,bazedoxifene,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-11,Feb-10,N/A,N/A,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,328,Osteoporosis ,7/7/14 12:28
1874,788,Alkermes,Small Biotech,1289,Vivitrol,naltrexone depot,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,,May-17,N/A,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,Global,Sales,20.2,28.9,41.2,58,77,90.6,103.288,114.6672,82.25484,41.92971552,32.08973123,22.1163936,-16.32351149,1264,Alcohol Addiction,7/7/14 12:28
1874,788,Alkermes,Small Biotech,1289,Vivitrol,naltrexone depot,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,,May-17,N/A,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1264,Alcohol Addiction,7/7/14 12:28
1874,788,Alkermes,Small Biotech,1289,Vivitrol,naltrexone depot,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-06,,May-17,N/A,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,US,Sales,20.2,28.9,41.2,58,77,90.6,103.288,114.6672,82.25484,41.92971552,32.08973123,22.1163936,-16.32351149,1264,Alcohol Addiction,7/7/14 12:28
1875,46,GlaxoSmithKline,Large Pharma,922,Volibris,ambrisentan,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-08,N/A,Jun-18,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1339,Pulmonary Hypertension,7/7/14 12:28
1875,46,GlaxoSmithKline,Large Pharma,922,Volibris,ambrisentan,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-08,N/A,Jun-18,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,4,Global,Sales,29.6259721,71.07000267,155.5085289,201.298667,229.8218621,237.0454603,245.6472392,263.6919138,282.7139148,244.5087657,141.5880565,107.5449185,-10.2807664,1339,Pulmonary Hypertension,7/7/14 12:28
1875,46,GlaxoSmithKline,Large Pharma,922,Volibris,ambrisentan,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-08,N/A,Jun-18,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1339,Pulmonary Hypertension,7/7/14 12:28
1875,46,GlaxoSmithKline,Large Pharma,922,Volibris,ambrisentan,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-08,N/A,Jun-18,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,4,ROW,Sales,29.6259721,71.07000267,155.5085289,201.298667,229.8218621,237.0454603,245.6472392,263.6919138,282.7139148,244.5087657,141.5880565,107.5449185,-10.2807664,1339,Pulmonary Hypertension,7/7/14 12:28
1875,46,GlaxoSmithKline,Large Pharma,922,Volibris,ambrisentan,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-08,N/A,Jun-18,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1339,Pulmonary Hypertension,7/7/14 12:28
1875,46,GlaxoSmithKline,Large Pharma,922,Volibris,ambrisentan,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-08,N/A,Jun-18,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1339,Pulmonary Hypertension,7/7/14 12:28
1877,40,Endo Health Solutions,Regional & Specialty Pharma,2325,Voltaren Gel,diclofenac sodium gel,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-08,,Jun-14,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1266,Osteoarthritis Pain,7/7/14 12:28
1877,40,Endo Health Solutions,Regional & Specialty Pharma,2325,Voltaren Gel,diclofenac sodium gel,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-08,,Jun-14,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,79,104.94,142.7,117.6,171,144.61413,71.9055225,55.3895163,45.69683628,38.54103444,33.09919571,29.18408011,-22.32035395,1266,Osteoarthritis Pain,7/7/14 12:28
1877,40,Endo Health Solutions,Regional & Specialty Pharma,2325,Voltaren Gel,diclofenac sodium gel,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-08,,Jun-14,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1266,Osteoarthritis Pain,7/7/14 12:28
1877,40,Endo Health Solutions,Regional & Specialty Pharma,2325,Voltaren Gel,diclofenac sodium gel,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-08,,Jun-14,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1266,Osteoarthritis Pain,7/7/14 12:28
1877,40,Endo Health Solutions,Regional & Specialty Pharma,2325,Voltaren Gel,diclofenac sodium gel,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-08,,Jun-14,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1266,Osteoarthritis Pain,7/7/14 12:28
1877,40,Endo Health Solutions,Regional & Specialty Pharma,2325,Voltaren Gel,diclofenac sodium gel,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-08,,Jun-14,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,79,104.94,142.7,117.6,171,144.61413,71.9055225,55.3895163,45.69683628,38.54103444,33.09919571,29.18408011,-22.32035395,1266,Osteoarthritis Pain,7/7/14 12:28
1878,67,Novartis,Large Pharma,759,Voltaren,diclofenac,Small Molecule (Chemical),Launched,In-House,Jan-88,Jan-73,Expired,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1745,Rheumatoid & Osteoarthritis,7/7/14 12:28
1878,67,Novartis,Large Pharma,759,Voltaren,diclofenac,Small Molecule (Chemical),Launched,In-House,Jan-88,Jan-73,Expired,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,797,795.3,793.71,759,675,651.14475,631.1994563,615.920153,607.5939535,601.8248839,598.0008133,595.5863031,-1.772197996,1745,Rheumatoid & Osteoarthritis,7/7/14 12:28
1878,67,Novartis,Large Pharma,759,Voltaren,diclofenac,Small Molecule (Chemical),Launched,In-House,Jan-88,Jan-73,Expired,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1745,Rheumatoid & Osteoarthritis,7/7/14 12:28
1878,67,Novartis,Large Pharma,759,Voltaren,diclofenac,Small Molecule (Chemical),Launched,In-House,Jan-88,Jan-73,Expired,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,792,791,790.1,758,673,649.4605,629.8001125,614.5486928,606.3444161,600.6700773,596.9131459,594.5634157,-1.754677683,1745,Rheumatoid & Osteoarthritis,7/7/14 12:28
1878,67,Novartis,Large Pharma,759,Voltaren,diclofenac,Small Molecule (Chemical),Launched,In-House,Jan-88,Jan-73,Expired,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1745,Rheumatoid & Osteoarthritis,7/7/14 12:28
1878,67,Novartis,Large Pharma,759,Voltaren,diclofenac,Small Molecule (Chemical),Launched,In-House,Jan-88,Jan-73,Expired,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,5,4.3,3.61,1,2,1.68425,1.39934375,1.371460156,1.249537402,1.154806624,1.087667423,1.022887384,-9.134351362,1745,Rheumatoid & Osteoarthritis,7/7/14 12:28
1879,67,Novartis,Large Pharma,465,AirFluSal,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1737,Asthma,7/7/14 12:28
1879,67,Novartis,Large Pharma,465,AirFluSal,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,29,77.33343,125.6668237,174.0007975,212.6677503,247.4680281,278.4016437,0,1737,Asthma,7/7/14 12:28
1879,67,Novartis,Large Pharma,465,AirFluSal,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1737,Asthma,7/7/14 12:28
1879,67,Novartis,Large Pharma,465,AirFluSal,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,29,77.33343,125.6668237,174.0007975,212.6677503,247.4680281,278.4016437,0,1737,Asthma,7/7/14 12:28
1879,67,Novartis,Large Pharma,465,AirFluSal,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1737,Asthma,7/7/14 12:28
1879,67,Novartis,Large Pharma,465,AirFluSal,salmeterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1737,Asthma,7/7/14 12:28
1880,67,Novartis,Large Pharma,393,VR632,formoterol + budesonide,Small Molecule (Chemical),Phase III,Licensed (Development),,Jul-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1688,Asthma,7/7/14 12:28
1880,67,Novartis,Large Pharma,393,VR632,formoterol + budesonide,Small Molecule (Chemical),Phase III,Licensed (Development),,Jul-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,10.5,38.500035,73.50003182,108.500012,135.3800089,160.1320024,182.0839958,0,1688,Asthma,7/7/14 12:28
1880,67,Novartis,Large Pharma,393,VR632,formoterol + budesonide,Small Molecule (Chemical),Phase III,Licensed (Development),,Jul-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1688,Asthma,7/7/14 12:28
1880,67,Novartis,Large Pharma,393,VR632,formoterol + budesonide,Small Molecule (Chemical),Phase III,Licensed (Development),,Jul-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,10.5,38.500035,73.50003182,108.500012,135.3800089,160.1320024,182.0839958,0,1688,Asthma,7/7/14 12:28
1880,67,Novartis,Large Pharma,393,VR632,formoterol + budesonide,Small Molecule (Chemical),Phase III,Licensed (Development),,Jul-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1688,Asthma,7/7/14 12:28
1880,67,Novartis,Large Pharma,393,VR632,formoterol + budesonide,Small Molecule (Chemical),Phase III,Licensed (Development),,Jul-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1688,Asthma,7/7/14 12:28
1882,61,Merck & Co,Large Pharma,1491,Vytorin,simvastatin + ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Apr-04,Apr-17,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1634,,7/7/14 12:28
1882,61,Merck & Co,Large Pharma,1491,Vytorin,simvastatin + ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Apr-04,Apr-17,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,440.8,2025,1882,1747,1643,1410.7382,1328.682095,1166.934583,863.3101389,382.9447203,295.0249515,207.7106432,-25.58013646,1634,,7/7/14 12:28
1882,61,Merck & Co,Large Pharma,1491,Vytorin,simvastatin + ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Apr-04,Apr-17,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1634,,7/7/14 12:28
1882,61,Merck & Co,Large Pharma,1491,Vytorin,simvastatin + ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Apr-04,Apr-17,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,183,948,994,983,970,971.855,1018.074435,900.3404707,735.5715808,348.2743734,270.8121916,193.4162285,-20.5744432,1634,,7/7/14 12:28
1882,61,Merck & Co,Large Pharma,1491,Vytorin,simvastatin + ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Apr-04,Apr-17,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1634,,7/7/14 12:28
1882,61,Merck & Co,Large Pharma,1491,Vytorin,simvastatin + ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Apr-04,Apr-17,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,257.8,1077,888,764,673,438.8832,310.60766,266.594112,127.7385581,34.6703469,24.21275993,14.29441471,-42.3204511,1634,,7/7/14 12:28
1882,61,Merck / Schering Plough,Large Pharma,1491,Vytorin,simvastatin + ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Apr-04,Apr-17,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Proforma,1671.2,0,0,0,0,0,0,0,0,0,0,0,0,1634,,7/7/14 12:28
1882,61,Merck / Schering Plough,Large Pharma,1491,Vytorin,simvastatin + ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Apr-04,Apr-17,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Proforma,710,0,0,0,0,0,0,0,0,0,0,0,0,1634,,7/7/14 12:28
1882,61,Merck / Schering Plough,Large Pharma,1491,Vytorin,simvastatin + ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Apr-04,Apr-17,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Proforma,961.2,0,0,0,0,0,0,0,0,0,0,0,0,1634,,7/7/14 12:28
1883,96,Shire,Regional & Specialty Pharma,1437,Vyvanse / Elvanse,lisdexamphetamine,Small Molecule (Chemical),Launched,Licensed (Development),Jul-07,Feb-10,Jun-23,Jan-24,121,Stimulants,37,ADHD,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1274,ADHD,7/7/14 12:28
1883,96,Shire,Regional & Specialty Pharma,1437,Vyvanse / Elvanse,lisdexamphetamine,Small Molecule (Chemical),Launched,Licensed (Development),Jul-07,Feb-10,Jun-23,Jan-24,121,Stimulants,37,ADHD,12,Central Nervous System,6,Global,Sales,504.7,634.250003,804.85,1029.9224,1228,1354.113416,1460.00969,1543.372465,1606.834623,1657.383211,1687.706214,1708.539169,4.830942382,1274,ADHD,7/7/14 12:28
1883,96,Shire,Regional & Specialty Pharma,1437,Vyvanse / Elvanse,lisdexamphetamine,Small Molecule (Chemical),Launched,Licensed (Development),Jul-07,Feb-10,Jun-23,Jan-24,121,Stimulants,37,ADHD,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1274,ADHD,7/7/14 12:28
1883,96,Shire,Regional & Specialty Pharma,1437,Vyvanse / Elvanse,lisdexamphetamine,Small Molecule (Chemical),Launched,Licensed (Development),Jul-07,Feb-10,Jun-23,Jan-24,121,Stimulants,37,ADHD,12,Central Nervous System,6,ROW,Sales,0,8.250003,24,42.1224,82,104.8204155,126.4187897,146.9154551,163.9489976,179.1373541,182.9512028,183.8951365,12.22975266,1274,ADHD,7/7/14 12:28
1883,96,Shire,Regional & Specialty Pharma,1437,Vyvanse / Elvanse,lisdexamphetamine,Small Molecule (Chemical),Launched,Licensed (Development),Jul-07,Feb-10,Jun-23,Jan-24,121,Stimulants,37,ADHD,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1274,ADHD,7/7/14 12:28
1883,96,Shire,Regional & Specialty Pharma,1437,Vyvanse / Elvanse,lisdexamphetamine,Small Molecule (Chemical),Launched,Licensed (Development),Jul-07,Feb-10,Jun-23,Jan-24,121,Stimulants,37,ADHD,12,Central Nervous System,6,US,Sales,504.7,626,780.85,987.8,1146,1249.293,1333.5909,1396.45701,1442.885625,1478.245857,1504.755011,1524.644033,4.162635437,1274,ADHD,7/7/14 12:28
1884,34,Daiichi-Sankyo,Regional & Specialty Pharma,1483,Welchol,colesevelam hydrochloride,Small Molecule (Chemical),Launched,Licensed (Development),Sep-00,,Mar-15,Jan-19,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1276,Dyslipidemia,7/7/14 12:28
1884,34,Daiichi-Sankyo,Regional & Specialty Pharma,1483,Welchol,colesevelam hydrochloride,Small Molecule (Chemical),Launched,Licensed (Development),Sep-00,,Mar-15,Jan-19,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,Global,Sales,296.2646415,332.6757637,340.5986644,398.4823161,432.9120565,486.0092233,137.3514364,28.18819115,17.70304115,12.83783728,9.473288102,7.772873333,-43.68842622,1276,Dyslipidemia,7/7/14 12:28
1884,34,Daiichi-Sankyo,Regional & Specialty Pharma,1483,Welchol,colesevelam hydrochloride,Small Molecule (Chemical),Launched,Licensed (Development),Sep-00,,Mar-15,Jan-19,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1276,Dyslipidemia,7/7/14 12:28
1884,34,Daiichi-Sankyo,Regional & Specialty Pharma,1483,Welchol,colesevelam hydrochloride,Small Molecule (Chemical),Launched,Licensed (Development),Sep-00,,Mar-15,Jan-19,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1276,Dyslipidemia,7/7/14 12:28
1884,34,Daiichi-Sankyo,Regional & Specialty Pharma,1483,Welchol,colesevelam hydrochloride,Small Molecule (Chemical),Launched,Licensed (Development),Sep-00,,Mar-15,Jan-19,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1276,Dyslipidemia,7/7/14 12:28
1884,34,Daiichi-Sankyo,Regional & Specialty Pharma,1483,Welchol,colesevelam hydrochloride,Small Molecule (Chemical),Launched,Licensed (Development),Sep-00,,Mar-15,Jan-19,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,7,US,Sales,296.2646415,332.6757637,340.5986644,398.4823161,432.9120565,486.0092233,137.3514364,28.18819115,17.70304115,12.83783728,9.473288102,7.772873333,-43.68842622,1276,Dyslipidemia,7/7/14 12:28
1885,46,GlaxoSmithKline,Large Pharma,1528,Wellbutrin,bupropion,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-99,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1277,Depression,7/7/14 12:28
1885,46,GlaxoSmithKline,Large Pharma,1528,Wellbutrin,bupropion,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-99,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,4,Global,Sales,205.822543,125.1450047,136.2703604,133.1424254,151.6511607,159.2337188,164.3968936,167.8702134,170.1864992,171.721399,172.7337409,173.3990916,1.932912082,1277,Depression,7/7/14 12:28
1885,46,GlaxoSmithKline,Large Pharma,1528,Wellbutrin,bupropion,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-99,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1277,Depression,7/7/14 12:28
1885,46,GlaxoSmithKline,Large Pharma,1528,Wellbutrin,bupropion,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-99,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,4,ROW,Sales,68.60751434,88.0650033,110.619469,114.1220789,126.6365363,135.7825084,141.7273902,145.5915635,148.103276,149.7358892,150.7970878,151.4868669,2.592722447,1277,Depression,7/7/14 12:28
1885,46,GlaxoSmithKline,Large Pharma,1528,Wellbutrin,bupropion,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-99,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1277,Depression,7/7/14 12:28
1885,46,GlaxoSmithKline,Large Pharma,1528,Wellbutrin,bupropion,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-99,Expired,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,4,US,Sales,137.2150287,37.08000139,25.65089137,19.02034649,25.01462445,23.45121042,22.66950341,22.2786499,22.08322315,21.98550977,21.93665308,21.91222474,-1.873874947,1277,Depression,7/7/14 12:28
1888,76,Pfizer,Large Pharma,3052,Xalatan / Xalacom,latanoprost / latanoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-96,Apr-96,Mar-11,Jan-12,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1515,Glaucoma,7/7/14 12:28
1888,76,Pfizer,Large Pharma,3052,Xalatan / Xalacom,latanoprost / latanoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-96,Apr-96,Mar-11,Jan-12,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Sales,1737,1749,1250,806,589,437.14,332.3388,258.664456,206.8222875,170.3053885,144.5804675,126.4569534,-19.73118164,1515,Glaucoma,7/7/14 12:28
1888,76,Pfizer,Large Pharma,3052,Xalatan / Xalacom,latanoprost / latanoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-96,Apr-96,Mar-11,Jan-12,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1515,Glaucoma,7/7/14 12:28
1888,76,Pfizer,Large Pharma,3052,Xalatan / Xalacom,latanoprost / latanoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-96,Apr-96,Mar-11,Jan-12,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Sales,1161,1123,1074,768,559,410.54,306.1708,232.599016,180.7736923,144.2601921,118.5358799,100.4124825,-21.75035473,1515,Glaucoma,7/7/14 12:28
1888,76,Pfizer,Large Pharma,3052,Xalatan / Xalacom,latanoprost / latanoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-96,Apr-96,Mar-11,Jan-12,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1515,Glaucoma,7/7/14 12:28
1888,76,Pfizer,Large Pharma,3052,Xalatan / Xalacom,latanoprost / latanoprost + timolol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-96,Apr-96,Mar-11,Jan-12,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Sales,576,626,176,38,30,26.6,26.168,26.06544,26.0485952,26.04519642,26.04458762,26.04447094,-1.99961908,1515,Glaucoma,7/7/14 12:28
1890,76,Pfizer,Large Pharma,669,Xanax,alprazolam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-82,Jul-82,Expired,Expired,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1338,Anxiety,7/7/14 12:28
1890,76,Pfizer,Large Pharma,669,Xanax,alprazolam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-82,Jul-82,Expired,Expired,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,6,Global,Sales,302,267,306,274,276,268.5,263.25,260.625,259.3125,258.65625,258.328125,258.1640625,-0.949824894,1338,Anxiety,7/7/14 12:28
1890,76,Pfizer,Large Pharma,669,Xanax,alprazolam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-82,Jul-82,Expired,Expired,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1338,Anxiety,7/7/14 12:28
1890,76,Pfizer,Large Pharma,669,Xanax,alprazolam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-82,Jul-82,Expired,Expired,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,6,ROW,Sales,251,216,254,224,227,220,215,212.5,211.25,210.625,210.3125,210.15625,-1.095365822,1338,Anxiety,7/7/14 12:28
1890,76,Pfizer,Large Pharma,669,Xanax,alprazolam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-82,Jul-82,Expired,Expired,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1338,Anxiety,7/7/14 12:28
1890,76,Pfizer,Large Pharma,669,Xanax,alprazolam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-82,Jul-82,Expired,Expired,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,6,US,Sales,51,51,52,50,49,48.5,48.25,48.125,48.0625,48.03125,48.015625,48.0078125,-0.2918094,1338,Anxiety,7/7/14 12:28
1891,19,Bayer,Large Pharma,1034,Xarelto,rivaroxaban,Small Molecule (Chemical),Launched,In-House,Aug-11,Oct-08,N/A,Sep-23,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1620,Thrombosis,7/7/14 12:28
1891,19,Bayer,Large Pharma,1034,Xarelto,rivaroxaban,Small Molecule (Chemical),Launched,In-House,Aug-11,Oct-08,N/A,Sep-23,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,Global,Sales,45.25933584,66.2377405,182.1472519,413.857367,1260.300533,1635.973678,1940.337984,2165.508663,2374.46609,2540.483814,2690.422243,2825.172142,12.22290124,1620,Thrombosis,7/7/14 12:28
1891,19,Bayer,Large Pharma,1034,Xarelto,rivaroxaban,Small Molecule (Chemical),Launched,In-House,Aug-11,Oct-08,N/A,Sep-23,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1620,Thrombosis,7/7/14 12:28
1891,19,Bayer,Large Pharma,1034,Xarelto,rivaroxaban,Small Molecule (Chemical),Launched,In-House,Aug-11,Oct-08,N/A,Sep-23,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,ROW,Sales,45.25933584,66.2377405,168.2428815,343.1674441,1083.672534,1419.106369,1691.730755,1882.690716,2063.442402,2215.303018,2348.500711,2469.530571,12.48698675,1620,Thrombosis,7/7/14 12:28
1891,19,Bayer,Large Pharma,1034,Xarelto,rivaroxaban,Small Molecule (Chemical),Launched,In-House,Aug-11,Oct-08,N/A,Sep-23,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1620,Thrombosis,7/7/14 12:28
1891,19,Bayer,Large Pharma,1034,Xarelto,rivaroxaban,Small Molecule (Chemical),Launched,In-House,Aug-11,Oct-08,N/A,Sep-23,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,US,Sales,0,0,13.90437038,70.68992294,176.6279989,216.8673099,248.6072285,282.817947,311.0236871,325.1807957,341.9215323,355.6415712,10.51514801,1620,Thrombosis,7/7/14 12:28
1892,53,Johnson & Johnson,Large Pharma,1034,Xarelto,rivaroxaban,Small Molecule (Chemical),Launched,Licensed (Development),Aug-11,,Dec-20,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1620,Thrombosis,7/7/14 12:28
1892,53,Johnson & Johnson,Large Pharma,1034,Xarelto,rivaroxaban,Small Molecule (Chemical),Launched,Licensed (Development),Aug-11,,Dec-20,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,36,239,864,1160.35,1391.5512,1586.59024,1743.604192,1826.65,1893.29,1947.187632,12.30869651,1620,Thrombosis,7/7/14 12:28
1892,53,Johnson & Johnson,Large Pharma,1034,Xarelto,rivaroxaban,Small Molecule (Chemical),Launched,Licensed (Development),Aug-11,,Dec-20,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1620,Thrombosis,7/7/14 12:28
1892,53,Johnson & Johnson,Large Pharma,1034,Xarelto,rivaroxaban,Small Molecule (Chemical),Launched,Licensed (Development),Aug-11,,Dec-20,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1620,Thrombosis,7/7/14 12:28
1892,53,Johnson & Johnson,Large Pharma,1034,Xarelto,rivaroxaban,Small Molecule (Chemical),Launched,Licensed (Development),Aug-11,,Dec-20,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1620,Thrombosis,7/7/14 12:28
1892,53,Johnson & Johnson,Large Pharma,1034,Xarelto,rivaroxaban,Small Molecule (Chemical),Launched,Licensed (Development),Aug-11,,Dec-20,N/A,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,36,239,864,1160.35,1391.5512,1586.59024,1743.604192,1826.65,1893.29,1947.187632,12.30869651,1620,Thrombosis,7/7/14 12:28
1893,89,Sanofi,Large Pharma,189,Xatral,alfuzosin,Small Molecule (Chemical),Launched,In-House,Nov-03,Jul-88,Jul-11,Jul-09,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1279,Symptoms associated with BPH,7/7/14 12:28
1893,89,Sanofi,Large Pharma,189,Xatral,alfuzosin,Small Molecule (Chemical),Launched,In-House,Nov-03,Jul-88,Jul-11,Jul-09,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,Global,Sales,411.2915272,392.1274237,278.0874075,167.0852724,133.7515096,120.4740255,110.0223782,101.9552589,95.76584937,90.94041793,87.18724979,84.26434225,-6.387240167,1279,Symptoms associated with BPH,7/7/14 12:28
1893,89,Sanofi,Large Pharma,189,Xatral,alfuzosin,Small Molecule (Chemical),Launched,In-House,Nov-03,Jul-88,Jul-11,Jul-09,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1279,Symptoms associated with BPH,7/7/14 12:28
1893,89,Sanofi,Large Pharma,189,Xatral,alfuzosin,Small Molecule (Chemical),Launched,In-House,Nov-03,Jul-88,Jul-11,Jul-09,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,ROW,Sales,207.035262,186.7904282,173.8046297,141.3798459,129.7674194,117.8179654,108.1631361,100.5741076,94.6715526,90.01823385,86.36833333,83.50738636,-6.103080411,1279,Symptoms associated with BPH,7/7/14 12:28
1893,89,Sanofi,Large Pharma,189,Xatral,alfuzosin,Small Molecule (Chemical),Launched,In-House,Nov-03,Jul-88,Jul-11,Jul-09,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1279,Symptoms associated with BPH,7/7/14 12:28
1893,89,Sanofi,Large Pharma,189,Xatral,alfuzosin,Small Molecule (Chemical),Launched,In-House,Nov-03,Jul-88,Jul-11,Jul-09,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,US,Sales,204.2562652,205.3369955,104.2827778,25.70542652,3.9840902,2.656060133,1.859242093,1.381151269,1.094296775,0.922184078,0.81891646,0.756955889,-21.12067934,1279,Symptoms associated with BPH,7/7/14 12:28
1894,86,Roche,Large Pharma,1513,Xeloda,capecitabine,Small Molecule (Chemical),Launched,In-House,May-98,Jun-98,Mar-14,Dec-13,78,Anti-metabolites,51,Cytotoxics,3,Oncology,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1376,Solid Tumors,7/7/14 12:28
1894,86,Roche,Large Pharma,1513,Xeloda,capecitabine,Small Molecule (Chemical),Launched,In-House,May-98,Jun-98,Mar-14,Dec-13,78,Anti-metabolites,51,Cytotoxics,3,Oncology,5,Global,Sales,1159.8375,1366.755428,1524.360889,1631.34552,1628.743892,907.6372867,653.9687112,547.0522383,479.2827451,428.3395405,373.8554678,323.5285404,-20.61783695,1376,Solid Tumors,7/7/14 12:28
1894,86,Roche,Large Pharma,1513,Xeloda,capecitabine,Small Molecule (Chemical),Launched,In-House,May-98,Jun-98,Mar-14,Dec-13,78,Anti-metabolites,51,Cytotoxics,3,Oncology,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1376,Solid Tumors,7/7/14 12:28
1894,86,Roche,Large Pharma,1513,Xeloda,capecitabine,Small Molecule (Chemical),Launched,In-House,May-98,Jun-98,Mar-14,Dec-13,78,Anti-metabolites,51,Cytotoxics,3,Oncology,5,ROW,Sales,724.3009055,858.4673752,942.0372823,962.6566709,964.0040589,528.165805,447.380035,397.859692,360.9790861,331.0067168,291.5705437,251.7026967,-17.45570091,1376,Solid Tumors,7/7/14 12:28
1894,86,Roche,Large Pharma,1513,Xeloda,capecitabine,Small Molecule (Chemical),Launched,In-House,May-98,Jun-98,Mar-14,Dec-13,78,Anti-metabolites,51,Cytotoxics,3,Oncology,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1376,Solid Tumors,7/7/14 12:28
1894,86,Roche,Large Pharma,1513,Xeloda,capecitabine,Small Molecule (Chemical),Launched,In-House,May-98,Jun-98,Mar-14,Dec-13,78,Anti-metabolites,51,Cytotoxics,3,Oncology,5,US,Sales,435.536594,508.2880523,582.3236064,668.6888491,664.7398327,379.4714817,206.5886762,149.1925462,118.303659,97.33282367,82.28492408,71.82584375,-27.23087669,1376,Solid Tumors,7/7/14 12:28
1895,86,Roche,Large Pharma,1078,Xenical,orlistat,Small Molecule (Chemical),Launched,In-House,May-99,Sep-98,Sep-13,Dec-11,80,Obesity Treatments,38,Obesity,8,Metabolism,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1281,Obesity,7/7/14 12:28
1895,86,Roche,Large Pharma,1078,Xenical,orlistat,Small Molecule (Chemical),Launched,In-House,May-99,Sep-98,Sep-13,Dec-11,80,Obesity Treatments,38,Obesity,8,Metabolism,5,Global,Sales,365.5560842,323.1558615,250.6899574,142.1453723,88.89113726,62.02658291,51.91043396,48.26769633,42.90756468,39.45033715,35.98180168,35.19931848,-12.39575105,1281,Obesity,7/7/14 12:28
1895,86,Roche,Large Pharma,1078,Xenical,orlistat,Small Molecule (Chemical),Launched,In-House,May-99,Sep-98,Sep-13,Dec-11,80,Obesity Treatments,38,Obesity,8,Metabolism,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1281,Obesity,7/7/14 12:28
1895,86,Roche,Large Pharma,1078,Xenical,orlistat,Small Molecule (Chemical),Launched,In-House,May-99,Sep-98,Sep-13,Dec-11,80,Obesity Treatments,38,Obesity,8,Metabolism,5,ROW,Sales,334.249014,297.3005589,228.6493077,122.7722884,71.45478929,45.85904387,36.26063934,33.06117117,27.94202208,24.61457518,21.23593678,20.50333899,-16.33535546,1281,Obesity,7/7/14 12:28
1895,86,Roche,Large Pharma,1078,Xenical,orlistat,Small Molecule (Chemical),Launched,In-House,May-99,Sep-98,Sep-13,Dec-11,80,Obesity Treatments,38,Obesity,8,Metabolism,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1281,Obesity,7/7/14 12:28
1895,86,Roche,Large Pharma,1078,Xenical,orlistat,Small Molecule (Chemical),Launched,In-House,May-99,Sep-98,Sep-13,Dec-11,80,Obesity Treatments,38,Obesity,8,Metabolism,5,US,Sales,31.30707018,25.85530265,22.04064973,19.37308396,17.43634797,16.16753903,15.64979462,15.20652516,14.96554259,14.83576198,14.7458649,14.69597949,-2.413022038,1281,Obesity,7/7/14 12:28
1896,87,Salix,Small Biotech,1261,Xifaxan,rifaximin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-04,,Aug-17,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,117.9,250.5,371.653,514.48,645.63,732.9613257,834.2044367,900.0837596,932.1143972,955.5390594,972.3786109,1002.296071,6.484757897,1282,IBS-D,7/7/14 12:28
1896,87,Salix,Small Biotech,1261,Xifaxan,rifaximin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-04,,Aug-17,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1282,IBS-D,7/7/14 12:28
1896,87,Salix,Small Biotech,1261,Xifaxan,rifaximin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-04,,Aug-17,N/A,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,117.9,250.5,371.653,514.48,645.63,732.9613257,834.2044367,900.0837596,932.1143972,955.5390594,972.3786109,1002.296071,6.484757897,1282,IBS-D,7/7/14 12:28
1897,39,Eli Lilly,Large Pharma,943,Xigris,drotrecogin alfa activated,Recombinant Protein,Launched,In-House,Jul-01,Jul-02,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1283,sepsis,7/7/14 12:28
1897,39,Eli Lilly,Large Pharma,943,Xigris,drotrecogin alfa activated,Recombinant Protein,Launched,In-House,Jul-01,Jul-02,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,127.3,103.9,79.8,0,0,0,0,0,0,0,0,0,0,1283,sepsis,7/7/14 12:28
1897,39,Eli Lilly,Large Pharma,943,Xigris,drotrecogin alfa activated,Recombinant Protein,Launched,In-House,Jul-01,Jul-02,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1283,sepsis,7/7/14 12:28
1897,39,Eli Lilly,Large Pharma,943,Xigris,drotrecogin alfa activated,Recombinant Protein,Launched,In-House,Jul-01,Jul-02,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,56.8,46.6,37.3,0,0,0,0,0,0,0,0,0,0,1283,sepsis,7/7/14 12:28
1897,39,Eli Lilly,Large Pharma,943,Xigris,drotrecogin alfa activated,Recombinant Protein,Launched,In-House,Jul-01,Jul-02,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1283,sepsis,7/7/14 12:28
1897,39,Eli Lilly,Large Pharma,943,Xigris,drotrecogin alfa activated,Recombinant Protein,Launched,In-House,Jul-01,Jul-02,N/A,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,70.5,57.3,42.5,0,0,0,0,0,0,0,0,0,0,1283,sepsis,7/7/14 12:28
1899,258,Exelixis,Regional & Specialty Pharma,3702,Cometriq,cabozantinib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-13,Apr-14,Sep-24,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,15,31.00005,81.20395636,162.2687689,312.6634617,393.032143,463.6061267,510.546227,65.51939763,1286,Medullary Thyroid Cancer,7/7/14 12:28
1899,258,Exelixis,Regional & Specialty Pharma,3702,Cometriq,cabozantinib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-13,Apr-14,Sep-24,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,6,12,51.13050164,118.3802109,159.2367268,193.6475536,217.3784533,0,1286,Medullary Thyroid Cancer,7/7/14 12:28
1899,258,Exelixis,Regional & Specialty Pharma,3702,Cometriq,cabozantinib,Small Molecule (Chemical),Launched,Licensed (Development),Jan-13,Apr-14,Sep-24,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,15,25.00005,69.20395636,111.1382673,194.2832508,233.7954162,269.9585731,293.1677736,52.90861482,1286,Medullary Thyroid Cancer,7/7/14 12:28
1900,67,Novartis,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-02,N/A,Aug-17,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1570,Asthma,7/7/14 12:28
1900,67,Novartis,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-02,N/A,Aug-17,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,248,345,463,504,613,667.24,708.052,743.1388,736.819008,742.81457,744.1900634,737.7480804,2.681571025,1570,Asthma,7/7/14 12:28
1900,67,Novartis,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-02,N/A,Aug-17,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1570,Asthma,7/7/14 12:28
1900,67,Novartis,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-02,N/A,Aug-17,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,248,345,463,504,613,667.24,708.052,743.1388,736.819008,742.81457,744.1900634,737.7480804,2.681571025,1570,Asthma,7/7/14 12:28
1900,67,Novartis,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-02,N/A,Aug-17,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1570,Asthma,7/7/14 12:28
1900,67,Novartis,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jun-02,N/A,Aug-17,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1570,Asthma,7/7/14 12:28
1901,86,Roche,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-03,,Dec-18,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1570,Asthma,7/7/14 12:28
1901,86,Roche,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-03,,Dec-18,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,Global,Sales,570.8936327,614.740833,679.1898155,751.8750217,852.5072529,887.8485346,921.4497303,944.3237679,958.6165849,959.2912042,927.2032756,902.2835623,0.81396724,1570,Asthma,7/7/14 12:28
1901,86,Roche,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-03,,Dec-18,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1570,Asthma,7/7/14 12:28
1901,86,Roche,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-03,,Dec-18,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1570,Asthma,7/7/14 12:28
1901,86,Roche,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-03,,Dec-18,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1570,Asthma,7/7/14 12:28
1901,86,Roche,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-03,,Dec-18,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,US,Sales,570.8936327,614.740833,679.1898155,751.8750217,852.5072529,887.8485346,921.4497303,944.3237679,958.6165849,959.2912042,927.2032756,902.2835623,0.81396724,1570,Asthma,7/7/14 12:28
1903,35,Dainippon-Sumitomo,Regional & Specialty Pharma,903,Xopenex,levalbuterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,,Sep-09,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1518,Asthma,7/7/14 12:28
1903,35,Dainippon-Sumitomo,Regional & Specialty Pharma,903,Xopenex,levalbuterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,,Sep-09,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,Global,Sales,146.5163318,448.2368185,422.8994569,304.5801389,115.7788058,57.79663022,48.6708465,42.2827979,37.81116388,34.68102006,32.48991939,30.20316674,-17.46616989,1518,Asthma,7/7/14 12:28
1903,35,Dainippon-Sumitomo,Regional & Specialty Pharma,903,Xopenex,levalbuterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,,Sep-09,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1518,Asthma,7/7/14 12:28
1903,35,Dainippon-Sumitomo,Regional & Specialty Pharma,903,Xopenex,levalbuterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,,Sep-09,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1518,Asthma,7/7/14 12:28
1903,35,Dainippon-Sumitomo,Regional & Specialty Pharma,903,Xopenex,levalbuterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,,Sep-09,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1518,Asthma,7/7/14 12:28
1903,35,Dainippon-Sumitomo,Regional & Specialty Pharma,903,Xopenex,levalbuterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,,Sep-09,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,US,Sales,146.5163318,448.2368185,422.8994569,304.5801389,115.7788058,57.79663022,48.6708465,42.2827979,37.81116388,34.68102006,32.48991939,30.20316674,-17.46616989,1518,Asthma,7/7/14 12:28
1903,35,Sepracor,Regional & Specialty Pharma,903,Xopenex,levalbuterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,,Sep-09,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,Global,Proforma,343.6669842,0,0,0,0,0,0,0,0,0,0,0,0,1518,Asthma,7/7/14 12:28
1903,35,Sepracor,Regional & Specialty Pharma,903,Xopenex,levalbuterol,Small Molecule (Chemical),Launched,Corporate Acquisition,May-99,,Sep-09,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,7,US,Proforma,343.6669842,0,0,0,0,0,0,0,0,0,0,0,0,1518,Asthma,7/7/14 12:28
1905,52,Jazz Pharmaceuticals,Small Biotech,332,Xyrem,sodium oxybate,Small Molecule (Chemical),Launched,Acquisition (Marketed),Oct-02,,Dec-19,N/A,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,Global,Sales,96.8,142.6,233,378.7,569,663.164,743.1512,806.93288,851.76476,886.2934904,844.8598515,47.52156001,-29.85955771,1638,Cataplexy,7/7/14 12:28
1905,52,Jazz Pharmaceuticals,Small Biotech,332,Xyrem,sodium oxybate,Small Molecule (Chemical),Launched,Acquisition (Marketed),Oct-02,,Dec-19,N/A,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1638,Cataplexy,7/7/14 12:28
1905,52,Jazz Pharmaceuticals,Small Biotech,332,Xyrem,sodium oxybate,Small Molecule (Chemical),Launched,Acquisition (Marketed),Oct-02,,Dec-19,N/A,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,6,US,Sales,96.8,142.6,233,378.7,569,663.164,743.1512,806.93288,851.76476,886.2934904,844.8598515,47.52156001,-29.85955771,1638,Cataplexy,7/7/14 12:28
1907,105,UCB,Regional & Specialty Pharma,332,Xyrem,sodium oxybate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-06,N/A,Dec-19,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1638,Cataplexy,7/7/14 12:28
1907,105,UCB,Regional & Specialty Pharma,332,Xyrem,sodium oxybate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-06,N/A,Dec-19,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,2,Global,Sales,9.726488819,11.26841169,13.85876536,14.56658044,16.02941442,17.16664776,18.14662694,18.96807129,19.71380136,20.3660367,20.93733715,21.44171063,4.243457333,1638,Cataplexy,7/7/14 12:28
1907,105,UCB,Regional & Specialty Pharma,332,Xyrem,sodium oxybate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-06,N/A,Dec-19,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1638,Cataplexy,7/7/14 12:28
1907,105,UCB,Regional & Specialty Pharma,332,Xyrem,sodium oxybate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-06,N/A,Dec-19,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,2,ROW,Sales,9.726488819,11.26841169,13.85876536,14.56658044,16.02941442,17.16664776,18.14662694,18.96807129,19.71380136,20.3660367,20.93733715,21.44171063,4.243457333,1638,Cataplexy,7/7/14 12:28
1907,105,UCB,Regional & Specialty Pharma,332,Xyrem,sodium oxybate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-06,N/A,Dec-19,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1638,Cataplexy,7/7/14 12:28
1907,105,UCB,Regional & Specialty Pharma,332,Xyrem,sodium oxybate,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-06,N/A,Dec-19,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1638,Cataplexy,7/7/14 12:28
1909,89,Sanofi,Large Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,,Nov-10,N/A,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1520,Allergic Rhinitis,7/7/14 12:28
1909,89,Sanofi,Large Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,,Nov-10,N/A,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,Global,Sales,277.9546755,340.4619862,11.1234963,7.047116021,5.526666702,5.141085305,4.233929816,3.622590397,3.164137552,2.74829601,2.420888854,2.656060133,-9.938478811,1520,Allergic Rhinitis,7/7/14 12:28
1909,89,Sanofi,Large Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,,Nov-10,N/A,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1520,Allergic Rhinitis,7/7/14 12:28
1909,89,Sanofi,Large Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,,Nov-10,N/A,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1520,Allergic Rhinitis,7/7/14 12:28
1909,89,Sanofi,Large Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,,Nov-10,N/A,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1520,Allergic Rhinitis,7/7/14 12:28
1909,89,Sanofi,Large Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,,Nov-10,N/A,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,US,Sales,277.9546755,340.4619862,11.1234963,7.047116021,5.526666702,5.141085305,4.233929816,3.622590397,3.164137552,2.74829601,2.420888854,2.656060133,-9.938478811,1520,Allergic Rhinitis,7/7/14 12:28
1910,105,UCB,Regional & Specialty Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,Feb-01,N/A,Aug-10,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1520,Allergic Rhinitis,7/7/14 12:28
1910,105,UCB,Regional & Specialty Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,Feb-01,N/A,Aug-10,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,Global,Sales,183.4137892,152.3468031,148.776763,164.5147297,151.3954276,144.8880803,138.6410269,134.2316484,130.8878089,128.3979458,126.535485,123.0164793,-2.921844109,1520,Allergic Rhinitis,7/7/14 12:28
1910,105,UCB,Regional & Specialty Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,Feb-01,N/A,Aug-10,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1520,Allergic Rhinitis,7/7/14 12:28
1910,105,UCB,Regional & Specialty Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,Feb-01,N/A,Aug-10,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,ROW,Sales,183.4137892,152.3468031,148.776763,164.5147297,151.3954276,144.8880803,138.6410269,134.2316484,130.8878089,128.3979458,126.535485,123.0164793,-2.921844109,1520,Allergic Rhinitis,7/7/14 12:28
1910,105,UCB,Regional & Specialty Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,Feb-01,N/A,Aug-10,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1520,Allergic Rhinitis,7/7/14 12:28
1910,105,UCB,Regional & Specialty Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-07,Feb-01,N/A,Aug-10,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1520,Allergic Rhinitis,7/7/14 12:28
1912,19,Bayer,Large Pharma,645,Yasmin / Yaz / Yasminelle,drospirenone + ethinyl estradiol ,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-01,Nov-00,Jun-08,Nov-10,89,Contraceptives,3,Contraception,2,Genitourinary,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1429,Female contraception,7/7/14 12:28
1912,19,Bayer,Large Pharma,645,Yasmin / Yaz / Yasminelle,drospirenone + ethinyl estradiol ,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-01,Nov-00,Jun-08,Nov-10,89,Contraceptives,3,Contraception,2,Genitourinary,2,Global,Sales,1775.778959,1471.802594,1487.76763,1343.108536,1132.809647,967.8045675,860.4195253,792.2676031,755.5556206,733.908625,721.2575434,713.5125609,-6.390333531,1429,Female contraception,7/7/14 12:28
1912,19,Bayer,Large Pharma,645,Yasmin / Yaz / Yasminelle,drospirenone + ethinyl estradiol ,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-01,Nov-00,Jun-08,Nov-10,89,Contraceptives,3,Contraception,2,Genitourinary,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1429,Female contraception,7/7/14 12:28
1912,19,Bayer,Large Pharma,645,Yasmin / Yaz / Yasminelle,drospirenone + ethinyl estradiol ,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-01,Nov-00,Jun-08,Nov-10,89,Contraceptives,3,Contraception,2,Genitourinary,2,ROW,Sales,1032.397313,1120.742569,1238.8794,1098.906984,944.2293774,829.4875799,760.6425014,719.3354543,694.5512261,679.6806891,670.758367,665.4049737,-4.876689735,1429,Female contraception,7/7/14 12:28
1912,19,Bayer,Large Pharma,645,Yasmin / Yaz / Yasminelle,drospirenone + ethinyl estradiol ,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-01,Nov-00,Jun-08,Nov-10,89,Contraceptives,3,Contraception,2,Genitourinary,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1429,Female contraception,7/7/14 12:28
1912,19,Bayer,Large Pharma,645,Yasmin / Yaz / Yasminelle,drospirenone + ethinyl estradiol ,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-01,Nov-00,Jun-08,Nov-10,89,Contraceptives,3,Contraception,2,Genitourinary,2,US,Sales,743.3816454,351.0600246,248.8882297,244.201552,188.5802695,138.3169876,99.77702385,72.93214875,61.0043945,54.22793591,50.49917644,48.10758725,-17.72925751,1429,Female contraception,7/7/14 12:28
1914,15,Astellas Pharma,Regional & Specialty Pharma,1749,Bonoteo,minodronate,Small Molecule (Chemical),Launched,In-House,,Apr-09,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1547,Osteoporosis ,7/7/14 12:28
1914,15,Astellas Pharma,Regional & Specialty Pharma,1749,Bonoteo,minodronate,Small Molecule (Chemical),Launched,In-House,,Apr-09,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,12.82786783,23.34566763,63.39983741,127.6106511,136.8867558,163.5088606,187.0449709,205.0968974,220.0847496,232.4164578,242.4072744,250.5920182,9.022234046,1547,Osteoporosis ,7/7/14 12:28
1914,15,Astellas Pharma,Regional & Specialty Pharma,1749,Bonoteo,minodronate,Small Molecule (Chemical),Launched,In-House,,Apr-09,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1547,Osteoporosis ,7/7/14 12:28
1914,15,Astellas Pharma,Regional & Specialty Pharma,1749,Bonoteo,minodronate,Small Molecule (Chemical),Launched,In-House,,Apr-09,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,12.82786783,23.34566763,63.39983741,127.6106511,136.8867558,163.5088606,187.0449709,205.0968974,220.0847496,232.4164578,242.4072744,250.5920182,9.022234046,1547,Osteoporosis ,7/7/14 12:28
1914,15,Astellas Pharma,Regional & Specialty Pharma,1749,Bonoteo,minodronate,Small Molecule (Chemical),Launched,In-House,,Apr-09,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1547,Osteoporosis ,7/7/14 12:28
1914,15,Astellas Pharma,Regional & Specialty Pharma,1749,Bonoteo,minodronate,Small Molecule (Chemical),Launched,In-House,,Apr-09,N/A,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1547,Osteoporosis ,7/7/14 12:28
1916,15,Astellas Pharma,Regional & Specialty Pharma,1911,Roxadustat,ASP1517,Small Molecule (Chemical),Phase III,Licensed (Development),,Jun-18,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,154,Renal Anemia,7/7/14 12:28
1916,15,Astellas Pharma,Regional & Specialty Pharma,1911,Roxadustat,ASP1517,Small Molecule (Chemical),Phase III,Licensed (Development),,Jun-18,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,Global,Sales,0,0,0,0,0,0,0,0,0,16.77953036,48.10137631,81.66026352,0,154,Renal Anemia,7/7/14 12:28
1916,15,Astellas Pharma,Regional & Specialty Pharma,1911,Roxadustat,ASP1517,Small Molecule (Chemical),Phase III,Licensed (Development),,Jun-18,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,154,Renal Anemia,7/7/14 12:28
1916,15,Astellas Pharma,Regional & Specialty Pharma,1911,Roxadustat,ASP1517,Small Molecule (Chemical),Phase III,Licensed (Development),,Jun-18,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,16.77953036,48.10137631,81.66026352,0,154,Renal Anemia,7/7/14 12:28
1916,15,Astellas Pharma,Regional & Specialty Pharma,1911,Roxadustat,ASP1517,Small Molecule (Chemical),Phase III,Licensed (Development),,Jun-18,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,154,Renal Anemia,7/7/14 12:28
1916,15,Astellas Pharma,Regional & Specialty Pharma,1911,Roxadustat,ASP1517,Small Molecule (Chemical),Phase III,Licensed (Development),,Jun-18,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,154,Renal Anemia,7/7/14 12:28
1918,15,Astellas Pharma,Regional & Specialty Pharma,652,YM311,YM311,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1290,Renal Anemia,7/7/14 12:28
1918,15,Astellas Pharma,Regional & Specialty Pharma,652,YM311,YM311,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1290,Renal Anemia,7/7/14 12:28
1918,15,Astellas Pharma,Regional & Specialty Pharma,652,YM311,YM311,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1290,Renal Anemia,7/7/14 12:28
1918,15,Astellas Pharma,Regional & Specialty Pharma,652,YM311,YM311,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1290,Renal Anemia,7/7/14 12:28
1918,15,Astellas Pharma,Regional & Specialty Pharma,652,YM311,YM311,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1290,Renal Anemia,7/7/14 12:28
1918,15,Astellas Pharma,Regional & Specialty Pharma,652,YM311,YM311,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1290,Renal Anemia,7/7/14 12:28
1920,77,PharmaMar,Small Biotech,910,Yondelis,trabectedin,Small Molecule (Chemical),Launched,In-House,,Oct-07,N/A,May-20,84,Alkylating Agents,51,Cytotoxics,3,Oncology,2,Global,Sales,60.86003004,95.5148218,103.0452889,85.08496179,96.81339186,98.27847463,99.31922524,101.5107936,102.8716143,104.1084391,105.2804169,106.2637773,1.339449096,1291,Sarcoma,7/7/14 12:28
1920,77,PharmaMar,Small Biotech,910,Yondelis,trabectedin,Small Molecule (Chemical),Launched,In-House,,Oct-07,N/A,May-20,84,Alkylating Agents,51,Cytotoxics,3,Oncology,2,ROW,Sales,60.86003004,95.5148218,103.0452889,85.08496179,96.81339186,98.27847463,99.31922524,101.5107936,102.8716143,104.1084391,105.2804169,106.2637773,1.339449096,1291,Sarcoma,7/7/14 12:28
1920,77,PharmaMar,Small Biotech,910,Yondelis,trabectedin,Small Molecule (Chemical),Launched,In-House,,Oct-07,N/A,May-20,84,Alkylating Agents,51,Cytotoxics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1291,Sarcoma,7/7/14 12:28
1921,16,AstraZeneca,Large Pharma,3796,Caprelsa,vandetanib,Small Molecule (Chemical),Launched,In-House,Apr-11,Mar-12,Aug-21,Nov-20,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1292,Medullary Thyroid Cancer,7/7/14 12:28
1921,16,AstraZeneca,Large Pharma,3796,Caprelsa,vandetanib,Small Molecule (Chemical),Launched,In-House,Apr-11,Mar-12,Aug-21,Nov-20,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,8,25.8,37.23812,54.91597099,63.22485734,66.06729668,68.05189393,69.28139475,69.91721048,70.32179957,9.507316374,1292,Medullary Thyroid Cancer,7/7/14 12:28
1921,16,AstraZeneca,Large Pharma,3796,Caprelsa,vandetanib,Small Molecule (Chemical),Launched,In-House,Apr-11,Mar-12,Aug-21,Nov-20,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1292,Medullary Thyroid Cancer,7/7/14 12:28
1921,16,AstraZeneca,Large Pharma,3796,Caprelsa,vandetanib,Small Molecule (Chemical),Launched,In-House,Apr-11,Mar-12,Aug-21,Nov-20,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,6.8,10.15172,14.48437258,21.663407,23.8872698,25.54013869,26.71189876,27.32250407,27.71746585,15.42933874,1292,Medullary Thyroid Cancer,7/7/14 12:28
1921,16,AstraZeneca,Large Pharma,3796,Caprelsa,vandetanib,Small Molecule (Chemical),Launched,In-House,Apr-11,Mar-12,Aug-21,Nov-20,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1292,Medullary Thyroid Cancer,7/7/14 12:28
1921,16,AstraZeneca,Large Pharma,3796,Caprelsa,vandetanib,Small Molecule (Chemical),Launched,In-House,Apr-11,Mar-12,Aug-21,Nov-20,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,8,19,27.0864,40.43159842,41.56145034,42.18002689,42.51175524,42.56949599,42.59470641,42.60433372,6.68425472,1292,Medullary Thyroid Cancer,7/7/14 12:28
1922,84,Recordati,Regional & Specialty Pharma,1545,Zanidip,lercanidipine,Small Molecule (Chemical),Launched,In-House,,Jul-97,N/A,Jan-10,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1294,,7/7/14 12:28
1922,84,Recordati,Regional & Specialty Pharma,1545,Zanidip,lercanidipine,Small Molecule (Chemical),Launched,In-House,,Jul-97,N/A,Jan-10,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,298.6726817,197.0175353,173.4153073,147.292094,144.6224743,137.6244198,132.2472427,127.8496625,124.331068,121.4943504,119.2133899,117.3776241,-2.937841425,1294,,7/7/14 12:28
1922,84,Recordati,Regional & Specialty Pharma,1545,Zanidip,lercanidipine,Small Molecule (Chemical),Launched,In-House,,Jul-97,N/A,Jan-10,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1294,,7/7/14 12:28
1922,84,Recordati,Regional & Specialty Pharma,1545,Zanidip,lercanidipine,Small Molecule (Chemical),Launched,In-House,,Jul-97,N/A,Jan-10,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,298.6726817,197.0175353,173.4153073,147.292094,144.6224743,137.6244198,132.2472427,127.8496625,124.331068,121.4943504,119.2133899,117.3776241,-2.937841425,1294,,7/7/14 12:28
1922,84,Recordati,Regional & Specialty Pharma,1545,Zanidip,lercanidipine,Small Molecule (Chemical),Launched,In-House,,Jul-97,N/A,Jan-10,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1294,,7/7/14 12:28
1922,84,Recordati,Regional & Specialty Pharma,1545,Zanidip,lercanidipine,Small Molecule (Chemical),Launched,In-House,,Jul-97,N/A,Jan-10,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1294,,7/7/14 12:28
1926,37,Eisai,Regional & Specialty Pharma,1350,Zebinix,eslicarbazepine acetate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-09,N/A,Jun-21,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1451,Epilepsy,7/7/14 12:28
1926,37,Eisai,Regional & Specialty Pharma,1350,Zebinix,eslicarbazepine acetate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-09,N/A,Jun-21,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,Global,Sales,26.19929262,23.34566763,25.32332077,24.07748133,30.37605557,32.93620833,35.11233818,37.06445465,38.13491853,38.91296495,39.46325778,39.82458434,3.944812985,1451,Epilepsy,7/7/14 12:28
1926,37,Eisai,Regional & Specialty Pharma,1350,Zebinix,eslicarbazepine acetate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-09,N/A,Jun-21,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1451,Epilepsy,7/7/14 12:28
1926,37,Eisai,Regional & Specialty Pharma,1350,Zebinix,eslicarbazepine acetate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-09,N/A,Jun-21,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,ROW,Sales,26.19929262,23.34566763,25.32332077,24.07748133,30.37605557,32.93620833,35.11233818,37.06445465,38.13491853,38.91296495,39.46325778,39.82458434,3.944812985,1451,Epilepsy,7/7/14 12:28
1926,37,Eisai,Regional & Specialty Pharma,1350,Zebinix,eslicarbazepine acetate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-09,N/A,Jun-21,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1451,Epilepsy,7/7/14 12:28
1926,37,Eisai,Regional & Specialty Pharma,1350,Zebinix,eslicarbazepine acetate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-09,N/A,Jun-21,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1451,Epilepsy,7/7/14 12:28
1927,46,GlaxoSmithKline,Large Pharma,1220,Zeffix,lamivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,May-10,Feb-11,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1721,Hepatitis B,7/7/14 12:28
1927,46,GlaxoSmithKline,Large Pharma,1220,Zeffix,lamivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,May-10,Feb-11,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,4,Global,Sales,338.3597866,359.9850135,379.7798296,385.1620164,282.9779391,234.5121043,210.2791869,198.1627282,192.1044989,189.0753842,187.5608269,186.8035482,-5.760440808,1721,Hepatitis B,7/7/14 12:28
1927,46,GlaxoSmithKline,Large Pharma,1220,Zeffix,lamivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,May-10,Feb-11,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1721,Hepatitis B,7/7/14 12:28
1927,46,GlaxoSmithKline,Large Pharma,1220,Zeffix,lamivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,May-10,Feb-11,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,4,ROW,Sales,311.8523379,339.9000127,362.3188406,361.3865833,264.2169707,218.096257,195.0359001,183.5057217,177.7406325,174.8580879,173.4168156,172.6961794,-5.893968819,1721,Hepatitis B,7/7/14 12:28
1927,46,GlaxoSmithKline,Large Pharma,1220,Zeffix,lamivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,May-10,Feb-11,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1721,Hepatitis B,7/7/14 12:28
1927,46,GlaxoSmithKline,Large Pharma,1220,Zeffix,lamivudine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-98,Jul-99,May-10,Feb-11,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,4,US,Sales,26.50744872,20.08500075,17.46098897,23.77543311,18.76096834,16.4158473,15.24328678,14.65700652,14.36386639,14.21729633,14.1440113,14.10736878,-3.990770434,1721,Hepatitis B,7/7/14 12:28
1928,17,Basilea,Small Biotech,1434,Zeftera / Zevtera,ceftobiprole,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-09,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,5,Global,Sales,4.603980909,2.877102183,0,0,0,2.139866424,5.349666061,7.489532485,9.629398909,10.57094014,11.76926533,12.94947726,0,1297,Nosocomial Pneumonia / CAP,7/7/14 12:28
1928,17,Basilea,Small Biotech,1434,Zeftera / Zevtera,ceftobiprole,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-09,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,5,ROW,Sales,4.603980909,2.877102183,0,0,0,2.139866424,5.349666061,7.489532485,9.629398909,10.57094014,11.76926533,12.94947726,0,1297,Nosocomial Pneumonia / CAP,7/7/14 12:28
1928,17,Basilea,Small Biotech,1434,Zeftera / Zevtera,ceftobiprole,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-09,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1297,Nosocomial Pneumonia / CAP,7/7/14 12:28
1931,1,Abbott,Regional & Specialty Pharma,191,Zemplar,paricalcitol,Small Molecule (Chemical),Launched,In-House,Nov-98,Dec-03,Jun-13,N/A,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1300,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
1931,1,Abbott,Regional & Specialty Pharma,191,Zemplar,paricalcitol,Small Molecule (Chemical),Launched,In-House,Nov-98,Dec-03,Jun-13,N/A,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,Global,Sales,700,596,409,383,0,0,0,0,0,0,0,0,0,1300,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
1931,1,Abbott,Regional & Specialty Pharma,191,Zemplar,paricalcitol,Small Molecule (Chemical),Launched,In-House,Nov-98,Dec-03,Jun-13,N/A,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1300,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
1931,1,Abbott,Regional & Specialty Pharma,191,Zemplar,paricalcitol,Small Molecule (Chemical),Launched,In-House,Nov-98,Dec-03,Jun-13,N/A,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,ROW,Sales,108,120,154,153,0,0,0,0,0,0,0,0,0,1300,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
1931,1,Abbott,Regional & Specialty Pharma,191,Zemplar,paricalcitol,Small Molecule (Chemical),Launched,In-House,Nov-98,Dec-03,Jun-13,N/A,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1300,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
1931,1,Abbott,Regional & Specialty Pharma,191,Zemplar,paricalcitol,Small Molecule (Chemical),Launched,In-House,Nov-98,Dec-03,Jun-13,N/A,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,6,US,Sales,592,476,255,230,0,0,0,0,0,0,0,0,0,1300,Secondary Hyperparathyroidism in CKD,7/7/14 12:28
1933,24,Bristol-Myers Squibb,Large Pharma,590,Zerit,stavudine,Small Molecule (Chemical),Launched,In-House,Jul-94,Jul-96,Expired,May-09,104,NRTIs,32,HIV,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1301,HIV,7/7/14 12:28
1933,24,Bristol-Myers Squibb,Large Pharma,590,Zerit,stavudine,Small Molecule (Chemical),Launched,In-House,Jul-94,Jul-96,Expired,May-09,104,NRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,69.05305,58.04108125,48.94690712,40.66393772,33.62118905,27.54083255,22.23806303,17.64740271,13.65940483,10.18848639,7.167139186,4.533152754,-24.89237622,1301,HIV,7/7/14 12:28
1933,24,Bristol-Myers Squibb,Large Pharma,590,Zerit,stavudine,Small Molecule (Chemical),Launched,In-House,Jul-94,Jul-96,Expired,May-09,104,NRTIs,32,HIV,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1301,HIV,7/7/14 12:28
1933,24,Bristol-Myers Squibb,Large Pharma,590,Zerit,stavudine,Small Molecule (Chemical),Launched,In-House,Jul-94,Jul-96,Expired,May-09,104,NRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,48.94,41.0425,34.0924375,28.05022656,23.0360084,18.75366975,15.11326203,12.03245022,9.41570325,7.195179322,5.311593009,3.713118213,-22.95193027,1301,HIV,7/7/14 12:28
1933,24,Bristol-Myers Squibb,Large Pharma,590,Zerit,stavudine,Small Molecule (Chemical),Launched,In-House,Jul-94,Jul-96,Expired,May-09,104,NRTIs,32,HIV,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1301,HIV,7/7/14 12:28
1933,24,Bristol-Myers Squibb,Large Pharma,590,Zerit,stavudine,Small Molecule (Chemical),Launched,In-House,Jul-94,Jul-96,Expired,May-09,104,NRTIs,32,HIV,7,Anti-infectives,6,US,Sales,20.11305,16.99858125,14.85446963,12.61371115,10.58518065,8.787162801,7.124800996,5.614952492,4.243701583,2.993307071,1.855546176,0.820034541,-30.6087042,1301,HIV,7/7/14 12:28
1934,16,AstraZeneca,Large Pharma,440,Zestril,lisinopril,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-88,Jan-88,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1302,Hypertension,7/7/14 12:28
1934,16,AstraZeneca,Large Pharma,440,Zestril,lisinopril,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-88,Jan-88,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Sales,184,157.4,144.1,133.21,124.678,117.9229,112.58812,108.372451,105.0416038,102.4097621,100.3302436,98.68712703,-3.284556917,1302,Hypertension,7/7/14 12:28
1934,16,AstraZeneca,Large Pharma,440,Zestril,lisinopril,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-88,Jan-88,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1302,Hypertension,7/7/14 12:28
1934,16,AstraZeneca,Large Pharma,440,Zestril,lisinopril,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-88,Jan-88,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,166,147,134,123.35,115.01,108.4085,103.1966,99.079235,95.827031,93.25810385,91.22891696,89.62606575,-3.499757345,1302,Hypertension,7/7/14 12:28
1934,16,AstraZeneca,Large Pharma,440,Zestril,lisinopril,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-88,Jan-88,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1302,Hypertension,7/7/14 12:28
1934,16,AstraZeneca,Large Pharma,440,Zestril,lisinopril,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-88,Jan-88,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Sales,18,10.4,10.1,9.86,9.668,9.5144,9.39152,9.293216,9.2145728,9.15165824,9.101326592,9.061061274,-0.921940206,1302,Hypertension,7/7/14 12:28
1935,19,Bayer,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-07,N/A,Jun-20,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1460,Dyslipidemia,7/7/14 12:28
1935,19,Bayer,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-07,N/A,Jun-20,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,Global,Sales,140.3393387,182.8161638,248.8882297,266.0511645,228.4211715,227.8235579,233.3973001,236.3385215,234.2137813,232.4097243,231.0364392,219.5521634,-0.564135288,1460,Dyslipidemia,7/7/14 12:28
1935,19,Bayer,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-07,N/A,Jun-20,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1460,Dyslipidemia,7/7/14 12:28
1935,19,Bayer,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-07,N/A,Jun-20,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,ROW,Sales,140.3393387,182.8161638,248.8882297,266.0511645,228.4211715,227.8235579,233.3973001,236.3385215,234.2137813,232.4097243,231.0364392,219.5521634,-0.564135288,1460,Dyslipidemia,7/7/14 12:28
1935,19,Bayer,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-07,N/A,Jun-20,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1460,Dyslipidemia,7/7/14 12:28
1935,19,Bayer,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-07,N/A,Jun-20,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1460,Dyslipidemia,7/7/14 12:28
1936,61,Merck & Co,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-02,Apr-03,Dec-16,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1460,Dyslipidemia,7/7/14 12:28
1936,61,Merck & Co,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-02,Apr-03,Dec-16,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,402.9,2297,2428,2557,2664.34,2833.19244,3301.009296,2957.54738,1658.709461,756.0834226,601.4892985,526.9484928,-20.66694565,1460,Dyslipidemia,7/7/14 12:28
1936,61,Merck & Co,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-02,Apr-03,Dec-16,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1460,Dyslipidemia,7/7/14 12:28
1936,61,Merck & Co,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-02,Apr-03,Dec-16,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,170.2,1070,1205,1235,1282.94,1345.30044,1502.979296,1578.8557,1512.814197,682.9048434,557.49901,482.9083197,-13.0279266,1460,Dyslipidemia,7/7/14 12:28
1936,61,Merck & Co,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-02,Apr-03,Dec-16,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1460,Dyslipidemia,7/7/14 12:28
1936,61,Merck & Co,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-02,Apr-03,Dec-16,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,232.7,1227,1223,1322,1381.4,1487.892,1798.03,1378.69168,145.895264,73.1785792,43.99028851,44.04017311,-38.87502097,1460,Dyslipidemia,7/7/14 12:28
1936,61,Merck / Schering Plough,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-02,Apr-03,Dec-16,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Proforma,1841.1,0,0,0,0,0,0,0,0,0,0,0,0,1460,Dyslipidemia,7/7/14 12:28
1936,61,Merck / Schering Plough,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-02,Apr-03,Dec-16,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Proforma,777.8,0,0,0,0,0,0,0,0,0,0,0,0,1460,Dyslipidemia,7/7/14 12:28
1936,61,Merck / Schering Plough,Large Pharma,1303,Zetia,ezetimibe,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-02,Apr-03,Dec-16,Oct-17,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Proforma,1063.3,0,0,0,0,0,0,0,0,0,0,0,0,1460,Dyslipidemia,7/7/14 12:28
1937,174,Durata Therapeutics,Small Biotech,542,Dalvance,dalbavancin,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-14,Aug-15,Dec-23,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,8,32,51.85623,62.91864007,70,74.33225959,75.91885184,0,1303,cSSSI and BSI,7/7/14 12:28
1937,174,Durata Therapeutics,Small Biotech,542,Dalvance,dalbavancin,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-14,Aug-15,Dec-23,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,3,6.28476,8.918640068,12,13.19511839,13,0,1303,cSSSI and BSI,7/7/14 12:28
1937,174,Durata Therapeutics,Small Biotech,542,Dalvance,dalbavancin,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-14,Aug-15,Dec-23,N/A,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,8,29,45.57147,54,58,61.1371412,62.91885184,0,1303,cSSSI and BSI,7/7/14 12:28
1938,46,GlaxoSmithKline,Large Pharma,1216,Ziagen,abacavir,Small Molecule (Chemical),Launched,In-House,Jul-99,Jul-99,Jun-12,Jun-14,104,NRTIs,32,HIV,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1304,HIV,7/7/14 12:28
1938,46,GlaxoSmithKline,Large Pharma,1216,Ziagen,abacavir,Small Molecule (Chemical),Launched,In-House,Jul-99,Jul-99,Jun-12,Jun-14,104,NRTIs,32,HIV,7,Anti-infectives,4,Global,Sales,163.7224774,153.9335443,147.7071357,116.6109904,98.55069759,73.12669768,46.8437715,33.62341773,24.45492196,16.13215575,10.21588503,7.81707014,-30.37433698,1304,HIV,7/7/14 12:28
1938,46,GlaxoSmithKline,Large Pharma,1216,Ziagen,abacavir,Small Molecule (Chemical),Launched,In-House,Jul-99,Jul-99,Jun-12,Jun-14,104,NRTIs,32,HIV,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1304,HIV,7/7/14 12:28
1938,46,GlaxoSmithKline,Large Pharma,1216,Ziagen,abacavir,Small Molecule (Chemical),Launched,In-House,Jul-99,Jul-99,Jun-12,Jun-14,104,NRTIs,32,HIV,7,Anti-infectives,4,ROW,Sales,84.20013124,76.18726348,69.95844493,62.72000864,55.27636776,39.0853507,21.88779639,15.63414028,12.50731222,9.380484168,7.81707014,6.253656112,-26.75139649,1304,HIV,7/7/14 12:28
1938,46,GlaxoSmithKline,Large Pharma,1216,Ziagen,abacavir,Small Molecule (Chemical),Launched,In-House,Jul-99,Jul-99,Jun-12,Jun-14,104,NRTIs,32,HIV,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1304,HIV,7/7/14 12:28
1938,46,GlaxoSmithKline,Large Pharma,1216,Ziagen,abacavir,Small Molecule (Chemical),Launched,In-House,Jul-99,Jul-99,Jun-12,Jun-14,104,NRTIs,32,HIV,7,Anti-infectives,4,US,Sales,79.52234617,77.74628084,77.74869081,53.89098171,43.27432983,34.04134698,24.95597511,17.98927745,11.94760973,6.751671583,2.398814892,1.563414028,-37.77314229,1304,HIV,7/7/14 12:28
1940,46,GlaxoSmithKline,Large Pharma,394,Zinnat,cefuroxime axetil,Small Molecule (Chemical),Launched,In-House,Jul-88,Jul-87,Jul-03,Jul-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1307,,7/7/14 12:28
1940,46,GlaxoSmithKline,Large Pharma,394,Zinnat,cefuroxime axetil,Small Molecule (Chemical),Launched,In-House,Jul-88,Jul-87,Jul-03,Jul-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,4,Global,Sales,150.6461224,126.4630381,110.0209682,93.41522358,78.69060271,67.97202226,59.31011885,52.16704084,46.3648875,41.63272444,37.76569806,34.61155959,-11.07115232,1307,,7/7/14 12:28
1940,46,GlaxoSmithKline,Large Pharma,394,Zinnat,cefuroxime axetil,Small Molecule (Chemical),Launched,In-House,Jul-88,Jul-87,Jul-03,Jul-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1307,,7/7/14 12:28
1940,46,GlaxoSmithKline,Large Pharma,394,Zinnat,cefuroxime axetil,Small Molecule (Chemical),Launched,In-House,Jul-88,Jul-87,Jul-03,Jul-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,4,ROW,Sales,135.0535055,111.6569336,95.59189315,79.48033525,65.04307702,54.48891633,45.91534839,38.82875063,33.07040965,28.36650527,24.51876344,21.37806614,-14.69650374,1307,,7/7/14 12:28
1940,46,GlaxoSmithKline,Large Pharma,394,Zinnat,cefuroxime axetil,Small Molecule (Chemical),Launched,In-House,Jul-88,Jul-87,Jul-03,Jul-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1307,,7/7/14 12:28
1940,46,GlaxoSmithKline,Large Pharma,394,Zinnat,cefuroxime axetil,Small Molecule (Chemical),Launched,In-House,Jul-88,Jul-87,Jul-03,Jul-03,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,4,US,Sales,15.5926169,14.80610451,14.42907506,13.93488833,13.64752569,13.48310593,13.39477046,13.3382902,13.29447785,13.26621917,13.24693462,13.23349345,-0.439135933,1307,,7/7/14 12:28
1941,76,Pfizer,Large Pharma,362,Zithromax,azithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-92,Jul-91,Nov-05,Apr-15,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1308,,7/7/14 12:28
1941,76,Pfizer,Large Pharma,362,Zithromax,azithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-92,Jul-91,Nov-05,Apr-15,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,430,415,453,435,387,379.76,295.00808,229.046192,184.52228,151.6080158,126.3425466,111.9792903,-16.23529939,1308,,7/7/14 12:28
1941,76,Pfizer,Large Pharma,362,Zithromax,azithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-92,Jul-91,Nov-05,Apr-15,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1308,,7/7/14 12:28
1941,76,Pfizer,Large Pharma,362,Zithromax,azithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-92,Jul-91,Nov-05,Apr-15,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,412,401,433,423,380,372.76,288.62808,222.928192,178.46768,145.6002758,120.3537766,105.9977649,-16.67263158,1308,,7/7/14 12:28
1941,76,Pfizer,Large Pharma,362,Zithromax,azithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-92,Jul-91,Nov-05,Apr-15,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1308,,7/7/14 12:28
1941,76,Pfizer,Large Pharma,362,Zithromax,azithromycin,Small Molecule (Chemical),Launched,Licensed (Development),Jul-92,Jul-91,Nov-05,Apr-15,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,18,14,20,12,7,7,6.38,6.118,6.0546,6.00774,5.98877,5.9815254,-2.221165962,1308,,7/7/14 12:28
1942,76,Pfizer,Large Pharma,3588,AZCQ,azithromycin + chloroquine,Small Molecule (Chemical),Phase III,In-House,,Aug-15,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1309,Malaria,7/7/14 12:28
1942,76,Pfizer,Large Pharma,3588,AZCQ,azithromycin + chloroquine,Small Molecule (Chemical),Phase III,In-House,,Aug-15,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,5.2,10.893584,15.45897612,22.82703332,25.92321483,28.259008,0,1309,Malaria,7/7/14 12:28
1942,76,Pfizer,Large Pharma,3588,AZCQ,azithromycin + chloroquine,Small Molecule (Chemical),Phase III,In-House,,Aug-15,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1309,Malaria,7/7/14 12:28
1942,76,Pfizer,Large Pharma,3588,AZCQ,azithromycin + chloroquine,Small Molecule (Chemical),Phase III,In-House,,Aug-15,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,5.2,10.893584,15.45897612,22.82703332,25.92321483,28.259008,0,1309,Malaria,7/7/14 12:28
1942,76,Pfizer,Large Pharma,3588,AZCQ,azithromycin + chloroquine,Small Molecule (Chemical),Phase III,In-House,,Aug-15,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1309,Malaria,7/7/14 12:28
1942,76,Pfizer,Large Pharma,3588,AZCQ,azithromycin + chloroquine,Small Molecule (Chemical),Phase III,In-House,,Aug-15,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1309,Malaria,7/7/14 12:28
1943,61,Merck & Co,Large Pharma,712,Zocor,simvastatin,Small Molecule (Chemical),Launched,In-House,Jan-92,Jan-88,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1310,,7/7/14 12:28
1943,61,Merck & Co,Large Pharma,712,Zocor,simvastatin,Small Molecule (Chemical),Launched,In-House,Jan-92,Jan-88,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,558,468,455,383,299.75,261.4425,226.928375,200.0780063,181.4401484,167.0117559,156.1885879,148.1574158,-9.576639303,1310,,7/7/14 12:28
1943,61,Merck & Co,Large Pharma,712,Zocor,simvastatin,Small Molecule (Chemical),Launched,In-House,Jan-92,Jan-88,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1310,,7/7/14 12:28
1943,61,Merck & Co,Large Pharma,712,Zocor,simvastatin,Small Molecule (Chemical),Launched,In-House,Jan-92,Jan-88,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,513,426,423,356,276,239.58,206.214,180.0486,161.8227,147.641238,136.9662894,129.0240337,-10.29366301,1310,,7/7/14 12:28
1943,61,Merck & Co,Large Pharma,712,Zocor,simvastatin,Small Molecule (Chemical),Launched,In-House,Jan-92,Jan-88,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1310,,7/7/14 12:28
1943,61,Merck & Co,Large Pharma,712,Zocor,simvastatin,Small Molecule (Chemical),Launched,In-House,Jan-92,Jan-88,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,45,42,32,27,23.75,21.8625,20.714375,20.02940625,19.61744844,19.37051789,19.22229853,19.13338217,-3.040638572,1310,,7/7/14 12:28
1944,46,GlaxoSmithKline,Large Pharma,615,Zofran,ondansetron,Small Molecule (Chemical),Launched,In-House,Feb-91,Jan-90,Nov-06,Jul-05,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1311,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1944,46,GlaxoSmithKline,Large Pharma,615,Zofran,ondansetron,Small Molecule (Chemical),Launched,In-House,Feb-91,Jan-90,Nov-06,Jul-05,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,4,Global,Sales,169.9595242,145.2300054,150.6989868,131.5573965,119.2335975,111.9987501,104.8879822,99.43442962,95.02343268,91.34069232,88.3627102,85.92967419,-4.571563467,1311,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1944,46,GlaxoSmithKline,Large Pharma,615,Zofran,ondansetron,Small Molecule (Chemical),Launched,In-House,Feb-91,Jan-90,Nov-06,Jul-05,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1311,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1944,46,GlaxoSmithKline,Large Pharma,615,Zofran,ondansetron,Small Molecule (Chemical),Launched,In-House,Feb-91,Jan-90,Nov-06,Jul-05,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,4,ROW,Sales,155.926169,134.415005,139.4767218,120.4621944,108.4965573,101.2720528,94.16800772,88.71923877,84.30888956,80.62645955,77.64860806,75.21560084,-5.099105844,1311,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1944,46,GlaxoSmithKline,Large Pharma,615,Zofran,ondansetron,Small Molecule (Chemical),Launched,In-House,Feb-91,Jan-90,Nov-06,Jul-05,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1311,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1944,46,GlaxoSmithKline,Large Pharma,615,Zofran,ondansetron,Small Molecule (Chemical),Launched,In-House,Feb-91,Jan-90,Nov-06,Jul-05,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,4,US,Sales,14.03335521,10.81500041,11.22226497,11.09520212,10.73704022,10.72669732,10.71997443,10.71519084,10.71454312,10.71423277,10.71410215,10.71407335,-3.06E-02,1311,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
1945,16,AstraZeneca,Large Pharma,1518,Zoladex,goserelin,Small Molecule (Chemical),Launched,In-House,May-95,May-95,Expired,Jun-09,33,LHRH Analogs,55,Hormonals,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1312,Prostate Cancer,7/7/14 12:28
1945,16,AstraZeneca,Large Pharma,1518,Zoladex,goserelin,Small Molecule (Chemical),Launched,In-House,May-95,May-95,Expired,Jun-09,33,LHRH Analogs,55,Hormonals,3,Oncology,6,Global,Sales,1086,1115,1179,1093,996,972.04,949.154,934.0831,926.503765,921.4014998,918.2911098,916.4648485,-1.18186703,1312,Prostate Cancer,7/7/14 12:28
1945,16,AstraZeneca,Large Pharma,1518,Zoladex,goserelin,Small Molecule (Chemical),Launched,In-House,May-95,May-95,Expired,Jun-09,33,LHRH Analogs,55,Hormonals,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1312,Prostate Cancer,7/7/14 12:28
1945,16,AstraZeneca,Large Pharma,1518,Zoladex,goserelin,Small Molecule (Chemical),Launched,In-House,May-95,May-95,Expired,Jun-09,33,LHRH Analogs,55,Hormonals,3,Oncology,6,ROW,Sales,1032,1069,1140,1069,973,950.96,929.352,914.7056,907.42016,902.476864,899.44224,897.6592845,-1.144732096,1312,Prostate Cancer,7/7/14 12:28
1945,16,AstraZeneca,Large Pharma,1518,Zoladex,goserelin,Small Molecule (Chemical),Launched,In-House,May-95,May-95,Expired,Jun-09,33,LHRH Analogs,55,Hormonals,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1312,Prostate Cancer,7/7/14 12:28
1945,16,AstraZeneca,Large Pharma,1518,Zoladex,goserelin,Small Molecule (Chemical),Launched,In-House,May-95,May-95,Expired,Jun-09,33,LHRH Analogs,55,Hormonals,3,Oncology,6,US,Sales,54,46,39,24,23,21.08,19.802,19.3775,19.083605,18.92463575,18.84886981,18.80556399,-2.83533147,1312,Prostate Cancer,7/7/14 12:28
1948,76,Pfizer,Large Pharma,447,Zoloft,sertraline,Small Molecule (Chemical),Launched,In-House,Feb-92,Dec-90,Jun-06,Mar-04,127,Serotonergics,49,Depression,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1314,Depression,7/7/14 12:28
1948,76,Pfizer,Large Pharma,447,Zoloft,sertraline,Small Molecule (Chemical),Launched,In-House,Feb-92,Dec-90,Jun-06,Mar-04,127,Serotonergics,49,Depression,12,Central Nervous System,6,Global,Sales,516,531.84,573,541,469,428.2,403.33296,363.778002,342.8917118,330.050506,321.9993461,317.2192739,-5.432701044,1314,Depression,7/7/14 12:28
1948,76,Pfizer,Large Pharma,447,Zoloft,sertraline,Small Molecule (Chemical),Launched,In-House,Feb-92,Dec-90,Jun-06,Mar-04,127,Serotonergics,49,Depression,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1314,Depression,7/7/14 12:28
1948,76,Pfizer,Large Pharma,447,Zoloft,sertraline,Small Molecule (Chemical),Launched,In-House,Feb-92,Dec-90,Jun-06,Mar-04,127,Serotonergics,49,Depression,12,Central Nervous System,6,ROW,Sales,434,461,510,473,425,393.8,372.77296,334.754002,314.4821118,301.886666,293.9338101,289.1930595,-5.351408036,1314,Depression,7/7/14 12:28
1948,76,Pfizer,Large Pharma,447,Zoloft,sertraline,Small Molecule (Chemical),Launched,In-House,Feb-92,Dec-90,Jun-06,Mar-04,127,Serotonergics,49,Depression,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1314,Depression,7/7/14 12:28
1948,76,Pfizer,Large Pharma,447,Zoloft,sertraline,Small Molecule (Chemical),Launched,In-House,Feb-92,Dec-90,Jun-06,Mar-04,127,Serotonergics,49,Depression,12,Central Nervous System,6,US,Sales,82,70.84,63,68,44,34.4,30.56,29.024,28.4096,28.16384,28.065536,28.0262144,-6.240346389,1314,Depression,7/7/14 12:28
1949,67,Novartis,Large Pharma,1382,Zometa,zoledronate,Small Molecule (Chemical),Launched,In-House,Oct-01,Jun-01,Mar-13,Mar-13,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1315,Hypercalcemia of Malignancy,7/7/14 12:28
1949,67,Novartis,Large Pharma,1382,Zometa,zoledronate,Small Molecule (Chemical),Launched,In-House,Oct-01,Jun-01,Mar-13,Mar-13,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,6,Global,Sales,1469,1511,1487,1288,600,371,258.12,174.844,130.9492,106.17452,90.743268,81.684494,-24.78851269,1315,Hypercalcemia of Malignancy,7/7/14 12:28
1949,67,Novartis,Large Pharma,1382,Zometa,zoledronate,Small Molecule (Chemical),Launched,In-House,Oct-01,Jun-01,Mar-13,Mar-13,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1315,Hypercalcemia of Malignancy,7/7/14 12:28
1949,67,Novartis,Large Pharma,1382,Zometa,zoledronate,Small Molecule (Chemical),Launched,In-House,Oct-01,Jun-01,Mar-13,Mar-13,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,6,ROW,Sales,751,790,845,727,485,270,188.52,127.064,87.7952,66.04832,52.070208,43.523456,-29.13592911,1315,Hypercalcemia of Malignancy,7/7/14 12:28
1949,67,Novartis,Large Pharma,1382,Zometa,zoledronate,Small Molecule (Chemical),Launched,In-House,Oct-01,Jun-01,Mar-13,Mar-13,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1315,Hypercalcemia of Malignancy,7/7/14 12:28
1949,67,Novartis,Large Pharma,1382,Zometa,zoledronate,Small Molecule (Chemical),Launched,In-House,Oct-01,Jun-01,Mar-13,Mar-13,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,6,US,Sales,718,721,642,561,115,101,69.6,47.78,43.154,40.1262,38.67306,38.161038,-14.57983567,1315,Hypercalcemia of Malignancy,7/7/14 12:28
1950,16,AstraZeneca,Large Pharma,812,Zomig,zolmitriptan,Small Molecule (Chemical),Launched,Acquisition (Development),Jan-98,Jan-97,May-13,Mar-12,117,Triptans,8,Migraine,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1316,Migraine,7/7/14 12:28
1950,16,AstraZeneca,Large Pharma,812,Zomig,zolmitriptan,Small Molecule (Chemical),Launched,Acquisition (Development),Jan-98,Jan-97,May-13,Mar-12,117,Triptans,8,Migraine,12,Central Nervous System,6,Global,Sales,434,428,413,182,42,21,13,7.8966,5.148,3.156,2.972,2.792,-32.10940507,1316,Migraine,7/7/14 12:28
1950,16,AstraZeneca,Large Pharma,812,Zomig,zolmitriptan,Small Molecule (Chemical),Launched,Acquisition (Development),Jan-98,Jan-97,May-13,Mar-12,117,Triptans,8,Migraine,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1316,Migraine,7/7/14 12:28
1950,16,AstraZeneca,Large Pharma,812,Zomig,zolmitriptan,Small Molecule (Chemical),Launched,Acquisition (Development),Jan-98,Jan-97,May-13,Mar-12,117,Triptans,8,Migraine,12,Central Nervous System,6,ROW,Sales,252,252,255,170,42,21,13,7.8966,5.148,3.156,2.972,2.792,-32.10940507,1316,Migraine,7/7/14 12:28
1950,16,AstraZeneca,Large Pharma,812,Zomig,zolmitriptan,Small Molecule (Chemical),Launched,Acquisition (Development),Jan-98,Jan-97,May-13,Mar-12,117,Triptans,8,Migraine,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1316,Migraine,7/7/14 12:28
1950,16,AstraZeneca,Large Pharma,812,Zomig,zolmitriptan,Small Molecule (Chemical),Launched,Acquisition (Development),Jan-98,Jan-97,May-13,Mar-12,117,Triptans,8,Migraine,12,Central Nervous System,6,US,Sales,182,176,158,12,0,0,0,0,0,0,0,0,0,1316,Migraine,7/7/14 12:28
1951,37,Eisai,Regional & Specialty Pharma,12,Zonegran,zonisamide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-00,Mar-05,Jan-06,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1317,Epilepsy,7/7/14 12:28
1951,37,Eisai,Regional & Specialty Pharma,12,Zonegran,zonisamide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-00,Mar-05,Jan-06,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,Global,Sales,71.45964838,67.47610552,72.93116383,72.83438104,90.72475943,91.49136451,100.4276205,103.9791248,108.9412649,112.3434262,115.6888171,111.7119873,3.01739216,1317,Epilepsy,7/7/14 12:28
1951,37,Eisai,Regional & Specialty Pharma,12,Zonegran,zonisamide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-00,Mar-05,Jan-06,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1317,Epilepsy,7/7/14 12:28
1951,37,Eisai,Regional & Specialty Pharma,12,Zonegran,zonisamide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-00,Mar-05,Jan-06,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,ROW,Sales,49.55699458,50.1931854,56.97747174,57.7859552,70.47405572,70.47405572,79.33365121,82.87748941,87.83886289,91.24094756,94.58633082,90.60950021,3.65542854,1317,Epilepsy,7/7/14 12:28
1951,37,Eisai,Regional & Specialty Pharma,12,Zonegran,zonisamide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-00,Mar-05,Jan-06,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1317,Epilepsy,7/7/14 12:28
1951,37,Eisai,Regional & Specialty Pharma,12,Zonegran,zonisamide,Small Molecule (Chemical),Launched,Licensed (Development),Jan-00,Mar-05,Jan-06,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,US,Sales,21.9026538,17.28292012,15.95369209,15.04842583,20.25070371,21.0173088,21.09396931,21.10163536,21.10240196,21.10247862,21.10248629,21.10248706,0.590325854,1317,Epilepsy,7/7/14 12:28
1953,61,Merck & Co,Large Pharma,1621,Zostavax,varicella zoster vaccine,Vaccine,Launched,In-House,May-06,Aug-11,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1679,herpes zoster prevention,7/7/14 12:28
1953,61,Merck & Co,Large Pharma,1621,Zostavax,varicella zoster vaccine,Vaccine,Launched,In-House,May-06,Aug-11,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,277.4,243,332,651,758,859.86635,926.2095963,930.5739176,890.8400176,866.2793391,825.8324814,806.7717966,0.894799615,1679,herpes zoster prevention,7/7/14 12:28
1953,61,Merck & Co,Large Pharma,1621,Zostavax,varicella zoster vaccine,Vaccine,Launched,In-House,May-06,Aug-11,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1679,herpes zoster prevention,7/7/14 12:28
1953,61,Merck & Co,Large Pharma,1621,Zostavax,varicella zoster vaccine,Vaccine,Launched,In-House,May-06,Aug-11,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,12,44,105,157.06635,184.9695963,191.3084218,168.4449109,165.2223224,163.7827281,162.8159776,6.467084541,1679,herpes zoster prevention,7/7/14 12:28
1953,61,Merck & Co,Large Pharma,1621,Zostavax,varicella zoster vaccine,Vaccine,Launched,In-House,May-06,Aug-11,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1679,herpes zoster prevention,7/7/14 12:28
1953,61,Merck & Co,Large Pharma,1621,Zostavax,varicella zoster vaccine,Vaccine,Launched,In-House,May-06,Aug-11,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,277.4,243,320,607,653,702.8,741.24,739.2654958,722.3951067,701.0570167,662.0497533,643.955819,-0.199044438,1679,herpes zoster prevention,7/7/14 12:28
1955,76,Pfizer,Large Pharma,730,Zosyn,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-93,Jul-93,Sep-09,Oct-09,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1591,bacterial infections,7/7/14 12:28
1955,76,Pfizer,Large Pharma,730,Zosyn,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-93,Jul-93,Sep-09,Oct-09,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,215,952,636,484,395,299,238.84,191.283,151.372025,117.3952869,87.02972639,59.21734954,-23.74564173,1591,bacterial infections,7/7/14 12:28
1955,76,Pfizer,Large Pharma,730,Zosyn,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-93,Jul-93,Sep-09,Oct-09,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1591,bacterial infections,7/7/14 12:28
1955,76,Pfizer,Large Pharma,730,Zosyn,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-93,Jul-93,Sep-09,Oct-09,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,77,325,292,267,223,200,170,140.835,114.061625,87.33224688,61.46403039,36.47181354,-22.79156409,1591,bacterial infections,7/7/14 12:28
1955,76,Pfizer,Large Pharma,730,Zosyn,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-93,Jul-93,Sep-09,Oct-09,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1591,bacterial infections,7/7/14 12:28
1955,76,Pfizer,Large Pharma,730,Zosyn,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-93,Jul-93,Sep-09,Oct-09,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,138,627,344,217,172,99,68.84,50.448,37.3104,30.06304,25.565696,22.745536,-25.10010143,1591,bacterial infections,7/7/14 12:28
1955,76,Wyeth,Large Pharma,730,Zosyn,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-93,Jul-93,Sep-09,Oct-09,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,Global,Proforma,956,0,0,0,0,0,0,0,0,0,0,0,0,1591,bacterial infections,7/7/14 12:28
1955,76,Wyeth,Large Pharma,730,Zosyn,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-93,Jul-93,Sep-09,Oct-09,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,ROW,Proforma,329,0,0,0,0,0,0,0,0,0,0,0,0,1591,bacterial infections,7/7/14 12:28
1955,76,Wyeth,Large Pharma,730,Zosyn,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-93,Jul-93,Sep-09,Oct-09,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,US,Proforma,627,0,0,0,0,0,0,0,0,0,0,0,0,1591,bacterial infections,7/7/14 12:28
1956,46,GlaxoSmithKline,Large Pharma,1442,Zovirax,acyclovir,Small Molecule (Chemical),Launched,In-House,Jul-82,Jul-81,Mar-97,Mar-97,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,4,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1318,Herpes zoster and H simplex,7/7/14 12:28
1956,46,GlaxoSmithKline,Large Pharma,1442,Zovirax,acyclovir,Small Molecule (Chemical),Launched,In-House,Jul-82,Jul-81,Mar-97,Mar-97,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,4,Global,Sales,118.2565604,234.8400088,174.7466974,141.0675698,126.6365363,121.6336114,119.2572221,118.0815348,117.4949418,117.2017704,117.0551972,116.9819119,-1.126487943,1318,Herpes zoster and H simplex,7/7/14 12:28
1956,46,GlaxoSmithKline,Large Pharma,1442,Zovirax,acyclovir,Small Molecule (Chemical),Launched,In-House,Jul-82,Jul-81,Mar-97,Mar-97,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,4,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1318,Herpes zoster and H simplex,7/7/14 12:28
1956,46,GlaxoSmithKline,Large Pharma,1442,Zovirax,acyclovir,Small Molecule (Chemical),Launched,In-House,Jul-82,Jul-81,Mar-97,Mar-97,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,4,ROW,Sales,107.505964,152.9550057,157.1117096,136.3124832,125.0731222,120.3828802,118.0377592,116.8651987,116.2789184,115.9857783,115.8392082,115.7659232,-1.09860955,1318,Herpes zoster and H simplex,7/7/14 12:28
1956,46,GlaxoSmithKline,Large Pharma,1442,Zovirax,acyclovir,Small Molecule (Chemical),Launched,In-House,Jul-82,Jul-81,Mar-97,Mar-97,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1318,Herpes zoster and H simplex,7/7/14 12:28
1956,46,GlaxoSmithKline,Large Pharma,1442,Zovirax,acyclovir,Small Molecule (Chemical),Launched,In-House,Jul-82,Jul-81,Mar-97,Mar-97,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,4,US,Sales,10.7505964,81.88500307,17.63498782,4.755086622,1.563414028,1.250731223,1.219462942,1.216336114,1.216023431,1.215992163,1.215989036,1.215988723,-3.526518756,1318,Herpes zoster and H simplex,7/7/14 12:28
1958,8,Allergan,Regional & Specialty Pharma,3563,Zymar / Zymaxid,gatifloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-03,,Oct-13,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1320,Bacterial conjunctivitis ,7/7/14 12:28
1958,8,Allergan,Regional & Specialty Pharma,3563,Zymar / Zymaxid,gatifloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-03,,Oct-13,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Sales,101.196175,103,102.568452,103,98,64.74940478,33.57356194,24.23620622,19.03377432,15.91163746,13.82848221,11.72933058,-26.15984803,1320,Bacterial conjunctivitis ,7/7/14 12:28
1958,8,Allergan,Regional & Specialty Pharma,3563,Zymar / Zymaxid,gatifloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-03,,Oct-13,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1320,Bacterial conjunctivitis ,7/7/14 12:28
1958,8,Allergan,Regional & Specialty Pharma,3563,Zymar / Zymaxid,gatifloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-03,,Oct-13,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1320,Bacterial conjunctivitis ,7/7/14 12:28
1958,8,Allergan,Regional & Specialty Pharma,3563,Zymar / Zymaxid,gatifloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-03,,Oct-13,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1320,Bacterial conjunctivitis ,7/7/14 12:28
1958,8,Allergan,Regional & Specialty Pharma,3563,Zymar / Zymaxid,gatifloxacin,Small Molecule (Chemical),Launched,Licensed (Development),Apr-03,,Oct-13,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Sales,101.196175,103,102.568452,103,98,64.74940478,33.57356194,24.23620622,19.03377432,15.91163746,13.82848221,11.72933058,-26.15984803,1320,Bacterial conjunctivitis ,7/7/14 12:28
1959,39,Eli Lilly,Large Pharma,765,Zyprexa,olanzapine,Small Molecule (Chemical),Launched,In-House,Oct-96,Dec-96,Oct-11,Sep-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1321,Schizophrenia,7/7/14 12:28
1959,39,Eli Lilly,Large Pharma,765,Zyprexa,olanzapine,Small Molecule (Chemical),Launched,In-House,Oct-96,Dec-96,Oct-11,Sep-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,4916,5026.4,4622,1701.4,1194,1064.52,1025.0145,989.1321566,863.8852707,793.1124391,664.5703564,552.6001048,-10.42207548,1321,Schizophrenia,7/7/14 12:28
1959,39,Eli Lilly,Large Pharma,765,Zyprexa,olanzapine,Small Molecule (Chemical),Launched,In-House,Oct-96,Dec-96,Oct-11,Sep-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1321,Schizophrenia,7/7/14 12:28
1959,39,Eli Lilly,Large Pharma,765,Zyprexa,olanzapine,Small Molecule (Chemical),Launched,In-House,Oct-96,Dec-96,Oct-11,Sep-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,2584,2530.9,2456.7,1341,1071,988.02,951.2145,917.7921566,794.1852707,729.1524391,633.4103564,537.8401048,-9.371187959,1321,Schizophrenia,7/7/14 12:28
1959,39,Eli Lilly,Large Pharma,765,Zyprexa,olanzapine,Small Molecule (Chemical),Launched,In-House,Oct-96,Dec-96,Oct-11,Sep-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1321,Schizophrenia,7/7/14 12:28
1959,39,Eli Lilly,Large Pharma,765,Zyprexa,olanzapine,Small Molecule (Chemical),Launched,In-House,Oct-96,Dec-96,Oct-11,Sep-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,2332,2495.5,2165.3,360.4,123,76.5,73.8,71.34,69.7,63.96,31.16,14.76,-26.13229684,1321,Schizophrenia,7/7/14 12:28
1961,105,UCB,Regional & Specialty Pharma,983,Zyrtec,cetirizine,Small Molecule (Chemical),Launched,In-House,Feb-96,Oct-87,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1389,Allergic Rhinitis,7/7/14 12:28
1961,105,UCB,Regional & Specialty Pharma,983,Zyrtec,cetirizine,Small Molecule (Chemical),Launched,In-House,Feb-96,Oct-87,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,Global,Sales,372.3855719,303.3688515,361.5136298,320.0325602,271.3899852,267.882426,257.0794348,246.9999422,243.7724513,240.4556154,238.1917943,237.0008784,-1.916999639,1389,Allergic Rhinitis,7/7/14 12:28
1961,105,UCB,Regional & Specialty Pharma,983,Zyrtec,cetirizine,Small Molecule (Chemical),Launched,In-House,Feb-96,Oct-87,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1389,Allergic Rhinitis,7/7/14 12:28
1961,105,UCB,Regional & Specialty Pharma,983,Zyrtec,cetirizine,Small Molecule (Chemical),Launched,In-House,Feb-96,Oct-87,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,ROW,Sales,355.7115911,292.770813,350.3901335,309.7503896,261.6219231,258.3284086,247.7073553,237.7910717,234.6530781,231.4012918,229.1834786,228.0227718,-1.944485917,1389,Allergic Rhinitis,7/7/14 12:28
1961,105,UCB,Regional & Specialty Pharma,983,Zyrtec,cetirizine,Small Molecule (Chemical),Launched,In-House,Feb-96,Oct-87,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1389,Allergic Rhinitis,7/7/14 12:28
1961,105,UCB,Regional & Specialty Pharma,983,Zyrtec,cetirizine,Small Molecule (Chemical),Launched,In-House,Feb-96,Oct-87,Expired,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,2,US,Sales,16.67398083,10.59803848,11.1234963,10.28217061,9.768062079,9.554017466,9.372079544,9.208870527,9.119373123,9.054323628,9.008315741,8.978106605,-1.197472449,1389,Allergic Rhinitis,7/7/14 12:28
1962,76,Pfizer,Large Pharma,1571,Zyvox,linezolid,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-00,Feb-01,May-13,Jan-16,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1528,,7/7/14 12:28
1962,76,Pfizer,Large Pharma,1571,Zyvox,linezolid,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-00,Feb-01,May-13,Jan-16,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,1141,1176,1283,1345,1353,1365.96,1136.28784,658.54203,489.0529836,390.5111486,324.3999144,275.2916868,-20.3448769,1528,,7/7/14 12:28
1962,76,Pfizer,Large Pharma,1571,Zyvox,linezolid,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-00,Feb-01,May-13,Jan-16,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1528,,7/7/14 12:28
1962,76,Pfizer,Large Pharma,1571,Zyvox,linezolid,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-00,Feb-01,May-13,Jan-16,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,507,563,643,680,665,666.96,667.348,433.63203,325.5769836,260.195927,216.8289353,184.1380059,-16.76005894,1528,,7/7/14 12:28
1962,76,Pfizer,Large Pharma,1571,Zyvox,linezolid,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-00,Feb-01,May-13,Jan-16,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1528,,7/7/14 12:28
1962,76,Pfizer,Large Pharma,1571,Zyvox,linezolid,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-00,Feb-01,May-13,Jan-16,178,Oxazolidinones,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,634,613,640,665,688,699,468.93984,224.91,163.476,130.3152216,107.5709791,91.15368091,-25.07994407,1528,,7/7/14 12:28
1963,29,Chugai,Regional & Specialty Pharma,894,Mircera,PEG-epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-11,N/A,Jul-20,102,ESAs,24,Anemia,14,Hematology,3,Global,Alliance Revenue,0,0,74.00524099,214.2800122,230.6017004,266.473076,295.2194584,313.3172752,325.7408243,334.4360223,340.2831359,344.2915489,5.892753291,1584,Renal Anemia,7/7/14 12:28
1963,29,Chugai,Regional & Specialty Pharma,894,Mircera,PEG-epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-11,N/A,Jul-20,102,ESAs,24,Anemia,14,Hematology,3,ROW,Alliance Revenue,0,0,74.00524099,214.2800122,230.6017004,266.473076,295.2194584,313.3172752,325.7408243,334.4360223,340.2831359,344.2915489,5.892753291,1584,Renal Anemia,7/7/14 12:28
1963,29,Chugai,Regional & Specialty Pharma,894,Mircera,PEG-epoetin beta,Recombinant Protein,Launched,Licensed (Development),,Jul-11,N/A,Jul-20,102,ESAs,24,Anemia,14,Hematology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1584,Renal Anemia,7/7/14 12:28
1976,46,GlaxoSmithKline,Large Pharma,1738,Bosatria,mepolizumab,Antibody/Antibody Derivative,Phase III,In-House,Jul-15,Jul-15,N/A,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,28.92315952,106.0516813,202.4622043,298.8726813,352.4039715,395.9252366,0,267,Asthma,7/7/14 12:28
1976,46,GlaxoSmithKline,Large Pharma,1738,Bosatria,mepolizumab,Antibody/Antibody Derivative,Phase III,In-House,Jul-15,Jul-15,N/A,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,5.471949098,20.0638316,38.30366027,56.54348025,68.80064482,79.47459062,0,267,Asthma,7/7/14 12:28
1976,46,GlaxoSmithKline,Large Pharma,1738,Bosatria,mepolizumab,Antibody/Antibody Derivative,Phase III,In-House,Jul-15,Jul-15,N/A,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,23.45121042,85.98784971,164.158544,242.3292011,283.6033267,316.450646,0,267,Asthma,7/7/14 12:28
1982,29,Chugai,Regional & Specialty Pharma,1703,Perjeta,pertuzumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-13,N/A,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,3,Global,Alliance Revenue,0,0,0,0,24.59751471,53.29461521,74.12774676,98.66865424,107.3583541,149.1710104,190.5293866,220.9245768,36.83371602,1589,Breast Cancer,7/7/14 12:28
1982,29,Chugai,Regional & Specialty Pharma,1703,Perjeta,pertuzumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-13,N/A,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,3,ROW,Alliance Revenue,0,0,0,0,24.59751471,53.29461521,74.12774676,98.66865424,107.3583541,149.1710104,190.5293866,220.9245768,36.83371602,1589,Breast Cancer,7/7/14 12:28
1982,29,Chugai,Regional & Specialty Pharma,1703,Perjeta,pertuzumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-13,N/A,Dec-22,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1589,Breast Cancer,7/7/14 12:28
1988,100,Takeda,Large Pharma,1763,Seltouch,transdermal felbinac,Small Molecule (Chemical),Launched,In-House,,Sep-93,N/A,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,113.1192268,101.5536542,98.76095102,86.67893281,65.46228854,59.75265984,54.81623221,50.34730037,46.46144441,43.04472996,40.03040965,37.38293311,-7.691786141,1075,Rheumatoid Arthritis,7/7/14 12:28
1988,100,Takeda,Large Pharma,1763,Seltouch,transdermal felbinac,Small Molecule (Chemical),Launched,In-House,,Sep-93,N/A,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,113.1192268,101.5536542,98.76095102,86.67893281,65.46228854,59.75265984,54.81623221,50.34730037,46.46144441,43.04472996,40.03040965,37.38293311,-7.691786141,1075,Rheumatoid Arthritis,7/7/14 12:28
1988,100,Takeda,Large Pharma,1763,Seltouch,transdermal felbinac,Small Molecule (Chemical),Launched,In-House,,Sep-93,N/A,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1075,Rheumatoid Arthritis,7/7/14 12:28
1990,29,Chugai,Regional & Specialty Pharma,1513,Xeloda,capecitabine,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-03,,Jun-19,78,Anti-metabolites,51,Cytotoxics,3,Oncology,3,Global,Alliance Revenue,70.53561648,121.9292165,125.4326119,143.5928176,115.8132984,110.6888162,111.6141269,117.1164011,122.1391872,124.841301,112.1582926,92.17592173,-3.208544077,1376,Solid Tumors,7/7/14 12:28
1990,29,Chugai,Regional & Specialty Pharma,1513,Xeloda,capecitabine,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-03,,Jun-19,78,Anti-metabolites,51,Cytotoxics,3,Oncology,3,ROW,Alliance Revenue,70.53561648,121.9292165,125.4326119,143.5928176,115.8132984,110.6888162,111.6141269,117.1164011,122.1391872,124.841301,112.1582926,92.17592173,-3.208544077,1376,Solid Tumors,7/7/14 12:28
1990,29,Chugai,Regional & Specialty Pharma,1513,Xeloda,capecitabine,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-03,,Jun-19,78,Anti-metabolites,51,Cytotoxics,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1376,Solid Tumors,7/7/14 12:28
2003,100,Takeda,Large Pharma,296,motesanib,motesanib,Small Molecule (Chemical),Phase III,Licensed (Development),,,N/A,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1554,Non-small-cell Lung Cancer,7/7/14 12:28
2003,100,Takeda,Large Pharma,296,motesanib,motesanib,Small Molecule (Chemical),Phase III,Licensed (Development),,,N/A,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1554,Non-small-cell Lung Cancer,7/7/14 12:28
2003,100,Takeda,Large Pharma,296,motesanib,motesanib,Small Molecule (Chemical),Phase III,Licensed (Development),,,N/A,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1554,Non-small-cell Lung Cancer,7/7/14 12:28
2004,68,Novo Nordisk,Regional & Specialty Pharma,3894,NovoEight,turoctocog alfa,Recombinant Protein,Launched,In-House,Apr-15,Jan-14,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,Global,Sales,0,0,0,0,0,17.45115235,36.9650416,56.47889595,75.11698024,90.26494136,102.2126651,112.184772,0,786,Hemophilia A,7/7/14 12:28
2004,68,Novo Nordisk,Regional & Specialty Pharma,3894,NovoEight,turoctocog alfa,Recombinant Protein,Launched,In-House,Apr-15,Jan-14,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,ROW,Sales,0,0,0,0,0,17.45115235,29.0853121,40.71943693,52.35338726,60.49721845,67.41946642,73.1812108,0,786,Hemophilia A,7/7/14 12:28
2004,68,Novo Nordisk,Regional & Specialty Pharma,3894,NovoEight,turoctocog alfa,Recombinant Protein,Launched,In-House,Apr-15,Jan-14,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,US,Sales,0,0,0,0,0,0,7.879729507,15.75945901,22.76359298,29.7677229,34.79319864,39.00356119,0,786,Hemophilia A,7/7/14 12:28
2007,19,Bayer,Large Pharma,1790,rFVIIa,rFVIIa,Recombinant Protein,Phase III,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,959,Hemophilia A,7/7/14 12:28
2007,19,Bayer,Large Pharma,1790,rFVIIa,rFVIIa,Recombinant Protein,Phase III,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,959,Hemophilia A,7/7/14 12:28
2007,19,Bayer,Large Pharma,1790,rFVIIa,rFVIIa,Recombinant Protein,Phase III,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,959,Hemophilia A,7/7/14 12:28
2010,34,Daiichi-Sankyo,Regional & Specialty Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-07,N/A,Aug-13,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,100.4849647,78.72436538,70.57594325,57.15562934,46.85358601,44.50282577,42.11688775,40.21436519,38.5180305,37.00000376,35.66184271,34.47867247,-4.286643247,1605,Osteoporosis,7/7/14 12:28
2010,34,Daiichi-Sankyo,Regional & Specialty Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-07,N/A,Aug-13,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,100.4849647,78.72436538,70.57594325,57.15562934,46.85358601,44.50282577,42.11688775,40.21436519,38.5180305,37.00000376,35.66184271,34.47867247,-4.286643247,1605,Osteoporosis,7/7/14 12:28
2010,34,Daiichi-Sankyo,Regional & Specialty Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-07,N/A,Aug-13,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1605,Osteoporosis,7/7/14 12:28
2013,26,Celgene,Regional & Specialty Pharma,1795,Calsed,amrubicin,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,121,Small-cell Lung Cancer,7/7/14 12:28
2013,26,Celgene,Regional & Specialty Pharma,1795,Calsed,amrubicin,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,121,Small-cell Lung Cancer,7/7/14 12:28
2013,26,Celgene,Regional & Specialty Pharma,1795,Calsed,amrubicin,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,121,Small-cell Lung Cancer,7/7/14 12:28
2016,41,Enzon,Small Biotech,1798,PEG-SN38,EZN-2208,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,854,Colon Cancer,7/7/14 12:28
2016,41,Enzon,Small Biotech,1798,PEG-SN38,EZN-2208,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,854,Colon Cancer,7/7/14 12:28
2016,41,Enzon,Small Biotech,1798,PEG-SN38,EZN-2208,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,854,Colon Cancer,7/7/14 12:28
2017,100,Takeda,Large Pharma,1801,Rheumatrex,methotrexate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-99,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,99.41597568,106.0019101,117.4863575,119.2205601,103.3890978,107.1037284,110.9021004,114.2781008,117.4914949,120.5327493,123.3766102,126.0558973,2.872272508,1009,Rheumatoid arthritis,7/7/14 12:28
2017,100,Takeda,Large Pharma,1801,Rheumatrex,methotrexate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-99,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,99.41597568,106.0019101,117.4863575,119.2205601,103.3890978,107.1037284,110.9021004,114.2781008,117.4914949,120.5327493,123.3766102,126.0558973,2.872272508,1009,Rheumatoid arthritis,7/7/14 12:28
2017,100,Takeda,Large Pharma,1801,Rheumatrex,methotrexate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-99,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1009,Rheumatoid arthritis,7/7/14 12:28
2018,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1802,afacifenacin,SMP-986,Small Molecule (Chemical),Phase II,In-House,,,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1102,Overactive bladder,7/7/14 12:28
2018,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1802,afacifenacin,SMP-986,Small Molecule (Chemical),Phase II,In-House,,,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1102,Overactive bladder,7/7/14 12:28
2018,35,Dainippon-Sumitomo,Regional & Specialty Pharma,1802,afacifenacin,SMP-986,Small Molecule (Chemical),Phase II,In-House,,,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1102,Overactive bladder,7/7/14 12:28
2019,29,Chugai,Regional & Specialty Pharma,1803,Suvenyl,hyaluronic acid,Small Molecule (Chemical),Launched,In-House,,Aug-00,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,Global,Alliance Revenue,146.4148403,154.9754527,163.0623954,154.0967176,121.9626771,117.1712862,113.3926211,109.7503473,106.5964483,103.7080749,101.1401091,98.8211649,-2.961034319,1705,Osteoarthritis pain,7/7/14 12:28
2019,29,Chugai,Regional & Specialty Pharma,1803,Suvenyl,hyaluronic acid,Small Molecule (Chemical),Launched,In-House,,Aug-00,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,ROW,Alliance Revenue,146.4148403,154.9754527,163.0623954,154.0967176,121.9626771,117.1712862,113.3926211,109.7503473,106.5964483,103.7080749,101.1401091,98.8211649,-2.961034319,1705,Osteoarthritis pain,7/7/14 12:28
2019,29,Chugai,Regional & Specialty Pharma,1803,Suvenyl,hyaluronic acid,Small Molecule (Chemical),Launched,In-House,,Aug-00,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1705,Osteoarthritis pain,7/7/14 12:28
2019,86,Roche,Large Pharma,1803,Suvenyl,hyaluronic acid,Small Molecule (Chemical),Launched,In-House,,Aug-00,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,Global,Sales,146.4148403,154.9754527,163.0623954,154.0967176,121.9626771,117.1712862,113.3926211,109.7503473,106.5964483,103.7080749,101.1401091,98.8211649,-2.961034319,1705,Osteoarthritis pain,7/7/14 12:28
2019,86,Roche,Large Pharma,1803,Suvenyl,hyaluronic acid,Small Molecule (Chemical),Launched,In-House,,Aug-00,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,5,ROW,Sales,146.4148403,154.9754527,163.0623954,154.0967176,121.9626771,117.1712862,113.3926211,109.7503473,106.5964483,103.7080749,101.1401091,98.8211649,-2.961034319,1705,Osteoarthritis pain,7/7/14 12:28
2021,100,Takeda,Large Pharma,1805,namilumab,MT203,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,750,Rheumatoid arthritis,7/7/14 12:28
2021,100,Takeda,Large Pharma,1805,namilumab,MT203,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,750,Rheumatoid arthritis,7/7/14 12:28
2021,100,Takeda,Large Pharma,1805,namilumab,MT203,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,750,Rheumatoid arthritis,7/7/14 12:28
2023,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-11,Aug-21,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,0,0,11.39549435,63.80532554,95.91753913,165.0031059,204.3220795,238.5498948,268.458594,291.6191362,310.7980469,326.5615974,19.12680865,1487,Rheumatoid arthritis,7/7/14 12:28
2023,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-11,Aug-21,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,11.39549435,63.80532554,95.91753913,165.0031059,204.3220795,238.5498948,268.458594,291.6191362,310.7980469,326.5615974,19.12680865,1487,Rheumatoid arthritis,7/7/14 12:28
2023,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1336,Simponi,golimumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Sep-11,Aug-21,Aug-21,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1487,Rheumatoid arthritis,7/7/14 12:28
2027,21,Biogen Idec,Regional & Specialty Pharma,1810,Fumaderm,dimethylfumarate and monoethylfumarate salts,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-94,N/A,N/A,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,49.624,51.19,54.7,59.68,60.23,61.7126,62.85398,63.529262,64.115207,64.54950686,64.86630076,65.1098263,1.11914227,475,Psoriasis,7/7/14 12:28
2027,21,Biogen Idec,Regional & Specialty Pharma,1810,Fumaderm,dimethylfumarate and monoethylfumarate salts,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-94,N/A,N/A,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,49.624,51.19,54.7,59.68,60.23,61.7126,62.85398,63.529262,64.115207,64.54950686,64.86630076,65.1098263,1.11914227,475,Psoriasis,7/7/14 12:28
2027,21,Biogen Idec,Regional & Specialty Pharma,1810,Fumaderm,dimethylfumarate and monoethylfumarate salts,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-94,N/A,N/A,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,475,Psoriasis,7/7/14 12:28
2029,70,Ono,Regional & Specialty Pharma,1812,Kinedak,epalrestat,Small Molecule (Chemical),Launched,In-House,,Jan-92,N/A,Expired,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,167.6753386,154.0814063,141.8105963,104.7370438,81.00281485,70.87746299,63.78971669,58.82829428,55.3552986,52.92420162,51.22243373,40.27088898,-9.501448109,590,Painful Diabetic Neuropathy,7/7/14 12:28
2029,70,Ono,Regional & Specialty Pharma,1812,Kinedak,epalrestat,Small Molecule (Chemical),Launched,In-House,,Jan-92,N/A,Expired,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,167.6753386,154.0814063,141.8105963,104.7370438,81.00281485,70.87746299,63.78971669,58.82829428,55.3552986,52.92420162,51.22243373,40.27088898,-9.501448109,590,Painful Diabetic Neuropathy,7/7/14 12:28
2029,70,Ono,Regional & Specialty Pharma,1812,Kinedak,epalrestat,Small Molecule (Chemical),Launched,In-House,,Jan-92,N/A,Expired,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,590,Painful Diabetic Neuropathy,7/7/14 12:28
2030,40,Endo Health Solutions,Regional & Specialty Pharma,2008,Fortesta,testosterone gel,Small Molecule (Chemical),Launched,Licensed (Development),Feb-11,,Jun-15,N/A,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,Global,Sales,0,0,14.9,30.6,66,85.31688,53.70276806,10.83076611,6.00515458,3.839361545,6.86649011,4.118,-32.72128952,467,Hypogonadism,7/7/14 12:28
2030,40,Endo Health Solutions,Regional & Specialty Pharma,2008,Fortesta,testosterone gel,Small Molecule (Chemical),Launched,Licensed (Development),Feb-11,,Jun-15,N/A,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,467,Hypogonadism,7/7/14 12:28
2030,40,Endo Health Solutions,Regional & Specialty Pharma,2008,Fortesta,testosterone gel,Small Molecule (Chemical),Launched,Licensed (Development),Feb-11,,Jun-15,N/A,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,US,Sales,0,0,14.9,30.6,66,85.31688,53.70276806,10.83076611,6.00515458,3.839361545,6.86649011,4.118,-32.72128952,467,Hypogonadism,7/7/14 12:28
2031,26,Celgene,Regional & Specialty Pharma,1813,Pomalyst / Imnovid,pomalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Feb-13,Aug-13,Feb-20,Aug-23,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,305,558,806.49067,1036.593308,1103.633138,1152.993359,1176.057531,1182.211279,21.35463868,918,Multiple Myeloma,7/7/14 12:28
2031,26,Celgene,Regional & Specialty Pharma,1813,Pomalyst / Imnovid,pomalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Feb-13,Aug-13,Feb-20,Aug-23,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,59,163,248.04362,333.0878556,366.5290173,383.4904281,395.8624281,402.371466,31.5559874,918,Multiple Myeloma,7/7/14 12:28
2031,26,Celgene,Regional & Specialty Pharma,1813,Pomalyst / Imnovid,pomalidomide,Small Molecule (Chemical),Launched,Licensed (Development),Feb-13,Aug-13,Feb-20,Aug-23,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,246,395,558.44705,703.5054526,737.1041212,769.5029306,780.1951032,779.839813,17.91835155,918,Multiple Myeloma,7/7/14 12:28
2032,26,Celgene,Regional & Specialty Pharma,1814,CC-11050,CC-11050,Small Molecule (Chemical),Phase II,In-House,,,N/A,N/A,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,294,Cutaneous Lupus,7/7/14 12:28
2032,26,Celgene,Regional & Specialty Pharma,1814,CC-11050,CC-11050,Small Molecule (Chemical),Phase II,In-House,,,N/A,N/A,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,294,Cutaneous Lupus,7/7/14 12:28
2032,26,Celgene,Regional & Specialty Pharma,1814,CC-11050,CC-11050,Small Molecule (Chemical),Phase II,In-House,,,N/A,N/A,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,294,Cutaneous Lupus,7/7/14 12:28
2034,26,Celgene,Regional & Specialty Pharma,1816,ACE-011,sotatercept,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,65,Myelodysplastic syndromes,7/7/14 12:28
2034,26,Celgene,Regional & Specialty Pharma,1816,ACE-011,sotatercept,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,65,Myelodysplastic syndromes,7/7/14 12:28
2034,26,Celgene,Regional & Specialty Pharma,1816,ACE-011,sotatercept,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,65,Myelodysplastic syndromes,7/7/14 12:28
2036,15,Astellas Pharma,Regional & Specialty Pharma,266,Qutenza,capsaicin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-10,N/A,N/A,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,2.334566763,6.330830193,9.630992534,11.15373566,11.54357566,13.19457544,14.82875895,16.35905454,17.78609706,19.26554341,30.20316674,15.29342173,1377,Neuropathic Pain,7/7/14 12:28
2036,15,Astellas Pharma,Regional & Specialty Pharma,266,Qutenza,capsaicin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-10,N/A,N/A,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,2.334566763,6.330830193,9.630992534,11.15373566,11.54357566,13.19457544,14.82875895,16.35905454,17.78609706,19.26554341,30.20316674,15.29342173,1377,Neuropathic Pain,7/7/14 12:28
2036,15,Astellas Pharma,Regional & Specialty Pharma,266,Qutenza,capsaicin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-10,N/A,N/A,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1377,Neuropathic Pain,7/7/14 12:28
2039,89,Genzyme,Large Pharma,1547,Fludara,fludarabine phosphate,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-91,Dec-94,Expired,Dec-21,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,Global,Proforma,60,108,32.79430183,0,0,0,0,0,0,0,0,0,0,1470,Chronic Lymphocytic Leukemia,7/7/14 12:28
2039,89,Genzyme,Large Pharma,1547,Fludara,fludarabine phosphate,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-91,Dec-94,Expired,Dec-21,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,ROW,Proforma,60,108,32.79430183,0,0,0,0,0,0,0,0,0,0,1470,Chronic Lymphocytic Leukemia,7/7/14 12:28
2039,89,Sanofi,Large Pharma,1547,Fludara,fludarabine phosphate,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-91,Dec-94,Expired,Dec-21,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,Global,Sales,0,0,66.20282279,70.68992294,59.09945563,48.64280713,40.80032075,34.91845597,30.50705738,27.19850844,24.71709673,22.85603795,-12.69086265,1470,Chronic Lymphocytic Leukemia,7/7/14 12:28
2039,89,Sanofi,Large Pharma,1547,Fludara,fludarabine phosphate,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-91,Dec-94,Expired,Dec-21,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,ROW,Sales,0,0,66.20282279,70.68992294,59.09945563,48.64280713,40.80032075,34.91845597,30.50705738,27.19850844,24.71709673,22.85603795,-12.69086265,1470,Chronic Lymphocytic Leukemia,7/7/14 12:28
2039,89,Sanofi,Large Pharma,1547,Fludara,fludarabine phosphate,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-91,Dec-94,Expired,Dec-21,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1470,Chronic Lymphocytic Leukemia,7/7/14 12:28
2041,89,Genzyme,Large Pharma,1647,Campath,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-01,Aug-01,N/A,N/A,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,Global,Proforma,40,104,53.23723926,0,0,0,0,0,0,0,0,0,0,1334,Chronic Lymphocytic Leukemia,7/7/14 12:28
2041,89,Genzyme,Large Pharma,1647,Campath,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-01,Aug-01,N/A,N/A,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,ROW,Proforma,19,51,39.75,0,0,0,0,0,0,0,0,0,0,1334,Chronic Lymphocytic Leukemia,7/7/14 12:28
2041,89,Genzyme,Large Pharma,1647,Campath,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-01,Aug-01,N/A,N/A,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,US,Proforma,21,53,13.48723926,0,0,0,0,0,0,0,0,0,0,1334,Chronic Lymphocytic Leukemia,7/7/14 12:28
2041,89,Sanofi,Large Pharma,1647,Campath,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-01,Aug-01,N/A,N/A,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,Global,Sales,0,0,53.76276074,73.52591562,0,0,0,0,0,0,0,0,0,1334,Chronic Lymphocytic Leukemia,7/7/14 12:28
2041,89,Sanofi,Large Pharma,1647,Campath,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-01,Aug-01,N/A,N/A,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,ROW,Sales,0,0,13.25,32.67818472,0,0,0,0,0,0,0,0,0,1334,Chronic Lymphocytic Leukemia,7/7/14 12:28
2041,89,Sanofi,Large Pharma,1647,Campath,alemtuzumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jun-01,Aug-01,N/A,N/A,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,US,Sales,0,0,40.51276074,40.8477309,0,0,0,0,0,0,0,0,0,1334,Chronic Lymphocytic Leukemia,7/7/14 12:28
2056,34,Daiichi-Sankyo,Regional & Specialty Pharma,983,Zyrtec,cetirizine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-98,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,Global,Sales,103.423293,101.5536542,101.3428662,94.73643547,91.00580632,88.39436591,21.87870723,0,0,0,0,0,-100,1389,Allergic Rhinitis,7/7/14 12:28
2056,34,Daiichi-Sankyo,Regional & Specialty Pharma,983,Zyrtec,cetirizine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-98,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,ROW,Sales,103.423293,101.5536542,101.3428662,94.73643547,91.00580632,88.39436591,21.87870723,0,0,0,0,0,-100,1389,Allergic Rhinitis,7/7/14 12:28
2056,34,Daiichi-Sankyo,Regional & Specialty Pharma,983,Zyrtec,cetirizine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-98,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1389,Allergic Rhinitis,7/7/14 12:28
2059,45,Gilead,Regional & Specialty Pharma,1884,Stribild,elvitegravir / cobicistat / tenofovir / emtricitabine FDC,Small Molecule (Chemical),Launched,In-House,Aug-12,May-13,N/A,N/A,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,57.536,538.3,770,873,609,364,215.55,124.6475,63.152375,-26.37042057,950,HIV,7/7/14 12:28
2059,45,Gilead,Regional & Specialty Pharma,1884,Stribild,elvitegravir / cobicistat / tenofovir / emtricitabine FDC,Small Molecule (Chemical),Launched,In-House,Aug-12,May-13,N/A,N/A,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,29.3,144,227,251,147,75,53.16,34.498,2.360481018,950,HIV,7/7/14 12:28
2059,45,Gilead,Regional & Specialty Pharma,1884,Stribild,elvitegravir / cobicistat / tenofovir / emtricitabine FDC,Small Molecule (Chemical),Launched,In-House,Aug-12,May-13,N/A,N/A,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,57.536,509,626,646,358,217,140.55,71.4875,28.654375,-33.70262336,950,HIV,7/7/14 12:28
2060,45,Gilead,Regional & Specialty Pharma,2507,Tybost,cobicistat,Small Molecule (Chemical),Launched,In-House,Jun-14,Dec-13,,Jan-27,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0.6666664,40.93112969,121.444448,145.7777968,133,109,82,76.73777626,96.98930797,505,HIV,7/7/14 12:28
2060,45,Gilead,Regional & Specialty Pharma,2507,Tybost,cobicistat,Small Molecule (Chemical),Launched,In-House,Jun-14,Dec-13,,Jan-27,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0.6666664,9.111129689,22.44444799,35.77779676,35,32,28,26.77777626,69.48195959,505,HIV,7/7/14 12:28
2060,45,Gilead,Regional & Specialty Pharma,2507,Tybost,cobicistat,Small Molecule (Chemical),Launched,In-House,Jun-14,Dec-13,,Jan-27,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,31.82,99,110,98,77,54,49.96,0,505,HIV,7/7/14 12:28
2069,45,Gilead,Regional & Specialty Pharma,4625,Complera / Eviplera,Rilpivirine / Truvada FDC,Small Molecule (Chemical),Launched,Licensed (Development),Aug-11,Dec-11,,,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,38.75,342.13,809,1034.21338,1194.871656,1317.578517,1400.255952,1458.568925,1500.629361,1530.647199,9.537014649,1014,HIV,7/7/14 12:28
2069,45,Gilead,Regional & Specialty Pharma,4625,Complera / Eviplera,Rilpivirine / Truvada FDC,Small Molecule (Chemical),Launched,Licensed (Development),Aug-11,Dec-11,,,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0.24,62.13,306,433.21338,492.871656,539.5785168,566.2559525,581.968925,592.0493606,598.0851993,10.04677859,1014,HIV,7/7/14 12:28
2069,45,Gilead,Regional & Specialty Pharma,4625,Complera / Eviplera,Rilpivirine / Truvada FDC,Small Molecule (Chemical),Launched,Licensed (Development),Aug-11,Dec-11,,,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,6,US,Sales,0,0,38.51,280,503,601,702,778,834,876.6,908.58,932.562,9.219793647,1014,HIV,7/7/14 12:28
2070,190,Meda,Regional & Specialty Pharma,3580,Onsolis / Breakyl,fentanyl - BEMA,Small Molecule (Chemical),Launched,Acquisition (Marketed),Oct-09,Jul-11,Dec-19,Oct-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,9,Global,Sales,0.783728917,3.470575306,8.557780769,4.109635955,1.181302928,3.319012705,4.960911644,6.455147717,7.788931456,8.94376544,9.964884902,10.74860172,37.08771357,1463,Cancer Pain,7/7/14 12:28
2070,190,Meda,Regional & Specialty Pharma,3580,Onsolis / Breakyl,fentanyl - BEMA,Small Molecule (Chemical),Launched,Acquisition (Marketed),Oct-09,Jul-11,Dec-19,Oct-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,9,ROW,Sales,0,0,0.858197958,0.733863563,0.442988598,1.47662866,2.657931588,3.69157165,4.553922787,5.335945325,6.021101024,6.449161033,46.60828094,1463,Cancer Pain,7/7/14 12:28
2070,190,Meda,Regional & Specialty Pharma,3580,Onsolis / Breakyl,fentanyl - BEMA,Small Molecule (Chemical),Launched,Acquisition (Marketed),Oct-09,Jul-11,Dec-19,Oct-20,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,9,US,Sales,0.783728917,3.470575306,7.699582811,3.375772391,0.73831433,1.842384045,2.302980056,2.763576067,3.235008669,3.607820114,3.943783878,4.299440689,28.62043842,1463,Cancer Pain,7/7/14 12:28
2071,15,Astellas Pharma,Regional & Specialty Pharma,4229,Regnite,gabapentin enacarbil,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-12,N/A,Jun-21,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,7,Global,Sales,0,0,0,6.251059207,20.13544449,35.61597692,61.16438565,69.32435747,75.26060347,79.47092199,81.67813296,83.09971306,22.4470259,1479,Restless Legs Syndrome,7/7/14 12:28
2071,15,Astellas Pharma,Regional & Specialty Pharma,4229,Regnite,gabapentin enacarbil,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-12,N/A,Jun-21,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,7,ROW,Sales,0,0,0,6.251059207,20.13544449,35.61597692,61.16438565,69.32435747,75.26060347,79.47092199,81.67813296,83.09971306,22.4470259,1479,Restless Legs Syndrome,7/7/14 12:28
2071,15,Astellas Pharma,Regional & Specialty Pharma,4229,Regnite,gabapentin enacarbil,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-12,N/A,Jun-21,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1479,Restless Legs Syndrome,7/7/14 12:28
2073,21,Biogen Idec,Regional & Specialty Pharma,3784,Fampyra,dalfampridine,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-11,,Jul-21,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,13.6,57.4,74,108.82366,124.4611665,137.335686,146.2317316,152.3706013,156.724019,159.7610427,11.62164143,1409,Improving walking speed in MS patients,7/7/14 12:28
2073,21,Biogen Idec,Regional & Specialty Pharma,3784,Fampyra,dalfampridine,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-11,,Jul-21,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,13.6,57.4,74,108.82366,124.4611665,137.335686,146.2317316,152.3706013,156.724019,159.7610427,11.62164143,1409,Improving walking speed in MS patients,7/7/14 12:28
2073,21,Biogen Idec,Regional & Specialty Pharma,3784,Fampyra,dalfampridine,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-11,,Jul-21,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1409,Improving walking speed in MS patients,7/7/14 12:28
2076,16,AstraZeneca,Large Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-14,Nov-12,Oct-20,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,4,10,4.4,0,0,0,0,0,0,-100,1411,Type II Diabetes,7/7/14 12:28
2076,16,AstraZeneca,Large Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-14,Nov-12,Oct-20,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,86,222,408,696,901,1107,1296,0,1411,Type II Diabetes,7/7/14 12:28
2076,16,AstraZeneca,Large Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-14,Nov-12,Oct-20,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,4,10,4.4,0,0,0,0,0,0,-100,1411,Type II Diabetes,7/7/14 12:28
2076,16,AstraZeneca,Large Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-14,Nov-12,Oct-20,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,56,93,126,159,194,228,252,0,1411,Type II Diabetes,7/7/14 12:28
2076,16,AstraZeneca,Large Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-14,Nov-12,Oct-20,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1411,Type II Diabetes,7/7/14 12:28
2076,16,AstraZeneca,Large Pharma,4545,Forxiga / Xigduo,dapagliflozin / dapagliflozin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-14,Nov-12,Oct-20,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,30,129,282,537,707,879,1044,0,1411,Type II Diabetes,7/7/14 12:28
2077,151,Yakult Honsha,Regional & Specialty Pharma,1900,Elplat,oxaliplatin,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-05,N/A,Dec-14,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,Global,Sales,262.8999,341.1853,370.9866,328.296458,243.6388783,225.3526624,179.2668168,152.1616066,133.3421303,116.8739887,103.0474355,91.20395605,-13.09631027,1573,Colorectal Cancer,7/7/14 12:28
2077,151,Yakult Honsha,Regional & Specialty Pharma,1900,Elplat,oxaliplatin,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-05,N/A,Dec-14,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,ROW,Sales,262.8999,341.1853,370.9866,328.296458,243.6388783,225.3526624,179.2668168,152.1616066,133.3421303,116.8739887,103.0474355,91.20395605,-13.09631027,1573,Colorectal Cancer,7/7/14 12:28
2077,151,Yakult Honsha,Regional & Specialty Pharma,1900,Elplat,oxaliplatin,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-05,N/A,Dec-14,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1573,Colorectal Cancer,7/7/14 12:28
2078,16,AstraZeneca,Large Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Sep-09,Mar-21,Mar-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,12,84,211,323,378,43,0,0,0,0,0,0,-100,1630,Type II Diabetes,7/7/14 12:28
2078,16,AstraZeneca,Large Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Sep-09,Mar-21,Mar-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,957,1179,1290,1387,1468,1536.705,1594.85186,0,1630,Type II Diabetes,7/7/14 12:28
2078,16,AstraZeneca,Large Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Sep-09,Mar-21,Mar-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,1,15,55,86,113,14,0,0,0,0,0,0,-100,1630,Type II Diabetes,7/7/14 12:28
2078,16,AstraZeneca,Large Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Sep-09,Mar-21,Mar-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,315,394,440,475,505,531,551.93,0,1630,Type II Diabetes,7/7/14 12:28
2078,16,AstraZeneca,Large Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Sep-09,Mar-21,Mar-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,11,69,156,237,265,29,0,0,0,0,0,0,-100,1630,Type II Diabetes,7/7/14 12:28
2078,16,AstraZeneca,Large Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-09,Sep-09,Mar-21,Mar-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,642,785,850,912,963,1005.705,1042.92186,0,1630,Type II Diabetes,7/7/14 12:28
2080,67,Novartis,Large Pharma,4220,secukinumab,AIN457,Antibody/Antibody Derivative,Phase III,In-House,Aug-16,Sep-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,26.66667,114.4445409,231.1116012,347.7786785,436.4900632,0,1346,Rheumatoid Arthritis,7/7/14 12:28
2080,67,Novartis,Large Pharma,4220,secukinumab,AIN457,Antibody/Antibody Derivative,Phase III,In-House,Aug-16,Sep-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,9.99999,46.66665333,96.66670571,146.6665926,184.533226,0,1346,Rheumatoid Arthritis,7/7/14 12:28
2080,67,Novartis,Large Pharma,4220,secukinumab,AIN457,Antibody/Antibody Derivative,Phase III,In-House,Aug-16,Sep-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,16.66668,67.77788756,134.4448955,201.1120859,251.9568371,0,1346,Rheumatoid Arthritis,7/7/14 12:28
2081,70,Ono,Regional & Specialty Pharma,1908,Glactiv,sitagliptin,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-09,N/A,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,Global,Sales,15.719563,126.7414142,353.2603248,418.9481752,394.8887224,432.9120565,460.6708886,481.1865768,496.9006731,508.6387858,517.4506395,524.0927474,4.12665074,1636,Type II Diabetes,7/7/14 12:28
2081,70,Ono,Regional & Specialty Pharma,1908,Glactiv,sitagliptin,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-09,N/A,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,ROW,Sales,15.719563,126.7414142,353.2603248,418.9481752,394.8887224,432.9120565,460.6708886,481.1865768,496.9006731,508.6387858,517.4506395,524.0927474,4.12665074,1636,Type II Diabetes,7/7/14 12:28
2081,70,Ono,Regional & Specialty Pharma,1908,Glactiv,sitagliptin,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-09,N/A,Jul-22,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1636,Type II Diabetes,7/7/14 12:28
2082,150,Taisho,Regional & Specialty Pharma,3037,parogrelil,NT-702,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1565,Asthma,7/7/14 12:28
2082,150,Taisho,Regional & Specialty Pharma,3037,parogrelil,NT-702,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1565,Asthma,7/7/14 12:28
2082,150,Taisho,Regional & Specialty Pharma,3037,parogrelil,NT-702,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1565,Asthma,7/7/14 12:28
2084,11,Amgen,Large Pharma,2539,omecamtiv mecarbil,omecamtiv mecarbil,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,109,Heart Failure,7/7/14 12:28
2084,11,Amgen,Large Pharma,2539,omecamtiv mecarbil,omecamtiv mecarbil,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,109,Heart Failure,7/7/14 12:28
2084,11,Amgen,Large Pharma,2539,omecamtiv mecarbil,omecamtiv mecarbil,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,109,Heart Failure,7/7/14 12:28
2085,47,Grunenthal,Regional & Specialty Pharma,1920,axomadol,axomadol,Small Molecule (Chemical),Phase II,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,182,Pain,7/7/14 12:28
2085,47,Grunenthal,Regional & Specialty Pharma,1920,axomadol,axomadol,Small Molecule (Chemical),Phase II,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,182,Pain,7/7/14 12:28
2085,47,Grunenthal,Regional & Specialty Pharma,1920,axomadol,axomadol,Small Molecule (Chemical),Phase II,In-House,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,182,Pain,7/7/14 12:28
2096,61,Merck & Co,Large Pharma,4313,Saflutan / Zioptan,tafluprost,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-12,Sep-08,Dec-22,Dec-22,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,Global,Sales,8,14,24.18178,40,41.8990932,40.47882859,39.52254311,38.5128207,36.77174588,35.08298953,34.65077115,34.27703056,-2.827659118,1647,Glaucoma,7/7/14 12:28
2096,61,Merck & Co,Large Pharma,4313,Saflutan / Zioptan,tafluprost,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-12,Sep-08,Dec-22,Dec-22,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,ROW,Sales,8,14,24.18178,25,26.3990932,25.92882859,26.22254311,26.4228207,25.97174588,25.18298953,24.93077115,24.66503056,-0.965920716,1647,Glaucoma,7/7/14 12:28
2096,61,Merck & Co,Large Pharma,4313,Saflutan / Zioptan,tafluprost,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-12,Sep-08,Dec-22,Dec-22,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,6,US,Sales,0,0,0,15,15.5,14.55,13.3,12.09,10.8,9.9,9.72,9.612,-6.598336704,1647,Glaucoma,7/7/14 12:28
2098,67,Novartis,Large Pharma,1931,buparlisib,duvelisib,Small Molecule (Chemical),Phase III,In-House,Nov-17,Dec-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,19.166687,172.7781842,279.4452015,386.1126574,0,251,Breast Cancer,7/7/14 12:28
2098,67,Novartis,Large Pharma,1931,buparlisib,duvelisib,Small Molecule (Chemical),Phase III,In-House,Nov-17,Dec-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,7.499997,95.000212,155.0004459,215.0011185,0,251,Breast Cancer,7/7/14 12:28
2098,67,Novartis,Large Pharma,1931,buparlisib,duvelisib,Small Molecule (Chemical),Phase III,In-House,Nov-17,Dec-17,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,11.66669,77.77797222,124.4447556,171.1115389,0,251,Breast Cancer,7/7/14 12:28
2099,67,Novartis,Large Pharma,1933,LCL161,LCL161,Small Molecule (Chemical),Phase II,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,612,Solid Tumors,7/7/14 12:28
2099,67,Novartis,Large Pharma,1933,LCL161,LCL161,Small Molecule (Chemical),Phase II,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,612,Solid Tumors,7/7/14 12:28
2099,67,Novartis,Large Pharma,1933,LCL161,LCL161,Small Molecule (Chemical),Phase II,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,612,Solid Tumors,7/7/14 12:28
2100,67,Novartis,Large Pharma,1934,LDE225,sonidegib,Small Molecule (Chemical),Phase III,In-House,Jul-15,Oct-15,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,12.3875,27.62973063,39.17711936,57.73685866,68.79163133,78.17498144,0,615,Basal Cell Carcinoma,7/7/14 12:28
2100,67,Novartis,Large Pharma,1934,LDE225,sonidegib,Small Molecule (Chemical),Phase III,In-House,Jul-15,Oct-15,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,4.2,12.18,17.2199622,25.19986488,30.16842288,34.28879246,0,615,Basal Cell Carcinoma,7/7/14 12:28
2100,67,Novartis,Large Pharma,1934,LDE225,sonidegib,Small Molecule (Chemical),Phase III,In-House,Jul-15,Oct-15,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,8.1875,15.44973062,21.95715716,32.53699377,38.62320845,43.88618898,0,615,Basal Cell Carcinoma,7/7/14 12:28
2108,76,Pfizer,Large Pharma,3293,Xiapex,collagenase,Recombinant Protein,Launched,Licensed (Development),,Mar-11,N/A,Feb-21,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Sales,0,0,24.9375,52.19169375,24,0,0,0,0,0,0,0,-100,1401,Dupuytren's Disease,7/7/14 12:28
2108,76,Pfizer,Large Pharma,3293,Xiapex,collagenase,Recombinant Protein,Launched,Licensed (Development),,Mar-11,N/A,Feb-21,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,24.9375,52.19169375,24,0,0,0,0,0,0,0,-100,1401,Dupuytren's Disease,7/7/14 12:28
2108,76,Pfizer,Large Pharma,3293,Xiapex,collagenase,Recombinant Protein,Launched,Licensed (Development),,Mar-11,N/A,Feb-21,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1401,Dupuytren's Disease,7/7/14 12:28
2112,100,Takeda,Large Pharma,949,trebananib,trebananib,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Dec-15,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,4.027088898,9.665013355,13.69213447,20.13551603,24.02570443,27.30417746,0,1340,Ovarian Cancer,7/7/14 12:28
2112,100,Takeda,Large Pharma,949,trebananib,trebananib,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Dec-15,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,4.027088898,9.665013355,13.69213447,20.13551603,24.02570443,27.30417746,0,1340,Ovarian Cancer,7/7/14 12:28
2112,100,Takeda,Large Pharma,949,trebananib,trebananib,Antibody/Antibody Derivative,Phase III,Licensed (Development),,Dec-15,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1340,Ovarian Cancer,7/7/14 12:28
2114,102,Teva,Regional & Specialty Pharma,417,Nerventra,laquinimod,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1511,Crohn's Disease,7/7/14 12:28
2114,102,Teva,Regional & Specialty Pharma,417,Nerventra,laquinimod,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1511,Crohn's Disease,7/7/14 12:28
2114,102,Teva,Regional & Specialty Pharma,417,Nerventra,laquinimod,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1511,Crohn's Disease,7/7/14 12:28
2120,29,Chugai,Regional & Specialty Pharma,806,Femara,letrozole,Small Molecule (Chemical),Launched,Licensed (Development),,May-06,N/A,Jun-15,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,3,Global,Alliance Revenue,25.64931508,33.07430918,45.15574027,46.63741441,49.89144845,55.26471289,59.786387,61.76756364,57.8005562,55.26401859,53.69433069,51.69314789,0.508080474,1516,Breast Cancer,7/7/14 12:28
2120,29,Chugai,Regional & Specialty Pharma,806,Femara,letrozole,Small Molecule (Chemical),Launched,Licensed (Development),,May-06,N/A,Jun-15,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,3,ROW,Alliance Revenue,25.64931508,33.07430918,45.15574027,46.63741441,49.89144845,55.26471289,59.786387,61.76756364,57.8005562,55.26401859,53.69433069,51.69314789,0.508080474,1516,Breast Cancer,7/7/14 12:28
2120,29,Chugai,Regional & Specialty Pharma,806,Femara,letrozole,Small Molecule (Chemical),Launched,Licensed (Development),,May-06,N/A,Jun-15,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1516,Breast Cancer,7/7/14 12:28
2120,86,Roche,Large Pharma,806,Femara,letrozole,Small Molecule (Chemical),Launched,Licensed (Development),,May-06,N/A,Jun-15,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,5,Global,Sales,25.64931508,33.07430918,45.15574027,46.63741441,49.89144845,55.26471289,59.786387,61.76756364,57.8005562,55.26401859,53.69433069,51.69314789,0.508080474,1516,Breast Cancer,7/7/14 12:28
2120,86,Roche,Large Pharma,806,Femara,letrozole,Small Molecule (Chemical),Launched,Licensed (Development),,May-06,N/A,Jun-15,120,Aromatase Inhibitors,55,Hormonals,3,Oncology,5,ROW,Sales,25.64931508,33.07430918,45.15574027,46.63741441,49.89144845,55.26471289,59.786387,61.76756364,57.8005562,55.26401859,53.69433069,51.69314789,0.508080474,1516,Breast Cancer,7/7/14 12:28
2124,29,Chugai,Regional & Specialty Pharma,1958,Oxarol,maxacalcitol,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Dec-10,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,Global,Alliance Revenue,113.284475,134.0850372,153.7576059,154.0967176,125.0373664,114.788402,110.5114121,106.1768812,101.7767569,98.29210146,95.1486845,92.35098052,-4.236444829,833,Secondary Hyperparathyroidism,7/7/14 12:28
2124,29,Chugai,Regional & Specialty Pharma,1958,Oxarol,maxacalcitol,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Dec-10,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,ROW,Alliance Revenue,113.284475,134.0850372,153.7576059,154.0967176,125.0373664,114.788402,110.5114121,106.1768812,101.7767569,98.29210146,95.1486845,92.35098052,-4.236444829,833,Secondary Hyperparathyroidism,7/7/14 12:28
2124,29,Chugai,Regional & Specialty Pharma,1958,Oxarol,maxacalcitol,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Dec-10,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,833,Secondary Hyperparathyroidism,7/7/14 12:28
2124,86,Roche,Large Pharma,1958,Oxarol,maxacalcitol,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Dec-10,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,5,Global,Sales,113.284475,134.0850372,153.7576059,154.0967176,125.0373664,114.788402,110.5114121,106.1768812,101.7767569,98.29210146,95.1486845,92.35098052,-4.236444829,833,Secondary Hyperparathyroidism,7/7/14 12:28
2124,86,Roche,Large Pharma,1958,Oxarol,maxacalcitol,Small Molecule (Chemical),Launched,In-House,,Sep-00,N/A,Dec-10,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,5,ROW,Sales,113.284475,134.0850372,153.7576059,154.0967176,125.0373664,114.788402,110.5114121,106.1768812,101.7767569,98.29210146,95.1486845,92.35098052,-4.236444829,833,Secondary Hyperparathyroidism,7/7/14 12:28
2125,29,Chugai,Regional & Specialty Pharma,1959,Renagel,sevelamer,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-03,N/A,Apr-17,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,3,Global,Alliance Revenue,56.64223748,55.836744,37.2572072,37.81411979,33.0993191,29.72199694,29.47945921,28.75548723,28.56218529,28.37873051,28.30337916,28.25161794,-2.236913397,966,Hyperphosphatemia ,7/7/14 12:28
2125,29,Chugai,Regional & Specialty Pharma,1959,Renagel,sevelamer,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-03,N/A,Apr-17,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,3,ROW,Alliance Revenue,56.64223748,55.836744,37.2572072,37.81411979,33.0993191,29.72199694,29.47945921,28.75548723,28.56218529,28.37873051,28.30337916,28.25161794,-2.236913397,966,Hyperphosphatemia ,7/7/14 12:28
2125,29,Chugai,Regional & Specialty Pharma,1959,Renagel,sevelamer,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-03,N/A,Apr-17,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,966,Hyperphosphatemia ,7/7/14 12:28
2125,86,Roche,Large Pharma,1959,Renagel,sevelamer,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-03,N/A,Apr-17,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,5,Global,Sales,56.64223748,55.836744,37.2572072,37.81411979,33.0993191,29.72199694,29.47945921,28.75548723,28.56218529,28.37873051,28.30337916,28.25161794,-2.236913397,966,Hyperphosphatemia ,7/7/14 12:28
2125,86,Roche,Large Pharma,1959,Renagel,sevelamer,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-03,N/A,Apr-17,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,5,ROW,Sales,56.64223748,55.836744,37.2572072,37.81411979,33.0993191,29.72199694,29.47945921,28.75548723,28.56218529,28.37873051,28.30337916,28.25161794,-2.236913397,966,Hyperphosphatemia ,7/7/14 12:28
2128,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3983,Telavic,telaprevir,Small Molecule (Chemical),Launched,Licensed (Development),,Nov-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,7,Global,Sales,0,0,18.99249058,63.76080391,22.27577408,10.06772225,10.06772225,10.06772225,2.013544449,0,0,0,-100,1653,Hepatitis C,7/7/14 12:28
2128,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3983,Telavic,telaprevir,Small Molecule (Chemical),Launched,Licensed (Development),,Nov-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,7,ROW,Sales,0,0,18.99249058,63.76080391,22.27577408,10.06772225,10.06772225,10.06772225,2.013544449,0,0,0,-100,1653,Hepatitis C,7/7/14 12:28
2128,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3983,Telavic,telaprevir,Small Molecule (Chemical),Launched,Licensed (Development),,Nov-11,N/A,N/A,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1653,Hepatitis C,7/7/14 12:28
2131,46,GlaxoSmithKline,Large Pharma,1917,Prolia,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-10,N/A,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,4,Global,Alliance Revenue,0,4.866750183,20.84134924,41.21075072,79.73411543,109.8454696,139.3686674,166.0983477,190.9093097,213.7572294,234.8503786,254.3080009,18.02101199,1415,Osteoporosis,7/7/14 12:28
2131,46,GlaxoSmithKline,Large Pharma,1917,Prolia,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-10,N/A,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Osteoporosis,7/7/14 12:28
2131,46,GlaxoSmithKline,Large Pharma,1917,Prolia,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-10,N/A,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,4,ROW,Alliance Revenue,0,4.866750183,20.84134924,41.21075072,79.73411543,109.8454696,139.3686674,166.0983477,190.9093097,213.7572294,234.8503786,254.3080009,18.02101199,1415,Osteoporosis,7/7/14 12:28
2131,46,GlaxoSmithKline,Large Pharma,1917,Prolia,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-10,N/A,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Osteoporosis,7/7/14 12:28
2131,46,GlaxoSmithKline,Large Pharma,1917,Prolia,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-10,N/A,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,4,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Osteoporosis,7/7/14 12:28
2131,46,GlaxoSmithKline,Large Pharma,1917,Prolia,denosumab,Antibody/Antibody Derivative,Launched,Licensed (Development),,Jul-10,N/A,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1415,Osteoporosis,7/7/14 12:28
2132,46,GlaxoSmithKline,Large Pharma,1966,Relenza,zanamivir,Small Molecule (Chemical),Launched,Licensed (Development),Oct-99,Feb-99,Jul-13,Feb-14,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,4,Global,Sales,1122.668417,186.945007,43.28587918,42.57018825,41.43274746,41.43274746,41.43274746,41.43274746,41.43274746,41.43274746,41.43274746,41.43274746,0,962,Influenza,7/7/14 12:28
2132,46,GlaxoSmithKline,Large Pharma,1966,Relenza,zanamivir,Small Molecule (Chemical),Launched,Licensed (Development),Oct-99,Feb-99,Jul-13,Feb-14,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,4,ROW,Sales,909.049565,120.5100045,40.07951776,39.41684098,38.36365506,38.36365506,38.36365506,38.36365506,38.36365506,38.36365506,38.36365506,38.36365506,0,962,Influenza,7/7/14 12:28
2132,46,GlaxoSmithKline,Large Pharma,1966,Relenza,zanamivir,Small Molecule (Chemical),Launched,Licensed (Development),Oct-99,Feb-99,Jul-13,Feb-14,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,4,US,Sales,213.6188515,66.43500249,3.206361421,3.153347278,3.069092405,3.069092405,3.069092405,3.069092405,3.069092405,3.069092405,3.069092405,3.069092405,0,962,Influenza,7/7/14 12:28
2133,76,King,Large Pharma,1973,Embeda,morphine + naltrexone,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-09,,Jun-27,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Proforma,174,360,20.57,0,0,0,,,,0,0,0,0,415,Pain,7/7/14 12:28
2133,76,King,Large Pharma,1973,Embeda,morphine + naltrexone,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-09,,Jun-27,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Proforma,174,360,20.57,0,0,0,,,,0,0,0,0,415,Pain,7/7/14 12:28
2133,76,Pfizer,Large Pharma,1973,Embeda,morphine + naltrexone,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-09,,Jun-27,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,3.33,0,0,9,32,48,63,74.83,84.3605,88,0,415,Pain,7/7/14 12:28
2133,76,Pfizer,Large Pharma,1973,Embeda,morphine + naltrexone,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-09,,Jun-27,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,415,Pain,7/7/14 12:28
2133,76,Pfizer,Large Pharma,1973,Embeda,morphine + naltrexone,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-09,,Jun-27,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,3.33,0,0,9,32,48,63,74.83,84.3605,88,0,415,Pain,7/7/14 12:28
2135,100,Takeda,Large Pharma,1806,veltuzumab,IMMU-106,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1680,Immune Thrombocytopenic Purpura,7/7/14 12:28
2135,100,Takeda,Large Pharma,1806,veltuzumab,IMMU-106,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1680,Immune Thrombocytopenic Purpura,7/7/14 12:28
2135,100,Takeda,Large Pharma,1806,veltuzumab,IMMU-106,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1680,Immune Thrombocytopenic Purpura,7/7/14 12:28
2142,150,Taisho,Regional & Specialty Pharma,3364,Edirol,eldecalcitol,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-11,N/A,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,0,0,25.11595198,105.9409179,142.9616559,194.1625675,231.9796543,263.0152317,287.8598147,308.3672822,325.1072391,332.2348341,12.80228313,1440,Osteoporosis ,7/7/14 12:28
2142,150,Taisho,Regional & Specialty Pharma,3364,Edirol,eldecalcitol,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-11,N/A,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,25.11595198,105.9409179,142.9616559,194.1625675,231.9796543,263.0152317,287.8598147,308.3672822,325.1072391,332.2348341,12.80228313,1440,Osteoporosis ,7/7/14 12:28
2142,150,Taisho,Regional & Specialty Pharma,3364,Edirol,eldecalcitol,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-11,N/A,N/A,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1440,Osteoporosis ,7/7/14 12:28
2143,150,Taisho,Regional & Specialty Pharma,1983,Bonviva,ibandronate,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-13,,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,8.054177796,29.2510761,42.75161776,56.25215114,66.0175356,74.160608,80.95148875,86.40549604,40.35148686,1493,Osteoporosis,7/7/14 12:28
2143,150,Taisho,Regional & Specialty Pharma,1983,Bonviva,ibandronate,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-13,,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,8.054177796,29.2510761,42.75161776,56.25215114,66.0175356,74.160608,80.95148875,86.40549604,40.35148686,1493,Osteoporosis,7/7/14 12:28
2143,150,Taisho,Regional & Specialty Pharma,1983,Bonviva,ibandronate,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-13,,N/A,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1493,Osteoporosis,7/7/14 12:28
2144,150,Taisho,Regional & Specialty Pharma,1984,TT-063,TT-063,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1211,Osteoarthritis Pain,7/7/14 12:28
2144,150,Taisho,Regional & Specialty Pharma,1984,TT-063,TT-063,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1211,Osteoarthritis Pain,7/7/14 12:28
2144,150,Taisho,Regional & Specialty Pharma,1984,TT-063,TT-063,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1211,Osteoarthritis Pain,7/7/14 12:28
2145,150,Taisho,Regional & Specialty Pharma,1909,NT-702,parogrelil,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1565,Intermittent claudication,7/7/14 12:28
2145,150,Taisho,Regional & Specialty Pharma,1909,NT-702,parogrelil,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1565,Intermittent claudication,7/7/14 12:28
2145,150,Taisho,Regional & Specialty Pharma,1909,NT-702,parogrelil,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1565,Intermittent claudication,7/7/14 12:28
2146,150,Taisho,Regional & Specialty Pharma,1985,Lusefi,luseogliflozin,Small Molecule (Chemical),Launched,In-House,,May-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,0,0,9.228748747,16.22026422,25.16930561,32.53585798,39.91383509,47.21815951,54.19008203,0,1208,Diabetes,7/7/14 12:28
2146,150,Taisho,Regional & Specialty Pharma,1985,Lusefi,luseogliflozin,Small Molecule (Chemical),Launched,In-House,,May-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,0,0,9.228748747,16.22026422,25.16930561,32.53585798,39.91383509,47.21815951,54.19008203,0,1208,Diabetes,7/7/14 12:28
2146,150,Taisho,Regional & Specialty Pharma,1985,Lusefi,luseogliflozin,Small Molecule (Chemical),Launched,In-House,,May-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1208,Diabetes,7/7/14 12:28
2148,150,Taisho,Regional & Specialty Pharma,1988,Palux,alprostadil,Small Molecule (Chemical),Launched,In-House,,Sep-88,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,116.3512047,116.670467,120.4596911,107.5182184,80.54177796,76.20581936,73.53411208,72.03183331,71.16375108,70.6662903,70.38049777,70.21643468,-1.940825791,838,Intermittent claudication,7/7/14 12:28
2148,150,Taisho,Regional & Specialty Pharma,1988,Palux,alprostadil,Small Molecule (Chemical),Launched,In-House,,Sep-88,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,116.3512047,116.670467,120.4596911,107.5182184,80.54177796,76.20581936,73.53411208,72.03183331,71.16375108,70.6662903,70.38049777,70.21643468,-1.940825791,838,Intermittent claudication,7/7/14 12:28
2148,150,Taisho,Regional & Specialty Pharma,1988,Palux,alprostadil,Small Molecule (Chemical),Launched,In-House,,Sep-88,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,838,Intermittent claudication,7/7/14 12:28
2149,37,Eisai,Regional & Specialty Pharma,3570,NerBloc,botulinum toxin B,Recombinant Protein,Launched,Licensed (Development),,Mar-13,,Jun-20,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,1.000169473,7.067867611,9.935018786,14.33573536,17.32756564,19.70025789,21.77508485,30.20316674,33.92088597,25.11551189,395,Cervical Dystonia,7/7/14 12:28
2149,37,Eisai,Regional & Specialty Pharma,3570,NerBloc,botulinum toxin B,Recombinant Protein,Launched,Licensed (Development),,Mar-13,,Jun-20,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,1.000169473,7.067867611,9.935018786,14.33573536,17.32756564,19.70025789,21.77508485,30.20316674,33.92088597,25.11551189,395,Cervical Dystonia,7/7/14 12:28
2149,37,Eisai,Regional & Specialty Pharma,3570,NerBloc,botulinum toxin B,Recombinant Protein,Launched,Licensed (Development),,Mar-13,,Jun-20,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,395,Cervical Dystonia,7/7/14 12:28
2150,37,Eisai,Regional & Specialty Pharma,42,Lunesta,eszopiclone,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-12,N/A,Dec-21,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,Global,Sales,0,0,0,31.25529604,52.09226424,72.92916994,93.76576309,113.4399466,131.6698524,148.9359263,165.1690871,180.4172325,19.41861627,1452,Insomnia,7/7/14 12:28
2150,37,Eisai,Regional & Specialty Pharma,42,Lunesta,eszopiclone,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-12,N/A,Dec-21,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,ROW,Sales,0,0,0,31.25529604,52.09226424,72.92916994,93.76576309,113.4399466,131.6698524,148.9359263,165.1690871,180.4172325,19.41861627,1452,Insomnia,7/7/14 12:28
2150,37,Eisai,Regional & Specialty Pharma,42,Lunesta,eszopiclone,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-12,N/A,Dec-21,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1452,Insomnia,7/7/14 12:28
2151,37,Eisai,Regional & Specialty Pharma,4593,Fycompa,perampanel,Small Molecule (Chemical),Launched,In-House,Mar-14,Sep-12,Jun-21,Jul-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,Global,Sales,0,0,0,14.56893817,37.2192503,83.40179751,120.3025566,153.028115,180.9074935,204.6005798,225.0237306,242.5371776,30.70347261,855,Epilepsy,7/7/14 12:28
2151,37,Eisai,Regional & Specialty Pharma,4593,Fycompa,perampanel,Small Molecule (Chemical),Launched,In-House,Mar-14,Sep-12,Jun-21,Jul-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,ROW,Sales,0,0,0,14.56893817,34.68791334,51.33811175,67.98808815,80.46271586,90.65635838,99.17480177,106.0433698,111.6633516,18.17704857,855,Epilepsy,7/7/14 12:28
2151,37,Eisai,Regional & Specialty Pharma,4593,Fycompa,perampanel,Small Molecule (Chemical),Launched,In-House,Mar-14,Sep-12,Jun-21,Jul-22,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,US,Sales,0,0,0,0,2.531336951,32.06368576,52.31446842,72.56539914,90.25113508,105.4257781,118.9803608,130.8738259,75.70570999,855,Epilepsy,7/7/14 12:28
2152,37,Eisai,Regional & Specialty Pharma,660,Methycobal,mecobalamin,Small Molecule (Chemical),Phase III,In-House,,,N/A,Expired,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1535,Amyotrophic Lateral Sclerosis,7/7/14 12:28
2152,37,Eisai,Regional & Specialty Pharma,660,Methycobal,mecobalamin,Small Molecule (Chemical),Phase III,In-House,,,N/A,Expired,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1535,Amyotrophic Lateral Sclerosis,7/7/14 12:28
2152,37,Eisai,Regional & Specialty Pharma,660,Methycobal,mecobalamin,Small Molecule (Chemical),Phase III,In-House,,,N/A,Expired,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1535,Amyotrophic Lateral Sclerosis,7/7/14 12:28
2153,86,Roche,Large Pharma,1992,Madopar,levodopa + benserazide,Small Molecule (Chemical),Launched,In-House,,Jan-73,N/A,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,5,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,663,Parkinson's Disease,7/7/14 12:28
2153,86,Roche,Large Pharma,1992,Madopar,levodopa + benserazide,Small Molecule (Chemical),Launched,In-House,,Jan-73,N/A,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,5,Global,Sales,263.3514552,292.5069839,331.1530294,330.5558852,340.5476096,341.9352791,342.2731584,342.2355846,342.1191206,342.02379,341.9375331,340.5344029,-5.54E-04,663,Parkinson's Disease,7/7/14 12:28
2153,86,Roche,Large Pharma,1992,Madopar,levodopa + benserazide,Small Molecule (Chemical),Launched,In-House,,Jan-73,N/A,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,5,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,663,Parkinson's Disease,7/7/14 12:28
2153,86,Roche,Large Pharma,1992,Madopar,levodopa + benserazide,Small Molecule (Chemical),Launched,In-House,,Jan-73,N/A,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,5,ROW,Sales,263.3514552,292.5069839,331.1530294,330.5558852,340.5476096,341.9352791,342.2731584,342.2355846,342.1191206,342.02379,341.9375331,340.5344029,-5.54E-04,663,Parkinson's Disease,7/7/14 12:28
2153,86,Roche,Large Pharma,1992,Madopar,levodopa + benserazide,Small Molecule (Chemical),Launched,In-House,,Jan-73,N/A,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,5,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,663,Parkinson's Disease,7/7/14 12:28
2153,86,Roche,Large Pharma,1992,Madopar,levodopa + benserazide,Small Molecule (Chemical),Launched,In-House,,Jan-73,N/A,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,663,Parkinson's Disease,7/7/14 12:28
2157,37,Eisai,Regional & Specialty Pharma,1995,farletuzumab,farletuzumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,440,Ovarian Cancer,7/7/14 12:28
2157,37,Eisai,Regional & Specialty Pharma,1995,farletuzumab,farletuzumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,440,Ovarian Cancer,7/7/14 12:28
2157,37,Eisai,Regional & Specialty Pharma,1995,farletuzumab,farletuzumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,440,Ovarian Cancer,7/7/14 12:28
2159,37,Eisai,Regional & Specialty Pharma,3491,lenvatinib,E7080,Small Molecule (Chemical),Phase III,In-House,Dec-14,Apr-15,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,5.033861123,40.27088898,82.55388776,159.0589999,227.0670863,268.693358,291.1579092,0,399,Thyroid Cancer,7/7/14 12:28
2159,37,Eisai,Regional & Specialty Pharma,3491,lenvatinib,E7080,Small Molecule (Chemical),Phase III,In-House,Dec-14,Apr-15,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,10.06772225,24.16185102,61.40713498,98.65217843,121.1199428,132.9726589,0,399,Thyroid Cancer,7/7/14 12:28
2159,37,Eisai,Regional & Specialty Pharma,3491,lenvatinib,E7080,Small Molecule (Chemical),Phase III,In-House,Dec-14,Apr-15,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,5.033861123,30.20316674,58.39203674,97.65186495,128.4149079,147.5734152,158.1852504,0,399,Thyroid Cancer,7/7/14 12:28
2160,37,Eisai,Regional & Specialty Pharma,4178,E7820,E7820,Small Molecule (Chemical),Phase II,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,400,Colorectal Cancer,7/7/14 12:28
2160,37,Eisai,Regional & Specialty Pharma,4178,E7820,E7820,Small Molecule (Chemical),Phase II,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,400,Colorectal Cancer,7/7/14 12:28
2160,37,Eisai,Regional & Specialty Pharma,4178,E7820,E7820,Small Molecule (Chemical),Phase II,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,400,Colorectal Cancer,7/7/14 12:28
2161,37,Eisai,Regional & Specialty Pharma,3585,amatuximab,MORAb-009,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,742,Mesothelioma,7/7/14 12:28
2161,37,Eisai,Regional & Specialty Pharma,3585,amatuximab,MORAb-009,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,742,Mesothelioma,7/7/14 12:28
2161,37,Eisai,Regional & Specialty Pharma,3585,amatuximab,MORAb-009,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,742,Mesothelioma,7/7/14 12:28
2166,51,Ipsen,Regional & Specialty Pharma,2002,Tanakan,EGb761 ,Small Molecule (Chemical),Launched,In-House,,Jul-70,N/A,Expired,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,Global,Sales,150.0658275,127.7063637,134.0381304,101.5364348,88.97801446,77.02574386,71.7136236,68.26074542,65.07347326,63.7454432,62.88222365,59.761353,-5.527499159,1161,Alzheimer's Disease,7/7/14 12:28
2166,51,Ipsen,Regional & Specialty Pharma,2002,Tanakan,EGb761 ,Small Molecule (Chemical),Launched,In-House,,Jul-70,N/A,Expired,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,ROW,Sales,150.0658275,127.7063637,134.0381304,101.5364348,88.97801446,77.02574386,71.7136236,68.26074542,65.07347326,63.7454432,62.88222365,59.761353,-5.527499159,1161,Alzheimer's Disease,7/7/14 12:28
2166,51,Ipsen,Regional & Specialty Pharma,2002,Tanakan,EGb761 ,Small Molecule (Chemical),Launched,In-House,,Jul-70,N/A,Expired,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1161,Alzheimer's Disease,7/7/14 12:28
2168,51,Ipsen,Regional & Specialty Pharma,2004,Dysport,abobotulinumtoxin A,Recombinant Protein,Launched,In-House,Nov-09,Dec-90,N/A,N/A,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,2,Global,Sales,75.44976326,79.88271504,93.57641263,100.1226363,105.3385707,112.2839082,116.9585441,120.3625998,123.4893909,125.9854985,126.3949907,128.2743216,2.854132518,392,Cervical Dystonia,7/7/14 12:28
2168,51,Ipsen,Regional & Specialty Pharma,2004,Dysport,abobotulinumtoxin A,Recombinant Protein,Launched,In-House,Nov-09,Dec-90,N/A,N/A,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,2,ROW,Sales,70.86441854,74.18626936,86.20709633,91.25426416,92.29808963,96.94619486,99.41633079,100.7549851,102.1589785,103.1175506,103.8184796,104.3697804,1.771458995,392,Cervical Dystonia,7/7/14 12:28
2168,51,Ipsen,Regional & Specialty Pharma,2004,Dysport,abobotulinumtoxin A,Recombinant Protein,Launched,In-House,Nov-09,Dec-90,N/A,N/A,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,2,US,Sales,4.585344729,5.696445683,7.369316299,8.86837215,13.04048112,15.33771334,17.54221326,19.60761472,21.33041243,22.86794786,22.57651113,23.9045412,9.043071579,392,Cervical Dystonia,7/7/14 12:28
2169,67,Novartis,Large Pharma,2006,Ritalin / Focalin,methylphenidate / dexmethylphenidate,Small Molecule (Chemical),Launched,In-House,Jan-56,Jan-50,Expired,Expired,121,Stimulants,37,ADHD,12,Central Nervous System,6,Global,Sales,449,464,550,554,594,610.4,620.96,626.824,630.2256,632.17264,633.291616,633.9339104,0.933837914,1019,ADHD,7/7/14 12:28
2169,67,Novartis,Large Pharma,2006,Ritalin / Focalin,methylphenidate / dexmethylphenidate,Small Molecule (Chemical),Launched,In-House,Jan-56,Jan-50,Expired,Expired,121,Stimulants,37,ADHD,12,Central Nervous System,6,ROW,Sales,106,125,152,152,159,161.8,163.62,164.628,165.2132,165.54808,165.740552,165.8510288,0.60447281,1019,ADHD,7/7/14 12:28
2169,67,Novartis,Large Pharma,2006,Ritalin / Focalin,methylphenidate / dexmethylphenidate,Small Molecule (Chemical),Launched,In-House,Jan-56,Jan-50,Expired,Expired,121,Stimulants,37,ADHD,12,Central Nervous System,6,US,Sales,343,339,398,402,435,448.6,457.34,462.196,465.0124,466.62456,467.551064,468.0828816,1.052634094,1019,ADHD,7/7/14 12:28
2170,70,Ono,Regional & Specialty Pharma,2007,Foipan,camostat mesilate,Small Molecule (Chemical),Launched,In-House,,Jul-85,N/A,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,Global,Sales,136.8203981,128.401172,129.1489359,105.9409179,81.44254981,75.79296064,71.11909346,67.8415985,65.33910322,63.43754149,62.02332442,60.95647875,-4.054614816,463,Chronic Pancreatitis,7/7/14 12:28
2170,70,Ono,Regional & Specialty Pharma,2007,Foipan,camostat mesilate,Small Molecule (Chemical),Launched,In-House,,Jul-85,N/A,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,ROW,Sales,136.8203981,128.401172,129.1489359,105.9409179,81.44254981,75.79296064,71.11909346,67.8415985,65.33910322,63.43754149,62.02332442,60.95647875,-4.054614816,463,Chronic Pancreatitis,7/7/14 12:28
2170,70,Ono,Regional & Specialty Pharma,2007,Foipan,camostat mesilate,Small Molecule (Chemical),Launched,In-House,,Jul-85,N/A,Expired,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,463,Chronic Pancreatitis,7/7/14 12:28
2171,111,Actavis,Regional & Specialty Pharma,2009,Loestrin 24 Fe,norethindrone + ethinylestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-06,,Jan-14,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1732,Female contraception,7/7/14 12:28
2171,111,Actavis,Regional & Specialty Pharma,2009,Loestrin 24 Fe,norethindrone + ethinylestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-06,,Jan-14,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1732,Female contraception,7/7/14 12:28
2171,111,Actavis,Regional & Specialty Pharma,2009,Loestrin 24 Fe,norethindrone + ethinylestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-06,,Jan-14,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1732,Female contraception,7/7/14 12:28
2171,111,Warner Chilcott ,Regional & Specialty Pharma,2009,Loestrin 24 Fe,norethindrone + ethinylestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-06,,Jan-14,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Proforma,248,342,396,389,279,0,0,0,0,0,0,0,-100,1732,Female contraception,7/7/14 12:28
2171,111,Warner Chilcott ,Regional & Specialty Pharma,2009,Loestrin 24 Fe,norethindrone + ethinylestradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-06,,Jan-14,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Proforma,248,342,396,389,279,0,0,0,0,0,0,0,-100,1732,Female contraception,7/7/14 12:28
2173,111,Actavis,Regional & Specialty Pharma,3110,HRT range - Actavis,HRT range,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-01,,Expired,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Sales,0,0,0,0,64.5,265.6,272.48,276.528,278.7712,280.256,281.145984,281.6816128,23.44027418,2173,Estrogen deficiency,7/7/14 12:28
2173,111,Actavis,Regional & Specialty Pharma,3110,HRT range - Actavis,HRT range,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-01,,Expired,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2173,Estrogen deficiency,7/7/14 12:28
2173,111,Actavis,Regional & Specialty Pharma,3110,HRT range - Actavis,HRT range,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-01,,Expired,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Sales,0,0,0,0,64.5,265.6,272.48,276.528,278.7712,280.256,281.145984,281.6816128,23.44027418,2173,Estrogen deficiency,7/7/14 12:28
2173,111,Warner Chilcott ,Regional & Specialty Pharma,3110,HRT range - Actavis,HRT range,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-01,,Expired,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Proforma,203,213,202,236,193.5,0,0,0,0,0,0,0,-100,2173,Estrogen deficiency,7/7/14 12:28
2173,111,Warner Chilcott ,Regional & Specialty Pharma,3110,HRT range - Actavis,HRT range,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-01,,Expired,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Proforma,203,213,202,236,193.5,0,0,0,0,0,0,0,-100,2173,Estrogen deficiency,7/7/14 12:28
2174,51,Ipsen,Regional & Specialty Pharma,2011,Forlax,macrogol,Small Molecule (Chemical),Launched,In-House,,Feb-96,,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,2,Global,Sales,63.3263897,51.53296211,57.56409335,49.74000032,51.39476358,51.06541212,50.35996256,49.99873838,49.63224459,49.28608133,49.00186165,48.74645559,-0.752919104,465,Chronic Constipation,7/7/14 12:28
2174,51,Ipsen,Regional & Specialty Pharma,2011,Forlax,macrogol,Small Molecule (Chemical),Launched,In-House,,Feb-96,,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,2,ROW,Sales,63.3263897,51.53296211,57.56409335,49.74000032,51.39476358,51.06541212,50.35996256,49.99873838,49.63224459,49.28608133,49.00186165,48.74645559,-0.752919104,465,Chronic Constipation,7/7/14 12:28
2174,51,Ipsen,Regional & Specialty Pharma,2011,Forlax,macrogol,Small Molecule (Chemical),Launched,In-House,,Feb-96,,Expired,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,465,Chronic Constipation,7/7/14 12:28
2177,37,Eisai,Regional & Specialty Pharma,2312,avatrombopag,E5501,Small Molecule (Chemical),Phase III,Corporate Acquisition,Dec-14,Dec-14,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,7,Global,Sales,0,0,0,0,0,22.14898894,53.15757345,80.54177796,118.4439333,141.8015724,161.7699873,178.9703385,0,396,idiopathic thrombocytopenic purpura,7/7/14 12:28
2177,37,Eisai,Regional & Specialty Pharma,2312,avatrombopag,E5501,Small Molecule (Chemical),Phase III,Corporate Acquisition,Dec-14,Dec-14,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,7,ROW,Sales,0,0,0,0,0,12.08126669,28.99504007,45.3047501,66.62471245,79.87966666,91.27945213,101.0377122,0,396,idiopathic thrombocytopenic purpura,7/7/14 12:28
2177,37,Eisai,Regional & Specialty Pharma,2312,avatrombopag,E5501,Small Molecule (Chemical),Phase III,Corporate Acquisition,Dec-14,Dec-14,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,7,US,Sales,0,0,0,0,0,10.06772225,24.16253339,35.23702786,51.8192208,61.92190573,70.49053519,77.93262635,0,396,idiopathic thrombocytopenic purpura,7/7/14 12:28
2178,37,Eisai,Regional & Specialty Pharma,2014,Revovir,clevudine,Small Molecule (Chemical),Launched,Licensed (Development),,,,,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,318,Hepatitis B,7/7/14 12:28
2178,37,Eisai,Regional & Specialty Pharma,2014,Revovir,clevudine,Small Molecule (Chemical),Launched,Licensed (Development),,,,,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,318,Hepatitis B,7/7/14 12:28
2178,37,Eisai,Regional & Specialty Pharma,2014,Revovir,clevudine,Small Molecule (Chemical),Launched,Licensed (Development),,,,,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,318,Hepatitis B,7/7/14 12:28
2183,40,Endo Health Solutions,Regional & Specialty Pharma,2019,Valstar,valrubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-09,,N/A,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,3.4,14.12,21.5,27.06,23.66,24,23,23,22.826,22.61075,22.49088125,22.37139922,-0.796843664,1237,Bladder Cancer,7/7/14 12:28
2183,40,Endo Health Solutions,Regional & Specialty Pharma,2019,Valstar,valrubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-09,,N/A,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1237,Bladder Cancer,7/7/14 12:28
2183,40,Endo Health Solutions,Regional & Specialty Pharma,2019,Valstar,valrubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-09,,N/A,N/A,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,3.4,14.12,21.5,27.06,23.66,24,23,23,22.826,22.61075,22.49088125,22.37139922,-0.796843664,1237,Bladder Cancer,7/7/14 12:28
2190,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2101,MP-124,MP-124,Small Molecule (Chemical),Phase I,In-House,,,,,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,746,Stroke recovery,7/7/14 12:28
2190,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2101,MP-124,MP-124,Small Molecule (Chemical),Phase I,In-House,,,,,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,746,Stroke recovery,7/7/14 12:28
2190,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2101,MP-124,MP-124,Small Molecule (Chemical),Phase I,In-House,,,,,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,746,Stroke recovery,7/7/14 12:28
2191,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3984,Imusera,fingolimod,Small Molecule (Chemical),Launched,In-House,Oct-10,Nov-11,,Jun-23,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,Global,Alliance Revenue,0,1.984381748,70.90529817,234.755443,322.1671118,329.2145174,359.4176842,385.593762,399.6885731,238.2425792,198.3341282,191.3849836,-7.169742628,1469,Multiple Sclerosis,7/7/14 12:28
2191,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3984,Imusera,fingolimod,Small Molecule (Chemical),Launched,In-House,Oct-10,Nov-11,,Jun-23,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,Global,Sales,0,0,5.232494181,16.04633293,24.41834668,32.79042102,40.26043377,47.01760344,52.85280626,58.00381015,62.54580753,66.53247987,15.39530671,1469,Multiple Sclerosis,7/7/14 12:28
2191,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3984,Imusera,fingolimod,Small Molecule (Chemical),Launched,In-House,Oct-10,Nov-11,,Jun-23,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,18.48602416,100.8846468,151.0158337,147.995517,158.0632392,164.1038726,168.1309615,172.8023846,171.1512782,172.2563114,1.897764754,1469,Multiple Sclerosis,7/7/14 12:28
2191,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3984,Imusera,fingolimod,Small Molecule (Chemical),Launched,In-House,Oct-10,Nov-11,,Jun-23,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,ROW,Sales,0,0,5.232494181,16.04633293,24.41834668,32.79042102,40.26043377,47.01760344,52.85280626,58.00381015,62.54580753,66.53247987,15.39530671,1469,Multiple Sclerosis,7/7/14 12:28
2191,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3984,Imusera,fingolimod,Small Molecule (Chemical),Launched,In-House,Oct-10,Nov-11,,Jun-23,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,US,Alliance Revenue,0,1.984381748,52.419274,133.8707962,171.1512782,181.2190004,201.3544449,221.4898894,231.5576116,65.44019459,27.18285006,19.12867227,-26.87874081,1469,Multiple Sclerosis,7/7/14 12:28
2191,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3984,Imusera,fingolimod,Small Molecule (Chemical),Launched,In-House,Oct-10,Nov-11,,Jun-23,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1469,Multiple Sclerosis,7/7/14 12:28
2195,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1422,Kremezin,carbonaceous absorbent,Small Molecule (Chemical),Launched,Licensed (Development),Feb-14,Nov-09,N/A,N/A,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,7,Global,Sales,10.77325969,23.0438935,146.8752605,146.8726361,130.6170389,134.7481825,137.581661,139.4374679,140.6682726,141.4817557,142.0199241,140.9481114,1.093392425,1379,Chronic Renal Failure,7/7/14 12:28
2195,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1422,Kremezin,carbonaceous absorbent,Small Molecule (Chemical),Launched,Licensed (Development),Feb-14,Nov-09,N/A,N/A,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,7,ROW,Sales,10.77325969,23.0438935,146.8752605,146.8726361,130.6170389,134.7481825,137.581661,139.4374679,140.6682726,141.4817557,142.0199241,140.9481114,1.093392425,1379,Chronic Renal Failure,7/7/14 12:28
2195,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1422,Kremezin,carbonaceous absorbent,Small Molecule (Chemical),Launched,Licensed (Development),Feb-14,Nov-09,N/A,N/A,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1379,Chronic Renal Failure,7/7/14 12:28
2197,150,Taisho,Regional & Specialty Pharma,861,Geninax,garenoxacin,Small Molecule (Chemical),Launched,In-House,,Oct-07,N/A,Feb-22,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,57.72540524,52.52775216,77.23612836,73.43631807,69.86492781,75.82299351,80.23465707,84.78154977,88.61239661,91.94185577,94.9205455,97.52402709,4.880121306,1481,,7/7/14 12:28
2197,150,Taisho,Regional & Specialty Pharma,861,Geninax,garenoxacin,Small Molecule (Chemical),Launched,In-House,,Oct-07,N/A,Feb-22,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,57.72540524,52.52775216,77.23612836,73.43631807,69.86492781,75.82299351,80.23465707,84.78154977,88.61239661,91.94185577,94.9205455,97.52402709,4.880121306,1481,,7/7/14 12:28
2197,150,Taisho,Regional & Specialty Pharma,861,Geninax,garenoxacin,Small Molecule (Chemical),Launched,In-House,,Oct-07,N/A,Feb-22,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1481,,7/7/14 12:28
2198,150,Taisho,Regional & Specialty Pharma,730,Zosyn,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-08,N/A,Jan-20,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,115.2738787,172.8292012,222.8452228,258.8329244,253.1337964,269.2184844,281.3228083,289.5187131,294.4444974,297.7486351,299.8946784,301.2669173,2.518012146,1591,,7/7/14 12:28
2198,150,Taisho,Regional & Specialty Pharma,730,Zosyn,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-08,N/A,Jan-20,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,115.2738787,172.8292012,222.8452228,258.8329244,253.1337964,269.2184844,281.3228083,289.5187131,294.4444974,297.7486351,299.8946784,301.2669173,2.518012146,1591,,7/7/14 12:28
2198,150,Taisho,Regional & Specialty Pharma,730,Zosyn,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-08,N/A,Jan-20,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1591,,7/7/14 12:28
2199,150,Taisho,Regional & Specialty Pharma,2032,Clarith,clarithromycin,Small Molecule (Chemical),Launched,In-House,,Jan-91,N/A,Sep-04,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,251.0169508,267.3078943,273.4918644,228.7360727,161.0835559,151.0158337,139.4178176,130.5018427,130.8803892,127.9973157,126.1306151,125.0970772,-3.547447875,1396,Bacterial infections,7/7/14 12:28
2199,150,Taisho,Regional & Specialty Pharma,2032,Clarith,clarithromycin,Small Molecule (Chemical),Launched,In-House,,Jan-91,N/A,Sep-04,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,251.0169508,267.3078943,273.4918644,228.7360727,161.0835559,151.0158337,139.4178176,130.5018427,130.8803892,127.9973157,126.1306151,125.0970772,-3.547447875,1396,Bacterial infections,7/7/14 12:28
2199,150,Taisho,Regional & Specialty Pharma,2032,Clarith,clarithromycin,Small Molecule (Chemical),Launched,In-House,,Jan-91,N/A,Sep-04,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1396,Bacterial infections,7/7/14 12:28
2208,63,Merck KGaA,Regional & Specialty Pharma,2040,DI17E6,DI17E6,Antibody/Antibody Derivative,Phase II,In-House,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,369,Prostate Cancer,7/7/14 12:28
2208,63,Merck KGaA,Regional & Specialty Pharma,2040,DI17E6,DI17E6,Antibody/Antibody Derivative,Phase II,In-House,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,369,Prostate Cancer,7/7/14 12:28
2208,63,Merck KGaA,Regional & Specialty Pharma,2040,DI17E6,DI17E6,Antibody/Antibody Derivative,Phase II,In-House,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,369,Prostate Cancer,7/7/14 12:28
2216,28,Chiesi,Regional & Specialty Pharma,2048,Lixar,lixivaptan ,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,630,Hyponatremia,7/7/14 12:28
2216,28,Chiesi,Regional & Specialty Pharma,2048,Lixar,lixivaptan ,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,630,Hyponatremia,7/7/14 12:28
2216,28,Chiesi,Regional & Specialty Pharma,2048,Lixar,lixivaptan ,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,630,Hyponatremia,7/7/14 12:28
2217,63,Merck KGaA,Regional & Specialty Pharma,2049,sprifermin,recombinant FGF-18,Synthetic Peptide,Phase II,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,448,Cartilage Injury Repair,7/7/14 12:28
2217,63,Merck KGaA,Regional & Specialty Pharma,2049,sprifermin,recombinant FGF-18,Synthetic Peptide,Phase II,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,448,Cartilage Injury Repair,7/7/14 12:28
2217,63,Merck KGaA,Regional & Specialty Pharma,2049,sprifermin,recombinant FGF-18,Synthetic Peptide,Phase II,Licensed (Development),,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,448,Cartilage Injury Repair,7/7/14 12:28
2218,21,Biogen Idec,Regional & Specialty Pharma,3505,Alprolix,"Long-acting rFactor IX, rFIXfc",Recombinant Protein,Approved,Corporate Acquisition,May-14,May-14,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,0,0,0,0,0,22.5,47.325,67.579944,99.74488825,122.5524779,137.615038,150.0989655,0,634,Hemophilia B ,7/7/14 12:28
2218,21,Biogen Idec,Regional & Specialty Pharma,3505,Alprolix,"Long-acting rFactor IX, rFIXfc",Recombinant Protein,Approved,Corporate Acquisition,May-14,May-14,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,10.2,14.705034,20.99511229,31.45025831,36.25962029,40.33916456,0,634,Hemophilia B ,7/7/14 12:28
2218,21,Biogen Idec,Regional & Specialty Pharma,3505,Alprolix,"Long-acting rFactor IX, rFIXfc",Recombinant Protein,Approved,Corporate Acquisition,May-14,May-14,N/A,N/A,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,0,0,0,0,0,22.5,37.125,52.87491,78.74977596,91.10221954,101.3554177,109.7598009,0,634,Hemophilia B ,7/7/14 12:28
2220,42,Forest,Regional & Specialty Pharma,3528,Daliresp,roflumilast,Small Molecule (Chemical),Launched,Licensed (Development),Jun-11,,Mar-16,N/A,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,31.2,78,104,146.73984,181.10976,72.4893312,38.419056,29.363568,16.53106,12.86828,-25.80828015,1622,COPD,7/7/14 12:28
2220,42,Forest,Regional & Specialty Pharma,3528,Daliresp,roflumilast,Small Molecule (Chemical),Launched,Licensed (Development),Jun-11,,Mar-16,N/A,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1622,COPD,7/7/14 12:28
2220,42,Forest,Regional & Specialty Pharma,3528,Daliresp,roflumilast,Small Molecule (Chemical),Launched,Licensed (Development),Jun-11,,Mar-16,N/A,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,31.2,78,104,146.73984,181.10976,72.4893312,38.419056,29.363568,16.53106,12.86828,-25.80828015,1622,COPD,7/7/14 12:28
2221,89,Sanofi,Large Pharma,2448,Cerdelga,eliglustat tartrate,Small Molecule (Chemical),Filed,Corporate Acquisition,Nov-14,Nov-14,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Sales,0,0,0,0,0,6.8615024,52.60487461,121.2200428,189.8354358,244.3735108,296.8929816,345.0352538,0,408,Gaucher's Disease,7/7/14 12:28
2221,89,Sanofi,Large Pharma,2448,Cerdelga,eliglustat tartrate,Small Molecule (Chemical),Filed,Corporate Acquisition,Nov-14,Nov-14,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Sales,0,0,0,0,0,3.541420594,27.15090302,62.56518338,97.97957978,127.7276207,157.0506966,184.6526432,0,408,Gaucher's Disease,7/7/14 12:28
2221,89,Sanofi,Large Pharma,2448,Cerdelga,eliglustat tartrate,Small Molecule (Chemical),Filed,Corporate Acquisition,Nov-14,Nov-14,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Sales,0,0,0,0,0,3.320081807,25.45397158,58.65485942,91.85585605,116.6458901,139.842285,160.3826106,0,408,Gaucher's Disease,7/7/14 12:28
2223,89,Sanofi,Large Pharma,4574,SAR402665,recombinant human acid sphingomyelinase,Recombinant Protein,Phase II,Corporate Acquisition,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,66,Niemann-Pick Type B,7/7/14 12:28
2223,89,Sanofi,Large Pharma,4574,SAR402665,recombinant human acid sphingomyelinase,Recombinant Protein,Phase II,Corporate Acquisition,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,66,Niemann-Pick Type B,7/7/14 12:28
2223,89,Sanofi,Large Pharma,4574,SAR402665,recombinant human acid sphingomyelinase,Recombinant Protein,Phase II,Corporate Acquisition,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,66,Niemann-Pick Type B,7/7/14 12:28
2235,111,Actavis,Regional & Specialty Pharma,3709,Generess Fe,norethindrone + ethinyl estradiol,Small Molecule (Chemical),Launched,Licensed (Development),May-11,Jun-15,Apr-14,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,9,44,85,36.03119782,10.12259019,13.04111466,18.84035377,29.2304611,34.01016042,38.11312376,-10.82634516,800,Female contraception,7/7/14 12:28
2235,111,Actavis,Regional & Specialty Pharma,3709,Generess Fe,norethindrone + ethinyl estradiol,Small Molecule (Chemical),Launched,Licensed (Development),May-11,Jun-15,Apr-14,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,3.69,8.6764815,15.50799597,26.67778515,31.85677229,36.24081222,0,800,Female contraception,7/7/14 12:28
2235,111,Actavis,Regional & Specialty Pharma,3709,Generess Fe,norethindrone + ethinyl estradiol,Small Molecule (Chemical),Launched,Licensed (Development),May-11,Jun-15,Apr-14,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,9,44,85,36.03119782,6.432590194,4.364633158,3.332357798,2.552675947,2.153388122,1.872311539,-42.01974504,800,Female contraception,7/7/14 12:28
2242,58,Lundbeck,Regional & Specialty Pharma,2073,desmoteplase,desmoteplase,Recombinant Protein,Phase III,Licensed (Development),,,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,366,Stroke,7/7/14 12:28
2242,58,Lundbeck,Regional & Specialty Pharma,2073,desmoteplase,desmoteplase,Recombinant Protein,Phase III,Licensed (Development),,,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,366,Stroke,7/7/14 12:28
2242,58,Lundbeck,Regional & Specialty Pharma,2073,desmoteplase,desmoteplase,Recombinant Protein,Phase III,Licensed (Development),,,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,366,Stroke,7/7/14 12:28
2244,70,Ono,Regional & Specialty Pharma,2075,anamorelin,anamorelin,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,818,Cachexia,7/7/14 12:28
2244,70,Ono,Regional & Specialty Pharma,2075,anamorelin,anamorelin,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,818,Cachexia,7/7/14 12:28
2244,70,Ono,Regional & Specialty Pharma,2075,anamorelin,anamorelin,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,818,Cachexia,7/7/14 12:28
2245,58,Lundbeck,Regional & Specialty Pharma,2345,zicronapine,zicronapine,Small Molecule (Chemical),Phase III,In-House,,Sep-17,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,6.875754028,15.99665223,22.66197731,33.32647721,0,1306,Schizophrenia,7/7/14 12:28
2245,58,Lundbeck,Regional & Specialty Pharma,2345,zicronapine,zicronapine,Small Molecule (Chemical),Phase III,In-House,,Sep-17,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,6.875754028,15.99665223,22.66197731,33.32647721,0,1306,Schizophrenia,7/7/14 12:28
2245,58,Lundbeck,Regional & Specialty Pharma,2345,zicronapine,zicronapine,Small Molecule (Chemical),Phase III,In-House,,Sep-17,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1306,Schizophrenia,7/7/14 12:28
2247,70,Ono,Regional & Specialty Pharma,2078,ONO-4641,ONO-4641,Small Molecule (Chemical),Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,816,Multiple Sclerosis,7/7/14 12:28
2247,70,Ono,Regional & Specialty Pharma,2078,ONO-4641,ONO-4641,Small Molecule (Chemical),Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,816,Multiple Sclerosis,7/7/14 12:28
2247,70,Ono,Regional & Specialty Pharma,2078,ONO-4641,ONO-4641,Small Molecule (Chemical),Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,816,Multiple Sclerosis,7/7/14 12:28
2248,58,Lundbeck,Regional & Specialty Pharma,2079,tedatioxetine,Lu AA24530,Small Molecule (Chemical),Phase II,In-House,,,,,127,Serotonergics,49,Depression,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1531,Depression,7/7/14 12:28
2248,58,Lundbeck,Regional & Specialty Pharma,2079,tedatioxetine,Lu AA24530,Small Molecule (Chemical),Phase II,In-House,,,,,127,Serotonergics,49,Depression,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1531,Depression,7/7/14 12:28
2248,58,Lundbeck,Regional & Specialty Pharma,2079,tedatioxetine,Lu AA24530,Small Molecule (Chemical),Phase II,In-House,,,,,127,Serotonergics,49,Depression,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1531,Depression,7/7/14 12:28
2252,70,Ono,Regional & Specialty Pharma,2083,ONO-3849,methylnaltrexone,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1544,Opioid-induced Constipation,7/7/14 12:28
2252,70,Ono,Regional & Specialty Pharma,2083,ONO-3849,methylnaltrexone,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1544,Opioid-induced Constipation,7/7/14 12:28
2252,70,Ono,Regional & Specialty Pharma,2083,ONO-3849,methylnaltrexone,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1544,Opioid-induced Constipation,7/7/14 12:28
2253,58,Lundbeck,Regional & Specialty Pharma,2084,Lu AE58054,Lu AE58054,Small Molecule (Chemical),Phase III,Corporate Acquisition,Mar-17,Oct-17,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,192.021968,436.9718326,642.9429014,848.9149052,0,644,Alzheimer's Disease,7/7/14 12:28
2253,58,Lundbeck,Regional & Specialty Pharma,2084,Lu AE58054,Lu AE58054,Small Molecule (Chemical),Phase III,Corporate Acquisition,Mar-17,Oct-17,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,28.04649486,130.8837361,205.6746295,280.4661518,0,644,Alzheimer's Disease,7/7/14 12:28
2253,58,Lundbeck,Regional & Specialty Pharma,2084,Lu AE58054,Lu AE58054,Small Molecule (Chemical),Phase III,Corporate Acquisition,Mar-17,Oct-17,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,163.9754731,306.0880964,437.2682719,568.4487534,0,644,Alzheimer's Disease,7/7/14 12:28
2257,140,TAP,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jul-90,,Expired,N/A,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Endometriosis,7/7/14 12:28
2257,140,TAP,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jul-90,,Expired,N/A,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Endometriosis,7/7/14 12:28
2257,140,TAP,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Jul-90,,Expired,N/A,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Endometriosis,7/7/14 12:28
2259,1575,Transition Therapeutics,Small Biotech,3008,ELND005,scyllo-inositol,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,411,Alzheimer's Disease,7/7/14 12:28
2259,1575,Transition Therapeutics,Small Biotech,3008,ELND005,scyllo-inositol,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,411,Alzheimer's Disease,7/7/14 12:28
2259,1575,Transition Therapeutics,Small Biotech,3008,ELND005,scyllo-inositol,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,411,Alzheimer's Disease,7/7/14 12:28
2266,108,Vertex,Regional & Specialty Pharma,4297,Kalydeco+VX-809,ivacaftor/lumacaftor,Small Molecule (Chemical),Phase III,In-House,Feb-15,Aug-15,,,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,729,1823,2416,2468,2522,2545,0,1272,Cystic Fibrosis,7/7/14 12:28
2266,108,Vertex,Regional & Specialty Pharma,4297,Kalydeco+VX-809,ivacaftor/lumacaftor,Small Molecule (Chemical),Phase III,In-House,Feb-15,Aug-15,,,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,121,608,972,995,1019,1030,0,1272,Cystic Fibrosis,7/7/14 12:28
2266,108,Vertex,Regional & Specialty Pharma,4297,Kalydeco+VX-809,ivacaftor/lumacaftor,Small Molecule (Chemical),Phase III,In-House,Feb-15,Aug-15,,,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,US,Sales,0,0,0,0,0,0,608,1215,1444,1473,1503,1515,0,1272,Cystic Fibrosis,7/7/14 12:28
2267,108,Vertex,Regional & Specialty Pharma,2096,VX-509,decernotinib,Small Molecule (Chemical),Phase III,In-House,Sep-18,Oct-18,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,15.833325,81.38890278,173.0556175,0,1269,Rheumatoid Arthritis,7/7/14 12:28
2267,108,Vertex,Regional & Specialty Pharma,2096,VX-509,decernotinib,Small Molecule (Chemical),Phase III,In-House,Sep-18,Oct-18,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,7.5,42.500025,92.50002941,0,1269,Rheumatoid Arthritis,7/7/14 12:28
2267,108,Vertex,Regional & Specialty Pharma,2096,VX-509,decernotinib,Small Molecule (Chemical),Phase III,In-House,Sep-18,Oct-18,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,8.333325,38.88887778,80.5555881,0,1269,Rheumatoid Arthritis,7/7/14 12:28
2271,140,TAP,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Feb-99,,Expired,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Prostate Cancer,7/7/14 12:28
2271,140,TAP,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Feb-99,,Expired,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Prostate Cancer,7/7/14 12:28
2271,140,TAP,Regional & Specialty Pharma,1228,Lupron,leuprolide,Synthetic Peptide,Launched,Licensed (Development),Feb-99,,Expired,N/A,33,LHRH Analogs,55,Hormonals,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1517,Prostate Cancer,7/7/14 12:28
2273,108,Vertex,Regional & Specialty Pharma,4290,Kalydeco,ivacaftor,Small Molecule (Chemical),Launched,In-House,Feb-12,Sep-12,Jan-27,Jan-25,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,Global,Sales,0,0,0,171.6,371,503,846,954,1021.2,1066.875,1069.6125,1072.26875,16.37160919,1271,Cystic Fibrosis,7/7/14 12:28
2273,108,Vertex,Regional & Specialty Pharma,4290,Kalydeco,ivacaftor,Small Molecule (Chemical),Launched,In-House,Feb-12,Sep-12,Jan-27,Jan-25,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,ROW,Sales,0,0,0,9.5,151,233,402,454.5,487.2,509.5,511.3,512.9,19.08718557,1271,Cystic Fibrosis,7/7/14 12:28
2273,108,Vertex,Regional & Specialty Pharma,4290,Kalydeco,ivacaftor,Small Molecule (Chemical),Launched,In-House,Feb-12,Sep-12,Jan-27,Jan-25,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,US,Sales,0,0,0,162.1,220,270,444,499.5,534,557.375,558.3125,559.36875,14.26058542,1271,Cystic Fibrosis,7/7/14 12:28
2275,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4607,Tenelia,teneligliptin,Small Molecule (Chemical),Launched,In-House,,Sep-12,N/A,Dec-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,12.50211841,14.09481114,30.20316674,44.87888545,53.26276835,60.94338166,66.98228159,71.53254844,75.18745038,27.01918989,1176,Type II Diabetes,7/7/14 12:28
2275,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4607,Tenelia,teneligliptin,Small Molecule (Chemical),Launched,In-House,,Sep-12,N/A,Dec-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,12.50211841,14.09481114,30.20316674,44.87888545,53.26276835,60.94338166,66.98228159,71.53254844,75.18745038,27.01918989,1176,Type II Diabetes,7/7/14 12:28
2275,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,4607,Tenelia,teneligliptin,Small Molecule (Chemical),Launched,In-House,,Sep-12,N/A,Dec-21,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1176,Type II Diabetes,7/7/14 12:28
2276,35,Dainippon-Sumitomo,Regional & Specialty Pharma,3081,Melbin / Metgluco,metformin ,Small Molecule (Chemical),Launched,Licensed (Development),,May-10,N/A,N/A,110,Biguanides,22,Diabetes,8,Metabolism,7,Global,Sales,0,58.36416907,107.6241133,144.464888,161.0835559,183.7359309,202.0088467,216.4006556,226.7256081,234.6063694,240.5561063,244.9985587,6.173472083,1104,Type II Diabetes,7/7/14 12:28
2276,35,Dainippon-Sumitomo,Regional & Specialty Pharma,3081,Melbin / Metgluco,metformin ,Small Molecule (Chemical),Launched,Licensed (Development),,May-10,N/A,N/A,110,Biguanides,22,Diabetes,8,Metabolism,7,ROW,Sales,0,58.36416907,107.6241133,144.464888,161.0835559,183.7359309,202.0088467,216.4006556,226.7256081,234.6063694,240.5561063,244.9985587,6.173472083,1104,Type II Diabetes,7/7/14 12:28
2276,35,Dainippon-Sumitomo,Regional & Specialty Pharma,3081,Melbin / Metgluco,metformin ,Small Molecule (Chemical),Launched,Licensed (Development),,May-10,N/A,N/A,110,Biguanides,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1104,Type II Diabetes,7/7/14 12:28
2278,35,Dainippon-Sumitomo,Regional & Specialty Pharma,3463,Surepost,repaglinide,Small Molecule (Chemical),Launched,Licensed (Development),,May-11,,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,2.535993497,12.00980261,22.10716426,32.20461153,39.39587222,45.7221873,50.86020494,54.99381377,58.40524468,61.18662582,15.65393987,1613,Diabetes,7/7/14 12:28
2278,35,Dainippon-Sumitomo,Regional & Specialty Pharma,3463,Surepost,repaglinide,Small Molecule (Chemical),Launched,Licensed (Development),,May-11,,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,2.535993497,12.00980261,22.10716426,32.20461153,39.39587222,45.7221873,50.86020494,54.99381377,58.40524468,61.18662582,15.65393987,1613,Diabetes,7/7/14 12:28
2278,35,Dainippon-Sumitomo,Regional & Specialty Pharma,3463,Surepost,repaglinide,Small Molecule (Chemical),Launched,Licensed (Development),,May-11,,N/A,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1613,Diabetes,7/7/14 12:28
2280,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2108,Invokana / Vokanamet,canagliflozin / canagliflozin + metformin,Small Molecule (Chemical),Filed,In-House,,Oct-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,0,0,5.313234076,13.21396002,23.77125337,40.93552458,54.26499338,68.19046781,80.54177796,0,1373,Type II Diabetes,7/7/14 12:28
2280,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2108,Invokana / Vokanamet,canagliflozin / canagliflozin + metformin,Small Molecule (Chemical),Filed,In-House,,Oct-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,0,0,5.313234076,13.21396002,23.77125337,40.93552458,54.26499338,68.19046781,80.54177796,0,1373,Type II Diabetes,7/7/14 12:28
2280,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2108,Invokana / Vokanamet,canagliflozin / canagliflozin + metformin,Small Molecule (Chemical),Filed,In-House,,Oct-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1373,Type II Diabetes,7/7/14 12:28
2282,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2587,ranirestat,AS-3201,Small Molecule (Chemical),Phase III,In-House,,Apr-16,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,10.06772225,14.09481114,20.13542435,30.20313653,35.55915701,0,1609,Painful Diabetic Neuropathy,7/7/14 12:28
2282,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2587,ranirestat,AS-3201,Small Molecule (Chemical),Phase III,In-House,,Apr-16,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,10.06772225,14.09481114,20.13542435,30.20313653,35.55915701,0,1609,Painful Diabetic Neuropathy,7/7/14 12:28
2282,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2587,ranirestat,AS-3201,Small Molecule (Chemical),Phase III,In-House,,Apr-16,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1609,Painful Diabetic Neuropathy,7/7/14 12:28
2288,84,Recordati,Regional & Specialty Pharma,4382,Urorec,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-10,Dec-18,Jan-18,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,Global,Sales,0,2.781985101,27.53065334,42.02837236,62.41741313,73.04165366,82.4248501,90.01492374,95.69257225,47.61290176,31.66165397,21.63851558,-14.04431728,1633,Symptoms associated with BPH,7/7/14 12:28
2288,84,Recordati,Regional & Specialty Pharma,4382,Urorec,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-10,Dec-18,Jan-18,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,ROW,Sales,0,2.781985101,27.53065334,42.02837236,62.41741313,73.04165366,82.4248501,90.01492374,95.69257225,47.61290176,31.66165397,21.63851558,-14.04431728,1633,Symptoms associated with BPH,7/7/14 12:28
2288,84,Recordati,Regional & Specialty Pharma,4382,Urorec,silodosin,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-10,Dec-18,Jan-18,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1633,Symptoms associated with BPH,7/7/14 12:28
2289,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2116,Aimix,irbesartan + amlodipine,Small Molecule (Chemical),Launched,In-House,,Dec-12,,Jun-18,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,24.07748133,55.76867828,86.18770385,116.606792,133.894988,147.0144843,151.0186208,140.35525,130.2722988,12.88528574,386,Hypertension,7/7/14 12:28
2289,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2116,Aimix,irbesartan + amlodipine,Small Molecule (Chemical),Launched,In-House,,Dec-12,,Jun-18,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,24.07748133,55.76867828,86.18770385,116.606792,133.894988,147.0144843,151.0186208,140.35525,130.2722988,12.88528574,386,Hypertension,7/7/14 12:28
2289,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2116,Aimix,irbesartan + amlodipine,Small Molecule (Chemical),Launched,In-House,,Dec-12,,Jun-18,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,386,Hypertension,7/7/14 12:28
2291,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2118,DSP-3025,TLR-7 agonist,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,219,Asthma,7/7/14 12:28
2291,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2118,DSP-3025,TLR-7 agonist,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,219,Asthma,7/7/14 12:28
2291,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2118,DSP-3025,TLR-7 agonist,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,219,Asthma,7/7/14 12:28
2293,10,Almirall,Regional & Specialty Pharma,4093,Abediterol + ICS,LAS100977 + ICS,Small Molecule (Chemical),Phase II,In-House,,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3708,COPD,7/7/14 12:28
2293,10,Almirall,Regional & Specialty Pharma,4093,Abediterol + ICS,LAS100977 + ICS,Small Molecule (Chemical),Phase II,In-House,,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3708,COPD,7/7/14 12:28
2293,10,Almirall,Regional & Specialty Pharma,4093,Abediterol + ICS,LAS100977 + ICS,Small Molecule (Chemical),Phase II,In-House,,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3708,COPD,7/7/14 12:28
2302,95,Shionogi,Regional & Specialty Pharma,2129,S-555739,S-555739,Small Molecule (Chemical),Phase III,In-House,,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1041,Allergy,7/7/14 12:28
2302,95,Shionogi,Regional & Specialty Pharma,2129,S-555739,S-555739,Small Molecule (Chemical),Phase III,In-House,,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1041,Allergy,7/7/14 12:28
2302,95,Shionogi,Regional & Specialty Pharma,2129,S-555739,S-555739,Small Molecule (Chemical),Phase III,In-House,,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1041,Allergy,7/7/14 12:28
2303,95,Shionogi,Regional & Specialty Pharma,2130,S-888711,S-888711,Small Molecule (Chemical),Phase II,In-House,,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1042,Immune Thrombocytopenia,7/7/14 12:28
2303,95,Shionogi,Regional & Specialty Pharma,2130,S-888711,S-888711,Small Molecule (Chemical),Phase II,In-House,,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1042,Immune Thrombocytopenia,7/7/14 12:28
2303,95,Shionogi,Regional & Specialty Pharma,2130,S-888711,S-888711,Small Molecule (Chemical),Phase II,In-House,,,,,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1042,Immune Thrombocytopenia,7/7/14 12:28
2304,95,Shionogi,Regional & Specialty Pharma,4631,Naldemedine,S-297995,Small Molecule (Chemical),Phase III,In-House,,,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1038,Opioid-induced Constipation,7/7/14 12:28
2304,95,Shionogi,Regional & Specialty Pharma,4631,Naldemedine,S-297995,Small Molecule (Chemical),Phase III,In-House,,,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1038,Opioid-induced Constipation,7/7/14 12:28
2304,95,Shionogi,Regional & Specialty Pharma,4631,Naldemedine,S-297995,Small Molecule (Chemical),Phase III,In-House,,,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1038,Opioid-induced Constipation,7/7/14 12:28
2307,10,Almirall,Regional & Specialty Pharma,3838,Monovo,LAS41002,Small Molecule (Chemical),Launched,In-House,,Dec-13,,Jul-18,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,2,Global,Sales,0,0,0,0,1.328030067,15.9363608,26.00144755,36.0666079,40.45611684,43.34704481,45.2571843,46.33728427,66.10730512,608,Eczema and psoriasis,7/7/14 12:28
2307,10,Almirall,Regional & Specialty Pharma,3838,Monovo,LAS41002,Small Molecule (Chemical),Launched,In-House,,Dec-13,,Jul-18,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,2,ROW,Sales,0,0,0,0,1.328030067,15.9363608,26.00144755,36.0666079,40.45611684,43.34704481,45.2571843,46.33728427,66.10730512,608,Eczema and psoriasis,7/7/14 12:28
2307,10,Almirall,Regional & Specialty Pharma,3838,Monovo,LAS41002,Small Molecule (Chemical),Launched,In-House,,Dec-13,,Jul-18,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,608,Eczema and psoriasis,7/7/14 12:28
2308,10,Almirall,Regional & Specialty Pharma,3348,Actikerall,fluorouracil + salicyclic acid,Small Molecule (Chemical),Launched,In-House,,Jun-11,N/A,Expired,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,2,Global,Sales,0,0,0.417131111,5.141085305,6.586101573,8.722106035,10.18186936,11.15715692,11.96882112,12.56304374,13.00444459,13.34122462,10.61022627,609,Actinic keratosis,7/7/14 12:28
2308,10,Almirall,Regional & Specialty Pharma,3348,Actikerall,fluorouracil + salicyclic acid,Small Molecule (Chemical),Launched,In-House,,Jun-11,N/A,Expired,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,2,ROW,Sales,0,0,0.417131111,5.141085305,6.586101573,8.722106035,10.18186936,11.15715692,11.96882112,12.56304374,13.00444459,13.34122462,10.61022627,609,Actinic keratosis,7/7/14 12:28
2308,10,Almirall,Regional & Specialty Pharma,3348,Actikerall,fluorouracil + salicyclic acid,Small Molecule (Chemical),Launched,In-House,,Jun-11,N/A,Expired,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,609,Actinic keratosis,7/7/14 12:28
2309,46,GlaxoSmithKline,Large Pharma,4038,Tivicay,dolutegravir,Small Molecule (Chemical),Launched,In-House,Aug-13,May-14,,,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,4,Global,Sales,0,0,0,0,29.70486653,500.9178546,918.3836388,1253.85805,1442.690949,1671.289596,1860.462693,1971.801586,82.09186357,1039,HIV,7/7/14 12:28
2309,46,GlaxoSmithKline,Large Pharma,4038,Tivicay,dolutegravir,Small Molecule (Chemical),Launched,In-House,Aug-13,May-14,,,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,47.52778645,142.5833594,250.1462445,304.5255366,437.7559278,542.5046677,614.7582097,0,1039,HIV,7/7/14 12:28
2309,46,GlaxoSmithKline,Large Pharma,4038,Tivicay,dolutegravir,Small Molecule (Chemical),Launched,In-House,Aug-13,May-14,,,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,4,US,Sales,0,0,0,0,29.70486653,453.3900681,775.8002795,1003.711806,1138.165412,1233.533668,1317.958026,1357.043376,72.62719318,1039,HIV,7/7/14 12:28
2311,10,Almirall,Regional & Specialty Pharma,4725,Constella,linaclotide,Small Molecule (Chemical),Launched,Licensed (Development),,May-13,N/A,Jan-24,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,2,Global,Sales,0,0,0,0,26.34441947,83.42408279,149.2848934,215.1464027,266.4303471,313.2884168,354.8776328,390.964687,47.0109471,1527,IBS-C,7/7/14 12:28
2311,10,Almirall,Regional & Specialty Pharma,4725,Constella,linaclotide,Small Molecule (Chemical),Launched,Licensed (Development),,May-13,N/A,Jan-24,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,2,ROW,Sales,0,0,0,0,26.34441947,83.42408279,149.2848934,215.1464027,266.4303471,313.2884168,354.8776328,390.964687,47.0109471,1527,IBS-C,7/7/14 12:28
2311,10,Almirall,Regional & Specialty Pharma,4725,Constella,linaclotide,Small Molecule (Chemical),Launched,Licensed (Development),,May-13,N/A,Jan-24,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1527,IBS-C,7/7/14 12:28
2313,95,Shionogi,Regional & Specialty Pharma,2139,S-222611,S-222611,Small Molecule (Chemical),Phase I,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1033,Cancer,7/7/14 12:28
2313,95,Shionogi,Regional & Specialty Pharma,2139,S-222611,S-222611,Small Molecule (Chemical),Phase I,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1033,Cancer,7/7/14 12:28
2313,95,Shionogi,Regional & Specialty Pharma,2139,S-222611,S-222611,Small Molecule (Chemical),Phase I,In-House,,,,,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1033,Cancer,7/7/14 12:28
2316,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4448,Poteligeo,mogamulizumab,Antibody/Antibody Derivative,Launched,In-House,,May-12,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,3,Global,Sales,0,0,0,13.78100727,11.27386091,16.47719867,21.68053324,24.17813441,26.48841551,28.2554682,29.50114675,30.47015353,15.2619424,595,T-cell Lymphoma,7/7/14 12:28
2316,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4448,Poteligeo,mogamulizumab,Antibody/Antibody Derivative,Launched,In-House,,May-12,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,3,ROW,Sales,0,0,0,13.78100727,11.27386091,16.47719867,21.68053324,24.17813441,26.48841551,28.2554682,29.50114675,30.47015353,15.2619424,595,T-cell Lymphoma,7/7/14 12:28
2316,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4448,Poteligeo,mogamulizumab,Antibody/Antibody Derivative,Launched,In-House,,May-12,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,595,T-cell Lymphoma,7/7/14 12:28
2317,76,Pfizer,Large Pharma,3698,Oxecta,oxycodone - abuse-deterrent,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-12,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,26,43.33342,60.666788,77.999896,90.13316988,100.4464399,109.0307071,115.8996457,121.5503281,15.87517118,72,Pain,7/7/14 12:28
2317,76,Pfizer,Large Pharma,3698,Oxecta,oxycodone - abuse-deterrent,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-12,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,72,Pain,7/7/14 12:28
2317,76,Pfizer,Large Pharma,3698,Oxecta,oxycodone - abuse-deterrent,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-12,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,26,43.33342,60.666788,77.999896,90.13316988,100.4464399,109.0307071,115.8996457,121.5503281,15.87517118,72,Pain,7/7/14 12:28
2320,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1317,Neulasta,pegfilgrastim,Recombinant Protein,Launched,Licensed (Development),,May-12,,,118,G-CSFs,78,Neutropenia,3,Oncology,3,Global,Sales,0,0,0,1.254707768,2.509415536,3.764123304,50.18831072,87.82954377,138.0178545,156.6023553,181.6587321,215.2282537,88.88142575,1585,Neutropenia,7/7/14 12:28
2320,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1317,Neulasta,pegfilgrastim,Recombinant Protein,Launched,Licensed (Development),,May-12,,,118,G-CSFs,78,Neutropenia,3,Oncology,3,ROW,Sales,0,0,0,1.254707768,2.509415536,3.764123304,50.18831072,87.82954377,138.0178545,156.6023553,181.6587321,215.2282537,88.88142575,1585,Neutropenia,7/7/14 12:28
2320,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,1317,Neulasta,pegfilgrastim,Recombinant Protein,Launched,Licensed (Development),,May-12,,,118,G-CSFs,78,Neutropenia,3,Oncology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1585,Neutropenia,7/7/14 12:28
2325,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,709,Asacol,mesalamine,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-09,N/A,Dec-05,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,3,Global,Sales,2.137442924,7.976677714,35.12113132,51.36557254,55.3444081,58.54490185,64.03546296,68.12421705,71.25652037,73.59105443,75.34587973,76.66841986,4.766002923,1542,ulcerative colitis,7/7/14 12:28
2325,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,709,Asacol,mesalamine,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-09,N/A,Dec-05,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,3,ROW,Sales,2.137442924,7.976677714,35.12113132,51.36557254,55.3444081,58.54490185,64.03546296,68.12421705,71.25652037,73.59105443,75.34587973,76.66841986,4.766002923,1542,ulcerative colitis,7/7/14 12:28
2325,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,709,Asacol,mesalamine,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-09,N/A,Dec-05,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1542,ulcerative colitis,7/7/14 12:28
2326,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2696,Nouriast,istradefylline,Small Molecule (Chemical),Launched,In-House,,May-13,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,3,Global,Sales,0,0,0,0,5.124482231,25.36958156,45.1015347,77.51826277,97.47569667,116.3957975,133.9402984,143.4855025,60.96692767,601,Parkinson's Disease,7/7/14 12:28
2326,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2696,Nouriast,istradefylline,Small Molecule (Chemical),Launched,In-House,,May-13,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,3,ROW,Sales,0,0,0,0,5.124482231,25.36958156,45.1015347,77.51826277,97.47569667,116.3957975,133.9402984,143.4855025,60.96692767,601,Parkinson's Disease,7/7/14 12:28
2326,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2696,Nouriast,istradefylline,Small Molecule (Chemical),Launched,In-House,,May-13,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,601,Parkinson's Disease,7/7/14 12:28
2327,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4592,Apokyn,apomorphine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-12,,Dec-21,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,602,Parkinson's Disease,7/7/14 12:28
2327,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4592,Apokyn,apomorphine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-12,,Dec-21,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,3,Global,Sales,0,0,0,6.273538841,16.72945782,25.09418673,33.45883199,40.66778491,46.89723756,52.45751057,57.33012087,61.61034294,20.47074585,602,Parkinson's Disease,7/7/14 12:28
2327,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4592,Apokyn,apomorphine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-12,,Dec-21,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,602,Parkinson's Disease,7/7/14 12:28
2327,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4592,Apokyn,apomorphine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-12,,Dec-21,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,3,ROW,Sales,0,0,0,6.273538841,16.72945782,25.09418673,33.45883199,40.66778491,46.89723756,52.45751057,57.33012087,61.61034294,20.47074585,602,Parkinson's Disease,7/7/14 12:28
2327,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4592,Apokyn,apomorphine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-12,,Dec-21,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,602,Parkinson's Disease,7/7/14 12:28
2327,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4592,Apokyn,apomorphine,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-12,,Dec-21,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,602,Parkinson's Disease,7/7/14 12:28
2329,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2157,KW2478,KW2478,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,599,Multiple Myeloma,7/7/14 12:28
2329,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2157,KW2478,KW2478,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,599,Multiple Myeloma,7/7/14 12:28
2329,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2157,KW2478,KW2478,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,599,Multiple Myeloma,7/7/14 12:28
2332,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2159,BIW-8962,BIW-8962,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,250,Cancer,7/7/14 12:28
2332,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2159,BIW-8962,BIW-8962,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,250,Cancer,7/7/14 12:28
2332,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2159,BIW-8962,BIW-8962,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,250,Cancer,7/7/14 12:28
2334,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,415,ASKP1240,ASKP1240,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1351,Transplant Rejection,7/7/14 12:28
2334,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,415,ASKP1240,ASKP1240,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1351,Transplant Rejection,7/7/14 12:28
2334,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,415,ASKP1240,ASKP1240,Antibody/Antibody Derivative,Phase II,In-House,,,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1351,Transplant Rejection,7/7/14 12:28
2336,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2161,KW-3357,,Recombinant Protein,Phase III,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,600,Thrombosis,7/7/14 12:28
2336,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2161,KW-3357,,Recombinant Protein,Phase III,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,600,Thrombosis,7/7/14 12:28
2336,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2161,KW-3357,,Recombinant Protein,Phase III,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,600,Thrombosis,7/7/14 12:28
2337,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2162,KRN23,KRN23,Recombinant Protein,Phase II,In-House,,,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,593,Hypophosphatemic Rickets,7/7/14 12:28
2337,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2162,KRN23,KRN23,Recombinant Protein,Phase II,In-House,,,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,593,Hypophosphatemic Rickets,7/7/14 12:28
2337,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2162,KRN23,KRN23,Recombinant Protein,Phase II,In-House,,,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,593,Hypophosphatemic Rickets,7/7/14 12:28
2339,16,AstraZeneca,Large Pharma,3540,Zinforo,ceftaroline,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-12,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,6.3,22.05,40.949937,70.87492246,87.52265414,102.2795984,115.1300505,125.0573494,133.2964712,29.30934049,1385,Bacterial infections,7/7/14 12:28
2339,16,AstraZeneca,Large Pharma,3540,Zinforo,ceftaroline,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-12,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,6.3,22.05,40.949937,70.87492246,87.52265414,102.2795984,115.1300505,125.0573494,133.2964712,29.30934049,1385,Bacterial infections,7/7/14 12:28
2339,16,AstraZeneca,Large Pharma,3540,Zinforo,ceftaroline,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-12,N/A,N/A,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1385,Bacterial infections,7/7/14 12:28
2347,16,AstraZeneca,Large Pharma,2170,MEDI-573,MEDI-573,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,685,Metastatic breast cancer,7/7/14 12:28
2347,16,AstraZeneca,Large Pharma,2170,MEDI-573,MEDI-573,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,685,Metastatic breast cancer,7/7/14 12:28
2347,16,AstraZeneca,Large Pharma,2170,MEDI-573,MEDI-573,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,685,Metastatic breast cancer,7/7/14 12:28
2348,16,AstraZeneca,Large Pharma,2171,MEDI-550,,Vaccine,Phase I,Corporate Acquisition,,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,680,Pandemic Influenza,7/7/14 12:28
2348,16,AstraZeneca,Large Pharma,2171,MEDI-550,,Vaccine,Phase I,Corporate Acquisition,,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,680,Pandemic Influenza,7/7/14 12:28
2348,16,AstraZeneca,Large Pharma,2171,MEDI-550,,Vaccine,Phase I,Corporate Acquisition,,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,680,Pandemic Influenza,7/7/14 12:28
2351,67,Novartis,Large Pharma,4556,pradigastat,LCQ908,Small Molecule (Chemical),Phase III,,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,613,Hyperlipoproteinemia ,7/7/14 12:28
2351,67,Novartis,Large Pharma,4556,pradigastat,LCQ908,Small Molecule (Chemical),Phase III,,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,613,Hyperlipoproteinemia ,7/7/14 12:28
2351,67,Novartis,Large Pharma,4556,pradigastat,LCQ908,Small Molecule (Chemical),Phase III,,,,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,613,Hyperlipoproteinemia ,7/7/14 12:28
2352,700,Portola Pharmaceuticals,Regional & Specialty Pharma,2496,elinogrel,PRT128,Small Molecule (Chemical),Phase II,In-House,,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,939,Arterial Thrombosis,7/7/14 12:28
2352,700,Portola Pharmaceuticals,Regional & Specialty Pharma,2496,elinogrel,PRT128,Small Molecule (Chemical),Phase II,In-House,,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,939,Arterial Thrombosis,7/7/14 12:28
2352,700,Portola Pharmaceuticals,Regional & Specialty Pharma,2496,elinogrel,PRT128,Small Molecule (Chemical),Phase II,In-House,,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,939,Arterial Thrombosis,7/7/14 12:28
2355,76,Pfizer,Large Pharma,4546,Elelyso,taliglucerase alfa,Recombinant Protein,Launched,Licensed (Development),Jul-09,Jul-09,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Sales,2,12,19.54545,25.09089784,29.63998497,33.9977993,37.7199776,40.9825783,43.87819167,46.41500971,48.64670025,50.61151093,7.943344533,1226,Gaucher's Disease,7/7/14 12:28
2355,76,Pfizer,Large Pharma,4546,Elelyso,taliglucerase alfa,Recombinant Protein,Launched,Licensed (Development),Jul-09,Jul-09,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Sales,1,7,10,11,12,13.12,13.968,14.736,15.42592,16.021888,16.548736,17.01289472,5.113062149,1226,Gaucher's Disease,7/7/14 12:28
2355,76,Pfizer,Large Pharma,4546,Elelyso,taliglucerase alfa,Recombinant Protein,Launched,Licensed (Development),Jul-09,Jul-09,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Sales,1,5,9.54545,14.09089784,17.63998497,20.8777993,23.7519776,26.2465783,28.45227167,30.39312171,32.09796425,33.59861621,9.641432238,1226,Gaucher's Disease,7/7/14 12:28
2358,67,Novartis,Large Pharma,2197,Fanapt,iloperidone,Small Molecule (Chemical),Launched,Licensed (Development),Jan-10,,Nov-16,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,31.4,36,56,63,66.126,68.4249,59.05041375,14.00449245,7.033726009,3.524843756,3.529111621,-33.74945696,438,Schizophrenia,7/7/14 12:28
2358,67,Novartis,Large Pharma,2197,Fanapt,iloperidone,Small Molecule (Chemical),Launched,Licensed (Development),Jan-10,,Nov-16,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,438,Schizophrenia,7/7/14 12:28
2358,67,Novartis,Large Pharma,2197,Fanapt,iloperidone,Small Molecule (Chemical),Launched,Licensed (Development),Jan-10,,Nov-16,N/A,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,31.4,36,56,63,66.126,68.4249,59.05041375,14.00449245,7.033726009,3.524843756,3.529111621,-33.74945696,438,Schizophrenia,7/7/14 12:28
2361,236,BioTie,Regional & Specialty Pharma,2974,BTT-1023,BTT-1023,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1678,Psoriasis,7/7/14 12:28
2361,236,BioTie,Regional & Specialty Pharma,2974,BTT-1023,BTT-1023,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1678,Psoriasis,7/7/14 12:28
2361,236,BioTie,Regional & Specialty Pharma,2974,BTT-1023,BTT-1023,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1678,Psoriasis,7/7/14 12:28
2363,53,Johnson & Johnson,Large Pharma,2203,noscapine,CB3304,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,799,Multiple Myeloma,7/7/14 12:28
2363,53,Johnson & Johnson,Large Pharma,2203,noscapine,CB3304,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,799,Multiple Myeloma,7/7/14 12:28
2363,53,Johnson & Johnson,Large Pharma,2203,noscapine,CB3304,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,799,Multiple Myeloma,7/7/14 12:28
2365,42,Forest,Regional & Specialty Pharma,2205,Fetzima,levomilnacipran,Small Molecule (Chemical),Launched,Licensed (Development),Dec-13,,,,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,0,0,12.5,58.333375,120.833503,183.3334241,230.6667632,274.6001004,313.533424,347.2240887,60.78392532,623,Depression,7/7/14 12:28
2365,42,Forest,Regional & Specialty Pharma,2205,Fetzima,levomilnacipran,Small Molecule (Chemical),Launched,Licensed (Development),Dec-13,,,,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,623,Depression,7/7/14 12:28
2365,42,Forest,Regional & Specialty Pharma,2205,Fetzima,levomilnacipran,Small Molecule (Chemical),Launched,Licensed (Development),Dec-13,,,,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,12.5,58.333375,120.833503,183.3334241,230.6667632,274.6001004,313.533424,347.2240887,60.78392532,623,Depression,7/7/14 12:28
2366,76,Pfizer,Large Pharma,3963,Xalkori,crizotinib,Small Molecule (Chemical),Launched,In-House,Aug-11,Oct-12,Oct-29,Mar-25,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,37,122.38,282,432.64042,562.8715691,650.9373489,722.8344733,780.1334637,825.6657093,863.0670012,17.32735333,862,Non-small-cell Lung Cancer,7/7/14 12:28
2366,76,Pfizer,Large Pharma,3963,Xalkori,crizotinib,Small Molecule (Chemical),Launched,In-House,Aug-11,Oct-12,Oct-29,Mar-25,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,41.2,143,224.71449,306.4296671,349.2956349,380.4408524,402.8285697,417.3838784,427.495385,16.93435678,862,Non-small-cell Lung Cancer,7/7/14 12:28
2366,76,Pfizer,Large Pharma,3963,Xalkori,crizotinib,Small Molecule (Chemical),Launched,In-House,Aug-11,Oct-12,Oct-29,Mar-25,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,37,81.18,139,207.92593,256.441902,301.641714,342.3936209,377.304894,408.2818309,435.5716163,17.72358197,862,Non-small-cell Lung Cancer,7/7/14 12:28
2368,157,Teijin,Regional & Specialty Pharma,2209,Bonalon,alendronate,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-01,,Expired,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,229.4704314,241.9608817,259.5640379,191.4159766,151.0158337,138.7411551,126.9645013,119.5656029,113.2688053,108.2485959,104.4272955,101.3878483,-5.532915184,1335,Osteoporosis,7/7/14 12:28
2368,157,Teijin,Regional & Specialty Pharma,2209,Bonalon,alendronate,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-01,,Expired,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,229.4704314,241.9608817,259.5640379,191.4159766,151.0158337,138.7411551,126.9645013,119.5656029,113.2688053,108.2485959,104.4272955,101.3878483,-5.532915184,1335,Osteoporosis,7/7/14 12:28
2368,157,Teijin,Regional & Specialty Pharma,2209,Bonalon,alendronate,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-01,,Expired,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1335,Osteoporosis,7/7/14 12:28
2372,102,Teva,Regional & Specialty Pharma,2218,CEP-26401,irdabisant,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,303,Cognitive Impairment Associated with Schizophrenia,7/7/14 12:28
2372,102,Teva,Regional & Specialty Pharma,2218,CEP-26401,irdabisant,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,303,Cognitive Impairment Associated with Schizophrenia,7/7/14 12:28
2372,102,Teva,Regional & Specialty Pharma,2218,CEP-26401,irdabisant,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,303,Cognitive Impairment Associated with Schizophrenia,7/7/14 12:28
2375,39,Eli Lilly,Large Pharma,2222,TGF Beta antibody,TGF Beta antibody,Antibody/Antibody Derivative,Phase II,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1181,Diabetic Neuropathy,7/7/14 12:28
2375,39,Eli Lilly,Large Pharma,2222,TGF Beta antibody,TGF Beta antibody,Antibody/Antibody Derivative,Phase II,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1181,Diabetic Neuropathy,7/7/14 12:28
2375,39,Eli Lilly,Large Pharma,2222,TGF Beta antibody,TGF Beta antibody,Antibody/Antibody Derivative,Phase II,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1181,Diabetic Neuropathy,7/7/14 12:28
2377,29,Chugai,Regional & Specialty Pharma,492,Kadcyla,trastuzumab emtansine,Antibody/Antibody Derivative,Launched,Licensed (Development),,May-14,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,3,Global,Alliance Revenue,0,0,0,0,0,20.49792893,58.57499546,88.63387534,120.8809478,195.2870565,232.5783606,268.5266726,0,1671,Breast Cancer,7/7/14 12:28
2377,29,Chugai,Regional & Specialty Pharma,492,Kadcyla,trastuzumab emtansine,Antibody/Antibody Derivative,Launched,Licensed (Development),,May-14,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,3,ROW,Alliance Revenue,0,0,0,0,0,20.49792893,58.57499546,88.63387534,120.8809478,195.2870565,232.5783606,268.5266726,0,1671,Breast Cancer,7/7/14 12:28
2377,29,Chugai,Regional & Specialty Pharma,492,Kadcyla,trastuzumab emtansine,Antibody/Antibody Derivative,Launched,Licensed (Development),,May-14,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1671,Breast Cancer,7/7/14 12:28
2378,29,Chugai,Regional & Specialty Pharma,2645,gantenerumab,RG1450,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1480,Alzheimer's Disease,7/7/14 12:28
2378,29,Chugai,Regional & Specialty Pharma,2645,gantenerumab,RG1450,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1480,Alzheimer's Disease,7/7/14 12:28
2378,29,Chugai,Regional & Specialty Pharma,2645,gantenerumab,RG1450,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1480,Alzheimer's Disease,7/7/14 12:28
2382,40,Endo Health Solutions,Regional & Specialty Pharma,2309,Aveed,testosterone,Small Molecule (Chemical),Launched,Licensed (Development),Apr-14,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,Global,Sales,0,0,0,0,0,7.125,10.53054337,14.87310758,22.01782671,26.26472749,30.1671397,34.04345631,0,179,Hypogonadism,7/7/14 12:28
2382,40,Endo Health Solutions,Regional & Specialty Pharma,2309,Aveed,testosterone,Small Molecule (Chemical),Launched,Licensed (Development),Apr-14,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,179,Hypogonadism,7/7/14 12:28
2382,40,Endo Health Solutions,Regional & Specialty Pharma,2309,Aveed,testosterone,Small Molecule (Chemical),Launched,Licensed (Development),Apr-14,,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,US,Sales,0,0,0,0,0,7.125,10.53054337,14.87310758,22.01782671,26.26472749,30.1671397,34.04345631,0,179,Hypogonadism,7/7/14 12:28
2383,15,Astellas Pharma,Regional & Specialty Pharma,4584,Xtandi,enzalutamide,Small Molecule (Chemical),Launched,Licensed (Development),Sep-12,Jul-13,,,107,Anti-androgens,55,Hormonals,3,Oncology,7,Global,Sales,0,0,0,146.8726356,543.6570012,895.5535261,1291.070648,1750.373121,2134.47004,2469.944503,2703.238137,2942.978176,27.28586814,670,Prostate Cancer,7/7/14 12:28
2383,15,Astellas Pharma,Regional & Specialty Pharma,4584,Xtandi,enzalutamide,Small Molecule (Chemical),Launched,Licensed (Development),Sep-12,Jul-13,,,107,Anti-androgens,55,Hormonals,3,Oncology,7,ROW,Sales,0,0,0,0,90.60950021,261.6256359,456.397813,673.8855642,867.5006933,1035.506521,1171.086023,1256.336191,45.59048711,670,Prostate Cancer,7/7/14 12:28
2383,15,Astellas Pharma,Regional & Specialty Pharma,4584,Xtandi,enzalutamide,Small Molecule (Chemical),Launched,Licensed (Development),Sep-12,Jul-13,,,107,Anti-androgens,55,Hormonals,3,Oncology,7,US,Sales,0,0,0,146.8726356,453.047501,633.9278902,834.6728349,1076.487557,1266.969347,1434.437982,1532.152114,1686.641985,20.65743407,670,Prostate Cancer,7/7/14 12:28
2384,700,Portola Pharmaceuticals,Regional & Specialty Pharma,2429,betrixaban,betrixaban,Small Molecule (Chemical),Phase III,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,235,Thrombosis,7/7/14 12:28
2384,700,Portola Pharmaceuticals,Regional & Specialty Pharma,2429,betrixaban,betrixaban,Small Molecule (Chemical),Phase III,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,235,Thrombosis,7/7/14 12:28
2384,700,Portola Pharmaceuticals,Regional & Specialty Pharma,2429,betrixaban,betrixaban,Small Molecule (Chemical),Phase III,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,235,Thrombosis,7/7/14 12:28
2385,29,Chugai,Regional & Specialty Pharma,1424,CellCept,mycophenolate mofetil,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-99,N/A,Dec-13,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,3,Global,Alliance Revenue,47.02374432,59.25532016,71.49658876,81.43322476,73.79254413,65.11485151,63.10036954,60.94200962,58.33959718,56.6092968,54.76974948,53.89174638,-4.390418828,1557,Transplant Rejection,7/7/14 12:28
2385,29,Chugai,Regional & Specialty Pharma,1424,CellCept,mycophenolate mofetil,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-99,N/A,Dec-13,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,3,ROW,Alliance Revenue,47.02374432,59.25532016,71.49658876,81.43322476,73.79254413,65.11485151,63.10036954,60.94200962,58.33959718,56.6092968,54.76974948,53.89174638,-4.390418828,1557,Transplant Rejection,7/7/14 12:28
2385,29,Chugai,Regional & Specialty Pharma,1424,CellCept,mycophenolate mofetil,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-99,N/A,Dec-13,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1557,Transplant Rejection,7/7/14 12:28
2386,37,Eisai,Regional & Specialty Pharma,2016,Careram,iguratimod,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,7.352056581,14.72272434,21.78963202,28.85644548,34.75112764,39.93574096,44.55500016,48.59016018,52.14238453,19.80017464,284,Rheumatoid Arthritis,7/7/14 12:28
2386,37,Eisai,Regional & Specialty Pharma,2016,Careram,iguratimod,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,7.352056581,14.72272434,21.78963202,28.85644548,34.75112764,39.93574096,44.55500016,48.59016018,52.14238453,19.80017464,284,Rheumatoid Arthritis,7/7/14 12:28
2386,37,Eisai,Regional & Specialty Pharma,2016,Careram,iguratimod,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,284,Rheumatoid Arthritis,7/7/14 12:28
2387,58,Lundbeck,Regional & Specialty Pharma,2241,Xenazine,tetrabenazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-08,Nov-08,Aug-15,N/A,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,1,Global,Sales,55.60738944,108.5037598,159.0049129,206.6789354,252.8261881,282.6737235,243.1445028,104.2964402,79.1139274,65.03802013,54.97674162,47.45153084,-21.2584194,1280,Huntington's Disease,7/7/14 12:28
2387,58,Lundbeck,Regional & Specialty Pharma,2241,Xenazine,tetrabenazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-08,Nov-08,Aug-15,N/A,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,1,ROW,Sales,1.119611868,5.869875532,6.531891963,7.424556577,4.592449542,3.292349012,2.300538109,1.668456812,1.246040481,0.967430887,0.783008322,0.661052339,-24.18733622,1280,Huntington's Disease,7/7/14 12:28
2387,58,Lundbeck,Regional & Specialty Pharma,2241,Xenazine,tetrabenazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-08,Nov-08,Aug-15,N/A,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,1,US,Sales,54.48777757,102.6338843,152.473021,199.2543788,248.2337386,279.3813745,240.8439647,102.6279834,77.86788692,64.07058925,54.1937333,46.7904785,-21.21000778,1280,Huntington's Disease,7/7/14 12:28
2389,68,Novo Nordisk,Regional & Specialty Pharma,2243,N9-GP,NN7999,Recombinant Protein,Phase III,Licensed (Development),Apr-16,Jun-16,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,Global,Sales,0,0,0,0,0,0,0,86.57730371,147.6784537,210.2131375,312.6724925,365.6044945,0,789,Hemophilia B,7/7/14 12:28
2389,68,Novo Nordisk,Regional & Specialty Pharma,2243,N9-GP,NN7999,Recombinant Protein,Phase III,Licensed (Development),Apr-16,Jun-16,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,ROW,Sales,0,0,0,0,0,0,0,65.63592088,114.95147,163.5575496,243.030163,281.5389072,0,789,Hemophilia B,7/7/14 12:28
2389,68,Novo Nordisk,Regional & Specialty Pharma,2243,N9-GP,NN7999,Recombinant Protein,Phase III,Licensed (Development),Apr-16,Jun-16,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,US,Sales,0,0,0,0,0,0,0,20.94138283,32.72698367,46.65558791,69.64232952,84.06558732,0,789,Hemophilia B,7/7/14 12:28
2393,89,Sanofi,Large Pharma,2247,SAR153192,SAR153192,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1053,Cancer,7/7/14 12:28
2393,89,Sanofi,Large Pharma,2247,SAR153192,SAR153192,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1053,Cancer,7/7/14 12:28
2393,89,Sanofi,Large Pharma,2247,SAR153192,SAR153192,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1053,Cancer,7/7/14 12:28
2395,89,Sanofi,Large Pharma,3412,SAR256212,MM-121,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,738,Cancer,7/7/14 12:28
2395,89,Sanofi,Large Pharma,3412,SAR256212,MM-121,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,738,Cancer,7/7/14 12:28
2395,89,Sanofi,Large Pharma,3412,SAR256212,MM-121,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,738,Cancer,7/7/14 12:28
2398,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,990,Sancuso,granisetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-08,Jan-12,Jan-25,Feb-24,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1703,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
2398,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,990,Sancuso,granisetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-08,Jan-12,Jan-25,Feb-24,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,Global,Sales,0,0,7.525956711,19.41869206,20.59132544,29.06787362,31.86346882,34.63587095,36.93497079,38.4251958,39.59308959,40.47412808,10.13555837,1703,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
2398,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,990,Sancuso,granisetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-08,Jan-12,Jan-25,Feb-24,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1703,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
2398,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,990,Sancuso,granisetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-08,Jan-12,Jan-25,Feb-24,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,ROW,Sales,0,0,0,9.396141318,9.31595586,17.42323959,20.103805,22.56279359,24.75586599,26.17807351,27.29456743,28.14868164,17.11278481,1703,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
2398,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,990,Sancuso,granisetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-08,Jan-12,Jan-25,Feb-24,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1703,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
2398,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,990,Sancuso,granisetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-08,Jan-12,Jan-25,Feb-24,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,US,Sales,0,0,7.525956711,10.02255074,11.27536958,11.64463404,11.75966383,12.07307736,12.1791048,12.24712229,12.29852217,12.32544644,1.280199401,1703,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
2398,56,Prostrakan,Regional & Specialty Pharma,990,Sancuso,granisetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-08,Jan-12,Jan-25,Feb-24,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,Global,Proforma,11.38261033,10.25572849,7.525956711,0,0,0,0,0,0,0,0,0,0,1703,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
2398,56,Prostrakan,Regional & Specialty Pharma,990,Sancuso,granisetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-08,Jan-12,Jan-25,Feb-24,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,3,US,Proforma,11.38261033,10.25572849,7.525956711,0,0,0,0,0,0,0,0,0,0,1703,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
2399,15,Astellas Pharma,Regional & Specialty Pharma,3360,ASP-7035,ASP-7035,Small Molecule (Chemical),Phase I,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,161,Nocturia,7/7/14 12:28
2399,15,Astellas Pharma,Regional & Specialty Pharma,3360,ASP-7035,ASP-7035,Small Molecule (Chemical),Phase I,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,161,Nocturia,7/7/14 12:28
2399,15,Astellas Pharma,Regional & Specialty Pharma,3360,ASP-7035,ASP-7035,Small Molecule (Chemical),Phase I,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,161,Nocturia,7/7/14 12:28
2402,100,Takeda,Large Pharma,2256,Mepact,mifamurtide,Other,Launched,Corporate Acquisition,,Feb-10,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,691,Osteosarcoma,7/7/14 12:28
2402,100,Takeda,Large Pharma,2256,Mepact,mifamurtide,Other,Launched,Corporate Acquisition,,Feb-10,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,691,Osteosarcoma,7/7/14 12:28
2402,100,Takeda,Large Pharma,2256,Mepact,mifamurtide,Other,Launched,Corporate Acquisition,,Feb-10,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,691,Osteosarcoma,7/7/14 12:28
2406,100,Takeda,Large Pharma,3936,ixazomib citrate,ixazomib citrate,Small Molecule (Chemical),Phase III,In-House,Jun-15,Aug-15,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,78.27654046,122.3947843,174.4833945,260.444317,374.7525777,475.3354943,0,737,Multiple Myeloma,7/7/14 12:28
2406,100,Takeda,Large Pharma,3936,ixazomib citrate,ixazomib citrate,Small Molecule (Chemical),Phase III,In-House,Jun-15,Aug-15,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,35.23702786,58.14109597,82.80687452,123.3292466,164.688357,221.7605917,0,737,Multiple Myeloma,7/7/14 12:28
2406,100,Takeda,Large Pharma,3936,ixazomib citrate,ixazomib citrate,Small Molecule (Chemical),Phase III,In-House,Jun-15,Aug-15,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,43.0395126,64.25368836,91.67652001,137.1150704,210.0642206,253.5749026,0,737,Multiple Myeloma,7/7/14 12:28
2410,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2348,tivozanib,tivozanib,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1663,Renal Cell Carcinoma,7/7/14 12:28
2410,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2348,tivozanib,tivozanib,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1663,Renal Cell Carcinoma,7/7/14 12:28
2410,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2348,tivozanib,tivozanib,Small Molecule (Chemical),Phase I,Corporate Acquisition,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1663,Renal Cell Carcinoma,7/7/14 12:28
2411,24,Bristol-Myers Squibb,Large Pharma,3849,eldelumab,Anti-IP10,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,671,Ulcerative Colitis,7/7/14 12:28
2411,24,Bristol-Myers Squibb,Large Pharma,3849,eldelumab,Anti-IP10,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,671,Ulcerative Colitis,7/7/14 12:28
2411,24,Bristol-Myers Squibb,Large Pharma,3849,eldelumab,Anti-IP10,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,671,Ulcerative Colitis,7/7/14 12:28
2417,58,Lundbeck,Regional & Specialty Pharma,3490,Onfi,clobazam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-12,,Oct-18,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,1,Global,Sales,0,0,0,44.02934714,91.84899083,131.2127128,196.8190693,239.9393659,279.2312056,275.6880134,109.225673,85.31569119,-1.048568927,319,Epilepsy,7/7/14 12:28
2417,58,Lundbeck,Regional & Specialty Pharma,3490,Onfi,clobazam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-12,,Oct-18,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,319,Epilepsy,7/7/14 12:28
2417,58,Lundbeck,Regional & Specialty Pharma,3490,Onfi,clobazam,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-12,,Oct-18,N/A,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,1,US,Sales,0,0,0,44.02934714,91.84899083,131.2127128,196.8190693,239.9393659,279.2312056,275.6880134,109.225673,85.31569119,-1.048568927,319,Epilepsy,7/7/14 12:28
2418,16,AstraZeneca,Large Pharma,2278,naloxegol,naloxegol,Small Molecule (Chemical),Filed,Licensed (Development),Jan-15,Jan-15,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,55,91.66685,128.33359,164.99978,194.3329696,220.7328094,0,781,Opioid-induced Constipation,7/7/14 12:28
2418,16,AstraZeneca,Large Pharma,2278,naloxegol,naloxegol,Small Molecule (Chemical),Filed,Licensed (Development),Jan-15,Jan-15,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,25,41.66675,58.33345,74.9999,88.333168,100.3330952,0,781,Opioid-induced Constipation,7/7/14 12:28
2418,16,AstraZeneca,Large Pharma,2278,naloxegol,naloxegol,Small Molecule (Chemical),Filed,Licensed (Development),Jan-15,Jan-15,,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,30,50.0001,70.00014,89.99988,105.9998016,120.3997142,0,781,Opioid-induced Constipation,7/7/14 12:28
2419,61,Merck & Co,Large Pharma,2279,actoxumab + bezlotoxumab,MK-3415A,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jul-16,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,5,13.33335,20.000025,26.66663333,30,0,712,Clostridium Difficile infection,7/7/14 12:28
2419,61,Merck & Co,Large Pharma,2279,actoxumab + bezlotoxumab,MK-3415A,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jul-16,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,712,Clostridium Difficile infection,7/7/14 12:28
2419,61,Merck & Co,Large Pharma,2279,actoxumab + bezlotoxumab,MK-3415A,Antibody/Antibody Derivative,Phase III,Licensed (Development),Jul-16,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,5,13.33335,20.000025,26.66663333,30,0,712,Clostridium Difficile infection,7/7/14 12:28
2421,1771,Scynexis,Small Biotech,2280,SCY-078,,Small Molecule (Chemical),Phase I,In-House,,,,,60,Other Anti-fungals,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,710,fungal infection,7/7/14 12:28
2421,1771,Scynexis,Small Biotech,2280,SCY-078,,Small Molecule (Chemical),Phase I,In-House,,,,,60,Other Anti-fungals,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,710,fungal infection,7/7/14 12:28
2421,1771,Scynexis,Small Biotech,2280,SCY-078,,Small Molecule (Chemical),Phase I,In-House,,,,,60,Other Anti-fungals,25,Fungal Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,710,fungal infection,7/7/14 12:28
2423,61,Merck & Co,Large Pharma,3396,V114,pneumococcal vaccine,Vaccine,Phase II,In-House,Sep-16,Oct-16,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,5.83333,23.88889611,37.22219471,50.5555631,61.97779269,0,1231,Strep pneumoniae,7/7/14 12:28
2423,61,Merck & Co,Large Pharma,3396,V114,pneumococcal vaccine,Vaccine,Phase II,In-House,Sep-16,Oct-16,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,2.5,11.666675,18.3333631,25.00010725,30.73347806,0,1231,Strep pneumoniae,7/7/14 12:28
2423,61,Merck & Co,Large Pharma,3396,V114,pneumococcal vaccine,Vaccine,Phase II,In-House,Sep-16,Oct-16,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,3.33333,12.22222111,18.88883162,25.55545585,31.24431464,0,1231,Strep pneumoniae,7/7/14 12:28
2429,63,Merck KGaA,Regional & Specialty Pharma,2033,atacicept,atacicept,Recombinant Protein,Phase II,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,164,Systemic lupus erythematosus,7/7/14 12:28
2429,63,Merck KGaA,Regional & Specialty Pharma,2033,atacicept,atacicept,Recombinant Protein,Phase II,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,164,Systemic lupus erythematosus,7/7/14 12:28
2429,63,Merck KGaA,Regional & Specialty Pharma,2033,atacicept,atacicept,Recombinant Protein,Phase II,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,164,Systemic lupus erythematosus,7/7/14 12:28
2433,15,Astellas Pharma,Regional & Specialty Pharma,396,Linzess,linaclotide,Small Molecule (Chemical),Phase II,Licensed (Development),,Jan-16,N/A,Jan-24,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,Global,Sales,0,0,0,0,0,0,2.516930561,11.74568434,18.45752075,25.16941359,30.22008726,34.33697764,0,1527,IBS-C,7/7/14 12:28
2433,15,Astellas Pharma,Regional & Specialty Pharma,396,Linzess,linaclotide,Small Molecule (Chemical),Phase II,Licensed (Development),,Jan-16,N/A,Jan-24,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,0,0,2.516930561,11.74568434,18.45752075,25.16941359,30.22008726,34.33697764,0,1527,IBS-C,7/7/14 12:28
2433,15,Astellas Pharma,Regional & Specialty Pharma,396,Linzess,linaclotide,Small Molecule (Chemical),Phase II,Licensed (Development),,Jan-16,N/A,Jan-24,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1527,IBS-C,7/7/14 12:28
2434,24,Bristol-Myers Squibb,Large Pharma,4339,clazakizumab,BMS-945429,Antibody/Antibody Derivative,Phase II,Licensed (Development),Jun-17,Jun-17,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,43.749975,104.166503,154.1664244,204.1656792,0,91,Rheumatoid arthritis,7/7/14 12:28
2434,24,Bristol-Myers Squibb,Large Pharma,4339,clazakizumab,BMS-945429,Antibody/Antibody Derivative,Phase II,Licensed (Development),Jun-17,Jun-17,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,14.583325,34.72216766,51.38880813,68.05522639,0,91,Rheumatoid arthritis,7/7/14 12:28
2434,24,Bristol-Myers Squibb,Large Pharma,4339,clazakizumab,BMS-945429,Antibody/Antibody Derivative,Phase II,Licensed (Development),Jun-17,Jun-17,N/A,N/A,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,29.16665,69.44433532,102.7776163,136.1104528,0,91,Rheumatoid arthritis,7/7/14 12:28
2435,102,Teva,Regional & Specialty Pharma,2357,Quartette,levonorgestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-13,,Oct-25,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,0,0,9.99999,38.78256122,54.69543391,79.56490076,96.78873286,111.2302308,124.2515748,134.9674907,45.03112343,382,Female contraception,7/7/14 12:28
2435,102,Teva,Regional & Specialty Pharma,2357,Quartette,levonorgestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-13,,Oct-25,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,382,Female contraception,7/7/14 12:28
2435,102,Teva,Regional & Specialty Pharma,2357,Quartette,levonorgestrel + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-13,,Oct-25,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,9.99999,38.78256122,54.69543391,79.56490076,96.78873286,111.2302308,124.2515748,134.9674907,45.03112343,382,Female contraception,7/7/14 12:28
2437,102,Teva,Regional & Specialty Pharma,2295,Milprosa,progesterone ring ,Small Molecule (Chemical),Filed,Corporate Acquisition,Nov-14,,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,Global,Sales,0,0,0,0,0,3.000006,20.00005,32.00008,44.00011,54.40013624,63.36015874,71.36017883,0,932,Female infertility,7/7/14 12:28
2437,102,Teva,Regional & Specialty Pharma,2295,Milprosa,progesterone ring ,Small Molecule (Chemical),Filed,Corporate Acquisition,Nov-14,,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,932,Female infertility,7/7/14 12:28
2437,102,Teva,Regional & Specialty Pharma,2295,Milprosa,progesterone ring ,Small Molecule (Chemical),Filed,Corporate Acquisition,Nov-14,,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,US,Sales,0,0,0,0,0,3.000006,20.00005,32.00008,44.00011,54.40013624,63.36015874,71.36017883,0,932,Female infertility,7/7/14 12:28
2440,593,Andromeda Biotech,Small Biotech,4039,DiaPep-277,DiaPep-277,Synthetic Peptide,Phase III,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,370,Type I Diabetes,7/7/14 12:28
2440,593,Andromeda Biotech,Small Biotech,4039,DiaPep-277,DiaPep-277,Synthetic Peptide,Phase III,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,370,Type I Diabetes,7/7/14 12:28
2440,593,Andromeda Biotech,Small Biotech,4039,DiaPep-277,DiaPep-277,Synthetic Peptide,Phase III,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,370,Type I Diabetes,7/7/14 12:28
2447,89,Sanofi,Large Pharma,1780,fresolimumab,fresolimumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,173,Other Nephrology Treatments,82,Renal Disorders,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1482,Kidney Sclerosis,7/7/14 12:28
2447,89,Sanofi,Large Pharma,1780,fresolimumab,fresolimumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,173,Other Nephrology Treatments,82,Renal Disorders,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1482,Kidney Sclerosis,7/7/14 12:28
2447,89,Sanofi,Large Pharma,1780,fresolimumab,fresolimumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,173,Other Nephrology Treatments,82,Renal Disorders,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1482,Kidney Sclerosis,7/7/14 12:28
2452,106,United Therapeutics,Small Biotech,2311,Tyvaso,treprostinil,Small Molecule (Chemical),Launched,In-House,Sep-09,,Nov-18,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Sales,20.27,151.8,240.38,325.61,427,500.6185,548.798138,570.2685169,579.2201064,578.5426683,507.896116,428.3606804,4.55E-02,4349,Pulmonary Hypertension,7/7/14 12:28
2452,106,United Therapeutics,Small Biotech,2311,Tyvaso,treprostinil,Small Molecule (Chemical),Launched,In-House,Sep-09,,Nov-18,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4349,Pulmonary Hypertension,7/7/14 12:28
2452,106,United Therapeutics,Small Biotech,2311,Tyvaso,treprostinil,Small Molecule (Chemical),Launched,In-House,Sep-09,,Nov-18,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Sales,20.27,151.8,240.38,325.61,427,500.6185,548.798138,570.2685169,579.2201064,578.5426683,507.896116,428.3606804,4.55E-02,4349,Pulmonary Hypertension,7/7/14 12:28
2455,167,AMAG Pharmaceuticals,Regional & Specialty Pharma,2317,Feraheme / Rienso,ferumoxytol,Small Molecule (Chemical),Launched,In-House,Jul-08,,Mar-20,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,Global,Sales,16,59.3,52.1,58.287,71,78.98546,85.2371376,89.85604146,93.31786248,95.90312879,97.83553287,99.27961644,4.905975863,445,Iron-deficiency anemia,7/7/14 12:28
2455,167,AMAG Pharmaceuticals,Regional & Specialty Pharma,2317,Feraheme / Rienso,ferumoxytol,Small Molecule (Chemical),Launched,In-House,Jul-08,,Mar-20,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,445,Iron-deficiency anemia,7/7/14 12:28
2455,167,AMAG Pharmaceuticals,Regional & Specialty Pharma,2317,Feraheme / Rienso,ferumoxytol,Small Molecule (Chemical),Launched,In-House,Jul-08,,Mar-20,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,US,Sales,16,59.3,52.1,58.287,71,78.98546,85.2371376,89.85604146,93.31786248,95.90312879,97.83553287,99.27961644,4.905975863,445,Iron-deficiency anemia,7/7/14 12:28
2457,19,Bayer,Large Pharma,2319,Aspirin Cardio,acetyl salicylic acid,Small Molecule (Chemical),Launched,In-House,,Jul-97,Expired,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,Global,Sales,437.6919968,474.262222,561.7365632,611.7891512,600.2695901,605.5788675,612.4926934,611.3947324,612.802797,613.4951926,613.6061894,614.8779208,0.34408849,163,myocardial infarction ,7/7/14 12:28
2457,19,Bayer,Large Pharma,2319,Aspirin Cardio,acetyl salicylic acid,Small Molecule (Chemical),Launched,In-House,,Jul-97,Expired,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,ROW,Sales,437.6919968,474.262222,561.7365632,611.7891512,600.2695901,605.5788675,612.4926934,611.3947324,612.802797,613.4951926,613.6061894,614.8779208,0.34408849,163,myocardial infarction ,7/7/14 12:28
2457,19,Bayer,Large Pharma,2319,Aspirin Cardio,acetyl salicylic acid,Small Molecule (Chemical),Launched,In-House,,Jul-97,Expired,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,163,myocardial infarction ,7/7/14 12:28
2460,29,Chugai,Regional & Specialty Pharma,1619,Rocephin,ceftriaxone,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-82,N/A,Jul-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,3,Global,Alliance Revenue,58.7796804,61.53437093,63.97063204,57.59042846,45.09544364,44.27227414,43.86950569,43.70256763,43.63565431,43.60283596,43.5888618,43.58281875,-0.486216577,1386,,7/7/14 12:28
2460,29,Chugai,Regional & Specialty Pharma,1619,Rocephin,ceftriaxone,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-82,N/A,Jul-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,3,ROW,Alliance Revenue,58.7796804,61.53437093,63.97063204,57.59042846,45.09544364,44.27227414,43.86950569,43.70256763,43.63565431,43.60283596,43.5888618,43.58281875,-0.486216577,1386,,7/7/14 12:28
2460,29,Chugai,Regional & Specialty Pharma,1619,Rocephin,ceftriaxone,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-82,N/A,Jul-05,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1386,,7/7/14 12:28
2461,29,Chugai,Regional & Specialty Pharma,1278,Pegasys,peg-interferon alpha 2a,Recombinant Protein,Launched,Licensed (Marketed),,Dec-03,N/A,Jan-23,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,3,Global,Alliance Revenue,118.6280823,119.6501657,104.1090678,86.44450013,56.36930454,52.06473947,45.69603295,40.30876727,30.1618415,20.09394754,12.55610219,10.04425415,-21.84041366,1586,Hepatitis,7/7/14 12:28
2461,29,Chugai,Regional & Specialty Pharma,1278,Pegasys,peg-interferon alpha 2a,Recombinant Protein,Launched,Licensed (Marketed),,Dec-03,N/A,Jan-23,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,3,ROW,Alliance Revenue,118.6280823,119.6501657,104.1090678,86.44450013,56.36930454,52.06473947,45.69603295,40.30876727,30.1618415,20.09394754,12.55610219,10.04425415,-21.84041366,1586,Hepatitis,7/7/14 12:28
2461,29,Chugai,Regional & Specialty Pharma,1278,Pegasys,peg-interferon alpha 2a,Recombinant Protein,Launched,Licensed (Marketed),,Dec-03,N/A,Jan-23,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1586,Hepatitis,7/7/14 12:28
2463,29,Chugai,Regional & Specialty Pharma,1510,Copegus,ribavirin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-07,N/A,Jun-11,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,3,Global,Alliance Revenue,52.36735163,51.27864245,41.39276191,27.6035709,14.49148689,13.3236538,12.62929899,12.4896349,12.42708348,12.41191732,12.4060885,12.40451388,-2.196947467,1617,Hepatitis C,7/7/14 12:28
2463,29,Chugai,Regional & Specialty Pharma,1510,Copegus,ribavirin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-07,N/A,Jun-11,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,3,ROW,Alliance Revenue,52.36735163,51.27864245,41.39276191,27.6035709,14.49148689,13.3236538,12.62929899,12.4896349,12.42708348,12.41191732,12.4060885,12.40451388,-2.196947467,1617,Hepatitis C,7/7/14 12:28
2463,29,Chugai,Regional & Specialty Pharma,1510,Copegus,ribavirin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-07,N/A,Jun-11,42,Nucleoside Analogs,21,Hepatitis,7,Anti-infectives,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1617,Hepatitis C,7/7/14 12:28
2465,10,Almirall,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-11,,Jul-20,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Sales,0,0,5.005573335,10.41069774,14.85387943,22.21605623,27.10034921,31.47648258,35.57711453,39.0491262,42.12226388,44.84090286,17.09752359,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
2465,10,Almirall,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-11,,Jul-20,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Sales,0,0,5.005573335,10.41069774,14.85387943,22.21605623,27.10034921,31.47648258,35.57711453,39.0491262,42.12226388,44.84090286,17.09752359,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
2465,10,Almirall,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-11,,Jul-20,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
2466,169,Auxilium,Regional & Specialty Pharma,1943,Xiaflex,collagenase,Recombinant Protein,Launched,In-House,Mar-10,Mar-11,Feb-17,Feb-21,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,0,0,12.4,102.6,17.6,20.8,22,24,26,27.472,28.8608,31,8.42295869,1401,Dupuytren's Disease,7/7/14 12:28
2466,169,Auxilium,Regional & Specialty Pharma,1943,Xiaflex,collagenase,Recombinant Protein,Launched,In-House,Mar-10,Mar-11,Feb-17,Feb-21,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Sales,0,14.1,42.2,55.2,62.5,71.0605,76.9561625,81.49055031,45.51108212,27.74886998,20.59769634,16.67301413,-17.20211576,1401,Dupuytren's Disease,7/7/14 12:28
2466,169,Auxilium,Regional & Specialty Pharma,1943,Xiaflex,collagenase,Recombinant Protein,Launched,In-House,Mar-10,Mar-11,Feb-17,Feb-21,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,12.4,102.6,17.6,20.8,22,24,26,27.472,28.8608,31,8.42295869,1401,Dupuytren's Disease,7/7/14 12:28
2466,169,Auxilium,Regional & Specialty Pharma,1943,Xiaflex,collagenase,Recombinant Protein,Launched,In-House,Mar-10,Mar-11,Feb-17,Feb-21,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1401,Dupuytren's Disease,7/7/14 12:28
2466,169,Auxilium,Regional & Specialty Pharma,1943,Xiaflex,collagenase,Recombinant Protein,Launched,In-House,Mar-10,Mar-11,Feb-17,Feb-21,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1401,Dupuytren's Disease,7/7/14 12:28
2466,169,Auxilium,Regional & Specialty Pharma,1943,Xiaflex,collagenase,Recombinant Protein,Launched,In-House,Mar-10,Mar-11,Feb-17,Feb-21,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Sales,0,14.1,42.2,55.2,62.5,71.0605,76.9561625,81.49055031,45.51108212,27.74886998,20.59769634,16.67301413,-17.20211576,1401,Dupuytren's Disease,7/7/14 12:28
2468,29,Chugai,Regional & Specialty Pharma,2332,Alfarol,alfacalcidol,Small Molecule (Chemical),Launched,In-House,,Jun-81,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,3,Global,Alliance Revenue,145.3461188,140.1616227,140.4845253,101.4783262,65.59337256,55.3444081,46.99150206,41.62360692,38.00380079,35.45837438,33.74225734,32.56943351,-9.517547407,93,Osteoporosis,7/7/14 12:28
2468,29,Chugai,Regional & Specialty Pharma,2332,Alfarol,alfacalcidol,Small Molecule (Chemical),Launched,In-House,,Jun-81,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,3,ROW,Alliance Revenue,145.3461188,140.1616227,140.4845253,101.4783262,65.59337256,55.3444081,46.99150206,41.62360692,38.00380079,35.45837438,33.74225734,32.56943351,-9.517547407,93,Osteoporosis,7/7/14 12:28
2468,29,Chugai,Regional & Specialty Pharma,2332,Alfarol,alfacalcidol,Small Molecule (Chemical),Launched,In-House,,Jun-81,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,93,Osteoporosis,7/7/14 12:28
2468,86,Roche,Large Pharma,2332,Alfarol,alfacalcidol,Small Molecule (Chemical),Launched,In-House,,Jun-81,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,5,Global,Sales,145.3461188,140.1616227,140.4845253,101.4783262,65.59337256,55.3444081,46.99150206,41.62360692,38.00380079,35.45837438,33.74225734,32.56943351,-9.517547407,93,Osteoporosis,7/7/14 12:28
2468,86,Roche,Large Pharma,2332,Alfarol,alfacalcidol,Small Molecule (Chemical),Launched,In-House,,Jun-81,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,5,ROW,Sales,145.3461188,140.1616227,140.4845253,101.4783262,65.59337256,55.3444081,46.99150206,41.62360692,38.00380079,35.45837438,33.74225734,32.56943351,-9.517547407,93,Osteoporosis,7/7/14 12:28
2472,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2336,Celtect,oxatomide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-87,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,3,Global,Sales,24.58059362,30.76718547,31.35815296,23.80355801,20.04510148,20.41694633,20.65864548,10.24896446,10.24896446,10.24896446,10.24896446,10.24896446,-9.138120292,300,Allergic Rhinitis,7/7/14 12:28
2472,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2336,Celtect,oxatomide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-87,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,3,ROW,Sales,24.58059362,30.76718547,31.35815296,23.80355801,20.04510148,20.41694633,20.65864548,10.24896446,10.24896446,10.24896446,10.24896446,10.24896446,-9.138120292,300,Allergic Rhinitis,7/7/14 12:28
2472,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2336,Celtect,oxatomide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-87,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,300,Allergic Rhinitis,7/7/14 12:28
2473,111,Actavis,Regional & Specialty Pharma,2339,Doryx,doxycycline,Small Molecule (Chemical),Launched,Corporate Acquisition,May-05,,Dec-10,,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Sales,0,0,0,0,20.5,80,73.6,69,65.32,62.376,60.0208,58.13664,16.05685621,377,Severe acne,7/7/14 12:28
2473,111,Actavis,Regional & Specialty Pharma,2339,Doryx,doxycycline,Small Molecule (Chemical),Launched,Corporate Acquisition,May-05,,Dec-10,,160,Acne Treatments,73,Acne,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,377,Severe acne,7/7/14 12:28
2473,111,Actavis,Regional & Specialty Pharma,2339,Doryx,doxycycline,Small Molecule (Chemical),Launched,Corporate Acquisition,May-05,,Dec-10,,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Sales,0,0,0,0,20.5,80,73.6,69,65.32,62.376,60.0208,58.13664,16.05685621,377,Severe acne,7/7/14 12:28
2473,111,Warner Chilcott ,Regional & Specialty Pharma,2339,Doryx,doxycycline,Small Molecule (Chemical),Launched,Corporate Acquisition,May-05,,Dec-10,,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Proforma,210,173,173,92,61.5,0,0,0,0,0,0,0,-100,377,Severe acne,7/7/14 12:28
2473,111,Warner Chilcott ,Regional & Specialty Pharma,2339,Doryx,doxycycline,Small Molecule (Chemical),Launched,Corporate Acquisition,May-05,,Dec-10,,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Proforma,210,173,173,92,61.5,0,0,0,0,0,0,0,-100,377,Severe acne,7/7/14 12:28
2474,10,Almirall,Regional & Specialty Pharma,2120,Abediterol,abediterol,Small Molecule (Chemical),Phase II,In-House,,,,,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1513,COPD,7/7/14 12:28
2474,10,Almirall,Regional & Specialty Pharma,2120,Abediterol,abediterol,Small Molecule (Chemical),Phase II,In-House,,,,,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1513,COPD,7/7/14 12:28
2474,10,Almirall,Regional & Specialty Pharma,2120,Abediterol,abediterol,Small Molecule (Chemical),Phase II,In-House,,,,,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1513,COPD,7/7/14 12:28
2475,46,GlaxoSmithKline,Large Pharma,2342,249320,249320,Antibody/Antibody Derivative,Phase II,In-House,,,,,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4,Stroke Recovery,7/7/14 12:28
2475,46,GlaxoSmithKline,Large Pharma,2342,249320,249320,Antibody/Antibody Derivative,Phase II,In-House,,,,,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4,Stroke Recovery,7/7/14 12:28
2475,46,GlaxoSmithKline,Large Pharma,2342,249320,249320,Antibody/Antibody Derivative,Phase II,In-House,,,,,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4,Stroke Recovery,7/7/14 12:28
2478,96,Shire,Regional & Specialty Pharma,2346,Firazyr,icatibant,Synthetic Peptide,Launched,Corporate Acquisition,Sep-11,Sep-08,N/A,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Sales,6,11,33,116,235,333.07704,399.316152,455.8897528,500.668358,535.8936571,564.5244359,587.6499639,13.98936924,451,Hereditary Angioedema,7/7/14 12:28
2478,96,Shire,Regional & Specialty Pharma,2346,Firazyr,icatibant,Synthetic Peptide,Launched,Corporate Acquisition,Sep-11,Sep-08,N/A,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,ROW,Sales,6,11,25,58,89,111.56,133.304,152.376,168.83296,183.472064,196.328896,207.6181274,12.86351102,451,Hereditary Angioedema,7/7/14 12:28
2478,96,Shire,Regional & Specialty Pharma,2346,Firazyr,icatibant,Synthetic Peptide,Launched,Corporate Acquisition,Sep-11,Sep-08,N/A,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Sales,0,0,8,58,146,221.51704,266.012152,303.5137528,331.835398,352.4215931,368.1955399,380.0318365,14.64427891,451,Hereditary Angioedema,7/7/14 12:28
2479,102,Teva,Regional & Specialty Pharma,3470,custirsen,TV-1101,DNA/RNA Therapy,Phase III,Licensed (Development),Jan-15,Mar-15,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,38.333328,104.8890014,173.2222382,241.5561457,289.1407873,329.7121856,0,1215,Prostate Cancer,7/7/14 12:28
2479,102,Teva,Regional & Specialty Pharma,3470,custirsen,TV-1101,DNA/RNA Therapy,Phase III,Licensed (Development),Jan-15,Mar-15,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,13.333328,38.22225138,64.8887695,91.55545821,109.9732173,125.7527502,0,1215,Prostate Cancer,7/7/14 12:28
2479,102,Teva,Regional & Specialty Pharma,3470,custirsen,TV-1101,DNA/RNA Therapy,Phase III,Licensed (Development),Jan-15,Mar-15,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,25,66.66675,108.3334687,150.0006875,179.16757,203.9594354,0,1215,Prostate Cancer,7/7/14 12:28
2480,170,AVEO Pharmaceuticals,Regional & Specialty Pharma,2348,tivozanib,tivozanib,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1663,Cancer,7/7/14 12:28
2480,170,AVEO Pharmaceuticals,Regional & Specialty Pharma,2348,tivozanib,tivozanib,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1663,Cancer,7/7/14 12:28
2480,170,AVEO Pharmaceuticals,Regional & Specialty Pharma,2348,tivozanib,tivozanib,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1663,Cancer,7/7/14 12:28
2481,171,BioMarin,Small Biotech,93,Kuvan,sapropterin,Small Molecule (Chemical),Launched,In-House,Dec-07,,Nov-24,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Sales,76.8,99.4,116.8,143,167,183.338,197.7643,209.604485,219.0653927,226.8828313,233.2633513,238.4627225,5.220546508,1629,Phenylketonuria,7/7/14 12:28
2481,171,BioMarin,Small Biotech,93,Kuvan,sapropterin,Small Molecule (Chemical),Launched,In-House,Dec-07,,Nov-24,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1629,Phenylketonuria,7/7/14 12:28
2481,171,BioMarin,Small Biotech,93,Kuvan,sapropterin,Small Molecule (Chemical),Launched,In-House,Dec-07,,Nov-24,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Sales,76.8,99.4,116.8,143,167,183.338,197.7643,209.604485,219.0653927,226.8828313,233.2633513,238.4627225,5.220546508,1629,Phenylketonuria,7/7/14 12:28
2482,100,Takeda,Large Pharma,3700,Adcetris,brentuximab vedotin,Antibody/Antibody Derivative,Launched,Licensed (Development),,Nov-12,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,7,Global,Sales,0,0,0,46.95108841,131.8871614,200.697969,269.5092747,298.9386763,334.2931546,354.7502096,369.3982638,379.508943,16.29850922,270,Hodgkin's Lymphoma,7/7/14 12:28
2482,100,Takeda,Large Pharma,3700,Adcetris,brentuximab vedotin,Antibody/Antibody Derivative,Launched,Licensed (Development),,Nov-12,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,46.95108841,131.8871614,200.697969,269.5092747,298.9386763,334.2931546,354.7502096,369.3982638,379.508943,16.29850922,270,Hodgkin's Lymphoma,7/7/14 12:28
2482,100,Takeda,Large Pharma,3700,Adcetris,brentuximab vedotin,Antibody/Antibody Derivative,Launched,Licensed (Development),,Nov-12,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,270,Hodgkin's Lymphoma,7/7/14 12:28
2484,171,BioMarin,Small Biotech,2350,Naglazyme,galsulfase,Recombinant Protein,Launched,In-House,Jun-05,Feb-06,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Sales,168.72472,193.346608,224.9,257,271,289.3525427,307.1863598,320.9644969,333.6922747,344.9435494,354.7032279,363.3438497,4.277984355,758,Maroteaux-Lamy Syndrome,7/7/14 12:28
2484,171,BioMarin,Small Biotech,2350,Naglazyme,galsulfase,Recombinant Protein,Launched,In-House,Jun-05,Feb-06,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Sales,69.80472,83.646608,102.9,122,130,140.8645427,150.1863598,157.8025769,164.8246267,170.9528294,176.3079972,181.0443609,4.845256514,758,Maroteaux-Lamy Syndrome,7/7/14 12:28
2484,171,BioMarin,Small Biotech,2350,Naglazyme,galsulfase,Recombinant Protein,Launched,In-House,Jun-05,Feb-06,N/A,N/A,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Sales,98.92,109.7,122,135,141,148.488,157,163.16192,168.867648,173.99072,178.3952307,182.2994888,3.738038584,758,Maroteaux-Lamy Syndrome,7/7/14 12:28
2489,102,Teva,Regional & Specialty Pharma,2358,LeCette,desogestrel + ethinyl estradiol,Small Molecule (Chemical),Filed,Corporate Acquisition,Oct-14,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,0,0,0,5,23.33335,36.66672619,50.0002145,57.16692801,62.29196725,65.98158292,0,381,Female contraception,7/7/14 12:28
2489,102,Teva,Regional & Specialty Pharma,2358,LeCette,desogestrel + ethinyl estradiol,Small Molecule (Chemical),Filed,Corporate Acquisition,Oct-14,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,381,Female contraception,7/7/14 12:28
2489,102,Teva,Regional & Specialty Pharma,2358,LeCette,desogestrel + ethinyl estradiol,Small Molecule (Chemical),Filed,Corporate Acquisition,Oct-14,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,0,5,23.33335,36.66672619,50.0002145,57.16692801,62.29196725,65.98158292,0,381,Female contraception,7/7/14 12:28
2490,102,Teva,Regional & Specialty Pharma,4328,QNASL,beclomethasone dipropionate,Small Molecule (Chemical),Launched,Acquisition (Development),Apr-12,,Jan-27,N/A,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,Global,Sales,0,0,0,11.25,24.3313875,43.03784484,73.91018208,87.04135508,99.11701963,109.935811,117.0695516,122.9026515,26.03315569,1686,Allergic Rhinitis,7/7/14 12:28
2490,102,Teva,Regional & Specialty Pharma,4328,QNASL,beclomethasone dipropionate,Small Molecule (Chemical),Launched,Acquisition (Development),Apr-12,,Jan-27,N/A,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1686,Allergic Rhinitis,7/7/14 12:28
2490,102,Teva,Regional & Specialty Pharma,4328,QNASL,beclomethasone dipropionate,Small Molecule (Chemical),Launched,Acquisition (Development),Apr-12,,Jan-27,N/A,77,Nasal Steroids,62,Allergic Rhinitis,1,Respiratory,6,US,Sales,0,0,0,11.25,24.3313875,43.03784484,73.91018208,87.04135508,99.11701963,109.935811,117.0695516,122.9026515,26.03315569,1686,Allergic Rhinitis,7/7/14 12:28
2493,67,Novartis,Large Pharma,3489,Jakavi,ruxolitinib,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,N/A,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,30,163,240,303.5388381,395.3815004,511.3207501,583.3692811,616.5128039,635.5249205,21.45646229,1495,Myelofibrosis,7/7/14 12:28
2493,67,Novartis,Large Pharma,3489,Jakavi,ruxolitinib,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,N/A,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,30,163,240,303.5388381,395.3815004,511.3207501,583.3692811,616.5128039,635.5249205,21.45646229,1495,Myelofibrosis,7/7/14 12:28
2493,67,Novartis,Large Pharma,3489,Jakavi,ruxolitinib,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-12,N/A,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1495,Myelofibrosis,7/7/14 12:28
2494,172,Incyte,Regional & Specialty Pharma,4742,Jakafi,ruxolitinib,Small Molecule (Chemical),Launched,In-House,Dec-11,,Dec-27,N/A,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,2.3,136,235.4,316.44,395.84424,470.92968,531.9645408,558.4343366,580.8058221,596.7470804,14.21204823,1495,Myelofibrosis,7/7/14 12:28
2494,172,Incyte,Regional & Specialty Pharma,4742,Jakafi,ruxolitinib,Small Molecule (Chemical),Launched,In-House,Dec-11,,Dec-27,N/A,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1495,Myelofibrosis,7/7/14 12:28
2494,172,Incyte,Regional & Specialty Pharma,4742,Jakafi,ruxolitinib,Small Molecule (Chemical),Launched,In-House,Dec-11,,Dec-27,N/A,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,2.3,136,235.4,316.44,395.84424,470.92968,531.9645408,558.4343366,580.8058221,596.7470804,14.21204823,1495,Myelofibrosis,7/7/14 12:28
2497,95,Shionogi,Regional & Specialty Pharma,2370,S-234462,S-234462,Small Molecule (Chemical),Phase I,In-House,,,,,80,Obesity Treatments,38,Obesity,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034,Obesity,7/7/14 12:28
2497,95,Shionogi,Regional & Specialty Pharma,2370,S-234462,S-234462,Small Molecule (Chemical),Phase I,In-House,,,,,80,Obesity Treatments,38,Obesity,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034,Obesity,7/7/14 12:28
2497,95,Shionogi,Regional & Specialty Pharma,2370,S-234462,S-234462,Small Molecule (Chemical),Phase I,In-House,,,,,80,Obesity Treatments,38,Obesity,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1034,Obesity,7/7/14 12:28
2505,76,Pfizer,Large Pharma,4232,PF-03049423,PF-03049423,Small Molecule (Chemical),Phase II,In-House,,,,,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,866,Stroke recovery,7/7/14 12:28
2505,76,Pfizer,Large Pharma,4232,PF-03049423,PF-03049423,Small Molecule (Chemical),Phase II,In-House,,,,,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,866,Stroke recovery,7/7/14 12:28
2505,76,Pfizer,Large Pharma,4232,PF-03049423,PF-03049423,Small Molecule (Chemical),Phase II,In-House,,,,,159,Stroke Recovery Agents,72,Stroke Recovery,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,866,Stroke recovery,7/7/14 12:28
2509,26,Celgene,Regional & Specialty Pharma,2387,Istodax,romidepsin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-10,,Aug-21,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,15.781,30.9,50,54,56.15076,57.369836,57.7807892,52.13156778,40.65215472,31.9617682,29.06485168,-8.469085203,575,Cutaneous T-cell Lymphoma,7/7/14 12:28
2509,26,Celgene,Regional & Specialty Pharma,2387,Istodax,romidepsin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-10,,Aug-21,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,575,Cutaneous T-cell Lymphoma,7/7/14 12:28
2509,26,Celgene,Regional & Specialty Pharma,2387,Istodax,romidepsin,Small Molecule (Chemical),Launched,Corporate Acquisition,May-10,,Aug-21,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,15.781,30.9,50,54,56.15076,57.369836,57.7807892,52.13156778,40.65215472,31.9617682,29.06485168,-8.469085203,575,Cutaneous T-cell Lymphoma,7/7/14 12:28
2514,86,Roche,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-15,,Dec-18,N/A,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,5,Global,Sales,0,0,0,0,0,0,9.442321773,22.48169602,33.27291012,44.06398033,50.80844484,56.06912252,0,1570,Chronic idiopathic urticaria,7/7/14 12:28
2514,86,Roche,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-15,,Dec-18,N/A,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1570,Chronic idiopathic urticaria,7/7/14 12:28
2514,86,Roche,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,May-15,,Dec-18,N/A,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,5,US,Sales,0,0,0,0,0,0,9.442321773,22.48169602,33.27291012,44.06398033,50.80844484,56.06912252,0,1570,Chronic idiopathic urticaria,7/7/14 12:28
2516,86,Roche,Large Pharma,2398,RG7090,RG7090,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,987,Depression,7/7/14 12:28
2516,86,Roche,Large Pharma,2398,RG7090,RG7090,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,987,Depression,7/7/14 12:28
2516,86,Roche,Large Pharma,2398,RG7090,RG7090,Small Molecule (Chemical),Phase II,In-House,,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,987,Depression,7/7/14 12:28
2519,86,Roche,Large Pharma,2401,RG1662,RG1662,Small Molecule (Chemical),Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,977,Down Syndrome,7/7/14 12:28
2519,86,Roche,Large Pharma,2401,RG1662,RG1662,Small Molecule (Chemical),Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,977,Down Syndrome,7/7/14 12:28
2519,86,Roche,Large Pharma,2401,RG1662,RG1662,Small Molecule (Chemical),Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,977,Down Syndrome,7/7/14 12:28
2520,68,Novo Nordisk,Regional & Specialty Pharma,2404,NovoMix,biphasic insulin aspart,Recombinant Protein,Launched,In-House,Oct-02,Mar-02,Dec-16,Oct-15,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Sales,1212.726255,1391.160501,1544.885762,1613.028082,1737.814243,1804.471662,1842.923956,1863.771267,1851.258511,1813.663282,1807.043424,1799.941391,0.503060081,801,Diabetes,7/7/14 12:28
2520,68,Novo Nordisk,Regional & Specialty Pharma,2404,NovoMix,biphasic insulin aspart,Recombinant Protein,Launched,In-House,Oct-02,Mar-02,Dec-16,Oct-15,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Sales,916.0291099,1036.477719,1174.6208,1204.850135,1282.125479,1313.666906,1318.974831,1315.02275,1303.112297,1280.16215,1274.332764,1264.622206,-0.196175771,801,Diabetes,7/7/14 12:28
2520,68,Novo Nordisk,Regional & Specialty Pharma,2404,NovoMix,biphasic insulin aspart,Recombinant Protein,Launched,In-House,Oct-02,Mar-02,Dec-16,Oct-15,83,Insulins,22,Diabetes,8,Metabolism,1,US,Sales,296.697145,354.6827821,370.2649615,408.1779476,455.688764,490.8047563,523.9491245,548.7485167,548.1462136,533.5011322,532.7106594,535.3191851,2.327428337,801,Diabetes,7/7/14 12:28
2521,26,Celgene,Regional & Specialty Pharma,1816,ACE-011,sotatercept,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,65,Renal Anemia,7/7/14 12:28
2521,26,Celgene,Regional & Specialty Pharma,1816,ACE-011,sotatercept,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,65,Renal Anemia,7/7/14 12:28
2521,26,Celgene,Regional & Specialty Pharma,1816,ACE-011,sotatercept,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,65,Renal Anemia,7/7/14 12:28
2522,68,Novo Nordisk,Regional & Specialty Pharma,3892,Xultophy,IDegLira,Synthetic Peptide,Filed,In-House,Nov-16,Mar-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,0,31.31115369,89.75874495,163.3915967,299.4198053,465.137293,628.4504262,771.1701354,0,792,Type II Diabetes,7/7/14 12:28
2522,68,Novo Nordisk,Regional & Specialty Pharma,3892,Xultophy,IDegLira,Synthetic Peptide,Filed,In-House,Nov-16,Mar-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,0,31.31115369,89.75874495,152.3807285,215.0031127,270.6116876,323.8155471,374.0436282,0,792,Type II Diabetes,7/7/14 12:28
2522,68,Novo Nordisk,Regional & Specialty Pharma,3892,Xultophy,IDegLira,Synthetic Peptide,Filed,In-House,Nov-16,Mar-14,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,11.01086815,84.41669252,194.5256054,304.6348791,397.1265071,0,792,Type II Diabetes,7/7/14 12:28
2523,68,Novo Nordisk,Regional & Specialty Pharma,3792,OI338GT,NN1953,Synthetic Peptide,Phase I,Licensed (Development),,,,,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,785,Diabetes,7/7/14 12:28
2523,68,Novo Nordisk,Regional & Specialty Pharma,3792,OI338GT,NN1953,Synthetic Peptide,Phase I,Licensed (Development),,,,,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,785,Diabetes,7/7/14 12:28
2523,68,Novo Nordisk,Regional & Specialty Pharma,3792,OI338GT,NN1953,Synthetic Peptide,Phase I,Licensed (Development),,,,,83,Insulins,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,785,Diabetes,7/7/14 12:28
2524,68,Novo Nordisk,Regional & Specialty Pharma,2411,OG217SC,NN9924,Synthetic Peptide,Phase II,Licensed (Development),,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,794,Type II Diabetes,7/7/14 12:28
2524,68,Novo Nordisk,Regional & Specialty Pharma,2411,OG217SC,NN9924,Synthetic Peptide,Phase II,Licensed (Development),,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,794,Type II Diabetes,7/7/14 12:28
2524,68,Novo Nordisk,Regional & Specialty Pharma,2411,OG217SC,NN9924,Synthetic Peptide,Phase II,Licensed (Development),,,,,142,GLP-1 Analogs,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,794,Type II Diabetes,7/7/14 12:28
2529,67,Novartis,Large Pharma,2428,Ilaris,canakinumab,Antibody/Antibody Derivative,Launched,In-House,Oct-15,Dec-13,,,151,Gout Treatments,64,Gout,8,Metabolism,6,Global,Sales,0,0,0,0,2,15.33334,31.06663957,56.56652947,73.34313744,91.02159072,104.3021216,115.0115078,78.39680716,1374,Gout,7/7/14 12:28
2529,67,Novartis,Large Pharma,2428,Ilaris,canakinumab,Antibody/Antibody Derivative,Launched,In-House,Oct-15,Dec-13,,,151,Gout Treatments,64,Gout,8,Metabolism,6,ROW,Sales,0,0,0,0,2,15.33334,29.66663957,51.66652947,64.24315144,75.27160795,84.85264293,92.28270812,72.87291414,1374,Gout,7/7/14 12:28
2529,67,Novartis,Large Pharma,2428,Ilaris,canakinumab,Antibody/Antibody Derivative,Launched,In-House,Oct-15,Dec-13,,,151,Gout Treatments,64,Gout,8,Metabolism,6,US,Sales,0,0,0,0,0,0,1.4,4.9,9.099986,15.74998277,19.4494787,22.72879964,0,1374,Gout,7/7/14 12:28
2532,964,Paratek,Small Biotech,3995,omadacycline,,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,942,Staphylococcus aureas infection,7/7/14 12:28
2532,964,Paratek,Small Biotech,3995,omadacycline,,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,942,Staphylococcus aureas infection,7/7/14 12:28
2532,964,Paratek,Small Biotech,3995,omadacycline,,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,942,Staphylococcus aureas infection,7/7/14 12:28
2533,58,Lundbeck,Regional & Specialty Pharma,2420,I.V. carbamazepine,I.V. carbamazepine,Small Molecule (Chemical),Filed,Acquisition (Development),Jan-15,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,3.205313698,5.342200181,7.479080253,9.615928272,10.68435853,11.40554998,0,1689,Epilepsy,7/7/14 12:28
2533,58,Lundbeck,Regional & Specialty Pharma,2420,I.V. carbamazepine,I.V. carbamazepine,Small Molecule (Chemical),Filed,Acquisition (Development),Jan-15,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1689,Epilepsy,7/7/14 12:28
2533,58,Lundbeck,Regional & Specialty Pharma,2420,I.V. carbamazepine,I.V. carbamazepine,Small Molecule (Chemical),Filed,Acquisition (Development),Jan-15,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,3.205313698,5.342200181,7.479080253,9.615928272,10.68435853,11.40554998,0,1689,Epilepsy,7/7/14 12:28
2534,173,Alexion Pharmaceuticals,Small Biotech,2422,Soliris,eculizumab,Antibody/Antibody Derivative,Launched,In-House,Apr-07,Oct-07,Mar-21,May-20,108,Other Hematology Products,81,Other Hematological Disorders,14,Hematology,6,Global,Sales,386.8,541,783.43,1134,1551.1,1750.31385,1912.481859,2035.829346,2118.42115,2179.324713,2223.269064,2254.487947,5.487533251,1108,Paroxysmal Nocturnal Hemoglobinuria,7/7/14 12:28
2534,173,Alexion Pharmaceuticals,Small Biotech,2422,Soliris,eculizumab,Antibody/Antibody Derivative,Launched,In-House,Apr-07,Oct-07,Mar-21,May-20,108,Other Hematology Products,81,Other Hematological Disorders,14,Hematology,6,ROW,Sales,226.8,322.7,469.71,621,853,957.93395,1041.712686,1107.58594,1151.067311,1183.109436,1206.341505,1222.800225,5.279487067,1108,Paroxysmal Nocturnal Hemoglobinuria,7/7/14 12:28
2534,173,Alexion Pharmaceuticals,Small Biotech,2422,Soliris,eculizumab,Antibody/Antibody Derivative,Launched,In-House,Apr-07,Oct-07,Mar-21,May-20,108,Other Hematology Products,81,Other Hematological Disorders,14,Hematology,6,US,Sales,160,218.3,313.72,513,698.1,792.3799,870.7691725,928.2434059,967.3538391,996.2152767,1016.927559,1031.687722,5.73844566,1108,Paroxysmal Nocturnal Hemoglobinuria,7/7/14 12:28
2536,89,Sanofi,Large Pharma,2426,dupilumab,dupilumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1055,Asthma,7/7/14 12:28
2536,89,Sanofi,Large Pharma,2426,dupilumab,dupilumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1055,Asthma,7/7/14 12:28
2536,89,Sanofi,Large Pharma,2426,dupilumab,dupilumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1055,Asthma,7/7/14 12:28
2537,89,Sanofi,Large Pharma,2427,alirocumab,SAR236553,Antibody/Antibody Derivative,Phase III,In-House,Jun-19,Oct-19,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,69.16820165,268.0036613,0,1056,Hypercholesterolemia,7/7/14 12:28
2537,89,Sanofi,Large Pharma,2427,alirocumab,SAR236553,Antibody/Antibody Derivative,Phase III,In-House,Jun-19,Oct-19,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,14.94033825,84.66196655,0,1056,Hypercholesterolemia,7/7/14 12:28
2537,89,Sanofi,Large Pharma,2427,alirocumab,SAR236553,Antibody/Antibody Derivative,Phase III,In-House,Jun-19,Oct-19,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,54.2278634,183.3416948,0,1056,Hypercholesterolemia,7/7/14 12:28
2539,67,Novartis,Large Pharma,2428,Ilaris,canakinumab,Antibody/Antibody Derivative,Launched,In-House,Jul-09,Nov-09,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,7,26,48,72,117,138.525,156.868625,172.4083781,183.5180048,192.2986275,199.1521913,204.3980541,8.296133289,1374,Cryopyrin-associated periodic syndromes,7/7/14 12:28
2539,67,Novartis,Large Pharma,2428,Ilaris,canakinumab,Antibody/Antibody Derivative,Launched,In-House,Jul-09,Nov-09,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,4,17,33,50,76,89.845,101.624625,111.5327781,118.8498048,124.6912795,129.3046389,132.8942818,8.310447788,1374,Cryopyrin-associated periodic syndromes,7/7/14 12:28
2539,67,Novartis,Large Pharma,2428,Ilaris,canakinumab,Antibody/Antibody Derivative,Launched,In-House,Jul-09,Nov-09,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,3,9,15,22,41,48.68,55.244,60.8756,64.6682,67.607348,69.8475524,71.50377236,8.26956903,1374,Cryopyrin-associated periodic syndromes,7/7/14 12:28
2540,102,Teva,Regional & Specialty Pharma,2430,Cinquil,reslizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,May-15,May-15,N/A,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,16.666675,52.77785972,94.44439664,127,148.5999998,165.9399928,0,1614,Asthma,7/7/14 12:28
2540,102,Teva,Regional & Specialty Pharma,2430,Cinquil,reslizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,May-15,May-15,N/A,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,7.333337,23.22225828,41.55553452,55,64.23999992,71.63199683,0,1614,Asthma,7/7/14 12:28
2540,102,Teva,Regional & Specialty Pharma,2430,Cinquil,reslizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,May-15,May-15,N/A,N/A,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,9.333338,29.55560144,52.88886212,72,84.3599999,94.30799597,0,1614,Asthma,7/7/14 12:28
2542,111,Actavis,Regional & Specialty Pharma,2431,Gelnique,oxybutynin gel,Small Molecule (Chemical),Launched,In-House,May-09,Sep-12,May-20,May-20,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Sales,10,22,28,35,51.03,62.0815,72.5017856,78.78550965,83.34728584,86.72583051,89.08274519,90.791196,8.578894846,488,Overactive bladder,7/7/14 12:28
2542,111,Actavis,Regional & Specialty Pharma,2431,Gelnique,oxybutynin gel,Small Molecule (Chemical),Launched,In-House,May-09,Sep-12,May-20,May-20,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,ROW,Sales,0,0,0,3,15,23.18175,31.36351685,35.83622106,38.99983714,41.27982347,42.77163289,43.8029448,16.54331553,488,Overactive bladder,7/7/14 12:28
2542,111,Actavis,Regional & Specialty Pharma,2431,Gelnique,oxybutynin gel,Small Molecule (Chemical),Launched,In-House,May-09,Sep-12,May-20,May-20,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Sales,10,22,28,32,36.03,38.89975,41.13826875,42.94928859,44.3474487,45.44600704,46.3111123,46.9882512,3.866377774,488,Overactive bladder,7/7/14 12:28
2543,39,Eli Lilly,Large Pharma,4341,baricitinib,LY3009104,Small Molecule (Chemical),Phase III,Licensed (Development),Nov-16,Dec-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,8.333346,73.88905978,173.8892956,273.8898261,342.1789898,0,552,Rheumatoid arthritis,7/7/14 12:28
2543,39,Eli Lilly,Large Pharma,4341,baricitinib,LY3009104,Small Molecule (Chemical),Phase III,Licensed (Development),Nov-16,Dec-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,1.666666,22.77782422,56.11111997,89.44449189,111.0667263,0,552,Rheumatoid arthritis,7/7/14 12:28
2543,39,Eli Lilly,Large Pharma,4341,baricitinib,LY3009104,Small Molecule (Chemical),Phase III,Licensed (Development),Nov-16,Dec-16,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,6.66668,51.11123556,117.7781757,184.4453342,231.1122635,0,552,Rheumatoid arthritis,7/7/14 12:28
2544,102,Teva,Regional & Specialty Pharma,2433,Huntexil,pridopidine,Small Molecule (Chemical),Phase II,Acquisition (Development),Jun-17,Sep-17,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,157.499895,419.99953,629.9987203,839.9961881,0,533,Huntington's Disease,7/7/14 12:28
2544,102,Teva,Regional & Specialty Pharma,2433,Huntexil,pridopidine,Small Molecule (Chemical),Phase II,Acquisition (Development),Jun-17,Sep-17,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,34.999965,128.3333217,198.332732,268.3322864,0,533,Huntington's Disease,7/7/14 12:28
2544,102,Teva,Regional & Specialty Pharma,2433,Huntexil,pridopidine,Small Molecule (Chemical),Phase II,Acquisition (Development),Jun-17,Sep-17,,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,122.49993,291.6662083,431.6659883,571.6639017,0,533,Huntington's Disease,7/7/14 12:28
2545,73,Otsuka,Regional & Specialty Pharma,2434,TS1,gimeracil + oteracil + tegafur,Small Molecule (Chemical),Launched,In-House,,Mar-99,N/A,Nov-16,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,Global,Sales,401.8425865,433.0621345,462.1506041,445.4334047,415.1394261,428.1107558,440.2802845,446.4168244,393.3583574,366.1287911,347.9634821,329.0795024,-3.264315855,1209,Gastric Cancer,7/7/14 12:28
2545,73,Otsuka,Regional & Specialty Pharma,2434,TS1,gimeracil + oteracil + tegafur,Small Molecule (Chemical),Launched,In-House,,Mar-99,N/A,Nov-16,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,ROW,Sales,401.8425865,433.0621345,462.1506041,445.4334047,415.1394261,428.1107558,440.2802845,446.4168244,393.3583574,366.1287911,347.9634821,329.0795024,-3.264315855,1209,Gastric Cancer,7/7/14 12:28
2545,73,Otsuka,Regional & Specialty Pharma,2434,TS1,gimeracil + oteracil + tegafur,Small Molecule (Chemical),Launched,In-House,,Mar-99,N/A,Nov-16,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1209,Gastric Cancer,7/7/14 12:28
2546,73,Otsuka,Regional & Specialty Pharma,2435,UFT,tegafur + uracil,Small Molecule (Chemical),Launched,In-House,,Jul-84,N/A,May-17,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,Global,Sales,197.1506524,183.2634909,163.335419,134.8338955,99.87663292,90.87753771,84.31325215,79.64423791,74.27608514,67.37825957,62.75748767,56.70734142,-7.767870855,1220,Colorectal Cancer,7/7/14 12:28
2546,73,Otsuka,Regional & Specialty Pharma,2435,UFT,tegafur + uracil,Small Molecule (Chemical),Launched,In-House,,Jul-84,N/A,May-17,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,ROW,Sales,197.1506524,183.2634909,163.335419,134.8338955,99.87663292,90.87753771,84.31325215,79.64423791,74.27608514,67.37825957,62.75748767,56.70734142,-7.767870855,1220,Colorectal Cancer,7/7/14 12:28
2546,73,Otsuka,Regional & Specialty Pharma,2435,UFT,tegafur + uracil,Small Molecule (Chemical),Launched,In-House,,Jul-84,N/A,May-17,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1220,Colorectal Cancer,7/7/14 12:28
2547,73,Otsuka,Regional & Specialty Pharma,2436,Uzel,calcium folinate,Small Molecule (Chemical),Launched,In-House,,Sep-03,N/A,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,Global,Sales,162.6762214,164.5869568,160.8030869,158.9113762,121.8194392,118.6984453,115.9449232,114.5130414,113.5988545,113.0641068,112.7398171,112.5461035,-1.124725924,1230,Colorectal Cancer,7/7/14 12:28
2547,73,Otsuka,Regional & Specialty Pharma,2436,Uzel,calcium folinate,Small Molecule (Chemical),Launched,In-House,,Sep-03,N/A,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,ROW,Sales,162.6762214,164.5869568,160.8030869,158.9113762,121.8194392,118.6984453,115.9449232,114.5130414,113.5988545,113.0641068,112.7398171,112.5461035,-1.124725924,1230,Colorectal Cancer,7/7/14 12:28
2547,73,Otsuka,Regional & Specialty Pharma,2436,Uzel,calcium folinate,Small Molecule (Chemical),Launched,In-House,,Sep-03,N/A,N/A,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1230,Colorectal Cancer,7/7/14 12:28
2548,100,Takeda,Large Pharma,2439,TAK-733,TAK-733,Small Molecule (Chemical),Phase I,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1155,Various Malignancies,7/7/14 12:28
2548,100,Takeda,Large Pharma,2439,TAK-733,TAK-733,Small Molecule (Chemical),Phase I,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1155,Various Malignancies,7/7/14 12:28
2548,100,Takeda,Large Pharma,2439,TAK-733,TAK-733,Small Molecule (Chemical),Phase I,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1155,Various Malignancies,7/7/14 12:28
2550,526,Ambit,Small Biotech,4194,quizartinib ,AC-220,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-18,Dec-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,4.9,27.066681,47.27329448,0,58,Acute Myeloid Leukemia,7/7/14 12:28
2550,526,Ambit,Small Biotech,4194,quizartinib ,AC-220,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-18,Dec-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0.6,15.6,30.35994,0,58,Acute Myeloid Leukemia,7/7/14 12:28
2550,526,Ambit,Small Biotech,4194,quizartinib ,AC-220,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-18,Dec-18,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,4.3,11.466681,16.91335447,0,58,Acute Myeloid Leukemia,7/7/14 12:28
2551,15,Astellas Pharma,Regional & Specialty Pharma,338,Acofide,acotiamide,Small Molecule (Chemical),Launched,Licensed (Development),,May-13,May-21,May-21,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,0,0,0,0,46.47391547,81.68162435,115.4806637,149.2795443,174.8400648,197.099864,216.2682379,232.298911,25.84439793,68,Functional Dyspepsia,7/7/14 12:28
2551,15,Astellas Pharma,Regional & Specialty Pharma,338,Acofide,acotiamide,Small Molecule (Chemical),Launched,Licensed (Development),,May-13,May-21,May-21,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,46.47391547,81.68162435,115.4806637,149.2795443,174.8400648,197.099864,216.2682379,232.298911,25.84439793,68,Functional Dyspepsia,7/7/14 12:28
2551,15,Astellas Pharma,Regional & Specialty Pharma,338,Acofide,acotiamide,Small Molecule (Chemical),Launched,Licensed (Development),,May-13,May-21,May-21,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,68,Functional Dyspepsia,7/7/14 12:28
2552,15,Astellas Pharma,Regional & Specialty Pharma,2442,AGS-16M8F,AGS-16M8F,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,86,Cancer,7/7/14 12:28
2552,15,Astellas Pharma,Regional & Specialty Pharma,2442,AGS-16M8F,AGS-16M8F,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,86,Cancer,7/7/14 12:28
2552,15,Astellas Pharma,Regional & Specialty Pharma,2442,AGS-16M8F,AGS-16M8F,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,86,Cancer,7/7/14 12:28
2554,37,Eisai,Regional & Specialty Pharma,2444,Glufast,mitiglinide,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,496,Type II Diabetes,7/7/14 12:28
2554,37,Eisai,Regional & Specialty Pharma,2444,Glufast,mitiglinide,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,496,Type II Diabetes,7/7/14 12:28
2554,37,Eisai,Regional & Specialty Pharma,2444,Glufast,mitiglinide,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,496,Type II Diabetes,7/7/14 12:28
2554,37,Eisai,Regional & Specialty Pharma,2444,Glufast,mitiglinide,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,496,Type II Diabetes,7/7/14 12:28
2554,37,Eisai,Regional & Specialty Pharma,2444,Glufast,mitiglinide,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,496,Type II Diabetes,7/7/14 12:28
2554,37,Eisai,Regional & Specialty Pharma,2444,Glufast,mitiglinide,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,496,Type II Diabetes,7/7/14 12:28
2556,5,Actelion,Small Biotech,2445,Zavesca / Vevesca / Brazaves,miglustat,Small Molecule (Chemical),Launched,Licensed (Development),Jan-04,Mar-03,N/A,Dec-23,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,5,Global,Sales,48.89427725,66.06080535,78.44900878,90.58601278,103.5958181,111.3543066,118.8864149,124.8230757,129.5688382,133.531049,136.7455654,139.3671171,4.328404611,1296,Gaucher's Disease,7/7/14 12:28
2556,5,Actelion,Small Biotech,2445,Zavesca / Vevesca / Brazaves,miglustat,Small Molecule (Chemical),Launched,Licensed (Development),Jan-04,Mar-03,N/A,Dec-23,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,5,ROW,Sales,34.22599408,45.7459247,54.5732235,62.92287415,71.22212493,76.3699808,81.35170436,85.23389798,88.35952752,90.96619981,93.07842443,94.80269236,4.170238873,1296,Gaucher's Disease,7/7/14 12:28
2556,5,Actelion,Small Biotech,2445,Zavesca / Vevesca / Brazaves,miglustat,Small Molecule (Chemical),Launched,Licensed (Development),Jan-04,Mar-03,N/A,Dec-23,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,5,US,Sales,14.66828318,20.31488065,23.87578528,27.66313863,32.37369315,34.98432579,37.53471055,39.58917777,41.20931066,42.56484916,43.66714095,44.56442476,4.671389306,1296,Gaucher's Disease,7/7/14 12:28
2558,70,Ono,Regional & Specialty Pharma,3440,remimazolam,ONO-2745,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,814,Pain,7/7/14 12:28
2558,70,Ono,Regional & Specialty Pharma,3440,remimazolam,ONO-2745,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,814,Pain,7/7/14 12:28
2558,70,Ono,Regional & Specialty Pharma,3440,remimazolam,ONO-2745,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,814,Pain,7/7/14 12:28
2559,70,Ono,Regional & Specialty Pharma,2450,Staybla,imidafenacin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-07,N/A,Nov-19,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,Global,Sales,49.55699458,66.82729114,77.23612836,77.04794027,70.87746299,74.05150377,76.73229609,79.06021679,80.75217083,82.10450343,90.60950021,93.85728304,4.093308699,1117,Overactive bladder,7/7/14 12:28
2559,70,Ono,Regional & Specialty Pharma,2450,Staybla,imidafenacin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-07,N/A,Nov-19,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,ROW,Sales,49.55699458,66.82729114,77.23612836,77.04794027,70.87746299,74.05150377,76.73229609,79.06021679,80.75217083,82.10450343,90.60950021,93.85728304,4.093308699,1117,Overactive bladder,7/7/14 12:28
2559,70,Ono,Regional & Specialty Pharma,2450,Staybla,imidafenacin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-07,N/A,Nov-19,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1117,Overactive bladder,7/7/14 12:28
2562,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3514,Romiplate,romiplostim,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-11,,Nov-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,3,Global,Sales,0,0,9.3143018,21.29792032,25.62241116,36.52551578,42.44981284,47.17356138,50.96543196,53.66418352,56.36930454,58.1216406,12.41306457,1623,Immune Thrombocytopenic Purpura,7/7/14 12:28
2562,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3514,Romiplate,romiplostim,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-11,,Nov-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,3,ROW,Sales,0,0,9.3143018,21.29792032,25.62241116,36.52551578,42.44981284,47.17356138,50.96543196,53.66418352,56.36930454,58.1216406,12.41306457,1623,Immune Thrombocytopenic Purpura,7/7/14 12:28
2562,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3514,Romiplate,romiplostim,Antibody/Antibody Derivative,Launched,Licensed (Development),,Apr-11,,Nov-21,162,Thrombocytopenia Agents,74,Thrombocytopenia,14,Hematology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1623,Immune Thrombocytopenic Purpura,7/7/14 12:28
2563,65,Mundipharma,Regional & Specialty Pharma,2519,Levact / Ribomustin,bendamustine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-71,N/A,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,5,Global,Sales,41.71206703,65.21431614,99.24936552,113.0348973,129.4392029,139.2316387,145.5967219,149.7340261,152.4232738,154.1712847,155.3074919,156.0460265,2.706543769,1359,Hematological Malignancies,7/7/14 12:28
2563,65,Mundipharma,Regional & Specialty Pharma,2519,Levact / Ribomustin,bendamustine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-71,N/A,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,5,ROW,Sales,41.71206703,65.21431614,99.24936552,113.0348973,129.4392029,139.2316387,145.5967219,149.7340261,152.4232738,154.1712847,155.3074919,156.0460265,2.706543769,1359,Hematological Malignancies,7/7/14 12:28
2563,65,Mundipharma,Regional & Specialty Pharma,2519,Levact / Ribomustin,bendamustine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-71,N/A,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1359,Hematological Malignancies,7/7/14 12:28
2566,175,Durect,Small Biotech,4450,Posidur / Optesia,bupivacaine depot,Small Molecule (Chemical),Filed,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1371,Post-operative Pain,7/7/14 12:28
2566,175,Durect,Small Biotech,4450,Posidur / Optesia,bupivacaine depot,Small Molecule (Chemical),Filed,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1371,Post-operative Pain,7/7/14 12:28
2566,175,Durect,Small Biotech,4450,Posidur / Optesia,bupivacaine depot,Small Molecule (Chemical),Filed,In-House,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1371,Post-operative Pain,7/7/14 12:28
2571,95,Shionogi,Regional & Specialty Pharma,2464,Rapiacta,peramivir,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-10,,Oct-20,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,7,Global,Sales,10.68988986,17.28292012,17.72632454,25.58441039,29.06237052,33.16527924,37.23342571,40.59222802,43.19652681,40.27088898,40.26405081,40.01187534,4.673517578,955,Influenza,7/7/14 12:28
2571,95,Shionogi,Regional & Specialty Pharma,2464,Rapiacta,peramivir,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-10,,Oct-20,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,7,ROW,Sales,10.68988986,17.28292012,17.72632454,25.58441039,29.06237052,33.16527924,37.23342571,40.59222802,43.19652681,40.27088898,40.26405081,40.01187534,4.673517578,955,Influenza,7/7/14 12:28
2571,95,Shionogi,Regional & Specialty Pharma,2464,Rapiacta,peramivir,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-10,,Oct-20,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,955,Influenza,7/7/14 12:28
2572,85,Regeneron,Small Biotech,2465,Arcalyst,rilonacept,Recombinant Protein,Launched,In-House,Mar-08,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,18.4,25.2,19.9,20,17,15.229,13.99315,12.7686925,11.83266388,11.07489878,10.44169094,9.929893515,-7.393329142,140,Cryopyrin-associated periodic syndromes,7/7/14 12:28
2572,85,Regeneron,Small Biotech,2465,Arcalyst,rilonacept,Recombinant Protein,Launched,In-House,Mar-08,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,140,Cryopyrin-associated periodic syndromes,7/7/14 12:28
2572,85,Regeneron,Small Biotech,2465,Arcalyst,rilonacept,Recombinant Protein,Launched,In-House,Mar-08,,N/A,N/A,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,18.4,25.2,19.9,20,17,15.229,13.99315,12.7686925,11.83266388,11.07489878,10.44169094,9.929893515,-7.393329142,140,Cryopyrin-associated periodic syndromes,7/7/14 12:28
2576,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,721,Beleodaq,belinostat,Small Molecule (Chemical),Filed,Licensed (Development),Sep-14,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,4.4,10.56,14.9600352,18.93029401,17.9477038,17.44437,19.1612735,0,233,Peripheral T-cell Lymphoma,7/7/14 12:28
2576,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,721,Beleodaq,belinostat,Small Molecule (Chemical),Filed,Licensed (Development),Sep-14,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,233,Peripheral T-cell Lymphoma,7/7/14 12:28
2576,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,721,Beleodaq,belinostat,Small Molecule (Chemical),Filed,Licensed (Development),Sep-14,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,4.4,10.56,14.9600352,18.93029401,17.9477038,17.44437,19.1612735,0,233,Peripheral T-cell Lymphoma,7/7/14 12:28
2577,89,Sanofi,Large Pharma,2466,Rilutek,riluzole,Small Molecule (Chemical),Launched,Acquisition (Development),Jan-96,Oct-96,Jun-13,Oct-12,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,2,Global,Sales,166.7398083,163.9226155,179.5552528,160.3359729,75.50969041,52.69612437,44.98449641,38.81519405,33.87975216,29.93139864,26.56060133,23.9045412,-15.15236411,1015,Amyotrophic Lateral Sclerosis,7/7/14 12:28
2577,89,Sanofi,Large Pharma,2466,Rilutek,riluzole,Small Molecule (Chemical),Launched,Acquisition (Development),Jan-96,Oct-96,Jun-13,Oct-12,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,2,ROW,Sales,119.4968626,118.7492974,131.5625623,115.6744194,64.26356631,52.69612437,44.98449641,38.81519405,33.87975216,29.93139864,26.56060133,23.9045412,-13.17492931,1015,Amyotrophic Lateral Sclerosis,7/7/14 12:28
2577,89,Sanofi,Large Pharma,2466,Rilutek,riluzole,Small Molecule (Chemical),Launched,Acquisition (Development),Jan-96,Oct-96,Jun-13,Oct-12,157,ALS Treatments,70,Amyotrophic Lateral Sclerosis,12,Central Nervous System,2,US,Sales,47.24294569,45.17331815,47.99269055,44.66155359,11.2461241,0,0,0,0,0,0,0,-100,1015,Amyotrophic Lateral Sclerosis,7/7/14 12:28
2578,5,Actelion,Small Biotech,2467,selexipag,selexipag,Small Molecule (Chemical),Phase III,Licensed (Development),Sep-15,Jan-16,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,Global,Sales,0,0,0,0,0,0,17.9853671,127.0966973,245.8004769,364.5038725,457.1281756,536.3761202,0,1073,Pulmonary Hypertension,7/7/14 12:28
2578,5,Actelion,Small Biotech,2467,selexipag,selexipag,Small Molecule (Chemical),Phase III,Licensed (Development),Sep-15,Jan-16,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,ROW,Sales,0,0,0,0,0,0,0,43.1649242,71.94168421,100.7183579,129.4945999,151.0769563,0,1073,Pulmonary Hypertension,7/7/14 12:28
2578,5,Actelion,Small Biotech,2467,selexipag,selexipag,Small Molecule (Chemical),Phase III,Licensed (Development),Sep-15,Jan-16,N/A,N/A,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,US,Sales,0,0,0,0,0,0,17.9853671,83.93177307,173.8587927,263.7855146,327.6335757,385.2991639,0,1073,Pulmonary Hypertension,7/7/14 12:28
2580,106,United Therapeutics,Small Biotech,3097,L-314d QID - BPS,beraprost ,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,269,Pulmonary Hypertension,7/7/14 12:28
2580,106,United Therapeutics,Small Biotech,3097,L-314d QID - BPS,beraprost ,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,269,Pulmonary Hypertension,7/7/14 12:28
2580,106,United Therapeutics,Small Biotech,3097,L-314d QID - BPS,beraprost ,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,269,Pulmonary Hypertension,7/7/14 12:28
2581,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,1099,RotaTeq,rotavirus vaccine,Vaccine,Launched,Licensed (Marketed),,Mar-07,N/A,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,41.68495208,42.39215392,44.4939852,46.9124034,54.44923273,57.07873226,59.44528185,61.18732529,62.34611286,63.21253707,63.83362846,64.27485521,2.398301495,1625,infant diarhhea prevention,7/7/14 12:28
2581,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,1099,RotaTeq,rotavirus vaccine,Vaccine,Launched,Licensed (Marketed),,Mar-07,N/A,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,41.68495208,42.39215392,44.4939852,46.9124034,54.44923273,57.07873226,59.44528185,61.18732529,62.34611286,63.21253707,63.83362846,64.27485521,2.398301495,1625,infant diarhhea prevention,7/7/14 12:28
2581,88,Sanofi Pasteur MSD,Regional & Specialty Pharma,1099,RotaTeq,rotavirus vaccine,Vaccine,Launched,Licensed (Marketed),,Mar-07,N/A,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1625,infant diarhhea prevention,7/7/14 12:28
2582,61,Merck & Co,Large Pharma,2474,Ragwitek,MK-3641,Vaccine,Filed,Acquisition (Development),Jul-14,,Dec-24,N/A,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,Global,Sales,0,0,0,0,0,9,24.00003,36.000045,47.99994,55.5599148,61.42789014,65.98906561,0,954,Ragweed Allergy,7/7/14 12:28
2582,61,Merck & Co,Large Pharma,2474,Ragwitek,MK-3641,Vaccine,Filed,Acquisition (Development),Jul-14,,Dec-24,N/A,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,954,Ragweed Allergy,7/7/14 12:28
2582,61,Merck & Co,Large Pharma,2474,Ragwitek,MK-3641,Vaccine,Filed,Acquisition (Development),Jul-14,,Dec-24,N/A,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,US,Sales,0,0,0,0,0,9,24.00003,36.000045,47.99994,55.5599148,61.42789014,65.98906561,0,954,Ragweed Allergy,7/7/14 12:28
2585,46,GlaxoSmithKline,Large Pharma,983,Zyrtec,cetirizine,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Sep-98,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,4,Global,Sales,116.9446267,126.6900048,153.9053482,128.3873388,118.8194661,116.1929306,112.8534782,111.2450379,110.3124927,109.6658146,109.2958983,109.0697101,-1.21566386,1389,Allergic Rhinitis,7/7/14 12:28
2585,46,GlaxoSmithKline,Large Pharma,983,Zyrtec,cetirizine,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Sep-98,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,4,ROW,Sales,116.9446267,126.6900048,153.9053482,128.3873388,118.8194661,116.1929306,112.8534782,111.2450379,110.3124927,109.6658146,109.2958983,109.0697101,-1.21566386,1389,Allergic Rhinitis,7/7/14 12:28
2585,46,GlaxoSmithKline,Large Pharma,983,Zyrtec,cetirizine,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Sep-98,N/A,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1389,Allergic Rhinitis,7/7/14 12:28
2586,46,GlaxoSmithKline,Large Pharma,76,Levitra,vardenafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-03,Mar-03,Oct-18,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,4,Global,Alliance Revenue,116.9446267,154.493446,84.00924328,59.75558855,60.89020375,51.98394965,47.92836357,45.66448951,43.5422394,42.0968441,42.51357497,42.23096268,-5.093125067,622,Erectile Dysfunction,7/7/14 12:28
2586,46,GlaxoSmithKline,Large Pharma,76,Levitra,vardenafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-03,Mar-03,Oct-18,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,622,Erectile Dysfunction,7/7/14 12:28
2586,46,GlaxoSmithKline,Large Pharma,76,Levitra,vardenafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-03,Mar-03,Oct-18,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,4,ROW,Alliance Revenue,7.796308448,9.417940605,11.06452095,7.92514437,6.170712769,5.000231273,3.661233409,2.581301526,1.640692246,0.791025224,1.563414028,1.517951979,-18.15558585,622,Erectile Dysfunction,7/7/14 12:28
2586,46,GlaxoSmithKline,Large Pharma,76,Levitra,vardenafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-03,Mar-03,Oct-18,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,622,Erectile Dysfunction,7/7/14 12:28
2586,46,GlaxoSmithKline,Large Pharma,76,Levitra,vardenafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-03,Mar-03,Oct-18,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,4,US,Alliance Revenue,109.1483183,145.0755054,72.94472233,51.83044418,54.71949098,46.98371837,44.26713016,43.08318799,41.90154716,41.30581887,40.95016094,40.7130107,-4.135921961,622,Erectile Dysfunction,7/7/14 12:28
2586,46,GlaxoSmithKline,Large Pharma,76,Levitra,vardenafil,Small Molecule (Chemical),Launched,Licensed (Development),Aug-03,Mar-03,Oct-18,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,622,Erectile Dysfunction,7/7/14 12:28
2587,14,Asahi Kasei Pharma,Regional & Specialty Pharma,2479,Flivas,naftopidil,Small Molecule (Chemical),Launched,Acquisition (Development),,Feb-99,N/A,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,Global,Sales,147.5936578,162.25239,179.7955775,168.5423693,151.8802778,156.2531443,160.3038437,164.7227579,168.1621501,171.2465583,174.012802,176.4098601,2.161855592,1756,Symptoms associated with BPH,7/7/14 12:28
2587,14,Asahi Kasei Pharma,Regional & Specialty Pharma,2479,Flivas,naftopidil,Small Molecule (Chemical),Launched,Acquisition (Development),,Feb-99,N/A,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,ROW,Sales,147.5936578,162.25239,179.7955775,168.5423693,151.8802778,156.2531443,160.3038437,164.7227579,168.1621501,171.2465583,174.012802,176.4098601,2.161855592,1756,Symptoms associated with BPH,7/7/14 12:28
2587,14,Asahi Kasei Pharma,Regional & Specialty Pharma,2479,Flivas,naftopidil,Small Molecule (Chemical),Launched,Acquisition (Development),,Feb-99,N/A,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1756,Symptoms associated with BPH,7/7/14 12:28
2588,157,Teijin,Regional & Specialty Pharma,2481,Onealfa,alfacalcidol,Small Molecule (Chemical),Launched,Licensed (Development),,May-98,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,134.6926122,133.0703055,140.5444303,98.30755561,65.90843797,60.62308911,56.59057266,54.53177904,53.54291258,52.9673402,52.66847875,52.51251603,-3.193809642,3349,Osteoporosis,7/7/14 12:28
2588,157,Teijin,Regional & Specialty Pharma,2481,Onealfa,alfacalcidol,Small Molecule (Chemical),Launched,Licensed (Development),,May-98,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,134.6926122,133.0703055,140.5444303,98.30755561,65.90843797,60.62308911,56.59057266,54.53177904,53.54291258,52.9673402,52.66847875,52.51251603,-3.193809642,3349,Osteoporosis,7/7/14 12:28
2588,157,Teijin,Regional & Specialty Pharma,2481,Onealfa,alfacalcidol,Small Molecule (Chemical),Launched,Licensed (Development),,May-98,N/A,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3349,Osteoporosis,7/7/14 12:28
2589,940,Prosensa,Small Biotech,2484,drisapersen,drisapersen,DNA/RNA Therapy,Phase III,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1782,Duchenne Muscular Dystrophy,7/7/14 12:28
2589,940,Prosensa,Small Biotech,2484,drisapersen,drisapersen,DNA/RNA Therapy,Phase III,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1782,Duchenne Muscular Dystrophy,7/7/14 12:28
2589,940,Prosensa,Small Biotech,2484,drisapersen,drisapersen,DNA/RNA Therapy,Phase III,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1782,Duchenne Muscular Dystrophy,7/7/14 12:28
2590,89,Sanofi,Large Pharma,2485,Adult Booster Vaccines,booster vaccines,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,564.1363515,598.1057871,646.5532225,637.4945778,519.259756,670.9772807,678.0649971,686.7144768,709.0053229,718.2444337,726.2028651,733.0518188,5.049221257,1753,,7/7/14 12:28
2590,89,Sanofi,Large Pharma,2485,Adult Booster Vaccines,booster vaccines,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,133.3918467,141.0653776,175.1950667,159.3736444,163.3476982,166.3258554,166.7734215,167.4547208,168.3111616,168.8888603,169.4344934,169.9284249,0.565826675,1753,,7/7/14 12:28
2590,89,Sanofi,Large Pharma,2485,Adult Booster Vaccines,booster vaccines,Vaccine,Launched,Corporate Acquisition,Jul-00,Jul-00,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,430.7445048,457.0404094,471.3581557,478.1209333,355.9120578,504.6514253,511.2915756,519.259756,540.6941613,549.3555734,556.7683716,563.1233939,6.774073051,1753,,7/7/14 12:28
2591,89,Sanofi,Large Pharma,2486,Meningitis / Pneumonia Vaccines,,Vaccine,Launched,In-House,Mar-05,Aug-00,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,747.5501406,698.1457849,709.1228891,835.426362,658.702913,714.8785849,739.8787509,739.8140094,745.1016441,747.1090653,747.6017697,748.0291914,1.833306134,1760,meningococcus,7/7/14 12:28
2591,89,Sanofi,Large Pharma,2486,Meningitis / Pneumonia Vaccines,,Vaccine,Launched,In-House,Mar-05,Aug-00,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,140.3393387,158.9705772,166.8524445,227.4930247,191.2363296,191.6347386,192.7303634,188.6815318,187.8735085,187.1737404,186.4727117,186.111687,-0.387290978,1760,meningococcus,7/7/14 12:28
2591,89,Sanofi,Large Pharma,2486,Meningitis / Pneumonia Vaccines,,Vaccine,Launched,In-House,Mar-05,Aug-00,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,607.210802,539.1752077,542.2704446,607.9333373,467.4665834,523.2438462,547.1483874,551.1324776,557.2281356,559.9353249,561.129058,561.9175044,2.663819036,1760,meningococcus,7/7/14 12:28
2592,46,GlaxoSmithKline,Large Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Licensed (Development),,Jan-05,N/A,N/A,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,4,Global,Sales,55.97749466,60.05817094,68.01087121,71.29729647,75.02414149,78.38869338,81.27799227,83.83749949,86.09306241,88.07185714,89.81423128,89.1145996,2.489234681,1367,Muscle Spasms,7/7/14 12:28
2592,46,GlaxoSmithKline,Large Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Licensed (Development),,Jan-05,N/A,N/A,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,4,ROW,Sales,55.97749466,60.05817094,68.01087121,71.29729647,75.02414149,78.38869338,81.27799227,83.83749949,86.09306241,88.07185714,89.81423128,89.1145996,2.489234681,1367,Muscle Spasms,7/7/14 12:28
2592,46,GlaxoSmithKline,Large Pharma,598,Botox,onabotulinumtoxin A,Other (Biologic),Launched,Licensed (Development),,Jan-05,N/A,N/A,164,Neurotoxins,75,Muscle Spasticity,13,Musculoskeletal / Pain,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1367,Muscle Spasms,7/7/14 12:28
2593,61,Merck & Co,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1499,Melanoma,7/7/14 12:28
2593,61,Merck & Co,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,34.91428571,191,176,140,122,113,108.5,106.25,105.125,104.5625,75.66870295,59.140625,-9.827273975,1499,Melanoma,7/7/14 12:28
2593,61,Merck & Co,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1499,Melanoma,7/7/14 12:28
2593,61,Merck & Co,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,14.8,77,79,69,64,61.5,60.25,59.625,59.3125,59.15625,39.05164195,24.0390625,-13.05426512,1499,Melanoma,7/7/14 12:28
2593,61,Merck & Co,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1499,Melanoma,7/7/14 12:28
2593,61,Merck & Co,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,20.11428571,114,97,71,58,51.5,48.25,46.625,45.8125,45.40625,36.617061,35.1015625,-6.922937696,1499,Melanoma,7/7/14 12:28
2593,61,Schering-Plough,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Proforma,175.0857143,0,0,0,0,0,0,0,0,0,0,0,0,1499,Melanoma,7/7/14 12:28
2593,61,Schering-Plough,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Proforma,74.2,0,0,0,0,0,0,0,0,0,0,0,0,1499,Melanoma,7/7/14 12:28
2593,61,Schering-Plough,Large Pharma,572,Intron A,interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Jul-86,Jul-86,N/A,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Proforma,100.8857143,0,0,0,0,0,0,0,0,0,0,0,0,1499,Melanoma,7/7/14 12:28
2595,179,Zogenix,Small Biotech,2490,Sumavel DosePro,sumatriptan injectable,Small Molecule (Chemical),Launched,In-House,Jan-10,,Mar-17,N/A,117,Triptans,8,Migraine,12,Central Nervous System,6,Global,Sales,0,18.7,30.411,35.9,31.7,34,36,38,39.03,39.7875,40.331375,40.68396875,3.628822411,1758,Migraine,7/7/14 12:28
2595,179,Zogenix,Small Biotech,2490,Sumavel DosePro,sumatriptan injectable,Small Molecule (Chemical),Launched,In-House,Jan-10,,Mar-17,N/A,117,Triptans,8,Migraine,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1758,Migraine,7/7/14 12:28
2595,179,Zogenix,Small Biotech,2490,Sumavel DosePro,sumatriptan injectable,Small Molecule (Chemical),Launched,In-House,Jan-10,,Mar-17,N/A,117,Triptans,8,Migraine,12,Central Nervous System,6,US,Sales,0,18.7,30.411,35.9,31.7,34,36,38,39.03,39.7875,40.331375,40.68396875,3.628822411,1758,Migraine,7/7/14 12:28
2596,21,Biogen Idec,Regional & Specialty Pharma,2492,anti-LINGO1,BIIB033,Antibody/Antibody Derivative,Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1811,Multiple Sclerosis,7/7/14 12:28
2596,21,Biogen Idec,Regional & Specialty Pharma,2492,anti-LINGO1,BIIB033,Antibody/Antibody Derivative,Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1811,Multiple Sclerosis,7/7/14 12:28
2596,21,Biogen Idec,Regional & Specialty Pharma,2492,anti-LINGO1,BIIB033,Antibody/Antibody Derivative,Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1811,Multiple Sclerosis,7/7/14 12:28
2597,61,Merck & Co,Large Pharma,2493,Proventil,salbutamol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-81,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1757,Asthma,7/7/14 12:28
2597,61,Merck & Co,Large Pharma,2493,Proventil,salbutamol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-81,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Sales,37.6,210,155,145,130.3,117.49,109.801,103.4245,98.59033,95.069629,92.3780881,90.35679925,-5.095220806,1757,Asthma,7/7/14 12:28
2597,61,Merck & Co,Large Pharma,2493,Proventil,salbutamol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-81,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1757,Asthma,7/7/14 12:28
2597,61,Merck & Co,Large Pharma,2493,Proventil,salbutamol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-81,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1757,Asthma,7/7/14 12:28
2597,61,Merck & Co,Large Pharma,2493,Proventil,salbutamol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-81,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1757,Asthma,7/7/14 12:28
2597,61,Merck & Co,Large Pharma,2493,Proventil,salbutamol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-81,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Sales,37.6,210,155,145,130.3,117.49,109.801,103.4245,98.59033,95.069629,92.3780881,90.35679925,-5.095220806,1757,Asthma,7/7/14 12:28
2597,61,Schering-Plough,Large Pharma,2493,Proventil,salbutamol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-81,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Proforma,187.4,0,0,0,0,0,0,0,0,0,0,0,0,1757,Asthma,7/7/14 12:28
2597,61,Schering-Plough,Large Pharma,2493,Proventil,salbutamol,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-81,,N/A,N/A,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Proforma,187.4,0,0,0,0,0,0,0,0,0,0,0,0,1757,Asthma,7/7/14 12:28
2598,21,Biogen Idec,Regional & Specialty Pharma,3504,Eloctate,rFVIIIFc,Recombinant Protein,Approved,Corporate Acquisition,Sep-14,Jan-15,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,0,0,0,0,0,60,132.5,177.8337,256.1674009,324.4592612,350.0782383,376.0429087,0,1968,Hemophilia A,7/7/14 12:28
2598,21,Biogen Idec,Regional & Specialty Pharma,3504,Eloctate,rFVIIIFc,Recombinant Protein,Approved,Corporate Acquisition,Sep-14,Jan-15,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,35,47,66.99992,100.99988,94.99988,91.99988,0,1968,Hemophilia A,7/7/14 12:28
2598,21,Biogen Idec,Regional & Specialty Pharma,3504,Eloctate,rFVIIIFc,Recombinant Protein,Approved,Corporate Acquisition,Sep-14,Jan-15,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,0,0,0,0,0,60,97.5,130.8337,189.1674809,223.4593812,255.0783583,284.0430287,0,1968,Hemophilia A,7/7/14 12:28
2599,67,Novartis,Large Pharma,2497,Reasanz,serelaxin ,Recombinant Protein,Filed,Acquisition (Development),Nov-16,Mar-17,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,14.166695,154.4446906,381.6676124,615.0014803,832.2800408,0,2082,Heart Failure - Acute ,7/7/14 12:28
2599,67,Novartis,Large Pharma,2497,Reasanz,serelaxin ,Recombinant Protein,Filed,Acquisition (Development),Nov-16,Mar-17,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,45.833315,131.3889891,223.0551451,314.7218876,0,2082,Heart Failure - Acute ,7/7/14 12:28
2599,67,Novartis,Large Pharma,2497,Reasanz,serelaxin ,Recombinant Protein,Filed,Acquisition (Development),Nov-16,Mar-17,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,14.166695,108.6113756,250.2786233,391.9463352,517.5581532,0,2082,Heart Failure - Acute ,7/7/14 12:28
2600,84,Recordati,Regional & Specialty Pharma,2246,Carbaglu,carglumic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-10,Apr-08,N/A,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,Global,Sales,2.778996805,5.973027188,15.42129236,19.82983066,26.16481856,30.58463927,34.12984158,37.09336449,39.49386489,41.45270816,43.0573016,44.36633645,7.835617656,1850,NAGS Deficiency,7/7/14 12:28
2600,84,Recordati,Regional & Specialty Pharma,2246,Carbaglu,carglumic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-10,Apr-08,N/A,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,ROW,Sales,2.778996805,4.648272378,8.469107176,9.547660047,11.11778727,12.40927543,13.37300266,14.15686875,14.81441295,15.34408711,15.77729859,16.13221038,5.462115638,1850,NAGS Deficiency,7/7/14 12:28
2600,84,Recordati,Regional & Specialty Pharma,2246,Carbaglu,carglumic acid,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-10,Apr-08,N/A,N/A,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,US,Sales,0,1.32475481,6.952185188,10.28217061,15.04703129,18.17536384,20.75683891,22.93649573,24.67945194,26.10862106,27.28000301,28.23412607,9.407269373,1850,NAGS Deficiency,7/7/14 12:28
2601,84,Recordati,Regional & Specialty Pharma,2498,Vedrop,tocofersolan,Synthetic Peptide,Launched,Corporate Acquisition,,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2154,Vitamin E Deficiency in Cholestasis,7/7/14 12:28
2601,84,Recordati,Regional & Specialty Pharma,2498,Vedrop,tocofersolan,Synthetic Peptide,Launched,Corporate Acquisition,,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2154,Vitamin E Deficiency in Cholestasis,7/7/14 12:28
2601,84,Recordati,Regional & Specialty Pharma,2498,Vedrop,tocofersolan,Synthetic Peptide,Launched,Corporate Acquisition,,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2154,Vitamin E Deficiency in Cholestasis,7/7/14 12:28
2604,84,Recordati,Regional & Specialty Pharma,2501,Cystadrops,mercaptamine,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1871,Ocular Cystinosis,7/7/14 12:28
2604,84,Recordati,Regional & Specialty Pharma,2501,Cystadrops,mercaptamine,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1871,Ocular Cystinosis,7/7/14 12:28
2604,84,Recordati,Regional & Specialty Pharma,2501,Cystadrops,mercaptamine,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,8,Other Ophthalmology Treatments,57,Other Ophthalmic Disorders,4,Ophthalmology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1871,Ocular Cystinosis,7/7/14 12:28
2607,180,Vectura,Small Biotech,465,AirFluSal,salmeterol + fluticasone propionate,Small Molecule (Chemical),Phase III,In-House,Jan-16,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,10.9438982,62.01545959,134.9747873,207.9340589,262.799456,313.9293324,0,1737,Asthma,7/7/14 12:28
2607,180,Vectura,Small Biotech,465,AirFluSal,salmeterol + fluticasone propionate,Small Molecule (Chemical),Phase III,In-House,Jan-16,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1737,Asthma,7/7/14 12:28
2607,180,Vectura,Small Biotech,465,AirFluSal,salmeterol + fluticasone propionate,Small Molecule (Chemical),Phase III,In-House,Jan-16,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,10.9438982,62.01545959,134.9747873,207.9340589,262.799456,313.9293324,0,1737,Asthma,7/7/14 12:28
2611,14,Asahi Kasei Pharma,Regional & Specialty Pharma,2515,Toledomin,milnacipran,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-00,,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,7,Global,Sales,53.44944929,40.85491835,35.45264908,29.2694561,18.12190004,14.70136452,12.08574876,9.922710794,8.392524304,7.230247632,6.346566505,5.688629988,-15.25483634,1754,Depression,7/7/14 12:28
2611,14,Asahi Kasei Pharma,Regional & Specialty Pharma,2515,Toledomin,milnacipran,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-00,,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,7,ROW,Sales,53.44944929,40.85491835,35.45264908,29.2694561,18.12190004,14.70136452,12.08574876,9.922710794,8.392524304,7.230247632,6.346566505,5.688629988,-15.25483634,1754,Depression,7/7/14 12:28
2611,14,Asahi Kasei Pharma,Regional & Specialty Pharma,2515,Toledomin,milnacipran,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-00,,Expired,66,Noradrenergics,49,Depression,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1754,Depression,7/7/14 12:28
2612,10,Almirall,Regional & Specialty Pharma,2516,Esertia,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-04,N/A,Jun-10,127,Serotonergics,49,Depression,12,Central Nervous System,2,Global,Sales,90.31739617,85.31420976,42.54737335,21.84961254,18.8035195,12.29199578,5.32791519,3.532570909,2.642721859,2.120630316,1.755504748,1.564288244,-29.89878731,1450,Depression,7/7/14 12:28
2612,10,Almirall,Regional & Specialty Pharma,2516,Esertia,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-04,N/A,Jun-10,127,Serotonergics,49,Depression,12,Central Nervous System,2,ROW,Sales,90.31739617,85.31420976,42.54737335,21.84961254,18.8035195,12.29199578,5.32791519,3.532570909,2.642721859,2.120630316,1.755504748,1.564288244,-29.89878731,1450,Depression,7/7/14 12:28
2612,10,Almirall,Regional & Specialty Pharma,2516,Esertia,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-04,N/A,Jun-10,127,Serotonergics,49,Depression,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
2613,181,PTC Therapeutics,Small Biotech,2053,ataluren,ataluren,Small Molecule (Chemical),Phase III,In-House,Sep-16,Jan-17,May-24,N/A,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,83.666583,416.7777499,657.4433736,898.1091218,1075,0,165,Cystic Fibrosis,7/7/14 12:28
2613,181,PTC Therapeutics,Small Biotech,2053,ataluren,ataluren,Small Molecule (Chemical),Phase III,In-House,Sep-16,Jan-17,May-24,N/A,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,110,183.3337,256.66718,325,0,165,Cystic Fibrosis,7/7/14 12:28
2613,181,PTC Therapeutics,Small Biotech,2053,ataluren,ataluren,Small Molecule (Chemical),Phase III,In-House,Sep-16,Jan-17,May-24,N/A,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,83.666583,306.7777499,474.1096736,641.4419418,750,0,165,Cystic Fibrosis,7/7/14 12:28
2614,14,Asahi Kasei Pharma,Regional & Specialty Pharma,2517,Bredinin,mizoribine,Small Molecule (Chemical),Launched,In-House,,Jul-84,N/A,Expired,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,Global,Sales,70.026188,75.87341979,81.03462648,72.232444,65.44019459,66.10466423,66.72684944,67.63717285,68.10199956,68.47996802,68.78626617,69.00196914,0.759992301,1755,Transplant Rejection,7/7/14 12:28
2614,14,Asahi Kasei Pharma,Regional & Specialty Pharma,2517,Bredinin,mizoribine,Small Molecule (Chemical),Launched,In-House,,Jul-84,N/A,Expired,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,ROW,Sales,70.026188,75.87341979,81.03462648,72.232444,65.44019459,66.10466423,66.72684944,67.63717285,68.10199956,68.47996802,68.78626617,69.00196914,0.759992301,1755,Transplant Rejection,7/7/14 12:28
2614,14,Asahi Kasei Pharma,Regional & Specialty Pharma,2517,Bredinin,mizoribine,Small Molecule (Chemical),Launched,In-House,,Jul-84,N/A,Expired,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1755,Transplant Rejection,7/7/14 12:28
2615,29,Chugai,Regional & Specialty Pharma,1992,Madopar,levodopa + benserazide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-73,,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,3,Global,Alliance Revenue,21.18205937,23.01841283,24.7854841,23.40694015,23.28541672,22.73066462,22.48581739,22.27342564,22.1045163,21.9934521,21.90247507,20.49792893,-1.804987003,663,Parkinson's Disease,7/7/14 12:28
2615,29,Chugai,Regional & Specialty Pharma,1992,Madopar,levodopa + benserazide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-73,,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,3,ROW,Alliance Revenue,21.18205937,23.01841283,24.7854841,23.40694015,23.28541672,22.73066462,22.48581739,22.27342564,22.1045163,21.9934521,21.90247507,20.49792893,-1.804987003,663,Parkinson's Disease,7/7/14 12:28
2615,29,Chugai,Regional & Specialty Pharma,1992,Madopar,levodopa + benserazide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-73,,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,663,Parkinson's Disease,7/7/14 12:28
2616,111,Actavis,Regional & Specialty Pharma,2523,Trelstar,triptorelin,Synthetic Peptide,Launched,Licensed (Marketed),Feb-05,,N/A,,33,LHRH Analogs,55,Hormonals,3,Oncology,6,Global,Sales,48,51.065,53.00125,38,34.032,31.12081,29.8295168,29.1186119,28.76460335,28.58017237,28.48605066,28.43756487,-2.532941705,356,Prostate Cancer,7/7/14 12:28
2616,111,Actavis,Regional & Specialty Pharma,2523,Trelstar,triptorelin,Synthetic Peptide,Launched,Licensed (Marketed),Feb-05,,N/A,,33,LHRH Analogs,55,Hormonals,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,356,Prostate Cancer,7/7/14 12:28
2616,111,Actavis,Regional & Specialty Pharma,2523,Trelstar,triptorelin,Synthetic Peptide,Launched,Licensed (Marketed),Feb-05,,N/A,,33,LHRH Analogs,55,Hormonals,3,Oncology,6,US,Sales,48,51.065,53.00125,38,34.032,31.12081,29.8295168,29.1186119,28.76460335,28.58017237,28.48605066,28.43756487,-2.532941705,356,Prostate Cancer,7/7/14 12:28
2618,46,GlaxoSmithKline,Large Pharma,4304,Tafinlar,dabrafenib,Small Molecule (Chemical),Launched,In-House,Jul-13,Sep-13,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,4,Global,Sales,0,0,0,0,25.01462445,63.30057511,87.47757794,97.90907147,98.06279658,99.11475133,102.322462,102.214882,22.27322354,1778,Melanoma,7/7/14 12:28
2618,46,GlaxoSmithKline,Large Pharma,4304,Tafinlar,dabrafenib,Small Molecule (Chemical),Launched,In-House,Jul-13,Sep-13,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,4,ROW,Sales,0,0,0,0,9.380484168,27.60948225,36.94093864,42.52709421,40.54818525,37.40672338,37.69109442,34.79578135,20.59482768,1778,Melanoma,7/7/14 12:28
2618,46,GlaxoSmithKline,Large Pharma,4304,Tafinlar,dabrafenib,Small Molecule (Chemical),Launched,In-House,Jul-13,Sep-13,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,4,US,Sales,0,0,0,0,15.63414028,35.69109286,50.53663929,55.38197727,57.51461133,61.70802795,64.63136763,67.41910061,23.21756341,1778,Melanoma,7/7/14 12:28
2621,46,GlaxoSmithKline,Large Pharma,2529,danirixin,1325756,Small Molecule (Chemical),Phase I,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1774,COPD,7/7/14 12:28
2621,46,GlaxoSmithKline,Large Pharma,2529,danirixin,1325756,Small Molecule (Chemical),Phase I,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1774,COPD,7/7/14 12:28
2621,46,GlaxoSmithKline,Large Pharma,2529,danirixin,1325756,Small Molecule (Chemical),Phase I,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1774,COPD,7/7/14 12:28
2622,46,GlaxoSmithKline,Large Pharma,4681,dilmapimod,dilmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,19,Acute Respiratory Distress,7/7/14 12:28
2622,46,GlaxoSmithKline,Large Pharma,4681,dilmapimod,dilmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,19,Acute Respiratory Distress,7/7/14 12:28
2622,46,GlaxoSmithKline,Large Pharma,4681,dilmapimod,dilmapimod,Small Molecule (Chemical),Phase II,In-House,,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,19,Acute Respiratory Distress,7/7/14 12:28
2623,46,GlaxoSmithKline,Large Pharma,2530,1070806,1070806,Antibody/Antibody Derivative,Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1772,Anti-IL18 for Type II diabetes,7/7/14 12:28
2623,46,GlaxoSmithKline,Large Pharma,2530,1070806,1070806,Antibody/Antibody Derivative,Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1772,Anti-IL18 for Type II diabetes,7/7/14 12:28
2623,46,GlaxoSmithKline,Large Pharma,2530,1070806,1070806,Antibody/Antibody Derivative,Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1772,Anti-IL18 for Type II diabetes,7/7/14 12:28
2625,46,GlaxoSmithKline,Large Pharma,4660,2586881,2586881,Recombinant Protein,Phase II,Licensed (Development),,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1814,Acute Respiratory Distress Syndrome,7/7/14 12:28
2625,46,GlaxoSmithKline,Large Pharma,4660,2586881,2586881,Recombinant Protein,Phase II,Licensed (Development),,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1814,Acute Respiratory Distress Syndrome,7/7/14 12:28
2625,46,GlaxoSmithKline,Large Pharma,4660,2586881,2586881,Recombinant Protein,Phase II,Licensed (Development),,,,,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1814,Acute Respiratory Distress Syndrome,7/7/14 12:28
2632,11,Amgen,Large Pharma,2541,AMG 145,evolocumab ,Antibody/Antibody Derivative,Phase III,In-House,Jul-19,Nov-19,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,51.666685,226.1114239,0,1801,Hypercholesterolemia,7/7/14 12:28
2632,11,Amgen,Large Pharma,2541,AMG 145,evolocumab ,Antibody/Antibody Derivative,Phase III,In-House,Jul-19,Nov-19,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,9.166685,70.27794889,0,1801,Hypercholesterolemia,7/7/14 12:28
2632,11,Amgen,Large Pharma,2541,AMG 145,evolocumab ,Antibody/Antibody Derivative,Phase III,In-House,Jul-19,Nov-19,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,42.5,155.833475,0,1801,Hypercholesterolemia,7/7/14 12:28
2633,11,Amgen,Large Pharma,2542,AMG 151,,Small Molecule (Chemical),Phase II,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1802,Type II Diabetes,7/7/14 12:28
2633,11,Amgen,Large Pharma,2542,AMG 151,,Small Molecule (Chemical),Phase II,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1802,Type II Diabetes,7/7/14 12:28
2633,11,Amgen,Large Pharma,2542,AMG 151,,Small Molecule (Chemical),Phase II,,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1802,Type II Diabetes,7/7/14 12:28
2634,11,Amgen,Large Pharma,2543,AMG 157,AMG 157,Antibody/Antibody Derivative,Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1803,MAb against TSLP for asthma,7/7/14 12:28
2634,11,Amgen,Large Pharma,2543,AMG 157,AMG 157,Antibody/Antibody Derivative,Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1803,MAb against TSLP for asthma,7/7/14 12:28
2634,11,Amgen,Large Pharma,2543,AMG 157,AMG 157,Antibody/Antibody Derivative,Phase I,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1803,MAb against TSLP for asthma,7/7/14 12:28
2635,11,Amgen,Large Pharma,2544,AMG 167,AMG 167,Antibody/Antibody Derivative,Phase I,In-House,,,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1804,Osteopenia,7/7/14 12:28
2635,11,Amgen,Large Pharma,2544,AMG 167,AMG 167,Antibody/Antibody Derivative,Phase I,In-House,,,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1804,Osteopenia,7/7/14 12:28
2635,11,Amgen,Large Pharma,2544,AMG 167,AMG 167,Antibody/Antibody Derivative,Phase I,In-House,,,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1804,Osteopenia,7/7/14 12:28
2638,24,Bristol-Myers Squibb,Large Pharma,3991,asunaprevir,asunaprevir,Small Molecule (Chemical),Filed,In-House,Jun-15,Aug-14,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,75.4,166.706963,132.8333006,127.8332849,136.8331358,119.4851638,62,0,2010,Hepatitis C,7/7/14 12:28
2638,24,Bristol-Myers Squibb,Large Pharma,3991,asunaprevir,asunaprevir,Small Molecule (Chemical),Filed,In-House,Jun-15,Aug-14,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,75.4,157.956968,112,97,96,87.48516384,35,0,2010,Hepatitis C,7/7/14 12:28
2638,24,Bristol-Myers Squibb,Large Pharma,3991,asunaprevir,asunaprevir,Small Molecule (Chemical),Filed,In-House,Jun-15,Aug-14,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,8.749995,20.8333006,30.83328488,40.83313583,32,27,0,2010,Hepatitis C,7/7/14 12:28
2639,39,Eli Lilly,Large Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-10,,Jan-16,,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,Global,Alliance Revenue,0,5.7,15.718206,26.08184794,36.44547022,44.68110616,52.1208126,12,7,5,4.5,4,-27.06822719,1592,dyslipidemia,7/7/14 12:28
2639,39,Eli Lilly,Large Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-10,,Jan-16,,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1592,dyslipidemia,7/7/14 12:28
2639,39,Eli Lilly,Large Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-10,,Jan-16,,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1592,dyslipidemia,7/7/14 12:28
2639,39,Eli Lilly,Large Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-10,,Jan-16,,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1592,dyslipidemia,7/7/14 12:28
2639,39,Eli Lilly,Large Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-10,,Jan-16,,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,US,Alliance Revenue,0,5.7,15.718206,26.08184794,36.44547022,44.68110616,52.1208126,12,7,5,4.5,4,-27.06822719,1592,dyslipidemia,7/7/14 12:28
2639,39,Eli Lilly,Large Pharma,1178,Livalo,pitavastatin,Small Molecule (Chemical),Launched,Licensed (Development),Feb-10,,Jan-16,,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1592,dyslipidemia,7/7/14 12:28
2641,16,AstraZeneca,Large Pharma,4097,CAZ-AVI,ceftazidime + avibactam,Small Molecule (Chemical),Phase III,Acquisition (Development),,Dec-15,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,3.333332,45.55564844,112.2222399,178.8889838,222.1334527,260.6023558,0,1853,serious bacterial  infections,7/7/14 12:28
2641,16,AstraZeneca,Large Pharma,4097,CAZ-AVI,ceftazidime + avibactam,Small Molecule (Chemical),Phase III,Acquisition (Development),,Dec-15,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,3.333332,45.55564844,112.2222399,178.8889838,222.1334527,260.6023558,0,1853,serious bacterial  infections,7/7/14 12:28
2641,16,AstraZeneca,Large Pharma,4097,CAZ-AVI,ceftazidime + avibactam,Small Molecule (Chemical),Phase III,Acquisition (Development),,Dec-15,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1853,serious bacterial  infections,7/7/14 12:28
2642,16,AstraZeneca,Large Pharma,3299,CEF-104,ceftaroline + avibactam,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1856,MRSA,7/7/14 12:28
2642,16,AstraZeneca,Large Pharma,3299,CEF-104,ceftaroline + avibactam,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1856,MRSA,7/7/14 12:28
2642,16,AstraZeneca,Large Pharma,3299,CEF-104,ceftaroline + avibactam,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1856,MRSA,7/7/14 12:28
2649,76,Pfizer,Large Pharma,4561,PF-04971729,ertugliflozin,Small Molecule (Chemical),Phase III,In-House,Jan-18,Jan-18,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,10.4,27.733368,45.066723,0,2054,Type II Diabetes,7/7/14 12:28
2649,76,Pfizer,Large Pharma,4561,PF-04971729,ertugliflozin,Small Molecule (Chemical),Phase III,In-House,Jan-18,Jan-18,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,2.4,6.400008,10.400013,0,2054,Type II Diabetes,7/7/14 12:28
2649,76,Pfizer,Large Pharma,4561,PF-04971729,ertugliflozin,Small Molecule (Chemical),Phase III,In-House,Jan-18,Jan-18,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,8,21.33336,34.66671,0,2054,Type II Diabetes,7/7/14 12:28
2652,76,Pfizer,Large Pharma,2558,PF-3084014,PF-03084014,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2040,Cancer,7/7/14 12:28
2652,76,Pfizer,Large Pharma,2558,PF-3084014,PF-03084014,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2040,Cancer,7/7/14 12:28
2652,76,Pfizer,Large Pharma,2558,PF-3084014,PF-03084014,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2040,Cancer,7/7/14 12:28
2653,76,Pfizer,Large Pharma,2559,PF-3446962,PF-03446962,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2042,Hepatocellular carcinoma,7/7/14 12:28
2653,76,Pfizer,Large Pharma,2559,PF-3446962,PF-03446962,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2042,Hepatocellular carcinoma,7/7/14 12:28
2653,76,Pfizer,Large Pharma,2559,PF-3446962,PF-03446962,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2042,Hepatocellular carcinoma,7/7/14 12:28
2668,61,Merck & Co,Large Pharma,2212,HDM AIT,HDM AIT,Vaccine,Phase II,Licensed (Development),,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1887,Dust Mite Allergy,7/7/14 12:28
2668,61,Merck & Co,Large Pharma,2212,HDM AIT,HDM AIT,Vaccine,Phase II,Licensed (Development),,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1887,Dust Mite Allergy,7/7/14 12:28
2668,61,Merck & Co,Large Pharma,2212,HDM AIT,HDM AIT,Vaccine,Phase II,Licensed (Development),,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1887,Dust Mite Allergy,7/7/14 12:28
2669,61,Merck & Co,Large Pharma,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-11,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,6,14.4,20.400048,30.00010659,32.4841197,34.08072982,35.11978603,35.56838016,35.82498094,35.96618791,8.437731783,1412,MRSA SSSI and BSI,7/7/14 12:28
2669,61,Merck & Co,Large Pharma,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-11,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,6,14.4,20.400048,30.00010659,32.4841197,34.08072982,35.11978603,35.56838016,35.82498094,35.96618791,8.437731783,1412,MRSA SSSI and BSI,7/7/14 12:28
2669,61,Merck & Co,Large Pharma,1061,Cubicin,daptomycin injection,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-11,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1412,MRSA SSSI and BSI,7/7/14 12:28
2677,76,Pfizer,Large Pharma,2577,palbociclib,palbociclib,Small Molecule (Chemical),Phase III,Licensed (Development),Jun-16,Sep-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,217.083185,589.7216031,886.387027,1183.05024,1432.537373,0,2041,Breast Cancer,7/7/14 12:28
2677,76,Pfizer,Large Pharma,2577,palbociclib,palbociclib,Small Molecule (Chemical),Phase III,Licensed (Development),Jun-16,Sep-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,56.66661,207.7777589,321.1101375,434.4427494,531.1533488,0,2041,Breast Cancer,7/7/14 12:28
2677,76,Pfizer,Large Pharma,2577,palbociclib,palbociclib,Small Molecule (Chemical),Phase III,Licensed (Development),Jun-16,Sep-16,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,160.416575,381.9438442,565.2768895,748.6074903,901.3840245,0,2041,Breast Cancer,7/7/14 12:28
2679,182,NicOx,Small Biotech,4027,Beprana,naproxcinod,Small Molecule (Chemical),Filed,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1997,Duchenne Muscular Dystrophy,7/7/14 12:28
2679,182,NicOx,Small Biotech,4027,Beprana,naproxcinod,Small Molecule (Chemical),Filed,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1997,Duchenne Muscular Dystrophy,7/7/14 12:28
2679,182,NicOx,Small Biotech,4027,Beprana,naproxcinod,Small Molecule (Chemical),Filed,In-House,,,,,143,Other Musculoskeletal,34,Other Musculoskeletal Disorders,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1997,Duchenne Muscular Dystrophy,7/7/14 12:28
2680,100,Takeda,Large Pharma,2317,Feraheme / Rienso,ferumoxytol,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-12,N/A,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,Global,Sales,0,0,2.916392521,23.42144265,36.01102875,45.89497582,55.22094693,62.86005571,68.8759503,73.8913622,77.97956946,81.30590375,12.3379773,445,Iron-deficiency Anemia,7/7/14 12:28
2680,100,Takeda,Large Pharma,2317,Feraheme / Rienso,ferumoxytol,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-12,N/A,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,ROW,Sales,0,0,2.916392521,23.42144265,36.01102875,45.89497582,55.22094693,62.86005571,68.8759503,73.8913622,77.97956946,81.30590375,12.3379773,445,Iron-deficiency Anemia,7/7/14 12:28
2680,100,Takeda,Large Pharma,2317,Feraheme / Rienso,ferumoxytol,Small Molecule (Chemical),Launched,Licensed (Development),,Jan-12,N/A,,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,445,Iron-deficiency Anemia,7/7/14 12:28
2682,183,Nanotherapeutics,Small Biotech,2591,ramoplanin,,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2079,C. difficile associated diarrhoea,7/7/14 12:28
2682,183,Nanotherapeutics,Small Biotech,2591,ramoplanin,,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2079,C. difficile associated diarrhoea,7/7/14 12:28
2682,183,Nanotherapeutics,Small Biotech,2591,ramoplanin,,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2079,C. difficile associated diarrhoea,7/7/14 12:28
2683,184,Theravance,Small Biotech,4291,TD-1792,,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2124,,7/7/14 12:28
2683,184,Theravance,Small Biotech,4291,TD-1792,,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2124,,7/7/14 12:28
2683,184,Theravance,Small Biotech,4291,TD-1792,,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2124,,7/7/14 12:28
2684,550,Debiopharm,Small Biotech,2593,AFN-1252,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1794,Gram-positive infectioins,7/7/14 12:28
2684,550,Debiopharm,Small Biotech,2593,AFN-1252,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1794,Gram-positive infectioins,7/7/14 12:28
2684,550,Debiopharm,Small Biotech,2593,AFN-1252,,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1794,Gram-positive infectioins,7/7/14 12:28
2687,63,Merck KGaA,Regional & Specialty Pharma,2596,ATX-MS-1467,ATX-MS-1467,Synthetic Peptide,Phase I,Licensed (Development),,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1822,Multiple Sclerosis,7/7/14 12:28
2687,63,Merck KGaA,Regional & Specialty Pharma,2596,ATX-MS-1467,ATX-MS-1467,Synthetic Peptide,Phase I,Licensed (Development),,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1822,Multiple Sclerosis,7/7/14 12:28
2687,63,Merck KGaA,Regional & Specialty Pharma,2596,ATX-MS-1467,ATX-MS-1467,Synthetic Peptide,Phase I,Licensed (Development),,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1822,Multiple Sclerosis,7/7/14 12:28
2688,67,Novartis,Large Pharma,3538,alisporivir,DEB025,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1876,Hepatitis C,7/7/14 12:28
2688,67,Novartis,Large Pharma,3538,alisporivir,DEB025,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1876,Hepatitis C,7/7/14 12:28
2688,67,Novartis,Large Pharma,3538,alisporivir,DEB025,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1876,Hepatitis C,7/7/14 12:28
2691,89,Sanofi,Large Pharma,2602,KB001,Pseudomonas aeruginosa vaccine,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,Pseudomonas aeruginosa,7/7/14 12:28
2691,89,Sanofi,Large Pharma,2602,KB001,Pseudomonas aeruginosa vaccine,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,Pseudomonas aeruginosa,7/7/14 12:28
2691,89,Sanofi,Large Pharma,2602,KB001,Pseudomonas aeruginosa vaccine,Vaccine,Phase II,Licensed (Development),,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1952,Pseudomonas aeruginosa,7/7/14 12:28
2692,169,Auxilium,Regional & Specialty Pharma,2603,Testim,testosterone gel,Small Molecule (Chemical),Launched,Licensed (Development),Feb-03,Feb-06,Apr-23,N/A,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,Global,Sales,160.5,192.9,207.9,236,211,209.4325,184.5997289,145.5622024,136.114594,130.8240367,125.7263596,122.8529089,-7.435743378,2126,Hypogonadism,7/7/14 12:28
2692,169,Auxilium,Regional & Specialty Pharma,2603,Testim,testosterone gel,Small Molecule (Chemical),Launched,Licensed (Development),Feb-03,Feb-06,Apr-23,N/A,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,ROW,Sales,8.5,3,2.8,3,5,5,5.48,5.96,6.248,6.536,6.7808,6.9806,4.882547904,2126,Hypogonadism,7/7/14 12:28
2692,169,Auxilium,Regional & Specialty Pharma,2603,Testim,testosterone gel,Small Molecule (Chemical),Launched,Licensed (Development),Feb-03,Feb-06,Apr-23,N/A,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,US,Sales,152,189.9,205.1,233,206,204.4325,179.1197289,139.6022024,129.866594,124.2880367,118.9455596,115.8723089,-7.891053953,2126,Hypogonadism,7/7/14 12:28
2693,86,Roche,Large Pharma,2608,Zenapax,daclizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Dec-97,Mar-98,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2163,Transplant rejection,7/7/14 12:28
2693,86,Roche,Large Pharma,2608,Zenapax,daclizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Dec-97,Mar-98,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2163,Transplant rejection,7/7/14 12:28
2693,86,Roche,Large Pharma,2608,Zenapax,daclizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Dec-97,Mar-98,,,76,Immunomodulators - Transplant,45,Transplant Products,9,Transplant,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2163,Transplant rejection,7/7/14 12:28
2704,96,Shire,Regional & Specialty Pharma,2622,Reminyl,galantamine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-00,,Aug-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,42.2,42.9,32.7,13,9,7,6,5.5,5.25,5.125,4,4,-10.93885751,956,Alzheimer's Disease,7/7/14 12:28
2704,96,Shire,Regional & Specialty Pharma,2622,Reminyl,galantamine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-00,,Aug-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,42.2,42.9,32.7,13,9,7,6,5.5,5.25,5.125,4,4,-10.93885751,956,Alzheimer's Disease,7/7/14 12:28
2704,96,Shire,Regional & Specialty Pharma,2622,Reminyl,galantamine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-00,,Aug-11,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,956,Alzheimer's Disease,7/7/14 12:28
2706,76,Pfizer,Large Pharma,44,Sonata,zaleplon,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-99,,Apr-08,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2104,Insomnia,7/7/14 12:28
2706,76,Pfizer,Large Pharma,44,Sonata,zaleplon,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-99,,Apr-08,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2104,Insomnia,7/7/14 12:28
2706,76,Pfizer,Large Pharma,44,Sonata,zaleplon,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-99,,Apr-08,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2104,Insomnia,7/7/14 12:28
2707,16,AstraZeneca,Large Pharma,2623,Elavil,amitriptyline,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-61,,Expired,N/A,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1761,Depression,7/7/14 12:28
2707,16,AstraZeneca,Large Pharma,2623,Elavil,amitriptyline,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-61,,Expired,N/A,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1761,Depression,7/7/14 12:28
2707,16,AstraZeneca,Large Pharma,2623,Elavil,amitriptyline,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-61,,Expired,N/A,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1761,Depression,7/7/14 12:28
2708,16,AstraZeneca,Large Pharma,2624,Vivalan,viloxazine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-91,Jul-77,Expired,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2156,Depression,7/7/14 12:28
2708,16,AstraZeneca,Large Pharma,2624,Vivalan,viloxazine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-91,Jul-77,Expired,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2156,Depression,7/7/14 12:28
2708,16,AstraZeneca,Large Pharma,2624,Vivalan,viloxazine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-91,Jul-77,Expired,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2156,Depression,7/7/14 12:28
2709,34,Daiichi-Sankyo,Regional & Specialty Pharma,2625,Tolopelon,timiperone,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jul-84,N/A,Expired,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2133,Schizophrenia,7/7/14 12:28
2709,34,Daiichi-Sankyo,Regional & Specialty Pharma,2625,Tolopelon,timiperone,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jul-84,N/A,Expired,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2133,Schizophrenia,7/7/14 12:28
2709,34,Daiichi-Sankyo,Regional & Specialty Pharma,2625,Tolopelon,timiperone,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jul-84,N/A,Expired,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2133,Schizophrenia,7/7/14 12:28
2710,61,Merck & Co,Large Pharma,2628,Sinemet,levodopa + carbidopa,Small Molecule (Chemical),Launched,In-House,Jul-75,,Expired,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1521,Parkinson's disease,7/7/14 12:28
2710,61,Merck & Co,Large Pharma,2628,Sinemet,levodopa + carbidopa,Small Molecule (Chemical),Launched,In-House,Jul-75,,Expired,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1521,Parkinson's disease,7/7/14 12:28
2710,61,Merck & Co,Large Pharma,2628,Sinemet,levodopa + carbidopa,Small Molecule (Chemical),Launched,In-House,Jul-75,,Expired,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1521,Parkinson's disease,7/7/14 12:28
2711,24,Bristol-Myers Squibb,Large Pharma,2628,Sinemet,levodopa + carbidopa,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-75,,Expired,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1521,Parkinson's disease,7/7/14 12:28
2711,24,Bristol-Myers Squibb,Large Pharma,2628,Sinemet,levodopa + carbidopa,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-75,,Expired,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1521,Parkinson's disease,7/7/14 12:28
2711,24,Bristol-Myers Squibb,Large Pharma,2628,Sinemet,levodopa + carbidopa,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-75,,Expired,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1521,Parkinson's disease,7/7/14 12:28
2714,105,UCB,Regional & Specialty Pharma,2632,Parcopa,carbidopa + levodopa,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,,Expired,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2029,Parkinson's disease,7/7/14 12:28
2714,105,UCB,Regional & Specialty Pharma,2632,Parcopa,carbidopa + levodopa,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,,Expired,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2029,Parkinson's disease,7/7/14 12:28
2714,105,UCB,Regional & Specialty Pharma,2632,Parcopa,carbidopa + levodopa,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,,Expired,Expired,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2029,Parkinson's disease,7/7/14 12:28
2715,19,Bayer,Large Pharma,2633,Bayotensin,Nitrendipine,Small Molecule (Chemical),Launched,In-House,,Jul-85,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1829,,7/7/14 12:28
2715,19,Bayer,Large Pharma,2633,Bayotensin,Nitrendipine,Small Molecule (Chemical),Launched,In-House,,Jul-85,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1829,,7/7/14 12:28
2715,19,Bayer,Large Pharma,2633,Bayotensin,Nitrendipine,Small Molecule (Chemical),Launched,In-House,,Jul-85,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1829,,7/7/14 12:28
2716,19,Bayer,Large Pharma,2634,Baymycard,nisoldipine,Small Molecule (Chemical),Launched,In-House,,Jul-90,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1828,,7/7/14 12:28
2716,19,Bayer,Large Pharma,2634,Baymycard,nisoldipine,Small Molecule (Chemical),Launched,In-House,,Jul-90,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1828,,7/7/14 12:28
2716,19,Bayer,Large Pharma,2634,Baymycard,nisoldipine,Small Molecule (Chemical),Launched,In-House,,Jul-90,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1828,,7/7/14 12:28
2717,19,Bayer,Large Pharma,2635,Nimotop ,nimodipine,Small Molecule (Chemical),Launched,In-House,,Jul-85,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2004,,7/7/14 12:28
2717,19,Bayer,Large Pharma,2635,Nimotop ,nimodipine,Small Molecule (Chemical),Launched,In-House,,Jul-85,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2004,,7/7/14 12:28
2717,19,Bayer,Large Pharma,2635,Nimotop ,nimodipine,Small Molecule (Chemical),Launched,In-House,,Jul-85,Expired,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2004,,7/7/14 12:28
2718,19,Bayer,Large Pharma,2636,Betapace,sotalol,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-93,Jul-93,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1833,Arrhythmia ,7/7/14 12:28
2718,19,Bayer,Large Pharma,2636,Betapace,sotalol,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-93,Jul-93,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1833,Arrhythmia ,7/7/14 12:28
2718,19,Bayer,Large Pharma,2636,Betapace,sotalol,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-93,Jul-93,Expired,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1833,Arrhythmia ,7/7/14 12:28
2719,19,Bayer,Large Pharma,4270,Ilomedin / Ventavis,iloprost,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-92,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1248,Pulmonary Hypertension,7/7/14 12:28
2719,19,Bayer,Large Pharma,4270,Ilomedin / Ventavis,iloprost,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-92,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1248,Pulmonary Hypertension,7/7/14 12:28
2719,19,Bayer,Large Pharma,4270,Ilomedin / Ventavis,iloprost,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-92,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1248,Pulmonary Hypertension,7/7/14 12:28
2720,19,Bayer,Large Pharma,2638,Pritor ,telmisartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-02,N/A,Dec-13,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,227.877738,235.8063562,239.1551705,216.8171621,205.8446603,61.39596701,40.63281506,30.38138,24.37638841,20.178659,17.98058368,17.98048379,-29.40859396,1655,Hypertension,7/7/14 12:28
2720,19,Bayer,Large Pharma,2638,Pritor ,telmisartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-02,N/A,Dec-13,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,227.877738,235.8063562,239.1551705,216.8171621,205.8446603,61.39596701,40.63281506,30.38138,24.37638841,20.178659,17.98058368,17.98048379,-29.40859396,1655,Hypertension,7/7/14 12:28
2720,19,Bayer,Large Pharma,2638,Pritor ,telmisartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-02,N/A,Dec-13,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1655,Hypertension,7/7/14 12:28
2721,19,Bayer,Large Pharma,2639,Refludan,lepirudin,Recombinant Protein,Launched,Corporate Acquisition,Oct-01,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2081,,7/7/14 12:28
2721,19,Bayer,Large Pharma,2639,Refludan,lepirudin,Recombinant Protein,Launched,Corporate Acquisition,Oct-01,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2081,,7/7/14 12:28
2721,19,Bayer,Large Pharma,2639,Refludan,lepirudin,Recombinant Protein,Launched,Corporate Acquisition,Oct-01,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2081,,7/7/14 12:28
2722,19,Bayer,Large Pharma,2641,Trasylol ,aprotinin,Small Molecule (Chemical),Launched,In-House,Jul-94,Jul-59,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2140,Blood loss in cardiothoracic surgery,7/7/14 12:28
2722,19,Bayer,Large Pharma,2641,Trasylol ,aprotinin,Small Molecule (Chemical),Launched,In-House,Jul-94,Jul-59,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2140,Blood loss in cardiothoracic surgery,7/7/14 12:28
2722,19,Bayer,Large Pharma,2641,Trasylol ,aprotinin,Small Molecule (Chemical),Launched,In-House,Jul-94,Jul-59,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2140,Blood loss in cardiothoracic surgery,7/7/14 12:28
2723,188,Marinus,Small Biotech,2642,ganaxolone,ganaxolone,Small Molecule (Chemical),Phase II,In-House,,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1916,Epilepsy,7/7/14 12:28
2723,188,Marinus,Small Biotech,2642,ganaxolone,ganaxolone,Small Molecule (Chemical),Phase II,In-House,,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1916,Epilepsy,7/7/14 12:28
2723,188,Marinus,Small Biotech,2642,ganaxolone,ganaxolone,Small Molecule (Chemical),Phase II,In-House,,,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1916,Epilepsy,7/7/14 12:28
2724,86,Roche,Large Pharma,4272,Rivotril / Klonopin,clonazepam,Small Molecule (Chemical),Launched,In-House,Jul-73,Jul-73,Expired,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,5,Global,Sales,118.4203679,130.5342188,153.2244485,148.0292134,151.1748207,153.6375303,155.717673,157.3233381,158.4062753,159.2253178,159.8265701,160.2581644,0.837041823,2089,Epilepsy,7/7/14 12:28
2724,86,Roche,Large Pharma,4272,Rivotril / Klonopin,clonazepam,Small Molecule (Chemical),Launched,In-House,Jul-73,Jul-73,Expired,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,5,ROW,Sales,90.79648243,107.5174014,132.9501256,130.9844641,133.9088511,137.4067466,139.9115085,141.7070181,142.9955071,143.9211736,144.5869332,145.0663098,1.149868087,2089,Epilepsy,7/7/14 12:28
2724,86,Roche,Large Pharma,4272,Rivotril / Klonopin,clonazepam,Small Molecule (Chemical),Launched,In-House,Jul-73,Jul-73,Expired,Expired,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,5,US,Sales,27.62388545,23.01681746,20.27432285,17.04474926,17.26596968,16.23078378,15.80616449,15.61631994,15.41076819,15.30414425,15.23963687,15.1918546,-1.811645388,2089,Epilepsy,7/7/14 12:28
2725,58,Lundbeck,Regional & Specialty Pharma,2646,Cipramil,citalopram,Small Molecule (Chemical),Launched,In-House,,Jul-89,,,127,Serotonergics,49,Depression,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1764,Depression,7/7/14 12:28
2725,58,Lundbeck,Regional & Specialty Pharma,2646,Cipramil,citalopram,Small Molecule (Chemical),Launched,In-House,,Jul-89,,,127,Serotonergics,49,Depression,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1764,Depression,7/7/14 12:28
2725,58,Lundbeck,Regional & Specialty Pharma,2646,Cipramil,citalopram,Small Molecule (Chemical),Launched,In-House,,Jul-89,,,127,Serotonergics,49,Depression,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1764,Depression,7/7/14 12:28
2726,42,Forest,Regional & Specialty Pharma,1332,Celexa,citalopram,Small Molecule (Chemical),Launched,Acquisition (Development),Jul-98,,,,127,Serotonergics,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1764,Depression,7/7/14 12:28
2726,42,Forest,Regional & Specialty Pharma,1332,Celexa,citalopram,Small Molecule (Chemical),Launched,Acquisition (Development),Jul-98,,,,127,Serotonergics,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1764,Depression,7/7/14 12:28
2726,42,Forest,Regional & Specialty Pharma,1332,Celexa,citalopram,Small Molecule (Chemical),Launched,Acquisition (Development),Jul-98,,,,127,Serotonergics,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1764,Depression,7/7/14 12:28
2727,46,GlaxoSmithKline,Large Pharma,2647,Amerge / Naramig,naratriptan,Small Molecule (Chemical),Launched,In-House,Mar-98,May-97,Expired,Expired,117,Triptans,8,Migraine,12,Central Nervous System,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1998,Migraine,7/7/14 12:28
2727,46,GlaxoSmithKline,Large Pharma,2647,Amerge / Naramig,naratriptan,Small Molecule (Chemical),Launched,In-House,Mar-98,May-97,Expired,Expired,117,Triptans,8,Migraine,12,Central Nervous System,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1998,Migraine,7/7/14 12:28
2727,46,GlaxoSmithKline,Large Pharma,2647,Amerge / Naramig,naratriptan,Small Molecule (Chemical),Launched,In-House,Mar-98,May-97,Expired,Expired,117,Triptans,8,Migraine,12,Central Nervous System,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1998,Migraine,7/7/14 12:28
2728,46,GlaxoSmithKline,Large Pharma,2648,Zyban,buproprion,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-00,Expired,Expired,71,Smoking Cessation Agents,16,Addictions,12,Central Nervous System,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2167,Smoking cessation,7/7/14 12:28
2728,46,GlaxoSmithKline,Large Pharma,2648,Zyban,buproprion,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-00,Expired,Expired,71,Smoking Cessation Agents,16,Addictions,12,Central Nervous System,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2167,Smoking cessation,7/7/14 12:28
2728,46,GlaxoSmithKline,Large Pharma,2648,Zyban,buproprion,Small Molecule (Chemical),Launched,In-House,Jul-97,Jul-00,Expired,Expired,71,Smoking Cessation Agents,16,Addictions,12,Central Nervous System,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2167,Smoking cessation,7/7/14 12:28
2729,37,Eisai,Regional & Specialty Pharma,692,Maxalt,rizatriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-03,,,117,Triptans,8,Migraine,12,Central Nervous System,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,667,Migraine,7/7/14 12:28
2729,37,Eisai,Regional & Specialty Pharma,692,Maxalt,rizatriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-03,,,117,Triptans,8,Migraine,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,667,Migraine,7/7/14 12:28
2729,37,Eisai,Regional & Specialty Pharma,692,Maxalt,rizatriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-03,,,117,Triptans,8,Migraine,12,Central Nervous System,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,667,Migraine,7/7/14 12:28
2729,37,Eisai,Regional & Specialty Pharma,692,Maxalt,rizatriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-03,,,117,Triptans,8,Migraine,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,667,Migraine,7/7/14 12:28
2729,37,Eisai,Regional & Specialty Pharma,692,Maxalt,rizatriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-03,,,117,Triptans,8,Migraine,12,Central Nervous System,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,667,Migraine,7/7/14 12:28
2729,37,Eisai,Regional & Specialty Pharma,692,Maxalt,rizatriptan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-03,,,117,Triptans,8,Migraine,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,667,Migraine,7/7/14 12:28
2730,16,AstraZeneca,Large Pharma,2650,Imdur,isosorbide mononitrate,Small Molecule (Chemical),Launched,In-House,,Jul-86,,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1938,Angina,7/7/14 12:28
2730,16,AstraZeneca,Large Pharma,2650,Imdur,isosorbide mononitrate,Small Molecule (Chemical),Launched,In-House,,Jul-86,,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1938,Angina,7/7/14 12:28
2730,16,AstraZeneca,Large Pharma,2650,Imdur,isosorbide mononitrate,Small Molecule (Chemical),Launched,In-House,,Jul-86,,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1938,Angina,7/7/14 12:28
2731,16,AstraZeneca,Large Pharma,2651,Inderal ,propranolol,Small Molecule (Chemical),Launched,In-House,,,,,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1940,Hypertension,7/7/14 12:28
2731,16,AstraZeneca,Large Pharma,2651,Inderal ,propranolol,Small Molecule (Chemical),Launched,In-House,,,,,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1940,Hypertension,7/7/14 12:28
2731,16,AstraZeneca,Large Pharma,2651,Inderal ,propranolol,Small Molecule (Chemical),Launched,In-House,,,,,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1940,Hypertension,7/7/14 12:28
2732,46,GlaxoSmithKline,Large Pharma,2652,Argatroban,argatroban,Small Molecule (Chemical),Launched,Licensed (Development),Jul-00,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1817,,7/7/14 12:28
2732,46,GlaxoSmithKline,Large Pharma,2652,Argatroban,argatroban,Small Molecule (Chemical),Launched,Licensed (Development),Jul-00,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1817,,7/7/14 12:28
2732,46,GlaxoSmithKline,Large Pharma,2652,Argatroban,argatroban,Small Molecule (Chemical),Launched,Licensed (Development),Jul-00,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1817,,7/7/14 12:28
2733,46,GlaxoSmithKline,Large Pharma,2653,Lacipil ,lacidipine,Small Molecule (Chemical),Launched,In-House,,Jul-91,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1767,,7/7/14 12:28
2733,46,GlaxoSmithKline,Large Pharma,2653,Lacipil ,lacidipine,Small Molecule (Chemical),Launched,In-House,,Jul-91,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1767,,7/7/14 12:28
2733,46,GlaxoSmithKline,Large Pharma,2653,Lacipil ,lacidipine,Small Molecule (Chemical),Launched,In-House,,Jul-91,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1767,,7/7/14 12:28
2734,46,GlaxoSmithKline,Large Pharma,2654,Trandate,labetalol,Small Molecule (Chemical),Launched,In-House,,Jul-70,,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2139,Hypertension,7/7/14 12:28
2734,46,GlaxoSmithKline,Large Pharma,2654,Trandate,labetalol,Small Molecule (Chemical),Launched,In-House,,Jul-70,,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2139,Hypertension,7/7/14 12:28
2734,46,GlaxoSmithKline,Large Pharma,2654,Trandate,labetalol,Small Molecule (Chemical),Launched,In-House,,Jul-70,,Expired,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2139,Hypertension,7/7/14 12:28
2735,63,Merck KGaA,Regional & Specialty Pharma,2655,Adancor,nicorandil,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-94,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1088,Angina,7/7/14 12:28
2735,63,Merck KGaA,Regional & Specialty Pharma,2655,Adancor,nicorandil,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-94,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1088,Angina,7/7/14 12:28
2735,63,Merck KGaA,Regional & Specialty Pharma,2655,Adancor,nicorandil,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-94,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1088,Angina,7/7/14 12:28
2736,63,Merck KGaA,Regional & Specialty Pharma,2656,Dynorm ,cilazapril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-92,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,555,,7/7/14 12:28
2736,63,Merck KGaA,Regional & Specialty Pharma,2656,Dynorm ,cilazapril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-92,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,555,,7/7/14 12:28
2736,63,Merck KGaA,Regional & Specialty Pharma,2656,Dynorm ,cilazapril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-92,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,555,,7/7/14 12:28
2737,63,Merck KGaA,Regional & Specialty Pharma,2657,Fozitec ,fosinopril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-96,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,741,,7/7/14 12:28
2737,63,Merck KGaA,Regional & Specialty Pharma,2657,Fozitec ,fosinopril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-96,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,741,,7/7/14 12:28
2737,63,Merck KGaA,Regional & Specialty Pharma,2657,Fozitec ,fosinopril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-96,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,741,,7/7/14 12:28
2738,53,Johnson & Johnson,Large Pharma,706,ReoPro,abciximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jul-05,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,967,,7/7/14 12:28
2738,53,Johnson & Johnson,Large Pharma,706,ReoPro,abciximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jul-05,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,967,,7/7/14 12:28
2738,53,Johnson & Johnson,Large Pharma,706,ReoPro,abciximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Jul-05,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,967,,7/7/14 12:28
2739,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2658,Kerlong,betaxolol,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-86,,,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1955,Hypertension,7/7/14 12:28
2739,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2658,Kerlong,betaxolol,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-86,,,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1955,Hypertension,7/7/14 12:28
2739,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2658,Kerlong,betaxolol,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-86,,,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1955,Hypertension,7/7/14 12:28
2740,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2659,Kalgut,denopamine ,Small Molecule (Chemical),Launched,In-House,,Jul-88,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1951,Angina,7/7/14 12:28
2740,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2659,Kalgut,denopamine ,Small Molecule (Chemical),Launched,In-House,,Jul-88,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1951,Angina,7/7/14 12:28
2740,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2659,Kalgut,denopamine ,Small Molecule (Chemical),Launched,In-House,,Jul-88,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1951,Angina,7/7/14 12:28
2741,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2660,Tanadopa ,docarpamine,Small Molecule (Chemical),Launched,In-House,,Dec-94,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2118,Angina,7/7/14 12:28
2741,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2660,Tanadopa ,docarpamine,Small Molecule (Chemical),Launched,In-House,,Dec-94,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2118,Angina,7/7/14 12:28
2741,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2660,Tanadopa ,docarpamine,Small Molecule (Chemical),Launched,In-House,,Dec-94,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2118,Angina,7/7/14 12:28
2742,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2661,Adona AC-17,carbazochrome sodium sulphonate,Small Molecule (Chemical),Launched,In-House,,Jul-56,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1791,,7/7/14 12:28
2742,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2661,Adona AC-17,carbazochrome sodium sulphonate,Small Molecule (Chemical),Launched,In-House,,Jul-56,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1791,,7/7/14 12:28
2742,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2661,Adona AC-17,carbazochrome sodium sulphonate,Small Molecule (Chemical),Launched,In-House,,Jul-56,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1791,,7/7/14 12:28
2743,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2662,Novastan,argatroban,Small Molecule (Chemical),Launched,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,70.026188,75.87341979,82.30079251,79.92107794,78.57838618,77.23569442,75.89300266,74.5503109,73.20761914,71.86492738,70.52223562,70.47405572,-1.542999441,1817,,7/7/14 12:28
2743,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2662,Novastan,argatroban,Small Molecule (Chemical),Launched,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,70.026188,75.87341979,82.30079251,79.92107794,78.57838618,77.23569442,75.89300266,74.5503109,73.20761914,71.86492738,70.52223562,70.47405572,-1.542999441,1817,,7/7/14 12:28
2743,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2662,Novastan,argatroban,Small Molecule (Chemical),Launched,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1817,,7/7/14 12:28
2744,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2101,MP-124,MP-124,Small Molecule (Chemical),Phase I,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,746,Ischemic stroke ,7/7/14 12:28
2744,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2101,MP-124,MP-124,Small Molecule (Chemical),Phase I,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,746,Ischemic stroke ,7/7/14 12:28
2744,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2101,MP-124,MP-124,Small Molecule (Chemical),Phase I,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,746,Ischemic stroke ,7/7/14 12:28
2745,67,Novartis,Large Pharma,2663,Clozaril / Leponex,clozapine,Small Molecule (Chemical),Launched,,Jul-71,Jul-90,Expired,Expired,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1862,Schizophrenia,7/7/14 12:28
2745,67,Novartis,Large Pharma,2663,Clozaril / Leponex,clozapine,Small Molecule (Chemical),Launched,,Jul-71,Jul-90,Expired,Expired,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1862,Schizophrenia,7/7/14 12:28
2745,67,Novartis,Large Pharma,2663,Clozaril / Leponex,clozapine,Small Molecule (Chemical),Launched,,Jul-71,Jul-90,Expired,Expired,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1862,Schizophrenia,7/7/14 12:28
2746,189,Valeant,Regional & Specialty Pharma,2665,Tasmar,tolcapone,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-97,Jul-97,Jan-12,Nov-07,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2121,Parkinson's disease,7/7/14 12:28
2746,189,Valeant,Regional & Specialty Pharma,2665,Tasmar,tolcapone,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-97,Jul-97,Jan-12,Nov-07,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2121,Parkinson's disease,7/7/14 12:28
2746,189,Valeant,Regional & Specialty Pharma,2665,Tasmar,tolcapone,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-97,Jul-97,Jan-12,Nov-07,96,COMT inhibitors,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2121,Parkinson's disease,7/7/14 12:28
2747,15,Astellas Pharma,Regional & Specialty Pharma,2667,Bisphonal,incadronate disodium,Small Molecule (Chemical),Launched,In-House,,Oct-97,,,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1838,Hypercalcemia of Malignancy,7/7/14 12:28
2747,15,Astellas Pharma,Regional & Specialty Pharma,2667,Bisphonal,incadronate disodium,Small Molecule (Chemical),Launched,In-House,,Oct-97,,,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1838,Hypercalcemia of Malignancy,7/7/14 12:28
2747,15,Astellas Pharma,Regional & Specialty Pharma,2667,Bisphonal,incadronate disodium,Small Molecule (Chemical),Launched,In-House,,Oct-97,,,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1838,Hypercalcemia of Malignancy,7/7/14 12:28
2748,16,AstraZeneca,Large Pharma,2668,Ethyol,amifostine,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-97,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1899,Chemotherapy toxicity,7/7/14 12:28
2748,16,AstraZeneca,Large Pharma,2668,Ethyol,amifostine,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-97,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1899,Chemotherapy toxicity,7/7/14 12:28
2748,16,AstraZeneca,Large Pharma,2668,Ethyol,amifostine,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-97,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1899,Chemotherapy toxicity,7/7/14 12:28
2749,19,Bayer,Large Pharma,2669,Bonefos,clodronate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-90,,,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1842,Hypercalcemia of malignancy,7/7/14 12:28
2749,19,Bayer,Large Pharma,2669,Bonefos,clodronate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-90,,,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1842,Hypercalcemia of malignancy,7/7/14 12:28
2749,19,Bayer,Large Pharma,2669,Bonefos,clodronate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-90,,,130,Bone-resorption Inhibitors,6,Other Supportive Care,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1842,Hypercalcemia of malignancy,7/7/14 12:28
2751,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,2670,Zevalin,ibritumomab tiuxetan,Antibody/Antibody Derivative,Launched,Licensed (Development),Mar-02,Feb-04,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Sales,15.7,28.8,28,30.3,29.4,29.559,29.64589,29.8120179,29.96844467,30.14584287,30.30512085,30.45295407,0.503955515,2164,Follicular Lymphoma,7/7/14 12:28
2751,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,2670,Zevalin,ibritumomab tiuxetan,Antibody/Antibody Derivative,Launched,Licensed (Development),Mar-02,Feb-04,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,2,2.9,3.635,4.36125,4.8957875,5.338288125,5.707091219,6.003932683,6.247225932,11.58676761,2164,Follicular Lymphoma,7/7/14 12:28
2751,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,2670,Zevalin,ibritumomab tiuxetan,Antibody/Antibody Derivative,Launched,Licensed (Development),Mar-02,Feb-04,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Sales,15.7,28.8,28,28.3,26.5,25.924,25.28464,24.9162304,24.63015654,24.43875165,24.30118817,24.20572814,-1.285316022,2164,Follicular Lymphoma,7/7/14 12:28
2752,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3035,benralizumab,KHK-4563,Antibody/Antibody Derivative,Phase II,In-House,,Jul-17,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,3,Global,Sales,0,0,0,0,0,0,0,0,1.014647482,2.029294964,2.972199694,3.962923018,0,684,Asthma,7/7/14 12:28
2752,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3035,benralizumab,KHK-4563,Antibody/Antibody Derivative,Phase II,In-House,,Jul-17,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,3,ROW,Sales,0,0,0,0,0,0,0,0,1.014647482,2.029294964,2.972199694,3.962923018,0,684,Asthma,7/7/14 12:28
2752,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3035,benralizumab,KHK-4563,Antibody/Antibody Derivative,Phase II,In-House,,Jul-17,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,684,Asthma,7/7/14 12:28
2753,2221,AbbVie,Large Pharma,1130,daclizumab,daclizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Nov-15,May-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,10.2,65.678252,131.2565272,229.6741511,327.9565389,401.3822477,0,348,Multiple Sclerosis,7/7/14 12:28
2753,2221,AbbVie,Large Pharma,1130,daclizumab,daclizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Nov-15,May-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,20,45,80.0001,137.5001719,172.9002246,0,348,Multiple Sclerosis,7/7/14 12:28
2753,2221,AbbVie,Large Pharma,1130,daclizumab,daclizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Nov-15,May-16,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,10.2,45.678252,86.25652716,149.6740511,190.456367,228.4820231,0,348,Multiple Sclerosis,7/7/14 12:28
2754,190,Meda,Regional & Specialty Pharma,2672,Aerospan,flunisolide,Small Molecule (Chemical),Approved,Corporate Acquisition,May-14,,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,9,Global,Sales,0,0,0,0,0,22.00905263,69.69540668,124.7178394,179.7408558,222.5852628,261.7321388,296.4772295,0,3928,Asthma,7/7/14 12:28
2754,190,Meda,Regional & Specialty Pharma,2672,Aerospan,flunisolide,Small Molecule (Chemical),Approved,Corporate Acquisition,May-14,,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,9,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3928,Asthma,7/7/14 12:28
2754,190,Meda,Regional & Specialty Pharma,2672,Aerospan,flunisolide,Small Molecule (Chemical),Approved,Corporate Acquisition,May-14,,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,9,US,Sales,0,0,0,0,0,22.00905263,69.69540668,124.7178394,179.7408558,222.5852628,261.7321388,296.4772295,0,3928,Asthma,7/7/14 12:28
2758,190,Meda,Regional & Specialty Pharma,2304,OX-NLA,OX-NLA,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,9,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2024,Allergic Rhinitis,7/7/14 12:28
2758,190,Meda,Regional & Specialty Pharma,2304,OX-NLA,OX-NLA,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,9,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2024,Allergic Rhinitis,7/7/14 12:28
2758,190,Meda,Regional & Specialty Pharma,2304,OX-NLA,OX-NLA,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2024,Allergic Rhinitis,7/7/14 12:28
2759,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2679,Excegran,zonisamide,Small Molecule (Chemical),Launched,In-House,,Jul-89,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,Global,Sales,45.24769071,58.36416907,56.97747174,58.98982903,50.33861123,50.33861123,50.33861123,50.33861123,50.33861123,50.33861123,50.33861123,50.33861123,0,1317,Epilepsy,7/7/14 12:28
2759,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2679,Excegran,zonisamide,Small Molecule (Chemical),Launched,In-House,,Jul-89,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,ROW,Sales,45.24769071,58.36416907,56.97747174,58.98982903,50.33861123,50.33861123,50.33861123,50.33861123,50.33861123,50.33861123,50.33861123,50.33861123,0,1317,Epilepsy,7/7/14 12:28
2759,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2679,Excegran,zonisamide,Small Molecule (Chemical),Launched,In-House,,Jul-89,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1317,Epilepsy,7/7/14 12:28
2760,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2680,Trerief,zonisamide,Small Molecule (Chemical),Launched,In-House,,Mar-09,,Jun-14,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,7,Global,Sales,8.618607754,43.18948511,67.10680005,87.5148289,91.1281667,101.7320567,102.0369675,103.0364947,104.5907033,104.5354751,103.590463,101.7366296,1.585587113,2141,Parkinson's Disease,7/7/14 12:28
2760,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2680,Trerief,zonisamide,Small Molecule (Chemical),Launched,In-House,,Mar-09,,Jun-14,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,7,ROW,Sales,8.618607754,43.18948511,67.10680005,87.5148289,91.1281667,101.7320567,102.0369675,103.0364947,104.5907033,104.5354751,103.590463,101.7366296,1.585587113,2141,Parkinson's Disease,7/7/14 12:28
2760,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2680,Trerief,zonisamide,Small Molecule (Chemical),Launched,In-House,,Mar-09,,Jun-14,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2141,Parkinson's Disease,7/7/14 12:28
2761,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2681,Dops,droxidopa,Small Molecule (Chemical),Launched,In-House,,Jul-89,,Expired,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,7,Global,Sales,38.78373489,38.52035159,40.51731324,38.75656708,32.40112594,30.37605557,20.25070371,15.68324545,20.25070371,10.12535186,6.440607774,10.06772225,-15.37831642,1886,Parkinson's Disease,7/7/14 12:28
2761,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2681,Dops,droxidopa,Small Molecule (Chemical),Launched,In-House,,Jul-89,,Expired,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,7,ROW,Sales,38.78373489,38.52035159,40.51731324,38.75656708,32.40112594,30.37605557,20.25070371,15.68324545,20.25070371,10.12535186,6.440607774,10.06772225,-15.37831642,1886,Parkinson's Disease,7/7/14 12:28
2761,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2681,Dops,droxidopa,Small Molecule (Chemical),Launched,In-House,,Jul-89,,Expired,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1886,Parkinson's Disease,7/7/14 12:28
2762,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2682,Lullan,perospirone,Small Molecule (Chemical),Launched,In-House,,Feb-01,,Nov-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Sales,28.0104752,29.18208453,25.32332077,20.48074075,15.10158337,13.78469008,12.92870944,12.37232203,12.01067021,11.77559653,11.62279864,11.52348001,-3.789373918,1975,Schizophrenia,7/7/14 12:28
2762,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2682,Lullan,perospirone,Small Molecule (Chemical),Launched,In-House,,Feb-01,,Nov-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Sales,28.0104752,29.18208453,25.32332077,20.48074075,15.10158337,13.78469008,12.92870944,12.37232203,12.01067021,11.77559653,11.62279864,11.52348001,-3.789373918,1975,Schizophrenia,7/7/14 12:28
2762,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2682,Lullan,perospirone,Small Molecule (Chemical),Launched,In-House,,Feb-01,,Nov-11,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1975,Schizophrenia,7/7/14 12:28
2774,191,Oxagen,Regional & Specialty Pharma,3038,OC-000459,ODC-9101,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2013,Asthma,7/7/14 12:28
2774,191,Oxagen,Regional & Specialty Pharma,3038,OC-000459,ODC-9101,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2013,Asthma,7/7/14 12:28
2774,191,Oxagen,Regional & Specialty Pharma,3038,OC-000459,ODC-9101,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2013,Asthma,7/7/14 12:28
2775,192,Seattle Genetics,Small Biotech,3700,Adcetris,brentuximab vedotin,Antibody/Antibody Derivative,Launched,In-House,Sep-11,,Aug-23,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Sales,0,0,43.2,138.2,144.6,182.79609,202.8051125,224.7870953,250.6602876,263.5038486,271.2661296,276.0989662,9.680148433,270,Hodgkin's Lymphoma,7/7/14 12:28
2775,192,Seattle Genetics,Small Biotech,3700,Adcetris,brentuximab vedotin,Antibody/Antibody Derivative,Launched,In-House,Sep-11,,Aug-23,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,270,Hodgkin's Lymphoma,7/7/14 12:28
2775,192,Seattle Genetics,Small Biotech,3700,Adcetris,brentuximab vedotin,Antibody/Antibody Derivative,Launched,In-House,Sep-11,,Aug-23,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Sales,0,0,43.2,138.2,144.6,182.79609,202.8051125,224.7870953,250.6602876,263.5038486,271.2661296,276.0989662,9.680148433,270,Hodgkin's Lymphoma,7/7/14 12:28
2776,193,Pharmaxis,Regional & Specialty Pharma,3039,ASM8,TPI-ASM8,DNA/RNA Therapy,Phase II,Corporate Acquisition,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2137,Asthma,7/7/14 12:28
2776,193,Pharmaxis,Regional & Specialty Pharma,3039,ASM8,TPI-ASM8,DNA/RNA Therapy,Phase II,Corporate Acquisition,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2137,Asthma,7/7/14 12:28
2776,193,Pharmaxis,Regional & Specialty Pharma,3039,ASM8,TPI-ASM8,DNA/RNA Therapy,Phase II,Corporate Acquisition,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2137,Asthma,7/7/14 12:28
2777,24,Bristol-Myers Squibb,Large Pharma,2698,Paraplatin,carboplatin,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-86,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2028,Ovarian Cancer,7/7/14 12:28
2777,24,Bristol-Myers Squibb,Large Pharma,2698,Paraplatin,carboplatin,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-86,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2028,Ovarian Cancer,7/7/14 12:28
2777,24,Bristol-Myers Squibb,Large Pharma,2698,Paraplatin,carboplatin,Small Molecule (Chemical),Launched,In-House,Jul-89,Jul-86,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2028,Ovarian Cancer,7/7/14 12:28
2779,84,Recordati,Regional & Specialty Pharma,2700,Entact,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-03,,Jun-14,127,Serotonergics,49,Depression,12,Central Nervous System,2,Global,Sales,45.22817301,46.18095268,52.4750938,49.74000032,51.36484033,36.19734649,16.04520056,10.74415585,8.093113202,6.525206327,5.421788812,4.846019263,-28.62740952,1450,Depression,7/7/14 12:28
2779,84,Recordati,Regional & Specialty Pharma,2700,Entact,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-03,,Jun-14,127,Serotonergics,49,Depression,12,Central Nervous System,2,ROW,Sales,45.22817301,46.18095268,52.4750938,49.74000032,51.36484033,36.19734649,16.04520056,10.74415585,8.093113202,6.525206327,5.421788812,4.846019263,-28.62740952,1450,Depression,7/7/14 12:28
2779,84,Recordati,Regional & Specialty Pharma,2700,Entact,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-03,,Jun-14,127,Serotonergics,49,Depression,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
2781,84,Recordati,Regional & Specialty Pharma,2702,Elopram,citalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-95,,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1764,Depression,7/7/14 12:28
2781,84,Recordati,Regional & Specialty Pharma,2702,Elopram,citalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-95,,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1764,Depression,7/7/14 12:28
2781,84,Recordati,Regional & Specialty Pharma,2702,Elopram,citalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-95,,Expired,127,Serotonergics,49,Depression,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1764,Depression,7/7/14 12:28
2782,24,Bristol-Myers Squibb,Large Pharma,2703,ReVia,naltrexone oral,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-95,Jul-95,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2087,Alcohol Addiction,7/7/14 12:28
2782,24,Bristol-Myers Squibb,Large Pharma,2703,ReVia,naltrexone oral,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-95,Jul-95,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2087,Alcohol Addiction,7/7/14 12:28
2782,24,Bristol-Myers Squibb,Large Pharma,2703,ReVia,naltrexone oral,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-95,Jul-95,,,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2087,Alcohol Addiction,7/7/14 12:28
2783,102,Teva,Regional & Specialty Pharma,2704,Trisenox,arsenic trioxide,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-00,Mar-02,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2144,Acute Promyelocytic Leukemia,7/7/14 12:28
2783,102,Teva,Regional & Specialty Pharma,2704,Trisenox,arsenic trioxide,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-00,Mar-02,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2144,Acute Promyelocytic Leukemia,7/7/14 12:28
2783,102,Teva,Regional & Specialty Pharma,2704,Trisenox,arsenic trioxide,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-00,Mar-02,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2144,Acute Promyelocytic Leukemia,7/7/14 12:28
2784,1,Abbott,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-03,,,127,Serotonergics,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
2784,1,Abbott,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-03,,,127,Serotonergics,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
2784,1,Abbott,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-03,,,127,Serotonergics,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
2785,102,Teva,Regional & Specialty Pharma,2705,Myocet,liposomal doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-01,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1995,Breast Cancer,7/7/14 12:28
2785,102,Teva,Regional & Specialty Pharma,2705,Myocet,liposomal doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-01,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1995,Breast Cancer,7/7/14 12:28
2785,102,Teva,Regional & Specialty Pharma,2705,Myocet,liposomal doxorubicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-01,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1995,Breast Cancer,7/7/14 12:28
2786,37,Eisai,Regional & Specialty Pharma,2706,Targretin,bexarotene,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-00,Apr-01,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2120,Cutaneous T-cell Lymphoma,7/7/14 12:28
2786,37,Eisai,Regional & Specialty Pharma,2706,Targretin,bexarotene,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-00,Apr-01,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2120,Cutaneous T-cell Lymphoma,7/7/14 12:28
2786,37,Eisai,Regional & Specialty Pharma,2706,Targretin,bexarotene,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jan-00,Apr-01,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2120,Cutaneous T-cell Lymphoma,7/7/14 12:28
2787,194,MediciNova,Small Biotech,2707,tipelukast,MN-001,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2131,Asthma,7/7/14 12:28
2787,194,MediciNova,Small Biotech,2707,tipelukast,MN-001,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2131,Asthma,7/7/14 12:28
2787,194,MediciNova,Small Biotech,2707,tipelukast,MN-001,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2131,Asthma,7/7/14 12:28
2788,29,Chugai,Regional & Specialty Pharma,2708,Furtulon,doxifluridine,Small Molecule (Chemical),Launched,Licensed (Development),,May-95,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1914,Solid Tumors,7/7/14 12:28
2788,29,Chugai,Regional & Specialty Pharma,2708,Furtulon,doxifluridine,Small Molecule (Chemical),Launched,Licensed (Development),,May-95,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1914,Solid Tumors,7/7/14 12:28
2788,29,Chugai,Regional & Specialty Pharma,2708,Furtulon,doxifluridine,Small Molecule (Chemical),Launched,Licensed (Development),,May-95,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1914,Solid Tumors,7/7/14 12:28
2791,195,Logical Therapeutics,Small Biotech,2710,LT-NS001,LT-NS001,Small Molecule (Chemical),Phase II,In-House,,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1974,Osteoarthritis,7/7/14 12:28
2791,195,Logical Therapeutics,Small Biotech,2710,LT-NS001,LT-NS001,Small Molecule (Chemical),Phase II,In-House,,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1974,Osteoarthritis,7/7/14 12:28
2791,195,Logical Therapeutics,Small Biotech,2710,LT-NS001,LT-NS001,Small Molecule (Chemical),Phase II,In-House,,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1974,Osteoarthritis,7/7/14 12:28
2792,34,Daiichi-Sankyo,Regional & Specialty Pharma,1398,Krestin,polysaccharide-K ,Other,Launched,Licensed (Development),,Jul-97,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1957,Solid Tumors,7/7/14 12:28
2792,34,Daiichi-Sankyo,Regional & Specialty Pharma,1398,Krestin,polysaccharide-K ,Other,Launched,Licensed (Development),,Jul-97,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1957,Solid Tumors,7/7/14 12:28
2792,34,Daiichi-Sankyo,Regional & Specialty Pharma,1398,Krestin,polysaccharide-K ,Other,Launched,Licensed (Development),,Jul-97,,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1957,Solid Tumors,7/7/14 12:28
2793,10,Almirall,Regional & Specialty Pharma,2711,Astucor,atorvastatin + amlodipine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-09,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,276,hypertension - hypercholesterolemia,7/7/14 12:28
2793,10,Almirall,Regional & Specialty Pharma,2711,Astucor,atorvastatin + amlodipine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-09,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,276,hypertension - hypercholesterolemia,7/7/14 12:28
2793,10,Almirall,Regional & Specialty Pharma,2711,Astucor,atorvastatin + amlodipine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-09,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,276,hypertension - hypercholesterolemia,7/7/14 12:28
2795,34,Daiichi-Sankyo,Regional & Specialty Pharma,2713,Feron,interferon beta,Recombinant Protein,Launched,Licensed (Marketed),,Dec-85,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1905,Solid Tumors,7/7/14 12:28
2795,34,Daiichi-Sankyo,Regional & Specialty Pharma,2713,Feron,interferon beta,Recombinant Protein,Launched,Licensed (Marketed),,Dec-85,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1905,Solid Tumors,7/7/14 12:28
2795,34,Daiichi-Sankyo,Regional & Specialty Pharma,2713,Feron,interferon beta,Recombinant Protein,Launched,Licensed (Marketed),,Dec-85,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1905,Solid Tumors,7/7/14 12:28
2796,10,Almirall,Regional & Specialty Pharma,2714,Astudal ,amlodipine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-92,,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1343,Hypertension,7/7/14 12:28
2796,10,Almirall,Regional & Specialty Pharma,2714,Astudal ,amlodipine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-92,,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1343,Hypertension,7/7/14 12:28
2796,10,Almirall,Regional & Specialty Pharma,2714,Astudal ,amlodipine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-92,,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1343,Hypertension,7/7/14 12:28
2798,95,Shionogi,Regional & Specialty Pharma,2716,Dobutrex ,dobutamine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-82,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1885,Heart Failure - Acute ,7/7/14 12:28
2798,95,Shionogi,Regional & Specialty Pharma,2716,Dobutrex ,dobutamine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-82,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1885,Heart Failure - Acute ,7/7/14 12:28
2798,95,Shionogi,Regional & Specialty Pharma,2716,Dobutrex ,dobutamine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-82,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1885,Heart Failure - Acute ,7/7/14 12:28
2799,95,Shionogi,Regional & Specialty Pharma,2717,Longes,lisinopril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-91,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1302,,7/7/14 12:28
2799,95,Shionogi,Regional & Specialty Pharma,2717,Longes,lisinopril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-91,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1302,,7/7/14 12:28
2799,95,Shionogi,Regional & Specialty Pharma,2717,Longes,lisinopril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-91,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1302,,7/7/14 12:28
2800,95,Shionogi,Regional & Specialty Pharma,2718,Landel ,efonidipine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-95,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1960,hypertension,7/7/14 12:28
2800,95,Shionogi,Regional & Specialty Pharma,2718,Landel ,efonidipine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-95,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1960,hypertension,7/7/14 12:28
2800,95,Shionogi,Regional & Specialty Pharma,2718,Landel ,efonidipine,Small Molecule (Chemical),Launched,Licensed (Development),,Oct-95,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1960,hypertension,7/7/14 12:28
2801,95,Shionogi,Regional & Specialty Pharma,2719,Sular ,nisoldipine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-96,,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2109,hypertension,7/7/14 12:28
2801,95,Shionogi,Regional & Specialty Pharma,2719,Sular ,nisoldipine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-96,,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2109,hypertension,7/7/14 12:28
2801,95,Shionogi,Regional & Specialty Pharma,2719,Sular ,nisoldipine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-96,,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2109,hypertension,7/7/14 12:28
2805,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2199,Miripla,miriplatin,Small Molecule (Chemical),Launched,In-House,,Jan-10,N/A,Mar-24,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,Global,Sales,2.154651938,17.50925072,16.4601585,13.24261473,12.08126669,13.08803892,13.41020603,13.94178175,14.39281571,14.7523542,15.08946986,15.38277079,3.511560548,1987,Hepatocellular Carcinoma,7/7/14 12:28
2805,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2199,Miripla,miriplatin,Small Molecule (Chemical),Launched,In-House,,Jan-10,N/A,Mar-24,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,ROW,Sales,2.154651938,17.50925072,16.4601585,13.24261473,12.08126669,13.08803892,13.41020603,13.94178175,14.39281571,14.7523542,15.08946986,15.38277079,3.511560548,1987,Hepatocellular Carcinoma,7/7/14 12:28
2805,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2199,Miripla,miriplatin,Small Molecule (Chemical),Launched,In-House,,Jan-10,N/A,Mar-24,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1987,Hepatocellular Carcinoma,7/7/14 12:28
2806,37,Eisai,Regional & Specialty Pharma,3843,Treakisym / Symbenda,bendamustine,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-10,N/A,Oct-20,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,Global,Sales,0,9.338267051,40.51731324,42.13559234,41.27766121,47.40890403,51.24621635,54.7225253,57.60344302,59.87901282,61.76713823,63.30918026,6.300649351,1359,Non-Hodgkin's Lymphoma,7/7/14 12:28
2806,37,Eisai,Regional & Specialty Pharma,3843,Treakisym / Symbenda,bendamustine,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-10,N/A,Oct-20,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,9.338267051,40.51731324,42.13559234,41.27766121,47.40890403,51.24621635,54.7225253,57.60344302,59.87901282,61.76713823,63.30918026,6.300649351,1359,Non-Hodgkin's Lymphoma,7/7/14 12:28
2806,37,Eisai,Regional & Specialty Pharma,3843,Treakisym / Symbenda,bendamustine,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-10,N/A,Oct-20,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1359,Non-Hodgkin's Lymphoma,7/7/14 12:28
2810,2430,Symplmed,Regional & Specialty Pharma,2727,Aceon,perindopril,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-99,,Expired,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,334,Hypertension,7/7/14 12:28
2810,2430,Symplmed,Regional & Specialty Pharma,2727,Aceon,perindopril,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-99,,Expired,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,334,Hypertension,7/7/14 12:28
2810,2430,Symplmed,Regional & Specialty Pharma,2727,Aceon,perindopril,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-99,,Expired,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,334,Hypertension,7/7/14 12:28
2812,2221,AbbVie,Large Pharma,2730,Cardizem LA,diltiazem,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-03,,Expired,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,518,Hypertension,7/7/14 12:28
2812,2221,AbbVie,Large Pharma,2730,Cardizem LA,diltiazem,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-03,,Expired,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,518,Hypertension,7/7/14 12:28
2812,2221,AbbVie,Large Pharma,2730,Cardizem LA,diltiazem,Small Molecule (Chemical),Launched,Corporate Acquisition,Mar-03,,Expired,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,518,Hypertension,7/7/14 12:28
2814,1,Abbott,Regional & Specialty Pharma,2732,Omacor,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-01,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,638,Hypertriglyceridemia,7/7/14 12:28
2814,1,Abbott,Regional & Specialty Pharma,2732,Omacor,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-01,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,638,Hypertriglyceridemia,7/7/14 12:28
2814,1,Abbott,Regional & Specialty Pharma,2732,Omacor,omega-3-acid ethyl ester concentrate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-01,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,638,Hypertriglyceridemia,7/7/14 12:28
2815,95,Shionogi,Regional & Specialty Pharma,2733,Ifomide ,ifosfamide,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-85,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1936,,7/7/14 12:28
2815,95,Shionogi,Regional & Specialty Pharma,2733,Ifomide ,ifosfamide,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-85,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1936,,7/7/14 12:28
2815,95,Shionogi,Regional & Specialty Pharma,2733,Ifomide ,ifosfamide,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-85,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1936,,7/7/14 12:28
2816,95,Shionogi,Regional & Specialty Pharma,2734,Aqupla,nedaplatin,Small Molecule (Chemical),Launched,In-House,,Jul-95,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1815,Solid Tumors,7/7/14 12:28
2816,95,Shionogi,Regional & Specialty Pharma,2734,Aqupla,nedaplatin,Small Molecule (Chemical),Launched,In-House,,Jul-95,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1815,Solid Tumors,7/7/14 12:28
2816,95,Shionogi,Regional & Specialty Pharma,2734,Aqupla,nedaplatin,Small Molecule (Chemical),Launched,In-House,,Jul-95,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1815,Solid Tumors,7/7/14 12:28
2817,72,Orion,Regional & Specialty Pharma,2735,Simdax ,levosimendan,Small Molecule (Chemical),Launched,In-House,,Jul-00,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,Global,Sales,40.85125304,52.85771692,61.17922965,56.03782982,61.08938306,62.5395919,63.91952139,64.9002307,65.67056345,66.25397546,66.70161722,67.0434782,1.337481849,2099,Acute Heart Failure,7/7/14 12:28
2817,72,Orion,Regional & Specialty Pharma,2735,Simdax ,levosimendan,Small Molecule (Chemical),Launched,In-House,,Jul-00,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,ROW,Sales,40.85125304,52.85771692,61.17922965,56.03782982,61.08938306,62.5395919,63.91952139,64.9002307,65.67056345,66.25397546,66.70161722,67.0434782,1.337481849,2099,Acute Heart Failure,7/7/14 12:28
2817,72,Orion,Regional & Specialty Pharma,2735,Simdax ,levosimendan,Small Molecule (Chemical),Launched,In-House,,Jul-00,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2099,Acute Heart Failure,7/7/14 12:28
2818,95,Shionogi,Regional & Specialty Pharma,2736,Uromitexan ,mesna,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-94,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2150,Prevention of urothelial toxicity ,7/7/14 12:28
2818,95,Shionogi,Regional & Specialty Pharma,2736,Uromitexan ,mesna,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-94,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2150,Prevention of urothelial toxicity ,7/7/14 12:28
2818,95,Shionogi,Regional & Specialty Pharma,2736,Uromitexan ,mesna,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-94,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2150,Prevention of urothelial toxicity ,7/7/14 12:28
2819,37,Eisai,Regional & Specialty Pharma,2737,Cleactor,monteplase,Small Molecule (Chemical),Launched,In-House,,Jun-98,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1861,,7/7/14 12:28
2819,37,Eisai,Regional & Specialty Pharma,2737,Cleactor,monteplase,Small Molecule (Chemical),Launched,In-House,,Jun-98,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1861,,7/7/14 12:28
2819,37,Eisai,Regional & Specialty Pharma,2737,Cleactor,monteplase,Small Molecule (Chemical),Launched,In-House,,Jun-98,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1861,,7/7/14 12:28
2820,37,Eisai,Regional & Specialty Pharma,2738,Eril ,fasudil,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-06,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1895,Cerebral vasospasm,7/7/14 12:28
2820,37,Eisai,Regional & Specialty Pharma,2738,Eril ,fasudil,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-06,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1895,Cerebral vasospasm,7/7/14 12:28
2820,37,Eisai,Regional & Specialty Pharma,2738,Eril ,fasudil,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-06,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1895,Cerebral vasospasm,7/7/14 12:28
2821,37,Eisai,Regional & Specialty Pharma,2740,Neuquinon ,ubidecarenone,Small Molecule (Chemical),Launched,In-House,,Apr-74,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2003,Heart failure - Chronic ,7/7/14 12:28
2821,37,Eisai,Regional & Specialty Pharma,2740,Neuquinon ,ubidecarenone,Small Molecule (Chemical),Launched,In-House,,Apr-74,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2003,Heart failure - Chronic ,7/7/14 12:28
2821,37,Eisai,Regional & Specialty Pharma,2740,Neuquinon ,ubidecarenone,Small Molecule (Chemical),Launched,In-House,,Apr-74,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2003,Heart failure - Chronic ,7/7/14 12:28
2822,89,Sanofi,Large Pharma,2741,Anandron / Nilandron ,nilutamide,Small Molecule (Chemical),Launched,Acquisition (Marketed),Nov-96,Jul-87,,,107,Anti-androgens,55,Hormonals,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1807,Prostate Cancer,7/7/14 12:28
2822,89,Sanofi,Large Pharma,2741,Anandron / Nilandron ,nilutamide,Small Molecule (Chemical),Launched,Acquisition (Marketed),Nov-96,Jul-87,,,107,Anti-androgens,55,Hormonals,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1807,Prostate Cancer,7/7/14 12:28
2822,89,Sanofi,Large Pharma,2741,Anandron / Nilandron ,nilutamide,Small Molecule (Chemical),Launched,Acquisition (Marketed),Nov-96,Jul-87,,,107,Anti-androgens,55,Hormonals,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1807,Prostate Cancer,7/7/14 12:28
2823,37,Eisai,Regional & Specialty Pharma,2742,Nitorol ,isosorbide dinitrate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-81,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,473,Angina,7/7/14 12:28
2823,37,Eisai,Regional & Specialty Pharma,2742,Nitorol ,isosorbide dinitrate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-81,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,473,Angina,7/7/14 12:28
2823,37,Eisai,Regional & Specialty Pharma,2742,Nitorol ,isosorbide dinitrate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-81,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,473,Angina,7/7/14 12:28
2824,37,Eisai,Regional & Specialty Pharma,2743,Tambocor,flecainide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-91,,,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2116,,7/7/14 12:28
2824,37,Eisai,Regional & Specialty Pharma,2743,Tambocor,flecainide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-91,,,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2116,,7/7/14 12:28
2824,37,Eisai,Regional & Specialty Pharma,2743,Tambocor,flecainide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-91,,,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2116,,7/7/14 12:28
2825,29,Chugai,Regional & Specialty Pharma,118,Inhibace,cilazapril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-90,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,555,,7/7/14 12:28
2825,29,Chugai,Regional & Specialty Pharma,118,Inhibace,cilazapril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-90,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,555,,7/7/14 12:28
2825,29,Chugai,Regional & Specialty Pharma,118,Inhibace,cilazapril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-90,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,555,,7/7/14 12:28
2826,29,Chugai,Regional & Specialty Pharma,2744,Lanirapid ,metildigoxin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-79,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1961,Heart Failure,7/7/14 12:28
2826,29,Chugai,Regional & Specialty Pharma,2744,Lanirapid ,metildigoxin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-79,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1961,Heart Failure,7/7/14 12:28
2826,29,Chugai,Regional & Specialty Pharma,2744,Lanirapid ,metildigoxin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-79,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1961,Heart Failure,7/7/14 12:28
2828,105,UCB,Regional & Specialty Pharma,2746,Lortab,hydrocodone + acetaminophen,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-94,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1971,Pain,7/7/14 12:28
2828,105,UCB,Regional & Specialty Pharma,2746,Lortab,hydrocodone + acetaminophen,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-94,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1971,Pain,7/7/14 12:28
2828,105,UCB,Regional & Specialty Pharma,2746,Lortab,hydrocodone + acetaminophen,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-94,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1971,Pain,7/7/14 12:28
2829,8,Allergan,Regional & Specialty Pharma,3672,senrebotase,AGN-214868 / SXN-100323,Recombinant Protein,Phase II,Licensed (Development),,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2111,Neuropathic pain,7/7/14 12:28
2829,8,Allergan,Regional & Specialty Pharma,3672,senrebotase,AGN-214868 / SXN-100323,Recombinant Protein,Phase II,Licensed (Development),,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2111,Neuropathic pain,7/7/14 12:28
2829,8,Allergan,Regional & Specialty Pharma,3672,senrebotase,AGN-214868 / SXN-100323,Recombinant Protein,Phase II,Licensed (Development),,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2111,Neuropathic pain,7/7/14 12:28
2832,53,Johnson & Johnson,Large Pharma,3436,fulranumab,JNJ-42160443,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1949,Pain,7/7/14 12:28
2832,53,Johnson & Johnson,Large Pharma,3436,fulranumab,JNJ-42160443,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1949,Pain,7/7/14 12:28
2832,53,Johnson & Johnson,Large Pharma,3436,fulranumab,JNJ-42160443,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1949,Pain,7/7/14 12:28
2833,89,Sanofi,Large Pharma,2750,Granocyte,lenograstim,Recombinant Protein,Launched,Corporate Acquisition,,Aug-94,,,118,G-CSFs,78,Neutropenia,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,770,Neutropenia,7/7/14 12:28
2833,89,Sanofi,Large Pharma,2750,Granocyte,lenograstim,Recombinant Protein,Launched,Corporate Acquisition,,Aug-94,,,118,G-CSFs,78,Neutropenia,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,770,Neutropenia,7/7/14 12:28
2833,89,Sanofi,Large Pharma,2750,Granocyte,lenograstim,Recombinant Protein,Launched,Corporate Acquisition,,Aug-94,,,118,G-CSFs,78,Neutropenia,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,770,Neutropenia,7/7/14 12:28
2834,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2751,Inovan / Pre Dopa ,dopamine,Small Molecule (Chemical),Launched,In-House,,Mar-78,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,Global,Sales,35.26780824,34.18576163,35.12113132,30.06765222,24.13538442,23.57411458,23.20235724,23.06835153,22.98111632,22.93366509,22.91065589,22.89769979,-0.749214784,1943,Angina,7/7/14 12:28
2834,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2751,Inovan / Pre Dopa ,dopamine,Small Molecule (Chemical),Launched,In-House,,Mar-78,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,ROW,Sales,35.26780824,34.18576163,35.12113132,30.06765222,24.13538442,23.57411458,23.20235724,23.06835153,22.98111632,22.93366509,22.91065589,22.89769979,-0.749214784,1943,Angina,7/7/14 12:28
2834,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2751,Inovan / Pre Dopa ,dopamine,Small Molecule (Chemical),Launched,In-House,,Mar-78,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1943,Angina,7/7/14 12:28
2835,53,Johnson & Johnson,Large Pharma,2752,Leustatin,cladribine,Small Molecule (Chemical),Launched,Licensed (Development),Mar-93,,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1966,Hematological malignancies,7/7/14 12:28
2835,53,Johnson & Johnson,Large Pharma,2752,Leustatin,cladribine,Small Molecule (Chemical),Launched,Licensed (Development),Mar-93,,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1966,Hematological malignancies,7/7/14 12:28
2835,53,Johnson & Johnson,Large Pharma,2752,Leustatin,cladribine,Small Molecule (Chemical),Launched,Licensed (Development),Mar-93,,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1966,Hematological malignancies,7/7/14 12:28
2836,89,Sanofi,Large Pharma,2753,Suprefact ,buserelin,Recombinant Protein,Launched,Corporate Acquisition,,Feb-84,,,33,LHRH Analogs,55,Hormonals,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2110,Prostate Cancer,7/7/14 12:28
2836,89,Sanofi,Large Pharma,2753,Suprefact ,buserelin,Recombinant Protein,Launched,Corporate Acquisition,,Feb-84,,,33,LHRH Analogs,55,Hormonals,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2110,Prostate Cancer,7/7/14 12:28
2836,89,Sanofi,Large Pharma,2753,Suprefact ,buserelin,Recombinant Protein,Launched,Corporate Acquisition,,Feb-84,,,33,LHRH Analogs,55,Hormonals,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2110,Prostate Cancer,7/7/14 12:28
2837,53,Johnson & Johnson,Large Pharma,910,Yondelis,trabectedin,Small Molecule (Chemical),Launched,Licensed (Development),,May-08,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1291,Sarcoma,7/7/14 12:28
2837,53,Johnson & Johnson,Large Pharma,910,Yondelis,trabectedin,Small Molecule (Chemical),Launched,Licensed (Development),,May-08,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1291,Sarcoma,7/7/14 12:28
2837,53,Johnson & Johnson,Large Pharma,910,Yondelis,trabectedin,Small Molecule (Chemical),Launched,Licensed (Development),,May-08,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1291,Sarcoma,7/7/14 12:28
2838,89,Sanofi,Large Pharma,2754,Anzemet,dolasetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-98,Jul-97,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1812,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
2838,89,Sanofi,Large Pharma,2754,Anzemet,dolasetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-98,Jul-97,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1812,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
2838,89,Sanofi,Large Pharma,2754,Anzemet,dolasetron,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-98,Jul-97,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1812,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
2839,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2755,Activacin,alteplase,Recombinant Protein,Launched,Licensed (Marketed),,May-91,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,69,,7/7/14 12:28
2839,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2755,Activacin,alteplase,Recombinant Protein,Launched,Licensed (Marketed),,May-91,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,69,,7/7/14 12:28
2839,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2755,Activacin,alteplase,Recombinant Protein,Launched,Licensed (Marketed),,May-91,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,69,,7/7/14 12:28
2841,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2757,Leukoprol,mirimostim,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jul-91,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1965,Granulocytopenia,7/7/14 12:28
2841,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2757,Leukoprol,mirimostim,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jul-91,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1965,Granulocytopenia,7/7/14 12:28
2841,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2757,Leukoprol,mirimostim,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jul-91,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1965,Granulocytopenia,7/7/14 12:28
2843,23,Boehringer Ingelheim,Large Pharma,2759,Acardi ,pimobendan,Small Molecule (Chemical),Launched,In-House,,Jul-94,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1784,Heart Failure,7/7/14 12:28
2843,23,Boehringer Ingelheim,Large Pharma,2759,Acardi ,pimobendan,Small Molecule (Chemical),Launched,In-House,,Jul-94,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1784,Heart Failure,7/7/14 12:28
2843,23,Boehringer Ingelheim,Large Pharma,2759,Acardi ,pimobendan,Small Molecule (Chemical),Launched,In-House,,Jul-94,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1784,Heart Failure,7/7/14 12:28
2844,23,Boehringer Ingelheim,Large Pharma,2760,Mexitil ,mexiletine,Small Molecule (Chemical),Launched,In-House,Mar-86,Jul-84,Expired,Expired,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1984,arrhythmias ,7/7/14 12:28
2844,23,Boehringer Ingelheim,Large Pharma,2760,Mexitil ,mexiletine,Small Molecule (Chemical),Launched,In-House,Mar-86,Jul-84,Expired,Expired,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1984,arrhythmias ,7/7/14 12:28
2844,23,Boehringer Ingelheim,Large Pharma,2760,Mexitil ,mexiletine,Small Molecule (Chemical),Launched,In-House,Mar-86,Jul-84,Expired,Expired,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1984,arrhythmias ,7/7/14 12:28
2845,23,Boehringer Ingelheim,Large Pharma,2762,Motens / Caldine ,lacidipine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-93,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1767,hypertension,7/7/14 12:28
2845,23,Boehringer Ingelheim,Large Pharma,2762,Motens / Caldine ,lacidipine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-93,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1767,hypertension,7/7/14 12:28
2845,23,Boehringer Ingelheim,Large Pharma,2762,Motens / Caldine ,lacidipine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-93,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1767,hypertension,7/7/14 12:28
2846,70,Ono,Regional & Specialty Pharma,2763,Cataclot ,ozagrel hydrochloride,Small Molecule (Chemical),Launched,In-House,,Jul-88,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1852,acute cerebral thrombosis,7/7/14 12:28
2846,70,Ono,Regional & Specialty Pharma,2763,Cataclot ,ozagrel hydrochloride,Small Molecule (Chemical),Launched,In-House,,Jul-88,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1852,acute cerebral thrombosis,7/7/14 12:28
2846,70,Ono,Regional & Specialty Pharma,2763,Cataclot ,ozagrel hydrochloride,Small Molecule (Chemical),Launched,In-House,,Jul-88,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1852,acute cerebral thrombosis,7/7/14 12:28
2847,70,Ono,Regional & Specialty Pharma,2764,Onoact ,landiolol hydrochloride,Small Molecule (Chemical),Launched,In-House,,Sep-02,N/A,Dec-15,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,Global,Sales,33.39710505,42.02220173,41.78347928,44.54334047,45.3047501,50.37888205,54.07624091,49.14714484,46.92912804,45.41280592,43.51885071,41.75483453,-1.158897623,2015,Tachycardia,7/7/14 12:28
2847,70,Ono,Regional & Specialty Pharma,2764,Onoact ,landiolol hydrochloride,Small Molecule (Chemical),Launched,In-House,,Sep-02,N/A,Dec-15,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,33.39710505,42.02220173,41.78347928,44.54334047,45.3047501,50.37888205,54.07624091,49.14714484,46.92912804,45.41280592,43.51885071,41.75483453,-1.158897623,2015,Tachycardia,7/7/14 12:28
2847,70,Ono,Regional & Specialty Pharma,2764,Onoact ,landiolol hydrochloride,Small Molecule (Chemical),Launched,In-House,,Sep-02,N/A,Dec-15,22,Beta-blockers,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2015,Tachycardia,7/7/14 12:28
2848,89,Sanofi,Large Pharma,3997,Insuman,Human insulins,Recombinant Protein,Launched,In-House,Jul-97,Jul-97,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,2,Global,Sales,182.0242907,176.1923897,183.537689,173.511629,175.2999688,174.4500296,173.7913267,172.6864057,171.9503583,171.2853658,170.6659301,170.1407901,-0.425838053,1944,Diabetes,7/7/14 12:28
2848,89,Sanofi,Large Pharma,3997,Insuman,Human insulins,Recombinant Protein,Launched,In-House,Jul-97,Jul-97,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,2,ROW,Sales,182.0242907,176.1923897,183.537689,173.511629,175.2999688,174.4500296,173.7913267,172.6864057,171.9503583,171.2853658,170.6659301,170.1407901,-0.425838053,1944,Diabetes,7/7/14 12:28
2848,89,Sanofi,Large Pharma,3997,Insuman,Human insulins,Recombinant Protein,Launched,In-House,Jul-97,Jul-97,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1944,Diabetes,7/7/14 12:28
2849,196,Generex,Small Biotech,2765,Oral-lyn,buccal insulin,Recombinant Protein,Launched,In-House,,Dec-05,,,83,Insulins,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2020,Type II Diabetes,7/7/14 12:28
2849,196,Generex,Small Biotech,2765,Oral-lyn,buccal insulin,Recombinant Protein,Launched,In-House,,Dec-05,,,83,Insulins,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2020,Type II Diabetes,7/7/14 12:28
2849,196,Generex,Small Biotech,2765,Oral-lyn,buccal insulin,Recombinant Protein,Launched,In-House,,Dec-05,,,83,Insulins,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2020,Type II Diabetes,7/7/14 12:28
2850,15,Astellas Pharma,Regional & Specialty Pharma,2766,Milrila ,milrinone,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-96,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1986,Heart failure - Acute,7/7/14 12:28
2850,15,Astellas Pharma,Regional & Specialty Pharma,2766,Milrila ,milrinone,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-96,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1986,Heart failure - Acute,7/7/14 12:28
2850,15,Astellas Pharma,Regional & Specialty Pharma,2766,Milrila ,milrinone,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-96,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1986,Heart failure - Acute,7/7/14 12:28
2851,96,Shire,Regional & Specialty Pharma,3323,SHP609,idursulfase-IT,Recombinant Protein,Phase II,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1930,CNS Hunter Syndrome,7/7/14 12:28
2851,96,Shire,Regional & Specialty Pharma,3323,SHP609,idursulfase-IT,Recombinant Protein,Phase II,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1930,CNS Hunter Syndrome,7/7/14 12:28
2851,96,Shire,Regional & Specialty Pharma,3323,SHP609,idursulfase-IT,Recombinant Protein,Phase II,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1930,CNS Hunter Syndrome,7/7/14 12:28
2852,15,Astellas Pharma,Regional & Specialty Pharma,2768,Hypoca ,barnidipine,Small Molecule (Chemical),Launched,In-House,,Sep-92,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1932,Hypertension,7/7/14 12:28
2852,15,Astellas Pharma,Regional & Specialty Pharma,2768,Hypoca ,barnidipine,Small Molecule (Chemical),Launched,In-House,,Sep-92,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1932,Hypertension,7/7/14 12:28
2852,15,Astellas Pharma,Regional & Specialty Pharma,2768,Hypoca ,barnidipine,Small Molecule (Chemical),Launched,In-House,,Sep-92,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1932,Hypertension,7/7/14 12:28
2853,15,Astellas Pharma,Regional & Specialty Pharma,2769,Nivadil,nilvadipine,Small Molecule (Chemical),Launched,,,Apr-89,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2007,,7/7/14 12:28
2853,15,Astellas Pharma,Regional & Specialty Pharma,2769,Nivadil,nilvadipine,Small Molecule (Chemical),Launched,,,Apr-89,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2007,,7/7/14 12:28
2853,15,Astellas Pharma,Regional & Specialty Pharma,2769,Nivadil,nilvadipine,Small Molecule (Chemical),Launched,,,Apr-89,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2007,,7/7/14 12:28
2854,76,Pfizer,Large Pharma,2770,Neumega,oprelvekin,Recombinant Protein,Launched,Corporate Acquisition,Oct-97,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2002,Thrombocytopenia,7/7/14 12:28
2854,76,Pfizer,Large Pharma,2770,Neumega,oprelvekin,Recombinant Protein,Launched,Corporate Acquisition,Oct-97,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2002,Thrombocytopenia,7/7/14 12:28
2854,76,Pfizer,Large Pharma,2770,Neumega,oprelvekin,Recombinant Protein,Launched,Corporate Acquisition,Oct-97,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2002,Thrombocytopenia,7/7/14 12:28
2855,15,Astellas Pharma,Regional & Specialty Pharma,2771,Vaprisol ,conivaptan,Small Molecule (Chemical),Launched,In-House,May-06,,Dec-21,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,10.77325969,17.28292012,8.875977238,8.2060105,7.966427805,8.05084024,8.07967183,8.083666605,8.084562819,8.084714412,8.084744464,8.0847499,0.21084134,2153,Hyponatremia,7/7/14 12:28
2855,15,Astellas Pharma,Regional & Specialty Pharma,2771,Vaprisol ,conivaptan,Small Molecule (Chemical),Launched,In-House,May-06,,Dec-21,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2153,Hyponatremia,7/7/14 12:28
2855,15,Astellas Pharma,Regional & Specialty Pharma,2771,Vaprisol ,conivaptan,Small Molecule (Chemical),Launched,In-House,May-06,,Dec-21,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,10.77325969,17.28292012,8.875977238,8.2060105,7.966427805,8.05084024,8.07967183,8.083666605,8.084562819,8.084714412,8.084744464,8.0847499,0.21084134,2153,Hyponatremia,7/7/14 12:28
2856,100,Takeda,Large Pharma,2772,Adecut ,delapril,Small Molecule (Chemical),Launched,In-House,,Apr-89,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1788,Hypertension,7/7/14 12:28
2856,100,Takeda,Large Pharma,2772,Adecut ,delapril,Small Molecule (Chemical),Launched,In-House,,Apr-89,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1788,Hypertension,7/7/14 12:28
2856,100,Takeda,Large Pharma,2772,Adecut ,delapril,Small Molecule (Chemical),Launched,In-House,,Apr-89,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1788,Hypertension,7/7/14 12:28
2857,100,Takeda,Large Pharma,3228,Calslot ,manidipine,Small Molecule (Chemical),Launched,In-House,,Sep-90,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1851,Hypertension,7/7/14 12:28
2857,100,Takeda,Large Pharma,3228,Calslot ,manidipine,Small Molecule (Chemical),Launched,In-House,,Sep-90,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1851,Hypertension,7/7/14 12:28
2857,100,Takeda,Large Pharma,3228,Calslot ,manidipine,Small Molecule (Chemical),Launched,In-House,,Sep-90,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1851,Hypertension,7/7/14 12:28
2859,37,Eisai,Regional & Specialty Pharma,2775,Glucagon G,glucagon,Recombinant Protein,Launched,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1922,Hypoglycemia,7/7/14 12:28
2859,37,Eisai,Regional & Specialty Pharma,2775,Glucagon G,glucagon,Recombinant Protein,Launched,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1922,Hypoglycemia,7/7/14 12:28
2859,37,Eisai,Regional & Specialty Pharma,2775,Glucagon G,glucagon,Recombinant Protein,Launched,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1922,Hypoglycemia,7/7/14 12:28
2860,68,Novo Nordisk,Regional & Specialty Pharma,2776,Glucagon Novo / GlucaGen,glucagon,Recombinant Protein,Launched,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1922,Hypoglycemia,7/7/14 12:28
2860,68,Novo Nordisk,Regional & Specialty Pharma,2776,Glucagon Novo / GlucaGen,glucagon,Recombinant Protein,Launched,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1922,Hypoglycemia,7/7/14 12:28
2860,68,Novo Nordisk,Regional & Specialty Pharma,2776,Glucagon Novo / GlucaGen,glucagon,Recombinant Protein,Launched,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1922,Hypoglycemia,7/7/14 12:28
2861,67,Novartis,Large Pharma,2777,Starlix,nateglinide,Small Molecule (Chemical),Launched,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1560,Type II Diabetes,7/7/14 12:28
2861,67,Novartis,Large Pharma,2777,Starlix,nateglinide,Small Molecule (Chemical),Launched,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1560,Type II Diabetes,7/7/14 12:28
2861,67,Novartis,Large Pharma,2777,Starlix,nateglinide,Small Molecule (Chemical),Launched,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1560,Type II Diabetes,7/7/14 12:28
2864,42,Forest,Regional & Specialty Pharma,2779,Armour Thyroid,thyroid tablets,Small Molecule (Chemical),Launched,Licensed (Development),,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1818,Hypothyroidism,7/7/14 12:28
2864,42,Forest,Regional & Specialty Pharma,2779,Armour Thyroid,thyroid tablets,Small Molecule (Chemical),Launched,Licensed (Development),,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1818,Hypothyroidism,7/7/14 12:28
2864,42,Forest,Regional & Specialty Pharma,2779,Armour Thyroid,thyroid tablets,Small Molecule (Chemical),Launched,Licensed (Development),,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1818,Hypothyroidism,7/7/14 12:28
2865,63,Merck KGaA,Regional & Specialty Pharma,2780,Corticosteroids,Corticosteroids,Small Molecule (Chemical),Launched,In-House,,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1868,Steroid Hormone Replacement Therapy,7/7/14 12:28
2865,63,Merck KGaA,Regional & Specialty Pharma,2780,Corticosteroids,Corticosteroids,Small Molecule (Chemical),Launched,In-House,,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1868,Steroid Hormone Replacement Therapy,7/7/14 12:28
2865,63,Merck KGaA,Regional & Specialty Pharma,2780,Corticosteroids,Corticosteroids,Small Molecule (Chemical),Launched,In-House,,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1868,Steroid Hormone Replacement Therapy,7/7/14 12:28
2866,76,Pfizer,Large Pharma,2781,Cytomel,liothyronine,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1768,Hypothyroidism,7/7/14 12:28
2866,76,Pfizer,Large Pharma,2781,Cytomel,liothyronine,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1768,Hypothyroidism,7/7/14 12:28
2866,76,Pfizer,Large Pharma,2781,Cytomel,liothyronine,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1768,Hypothyroidism,7/7/14 12:28
2867,76,Pfizer,Large Pharma,2782,Lopid ,gemfibrozil,Small Molecule (Chemical),Launched,In-House,Feb-82,,,,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1969,,7/7/14 12:28
2867,76,Pfizer,Large Pharma,2782,Lopid ,gemfibrozil,Small Molecule (Chemical),Launched,In-House,Feb-82,,,,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1969,,7/7/14 12:28
2867,76,Pfizer,Large Pharma,2782,Lopid ,gemfibrozil,Small Molecule (Chemical),Launched,In-House,Feb-82,,,,14,Fibrates,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1969,,7/7/14 12:28
2868,42,Forest,Regional & Specialty Pharma,2783,Levothroid,levothyroxine,Small Molecule (Chemical),Launched,In-House,,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1525,Hypothyroidism,7/7/14 12:28
2868,42,Forest,Regional & Specialty Pharma,2783,Levothroid,levothyroxine,Small Molecule (Chemical),Launched,In-House,,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1525,Hypothyroidism,7/7/14 12:28
2868,42,Forest,Regional & Specialty Pharma,2783,Levothroid,levothyroxine,Small Molecule (Chemical),Launched,In-House,,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1525,Hypothyroidism,7/7/14 12:28
2869,76,Pfizer,Large Pharma,2784,Tapazole,methimazole,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2119,Hyperthyroidism,7/7/14 12:28
2869,76,Pfizer,Large Pharma,2784,Tapazole,methimazole,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2119,Hyperthyroidism,7/7/14 12:28
2869,76,Pfizer,Large Pharma,2784,Tapazole,methimazole,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2119,Hyperthyroidism,7/7/14 12:28
2870,42,Forest,Regional & Specialty Pharma,2785,Thyrolar,liothyronine,Small Molecule (Chemical),Launched,In-House,,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1768,Hypothyroidism,7/7/14 12:28
2870,42,Forest,Regional & Specialty Pharma,2785,Thyrolar,liothyronine,Small Molecule (Chemical),Launched,In-House,,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1768,Hypothyroidism,7/7/14 12:28
2870,42,Forest,Regional & Specialty Pharma,2785,Thyrolar,liothyronine,Small Molecule (Chemical),Launched,In-House,,,,,153,Thyroid Disorder Treatments,66,Thyroid Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1768,Hypothyroidism,7/7/14 12:28
2872,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2787,Rocaltrol,calcitriol,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2169,Bone Disease in Secondary Hyperparathyroidism,7/7/14 12:28
2872,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2787,Rocaltrol,calcitriol,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2169,Bone Disease in Secondary Hyperparathyroidism,7/7/14 12:28
2872,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2787,Rocaltrol,calcitriol,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2169,Bone Disease in Secondary Hyperparathyroidism,7/7/14 12:28
2872,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2787,Rocaltrol,calcitriol,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2169,Bone Disease in Secondary Hyperparathyroidism,7/7/14 12:28
2872,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2787,Rocaltrol,calcitriol,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2169,Bone Disease in Secondary Hyperparathyroidism,7/7/14 12:28
2872,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2787,Rocaltrol,calcitriol,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2169,Bone Disease in Secondary Hyperparathyroidism,7/7/14 12:28
2874,76,Pfizer,Large Pharma,55,Cordarone ,amiodarone,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-86,,,,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,331,,7/7/14 12:28
2874,76,Pfizer,Large Pharma,55,Cordarone ,amiodarone,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-86,,,,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,331,,7/7/14 12:28
2874,76,Pfizer,Large Pharma,55,Cordarone ,amiodarone,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-86,,,,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,331,,7/7/14 12:28
2875,29,Chugai,Regional & Specialty Pharma,2789,Euglucon,glibenclamide,Small Molecule (Chemical),Launched,In-House,,,,,10,Sulphonylureas,22,Diabetes,8,Metabolism,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1900,Type II Diabetes,7/7/14 12:28
2875,29,Chugai,Regional & Specialty Pharma,2789,Euglucon,glibenclamide,Small Molecule (Chemical),Launched,In-House,,,,,10,Sulphonylureas,22,Diabetes,8,Metabolism,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1900,Type II Diabetes,7/7/14 12:28
2875,29,Chugai,Regional & Specialty Pharma,2789,Euglucon,glibenclamide,Small Molecule (Chemical),Launched,In-House,,,,,10,Sulphonylureas,22,Diabetes,8,Metabolism,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1900,Type II Diabetes,7/7/14 12:28
2876,76,Pfizer,Large Pharma,2790,Aldactone,spironolactone,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-62,Jul-62,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1798,,7/7/14 12:28
2876,76,Pfizer,Large Pharma,2790,Aldactone,spironolactone,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-62,Jul-62,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1798,,7/7/14 12:28
2876,76,Pfizer,Large Pharma,2790,Aldactone,spironolactone,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-62,Jul-62,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1798,,7/7/14 12:28
2877,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2791,Glimicron,gliclazide,Small Molecule (Chemical),Launched,In-House,,,,,10,Sulphonylureas,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1921,Type II Diabetes,7/7/14 12:28
2877,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2791,Glimicron,gliclazide,Small Molecule (Chemical),Launched,In-House,,,,,10,Sulphonylureas,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1921,Type II Diabetes,7/7/14 12:28
2877,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2791,Glimicron,gliclazide,Small Molecule (Chemical),Launched,In-House,,,,,10,Sulphonylureas,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1921,Type II Diabetes,7/7/14 12:28
2878,76,Pfizer,Large Pharma,2792,Glucotrol / Glucotrol XL,glipizide,Small Molecule (Chemical),Launched,In-House,,,,,10,Sulphonylureas,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1924,Type II Diabetes,7/7/14 12:28
2878,76,Pfizer,Large Pharma,2792,Glucotrol / Glucotrol XL,glipizide,Small Molecule (Chemical),Launched,In-House,,,,,10,Sulphonylureas,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1924,Type II Diabetes,7/7/14 12:28
2878,76,Pfizer,Large Pharma,2792,Glucotrol / Glucotrol XL,glipizide,Small Molecule (Chemical),Launched,In-House,,,,,10,Sulphonylureas,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1924,Type II Diabetes,7/7/14 12:28
2879,716,JCR Pharmaceuticals,Small Biotech,2793,Growject,somatropin,Recombinant Protein,Launched,In-House,,Jan-99,N/A,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,7,Global,Sales,91.56193412,98.34362488,106.3073006,106.3566758,110.7449447,120.4783621,130.3104489,140.0675117,147.8873845,154.9301625,161.1851733,166.628624,6.00991904,1926,Growth Hormone Disorders,7/7/14 12:28
2879,716,JCR Pharmaceuticals,Small Biotech,2793,Growject,somatropin,Recombinant Protein,Launched,In-House,,Jan-99,N/A,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,7,ROW,Sales,91.56193412,98.34362488,106.3073006,106.3566758,110.7449447,120.4783621,130.3104489,140.0675117,147.8873845,154.9301625,161.1851733,166.628624,6.00991904,1926,Growth Hormone Disorders,7/7/14 12:28
2879,716,JCR Pharmaceuticals,Small Biotech,2793,Growject,somatropin,Recombinant Protein,Launched,In-House,,Jan-99,N/A,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1926,Growth Hormone Disorders,7/7/14 12:28
2880,51,Ipsen,Regional & Specialty Pharma,2794,Increlex,mecasermin,Recombinant Protein,Launched,Corporate Acquisition,Jan-06,Oct-07,N/A,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,Global,Sales,29.17946646,34.57610054,34.76092594,34.70232581,16.60037583,27.8886314,38.51287193,41.75326529,42.49696213,43.8249922,46.08264331,48.31240579,16.4869255,1939,Severe Primary IGF-1 Deficiency,7/7/14 12:28
2880,51,Ipsen,Regional & Specialty Pharma,2794,Increlex,mecasermin,Recombinant Protein,Launched,Corporate Acquisition,Jan-06,Oct-07,N/A,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,ROW,Sales,11.11598722,13.38002358,15.29480741,15.42325591,6.640150333,14.60833073,19.920451,21.8328143,21.24848107,21.24848107,22.57651113,23.9045412,20.08028399,1939,Severe Primary IGF-1 Deficiency,7/7/14 12:28
2880,51,Ipsen,Regional & Specialty Pharma,2794,Increlex,mecasermin,Recombinant Protein,Launched,Corporate Acquisition,Jan-06,Oct-07,N/A,N/A,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,US,Sales,18.06347923,21.19607696,19.46611853,19.27906989,9.9602255,13.28030067,18.59242093,19.920451,21.24848107,22.57651113,23.50613218,24.40786459,13.66024912,1939,Severe Primary IGF-1 Deficiency,7/7/14 12:28
2883,89,Sanofi,Large Pharma,2796,Panaldine / Ticlid ,ticlopidine,Small Molecule (Chemical),Launched,In-House,,Jul-78,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,839,,7/7/14 12:28
2883,89,Sanofi,Large Pharma,2796,Panaldine / Ticlid ,ticlopidine,Small Molecule (Chemical),Launched,In-House,,Jul-78,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,839,,7/7/14 12:28
2883,89,Sanofi,Large Pharma,2796,Panaldine / Ticlid ,ticlopidine,Small Molecule (Chemical),Launched,In-House,,Jul-78,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,839,,7/7/14 12:28
2884,2221,AbbVie,Large Pharma,2797,elagolix,elagolix,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-17,Oct-17,Jul-24,Jul-24,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,6.3,22.05,40.949937,70.87492246,0,1890,Endometriosis,7/7/14 12:28
2884,2221,AbbVie,Large Pharma,2797,elagolix,elagolix,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-17,Oct-17,Jul-24,Jul-24,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,3.5,12.25,22.749965,39.37495692,0,1890,Endometriosis,7/7/14 12:28
2884,2221,AbbVie,Large Pharma,2797,elagolix,elagolix,Small Molecule (Chemical),Phase III,Licensed (Development),Oct-17,Oct-17,Jul-24,Jul-24,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,2.8,9.8,18.199972,31.49996554,0,1890,Endometriosis,7/7/14 12:28
2886,100,Takeda,Large Pharma,2800,Osten,ipriflavone,Small Molecule (Chemical),Launched,In-House,,Jul-88,,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2021,Osteoporosis,7/7/14 12:28
2886,100,Takeda,Large Pharma,2800,Osten,ipriflavone,Small Molecule (Chemical),Launched,In-House,,Jul-88,,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2021,Osteoporosis,7/7/14 12:28
2886,100,Takeda,Large Pharma,2800,Osten,ipriflavone,Small Molecule (Chemical),Launched,In-House,,Jul-88,,Expired,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2021,Osteoporosis,7/7/14 12:28
2887,46,GlaxoSmithKline,Large Pharma,2802,Streptococcus pneumoniae vaccine ,Streptococcus pneumoniae vaccine,Vaccine,Phase II,Corporate Acquisition,,,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2108,Pneumococcus,7/7/14 12:28
2887,46,GlaxoSmithKline,Large Pharma,2802,Streptococcus pneumoniae vaccine ,Streptococcus pneumoniae vaccine,Vaccine,Phase II,Corporate Acquisition,,,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2108,Pneumococcus,7/7/14 12:28
2887,46,GlaxoSmithKline,Large Pharma,2802,Streptococcus pneumoniae vaccine ,Streptococcus pneumoniae vaccine,Vaccine,Phase II,Corporate Acquisition,,,N/A,N/A,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2108,Pneumococcus,7/7/14 12:28
2888,86,Roche,Large Pharma,2787,Rocaltrol,calcitriol,Small Molecule (Chemical),Launched,In-House,Jul-78,Jul-86,Expired,Expired,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2169,Bone Disease in Secondary Hyperparathyroidism,7/7/14 12:28
2888,86,Roche,Large Pharma,2787,Rocaltrol,calcitriol,Small Molecule (Chemical),Launched,In-House,Jul-78,Jul-86,Expired,Expired,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2169,Bone Disease in Secondary Hyperparathyroidism,7/7/14 12:28
2888,86,Roche,Large Pharma,2787,Rocaltrol,calcitriol,Small Molecule (Chemical),Launched,In-House,Jul-78,Jul-86,Expired,Expired,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2169,Bone Disease in Secondary Hyperparathyroidism,7/7/14 12:28
2889,29,Chugai,Regional & Specialty Pharma,2787,Rocaltrol,calcitriol,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-86,,Expired,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2169,Bone Disease in Secondary Hyperparathyroidism,7/7/14 12:28
2889,29,Chugai,Regional & Specialty Pharma,2787,Rocaltrol,calcitriol,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-86,,Expired,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2169,Bone Disease in Secondary Hyperparathyroidism,7/7/14 12:28
2889,29,Chugai,Regional & Specialty Pharma,2787,Rocaltrol,calcitriol,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-86,,Expired,154,Parathyroid Disorder Treatments,67,Parathyroid Disorders,8,Metabolism,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2169,Bone Disease in Secondary Hyperparathyroidism,7/7/14 12:28
2890,111,Actavis,Regional & Specialty Pharma,3085,Ella,ulipristal acetate,Small Molecule (Chemical),Launched,Licensed (Development),Dec-10,Nov-14,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,1,7.66667,12,16.6452,22.3099464,30.59706776,36.3546617,43.25237492,47.93840766,51.79336616,55.07513613,18.64187619,1893,Emergency contraception,7/7/14 12:28
2890,111,Actavis,Regional & Specialty Pharma,3085,Ella,ulipristal acetate,Small Molecule (Chemical),Launched,Licensed (Development),Dec-10,Nov-14,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,1.7,6.593042,9.298233063,13.52604665,15.86849016,17.65685259,19.12233878,0,1893,Emergency contraception,7/7/14 12:28
2890,111,Actavis,Regional & Specialty Pharma,3085,Ella,ulipristal acetate,Small Molecule (Chemical),Launched,Licensed (Development),Dec-10,Nov-14,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,1,7.66667,12,16.6452,20.6099464,24.00402576,27.05642864,29.72632826,32.0699175,34.13651357,35.95279735,11.62915036,1893,Emergency contraception,7/7/14 12:28
2891,86,Roche,Large Pharma,3253,Naprosyn,naproxen,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-72,,Expired,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1996,Pain,7/7/14 12:28
2891,86,Roche,Large Pharma,3253,Naprosyn,naproxen,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-72,,Expired,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1996,Pain,7/7/14 12:28
2891,86,Roche,Large Pharma,3253,Naprosyn,naproxen,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-72,,Expired,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1996,Pain,7/7/14 12:28
2892,86,Roche,Large Pharma,2807,Toradol,ketorolac ,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-90,,Expired,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2135,Pain,7/7/14 12:28
2892,86,Roche,Large Pharma,2807,Toradol,ketorolac ,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-90,,Expired,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2135,Pain,7/7/14 12:28
2892,86,Roche,Large Pharma,2807,Toradol,ketorolac ,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-90,,Expired,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2135,Pain,7/7/14 12:28
2893,111,Actavis,Regional & Specialty Pharma,2808,Fiorinal,aspirin+butalbital+caffeine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-63,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1908,Pain,7/7/14 12:28
2893,111,Actavis,Regional & Specialty Pharma,2808,Fiorinal,aspirin+butalbital+caffeine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-63,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1908,Pain,7/7/14 12:28
2893,111,Actavis,Regional & Specialty Pharma,2808,Fiorinal,aspirin+butalbital+caffeine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-63,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1908,Pain,7/7/14 12:28
2894,111,Actavis,Regional & Specialty Pharma,2809,Fioricet,acetaminophen+butalbital+caffeine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Feb-85,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1907,Pain,7/7/14 12:28
2894,111,Actavis,Regional & Specialty Pharma,2809,Fioricet,acetaminophen+butalbital+caffeine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Feb-85,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1907,Pain,7/7/14 12:28
2894,111,Actavis,Regional & Specialty Pharma,2809,Fioricet,acetaminophen+butalbital+caffeine,Small Molecule (Chemical),Launched,Acquisition (Marketed),Feb-85,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1907,Pain,7/7/14 12:28
2895,63,Merck KGaA,Regional & Specialty Pharma,2435,UFT,tegafur + uracil,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Nov-98,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1220,Colon Cancer,7/7/14 12:28
2895,63,Merck KGaA,Regional & Specialty Pharma,2435,UFT,tegafur + uracil,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Nov-98,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1220,Colon Cancer,7/7/14 12:28
2895,63,Merck KGaA,Regional & Specialty Pharma,2435,UFT,tegafur + uracil,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Nov-98,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1220,Colon Cancer,7/7/14 12:28
2896,67,Novartis,Large Pharma,2811,Navoban,tropisetron,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-93,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2000,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
2896,67,Novartis,Large Pharma,2811,Navoban,tropisetron,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-93,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2000,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
2896,67,Novartis,Large Pharma,2811,Navoban,tropisetron,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-93,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2000,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
2897,67,Novartis,Large Pharma,2812,Proleukin,aldesleukin,Recombinant Protein,Launched,Corporate Acquisition,,Jul-89,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2074,Cancer,7/7/14 12:28
2897,67,Novartis,Large Pharma,2812,Proleukin,aldesleukin,Recombinant Protein,Launched,Corporate Acquisition,,Jul-89,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2074,Cancer,7/7/14 12:28
2897,67,Novartis,Large Pharma,2812,Proleukin,aldesleukin,Recombinant Protein,Launched,Corporate Acquisition,,Jul-89,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2074,Cancer,7/7/14 12:28
2898,61,Merck & Co,Large Pharma,2813,Leucomax,molgramostim,Recombinant Protein,Launched,Corporate Acquisition,,Jul-92,,,118,G-CSFs,78,Neutropenia,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1964,Neutropenia,7/7/14 12:28
2898,61,Merck & Co,Large Pharma,2813,Leucomax,molgramostim,Recombinant Protein,Launched,Corporate Acquisition,,Jul-92,,,118,G-CSFs,78,Neutropenia,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1964,Neutropenia,7/7/14 12:28
2898,61,Merck & Co,Large Pharma,2813,Leucomax,molgramostim,Recombinant Protein,Launched,Corporate Acquisition,,Jul-92,,,118,G-CSFs,78,Neutropenia,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1964,Neutropenia,7/7/14 12:28
2900,61,Merck & Co,Large Pharma,2817,Fareston,toremifene,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-96,,,53,Anti-estrogens,55,Hormonals,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1903,Breast Cancer,7/7/14 12:28
2900,61,Merck & Co,Large Pharma,2817,Fareston,toremifene,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-96,,,53,Anti-estrogens,55,Hormonals,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1903,Breast Cancer,7/7/14 12:28
2900,61,Merck & Co,Large Pharma,2817,Fareston,toremifene,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-96,,,53,Anti-estrogens,55,Hormonals,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1903,Breast Cancer,7/7/14 12:28
2902,67,Novartis,Large Pharma,2820,Desferal,deferoxamine mesylate,Small Molecule (Chemical),Launched,In-House,Jan-68,Jul-62,,,56,Iron Chelators,59,Iron Overload,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1878,Iron Overload,7/7/14 12:28
2902,67,Novartis,Large Pharma,2820,Desferal,deferoxamine mesylate,Small Molecule (Chemical),Launched,In-House,Jan-68,Jul-62,,,56,Iron Chelators,59,Iron Overload,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1878,Iron Overload,7/7/14 12:28
2902,67,Novartis,Large Pharma,2820,Desferal,deferoxamine mesylate,Small Molecule (Chemical),Launched,In-House,Jan-68,Jul-62,,,56,Iron Chelators,59,Iron Overload,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1878,Iron Overload,7/7/14 12:28
2903,61,Merck & Co,Large Pharma,2821,Prinivil ,lisinopril,Small Molecule (Chemical),Launched,In-House,Dec-87,Nov-87,Expired,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1302,,7/7/14 12:28
2903,61,Merck & Co,Large Pharma,2821,Prinivil ,lisinopril,Small Molecule (Chemical),Launched,In-House,Dec-87,Nov-87,Expired,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1302,,7/7/14 12:28
2903,61,Merck & Co,Large Pharma,2821,Prinivil ,lisinopril,Small Molecule (Chemical),Launched,In-House,Dec-87,Nov-87,Expired,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1302,,7/7/14 12:28
2904,61,Merck & Co,Large Pharma,2822,Nitro-Dur,nitroglycerin patch ,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-85,Apr-84,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2006,Angina,7/7/14 12:28
2904,61,Merck & Co,Large Pharma,2822,Nitro-Dur,nitroglycerin patch ,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-85,Apr-84,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2006,Angina,7/7/14 12:28
2904,61,Merck & Co,Large Pharma,2822,Nitro-Dur,nitroglycerin patch ,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-85,Apr-84,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2006,Angina,7/7/14 12:28
2905,61,Merck & Co,Large Pharma,2823,Mevacor ,lovastatin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-87,Aug-87,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1983,,7/7/14 12:28
2905,61,Merck & Co,Large Pharma,2823,Mevacor ,lovastatin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-87,Aug-87,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1983,,7/7/14 12:28
2905,61,Merck & Co,Large Pharma,2823,Mevacor ,lovastatin,Small Molecule (Chemical),Launched,Licensed (Development),Aug-87,Aug-87,Expired,Expired,113,Statins,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1983,,7/7/14 12:28
2906,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2824,Busulfex,busulfan,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-06,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1847,Stem Cell Transplant Conditioning,7/7/14 12:28
2906,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2824,Busulfex,busulfan,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-06,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1847,Stem Cell Transplant Conditioning,7/7/14 12:28
2906,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2824,Busulfex,busulfan,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-06,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1847,Stem Cell Transplant Conditioning,7/7/14 12:28
2907,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2150,Phosblock,sevelamer,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-03,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,966,Hyperphosphatemia,7/7/14 12:28
2907,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2150,Phosblock,sevelamer,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-03,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,966,Hyperphosphatemia,7/7/14 12:28
2907,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2150,Phosblock,sevelamer,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-03,,,171,Phosphate Regulators,82,Renal Disorders,8,Metabolism,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,966,Hyperphosphatemia,7/7/14 12:28
2908,53,Johnson & Johnson,Large Pharma,1065,Evithrom,human thrombin,Recombinant Protein,Launched,Corporate Acquisition,Oct-07,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1902,,7/7/14 12:28
2908,53,Johnson & Johnson,Large Pharma,1065,Evithrom,human thrombin,Recombinant Protein,Launched,Corporate Acquisition,Oct-07,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1902,,7/7/14 12:28
2908,53,Johnson & Johnson,Large Pharma,1065,Evithrom,human thrombin,Recombinant Protein,Launched,Corporate Acquisition,Oct-07,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1902,,7/7/14 12:28
2909,103,The Medicines Company,Small Biotech,255,Recothrom,thrombin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-13,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,0,0,0,0,63.3,69,70,71,71,72,72.6,72.96,2.049663989,960,Surgical hemostasis,7/7/14 12:28
2909,103,The Medicines Company,Small Biotech,255,Recothrom,thrombin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-13,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,960,Surgical hemostasis,7/7/14 12:28
2909,103,The Medicines Company,Small Biotech,255,Recothrom,thrombin alfa,Recombinant Protein,Launched,Licensed (Development),Jan-13,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,0,0,0,0,63.3,69,70,71,71,72,72.6,72.96,2.049663989,960,Surgical hemostasis,7/7/14 12:28
2910,100,Takeda,Large Pharma,988,Ebrantil,urapidil,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-77,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1888,,7/7/14 12:28
2910,100,Takeda,Large Pharma,988,Ebrantil,urapidil,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-77,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1888,,7/7/14 12:28
2910,100,Takeda,Large Pharma,988,Ebrantil,urapidil,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-77,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1888,,7/7/14 12:28
2911,84,Recordati,Regional & Specialty Pharma,2826,Nitrocor,nitroglycerin patch,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-02,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2005,Angina,7/7/14 12:28
2911,84,Recordati,Regional & Specialty Pharma,2826,Nitrocor,nitroglycerin patch,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-02,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2005,Angina,7/7/14 12:28
2911,84,Recordati,Regional & Specialty Pharma,2826,Nitrocor,nitroglycerin patch,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-02,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2005,Angina,7/7/14 12:28
2912,151,Yakult Honsha,Regional & Specialty Pharma,2827,satraplatin,Orplatna,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2093,Head & Neck Cancer,7/7/14 12:28
2912,151,Yakult Honsha,Regional & Specialty Pharma,2827,satraplatin,Orplatna,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2093,Head & Neck Cancer,7/7/14 12:28
2912,151,Yakult Honsha,Regional & Specialty Pharma,2827,satraplatin,Orplatna,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2093,Head & Neck Cancer,7/7/14 12:28
2914,183,Nanotherapeutics,Small Biotech,2828,Cloretazine,laromustine,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2016,Acute Myeloid Leukemia ,7/7/14 12:28
2914,183,Nanotherapeutics,Small Biotech,2828,Cloretazine,laromustine,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2016,Acute Myeloid Leukemia ,7/7/14 12:28
2914,183,Nanotherapeutics,Small Biotech,2828,Cloretazine,laromustine,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2016,Acute Myeloid Leukemia ,7/7/14 12:28
2916,169,Auxilium,Regional & Specialty Pharma,2829,Edex,alprostadil alfadex,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jun-97,Jun-95,Expired,Expired,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,Global,Sales,0,0,0,0,22,26,29,32,33.6,34.75,35.5775,36.116875,7.338451145,1889,Erectile dysfunction,7/7/14 12:28
2916,169,Auxilium,Regional & Specialty Pharma,2829,Edex,alprostadil alfadex,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jun-97,Jun-95,Expired,Expired,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1889,Erectile dysfunction,7/7/14 12:28
2916,169,Auxilium,Regional & Specialty Pharma,2829,Edex,alprostadil alfadex,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jun-97,Jun-95,Expired,Expired,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,US,Sales,0,0,0,0,22,26,29,32,33.6,34.75,35.5775,36.116875,7.338451145,1889,Erectile dysfunction,7/7/14 12:28
2917,200,Access Pharmaceuticals,Regional & Specialty Pharma,2830,ProLindac,AP5346 ,Small Molecule (Chemical),Phase II,In-House,,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2075,Ovarian Cancer,7/7/14 12:28
2917,200,Access Pharmaceuticals,Regional & Specialty Pharma,2830,ProLindac,AP5346 ,Small Molecule (Chemical),Phase II,In-House,,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2075,Ovarian Cancer,7/7/14 12:28
2917,200,Access Pharmaceuticals,Regional & Specialty Pharma,2830,ProLindac,AP5346 ,Small Molecule (Chemical),Phase II,In-House,,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2075,Ovarian Cancer,7/7/14 12:28
2922,1,Abbott,Regional & Specialty Pharma,2835,Hytrin,terazosin,Small Molecule (Chemical),Launched,In-House,Nov-93,Sep-96,Expired,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,Global,Sales,48,39,24,19,13,11.4,10.12,9.096,8.2768,7.62144,7.097152,6.6777216,-9.077928699,1934,Symptoms associated with BPH,7/7/14 12:28
2922,1,Abbott,Regional & Specialty Pharma,2835,Hytrin,terazosin,Small Molecule (Chemical),Launched,In-House,Nov-93,Sep-96,Expired,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,ROW,Sales,26,20,17,15,13,11.4,10.12,9.096,8.2768,7.62144,7.097152,6.6777216,-9.077928699,1934,Symptoms associated with BPH,7/7/14 12:28
2922,1,Abbott,Regional & Specialty Pharma,2835,Hytrin,terazosin,Small Molecule (Chemical),Launched,In-House,Nov-93,Sep-96,Expired,Expired,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,6,US,Sales,22,19,7,4,0,0,0,0,0,0,0,0,0,1934,Symptoms associated with BPH,7/7/14 12:28
2923,105,UCB,Regional & Specialty Pharma,2836,Bup-4,propiverine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-93,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1844,Overactive bladder,7/7/14 12:28
2923,105,UCB,Regional & Specialty Pharma,2836,Bup-4,propiverine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-93,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1844,Overactive bladder,7/7/14 12:28
2923,105,UCB,Regional & Specialty Pharma,2836,Bup-4,propiverine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-93,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1844,Overactive bladder,7/7/14 12:28
2925,73,Otsuka,Regional & Specialty Pharma,2836,Bup-4,propiverine,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,Global,Sales,81.87677366,80.65362724,79.76846044,76.26292233,52.35215568,48.25140169,45.00674969,41.92424544,39.92336632,30.20316674,26.55704811,23.4734711,-10.82672278,1844,Overactive bladder,7/7/14 12:28
2925,73,Otsuka,Regional & Specialty Pharma,2836,Bup-4,propiverine,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,ROW,Sales,81.87677366,80.65362724,79.76846044,76.26292233,52.35215568,48.25140169,45.00674969,41.92424544,39.92336632,30.20316674,26.55704811,23.4734711,-10.82672278,1844,Overactive bladder,7/7/14 12:28
2925,73,Otsuka,Regional & Specialty Pharma,2836,Bup-4,propiverine,Small Molecule (Chemical),Launched,In-House,,Jul-93,N/A,Expired,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1844,Overactive bladder,7/7/14 12:28
2927,111,Actavis,Regional & Specialty Pharma,376,Oxytrol,oxybutynin patch,Small Molecule (Chemical),Launched,In-House,Apr-03,,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1770,Overactive bladder,7/7/14 12:28
2927,111,Actavis,Regional & Specialty Pharma,376,Oxytrol,oxybutynin patch,Small Molecule (Chemical),Launched,In-House,Apr-03,,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1770,Overactive bladder,7/7/14 12:28
2927,111,Actavis,Regional & Specialty Pharma,376,Oxytrol,oxybutynin patch,Small Molecule (Chemical),Launched,In-House,Apr-03,,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1770,Overactive bladder,7/7/14 12:28
2928,105,UCB,Regional & Specialty Pharma,1430,Kentera,oxybutynin patch,Small Molecule (Chemical),Launched,,,Apr-05,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1770,Overactive bladder,7/7/14 12:28
2928,105,UCB,Regional & Specialty Pharma,1430,Kentera,oxybutynin patch,Small Molecule (Chemical),Launched,,,Apr-05,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1770,Overactive bladder,7/7/14 12:28
2928,105,UCB,Regional & Specialty Pharma,1430,Kentera,oxybutynin patch,Small Molecule (Chemical),Launched,,,Apr-05,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1770,Overactive bladder,7/7/14 12:28
2929,84,Recordati,Regional & Specialty Pharma,1430,Kentera,oxybutynin patch,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-05,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1770,Overactive bladder,7/7/14 12:28
2929,84,Recordati,Regional & Specialty Pharma,1430,Kentera,oxybutynin patch,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-05,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1770,Overactive bladder,7/7/14 12:28
2929,84,Recordati,Regional & Specialty Pharma,1430,Kentera,oxybutynin patch,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-05,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1770,Overactive bladder,7/7/14 12:28
2932,1,Abbott,Regional & Specialty Pharma,2842,Estrogel,estradiol gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Jul-79,,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1898,Estrogen deficiency,7/7/14 12:28
2932,1,Abbott,Regional & Specialty Pharma,2842,Estrogel,estradiol gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Jul-79,,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1898,Estrogen deficiency,7/7/14 12:28
2932,1,Abbott,Regional & Specialty Pharma,2842,Estrogel,estradiol gel,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-04,Jul-79,,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1898,Estrogen deficiency,7/7/14 12:28
2934,61,Merck & Co,Large Pharma,4319,Pneumovax,PPSV23,Vaccine,Launched,In-House,Jul-83,Jul-81,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,346,376,498,579,653,678.71,694.0865,703.146875,707.4324162,709.8132712,711.0997206,711.7640975,1.238598117,2063,pneumococcal vaccine,7/7/14 12:28
2934,61,Merck & Co,Large Pharma,4319,Pneumovax,PPSV23,Vaccine,Launched,In-House,Jul-83,Jul-81,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,101,80,148,118,162,169.98,173.337,177.19875,178.5589425,179.3119489,179.7790222,179.9984653,1.516409476,2063,pneumococcal vaccine,7/7/14 12:28
2934,61,Merck & Co,Large Pharma,4319,Pneumovax,PPSV23,Vaccine,Launched,In-House,Jul-83,Jul-81,N/A,N/A,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,245,296,350,461,491,508.73,520.7495,525.948125,528.8734738,530.5013223,531.3206985,531.7656322,1.145925188,2063,pneumococcal vaccine,7/7/14 12:28
2940,63,Merck KGaA,Regional & Specialty Pharma,2854,Ovidrel,choriogonadotropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Feb-01,Feb-02,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2023,Female infertility,7/7/14 12:28
2940,63,Merck KGaA,Regional & Specialty Pharma,2854,Ovidrel,choriogonadotropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Feb-01,Feb-02,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2023,Female infertility,7/7/14 12:28
2940,63,Merck KGaA,Regional & Specialty Pharma,2854,Ovidrel,choriogonadotropin alfa,Recombinant Protein,Launched,Corporate Acquisition,Feb-01,Feb-02,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2023,Female infertility,7/7/14 12:28
2941,63,Merck KGaA,Regional & Specialty Pharma,2855,Luveris,recombinant human lutenizing hormone,Recombinant Protein,Launched,Corporate Acquisition,Oct-04,May-01,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1976,Female infertility,7/7/14 12:28
2941,63,Merck KGaA,Regional & Specialty Pharma,2855,Luveris,recombinant human lutenizing hormone,Recombinant Protein,Launched,Corporate Acquisition,Oct-04,May-01,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1976,Female infertility,7/7/14 12:28
2941,63,Merck KGaA,Regional & Specialty Pharma,2855,Luveris,recombinant human lutenizing hormone,Recombinant Protein,Launched,Corporate Acquisition,Oct-04,May-01,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1976,Female infertility,7/7/14 12:28
2943,39,Eli Lilly,Large Pharma,793,Yentreve,duloxetine,Small Molecule (Chemical),Launched,In-House,,Aug-04,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2161,Stress urinary incontinence,7/7/14 12:28
2943,39,Eli Lilly,Large Pharma,793,Yentreve,duloxetine,Small Molecule (Chemical),Launched,In-House,,Aug-04,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,Global,Sales,21.6,20,18,17,16,15.16,14.516,13.9742,13.53173,13.1729275,12.87857593,12.63825855,-3.313293892,2161,Stress urinary incontinence,7/7/14 12:28
2943,39,Eli Lilly,Large Pharma,793,Yentreve,duloxetine,Small Molecule (Chemical),Launched,In-House,,Aug-04,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2161,Stress urinary incontinence,7/7/14 12:28
2943,39,Eli Lilly,Large Pharma,793,Yentreve,duloxetine,Small Molecule (Chemical),Launched,In-House,,Aug-04,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,ROW,Sales,21.6,20,18,17,16,15.16,14.516,13.9742,13.53173,13.1729275,12.87857593,12.63825855,-3.313293892,2161,Stress urinary incontinence,7/7/14 12:28
2943,39,Eli Lilly,Large Pharma,793,Yentreve,duloxetine,Small Molecule (Chemical),Launched,In-House,,Aug-04,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2161,Stress urinary incontinence,7/7/14 12:28
2943,39,Eli Lilly,Large Pharma,793,Yentreve,duloxetine,Small Molecule (Chemical),Launched,In-House,,Aug-04,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2161,Stress urinary incontinence,7/7/14 12:28
2944,202,Cyclacel,Regional & Specialty Pharma,2858,sapacitabine,CYC682,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2092,Acute Myeloid Leukemia,7/7/14 12:28
2944,202,Cyclacel,Regional & Specialty Pharma,2858,sapacitabine,CYC682,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2092,Acute Myeloid Leukemia,7/7/14 12:28
2944,202,Cyclacel,Regional & Specialty Pharma,2858,sapacitabine,CYC682,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2092,Acute Myeloid Leukemia,7/7/14 12:28
2945,203,Cell Therapeutics,Regional & Specialty Pharma,2859,Pixuvri,pixantrone,Small Molecule (Chemical),Launched,Licensed (Development),,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2062,Non-Hodgkin's Lymphoma,7/7/14 12:28
2945,203,Cell Therapeutics,Regional & Specialty Pharma,2859,Pixuvri,pixantrone,Small Molecule (Chemical),Launched,Licensed (Development),,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2062,Non-Hodgkin's Lymphoma,7/7/14 12:28
2945,203,Cell Therapeutics,Regional & Specialty Pharma,2859,Pixuvri,pixantrone,Small Molecule (Chemical),Launched,Licensed (Development),,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2062,Non-Hodgkin's Lymphoma,7/7/14 12:28
2946,204,Infinity Pharmaceuticals,Regional & Specialty Pharma,2860,retaspimycin,IPI504,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2085,Breast Cancer,7/7/14 12:28
2946,204,Infinity Pharmaceuticals,Regional & Specialty Pharma,2860,retaspimycin,IPI504,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2085,Breast Cancer,7/7/14 12:28
2946,204,Infinity Pharmaceuticals,Regional & Specialty Pharma,2860,retaspimycin,IPI504,Small Molecule (Chemical),Phase II,In-House,,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2085,Breast Cancer,7/7/14 12:28
2947,34,Daiichi-Sankyo,Regional & Specialty Pharma,2861,Slonnon ,argatroban,Small Molecule (Chemical),Launched,In-House,,Feb-85,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1817,,7/7/14 12:28
2947,34,Daiichi-Sankyo,Regional & Specialty Pharma,2861,Slonnon ,argatroban,Small Molecule (Chemical),Launched,In-House,,Feb-85,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1817,,7/7/14 12:28
2947,34,Daiichi-Sankyo,Regional & Specialty Pharma,2861,Slonnon ,argatroban,Small Molecule (Chemical),Launched,In-House,,Feb-85,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1817,,7/7/14 12:28
2948,34,Daiichi-Sankyo,Regional & Specialty Pharma,2862,Captoril ,captopril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-83,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1763,,7/7/14 12:28
2948,34,Daiichi-Sankyo,Regional & Specialty Pharma,2862,Captoril ,captopril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-83,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1763,,7/7/14 12:28
2948,34,Daiichi-Sankyo,Regional & Specialty Pharma,2862,Captoril ,captopril,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-83,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1763,,7/7/14 12:28
2950,89,Sanofi,Large Pharma,2864,Lasix ,furosemide,Small Molecule (Chemical),Launched,In-House,Aug-66,Mar-59,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1963,,7/7/14 12:28
2950,89,Sanofi,Large Pharma,2864,Lasix ,furosemide,Small Molecule (Chemical),Launched,In-House,Aug-66,Mar-59,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1963,,7/7/14 12:28
2950,89,Sanofi,Large Pharma,2864,Lasix ,furosemide,Small Molecule (Chemical),Launched,In-House,Aug-66,Mar-59,Expired,Expired,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1963,,7/7/14 12:28
2951,37,Eisai,Regional & Specialty Pharma,926,Ontak,denileukin diftitox,Recombinant Protein,Launched,Acquisition (Marketed),Feb-99,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2017,Cutaneous T-cell Lymphoma ,7/7/14 12:28
2951,37,Eisai,Regional & Specialty Pharma,926,Ontak,denileukin diftitox,Recombinant Protein,Launched,Acquisition (Marketed),Feb-99,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2017,Cutaneous T-cell Lymphoma ,7/7/14 12:28
2951,37,Eisai,Regional & Specialty Pharma,926,Ontak,denileukin diftitox,Recombinant Protein,Launched,Acquisition (Marketed),Feb-99,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2017,Cutaneous T-cell Lymphoma ,7/7/14 12:28
2952,34,Daiichi-Sankyo,Regional & Specialty Pharma,2866,Acecol ,temocapril,Small Molecule (Chemical),Launched,In-House,,Aug-94,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,Global,Sales,53.86629846,44.35676849,37.98498116,30.09685155,22.14898894,19.60185521,17.84931646,16.61485641,15.70602629,15.05963283,14.59612706,14.26203674,-6.094789444,1785,Hyptertension,7/7/14 12:28
2952,34,Daiichi-Sankyo,Regional & Specialty Pharma,2866,Acecol ,temocapril,Small Molecule (Chemical),Launched,In-House,,Aug-94,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,53.86629846,44.35676849,37.98498116,30.09685155,22.14898894,19.60185521,17.84931646,16.61485641,15.70602629,15.05963283,14.59612706,14.26203674,-6.094789444,1785,Hyptertension,7/7/14 12:28
2952,34,Daiichi-Sankyo,Regional & Specialty Pharma,2866,Acecol ,temocapril,Small Molecule (Chemical),Launched,In-House,,Aug-94,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1785,Hyptertension,7/7/14 12:28
2953,94,Servier,Regional & Specialty Pharma,963,Coversyl ,perindopril,Small Molecule (Chemical),Launched,In-House,,Dec-98,,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,334,Hyertension,7/7/14 12:28
2953,94,Servier,Regional & Specialty Pharma,963,Coversyl ,perindopril,Small Molecule (Chemical),Launched,In-House,,Dec-98,,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,334,Hyertension,7/7/14 12:28
2953,94,Servier,Regional & Specialty Pharma,963,Coversyl ,perindopril,Small Molecule (Chemical),Launched,In-House,,Dec-98,,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,334,Hyertension,7/7/14 12:28
2956,24,Bristol-Myers Squibb,Large Pharma,2868,Capoten ,captopril,Small Molecule (Chemical),Launched,In-House,Apr-81,Nov-80,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1763,,7/7/14 12:28
2956,24,Bristol-Myers Squibb,Large Pharma,2868,Capoten ,captopril,Small Molecule (Chemical),Launched,In-House,Apr-81,Nov-80,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1763,,7/7/14 12:28
2956,24,Bristol-Myers Squibb,Large Pharma,2868,Capoten ,captopril,Small Molecule (Chemical),Launched,In-House,Apr-81,Nov-80,Expired,Expired,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1763,,7/7/14 12:28
2957,86,Roche,Large Pharma,2869,Roferon-A,interferon alfa-2a,Recombinant Protein,Launched,In-House,,Jul-86,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2090,Renal Cell Carcinoma,7/7/14 12:28
2957,86,Roche,Large Pharma,2869,Roferon-A,interferon alfa-2a,Recombinant Protein,Launched,In-House,,Jul-86,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2090,Renal Cell Carcinoma,7/7/14 12:28
2957,86,Roche,Large Pharma,2869,Roferon-A,interferon alfa-2a,Recombinant Protein,Launched,In-House,,Jul-86,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2090,Renal Cell Carcinoma,7/7/14 12:28
2959,203,Cell Therapeutics,Regional & Specialty Pharma,1371,Opaxio,paclitaxel polyglumex,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2018,Ovarian Cancer,7/7/14 12:28
2959,203,Cell Therapeutics,Regional & Specialty Pharma,1371,Opaxio,paclitaxel polyglumex,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2018,Ovarian Cancer,7/7/14 12:28
2959,203,Cell Therapeutics,Regional & Specialty Pharma,1371,Opaxio,paclitaxel polyglumex,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2018,Ovarian Cancer,7/7/14 12:28
2960,205,Genta,Regional & Specialty Pharma,2870,tesetaxel,tesetaxel,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2125,Solid Tumors,7/7/14 12:28
2960,205,Genta,Regional & Specialty Pharma,2870,tesetaxel,tesetaxel,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2125,Solid Tumors,7/7/14 12:28
2960,205,Genta,Regional & Specialty Pharma,2870,tesetaxel,tesetaxel,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2125,Solid Tumors,7/7/14 12:28
2964,37,Eisai,Regional & Specialty Pharma,2873,Prialt,ziconotide,Synthetic Peptide,Launched,Licensed (Marketed),,Jul-06,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2071,Pain,7/7/14 12:28
2964,37,Eisai,Regional & Specialty Pharma,2873,Prialt,ziconotide,Synthetic Peptide,Launched,Licensed (Marketed),,Jul-06,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2071,Pain,7/7/14 12:28
2964,37,Eisai,Regional & Specialty Pharma,2873,Prialt,ziconotide,Synthetic Peptide,Launched,Licensed (Marketed),,Jul-06,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2071,Pain,7/7/14 12:28
2967,61,Merck & Co,Large Pharma,490,Eulexin,flutamide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-84,,,107,Anti-androgens,55,Hormonals,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1901,Prostate Cancer,7/7/14 12:28
2967,61,Merck & Co,Large Pharma,490,Eulexin,flutamide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-84,,,107,Anti-androgens,55,Hormonals,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1901,Prostate Cancer,7/7/14 12:28
2967,61,Merck & Co,Large Pharma,490,Eulexin,flutamide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-84,,,107,Anti-androgens,55,Hormonals,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1901,Prostate Cancer,7/7/14 12:28
2968,207,CytRx,Regional & Specialty Pharma,1820,tamibarotene,INNO-507,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2117,Acute Promyelocytic Leukemia ,7/7/14 12:28
2968,207,CytRx,Regional & Specialty Pharma,1820,tamibarotene,INNO-507,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2117,Acute Promyelocytic Leukemia ,7/7/14 12:28
2968,207,CytRx,Regional & Specialty Pharma,1820,tamibarotene,INNO-507,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2117,Acute Promyelocytic Leukemia ,7/7/14 12:28
2969,208,Boryung Pharmaceutical,Regional & Specialty Pharma,3688,Kanarb,fimasartan ,Small Molecule (Chemical),Launched,In-House,,,,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1906,hypertension,7/7/14 12:28
2969,208,Boryung Pharmaceutical,Regional & Specialty Pharma,3688,Kanarb,fimasartan ,Small Molecule (Chemical),Launched,In-House,,,,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1906,hypertension,7/7/14 12:28
2969,208,Boryung Pharmaceutical,Regional & Specialty Pharma,3688,Kanarb,fimasartan ,Small Molecule (Chemical),Launched,In-House,,,,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1906,hypertension,7/7/14 12:28
2971,39,Eli Lilly,Large Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,In-House,Sep-07,,Sep-14,Aug-13,53,Anti-estrogens,55,Hormonals,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1605,Breast cancer prevention,7/7/14 12:28
2971,39,Eli Lilly,Large Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,In-House,Sep-07,,Sep-14,Aug-13,53,Anti-estrogens,55,Hormonals,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1605,Breast cancer prevention,7/7/14 12:28
2971,39,Eli Lilly,Large Pharma,992,Evista,raloxifene,Small Molecule (Chemical),Launched,In-House,Sep-07,,Sep-14,Aug-13,53,Anti-estrogens,55,Hormonals,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1605,Breast cancer prevention,7/7/14 12:28
2972,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4101,Tostran,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jun-07,,May-19,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,3,Global,Sales,0,0,6.020765369,11.09496367,20.70212413,26.33365747,31.779168,37.16904281,41.53296059,45.44337934,48.91726708,51.94354952,14.04434609,467,Hypogonadism,7/7/14 12:28
2972,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4101,Tostran,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jun-07,,May-19,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,3,ROW,Sales,0,0,6.020765369,11.09496367,20.70212413,26.33365747,31.779168,37.16904281,41.53296059,45.44337934,48.91726708,51.94354952,14.04434609,467,Hypogonadism,7/7/14 12:28
2972,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,4101,Tostran,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jun-07,,May-19,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,467,Hypogonadism,7/7/14 12:28
2972,56,Prostrakan,Regional & Specialty Pharma,4101,Tostran,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jun-07,,May-19,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,3,Global,Proforma,3.419908678,4.672054089,2.00692179,0,0,0,0,0,0,0,0,0,0,467,Hypogonadism,7/7/14 12:28
2972,56,Prostrakan,Regional & Specialty Pharma,4101,Tostran,testosterone gel,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jun-07,,May-19,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,3,ROW,Proforma,3.419908678,4.672054089,2.00692179,0,0,0,0,0,0,0,0,0,0,467,Hypogonadism,7/7/14 12:28
2973,19,Bayer,Large Pharma,1741,Testogel,testosterone gel,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-03,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1658,Hypogonadism,7/7/14 12:28
2973,19,Bayer,Large Pharma,1741,Testogel,testosterone gel,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-03,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1658,Hypogonadism,7/7/14 12:28
2973,19,Bayer,Large Pharma,1741,Testogel,testosterone gel,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-03,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1658,Hypogonadism,7/7/14 12:28
2974,209,ZIOPHARM Oncology,Regional & Specialty Pharma,1819,Zinapar,darinaparsin,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2165,Peripheral T-cell Lymphoma,7/7/14 12:28
2974,209,ZIOPHARM Oncology,Regional & Specialty Pharma,1819,Zinapar,darinaparsin,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2165,Peripheral T-cell Lymphoma,7/7/14 12:28
2974,209,ZIOPHARM Oncology,Regional & Specialty Pharma,1819,Zinapar,darinaparsin,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,49,Other Cytotoxics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2165,Peripheral T-cell Lymphoma,7/7/14 12:28
2976,211,Ferring Pharmaceuticals,Regional & Specialty Pharma,2879,Firmagon,degarelix,Synthetic Peptide,Launched,In-House,Mar-09,Mar-09,,,33,LHRH Analogs,55,Hormonals,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,357,Prostate Cancer,7/7/14 12:28
2976,211,Ferring Pharmaceuticals,Regional & Specialty Pharma,2879,Firmagon,degarelix,Synthetic Peptide,Launched,In-House,Mar-09,Mar-09,,,33,LHRH Analogs,55,Hormonals,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,357,Prostate Cancer,7/7/14 12:28
2976,211,Ferring Pharmaceuticals,Regional & Specialty Pharma,2879,Firmagon,degarelix,Synthetic Peptide,Launched,In-House,Mar-09,Mar-09,,,33,LHRH Analogs,55,Hormonals,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,357,Prostate Cancer,7/7/14 12:28
2978,40,Endo Health Solutions,Regional & Specialty Pharma,2881,Vantas,histrelin,Synthetic Peptide,Launched,Corporate Acquisition,Nov-04,Nov-05,,,33,LHRH Analogs,55,Hormonals,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2152,Prostate Cancer,7/7/14 12:28
2978,40,Endo Health Solutions,Regional & Specialty Pharma,2881,Vantas,histrelin,Synthetic Peptide,Launched,Corporate Acquisition,Nov-04,Nov-05,,,33,LHRH Analogs,55,Hormonals,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2152,Prostate Cancer,7/7/14 12:28
2978,40,Endo Health Solutions,Regional & Specialty Pharma,2881,Vantas,histrelin,Synthetic Peptide,Launched,Corporate Acquisition,Nov-04,Nov-05,,,33,LHRH Analogs,55,Hormonals,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2152,Prostate Cancer,7/7/14 12:28
2979,70,Ono,Regional & Specialty Pharma,2882,Elaspol,sivelestat sodium hydrate,Small Molecule (Chemical),Launched,In-House,,Jun-02,,Dec-13,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,7,Global,Sales,56.0209504,58.36416907,55.7113057,46.9510886,38.53108681,38.19255839,32.90872693,30.25759403,28.49265502,26.76682578,24.92609666,23.77565561,-6.664701288,1891,Systemic Inflammatory Response Syndrome,7/7/14 12:28
2979,70,Ono,Regional & Specialty Pharma,2882,Elaspol,sivelestat sodium hydrate,Small Molecule (Chemical),Launched,In-House,,Jun-02,,Dec-13,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,7,ROW,Sales,56.0209504,58.36416907,55.7113057,46.9510886,38.53108681,38.19255839,32.90872693,30.25759403,28.49265502,26.76682578,24.92609666,23.77565561,-6.664701288,1891,Systemic Inflammatory Response Syndrome,7/7/14 12:28
2979,70,Ono,Regional & Specialty Pharma,2882,Elaspol,sivelestat sodium hydrate,Small Molecule (Chemical),Launched,In-House,,Jun-02,,Dec-13,100,Other Respiratory Agents,48,Other Respiratory Disorders,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1891,Systemic Inflammatory Response Syndrome,7/7/14 12:28
2980,19,Bayer,Large Pharma,932,Nebido,testosterone injection,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-03,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,179,Hypogonadism,7/7/14 12:28
2980,19,Bayer,Large Pharma,932,Nebido,testosterone injection,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-03,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,179,Hypogonadism,7/7/14 12:28
2980,19,Bayer,Large Pharma,932,Nebido,testosterone injection,Small Molecule (Chemical),Launched,Corporate Acquisition,,Nov-03,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,179,Hypogonadism,7/7/14 12:28
2981,111,Actavis,Regional & Specialty Pharma,2883,Androderm,testosterone patch,Small Molecule (Chemical),Launched,Licensed (Marketed),Aug-11,Jul-12,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,Global,Sales,0,0,30,74,135.99146,177.0490474,210.2859203,239.2197236,253.4405444,266.2877196,277.8980628,287.895481,11.30939977,1808,Hypogonadism,7/7/14 12:28
2981,111,Actavis,Regional & Specialty Pharma,2883,Androderm,testosterone patch,Small Molecule (Chemical),Launched,Licensed (Marketed),Aug-11,Jul-12,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,ROW,Sales,0,0,0,4,16.21376,26.82744943,33.35564098,39.5793092,44.61442982,48.59763918,51.92045134,54.62482645,18.94822667,1808,Hypogonadism,7/7/14 12:28
2981,111,Actavis,Regional & Specialty Pharma,2883,Androderm,testosterone patch,Small Molecule (Chemical),Launched,Licensed (Marketed),Aug-11,Jul-12,,,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,US,Sales,0,0,30,70,119.7777,150.221598,176.9302793,199.6404144,208.8261146,217.6900804,225.9776115,233.2706546,9.990413714,1808,Hypogonadism,7/7/14 12:28
2982,16,AstraZeneca,Large Pharma,1518,Zoladex,goserelin,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-90,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1312,Endometriosis,7/7/14 12:28
2982,16,AstraZeneca,Large Pharma,1518,Zoladex,goserelin,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-90,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1312,Endometriosis,7/7/14 12:28
2982,16,AstraZeneca,Large Pharma,1518,Zoladex,goserelin,Small Molecule (Chemical),Launched,In-House,Jul-93,Jul-90,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1312,Endometriosis,7/7/14 12:28
2986,15,Astellas Pharma,Regional & Specialty Pharma,2886,Nasanyl,nafarelin,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-95,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1999,Endometriosis,7/7/14 12:28
2986,15,Astellas Pharma,Regional & Specialty Pharma,2886,Nasanyl,nafarelin,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-95,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1999,Endometriosis,7/7/14 12:28
2986,15,Astellas Pharma,Regional & Specialty Pharma,2886,Nasanyl,nafarelin,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-95,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1999,Endometriosis,7/7/14 12:28
2989,42,Forest,Regional & Specialty Pharma,2891,Tiazac ,diltiazem,Small Molecule (Chemical),Launched,Licensed (Development),Jan-96,,Expired,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,518,,7/7/14 12:28
2989,42,Forest,Regional & Specialty Pharma,2891,Tiazac ,diltiazem,Small Molecule (Chemical),Launched,Licensed (Development),Jan-96,,Expired,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,518,,7/7/14 12:28
2989,42,Forest,Regional & Specialty Pharma,2891,Tiazac ,diltiazem,Small Molecule (Chemical),Launched,Licensed (Development),Jan-96,,Expired,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,518,,7/7/14 12:28
2990,76,Pfizer,Large Pharma,2892,Procardia ,nifedipine,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-82,,Expired,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2072,,7/7/14 12:28
2990,76,Pfizer,Large Pharma,2892,Procardia ,nifedipine,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-82,,Expired,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2072,,7/7/14 12:28
2990,76,Pfizer,Large Pharma,2892,Procardia ,nifedipine,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-82,,Expired,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2072,,7/7/14 12:28
2991,89,Sanofi,Large Pharma,2893,Tildiem,diltiazem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-82,,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,518,,7/7/14 12:28
2991,89,Sanofi,Large Pharma,2893,Tildiem,diltiazem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-82,,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,518,,7/7/14 12:28
2991,89,Sanofi,Large Pharma,2893,Tildiem,diltiazem,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-82,,Expired,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,518,,7/7/14 12:28
2992,212,Momenta Pharmaceuticals ,Small Biotech,2894,M118 ,adomiparin,Small Molecule (Chemical),Phase II,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1978,Thrombosis,7/7/14 12:28
2992,212,Momenta Pharmaceuticals ,Small Biotech,2894,M118 ,adomiparin,Small Molecule (Chemical),Phase II,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1978,Thrombosis,7/7/14 12:28
2992,212,Momenta Pharmaceuticals ,Small Biotech,2894,M118 ,adomiparin,Small Molecule (Chemical),Phase II,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1978,Thrombosis,7/7/14 12:28
2995,214,Medicure ,Regional & Specialty Pharma,2896,Aggrastat ,tirofiban,Small Molecule (Chemical),Launched,Licensed (Marketed),May-98,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,8,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1795,,7/7/14 12:28
2995,214,Medicure ,Regional & Specialty Pharma,2896,Aggrastat ,tirofiban,Small Molecule (Chemical),Launched,Licensed (Marketed),May-98,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,8,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1795,,7/7/14 12:28
2995,214,Medicure ,Regional & Specialty Pharma,2896,Aggrastat ,tirofiban,Small Molecule (Chemical),Launched,Licensed (Marketed),May-98,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,8,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1795,,7/7/14 12:28
2996,215,Correvio,Regional & Specialty Pharma,2896,Aggrastat ,tirofiban,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-98,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1795,,7/7/14 12:28
2996,215,Correvio,Regional & Specialty Pharma,2896,Aggrastat ,tirofiban,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-98,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1795,,7/7/14 12:28
2996,215,Correvio,Regional & Specialty Pharma,2896,Aggrastat ,tirofiban,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-98,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1795,,7/7/14 12:28
2997,86,Roche,Large Pharma,2796,Panaldine / Ticlid ,ticlopidine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-91,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,839,,7/7/14 12:28
2997,86,Roche,Large Pharma,2796,Panaldine / Ticlid ,ticlopidine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-91,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,839,,7/7/14 12:28
2997,86,Roche,Large Pharma,2796,Panaldine / Ticlid ,ticlopidine,Small Molecule (Chemical),Launched,Licensed (Development),Oct-91,,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,839,,7/7/14 12:28
2998,216,Swedish Orphan Biovitrum,Regional & Specialty Pharma,679,Kepivance,palifermin,Recombinant Protein,Launched,Acquisition (Marketed),Apr-05,Mar-06,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,9,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1954,Oral Mucositis,7/7/14 12:28
2998,216,Swedish Orphan Biovitrum,Regional & Specialty Pharma,679,Kepivance,palifermin,Recombinant Protein,Launched,Acquisition (Marketed),Apr-05,Mar-06,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,9,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1954,Oral Mucositis,7/7/14 12:28
2998,216,Swedish Orphan Biovitrum,Regional & Specialty Pharma,679,Kepivance,palifermin,Recombinant Protein,Launched,Acquisition (Marketed),Apr-05,Mar-06,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1954,Oral Mucositis,7/7/14 12:28
3000,77,PharmaMar,Small Biotech,2899,aplidin,plitidepsin,Small Molecule (Chemical),Phase III,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1813,Multiple Myeloma,7/7/14 12:28
3000,77,PharmaMar,Small Biotech,2899,aplidin,plitidepsin,Small Molecule (Chemical),Phase III,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1813,Multiple Myeloma,7/7/14 12:28
3000,77,PharmaMar,Small Biotech,2899,aplidin,plitidepsin,Small Molecule (Chemical),Phase III,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1813,Multiple Myeloma,7/7/14 12:28
3001,217,Zealand Pharma,Regional & Specialty Pharma,2900,danegaptide ,danegaptide ,Synthetic Peptide,Phase II,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1873,Reperfusion Injury,7/7/14 12:28
3001,217,Zealand Pharma,Regional & Specialty Pharma,2900,danegaptide ,danegaptide ,Synthetic Peptide,Phase II,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1873,Reperfusion Injury,7/7/14 12:28
3001,217,Zealand Pharma,Regional & Specialty Pharma,2900,danegaptide ,danegaptide ,Synthetic Peptide,Phase II,In-House,,,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1873,Reperfusion Injury,7/7/14 12:28
3002,218,Antisoma,Small Biotech,2901,AS1411,ACT-GRO-777,DNA/RNA Therapy,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1819,Acute Myeloid Leukemia,7/7/14 12:28
3002,218,Antisoma,Small Biotech,2901,AS1411,ACT-GRO-777,DNA/RNA Therapy,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1819,Acute Myeloid Leukemia,7/7/14 12:28
3002,218,Antisoma,Small Biotech,2901,AS1411,ACT-GRO-777,DNA/RNA Therapy,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1819,Acute Myeloid Leukemia,7/7/14 12:28
3003,219,Celldex Therapeutics,Small Biotech,2902,CR011-vcMMAE,glembatumumab vedotin,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1870,Melanoma,7/7/14 12:28
3003,219,Celldex Therapeutics,Small Biotech,2902,CR011-vcMMAE,glembatumumab vedotin,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1870,Melanoma,7/7/14 12:28
3003,219,Celldex Therapeutics,Small Biotech,2902,CR011-vcMMAE,glembatumumab vedotin,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1870,Melanoma,7/7/14 12:28
3004,220,BioNumerik Pharmaceuticals,Regional & Specialty Pharma,2903,Tavocept,dimesna,Small Molecule (Chemical),Phase III,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2122,Chemotherapy-Induced Neuropathy,7/7/14 12:28
3004,220,BioNumerik Pharmaceuticals,Regional & Specialty Pharma,2903,Tavocept,dimesna,Small Molecule (Chemical),Phase III,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2122,Chemotherapy-Induced Neuropathy,7/7/14 12:28
3004,220,BioNumerik Pharmaceuticals,Regional & Specialty Pharma,2903,Tavocept,dimesna,Small Molecule (Chemical),Phase III,In-House,,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2122,Chemotherapy-Induced Neuropathy,7/7/14 12:28
3011,60,Menarini,Regional & Specialty Pharma,2909,ibodutant,ibodutant,Small Molecule (Chemical),Phase III,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1935,IBS-D,7/7/14 12:28
3011,60,Menarini,Regional & Specialty Pharma,2909,ibodutant,ibodutant,Small Molecule (Chemical),Phase III,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1935,IBS-D,7/7/14 12:28
3011,60,Menarini,Regional & Specialty Pharma,2909,ibodutant,ibodutant,Small Molecule (Chemical),Phase III,In-House,,,,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1935,IBS-D,7/7/14 12:28
3013,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2911,Liple ,alprostadil,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-97,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,86.18607754,85.21168684,77.34780165,61.3975774,39.54506278,33.89147288,30.14266828,27.98254819,26.66418546,25.8787405,25.40608035,25.12283255,-6.275358005,838,,7/7/14 12:28
3013,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2911,Liple ,alprostadil,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-97,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,86.18607754,85.21168684,77.34780165,61.3975774,39.54506278,33.89147288,30.14266828,27.98254819,26.66418546,25.8787405,25.40608035,25.12283255,-6.275358005,838,,7/7/14 12:28
3013,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2911,Liple ,alprostadil,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-97,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,838,,7/7/14 12:28
3014,224,Prometheus,Regional & Specialty Pharma,2912,Lotronex,alosetron,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-00,,Oct-18,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1973,IBS-D,7/7/14 12:28
3014,224,Prometheus,Regional & Specialty Pharma,2912,Lotronex,alosetron,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-00,,Oct-18,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1973,IBS-D,7/7/14 12:28
3014,224,Prometheus,Regional & Specialty Pharma,2912,Lotronex,alosetron,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-00,,Oct-18,,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1973,IBS-D,7/7/14 12:28
3015,225,Dyax ,Regional & Specialty Pharma,2914,Kalbitor ,ecallantide ,Recombinant Protein,Launched,In-House,Feb-10,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,Global,Sales,0,8.8,22.9,40,40.5,43,46.374,48.1499,49.830005,51.26334075,52.36645631,53.28876197,3.998190764,1950,Hereditary Angioedema,7/7/14 12:28
3015,225,Dyax ,Regional & Specialty Pharma,2914,Kalbitor ,ecallantide ,Recombinant Protein,Launched,In-House,Feb-10,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1950,Hereditary Angioedema,7/7/14 12:28
3015,225,Dyax ,Regional & Specialty Pharma,2914,Kalbitor ,ecallantide ,Recombinant Protein,Launched,In-House,Feb-10,,,,111,Other Endocrinology Agents,23,Other Endocrinology Disorders,8,Metabolism,6,US,Sales,0,8.8,22.9,40,40.5,43,46.374,48.1499,49.830005,51.26334075,52.36645631,53.28876197,3.998190764,1950,Hereditary Angioedema,7/7/14 12:28
3017,63,Merck KGaA,Regional & Specialty Pharma,2916,Praxilene,naftidrofuryl oxalate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-75,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2067,Peripheral vascular disease,7/7/14 12:28
3017,63,Merck KGaA,Regional & Specialty Pharma,2916,Praxilene,naftidrofuryl oxalate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-75,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2067,Peripheral vascular disease,7/7/14 12:28
3017,63,Merck KGaA,Regional & Specialty Pharma,2916,Praxilene,naftidrofuryl oxalate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-75,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2067,Peripheral vascular disease,7/7/14 12:28
3018,70,Ono,Regional & Specialty Pharma,2917,Prostandin ,alprostadil alfadex,Small Molecule (Chemical),Launched,In-House,,Oct-79,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2076,Peripheral Arterial Disease,7/7/14 12:28
3018,70,Ono,Regional & Specialty Pharma,2917,Prostandin ,alprostadil alfadex,Small Molecule (Chemical),Launched,In-House,,Oct-79,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2076,Peripheral Arterial Disease,7/7/14 12:28
3018,70,Ono,Regional & Specialty Pharma,2917,Prostandin ,alprostadil alfadex,Small Molecule (Chemical),Launched,In-House,,Oct-79,,,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2076,Peripheral Arterial Disease,7/7/14 12:28
3019,89,Sanofi,Large Pharma,2918,Cholestagel ,colesevelam hydrochloride,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-07,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1276,,7/7/14 12:28
3019,89,Sanofi,Large Pharma,2918,Cholestagel ,colesevelam hydrochloride,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-07,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1276,,7/7/14 12:28
3019,89,Sanofi,Large Pharma,2918,Cholestagel ,colesevelam hydrochloride,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-07,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1276,,7/7/14 12:28
3021,920,Tesaro,Regional & Specialty Pharma,49,rolapitant,SCH-619734,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2091,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
3021,920,Tesaro,Regional & Specialty Pharma,49,rolapitant,SCH-619734,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2091,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
3021,920,Tesaro,Regional & Specialty Pharma,49,rolapitant,SCH-619734,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2091,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
3022,448,Zydus Cadila,Small Biotech,2920,Kinlytic ,urokinase,Recombinant Protein,Launched,Licensed (Marketed),Jul-78,,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1956,Thrombosis,7/7/14 12:28
3022,448,Zydus Cadila,Small Biotech,2920,Kinlytic ,urokinase,Recombinant Protein,Launched,Licensed (Marketed),Jul-78,,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1956,Thrombosis,7/7/14 12:28
3022,448,Zydus Cadila,Small Biotech,2920,Kinlytic ,urokinase,Recombinant Protein,Launched,Licensed (Marketed),Jul-78,,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1956,Thrombosis,7/7/14 12:28
3023,28,Chiesi,Regional & Specialty Pharma,2921,Retavase ,reteplase,Recombinant Protein,Launched,Corporate Acquisition,Jan-97,,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2086,,7/7/14 12:28
3023,28,Chiesi,Regional & Specialty Pharma,2921,Retavase ,reteplase,Recombinant Protein,Launched,Corporate Acquisition,Jan-97,,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2086,,7/7/14 12:28
3023,28,Chiesi,Regional & Specialty Pharma,2921,Retavase ,reteplase,Recombinant Protein,Launched,Corporate Acquisition,Jan-97,,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2086,,7/7/14 12:28
3024,111,Actavis,Regional & Specialty Pharma,2922,Rapilysin ,reteplase ,Recombinant Protein,Launched,Licensed (Marketed),,Oct-96,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2080,Thrombosis,7/7/14 12:28
3024,111,Actavis,Regional & Specialty Pharma,2922,Rapilysin ,reteplase ,Recombinant Protein,Launched,Licensed (Marketed),,Oct-96,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2080,Thrombosis,7/7/14 12:28
3024,111,Actavis,Regional & Specialty Pharma,2922,Rapilysin ,reteplase ,Recombinant Protein,Launched,Licensed (Marketed),,Oct-96,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2080,Thrombosis,7/7/14 12:28
3024,111,Actavis,Regional & Specialty Pharma,2922,Rapilysin ,reteplase ,Recombinant Protein,Launched,Licensed (Marketed),,Oct-96,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2080,Thrombosis,7/7/14 12:28
3024,111,Actavis,Regional & Specialty Pharma,2922,Rapilysin ,reteplase ,Recombinant Protein,Launched,Licensed (Marketed),,Oct-96,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2080,Thrombosis,7/7/14 12:28
3024,111,Actavis,Regional & Specialty Pharma,2922,Rapilysin ,reteplase ,Recombinant Protein,Launched,Licensed (Marketed),,Oct-96,,,7,Thrombolytics,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2080,Thrombosis,7/7/14 12:28
3028,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2923,Anpec,morphine,Small Molecule (Chemical),Launched,In-House,,Jul-91,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1985,Pain,7/7/14 12:28
3028,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2923,Anpec,morphine,Small Molecule (Chemical),Launched,In-House,,Jul-91,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1985,Pain,7/7/14 12:28
3028,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2923,Anpec,morphine,Small Molecule (Chemical),Launched,In-House,,Jul-91,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1985,Pain,7/7/14 12:28
3029,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2924,Opso,morphine,Small Molecule (Chemical),Launched,In-House,,Jul-03,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2019,Pain,7/7/14 12:28
3029,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2924,Opso,morphine,Small Molecule (Chemical),Launched,In-House,,Jul-03,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2019,Pain,7/7/14 12:28
3029,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2924,Opso,morphine,Small Molecule (Chemical),Launched,In-House,,Jul-03,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2019,Pain,7/7/14 12:28
3030,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2925,Didronel,etidronate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-90,,,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1880,Osteoporosis,7/7/14 12:28
3030,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2925,Didronel,etidronate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-90,,,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1880,Osteoporosis,7/7/14 12:28
3030,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2925,Didronel,etidronate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-90,,,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1880,Osteoporosis,7/7/14 12:28
3031,224,Prometheus,Regional & Specialty Pharma,2926,Entocort CR,budesonide,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-00,Jul-96,,,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1894,crohn's disease,7/7/14 12:28
3031,224,Prometheus,Regional & Specialty Pharma,2926,Entocort CR,budesonide,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-00,Jul-96,,,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1894,crohn's disease,7/7/14 12:28
3031,224,Prometheus,Regional & Specialty Pharma,2926,Entocort CR,budesonide,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-00,Jul-96,,,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1894,crohn's disease,7/7/14 12:28
3032,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2927,Omeprazon,omeprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-00,N/A,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,927,GERD,7/7/14 12:28
3032,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2927,Omeprazon,omeprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-00,N/A,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,59.25292831,56.02960231,54.44513966,49.90509758,39.7984333,38.33334452,37.358522,36.57003285,35.9822074,35.54695301,35.21594941,34.96776349,-1.831601698,927,GERD,7/7/14 12:28
3032,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2927,Omeprazon,omeprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-00,N/A,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,927,GERD,7/7/14 12:28
3032,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2927,Omeprazon,omeprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-00,N/A,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,59.25292831,56.02960231,54.44513966,49.90509758,39.7984333,38.33334452,37.358522,36.57003285,35.9822074,35.54695301,35.21594941,34.96776349,-1.831601698,927,GERD,7/7/14 12:28
3032,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2927,Omeprazon,omeprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-00,N/A,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,927,GERD,7/7/14 12:28
3032,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2927,Omeprazon,omeprazole,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-00,N/A,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,927,GERD,7/7/14 12:28
3033,10,Almirall,Regional & Specialty Pharma,2928,Opiren,lansoprazole,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-94,N/A,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,2,Global,Sales,48.49349425,45.57156546,30.45057112,16.45147297,12.94934739,9.809736796,7.989158857,7.057437983,6.483453405,6.157734956,5.975245386,5.868930354,-10.68968295,1510,GERD,7/7/14 12:28
3033,10,Almirall,Regional & Specialty Pharma,2928,Opiren,lansoprazole,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-94,N/A,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,2,ROW,Sales,48.49349425,45.57156546,30.45057112,16.45147297,12.94934739,9.809736796,7.989158857,7.057437983,6.483453405,6.157734956,5.975245386,5.868930354,-10.68968295,1510,GERD,7/7/14 12:28
3033,10,Almirall,Regional & Specialty Pharma,2928,Opiren,lansoprazole,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-94,N/A,Expired,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1510,GERD,7/7/14 12:28
3036,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,62,Gastrom,ecabet,Small Molecule (Chemical),Launched,In-House,,Dec-93,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1918,GERD,7/7/14 12:28
3036,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,62,Gastrom,ecabet,Small Molecule (Chemical),Launched,In-House,,Dec-93,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1918,GERD,7/7/14 12:28
3036,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,62,Gastrom,ecabet,Small Molecule (Chemical),Launched,In-House,,Dec-93,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1918,GERD,7/7/14 12:28
3037,37,Eisai,Regional & Specialty Pharma,149,Selbex,teprenone,Small Molecule (Chemical),Launched,In-House,,Dec-84,N/A,Expired,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,152.9802876,133.0703055,125.2281366,93.90217721,70.87746299,60.33454906,50.91400321,43.3913622,36.43450856,30.33904592,25.02759343,20.32700482,-16.34163058,2097,GERD,7/7/14 12:28
3037,37,Eisai,Regional & Specialty Pharma,149,Selbex,teprenone,Small Molecule (Chemical),Launched,In-House,,Dec-84,N/A,Expired,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,152.9802876,133.0703055,125.2281366,93.90217721,70.87746299,60.33454906,50.91400321,43.3913622,36.43450856,30.33904592,25.02759343,20.32700482,-16.34163058,2097,GERD,7/7/14 12:28
3037,37,Eisai,Regional & Specialty Pharma,149,Selbex,teprenone,Small Molecule (Chemical),Launched,In-House,,Dec-84,N/A,Expired,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2097,GERD,7/7/14 12:28
3038,105,UCB,Regional & Specialty Pharma,2931,Stogar,lafutidine,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-00,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2107,GERD,7/7/14 12:28
3038,105,UCB,Regional & Specialty Pharma,2931,Stogar,lafutidine,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-00,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2107,GERD,7/7/14 12:28
3038,105,UCB,Regional & Specialty Pharma,2931,Stogar,lafutidine,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-00,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2107,GERD,7/7/14 12:28
3040,10,Almirall,Regional & Specialty Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-00,,,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
3040,10,Almirall,Regional & Specialty Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-00,,,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
3040,10,Almirall,Regional & Specialty Pharma,446,Actonel,risedronate,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-00,,,30,Bisphosphonates (ex-Oncology),9,Osteoporosis,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1618,Osteoporosis,7/7/14 12:28
3041,100,Takeda,Large Pharma,4029,Pacif,morphine,Small Molecule (Chemical),Launched,In-House,,Jul-01,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1985,Pain,7/7/14 12:28
3041,100,Takeda,Large Pharma,4029,Pacif,morphine,Small Molecule (Chemical),Launched,In-House,,Jul-01,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1985,Pain,7/7/14 12:28
3041,100,Takeda,Large Pharma,4029,Pacif,morphine,Small Molecule (Chemical),Launched,In-House,,Jul-01,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1985,Pain,7/7/14 12:28
3043,10,Almirall,Regional & Specialty Pharma,2934,Calmatel / Picalm,piketoprofen,Small Molecule (Chemical),Launched,In-House,,Jul-84,,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1849,Pain,7/7/14 12:28
3043,10,Almirall,Regional & Specialty Pharma,2934,Calmatel / Picalm,piketoprofen,Small Molecule (Chemical),Launched,In-House,,Jul-84,,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1849,Pain,7/7/14 12:28
3043,10,Almirall,Regional & Specialty Pharma,2934,Calmatel / Picalm,piketoprofen,Small Molecule (Chemical),Launched,In-House,,Jul-84,,Expired,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1849,Pain,7/7/14 12:28
3044,19,Bayer,Large Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
3044,19,Bayer,Large Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
3044,19,Bayer,Large Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,,148,Other MS Treatments,40,Multiple Sclerosis,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Multiple Sclerosis adjunct therapy,7/7/14 12:28
3045,10,Almirall,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Phase III,Licensed (Marketed),,Jan-16,,Jul-20,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,7.9681804,11.15545256,15.93634486,23.90451729,28.74916397,0,1059,Cancer Pain,7/7/14 12:28
3045,10,Almirall,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Phase III,Licensed (Marketed),,Jan-16,,Jul-20,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,7.9681804,11.15545256,15.93634486,23.90451729,28.74916397,0,1059,Cancer Pain,7/7/14 12:28
3045,10,Almirall,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Phase III,Licensed (Marketed),,Jan-16,,Jul-20,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Cancer Pain,7/7/14 12:28
3046,73,Otsuka,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,10.06772225,16.77957063,23.49139889,30.20312646,35.57255202,40.40502938,0,1059,Cancer Pain,7/7/14 12:28
3046,73,Otsuka,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1059,Cancer Pain,7/7/14 12:28
3046,73,Otsuka,Regional & Specialty Pharma,2124,Sativex,nabiximols,Small Molecule (Chemical),Phase III,Licensed (Development),Apr-15,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,10.06772225,16.77957063,23.49139889,30.20312646,35.57255202,40.40502938,0,1059,Cancer Pain,7/7/14 12:28
3048,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2936,Tagamet,cimetidine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Dec-00,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2114,GERD,7/7/14 12:28
3048,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2936,Tagamet,cimetidine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Dec-00,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2114,GERD,7/7/14 12:28
3048,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2936,Tagamet,cimetidine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Dec-00,,,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2114,GERD,7/7/14 12:28
3049,1,Abbott,Regional & Specialty Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,,Jun-08,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1428,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
3049,1,Abbott,Regional & Specialty Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,,Jun-08,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1428,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
3049,1,Abbott,Regional & Specialty Pharma,140,Marinol,dronabinol,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-87,,Jun-08,,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1428,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
3050,70,Ono,Regional & Specialty Pharma,3942,Emend / Proemend,aprepitant / fosaprepitant,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-09,N/A,Jun-21,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,Global,Sales,5.386629846,54.86231893,83.56695855,95.10605127,94.6365891,97.17738911,101.795484,105.0457128,107.2139177,108.7053128,109.7284151,110.4247205,2.228609072,418,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
3050,70,Ono,Regional & Specialty Pharma,3942,Emend / Proemend,aprepitant / fosaprepitant,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-09,N/A,Jun-21,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,ROW,Sales,5.386629846,54.86231893,83.56695855,95.10605127,94.6365891,97.17738911,101.795484,105.0457128,107.2139177,108.7053128,109.7284151,110.4247205,2.228609072,418,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
3050,70,Ono,Regional & Specialty Pharma,3942,Emend / Proemend,aprepitant / fosaprepitant,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-09,N/A,Jun-21,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,418,Chemotherapy-induced nausea and vomiting,7/7/14 12:28
3052,95,Shionogi,Regional & Specialty Pharma,2938,Differin,adapelene,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-08,Apr-23,,160,Acne Treatments,73,Acne,6,Dermatology,7,Global,Sales,23.70117132,37.3530682,46.84814343,49.50838892,54.30920239,61.27372723,60.40633347,63.79589776,66.05787295,67.63737546,69.35438079,70.78217956,3.856999234,1882,Acne,7/7/14 12:28
3052,95,Shionogi,Regional & Specialty Pharma,2938,Differin,adapelene,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-08,Apr-23,,160,Acne Treatments,73,Acne,6,Dermatology,7,ROW,Sales,23.70117132,37.3530682,46.84814343,49.50838892,54.30920239,61.27372723,60.40633347,63.79589776,66.05787295,67.63737546,69.35438079,70.78217956,3.856999234,1882,Acne,7/7/14 12:28
3052,95,Shionogi,Regional & Specialty Pharma,2938,Differin,adapelene,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-08,Apr-23,,160,Acne Treatments,73,Acne,6,Dermatology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1882,Acne,7/7/14 12:28
3055,17,Basilea,Small Biotech,2940,Toctino,alitretinoin,Small Molecule (Chemical),Launched,In-House,Nov-13,Feb-09,N/A,Dec-23,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,5,Global,Sales,16.57433127,28.00379458,34.91688936,21.54308573,0,0,0,0,0,0,0,0,0,2132,Chronic hand eczema,7/7/14 12:28
3055,17,Basilea,Small Biotech,2940,Toctino,alitretinoin,Small Molecule (Chemical),Launched,In-House,Nov-13,Feb-09,N/A,Dec-23,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,5,ROW,Sales,16.57433127,28.00379458,34.91688936,21.54308573,0,0,0,0,0,0,0,0,0,2132,Chronic hand eczema,7/7/14 12:28
3055,17,Basilea,Small Biotech,2940,Toctino,alitretinoin,Small Molecule (Chemical),Launched,In-House,Nov-13,Feb-09,N/A,Dec-23,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2132,Chronic hand eczema,7/7/14 12:28
3056,8,Allergan,Regional & Specialty Pharma,2941,Azelex,azelaic acid,Small Molecule (Chemical),Launched,Licensed (Development),Dec-95,,,,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1826,Acne ,7/7/14 12:28
3056,8,Allergan,Regional & Specialty Pharma,2941,Azelex,azelaic acid,Small Molecule (Chemical),Launched,Licensed (Development),Dec-95,,,,160,Acne Treatments,73,Acne,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1826,Acne ,7/7/14 12:28
3056,8,Allergan,Regional & Specialty Pharma,2941,Azelex,azelaic acid,Small Molecule (Chemical),Launched,Licensed (Development),Dec-95,,,,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1826,Acne ,7/7/14 12:28
3060,8,Allergan,Regional & Specialty Pharma,2945,Elestat,epinastine,Small Molecule (Chemical),Launched,Licensed (Development),Feb-04,Mar-04,Nov-20,Oct-20,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1892,Allergic conjunctivitis,7/7/14 12:28
3060,8,Allergan,Regional & Specialty Pharma,2945,Elestat,epinastine,Small Molecule (Chemical),Launched,Licensed (Development),Feb-04,Mar-04,Nov-20,Oct-20,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1892,Allergic conjunctivitis,7/7/14 12:28
3060,8,Allergan,Regional & Specialty Pharma,2945,Elestat,epinastine,Small Molecule (Chemical),Launched,Licensed (Development),Feb-04,Mar-04,Nov-20,Oct-20,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1892,Allergic conjunctivitis,7/7/14 12:28
3062,8,Allergan,Regional & Specialty Pharma,2948,Acular,ketorolac,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-93,Jul-92,Nov-09,Sep-08,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1786,Allergic conjunctivitis,7/7/14 12:28
3062,8,Allergan,Regional & Specialty Pharma,2948,Acular,ketorolac,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-93,Jul-92,Nov-09,Sep-08,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1786,Allergic conjunctivitis,7/7/14 12:28
3062,8,Allergan,Regional & Specialty Pharma,2948,Acular,ketorolac,Small Molecule (Chemical),Launched,Licensed (Marketed),Jan-93,Jul-92,Nov-09,Sep-08,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1786,Allergic conjunctivitis,7/7/14 12:28
3063,61,Merck & Co,Large Pharma,2949,Lotrisone,clotrimazole + betamethasone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-84,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1972,Fungal skin infections,7/7/14 12:28
3063,61,Merck & Co,Large Pharma,2949,Lotrisone,clotrimazole + betamethasone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-84,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1972,Fungal skin infections,7/7/14 12:28
3063,61,Merck & Co,Large Pharma,2949,Lotrisone,clotrimazole + betamethasone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-84,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1972,Fungal skin infections,7/7/14 12:28
3064,8,Allergan,Regional & Specialty Pharma,2950,Alocril,nedocromil,Small Molecule (Chemical),Launched,Licensed (Marketed),Feb-00,Feb-00,Aug-12,Dec-07,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1799,Allergic conjunctivitis,7/7/14 12:28
3064,8,Allergan,Regional & Specialty Pharma,2950,Alocril,nedocromil,Small Molecule (Chemical),Launched,Licensed (Marketed),Feb-00,Feb-00,Aug-12,Dec-07,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1799,Allergic conjunctivitis,7/7/14 12:28
3064,8,Allergan,Regional & Specialty Pharma,2950,Alocril,nedocromil,Small Molecule (Chemical),Launched,Licensed (Marketed),Feb-00,Feb-00,Aug-12,Dec-07,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1799,Allergic conjunctivitis,7/7/14 12:28
3065,10,Almirall,Regional & Specialty Pharma,2951,Solaraze,diclofenac + hyaluronic acid gel,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-01,N/A,Expired,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,2,Global,Sales,33.76481118,32.72144381,36.9856252,37.27286846,35.5649485,35.55575845,35.37969611,34.90343511,34.69848406,34.50208765,34.32363265,34.191237,-0.561150171,2103,Actinic keratosis,7/7/14 12:28
3065,10,Almirall,Regional & Specialty Pharma,2951,Solaraze,diclofenac + hyaluronic acid gel,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-01,N/A,Expired,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,2,ROW,Sales,33.76481118,32.72144381,36.9856252,37.27286846,35.5649485,35.55575845,35.37969611,34.90343511,34.69848406,34.50208765,34.32363265,34.191237,-0.561150171,2103,Actinic keratosis,7/7/14 12:28
3065,10,Almirall,Regional & Specialty Pharma,2951,Solaraze,diclofenac + hyaluronic acid gel,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-01,N/A,Expired,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2103,Actinic keratosis,7/7/14 12:28
3066,61,Merck & Co,Large Pharma,2952,Diprolene AF,betamethasone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-83,Jul-83,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1016,Various skin disorders,7/7/14 12:28
3066,61,Merck & Co,Large Pharma,2952,Diprolene AF,betamethasone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-83,Jul-83,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1016,Various skin disorders,7/7/14 12:28
3066,61,Merck & Co,Large Pharma,2952,Diprolene AF,betamethasone,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-83,Jul-83,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1016,Various skin disorders,7/7/14 12:28
3068,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2954,Flumark,enoxacin,Small Molecule (Chemical),Launched,In-House,,Jan-86,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1911,,7/7/14 12:28
3068,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2954,Flumark,enoxacin,Small Molecule (Chemical),Launched,In-House,,Jan-86,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1911,,7/7/14 12:28
3068,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2954,Flumark,enoxacin,Small Molecule (Chemical),Launched,In-House,,Jan-86,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1911,,7/7/14 12:28
3069,189,Valeant,Regional & Specialty Pharma,2955,Vanos,fluocinonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,,N/A,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2151,Psoriasis,7/7/14 12:28
3069,189,Valeant,Regional & Specialty Pharma,2955,Vanos,fluocinonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,,N/A,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2151,Psoriasis,7/7/14 12:28
3069,189,Valeant,Regional & Specialty Pharma,2955,Vanos,fluocinonide,Small Molecule (Chemical),Launched,Corporate Acquisition,Apr-05,,N/A,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2151,Psoriasis,7/7/14 12:28
3070,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2956,Spara,sparfloxacin,Small Molecule (Chemical),Launched,In-House,,Aug-93,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2105,,7/7/14 12:28
3070,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2956,Spara,sparfloxacin,Small Molecule (Chemical),Launched,In-House,,Aug-93,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2105,,7/7/14 12:28
3070,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2956,Spara,sparfloxacin,Small Molecule (Chemical),Launched,In-House,,Aug-93,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2105,,7/7/14 12:28
3073,46,GlaxoSmithKline,Large Pharma,2959,Malarone,atovaquone and proguanil,Small Molecule (Chemical),Launched,In-House,,Jun-97,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1979,malaria,7/7/14 12:28
3073,46,GlaxoSmithKline,Large Pharma,2959,Malarone,atovaquone and proguanil,Small Molecule (Chemical),Launched,In-House,,Jun-97,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1979,malaria,7/7/14 12:28
3073,46,GlaxoSmithKline,Large Pharma,2959,Malarone,atovaquone and proguanil,Small Molecule (Chemical),Launched,In-House,,Jun-97,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1979,malaria,7/7/14 12:28
3076,46,GlaxoSmithKline,Large Pharma,2962,Penbritin,ampicillin,Small Molecule (Chemical),Launched,In-House,,Jun-97,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2033,,7/7/14 12:28
3076,46,GlaxoSmithKline,Large Pharma,2962,Penbritin,ampicillin,Small Molecule (Chemical),Launched,In-House,,Jun-97,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2033,,7/7/14 12:28
3076,46,GlaxoSmithKline,Large Pharma,2962,Penbritin,ampicillin,Small Molecule (Chemical),Launched,In-House,,Jun-97,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2033,,7/7/14 12:28
3077,46,GlaxoSmithKline,Large Pharma,2963,Amoxil,amoxicillin,Small Molecule (Chemical),Launched,In-House,,Apr-72,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1762,Bacterial infections,7/7/14 12:28
3077,46,GlaxoSmithKline,Large Pharma,2963,Amoxil,amoxicillin,Small Molecule (Chemical),Launched,In-House,,Apr-72,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1762,Bacterial infections,7/7/14 12:28
3077,46,GlaxoSmithKline,Large Pharma,2963,Amoxil,amoxicillin,Small Molecule (Chemical),Launched,In-House,,Apr-72,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1762,Bacterial infections,7/7/14 12:28
3078,46,GlaxoSmithKline,Large Pharma,2965,Timentin,ticarcillin + clavulanic acid ,Small Molecule (Chemical),Launched,In-House,,Apr-85,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2130,,7/7/14 12:28
3078,46,GlaxoSmithKline,Large Pharma,2965,Timentin,ticarcillin + clavulanic acid ,Small Molecule (Chemical),Launched,In-House,,Apr-85,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2130,,7/7/14 12:28
3078,46,GlaxoSmithKline,Large Pharma,2965,Timentin,ticarcillin + clavulanic acid ,Small Molecule (Chemical),Launched,In-House,,Apr-85,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2130,,7/7/14 12:28
3080,46,GlaxoSmithKline,Large Pharma,2967,Bactroban,mupirocin,Small Molecule (Chemical),Launched,,,Apr-85,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1827,,7/7/14 12:28
3080,46,GlaxoSmithKline,Large Pharma,2967,Bactroban,mupirocin,Small Molecule (Chemical),Launched,,,Apr-85,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1827,,7/7/14 12:28
3080,46,GlaxoSmithKline,Large Pharma,2967,Bactroban,mupirocin,Small Molecule (Chemical),Launched,,,Apr-85,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1827,,7/7/14 12:28
3086,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2975,Pasetocin,amoxicillin,Small Molecule (Chemical),Launched,,,Jul-85,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1762,Bacterial infections,7/7/14 12:28
3086,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2975,Pasetocin,amoxicillin,Small Molecule (Chemical),Launched,,,Jul-85,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1762,Bacterial infections,7/7/14 12:28
3086,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,2975,Pasetocin,amoxicillin,Small Molecule (Chemical),Launched,,,Jul-85,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1762,Bacterial infections,7/7/14 12:28
3087,53,Johnson & Johnson,Large Pharma,2976,guselkumab,CNTO-1959,Small Molecule (Chemical),Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1863,Psoriasis,7/7/14 12:28
3087,53,Johnson & Johnson,Large Pharma,2976,guselkumab,CNTO-1959,Small Molecule (Chemical),Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1863,Psoriasis,7/7/14 12:28
3087,53,Johnson & Johnson,Large Pharma,2976,guselkumab,CNTO-1959,Small Molecule (Chemical),Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1863,Psoriasis,7/7/14 12:28
3090,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2979,Pazucross,pazufloxacin mesilate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-02,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2030,,7/7/14 12:28
3090,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2979,Pazucross,pazufloxacin mesilate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-02,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2030,,7/7/14 12:28
3090,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,2979,Pazucross,pazufloxacin mesilate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-02,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2030,,7/7/14 12:28
3092,67,Novartis,Large Pharma,2982,Symmetrel,amantadine,Small Molecule (Chemical),Launched,,,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2112,Influenza,7/7/14 12:28
3092,67,Novartis,Large Pharma,2982,Symmetrel,amantadine,Small Molecule (Chemical),Launched,,,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2112,Influenza,7/7/14 12:28
3092,67,Novartis,Large Pharma,2982,Symmetrel,amantadine,Small Molecule (Chemical),Launched,,,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2112,Influenza,7/7/14 12:28
3093,67,Novartis,Large Pharma,2983,Coartem/Riatem ,artemether and lumefantrine,Small Molecule (Chemical),Launched,,,Mar-99,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1864,,7/7/14 12:28
3093,67,Novartis,Large Pharma,2983,Coartem/Riatem ,artemether and lumefantrine,Small Molecule (Chemical),Launched,,,Mar-99,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1864,,7/7/14 12:28
3093,67,Novartis,Large Pharma,2983,Coartem/Riatem ,artemether and lumefantrine,Small Molecule (Chemical),Launched,,,Mar-99,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1864,,7/7/14 12:28
3095,46,GlaxoSmithKline,Large Pharma,2985,Rescriptor,delavirdine mesylate,Small Molecule (Chemical),Launched,Licensed (Marketed),May-97,May-97,,,91,NNRTIs,32,HIV,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2084,HIV,7/7/14 12:28
3095,46,GlaxoSmithKline,Large Pharma,2985,Rescriptor,delavirdine mesylate,Small Molecule (Chemical),Launched,Licensed (Marketed),May-97,May-97,,,91,NNRTIs,32,HIV,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2084,HIV,7/7/14 12:28
3095,46,GlaxoSmithKline,Large Pharma,2985,Rescriptor,delavirdine mesylate,Small Molecule (Chemical),Launched,Licensed (Marketed),May-97,May-97,,,91,NNRTIs,32,HIV,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2084,HIV,7/7/14 12:28
3096,84,Recordati,Regional & Specialty Pharma,2986,Octegra,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-00,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
3096,84,Recordati,Regional & Specialty Pharma,2986,Octegra,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-00,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
3096,84,Recordati,Regional & Specialty Pharma,2986,Octegra,moxifloxacin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-00,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1555,Bacterial infections,7/7/14 12:28
3097,84,Recordati,Regional & Specialty Pharma,2987,Darilin,valganciclovir,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-01,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1236,CMV,7/7/14 12:28
3097,84,Recordati,Regional & Specialty Pharma,2987,Darilin,valganciclovir,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-01,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1236,CMV,7/7/14 12:28
3097,84,Recordati,Regional & Specialty Pharma,2987,Darilin,valganciclovir,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-01,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1236,CMV,7/7/14 12:28
3098,84,Recordati,Regional & Specialty Pharma,2988,Diezme,cefodizime,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-93,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1881,,7/7/14 12:28
3098,84,Recordati,Regional & Specialty Pharma,2988,Diezme,cefodizime,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-93,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1881,,7/7/14 12:28
3098,84,Recordati,Regional & Specialty Pharma,2988,Diezme,cefodizime,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-93,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1881,,7/7/14 12:28
3099,84,Recordati,Regional & Specialty Pharma,2989,Lomexin,fenticonazole,Small Molecule (Chemical),Launched,In-House,,Oct-86,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1967,,7/7/14 12:28
3099,84,Recordati,Regional & Specialty Pharma,2989,Lomexin,fenticonazole,Small Molecule (Chemical),Launched,In-House,,Oct-86,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1967,,7/7/14 12:28
3099,84,Recordati,Regional & Specialty Pharma,2989,Lomexin,fenticonazole,Small Molecule (Chemical),Launched,In-House,,Oct-86,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1967,,7/7/14 12:28
3100,86,Roche,Large Pharma,2990,Lariam,mefloquine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-90,Aug-85,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1962,,7/7/14 12:28
3100,86,Roche,Large Pharma,2990,Lariam,mefloquine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-90,Aug-85,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1962,,7/7/14 12:28
3100,86,Roche,Large Pharma,2990,Lariam,mefloquine,Small Molecule (Chemical),Launched,Licensed (Development),Apr-90,Aug-85,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1962,,7/7/14 12:28
3101,89,Sanofi,Large Pharma,2991,Flisint,fumagillin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-06,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1909,,7/7/14 12:28
3101,89,Sanofi,Large Pharma,2991,Flisint,fumagillin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-06,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1909,,7/7/14 12:28
3101,89,Sanofi,Large Pharma,2991,Flisint,fumagillin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-06,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1909,,7/7/14 12:28
3102,58,Lundbeck,Regional & Specialty Pharma,2613,Cisordinol / Clopixol,zuclopenthixol,Small Molecule (Chemical),Launched,In-House,,Jun-82,,Expired,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1860,Schizophrenia,7/7/14 12:28
3102,58,Lundbeck,Regional & Specialty Pharma,2613,Cisordinol / Clopixol,zuclopenthixol,Small Molecule (Chemical),Launched,In-House,,Jun-82,,Expired,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1860,Schizophrenia,7/7/14 12:28
3102,58,Lundbeck,Regional & Specialty Pharma,2613,Cisordinol / Clopixol,zuclopenthixol,Small Molecule (Chemical),Launched,In-House,,Jun-82,,Expired,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1860,Schizophrenia,7/7/14 12:28
3103,58,Lundbeck,Regional & Specialty Pharma,2615,Fluanxol,flupenthixol,Small Molecule (Chemical),Launched,In-House,,Jul-65,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1910,Schizophrenia,7/7/14 12:28
3103,58,Lundbeck,Regional & Specialty Pharma,2615,Fluanxol,flupenthixol,Small Molecule (Chemical),Launched,In-House,,Jul-65,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1910,Schizophrenia,7/7/14 12:28
3103,58,Lundbeck,Regional & Specialty Pharma,2615,Fluanxol,flupenthixol,Small Molecule (Chemical),Launched,In-House,,Jul-65,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1910,Schizophrenia,7/7/14 12:28
3104,58,Lundbeck,Regional & Specialty Pharma,2618,Truxal,chlorprothixene,Small Molecule (Chemical),Launched,In-House,,Jul-59,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2146,Schizophrenia,7/7/14 12:28
3104,58,Lundbeck,Regional & Specialty Pharma,2618,Truxal,chlorprothixene,Small Molecule (Chemical),Launched,In-House,,Jul-59,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2146,Schizophrenia,7/7/14 12:28
3104,58,Lundbeck,Regional & Specialty Pharma,2618,Truxal,chlorprothixene,Small Molecule (Chemical),Launched,In-House,,Jul-59,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2146,Schizophrenia,7/7/14 12:28
3105,95,Shionogi,Regional & Specialty Pharma,2992,Broact,cefpirome,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-93,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1843,,7/7/14 12:28
3105,95,Shionogi,Regional & Specialty Pharma,2992,Broact,cefpirome,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-93,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1843,,7/7/14 12:28
3105,95,Shionogi,Regional & Specialty Pharma,2992,Broact,cefpirome,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-93,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1843,,7/7/14 12:28
3106,95,Shionogi,Regional & Specialty Pharma,2993,Keflex,cephalexin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-70,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1953,,7/7/14 12:28
3106,95,Shionogi,Regional & Specialty Pharma,2993,Keflex,cephalexin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-70,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1953,,7/7/14 12:28
3106,95,Shionogi,Regional & Specialty Pharma,2993,Keflex,cephalexin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-70,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1953,,7/7/14 12:28
3107,53,Johnson & Johnson,Large Pharma,2674,Haldol,haloperidol,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-67,Jul-59,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1765,Schizophrenia,7/7/14 12:28
3107,53,Johnson & Johnson,Large Pharma,2674,Haldol,haloperidol,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-67,Jul-59,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1765,Schizophrenia,7/7/14 12:28
3107,53,Johnson & Johnson,Large Pharma,2674,Haldol,haloperidol,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-67,Jul-59,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1765,Schizophrenia,7/7/14 12:28
3108,95,Shionogi,Regional & Specialty Pharma,2995,Shiomarin,moxalactam,Small Molecule (Chemical),Launched,In-House,,Jan-82,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2098,,7/7/14 12:28
3108,95,Shionogi,Regional & Specialty Pharma,2995,Shiomarin,moxalactam,Small Molecule (Chemical),Launched,In-House,,Jan-82,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2098,,7/7/14 12:28
3108,95,Shionogi,Regional & Specialty Pharma,2995,Shiomarin,moxalactam,Small Molecule (Chemical),Launched,In-House,,Jan-82,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2098,,7/7/14 12:28
3109,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2685,Serenace,haloperidol,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-59,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1765,Schizophrenia,7/7/14 12:28
3109,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2685,Serenace,haloperidol,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-59,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1765,Schizophrenia,7/7/14 12:28
3109,35,Dainippon-Sumitomo,Regional & Specialty Pharma,2685,Serenace,haloperidol,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-59,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1765,Schizophrenia,7/7/14 12:28
3110,150,Taisho,Regional & Specialty Pharma,2996,Ozex,tosufloxacin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-90,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,30.16512714,47.85861864,77.23612836,98.71767347,75.94013892,78.76500376,80.22753203,80.32980676,80.75175429,80.96541902,81.06696765,81.14667295,0.95182768,2025,bacterial infection,7/7/14 12:28
3110,150,Taisho,Regional & Specialty Pharma,2996,Ozex,tosufloxacin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-90,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,30.16512714,47.85861864,77.23612836,98.71767347,75.94013892,78.76500376,80.22753203,80.32980676,80.75175429,80.96541902,81.06696765,81.14667295,0.95182768,2025,bacterial infection,7/7/14 12:28
3110,150,Taisho,Regional & Specialty Pharma,2996,Ozex,tosufloxacin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Apr-90,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2025,bacterial infection,7/7/14 12:28
3111,150,Taisho,Regional & Specialty Pharma,2997,Pentcillin,piperacillin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-80,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,46.32501668,44.35676849,37.98498116,27.68910354,21.2632389,19.39471154,18.23011095,17.62156576,17.21062247,16.96224034,16.8145671,16.72235113,-3.373681733,2036,,7/7/14 12:28
3111,150,Taisho,Regional & Specialty Pharma,2997,Pentcillin,piperacillin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-80,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,46.32501668,44.35676849,37.98498116,27.68910354,21.2632389,19.39471154,18.23011095,17.62156576,17.21062247,16.96224034,16.8145671,16.72235113,-3.373681733,2036,,7/7/14 12:28
3111,150,Taisho,Regional & Specialty Pharma,2997,Pentcillin,piperacillin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-80,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2036,,7/7/14 12:28
3113,58,Lundbeck,Regional & Specialty Pharma,2614,Dixeran,melitracen,Small Molecule (Chemical),Launched,In-House,,Jul-68,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1884,Depression,7/7/14 12:28
3113,58,Lundbeck,Regional & Specialty Pharma,2614,Dixeran,melitracen,Small Molecule (Chemical),Launched,In-House,,Jul-68,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1884,Depression,7/7/14 12:28
3113,58,Lundbeck,Regional & Specialty Pharma,2614,Dixeran,melitracen,Small Molecule (Chemical),Launched,In-House,,Jul-68,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1884,Depression,7/7/14 12:28
3114,100,Takeda,Large Pharma,2998,Bestcall,cefmenoxime,Small Molecule (Chemical),Launched,In-House,,Feb-83,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1832,,7/7/14 12:28
3114,100,Takeda,Large Pharma,2998,Bestcall,cefmenoxime,Small Molecule (Chemical),Launched,In-House,,Feb-83,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1832,,7/7/14 12:28
3114,100,Takeda,Large Pharma,2998,Bestcall,cefmenoxime,Small Molecule (Chemical),Launched,In-House,,Feb-83,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1832,,7/7/14 12:28
3115,100,Takeda,Large Pharma,2999,Amasulin,carumonam,Small Molecule (Chemical),Launched,In-House,,Jan-88,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1800,bacterial infections,7/7/14 12:28
3115,100,Takeda,Large Pharma,2999,Amasulin,carumonam,Small Molecule (Chemical),Launched,In-House,,Jan-88,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1800,bacterial infections,7/7/14 12:28
3115,100,Takeda,Large Pharma,2999,Amasulin,carumonam,Small Molecule (Chemical),Launched,In-House,,Jan-88,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1800,bacterial infections,7/7/14 12:28
3116,58,Lundbeck,Regional & Specialty Pharma,2616,Noritren,nortriptyline,Small Molecule (Chemical),Launched,In-House,,Jul-63,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2008,Depression,7/7/14 12:28
3116,58,Lundbeck,Regional & Specialty Pharma,2616,Noritren,nortriptyline,Small Molecule (Chemical),Launched,In-House,,Jul-63,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2008,Depression,7/7/14 12:28
3116,58,Lundbeck,Regional & Specialty Pharma,2616,Noritren,nortriptyline,Small Molecule (Chemical),Launched,In-House,,Jul-63,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2008,Depression,7/7/14 12:28
3117,58,Lundbeck,Regional & Specialty Pharma,2617,Saroten,amitriptyline,Small Molecule (Chemical),Launched,In-House,,Jul-61,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1761,Depression,7/7/14 12:28
3117,58,Lundbeck,Regional & Specialty Pharma,2617,Saroten,amitriptyline,Small Molecule (Chemical),Launched,In-House,,Jul-61,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1761,Depression,7/7/14 12:28
3117,58,Lundbeck,Regional & Specialty Pharma,2617,Saroten,amitriptyline,Small Molecule (Chemical),Launched,In-House,,Jul-61,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1761,Depression,7/7/14 12:28
3118,58,Lundbeck,Regional & Specialty Pharma,2619,Tymelyt,lofepramine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-80,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1769,Depression,7/7/14 12:28
3118,58,Lundbeck,Regional & Specialty Pharma,2619,Tymelyt,lofepramine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-80,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1769,Depression,7/7/14 12:28
3118,58,Lundbeck,Regional & Specialty Pharma,2619,Tymelyt,lofepramine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-80,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1769,Depression,7/7/14 12:28
3119,63,Merck KGaA,Regional & Specialty Pharma,2692,Gamanil,lofepramine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-80,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1769,Depression,7/7/14 12:28
3119,63,Merck KGaA,Regional & Specialty Pharma,2692,Gamanil,lofepramine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-80,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1769,Depression,7/7/14 12:28
3119,63,Merck KGaA,Regional & Specialty Pharma,2692,Gamanil,lofepramine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-80,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1769,Depression,7/7/14 12:28
3120,61,Merck & Co,Large Pharma,2630,Tolvon,mianserin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-74,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2134,Depression,7/7/14 12:28
3120,61,Merck & Co,Large Pharma,2630,Tolvon,mianserin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-74,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2134,Depression,7/7/14 12:28
3120,61,Merck & Co,Large Pharma,2630,Tolvon,mianserin,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jul-74,,Expired,46,Other Anti-depressants,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2134,Depression,7/7/14 12:28
3122,238,Bayhill Therapeutics,Small Biotech,3003,BHT-3009,BHT-3009,Vaccine,Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1835,Multiple sclerosis,7/7/14 12:28
3122,238,Bayhill Therapeutics,Small Biotech,3003,BHT-3009,BHT-3009,Vaccine,Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1835,Multiple sclerosis,7/7/14 12:28
3122,238,Bayhill Therapeutics,Small Biotech,3003,BHT-3009,BHT-3009,Vaccine,Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1835,Multiple sclerosis,7/7/14 12:28
3123,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Phase III,In-House,Aug-17,Oct-17,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,12.916675,82.36120472,210.6946458,339.0285663,0,1168,Ulcerative Colitis,7/7/14 12:28
3123,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Phase III,In-House,Aug-17,Oct-17,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,2.5,19.166675,55.83329094,92.50012977,0,1168,Ulcerative Colitis,7/7/14 12:28
3123,76,Pfizer,Large Pharma,3498,Xeljanz,tofacitinib,Small Molecule (Chemical),Phase III,In-House,Aug-17,Oct-17,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,10.416675,63.19452972,154.8613548,246.5284366,0,1168,Ulcerative Colitis,7/7/14 12:28
3124,46,GlaxoSmithKline,Large Pharma,3016,S/GSK1265744,S/GSK1265744,Small Molecule (Chemical),Phase II,In-House,,,,,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2193,HIV,7/7/14 12:28
3124,46,GlaxoSmithKline,Large Pharma,3016,S/GSK1265744,S/GSK1265744,Small Molecule (Chemical),Phase II,In-House,,,,,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2193,HIV,7/7/14 12:28
3124,46,GlaxoSmithKline,Large Pharma,3016,S/GSK1265744,S/GSK1265744,Small Molecule (Chemical),Phase II,In-House,,,,,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2193,HIV,7/7/14 12:28
3125,46,GlaxoSmithKline,Large Pharma,342,Selzentry,maraviroc,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-07,Oct-07,May-21,Dec-22,26,Other HIV Treatments,32,HIV,7,Anti-infectives,4,Global,Sales,0,123.6000046,176.3498782,202.8836959,223.3065612,226.2483315,227.653936,228.2762607,228.4083805,228.4617683,228.4808478,228.4860458,0.328102442,1076,HIV,7/7/14 12:28
3125,46,GlaxoSmithKline,Large Pharma,342,Selzentry,maraviroc,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-07,Oct-07,May-21,Dec-22,26,Other HIV Treatments,32,HIV,7,Anti-infectives,4,ROW,Sales,0,71.07000267,104.2067462,112.53705,132.8901924,134.8600941,135.8028327,136.3468226,136.4417023,136.4816208,136.4973429,136.5012241,0.383739972,1076,HIV,7/7/14 12:28
3125,46,GlaxoSmithKline,Large Pharma,342,Selzentry,maraviroc,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-07,Oct-07,May-21,Dec-22,26,Other HIV Treatments,32,HIV,7,Anti-infectives,4,US,Sales,0,52.53000197,72.14313197,90.34664581,90.41636884,91.38823744,91.85110332,91.92943806,91.96667814,91.9801475,91.98350487,91.98482162,0.245991228,1076,HIV,7/7/14 12:28
3126,37,Eisai,Regional & Specialty Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-11,N/A,Dec-21,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,Global,Sales,0,0,25.11596454,30.09685155,28.18962229,37.09162311,40.29004454,42.72698168,44.70617927,45.88636138,46.72198026,47.30583205,7.675745245,1579,Pancreatic Insufficiency,7/7/14 12:28
3126,37,Eisai,Regional & Specialty Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-11,N/A,Dec-21,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,ROW,Sales,0,0,25.11596454,30.09685155,28.18962229,37.09162311,40.29004454,42.72698168,44.70617927,45.88636138,46.72198026,47.30583205,7.675745245,1579,Pancreatic Insufficiency,7/7/14 12:28
3126,37,Eisai,Regional & Specialty Pharma,768,Creon,pancrelipase,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-11,N/A,Dec-21,114,Other Lower GI,14,Other Lower GI Disorders,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1579,Pancreatic Insufficiency,7/7/14 12:28
3128,102,Teva,Regional & Specialty Pharma,3020,CEP-33237,hydrocodone - extended release,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2194,Pain,7/7/14 12:28
3128,102,Teva,Regional & Specialty Pharma,3020,CEP-33237,hydrocodone - extended release,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2194,Pain,7/7/14 12:28
3128,102,Teva,Regional & Specialty Pharma,3020,CEP-33237,hydrocodone - extended release,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2194,Pain,7/7/14 12:28
3134,86,Roche,Large Pharma,3027,RG7449,Anti-M1 prime MAb,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2183,Asthma,7/7/14 12:28
3134,86,Roche,Large Pharma,3027,RG7449,Anti-M1 prime MAb,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2183,Asthma,7/7/14 12:28
3134,86,Roche,Large Pharma,3027,RG7449,Anti-M1 prime MAb,Antibody/Antibody Derivative,Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2183,Asthma,7/7/14 12:28
3140,63,Merck KGaA,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-97,,Expired,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,280,Alcohol Addiction,7/7/14 12:28
3140,63,Merck KGaA,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-97,,Expired,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,280,Alcohol Addiction,7/7/14 12:28
3140,63,Merck KGaA,Regional & Specialty Pharma,315,Campral / Regtect,acamprosate,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-97,,Expired,15,Alcohol Dependence Treatments,16,Addictions,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,280,Alcohol Addiction,7/7/14 12:28
3142,78,Pierre Fabre,Regional & Specialty Pharma,3033,Ixel,milnacipran,Small Molecule (Chemical),Launched,In-House,,Sep-97,,Nov-22,66,Noradrenergics,49,Depression,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1754,Depression,7/7/14 12:28
3142,78,Pierre Fabre,Regional & Specialty Pharma,3033,Ixel,milnacipran,Small Molecule (Chemical),Launched,In-House,,Sep-97,,Nov-22,66,Noradrenergics,49,Depression,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1754,Depression,7/7/14 12:28
3142,78,Pierre Fabre,Regional & Specialty Pharma,3033,Ixel,milnacipran,Small Molecule (Chemical),Launched,In-House,,Sep-97,,Nov-22,66,Noradrenergics,49,Depression,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1754,Depression,7/7/14 12:28
3143,53,Johnson & Johnson,Large Pharma,2515,Toledomin,milnacipran,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-01,,,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1754,Depression,7/7/14 12:28
3143,53,Johnson & Johnson,Large Pharma,2515,Toledomin,milnacipran,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-01,,,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1754,Depression,7/7/14 12:28
3143,53,Johnson & Johnson,Large Pharma,2515,Toledomin,milnacipran,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-01,,,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1754,Depression,7/7/14 12:28
3144,95,Shionogi,Regional & Specialty Pharma,3034,Irtra,irbesartan + trichloromethiazide ,Small Molecule (Chemical),Launched,In-House,,Sep-13,,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,10.13976476,24.1422729,35.73056389,47.31870037,55.76844039,62.78171879,68.63315075,73.336904,32.6649696,2186,Hypertension,7/7/14 12:28
3144,95,Shionogi,Regional & Specialty Pharma,3034,Irtra,irbesartan + trichloromethiazide ,Small Molecule (Chemical),Launched,In-House,,Sep-13,,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,10.13976476,24.1422729,35.73056389,47.31870037,55.76844039,62.78171879,68.63315075,73.336904,32.6649696,2186,Hypertension,7/7/14 12:28
3144,95,Shionogi,Regional & Specialty Pharma,3034,Irtra,irbesartan + trichloromethiazide ,Small Molecule (Chemical),Launched,In-House,,Sep-13,,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2186,Hypertension,7/7/14 12:28
3145,244,Dong A,Regional & Specialty Pharma,3040,Udenafil ED,udenafil,Small Molecule (Chemical),Launched,In-House,,Dec-05,,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2180,erectile dysfunction,7/7/14 12:28
3145,244,Dong A,Regional & Specialty Pharma,3040,Udenafil ED,udenafil,Small Molecule (Chemical),Launched,In-House,,Dec-05,,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,3,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2180,erectile dysfunction,7/7/14 12:28
3145,244,Dong A,Regional & Specialty Pharma,3040,Udenafil ED,udenafil,Small Molecule (Chemical),Launched,In-House,,Dec-05,,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2180,erectile dysfunction,7/7/14 12:28
3145,244,Dong A,Regional & Specialty Pharma,3040,Udenafil ED,udenafil,Small Molecule (Chemical),Launched,In-House,,Dec-05,,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,3,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2180,erectile dysfunction,7/7/14 12:28
3145,244,Dong A,Regional & Specialty Pharma,3040,Udenafil ED,udenafil,Small Molecule (Chemical),Launched,In-House,,Dec-05,,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,2180,erectile dysfunction,7/7/14 12:28
3145,244,Dong A,Regional & Specialty Pharma,3040,Udenafil ED,udenafil,Small Molecule (Chemical),Launched,In-House,,Dec-05,,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2180,erectile dysfunction,7/7/14 12:28
3146,111,Actavis,Regional & Specialty Pharma,3040,Udenafil ED,udenafil,Small Molecule (Chemical),Phase III,Corporate Acquisition,May-15,,May-20,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,6.66667,14.44447389,21.11117637,27.77787475,33.28901132,38.16014596,0,2180,Erectile dysfunction,7/7/14 12:28
3146,111,Actavis,Regional & Specialty Pharma,3040,Udenafil ED,udenafil,Small Molecule (Chemical),Phase III,Corporate Acquisition,May-15,,May-20,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2180,Erectile dysfunction,7/7/14 12:28
3146,111,Actavis,Regional & Specialty Pharma,3040,Udenafil ED,udenafil,Small Molecule (Chemical),Phase III,Corporate Acquisition,May-15,,May-20,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,6.66667,14.44447389,21.11117637,27.77787475,33.28901132,38.16014596,0,2180,Erectile dysfunction,7/7/14 12:28
3148,245,InterMune,Regional & Specialty Pharma,3046,Esbriet,pirfenidone,Small Molecule (Chemical),Launched,Licensed (Development),Aug-15,Sep-11,Jan-22,Jan-22,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,Global,Sales,0,0,2.8,26.174,70.339,88.91904685,118.9983571,181.7657405,235.2402228,270.1032399,305.3305532,335.1092748,24.98435529,911,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3148,245,InterMune,Regional & Specialty Pharma,3046,Esbriet,pirfenidone,Small Molecule (Chemical),Launched,Licensed (Development),Aug-15,Sep-11,Jan-22,Jan-22,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,ROW,Sales,0,0,2.8,26.174,70.339,88.91904685,106.6083571,121.721942,132.4986787,141.2478776,148.1575969,153.5103252,11.79442637,911,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3148,245,InterMune,Regional & Specialty Pharma,3046,Esbriet,pirfenidone,Small Molecule (Chemical),Launched,Licensed (Development),Aug-15,Sep-11,Jan-22,Jan-22,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,US,Sales,0,0,0,0,0,0,12.39,60.0437985,102.7415441,128.8553623,157.1729563,181.5989496,0,911,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3149,157,Teijin,Regional & Specialty Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-07,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,Global,Sales,11.85058566,14.00740058,16.4601585,15.65036287,16.2236155,17.63892968,18.95759373,20.32642699,21.41688994,22.39258135,23.26358235,24.02062275,5.766483164,1391,Asthma,7/7/14 12:28
3149,157,Teijin,Regional & Specialty Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-07,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,ROW,Sales,11.85058566,14.00740058,16.4601585,15.65036287,16.2236155,17.63892968,18.95759373,20.32642699,21.41688994,22.39258135,23.26358235,24.02062275,5.766483164,1391,Asthma,7/7/14 12:28
3149,157,Teijin,Regional & Specialty Pharma,1439,Alvesco,ciclesonide,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-07,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1391,Asthma,7/7/14 12:28
3152,46,GlaxoSmithKline,Large Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-01,N/A,May-19,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,4,Global,Sales,55.66564232,68.43263911,102.6035655,204.4687247,214.1877218,237.7839756,257.5150622,268.2102972,277.0027041,283.3557493,287.7300597,286.0022892,4.217165941,1520,Allergic Rhinitis,7/7/14 12:28
3152,46,GlaxoSmithKline,Large Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-01,N/A,May-19,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,4,ROW,Sales,55.66564232,68.43263911,102.6035655,204.4687247,214.1877218,237.7839756,257.5150622,268.2102972,277.0027041,283.3557493,287.7300597,286.0022892,4.217165941,1520,Allergic Rhinitis,7/7/14 12:28
3152,46,GlaxoSmithKline,Large Pharma,183,Xyzal,levocetirizine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Feb-01,N/A,May-19,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1520,Allergic Rhinitis,7/7/14 12:28
3153,246,Senju,Regional & Specialty Pharma,3053,Y-39983,Y-39983,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2200,Glaucoma,7/7/14 12:28
3153,246,Senju,Regional & Specialty Pharma,3053,Y-39983,Y-39983,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2200,Glaucoma,7/7/14 12:28
3153,246,Senju,Regional & Specialty Pharma,3053,Y-39983,Y-39983,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2200,Glaucoma,7/7/14 12:28
3156,91,Santen,Regional & Specialty Pharma,3059,lomerizine,lomerizine,Small Molecule (Chemical),Phase II,Licensed (Marketed),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2187,Glaucoma,7/7/14 12:28
3156,91,Santen,Regional & Specialty Pharma,3059,lomerizine,lomerizine,Small Molecule (Chemical),Phase II,Licensed (Marketed),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2187,Glaucoma,7/7/14 12:28
3156,91,Santen,Regional & Specialty Pharma,3059,lomerizine,lomerizine,Small Molecule (Chemical),Phase II,Licensed (Marketed),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2187,Glaucoma,7/7/14 12:28
3160,91,Santen,Regional & Specialty Pharma,3569,Diquas,diquafosol tetrasodium,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-10,N/A,Nov-20,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,Global,Sales,0,11.52194675,36.03508546,66.97151433,78.96844845,93.02650003,104.6595034,113.4352588,119.8488922,124.7485786,128.4260292,131.1808439,7.519710162,2073,Dry Eye,7/7/14 12:28
3160,91,Santen,Regional & Specialty Pharma,3569,Diquas,diquafosol tetrasodium,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-10,N/A,Nov-20,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,ROW,Sales,0,11.52194675,36.03508546,66.97151433,78.96844845,93.02650003,104.6595034,113.4352588,119.8488922,124.7485786,128.4260292,131.1808439,7.519710162,2073,Dry Eye,7/7/14 12:28
3160,91,Santen,Regional & Specialty Pharma,3569,Diquas,diquafosol tetrasodium,Small Molecule (Chemical),Launched,Licensed (Development),,Dec-10,N/A,Nov-20,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2073,Dry Eye,7/7/14 12:28
3161,91,Santen,Regional & Specialty Pharma,3065,Cyclokat,cyclosporin A,Small Molecule (Chemical),Phase III,Corporate Acquisition,Sep-16,Mar-15,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,4.194882591,53.13531931,92.56735891,134.2369002,155.9105489,173.0704024,183.6884163,0,2196,Dry Eye,7/7/14 12:28
3161,91,Santen,Regional & Specialty Pharma,3065,Cyclokat,cyclosporin A,Small Molecule (Chemical),Phase III,Corporate Acquisition,Sep-16,Mar-15,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,4.194882591,53.13531931,86.69452429,120.2539746,135.2158191,145.6639577,152.7862632,0,2196,Dry Eye,7/7/14 12:28
3161,91,Santen,Regional & Specialty Pharma,3065,Cyclokat,cyclosporin A,Small Molecule (Chemical),Phase III,Corporate Acquisition,Sep-16,Mar-15,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,5.87283462,13.98292559,20.69472987,27.40644466,30.9021531,0,2196,Dry Eye,7/7/14 12:28
3162,250,EyeGate,Small Biotech,3067,EGP-437,EGP-437,Small Molecule (Chemical),Phase III,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2197,Uveitis,7/7/14 12:28
3162,250,EyeGate,Small Biotech,3067,EGP-437,EGP-437,Small Molecule (Chemical),Phase III,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2197,Uveitis,7/7/14 12:28
3162,250,EyeGate,Small Biotech,3067,EGP-437,EGP-437,Small Molecule (Chemical),Phase III,In-House,,,,,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2197,Uveitis,7/7/14 12:28
3165,89,Sanofi,Large Pharma,1274,Ferrlecit,ferric gluconate complex,Small Molecule (Chemical),Launched,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,446,Iron-deficiency Anemia,7/7/14 12:28
3165,89,Sanofi,Large Pharma,1274,Ferrlecit,ferric gluconate complex,Small Molecule (Chemical),Launched,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,446,Iron-deficiency Anemia,7/7/14 12:28
3165,89,Sanofi,Large Pharma,1274,Ferrlecit,ferric gluconate complex,Small Molecule (Chemical),Launched,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,446,Iron-deficiency Anemia,7/7/14 12:28
3166,96,Shire,Regional & Specialty Pharma,3069,Resolor,prucalopride,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-10,N/A,Dec-15,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,0.3,6.1,11.8,18.178372,22.1168429,25.1278122,25.23588658,24.04195054,23.73697615,23.03441284,22.02710353,2.78142097,2199,Constipation,7/7/14 12:28
3166,96,Shire,Regional & Specialty Pharma,3069,Resolor,prucalopride,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-10,N/A,Dec-15,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0.3,6.1,11.8,18.178372,22.1168429,25.1278122,25.23588658,24.04195054,23.73697615,23.03441284,22.02710353,2.78142097,2199,Constipation,7/7/14 12:28
3166,96,Shire,Regional & Specialty Pharma,3069,Resolor,prucalopride,Small Molecule (Chemical),Launched,Corporate Acquisition,,Oct-10,N/A,Dec-15,5,IBS Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2199,Constipation,7/7/14 12:28
3169,252,BioLineRx,Small Biotech,3073,BL-1020,BL-1020,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2203,Schizophrenia,7/7/14 12:28
3169,252,BioLineRx,Small Biotech,3073,BL-1020,BL-1020,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2203,Schizophrenia,7/7/14 12:28
3169,252,BioLineRx,Small Biotech,3073,BL-1020,BL-1020,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,67,Other Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2203,Schizophrenia,7/7/14 12:28
3170,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1368,cariprazine,cariprazine,Small Molecule (Chemical),Phase III,Licensed (Development),,May-18,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,11.46027938,20.14235783,30.20316674,0,1380,Schizophrenia,7/7/14 12:28
3170,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1368,cariprazine,cariprazine,Small Molecule (Chemical),Phase III,Licensed (Development),,May-18,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,11.46027938,20.14235783,30.20316674,0,1380,Schizophrenia,7/7/14 12:28
3170,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1368,cariprazine,cariprazine,Small Molecule (Chemical),Phase III,Licensed (Development),,May-18,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1380,Schizophrenia,7/7/14 12:28
3171,39,Eli Lilly,Large Pharma,3075,Permax,pergolide,Small Molecule (Chemical),Launched,In-House,,Jul-89,,,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2213,Parkinson's disease,7/7/14 12:28
3171,39,Eli Lilly,Large Pharma,3075,Permax,pergolide,Small Molecule (Chemical),Launched,In-House,,Jul-89,,,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2213,Parkinson's disease,7/7/14 12:28
3171,39,Eli Lilly,Large Pharma,3075,Permax,pergolide,Small Molecule (Chemical),Launched,In-House,,Jul-89,,,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2213,Parkinson's disease,7/7/14 12:28
3172,253,NeurAxon,Small Biotech,3076,NXN-188,NXN-188,Small Molecule (Chemical),Phase II,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,8,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2212,Migraine,7/7/14 12:28
3172,253,NeurAxon,Small Biotech,3076,NXN-188,NXN-188,Small Molecule (Chemical),Phase II,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,8,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2212,Migraine,7/7/14 12:28
3172,253,NeurAxon,Small Biotech,3076,NXN-188,NXN-188,Small Molecule (Chemical),Phase II,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,8,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2212,Migraine,7/7/14 12:28
3174,254,Noven,Regional & Specialty Pharma,3077,Lithobid,lithium carbonate,Small Molecule (Chemical),Launched,Acquisition (Marketed),May-79,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2210,Bipolar disorder,7/7/14 12:28
3174,254,Noven,Regional & Specialty Pharma,3077,Lithobid,lithium carbonate,Small Molecule (Chemical),Launched,Acquisition (Marketed),May-79,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2210,Bipolar disorder,7/7/14 12:28
3174,254,Noven,Regional & Specialty Pharma,3077,Lithobid,lithium carbonate,Small Molecule (Chemical),Launched,Acquisition (Marketed),May-79,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2210,Bipolar disorder,7/7/14 12:28
3175,15,Astellas Pharma,Regional & Specialty Pharma,1418,Symbicort,formoterol + budesonide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-10,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,7,Global,Sales,16.15988954,138.9067224,253.2332077,333.4731165,360.9754449,417.4065872,465.2513946,505.3415523,537.320877,563.6308468,585.1676165,602.707685,7.597980679,1370,Asthma,7/7/14 12:28
3175,15,Astellas Pharma,Regional & Specialty Pharma,1418,Symbicort,formoterol + budesonide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-10,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,7,ROW,Sales,16.15988954,138.9067224,253.2332077,333.4731165,360.9754449,417.4065872,465.2513946,505.3415523,537.320877,563.6308468,585.1676165,602.707685,7.597980679,1370,Asthma,7/7/14 12:28
3175,15,Astellas Pharma,Regional & Specialty Pharma,1418,Symbicort,formoterol + budesonide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jan-10,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1370,Asthma,7/7/14 12:28
3176,255,Kyorin,Regional & Specialty Pharma,735,Flutiform,formoterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Development),,Nov-13,N/A,Dec-21,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,3,Global,Sales,0,0,0,0,0.595186069,7.597371613,14.36146351,18.44370951,22.82033965,26.63298545,29.86159437,32.76833375,77.29059368,1472,Asthma,7/7/14 12:28
3176,255,Kyorin,Regional & Specialty Pharma,735,Flutiform,formoterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Development),,Nov-13,N/A,Dec-21,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,3,ROW,Sales,0,0,0,0,0.595186069,7.597371613,14.36146351,18.44370951,22.82033965,26.63298545,29.86159437,32.76833375,77.29059368,1472,Asthma,7/7/14 12:28
3176,255,Kyorin,Regional & Specialty Pharma,735,Flutiform,formoterol + fluticasone propionate,Small Molecule (Chemical),Launched,Licensed (Development),,Nov-13,N/A,Dec-21,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1472,Asthma,7/7/14 12:28
3177,256,Dynavax Technologies,Small Biotech,3078,Heplisav,Hepatitis B vaccine,Vaccine,Filed,In-House,Sep-14,Jul-18,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,3.999996,14.66666533,22.66659794,30.66654702,41.63984875,54.86383422,65.61661787,0,2209,Hepatitis B,7/7/14 12:28
3177,256,Dynavax Technologies,Small Biotech,3078,Heplisav,Hepatitis B vaccine,Vaccine,Filed,In-House,Sep-14,Jul-18,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,5,13.33335,20.000025,0,2209,Hepatitis B,7/7/14 12:28
3177,256,Dynavax Technologies,Small Biotech,3078,Heplisav,Hepatitis B vaccine,Vaccine,Filed,In-House,Sep-14,Jul-18,N/A,N/A,17,Hepatitis Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,3.999996,14.66666533,22.66659794,30.66654702,36.63984875,41.53048422,45.61659287,0,2209,Hepatitis B,7/7/14 12:28
3179,34,Daiichi-Sankyo,Regional & Specialty Pharma,2713,Feron,interferon beta,Recombinant Protein,Launched,Licensed (Marketed),,Jul-92,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1905,Hepatitis,7/7/14 12:28
3179,34,Daiichi-Sankyo,Regional & Specialty Pharma,2713,Feron,interferon beta,Recombinant Protein,Launched,Licensed (Marketed),,Jul-92,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1905,Hepatitis,7/7/14 12:28
3179,34,Daiichi-Sankyo,Regional & Specialty Pharma,2713,Feron,interferon beta,Recombinant Protein,Launched,Licensed (Marketed),,Jul-92,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1905,Hepatitis,7/7/14 12:28
3180,19,Bayer,Large Pharma,3083,FC Patch Low,gestodene + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-09,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,2,Global,Sales,6.947492013,10.94958238,13.90437038,16.67248765,38.55813978,86.32195433,111.1784134,135.9972705,159.5325739,178.8802544,196.2388165,211.5913332,27.53396618,2205,Female contraception,7/7/14 12:28
3180,19,Bayer,Large Pharma,3083,FC Patch Low,gestodene + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-09,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,2,ROW,Sales,6.947492013,10.94958238,13.90437038,16.67248765,38.55813978,86.32195433,111.1784134,135.9972705,159.5325739,178.8802544,196.2388165,211.5913332,27.53396618,2205,Female contraception,7/7/14 12:28
3180,19,Bayer,Large Pharma,3083,FC Patch Low,gestodene + ethinyl estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-09,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2205,Female contraception,7/7/14 12:28
3181,197,HRA Pharma,Regional & Specialty Pharma,2804,EllaOne,ulipristal acetate,Small Molecule (Chemical),Launched,In-House,,Oct-09,N/A,May-19,89,Contraceptives,3,Contraception,2,Genitourinary,2,Global,Sales,11.11598722,23.84558658,37.54180001,45.38636766,53.35432498,58.71311365,62.80793374,65.77592555,68.04644535,69.75321823,71.03010267,71.9928495,4.373083681,1893,Emergency contraception,7/7/14 12:28
3181,197,HRA Pharma,Regional & Specialty Pharma,2804,EllaOne,ulipristal acetate,Small Molecule (Chemical),Launched,In-House,,Oct-09,N/A,May-19,89,Contraceptives,3,Contraception,2,Genitourinary,2,ROW,Sales,11.11598722,23.84558658,37.54180001,45.38636766,53.35432498,58.71311365,62.80793374,65.77592555,68.04644535,69.75321823,71.03010267,71.9928495,4.373083681,1893,Emergency contraception,7/7/14 12:28
3181,197,HRA Pharma,Regional & Specialty Pharma,2804,EllaOne,ulipristal acetate,Small Molecule (Chemical),Launched,In-House,,Oct-09,N/A,May-19,89,Contraceptives,3,Contraception,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1893,Emergency contraception,7/7/14 12:28
3182,34,Daiichi-Sankyo,Regional & Specialty Pharma,3087,Rezaltas,olmesartan + azelnidipine,Small Molecule (Chemical),Launched,In-House,,Apr-10,N/A,Dec-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,54.29058493,170.9324152,203.4547173,211.4221671,240.3253894,256.694539,278.4423395,289.0674966,252.5707593,236.1129266,224.30747,0.848735204,2217,hypertension,7/7/14 12:28
3182,34,Daiichi-Sankyo,Regional & Specialty Pharma,3087,Rezaltas,olmesartan + azelnidipine,Small Molecule (Chemical),Launched,In-House,,Apr-10,N/A,Dec-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,54.29058493,170.9324152,203.4547173,211.4221671,240.3253894,256.694539,278.4423395,289.0674966,252.5707593,236.1129266,224.30747,0.848735204,2217,hypertension,7/7/14 12:28
3182,34,Daiichi-Sankyo,Regional & Specialty Pharma,3087,Rezaltas,olmesartan + azelnidipine,Small Molecule (Chemical),Launched,In-House,,Apr-10,N/A,Dec-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2217,hypertension,7/7/14 12:28
3184,53,Johnson & Johnson,Large Pharma,3093,Monistat,miconazole,Small Molecule (Chemical),Launched,In-House,Jul-74,Jul-74,Expired,Expired,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2211,,7/7/14 12:28
3184,53,Johnson & Johnson,Large Pharma,3093,Monistat,miconazole,Small Molecule (Chemical),Launched,In-House,Jul-74,Jul-74,Expired,Expired,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2211,,7/7/14 12:28
3184,53,Johnson & Johnson,Large Pharma,3093,Monistat,miconazole,Small Molecule (Chemical),Launched,In-House,Jul-74,Jul-74,Expired,Expired,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2211,,7/7/14 12:28
3185,53,Johnson & Johnson,Large Pharma,3094,Pevaryl/Spectazole ,econazole,Small Molecule (Chemical),Launched,In-House,,Jan-74,Expired,Expired,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2214,,7/7/14 12:28
3185,53,Johnson & Johnson,Large Pharma,3094,Pevaryl/Spectazole ,econazole,Small Molecule (Chemical),Launched,In-House,,Jan-74,Expired,Expired,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2214,,7/7/14 12:28
3185,53,Johnson & Johnson,Large Pharma,3094,Pevaryl/Spectazole ,econazole,Small Molecule (Chemical),Launched,In-House,,Jan-74,Expired,Expired,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2214,,7/7/14 12:28
3186,76,Pfizer,Large Pharma,3095,Prodif,fosfluconazole,Small Molecule (Chemical),Launched,In-House,,Jan-04,N/A,,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2215,,7/7/14 12:28
3186,76,Pfizer,Large Pharma,3095,Prodif,fosfluconazole,Small Molecule (Chemical),Launched,In-House,,Jan-04,N/A,,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2215,,7/7/14 12:28
3186,76,Pfizer,Large Pharma,3095,Prodif,fosfluconazole,Small Molecule (Chemical),Launched,In-House,,Jan-04,N/A,,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2215,,7/7/14 12:28
3187,259,Ardea Biosciences,Small Biotech,3098,RDEA806,RDEA806,Small Molecule (Chemical),Phase II,In-House,,,,,91,NNRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2216,HIV treatment,7/7/14 12:28
3187,259,Ardea Biosciences,Small Biotech,3098,RDEA806,RDEA806,Small Molecule (Chemical),Phase II,In-House,,,,,91,NNRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2216,HIV treatment,7/7/14 12:28
3187,259,Ardea Biosciences,Small Biotech,3098,RDEA806,RDEA806,Small Molecule (Chemical),Phase II,In-House,,,,,91,NNRTIs,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2216,HIV treatment,7/7/14 12:28
3189,261,Achillion,Small Biotech,3099,elvucitabine,elvucitabine,Small Molecule (Chemical),Phase II,In-House,,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2204,,7/7/14 12:28
3189,261,Achillion,Small Biotech,3099,elvucitabine,elvucitabine,Small Molecule (Chemical),Phase II,In-House,,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2204,,7/7/14 12:28
3189,261,Achillion,Small Biotech,3099,elvucitabine,elvucitabine,Small Molecule (Chemical),Phase II,In-House,,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2204,,7/7/14 12:28
3190,105,UCB,Regional & Specialty Pharma,2889,CDP-7657,CDP-7657,Antibody/Antibody Derivative,Phase I,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1855,Anti-CD40L antibody fragment for Systemic Lupus Erythematosus,7/7/14 12:28
3190,105,UCB,Regional & Specialty Pharma,2889,CDP-7657,CDP-7657,Antibody/Antibody Derivative,Phase I,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1855,Anti-CD40L antibody fragment for Systemic Lupus Erythematosus,7/7/14 12:28
3190,105,UCB,Regional & Specialty Pharma,2889,CDP-7657,CDP-7657,Antibody/Antibody Derivative,Phase I,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1855,Anti-CD40L antibody fragment for Systemic Lupus Erythematosus,7/7/14 12:28
3191,176,Anthera,Small Biotech,4351,blisibimod,A-623,Synthetic Peptide,Phase III,Licensed (Development),Sep-16,Sep-17,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,3.33333,20.55554611,55.5555619,97.22221705,134.8443716,0,2201,Systemic lupus erythematosus,7/7/14 12:28
3191,176,Anthera,Small Biotech,4351,blisibimod,A-623,Synthetic Peptide,Phase III,Licensed (Development),Sep-16,Sep-17,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,4.999995,23.33332667,48.33335286,73.33329629,0,2201,Systemic lupus erythematosus,7/7/14 12:28
3191,176,Anthera,Small Biotech,4351,blisibimod,A-623,Synthetic Peptide,Phase III,Licensed (Development),Sep-16,Sep-17,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,3.33333,15.55555111,32.22223524,48.88886419,61.51107534,0,2201,Systemic lupus erythematosus,7/7/14 12:28
3194,111,Actavis,Regional & Specialty Pharma,758,Enablex,darifenacin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,,Mar-16,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,421,Overactive bladder,7/7/14 12:28
3194,111,Actavis,Regional & Specialty Pharma,758,Enablex,darifenacin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,,Mar-16,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Sales,0,0,0,0,30,94.5024,80.46216,17.25505732,6.726688693,2.761405163,3.959741849,5.373331615,-21.78261269,421,Overactive bladder,7/7/14 12:28
3194,111,Actavis,Regional & Specialty Pharma,758,Enablex,darifenacin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,,Mar-16,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,421,Overactive bladder,7/7/14 12:28
3194,111,Actavis,Regional & Specialty Pharma,758,Enablex,darifenacin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,,Mar-16,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,421,Overactive bladder,7/7/14 12:28
3194,111,Actavis,Regional & Specialty Pharma,758,Enablex,darifenacin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,,Mar-16,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,421,Overactive bladder,7/7/14 12:28
3194,111,Actavis,Regional & Specialty Pharma,758,Enablex,darifenacin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,,Mar-16,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Sales,0,0,0,0,30,94.5024,80.46216,17.25505732,6.726688693,2.761405163,3.959741849,5.373331615,-21.78261269,421,Overactive bladder,7/7/14 12:28
3194,111,Warner Chilcott ,Regional & Specialty Pharma,758,Enablex,darifenacin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,,Mar-16,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,Global,Proforma,78,107,171,170,90,0,0,0,0,0,0,0,-100,421,Overactive bladder,7/7/14 12:28
3194,111,Warner Chilcott ,Regional & Specialty Pharma,758,Enablex,darifenacin,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-05,,Mar-16,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,6,US,Proforma,78,107,171,170,90,0,0,0,0,0,0,0,-100,421,Overactive bladder,7/7/14 12:28
3196,28,Chiesi,Regional & Specialty Pharma,3108,Foster,formoterol + beclomethasone,Small Molecule (Chemical),Launched,In-House,,Oct-06,N/A,May-21,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,Global,Sales,188.9717828,239.2507187,323.9718297,354.734886,410.3612906,442.138394,466.4126588,484.673816,498.3347832,508.6329934,516.3727694,522.1876961,3.502645171,2207,Asthma,7/7/14 12:28
3196,28,Chiesi,Regional & Specialty Pharma,3108,Foster,formoterol + beclomethasone,Small Molecule (Chemical),Launched,In-House,,Oct-06,N/A,May-21,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,188.9717828,239.2507187,323.9718297,354.734886,410.3612906,442.138394,466.4126588,484.673816,498.3347832,508.6329934,516.3727694,522.1876961,3.502645171,2207,Asthma,7/7/14 12:28
3196,28,Chiesi,Regional & Specialty Pharma,3108,Foster,formoterol + beclomethasone,Small Molecule (Chemical),Launched,In-House,,Oct-06,N/A,May-21,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2207,Asthma,7/7/14 12:28
3200,254,Noven,Regional & Specialty Pharma,970,Daytrana,methylphenidate patch,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jun-06,,Sep-15,,121,Stimulants,37,ADHD,12,Central Nervous System,6,Global,Sales,0,16,70,72,73.6,74.88,64.5184,49.87008,38.68928,27.2659968,19.5805696,15.73156454,-19.78221208,1727,ADHD,7/7/14 12:28
3200,254,Noven,Regional & Specialty Pharma,970,Daytrana,methylphenidate patch,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jun-06,,Sep-15,,121,Stimulants,37,ADHD,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1727,ADHD,7/7/14 12:28
3200,254,Noven,Regional & Specialty Pharma,970,Daytrana,methylphenidate patch,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jun-06,,Sep-15,,121,Stimulants,37,ADHD,12,Central Nervous System,6,US,Sales,0,16,70,72,73.6,74.88,64.5184,49.87008,38.68928,27.2659968,19.5805696,15.73156454,-19.78221208,1727,ADHD,7/7/14 12:28
3204,34,Daiichi-Sankyo,Regional & Specialty Pharma,3151,Banan,cefpodoxime,Small Molecule (Chemical),Launched,In-House,,,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2242,,7/7/14 12:28
3204,34,Daiichi-Sankyo,Regional & Specialty Pharma,3151,Banan,cefpodoxime,Small Molecule (Chemical),Launched,In-House,,,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2242,,7/7/14 12:28
3204,34,Daiichi-Sankyo,Regional & Specialty Pharma,3151,Banan,cefpodoxime,Small Molecule (Chemical),Launched,In-House,,,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2242,,7/7/14 12:28
3205,89,Sanofi,Large Pharma,3152,Claforan,cefotaxime,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2241,,7/7/14 12:28
3205,89,Sanofi,Large Pharma,3152,Claforan,cefotaxime,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2241,,7/7/14 12:28
3205,89,Sanofi,Large Pharma,3152,Claforan,cefotaxime,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2241,,7/7/14 12:28
3207,95,Shionogi,Regional & Specialty Pharma,3154,Kefral,cefaclor,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,Expired,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,296,Bacterial infections,7/7/14 12:28
3207,95,Shionogi,Regional & Specialty Pharma,3154,Kefral,cefaclor,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,Expired,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,296,Bacterial infections,7/7/14 12:28
3207,95,Shionogi,Regional & Specialty Pharma,3154,Kefral,cefaclor,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,Expired,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,296,Bacterial infections,7/7/14 12:28
3208,76,Pfizer,Large Pharma,3155,Sulperazon,cefoperazone/ sulbactam,Small Molecule (Chemical),Launched,In-House,,Jul-86,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,204,213,218,262,309,324.08,336.256,344.2608,348.52928,351.317632,353.027904,354.046039,1.963099498,2240,,7/7/14 12:28
3208,76,Pfizer,Large Pharma,3155,Sulperazon,cefoperazone/ sulbactam,Small Molecule (Chemical),Launched,In-House,,Jul-86,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,204,213,218,262,309,324.08,336.256,344.2608,348.52928,351.317632,353.027904,354.046039,1.963099498,2240,,7/7/14 12:28
3208,76,Pfizer,Large Pharma,3155,Sulperazon,cefoperazone/ sulbactam,Small Molecule (Chemical),Launched,In-House,,Jul-86,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2240,,7/7/14 12:28
3209,84,Recordati,Regional & Specialty Pharma,3156,Isocef ,ceftibuten,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2243,,7/7/14 12:28
3209,84,Recordati,Regional & Specialty Pharma,3156,Isocef ,ceftibuten,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2243,,7/7/14 12:28
3209,84,Recordati,Regional & Specialty Pharma,3156,Isocef ,ceftibuten,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2243,,7/7/14 12:28
3210,15,Astellas Pharma,Regional & Specialty Pharma,3157,Cefspan,cefixime,Small Molecule (Chemical),Launched,In-House,,,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2239,,7/7/14 12:28
3210,15,Astellas Pharma,Regional & Specialty Pharma,3157,Cefspan,cefixime,Small Molecule (Chemical),Launched,In-House,,,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2239,,7/7/14 12:28
3210,15,Astellas Pharma,Regional & Specialty Pharma,3157,Cefspan,cefixime,Small Molecule (Chemical),Launched,In-House,,,,,116,Cephalosporins,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2239,,7/7/14 12:28
3211,89,Sanofi,Large Pharma,3158,Dogmatil,sulpiride,Small Molecule (Chemical),Launched,In-House,,Jun-69,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2231,Schizophrenia,7/7/14 12:28
3211,89,Sanofi,Large Pharma,3158,Dogmatil,sulpiride,Small Molecule (Chemical),Launched,In-House,,Jun-69,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2231,Schizophrenia,7/7/14 12:28
3211,89,Sanofi,Large Pharma,3158,Dogmatil,sulpiride,Small Molecule (Chemical),Launched,In-House,,Jun-69,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2231,Schizophrenia,7/7/14 12:28
3213,15,Astellas Pharma,Regional & Specialty Pharma,908,Dogmatyl,sulpiride,Small Molecule (Chemical),Launched,Licensed (Development),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2231,Schizophrenia,7/7/14 12:28
3213,15,Astellas Pharma,Regional & Specialty Pharma,908,Dogmatyl,sulpiride,Small Molecule (Chemical),Launched,Licensed (Development),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2231,Schizophrenia,7/7/14 12:28
3213,15,Astellas Pharma,Regional & Specialty Pharma,908,Dogmatyl,sulpiride,Small Molecule (Chemical),Launched,Licensed (Development),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2231,Schizophrenia,7/7/14 12:28
3214,89,Sanofi,Large Pharma,3160,Solian,amisulpiride,Small Molecule (Chemical),Launched,In-House,,Jun-86,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2228,Schizophrenia,7/7/14 12:28
3214,89,Sanofi,Large Pharma,3160,Solian,amisulpiride,Small Molecule (Chemical),Launched,In-House,,Jun-86,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2228,Schizophrenia,7/7/14 12:28
3214,89,Sanofi,Large Pharma,3160,Solian,amisulpiride,Small Molecule (Chemical),Launched,In-House,,Jun-86,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2228,Schizophrenia,7/7/14 12:28
3216,638,Acadia,Small Biotech,3162,pimavanserin,pimavanserin,Small Molecule (Chemical),Phase III,In-House,Nov-15,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,4.166675,27.77784722,44.44455556,61.11126389,73.75018467,84.00715486,0,2275,Parkinson's Disease Psychosis,7/7/14 12:28
3216,638,Acadia,Small Biotech,3162,pimavanserin,pimavanserin,Small Molecule (Chemical),Phase III,In-House,Nov-15,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2275,Parkinson's Disease Psychosis,7/7/14 12:28
3216,638,Acadia,Small Biotech,3162,pimavanserin,pimavanserin,Small Molecule (Chemical),Phase III,In-House,Nov-15,,,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,4.166675,27.77784722,44.44455556,61.11126389,73.75018467,84.00715486,0,2275,Parkinson's Disease Psychosis,7/7/14 12:28
3217,2115,Synergy Pharmaceuticals,Small Biotech,3163,FV-100,FV-100,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2254,shingles,7/7/14 12:28
3217,2115,Synergy Pharmaceuticals,Small Biotech,3163,FV-100,FV-100,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2254,shingles,7/7/14 12:28
3217,2115,Synergy Pharmaceuticals,Small Biotech,3163,FV-100,FV-100,Small Molecule (Chemical),Phase II,Acquisition (Development),,,,,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2254,shingles,7/7/14 12:28
3219,86,Roche,Large Pharma,3165,Valium,diazepam,Small Molecule (Chemical),Launched,In-House,,,,,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2250,Anxiety,7/7/14 12:28
3219,86,Roche,Large Pharma,3165,Valium,diazepam,Small Molecule (Chemical),Launched,In-House,,,,,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2250,Anxiety,7/7/14 12:28
3219,86,Roche,Large Pharma,3165,Valium,diazepam,Small Molecule (Chemical),Launched,In-House,,,,,94,Benzodiazepines,31,Sleep Disorders,12,Central Nervous System,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2250,Anxiety,7/7/14 12:28
3220,15,Astellas Pharma,Regional & Specialty Pharma,3166,Advaferon,interferon alphacon-1,Recombinant Protein,Launched,Licensed (Development),,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2230,Hepatitis C,7/7/14 12:28
3220,15,Astellas Pharma,Regional & Specialty Pharma,3166,Advaferon,interferon alphacon-1,Recombinant Protein,Launched,Licensed (Development),,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2230,Hepatitis C,7/7/14 12:28
3220,15,Astellas Pharma,Regional & Specialty Pharma,3166,Advaferon,interferon alphacon-1,Recombinant Protein,Launched,Licensed (Development),,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2230,Hepatitis C,7/7/14 12:28
3221,61,Merck & Co,Large Pharma,3167,Rebetron,combination therapy,Synthetic Peptide,Launched,Corporate Acquisition,,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2248,Hepatitis C,7/7/14 12:28
3221,61,Merck & Co,Large Pharma,3167,Rebetron,combination therapy,Synthetic Peptide,Launched,Corporate Acquisition,,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2248,Hepatitis C,7/7/14 12:28
3221,61,Merck & Co,Large Pharma,3167,Rebetron,combination therapy,Synthetic Peptide,Launched,Corporate Acquisition,,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2248,Hepatitis C,7/7/14 12:28
3223,272,Three Rivers Pharmaceuticals,Regional & Specialty Pharma,3169,Infergen,interferon alphacon-1 ,Recombinant Protein,Launched,Acquisition (Marketed),,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2230,Hepatitis C,7/7/14 12:28
3223,272,Three Rivers Pharmaceuticals,Regional & Specialty Pharma,3169,Infergen,interferon alphacon-1 ,Recombinant Protein,Launched,Acquisition (Marketed),,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2230,Hepatitis C,7/7/14 12:28
3223,272,Three Rivers Pharmaceuticals,Regional & Specialty Pharma,3169,Infergen,interferon alphacon-1 ,Recombinant Protein,Launched,Acquisition (Marketed),,,,,88,Immunomodulators - Hepatitis,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2230,Hepatitis C,7/7/14 12:28
3225,273,Vanda Pharmaceuticals,Small Biotech,3443,Hetlioz,tasimelteon,Small Molecule (Chemical),Launched,Licensed (Development),Apr-14,,,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,12,18.75348,26.73496109,39.90700907,44.03947479,47.08513218,49.24392339,0,2285,Circadian Rhythm Sleep Disorders,7/7/14 12:28
3225,273,Vanda Pharmaceuticals,Small Biotech,3443,Hetlioz,tasimelteon,Small Molecule (Chemical),Launched,Licensed (Development),Apr-14,,,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2285,Circadian Rhythm Sleep Disorders,7/7/14 12:28
3225,273,Vanda Pharmaceuticals,Small Biotech,3443,Hetlioz,tasimelteon,Small Molecule (Chemical),Launched,Licensed (Development),Apr-14,,,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,12,18.75348,26.73496109,39.90700907,44.03947479,47.08513218,49.24392339,0,2285,Circadian Rhythm Sleep Disorders,7/7/14 12:28
3226,89,Sanofi,Large Pharma,3172,Rulid,roxithromycin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2281,,7/7/14 12:28
3226,89,Sanofi,Large Pharma,3172,Rulid,roxithromycin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2281,,7/7/14 12:28
3226,89,Sanofi,Large Pharma,3172,Rulid,roxithromycin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2281,,7/7/14 12:28
3228,32,Cubist Pharmaceuticals,Small Biotech,3668,Dificid,fidaxomicin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-11,,Jan-27,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,77,93,102,111,117,125,127.66,129.3855,7.695916587,2293,Clostridium difficile infection ,7/7/14 12:28
3228,32,Cubist Pharmaceuticals,Small Biotech,3668,Dificid,fidaxomicin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-11,,Jan-27,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2293,Clostridium difficile infection ,7/7/14 12:28
3228,32,Cubist Pharmaceuticals,Small Biotech,3668,Dificid,fidaxomicin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-11,,Jan-27,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,77,93,102,111,117,125,127.66,129.3855,7.695916587,2293,Clostridium difficile infection ,7/7/14 12:28
3228,32,Optimer,Small Biotech,3668,Dificid,fidaxomicin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-11,,Jan-27,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,Global,Proforma,0,0,22,64,0,0,0,0,0,0,0,0,0,2293,Clostridium difficile infection ,7/7/14 12:28
3228,32,Optimer,Small Biotech,3668,Dificid,fidaxomicin,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-11,,Jan-27,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,US,Proforma,0,0,22,64,0,0,0,0,0,0,0,0,0,2293,Clostridium difficile infection ,7/7/14 12:28
3229,276,Enanta,Small Biotech,3175,Modithromycin,EDP-420,Small Molecule (Chemical),Phase II,In-House,,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2292,bacterial infections,7/7/14 12:28
3229,276,Enanta,Small Biotech,3175,Modithromycin,EDP-420,Small Molecule (Chemical),Phase II,In-House,,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2292,bacterial infections,7/7/14 12:28
3229,276,Enanta,Small Biotech,3175,Modithromycin,EDP-420,Small Molecule (Chemical),Phase II,In-House,,,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2292,bacterial infections,7/7/14 12:28
3231,45,Gilead,Regional & Specialty Pharma,3177,Emtriva,emtricitabine,Small Molecule (Chemical),Launched,Corporate Acquisition,,,Sep-21,Feb-16,104,NRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2252,HIV,7/7/14 12:28
3231,45,Gilead,Regional & Specialty Pharma,3177,Emtriva,emtricitabine,Small Molecule (Chemical),Launched,Corporate Acquisition,,,Sep-21,Feb-16,104,NRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2252,HIV,7/7/14 12:28
3231,45,Gilead,Regional & Specialty Pharma,3177,Emtriva,emtricitabine,Small Molecule (Chemical),Launched,Corporate Acquisition,,,Sep-21,Feb-16,104,NRTIs,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2252,HIV,7/7/14 12:28
3232,46,GlaxoSmithKline,Large Pharma,3178,Retrovir,zidovudine,Small Molecule (Chemical),Launched,In-House,,,Sep-05,,104,NRTIs,32,HIV,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2291,HIV,7/7/14 12:28
3232,46,GlaxoSmithKline,Large Pharma,3178,Retrovir,zidovudine,Small Molecule (Chemical),Launched,In-House,,,Sep-05,,104,NRTIs,32,HIV,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2291,HIV,7/7/14 12:28
3232,46,GlaxoSmithKline,Large Pharma,3178,Retrovir,zidovudine,Small Molecule (Chemical),Launched,In-House,,,Sep-05,,104,NRTIs,32,HIV,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2291,HIV,7/7/14 12:28
3233,24,Bristol-Myers Squibb,Large Pharma,3179,Videx,didanosine,Small Molecule (Chemical),Launched,In-House,,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2251,,7/7/14 12:28
3233,24,Bristol-Myers Squibb,Large Pharma,3179,Videx,didanosine,Small Molecule (Chemical),Launched,In-House,,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2251,,7/7/14 12:28
3233,24,Bristol-Myers Squibb,Large Pharma,3179,Videx,didanosine,Small Molecule (Chemical),Launched,In-House,,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2251,,7/7/14 12:28
3234,277,RFS Pharma,Small Biotech,3180,Amdoxovir,,Small Molecule (Chemical),Phase II,In-House,,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2294,HIV,7/7/14 12:28
3234,277,RFS Pharma,Small Biotech,3180,Amdoxovir,,Small Molecule (Chemical),Phase II,In-House,,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2294,HIV,7/7/14 12:28
3234,277,RFS Pharma,Small Biotech,3180,Amdoxovir,,Small Molecule (Chemical),Phase II,In-House,,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2294,HIV,7/7/14 12:28
3235,86,Roche,Large Pharma,3181,Bactrim,co-trimoxazole,Small Molecule (Chemical),Launched,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2249,,7/7/14 12:28
3235,86,Roche,Large Pharma,3181,Bactrim,co-trimoxazole,Small Molecule (Chemical),Launched,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2249,,7/7/14 12:28
3235,86,Roche,Large Pharma,3181,Bactrim,co-trimoxazole,Small Molecule (Chemical),Launched,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2249,,7/7/14 12:28
3236,61,Merck & Co,Large Pharma,3182,Garamycin,gentamicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2256,bacterial infection,7/7/14 12:28
3236,61,Merck & Co,Large Pharma,3182,Garamycin,gentamicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2256,bacterial infection,7/7/14 12:28
3236,61,Merck & Co,Large Pharma,3182,Garamycin,gentamicin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2256,bacterial infection,7/7/14 12:28
3237,15,Astellas Pharma,Regional & Specialty Pharma,3183,Targocid,teicoplanin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2220,,7/7/14 12:28
3237,15,Astellas Pharma,Regional & Specialty Pharma,3183,Targocid,teicoplanin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2220,,7/7/14 12:28
3237,15,Astellas Pharma,Regional & Specialty Pharma,3183,Targocid,teicoplanin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2220,,7/7/14 12:28
3238,89,Sanofi,Large Pharma,3183,Targocid,teicoplanin,Small Molecule (Chemical),Launched,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2220,,7/7/14 12:28
3238,89,Sanofi,Large Pharma,3183,Targocid,teicoplanin,Small Molecule (Chemical),Launched,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2220,,7/7/14 12:28
3238,89,Sanofi,Large Pharma,3183,Targocid,teicoplanin,Small Molecule (Chemical),Launched,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2220,,7/7/14 12:28
3239,76,Pfizer,Large Pharma,3184,Minocin,minocycline,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2267,,7/7/14 12:28
3239,76,Pfizer,Large Pharma,3184,Minocin,minocycline,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2267,,7/7/14 12:28
3239,76,Pfizer,Large Pharma,3184,Minocin,minocycline,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2267,,7/7/14 12:28
3240,15,Astellas Pharma,Regional & Specialty Pharma,3185,Synercid,quinupristin / dalfopristin,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2279,,7/7/14 12:28
3240,15,Astellas Pharma,Regional & Specialty Pharma,3185,Synercid,quinupristin / dalfopristin,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2279,,7/7/14 12:28
3240,15,Astellas Pharma,Regional & Specialty Pharma,3185,Synercid,quinupristin / dalfopristin,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2279,,7/7/14 12:28
3241,67,Novartis,Large Pharma,3186,Lampren,clofazimine,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1959,,7/7/14 12:28
3241,67,Novartis,Large Pharma,3186,Lampren,clofazimine,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1959,,7/7/14 12:28
3241,67,Novartis,Large Pharma,3186,Lampren,clofazimine,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1959,,7/7/14 12:28
3242,278,Acino,Regional & Specialty Pharma,3187,iclaprim,iclaprim,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2258,bacterial infections,7/7/14 12:28
3242,278,Acino,Regional & Specialty Pharma,3187,iclaprim,iclaprim,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2258,bacterial infections,7/7/14 12:28
3242,278,Acino,Regional & Specialty Pharma,3187,iclaprim,iclaprim,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2258,bacterial infections,7/7/14 12:28
3243,103,The Medicines Company,Small Biotech,3188,Orbactiv,oritavancin,Small Molecule (Chemical),Filed,Corporate Acquisition,Oct-14,Oct-15,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,30,49,69,84,93.4,98.32,101.256,0,2272,cSSSIs and BSI,7/7/14 12:28
3243,103,The Medicines Company,Small Biotech,3188,Orbactiv,oritavancin,Small Molecule (Chemical),Filed,Corporate Acquisition,Oct-14,Oct-15,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,3,7,10,11,12.32,13.256,0,2272,cSSSIs and BSI,7/7/14 12:28
3243,103,The Medicines Company,Small Biotech,3188,Orbactiv,oritavancin,Small Molecule (Chemical),Filed,Corporate Acquisition,Oct-14,Oct-15,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,30,46,62,74,82.4,86,88,0,2272,cSSSIs and BSI,7/7/14 12:28
3246,2313,Sequella,Small Biotech,3282,sutezolid,SQ109,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2274,Tuberculosis,7/7/14 12:28
3246,2313,Sequella,Small Biotech,3282,sutezolid,SQ109,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2274,Tuberculosis,7/7/14 12:28
3246,2313,Sequella,Small Biotech,3282,sutezolid,SQ109,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2274,Tuberculosis,7/7/14 12:28
3247,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3192,Valixa,valganciclovir,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2289,CMV,7/7/14 12:28
3247,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3192,Valixa,valganciclovir,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2289,CMV,7/7/14 12:28
3247,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3192,Valixa,valganciclovir,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2289,CMV,7/7/14 12:28
3248,279,CSL,Regional & Specialty Pharma,3193,CytoGam,CMV-IGIV,Antibody/Antibody Derivative,Launched,Acquisition (Marketed),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2247,CMV,7/7/14 12:28
3248,279,CSL,Regional & Specialty Pharma,3193,CytoGam,CMV-IGIV,Antibody/Antibody Derivative,Launched,Acquisition (Marketed),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2247,CMV,7/7/14 12:28
3248,279,CSL,Regional & Specialty Pharma,3193,CytoGam,CMV-IGIV,Antibody/Antibody Derivative,Launched,Acquisition (Marketed),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2247,CMV,7/7/14 12:28
3249,45,Gilead,Regional & Specialty Pharma,3194,Vistide,cidofovir,Small Molecule (Chemical),Launched,Licensed (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2246,CMV,7/7/14 12:28
3249,45,Gilead,Regional & Specialty Pharma,3194,Vistide,cidofovir,Small Molecule (Chemical),Launched,Licensed (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2246,CMV,7/7/14 12:28
3249,45,Gilead,Regional & Specialty Pharma,3194,Vistide,cidofovir,Small Molecule (Chemical),Launched,Licensed (Development),,,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2246,CMV,7/7/14 12:28
3251,86,Roche,Large Pharma,4274,setrobuvir,RG7790,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2233,Hepatitis C,7/7/14 12:28
3251,86,Roche,Large Pharma,4274,setrobuvir,RG7790,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2233,Hepatitis C,7/7/14 12:28
3251,86,Roche,Large Pharma,4274,setrobuvir,RG7790,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2233,Hepatitis C,7/7/14 12:28
3254,23,Boehringer Ingelheim,Large Pharma,3199,deleobuvir,BI-207127 ,Small Molecule (Chemical),Phase III,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2237,Hepatitis C,7/7/14 12:28
3254,23,Boehringer Ingelheim,Large Pharma,3199,deleobuvir,BI-207127 ,Small Molecule (Chemical),Phase III,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2237,Hepatitis C,7/7/14 12:28
3254,23,Boehringer Ingelheim,Large Pharma,3199,deleobuvir,BI-207127 ,Small Molecule (Chemical),Phase III,In-House,,,,,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2237,Hepatitis C,7/7/14 12:28
3256,283,Peregrine Pharmaceuticals ,Small Biotech,3201,bavituximab,bavituximab,Antibody/Antibody Derivative,Phase II,In-House,,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2235,Hepatitis C,7/7/14 12:28
3256,283,Peregrine Pharmaceuticals ,Small Biotech,3201,bavituximab,bavituximab,Antibody/Antibody Derivative,Phase II,In-House,,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2235,Hepatitis C,7/7/14 12:28
3256,283,Peregrine Pharmaceuticals ,Small Biotech,3201,bavituximab,bavituximab,Antibody/Antibody Derivative,Phase II,In-House,,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2235,Hepatitis C,7/7/14 12:28
3257,284,Tripep,Small Biotech,3202,ChronVac-C,ChronVac-C,DNA/RNA Therapy,Phase II,In-House,,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,9,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2245,Hepatitis C,7/7/14 12:28
3257,284,Tripep,Small Biotech,3202,ChronVac-C,ChronVac-C,DNA/RNA Therapy,Phase II,In-House,,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,9,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2245,Hepatitis C,7/7/14 12:28
3257,284,Tripep,Small Biotech,3202,ChronVac-C,ChronVac-C,DNA/RNA Therapy,Phase II,In-House,,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2245,Hepatitis C,7/7/14 12:28
3258,285,GlobeImmune,Small Biotech,3203,GI-5005,GI-5005,DNA/RNA Therapy,Phase I,In-House,,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2257,,7/7/14 12:28
3258,285,GlobeImmune,Small Biotech,3203,GI-5005,GI-5005,DNA/RNA Therapy,Phase I,In-House,,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2257,,7/7/14 12:28
3258,285,GlobeImmune,Small Biotech,3203,GI-5005,GI-5005,DNA/RNA Therapy,Phase I,In-House,,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2257,,7/7/14 12:28
3262,287,TaiMed Biologics,Small Biotech,3207,ibalizumab,,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2295,HIV treatment,7/7/14 12:28
3262,287,TaiMed Biologics,Small Biotech,3207,ibalizumab,,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2295,HIV treatment,7/7/14 12:28
3262,287,TaiMed Biologics,Small Biotech,3207,ibalizumab,,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2295,HIV treatment,7/7/14 12:28
3264,161,Progenics,Small Biotech,3209,PRO-140,PRO-140,Antibody/Antibody Derivative,Phase II,In-House,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2277,HIV treatment,7/7/14 12:28
3264,161,Progenics,Small Biotech,3209,PRO-140,PRO-140,Antibody/Antibody Derivative,Phase II,In-House,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2277,HIV treatment,7/7/14 12:28
3264,161,Progenics,Small Biotech,3209,PRO-140,PRO-140,Antibody/Antibody Derivative,Phase II,In-House,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2277,HIV treatment,7/7/14 12:28
3265,930,Synageva BioPharma,Small Biotech,3210,TRI-1144,TRI-1144,Recombinant Protein,Phase I,Corporate Acquisition,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2287,HIV treatment,7/7/14 12:28
3265,930,Synageva BioPharma,Small Biotech,3210,TRI-1144,TRI-1144,Recombinant Protein,Phase I,Corporate Acquisition,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2287,HIV treatment,7/7/14 12:28
3265,930,Synageva BioPharma,Small Biotech,3210,TRI-1144,TRI-1144,Recombinant Protein,Phase I,Corporate Acquisition,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2287,HIV treatment,7/7/14 12:28
3266,290,VIRxSYS ,Small Biotech,3211,VRX-496 ,VRX-496 ,Gene Therapy,Phase II,In-House,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2290,HIV treatment,7/7/14 12:28
3266,290,VIRxSYS ,Small Biotech,3211,VRX-496 ,VRX-496 ,Gene Therapy,Phase II,In-House,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2290,HIV treatment,7/7/14 12:28
3266,290,VIRxSYS ,Small Biotech,3211,VRX-496 ,VRX-496 ,Gene Therapy,Phase II,In-House,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2290,HIV treatment,7/7/14 12:28
3267,291,Meiji-Seika ,Regional & Specialty Pharma,3488,Orapenem,tebipenem,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-09,,Dec-21,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,4.309303877,11.67283381,16.4601585,25.15378564,22.41235431,23.14769875,23.62174223,23.76834009,23.84085626,23.87586549,23.8895813,23.89595408,0.919873017,2266,Bacterial Infections,7/7/14 12:28
3267,291,Meiji-Seika ,Regional & Specialty Pharma,3488,Orapenem,tebipenem,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-09,,Dec-21,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,4.309303877,11.67283381,16.4601585,25.15378564,22.41235431,23.14769875,23.62174223,23.76834009,23.84085626,23.87586549,23.8895813,23.89595408,0.919873017,2266,Bacterial Infections,7/7/14 12:28
3267,291,Meiji-Seika ,Regional & Specialty Pharma,3488,Orapenem,tebipenem,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-09,,Dec-21,141,Penems,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2266,Bacterial Infections,7/7/14 12:28
3268,76,Pfizer,Large Pharma,3213,Bicillin,penicillin G benzathine + penicillin G procaine,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2273,,7/7/14 12:28
3268,76,Pfizer,Large Pharma,3213,Bicillin,penicillin G benzathine + penicillin G procaine,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2273,,7/7/14 12:28
3268,76,Pfizer,Large Pharma,3213,Bicillin,penicillin G benzathine + penicillin G procaine,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,6,Penicillins,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2273,,7/7/14 12:28
3270,61,Merck & Co,Large Pharma,3215,Crixivan,indinavir,Small Molecule (Chemical),Launched,In-House,,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2262,HIV,7/7/14 12:28
3270,61,Merck & Co,Large Pharma,3215,Crixivan,indinavir,Small Molecule (Chemical),Launched,In-House,,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2262,HIV,7/7/14 12:28
3270,61,Merck & Co,Large Pharma,3215,Crixivan,indinavir,Small Molecule (Chemical),Launched,In-House,,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2262,HIV,7/7/14 12:28
3271,46,GlaxoSmithKline,Large Pharma,3216,Viracept,nelfinavir,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2221,HIV,7/7/14 12:28
3271,46,GlaxoSmithKline,Large Pharma,3216,Viracept,nelfinavir,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2221,HIV,7/7/14 12:28
3271,46,GlaxoSmithKline,Large Pharma,3216,Viracept,nelfinavir,Small Molecule (Chemical),Launched,Acquisition (Marketed),,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2221,HIV,7/7/14 12:28
3272,86,Roche,Large Pharma,3216,Viracept,nelfinavir,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2221,,7/7/14 12:28
3272,86,Roche,Large Pharma,3216,Viracept,nelfinavir,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2221,,7/7/14 12:28
3272,86,Roche,Large Pharma,3216,Viracept,nelfinavir,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2221,,7/7/14 12:28
3273,292,Ambrila,Small Biotech,3217,PPL-100,PPL-100,Small Molecule (Chemical),Phase II,In-House,,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2276,,7/7/14 12:28
3273,292,Ambrila,Small Biotech,3217,PPL-100,PPL-100,Small Molecule (Chemical),Phase II,In-House,,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2276,,7/7/14 12:28
3273,292,Ambrila,Small Biotech,3217,PPL-100,PPL-100,Small Molecule (Chemical),Phase II,In-House,,,,,103,Protease Inhibitors,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2276,,7/7/14 12:28
3274,28,Chiesi,Regional & Specialty Pharma,3218,Factive,gemifloxacin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2255,,7/7/14 12:28
3274,28,Chiesi,Regional & Specialty Pharma,3218,Factive,gemifloxacin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2255,,7/7/14 12:28
3274,28,Chiesi,Regional & Specialty Pharma,3218,Factive,gemifloxacin,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,85,Quinolones,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2255,,7/7/14 12:28
3276,613,Santhera,Small Biotech,3219,fipamezole,fipamezole,Small Molecule (Chemical),Phase II,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2219,Parkinson's disease,7/7/14 12:28
3276,613,Santhera,Small Biotech,3219,fipamezole,fipamezole,Small Molecule (Chemical),Phase II,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2219,Parkinson's disease,7/7/14 12:28
3276,613,Santhera,Small Biotech,3219,fipamezole,fipamezole,Small Molecule (Chemical),Phase II,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2219,Parkinson's disease,7/7/14 12:28
3279,32,Cubist Pharmaceuticals,Small Biotech,3222,ALN-RSV01 ,ALN-RSV01 ,DNA/RNA Therapy,Phase II,Licensed (Development),,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2218,RSV treatment,7/7/14 12:28
3279,32,Cubist Pharmaceuticals,Small Biotech,3222,ALN-RSV01 ,ALN-RSV01 ,DNA/RNA Therapy,Phase II,Licensed (Development),,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2218,RSV treatment,7/7/14 12:28
3279,32,Cubist Pharmaceuticals,Small Biotech,3222,ALN-RSV01 ,ALN-RSV01 ,DNA/RNA Therapy,Phase II,Licensed (Development),,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2218,RSV treatment,7/7/14 12:28
3281,1524,Toyama Chemical,Small Biotech,3223,favipiravir,favipiravir,Small Molecule (Chemical),Filed,Licensed (Marketed),,Jun-14,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,5.87283462,13.98292559,20.69472987,27.40644466,32.30043648,36.36244632,39.75152811,0,2253,Influenza treatment,7/7/14 12:28
3281,1524,Toyama Chemical,Small Biotech,3223,favipiravir,favipiravir,Small Molecule (Chemical),Filed,Licensed (Marketed),,Jun-14,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,5.87283462,13.98292559,20.69472987,27.40644466,32.30043648,36.36244632,39.75152811,0,2253,Influenza treatment,7/7/14 12:28
3281,1524,Toyama Chemical,Small Biotech,3223,favipiravir,favipiravir,Small Molecule (Chemical),Filed,Licensed (Marketed),,Jun-14,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2253,Influenza treatment,7/7/14 12:28
3284,68,Novo Nordisk,Regional & Specialty Pharma,3231,FIAsp,NN1218,Recombinant Protein,Phase III,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2268,Diabetes,7/7/14 12:28
3284,68,Novo Nordisk,Regional & Specialty Pharma,3231,FIAsp,NN1218,Recombinant Protein,Phase III,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2268,Diabetes,7/7/14 12:28
3284,68,Novo Nordisk,Regional & Specialty Pharma,3231,FIAsp,NN1218,Recombinant Protein,Phase III,In-House,,,,,83,Insulins,22,Diabetes,8,Metabolism,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2268,Diabetes,7/7/14 12:28
3286,294,Salvat,Regional & Specialty Pharma,4218,tarafenacin,tarafenacin,Small Molecule (Chemical),Phase II,In-House,,,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2330,Overactive bladder,7/7/14 12:28
3286,294,Salvat,Regional & Specialty Pharma,4218,tarafenacin,tarafenacin,Small Molecule (Chemical),Phase II,In-House,,,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2330,Overactive bladder,7/7/14 12:28
3286,294,Salvat,Regional & Specialty Pharma,4218,tarafenacin,tarafenacin,Small Molecule (Chemical),Phase II,In-House,,,,,115,Anti-muscarinics,60,Incontinence,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2330,Overactive bladder,7/7/14 12:28
3288,234,Galderma,Regional & Specialty Pharma,2938,Differin,adapelene,Small Molecule (Chemical),Launched,In-House,,Oct-08,Jun-26,,160,Acne Treatments,73,Acne,6,Dermatology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1882,Acne ,7/7/14 12:28
3288,234,Galderma,Regional & Specialty Pharma,2938,Differin,adapelene,Small Molecule (Chemical),Launched,In-House,,Oct-08,Jun-26,,160,Acne Treatments,73,Acne,6,Dermatology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1882,Acne ,7/7/14 12:28
3288,234,Galderma,Regional & Specialty Pharma,2938,Differin,adapelene,Small Molecule (Chemical),Launched,In-House,,Oct-08,Jun-26,,160,Acne Treatments,73,Acne,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1882,Acne ,7/7/14 12:28
3290,95,Shionogi,Regional & Specialty Pharma,3236,MS Contin,morphine,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-89,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2320,Pain,7/7/14 12:28
3290,95,Shionogi,Regional & Specialty Pharma,3236,MS Contin,morphine,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-89,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2320,Pain,7/7/14 12:28
3290,95,Shionogi,Regional & Specialty Pharma,3236,MS Contin,morphine,Small Molecule (Chemical),Launched,Licensed (Development),,Jun-89,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2320,Pain,7/7/14 12:28
3296,76,Pfizer,Large Pharma,4064,MnB rLp2086,MnB rLp2086,Vaccine,Filed,Corporate Acquisition,Sep-14,Dec-14,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,13.6,40.106672,56.69343256,82.93350317,101.6514215,118.0900874,133.3562655,0,739,invasive meningitis,7/7/14 12:28
3296,76,Pfizer,Large Pharma,4064,MnB rLp2086,MnB rLp2086,Vaccine,Filed,Corporate Acquisition,Sep-14,Dec-14,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,1.6,11.306672,15.89333656,22.93328999,28.40313838,33.01453289,37.29824686,0,739,invasive meningitis,7/7/14 12:28
3296,76,Pfizer,Large Pharma,4064,MnB rLp2086,MnB rLp2086,Vaccine,Filed,Corporate Acquisition,Sep-14,Dec-14,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,12,28.8,40.800096,60.00021318,73.24828309,85.07555453,96.05801864,0,739,invasive meningitis,7/7/14 12:28
3297,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3242,Pguard,morphine,Small Molecule (Chemical),Launched,In-House,,Mar-05,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2313,Cancer pain,7/7/14 12:28
3297,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3242,Pguard,morphine,Small Molecule (Chemical),Launched,In-House,,Mar-05,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2313,Cancer pain,7/7/14 12:28
3297,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3242,Pguard,morphine,Small Molecule (Chemical),Launched,In-House,,Mar-05,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2313,Cancer pain,7/7/14 12:28
3299,47,Grunenthal,Regional & Specialty Pharma,3959,Transtec / Norspan,buprenorphine - transdermal,Small Molecule (Chemical),Launched,In-House,,Jan-01,,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,Global,Sales,170.9083035,162.9448416,158.5098223,136.2387606,131.3977897,124.8985574,119.7399527,115.9511557,113.0432502,110.8668219,109.2144133,107.9700414,-2.766376491,2298,Pain,7/7/14 12:28
3299,47,Grunenthal,Regional & Specialty Pharma,3959,Transtec / Norspan,buprenorphine - transdermal,Small Molecule (Chemical),Launched,In-House,,Jan-01,,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,ROW,Sales,170.9083035,162.9448416,158.5098223,136.2387606,131.3977897,124.8985574,119.7399527,115.9511557,113.0432502,110.8668219,109.2144133,107.9700414,-2.766376491,2298,Pain,7/7/14 12:28
3299,47,Grunenthal,Regional & Specialty Pharma,3959,Transtec / Norspan,buprenorphine - transdermal,Small Molecule (Chemical),Launched,In-House,,Jan-01,,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2298,Pain,7/7/14 12:28
3303,295,Archimedes Pharma,Small Biotech,3707,Lazanda / PecFent,fentanyl - intranasal,Small Molecule (Chemical),Launched,In-House,Oct-11,Oct-10,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2326,Cancer Pain,7/7/14 12:28
3303,295,Archimedes Pharma,Small Biotech,3707,Lazanda / PecFent,fentanyl - intranasal,Small Molecule (Chemical),Launched,In-House,Oct-11,Oct-10,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2326,Cancer Pain,7/7/14 12:28
3303,295,Archimedes Pharma,Small Biotech,3707,Lazanda / PecFent,fentanyl - intranasal,Small Molecule (Chemical),Launched,In-House,Oct-11,Oct-10,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2326,Cancer Pain,7/7/14 12:28
3307,84,Recordati,Regional & Specialty Pharma,2807,Toradol,ketorolac ,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-90,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2135,Pain,7/7/14 12:28
3307,84,Recordati,Regional & Specialty Pharma,2807,Toradol,ketorolac ,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-90,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2135,Pain,7/7/14 12:28
3307,84,Recordati,Regional & Specialty Pharma,2807,Toradol,ketorolac ,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-90,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2135,Pain,7/7/14 12:28
3308,297,CrystalGenomics,Small Biotech,4287,polmacoxib,polmacoxib,Small Molecule (Chemical),Phase II,In-House,,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2324,Osteoarthritis,7/7/14 12:28
3308,297,CrystalGenomics,Small Biotech,4287,polmacoxib,polmacoxib,Small Molecule (Chemical),Phase II,In-House,,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2324,Osteoarthritis,7/7/14 12:28
3308,297,CrystalGenomics,Small Biotech,4287,polmacoxib,polmacoxib,Small Molecule (Chemical),Phase II,In-House,,,,,23,NSAIDs,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2324,Osteoarthritis,7/7/14 12:28
3309,1,Abbott,Regional & Specialty Pharma,3256,Grippol Plus and Grippol Neo ,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-09,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2304,prevention of influenza,7/7/14 12:28
3309,1,Abbott,Regional & Specialty Pharma,3256,Grippol Plus and Grippol Neo ,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-09,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2304,prevention of influenza,7/7/14 12:28
3309,1,Abbott,Regional & Specialty Pharma,3256,Grippol Plus and Grippol Neo ,influenza vaccine,Vaccine,Launched,Corporate Acquisition,,Jul-09,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2304,prevention of influenza,7/7/14 12:28
3310,61,Merck & Co,Large Pharma,3257,Fluvax,influenza vaccine,Vaccine,Launched,Licensed (Marketed),Oct-07,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2305,influenza vaccine,7/7/14 12:28
3310,61,Merck & Co,Large Pharma,3257,Fluvax,influenza vaccine,Vaccine,Launched,Licensed (Marketed),Oct-07,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2305,influenza vaccine,7/7/14 12:28
3310,61,Merck & Co,Large Pharma,3257,Fluvax,influenza vaccine,Vaccine,Launched,Licensed (Marketed),Oct-07,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2305,influenza vaccine,7/7/14 12:28
3311,279,CSL,Regional & Specialty Pharma,3257,Fluvax,influenza vaccine,Vaccine,Launched,In-House,Oct-07,Aug-97,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2305,influenza,7/7/14 12:28
3311,279,CSL,Regional & Specialty Pharma,3257,Fluvax,influenza vaccine,Vaccine,Launched,In-House,Oct-07,Aug-97,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2305,influenza,7/7/14 12:28
3311,279,CSL,Regional & Specialty Pharma,3257,Fluvax,influenza vaccine,Vaccine,Launched,In-House,Oct-07,Aug-97,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2305,influenza,7/7/14 12:28
3312,18,Baxter Healthcare,Regional & Specialty Pharma,3258,Celvapan,pandemic influenza vaccine,Vaccine,Launched,In-House,,Mar-09,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2316,pandemic influenza,7/7/14 12:28
3312,18,Baxter Healthcare,Regional & Specialty Pharma,3258,Celvapan,pandemic influenza vaccine,Vaccine,Launched,In-House,,Mar-09,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2316,pandemic influenza,7/7/14 12:28
3312,18,Baxter Healthcare,Regional & Specialty Pharma,3258,Celvapan,pandemic influenza vaccine,Vaccine,Launched,In-House,,Mar-09,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2316,pandemic influenza,7/7/14 12:28
3314,298,Protein Sciences,Small Biotech,3260,FluBlok,seasonal influenza vaccine,Vaccine,Launched,In-House,Nov-13,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,2.500005,16.66670833,26.66673333,36.66675833,43.70844277,49.24699833,53.72016061,57.16937566,56.37756956,2329,Seasonal influenza,7/7/14 12:28
3314,298,Protein Sciences,Small Biotech,3260,FluBlok,seasonal influenza vaccine,Vaccine,Launched,In-House,Nov-13,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2329,Seasonal influenza,7/7/14 12:28
3314,298,Protein Sciences,Small Biotech,3260,FluBlok,seasonal influenza vaccine,Vaccine,Launched,In-House,Nov-13,,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,2.500005,16.66670833,26.66673333,36.66675833,43.70844277,49.24699833,53.72016061,57.16937566,56.37756956,2329,Seasonal influenza,7/7/14 12:28
3317,300,Sinovac,Regional & Specialty Pharma,3263,PanFlu,pandemic influenza vaccine,Vaccine,Launched,Licensed (Development),,Sep-09,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,9.6,21.8,0,25,27.52,28.84,30.7648,31.32352,31.65976,31.8759688,33,4.045866191,2328,pandemic influenza prevention,7/7/14 12:28
3317,300,Sinovac,Regional & Specialty Pharma,3263,PanFlu,pandemic influenza vaccine,Vaccine,Launched,Licensed (Development),,Sep-09,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,9.6,21.8,0,25,27.52,28.84,30.7648,31.32352,31.65976,31.8759688,33,4.045866191,2328,pandemic influenza prevention,7/7/14 12:28
3317,300,Sinovac,Regional & Specialty Pharma,3263,PanFlu,pandemic influenza vaccine,Vaccine,Launched,Licensed (Development),,Sep-09,,,138,Influenza Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2328,pandemic influenza prevention,7/7/14 12:28
3324,100,Nycomed,Large Pharma,3270,Preotact,recombinant human PTH,Recombinant Protein,Launched,Corporate Acquisition,,May-06,,Apr-21,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Proforma,75.41281784,70.03700288,53.40199699,0,0,0,0,0,0,0,0,0,0,2332,Postmenopausal osteoporosis,7/7/14 12:28
3324,100,Nycomed,Large Pharma,3270,Preotact,recombinant human PTH,Recombinant Protein,Launched,Corporate Acquisition,,May-06,,Apr-21,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Proforma,75.41281784,70.03700288,53.40199699,0,0,0,0,0,0,0,0,0,0,2332,Postmenopausal osteoporosis,7/7/14 12:28
3324,100,Takeda,Large Pharma,3270,Preotact,recombinant human PTH,Recombinant Protein,Launched,Corporate Acquisition,,May-06,,Apr-21,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,Global,Sales,0,0,11.177,56.95091488,52.86229829,50.40912833,48.93722636,48.05408518,47.52420047,47.20626964,47.01551114,47.31829455,-1.57030128,2332,Postmenopausal osteoporosis,7/7/14 12:28
3324,100,Takeda,Large Pharma,3270,Preotact,recombinant human PTH,Recombinant Protein,Launched,Corporate Acquisition,,May-06,,Apr-21,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,11.177,56.95091488,52.86229829,50.40912833,48.93722636,48.05408518,47.52420047,47.20626964,47.01551114,47.31829455,-1.57030128,2332,Postmenopausal osteoporosis,7/7/14 12:28
3324,100,Takeda,Large Pharma,3270,Preotact,recombinant human PTH,Recombinant Protein,Launched,Corporate Acquisition,,May-06,,Apr-21,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2332,Postmenopausal osteoporosis,7/7/14 12:28
3325,302,Zosano Pharma,Small Biotech,4169,ZP-PTH ,human parathyroid hormone,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3330,Osteoporosis,7/7/14 12:28
3325,302,Zosano Pharma,Small Biotech,4169,ZP-PTH ,human parathyroid hormone,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3330,Osteoporosis,7/7/14 12:28
3325,302,Zosano Pharma,Small Biotech,4169,ZP-PTH ,human parathyroid hormone,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,119,Hormonal Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3330,Osteoporosis,7/7/14 12:28
3327,67,Novartis,Large Pharma,3275,Group B Streptococcus,Group B Streptococcus,Vaccine,Phase II,Licensed (Development),,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3332,Streptococcus B,7/7/14 12:28
3327,67,Novartis,Large Pharma,3275,Group B Streptococcus,Group B Streptococcus,Vaccine,Phase II,Licensed (Development),,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3332,Streptococcus B,7/7/14 12:28
3327,67,Novartis,Large Pharma,3275,Group B Streptococcus,Group B Streptococcus,Vaccine,Phase II,Licensed (Development),,,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3332,Streptococcus B,7/7/14 12:28
3328,39,Eli Lilly,Large Pharma,3799,evacetrapib,evacetrapib,Small Molecule (Chemical),Phase III,In-House,Jun-17,Oct-17,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,72.0833,275.1386831,533.4717286,791.8064709,0,3333,Secondary prevention of cardiac events,7/7/14 12:28
3328,39,Eli Lilly,Large Pharma,3799,evacetrapib,evacetrapib,Small Molecule (Chemical),Phase III,In-House,Jun-17,Oct-17,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,13.75,77.9167125,169.5833873,261.2499914,0,3333,Secondary prevention of cardiac events,7/7/14 12:28
3328,39,Eli Lilly,Large Pharma,3799,evacetrapib,evacetrapib,Small Molecule (Chemical),Phase III,In-House,Jun-17,Oct-17,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,58.3333,197.2219706,363.8883414,530.5564795,0,3333,Secondary prevention of cardiac events,7/7/14 12:28
3332,72,Orion,Regional & Specialty Pharma,3279,Eldepryl,selegiline,Small Molecule (Chemical),Launched,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3335,Parkinson's disease,7/7/14 12:28
3332,72,Orion,Regional & Specialty Pharma,3279,Eldepryl,selegiline,Small Molecule (Chemical),Launched,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3335,Parkinson's disease,7/7/14 12:28
3332,72,Orion,Regional & Specialty Pharma,3279,Eldepryl,selegiline,Small Molecule (Chemical),Launched,In-House,,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3335,Parkinson's disease,7/7/14 12:28
3333,304,Mylan ,Regional & Specialty Pharma,3279,Eldepryl,selegiline,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-89,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3335,Parkinson's disease,7/7/14 12:28
3333,304,Mylan ,Regional & Specialty Pharma,3279,Eldepryl,selegiline,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-89,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3335,Parkinson's disease,7/7/14 12:28
3333,304,Mylan ,Regional & Specialty Pharma,3279,Eldepryl,selegiline,Small Molecule (Chemical),Launched,Licensed (Marketed),Sep-89,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3335,Parkinson's disease,7/7/14 12:28
3334,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1546,Modiodal,modafinil,Small Molecule (Chemical),Launched,Licensed (Development),,,,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3339,Excessive Daytime Sleepiness,7/7/14 12:28
3334,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1546,Modiodal,modafinil,Small Molecule (Chemical),Launched,Licensed (Development),,,,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3339,Excessive Daytime Sleepiness,7/7/14 12:28
3334,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1546,Modiodal,modafinil,Small Molecule (Chemical),Launched,Licensed (Development),,,,,45,Wakefulness-promoting Agents,31,Sleep Disorders,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3339,Excessive Daytime Sleepiness,7/7/14 12:28
3335,305,Afferent Pharmaceuticals,Small Biotech,1858,RG1646,RG1646,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3341,Pain,7/7/14 12:28
3335,305,Afferent Pharmaceuticals,Small Biotech,1858,RG1646,RG1646,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3341,Pain,7/7/14 12:28
3335,305,Afferent Pharmaceuticals,Small Biotech,1858,RG1646,RG1646,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3341,Pain,7/7/14 12:28
3336,111,Actavis,Regional & Specialty Pharma,3281,INFeD,iron dextran injectable,Small Molecule (Chemical),Launched,Corporate Acquisition,May-92,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3336,Iron Deficiency Anemia,7/7/14 12:28
3336,111,Actavis,Regional & Specialty Pharma,3281,INFeD,iron dextran injectable,Small Molecule (Chemical),Launched,Corporate Acquisition,May-92,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3336,Iron Deficiency Anemia,7/7/14 12:28
3336,111,Actavis,Regional & Specialty Pharma,3281,INFeD,iron dextran injectable,Small Molecule (Chemical),Launched,Corporate Acquisition,May-92,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3336,Iron Deficiency Anemia,7/7/14 12:28
3338,76,Pfizer,Large Pharma,4235,PF-04958242,PF-04958242,Small Molecule (Chemical),Phase I,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3343,Schizophrenia,7/7/14 12:28
3338,76,Pfizer,Large Pharma,4235,PF-04958242,PF-04958242,Small Molecule (Chemical),Phase I,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3343,Schizophrenia,7/7/14 12:28
3338,76,Pfizer,Large Pharma,4235,PF-04958242,PF-04958242,Small Molecule (Chemical),Phase I,In-House,,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3343,Schizophrenia,7/7/14 12:28
3339,10,Almirall,Regional & Specialty Pharma,3285,Vaniqa,eflornithine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-04,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3345,Female hirsutism,7/7/14 12:28
3339,10,Almirall,Regional & Specialty Pharma,3285,Vaniqa,eflornithine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-04,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3345,Female hirsutism,7/7/14 12:28
3339,10,Almirall,Regional & Specialty Pharma,3285,Vaniqa,eflornithine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-04,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3345,Female hirsutism,7/7/14 12:28
3340,89,Sanofi,Large Pharma,3286,Rabies VRVg,purified vero rabies vaccine,Vaccine,Phase II,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3346,rabies prophylaxis,7/7/14 12:28
3340,89,Sanofi,Large Pharma,3286,Rabies VRVg,purified vero rabies vaccine,Vaccine,Phase II,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3346,rabies prophylaxis,7/7/14 12:28
3340,89,Sanofi,Large Pharma,3286,Rabies VRVg,purified vero rabies vaccine,Vaccine,Phase II,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3346,rabies prophylaxis,7/7/14 12:28
3341,89,Sanofi,Large Pharma,3287,Rotavirus vaccine,rotavirus vaccine,Vaccine,Phase II,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3347,prevention of rotavirus infection and disease,7/7/14 12:28
3341,89,Sanofi,Large Pharma,3287,Rotavirus vaccine,rotavirus vaccine,Vaccine,Phase II,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3347,prevention of rotavirus infection and disease,7/7/14 12:28
3341,89,Sanofi,Large Pharma,3287,Rotavirus vaccine,rotavirus vaccine,Vaccine,Phase II,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3347,prevention of rotavirus infection and disease,7/7/14 12:28
3342,89,Sanofi,Large Pharma,3413,SAR279356,Anti-PNAG mAb,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3344,prevention and treatment of serious bacterial infections,7/7/14 12:28
3342,89,Sanofi,Large Pharma,3413,SAR279356,Anti-PNAG mAb,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3344,prevention and treatment of serious bacterial infections,7/7/14 12:28
3342,89,Sanofi,Large Pharma,3413,SAR279356,Anti-PNAG mAb,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3344,prevention and treatment of serious bacterial infections,7/7/14 12:28
3344,738,TransTech Pharma,Small Biotech,4047,GK1-399,TTP-399,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3369,Diabetes,7/7/14 12:28
3344,738,TransTech Pharma,Small Biotech,4047,GK1-399,TTP-399,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3369,Diabetes,7/7/14 12:28
3344,738,TransTech Pharma,Small Biotech,4047,GK1-399,TTP-399,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3369,Diabetes,7/7/14 12:28
3345,95,Shionogi,Regional & Specialty Pharma,3296,Osphena,ospemifene,Small Molecule (Chemical),Launched,Licensed (Development),Apr-13,May-14,,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,7,Global,Sales,0,0,0,0,25.00423683,52.12105938,74.68278997,110.241462,139.1866285,156.9781471,171.7927733,182.9130545,32.88056377,3366,Vaginal atrophy,7/7/14 12:28
3345,95,Shionogi,Regional & Specialty Pharma,3296,Osphena,ospemifene,Small Molecule (Chemical),Launched,Licensed (Development),Apr-13,May-14,,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,7,ROW,Sales,0,0,0,0,0,17.11512782,24.67436632,35.22882651,52.77207754,60.8419643,67.68725074,73.29860641,0,3366,Vaginal atrophy,7/7/14 12:28
3345,95,Shionogi,Regional & Specialty Pharma,3296,Osphena,ospemifene,Small Molecule (Chemical),Launched,Licensed (Development),Apr-13,May-14,,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,7,US,Sales,0,0,0,0,25.00423683,35.00593156,50.00842365,75.01263547,86.41455097,96.13618279,104.1055225,109.6144481,23.50750972,3366,Vaginal atrophy,7/7/14 12:28
3346,84,Recordati,Regional & Specialty Pharma,3297,REC-0422,REC-0422,Small Molecule (Chemical),Phase II,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3367,Overactive bladder,7/7/14 12:28
3346,84,Recordati,Regional & Specialty Pharma,3297,REC-0422,REC-0422,Small Molecule (Chemical),Phase II,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3367,Overactive bladder,7/7/14 12:28
3346,84,Recordati,Regional & Specialty Pharma,3297,REC-0422,REC-0422,Small Molecule (Chemical),Phase II,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3367,Overactive bladder,7/7/14 12:28
3348,42,Forest,Regional & Specialty Pharma,3299,CEF-104,ceftaroline + avibactam,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1856,bacterial infections,7/7/14 12:28
3348,42,Forest,Regional & Specialty Pharma,3299,CEF-104,ceftaroline + avibactam,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1856,bacterial infections,7/7/14 12:28
3348,42,Forest,Regional & Specialty Pharma,3299,CEF-104,ceftaroline + avibactam,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1856,bacterial infections,7/7/14 12:28
3349,39,Eli Lilly,Large Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-04,Dec-03,Feb-17,Jun-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Alliance Revenue,391,386,409.2,396.9,373.7,383,382,382,370,211,62,47,-25.63510801,1390,Colorectal Cancer,7/7/14 12:28
3349,39,Eli Lilly,Large Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-04,Dec-03,Feb-17,Jun-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,150.2117647,435.2496218,332,0,1390,Colorectal Cancer,7/7/14 12:28
3349,39,Eli Lilly,Large Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-04,Dec-03,Feb-17,Jun-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Alliance Revenue,105,105,103.4,105.7,94.1,95,93,93,90,78,62,47,-9.441381029,1390,Colorectal Cancer,7/7/14 12:28
3349,39,Eli Lilly,Large Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-04,Dec-03,Feb-17,Jun-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1390,Colorectal Cancer,7/7/14 12:28
3349,39,Eli Lilly,Large Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-04,Dec-03,Feb-17,Jun-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Alliance Revenue,286,281,305.8,291.2,279.6,288,289,289,280,133,0,0,-100,1390,Colorectal Cancer,7/7/14 12:28
3349,39,Eli Lilly,Large Pharma,267,Erbitux,cetuximab,Antibody/Antibody Derivative,Launched,Corporate Acquisition,Feb-04,Dec-03,Feb-17,Jun-17,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,150.2117647,435.2496218,332,0,1390,Colorectal Cancer,7/7/14 12:28
3350,180,Vectura,Small Biotech,393,VR632,formoterol + budesonide,Small Molecule (Chemical),Phase III,In-House,Jan-16,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,0,9.771337675,55.37094606,120.513203,185.6554097,222.395631,252.9603654,0,1688,Asthma,7/7/14 12:28
3350,180,Vectura,Small Biotech,393,VR632,formoterol + budesonide,Small Molecule (Chemical),Phase III,In-House,Jan-16,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1688,Asthma,7/7/14 12:28
3350,180,Vectura,Small Biotech,393,VR632,formoterol + budesonide,Small Molecule (Chemical),Phase III,In-House,Jan-16,,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,9.771337675,55.37094606,120.513203,185.6554097,222.395631,252.9603654,0,1688,Asthma,7/7/14 12:28
3351,26,Celgene,Regional & Specialty Pharma,277,Otezla,apremilast,Small Molecule (Chemical),Launched,In-House,Apr-14,Sep-14,May-20,May-20,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,25,54.94185,97.38384312,167.2969954,210.2390306,250.9857202,288.7765888,0,137,Psoriatic Arthritis,7/7/14 12:28
3351,26,Celgene,Regional & Specialty Pharma,277,Otezla,apremilast,Small Molecule (Chemical),Launched,In-House,Apr-14,Sep-14,May-20,May-20,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,15,32.44185,57.38379312,98.54690943,123.7889183,147.7555807,169.9864264,0,137,Psoriatic Arthritis,7/7/14 12:28
3351,26,Celgene,Regional & Specialty Pharma,277,Otezla,apremilast,Small Molecule (Chemical),Launched,In-House,Apr-14,Sep-14,May-20,May-20,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,10,22.5,40.00005,68.75008594,86.45011231,103.2301395,118.7901624,0,137,Psoriatic Arthritis,7/7/14 12:28
3361,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3312,EVP-6124,encenicline,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3361,Alzheimer's Disease,7/7/14 12:28
3361,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3312,EVP-6124,encenicline,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3361,Alzheimer's Disease,7/7/14 12:28
3361,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3312,EVP-6124,encenicline,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3361,Alzheimer's Disease,7/7/14 12:28
3362,102,Teva,Regional & Specialty Pharma,3313,FSC Combination,salmeterol + fluticasone propionate,Small Molecule (Chemical),Phase III,In-House,Jan-16,Jan-16,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,66,176.00022,286.0003575,396.001815,484.0024662,0,3368,Asthma,7/7/14 12:28
3362,102,Teva,Regional & Specialty Pharma,3313,FSC Combination,salmeterol + fluticasone propionate,Small Molecule (Chemical),Phase III,In-House,Jan-16,Jan-16,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,38,101.33346,164.6668725,228.001045,278.6680866,0,3368,Asthma,7/7/14 12:28
3362,102,Teva,Regional & Specialty Pharma,3313,FSC Combination,salmeterol + fluticasone propionate,Small Molecule (Chemical),Phase III,In-House,Jan-16,Jan-16,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,28,74.66676,121.333485,168.00077,205.3343796,0,3368,Asthma,7/7/14 12:28
3363,102,Teva,Regional & Specialty Pharma,3314,DuoResp,formoterol / budesonide,Small Molecule (Chemical),Approved,In-House,,May-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,16.666675,52.77785972,94.44439664,136.1113755,168.5559255,198.2004664,224.5116913,0,3356,Asthma,7/7/14 12:28
3363,102,Teva,Regional & Specialty Pharma,3314,DuoResp,formoterol / budesonide,Small Molecule (Chemical),Approved,In-House,,May-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,16.666675,52.77785972,94.44439664,136.1113755,168.5559255,198.2004664,224.5116913,0,3356,Asthma,7/7/14 12:28
3363,102,Teva,Regional & Specialty Pharma,3314,DuoResp,formoterol / budesonide,Small Molecule (Chemical),Approved,In-House,,May-14,N/A,N/A,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3356,Asthma,7/7/14 12:28
3364,102,Teva,Regional & Specialty Pharma,3315,fluticasone MDPI,fluticasone propionate,Small Molecule (Chemical),Phase III,In-House,,,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3354,Asthma,7/7/14 12:28
3364,102,Teva,Regional & Specialty Pharma,3315,fluticasone MDPI,fluticasone propionate,Small Molecule (Chemical),Phase III,In-House,,,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3354,Asthma,7/7/14 12:28
3364,102,Teva,Regional & Specialty Pharma,3315,fluticasone MDPI,fluticasone propionate,Small Molecule (Chemical),Phase III,In-House,,,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3354,Asthma,7/7/14 12:28
3365,180,Vectura,Small Biotech,3316,VR506,fluticasone propionate,Small Molecule (Chemical),Phase III,In-House,Jan-16,Nov-14,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,Global,Sales,0,0,0,0,0,3.257115164,15.59073357,39.56315651,68.22585075,93.79640504,114.739261,133.8393676,0,3355,Asthma,7/7/14 12:28
3365,180,Vectura,Small Biotech,3316,VR506,fluticasone propionate,Small Molecule (Chemical),Phase III,In-House,Jan-16,Nov-14,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,ROW,Sales,0,0,0,0,0,3.257115164,13.24561252,26.27412946,39.30268203,49.23910671,58.4250919,66.56879631,0,3355,Asthma,7/7/14 12:28
3365,180,Vectura,Small Biotech,3316,VR506,fluticasone propionate,Small Molecule (Chemical),Phase III,In-House,Jan-16,Nov-14,N/A,N/A,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,4,US,Sales,0,0,0,0,0,0,2.345121042,13.28902706,28.92316872,44.55729833,56.31416914,67.27057124,0,3355,Asthma,7/7/14 12:28
3366,84,Recordati,Regional & Specialty Pharma,3318,Cystagon,mercaptamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3360,Nephropathic Cystinosis,7/7/14 12:28
3366,84,Recordati,Regional & Specialty Pharma,3318,Cystagon,mercaptamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3360,Nephropathic Cystinosis,7/7/14 12:28
3366,84,Recordati,Regional & Specialty Pharma,3318,Cystagon,mercaptamine,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3360,Nephropathic Cystinosis,7/7/14 12:28
3367,84,Recordati,Regional & Specialty Pharma,3319,Normosang,human hemin,Recombinant Protein,Launched,Corporate Acquisition,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3358,Hepatic porphyria,7/7/14 12:28
3367,84,Recordati,Regional & Specialty Pharma,3319,Normosang,human hemin,Recombinant Protein,Launched,Corporate Acquisition,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3358,Hepatic porphyria,7/7/14 12:28
3367,84,Recordati,Regional & Specialty Pharma,3319,Normosang,human hemin,Recombinant Protein,Launched,Corporate Acquisition,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3358,Hepatic porphyria,7/7/14 12:28
3368,68,Novo Nordisk,Regional & Specialty Pharma,3320,N8-GP,NN7088,Recombinant Protein,Phase III,Licensed (Development),Jan-15,Mar-15,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,Global,Sales,0,0,0,0,0,0,154.4782782,274.8264209,389.3866617,503.9463879,584.9486826,653.395462,0,3362,Hemophilia A,7/7/14 12:28
3368,68,Novo Nordisk,Regional & Specialty Pharma,3320,N8-GP,NN7088,Recombinant Protein,Phase III,Licensed (Development),Jan-15,Mar-15,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,ROW,Sales,0,0,0,0,0,0,86.81054459,162.0466393,231.4949675,300.9434577,350.3676315,391.9730412,0,3362,Hemophilia A,7/7/14 12:28
3368,68,Novo Nordisk,Regional & Specialty Pharma,3320,N8-GP,NN7088,Recombinant Protein,Phase III,Licensed (Development),Jan-15,Mar-15,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,US,Sales,0,0,0,0,0,0,67.66773362,112.7797816,157.8916942,203.0029302,234.5810511,261.4224208,0,3362,Hemophilia A,7/7/14 12:28
3369,68,Novo Nordisk,Regional & Specialty Pharma,3321,mAb2021,NN7415,Recombinant Protein,Phase I,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3371,Hemophilia A and B,7/7/14 12:28
3369,68,Novo Nordisk,Regional & Specialty Pharma,3321,mAb2021,NN7415,Recombinant Protein,Phase I,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3371,Hemophilia A and B,7/7/14 12:28
3369,68,Novo Nordisk,Regional & Specialty Pharma,3321,mAb2021,NN7415,Recombinant Protein,Phase I,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3371,Hemophilia A and B,7/7/14 12:28
3372,42,Forest,Regional & Specialty Pharma,4097,CAZ-AVI,ceftazidime + avibactam,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-15,,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,21.5,89.583405,157.6667928,200.6672572,239.5466079,271.7161524,0,1853,Bacterial Infections,7/7/14 12:28
3372,42,Forest,Regional & Specialty Pharma,4097,CAZ-AVI,ceftazidime + avibactam,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-15,,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1853,Bacterial Infections,7/7/14 12:28
3372,42,Forest,Regional & Specialty Pharma,4097,CAZ-AVI,ceftazidime + avibactam,Small Molecule (Chemical),Phase III,Licensed (Development),Jul-15,,,,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,21.5,89.583405,157.6667928,200.6672572,239.5466079,271.7161524,0,1853,Bacterial Infections,7/7/14 12:28
3373,95,Shionogi,Regional & Specialty Pharma,3327,Kapvay,clonidine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-11,,Oct-13,N/A,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,7,Global,Sales,0,17.31936038,52.73671345,56.25953287,30.20316674,0,0,0,0,0,0,0,-100,3372,ADHD,7/7/14 12:28
3373,95,Shionogi,Regional & Specialty Pharma,3327,Kapvay,clonidine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-11,,Oct-13,N/A,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3372,ADHD,7/7/14 12:28
3373,95,Shionogi,Regional & Specialty Pharma,3327,Kapvay,clonidine,Small Molecule (Chemical),Launched,Corporate Acquisition,Jan-11,,Oct-13,N/A,44,Other ADHD Agents,37,ADHD,12,Central Nervous System,7,US,Sales,0,17.31936038,52.73671345,56.25953287,30.20316674,0,0,0,0,0,0,0,-100,3372,ADHD,7/7/14 12:28
3375,100,Takeda,Large Pharma,3436,fulranumab,JNJ-42160443,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1949,Pain,7/7/14 12:28
3375,100,Takeda,Large Pharma,3436,fulranumab,JNJ-42160443,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1949,Pain,7/7/14 12:28
3375,100,Takeda,Large Pharma,3436,fulranumab,JNJ-42160443,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1949,Pain,7/7/14 12:28
3380,100,Takeda,Large Pharma,2622,Reminyl,galantamine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-11,,Jun-20,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,Global,Sales,0,5.836416907,34.18648304,101.1254216,135.7724368,168.7422345,198.9988675,223.5961304,243.174837,259.4287381,272.6727487,281.8962229,11.00060156,956,Alzheimer's Disease,7/7/14 12:28
3380,100,Takeda,Large Pharma,2622,Reminyl,galantamine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-11,,Jun-20,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,ROW,Sales,0,5.836416907,34.18648304,101.1254216,135.7724368,168.7422345,198.9988675,223.5961304,243.174837,259.4287381,272.6727487,281.8962229,11.00060156,956,Alzheimer's Disease,7/7/14 12:28
3380,100,Takeda,Large Pharma,2622,Reminyl,galantamine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-11,,Jun-20,18,AChEIs,39,Alzheimer's Disease,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,956,Alzheimer's Disease,7/7/14 12:28
3381,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3338,Tetrabik SC,BK-4SP,Vaccine,Launched,Licensed (Development),,Apr-13,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,7,Global,Sales,0,0,0,0,70.87746299,99.22844819,120.8126669,140.9481114,161.0835559,167.2111157,181.2190004,185.0797902,14.69647206,3377,Prophylaxis of pertussis diphtheria tetanus poliomyelitis,7/7/14 12:28
3381,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3338,Tetrabik SC,BK-4SP,Vaccine,Launched,Licensed (Development),,Apr-13,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,7,ROW,Sales,0,0,0,0,70.87746299,99.22844819,120.8126669,140.9481114,161.0835559,167.2111157,181.2190004,185.0797902,14.69647206,3377,Prophylaxis of pertussis diphtheria tetanus poliomyelitis,7/7/14 12:28
3381,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,3338,Tetrabik SC,BK-4SP,Vaccine,Launched,Licensed (Development),,Apr-13,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3377,Prophylaxis of pertussis diphtheria tetanus poliomyelitis,7/7/14 12:28
3386,236,BioTie,Regional & Specialty Pharma,4217,tozadenant,SYN115,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3381,Parkinson's Disease,7/7/14 12:28
3386,236,BioTie,Regional & Specialty Pharma,4217,tozadenant,SYN115,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3381,Parkinson's Disease,7/7/14 12:28
3386,236,BioTie,Regional & Specialty Pharma,4217,tozadenant,SYN115,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,146,Other PD treatments,58,Parkinson's Disease,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3381,Parkinson's Disease,7/7/14 12:28
3388,2423,Crealta,Regional & Specialty Pharma,3351,Krystexxa,pegloticase,Recombinant Protein,Launched,Licensed (Development),Feb-11,Oct-13,N/A,,151,Gout Treatments,64,Gout,8,Metabolism,6,Global,Sales,0,0,0,0,0,29,36.86302163,47.19526026,55.51784704,63.63058652,71.38822067,77.6182335,0,3417,Gout,7/7/14 12:28
3388,2423,Crealta,Regional & Specialty Pharma,3351,Krystexxa,pegloticase,Recombinant Protein,Launched,Licensed (Development),Feb-11,Oct-13,N/A,,151,Gout Treatments,64,Gout,8,Metabolism,6,ROW,Sales,0,0,0,0,0,4,6.76902163,12.73896026,16.82313204,20.93384377,24.96097938,28.6182335,0,3417,Gout,7/7/14 12:28
3388,2423,Crealta,Regional & Specialty Pharma,3351,Krystexxa,pegloticase,Recombinant Protein,Launched,Licensed (Development),Feb-11,Oct-13,N/A,,151,Gout Treatments,64,Gout,8,Metabolism,6,US,Sales,0,0,0,0,0,25,30.094,34.4563,38.694715,42.69674275,46.42724129,49,0,3417,Gout,7/7/14 12:28
3388,2423,Savient Pharmaceuticals,Regional & Specialty Pharma,3351,Krystexxa,pegloticase,Recombinant Protein,Launched,Licensed (Development),Feb-11,Oct-13,N/A,,151,Gout Treatments,64,Gout,8,Metabolism,6,Global,Proforma,0,0,6,16,21,0,0,0,0,0,0,0,-100,3417,Gout,7/7/14 12:28
3388,2423,Savient Pharmaceuticals,Regional & Specialty Pharma,3351,Krystexxa,pegloticase,Recombinant Protein,Launched,Licensed (Development),Feb-11,Oct-13,N/A,,151,Gout Treatments,64,Gout,8,Metabolism,6,ROW,Proforma,0,0,0,0,1,0,0,0,0,0,0,0,-100,3417,Gout,7/7/14 12:28
3388,2423,Savient Pharmaceuticals,Regional & Specialty Pharma,3351,Krystexxa,pegloticase,Recombinant Protein,Launched,Licensed (Development),Feb-11,Oct-13,N/A,,151,Gout Treatments,64,Gout,8,Metabolism,6,US,Proforma,0,0,6,16,20,0,0,0,0,0,0,0,-100,3417,Gout,7/7/14 12:28
3389,100,Takeda,Large Pharma,3352,Uloric,febuxostat,Small Molecule (Chemical),Launched,Licensed (Development),Mar-09,,Jun-19,,151,Gout Treatments,64,Gout,8,Metabolism,7,Global,Sales,47.40234265,106.2227877,163.335419,221.2874959,273.3845001,328.0805832,379.9869058,428.0087909,468.4264356,504.4237575,258.9877021,28.76530912,-27.5064366,3437,Gout,7/7/14 12:28
3389,100,Takeda,Large Pharma,3352,Uloric,febuxostat,Small Molecule (Chemical),Launched,Licensed (Development),Mar-09,,Jun-19,,151,Gout Treatments,64,Gout,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3437,Gout,7/7/14 12:28
3389,100,Takeda,Large Pharma,3352,Uloric,febuxostat,Small Molecule (Chemical),Launched,Licensed (Development),Mar-09,,Jun-19,,151,Gout Treatments,64,Gout,8,Metabolism,7,US,Sales,47.40234265,106.2227877,163.335419,221.2874959,273.3845001,328.0805832,379.9869058,428.0087909,468.4264356,504.4237575,258.9877021,28.76530912,-27.5064366,3437,Gout,7/7/14 12:28
3390,73,Otsuka,Regional & Specialty Pharma,498,Abraxane,nab-paclitaxel,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-10,N/A,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,7,Global,Sales,0,12.8401172,40.51731324,44.54334047,85.57563908,104.1143428,134.5775,158.8892325,176.6080184,192.4658718,202.0936776,209.091511,13.61261387,49,Breast Cancer,7/7/14 12:28
3390,73,Otsuka,Regional & Specialty Pharma,498,Abraxane,nab-paclitaxel,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-10,N/A,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,12.8401172,40.51731324,44.54334047,85.57563908,104.1143428,134.5775,158.8892325,176.6080184,192.4658718,202.0936776,209.091511,13.61261387,49,Breast Cancer,7/7/14 12:28
3390,73,Otsuka,Regional & Specialty Pharma,498,Abraxane,nab-paclitaxel,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-10,N/A,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,49,Breast Cancer,7/7/14 12:28
3393,58,Lundbeck,Regional & Specialty Pharma,4018,Sycrest,asenapine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-11,N/A,Mar-20,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,Global,Sales,0,0,12.31728199,18.8203876,25.82058257,37.77128288,43.12524204,47.7942246,51.38626807,53.68148078,56.17370933,58.14800823,12.29668136,1049,Bipolar Disorder,7/7/14 12:28
3393,58,Lundbeck,Regional & Specialty Pharma,4018,Sycrest,asenapine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-11,N/A,Mar-20,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,ROW,Sales,0,0,12.31728199,18.8203876,25.82058257,37.77128288,43.12524204,47.7942246,51.38626807,53.68148078,56.17370933,58.14800823,12.29668136,1049,Bipolar Disorder,7/7/14 12:28
3393,58,Lundbeck,Regional & Specialty Pharma,4018,Sycrest,asenapine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Apr-11,N/A,Mar-20,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1049,Bipolar Disorder,7/7/14 12:28
3397,86,Roche,Large Pharma,3368,RG7593,anti-CD22,Antibody/Antibody Derivative,Phase II,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3387,Hematological Malignancies,7/7/14 12:28
3397,86,Roche,Large Pharma,3368,RG7593,anti-CD22,Antibody/Antibody Derivative,Phase II,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3387,Hematological Malignancies,7/7/14 12:28
3397,86,Roche,Large Pharma,3368,RG7593,anti-CD22,Antibody/Antibody Derivative,Phase II,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3387,Hematological Malignancies,7/7/14 12:28
3398,86,Roche,Large Pharma,3369,RG7597,anti-HER3 MAb,Antibody/Antibody Derivative,Phase II,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3388,Head & Neck Cancer,7/7/14 12:28
3398,86,Roche,Large Pharma,3369,RG7597,anti-HER3 MAb,Antibody/Antibody Derivative,Phase II,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3388,Head & Neck Cancer,7/7/14 12:28
3398,86,Roche,Large Pharma,3369,RG7597,anti-HER3 MAb,Antibody/Antibody Derivative,Phase II,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3388,Head & Neck Cancer,7/7/14 12:28
3399,45,Gilead,Regional & Specialty Pharma,3376,GS 9451,GS 9451,Small Molecule (Chemical),Phase II,In-House,,,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3389,Hepatitis C,7/7/14 12:28
3399,45,Gilead,Regional & Specialty Pharma,3376,GS 9451,GS 9451,Small Molecule (Chemical),Phase II,In-House,,,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3389,Hepatitis C,7/7/14 12:28
3399,45,Gilead,Regional & Specialty Pharma,3376,GS 9451,GS 9451,Small Molecule (Chemical),Phase II,In-House,,,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3389,Hepatitis C,7/7/14 12:28
3401,45,Gilead,Regional & Specialty Pharma,3378,GS 9620,,Small Molecule (Chemical),Phase I,In-House,,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3391,Hepatitis C and Hepatitis B,7/7/14 12:28
3401,45,Gilead,Regional & Specialty Pharma,3378,GS 9620,,Small Molecule (Chemical),Phase I,In-House,,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3391,Hepatitis C and Hepatitis B,7/7/14 12:28
3401,45,Gilead,Regional & Specialty Pharma,3378,GS 9620,,Small Molecule (Chemical),Phase I,In-House,,,,,150,Other Hepatitis Treatments,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3391,Hepatitis C and Hepatitis B,7/7/14 12:28
3402,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-11,N/A,Dec-20,127,Serotonergics,49,Depression,12,Central Nervous System,7,Global,Sales,0,0,15.19399246,60.01016839,73.87239074,97.20055301,115.6742757,130.3552099,142.6389614,152.6075918,160.731531,167.3880473,12.39548033,1450,Depression,7/7/14 12:28
3402,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-11,N/A,Dec-20,127,Serotonergics,49,Depression,12,Central Nervous System,7,ROW,Sales,0,0,15.19399246,60.01016839,73.87239074,97.20055301,115.6742757,130.3552099,142.6389614,152.6075918,160.731531,167.3880473,12.39548033,1450,Depression,7/7/14 12:28
3402,64,Mitsubishi Tanabe Pharma,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-11,N/A,Dec-20,127,Serotonergics,49,Depression,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
3403,610,Mochida,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-11,N/A,Dec-20,127,Serotonergics,49,Depression,12,Central Nervous System,7,Global,Sales,0,0,15.19399246,60.01016839,73.87239074,97.20055301,115.6742757,130.3552099,142.6389614,152.6075918,160.731531,167.3880473,12.39548033,1450,Depression,7/7/14 12:28
3403,610,Mochida,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-11,N/A,Dec-20,127,Serotonergics,49,Depression,12,Central Nervous System,7,ROW,Sales,0,0,15.19399246,60.01016839,73.87239074,97.20055301,115.6742757,130.3552099,142.6389614,152.6075918,160.731531,167.3880473,12.39548033,1450,Depression,7/7/14 12:28
3403,610,Mochida,Regional & Specialty Pharma,1620,Lexapro,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Aug-11,N/A,Dec-20,127,Serotonergics,49,Depression,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
3404,70,Ono,Regional & Specialty Pharma,1735,Kyprolis,carfilzomib,Small Molecule (Chemical),Phase II,Licensed (Development),,Nov-16,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,7.852823351,16.4510367,23.34550166,31.20993896,34.23025563,0,285,Multiple Myeloma,7/7/14 12:28
3404,70,Ono,Regional & Specialty Pharma,1735,Kyprolis,carfilzomib,Small Molecule (Chemical),Phase II,Licensed (Development),,Nov-16,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,7.852823351,16.4510367,23.34550166,31.20993896,34.23025563,0,285,Multiple Myeloma,7/7/14 12:28
3404,70,Ono,Regional & Specialty Pharma,1735,Kyprolis,carfilzomib,Small Molecule (Chemical),Phase II,Licensed (Development),,Nov-16,,,190,Proteasome Inhibitors,84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,285,Multiple Myeloma,7/7/14 12:28
3406,10,Almirall,Regional & Specialty Pharma,3381,LAS41004,LAS41004,Small Molecule (Chemical),Phase II,In-House,,,,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3393,Psoriasis,7/7/14 12:28
3406,10,Almirall,Regional & Specialty Pharma,3381,LAS41004,LAS41004,Small Molecule (Chemical),Phase II,In-House,,,,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3393,Psoriasis,7/7/14 12:28
3406,10,Almirall,Regional & Specialty Pharma,3381,LAS41004,LAS41004,Small Molecule (Chemical),Phase II,In-House,,,,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3393,Psoriasis,7/7/14 12:28
3410,39,Eli Lilly,Large Pharma,3385,Axiron,testosterone ,Small Molecule (Chemical),Launched,Licensed (Development),Mar-11,Mar-13,Jan-17,Jun-26,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,Global,Sales,0,0,24,73.9,178,228.62027,275.9626761,317.0610465,93.7369709,36.84310161,20.90834367,14.08562313,-30.39788256,3396,Hypogonadism,7/7/14 12:28
3410,39,Eli Lilly,Large Pharma,3385,Axiron,testosterone ,Small Molecule (Chemical),Launched,Licensed (Development),Mar-11,Mar-13,Jan-17,Jun-26,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,ROW,Sales,0,0,0,0,1,2.86667,4.866659659,6.866662112,8.149327993,9.216193539,10.07304501,10.72630708,40.34825845,3396,Hypogonadism,7/7/14 12:28
3410,39,Eli Lilly,Large Pharma,3385,Axiron,testosterone ,Small Molecule (Chemical),Launched,Licensed (Development),Mar-11,Mar-13,Jan-17,Jun-26,174,Men's Hormone Replacement Therapy,83,Low Testosterone,2,Genitourinary,6,US,Sales,0,0,24,73.9,177,225.7536,271.0960164,310.1943844,85.58764291,27.62690807,10.83529866,3.35931605,-43.24032463,3396,Hypogonadism,7/7/14 12:28
3411,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,3386,EOquin,apaziquone,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3397,Bladder Cancer,7/7/14 12:28
3411,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,3386,EOquin,apaziquone,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3397,Bladder Cancer,7/7/14 12:28
3411,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,3386,EOquin,apaziquone,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3397,Bladder Cancer,7/7/14 12:28
3412,11,Amgen,Large Pharma,3387,AMG 820,AMG 820,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3398,Various Cancer Types,7/7/14 12:28
3412,11,Amgen,Large Pharma,3387,AMG 820,AMG 820,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3398,Various Cancer Types,7/7/14 12:28
3412,11,Amgen,Large Pharma,3387,AMG 820,AMG 820,Antibody/Antibody Derivative,Phase I,In-House,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3398,Various Cancer Types,7/7/14 12:28
3414,11,Amgen,Large Pharma,3389,AMG 900,AMG 900,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3400,Various Cancer Types,7/7/14 12:28
3414,11,Amgen,Large Pharma,3389,AMG 900,AMG 900,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3400,Various Cancer Types,7/7/14 12:28
3414,11,Amgen,Large Pharma,3389,AMG 900,AMG 900,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3400,Various Cancer Types,7/7/14 12:28
3420,61,Merck & Co,Large Pharma,3394,omarigliptin,MK-3102,Small Molecule (Chemical),Phase III,In-House,Dec-17,Dec-17,,,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,7.9166635,119.1280207,485.1111678,811.5537481,0,3406,Type II Diabetes,7/7/14 12:28
3420,61,Merck & Co,Large Pharma,3394,omarigliptin,MK-3102,Small Molecule (Chemical),Phase III,In-House,Dec-17,Dec-17,,,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,1.2499995,17.08336817,126,239.109,0,3406,Type II Diabetes,7/7/14 12:28
3420,61,Merck & Co,Large Pharma,3394,omarigliptin,MK-3102,Small Molecule (Chemical),Phase III,In-House,Dec-17,Dec-17,,,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,6.666664,102.0446525,359.1111678,572.4447481,0,3406,Type II Diabetes,7/7/14 12:28
3422,61,Merck & Co,Large Pharma,4269,MK-8342B,etonogestrel + ethinylestradiol vaginal ring,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3408,Female contraception,7/7/14 12:28
3422,61,Merck & Co,Large Pharma,4269,MK-8342B,etonogestrel + ethinylestradiol vaginal ring,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3408,Female contraception,7/7/14 12:28
3422,61,Merck & Co,Large Pharma,4269,MK-8342B,etonogestrel + ethinylestradiol vaginal ring,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3408,Female contraception,7/7/14 12:28
3427,76,Pfizer,Large Pharma,1004,PF-3715455,PF-3715455,Small Molecule (Chemical),Phase I,,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3419,COPD,7/7/14 12:28
3427,76,Pfizer,Large Pharma,1004,PF-3715455,PF-3715455,Small Molecule (Chemical),Phase I,,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3419,COPD,7/7/14 12:28
3427,76,Pfizer,Large Pharma,1004,PF-3715455,PF-3715455,Small Molecule (Chemical),Phase I,,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3419,COPD,7/7/14 12:28
3428,76,Pfizer,Large Pharma,4560,PF-04937319,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3422,Type II Diabetes,7/7/14 12:28
3428,76,Pfizer,Large Pharma,4560,PF-04937319,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3422,Type II Diabetes,7/7/14 12:28
3428,76,Pfizer,Large Pharma,4560,PF-04937319,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3422,Type II Diabetes,7/7/14 12:28
3432,76,Pfizer,Large Pharma,3405,RN316,bococizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jan-19,Apr-19,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,148.75,412.917,0,3426,Hypercholesterolemia,7/7/14 12:28
3432,76,Pfizer,Large Pharma,3405,RN316,bococizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jan-19,Apr-19,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,48.75,146.25,0,3426,Hypercholesterolemia,7/7/14 12:28
3432,76,Pfizer,Large Pharma,3405,RN316,bococizumab,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Jan-19,Apr-19,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,100,266.667,0,3426,Hypercholesterolemia,7/7/14 12:28
3437,76,Pfizer,Large Pharma,3410,PF-4449913,PF-04449913,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3420,Acute Myeloid Leukemia,7/7/14 12:28
3437,76,Pfizer,Large Pharma,3410,PF-4449913,PF-04449913,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3420,Acute Myeloid Leukemia,7/7/14 12:28
3437,76,Pfizer,Large Pharma,3410,PF-4449913,PF-04449913,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3420,Acute Myeloid Leukemia,7/7/14 12:28
3438,89,Sanofi,Large Pharma,3414,SAR650984,anti-CD38 MAb,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3434,Hematological Malignancies,7/7/14 12:28
3438,89,Sanofi,Large Pharma,3414,SAR650984,anti-CD38 MAb,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3434,Hematological Malignancies,7/7/14 12:28
3438,89,Sanofi,Large Pharma,3414,SAR650984,anti-CD38 MAb,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3434,Hematological Malignancies,7/7/14 12:28
3439,89,Sanofi,Large Pharma,3415,SAR566658,SAR566658,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3433,Solid Tumors,7/7/14 12:28
3439,89,Sanofi,Large Pharma,3415,SAR566658,SAR566658,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3433,Solid Tumors,7/7/14 12:28
3439,89,Sanofi,Large Pharma,3415,SAR566658,SAR566658,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3433,Solid Tumors,7/7/14 12:28
3448,8,Allergan,Regional & Specialty Pharma,3388,SER-120,desmopressin,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3435,Overactive bladder (nocturia),7/7/14 12:28
3448,8,Allergan,Regional & Specialty Pharma,3388,SER-120,desmopressin,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3435,Overactive bladder (nocturia),7/7/14 12:28
3448,8,Allergan,Regional & Specialty Pharma,3388,SER-120,desmopressin,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3435,Overactive bladder (nocturia),7/7/14 12:28
3449,211,Ferring Pharmaceuticals,Regional & Specialty Pharma,3424,Lysteda,tranexamic acid,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jun-10,,Jan-25,N/A,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,5,Global,Sales,0,2.693259153,7.602085641,10.62793098,14.07478156,16.91653416,19.4055438,21.61452049,23.5501539,25.25280321,26.75185122,28.06980761,10.36419767,3418,Menorrhagia,7/7/14 12:28
3449,211,Ferring Pharmaceuticals,Regional & Specialty Pharma,3424,Lysteda,tranexamic acid,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jun-10,,Jan-25,N/A,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3418,Menorrhagia,7/7/14 12:28
3449,211,Ferring Pharmaceuticals,Regional & Specialty Pharma,3424,Lysteda,tranexamic acid,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jun-10,,Jan-25,N/A,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,5,US,Sales,0,2.693259153,7.602085641,10.62793098,14.07478156,16.91653416,19.4055438,21.61452049,23.5501539,25.25280321,26.75185122,28.06980761,10.36419767,3418,Menorrhagia,7/7/14 12:28
3450,614,Kissei,Regional & Specialty Pharma,3425,Xanbon,ozagrel hydrochloride,Small Molecule (Chemical),Launched,In-House,,Jan-88,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,21.86971717,19.80879898,18.57465579,14.67522487,10.91261217,9.871943756,9.086722171,8.549482404,8.157706381,7.874949038,7.673451351,7.528289163,-5.165399524,1852,acute cerebral thrombosis,7/7/14 12:28
3450,614,Kissei,Regional & Specialty Pharma,3425,Xanbon,ozagrel hydrochloride,Small Molecule (Chemical),Launched,In-House,,Jan-88,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,21.86971717,19.80879898,18.57465579,14.67522487,10.91261217,9.871943756,9.086722171,8.549482404,8.157706381,7.874949038,7.673451351,7.528289163,-5.165399524,1852,acute cerebral thrombosis,7/7/14 12:28
3450,614,Kissei,Regional & Specialty Pharma,3425,Xanbon,ozagrel hydrochloride,Small Molecule (Chemical),Launched,In-House,,Jan-88,,,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1852,acute cerebral thrombosis,7/7/14 12:28
3451,615,Kaken Pharmaceutical,Regional & Specialty Pharma,3426,Procylin,beraprost,Small Molecule (Chemical),Launched,In-House,,,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1360,,7/7/14 12:28
3451,615,Kaken Pharmaceutical,Regional & Specialty Pharma,3426,Procylin,beraprost,Small Molecule (Chemical),Launched,In-House,,,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1360,,7/7/14 12:28
3451,615,Kaken Pharmaceutical,Regional & Specialty Pharma,3426,Procylin,beraprost,Small Molecule (Chemical),Launched,In-House,,,N/A,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1360,,7/7/14 12:28
3455,637,Impax Pharmaceuticals,Small Biotech,4618,Rytary,levodopa + carbidopa XR / IPX066,Small Molecule (Chemical),Filed,In-House,Mar-15,,,,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,29.166655,54.44451989,77.77780778,101.1111501,120.0889345,137.0133765,0,3438,Parkinson's Disease,7/7/14 12:28
3455,637,Impax Pharmaceuticals,Small Biotech,4618,Rytary,levodopa + carbidopa XR / IPX066,Small Molecule (Chemical),Filed,In-House,Mar-15,,,,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3438,Parkinson's Disease,7/7/14 12:28
3455,637,Impax Pharmaceuticals,Small Biotech,4618,Rytary,levodopa + carbidopa XR / IPX066,Small Molecule (Chemical),Filed,In-House,Mar-15,,,,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,29.166655,54.44451989,77.77780778,101.1111501,120.0889345,137.0133765,0,3438,Parkinson's Disease,7/7/14 12:28
3456,671,Amicus Therapeutics,Small Biotech,2059,Amigal,migalastat,Small Molecule (Chemical),Phase III,Licensed (Development),May-17,May-17,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,14.666674,31.77784256,46.44458801,61.11132446,0,3439,Fabry's Disease,7/7/14 12:28
3456,671,Amicus Therapeutics,Small Biotech,2059,Amigal,migalastat,Small Molecule (Chemical),Phase III,Licensed (Development),May-17,May-17,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,8.000004,17.33336867,25.33341164,33.3334497,0,3439,Fabry's Disease,7/7/14 12:28
3456,671,Amicus Therapeutics,Small Biotech,2059,Amigal,migalastat,Small Molecule (Chemical),Phase III,Licensed (Development),May-17,May-17,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,6.66667,14.44447389,21.11117637,27.77787475,0,3439,Fabry's Disease,7/7/14 12:28
3459,58,Lundbeck,Regional & Specialty Pharma,2919,ATryn,recombinant anti-thrombin,Recombinant Protein,Launched,Corporate Acquisition,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3445,Prevention of Thromboembolic Events,7/7/14 12:28
3459,58,Lundbeck,Regional & Specialty Pharma,2919,ATryn,recombinant anti-thrombin,Recombinant Protein,Launched,Corporate Acquisition,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3445,Prevention of Thromboembolic Events,7/7/14 12:28
3459,58,Lundbeck,Regional & Specialty Pharma,2919,ATryn,recombinant anti-thrombin,Recombinant Protein,Launched,Corporate Acquisition,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3445,Prevention of Thromboembolic Events,7/7/14 12:28
3460,39,Eli Lilly,Large Pharma,3766,Jardiance,empagliflozin,Small Molecule (Chemical),Filed,Licensed (Development),Nov-14,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,8,56,126.58822,197.6228,250.23192,299.98504,343.5321248,0,241,Diabetes,7/7/14 12:28
3460,39,Eli Lilly,Large Pharma,3766,Jardiance,empagliflozin,Small Molecule (Chemical),Filed,Licensed (Development),Nov-14,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,241,Diabetes,7/7/14 12:28
3460,39,Eli Lilly,Large Pharma,3766,Jardiance,empagliflozin,Small Molecule (Chemical),Filed,Licensed (Development),Nov-14,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,4,26,56.58822,88,111,133,152,0,241,Diabetes,7/7/14 12:28
3460,39,Eli Lilly,Large Pharma,3766,Jardiance,empagliflozin,Small Molecule (Chemical),Filed,Licensed (Development),Nov-14,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,241,Diabetes,7/7/14 12:28
3460,39,Eli Lilly,Large Pharma,3766,Jardiance,empagliflozin,Small Molecule (Chemical),Filed,Licensed (Development),Nov-14,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,4,30,70,109.6228,139.23192,166.98504,191.5321248,0,241,Diabetes,7/7/14 12:28
3460,39,Eli Lilly,Large Pharma,3766,Jardiance,empagliflozin,Small Molecule (Chemical),Filed,Licensed (Development),Nov-14,Oct-14,,,192,SGLT Inhibitors,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,241,Diabetes,7/7/14 12:28
3461,39,Eli Lilly,Large Pharma,3703,Tradjenta / Trajenta / Jentadueto,linagliptin / linagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),May-11,Sep-11,Aug-23,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,15.1,88.6,249.6,459.84582,565.610857,667.9017821,753.4351557,816.7890714,869.986618,912.6095372,20.34672203,813,Type II Diabetes,7/7/14 12:28
3461,39,Eli Lilly,Large Pharma,3703,Tradjenta / Trajenta / Jentadueto,linagliptin / linagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),May-11,Sep-11,Aug-23,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,813,Type II Diabetes,7/7/14 12:28
3461,39,Eli Lilly,Large Pharma,3703,Tradjenta / Trajenta / Jentadueto,linagliptin / linagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),May-11,Sep-11,Aug-23,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,3.5,32.7,131,249.84582,316.172857,378.1069421,430.3509645,470.9283154,504.7724048,532.453243,22.18035071,813,Type II Diabetes,7/7/14 12:28
3461,39,Eli Lilly,Large Pharma,3703,Tradjenta / Trajenta / Jentadueto,linagliptin / linagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),May-11,Sep-11,Aug-23,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,813,Type II Diabetes,7/7/14 12:28
3461,39,Eli Lilly,Large Pharma,3703,Tradjenta / Trajenta / Jentadueto,linagliptin / linagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),May-11,Sep-11,Aug-23,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,11.6,55.9,118.6,210,249.438,289.79484,323.0841912,345.860756,365.2142132,380.1562942,18.10496126,813,Type II Diabetes,7/7/14 12:28
3461,39,Eli Lilly,Large Pharma,3703,Tradjenta / Trajenta / Jentadueto,linagliptin / linagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),May-11,Sep-11,Aug-23,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,813,Type II Diabetes,7/7/14 12:28
3462,177,Active Biotech,Small Biotech,3447,tasquinimod,TASQ,Small Molecule (Chemical),Phase III,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,9,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3447,Prostate Cancer,7/7/14 12:28
3462,177,Active Biotech,Small Biotech,3447,tasquinimod,TASQ,Small Molecule (Chemical),Phase III,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,9,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3447,Prostate Cancer,7/7/14 12:28
3462,177,Active Biotech,Small Biotech,3447,tasquinimod,TASQ,Small Molecule (Chemical),Phase III,In-House,,,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3447,Prostate Cancer,7/7/14 12:28
3464,190,Meda,Regional & Specialty Pharma,3453,Astepro,azelastine,Small Molecule (Chemical),Launched,Licensed (Development),Dec-08,Sep-14,Jan-28,Jan-28,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,9,Global,Sales,54.33853824,63.02564755,68.06431205,65.85763823,44.22281851,39.70021474,37.14845348,34.22988563,33.58884138,32.22375187,31.09951659,30.2606338,-5.275639739,3442,Allergic Rhinitis,7/7/14 12:28
3464,190,Meda,Regional & Specialty Pharma,3453,Astepro,azelastine,Small Molecule (Chemical),Launched,Licensed (Development),Dec-08,Sep-14,Jan-28,Jan-28,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,9,ROW,Sales,0,0,0,0,0,2.866292155,6.824498306,10.10025749,13.375973,15.08208637,16.32754796,17.22240191,0,3442,Allergic Rhinitis,7/7/14 12:28
3464,190,Meda,Regional & Specialty Pharma,3453,Astepro,azelastine,Small Molecule (Chemical),Launched,Licensed (Development),Dec-08,Sep-14,Jan-28,Jan-28,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,9,US,Sales,54.33853824,63.02564755,68.06431205,65.85763823,44.22281851,36.83392259,30.32395518,24.12962814,20.21286838,17.1416655,14.77196863,13.03823188,-16.01055964,3442,Allergic Rhinitis,7/7/14 12:28
3465,255,Kyorin,Regional & Specialty Pharma,3454,Kipres,montelukast,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-01,N/A,Dec-16,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,3,Global,Sales,312.0666668,393.1362587,461.5920116,495.0876657,436.7641572,457.0253277,474.6833186,465.08484,375.9867121,357.7181196,337.3341951,315.2655834,-4.550057016,1092,Asthma,7/7/14 12:28
3465,255,Kyorin,Regional & Specialty Pharma,3454,Kipres,montelukast,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-01,N/A,Dec-16,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,3,ROW,Sales,312.0666668,393.1362587,461.5920116,495.0876657,436.7641572,457.0253277,474.6833186,465.08484,375.9867121,357.7181196,337.3341951,315.2655834,-4.550057016,1092,Asthma,7/7/14 12:28
3465,255,Kyorin,Regional & Specialty Pharma,3454,Kipres,montelukast,Small Molecule (Chemical),Launched,Licensed (Development),,Aug-01,N/A,Dec-16,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1092,Asthma,7/7/14 12:28
3466,76,Pfizer,Large Pharma,4236,PF-05089771,PF-05089771,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3444,Pain,7/7/14 12:28
3466,76,Pfizer,Large Pharma,4236,PF-05089771,PF-05089771,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3444,Pain,7/7/14 12:28
3466,76,Pfizer,Large Pharma,4236,PF-05089771,PF-05089771,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3444,Pain,7/7/14 12:28
3467,8,Allergan,Regional & Specialty Pharma,2180,Levadex,dihydroergotamine,Small Molecule (Chemical),Filed,Acquisition (Development),Aug-14,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,25.00002,101.6668313,201.6673433,301.6681288,349.3350831,386.2519907,412.6313393,0,3443,Migraine,7/7/14 12:28
3467,8,Allergan,Regional & Specialty Pharma,2180,Levadex,dihydroergotamine,Small Molecule (Chemical),Filed,Acquisition (Development),Aug-14,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3443,Migraine,7/7/14 12:28
3467,8,Allergan,Regional & Specialty Pharma,2180,Levadex,dihydroergotamine,Small Molecule (Chemical),Filed,Acquisition (Development),Aug-14,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,US,Sales,0,0,0,0,0,25.00002,101.6668313,201.6673433,301.6681288,349.3350831,386.2519907,412.6313393,0,3443,Migraine,7/7/14 12:28
3468,687,NPS,Regional & Specialty Pharma,4663,Gattex / Revestive,teduglutide,Recombinant Protein,Launched,In-House,Feb-13,Dec-13,Jun-22,Jun-22,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,0,31,130.92157,195.7254769,250.6075491,292.0724658,323.6144423,348.421223,367.9795925,42.39489632,484,Short Bowel Syndrome,7/7/14 12:28
3468,687,NPS,Regional & Specialty Pharma,4663,Gattex / Revestive,teduglutide,Recombinant Protein,Launched,In-House,Feb-13,Dec-13,Jun-22,Jun-22,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,5,35.33335,49.66667676,71.66653123,81.2814991,87.70484663,92.42810739,95.22334009,52.3437317,484,Short Bowel Syndrome,7/7/14 12:28
3468,687,NPS,Regional & Specialty Pharma,4663,Gattex / Revestive,teduglutide,Recombinant Protein,Launched,In-House,Feb-13,Dec-13,Jun-22,Jun-22,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,26,95.58822,146.0588002,178.9410178,210.7909667,235.9095957,255.9931156,272.7562525,39.90351333,484,Short Bowel Syndrome,7/7/14 12:28
3469,688,Depomed,Small Biotech,3459,DM-1992,levodopa + carbidopa GR,Small Molecule (Chemical),Phase II,In-House,,,,,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3449,Parkinson's disease,7/7/14 12:28
3469,688,Depomed,Small Biotech,3459,DM-1992,levodopa + carbidopa GR,Small Molecule (Chemical),Phase II,In-House,,,,,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3449,Parkinson's disease,7/7/14 12:28
3469,688,Depomed,Small Biotech,3459,DM-1992,levodopa + carbidopa GR,Small Molecule (Chemical),Phase II,In-House,,,,,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3449,Parkinson's disease,7/7/14 12:28
3470,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3577,Fentos,fentanyl - transdermal,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,Apr-18,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,3,Global,Sales,0,9.116203101,38.88410967,57.62966675,54.31951165,63.35909831,70.18183395,75.47250314,80.02255397,83.68129529,86.65805911,89.10526924,7.326448688,3455,Cancer Pain,7/7/14 12:28
3470,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3577,Fentos,fentanyl - transdermal,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,Apr-18,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,3,ROW,Sales,0,9.116203101,38.88410967,57.62966675,54.31951165,63.35909831,70.18183395,75.47250314,80.02255397,83.68129529,86.65805911,89.10526924,7.326448688,3455,Cancer Pain,7/7/14 12:28
3470,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,3577,Fentos,fentanyl - transdermal,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,Apr-18,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3455,Cancer Pain,7/7/14 12:28
3471,34,Daiichi-Sankyo,Regional & Specialty Pharma,3464,CS-3150,,Small Molecule (Chemical),Phase II,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3462,hypertension,7/7/14 12:28
3471,34,Daiichi-Sankyo,Regional & Specialty Pharma,3464,CS-3150,,Small Molecule (Chemical),Phase II,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3462,hypertension,7/7/14 12:28
3471,34,Daiichi-Sankyo,Regional & Specialty Pharma,3464,CS-3150,,Small Molecule (Chemical),Phase II,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3462,hypertension,7/7/14 12:28
3472,243,Gedeon Richter,Regional & Specialty Pharma,3465,Cavinton,vinpocetine,Small Molecule (Chemical),Launched,In-House,,Jun-78,N/A,Expired,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,10,Global,Sales,91.48010872,88.67215361,97.07176051,87.56658246,88.97387079,90.62186044,91.72394123,92.78105625,93.87552386,94.85385334,95.7782077,96.66054651,1.190784011,3461,Cerebrovascular Diseases,7/7/14 12:28
3472,243,Gedeon Richter,Regional & Specialty Pharma,3465,Cavinton,vinpocetine,Small Molecule (Chemical),Launched,In-House,,Jun-78,N/A,Expired,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,10,ROW,Sales,91.48010872,88.67215361,97.07176051,87.56658246,88.97387079,90.62186044,91.72394123,92.78105625,93.87552386,94.85385334,95.7782077,96.66054651,1.190784011,3461,Cerebrovascular Diseases,7/7/14 12:28
3472,243,Gedeon Richter,Regional & Specialty Pharma,3465,Cavinton,vinpocetine,Small Molecule (Chemical),Launched,In-House,,Jun-78,N/A,Expired,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3461,Cerebrovascular Diseases,7/7/14 12:28
3473,189,Valeant,Regional & Specialty Pharma,3456,Potiga / Trobalt,ezogabine / retigabine,Small Molecule (Chemical),Launched,In-House,Apr-12,May-11,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,970,Epilepsy,7/7/14 12:28
3473,189,Valeant,Regional & Specialty Pharma,3456,Potiga / Trobalt,ezogabine / retigabine,Small Molecule (Chemical),Launched,In-House,Apr-12,May-11,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,970,Epilepsy,7/7/14 12:28
3473,189,Valeant,Regional & Specialty Pharma,3456,Potiga / Trobalt,ezogabine / retigabine,Small Molecule (Chemical),Launched,In-House,Apr-12,May-11,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,970,Epilepsy,7/7/14 12:28
3473,189,Valeant,Regional & Specialty Pharma,3456,Potiga / Trobalt,ezogabine / retigabine,Small Molecule (Chemical),Launched,In-House,Apr-12,May-11,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,970,Epilepsy,7/7/14 12:28
3473,189,Valeant,Regional & Specialty Pharma,3456,Potiga / Trobalt,ezogabine / retigabine,Small Molecule (Chemical),Launched,In-House,Apr-12,May-11,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,970,Epilepsy,7/7/14 12:28
3473,189,Valeant,Regional & Specialty Pharma,3456,Potiga / Trobalt,ezogabine / retigabine,Small Molecule (Chemical),Launched,In-House,Apr-12,May-11,,,9,Anti-convulsants,5,Epilepsy,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,970,Epilepsy,7/7/14 12:28
3474,189,Valeant,Regional & Specialty Pharma,1904,Wellbutrin XL,bupropion extended-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-03,Apr-06,May-08,N/A,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Alliance Revenue,56.2,9,9.4,9.7,9.824,9.9046,9.95699,9.9910435,10.01317827,10.02756588,10.03691782,10.04299658,0.315455672,4235,Depression,7/7/14 12:28
3474,189,Valeant,Regional & Specialty Pharma,1904,Wellbutrin XL,bupropion extended-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-03,Apr-06,May-08,N/A,66,Noradrenergics,49,Depression,12,Central Nervous System,6,Global,Sales,124.3,239,212.3,173.272,166.13792,149.700768,138.0666192,131.3044225,125.8589946,121.4794665,117.9607732,115.1360226,-5.103773188,4235,Depression,7/7/14 12:28
3474,189,Valeant,Regional & Specialty Pharma,1904,Wellbutrin XL,bupropion extended-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-03,Apr-06,May-08,N/A,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Alliance Revenue,2.7,9,9.4,9.7,9.824,9.9046,9.95699,9.9910435,10.01317827,10.02756588,10.03691782,10.04299658,0.315455672,4235,Depression,7/7/14 12:28
3474,189,Valeant,Regional & Specialty Pharma,1904,Wellbutrin XL,bupropion extended-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-03,Apr-06,May-08,N/A,66,Noradrenergics,49,Depression,12,Central Nervous System,6,ROW,Sales,15.6,51,53.1,55.272,56.13792,56.700768,57.0666192,57.30442248,57.45899461,57.5594665,57.62477322,57.6672226,0.384700928,4235,Depression,7/7/14 12:28
3474,189,Valeant,Regional & Specialty Pharma,1904,Wellbutrin XL,bupropion extended-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-03,Apr-06,May-08,N/A,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Alliance Revenue,53.5,0,0,0,0,0,0,0,0,0,0,0,0,4235,Depression,7/7/14 12:28
3474,189,Valeant,Regional & Specialty Pharma,1904,Wellbutrin XL,bupropion extended-release,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-03,Apr-06,May-08,N/A,66,Noradrenergics,49,Depression,12,Central Nervous System,6,US,Sales,108.7,188,159.2,118,110,93,81,74,68.4,63.92,60.336,57.4688,-8.857704853,4235,Depression,7/7/14 12:28
3475,45,Gilead,Regional & Specialty Pharma,3677,idelalisib,GS-1101,Small Molecule (Chemical),Filed,Corporate Acquisition,Aug-14,Nov-14,Aug-25,Aug-25,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,62.50007,314.1672797,664.1689019,1014.171572,1245.406256,1448.839183,1617.600366,0,3463,Non-Hodgkin's Lymphoma,7/7/14 12:28
3475,45,Gilead,Regional & Specialty Pharma,3677,idelalisib,GS-1101,Small Molecule (Chemical),Filed,Corporate Acquisition,Aug-14,Nov-14,Aug-25,Aug-25,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,16.6667,127.7780889,294.4454391,461.1133355,570.0028372,666.4478501,746.4039055,0,3463,Non-Hodgkin's Lymphoma,7/7/14 12:28
3475,45,Gilead,Regional & Specialty Pharma,3677,idelalisib,GS-1101,Small Molecule (Chemical),Filed,Corporate Acquisition,Aug-14,Nov-14,Aug-25,Aug-25,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,45.83337,186.3891908,369.7234627,553.0582362,675.4034189,782.3913334,871.1964601,0,3463,Non-Hodgkin's Lymphoma,7/7/14 12:28
3476,73,Otsuka,Regional & Specialty Pharma,3468,Pletaal,cilostazol,Small Molecule (Chemical),Launched,In-House,Apr-99,Apr-88,Expired,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,554.8228741,610.6631777,637.3369742,554.2150942,445.1634025,428.390662,417.1981174,408.8509199,402.8801772,398.5416223,395.4067946,391.3121582,-1.825078312,3453,Intermittent claudication,7/7/14 12:28
3476,73,Otsuka,Regional & Specialty Pharma,3468,Pletaal,cilostazol,Small Molecule (Chemical),Launched,In-House,Apr-99,Apr-88,Expired,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,537.5856586,594.5324522,621.3184067,539.3355819,432.9120565,416.2820387,405.1816097,396.888061,390.9499128,386.6308133,383.5076841,381.2444359,-1.799241748,3453,Intermittent claudication,7/7/14 12:28
3476,73,Otsuka,Regional & Specialty Pharma,3468,Pletaal,cilostazol,Small Molecule (Chemical),Launched,In-House,Apr-99,Apr-88,Expired,Expired,12,Anti-platelets,33,Thrombosis,10,Cardiovasculars,7,US,Sales,17.23721551,16.13072545,16.01856751,14.87951229,12.25134594,12.1086233,12.01650771,11.96285886,11.93026443,11.91080905,11.8991105,10.06772225,-2.765346139,3453,Intermittent claudication,7/7/14 12:28
3477,190,Meda,Regional & Specialty Pharma,2743,Tambocor,flecainide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-82,,Expired,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,9,Global,Sales,120.3023887,109.6701797,118.265592,111.1901381,119.1559277,119.5551614,120.8327095,121.3776636,121.9699769,122.3395887,122.6522144,122.8739416,0.439907366,2116,Atrial fibrillation,7/7/14 12:28
3477,190,Meda,Regional & Specialty Pharma,2743,Tambocor,flecainide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-82,,Expired,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,9,ROW,Sales,120.3023887,109.6701797,118.265592,111.1901381,119.1559277,119.5551614,120.8327095,121.3776636,121.9699769,122.3395887,122.6522144,122.8739416,0.439907366,2116,Atrial fibrillation,7/7/14 12:28
3477,190,Meda,Regional & Specialty Pharma,2743,Tambocor,flecainide,Small Molecule (Chemical),Launched,Corporate Acquisition,,Aug-82,,Expired,139,Class Ic Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2116,Atrial fibrillation,7/7/14 12:28
3479,190,Meda,Regional & Specialty Pharma,3471,Minitran,nitroglycerine patch,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-91,,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,9,Global,Sales,69.09876617,61.3597714,55.89897121,42.08391681,40.998238,36.48382527,33.81387261,31.42845692,29.67899559,28.27630544,27.1973264,26.35140197,-6.119161299,3457,Angina,7/7/14 12:28
3479,190,Meda,Regional & Specialty Pharma,3471,Minitran,nitroglycerine patch,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-91,,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,9,ROW,Sales,69.09876617,61.3597714,55.89897121,42.08391681,40.998238,36.48382527,33.81387261,31.42845692,29.67899559,28.27630544,27.1973264,26.35140197,-6.119161299,3457,Angina,7/7/14 12:28
3479,190,Meda,Regional & Specialty Pharma,3471,Minitran,nitroglycerine patch,Small Molecule (Chemical),Launched,Corporate Acquisition,,May-91,,Expired,57,Other Cardiology Agents,18,Other Cardiovascular Disorders,10,Cardiovasculars,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3457,Angina,7/7/14 12:28
3480,243,Gedeon Richter,Regional & Specialty Pharma,3472,Mydeton / Mydocalm,tolperisone,Small Molecule (Chemical),Launched,In-House,,Jun-59,N/A,Expired,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,10,Global,Sales,48.68297504,61.65361714,73.67732209,82.04588726,80.52280163,84.78514193,85.44918659,86.92710208,87.56969013,88.20584119,93.94326856,95.85534209,2.521254042,3460,Muscle Relaxant,7/7/14 12:28
3480,243,Gedeon Richter,Regional & Specialty Pharma,3472,Mydeton / Mydocalm,tolperisone,Small Molecule (Chemical),Launched,In-House,,Jun-59,N/A,Expired,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,10,ROW,Sales,48.68297504,61.65361714,73.67732209,82.04588726,80.52280163,84.78514193,85.44918659,86.92710208,87.56969013,88.20584119,93.94326856,95.85534209,2.521254042,3460,Muscle Relaxant,7/7/14 12:28
3480,243,Gedeon Richter,Regional & Specialty Pharma,3472,Mydeton / Mydocalm,tolperisone,Small Molecule (Chemical),Launched,In-House,,Jun-59,N/A,Expired,165,Other Muscle Relaxants,75,Muscle Spasticity,13,Musculoskeletal / Pain,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3460,Muscle Relaxant,7/7/14 12:28
3481,243,Gedeon Richter,Regional & Specialty Pharma,3473,Lisopress,lisinopril,Small Molecule (Chemical),Launched,In-House,,Jan-94,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,10,Global,Sales,89.55769706,79.54576418,78.83135494,71.55567738,70.215842,69.32235904,68.74169915,68.05316047,67.53028754,67.09219001,66.70697622,66.38551817,-0.798154358,4354,hypertension,7/7/14 12:28
3481,243,Gedeon Richter,Regional & Specialty Pharma,3473,Lisopress,lisinopril,Small Molecule (Chemical),Launched,In-House,,Jan-94,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,10,ROW,Sales,89.55769706,79.54576418,78.83135494,71.55567738,70.215842,69.32235904,68.74169915,68.05316047,67.53028754,67.09219001,66.70697622,66.38551817,-0.798154358,4354,hypertension,7/7/14 12:28
3481,243,Gedeon Richter,Regional & Specialty Pharma,3473,Lisopress,lisinopril,Small Molecule (Chemical),Launched,In-House,,Jan-94,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4354,hypertension,7/7/14 12:28
3482,190,Meda,Regional & Specialty Pharma,3474,Soma,carisoprodol,Small Molecule (Chemical),Launched,In-House,Apr-65,,Expired,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,9,Global,Sales,58.64904728,55.25155887,46.35148852,26.72697874,17.86720678,12.90440367,10.42300211,9.182301326,8.561950936,8.251775741,8.096688144,8.019144345,-10.81414928,3452,Pain,7/7/14 12:28
3482,190,Meda,Regional & Specialty Pharma,3474,Soma,carisoprodol,Small Molecule (Chemical),Launched,In-House,Apr-65,,Expired,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,9,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3452,Pain,7/7/14 12:28
3482,190,Meda,Regional & Specialty Pharma,3474,Soma,carisoprodol,Small Molecule (Chemical),Launched,In-House,Apr-65,,Expired,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,9,US,Sales,58.64904728,55.25155887,46.35148852,26.72697874,17.86720678,12.90440367,10.42300211,9.182301326,8.561950936,8.251775741,8.096688144,8.019144345,-10.81414928,3452,Pain,7/7/14 12:28
3483,189,Valeant,Regional & Specialty Pharma,3589,Ralivia / Ultram ER,tramadol - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-06,Nov-07,Expired,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Alliance Revenue,53.986,25.2,15,9.39,1,0,0,0,0,0,0,0,-100,1223,Pain,7/7/14 12:28
3483,189,Valeant,Regional & Specialty Pharma,3589,Ralivia / Ultram ER,tramadol - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-06,Nov-07,Expired,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,4.675,5.5,6.3,6.88807,7.167684,7.3581752,7.47687272,7.545840288,7.5891168,7.615544012,7.631540041,7.641372634,0.918400182,1223,Pain,7/7/14 12:28
3483,189,Valeant,Regional & Specialty Pharma,3589,Ralivia / Ultram ER,tramadol - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-06,Nov-07,Expired,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1223,Pain,7/7/14 12:28
3483,189,Valeant,Regional & Specialty Pharma,3589,Ralivia / Ultram ER,tramadol - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-06,Nov-07,Expired,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,4.675,5.5,6.3,6.88807,7.167684,7.3581752,7.47687272,7.545840288,7.5891168,7.615544012,7.631540041,7.641372634,0.918400182,1223,Pain,7/7/14 12:28
3483,189,Valeant,Regional & Specialty Pharma,3589,Ralivia / Ultram ER,tramadol - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-06,Nov-07,Expired,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Alliance Revenue,53.986,25.2,15,9.39,1,0,0,0,0,0,0,0,-100,1223,Pain,7/7/14 12:28
3483,189,Valeant,Regional & Specialty Pharma,3589,Ralivia / Ultram ER,tramadol - extended release,Small Molecule (Chemical),Launched,Corporate Acquisition,Feb-06,Nov-07,Expired,N/A,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1223,Pain,7/7/14 12:28
3484,190,Meda,Regional & Specialty Pharma,3476,Zamadol,tramadol,Small Molecule (Chemical),Launched,In-House,,Jun-98,N/A,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,9,Global,Sales,51.59548703,43.1739568,38.03593909,34.25778491,31.32449645,29.09800038,27.77361909,26.872464,26.31329679,25.96125369,25.73706413,25.59543511,-2.844283702,1223,Pain,7/7/14 12:28
3484,190,Meda,Regional & Specialty Pharma,3476,Zamadol,tramadol,Small Molecule (Chemical),Launched,In-House,,Jun-98,N/A,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,9,ROW,Sales,51.59548703,43.1739568,38.03593909,34.25778491,31.32449645,29.09800038,27.77361909,26.872464,26.31329679,25.96125369,25.73706413,25.59543511,-2.844283702,1223,Pain,7/7/14 12:28
3484,190,Meda,Regional & Specialty Pharma,3476,Zamadol,tramadol,Small Molecule (Chemical),Launched,In-House,,Jun-98,N/A,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1223,Pain,7/7/14 12:28
3486,87,Salix,Small Biotech,1202,Relistor,methylnaltrexone,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-11,Apr-11,Nov-17,N/A,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,0,19.8,33,39,53.21991,56.04514313,58.433747,60.85119543,62.02974182,62.9711689,62.44786056,6.956587007,1544,Opioid-induced Constipation,7/7/14 12:28
3486,87,Salix,Small Biotech,1202,Relistor,methylnaltrexone,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-11,Apr-11,Nov-17,N/A,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,6.6,10,12,17.91228,19.0288325,20.02320629,21.00816016,21.48674158,21.86682804,21.72166574,8.846870278,1544,Opioid-induced Constipation,7/7/14 12:28
3486,87,Salix,Small Biotech,1202,Relistor,methylnaltrexone,Small Molecule (Chemical),Launched,Licensed (Marketed),Apr-11,Apr-11,Nov-17,N/A,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,13.2,23,27,35.30763,37.01631063,38.41054071,39.84303527,40.54300024,41.10434085,40.72619482,6.047738895,1544,Opioid-induced Constipation,7/7/14 12:28
3487,32,Cubist Pharmaceuticals,Small Biotech,4325,bevenopran,bevenopran,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,May-25,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3450,Functional Bowel Disorder,7/7/14 12:28
3487,32,Cubist Pharmaceuticals,Small Biotech,4325,bevenopran,bevenopran,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,May-25,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3450,Functional Bowel Disorder,7/7/14 12:28
3487,32,Cubist Pharmaceuticals,Small Biotech,4325,bevenopran,bevenopran,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,May-25,,2,Bowel Dysfunction Treatments,50,Motility Disorders,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3450,Functional Bowel Disorder,7/7/14 12:28
3489,42,Forest,Regional & Specialty Pharma,3479,Colobreathe,inhalant colistin,Small Molecule (Chemical),Launched,Acquisition (Development),,Feb-13,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,6,8.46186,12.30938312,18,20.24596869,22.0458057,23.40172195,24.23527343,22.07134336,3454,Cystic Fibrosis,7/7/14 12:28
3489,42,Forest,Regional & Specialty Pharma,3479,Colobreathe,inhalant colistin,Small Molecule (Chemical),Launched,Acquisition (Development),,Feb-13,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,6,8.46186,12.30938312,18,20.24596869,22.0458057,23.40172195,24.23527343,22.07134336,3454,Cystic Fibrosis,7/7/14 12:28
3489,42,Forest,Regional & Specialty Pharma,3479,Colobreathe,inhalant colistin,Small Molecule (Chemical),Launched,Acquisition (Development),,Feb-13,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3454,Cystic Fibrosis,7/7/14 12:28
3491,42,Forest,Regional & Specialty Pharma,3481,cebranopadol,GRT 6005,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3456,Pain,7/7/14 12:28
3491,42,Forest,Regional & Specialty Pharma,3481,cebranopadol,GRT 6005,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3456,Pain,7/7/14 12:28
3491,42,Forest,Regional & Specialty Pharma,3481,cebranopadol,GRT 6005,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3456,Pain,7/7/14 12:28
3493,100,Takeda,Large Pharma,3485,TAK-272,TAK-272,Small Molecule (Chemical),Phase I,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3459,hypertension,7/7/14 12:28
3493,100,Takeda,Large Pharma,3485,TAK-272,TAK-272,Small Molecule (Chemical),Phase I,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3459,hypertension,7/7/14 12:28
3493,100,Takeda,Large Pharma,3485,TAK-272,TAK-272,Small Molecule (Chemical),Phase I,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3459,hypertension,7/7/14 12:28
3494,15,Astellas Pharma,Regional & Specialty Pharma,3486,ASP8477,ASP8477,Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3451,Neuropathic pain,7/7/14 12:28
3494,15,Astellas Pharma,Regional & Specialty Pharma,3486,ASP8477,ASP8477,Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3451,Neuropathic pain,7/7/14 12:28
3494,15,Astellas Pharma,Regional & Specialty Pharma,3486,ASP8477,ASP8477,Small Molecule (Chemical),Phase I,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3451,Neuropathic pain,7/7/14 12:28
3495,86,Roche,Large Pharma,3487,MabThera SC,subcutaneous rituximab,Antibody/Antibody Derivative,Launched,In-House,,Apr-14,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,48.56053972,105.0262497,185.772531,319.0327407,380.3210194,432.3838945,475.0258724,0,3458,Non-Hodgkin's Lymphoma,7/7/14 12:28
3495,86,Roche,Large Pharma,3487,MabThera SC,subcutaneous rituximab,Antibody/Antibody Derivative,Launched,In-House,,Apr-14,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,48.56053972,105.0262497,185.772531,319.0327407,380.3210194,432.3838945,475.0258724,0,3458,Non-Hodgkin's Lymphoma,7/7/14 12:28
3495,86,Roche,Large Pharma,3487,MabThera SC,subcutaneous rituximab,Antibody/Antibody Derivative,Launched,In-House,,Apr-14,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3458,Non-Hodgkin's Lymphoma,7/7/14 12:28
3496,15,Astellas Pharma,Regional & Specialty Pharma,4098,Dificlir,fidaxomicin,Small Molecule (Chemical),Launched,Licensed (Development),,May-12,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,11.55324257,31.85899066,52.86489756,73.8707646,88.74167761,101.2985562,111.7571768,120.1365664,127.0236261,21.84491611,2293,Clostridium difficile infection ,7/7/14 12:28
3496,15,Astellas Pharma,Regional & Specialty Pharma,4098,Dificlir,fidaxomicin,Small Molecule (Chemical),Launched,Licensed (Development),,May-12,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,11.55324257,31.85899066,52.86489756,73.8707646,88.74167761,101.2985562,111.7571768,120.1365664,127.0236261,21.84491611,2293,Clostridium difficile infection ,7/7/14 12:28
3496,15,Astellas Pharma,Regional & Specialty Pharma,4098,Dificlir,fidaxomicin,Small Molecule (Chemical),Launched,Licensed (Development),,May-12,,,55,Macrolides,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2293,Clostridium difficile infection ,7/7/14 12:28
3497,189,Valeant,Regional & Specialty Pharma,1442,Zovirax,acyclovir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-82,,Mar-97,N/A,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,6,Global,Sales,146.27,161.8,207.1,239,247.1615,252.8391875,255.7560109,256.9545154,257.6069746,257.924261,258.0727815,258.147766,0.623221778,1318,Herpes zoster and H simplex,7/7/14 12:28
3497,189,Valeant,Regional & Specialty Pharma,1442,Zovirax,acyclovir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-82,,Mar-97,N/A,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1318,Herpes zoster and H simplex,7/7/14 12:28
3497,189,Valeant,Regional & Specialty Pharma,1442,Zovirax,acyclovir,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-82,,Mar-97,N/A,147,Herpes Treatments,68,Herpes Infection,7,Anti-infectives,6,US,Sales,146.27,161.8,207.1,239,247.1615,252.8391875,255.7560109,256.9545154,257.6069746,257.924261,258.0727815,258.147766,0.623221778,1318,Herpes zoster and H simplex,7/7/14 12:28
3498,696,Nippon Shinyaku,Regional & Specialty Pharma,217,Vidaza,azacitidine,Small Molecule (Chemical),Launched,Licensed (Development),,Mar-11,N/A,Jan-21,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,Global,Sales,0,3.525196,48.03857,84.27118467,101.3975969,114.6363382,123.7456713,130.0110105,133.4162976,135.5779424,136.920133,145.9819726,5.344096092,1354,Myelodysplastic Syndrome,7/7/14 12:28
3498,696,Nippon Shinyaku,Regional & Specialty Pharma,217,Vidaza,azacitidine,Small Molecule (Chemical),Launched,Licensed (Development),,Mar-11,N/A,Jan-21,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,3.525196,48.03857,84.27118467,101.3975969,114.6363382,123.7456713,130.0110105,133.4162976,135.5779424,136.920133,145.9819726,5.344096092,1354,Myelodysplastic Syndrome,7/7/14 12:28
3498,696,Nippon Shinyaku,Regional & Specialty Pharma,217,Vidaza,azacitidine,Small Molecule (Chemical),Launched,Licensed (Development),,Mar-11,N/A,Jan-21,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1354,Myelodysplastic Syndrome,7/7/14 12:28
3499,10,Almirall,Regional & Specialty Pharma,2712,Parapres,candesartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-98,N/A,Apr-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,61.13792972,60.27634385,66.6019341,41.12868244,27.75582839,17.49254275,13.81151269,11.31277211,9.945172866,9.148259111,8.692733685,8.430832139,-15.65218754,1375,hypertension,7/7/14 12:28
3499,10,Almirall,Regional & Specialty Pharma,2712,Parapres,candesartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-98,N/A,Apr-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,61.13792972,60.27634385,66.6019341,41.12868244,27.75582839,17.49254275,13.81151269,11.31277211,9.945172866,9.148259111,8.692733685,8.430832139,-15.65218754,1375,hypertension,7/7/14 12:28
3499,10,Almirall,Regional & Specialty Pharma,2712,Parapres,candesartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-98,N/A,Apr-12,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1375,hypertension,7/7/14 12:28
3500,189,Valeant,Regional & Specialty Pharma,3499,Xenazine / Nitoman,tetrabenazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-08,,Aug-15,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,Global,Alliance Revenue,39.6,66.8,105.3,107,109,111,113,69,55,41.14,27.189,21,-20.96351009,1280,Huntington's Disease,7/7/14 12:28
3500,189,Valeant,Regional & Specialty Pharma,3499,Xenazine / Nitoman,tetrabenazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-08,,Aug-15,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1280,Huntington's Disease,7/7/14 12:28
3500,189,Valeant,Regional & Specialty Pharma,3499,Xenazine / Nitoman,tetrabenazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-08,,Aug-15,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1280,Huntington's Disease,7/7/14 12:28
3500,189,Valeant,Regional & Specialty Pharma,3499,Xenazine / Nitoman,tetrabenazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-08,,Aug-15,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1280,Huntington's Disease,7/7/14 12:28
3500,189,Valeant,Regional & Specialty Pharma,3499,Xenazine / Nitoman,tetrabenazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-08,,Aug-15,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,US,Alliance Revenue,39.6,66.8,105.3,107,109,111,113,69,55,41.14,27.189,21,-20.96351009,1280,Huntington's Disease,7/7/14 12:28
3500,189,Valeant,Regional & Specialty Pharma,3499,Xenazine / Nitoman,tetrabenazine,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-08,,Aug-15,,158,Huntingtons Disease Treatments,71,Huntington's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1280,Huntington's Disease,7/7/14 12:28
3505,21,Biogen Idec,Regional & Specialty Pharma,2042,Neublastin,BG00010,Synthetic Peptide,Phase II,Licensed (Development),,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3536,Neuropathic pain,7/7/14 12:28
3505,21,Biogen Idec,Regional & Specialty Pharma,2042,Neublastin,BG00010,Synthetic Peptide,Phase II,Licensed (Development),,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3536,Neuropathic pain,7/7/14 12:28
3505,21,Biogen Idec,Regional & Specialty Pharma,2042,Neublastin,BG00010,Synthetic Peptide,Phase II,Licensed (Development),,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3536,Neuropathic pain,7/7/14 12:28
3506,21,Biogen Idec,Regional & Specialty Pharma,2046,Anti-TWEAK,BIIB-023,Antibody/Antibody Derivative,Phase II,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3492,Lupus nephritis,7/7/14 12:28
3506,21,Biogen Idec,Regional & Specialty Pharma,2046,Anti-TWEAK,BIIB-023,Antibody/Antibody Derivative,Phase II,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3492,Lupus nephritis,7/7/14 12:28
3506,21,Biogen Idec,Regional & Specialty Pharma,2046,Anti-TWEAK,BIIB-023,Antibody/Antibody Derivative,Phase II,In-House,,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3492,Lupus nephritis,7/7/14 12:28
3507,21,Biogen Idec,Regional & Specialty Pharma,3507,CD40L-Fab,CD40L-Fab,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1855,Lupus,7/7/14 12:28
3507,21,Biogen Idec,Regional & Specialty Pharma,3507,CD40L-Fab,CD40L-Fab,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1855,Lupus,7/7/14 12:28
3507,21,Biogen Idec,Regional & Specialty Pharma,3507,CD40L-Fab,CD40L-Fab,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1855,Lupus,7/7/14 12:28
3508,89,Sanofi,Large Pharma,3510,RetinoStat,RetinoStat,Gene Therapy,Phase I,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3549,AMD,7/7/14 12:28
3508,89,Sanofi,Large Pharma,3510,RetinoStat,RetinoStat,Gene Therapy,Phase I,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3549,AMD,7/7/14 12:28
3508,89,Sanofi,Large Pharma,3510,RetinoStat,RetinoStat,Gene Therapy,Phase I,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3549,AMD,7/7/14 12:28
3510,85,Regeneron,Small Biotech,4066,REGN846,REGN846,Antibody/Antibody Derivative,Phase II,In-House,,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3553,Atopic dermatitis,7/7/14 12:28
3510,85,Regeneron,Small Biotech,4066,REGN846,REGN846,Antibody/Antibody Derivative,Phase II,In-House,,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3553,Atopic dermatitis,7/7/14 12:28
3510,85,Regeneron,Small Biotech,4066,REGN846,REGN846,Antibody/Antibody Derivative,Phase II,In-House,,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3553,Atopic dermatitis,7/7/14 12:28
3512,46,GlaxoSmithKline,Large Pharma,1519,otelixizumab,anti-CD3 mAb,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,832,Rheumatoid Arthritis,7/7/14 12:28
3512,46,GlaxoSmithKline,Large Pharma,1519,otelixizumab,anti-CD3 mAb,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,832,Rheumatoid Arthritis,7/7/14 12:28
3512,46,GlaxoSmithKline,Large Pharma,1519,otelixizumab,anti-CD3 mAb,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,832,Rheumatoid Arthritis,7/7/14 12:28
3515,46,GlaxoSmithKline,Large Pharma,1438,2245840,2245840,Small Molecule (Chemical),Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1323,Psoriasis,7/7/14 12:28
3515,46,GlaxoSmithKline,Large Pharma,1438,2245840,2245840,Small Molecule (Chemical),Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1323,Psoriasis,7/7/14 12:28
3515,46,GlaxoSmithKline,Large Pharma,1438,2245840,2245840,Small Molecule (Chemical),Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1323,Psoriasis,7/7/14 12:28
3517,46,GlaxoSmithKline,Large Pharma,3518,2336805,2336805,Small Molecule (Chemical),Phase II,In-House,,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3479,Hepatitis C,7/7/14 12:28
3517,46,GlaxoSmithKline,Large Pharma,3518,2336805,2336805,Small Molecule (Chemical),Phase II,In-House,,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3479,Hepatitis C,7/7/14 12:28
3517,46,GlaxoSmithKline,Large Pharma,3518,2336805,2336805,Small Molecule (Chemical),Phase II,In-House,,,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3479,Hepatitis C,7/7/14 12:28
3520,46,GlaxoSmithKline,Large Pharma,3521,2256098,Focal adhesion kinase inhibitor,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3478,Cancer,7/7/14 12:28
3520,46,GlaxoSmithKline,Large Pharma,3521,2256098,Focal adhesion kinase inhibitor,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3478,Cancer,7/7/14 12:28
3520,46,GlaxoSmithKline,Large Pharma,3521,2256098,Focal adhesion kinase inhibitor,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3478,Cancer,7/7/14 12:28
3525,46,GlaxoSmithKline,Large Pharma,551,GW870086X,870086,Small Molecule (Chemical),Phase II,In-House,,,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,24,Atopic dermatitis,7/7/14 12:28
3525,46,GlaxoSmithKline,Large Pharma,551,GW870086X,870086,Small Molecule (Chemical),Phase II,In-House,,,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,24,Atopic dermatitis,7/7/14 12:28
3525,46,GlaxoSmithKline,Large Pharma,551,GW870086X,870086,Small Molecule (Chemical),Phase II,In-House,,,,,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,24,Atopic dermatitis,7/7/14 12:28
3527,46,GlaxoSmithKline,Large Pharma,3527,HIV immunotherapy,,Vaccine,Phase II,In-House,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3524,HIV,7/7/14 12:28
3527,46,GlaxoSmithKline,Large Pharma,3527,HIV immunotherapy,,Vaccine,Phase II,In-House,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3524,HIV,7/7/14 12:28
3527,46,GlaxoSmithKline,Large Pharma,3527,HIV immunotherapy,,Vaccine,Phase II,In-House,,,,,26,Other HIV Treatments,32,HIV,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3524,HIV,7/7/14 12:28
3531,46,GlaxoSmithKline,Large Pharma,3582,Duac,clindamycin + benzoyl peroxide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Sep-06,Jun-12,,160,Acne Treatments,73,Acne,6,Dermatology,4,Global,Sales,99.79274813,179.2200067,174.7466974,137.897512,112.56581,114.129224,112.56581,113.8478095,115.4831406,115.937156,117.7915214,118.6030083,0.74913164,3516,Acne,7/7/14 12:28
3531,46,GlaxoSmithKline,Large Pharma,3582,Duac,clindamycin + benzoyl peroxide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Sep-06,Jun-12,,160,Acne Treatments,73,Acne,6,Dermatology,4,ROW,Sales,43.65932731,75.70500284,78.55585482,77.66641482,89.1145996,100.0584978,103.1853258,107.5941534,110.7928985,112.9213304,114.6646934,115.9546694,3.832708082,3516,Acne,7/7/14 12:28
3531,46,GlaxoSmithKline,Large Pharma,3582,Duac,clindamycin + benzoyl peroxide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Sep-06,Jun-12,,160,Acne Treatments,73,Acne,6,Dermatology,4,US,Sales,56.13342083,103.5150039,96.19084263,60.23109721,23.45121042,14.07072625,9.380484168,6.253656112,4.690242084,3.01582566,3.126828056,2.648338939,-26.77033697,3516,Acne,7/7/14 12:28
3531,46,Stiefel,Large Pharma,3582,Duac,clindamycin + benzoyl peroxide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Sep-06,Jun-12,,160,Acne Treatments,73,Acne,6,Dermatology,4,Global,Proforma,78,0,0,0,0,0,0,0,0,0,0,0,0,3516,Acne,7/7/14 12:28
3531,46,Stiefel,Large Pharma,3582,Duac,clindamycin + benzoyl peroxide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Sep-06,Jun-12,,160,Acne Treatments,73,Acne,6,Dermatology,4,ROW,Proforma,34.3,0,0,0,0,0,0,0,0,0,0,0,0,3516,Acne,7/7/14 12:28
3531,46,Stiefel,Large Pharma,3582,Duac,clindamycin + benzoyl peroxide,Small Molecule (Chemical),Launched,Corporate Acquisition,Jul-02,Sep-06,Jun-12,,160,Acne Treatments,73,Acne,6,Dermatology,4,US,Proforma,43.7,0,0,0,0,0,0,0,0,0,0,0,0,3516,Acne,7/7/14 12:28
3532,46,GlaxoSmithKline,Large Pharma,3583,Fabior,tazarotene,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-12,,N/A,,160,Acne Treatments,73,Acne,6,Dermatology,4,Global,Sales,0,0,0,22.09307995,52.60251871,77.85172769,103.1006,118.9174057,131.2371495,140.8099623,147.7973767,153.0950766,16.48745968,1170,Acne,7/7/14 12:28
3532,46,GlaxoSmithKline,Large Pharma,3583,Fabior,tazarotene,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-12,,N/A,,160,Acne Treatments,73,Acne,6,Dermatology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1170,Acne,7/7/14 12:28
3532,46,GlaxoSmithKline,Large Pharma,3583,Fabior,tazarotene,Small Molecule (Chemical),Launched,Corporate Acquisition,Jun-12,,N/A,,160,Acne Treatments,73,Acne,6,Dermatology,4,US,Sales,0,0,0,22.09307995,52.60251871,77.85172769,103.1006,118.9174057,131.2371495,140.8099623,147.7973767,153.0950766,16.48745968,1170,Acne,7/7/14 12:28
3533,46,GlaxoSmithKline,Large Pharma,3535,Sorilux,calcipotriol,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-10,,Oct-26,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,4,Global,Sales,0,6.180000232,30.13119976,46.60767754,61.97456664,72.53681862,80.57653463,86.80995147,91.39459564,94.85676984,97.46866808,99.4255862,6.985852319,3469,Psoriasis,7/7/14 12:28
3533,46,GlaxoSmithKline,Large Pharma,3535,Sorilux,calcipotriol,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-10,,Oct-26,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3469,Psoriasis,7/7/14 12:28
3533,46,GlaxoSmithKline,Large Pharma,3535,Sorilux,calcipotriol,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-10,,Oct-26,,40,Other Psoriasis Treatments,63,Psoriasis,6,Dermatology,4,US,Sales,0,6.180000232,30.13119976,46.60767754,61.97456664,72.53681862,80.57653463,86.80995147,91.39459564,94.85676984,97.46866808,99.4255862,6.985852319,3469,Psoriasis,7/7/14 12:28
3534,46,GlaxoSmithKline,Large Pharma,4627,Hyphanox,itraconazole,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3470,Onychomycosis,7/7/14 12:28
3534,46,GlaxoSmithKline,Large Pharma,4627,Hyphanox,itraconazole,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3470,Onychomycosis,7/7/14 12:28
3534,46,GlaxoSmithKline,Large Pharma,4627,Hyphanox,itraconazole,Small Molecule (Chemical),Launched,Corporate Acquisition,,,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3470,Onychomycosis,7/7/14 12:28
3535,46,GlaxoSmithKline,Large Pharma,3537,Veltin,clindamycin phosphate + tretinoin,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-10,,Nov-14,,160,Acne Treatments,73,Acne,6,Dermatology,4,Global,Sales,0,6.180000232,35.10820321,54.30622834,74.05414522,79.48818046,11.69301349,9.576545466,7.88541629,7.085871504,5.88089035,5.239314836,-31.50242731,3566,Acne,7/7/14 12:28
3535,46,GlaxoSmithKline,Large Pharma,3537,Veltin,clindamycin phosphate + tretinoin,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-10,,Nov-14,,160,Acne Treatments,73,Acne,6,Dermatology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3566,Acne,7/7/14 12:28
3535,46,GlaxoSmithKline,Large Pharma,3537,Veltin,clindamycin phosphate + tretinoin,Small Molecule (Chemical),Launched,Corporate Acquisition,Oct-10,,Nov-14,,160,Acne Treatments,73,Acne,6,Dermatology,4,US,Sales,0,6.180000232,35.10820321,54.30622834,74.05414522,79.48818046,11.69301349,9.576545466,7.88541629,7.085871504,5.88089035,5.239314836,-31.50242731,3566,Acne,7/7/14 12:28
3539,16,AstraZeneca,Large Pharma,3544,MEDI-551,MEDI-551,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3529,Hematological Malignancies,7/7/14 12:28
3539,16,AstraZeneca,Large Pharma,3544,MEDI-551,MEDI-551,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3529,Hematological Malignancies,7/7/14 12:28
3539,16,AstraZeneca,Large Pharma,3544,MEDI-551,MEDI-551,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3529,Hematological Malignancies,7/7/14 12:28
3540,16,AstraZeneca,Large Pharma,3545,AZD4547,AZD4547,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3499,Solid Tumors,7/7/14 12:28
3540,16,AstraZeneca,Large Pharma,3545,AZD4547,AZD4547,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3499,Solid Tumors,7/7/14 12:28
3540,16,AstraZeneca,Large Pharma,3545,AZD4547,AZD4547,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3499,Solid Tumors,7/7/14 12:28
3542,16,AstraZeneca,Large Pharma,3547,MEDI-3617,MEDI-3617,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3527,Solid Tumors,7/7/14 12:28
3542,16,AstraZeneca,Large Pharma,3547,MEDI-3617,MEDI-3617,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3527,Solid Tumors,7/7/14 12:28
3542,16,AstraZeneca,Large Pharma,3547,MEDI-3617,MEDI-3617,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3527,Solid Tumors,7/7/14 12:28
3544,16,AstraZeneca,Large Pharma,3549,MEDI-565,MEDI-565,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3531,Solid Tumors,7/7/14 12:28
3544,16,AstraZeneca,Large Pharma,3549,MEDI-565,MEDI-565,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3531,Solid Tumors,7/7/14 12:28
3544,16,AstraZeneca,Large Pharma,3549,MEDI-565,MEDI-565,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3531,Solid Tumors,7/7/14 12:28
3545,16,AstraZeneca,Large Pharma,3550,AZD5847,AZD5847,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3504,Tuberculosis,7/7/14 12:28
3545,16,AstraZeneca,Large Pharma,3550,AZD5847,AZD5847,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3504,Tuberculosis,7/7/14 12:28
3545,16,AstraZeneca,Large Pharma,3550,AZD5847,AZD5847,Small Molecule (Chemical),Phase II,In-House,,,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3504,Tuberculosis,7/7/14 12:28
3550,16,AstraZeneca,Large Pharma,3554,AZD5069,AZD5069,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3500,Asthma,7/7/14 12:28
3550,16,AstraZeneca,Large Pharma,3554,AZD5069,AZD5069,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3500,Asthma,7/7/14 12:28
3550,16,AstraZeneca,Large Pharma,3554,AZD5069,AZD5069,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3500,Asthma,7/7/14 12:28
3551,16,AstraZeneca,Large Pharma,3544,MEDI-551,MEDI-551,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3529,Multiple sclerosis,7/7/14 12:28
3551,16,AstraZeneca,Large Pharma,3544,MEDI-551,MEDI-551,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3529,Multiple sclerosis,7/7/14 12:28
3551,16,AstraZeneca,Large Pharma,3544,MEDI-551,MEDI-551,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3529,Multiple sclerosis,7/7/14 12:28
3554,19,Bayer,Large Pharma,3557,molidustat,hypoxia-inducible factor prolyl hydroxylase,Small Molecule (Chemical),Phase II,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3523,Anemia,7/7/14 12:28
3554,19,Bayer,Large Pharma,3557,molidustat,hypoxia-inducible factor prolyl hydroxylase,Small Molecule (Chemical),Phase II,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3523,Anemia,7/7/14 12:28
3554,19,Bayer,Large Pharma,3557,molidustat,hypoxia-inducible factor prolyl hydroxylase,Small Molecule (Chemical),Phase II,In-House,,,,,161,Other Anemia Treatments,24,Anemia,14,Hematology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3523,Anemia,7/7/14 12:28
3555,19,Bayer,Large Pharma,3558,MR Antagonist - Bayer,finerrnone,Small Molecule (Chemical),Phase II,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3534,Chronic Heart Failure,7/7/14 12:28
3555,19,Bayer,Large Pharma,3558,MR Antagonist - Bayer,finerrnone,Small Molecule (Chemical),Phase II,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3534,Chronic Heart Failure,7/7/14 12:28
3555,19,Bayer,Large Pharma,3558,MR Antagonist - Bayer,finerrnone,Small Molecule (Chemical),Phase II,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3534,Chronic Heart Failure,7/7/14 12:28
3556,19,Bayer,Large Pharma,3559,peg rFVIII,pegylated Factor VIII,Recombinant Protein,Phase III,,Oct-16,Dec-16,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,Global,Sales,0,0,0,0,0,0,0,18.37107949,147.7067096,238.0130868,328.3201553,396.9989568,0,3509,Hemophilia A,7/7/14 12:28
3556,19,Bayer,Large Pharma,3559,peg rFVIII,pegylated Factor VIII,Recombinant Protein,Phase III,,Oct-16,Dec-16,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,ROW,Sales,0,0,0,0,0,0,0,7.746838956,98.12688501,160.101863,222.0772942,269.436647,0,3509,Hemophilia A,7/7/14 12:28
3556,19,Bayer,Large Pharma,3559,peg rFVIII,pegylated Factor VIII,Recombinant Protein,Phase III,,Oct-16,Dec-16,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,2,US,Sales,0,0,0,0,0,0,0,10.62424053,49.57982457,77.91122372,106.2428611,127.5623098,0,3509,Hemophilia A,7/7/14 12:28
3559,19,Bayer,Large Pharma,4369,BAY 1002670,BAY 1002670,Small Molecule (Chemical),Phase I,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4324,Uterine fibroids ,7/7/14 12:28
3559,19,Bayer,Large Pharma,4369,BAY 1002670,BAY 1002670,Small Molecule (Chemical),Phase I,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4324,Uterine fibroids ,7/7/14 12:28
3559,19,Bayer,Large Pharma,4369,BAY 1002670,BAY 1002670,Small Molecule (Chemical),Phase I,In-House,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4324,Uterine fibroids ,7/7/14 12:28
3562,16,AstraZeneca,Large Pharma,3568,anifrolumab,MEDI-546,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3528,Systemic Lupus Erythematosus,7/7/14 12:28
3562,16,AstraZeneca,Large Pharma,3568,anifrolumab,MEDI-546,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3528,Systemic Lupus Erythematosus,7/7/14 12:28
3562,16,AstraZeneca,Large Pharma,3568,anifrolumab,MEDI-546,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3528,Systemic Lupus Erythematosus,7/7/14 12:28
3564,697,Amarin,Regional & Specialty Pharma,4691,Vascepa,ethyl icosapentate,Small Molecule (Chemical),Launched,In-House,Jan-13,Jan-19,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,26.4,68.4,123.3,156.6,209.0912,256.8544,323.46384,393.8853875,47.12303699,3491,Hypertriglyceridemia,7/7/14 12:28
3564,697,Amarin,Regional & Specialty Pharma,4691,Vascepa,ethyl icosapentate,Small Molecule (Chemical),Launched,In-House,Jan-13,Jan-19,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,21,56,0,3491,Hypertriglyceridemia,7/7/14 12:28
3564,697,Amarin,Regional & Specialty Pharma,4691,Vascepa,ethyl icosapentate,Small Molecule (Chemical),Launched,In-House,Jan-13,Jan-19,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,26.4,68.4,123.3,156.6,209.0912,256.8544,302.46384,337.8853875,43.93497592,3491,Hypertriglyceridemia,7/7/14 12:28
3565,16,AstraZeneca,Large Pharma,3576,Epanova ,EPA + DHA,Small Molecule (Chemical),Approved,Acquisition (Development),May-14,Jun-15,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,36.666685,139.4446114,286.6664609,445.0003627,612.1979093,788.0588966,941.944347,0,3517,Hypertriglyceridemia ,7/7/14 12:28
3565,16,AstraZeneca,Large Pharma,3576,Epanova ,EPA + DHA,Small Molecule (Chemical),Approved,Acquisition (Development),May-14,Jun-15,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,23.33332,78.88878825,145.5553365,222.8337214,286.6117167,349.2334819,0,3517,Hypertriglyceridemia ,7/7/14 12:28
3565,16,AstraZeneca,Large Pharma,3576,Epanova ,EPA + DHA,Small Molecule (Chemical),Approved,Acquisition (Development),May-14,Jun-15,,,90,Other Lipid-modifying Agents,20,Lipid Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,36.666685,116.1112914,207.7776726,299.4450262,389.364188,501.4471799,592.7108651,0,3517,Hypertriglyceridemia ,7/7/14 12:28
3567,255,Kyorin,Regional & Specialty Pharma,419,Pentasa,mesalazine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-01,N/A,,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,3,Global,Sales,207.332,221.0679,225.7787,220.4961163,178.3280946,175.2522419,173.4678735,172.1324679,171.0415576,170.2597873,169.6686437,169.2196727,-0.746163979,1725,ulcerative colitis,7/7/14 12:28
3567,255,Kyorin,Regional & Specialty Pharma,419,Pentasa,mesalazine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-01,N/A,,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,3,ROW,Sales,207.332,221.0679,225.7787,220.4961163,178.3280946,175.2522419,173.4678735,172.1324679,171.0415576,170.2597873,169.6686437,169.2196727,-0.746163979,1725,ulcerative colitis,7/7/14 12:28
3567,255,Kyorin,Regional & Specialty Pharma,419,Pentasa,mesalazine,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jul-01,N/A,,101,Other IBD Treatments,19,Inflammatory Bowel Disease,11,Gastrointestinal,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1725,ulcerative colitis,7/7/14 12:28
3569,614,Kissei,Regional & Specialty Pharma,3586,Utemerin,ritodrine,Small Molecule (Chemical),Launched,In-House,,Aug-86,N/A,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,Global,Sales,52.5735073,54.04522056,54.44513966,53.75910918,40.55903875,39.37713194,38.58851508,37.7742279,37.3341729,37.02315439,36.79796279,36.65100661,-1.436970801,3564,Pre-term labor,7/7/14 12:28
3569,614,Kissei,Regional & Specialty Pharma,3586,Utemerin,ritodrine,Small Molecule (Chemical),Launched,In-House,,Aug-86,N/A,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,ROW,Sales,52.5735073,54.04522056,54.44513966,53.75910918,40.55903875,39.37713194,38.58851508,37.7742279,37.3341729,37.02315439,36.79796279,36.65100661,-1.436970801,3564,Pre-term labor,7/7/14 12:28
3569,614,Kissei,Regional & Specialty Pharma,3586,Utemerin,ritodrine,Small Molecule (Chemical),Launched,In-House,,Aug-86,N/A,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3564,Pre-term labor,7/7/14 12:28
3570,614,Kissei,Regional & Specialty Pharma,484,Urief,silodosin,Small Molecule (Chemical),Launched,In-House,,May-06,N/A,Jan-18,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,Global,Sales,93.83509192,113.4599447,141.8105963,144.6495101,140.9481114,140.9481114,147.0569349,152.6974321,156.4197486,149.9844587,140.3376245,136.4525861,-0.461995024,1633,Symptoms associated with BPH,7/7/14 12:28
3570,614,Kissei,Regional & Specialty Pharma,484,Urief,silodosin,Small Molecule (Chemical),Launched,In-House,,May-06,N/A,Jan-18,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,ROW,Sales,93.83509192,113.4599447,141.8105963,144.6495101,140.9481114,140.9481114,147.0569349,152.6974321,156.4197486,149.9844587,140.3376245,136.4525861,-0.461995024,1633,Symptoms associated with BPH,7/7/14 12:28
3570,614,Kissei,Regional & Specialty Pharma,484,Urief,silodosin,Small Molecule (Chemical),Launched,In-House,,May-06,N/A,Jan-18,41,Alpha Blockers,11,Benign Prostatic Hyperplasia,2,Genitourinary,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1633,Symptoms associated with BPH,7/7/14 12:28
3571,86,Roche,Large Pharma,3587,Herceptin SC,trastuzumab SC,Antibody/Antibody Derivative,Launched,In-House,,Sep-13,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,39.16600886,143.6088297,221.9402658,300.2718633,350.4041395,388.9432823,406.3607677,420.1559226,40.35061046,3521,Breast Cancer,7/7/14 12:28
3571,86,Roche,Large Pharma,3587,Herceptin SC,trastuzumab SC,Antibody/Antibody Derivative,Launched,In-House,,Sep-13,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,39.16600886,143.6088297,221.9402658,300.2718633,350.4041395,388.9432823,406.3607677,420.1559226,40.35061046,3521,Breast Cancer,7/7/14 12:28
3571,86,Roche,Large Pharma,3587,Herceptin SC,trastuzumab SC,Antibody/Antibody Derivative,Launched,In-House,,Sep-13,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3521,Breast Cancer,7/7/14 12:28
3572,73,Otsuka,Regional & Specialty Pharma,4221,Protecadin,lafutidine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-00,N/A,Expired,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,54.94362443,67.70243612,79.76846044,71.02856994,55.68943521,54.0443012,51.8514831,49.9859035,48.45017387,47.03729202,45.80507143,44.72737481,-3.082969587,2107,GERD,7/7/14 12:28
3572,73,Otsuka,Regional & Specialty Pharma,4221,Protecadin,lafutidine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-00,N/A,Expired,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,54.94362443,67.70243612,79.76846044,71.02856994,55.68943521,54.0443012,51.8514831,49.9859035,48.45017387,47.03729202,45.80507143,44.72737481,-3.082969587,2107,GERD,7/7/14 12:28
3572,73,Otsuka,Regional & Specialty Pharma,4221,Protecadin,lafutidine,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-00,N/A,Expired,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2107,GERD,7/7/14 12:28
3573,73,Otsuka,Regional & Specialty Pharma,3591,Mucosta,rebamipide,Small Molecule (Chemical),Launched,In-House,,Jan-90,N/A,Expired,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,399.6879346,356.0214313,363.3896531,276.8910354,216.9908573,194.3070154,175.842806,162.2820059,150.1392653,140.3572846,132.3198506,125.6304309,-7.510298311,3471,Gastritis,7/7/14 12:28
3573,73,Otsuka,Regional & Specialty Pharma,3591,Mucosta,rebamipide,Small Molecule (Chemical),Launched,In-House,,Jan-90,N/A,Expired,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,399.6879346,356.0214313,363.3896531,276.8910354,216.9908573,194.3070154,175.842806,162.2820059,150.1392653,140.3572846,132.3198506,125.6304309,-7.510298311,3471,Gastritis,7/7/14 12:28
3573,73,Otsuka,Regional & Specialty Pharma,3591,Mucosta,rebamipide,Small Molecule (Chemical),Launched,In-House,,Jan-90,N/A,Expired,62,Other GERD/PUD Agents,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3471,Gastritis,7/7/14 12:28
3574,2221,AbbVie,Large Pharma,3592,Ombitasvir,ABT-267,Small Molecule (Chemical),Filed,In-House,Apr-15,Nov-15,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,778,1393,1633,1659,1462,1112,0,3482,Hepatitis C,7/7/14 12:28
3574,2221,AbbVie,Large Pharma,3592,Ombitasvir,ABT-267,Small Molecule (Chemical),Filed,In-House,Apr-15,Nov-15,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,262,613,649,664,606,380,0,3482,Hepatitis C,7/7/14 12:28
3574,2221,AbbVie,Large Pharma,3592,Ombitasvir,ABT-267,Small Molecule (Chemical),Filed,In-House,Apr-15,Nov-15,,,179,NS5A inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,516,780,984,995,856,732,0,3482,Hepatitis C,7/7/14 12:28
3575,2221,AbbVie,Large Pharma,3593,ABT-126,ABT-126,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3481,Alzheimer's Disease,7/7/14 12:28
3575,2221,AbbVie,Large Pharma,3593,ABT-126,ABT-126,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3481,Alzheimer's Disease,7/7/14 12:28
3575,2221,AbbVie,Large Pharma,3593,ABT-126,ABT-126,Small Molecule (Chemical),Phase II,In-House,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3481,Alzheimer's Disease,7/7/14 12:28
3580,11,Amgen,Large Pharma,3598,AMG-181,AMG-181,Antibody/Antibody Derivative,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3487,Ulcerative Colitis,7/7/14 12:28
3580,11,Amgen,Large Pharma,3598,AMG-181,AMG-181,Antibody/Antibody Derivative,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3487,Ulcerative Colitis,7/7/14 12:28
3580,11,Amgen,Large Pharma,3598,AMG-181,AMG-181,Antibody/Antibody Derivative,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3487,Ulcerative Colitis,7/7/14 12:28
3583,11,Amgen,Large Pharma,3601,AMG 780,AMG 780,Antibody/Antibody Derivative,Phase I,In-House,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3490,Various Cancer Types,7/7/14 12:28
3583,11,Amgen,Large Pharma,3601,AMG 780,AMG 780,Antibody/Antibody Derivative,Phase I,In-House,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3490,Various Cancer Types,7/7/14 12:28
3583,11,Amgen,Large Pharma,3601,AMG 780,AMG 780,Antibody/Antibody Derivative,Phase I,In-House,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3490,Various Cancer Types,7/7/14 12:28
3584,11,Amgen,Large Pharma,4332,T-VEC,talimogene laherparepvec,Vaccine,Phase III,Corporate Acquisition,Feb-15,,Feb-23,Feb-21,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,27.50001,48.33346758,68.33337312,88.33318477,102.4497831,114.3905397,0,3538,Melanoma,7/7/14 12:28
3584,11,Amgen,Large Pharma,4332,T-VEC,talimogene laherparepvec,Vaccine,Phase III,Corporate Acquisition,Feb-15,,Feb-23,Feb-21,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3538,Melanoma,7/7/14 12:28
3584,11,Amgen,Large Pharma,4332,T-VEC,talimogene laherparepvec,Vaccine,Phase III,Corporate Acquisition,Feb-15,,Feb-23,Feb-21,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,27.50001,48.33346758,68.33337312,88.33318477,102.4497831,114.3905397,0,3538,Melanoma,7/7/14 12:28
3585,24,Bristol-Myers Squibb,Large Pharma,3603,festinavir,BMS-986001,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3519,HIV,7/7/14 12:28
3585,24,Bristol-Myers Squibb,Large Pharma,3603,festinavir,BMS-986001,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3519,HIV,7/7/14 12:28
3585,24,Bristol-Myers Squibb,Large Pharma,3603,festinavir,BMS-986001,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3519,HIV,7/7/14 12:28
3594,61,Merck & Co,Large Pharma,4133,V212,herpes zoster vaccine,Vaccine,Phase III,In-House,Nov-15,Sep-16,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,2.125,9.6413025,14.98279133,21.66756952,27.8116557,32.53507414,0,3522,herpes zoster prevention,7/7/14 12:28
3594,61,Merck & Co,Large Pharma,4133,V212,herpes zoster vaccine,Vaccine,Phase III,In-House,Nov-15,Sep-16,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,1.4,3.36,4.7600112,7.000024871,8.352432007,0,3522,herpes zoster prevention,7/7/14 12:28
3594,61,Merck & Co,Large Pharma,4133,V212,herpes zoster vaccine,Vaccine,Phase III,In-House,Nov-15,Sep-16,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,2.125,8.2413025,11.62279133,16.90755832,20.81163083,24.18264213,0,3522,herpes zoster prevention,7/7/14 12:28
3595,61,Merck & Co,Large Pharma,3877,tildrakizumab,MK-3222,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Oct-16,Nov-16,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,5.000005,33.33338833,75.00015901,116.6669988,147.867101,0,3555,Psoriasis,7/7/14 12:28
3595,61,Merck & Co,Large Pharma,3877,tildrakizumab,MK-3222,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Oct-16,Nov-16,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,2.500005,19.16671333,44.16681587,69.16700032,87.83377205,0,3555,Psoriasis,7/7/14 12:28
3595,61,Merck & Co,Large Pharma,3877,tildrakizumab,MK-3222,Antibody/Antibody Derivative,Phase III,Corporate Acquisition,Oct-16,Nov-16,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,2.5,14.166675,30.83334314,47.49999844,60.03332891,0,3555,Psoriasis,7/7/14 12:28
3597,76,Pfizer,Large Pharma,4563,PF-05175157,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3541,Type II Diabetes,7/7/14 12:28
3597,76,Pfizer,Large Pharma,4563,PF-05175157,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3541,Type II Diabetes,7/7/14 12:28
3597,76,Pfizer,Large Pharma,4563,PF-05175157,,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3541,Type II Diabetes,7/7/14 12:28
3600,76,Pfizer,Large Pharma,4240,PF-05236812,AAB-003,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3546,Alzheimer's Disease,7/7/14 12:28
3600,76,Pfizer,Large Pharma,4240,PF-05236812,AAB-003,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3546,Alzheimer's Disease,7/7/14 12:28
3600,76,Pfizer,Large Pharma,4240,PF-05236812,AAB-003,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3546,Alzheimer's Disease,7/7/14 12:28
3603,102,Teva,Regional & Specialty Pharma,3623,Ovaleap,follitropin alfa,Recombinant Protein,Approved,Corporate Acquisition,Oct-15,Oct-15,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,4.5,21.000015,32.80005357,43.90019305,52.63025207,59.75371922,0,3568,Female infertility,7/7/14 12:28
3603,102,Teva,Regional & Specialty Pharma,3623,Ovaleap,follitropin alfa,Recombinant Protein,Approved,Corporate Acquisition,Oct-15,Oct-15,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,2.5,11.666675,18.3333631,25.00010725,30.01680671,34.10600412,0,3568,Female infertility,7/7/14 12:28
3603,102,Teva,Regional & Specialty Pharma,3623,Ovaleap,follitropin alfa,Recombinant Protein,Approved,Corporate Acquisition,Oct-15,Oct-15,,,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,2,9.33334,14.46669048,18.9000858,22.61344536,25.6477151,0,3568,Female infertility,7/7/14 12:28
3606,29,Chugai,Regional & Specialty Pharma,3625,SA-237,anti-IL6 MAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3551,Rheumatoid Arthritis,7/7/14 12:28
3606,29,Chugai,Regional & Specialty Pharma,3625,SA-237,anti-IL6 MAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3551,Rheumatoid Arthritis,7/7/14 12:28
3606,29,Chugai,Regional & Specialty Pharma,3625,SA-237,anti-IL6 MAb,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3551,Rheumatoid Arthritis,7/7/14 12:28
3611,76,Pfizer,Large Pharma,3886,Vyndaqel,tafamidis meglumine,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-14,Mar-12,,Nov-21,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,24.99999,71.66672133,129.9997678,210.5553619,286.7553706,358.0085671,410.2269709,454.1345847,490.4435618,31.62075597,3557,TTR Amyloidosis,7/7/14 12:28
3611,76,Pfizer,Large Pharma,3886,Vyndaqel,tafamidis meglumine,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-14,Mar-12,,Nov-21,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,24.99999,71.66672133,121.6664428,171.6664841,206.1997825,235.7864066,260.3937235,280.0541372,296.244946,22.4750266,3557,TTR Amyloidosis,7/7/14 12:28
3611,76,Pfizer,Large Pharma,3886,Vyndaqel,tafamidis meglumine,Small Molecule (Chemical),Launched,Corporate Acquisition,Sep-14,Mar-12,,Nov-21,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,8.333325,38.88887778,80.5555881,122.2221605,149.8332474,174.0804474,194.1986158,0,3557,TTR Amyloidosis,7/7/14 12:28
3615,34,Daiichi-Sankyo,Regional & Specialty Pharma,3639,U3-1565,U3-1565,Antibody/Antibody Derivative,Phase I,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3562,Cancer,7/7/14 12:28
3615,34,Daiichi-Sankyo,Regional & Specialty Pharma,3639,U3-1565,U3-1565,Antibody/Antibody Derivative,Phase I,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3562,Cancer,7/7/14 12:28
3615,34,Daiichi-Sankyo,Regional & Specialty Pharma,3639,U3-1565,U3-1565,Antibody/Antibody Derivative,Phase I,In-House,,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3562,Cancer,7/7/14 12:28
3616,70,Ono,Regional & Specialty Pharma,3641,ONO-6950,,Small Molecule (Chemical),Phase II,In-House,,,,,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3539,Asthma,7/7/14 12:28
3616,70,Ono,Regional & Specialty Pharma,3641,ONO-6950,,Small Molecule (Chemical),Phase II,In-House,,,,,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3539,Asthma,7/7/14 12:28
3616,70,Ono,Regional & Specialty Pharma,3641,ONO-6950,,Small Molecule (Chemical),Phase II,In-House,,,,,92,Leukotriene Antagonists,61,Asthma & COPD,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3539,Asthma,7/7/14 12:28
3620,73,Otsuka,Regional & Specialty Pharma,3645,OVF,fentanyl - buccal,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-13,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,5.906451874,19.96941846,36.84497493,53.72071034,65.13989992,75.04309861,70.47405572,80.54177796,45.24428677,444,Cancer Pain,7/7/14 12:28
3620,73,Otsuka,Regional & Specialty Pharma,3645,OVF,fentanyl - buccal,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-13,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,5.906451874,19.96941846,36.84497493,53.72071034,65.13989992,75.04309861,70.47405572,80.54177796,45.24428677,444,Cancer Pain,7/7/14 12:28
3620,73,Otsuka,Regional & Specialty Pharma,3645,OVF,fentanyl - buccal,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-13,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,444,Cancer Pain,7/7/14 12:28
3621,73,Otsuka,Regional & Specialty Pharma,3646,TSU-68,orantinib,Small Molecule (Chemical),Phase III,Licensed (Development),,Nov-18,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,5.235215568,10.9673578,15.56366778,0,3561,Hepatocellular Carcinoma,7/7/14 12:28
3621,73,Otsuka,Regional & Specialty Pharma,3646,TSU-68,orantinib,Small Molecule (Chemical),Phase III,Licensed (Development),,Nov-18,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,5.235215568,10.9673578,15.56366778,0,3561,Hepatocellular Carcinoma,7/7/14 12:28
3621,73,Otsuka,Regional & Specialty Pharma,3646,TSU-68,orantinib,Small Molecule (Chemical),Phase III,Licensed (Development),,Nov-18,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3561,Hepatocellular Carcinoma,7/7/14 12:28
3622,73,Otsuka,Regional & Specialty Pharma,3647,TAS-102,trifluridine + TPI,Small Molecule (Chemical),Launched,In-House,Aug-15,Sep-14,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,Global,Sales,0,0,0,0,0,8.255532241,19.49218751,28.87775597,42.3973176,50.60799769,54.08009054,56.48729958,0,3558,Colorectal Cancer,7/7/14 12:28
3622,73,Otsuka,Regional & Specialty Pharma,3647,TAS-102,trifluridine + TPI,Small Molecule (Chemical),Launched,In-House,Aug-15,Sep-14,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,0,0,0,0,8.255532241,14.45832639,20.57188512,30.5677641,32.98953388,34.61924198,35.68141022,0,3558,Colorectal Cancer,7/7/14 12:28
3622,73,Otsuka,Regional & Specialty Pharma,3647,TAS-102,trifluridine + TPI,Small Molecule (Chemical),Launched,In-House,Aug-15,Sep-14,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,5.033861123,8.305870852,11.8295535,17.6184638,19.46084856,20.80588936,0,3558,Colorectal Cancer,7/7/14 12:28
3623,73,Otsuka,Regional & Specialty Pharma,3648,TAS-106,ethynylcytidine,Small Molecule (Chemical),Phase II,In-House,,,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3559,Solid Tumors,7/7/14 12:28
3623,73,Otsuka,Regional & Specialty Pharma,3648,TAS-106,ethynylcytidine,Small Molecule (Chemical),Phase II,In-House,,,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3559,Solid Tumors,7/7/14 12:28
3623,73,Otsuka,Regional & Specialty Pharma,3648,TAS-106,ethynylcytidine,Small Molecule (Chemical),Phase II,In-House,,,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3559,Solid Tumors,7/7/14 12:28
3624,73,Otsuka,Regional & Specialty Pharma,3649,ET-743,trabectedin,Small Molecule (Chemical),Phase II,,,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1291,Soft Tissue Sarcoma,7/7/14 12:28
3624,73,Otsuka,Regional & Specialty Pharma,3649,ET-743,trabectedin,Small Molecule (Chemical),Phase II,,,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1291,Soft Tissue Sarcoma,7/7/14 12:28
3624,73,Otsuka,Regional & Specialty Pharma,3649,ET-743,trabectedin,Small Molecule (Chemical),Phase II,,,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1291,Soft Tissue Sarcoma,7/7/14 12:28
3629,73,Otsuka,Regional & Specialty Pharma,4230,Neupro Patch,rotigotine patch,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-13,,Jun-22,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,7,Global,Sales,0,0,0,1.268230485,16.18858167,30.60159971,39.30010442,47.48923341,54.19993707,59.4861911,63.89210584,67.48378786,22.62245432,1626,Parkinson's Disease,7/7/14 12:28
3629,73,Otsuka,Regional & Specialty Pharma,4230,Neupro Patch,rotigotine patch,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-13,,Jun-22,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,7,ROW,Sales,0,0,0,1.268230485,16.18858167,30.60159971,39.30010442,47.48923341,54.19993707,59.4861911,63.89210584,67.48378786,22.62245432,1626,Parkinson's Disease,7/7/14 12:28
3629,73,Otsuka,Regional & Specialty Pharma,4230,Neupro Patch,rotigotine patch,Small Molecule (Chemical),Launched,Licensed (Development),,Feb-13,,Jun-22,74,Dopaminergics,58,Parkinson's Disease,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1626,Parkinson's Disease,7/7/14 12:28
3630,73,Otsuka,Regional & Specialty Pharma,3654,brexpiprazole,brexpiprazole,Small Molecule (Chemical),Phase III,In-House,Jul-15,Sep-16,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Sales,0,0,0,0,0,0,113.2618753,253.6226861,396.4014723,536.1739175,649.5467714,737.2386322,0,3570,Schizophrenia,7/7/14 12:28
3630,73,Otsuka,Regional & Specialty Pharma,3654,brexpiprazole,brexpiprazole,Small Molecule (Chemical),Phase III,In-House,Jul-15,Sep-16,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Sales,0,0,0,0,0,0,0,29.3641731,74.10950562,118.9946968,164.438668,193.4270733,0,3570,Schizophrenia,7/7/14 12:28
3630,73,Otsuka,Regional & Specialty Pharma,3654,brexpiprazole,brexpiprazole,Small Molecule (Chemical),Phase III,In-House,Jul-15,Sep-16,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,113.2618753,224.258513,322.2919667,417.1792207,485.1081034,543.8115589,0,3570,Schizophrenia,7/7/14 12:28
3631,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-13,N/A,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,3,Global,Sales,0,0,0,0,11.27386091,30.06366667,45.0955,60.12718302,71.96469752,82.04066913,90.7373517,98.04132845,36.20429308,1630,Type II Diabetes,7/7/14 12:28
3631,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-13,N/A,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,3,ROW,Sales,0,0,0,0,11.27386091,30.06366667,45.0955,60.12718302,71.96469752,82.04066913,90.7373517,98.04132845,36.20429308,1630,Type II Diabetes,7/7/14 12:28
3631,56,Kyowa Hakko Kirin,Regional & Specialty Pharma,736,Onglyza / Kombiglyze XR,saxagliptin / saxagliptin + metformin,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-13,N/A,N/A,144,DPP-IV Inhibitors,22,Diabetes,8,Metabolism,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1630,Type II Diabetes,7/7/14 12:28
3632,73,Otsuka,Regional & Specialty Pharma,3655,Deltyba,delamanid,Small Molecule (Chemical),Approved,In-House,Jul-16,Jun-14,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,7.1732521,10.70894806,21.32005335,32.29275312,39.24293318,48.19967348,49.97837322,0,3572,Tuberculosis,7/7/14 12:28
3632,73,Otsuka,Regional & Specialty Pharma,3655,Deltyba,delamanid,Small Molecule (Chemical),Approved,In-House,Jul-16,Jun-14,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,7.1732521,10.70894806,15.27942,22.85251173,25.78492505,28.11103934,29.88973908,0,3572,Tuberculosis,7/7/14 12:28
3632,73,Otsuka,Regional & Specialty Pharma,3655,Deltyba,delamanid,Small Molecule (Chemical),Approved,In-House,Jul-16,Jun-14,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,6.040633347,9.440241389,13.45800812,20.08863415,20.08863415,0,3572,Tuberculosis,7/7/14 12:28
3634,73,Otsuka,Regional & Specialty Pharma,3656,tetomilast,OPC-6535,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3571,COPD,7/7/14 12:28
3634,73,Otsuka,Regional & Specialty Pharma,3656,tetomilast,OPC-6535,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3571,COPD,7/7/14 12:28
3634,73,Otsuka,Regional & Specialty Pharma,3656,tetomilast,OPC-6535,Small Molecule (Chemical),Phase II,In-House,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3571,COPD,7/7/14 12:28
3635,73,Otsuka,Regional & Specialty Pharma,3657,Samsca,tolvaptan,Small Molecule (Chemical),Launched,In-House,Jun-09,Sep-09,May-15,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,Global,Sales,6.463955815,42.02220173,84.83312459,154.0958805,200.7672418,247.004546,222.3647018,174.0627746,170.5255984,172.3219825,175.3655274,178.9034243,-1.633651489,3574,Hyponatremia,7/7/14 12:28
3635,73,Otsuka,Regional & Specialty Pharma,3657,Samsca,tolvaptan,Small Molecule (Chemical),Launched,In-House,Jun-09,Sep-09,May-15,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,ROW,Sales,1.077325969,4.669133526,21.52482266,42.13559234,58.81060619,74.6286313,89.47323948,102.9388403,114.4186707,124.6174843,133.6066652,140.9481114,13.29977104,3574,Hyponatremia,7/7/14 12:28
3635,73,Otsuka,Regional & Specialty Pharma,3657,Samsca,tolvaptan,Small Molecule (Chemical),Launched,In-House,Jun-09,Sep-09,May-15,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,7,US,Sales,5.386629846,37.3530682,63.30830193,111.9602882,141.9566356,172.3759147,132.8914623,71.12393427,56.10692767,47.70449818,41.75886217,37.95531286,-17.17534495,3574,Hyponatremia,7/7/14 12:28
3636,73,Otsuka,Regional & Specialty Pharma,3658,Emixustat,Emixustat,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,188,Dry AMD Treatments,30,AMD,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3575,Dry AMD,7/7/14 12:28
3636,73,Otsuka,Regional & Specialty Pharma,3658,Emixustat,Emixustat,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,188,Dry AMD Treatments,30,AMD,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3575,Dry AMD,7/7/14 12:28
3636,73,Otsuka,Regional & Specialty Pharma,3658,Emixustat,Emixustat,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,188,Dry AMD Treatments,30,AMD,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3575,Dry AMD,7/7/14 12:28
3637,73,Otsuka,Regional & Specialty Pharma,3659,TAC-201,TAC-201,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3579,Cedar Pollen Allergy,7/7/14 12:28
3637,73,Otsuka,Regional & Specialty Pharma,3659,TAC-201,TAC-201,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3579,Cedar Pollen Allergy,7/7/14 12:28
3637,73,Otsuka,Regional & Specialty Pharma,3659,TAC-201,TAC-201,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3579,Cedar Pollen Allergy,7/7/14 12:28
3639,73,Otsuka,Regional & Specialty Pharma,3661,Zosyn / Tazocin,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-01,,Jan-20,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,7,Global,Sales,120.6605086,130.7357387,135.4797661,149.2803843,128.1665625,132.2549493,133.7379879,134.852273,135.3717378,135.6984877,135.8677307,135.9669293,0.847585303,1591,bacterial infection,7/7/14 12:28
3639,73,Otsuka,Regional & Specialty Pharma,3661,Zosyn / Tazocin,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-01,,Jan-20,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,7,ROW,Sales,120.6605086,130.7357387,135.4797661,149.2803843,128.1665625,132.2549493,133.7379879,134.852273,135.3717378,135.6984877,135.8677307,135.9669293,0.847585303,1591,bacterial infection,7/7/14 12:28
3639,73,Otsuka,Regional & Specialty Pharma,3661,Zosyn / Tazocin,piperacillin + tazobactam,Small Molecule (Chemical),Launched,Licensed (Development),,Jul-01,,Jan-20,168,Beta-lactams / Beta-lactamase Inhibitors,27,Bacterial Infection,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1591,bacterial infection,7/7/14 12:28
3640,67,Novartis,Large Pharma,2428,Ilaris,canakinumab,Antibody/Antibody Derivative,Phase III,In-House,Apr-18,Aug-18,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,50.00001,163.3334157,296.6669217,0,1374,Secondary prevention of cardiac events,7/7/14 12:28
3640,67,Novartis,Large Pharma,2428,Ilaris,canakinumab,Antibody/Antibody Derivative,Phase III,In-House,Apr-18,Aug-18,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,12.50001,50.83341567,100.8336717,0,1374,Secondary prevention of cardiac events,7/7/14 12:28
3640,67,Novartis,Large Pharma,2428,Ilaris,canakinumab,Antibody/Antibody Derivative,Phase III,In-House,Apr-18,Aug-18,,,122,Other Risk Factor Treatments,18,Other Cardiovascular Disorders,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,37.5,112.5,195.83325,0,1374,Secondary prevention of cardiac events,7/7/14 12:28
3641,58,Lundbeck,Regional & Specialty Pharma,3662,Lu AF11167,Lu AF11167,Small Molecule (Chemical),Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3580,Neurological disorders,7/7/14 12:28
3641,58,Lundbeck,Regional & Specialty Pharma,3662,Lu AF11167,Lu AF11167,Small Molecule (Chemical),Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3580,Neurological disorders,7/7/14 12:28
3641,58,Lundbeck,Regional & Specialty Pharma,3662,Lu AF11167,Lu AF11167,Small Molecule (Chemical),Phase I,In-House,,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3580,Neurological disorders,7/7/14 12:28
3642,5,Actelion,Small Biotech,2969,ponesimod,ACT-128800,Small Molecule (Chemical),Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2064,Multiple sclerosis,7/7/14 12:28
3642,5,Actelion,Small Biotech,2969,ponesimod,ACT-128800,Small Molecule (Chemical),Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2064,Multiple sclerosis,7/7/14 12:28
3642,5,Actelion,Small Biotech,2969,ponesimod,ACT-128800,Small Molecule (Chemical),Phase II,In-House,,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2064,Multiple sclerosis,7/7/14 12:28
3644,42,Forest,Regional & Specialty Pharma,3666,Colomycin,colistin,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jun-59,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3581,Cystic fibrosis,7/7/14 12:28
3644,42,Forest,Regional & Specialty Pharma,3666,Colomycin,colistin,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jun-59,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3581,Cystic fibrosis,7/7/14 12:28
3644,42,Forest,Regional & Specialty Pharma,3666,Colomycin,colistin,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Jun-59,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3581,Cystic fibrosis,7/7/14 12:28
3645,61,Inspire Pharmaceuticals,Large Pharma,3667,AzaSite,azithromycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-07,,Mar-19,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Proforma,34.961,42.671,21.2444,0,0,0,0,0,0,0,0,0,0,3582,Bacterial Conjunctivitis,7/7/14 12:28
3645,61,Inspire Pharmaceuticals,Large Pharma,3667,AzaSite,azithromycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-07,,Mar-19,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Proforma,34.961,42.671,21.2444,0,0,0,0,0,0,0,0,0,0,3582,Bacterial Conjunctivitis,7/7/14 12:28
3645,61,Merck & Co,Large Pharma,3667,AzaSite,azithromycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-07,,Mar-19,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,Global,Sales,0,0,26.7556,30.4,21.6,0,0,0,0,0,0,0,-100,3582,Bacterial Conjunctivitis,7/7/14 12:28
3645,61,Merck & Co,Large Pharma,3667,AzaSite,azithromycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-07,,Mar-19,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3582,Bacterial Conjunctivitis,7/7/14 12:28
3645,61,Merck & Co,Large Pharma,3667,AzaSite,azithromycin,Small Molecule (Chemical),Launched,Corporate Acquisition,Aug-07,,Mar-19,N/A,38,Corneal & External Eye Treatments,15,Corneal & External Eye Diseases,4,Ophthalmology,6,US,Sales,0,0,26.7556,30.4,21.6,0,0,0,0,0,0,0,-100,3582,Bacterial Conjunctivitis,7/7/14 12:28
3648,96,Shire,Regional & Specialty Pharma,3671,SHP610,heparan N-sulfatase,Recombinant Protein,Phase II,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3585,Sanfilippo A Syndrome,7/7/14 12:28
3648,96,Shire,Regional & Specialty Pharma,3671,SHP610,heparan N-sulfatase,Recombinant Protein,Phase II,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3585,Sanfilippo A Syndrome,7/7/14 12:28
3648,96,Shire,Regional & Specialty Pharma,3671,SHP610,heparan N-sulfatase,Recombinant Protein,Phase II,In-House,,,,,149,Lysosomal Storage Disorder Treatments,65,Lysosomal Storage Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3585,Sanfilippo A Syndrome,7/7/14 12:28
3649,37,Eisai,Regional & Specialty Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,Dec-22,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Alliance Revenue,0,32.68393468,143.0767624,167.3384953,181.2190004,211.0446272,234.2727499,252.1886547,266.0239996,276.7065503,284.9549229,291.3237657,7.017090558,1598,Neuropathic Pain,7/7/14 12:28
3649,37,Eisai,Regional & Specialty Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,Dec-22,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1598,Neuropathic Pain,7/7/14 12:28
3649,37,Eisai,Regional & Specialty Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,Dec-22,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Alliance Revenue,0,32.68393468,143.0767624,167.3384953,181.2190004,211.0446272,234.2727499,252.1886547,266.0239996,276.7065503,284.9549229,291.3237657,7.017090558,1598,Neuropathic Pain,7/7/14 12:28
3649,37,Eisai,Regional & Specialty Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,Dec-22,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1598,Neuropathic Pain,7/7/14 12:28
3649,37,Eisai,Regional & Specialty Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,Dec-22,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,1598,Neuropathic Pain,7/7/14 12:28
3649,37,Eisai,Regional & Specialty Pharma,1356,Lyrica,pregabalin,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-10,,Dec-22,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1598,Neuropathic Pain,7/7/14 12:28
3650,65,Mundipharma,Regional & Specialty Pharma,2154,Folotyn,pralatrexate,Small Molecule (Chemical),Filed,Licensed (Development),,,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,464,Peripheral T-cell Lymphoma,7/7/14 12:28
3650,65,Mundipharma,Regional & Specialty Pharma,2154,Folotyn,pralatrexate,Small Molecule (Chemical),Filed,Licensed (Development),,,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,464,Peripheral T-cell Lymphoma,7/7/14 12:28
3650,65,Mundipharma,Regional & Specialty Pharma,2154,Folotyn,pralatrexate,Small Molecule (Chemical),Filed,Licensed (Development),,,,,78,Anti-metabolites,51,Cytotoxics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,464,Peripheral T-cell Lymphoma,7/7/14 12:28
3654,213,Isis Pharmaceuticals,Small Biotech,2895,ISIS-FXIRx,,DNA/RNA Therapy,Phase II,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3589,Thrombosis,7/7/14 12:28
3654,213,Isis Pharmaceuticals,Small Biotech,2895,ISIS-FXIRx,,DNA/RNA Therapy,Phase II,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3589,Thrombosis,7/7/14 12:28
3654,213,Isis Pharmaceuticals,Small Biotech,2895,ISIS-FXIRx,,DNA/RNA Therapy,Phase II,In-House,,,,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3589,Thrombosis,7/7/14 12:28
3655,100,Takeda,Large Pharma,3311,Latuda,lurasidone,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-13,N/A,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,Global,Sales,0,0,0,0,10.06772225,20.13544449,29.20444869,37.09742179,40.79104067,44.13470739,46.5322323,48.08145611,25.02778278,649,Schizophrenia,7/7/14 12:28
3655,100,Takeda,Large Pharma,3311,Latuda,lurasidone,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-13,N/A,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,ROW,Sales,0,0,0,0,10.06772225,20.13544449,29.20444869,37.09742179,40.79104067,44.13470739,46.5322323,48.08145611,25.02778278,649,Schizophrenia,7/7/14 12:28
3655,100,Takeda,Large Pharma,3311,Latuda,lurasidone,Small Molecule (Chemical),Launched,Licensed (Development),,Sep-13,N/A,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,649,Schizophrenia,7/7/14 12:28
3657,102,Teva,Regional & Specialty Pharma,3687,Synribo,omacetaxine mepesuccinate,Small Molecule (Chemical),Launched,Corporate Acquisition,,,Oct-19,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3590,Chronic Myeloid Leukemia,7/7/14 12:28
3657,102,Teva,Regional & Specialty Pharma,3687,Synribo,omacetaxine mepesuccinate,Small Molecule (Chemical),Launched,Corporate Acquisition,,,Oct-19,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3590,Chronic Myeloid Leukemia,7/7/14 12:28
3657,102,Teva,Regional & Specialty Pharma,3687,Synribo,omacetaxine mepesuccinate,Small Molecule (Chemical),Launched,Corporate Acquisition,,,Oct-19,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3590,Chronic Myeloid Leukemia,7/7/14 12:28
3658,51,Ipsen,Regional & Specialty Pharma,3447,tasquinimod,TASQ,Small Molecule (Chemical),Phase III,Licensed (Development),,Sep-15,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,Global,Sales,0,0,0,0,0,0,19.38923897,46.53417353,65.92356762,96.94653931,113.0009139,125.7280885,0,3447,Prostate Cancer,7/7/14 12:28
3658,51,Ipsen,Regional & Specialty Pharma,3447,tasquinimod,TASQ,Small Molecule (Chemical),Phase III,Licensed (Development),,Sep-15,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,19.38923897,46.53417353,65.92356762,96.94653931,113.0009139,125.7280885,0,3447,Prostate Cancer,7/7/14 12:28
3658,51,Ipsen,Regional & Specialty Pharma,3447,tasquinimod,TASQ,Small Molecule (Chemical),Phase III,Licensed (Development),,Sep-15,,,182,Angiogenesis Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3447,Prostate Cancer,7/7/14 12:28
3659,1622,Cangene,Small Biotech,4271,Ixinity,IB1001,Recombinant Protein,Filed,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3591,Hemophilia B,7/7/14 12:28
3659,1622,Cangene,Small Biotech,4271,Ixinity,IB1001,Recombinant Protein,Filed,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3591,Hemophilia B,7/7/14 12:28
3659,1622,Cangene,Small Biotech,4271,Ixinity,IB1001,Recombinant Protein,Filed,In-House,,,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3591,Hemophilia B,7/7/14 12:28
3661,51,Ipsen,Regional & Specialty Pharma,3922,Nisis / Nisisco,valsartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-03,N/A,Nov-11,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,77.11716135,72.99399003,63.82106002,23.39193814,10.35863452,6.677335176,5.535866774,5.205979856,5.107539213,5.078593233,5.070024251,5.067495374,-9.709596375,374,Hypertension,7/7/14 12:28
3661,51,Ipsen,Regional & Specialty Pharma,3922,Nisis / Nisisco,valsartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-03,N/A,Nov-11,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,77.11716135,72.99399003,63.82106002,23.39193814,10.35863452,6.677335176,5.535866774,5.205979856,5.107539213,5.078593233,5.070024251,5.067495374,-9.709596375,374,Hypertension,7/7/14 12:28
3661,51,Ipsen,Regional & Specialty Pharma,3922,Nisis / Nisisco,valsartan,Small Molecule (Chemical),Launched,Licensed (Marketed),,Mar-03,N/A,Nov-11,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,374,Hypertension,7/7/14 12:28
3662,51,Ipsen,Regional & Specialty Pharma,3693,NutropinAq,somatropin,Recombinant Protein,Launched,Acquisition (Marketed),,Jul-03,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,Global,Sales,56.13573547,64.1181328,70.77324521,69.40465161,74.36968373,76.30595157,77.85894993,78.99210487,79.8439432,80.48982239,80.97289564,81.33629647,1.287415263,1750,Growth Hormone Disorders,7/7/14 12:28
3662,51,Ipsen,Regional & Specialty Pharma,3693,NutropinAq,somatropin,Recombinant Protein,Launched,Acquisition (Marketed),,Jul-03,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,ROW,Sales,56.13573547,64.1181328,70.77324521,69.40465161,74.36968373,76.30595157,77.85894993,78.99210487,79.8439432,80.48982239,80.97289564,81.33629647,1.287415263,1750,Growth Hormone Disorders,7/7/14 12:28
3662,51,Ipsen,Regional & Specialty Pharma,3693,NutropinAq,somatropin,Recombinant Protein,Launched,Acquisition (Marketed),,Jul-03,Expired,Expired,70,Growth Hormone-related Treatments,28,Growth Hormone Disorders,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1750,Growth Hormone Disorders,7/7/14 12:28
3664,111,Actavis,Regional & Specialty Pharma,3696,sarecycline,sarecycline,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3593,Acne,7/7/14 12:28
3664,111,Actavis,Regional & Specialty Pharma,3696,sarecycline,sarecycline,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,160,Acne Treatments,73,Acne,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3593,Acne,7/7/14 12:28
3664,111,Actavis,Regional & Specialty Pharma,3696,sarecycline,sarecycline,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3593,Acne,7/7/14 12:28
3665,111,Actavis,Regional & Specialty Pharma,3697,Vitaros,topical alprostadil,Small Molecule (Chemical),Approved,Corporate Acquisition,,,,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3594,Erectile Dysfunction,7/7/14 12:28
3665,111,Actavis,Regional & Specialty Pharma,3697,Vitaros,topical alprostadil,Small Molecule (Chemical),Approved,Corporate Acquisition,,,,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3594,Erectile Dysfunction,7/7/14 12:28
3665,111,Actavis,Regional & Specialty Pharma,3697,Vitaros,topical alprostadil,Small Molecule (Chemical),Approved,Corporate Acquisition,,,,,132,Erectile Dysfunction Treatments,29,Erectile Dysfunction,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3594,Erectile Dysfunction,7/7/14 12:28
3666,61,Merck & Co,Large Pharma,3701,Sylatron,peg-interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Apr-11,,Mar-18,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,31.8,34.4,52,77.61988,90.42982,96.83479,100.037275,101.6385175,68.38944611,63.68735989,2.938668141,3595,Melanoma,7/7/14 12:28
3666,61,Merck & Co,Large Pharma,3701,Sylatron,peg-interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Apr-11,,Mar-18,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3595,Melanoma,7/7/14 12:28
3666,61,Merck & Co,Large Pharma,3701,Sylatron,peg-interferon alpha 2b,Recombinant Protein,Launched,Corporate Acquisition,Apr-11,,Mar-18,N/A,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,31.8,34.4,52,77.61988,90.42982,96.83479,100.037275,101.6385175,68.38944611,63.68735989,2.938668141,3595,Melanoma,7/7/14 12:28
3667,39,Eli Lilly,Large Pharma,3704,Abasria,insulin glargine,Recombinant Protein,Approved,In-House,Jul-16,Dec-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,6,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3596,Diabetes,7/7/14 12:28
3667,39,Eli Lilly,Large Pharma,3704,Abasria,insulin glargine,Recombinant Protein,Approved,In-House,Jul-16,Dec-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,6,Global,Sales,0,0,0,0,0,8,50,216,400,570,744.9988,837,0,3596,Diabetes,7/7/14 12:28
3667,39,Eli Lilly,Large Pharma,3704,Abasria,insulin glargine,Recombinant Protein,Approved,In-House,Jul-16,Dec-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,6,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3596,Diabetes,7/7/14 12:28
3667,39,Eli Lilly,Large Pharma,3704,Abasria,insulin glargine,Recombinant Protein,Approved,In-House,Jul-16,Dec-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,6,ROW,Sales,0,0,0,0,0,8,50,106,160,210,265,287,0,3596,Diabetes,7/7/14 12:28
3667,39,Eli Lilly,Large Pharma,3704,Abasria,insulin glargine,Recombinant Protein,Approved,In-House,Jul-16,Dec-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,6,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3596,Diabetes,7/7/14 12:28
3667,39,Eli Lilly,Large Pharma,3704,Abasria,insulin glargine,Recombinant Protein,Approved,In-House,Jul-16,Dec-14,N/A,N/A,83,Insulins,22,Diabetes,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,110,240,360,479.9988,550,0,3596,Diabetes,7/7/14 12:28
3669,39,Eli Lilly,Large Pharma,3710,blosozumab,Sclerostin MAb,Antibody/Antibody Derivative,Phase II,In-House,,,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3597,Osteoporosis,7/7/14 12:28
3669,39,Eli Lilly,Large Pharma,3710,blosozumab,Sclerostin MAb,Antibody/Antibody Derivative,Phase II,In-House,,,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3597,Osteoporosis,7/7/14 12:28
3669,39,Eli Lilly,Large Pharma,3710,blosozumab,Sclerostin MAb,Antibody/Antibody Derivative,Phase II,In-House,,,,,13,Other Osteoporosis Treatments,9,Osteoporosis,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3597,Osteoporosis,7/7/14 12:28
3671,39,Eli Lilly,Large Pharma,3931,LY2090314,GSK3 inhibitor,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3599,Hematological Malignancies,7/7/14 12:28
3671,39,Eli Lilly,Large Pharma,3931,LY2090314,GSK3 inhibitor,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3599,Hematological Malignancies,7/7/14 12:28
3671,39,Eli Lilly,Large Pharma,3931,LY2090314,GSK3 inhibitor,Small Molecule (Chemical),Phase II,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3599,Hematological Malignancies,7/7/14 12:28
3674,111,Actavis,Regional & Specialty Pharma,3716,Crinone / Prochieve,progesterone gel,Small Molecule (Chemical),Launched,Acquisition (Development),Jun-97,Jul-96,Sep-13,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,Global,Sales,0,0,17,39.2,37,16,9,6,4,3,1.98,1.254,-38.33852667,3601,Female infertility,7/7/14 12:28
3674,111,Actavis,Regional & Specialty Pharma,3716,Crinone / Prochieve,progesterone gel,Small Molecule (Chemical),Launched,Acquisition (Development),Jun-97,Jul-96,Sep-13,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3601,Female infertility,7/7/14 12:28
3674,111,Actavis,Regional & Specialty Pharma,3716,Crinone / Prochieve,progesterone gel,Small Molecule (Chemical),Launched,Acquisition (Development),Jun-97,Jul-96,Sep-13,N/A,87,Infertility Treatments,56,Infertility,2,Genitourinary,6,US,Sales,0,0,17,39.2,37,16,9,6,4,3,1.98,1.254,-38.33852667,3601,Female infertility,7/7/14 12:28
3677,61,Merck & Co,Large Pharma,3719,vintafolide,EC-145,Small Molecule (Chemical),Phase III,Licensed (Development),Jan-15,May-14,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,5.6,24,38,47.7478,55.23562,59.6101125,63.38531143,0,3604,Ovarian Cancer,7/7/14 12:28
3677,61,Merck & Co,Large Pharma,3719,vintafolide,EC-145,Small Molecule (Chemical),Phase III,Licensed (Development),Jan-15,May-14,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,5.6,15,20,24.3478,28.23553,30,32.0426798,0,3604,Ovarian Cancer,7/7/14 12:28
3677,61,Merck & Co,Large Pharma,3719,vintafolide,EC-145,Small Molecule (Chemical),Phase III,Licensed (Development),Jan-15,May-14,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,9,18,23.4,27.00009,29.6101125,31.34263163,0,3604,Ovarian Cancer,7/7/14 12:28
3678,29,Chugai,Regional & Specialty Pharma,1591,Pulmozyme,dornase alpha,Recombinant Protein,Launched,Licensed (Development),,Sep-12,N/A,N/A,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,3,Global,Alliance Revenue,0,0,0,5.01127537,8.19917157,14.86099847,21.85443574,26.27506444,30.22356208,33.5129495,36.11230762,38.26564399,24.61689095,943,Cystic Fibrosis,7/7/14 12:28
3678,29,Chugai,Regional & Specialty Pharma,1591,Pulmozyme,dornase alpha,Recombinant Protein,Launched,Licensed (Development),,Sep-12,N/A,N/A,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,3,ROW,Alliance Revenue,0,0,0,5.01127537,8.19917157,14.86099847,21.85443574,26.27506444,30.22356208,33.5129495,36.11230762,38.26564399,24.61689095,943,Cystic Fibrosis,7/7/14 12:28
3678,29,Chugai,Regional & Specialty Pharma,1591,Pulmozyme,dornase alpha,Recombinant Protein,Launched,Licensed (Development),,Sep-12,N/A,N/A,166,Cystic Fibrosis Treatments,79,Cystic Fibrosis,1,Respiratory,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,943,Cystic Fibrosis,7/7/14 12:28
3680,42,Forest,Regional & Specialty Pharma,3722,azimilide,NE-10064,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3606,Ventricular arrythmia,7/7/14 12:28
3680,42,Forest,Regional & Specialty Pharma,3722,azimilide,NE-10064,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3606,Ventricular arrythmia,7/7/14 12:28
3680,42,Forest,Regional & Specialty Pharma,3722,azimilide,NE-10064,Small Molecule (Chemical),Phase III,Acquisition (Development),,,,,50,Class III Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3606,Ventricular arrythmia,7/7/14 12:28
3683,189,Valeant,Regional & Specialty Pharma,3725,Jublia,efinaconazole,Small Molecule (Chemical),Approved,Corporate Acquisition,Jun-14,Dec-13,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0.24,39.1959858,72.38409748,103.4400321,133.8502823,155.4640966,173.6230629,188.6987098,159.209363,3609,Onychomycosis,7/7/14 12:28
3683,189,Valeant,Regional & Specialty Pharma,3725,Jublia,efinaconazole,Small Molecule (Chemical),Approved,Corporate Acquisition,Jun-14,Dec-13,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0.24,1.6960008,2.384000485,3.439993499,3.850232128,4.114038991,4.30050844,4.402278243,51.52873498,3609,Onychomycosis,7/7/14 12:28
3683,189,Valeant,Regional & Specialty Pharma,3725,Jublia,efinaconazole,Small Molecule (Chemical),Approved,Corporate Acquisition,Jun-14,Dec-13,,,131,Azoles,25,Fungal Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,37.499985,70.000097,100.0000386,130.0000501,151.3500576,169.3225545,184.2964316,0,3609,Onychomycosis,7/7/14 12:28
3686,189,Valeant,Regional & Specialty Pharma,278,Elidel,pimecrolimus,Small Molecule (Chemical),Launched,Licensed (Marketed),Feb-02,,Apr-16,N/A,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,Global,Sales,0,0,20,25.5,30.3125,30.7434375,29.36100781,15.34131934,6.805207231,2.822460538,1.561580968,1.292811407,-36.28032657,407,Atopic dermatitis,7/7/14 12:28
3686,189,Valeant,Regional & Specialty Pharma,278,Elidel,pimecrolimus,Small Molecule (Chemical),Launched,Licensed (Marketed),Feb-02,,Apr-16,N/A,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,407,Atopic dermatitis,7/7/14 12:28
3686,189,Valeant,Regional & Specialty Pharma,278,Elidel,pimecrolimus,Small Molecule (Chemical),Launched,Licensed (Marketed),Feb-02,,Apr-16,N/A,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,6,US,Sales,0,0,20,25.5,30.3125,30.7434375,29.36100781,15.34131934,6.805207231,2.822460538,1.561580968,1.292811407,-36.28032657,407,Atopic dermatitis,7/7/14 12:28
3687,189,Valeant,Regional & Specialty Pharma,3728,Xerese,aciclovir + hydrocortisone,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-11,,Feb-16,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3611,Herpes simplex infection,7/7/14 12:28
3687,189,Valeant,Regional & Specialty Pharma,3728,Xerese,aciclovir + hydrocortisone,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-11,,Feb-16,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3611,Herpes simplex infection,7/7/14 12:28
3687,189,Valeant,Regional & Specialty Pharma,3728,Xerese,aciclovir + hydrocortisone,Small Molecule (Chemical),Launched,Licensed (Marketed),Mar-11,,Feb-16,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3611,Herpes simplex infection,7/7/14 12:28
3689,209,ZIOPHARM Oncology,Regional & Specialty Pharma,3730,Zybulin,indibulin,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3613,Breast Cancer,7/7/14 12:28
3689,209,ZIOPHARM Oncology,Regional & Specialty Pharma,3730,Zybulin,indibulin,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3613,Breast Cancer,7/7/14 12:28
3689,209,ZIOPHARM Oncology,Regional & Specialty Pharma,3730,Zybulin,indibulin,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3613,Breast Cancer,7/7/14 12:28
3690,261,Achillion,Small Biotech,3731,sovaprevir,ACH-1625,Small Molecule (Chemical),Phase II,In-House,,,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3614,Hepatitis C,7/7/14 12:28
3690,261,Achillion,Small Biotech,3731,sovaprevir,ACH-1625,Small Molecule (Chemical),Phase II,In-House,,,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3614,Hepatitis C,7/7/14 12:28
3690,261,Achillion,Small Biotech,3731,sovaprevir,ACH-1625,Small Molecule (Chemical),Phase II,In-House,,,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3614,Hepatitis C,7/7/14 12:28
3693,3,Acorda Therapeutics,Small Biotech,3733,AC105,AC105,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3616,Spinal cord injury,7/7/14 12:28
3693,3,Acorda Therapeutics,Small Biotech,3733,AC105,AC105,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3616,Spinal cord injury,7/7/14 12:28
3693,3,Acorda Therapeutics,Small Biotech,3733,AC105,AC105,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,81,Other Neurology,36,Other Neurological Disorders,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3616,Spinal cord injury,7/7/14 12:28
3694,177,Active Biotech,Small Biotech,3734,Anyara,naptumomab estafenatox,Antibody/Antibody Derivative,Phase III,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,9,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3617,Renal Cell Carcinoma,7/7/14 12:28
3694,177,Active Biotech,Small Biotech,3734,Anyara,naptumomab estafenatox,Antibody/Antibody Derivative,Phase III,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,9,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3617,Renal Cell Carcinoma,7/7/14 12:28
3694,177,Active Biotech,Small Biotech,3734,Anyara,naptumomab estafenatox,Antibody/Antibody Derivative,Phase III,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3617,Renal Cell Carcinoma,7/7/14 12:28
3695,5,Actelion,Small Biotech,3740,Cadazolid,cadazolid,Small Molecule (Chemical),Phase III,In-House,,Jun-17,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3618,Clostridium difficile infection,7/7/14 12:28
3695,5,Actelion,Small Biotech,3740,Cadazolid,cadazolid,Small Molecule (Chemical),Phase III,In-House,,Jun-17,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3618,Clostridium difficile infection,7/7/14 12:28
3695,5,Actelion,Small Biotech,3740,Cadazolid,cadazolid,Small Molecule (Chemical),Phase III,In-House,,Jun-17,,,39,Other Antibiotics,27,Bacterial Infection,7,Anti-infectives,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3618,Clostridium difficile infection,7/7/14 12:28
3697,96,Shire,Regional & Specialty Pharma,4586,deferitazole,SPD-602,Small Molecule (Chemical),Phase II,In-House,,,,,56,Iron Chelators,59,Iron Overload,14,Hematology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3620,Iron Overload,7/7/14 12:28
3697,96,Shire,Regional & Specialty Pharma,4586,deferitazole,SPD-602,Small Molecule (Chemical),Phase II,In-House,,,,,56,Iron Chelators,59,Iron Overload,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3620,Iron Overload,7/7/14 12:28
3697,96,Shire,Regional & Specialty Pharma,4586,deferitazole,SPD-602,Small Molecule (Chemical),Phase II,In-House,,,,,56,Iron Chelators,59,Iron Overload,14,Hematology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3620,Iron Overload,7/7/14 12:28
3699,190,Meda,Regional & Specialty Pharma,3742,Dexpirronium,dexpirronium,Small Molecule (Chemical),Phase I,In-House,,,,,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,9,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3622,COPD,7/7/14 12:28
3699,190,Meda,Regional & Specialty Pharma,3742,Dexpirronium,dexpirronium,Small Molecule (Chemical),Phase I,In-House,,,,,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,9,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3622,COPD,7/7/14 12:28
3699,190,Meda,Regional & Specialty Pharma,3742,Dexpirronium,dexpirronium,Small Molecule (Chemical),Phase I,In-House,,,,,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3622,COPD,7/7/14 12:28
3702,67,Novartis,Large Pharma,3744,QAW039,QAW039,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3625,Asthma,7/7/14 12:28
3702,67,Novartis,Large Pharma,3744,QAW039,QAW039,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3625,Asthma,7/7/14 12:28
3702,67,Novartis,Large Pharma,3744,QAW039,QAW039,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3625,Asthma,7/7/14 12:28
3703,190,Meda,Regional & Specialty Pharma,3745,Sotirimod ,sotirimod ,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,9,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3626,Actinic keratosis ,7/7/14 12:28
3703,190,Meda,Regional & Specialty Pharma,3745,Sotirimod ,sotirimod ,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,9,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3626,Actinic keratosis ,7/7/14 12:28
3703,190,Meda,Regional & Specialty Pharma,3745,Sotirimod ,sotirimod ,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3626,Actinic keratosis ,7/7/14 12:28
3704,67,Novartis,Large Pharma,2417,QGE031,QGE031,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3627,Asthma,7/7/14 12:28
3704,67,Novartis,Large Pharma,2417,QGE031,QGE031,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3627,Asthma,7/7/14 12:28
3704,67,Novartis,Large Pharma,2417,QGE031,QGE031,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3627,Asthma,7/7/14 12:28
3706,36,Dendreon,Small Biotech,3747,D-3263 HCI,D-3263 HCI,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3629,Solid Tumors,7/7/14 12:28
3706,36,Dendreon,Small Biotech,3747,D-3263 HCI,D-3263 HCI,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3629,Solid Tumors,7/7/14 12:28
3706,36,Dendreon,Small Biotech,3747,D-3263 HCI,D-3263 HCI,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3629,Solid Tumors,7/7/14 12:28
3707,86,Roche,Large Pharma,3749,RG7686,GC33,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,487,Hepatocellular Carcinoma,7/7/14 12:28
3707,86,Roche,Large Pharma,3749,RG7686,GC33,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,487,Hepatocellular Carcinoma,7/7/14 12:28
3707,86,Roche,Large Pharma,3749,RG7686,GC33,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,487,Hepatocellular Carcinoma,7/7/14 12:28
3708,243,Gedeon Richter,Regional & Specialty Pharma,1368,cariprazine,cariprazine,Small Molecule (Chemical),Filed,In-House,,Feb-16,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,10,Global,Sales,0,0,0,0,0,0,0,19.01232816,26.58721805,37.1772222,55.69073532,65.62630997,0,1380,Schizophrenia,7/7/14 12:28
3708,243,Gedeon Richter,Regional & Specialty Pharma,1368,cariprazine,cariprazine,Small Molecule (Chemical),Filed,In-House,,Feb-16,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,10,ROW,Sales,0,0,0,0,0,0,0,19.01232816,26.58721805,37.1772222,55.69073532,65.62630997,0,1380,Schizophrenia,7/7/14 12:28
3708,243,Gedeon Richter,Regional & Specialty Pharma,1368,cariprazine,cariprazine,Small Molecule (Chemical),Filed,In-House,,Feb-16,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1380,Schizophrenia,7/7/14 12:28
3710,803,Plexxikon,Small Biotech,3751,RG7256,BRAF Kinase Inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3633,Melanoma   ,7/7/14 12:28
3710,803,Plexxikon,Small Biotech,3751,RG7256,BRAF Kinase Inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3633,Melanoma   ,7/7/14 12:28
3710,803,Plexxikon,Small Biotech,3751,RG7256,BRAF Kinase Inhibitor,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3633,Melanoma   ,7/7/14 12:28
3713,86,Roche,Large Pharma,3754,MPDL3280A,MPDL3280A ,Antibody/Antibody Derivative,Phase III,In-House,Jun-17,Jan-18,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,44.06416827,164.2663522,304.7442922,524.2122956,0,3636,Non-small-cell Lung Cancer,7/7/14 12:28
3713,86,Roche,Large Pharma,3754,MPDL3280A,MPDL3280A ,Antibody/Antibody Derivative,Phase III,In-House,Jun-17,Jan-18,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,59.35177077,113.7577882,221.5803874,0,3636,Non-small-cell Lung Cancer,7/7/14 12:28
3713,86,Roche,Large Pharma,3754,MPDL3280A,MPDL3280A ,Antibody/Antibody Derivative,Phase III,In-House,Jun-17,Jan-18,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,44.06416827,104.9145814,190.9865041,302.6319082,0,3636,Non-small-cell Lung Cancer,7/7/14 12:28
3714,86,Roche,Large Pharma,3755,RG7450,RG7450,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3637,Prostate Cancer,7/7/14 12:28
3714,86,Roche,Large Pharma,3755,RG7450,RG7450,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3637,Prostate Cancer,7/7/14 12:28
3714,86,Roche,Large Pharma,3755,RG7450,RG7450,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3637,Prostate Cancer,7/7/14 12:28
3715,86,Roche,Large Pharma,3756,RG7458,RG7458,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3638,Ovarian Cancer,7/7/14 12:28
3715,86,Roche,Large Pharma,3756,RG7458,RG7458,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3638,Ovarian Cancer,7/7/14 12:28
3715,86,Roche,Large Pharma,3756,RG7458,RG7458,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3638,Ovarian Cancer,7/7/14 12:28
3716,86,Roche,Large Pharma,3757,RG7596,RG7596,Antibody/Antibody Derivative,Phase II,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3639,Hematological Malignancies,7/7/14 12:28
3716,86,Roche,Large Pharma,3757,RG7596,RG7596,Antibody/Antibody Derivative,Phase II,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3639,Hematological Malignancies,7/7/14 12:28
3716,86,Roche,Large Pharma,3757,RG7596,RG7596,Antibody/Antibody Derivative,Phase II,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3639,Hematological Malignancies,7/7/14 12:28
3717,86,Roche,Large Pharma,3758,RG7599,RG7599,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3640,Ovarian cancer ,7/7/14 12:28
3717,86,Roche,Large Pharma,3758,RG7599,RG7599,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3640,Ovarian cancer ,7/7/14 12:28
3717,86,Roche,Large Pharma,3758,RG7599,RG7599,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3640,Ovarian cancer ,7/7/14 12:28
3718,86,Roche,Large Pharma,3759,RG7601,ABT-199,Small Molecule (Chemical),Phase III,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3641,Chronic Lymphocytic Leukemia,7/7/14 12:28
3718,86,Roche,Large Pharma,3759,RG7601,ABT-199,Small Molecule (Chemical),Phase III,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3641,Chronic Lymphocytic Leukemia,7/7/14 12:28
3718,86,Roche,Large Pharma,3759,RG7601,ABT-199,Small Molecule (Chemical),Phase III,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3641,Chronic Lymphocytic Leukemia,7/7/14 12:28
3724,23,Boehringer Ingelheim,Large Pharma,3775,BI-671800,BI-671800,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3647,Asthma,7/7/14 12:28
3724,23,Boehringer Ingelheim,Large Pharma,3775,BI-671800,BI-671800,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3647,Asthma,7/7/14 12:28
3724,23,Boehringer Ingelheim,Large Pharma,3775,BI-671800,BI-671800,Small Molecule (Chemical),Phase II,In-House,,,,,98,Other Asthma Agents,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3647,Asthma,7/7/14 12:28
3726,23,Boehringer Ingelheim,Large Pharma,3772,BI-836826,BI-836826,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3649,Chronic Lymphocytic Leukemia,7/7/14 12:28
3726,23,Boehringer Ingelheim,Large Pharma,3772,BI-836826,BI-836826,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3649,Chronic Lymphocytic Leukemia,7/7/14 12:28
3726,23,Boehringer Ingelheim,Large Pharma,3772,BI-836826,BI-836826,Antibody/Antibody Derivative,Phase I,In-House,,,,,134,Immune Receptor-targeted Agents,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3649,Chronic Lymphocytic Leukemia,7/7/14 12:28
3727,23,Boehringer Ingelheim,Large Pharma,3773,BI-836845,BI-836845,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3650,Solid Tumors,7/7/14 12:28
3727,23,Boehringer Ingelheim,Large Pharma,3773,BI-836845,BI-836845,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3650,Solid Tumors,7/7/14 12:28
3727,23,Boehringer Ingelheim,Large Pharma,3773,BI-836845,BI-836845,Antibody/Antibody Derivative,Phase I,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3650,Solid Tumors,7/7/14 12:28
3728,23,Boehringer Ingelheim,Large Pharma,3771,BI-847325,BI-847325,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3651,Cancer,7/7/14 12:28
3728,23,Boehringer Ingelheim,Large Pharma,3771,BI-847325,BI-847325,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3651,Cancer,7/7/14 12:28
3728,23,Boehringer Ingelheim,Large Pharma,3771,BI-847325,BI-847325,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3651,Cancer,7/7/14 12:28
3730,1106,AbGenomics,Small Biotech,3777,AbGn-168,AbGn-168,Antibody/Antibody Derivative,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3653,Psoriasis,7/7/14 12:28
3730,1106,AbGenomics,Small Biotech,3777,AbGn-168,AbGn-168,Antibody/Antibody Derivative,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3653,Psoriasis,7/7/14 12:28
3730,1106,AbGenomics,Small Biotech,3777,AbGn-168,AbGn-168,Antibody/Antibody Derivative,Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3653,Psoriasis,7/7/14 12:28
3732,23,Boehringer Ingelheim,Large Pharma,3778,BI-853520,BI-853520,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3655,Solid Tumors,7/7/14 12:28
3732,23,Boehringer Ingelheim,Large Pharma,3778,BI-853520,BI-853520,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3655,Solid Tumors,7/7/14 12:28
3732,23,Boehringer Ingelheim,Large Pharma,3778,BI-853520,BI-853520,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3655,Solid Tumors,7/7/14 12:28
3733,29,Chugai,Regional & Specialty Pharma,2398,RG7090,RG7090,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,3,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,987,Depression,7/7/14 12:28
3733,29,Chugai,Regional & Specialty Pharma,2398,RG7090,RG7090,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,3,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,987,Depression,7/7/14 12:28
3733,29,Chugai,Regional & Specialty Pharma,2398,RG7090,RG7090,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,46,Other Anti-depressants,49,Depression,12,Central Nervous System,3,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,987,Depression,7/7/14 12:28
3734,23,Boehringer Ingelheim,Large Pharma,3779,BI-135585,BI-135585,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3657,11-beta HSD-1 inhibitor for Type II Diabetes,7/7/14 12:28
3734,23,Boehringer Ingelheim,Large Pharma,3779,BI-135585,BI-135585,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3657,11-beta HSD-1 inhibitor for Type II Diabetes,7/7/14 12:28
3734,23,Boehringer Ingelheim,Large Pharma,3779,BI-135585,BI-135585,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3657,11-beta HSD-1 inhibitor for Type II Diabetes,7/7/14 12:28
3735,45,Gilead,Regional & Specialty Pharma,4209,BI 224436,BI 224436,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3709,HIV,7/7/14 12:28
3735,45,Gilead,Regional & Specialty Pharma,4209,BI 224436,BI 224436,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3709,HIV,7/7/14 12:28
3735,45,Gilead,Regional & Specialty Pharma,4209,BI 224436,BI 224436,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,169,Integrase Inhibitors,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3709,HIV,7/7/14 12:28
3743,84,Recordati,Regional & Specialty Pharma,3787,REC 0482,NX-1207,Recombinant Protein,Phase III,Licensed (Development),,Oct-17,,Jan-23,176,Other BPH Treatments,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,5.763650489,16.71458642,23.63091513,34.58171751,0,3665,Symptoms associated with BPH,7/7/14 12:28
3743,84,Recordati,Regional & Specialty Pharma,3787,REC 0482,NX-1207,Recombinant Protein,Phase III,Licensed (Development),,Oct-17,,Jan-23,176,Other BPH Treatments,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,5.763650489,16.71458642,23.63091513,34.58171751,0,3665,Symptoms associated with BPH,7/7/14 12:28
3743,84,Recordati,Regional & Specialty Pharma,3787,REC 0482,NX-1207,Recombinant Protein,Phase III,Licensed (Development),,Oct-17,,Jan-23,176,Other BPH Treatments,11,Benign Prostatic Hyperplasia,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3665,Symptoms associated with BPH,7/7/14 12:28
3745,21,Biogen Idec,Regional & Specialty Pharma,4244,BIIB037,BART,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3666,Alzheimer's Disease,7/7/14 12:28
3745,21,Biogen Idec,Regional & Specialty Pharma,4244,BIIB037,BART,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3666,Alzheimer's Disease,7/7/14 12:28
3745,21,Biogen Idec,Regional & Specialty Pharma,4244,BIIB037,BART,Antibody/Antibody Derivative,Phase I,Corporate Acquisition,,,,,63,Other Alzheimers Disease Agents,39,Alzheimer's Disease,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3666,Alzheimer's Disease,7/7/14 12:28
3746,89,Sanofi,Large Pharma,2426,dupilumab,dupilumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1055,Atopic dermatitis,7/7/14 12:28
3746,89,Sanofi,Large Pharma,2426,dupilumab,dupilumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1055,Atopic dermatitis,7/7/14 12:28
3746,89,Sanofi,Large Pharma,2426,dupilumab,dupilumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,180,Other Atopic Dermatitis Treatments,10,Atopic Dermatitis,6,Dermatology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1055,Atopic dermatitis,7/7/14 12:28
3747,89,Sanofi,Large Pharma,4294,SAR307746,REGN910,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3668,Cancer,7/7/14 12:28
3747,89,Sanofi,Large Pharma,4294,SAR307746,REGN910,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3668,Cancer,7/7/14 12:28
3747,89,Sanofi,Large Pharma,4294,SAR307746,REGN910,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3668,Cancer,7/7/14 12:28
3750,89,Sanofi,Large Pharma,3793,vatelizumab,SAR339658,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3671,Ulcerative Colitis,7/7/14 12:28
3750,89,Sanofi,Large Pharma,3793,vatelizumab,SAR339658,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3671,Ulcerative Colitis,7/7/14 12:28
3750,89,Sanofi,Large Pharma,3793,vatelizumab,SAR339658,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3671,Ulcerative Colitis,7/7/14 12:28
3751,89,Sanofi,Large Pharma,3794,SAR156597,SAR156597,Antibody/Antibody Derivative,Phase II,In-House,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3672,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3751,89,Sanofi,Large Pharma,3794,SAR156597,SAR156597,Antibody/Antibody Derivative,Phase II,In-House,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3672,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3751,89,Sanofi,Large Pharma,3794,SAR156597,SAR156597,Antibody/Antibody Derivative,Phase II,In-House,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3672,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3752,8,Allergan,Regional & Specialty Pharma,3672,senrebotase,AGN-214868 / SXN-100323,Recombinant Protein,Phase II,Licensed (Development),,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2111,Overactive bladder,7/7/14 12:28
3752,8,Allergan,Regional & Specialty Pharma,3672,senrebotase,AGN-214868 / SXN-100323,Recombinant Protein,Phase II,Licensed (Development),,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2111,Overactive bladder,7/7/14 12:28
3752,8,Allergan,Regional & Specialty Pharma,3672,senrebotase,AGN-214868 / SXN-100323,Recombinant Protein,Phase II,Licensed (Development),,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,2111,Overactive bladder,7/7/14 12:28
3753,95,Shionogi,Regional & Specialty Pharma,3797,S-707106,S-707106,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3674,Type II Diabetes,7/7/14 12:28
3753,95,Shionogi,Regional & Specialty Pharma,3797,S-707106,S-707106,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3674,Type II Diabetes,7/7/14 12:28
3753,95,Shionogi,Regional & Specialty Pharma,3797,S-707106,S-707106,Small Molecule (Chemical),Phase II,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3674,Type II Diabetes,7/7/14 12:28
3755,190,Meda,Regional & Specialty Pharma,3817,Edluar / Sublinox,sublingual zolpidem,Small Molecule (Chemical),Launched,Acquisition (Development),Sep-09,Jan-12,,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,9,Global,Sales,1.306214861,5.136451452,8.777524404,12.42813152,16.548443,20.14966157,23.45161015,25.87100536,27.91537349,29.60124813,30.95933689,32.07491316,9.915336744,3676,Insomnia,7/7/14 12:28
3755,190,Meda,Regional & Specialty Pharma,3817,Edluar / Sublinox,sublingual zolpidem,Small Molecule (Chemical),Launched,Acquisition (Development),Sep-09,Jan-12,,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,9,ROW,Sales,0,0,0,1.168090683,3.114912381,5.061732619,7.008576219,8.364837313,9.520920686,10.4829228,11.2522776,11.8854239,21.0824444,3676,Insomnia,7/7/14 12:28
3755,190,Meda,Regional & Specialty Pharma,3817,Edluar / Sublinox,sublingual zolpidem,Small Molecule (Chemical),Launched,Acquisition (Development),Sep-09,Jan-12,,,112,Hypnotics,31,Sleep Disorders,12,Central Nervous System,9,US,Sales,1.306214861,5.136451452,8.777524404,11.26004083,13.43353062,15.08792896,16.44303393,17.50616805,18.3944528,19.11832533,19.70705929,20.18948927,5.99281503,3676,Insomnia,7/7/14 12:28
3767,16,AstraZeneca,Large Pharma,3810,AZD2115,AZD2115,Small Molecule (Chemical),Phase II,In-House,,,,,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3687,COPD,7/7/14 12:28
3767,16,AstraZeneca,Large Pharma,3810,AZD2115,AZD2115,Small Molecule (Chemical),Phase II,In-House,,,,,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3687,COPD,7/7/14 12:28
3767,16,AstraZeneca,Large Pharma,3810,AZD2115,AZD2115,Small Molecule (Chemical),Phase II,In-House,,,,,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3687,COPD,7/7/14 12:28
3770,16,AstraZeneca,Large Pharma,3812,MEDI-8968,MEDI-8968,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3690,COPD,7/7/14 12:28
3770,16,AstraZeneca,Large Pharma,3812,MEDI-8968,MEDI-8968,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3690,COPD,7/7/14 12:28
3770,16,AstraZeneca,Large Pharma,3812,MEDI-8968,MEDI-8968,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,54,Other COPD Agents,61,Asthma & COPD,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3690,COPD,7/7/14 12:28
3771,37,Eisai,Regional & Specialty Pharma,3813,Vasolan,verapamil,Small Molecule (Chemical),Launched,In-House,,,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,573,Arrhythmia ,7/7/14 12:28
3771,37,Eisai,Regional & Specialty Pharma,3813,Vasolan,verapamil,Small Molecule (Chemical),Launched,In-House,,,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,573,Arrhythmia ,7/7/14 12:28
3771,37,Eisai,Regional & Specialty Pharma,3813,Vasolan,verapamil,Small Molecule (Chemical),Launched,In-House,,,,,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,573,Arrhythmia ,7/7/14 12:28
3775,19,Bayer,Large Pharma,3822,Vaginorm,dehydroepiandrosterone,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3695,Vaginal atrophy,7/7/14 12:28
3775,19,Bayer,Large Pharma,3822,Vaginorm,dehydroepiandrosterone,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3695,Vaginal atrophy,7/7/14 12:28
3775,19,Bayer,Large Pharma,3822,Vaginorm,dehydroepiandrosterone,Small Molecule (Chemical),Phase III,Licensed (Development),,,,,181,Menopausal Treatments,52,Menopausal Symptoms,2,Genitourinary,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3695,Vaginal atrophy,7/7/14 12:28
3777,168,AEterna Zentaris,Regional & Specialty Pharma,3824,AEZS-112,AEZS-112,Small Molecule (Chemical),Phase I,In-House,,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3697,Solid Tumors,7/7/14 12:28
3777,168,AEterna Zentaris,Regional & Specialty Pharma,3824,AEZS-112,AEZS-112,Small Molecule (Chemical),Phase I,In-House,,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3697,Solid Tumors,7/7/14 12:28
3777,168,AEterna Zentaris,Regional & Specialty Pharma,3824,AEZS-112,AEZS-112,Small Molecule (Chemical),Phase I,In-House,,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3697,Solid Tumors,7/7/14 12:28
3779,168,AEterna Zentaris,Regional & Specialty Pharma,3826,AEZS-108,zoptarelin doxorubicin,Synthetic Peptide,Phase II,Licensed (Development),,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3698,Ovarian Cancer,7/7/14 12:28
3779,168,AEterna Zentaris,Regional & Specialty Pharma,3826,AEZS-108,zoptarelin doxorubicin,Synthetic Peptide,Phase II,Licensed (Development),,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3698,Ovarian Cancer,7/7/14 12:28
3779,168,AEterna Zentaris,Regional & Specialty Pharma,3826,AEZS-108,zoptarelin doxorubicin,Synthetic Peptide,Phase II,Licensed (Development),,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3698,Ovarian Cancer,7/7/14 12:28
3783,262,Anacor,Small Biotech,3830,AN-2728,AN-2728,Small Molecule (Chemical),Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3702,PDE4 inhibitor for psoriasis and atopic dermatitis,7/7/14 12:28
3783,262,Anacor,Small Biotech,3830,AN-2728,AN-2728,Small Molecule (Chemical),Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3702,PDE4 inhibitor for psoriasis and atopic dermatitis,7/7/14 12:28
3783,262,Anacor,Small Biotech,3830,AN-2728,AN-2728,Small Molecule (Chemical),Phase II,In-House,,,,,31,Immunomodulators - Psoriasis,63,Psoriasis,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3702,PDE4 inhibitor for psoriasis and atopic dermatitis,7/7/14 12:28
3784,190,Meda,Regional & Specialty Pharma,278,Elidel,pimecrolimus,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Aug-02,,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,9,Global,Sales,0,0,40.8077889,53.74928322,63.72385307,59.88506674,59.27086092,59.0251786,58.92690567,58.8875965,58.87187283,58.86558336,-1.126496627,407,Atopic dermatitis,7/7/14 12:28
3784,190,Meda,Regional & Specialty Pharma,278,Elidel,pimecrolimus,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Aug-02,,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,9,ROW,Sales,0,0,40.8077889,53.74928322,63.72385307,59.88506674,59.27086092,59.0251786,58.92690567,58.8875965,58.87187283,58.86558336,-1.126496627,407,Atopic dermatitis,7/7/14 12:28
3784,190,Meda,Regional & Specialty Pharma,278,Elidel,pimecrolimus,Small Molecule (Chemical),Launched,Acquisition (Marketed),,Aug-02,,Expired,27,Topical Immunomodulators,10,Atopic Dermatitis,6,Dermatology,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,407,Atopic dermatitis,7/7/14 12:28
3787,243,Gedeon Richter,Regional & Specialty Pharma,3718,Esmya / Fibristal,ulipristal acetate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-12,N/A,Feb-28,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,10,Global,Sales,0,0,0,4.622804353,18.20567981,26.00808801,33.81051441,40.97258315,46.95837829,52.31998106,57.047144,61.18252107,18.90574787,4276,Uterine fibroids,7/7/14 12:28
3787,243,Gedeon Richter,Regional & Specialty Pharma,3718,Esmya / Fibristal,ulipristal acetate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-12,N/A,Feb-28,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,10,ROW,Sales,0,0,0,4.622804353,18.20567981,26.00808801,33.81051441,40.97258315,46.95837829,52.31998106,57.047144,61.18252107,18.90574787,4276,Uterine fibroids,7/7/14 12:28
3787,243,Gedeon Richter,Regional & Specialty Pharma,3718,Esmya / Fibristal,ulipristal acetate,Small Molecule (Chemical),Launched,Corporate Acquisition,,Mar-12,N/A,Feb-28,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4276,Uterine fibroids,7/7/14 12:28
3788,243,Gedeon Richter,Regional & Specialty Pharma,3836,PGL-2001 ,PGL2-2001,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,10,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3707,Endometriosis,7/7/14 12:28
3788,243,Gedeon Richter,Regional & Specialty Pharma,3836,PGL-2001 ,PGL2-2001,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,10,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3707,Endometriosis,7/7/14 12:28
3788,243,Gedeon Richter,Regional & Specialty Pharma,3836,PGL-2001 ,PGL2-2001,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3707,Endometriosis,7/7/14 12:28
3789,100,Takeda,Large Pharma,3839,TAK-816,Vaxem Hib,Vaccine,Filed,Licensed (Development),,Oct-16,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,Global,Sales,0,0,0,0,0,0,0,6.594358071,12.44348774,17.68468477,26.20587328,31.10781879,0,3710,Hib vaccine,7/7/14 12:28
3789,100,Takeda,Large Pharma,3839,TAK-816,Vaxem Hib,Vaccine,Filed,Licensed (Development),,Oct-16,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,ROW,Sales,0,0,0,0,0,0,0,6.594358071,12.44348774,17.68468477,26.20587328,31.10781879,0,3710,Hib vaccine,7/7/14 12:28
3789,100,Takeda,Large Pharma,3839,TAK-816,Vaxem Hib,Vaccine,Filed,Licensed (Development),,Oct-16,,,20,Pediatric Vaccines,43,Vaccine Products,5,Vaccines,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3710,Hib vaccine,7/7/14 12:28
3790,15,Astellas Pharma,Regional & Specialty Pharma,3840,TransVax,ASP-0113,Vaccine,Phase III,Acquisition (Development),May-16,May-17,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,7,Global,Sales,0,0,0,0,0,0,0,36.91499499,73.4386208,111.8636339,147.3235768,173.9448888,0,3711,CMV DNA vaccine,7/7/14 12:28
3790,15,Astellas Pharma,Regional & Specialty Pharma,3840,TransVax,ASP-0113,Vaccine,Phase III,Acquisition (Development),May-16,May-17,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,7,ROW,Sales,0,0,0,0,0,0,0,0,8.557563908,20.13544449,28.74838087,43.06449958,0,3711,CMV DNA vaccine,7/7/14 12:28
3790,15,Astellas Pharma,Regional & Specialty Pharma,3840,TransVax,ASP-0113,Vaccine,Phase III,Acquisition (Development),May-16,May-17,,,43,Other Anti-viral Agents,7,Other Viral Infections,7,Anti-infectives,7,US,Sales,0,0,0,0,0,0,0,36.91499499,64.88105689,91.72818943,118.5751959,130.8803892,0,3711,CMV DNA vaccine,7/7/14 12:28
3793,243,Gedeon Richter,Regional & Specialty Pharma,3845,Verospiron,spironolactone,Small Molecule (Chemical),Launched,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,10,Global,Sales,39.68865827,44.62698655,49.63676577,53.5178504,56.82560026,59.26023774,61.23202334,62.38664465,63.21453156,63.79187505,64.17585609,64.44124156,1.812905268,3712,Hypertension,7/7/14 12:28
3793,243,Gedeon Richter,Regional & Specialty Pharma,3845,Verospiron,spironolactone,Small Molecule (Chemical),Launched,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,10,ROW,Sales,39.68865827,44.62698655,49.63676577,53.5178504,56.82560026,59.26023774,61.23202334,62.38664465,63.21453156,63.79187505,64.17585609,64.44124156,1.812905268,3712,Hypertension,7/7/14 12:28
3793,243,Gedeon Richter,Regional & Specialty Pharma,3845,Verospiron,spironolactone,Small Molecule (Chemical),Launched,In-House,,,,,109,Other Anti-hypertensives,35,Hypertension,10,Cardiovasculars,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3712,Hypertension,7/7/14 12:28
3794,243,Gedeon Richter,Regional & Specialty Pharma,3846,Lisonorm,lisinopril + amlodipine,Small Molecule (Chemical),Launched,In-House,,,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,10,Global,Sales,18.01828515,22.76788938,29.22441,31.94624508,33.55116734,35.98617686,37.95103163,39.34611108,40.58790972,41.59058559,42.39761099,43.06448362,3.630443603,4304,Hypertension,7/7/14 12:28
3794,243,Gedeon Richter,Regional & Specialty Pharma,3846,Lisonorm,lisinopril + amlodipine,Small Molecule (Chemical),Launched,In-House,,,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,10,ROW,Sales,18.01828515,22.76788938,29.22441,31.94624508,33.55116734,35.98617686,37.95103163,39.34611108,40.58790972,41.59058559,42.39761099,43.06448362,3.630443603,4304,Hypertension,7/7/14 12:28
3794,243,Gedeon Richter,Regional & Specialty Pharma,3846,Lisonorm,lisinopril + amlodipine,Small Molecule (Chemical),Launched,In-House,,,,,37,ACE Inhibitors,35,Hypertension,10,Cardiovasculars,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,4304,Hypertension,7/7/14 12:28
3795,24,Bristol-Myers Squibb,Large Pharma,3849,eldelumab,Anti-IP10,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,671,Rheumatoid arthritis,7/7/14 12:28
3795,24,Bristol-Myers Squibb,Large Pharma,3849,eldelumab,Anti-IP10,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,671,Rheumatoid arthritis,7/7/14 12:28
3795,24,Bristol-Myers Squibb,Large Pharma,3849,eldelumab,Anti-IP10,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,671,Rheumatoid arthritis,7/7/14 12:28
3797,24,Bristol-Myers Squibb,Large Pharma,3851,Anti-CD28,Anti-CD28,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3716,Rheumatoid arthritis,7/7/14 12:28
3797,24,Bristol-Myers Squibb,Large Pharma,3851,Anti-CD28,Anti-CD28,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3716,Rheumatoid arthritis,7/7/14 12:28
3797,24,Bristol-Myers Squibb,Large Pharma,3851,Anti-CD28,Anti-CD28,Antibody/Antibody Derivative,Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3716,Rheumatoid arthritis,7/7/14 12:28
3799,15,Astellas Pharma,Regional & Specialty Pharma,3853,Micombi,telmisartan + hydrochlorothiazide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-09,N/A,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,17.23721551,71.20428626,131.681268,143.7743618,125.8465281,141.759456,151.9257249,160.3447533,163.0338292,151.5428016,144.4949113,141.8459477,1.724389435,3718,hypertension,7/7/14 12:28
3799,15,Astellas Pharma,Regional & Specialty Pharma,3853,Micombi,telmisartan + hydrochlorothiazide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-09,N/A,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,17.23721551,71.20428626,131.681268,143.7743618,125.8465281,141.759456,151.9257249,160.3447533,163.0338292,151.5428016,144.4949113,141.8459477,1.724389435,3718,hypertension,7/7/14 12:28
3799,15,Astellas Pharma,Regional & Specialty Pharma,3853,Micombi,telmisartan + hydrochlorothiazide,Small Molecule (Chemical),Launched,Licensed (Marketed),,Jun-09,N/A,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3718,hypertension,7/7/14 12:28
3800,15,Astellas Pharma,Regional & Specialty Pharma,3854,Micamlo,telmisartan + amlodipine ,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-10,,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,26.84751777,134.2136001,195.0330473,221.4898894,271.7472297,314.8847498,353.5436366,373.0675199,357.892907,349.7835592,349.767158,6.744723753,3719,Hypertension,7/7/14 12:28
3800,15,Astellas Pharma,Regional & Specialty Pharma,3854,Micamlo,telmisartan + amlodipine ,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-10,,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,26.84751777,134.2136001,195.0330473,221.4898894,271.7472297,314.8847498,353.5436366,373.0675199,357.892907,349.7835592,349.767158,6.744723753,3719,Hypertension,7/7/14 12:28
3800,15,Astellas Pharma,Regional & Specialty Pharma,3854,Micamlo,telmisartan + amlodipine ,Small Molecule (Chemical),Launched,Licensed (Marketed),,Oct-10,,Jun-17,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3719,Hypertension,7/7/14 12:28
3801,24,Bristol-Myers Squibb,Large Pharma,3941,denenicokin,BMS-982470,Recombinant Protein,Phase I,Corporate Acquisition,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3720,Melanoma,7/7/14 12:28
3801,24,Bristol-Myers Squibb,Large Pharma,3941,denenicokin,BMS-982470,Recombinant Protein,Phase I,Corporate Acquisition,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3720,Melanoma,7/7/14 12:28
3801,24,Bristol-Myers Squibb,Large Pharma,3941,denenicokin,BMS-982470,Recombinant Protein,Phase I,Corporate Acquisition,,,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3720,Melanoma,7/7/14 12:28
3804,24,Bristol-Myers Squibb,Large Pharma,3858,AM152,AM152,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3722,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3804,24,Bristol-Myers Squibb,Large Pharma,3858,AM152,AM152,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3722,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3804,24,Bristol-Myers Squibb,Large Pharma,3858,AM152,AM152,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3722,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3806,2221,AbbVie,Large Pharma,3860,tregalizumab,tregalizumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3724,Rheumatoid Arthritis,7/7/14 12:28
3806,2221,AbbVie,Large Pharma,3860,tregalizumab,tregalizumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3724,Rheumatoid Arthritis,7/7/14 12:28
3806,2221,AbbVie,Large Pharma,3860,tregalizumab,tregalizumab,Antibody/Antibody Derivative,Phase II,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3724,Rheumatoid Arthritis,7/7/14 12:28
3807,2221,AbbVie,Large Pharma,3861,atrasentan,ABT-627,Small Molecule (Chemical),Phase III,In-House,Jan-18,Jan-18,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,32,112,179.99995,0,3725,Chronic Kidney Disease,7/7/14 12:28
3807,2221,AbbVie,Large Pharma,3861,atrasentan,ABT-627,Small Molecule (Chemical),Phase III,In-House,Jan-18,Jan-18,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,10,35,49.99995,0,3725,Chronic Kidney Disease,7/7/14 12:28
3807,2221,AbbVie,Large Pharma,3861,atrasentan,ABT-627,Small Molecule (Chemical),Phase III,In-House,Jan-18,Jan-18,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,22,77,130,0,3725,Chronic Kidney Disease,7/7/14 12:28
3808,2221,AbbVie,Large Pharma,3863,ABT-639,ABT-639,Small Molecule (Chemical),Phase II,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3726,Neuropathic Pain,7/7/14 12:28
3808,2221,AbbVie,Large Pharma,3863,ABT-639,ABT-639,Small Molecule (Chemical),Phase II,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3726,Neuropathic Pain,7/7/14 12:28
3808,2221,AbbVie,Large Pharma,3863,ABT-639,ABT-639,Small Molecule (Chemical),Phase II,In-House,,,,,140,Neuropathic Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3726,Neuropathic Pain,7/7/14 12:28
3809,2221,AbbVie,Large Pharma,3759,RG7601,ABT-199,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3641,Chronic Lymphocytic Leukemia,7/7/14 12:28
3809,2221,AbbVie,Large Pharma,3759,RG7601,ABT-199,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3641,Chronic Lymphocytic Leukemia,7/7/14 12:28
3809,2221,AbbVie,Large Pharma,3759,RG7601,ABT-199,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3641,Chronic Lymphocytic Leukemia,7/7/14 12:28
3810,2221,AbbVie,Large Pharma,3865,ABT-767,ABT-767,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3728,Solid Tumors,7/7/14 12:28
3810,2221,AbbVie,Large Pharma,3865,ABT-767,ABT-767,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3728,Solid Tumors,7/7/14 12:28
3810,2221,AbbVie,Large Pharma,3865,ABT-767,ABT-767,Small Molecule (Chemical),Phase I,In-House,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3728,Solid Tumors,7/7/14 12:28
3811,2221,AbbVie,Large Pharma,3866,ABT-413,S1P1 + S1P5 modulator,Small Molecule (Chemical),Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3729,Rheumatoid Arthritis,7/7/14 12:28
3811,2221,AbbVie,Large Pharma,3866,ABT-413,S1P1 + S1P5 modulator,Small Molecule (Chemical),Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3729,Rheumatoid Arthritis,7/7/14 12:28
3811,2221,AbbVie,Large Pharma,3866,ABT-413,S1P1 + S1P5 modulator,Small Molecule (Chemical),Phase I,In-House,,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3729,Rheumatoid Arthritis,7/7/14 12:28
3812,2221,AbbVie,Large Pharma,3867,ABT-806,,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3730,Solid Tumors,7/7/14 12:28
3812,2221,AbbVie,Large Pharma,3867,ABT-806,,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3730,Solid Tumors,7/7/14 12:28
3812,2221,AbbVie,Large Pharma,3867,ABT-806,,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,136,EGF Pathway Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3730,Solid Tumors,7/7/14 12:28
3815,8,Allergan,Regional & Specialty Pharma,3870,AGN-199201,oxymetazoline,Small Molecule (Chemical),Phase III,Corporate Acquisition,May-17,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,Global,Sales,0,0,0,0,0,0,0,0,10.000005,21.66671083,31.66676455,41.66681213,0,3733,Rosacea,7/7/14 12:28
3815,8,Allergan,Regional & Specialty Pharma,3870,AGN-199201,oxymetazoline,Small Molecule (Chemical),Phase III,Corporate Acquisition,May-17,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3733,Rosacea,7/7/14 12:28
3815,8,Allergan,Regional & Specialty Pharma,3870,AGN-199201,oxymetazoline,Small Molecule (Chemical),Phase III,Corporate Acquisition,May-17,,,,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,US,Sales,0,0,0,0,0,0,0,0,10.000005,21.66671083,31.66676455,41.66681213,0,3733,Rosacea,7/7/14 12:28
3817,53,Johnson & Johnson,Large Pharma,4265,Mavatrep,TRPV1 antagonist,Small Molecule (Chemical),Phase I,,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3735,Osteoarthritis pain,7/7/14 12:28
3817,53,Johnson & Johnson,Large Pharma,4265,Mavatrep,TRPV1 antagonist,Small Molecule (Chemical),Phase I,,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3735,Osteoarthritis pain,7/7/14 12:28
3817,53,Johnson & Johnson,Large Pharma,4265,Mavatrep,TRPV1 antagonist,Small Molecule (Chemical),Phase I,,,,,,61,Other Pain,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3735,Osteoarthritis pain,7/7/14 12:28
3819,53,Johnson & Johnson,Large Pharma,3874,CNTO-888,carlumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3737,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3819,53,Johnson & Johnson,Large Pharma,3874,CNTO-888,carlumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3737,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3819,53,Johnson & Johnson,Large Pharma,3874,CNTO-888,carlumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3737,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3820,53,Johnson & Johnson,Large Pharma,3875,flu-mAb,flu-mAb,Antibody/Antibody Derivative,Phase I,Acquisition (Development),,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3738,Influenza,7/7/14 12:28
3820,53,Johnson & Johnson,Large Pharma,3875,flu-mAb,flu-mAb,Antibody/Antibody Derivative,Phase I,Acquisition (Development),,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3738,Influenza,7/7/14 12:28
3820,53,Johnson & Johnson,Large Pharma,3875,flu-mAb,flu-mAb,Antibody/Antibody Derivative,Phase I,Acquisition (Development),,,,,51,Respiratory Virus Treatments,69,Respiratory Virus Infection,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3738,Influenza,7/7/14 12:28
3821,61,Merck & Co,Large Pharma,3876,MK-5172,,Small Molecule (Chemical),Phase II,In-House,Jul-16,Nov-16,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,184,450,590,788,871,0,3739,Hepatitis C,7/7/14 12:28
3821,61,Merck & Co,Large Pharma,3876,MK-5172,,Small Molecule (Chemical),Phase II,In-House,Jul-16,Nov-16,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,45,150,205,266,280,0,3739,Hepatitis C,7/7/14 12:28
3821,61,Merck & Co,Large Pharma,3876,MK-5172,,Small Molecule (Chemical),Phase II,In-House,Jul-16,Nov-16,,,156,HCV Protease Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,139,300,385,522,591,0,3739,Hepatitis C,7/7/14 12:28
3822,61,Merck & Co,Large Pharma,2283,MK-4618,MK-4618,Small Molecule (Chemical),Phase II,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,718,Overactive bladder,7/7/14 12:28
3822,61,Merck & Co,Large Pharma,2283,MK-4618,MK-4618,Small Molecule (Chemical),Phase II,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,718,Overactive bladder,7/7/14 12:28
3822,61,Merck & Co,Large Pharma,2283,MK-4618,MK-4618,Small Molecule (Chemical),Phase II,In-House,,,,,129,Other Incontinence Treatments,60,Incontinence,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,718,Overactive bladder,7/7/14 12:28
3823,837,Bavarian Nordic,Regional & Specialty Pharma,3878,Prostvac,Prostvac-VF,Vaccine,Phase III,Licensed (Development),Dec-16,Apr-17,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,1,Global,Sales,0,0,0,0,0,0,0,2.644383801,96.01339109,206.4974128,280.1628319,333.3538785,0,3741,Prostate Cancer,7/7/14 12:28
3823,837,Bavarian Nordic,Regional & Specialty Pharma,3878,Prostvac,Prostvac-VF,Vaccine,Phase III,Licensed (Development),Dec-16,Apr-17,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,1,ROW,Sales,0,0,0,0,0,0,0,0,27.25941227,72.69185692,107.220489,129.0280642,0,3741,Prostate Cancer,7/7/14 12:28
3823,837,Bavarian Nordic,Regional & Specialty Pharma,3878,Prostvac,Prostvac-VF,Vaccine,Phase III,Licensed (Development),Dec-16,Apr-17,,,72,Immunomodulators - Oncology (Biologics),41,Biologics,3,Oncology,1,US,Sales,0,0,0,0,0,0,0,2.644383801,68.75397882,133.8055559,172.9423429,204.3258143,0,3741,Prostate Cancer,7/7/14 12:28
3830,76,Pfizer,Large Pharma,3885,PF-547659,,Antibody/Antibody Derivative,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3747,Crohn's Disease,7/7/14 12:28
3830,76,Pfizer,Large Pharma,3885,PF-547659,,Antibody/Antibody Derivative,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3747,Crohn's Disease,7/7/14 12:28
3830,76,Pfizer,Large Pharma,3885,PF-547659,,Antibody/Antibody Derivative,Phase II,In-House,,,,,145,Immunomodulators - IBD,19,Inflammatory Bowel Disease,11,Gastrointestinal,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3747,Crohn's Disease,7/7/14 12:28
3831,76,Pfizer,Large Pharma,3887,ALO-02,oxycodone + naltrexone,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3748,Pain,7/7/14 12:28
3831,76,Pfizer,Large Pharma,3887,ALO-02,oxycodone + naltrexone,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3748,Pain,7/7/14 12:28
3831,76,Pfizer,Large Pharma,3887,ALO-02,oxycodone + naltrexone,Small Molecule (Chemical),Phase III,Corporate Acquisition,,,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3748,Pain,7/7/14 12:28
3832,76,Pfizer,Large Pharma,3888,PD-0325901,PD-325901,Small Molecule (Chemical),Phase I,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3749,Cancer,7/7/14 12:28
3832,76,Pfizer,Large Pharma,3888,PD-0325901,PD-325901,Small Molecule (Chemical),Phase I,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3749,Cancer,7/7/14 12:28
3832,76,Pfizer,Large Pharma,3888,PD-0325901,PD-325901,Small Molecule (Chemical),Phase I,In-House,,,,,189,BRAF/MEK Inhibitors,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3749,Cancer,7/7/14 12:28
3834,76,Pfizer,Large Pharma,3890,PF-06290510,4-antigen Staph Aureas,Vaccine,Phase II,Corporate Acquisition,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3751,Staph aureus infection,7/7/14 12:28
3834,76,Pfizer,Large Pharma,3890,PF-06290510,4-antigen Staph Aureas,Vaccine,Phase II,Corporate Acquisition,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3751,Staph aureus infection,7/7/14 12:28
3834,76,Pfizer,Large Pharma,3890,PF-06290510,4-antigen Staph Aureas,Vaccine,Phase II,Corporate Acquisition,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3751,Staph aureus infection,7/7/14 12:28
3835,76,Pfizer,Large Pharma,4559,PF-00489791,,Small Molecule (Chemical),Phase II,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3752,Chronic Renal Failure,7/7/14 12:28
3835,76,Pfizer,Large Pharma,4559,PF-00489791,,Small Molecule (Chemical),Phase II,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3752,Chronic Renal Failure,7/7/14 12:28
3835,76,Pfizer,Large Pharma,4559,PF-00489791,,Small Molecule (Chemical),Phase II,In-House,,,,,172,Acute / Chronic Renal Disorder Treatments,82,Renal Disorders,8,Metabolism,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3752,Chronic Renal Failure,7/7/14 12:28
3836,68,Novo Nordisk,Regional & Specialty Pharma,3891,NN-8765,Anti-NKG2A,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3753,Rheumatoid Arthritis,7/7/14 12:28
3836,68,Novo Nordisk,Regional & Specialty Pharma,3891,NN-8765,Anti-NKG2A,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3753,Rheumatoid Arthritis,7/7/14 12:28
3836,68,Novo Nordisk,Regional & Specialty Pharma,3891,NN-8765,Anti-NKG2A,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,11,Immunomodulators - Rheumatic Diseases,42,Rheumatic Diseases,13,Musculoskeletal / Pain,1,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3753,Rheumatoid Arthritis,7/7/14 12:28
3838,39,Eli Lilly,Large Pharma,3946,LY2787106,anti-hepcidin MAb,Antibody/Antibody Derivative,Phase I,,,,,,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3755,Chemotherapy-induced anemia,7/7/14 12:28
3838,39,Eli Lilly,Large Pharma,3946,LY2787106,anti-hepcidin MAb,Antibody/Antibody Derivative,Phase I,,,,,,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3755,Chemotherapy-induced anemia,7/7/14 12:28
3838,39,Eli Lilly,Large Pharma,3946,LY2787106,anti-hepcidin MAb,Antibody/Antibody Derivative,Phase I,,,,,,47,ESAs (Oncology),12,Anemia (Oncology),3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3755,Chemotherapy-induced anemia,7/7/14 12:28
3840,39,Eli Lilly,Large Pharma,3898,LY3039478,LY3039478,Small Molecule (Chemical),Phase I,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3757,Cancer,7/7/14 12:28
3840,39,Eli Lilly,Large Pharma,3898,LY3039478,LY3039478,Small Molecule (Chemical),Phase I,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3757,Cancer,7/7/14 12:28
3840,39,Eli Lilly,Large Pharma,3898,LY3039478,LY3039478,Small Molecule (Chemical),Phase I,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3757,Cancer,7/7/14 12:28
3841,39,Eli Lilly,Large Pharma,3899,LY2228820,ralimetinib,Small Molecule (Chemical),Phase II,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3758,Cancer,7/7/14 12:28
3841,39,Eli Lilly,Large Pharma,3899,LY2228820,ralimetinib,Small Molecule (Chemical),Phase II,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3758,Cancer,7/7/14 12:28
3841,39,Eli Lilly,Large Pharma,3899,LY2228820,ralimetinib,Small Molecule (Chemical),Phase II,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3758,Cancer,7/7/14 12:28
3844,39,Eli Lilly,Large Pharma,3929,LY2874455,FGFR inhibitor,Small Molecule (Chemical),Phase II,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3761,Cancer,7/7/14 12:28
3844,39,Eli Lilly,Large Pharma,3929,LY2874455,FGFR inhibitor,Small Molecule (Chemical),Phase II,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3761,Cancer,7/7/14 12:28
3844,39,Eli Lilly,Large Pharma,3929,LY2874455,FGFR inhibitor,Small Molecule (Chemical),Phase II,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3761,Cancer,7/7/14 12:28
3847,39,Eli Lilly,Large Pharma,3905,IMC-3C5,VEGFR3 inhibitor,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3764,Cancer,7/7/14 12:28
3847,39,Eli Lilly,Large Pharma,3905,IMC-3C5,VEGFR3 inhibitor,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3764,Cancer,7/7/14 12:28
3847,39,Eli Lilly,Large Pharma,3905,IMC-3C5,VEGFR3 inhibitor,Antibody/Antibody Derivative,Phase I,Licensed (Development),,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3764,Cancer,7/7/14 12:28
3850,39,Eli Lilly,Large Pharma,3925,LY2875358,emibetuzumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3767,Cancer,7/7/14 12:28
3850,39,Eli Lilly,Large Pharma,3925,LY2875358,emibetuzumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3767,Cancer,7/7/14 12:28
3850,39,Eli Lilly,Large Pharma,3925,LY2875358,emibetuzumab,Antibody/Antibody Derivative,Phase II,In-House,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3767,Cancer,7/7/14 12:28
3851,39,Eli Lilly,Large Pharma,3978,LY2951742,LY2951742,Antibody/Antibody Derivative,Phase II,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3768,Migraine Prevention,7/7/14 12:28
3851,39,Eli Lilly,Large Pharma,3978,LY2951742,LY2951742,Antibody/Antibody Derivative,Phase II,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3768,Migraine Prevention,7/7/14 12:28
3851,39,Eli Lilly,Large Pharma,3978,LY2951742,LY2951742,Antibody/Antibody Derivative,Phase II,In-House,,,,,105,Other Migraine Treatments,8,Migraine,12,Central Nervous System,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3768,Migraine Prevention,7/7/14 12:28
3855,24,Bristol-Myers Squibb,Large Pharma,3937,BMS-906024,Notch inhibitor,Small Molecule (Chemical),Phase I,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3771,Cancer,7/7/14 12:28
3855,24,Bristol-Myers Squibb,Large Pharma,3937,BMS-906024,Notch inhibitor,Small Molecule (Chemical),Phase I,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3771,Cancer,7/7/14 12:28
3855,24,Bristol-Myers Squibb,Large Pharma,3937,BMS-906024,Notch inhibitor,Small Molecule (Chemical),Phase I,,,,,,184,Other Targeted Small Molecules,84,Targeted Small Molecules,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3771,Cancer,7/7/14 12:28
3856,89,Sanofi,Large Pharma,3913,LixiLan,lixisenatide + Lantus,Synthetic Peptide,Phase III,Corporate Acquisition,Jul-16,Jul-16,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,Global,Sales,0,0,0,0,0,0,0,29.8806765,169.3239331,388.4494214,607.57374,790.4433514,0,3772,Type II Diabetes,7/7/14 12:28
3856,89,Sanofi,Large Pharma,3913,LixiLan,lixisenatide + Lantus,Synthetic Peptide,Phase III,Corporate Acquisition,Jul-16,Jul-16,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,ROW,Sales,0,0,0,0,0,0,0,11.9522706,67.72957324,155.3797686,243.029496,316.1773406,0,3772,Type II Diabetes,7/7/14 12:28
3856,89,Sanofi,Large Pharma,3913,LixiLan,lixisenatide + Lantus,Synthetic Peptide,Phase III,Corporate Acquisition,Jul-16,Jul-16,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,2,US,Sales,0,0,0,0,0,0,0,17.9284059,101.5943599,233.0696528,364.544244,474.2660108,0,3772,Type II Diabetes,7/7/14 12:28
3857,37,Eisai,Regional & Specialty Pharma,3914,Warfarin,warfarin ,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-62,Expired,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,Global,Sales,93.72735932,112.0592046,125.3504378,121.5912807,102.994609,103.3749823,103.5398437,103.5972224,103.6196283,103.6278528,103.6309725,103.6321353,0.088193355,3773,Thrombosis,7/7/14 12:28
3857,37,Eisai,Regional & Specialty Pharma,3914,Warfarin,warfarin ,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-62,Expired,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,ROW,Sales,93.72735932,112.0592046,125.3504378,121.5912807,102.994609,103.3749823,103.5398437,103.5972224,103.6196283,103.6278528,103.6309725,103.6321353,0.088193355,3773,Thrombosis,7/7/14 12:28
3857,37,Eisai,Regional & Specialty Pharma,3914,Warfarin,warfarin ,Small Molecule (Chemical),Launched,Licensed (Marketed),,May-62,Expired,,21,Anti-coagulants,33,Thrombosis,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3773,Thrombosis,7/7/14 12:28
3858,24,Bristol-Myers Squibb,Large Pharma,3917,IKur antagonist,BMS 394136,Small Molecule (Chemical),Phase II,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3774,Atrial fibrillation,7/7/14 12:28
3858,24,Bristol-Myers Squibb,Large Pharma,3917,IKur antagonist,BMS 394136,Small Molecule (Chemical),Phase II,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3774,Atrial fibrillation,7/7/14 12:28
3858,24,Bristol-Myers Squibb,Large Pharma,3917,IKur antagonist,BMS 394136,Small Molecule (Chemical),Phase II,In-House,,,,,25,Other Anti-arrhythmics,1,Arrhythmias,10,Cardiovasculars,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3774,Atrial fibrillation,7/7/14 12:28
3862,84,Recordati,Regional & Specialty Pharma,3920,Zanipress,Lercanidipine + enalapril ,Small Molecule (Chemical),Launched,In-House,,Apr-07,,Apr-17,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,Global,Sales,28.85988182,41.94173728,57.82827639,63.36387638,79.41619798,88.73149888,97.1409484,104.9311664,89.02361748,70.12981411,66.97525179,62.97807582,-3.258796647,3776,hypertension,7/7/14 12:28
3862,84,Recordati,Regional & Specialty Pharma,3920,Zanipress,Lercanidipine + enalapril ,Small Molecule (Chemical),Launched,In-House,,Apr-07,,Apr-17,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,ROW,Sales,28.85988182,41.94173728,57.82827639,63.36387638,79.41619798,88.73149888,97.1409484,104.9311664,89.02361748,70.12981411,66.97525179,62.97807582,-3.258796647,3776,hypertension,7/7/14 12:28
3862,84,Recordati,Regional & Specialty Pharma,3920,Zanipress,Lercanidipine + enalapril ,Small Molecule (Chemical),Launched,In-House,,Apr-07,,Apr-17,125,Calcium Antagonists,35,Hypertension,10,Cardiovasculars,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3776,hypertension,7/7/14 12:28
3864,73,Otsuka,Regional & Specialty Pharma,1015,Aloxi,palonosetron,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-10,N/A,Jun-19,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,Global,Sales,0,50.1931854,100.0271171,120.3874067,121.5042223,138.3076697,151.5224565,162.5921358,171.5941114,178.9195057,178.0813918,162.8686431,4.274471482,1578,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
3864,73,Otsuka,Regional & Specialty Pharma,1015,Aloxi,palonosetron,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-10,N/A,Jun-19,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,ROW,Sales,0,50.1931854,100.0271171,120.3874067,121.5042223,138.3076697,151.5224565,162.5921358,171.5941114,178.9195057,178.0813918,162.8686431,4.274471482,1578,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
3864,73,Otsuka,Regional & Specialty Pharma,1015,Aloxi,palonosetron,Small Molecule (Chemical),Launched,Licensed (Development),,Apr-10,N/A,Jun-19,137,Anti-emetics,77,Nausea & Vomiting,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1578,Chemotherapy-induced Nausea and Vomiting,7/7/14 12:28
3865,243,Gedeon Richter,Regional & Specialty Pharma,3973,Oral contraceptives,oral contraceptives,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-95,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,10,Global,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3778,Female contraception,7/7/14 12:28
3865,243,Gedeon Richter,Regional & Specialty Pharma,3973,Oral contraceptives,oral contraceptives,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-95,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,10,Global,Sales,345.5893254,337.3590536,401.4380265,367.1573457,368.9115453,377.6603387,382.2648974,385.9165643,389.4242907,392.0454763,394.1479459,395.8402663,1.011564799,3778,Female contraception,7/7/14 12:28
3865,243,Gedeon Richter,Regional & Specialty Pharma,3973,Oral contraceptives,oral contraceptives,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-95,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,10,ROW,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3778,Female contraception,7/7/14 12:28
3865,243,Gedeon Richter,Regional & Specialty Pharma,3973,Oral contraceptives,oral contraceptives,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-95,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,10,ROW,Sales,202.7674821,216.667602,315.802553,306.7052888,319.4297587,336.9744185,347.1054699,354.5939063,360.7693857,365.1856742,368.5207594,371.0572744,2.163337724,3778,Female contraception,7/7/14 12:28
3865,243,Gedeon Richter,Regional & Specialty Pharma,3973,Oral contraceptives,oral contraceptives,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-95,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,10,US,Alliance Revenue,0,0,0,0,0,0,0,0,0,0,0,0,0,3778,Female contraception,7/7/14 12:28
3865,243,Gedeon Richter,Regional & Specialty Pharma,3973,Oral contraceptives,oral contraceptives,Small Molecule (Chemical),Launched,In-House,Jul-95,Jul-95,N/A,N/A,89,Contraceptives,3,Contraception,2,Genitourinary,10,US,Sales,142.8218433,120.6914516,85.63547353,60.45205693,49.4817866,40.68592013,35.15942748,31.32265799,28.65490507,26.85980215,25.62718654,24.7829919,-9.405624076,3778,Female contraception,7/7/14 12:28
3868,100,Takeda,Large Pharma,4355,Azilva,azilsartan,Small Molecule (Chemical),Launched,In-House,,May-12,,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,Global,Sales,0,0,0,40.93171827,192.6554341,319.680868,446.7060608,529.2724832,591.610118,636.0741942,668.4611877,689.6389738,19.98307749,3779,Hyptertension,7/7/14 12:28
3868,100,Takeda,Large Pharma,4355,Azilva,azilsartan,Small Molecule (Chemical),Launched,In-House,,May-12,,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,ROW,Sales,0,0,0,40.93171827,192.6554341,319.680868,446.7060608,529.2724832,591.610118,636.0741942,668.4611877,689.6389738,19.98307749,3779,Hyptertension,7/7/14 12:28
3868,100,Takeda,Large Pharma,4355,Azilva,azilsartan,Small Molecule (Chemical),Launched,In-House,,May-12,,,79,Angiotensin II Antagonists,35,Hypertension,10,Cardiovasculars,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3779,Hyptertension,7/7/14 12:28
3869,46,GlaxoSmithKline,Large Pharma,145,ronacaleret,ronacaleret,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,4,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3780,Allogeneic hematopoietic stem cell mobilization,7/7/14 12:28
3869,46,GlaxoSmithKline,Large Pharma,145,ronacaleret,ronacaleret,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,4,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3780,Allogeneic hematopoietic stem cell mobilization,7/7/14 12:28
3869,46,GlaxoSmithKline,Large Pharma,145,ronacaleret,ronacaleret,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,4,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3780,Allogeneic hematopoietic stem cell mobilization,7/7/14 12:28
3870,243,Gedeon Richter,Regional & Specialty Pharma,3953,bentamapimod,bentamapimod,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,10,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3781,Endometriosis,7/7/14 12:28
3870,243,Gedeon Richter,Regional & Specialty Pharma,3953,bentamapimod,bentamapimod,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,10,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3781,Endometriosis,7/7/14 12:28
3870,243,Gedeon Richter,Regional & Specialty Pharma,3953,bentamapimod,bentamapimod,Small Molecule (Chemical),Phase II,Corporate Acquisition,,,,,86,Other Womens Health,13,Other Women's Health Disorders,2,Genitourinary,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3781,Endometriosis,7/7/14 12:28
3871,840,Apotex,Regional & Specialty Pharma,3954,Ferriprox,deferiprone,Small Molecule (Chemical),Launched,In-House,Nov-11,Mar-00,Oct-18,,56,Iron Chelators,59,Iron Overload,14,Hematology,8,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3782,Iron Overload,7/7/14 12:28
3871,840,Apotex,Regional & Specialty Pharma,3954,Ferriprox,deferiprone,Small Molecule (Chemical),Launched,In-House,Nov-11,Mar-00,Oct-18,,56,Iron Chelators,59,Iron Overload,14,Hematology,8,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3782,Iron Overload,7/7/14 12:28
3871,840,Apotex,Regional & Specialty Pharma,3954,Ferriprox,deferiprone,Small Molecule (Chemical),Launched,In-House,Nov-11,Mar-00,Oct-18,,56,Iron Chelators,59,Iron Overload,14,Hematology,8,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3782,Iron Overload,7/7/14 12:28
3872,23,Boehringer Ingelheim,Large Pharma,3956,BI-54903 + Spiriva,BI-54903 + Spiriva,Small Molecule (Chemical),Phase I,In-House,,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3783,COPD,7/7/14 12:28
3872,23,Boehringer Ingelheim,Large Pharma,3956,BI-54903 + Spiriva,BI-54903 + Spiriva,Small Molecule (Chemical),Phase I,In-House,,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3783,COPD,7/7/14 12:28
3872,23,Boehringer Ingelheim,Large Pharma,3956,BI-54903 + Spiriva,BI-54903 + Spiriva,Small Molecule (Chemical),Phase I,In-House,,,,,123,Asthma & COPD Combination Products,61,Asthma & COPD,1,Respiratory,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3783,COPD,7/7/14 12:28
3873,23,Boehringer Ingelheim,Large Pharma,4637,nintedanib,nintedanib,Small Molecule (Chemical),Phase III,In-House,Sep-15,Sep-15,Dec-20,Oct-20,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,2,Global,Sales,0,0,0,0,0,0,29.21666147,175.2999688,309.6971959,391.5037102,479.8549795,556.3326071,0,1241,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3873,23,Boehringer Ingelheim,Large Pharma,4637,nintedanib,nintedanib,Small Molecule (Chemical),Phase III,In-House,Sep-15,Sep-15,Dec-20,Oct-20,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,2,ROW,Sales,0,0,0,0,0,0,9.9602255,59.761353,105.5785895,133.4671739,163.5869248,189.6588433,0,1241,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3873,23,Boehringer Ingelheim,Large Pharma,4637,nintedanib,nintedanib,Small Molecule (Chemical),Phase III,In-House,Sep-15,Sep-15,Dec-20,Oct-20,167,Pulmonary Fibrosis Treatments,80,Pulmonary Fibrosis,1,Respiratory,2,US,Sales,0,0,0,0,0,0,19.25643597,115.5386158,204.1186064,258.0365362,316.2680547,366.6737637,0,1241,Idiopathic Pulmonary Fibrosis,7/7/14 12:28
3874,47,Grunenthal,Regional & Specialty Pharma,3961,Tramal / Zaldiar,tramadol / tramadol + acetaminophen,Small Molecule (Chemical),Launched,In-House,,Jul-77,N/A,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,Global,Sales,407.123032,402.7254622,431.0354816,359.8759713,229.8312163,181.6483294,143.8988379,118.2456973,102.478187,92.01248826,85.22499507,80.83051679,-13.86757298,1223,Pain,7/7/14 12:28
3874,47,Grunenthal,Regional & Specialty Pharma,3961,Tramal / Zaldiar,tramadol / tramadol + acetaminophen,Small Molecule (Chemical),Launched,In-House,,Jul-77,N/A,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,ROW,Sales,407.123032,402.7254622,431.0354816,359.8759713,229.8312163,181.6483294,143.8988379,118.2456973,102.478187,92.01248826,85.22499507,80.83051679,-13.86757298,1223,Pain,7/7/14 12:28
3874,47,Grunenthal,Regional & Specialty Pharma,3961,Tramal / Zaldiar,tramadol / tramadol + acetaminophen,Small Molecule (Chemical),Launched,In-House,,Jul-77,N/A,Expired,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1223,Pain,7/7/14 12:28
3879,15,Astellas Pharma,Regional & Specialty Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-04,Sep-05,Nov-20,Mar-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,Global,Alliance Revenue,0,284.8171451,426.9524237,439.4140344,453.047501,482.2438955,498.3522511,513.4538345,527.5486456,538.6231401,548.6908624,465.1287677,0.376668792,1448,Non-small-cell Lung Cancer,7/7/14 12:28
3879,15,Astellas Pharma,Regional & Specialty Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-04,Sep-05,Nov-20,Mar-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1448,Non-small-cell Lung Cancer,7/7/14 12:28
3879,15,Astellas Pharma,Regional & Specialty Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-04,Sep-05,Nov-20,Mar-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,ROW,Alliance Revenue,0,120.2301883,176.251548,155.2997546,161.0835559,158.0632392,158.0632392,158.0632392,159.0700115,159.0700115,159.0700115,119.8058947,-4.141099375,1448,Non-small-cell Lung Cancer,7/7/14 12:28
3879,15,Astellas Pharma,Regional & Specialty Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-04,Sep-05,Nov-20,Mar-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1448,Non-small-cell Lung Cancer,7/7/14 12:28
3879,15,Astellas Pharma,Regional & Specialty Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-04,Sep-05,Nov-20,Mar-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,US,Alliance Revenue,0,164.5869568,250.7008757,284.1142798,291.9639451,324.1806563,340.2890119,355.3905953,368.4786342,379.5531286,389.6208509,345.322873,2.426827486,1448,Non-small-cell Lung Cancer,7/7/14 12:28
3879,15,Astellas Pharma,Regional & Specialty Pharma,1733,Tarceva,erlotinib,Small Molecule (Chemical),Launched,Corporate Acquisition,Nov-04,Sep-05,Nov-20,Mar-20,183,EGF Pathway Inhibitors (Small-molecule),84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1448,Non-small-cell Lung Cancer,7/7/14 12:28
3880,5,Actelion,Small Biotech,3969,Veletri,epoprostenol,Small Molecule (Chemical),Launched,Acquisition (Development),Apr-10,Jun-13,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,Global,Sales,0,2.685295371,16.55736366,25.59574542,43.21732323,64.13117351,85.96309857,106.5903457,123.3712702,138.4570233,151.7618315,163.3383919,20.91772742,4361,Pulmonary Hypertension,7/7/14 12:28
3880,5,Actelion,Small Biotech,3969,Veletri,epoprostenol,Small Molecule (Chemical),Launched,Acquisition (Development),Apr-10,Jun-13,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,ROW,Sales,0,0,0,0,4.368891453,14.77100356,27.25353554,39.73619988,49.38941123,58.24374033,66.09946899,72.91131325,49.49675905,4361,Pulmonary Hypertension,7/7/14 12:28
3880,5,Actelion,Small Biotech,3969,Veletri,epoprostenol,Small Molecule (Chemical),Launched,Acquisition (Development),Apr-10,Jun-13,,,152,Pulmonary Hypertension Treatments,35,Hypertension,10,Cardiovasculars,5,US,Sales,0,2.685295371,16.55736366,25.59574542,38.84843178,49.36016995,58.70956304,66.85414583,73.98185895,80.21328295,85.6623625,90.42707868,12.828238,4361,Pulmonary Hypertension,7/7/14 12:28
3881,189,Valeant,Regional & Specialty Pharma,4043,Retin A,tretinoin,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-71,,Expired,N/A,160,Acne Treatments,73,Acne,6,Dermatology,6,Global,Sales,0,0,0,121,112,110,108,104.6,101.9,99.13,96.255,93.4465,-2.55409685,971,Acne,7/7/14 12:28
3881,189,Valeant,Regional & Specialty Pharma,4043,Retin A,tretinoin,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-71,,Expired,N/A,160,Acne Treatments,73,Acne,6,Dermatology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,971,Acne,7/7/14 12:28
3881,189,Valeant,Regional & Specialty Pharma,4043,Retin A,tretinoin,Small Molecule (Chemical),Launched,Acquisition (Marketed),Jul-71,,Expired,N/A,160,Acne Treatments,73,Acne,6,Dermatology,6,US,Sales,0,0,0,121,112,110,108,104.6,101.9,99.13,96.255,93.4465,-2.55409685,971,Acne,7/7/14 12:28
3882,73,Otsuka,Regional & Specialty Pharma,1294,Sprycel,dasatinib,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-06,Nov-06,Jun-20,Apr-20,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,7,Global,Alliance Revenue,21.54651938,93.38267051,96.22861894,147.7085322,261.7607784,298.1052557,299.3133823,299.4140596,300.8235407,301.1255724,301.5282812,301.7296357,2.050747568,1113,Chronic Myeloid Leukemia,7/7/14 12:28
3882,73,Otsuka,Regional & Specialty Pharma,1294,Sprycel,dasatinib,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-06,Nov-06,Jun-20,Apr-20,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1113,Chronic Myeloid Leukemia,7/7/14 12:28
3882,73,Otsuka,Regional & Specialty Pharma,1294,Sprycel,dasatinib,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-06,Nov-06,Jun-20,Apr-20,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,7,ROW,Alliance Revenue,0,62.90360444,60.99672109,87.5148289,151.0158337,169.2384109,168.4329932,168.5336704,168.8357021,169.2384109,169.5404426,169.9431515,1.701152856,1113,Chronic Myeloid Leukemia,7/7/14 12:28
3882,73,Otsuka,Regional & Specialty Pharma,1294,Sprycel,dasatinib,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-06,Nov-06,Jun-20,Apr-20,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1113,Chronic Myeloid Leukemia,7/7/14 12:28
3882,73,Otsuka,Regional & Specialty Pharma,1294,Sprycel,dasatinib,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-06,Nov-06,Jun-20,Apr-20,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,7,US,Alliance Revenue,21.54651938,30.47906607,35.23189785,60.19370334,110.7449447,128.8668447,130.8803892,130.8803892,131.9878386,131.8871614,131.9878386,131.7864842,2.516179365,1113,Chronic Myeloid Leukemia,7/7/14 12:28
3882,73,Otsuka,Regional & Specialty Pharma,1294,Sprycel,dasatinib,Small Molecule (Chemical),Launched,Licensed (Marketed),Jul-06,Nov-06,Jun-20,Apr-20,1,Abl Inhibitors,84,Targeted Small Molecules,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1113,Chronic Myeloid Leukemia,7/7/14 12:28
3883,243,Gedeon Richter,Regional & Specialty Pharma,287,Avonex,interferon-beta 1a,Recombinant Protein,Launched,Licensed (Marketed),,Mar-03,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,10,Global,Sales,30.51148999,34.10134561,33.99574225,29.15884566,28.16285929,26.45451957,25.66577671,25.33686843,25.11575985,24.6071321,24.12506664,24.05830063,-2.225209112,1719,Multiple Sclerosis,7/7/14 12:28
3883,243,Gedeon Richter,Regional & Specialty Pharma,287,Avonex,interferon-beta 1a,Recombinant Protein,Launched,Licensed (Marketed),,Mar-03,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,10,ROW,Sales,30.51148999,34.10134561,33.99574225,29.15884566,28.16285929,26.45451957,25.66577671,25.33686843,25.11575985,24.6071321,24.12506664,24.05830063,-2.225209112,1719,Multiple Sclerosis,7/7/14 12:28
3883,243,Gedeon Richter,Regional & Specialty Pharma,287,Avonex,interferon-beta 1a,Recombinant Protein,Launched,Licensed (Marketed),,Mar-03,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1719,Multiple Sclerosis,7/7/14 12:28
3885,63,Merck KGaA,Regional & Specialty Pharma,3976,PI-2301,plovamer,Synthetic Peptide,Phase I,Acquisition (Development),,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3799,Multiple Sclerosis,7/7/14 12:28
3885,63,Merck KGaA,Regional & Specialty Pharma,3976,PI-2301,plovamer,Synthetic Peptide,Phase I,Acquisition (Development),,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3799,Multiple Sclerosis,7/7/14 12:28
3885,63,Merck KGaA,Regional & Specialty Pharma,3976,PI-2301,plovamer,Synthetic Peptide,Phase I,Acquisition (Development),,,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,2,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3799,Multiple Sclerosis,7/7/14 12:28
3886,45,Gilead,Regional & Specialty Pharma,3977,simtuzumab,simtuzumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3792,Myelofibrosis,7/7/14 12:28
3886,45,Gilead,Regional & Specialty Pharma,3977,simtuzumab,simtuzumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3792,Myelofibrosis,7/7/14 12:28
3886,45,Gilead,Regional & Specialty Pharma,3977,simtuzumab,simtuzumab,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,58,Other Targeted Biologics,41,Biologics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3792,Myelofibrosis,7/7/14 12:28
3887,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,3985,Marqibo,liposomal vincristine sulfate,Small Molecule (Chemical),Launched,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3793,Acute Lymphoblastic Leukemia,7/7/14 12:28
3887,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,3985,Marqibo,liposomal vincristine sulfate,Small Molecule (Chemical),Launched,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3793,Acute Lymphoblastic Leukemia,7/7/14 12:28
3887,178,Spectrum Pharmaceuticals,Regional & Specialty Pharma,3985,Marqibo,liposomal vincristine sulfate,Small Molecule (Chemical),Launched,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3793,Acute Lymphoblastic Leukemia,7/7/14 12:28
3888,862,Talon Therapeutics,Regional & Specialty Pharma,3986,Brakiva,liposomal topotecan,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3790,Solid Tumors,7/7/14 12:28
3888,862,Talon Therapeutics,Regional & Specialty Pharma,3986,Brakiva,liposomal topotecan,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3790,Solid Tumors,7/7/14 12:28
3888,862,Talon Therapeutics,Regional & Specialty Pharma,3986,Brakiva,liposomal topotecan,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,34,Anti-neoplastic Antibiotics,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3790,Solid Tumors,7/7/14 12:28
3889,862,Talon Therapeutics,Regional & Specialty Pharma,3987,Alocrest,liposomal vinorelbine,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3788,Solid Tumors,7/7/14 12:28
3889,862,Talon Therapeutics,Regional & Specialty Pharma,3987,Alocrest,liposomal vinorelbine,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3788,Solid Tumors,7/7/14 12:28
3889,862,Talon Therapeutics,Regional & Specialty Pharma,3987,Alocrest,liposomal vinorelbine,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,16,Microtubule Modulators,51,Cytotoxics,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3788,Solid Tumors,7/7/14 12:28
3890,862,Talon Therapeutics,Regional & Specialty Pharma,3988,menadione,vitamin K3,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3794,EGFR Inhibitor-induced Rash,7/7/14 12:28
3890,862,Talon Therapeutics,Regional & Specialty Pharma,3988,menadione,vitamin K3,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3794,EGFR Inhibitor-induced Rash,7/7/14 12:28
3890,862,Talon Therapeutics,Regional & Specialty Pharma,3988,menadione,vitamin K3,Small Molecule (Chemical),Phase I,Licensed (Development),,,,,126,Other Supportive Care,6,Other Supportive Care,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3794,EGFR Inhibitor-induced Rash,7/7/14 12:28
3891,37,Eisai,Regional & Specialty Pharma,3989,MORAb-004,anti-endosialin MAb,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3795,Melanoma,7/7/14 12:28
3891,37,Eisai,Regional & Specialty Pharma,3989,MORAb-004,anti-endosialin MAb,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3795,Melanoma,7/7/14 12:28
3891,37,Eisai,Regional & Specialty Pharma,3989,MORAb-004,anti-endosialin MAb,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,19,Angiogenesis Inhibitors (Biologics),41,Biologics,3,Oncology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3795,Melanoma,7/7/14 12:28
3892,40,Endo Health Solutions,Regional & Specialty Pharma,3990,ODM-201,ODM-201,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,107,Anti-androgens,55,Hormonals,3,Oncology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3789,Prostate Cancer,7/7/14 12:28
3892,40,Endo Health Solutions,Regional & Specialty Pharma,3990,ODM-201,ODM-201,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,107,Anti-androgens,55,Hormonals,3,Oncology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3789,Prostate Cancer,7/7/14 12:28
3892,40,Endo Health Solutions,Regional & Specialty Pharma,3990,ODM-201,ODM-201,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,107,Anti-androgens,55,Hormonals,3,Oncology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3789,Prostate Cancer,7/7/14 12:28
3894,45,Gilead,Regional & Specialty Pharma,4314,Sovaldi,sofosbuvir,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-13,Mar-14,N/A,N/A,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,Global,Sales,0,0,0,0,121,10278.125,16238,16940,16695,15371,12956,11405,91.44498406,3800,Hepatitis C,7/7/14 12:28
3894,45,Gilead,Regional & Specialty Pharma,4314,Sovaldi,sofosbuvir,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-13,Mar-14,N/A,N/A,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,2173.125,5118,5620,4915,4602,3951,3109,0,3800,Hepatitis C,7/7/14 12:28
3894,45,Gilead,Regional & Specialty Pharma,4314,Sovaldi,sofosbuvir,Small Molecule (Chemical),Launched,Corporate Acquisition,Dec-13,Mar-14,N/A,N/A,155,HCV Polymerase Inhibitors,21,Hepatitis,7,Anti-infectives,6,US,Sales,0,0,0,0,121,8105,11120,11320,11780,10769,9005,8296,82.93523492,3800,Hepatitis C,7/7/14 12:28
3896,102,Teva,Regional & Specialty Pharma,3960,Zoely,nomegestrol + estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-11,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,Global,Sales,0,0,1.666666,21.11115822,34.44454353,47.77802633,56.5114196,63.13147072,68.28951478,72.07654439,74.93550734,77.09382684,12.19811118,796,Female contraception,7/7/14 12:28
3896,102,Teva,Regional & Specialty Pharma,3960,Zoely,nomegestrol + estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-11,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,ROW,Sales,0,0,1.666666,21.11115822,34.44454353,47.77802633,56.5114196,63.13147072,68.28951478,72.07654439,74.93550734,77.09382684,12.19811118,796,Female contraception,7/7/14 12:28
3896,102,Teva,Regional & Specialty Pharma,3960,Zoely,nomegestrol + estradiol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Dec-11,,,89,Contraceptives,3,Contraception,2,Genitourinary,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,796,Female contraception,7/7/14 12:28
3901,34,Daiichi-Sankyo,Regional & Specialty Pharma,888,Nexium,esomeprazole,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-11,N/A,Dec-19,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,Global,Sales,0,0,49.38047551,260.0367984,563.7924457,634.2665014,704.1767647,754.3220756,778.3782938,794.7997958,788.8828179,770.3683753,4.560689123,773,GERD,7/7/14 12:28
3901,34,Daiichi-Sankyo,Regional & Specialty Pharma,888,Nexium,esomeprazole,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-11,N/A,Dec-19,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,ROW,Sales,0,0,49.38047551,260.0367984,563.7924457,634.2665014,704.1767647,754.3220756,778.3782938,794.7997958,788.8828179,770.3683753,4.560689123,773,GERD,7/7/14 12:28
3901,34,Daiichi-Sankyo,Regional & Specialty Pharma,888,Nexium,esomeprazole,Small Molecule (Chemical),Launched,Licensed (Marketed),,Sep-11,N/A,Dec-19,4,Proton Pump Inhibitors,44,GERD/PUD,11,Gastrointestinal,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,773,GERD,7/7/14 12:28
3902,73,Otsuka,Regional & Specialty Pharma,4007,OPA-6566,OPA-6566,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3796,Glaucoma,7/7/14 12:28
3902,73,Otsuka,Regional & Specialty Pharma,4007,OPA-6566,OPA-6566,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3796,Glaucoma,7/7/14 12:28
3902,73,Otsuka,Regional & Specialty Pharma,4007,OPA-6566,OPA-6566,Small Molecule (Chemical),Phase II,Licensed (Development),,,,,36,Glaucoma Treatments,26,Glaucoma,4,Ophthalmology,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3796,Glaucoma,7/7/14 12:28
3903,67,Novartis,Large Pharma,4008,RTH-258,RTH-258,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3791,Age-related macular degeneration,7/7/14 12:28
3903,67,Novartis,Large Pharma,4008,RTH-258,RTH-258,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3791,Age-related macular degeneration,7/7/14 12:28
3903,67,Novartis,Large Pharma,4008,RTH-258,RTH-258,Antibody/Antibody Derivative,Phase II,Corporate Acquisition,,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3791,Age-related macular degeneration,7/7/14 12:28
3904,5,Actelion,Small Biotech,4010,Valchlor,mechlorethamine ,Small Molecule (Chemical),Launched,Acquisition (Development),,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,5,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3785,Cutaneous T-cell Lymphoma,7/7/14 12:28
3904,5,Actelion,Small Biotech,4010,Valchlor,mechlorethamine ,Small Molecule (Chemical),Launched,Acquisition (Development),,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,5,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3785,Cutaneous T-cell Lymphoma,7/7/14 12:28
3904,5,Actelion,Small Biotech,4010,Valchlor,mechlorethamine ,Small Molecule (Chemical),Launched,Acquisition (Development),,,,,84,Alkylating Agents,51,Cytotoxics,3,Oncology,5,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3785,Cutaneous T-cell Lymphoma,7/7/14 12:28
3905,243,Gedeon Richter,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Marketed),,Feb-10,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,10,Global,Sales,0,2.519614368,4.769631791,5.972829179,7.720956823,8.601023792,9.249326934,13.42046694,14.64850411,15.64601471,13.42046694,17.89395592,12.75812334,1559,Multiple Sclerosis,7/7/14 12:28
3905,243,Gedeon Richter,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Marketed),,Feb-10,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,10,ROW,Sales,0,2.519614368,4.769631791,5.972829179,7.720956823,8.601023792,9.249326934,13.42046694,14.64850411,15.64601471,13.42046694,17.89395592,12.75812334,1559,Multiple Sclerosis,7/7/14 12:28
3905,243,Gedeon Richter,Regional & Specialty Pharma,1393,Tysabri,natalizumab,Antibody/Antibody Derivative,Launched,Licensed (Marketed),,Feb-10,,,135,Immunomodulators - MS,40,Multiple Sclerosis,12,Central Nervous System,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1559,Multiple Sclerosis,7/7/14 12:28
3906,243,Gedeon Richter,Regional & Specialty Pharma,4012,Nepanil / Lenuxin,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-09,,,127,Serotonergics,49,Depression,12,Central Nervous System,10,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
3906,243,Gedeon Richter,Regional & Specialty Pharma,4012,Nepanil / Lenuxin,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-09,,,127,Serotonergics,49,Depression,12,Central Nervous System,10,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
3906,243,Gedeon Richter,Regional & Specialty Pharma,4012,Nepanil / Lenuxin,escitalopram,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-09,,,127,Serotonergics,49,Depression,12,Central Nervous System,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1450,Depression,7/7/14 12:28
3907,243,Gedeon Richter,Regional & Specialty Pharma,4013,Parnassan,olanzapine,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,10,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1321,Schizophrenia,7/7/14 12:28
3907,243,Gedeon Richter,Regional & Specialty Pharma,4013,Parnassan,olanzapine,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,10,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1321,Schizophrenia,7/7/14 12:28
3907,243,Gedeon Richter,Regional & Specialty Pharma,4013,Parnassan,olanzapine,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1321,Schizophrenia,7/7/14 12:28
3908,243,Gedeon Richter,Regional & Specialty Pharma,4014,Ridonex,risperidone,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,10,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1018,Schizophrenia,7/7/14 12:28
3908,243,Gedeon Richter,Regional & Specialty Pharma,4014,Ridonex,risperidone,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,10,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1018,Schizophrenia,7/7/14 12:28
3908,243,Gedeon Richter,Regional & Specialty Pharma,4014,Ridonex,risperidone,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,69,Atypical Anti-psychotics,46,Schizophrenia,12,Central Nervous System,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1018,Schizophrenia,7/7/14 12:28
3909,243,Gedeon Richter,Regional & Specialty Pharma,4015,Jarvis,venlafaxine,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,66,Noradrenergics,49,Depression,12,Central Nervous System,10,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1681,Depression,7/7/14 12:28
3909,243,Gedeon Richter,Regional & Specialty Pharma,4015,Jarvis,venlafaxine,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,66,Noradrenergics,49,Depression,12,Central Nervous System,10,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1681,Depression,7/7/14 12:28
3909,243,Gedeon Richter,Regional & Specialty Pharma,4015,Jarvis,venlafaxine,Small Molecule (Chemical),Launched,Licensed (Marketed),,,,,66,Noradrenergics,49,Depression,12,Central Nervous System,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1681,Depression,7/7/14 12:28
3910,8,Allergan,Regional & Specialty Pharma,4016,DARPin Anti-VEGF,DARPin Anti-VEGF,Recombinant Protein,Phase II,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3786,Age-related macular degeneration,7/7/14 12:28
3910,8,Allergan,Regional & Specialty Pharma,4016,DARPin Anti-VEGF,DARPin Anti-VEGF,Recombinant Protein,Phase II,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3786,Age-related macular degeneration,7/7/14 12:28
3910,8,Allergan,Regional & Specialty Pharma,4016,DARPin Anti-VEGF,DARPin Anti-VEGF,Recombinant Protein,Phase II,Licensed (Development),,,,,29,Wet AMD Treatments,30,AMD,4,Ophthalmology,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3786,Age-related macular degeneration,7/7/14 12:28
3911,243,Gedeon Richter,Regional & Specialty Pharma,4017,Lunaldin / Dolforin,fentanyl - sublingual,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-08,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,10,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,596,Pain,7/7/14 12:28
3911,243,Gedeon Richter,Regional & Specialty Pharma,4017,Lunaldin / Dolforin,fentanyl - sublingual,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-08,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,10,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,596,Pain,7/7/14 12:28
3911,243,Gedeon Richter,Regional & Specialty Pharma,4017,Lunaldin / Dolforin,fentanyl - sublingual,Small Molecule (Chemical),Launched,Licensed (Marketed),,Nov-08,,,97,Opioid Analgesics,54,Pain,13,Musculoskeletal / Pain,10,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,596,Pain,7/7/14 12:28
3912,18,Baxter Healthcare,Regional & Specialty Pharma,3690,OBI-1,Recombinant porcine Factor VIII,Recombinant Protein,Filed,Acquisition (Development),Sep-14,Feb-15,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,Global,Sales,0,0,0,0,0,2,25.48,46.31280572,62.84588474,76.12211952,85.0096928,90.96478468,0,3592,Acquired Hemophilia A,7/7/14 12:28
3912,18,Baxter Healthcare,Regional & Specialty Pharma,3690,OBI-1,Recombinant porcine Factor VIII,Recombinant Protein,Filed,Acquisition (Development),Sep-14,Feb-15,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,ROW,Sales,0,0,0,0,0,0,13,25,32.13875,38,42.380575,45,0,3592,Acquired Hemophilia A,7/7/14 12:28
3912,18,Baxter Healthcare,Regional & Specialty Pharma,3690,OBI-1,Recombinant porcine Factor VIII,Recombinant Protein,Filed,Acquisition (Development),Sep-14,Feb-15,,,124,Recombinant Blood Products,47,Blood Clotting Disorders,14,Hematology,6,US,Sales,0,0,0,0,0,2,12.48,21.31280572,30.70713474,38.12211952,42.6291178,45.96478468,0,3592,Acquired Hemophilia A,7/7/14 12:28
3913,190,Meda,Regional & Specialty Pharma,4020,Ceplene,histamine dihydrochloride,Small Molecule (Chemical),Launched,Acquisition (Development),,Apr-10,N/A,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,9,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3802,Acute Myeloid Leukemia,7/7/14 12:28
3913,190,Meda,Regional & Specialty Pharma,4020,Ceplene,histamine dihydrochloride,Small Molecule (Chemical),Launched,Acquisition (Development),,Apr-10,N/A,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,9,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3802,Acute Myeloid Leukemia,7/7/14 12:28
3913,190,Meda,Regional & Specialty Pharma,4020,Ceplene,histamine dihydrochloride,Small Molecule (Chemical),Launched,Acquisition (Development),,Apr-10,N/A,,185,Immunomodulators - Oncology (Small-molecule),84,Targeted Small Molecules,3,Oncology,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3802,Acute Myeloid Leukemia,7/7/14 12:28
3914,190,Meda,Regional & Specialty Pharma,4021,Novopulmon,budesonide,Small Molecule (Chemical),Launched,In-House,,Jan-01,N/A,Expired,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,9,Global,Sales,26.90802615,25.95990329,27.87248978,25.10268722,28.25346738,28.42621277,28.60327679,28.85991165,28.95710522,29.02955524,29.08207477,29.11241984,0.428754567,3803,Asthma,7/7/14 12:28
3914,190,Meda,Regional & Specialty Pharma,4021,Novopulmon,budesonide,Small Molecule (Chemical),Launched,In-House,,Jan-01,N/A,Expired,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,9,ROW,Sales,26.90802615,25.95990329,27.87248978,25.10268722,28.25346738,28.42621277,28.60327679,28.85991165,28.95710522,29.02955524,29.08207477,29.11241984,0.428754567,3803,Asthma,7/7/14 12:28
3914,190,Meda,Regional & Specialty Pharma,4021,Novopulmon,budesonide,Small Molecule (Chemical),Launched,In-House,,Jan-01,N/A,Expired,59,Inhaled Steroids,61,Asthma & COPD,1,Respiratory,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3803,Asthma,7/7/14 12:28
3915,190,Meda,Regional & Specialty Pharma,4022,Formatris,formoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-05,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,9,Global,Sales,22.98938156,31.23517775,34.34013934,30.86153899,36.54524586,37.15330961,37.63730379,38.16330965,38.37523522,38.51946057,38.61581718,38.66934959,0.810353219,3804,COPD,7/7/14 12:28
3915,190,Meda,Regional & Specialty Pharma,4022,Formatris,formoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-05,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,9,ROW,Sales,22.98938156,31.23517775,34.34013934,30.86153899,36.54524586,37.15330961,37.63730379,38.16330965,38.37523522,38.51946057,38.61581718,38.66934959,0.810353219,3804,COPD,7/7/14 12:28
3915,190,Meda,Regional & Specialty Pharma,4022,Formatris,formoterol,Small Molecule (Chemical),Launched,Corporate Acquisition,,Jan-05,N/A,Expired,24,Beta-2 Agonists,61,Asthma & COPD,1,Respiratory,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3804,COPD,7/7/14 12:28
3916,190,Meda,Regional & Specialty Pharma,4023,Dymista,azelastine + fluticasone,Small Molecule (Chemical),Launched,In-House,Sep-12,Apr-13,Jun-26,Nov-25,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,9,Global,Sales,0,0,0,9.450423423,68.94460247,143.3610279,220.7715205,266.2698618,296.4424125,320.2602622,337.9732078,351.0022495,26.17482266,3805,Allergic Rhinitis,7/7/14 12:28
3916,190,Meda,Regional & Specialty Pharma,4023,Dymista,azelastine + fluticasone,Small Molecule (Chemical),Launched,In-House,Sep-12,Apr-13,Jun-26,Nov-25,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,9,ROW,Sales,0,0,0,0,5.988506674,12.95188235,22.90954854,39.34325499,48.6630911,57.97936809,67.14142694,74.54595292,43.36511622,3805,Allergic Rhinitis,7/7/14 12:28
3916,190,Meda,Regional & Specialty Pharma,4023,Dymista,azelastine + fluticasone,Small Molecule (Chemical),Launched,In-House,Sep-12,Apr-13,Jun-26,Nov-25,177,Other Allergic Rhinitis Treatments,62,Allergic Rhinitis,1,Respiratory,9,US,Sales,0,0,0,9.450423423,62.9560958,130.4091455,197.861972,226.9266068,247.7793214,262.2808941,270.8317809,276.4562966,23.53735359,3805,Allergic Rhinitis,7/7/14 12:28
3917,190,Meda,Regional & Specialty Pharma,4024,Astelin,azelastine,Small Molecule (Chemical),Launched,Acquisition (Development),Sep-97,Jul-99,Mar-10,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,9,Global,Sales,178.8208145,97.68613728,40.96178055,33.81479631,35.77748859,24.61670735,20.53324736,17.10346522,13.98888305,11.69082113,10.11136319,8.693625681,-18.29899747,3806,Allergic Rhinitis,7/7/14 12:28
3917,190,Meda,Regional & Specialty Pharma,4024,Astelin,azelastine,Small Molecule (Chemical),Launched,Acquisition (Development),Sep-97,Jul-99,Mar-10,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,9,ROW,Sales,74.24616291,44.2845409,32.49223946,26.87464161,29.32832756,19.85721524,16.73179494,14.16424854,11.79644604,10.15731891,8.882951566,7.772316962,-17.28026933,3806,Allergic Rhinitis,7/7/14 12:28
3917,190,Meda,Regional & Specialty Pharma,4024,Astelin,azelastine,Small Molecule (Chemical),Launched,Acquisition (Development),Sep-97,Jul-99,Mar-10,Expired,65,Anti-histamines,62,Allergic Rhinitis,1,Respiratory,9,US,Sales,104.5746516,53.40159638,8.469541092,6.940154701,6.449161033,4.759492116,3.801452413,2.93921668,2.192437013,1.533502219,1.228411625,0.921308719,-24.26932474,3806,Allergic Rhinitis,7/7/14 12:28
3918,190,Meda,Regional & Specialty Pharma,4026,Axorid,ketoprofen + omeprazole,Small Molecule (Chemical),Launched,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,9,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3807,Rheumatoid arthritis,7/7/14 12:28
3918,190,Meda,Regional & Specialty Pharma,4026,Axorid,ketoprofen + omeprazole,Small Molecule (Chemical),Launched,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,9,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3807,Rheumatoid arthritis,7/7/14 12:28
3918,190,Meda,Regional & Specialty Pharma,4026,Axorid,ketoprofen + omeprazole,Small Molecule (Chemical),Launched,Licensed (Development),,,,,64,Other Rheumatic Disease Agents,42,Rheumatic Diseases,13,Musculoskeletal / Pain,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3807,Rheumatoid arthritis,7/7/14 12:28
3920,255,Kyorin,Regional & Specialty Pharma,4317,Tudorza,aclidinium,Small Molecule (Chemical),Phase III,Licensed (Development),,Sep-14,N/A,N/A,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,3,Global,Sales,0,0,0,0,0,3.416318071,12.52651098,12.29875736,16.63948078,19.77874014,22.03977693,24.39212963,0,1325,COPD,7/7/14 12:28
3920,255,Kyorin,Regional & Specialty Pharma,4317,Tudorza,aclidinium,Small Molecule (Chemical),Phase III,Licensed (Development),,Sep-14,N/A,N/A,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,3,ROW,Sales,0,0,0,0,0,3.416318071,12.52651098,12.29875736,16.63948078,19.77874014,22.03977693,24.39212963,0,1325,COPD,7/7/14 12:28
3920,255,Kyorin,Regional & Specialty Pharma,4317,Tudorza,aclidinium,Small Molecule (Chemical),Phase III,Licensed (Development),,Sep-14,N/A,N/A,128,Anti-cholinergics,61,Asthma & COPD,1,Respiratory,3,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,1325,COPD,7/7/14 12:28
3921,34,Daiichi-Sankyo,Regional & Specialty Pharma,4032,Injectafer,ferric carboxymaltose,Small Molecule (Chemical),Launched,Licensed (Development),Aug-13,,,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,Global,Sales,0,0,0,0,40.55903875,66.92241394,95.31357883,141.9562318,164.2230423,182.7057028,197.8556452,208.3995241,26.3409247,3808,Iron-deficiency Anemia,7/7/14 12:28
3921,34,Daiichi-Sankyo,Regional & Specialty Pharma,4032,Injectafer,ferric carboxymaltose,Small Molecule (Chemical),Launched,Licensed (Development),Aug-13,,,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3808,Iron-deficiency Anemia,7/7/14 12:28
3921,34,Daiichi-Sankyo,Regional & Specialty Pharma,4032,Injectafer,ferric carboxymaltose,Small Molecule (Chemical),Launched,Licensed (Development),Aug-13,,,N/A,161,Other Anemia Treatments,24,Anemia,14,Hematology,7,US,Sales,0,0,0,0,40.55903875,66.92241394,95.31357883,141.9562318,164.2230423,182.7057028,197.8556452,208.3995241,26.3409247,3808,Iron-deficiency Anemia,7/7/14 12:28
3923,895,Avanir Pharmaceuticals,Regional & Specialty Pharma,4035,Nuedexta,dextromethorphan + quinidine,Small Molecule (Chemical),Launched,Licensed (Development),Feb-11,Oct-14,Jan-16,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,Global,Sales,0,0,6,37,71,91.43469,110.905097,68.15539594,52.77519941,45.47226882,41.62041725,38.87509948,-8.244841565,3809,Pseudobulbar affect,7/7/14 12:28
3923,895,Avanir Pharmaceuticals,Regional & Specialty Pharma,4035,Nuedexta,dextromethorphan + quinidine,Small Molecule (Chemical),Launched,Licensed (Development),Feb-11,Oct-14,Jan-16,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,ROW,Sales,0,0,0,0,0,5,10,13,15.00005,16.740065,17.9820785,18.90789125,0,3809,Pseudobulbar affect,7/7/14 12:28
3923,895,Avanir Pharmaceuticals,Regional & Specialty Pharma,4035,Nuedexta,dextromethorphan + quinidine,Small Molecule (Chemical),Launched,Licensed (Development),Feb-11,Oct-14,Jan-16,,35,Other Psychiatry,17,Other Psychiatric Disorders,12,Central Nervous System,6,US,Sales,0,0,6,37,71,86.43469,100.905097,55.15539594,37.77514941,28.73220382,23.63833875,19.96720823,-16.57538304,3809,Pseudobulbar affect,7/7/14 12:28
3924,45,Gilead,Regional & Specialty Pharma,4037,tenofovir alafenamide,GS 7340,Small Molecule (Chemical),Phase III,In-House,,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3810,"Hepatitis B, HIV",7/7/14 12:28
3924,45,Gilead,Regional & Specialty Pharma,4037,tenofovir alafenamide,GS 7340,Small Molecule (Chemical),Phase III,In-House,,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3810,"Hepatitis B, HIV",7/7/14 12:28
3924,45,Gilead,Regional & Specialty Pharma,4037,tenofovir alafenamide,GS 7340,Small Molecule (Chemical),Phase III,In-House,,,,,104,NRTIs,32,HIV,7,Anti-infectives,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3810,"Hepatitis B, HIV",7/7/14 12:28
3925,34,Daiichi-Sankyo,Regional & Specialty Pharma,4034,DS-7309,DS-7309,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3811,Diabetes,7/7/14 12:28
3925,34,Daiichi-Sankyo,Regional & Specialty Pharma,4034,DS-7309,DS-7309,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3811,Diabetes,7/7/14 12:28
3925,34,Daiichi-Sankyo,Regional & Specialty Pharma,4034,DS-7309,DS-7309,Small Molecule (Chemical),Phase I,In-House,,,,,32,Other Diabetes Agents,22,Diabetes,8,Metabolism,7,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3811,Diabetes,7/7/14 12:28
3926,190,Meda,Regional & Specialty Pharma,4040,Aldara / Zyclara,imiquimod,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-07,N/A,,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,9,Global,Sales,62.82893484,59.27742622,63.44456236,59.50813499,65.10581615,59.88506674,58.0424493,54.84857908,52.19520997,49.32564041,46.54255103,43.72486958,-5.528399599,3812,Actinic keratosis,7/7/14 12:28
3926,190,Meda,Regional & Specialty Pharma,4040,Aldara / Zyclara,imiquimod,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-07,N/A,,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,9,ROW,Sales,62.82893484,59.27742622,63.44456236,59.50813499,65.10581615,59.88506674,58.0424493,54.84857908,52.19520997,49.32564041,46.54255103,43.72486958,-5.528399599,3812,Actinic keratosis,7/7/14 12:28
3926,190,Meda,Regional & Specialty Pharma,4040,Aldara / Zyclara,imiquimod,Small Molecule (Chemical),Launched,Corporate Acquisition,,Feb-07,N/A,,186,Actinic Keratosis Treatments,85,Actinic Keratosis,6,Dermatology,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3812,Actinic keratosis,7/7/14 12:28
3927,190,Meda,Regional & Specialty Pharma,4042,Acnex,clindamycin + tretinoin,Small Molecule (Chemical),Approved,Licensed (Development),,Jun-14,,,160,Acne Treatments,73,Acne,6,Dermatology,9,Global,Sales,0,0,0,0,0,5.980829101,14.06302251,25.13568391,43.2399116,54.43219236,65.02574513,74.84599005,0,3814,Acne,7/7/14 12:28
3927,190,Meda,Regional & Specialty Pharma,4042,Acnex,clindamycin + tretinoin,Small Molecule (Chemical),Approved,Licensed (Development),,Jun-14,,,160,Acne Treatments,73,Acne,6,Dermatology,9,ROW,Sales,0,0,0,0,0,5.980829101,14.06302251,25.13568391,43.2399116,54.43219236,65.02574513,74.84599005,0,3814,Acne,7/7/14 12:28
3927,190,Meda,Regional & Specialty Pharma,4042,Acnex,clindamycin + tretinoin,Small Molecule (Chemical),Approved,Licensed (Development),,Jun-14,,,160,Acne Treatments,73,Acne,6,Dermatology,9,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3814,Acne,7/7/14 12:28
3928,46,GlaxoSmithKline,Large Pharma,4089,572-Trii,dolutegravir / abacavir / lamivudine FDC,Small Molecule (Chemical),Filed,In-House,Jun-14,Sep-14,,,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,4,Global,Sales,0,0,0,0,0,172.4965868,612.8582427,1199.909894,1958.957777,2820.398907,3303.49447,3865.1446,0,3813,HIV,7/7/14 12:28
3928,46,GlaxoSmithKline,Large Pharma,4089,572-Trii,dolutegravir / abacavir / lamivudine FDC,Small Molecule (Chemical),Filed,In-House,Jun-14,Sep-14,,,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,4,ROW,Sales,0,0,0,0,0,42.21213654,196.9901112,408.0512261,634.7460954,766.0728737,889.1917248,1147.545897,0,3813,HIV,7/7/14 12:28
3928,46,GlaxoSmithKline,Large Pharma,4089,572-Trii,dolutegravir / abacavir / lamivudine FDC,Small Molecule (Chemical),Filed,In-House,Jun-14,Sep-14,,,170,Single Tablet Regimens,32,HIV,7,Anti-infectives,4,US,Sales,0,0,0,0,0,130.2844502,415.8681315,791.8586678,1324.211682,2054.326033,2414.302745,2717.598704,0,3813,HIV,7/7/14 12:28
3930,67,Novartis,Large Pharma,4055,Staph aureus vaccine,Staph aureus,Vaccine,Phase I,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,Global,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3816,Staphylococcus Aureus Prophylaxis,7/7/14 12:28
3930,67,Novartis,Large Pharma,4055,Staph aureus vaccine,Staph aureus,Vaccine,Phase I,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,ROW,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3816,Staphylococcus Aureus Prophylaxis,7/7/14 12:28
3930,67,Novartis,Large Pharma,4055,Staph aureus vaccine,Staph aureus,Vaccine,Phase I,In-House,,,,,82,Other Vaccines,43,Vaccine Products,5,Vaccines,6,US,Sales,0,0,0,0,0,0,0,0,0,0,0,0,0,3816,Staphylococcus Aureus Prophylaxis,7/7/14 12:28
3931,67,Novartis,Large Pharma,1327,Xolair,omalizumab,Antibody/Antibody Derivative,Launched,Licensed (Development),Mar-14,Mar-14,N/A,Aug-17,75,Other Dermatology Products,2,Other Dermatology Disorders,6,Dermatology,6,Global,Sales,0,0,0,0,0,13.333328,29.44446169,46.63817463,63.8319759,67.89864399,71.42364342,74.46051884,0,1570,Chronic idiopathic urticaria,7/7/14 12:28